,file,sent_id,sent_start,sent_end,sentence,nonoseaeaeonlyasinstruction,nonoseaegeneralterm,notaecandidatepreexistingconditionorriskfactor,notaecandidateindication,nonoseaemanifestationorcomplication,nonoseaeaefromdruginteraction,nonoseaeaeratelteqplacebo,nonoseaenegation,nonoseaeaeanimal,nonoseaeodorwithdrawal,nonoseaeaefromofflabel,notaecandidatecontraindication,nonoseaeaeforanotherdruginclass,notaecandidateother,nonoseaeother
0,carboplatin,0,0,49,"['  ADVERSE REACTIONS\n', '\n', '  For a comparison of toxicities when carboplatin or cisplatin was given in combination with cyclophosphamide, see    CLINICAL STUDIES, Use with Cyclophosphamide for Initial Treatment of  notaecandidateindication  Comparative Toxicity  .  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
1,carboplatin,1,49,155,"\n', '\n', ' ADVERSE EXPERIENCES IN PATIENTS WITH OVARIAN CANCER \n', '                                                    First Line    Combination Therapy   [note: Use with Cyclophosphamide for Initial Treatment of  notaecandidateindication  Data are based on the experience of 393 patients with  notaecandidateindication (regardless of baseline status) who received initial combination therapy with carboplatin and cyclophosphamide in two randomized controlled studies conducted by SWOG and NCIC (see CLINICAL STUDIES).Combination with cyclophosphamide as well as duration of treatment may be responsible for the differences that can be noted in the adverse experience table.]   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
2,carboplatin,2,155,157,Percent      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,carboplatin,3,157,163,Second Line    Single Agent    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,carboplatin,4,163,165,Therapy   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,carboplatin,5,165,168,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,carboplatin,6,168,179,Single Agent Use for the Secondary Treatment of Ovarian Cancer:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,carboplatin,7,179,207,Data are based on the experience of 553 patients with previously treated ovarian carcinoma (regardless of baseline status) who received single agent carboplatin.]   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,carboplatin,8,207,209,Percent     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,carboplatin,9,209,231,"\n', '  \n', '   nonoseaegeneralterm                                                                            \n', '   oselabeledaefromdruguse      < 100,000/mm3              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
10,carboplatin,10,231,233,66                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,carboplatin,11,233,235,62               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,carboplatin,12,235,243,"\n', '                        < 50,000/mm3               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,carboplatin,13,243,254,"33                   35               \n', '   oselabeledaefromdruguse           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,carboplatin,14,254,273,"< 2,000 cells/mm3          96                   67               \n', '                        < 1,000 cells/",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,carboplatin,15,273,277,mm3          82                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,carboplatin,16,277,279,21               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,carboplatin,17,279,305,"\n', '   oselabeledaefromdruguse            < 4,000 cells/mm3          97                   85               \n', '                        < 2,000 cells/",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,carboplatin,18,305,311,mm3          71                   26               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,carboplatin,19,311,318,"\n', '   oselabeledaefromdruguse                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,carboplatin,20,318,324,< 11 g/dL                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,carboplatin,21,324,326,90                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,carboplatin,22,326,328,90               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,carboplatin,23,328,338,"\n', '                        < 8g/dL                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,carboplatin,24,338,340,14                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,carboplatin,25,340,342,21               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,carboplatin,26,342,353,"\n', '   oselabeledaefromdruguse                                       16                   5                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,carboplatin,27,353,364,"\n', '   oselabeledaefromdruguse                                         8                    5                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,carboplatin,28,364,392,"\n', '   oselabeledaefromdruguse                                     35                   44               \n', '   nonoseaegeneralterm                                                      \n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,carboplatin,29,392,394,93                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,carboplatin,30,394,396,92                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,carboplatin,31,396,418,"\n', '   oselabeledaefromdruguse              83                         81                   \n', '  Other  oselabeledaefromdruguse    46                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,carboplatin,32,418,434,"21                   \n', '   nonoseaegeneralterm                                                            \n', '   oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,carboplatin,33,434,458,"15                         6                    \n', '   oselabeledaefromdruguse           12                         1                    \n', '  Other  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,carboplatin,34,458,462,5                          1                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,carboplatin,35,462,471,"\n', '   oselabeledaefromdruguse    26                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,carboplatin,36,471,473,5                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,carboplatin,37,473,480,"\n', '   nonoseaegeneralterm                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,carboplatin,38,480,487,"\n', '   oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,carboplatin,39,487,500,"6                          10                   \n', '   oselabeledaefromdruguse    17                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,carboplatin,40,500,502,22                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,carboplatin,41,502,509,"\n', '   nonoseaegeneralterm                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,carboplatin,42,509,516,"\n', '   oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,carboplatin,43,516,520,5                          5                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,carboplatin,44,520,538,"\n', '   oselabeledaefromdruguse       20                         19                   \n', '   oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,carboplatin,45,538,542,29                         37                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,carboplatin,46,542,558,"\n', '   nonoseaegeneralterm  oselabeledaefromdruguse  oselabeledaefromdruguse                                                     \n', '  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
47,carboplatin,47,558,562,Sodium                10                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,carboplatin,48,562,564,47                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,carboplatin,49,564,578,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse                                                     \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,carboplatin,50,578,582,Sodium                10                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,carboplatin,51,582,584,47                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,carboplatin,52,584,593,"\n', '  Potassium             16                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,carboplatin,53,593,595,28                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,carboplatin,54,595,609,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse                                                     \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,carboplatin,55,609,613,Sodium                10                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,carboplatin,56,613,615,47                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,carboplatin,57,615,624,"\n', '  Potassium             16                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,carboplatin,58,624,626,28                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,carboplatin,59,626,635,"\n', '  Calcium               16                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,carboplatin,60,635,637,31                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,carboplatin,61,637,646,"\n', '   oselabeledaefromdruguse             61                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,carboplatin,62,646,648,43                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,carboplatin,63,648,657,"\n', '   nonoseaegeneralterm  oselabeledaefromdruguse                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,carboplatin,64,657,666,"\n', '  Pain                  44                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,carboplatin,65,666,668,23                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,carboplatin,66,668,675,"\n', '  Asthenia              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,carboplatin,67,675,677,41                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,carboplatin,68,677,679,11                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,carboplatin,69,679,688,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,carboplatin,70,688,697,"\n', '  Pain                  44                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,carboplatin,71,697,699,23                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,carboplatin,72,699,706,"\n', '  Asthenia              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,carboplatin,73,706,708,41                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,carboplatin,74,708,710,11                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,carboplatin,75,710,715,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,carboplatin,76,715,721,Cardiovascular        19                         6                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,carboplatin,77,721,739,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse                                                    \n', '  Pain                  44                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,carboplatin,78,739,741,23                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,carboplatin,79,741,748,"\n', '  Asthenia              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,carboplatin,80,748,750,41                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,carboplatin,81,750,752,11                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,carboplatin,82,752,757,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,carboplatin,83,757,763,Cardiovascular        19                         6                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,carboplatin,84,763,779,"\n', '  Respiratory           10                         6                    \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,carboplatin,85,779,796,"Allergic              11                         2                    \n', '   oselabeledaefromdruguse  oselabeledaefromdruguse                  44                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,carboplatin,86,796,798,23                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,carboplatin,87,798,807,"\n', '   oselabeledaefromdruguse              41                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,carboplatin,88,807,809,11                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,carboplatin,89,809,814,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,carboplatin,90,814,820,Cardiovascular        19                         6                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,carboplatin,91,820,831,"\n', '  Respiratory           10                         6                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,carboplatin,92,831,858,"\n', '   oselabeledaefromdruguse              11                         2                    \n', '  Genitourinary         10                         2                    \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,carboplatin,93,858,880,"oselabeledaefromdruguse              49                         2                    \n', '   oselabeledaefromdruguse             8                          1                    \n', '          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,carboplatin,94,880,940,"In the narrative section that follows, the incidences of adverse events are based on data from 1,893 patients with various types of tumors who received carboplatin as single agent therapy.\n', ' \n', '\n', '    oselabeledaefromdruguse \n', '   oselabeledaefromdruguse is the dose-limiting toxicity of carboplatin.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,carboplatin,95,940,1008,oselabeledaefromdruguse with  oselabeledaefromdruguse  occurs in 25% of the patients (35% of pretreated  notaecandidateindication patients);  oselabeledaefromdruguse with  oselabeledaefromdruguse  occurs in 16% of the patients (21% of pretreated  notaecandidateindication patients);  oselabeledaefromdruguse with  oselabeledaefromdruguse  occurs in 15% of the patients (26% of pretreated  notaecandidateindication patients).,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
96,carboplatin,96,1008,1022,The nadir usually occurs about day 21 in patients receiving single agent therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,carboplatin,97,1022,1139,"By day 28, 90% of patients have  nonoseaeaeonlyasinstruction  ; 74% have  nonoseaeaeonlyasinstruction  ; 67% have  nonoseaeaeonlyasinstruction  .\n', '\n', '  nonoseaeaeonlyasinstruction is usually more severe in patients with  notaecandidatepreexistingconditionorriskfactor  Patients with poor performance status have also experienced a higher incidence of severe  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction \n', '\n', ' The  oselabeledaefromdruguse  although usually reversible, have resulted in  oselabeledaefromdruguse or hemorrhagic  oselabeledaefromdruguse  oselabeledaefromdruguse in 5% of the patients treated with carboplatin, with drug related  nonoseaegeneralterm occurring in less than 1% of the patients.  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
98,carboplatin,98,1139,1140,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,carboplatin,99,1140,1172,"\n', '\n', '  oselabeledaefromdruguse with  oselabeledaefromdruguse has been observed in 71% of the patients who started therapy with a baseline above that value.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,carboplatin,100,1172,1184,The incidence of  oselabeledaefromdruguse increases with increasing exposure to carboplatin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,carboplatin,101,1184,1276,"Transfusions have been administered to 26% of the patients treated with carboplatin (44% of previously treated  notaecandidateindication patients).\n', '\n', '  oselabeledaefromdruguse may be more severe when carboplatin is combined with other  nonoseaeaeonlyasinstruction drugs or with radiotherapy.\n', '\n', '    oselabeledaefromdruguse \n', '   oselabeledaefromdruguse occurs in 65% of the patients (81% of previously treated  notaecandidateindication patients) and in about one-third of these patients it is severe.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
102,carboplatin,102,1276,1329,"Carboplatin, as a single agent or in combination, is significantly less  oselabeledaefromdruguse than cisplatin; however, patients previously treated with  nonoseaeaeonlyasinstruction  especially cisplatin, appear to be more prone to  nonoseaeaeonlyasinstruction   oselabeledaefromdruguse alone occurs in an additional 10% to 15% of patients.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,carboplatin,103,1329,1350,Both  oselabeledaefromdruguse and  oselabeledaefromdruguse usually cease within 24 hours of treatment and are often responsive to antiemetic measures.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,carboplatin,104,1350,1398,"Although no conclusive efficacy data exist with the following schedules, prolonged administration of carboplatin, either by continuous 24-hour infusion or by daily pulse doses given for 5 consecutive days, was associated with less severe  oselabeledaefromdruguse than the single-dose intermittent schedule.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,carboplatin,105,1398,1412,nonoseaeaefromdruginteraction was increased when carboplatin was used in combination with other emetogenic compounds.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
106,carboplatin,106,1412,1420,Other  oselabeledaefromdruguse effects observed frequently were  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,carboplatin,107,1420,1492,"oselabeledaefromdruguse  oselabeledaefromdruguse observed frequently were pain, in 17% of the patients;  oselabeledaefromdruguse  in 6%; and  oselabeledaefromdruguse  also in 6%.\n', '\n', '    oselabeledaefromdruguse \n', '   oselabeledaefromdruguse have been observed in 4% of the patients receiving carboplatin (6% of pretreated  notaecandidatepreexistingconditionorriskfactor patients) with mild  oselabeledaefromdruguse occurring most frequently.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
108,carboplatin,108,1492,1508,Carboplatin therapy produces significantly fewer and less severe  oselabeledaefromdruguse than does therapy with cisplatin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,carboplatin,109,1508,1534,"However, patients older than 65 years and/or previously treated with cisplatin appear to have an increased risk (10%) for  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,carboplatin,110,1534,1561,In 70% of the patients with pre-existing cisplatin-induced  notaecandidatepreexistingconditionorriskfactor  there was no worsening of symptoms during therapy with carboplatin.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
111,carboplatin,111,1561,1587,Clinical  oselabeledaefromdruguse and other  oselabeledaefromdruguse such as  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in only 1% of the patients.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,carboplatin,112,1587,1691,"oselabeledaefromdruguse have been reported in 5% of the patients and appear to be most often related to the use of antiemetics.\n', '\n', ' Although the overall incidence of  oselabeledaefromdruguse induced by carboplatin is low, prolonged treatment, particularly in cisplatin pretreated patients, may result in cumulative  oselabeledaefromdruguse \n', '\n', '    oselabeledaefromdruguse \n', '  Development of  oselabeledaefromdruguse results is uncommon, despite the fact that carboplatin, unlike cisplatin, has usually been administered without high-volume fluid hydration and/or forced  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,carboplatin,113,1691,1742,"The incidences of  oselabeledaefromdruguse  oselabeledaefromdruguse renal function tests reported are 6% for  oselabeledaefromdruguse  oselabeledaefromdruguse renal function tests reported are 6% for serum creatinine and 14% for  oselabeledaefromdruguse (10% and 22%, respectively, in pretreated  notaecandidatepreexistingconditionorriskfactor patients).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
114,carboplatin,114,1742,1882,"Most of these reported abnormalities have been mild and about one-half of them were reversible.\n', '\n', ' Creatinine clearance has proven to be the most sensitive measure of kidney function in patients receiving carboplatin, and it appears to be the most useful test for correlating drug clearance and  nonoseaeaeonlyasinstruction  Twenty-seven percent of the patients who had a baseline value of 60 mL/min or more demonstrated a reduction below this value during carboplatin therapy.\n', '\n', '    oselabeledaefromdruguse \n', '  The incidences of  oselabeledaefromdruguse  oselabeledaefromdruguse liver function tests in patients with normal baseline values were reported as follows:  oselabeledaefromdruguse  oselabeledaefromdruguse liver function tests in patients with normal baseline values were reported as follows:",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,carboplatin,115,1882,1889,"total bilirubin, 5%;  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,carboplatin,116,1889,1906,oselabeledaefromdruguse  oselabeledaefromdruguse liver function tests in patients with normal baseline values were reported as follows:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,carboplatin,117,1906,1944,"total bilirubin, 5%; SGOT, 15%; and  oselabeledaefromdruguse  24%; (5%, 19%, and 37%, respectively, in pretreated  notaecandidateindication patients).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
118,carboplatin,118,1944,1975,"These abnormalities have generally been mild and reversible in about one-half of the cases, although the role of  notaecandidatepreexistingconditionorriskfactor may complicate the assessment in many patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
119,carboplatin,119,1975,2068,"In a limited series of patients receiving very high dosages of carboplatin and  notaecandidatepreexistingconditionorriskfactor  severe  oselabeledaefromdruguse were reported.\n', '\n', '    oselabeledaefromdruguse \n', '  The incidences of abnormally  oselabeledaefromdruguse  oselabeledaefromdruguse serum electrolyte values reported were as follows:  oselabeledaefromdruguse  oselabeledaefromdruguse serum electrolyte values reported were as follows: sodium, 29%;  oselabeledaefromdruguse  oselabeledaefromdruguse serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%;  oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
120,carboplatin,120,2068,2122,"oselabeledaefromdruguse serum electrolyte values reported were as follows: sodium, 29%; potassium, 20%; calcium, 22%; and  oselabeledaefromdruguse  29%; (47%, 28%, 31%, and 43%, respectively, in pretreated  notaecandidatepreexistingconditionorriskfactor patients).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
121,carboplatin,121,2122,2172,"Electrolyte supplementation was not routinely administered concomitantly with carboplatin, and these  oselabeledaefromdruguse were rarely associated with symptoms.\n', '\n', '   Allergic Reactions\n', '\n', '   oselabeledaefromdruguse to carboplatin has been reported in 2% of the patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,carboplatin,122,2172,2227,"These  oselabeledaefromdruguse have been similar in nature and severity to those reported with other platinum-containing compounds, i.e.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and rarely  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse have been reported as part of postmarketing surveillance (see      WARNINGS      ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,carboplatin,123,2227,2299,"These reactions have been successfully managed with standard epinephrine, corticosteroid, and antihistamine therapy.\n', '\n', '   Injection Site Reactions\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including redness,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including redness, swelling, and  oselabeledaefromdruguse  have been reported during postmarketing surveillance.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,carboplatin,124,2299,2349,"oselabeledaefromdruguse has also been reported.\n', '\n', '   Other Events\n', '\n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse were the most frequently reported miscellaneous adverse effects; their relationship to the  nonoseaeaeonlyasinstruction and to  nonoseaeaeonlyasinstruction was likely.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,carboplatin,125,2349,2358,oselabeledaefromdruguse was reported (3%).  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,carboplatin,126,2358,2398,"oselabeledaefromdruguse  respiratory, genitourinary, and mucosal  oselabeledaefromdruguse  oselabeledaefromdruguse  genitourinary, and mucosal  oselabeledaefromdruguse  oselabeledaefromdruguse  and mucosal  oselabeledaefromdruguse  oselabeledaefromdruguse have occurred in 6% or less of the patients.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,carboplatin,127,2398,2428,oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  were  nonoseaegeneralterm in less than 1% of the patients and did not appear to be related to chemotherapy.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
128,carboplatin,128,2428,2456,"notaecandidatepreexistingconditionorriskfactor associated  notaecandidatepreexistingconditionorriskfactor has been reported rarely.\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
129,carboplatin,129,2456,2467,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,carboplatin,130,2467,2510,"WARNING\n', '\n', '  WARNING\n', '\n', '  Carboplatin injection 10 mg/mL should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,carboplatin,131,2510,2527,Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,carboplatin,132,2527,2549,"\n', '\n', '  oselabeledaefromdruguse is dose related and may be severe, resulting in  nonoseaemanifestationorcomplication",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
133,carboplatin,133,2549,2564,and/or  nonoseaemanifestationorcomplication   oselabeledaefromdruguse may be cumulative and may require transfusion support.  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
134,carboplatin,134,2564,2629,"oselabeledaefromdruguse is another frequent drug related side effect.\n', '\n', '  oselabeledaefromdruguse    PRECAUTIONS\n', '\n', '   General\n', '\n', '   Needles or intravenous administration sets containing aluminum parts that may come in contact with carboplatin injection should not be used for the preparation or administration of the drug.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,carboplatin,135,2629,2643,Aluminum can react with carboplatin causing precipitate formation and loss of potency.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,carboplatin,136,2643,2658,"\n', '\n', '    Drug Interactions\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,carboplatin,137,2658,2676,"', '  The renal effects of  nonoseaeaeonlyasinstruction compounds may be potentiated by carboplatin.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,carboplatin,138,2676,2725,"'\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility\n', '\n', '  The carcinogenic potential of carboplatin has not been studied, but compounds with similar mechanisms of action and mutagenicity profiles have been reported to be  nonoseaeaeforanotherdruginclass  ",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
139,carboplatin,139,2725,2742,Carboplatin has been shown to be  oselabeledaefromdruguse both in vitro  and in vivo  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,carboplatin,140,2742,2763,It has also been shown to be  nonoseaeaeanimal and  nonoseaeaeanimal in rats receiving the drug during organogenesis.  ,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
141,carboplatin,141,2763,2795,"nonoseaeaefromdruginteraction have been reported in association with multi-drug therapy.\n', '\n', '    Pregnancy\n', '\n', '    Pregnancy Category D  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
142,carboplatin,142,2795,2839,"\n', '\n', '  See   WARNINGS    .\n', '\n', '    Nursing Mothers\n', '\n', '  It is not known whether carboplatin is excreted in human milk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,carboplatin,143,2839,2955,"Because there is a possibility of toxicity in nursing infants secondary to carboplatin treatment of the mother, it is recommended that breastfeeding be discontinued if the mother is treated with carboplatin injection.\n', '\n', '    Pediatric Use\n', '\n', '  Safety and effectiveness in pediatric patients have not been established (see   WARNINGS,  nonoseaeaefromofflabel    ).\n', '\n', '    Geriatric Use\n', '\n', '  Of the 789 patients in initial treatment combination therapy studies (NCIC and SWOG), 395 patients were treated with carboplatin in combination with cyclophosphamide.",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
144,carboplatin,144,2955,2973,"Of these, 141 were over 65 years of age and 22 were 75 years or older.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,carboplatin,145,2973,2986,"In these trials, age was not a prognostic factor for survival.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,carboplatin,146,2986,3008,"In terms of safety, elderly patients treated with carboplatin were more likely to develop severe  oselabeledaefromdruguse than younger patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,carboplatin,147,3008,3057,"In a combined database of 1,942 patients (414 were >= 65 years of age) that received single agent carboplatin for different  notaecandidatepreexistingconditionorriskfactor types, a similar incidence of adverse events was seen in patients 65 years and older and in patients less than 65.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
148,carboplatin,148,3057,3086,"Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,carboplatin,149,3086,3122,"Because  nonoseaeaeonlyasinstruction    WARNINGS\n', '\n', '   oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  is dose-dependent and is also the dose-limiting toxicity.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,carboplatin,150,3122,3143,"Peripheral blood counts should be frequently monitored during carboplatin injection treatment and, when appropriate, until recovery is achieved.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,carboplatin,151,3143,3156,Median nadir occurs at day 21 in patients receiving single agent carboplatin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,carboplatin,152,3156,3231,"In general, single intermittent courses of carboplatin should not be repeated until leukocyte, neutrophil, and platelet counts have recovered.\n', '\n', ' Since  oselabeledaefromdruguse is cumulative, transfusions may be needed during treatment with carboplatin, particularly in patients receiving prolonged therapy.\n', '\n', '  nonoseaeaeonlyasinstruction is increased in patients who have received prior therapy, especially regimens including cisplatin.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,carboplatin,153,3231,3270,nonoseaeaeonlyasinstruction is also increased in patients with  notaecandidatepreexistingconditionorriskfactor  Initial carboplatin injection dosages in these patients should be appropriately reduced (see   DOSAGE AND ADMINISTRATION    ) and blood counts should be carefully monitored between courses.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
154,carboplatin,154,3270,3340,"The use of carboplatin in combination with other  nonoseaeaeonlyasinstruction therapies must be carefully managed with respect to dosage and timing in order to minimize additive effects.\n', '\n', ' Carboplatin has limited  oselabeledaefromdruguse potential, but concomitant treatment with aminoglycosides has resulted in  nonoseaeaefromdruginteraction and/or audiologic  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction  and caution must be exercised when a patient receives both drugs.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
155,carboplatin,155,3340,3394,"Clinically significant  nonoseaeaefromdruginteraction has been reported to occur in pediatric patients when carboplatin was administered at higher than recommended doses in combination with other  nonoseaeaeonlyasinstruction agents.\n', '\n', ' Carboplatin can induce  oselabeledaefromdruguse  which can be more severe in patients previously receiving  nonoseaeaeonlyasinstruction therapy.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
156,carboplatin,156,3394,3410,The incidence and intensity of  nonoseaeaeonlyasinstruction have been reduced by using premedication with antiemetics.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,carboplatin,157,3410,3482,"Although no conclusive efficacy data exist with the following schedules of carboplatin, lengthening the duration of single intravenous administration to 24 hours or dividing the total dose over five consecutive daily pulse doses has resulted in reduced  nonoseaeaeonlyasinstruction \n', '\n', ' Although  nonoseaeaeonlyasinstruction is infrequent, its incidence is increased in patients older than 65 years and in patients previously treated with cisplatin.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,carboplatin,158,3482,3543,"Pre-existing cisplatin-induced  notaecandidatepreexistingconditionorriskfactor does not worsen in about 70% of the patients receiving carboplatin as secondary treatment.\n', '\n', '  nonoseaeaefromofflabel  which can be complete for light and colors, has been reported after the use of carboplatin with doses higher than those recommended in the package insert.",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
159,carboplatin,159,3543,3586,"Vision appears to recover totally or to a significant extent within weeks of stopping these high doses.\n', '\n', ' As in the case of other platinum-coordination compounds,  oselabeledaefromdruguse to carboplatin have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,carboplatin,160,3586,3602,These may occur within minutes of administration and should be managed with appropriate supportive therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,carboplatin,161,3602,3682,"There is increased risk of  nonoseaeaeonlyasinstruction including  nonoseaeaeonlyasinstruction in patients previously exposed to platinum therapy (see   CONTRAINDICATIONS    and   ADVERSE REACTIONS, Allergic Reactions    ).\n', '\n', ' High dosages of carboplatin (more than 4 times the recommended dose) have resulted in severe  nonoseaeaefromofflabel \n', '\n', ' Carboplatin injection may cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",1,0,1,0,0,0,0,0,0,0,1,0,0,0,0
162,carboplatin,162,3682,3696,Carboplatin has been shown to be  nonoseaeaeanimal and  nonoseaeaeanimal in rats.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
163,carboplatin,163,3696,3710,There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
164,carboplatin,164,3710,3756,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while receiving this drug, the patient should be apprised of the potential  oselabeledaefromdruguse  Women of childbearing potential should be advised to avoid becoming  nonoseaeaeonlyasinstruction ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,valium,0,0,6,['    ADVERSE REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,valium,1,6,32,"\n', '\n', '  Side effects most commonly reported were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,valium,2,32,73,"The following have also been reported:\n', '\n', '     Central Nervous System:  \n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,valium,3,73,96,"\n', '     Gastrointestinal System:  \n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,valium,4,96,162,"\n', '     Special Senses:  \n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '     Cardiovascular System:  \n', '\n', '   oselabeledaefromdruguse \n', '     Psychiatric and Paradoxical Reactions:  \n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,valium,5,162,190,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,valium,6,190,202,oselabeledaefromdruguse and other  oselabeledaefromdruguse have been reported when using benzodiazepines.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,valium,7,202,214,"Should these occur, use of the drug should be discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,valium,8,214,252,"They are more likely to occur in children and in the elderly.\n', '\n', '     Urogenital System:  \n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,valium,9,252,277,"\n', '     Skin and Appendages:  \n', '\n', '   oselabeledaefromdruguse \n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,valium,10,277,301,"Laboratories:  \n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse transaminases and  oselabeledaefromdruguse \n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,valium,11,301,320,"Other:  \n', '\n', '   oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,valium,12,320,340,"\n', '  oselabeledaefromdruguse may occur using therapeutic dosages, the risk increasing at higher dosages.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,valium,13,340,347,oselabeledaefromdruguse may be associated with  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,valium,14,347,558,"\n', '\n', ' Minor  oselabeledaefromdruguse patterns, usually low-voltage fast activity, have been observed in patients during and after Valium therapy and are of no known significance.\n', '\n', ' Because of isolated reports of  oselabeledaefromdruguse and  oselabeledaefromdruguse  periodic blood counts and liver function tests are advisable during long-term therapy.\n', '\n', '   Postmarketing Experience\n', '\n', '  Injury, Poisoning and Procedural Complications\n', '\n', '  There have been reports of  oselabeledaeclasseffect and  oselabeledaeclasseffect \n', '\n', '    BOXED WARNING: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS\n', '\n', '    WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS  \n', '\n', '  Concomitant use of benzodiazepines and opioids may result in profound  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  and  nonoseaegeneralterm (see     Drug Interactions    ).\n', '\n', ' *  Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.",0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
15,valium,15,558,573,"\n', ' *  Limit dosages and durations to the minimum required.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,valium,16,573,753,"\n', ' *  Follow patients for signs and symptoms of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction    PRECAUTIONS\n', '\n', '   General\n', '\n', '  If Valium is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed - particularly with known compounds that may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants (see  Drug Interactions  ).\n', '\n', ' The usual precautions are indicated for severely  notaecandidatepreexistingconditionorriskfactor patients or those in whom there is any evidence of latent  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor associated  notaecandidatepreexistingconditionorriskfactor  particularly the recognition that  notaecandidatepreexistingconditionorriskfactor may be present and protective measures may be necessary.\n', '\n', '  oselabeledaeclasseffect and paradoxical  oselabeledaeclasseffect  oselabeledaeclasseffect are known to occur when using benzodiazepines (see  ADVERSE REACTIONS  ).",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
17,valium,17,753,765,"Should this occur, use of the drug should be discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,valium,18,765,984,"These reactions are more likely to occur in children and the elderly.\n', '\n', ' A lower dose is recommended for patients with  notaecandidatepreexistingconditionorriskfactor  due to the risk of  nonoseaeaeonlyasinstruction \n', '\n', ' Benzodiazepines should be used with extreme caution in patients with a history of  notaecandidatepreexistingconditionorriskfactor or drug  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor (see  DRUG ABUSE AND DEPENDENCE  ).\n', '\n', ' In  notaecandidatepreexistingconditionorriskfactor patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (2 mg to 2.5 mg once or twice daily, initially, to be increased gradually as needed and tolerated).\n', '\n', ' Some  oselabeledaeclasseffect of benzodiazepines may develop after repeated use of Valium for a prolonged time.\n', '\n', '    Information For Patients\n', '\n', '  To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
19,valium,19,984,1035,"The risk of dependence increases with duration of treatment; it is also greater in patients with a history of alcohol or drug abuse.\n', '\n', ' Patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,valium,20,1035,1081,"As is true of most CNS-acting drugs, patients receiving Valium should be cautioned against engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.\n', '\n', '     Drug Interactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,valium,21,1081,1126,"\n', '\n', '   Opioids\n', '\n', '  The concomitant use of benzodiazepines and opioids increases the risk of  nonoseaeaefromdruginteraction because of actions at different receptor sites in the CNS that control respiration.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
22,valium,22,1126,1138,Benzodiazepines interact at GABAAsites and opioids interact primarily at mu receptors.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,valium,23,1138,1159,"When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related  nonoseaeaefromdruginteraction exists.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
24,valium,24,1159,1329,"Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction \n', '\n', '    Centrally Acting Agents\n', '\n', '  If Valium is to be combined with other centrally acting agents careful consideration should be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants.\n', '\n', '    Alcohol\n', '\n', '  Concomitant use with alcohol is not recommended due to  nonoseaeaefromdruginteraction \n', '\n', '    Antacids\n', '\n', '  Diazepam peak concentrations are 30% lower when antacids are administered concurrently.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
25,valium,25,1329,1341,"However, there is no effect on the extent of absorption.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,valium,26,1341,1375,"The lower peak concentrations appear due to a slower rate of absorption, with the time required to achieve peak concentrations on average 20 - 25 minutes greater in the presence of antacids.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,valium,27,1375,1429,"However, this difference was not statistically significant.\n', '\n', '    Compounds Which Inhibit Certain Hepatic Enzymes\n', '\n', '  There is a potentially relevant interaction between diazepam and compounds which inhibit certain hepatic enzymes (particularly cytochrome P450 3A and 2C19).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,valium,28,1429,1449,Data indicate that these compounds influence the pharmacokinetics of diazepam and may lead to increased and prolonged  nonoseaeaefromdruginteraction  ,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
29,valium,29,1449,1601,"At present, this reaction is known to occur with cimetidine, ketoconazole, fluvoxamine, fluoxetine, and omeprazole.\n', '\n', '    Phenytoin\n', '\n', '  There have also been reports that the metabolic elimination of phenytoin is decreased by diazepam.\n', '\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility\n', '\n', '  In studies in which mice and rats were administered diazepam in the diet at a dose of 75 mg/kg/day (approximately 6 and 12 times, respectively, the maximum recommended human dose [MRHD=1 mg/kg/day] on a mg/m  2  basis) for 80 and 104 weeks, respectively, an increased incidence of  nonoseaeaeanimal was observed in males of both species.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
30,valium,30,1601,1616,The data currently available are inadequate to determine the  nonoseaeaeonlyasinstruction potential of diazepam.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,valium,31,1616,1673,Reproduction studies in rats showed  nonoseaeaeanimal  nonoseaeaeanimal pregnancies and in the number of  nonoseaeaeanimal following administration of an oral dose of 100 mg/kg/day (approximately 16 times the MRHD on a mg/m  2  basis) prior to and during mating and throughout gestation and lactation.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
32,valium,32,1673,1788,"No adverse effects on  nonoseaenegation or  nonoseaenegation were noted at a dose of 80 mg/kg/day (approximately 13 times the MRHD on a mg/m  2  basis).\n', '\n', '     Pregnancy  \n', '\n', '   Category D  (see  WARNINGS:  nonoseaeaeonlyasinstruction  ).\n', '\n', '     Pediatric Use  \n', '\n', '  Safety and effectiveness in pediatric patients below the age of 6 months have not been established.\n', '\n', '     Geriatric Use  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
33,valium,33,1788,1850,"\n', '\n', '  In elderly patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (2 mg to 2.5 mg once or twice daily, initially to be increased gradually as needed and tolerated).\n', '\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,valium,34,1850,1876,"' Extensive accumulation of diazepam and its major metabolite, desmethyldiazepam, has been noted following chronic administration of diazepam in healthy elderly male subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,valium,35,1876,1979,"Metabolites of this drug are known to be substantially excreted by the kidney, and the risk of  nonoseaegeneralterm may be greater in patients with  notaecandidatepreexistingconditionorriskfactor  Because elderly patients are more likely to have  notaecandidatepreexistingconditionorriskfactor  care should be taken in dose selection, and it may be useful to monitor renal function.\n', '\n', '     Hepatic Insufficiency  \n', '\n', '  Decreases in clearance and protein binding, and increases in volume of distribution and half-life have been reported in patients with  notaecandidatepreexistingconditionorriskfactor  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
36,valium,36,1979,1998,"In such patients, a 2- to 5- fold increase in mean half-life has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,valium,37,1998,2010,Delayed elimination has also been reported for the active metabolite desmethyldiazepam.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,valium,38,2010,2133,"Benzodiazepines are commonly implicated in  oselabeledaeclasseffect  Increases in half-life have also been reported in  notaecandidatepreexistingconditionorriskfactor and in both  notaecandidatepreexistingconditionorriskfactor and chronic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor    WARNINGS\n', '\n', '  Concomitant use of benzodiazepiones, including Valium, and opioids may result in profound  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  and  nonoseaegeneralterm  Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.\n', '\n', ' Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related  nonoseaegeneralterm compared to use of opioids alone.",0,1,1,0,0,1,0,0,0,0,0,0,0,0,0
39,valium,39,2133,2172,"If a decision is made to prescribe Valium concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,valium,40,2172,2202,"In patients already receiving an opioid analgesic, prescribe a lower initial dose of Valium than indicated in the absence of an opioid and titrate based on clinical response.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,valium,41,2202,2256,"If an opioid is initiated in a patient already taking Valium, prescribe a lower initial dose of the opioid and titrate based upon clinical response.\n', '\n', ' Advise both patients and caregivers about the risks of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction when Valium is used with opioids.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,valium,42,2256,2398,"Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see   Drug Interactions    ).\n', '\n', ' Valium is not recommended in the treatment of  notaecandidatepreexistingconditionorriskfactor patients and should not be employed instead of appropriate treatment.\n', '\n', ' Since Valium has a  oselabeledaefromdruguse  patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during Valium therapy.\n', '\n', ' As with other agents that have anticonvulsant activity, when Valium is used as an adjunct in treating  notaecandidateindication  the possibility of an increase in the frequency and/or severity of  notaecandidatepreexistingconditionorriskfactor may require an increase in the dosage of standard anticonvulsant medication.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
43,valium,43,2398,2464,"Abrupt withdrawal of Valium in such cases may also be associated with a temporary increase in the frequency and/or severity of  nonoseaeodorwithdrawal \n', '\n', '    Pregnancy\n', '\n', '  An increased risk of  oselabeledaeclasseffect  and other  oselabeledaeclasseffect associated with the use of benzodiazepine drugs during  notaecandidatepreexistingconditionorriskfactor has been suggested.",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
44,valium,44,2464,2480,There may also be  oselabeledaeclasseffect associated with the use of benzodiazepines during  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
45,valium,45,2480,2535,"There have been reports of  oselabeledaeclasseffect  oselabeledaeclasseffect flaccidity, respiratory and feeding difficulties, and  oselabeledaeclasseffect  oselabeledaeclasseffect flaccidity,  oselabeledaeclasseffect and feeding  oselabeledaeclasseffect  oselabeledaeclasseffect flaccidity, respiratory and  oselabeledaeclasseffect  and hypothermia in children born to mothers who have been receiving benzodiazepines late in  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
46,valium,46,2535,2629,"In addition, children born to mothers receiving benzodiazepines on a regular basis late in  notaecandidatepreexistingconditionorriskfactor may be at some risk of experiencing  oselabeledaeclasseffect during the  oselabeledaeclasseffect period.\n', '\n', ' Diazepam has been shown to be  nonoseaeaeanimal in mice and hamsters when given orally at daily doses of 100 mg/kg or greater (approximately eight times the maximum recommended human dose [MRHD=1 mg/kg/day] or greater on a mg/m  2  basis).  ",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
47,valium,47,2629,2659,"nonoseaeaeanimal and  nonoseaeaeanimal are the most common and consistently reported  nonoseaeaeanimal produced in these species by administration of high, maternally toxic doses of diazepam during organogenesis.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
48,valium,48,2659,2743,"Rodent studies have indicated that prenatal exposure to diazepam doses similar to those used clinically can produce long-term  nonoseaeaeanimal  nonoseaeaeanimal cellular immune responses,  nonoseaeaeanimal  nonoseaeaeanimal cellular immune responses, brain neurochemistry, and  nonoseaeaeanimal \n', '\n', ' In general, the use of diazepam in women of childbearing potential, and more specifically during known  notaecandidatepreexistingconditionorriskfactor  should be considered only when the clinical situation warrants the  oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
49,valium,49,2743,2766,The possibility that a woman of childbearing potential may be  nonoseaeaeonlyasinstruction at the time of institution of therapy should be considered.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,valium,50,2766,2945,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while taking this drug, the patient should be apprised of the potential  oselabeledaefromdruguse  Patients should also be advised that if they become  nonoseaeaeonlyasinstruction during therapy or intend to become  nonoseaeaeonlyasinstruction they should communicate with their physician about the desirability of discontinuing the drug.\n', '\n', '    Labor and Delivery\n', '\n', '  Special care must be taken when Valium is used during labor and delivery, as high single doses may produce  oselabeledaefromdruguse and  oselabeledaefromdruguse  poor sucking, hypothermia, and moderate respiratory depression in the  oselabeledaefromdruguse  oselabeledaefromdruguse  hypothermia, and moderate respiratory depression in the  oselabeledaefromdruguse  oselabeledaefromdruguse  and moderate respiratory depression in the  oselabeledaefromdruguse  oselabeledaefromdruguse  With newborn infants it must be remembered that the enzyme system involved in the breakdown of the drug is not yet fully developed (especially in  notaecandidatepreexistingconditionorriskfactor ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,cytoxan,0,0,48,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in more detail in other sections of the labeling.\n', '\n', ' *     oselabeledaefromdruguse [see  Contraindications (4)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,cytoxan,1,48,74,"\n', ' *     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,cytoxan,2,74,98,"\n', ' *     oselabeledaefromdruguse and Renal  oselabeledaefromdruguse  oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,cytoxan,3,98,116,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,cytoxan,4,116,134,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,cytoxan,5,134,152,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,cytoxan,6,152,170,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,cytoxan,7,170,188,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.7)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,cytoxan,8,188,220,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.8)  and  Use in Specific Populations (8.4  and  8.6)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,cytoxan,9,220,238,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.9)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,cytoxan,10,238,256,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.10)  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,cytoxan,11,256,264,"\n', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,cytoxan,12,264,286,"Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,cytoxan,13,286,291,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,cytoxan,14,291,380,"\n', ' \n', '\n', ' To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .\n', '\n', ' \n', '\n', '  6.1 Common Adverse Reactions\n', '\n', '    Hematopoietic system:  \n', '\n', '  oselabeledaefromdruguse occurs in patients treated with cyclophosphamide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,cytoxan,15,380,439,"The degree of  nonoseaeaeonlyasinstruction is particularly important because it correlates with a  nonoseaemanifestationorcomplication   nonoseaeaeonlyasinstruction without documented  nonoseaenegation has been reported in  nonoseaeaeonlyasinstruction patients.\n', '\n', '   Gastrointestinal system:  \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse occur with cyclophosphamide therapy.  ",1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
16,cytoxan,16,439,459,"oselabeledaefromdruguse and, less frequently,  oselabeledaefromdruguse  oselabeledaefromdruguse discomfort or  oselabeledaefromdruguse and  oselabeledaefromdruguse may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,cytoxan,17,459,506,"There are isolated reports of  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse occurring during therapy.\n', '\n', '   Skin and its structures:  \n', '\n', '  oselabeledaefromdruguse occurs in patients treated with cyclophosphamide.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,cytoxan,18,506,516,oselabeledaefromdruguse occurs occasionally in patients receiving the drug.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,cytoxan,19,516,562,"oselabeledaefromdruguse  oselabeledaefromdruguse of the skin and  oselabeledaefromdruguse can occur.\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified from clinical trials or post-marketing surveillance.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,cytoxan,20,562,641,"Because they are reported from a population from unknown size, precise estimates of frequency cannot be made.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (progressing to  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  nonoseaegeneralterm outcomes),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,cytoxan,21,641,683,"\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse .\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,cytoxan,22,683,695,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,cytoxan,23,695,737,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,cytoxan,24,737,759,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse infusion  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,cytoxan,25,759,806,"oselabeledaefromdruguse infusion  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse infusion  oselabeledaefromdruguse (thrombosis,  oselabeledaefromdruguse  oselabeledaefromdruguse infusion  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis,  oselabeledaefromdruguse  oselabeledaefromdruguse infusion  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis, inflammation,  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,cytoxan,26,806,936,"oselabeledaefromdruguse infusion  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis, inflammation, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse infusion  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis, inflammation, pain, swelling,  oselabeledaefromdruguse  oselabeledaefromdruguse infusion  oselabeledaefromdruguse reactions (thrombosis, necrosis,  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse (thrombosis,  oselabeledaefromdruguse  oselabeledaefromdruguse (thrombosis, necrosis,  oselabeledaefromdruguse  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis,  oselabeledaefromdruguse  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis, inflammation,  oselabeledaefromdruguse  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis, inflammation, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse (thrombosis, necrosis, phlebitis, inflammation, pain, swelling,  oselabeledaefromdruguse ,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,cytoxan,27,936,940,oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,cytoxan,28,940,955,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,cytoxan,29,955,1015,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse (with  oselabeledaefromdruguse .\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse with  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,cytoxan,30,1015,1198,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm   The following manifestations have been associated with  oselabeledaefromdruguse and  oselabeledaefromdruguse caused by cyclophosphamide: increased risk for and severity of  nonoseaemanifestationorcomplication (including  nonoseaegeneralterm outcomes), other  nonoseaemanifestationorcomplication  fungal, viral, protozoal and, parasitic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  viral, protozoal and, parasitic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  protozoal and, parasitic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and, parasitic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication of latent infections, (including  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication of latent infections, (including viral hepatitis,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  (including viral hepatitis, tuberculosis),   nonoseaemanifestationorcomplication  ,  nonoseaemanifestationorcomplication    nonoseaemanifestationorcomplication  ,  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
31,cytoxan,31,1198,1248,"\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,cytoxan,32,1248,1296,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse has been reported and manifested as  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,cytoxan,33,1296,1308,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,cytoxan,34,1308,1320,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,cytoxan,35,1320,1352,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,cytoxan,36,1352,1378,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,cytoxan,37,1378,1440,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse as manifested by  nonoseaemanifestationorcomplication (including  nonoseaegeneralterm outcomes),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
38,cytoxan,38,1440,1478,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,cytoxan,39,1478,1538,"\n', '\n', '    nonoseaegeneralterm  :    like other cytotoxic drugs, cyclophosphamide may induce  oselabeledaefromdruguse and  oselabeledaefromdruguse in patients with rapidly growing  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
40,cytoxan,40,1538,1553,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,cytoxan,41,1553,1576,"*    Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections - Severe immunosuppression may lead to serious and sometimes fatal infections.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,cytoxan,42,1576,1582,Close hematological monitoring is required.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,cytoxan,43,1582,1611,"(  5.1  ) \n', ' *    Urinary Tract and Renal Toxicity - Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria can occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,cytoxan,44,1611,1622,Exclude or correct any urinary tract obstructions prior to treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,cytoxan,45,1622,1627,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,cytoxan,46,1627,1657,"\n', ' *    Cardiotoxicity - Myocarditis, myopericarditis, pericardial effusion, arrythmias and congestive heart failure, which may be fatal, have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,cytoxan,47,1657,1674,"Monitor patients, especially those with risk factors for cardiotoxicity or pre-existing cardiac disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,cytoxan,48,1674,1705,"(  5.3  ) \n', ' *    Pulmonary Toxicity - Pneumonitis, pulmonary fibrosis and pulmonary veno-occlusive disease leading to respiratory failure may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,cytoxan,49,1705,1715,Monitor patients for signs and symptoms of pulmonary toxicity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,cytoxan,50,1715,1733,"(  5.4  ) \n', ' *    Secondary malignancies(  5.5  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,cytoxan,51,1733,1750,"\n', ' *    Veno-occlusive Liver Disease - Fatal outcome can occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,cytoxan,52,1750,1771,"(  5.6  ) \n', ' *    Embryo-Fetal Toxicity - Can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,cytoxan,53,1771,1781,Advise female patients of reproductive potential to avoid pregnancy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,cytoxan,54,1781,1794,"(  5.7  ,  8.1  ,  8.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,cytoxan,55,1794,1909,"\n', '    \n', ' \n', '\n', '   5.1 Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections\n', '\n', '  Cyclophosphamide can cause  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse ,  oselabeledaefromdruguse  and severe  oselabeledaefromdruguse which may lead to serious and sometimes  nonoseaegeneralterm  nonoseaemanifestationorcomplication  including  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication   oselabeledaefromdruguse [see  Adverse Reactions (6.2)  ].\n', '\n', ' Antimicrobial prophylaxis may be indicated in certain cases of  nonoseaeaeonlyasinstruction at the discretion of the managing physician.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
56,cytoxan,56,1909,1920,In case of  nonoseaeaeonlyasinstruction  antibiotic therapy is indicated.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,cytoxan,57,1920,1955,"Antimycotics and/or antivirals may also be indicated.\n', '\n', ' Monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,cytoxan,58,1955,1971,Cyclophosphamide should not be administered to patients with  notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
59,cytoxan,59,1971,2000,"Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,cytoxan,60,2000,2019,G-CSF may be administered to reduce the risks of  nonoseaeaeonlyasinstruction complications associated with cyclophosphamide use.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,cytoxan,61,2019,2044,Primary and secondary prophylaxis with G-CSF should be considered in all patients considered to be at increased risk for  nonoseaeaeonlyasinstruction complications.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,cytoxan,62,2044,2068,The nadirs of the  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction leukocyte count and  nonoseaeaeonlyasinstruction are usually reached in weeks 1 and 2 of treatment.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,cytoxan,63,2068,2082,Peripheral blood cell counts are expected to normalize after approximately 20 days.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,cytoxan,64,2082,2087,oselabeledaefromdruguse has been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,cytoxan,65,2087,2142,"Severe  nonoseaeaefromdruginteraction may be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.\n', '\n', '    5.2 Urinary Tract and Renal Toxicity\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported with cyclophosphamide.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
66,cytoxan,66,2142,2159,Medical and/or surgical supportive treatment may be required to treat protracted cases of severe  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,cytoxan,67,2159,2219,"Discontinue cyclophosphamide therapy in case of severe  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction ( nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication ulceration,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication ulceration, necrosis,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication ulceration, necrosis, fibrosis,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication ulceration, necrosis, fibrosis, contracture and  nonoseaemanifestationorcomplication  may require interruption of cyclophosphamide treatment or cystectomy.  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
68,cytoxan,68,2219,2266,"nonoseaeaeonlyasinstruction can be  nonoseaegeneralterm   oselabeledaefromdruguse can occur with short-term or long-term use of cyclophosphamide.\n', '\n', ' Before starting treatment, exclude or correct any  notaecandidatecontraindication [see  Contraindications (4)  ].",1,1,0,0,0,0,0,0,0,0,0,1,0,0,0
69,cytoxan,69,2266,2325,"Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of  nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction  Cyclophosphamide should be used with caution, if at all, in patients with active  notaecandidatepreexistingconditionorriskfactor  Aggressive hydration with forced  nonoseaeaeonlyasinstruction and frequent  nonoseaeaeonlyasinstruction can reduce the frequency and severity of  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
70,cytoxan,70,2325,2567,"Mesna has been used to prevent severe  nonoseaeaeonlyasinstruction \n', '\n', '    5.3 Cardiotoxicity\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse  and  oselabeledaefromdruguse  which may be  nonoseaegeneralterm  have been reported with cyclophosphamide therapy\n', '\n', '  oselabeledaefromdruguse (including  oselabeledaefromdruguse fibrillation and  oselabeledaefromdruguse  oselabeledaefromdruguse and flutter) and  oselabeledaefromdruguse (including severe  oselabeledaefromdruguse associated with  oselabeledaefromdruguse  have been reported after treatment with regimens that included cyclophosphamide.\n', '\n', ' The risk of  oselabeledaefromdruguse may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other  nonoseaeaeonlyasinstruction \n', '\n', ' Particular caution is necessary in patients with risk factors for  nonoseaeaeonlyasinstruction and in patients with pre-existing  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Monitor patients with risk factors for  nonoseaeaeonlyasinstruction and with pre-existing  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.4 Pulmonary Toxicity\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and other forms of  oselabeledaefromdruguse leading to  nonoseaemanifestationorcomplication have been reported during and following treatment with cyclophosphamide.",1,1,1,0,1,0,0,0,0,0,0,0,0,0,0
71,cytoxan,71,2567,2650,"Late onset  nonoseaeaeonlyasinstruction (greater than 6 months after start of cyclophosphamide) appears to be associated with increased  nonoseaegeneralterm   oselabeledaefromdruguse may develop years after treatment with cyclophosphamide.\n', '\n', ' Monitor patients for signs and symptoms of  nonoseaeaeonlyasinstruction \n', '\n', '    5.5 Secondary Malignancies\n', '\n', '  Cyclophosphamide is  oselabeledaefromdruguse [see  Nonclinical Toxicology (13.1)  ].  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
72,cytoxan,72,2650,2679,oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  have been reported in patients treated with cyclophosphamide-containing regimens .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,cytoxan,73,2679,2732,"The risk of  nonoseaeaeonlyasinstruction may be reduced by prevention of  nonoseaeaeonlyasinstruction \n', '\n', '    5.6 Veno-occlusive Liver Disease\n', '\n', '   oselabeledaefromdruguse  including  nonoseaegeneralterm outcome has been reported in patients receiving cyclophosphamide-containing regimens.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,cytoxan,74,2732,2767,"A cytoreductive regimen in preparation for  notaecandidatepreexistingconditionorriskfactor that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified as a major risk factor.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
75,cytoxan,75,2767,2790,oselabeledaefromdruguse has also been reported to develop gradually in patients receiving long-term low-dose  nonoseaeaeonlyasinstruction doses of cyclophosphamide.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,cytoxan,76,2790,2858,"Other risk factors predisposing to the development of  nonoseaeaeonlyasinstruction include preexisting  notaecandidatepreexistingconditionorriskfactor  previous radiation therapy of the abdomen, and a low performance status.\n', '\n', '    5.7  oselabeledaefromdruguse \n', '  Cyclophosphamide can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman [see  Use in Specific Populations (8.1)  ].",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
77,cytoxan,77,2858,2880,Exposure to cyclophosphamide during  notaecandidatepreexistingconditionorriskfactor may cause  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse in the newborn.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
78,cytoxan,78,2880,2897,"Cyclophosphamide is  nonoseaeaeanimal and  nonoseaeaeanimal in mice, rats, rabbits and monkeys.\n',",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
79,cytoxan,79,2897,2985,"'\n', ' Advise female patients of reproductive potential to avoid becoming  nonoseaeaeonlyasinstruction and to use highly effective contraception during treatment and for up to 1 year after completion of therapy [see  Use in Specific Populations (8.6)  ].\n', '\n', '    5.8 Infertility\n', '\n', '   oselabeledaefromdruguse and female  oselabeledaefromdruguse and fertility may be  oselabeledaefromdruguse  oselabeledaefromdruguse and female reproductive function and  oselabeledaefromdruguse may be  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,cytoxan,80,2985,3012,oselabeledaefromdruguse  oselabeledaefromdruguse and fertility may be  oselabeledaefromdruguse  oselabeledaefromdruguse reproductive function and  oselabeledaefromdruguse may be  oselabeledaefromdruguse in patients being treated with cyclophosphamide.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,cytoxan,81,3012,3022,Cyclophosphamide  oselabeledaefromdruguse  oselabeledaefromdruguse oogenesis and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,cytoxan,82,3022,3031,It may cause  oselabeledaefromdruguse in both sexes.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,cytoxan,83,3031,3061,"Development of  nonoseaeaeonlyasinstruction appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,cytoxan,84,3061,3069,nonoseaeaeonlyasinstruction may be irreversible in some patients.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,cytoxan,85,3069,3094,Advise patients on the potential risks for  nonoseaeaeonlyasinstruction [see  Use in Specific Populations (8.4  and  8.6  )],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,cytoxan,86,3094,3159,".\n', '\n', '    5.9 Impairment of Wound Healing\n', '\n', '  Cyclophosphamide may  oselabeledaefromdruguse \n', '\n', '    5.10 Hyponatremia\n', '\n', '   oselabeledaefromdruguse associated with  oselabeledaefromdruguse   oselabeledaefromdruguse  and a  oselabeledaefromdruguse , which may be  nonoseaegeneralterm ']",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
0,sensipar,0,0,8,['    6          ADVERSE REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,sensipar,1,8,41,"\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of labeling:\n', '\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,sensipar,2,41,53,[see Warnings and Precautions (    5.1    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,sensipar,3,53,60,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,sensipar,4,60,65,[see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,sensipar,5,65,72,(    5.2    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,sensipar,6,72,98,"\n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse and/or  oselabeledaefromdruguse [ see Warnings and  Precautions  (    5.3    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,sensipar,7,98,105,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,sensipar,8,105,117,[see Warnings and Precautions (    5.4    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,sensipar,9,117,118,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,sensipar,10,118,125,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,sensipar,11,125,146,"The most common adverse reactions (i.e., >= 25%) associated with Sensipar were nausea and vomiting.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,sensipar,12,146,199,"(  6  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,sensipar,13,199,229,"\n', '\n', ' \n', '\n', '  6.1       Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,sensipar,14,229,337,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '   Secondary Hyperparathyroidism in Patients with         Chronic Kidney Disease on Dialysis  \n', '\n', ' In three double-blind, placebo-controlled clinical trials, 1126 patients with  notaecandidatepreexistingconditionorriskfactor on dialysis received study drug (656 Sensipar, 470 placebo) for up to 6 months.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
15,sensipar,15,337,349,The most frequently reported adverse reactions are listed in Table 1.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,sensipar,16,349,399,"\n', '\n', '  oselabeledaefromdruguse were observed in 1.4% (13/910) of Sensipar-treated patients and 0.7% (5/641) of placebo-treated patients across all completed placebo controlled trials.\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,sensipar,17,399,421,Adverse Reactions with Frequency >= 5% in Patients on Dialysis in Short-Term Studies for up to 6 Months,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,sensipar,18,421,445,"\n', '                                   Placebo          Sensipar          \n', '                                   (n = 470)        (n = 656",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,sensipar,19,445,468,")         \n', '                                                                      \n', ' Event*:          (%)              (%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,sensipar,20,468,484,"\n', '                                                                      \n', '  oselabeledaefromdruguse           19               31                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,sensipar,21,484,559,"\n', '  oselabeledaefromdruguse         15               27                \n', '  oselabeledaefromdruguse         20               21                \n', '  oselabeledaefromdruguse          14               15                \n', '  oselabeledaefromdruguse        8                10                \n', '  oselabeledaefromdruguse     5                7                 \n', '  oselabeledaefromdruguse         4                7                 \n', '  oselabeledaefromdruguse         4                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,sensipar,22,559,568,"6                 \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,sensipar,23,568,570,4                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,sensipar,24,570,588,"6                 \n', '  oselabeledaefromdruguse  4                5                 \n', '           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,sensipar,25,588,709,"*Included are events that were reported at a greater incidence in the Sensipar group than in the placebo group.\n', ' \n', '\n', ' In a randomized, double-blind placebo controlled study of 3883 patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor receiving dialysis in which patients were treated for up to 64 months (mean duration of treatment was 21 months in the Sensipar group), the most frequently reported adverse reactions (incidence of  >=   5% in the Sensipar group and a difference >= 1% compared to placebo) are listed in Table 2.\n', '\n', ' Table 2.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
26,sensipar,26,709,728,Frequency of Adverse Reactions in Dialysis Patients Treated for up to 64 Months in a Long-Term Study1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,sensipar,27,728,747,"\n', '                  Placebo (n = 1923)  Sensipar (n = 1938)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,sensipar,28,747,791,"\n', '                  3699 subject-years  4044 subject-years   \n', ' Percent of subjects reporting Adverse Reactions (%)  90.9             93.2              \n', '  oselabeledaefromdruguse           15.5             29.1              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,sensipar,29,791,802,"\n', '  oselabeledaefromdruguse         13.7             25.6              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,sensipar,30,802,807,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,sensipar,31,807,813,oselabeledaefromdruguse         18.7             20.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,sensipar,32,813,824,"\n', '  oselabeledaefromdruguse          11.5             13.4              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,sensipar,33,824,844,"\n', '  oselabeledaefromdruguse            9.8              11.7              \n', '  oselabeledaefromdruguse      10.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,sensipar,34,844,857,"11.6              \n', '  oselabeledaefromdruguse         9.6              11.5              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,sensipar,35,857,877,"\n', '  oselabeledaefromdruguse     1.4              11.2              \n', '  oselabeledaefromdruguse    9.2              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,sensipar,36,877,899,"11.1              \n', '  oselabeledaefromdruguse   9.6              10.9              \n', '  oselabeledaefromdruguse  6.3              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,sensipar,37,899,910,"8.2               \n', '  oselabeledaefromdruguse     6.1              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,sensipar,38,910,912,8.1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,sensipar,39,912,921,"\n', '  oselabeledaefromdruguse  6.3              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,sensipar,40,921,923,7.6               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,sensipar,41,923,930,"\n', '  oselabeledaefromdruguse        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,sensipar,42,930,941,"4.6              7.4               \n', '  oselabeledaefromdruguse        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,sensipar,43,941,952,"4.7              7.3               \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,sensipar,44,952,954,3.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,sensipar,45,954,965,"5.9               \n', '  oselabeledaefromdruguse         3.8              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,sensipar,46,965,976,"5.4               \n', '  oselabeledaefromdruguse     3.8              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,sensipar,47,976,1167,"5.0               \n', '           1  Adverse reactions that occurred in >= 5% frequency in the Sensipar group and a difference >= 1% compared to the placebo group (Safety Analysis Set)\n', ' \n', '\n', ' Crude incidence rate = 100 * Total number of subjects with event/ n\n', '\n', ' n = Number of subjects receiving at least one dose of study drug\n', '\n', ' Additional adverse reaction rates from the long-term, randomized, double-blind placebo controlled study for Sensipar versus placebo are as follows:  oselabeledaefromdruguse (2.5%, 1.6%),  oselabeledaefromdruguse (2.2%, 1.9%),  oselabeledaefromdruguse (9.4%, 8.3%).\n', '\n', '   Patients with    Parathyroid Carcinoma and Primary Hyperparathyroidism  \n', '\n', ' The safety profile of Sensipar in these patient populations is generally consistent with that seen in patients with  notaecandidatepreexistingconditionorriskfactor on dialysis.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
48,sensipar,48,1167,1208,"Forty six patients were treated with Sensipar in a single arm study, 29 with  notaecandidateindication and 17 with intractable  notaecandidateindication  Nine (20%) of the patients withdrew from the study due to adverse events.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
49,sensipar,49,1208,1332,"The most frequent adverse reactions and the most frequent cause of withdrawal in these patient populations were  oselabeledaefromdruguse and  oselabeledaefromdruguse  Severe or prolonged cases of  oselabeledaefromdruguse and  oselabeledaefromdruguse can lead to  nonoseaemanifestationorcomplication and worsening  nonoseaemanifestationorcomplication so careful monitoring of electrolytes is recommended in patients with these symptoms.\n', '\n', ' Eight patients died during treatment with Sensipar in this study, 7 with  notaecandidateindication (24%) and 1 (6%) with intractable  notaecandidateindication  Causes of  nonoseaegeneralterm were  nonoseaeaeonlyasinstruction (5 patients),  nonoseaeaeonlyasinstruction (1 patient),  nonoseaeaeonlyasinstruction (1 patient) and  nonoseaeaeonlyasinstruction (1 patient).",1,1,0,1,1,0,0,0,0,0,0,0,0,0,0
50,sensipar,50,1332,1391,"Adverse events of  oselabeledaefromdruguse were reported in three patients (7%).\n', '\n', '  oselabeledaefromdruguse were observed in 0.7% (1/140) of cinacalcet-treated patients and 0.0% (0/46) of placebo-treated patients in all clinical studies.\n', '\n', ' Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,sensipar,51,1391,1422,"Adverse Reactions with Frequency >= 10% in a Single Arm, Open-Label Study in Patients with Primary Hyperparathyroidism or Parathyroid Carcinoma  \n', '                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,sensipar,52,1422,1449,"Sensipar          \n', '                                    \n', '                  ParathyroidCarcinoma(n = 29)  IntractablepHPT(n = 17)  Total(n = 46)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,sensipar,53,1449,1474,"\n', '                                    \n', '                  n (%)            n (%)            n (%)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,sensipar,54,1474,1498,"\n', ' Number of Subjects Reporting Adverse Reactions  28 (97)          17 (100)         45 (98",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,sensipar,55,1498,1517,")           \n', '                                                                      \n', '  oselabeledaefromdruguse           19 (66)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,sensipar,56,1517,1525,10 (59)          29 (63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,sensipar,57,1525,1539,")           \n', '  oselabeledaefromdruguse         15 (52)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,sensipar,58,1539,1544,6 (35)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,sensipar,59,1544,1571,"21 (46)           \n', '  oselabeledaefromdruguse      4 (14)           5 (29)           9 (20)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,sensipar,60,1571,1615,"\n', '  oselabeledaefromdruguse          6 (21)           2 (12)           8 (17)            \n', '  oselabeledaefromdruguse         6 (21)           2 (12)           8 (17)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,sensipar,61,1615,1645,"\n', '  oselabeledaefromdruguse    6 (21)           2 (12)           8 (17)            \n', '  oselabeledaefromdruguse         6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,sensipar,62,1645,1664,"(21)           1 (6)            7 (15)            \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,sensipar,63,1664,1681,oselabeledaefromdruguse         5 (17)           2 (12)           7 (15)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,sensipar,64,1681,1694,"\n', '  oselabeledaefromdruguse      7 (24)           0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,sensipar,65,1694,1703,(0)            7 (15)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,sensipar,66,1703,1769,"\n', '  oselabeledaefromdruguse           5 (17)           1 (6)            6 (13)            \n', '  oselabeledaefromdruguse       5 (17)           1 (6)            6 (13)            \n', '  oselabeledaefromdruguse     3 (10)           3 (18)           6 (13)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,sensipar,67,1769,1791,"\n', '  oselabeledaefromdruguse       3 (10)           3 (18)           6 (13)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,sensipar,68,1791,1821,"\n', '  oselabeledaefromdruguse         6 (21)           0 (0)            6 (13)            \n', '  oselabeledaefromdruguse  3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,sensipar,69,1821,1835,(10)           2 (12)           5 (11)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,sensipar,70,1835,1943,"\n', '  oselabeledaefromdruguse        3 (10)           2 (12)           5 (11)            \n', '            n = Number of subjects receiving at least one dose of study drug.\n', ' \n', '\n', '  notaecandidateindication \n', ' In a randomized double-blind, placebo-controlled study of 67 patients with  notaecandidateindication for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery, the most common adverse reactions are listed in Table 4.\n',",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
71,sensipar,71,1943,1951,"'\n', ' Table 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,sensipar,72,1951,1985,"Adverse Reactions Occurring in >= 10% of Subjects in a Double-Blind, Placebo-Controlled Study in Patients with Primary Hyperparathyroidism \n', ' Adverse Reaction  Placebo(n =",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,sensipar,73,1985,1986,34)n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,sensipar,74,1986,1992,(%)  Cinacalcet(n =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,sensipar,75,1992,1997,33)n (%)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,sensipar,76,1997,2055,"\n', '  oselabeledaefromdruguse           6 (18)           10 (30)           \n', '  oselabeledaefromdruguse    0 (0)            6 (18)            \n', '  oselabeledaefromdruguse         2 (6)            4 (12)            \n', '  oselabeledaefromdruguse        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,sensipar,77,2055,2065,2 (6)            4 (12)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,sensipar,78,2065,2066,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,sensipar,79,2066,2090,"', '         n = Number of subjects receiving at least one dose of study drug Coded using MedDRA version 16.0\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,sensipar,80,2090,2197,"' \n', '\n', '   Hypocalcemia  \n', '\n', ' In 26-week studies of patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor on dialysis 66% of patients receiving Sensipar compared with 25% of patients receiving placebo developed at least one serum calcium value less than 8.4 mg/dL, whereas, 29% of patients receiving Sensipar compared with 11% of patients receiving placebo developed at least one serum calcium value less than 7.5 mg/dL. Less than 1% of patients in each group permanently discontinued study drug due to  oselabeledaefromdruguse",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
81,sensipar,81,2197,2317,"\n', '\n', ' In a randomized, double-blind, placebo-controlled study in patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor receiving dialysis in which patients were treated for up to 64 months (mean duration of treatment was 21 months in the cinacalcet group), 75% of patients receiving Sensipar compared with 29% of patients receiving placebo developed at least one  oselabeledaefromdruguse and 33% of cinacalcet patients compared with 12% of patients receiving placebo had at least one  oselabeledaefromdruguse   Most of the cases of severe  oselabeledaefromdruguse less than 7.5 mg/dL (21/33=64%) occurred during the first 6 months.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
82,sensipar,82,2317,2342,"In this trial, 1.1% of patients receiving Sensipar and 0.1% of patients receiving placebo permanently discontinued study drug due to  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,sensipar,83,2342,2463,"\n', '\n', ' During a placebo-controlled part of a 52-week study in patients with  notaecandidateindication who met criteria for parathyroidectomy on the basis of corrected total serum calcium (> 11.3 mg/dL [2.82 mmol/L] and <= 12.5 mg/dL [3.12 mmol/L]),  oselabeledaefromdruguse was observed in 6.1% (2/33) of Sensipar treated patients and 0% (0/34) of placebo treated patients.\n', '\n', '   6.2       Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post approval use of Sensipar.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
84,sensipar,84,2463,2517,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse (including  oselabeledaefromdruguse and  oselabeledaefromdruguse , and  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,sensipar,85,2517,2518,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,sensipar,86,2518,2591,"\n', ' *  Isolated, idiosyncratic cases of  oselabeledaefromdruguse   oselabeledaefromdruguse  and/or  oselabeledaefromdruguse have been \n', ' *  reported in patients with  notaecandidatepreexistingconditionorriskfactor \n', ' *   oselabeledaefromdruguse     5         WARNINGS AND PRECAUTIONS  \n', '\n', '     EXCERPT:    *   Hypocalcemia  : Life threatening events and fatal outcomes were reported.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
87,sensipar,87,2591,2615,"Hypocalcemia can prolong QT interval, lower the threshold for seizures, and cause hypotension, worsening heart failure, and/or arrhythmia.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,sensipar,88,2615,2635,"Monitor serum calcium carefully for the occurrence of hypocalcemia during treatment (  2.4  ,  5.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,sensipar,89,2635,2636,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,sensipar,90,2636,2662,"', ' *   Upper Gastrointestinal (GI) Bleeding: Patients with risk factors for upper GI bleeding may be at increased risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,sensipar,91,2662,2674,Monitor patients and promptly evaluate and treat any suspected GI bleeding.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,sensipar,92,2674,2679,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,sensipar,93,2679,2693,"\n', ' *   Hypotension, Worsening Heart Failure and/or Arrhythmias :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,sensipar,94,2693,2721,"In postmarketing safety surveillance, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia have been reported in patients with impaired cardiac function.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,sensipar,95,2721,2732,"(  5.3  ) \n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,sensipar,96,2732,2736,Adynamic  B  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,sensipar,97,2736,2742,one  D  isease :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,sensipar,98,2742,2809,"May develop if iPTH levels are suppressed below 100 pg/mL. (  5.4  ) \n', '    \n', ' \n', '\n', '   5.1       Hypocalcemia\n', '\n', '   Sensipar  nonoseaeaeonlyasinstruction and can lead to  oselabeledaefromdruguse [see Adverse Reactions (     6.1     )].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,sensipar,99,2809,2855,"Significant  nonoseaeaeonlyasinstruction can cause  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  Life threatening events and  nonoseaegeneralterm outcomes associated with  oselabeledaefromdruguse have been reported in patients treated with Sensipar, including in pediatric patients.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
100,sensipar,100,2855,2881,The safety and effectiveness of Sensipar have not been established in pediatric patients  [see Pediatric Use (     8.4     )].    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,sensipar,101,2881,2905,"\n', '\n', ' Sensipar is not indicated for patients with  notaecandidatepreexistingconditionorriskfactor not on dialysis  [see   ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
102,sensipar,102,2905,2919,I   ndications and Usage (     1     )]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,sensipar,103,2919,2945,"In patients with  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor not on dialysis, the long term safety and efficacy of Sensipar have not been established.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,sensipar,104,2945,2989,"Clinical studies indicate that Sensipar-treated patients with  notaecandidatepreexistingconditionorriskfactor not on dialysis have an increased risk for  nonoseaeaefromofflabel compared with Sensipar-treated patients with  notaecandidatepreexistingconditionorriskfactor on dialysis, which may be due to lower baseline calcium levels.  ",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
105,sensipar,105,2989,3108,"In a phase 3 study of 32 weeks duration and including 404 patients with  notaecandidatepreexistingconditionorriskfactor not on dialysis (302 cinacalcet, 102 placebo), in which the median dose for cinacalcet was 60 mg per day at the completion of the study, 80% of Sensipar-treated patients experienced at least one  oselabeledaefromdruguse compared with 5% of patients receiving placebo.\n', '\n', '  QT Interval Prolongation and Ventricular Arrhythmia  \n', '\n', '   nonoseaeaeonlyasinstruction can also  nonoseaeaeonlyasinstruction  potentially resulting in  nonoseaeaeonlyasinstruction  Cases of  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in patients treated with Sensipar.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
106,sensipar,106,3108,3158,Patients with  notaecandidatepreexistingconditionorriskfactor  history of  notaecandidatepreexistingconditionorriskfactor  family history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  and other conditions that predispose to  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor may be at increased risk for  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction if they develop  nonoseaeaeonlyasinstruction due to Sensipar.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
107,sensipar,107,3158,3174,Closely monitor corrected serum calcium and QT interval in patients at risk receiving Sensipar.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,sensipar,108,3174,3185,"\n', '\n', '  Seizures  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,sensipar,109,3185,3239,"\n', '\n', ' In clinical studies,  oselabeledaefromdruguse  oselabeledaefromdruguse (primarily  oselabeledaefromdruguse  oselabeledaefromdruguse (primarily generalized or  oselabeledaefromdruguse  were observed in 1.4% (43/3049) of Sensipar-treated patients and 0.7% (5/687) of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,sensipar,110,3239,3275,"While the basis for the reported difference in  nonoseaeaeonlyasinstruction rate is not clear, the  nonoseaeaeonlyasinstruction by significant  nonoseaeaeonlyasinstruction  Monitor serum calcium levels in patients with  notaecandidatepreexistingconditionorriskfactor receiving Sensipar .  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
111,sensipar,111,3275,3304,"\n', '\n', '  Concurrent administration of Sensipar with  nonoseaeaeonlyasinstruction including other calcium-sensing receptor agonists could result in  nonoseaeaefromdruginteraction  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
112,sensipar,112,3304,3350,"Closely monitor serum calcium in patients receiving Sensipar and concomitant therapies known to  nonoseaeaeonlyasinstruction   \n', '\n', '  Educate patients on the symptoms of  nonoseaeaeonlyasinstruction and advise them to contact a healthcare provider if they occur.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,sensipar,113,3350,3395,"\n', '\n', '  If  nonoseaeaeonlyasinstruction or symptoms of  nonoseaeaeonlyasinstruction develop, start or  nonoseaeaeonlyasinstruction (including calcium, calcium-containing phosphate binders, and/or vitamin D sterols or increases in dialysate calcium concentration).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,sensipar,114,3395,3418,Sensipar dose reduction or discontinuation of Sensipar may be necessary [see Dosage and Administration (     2.2     )].    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,sensipar,115,3418,3443,"\n', '\n', '    5.2       Upper Gastrointestinal Bleeding\n', '\n', '   Cases of  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,sensipar,116,3443,3447,oselabeledaefromdruguse  mostly  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,sensipar,117,3447,3466,"oselabeledaefromdruguse  have occurred in patients using calcimimetics, including Sensipar, from postmarketing and clinical trial sources.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,sensipar,118,3466,3479,The exact cause of GI bleeding in these patients is unknown.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,sensipar,119,3479,3489,"\n', '\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,sensipar,120,3489,3532,"', '\n', '  Patients with risk factors for  notaecandidatepreexistingconditionorriskfactor (such as known  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or severe  notaecandidatepreexistingconditionorriskfactor  may be at increased risk for  nonoseaeaeonlyasinstruction when receiving Sensipar treatment.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
121,sensipar,121,3532,3575,Monitor patients for worsening of common  nonoseaeaeonlyasinstruction of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction associated with Sensipar [see Adverse Reactions (     6.1     )]  and for signs and symptoms of  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication during Sensipar therapy.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
122,sensipar,122,3575,3670,"Promptly evaluate and treat any suspected  nonoseaeaeonlyasinstruction   \n', '\n', '    5.3        Hypotension, Worsening Heart Failure and/or Arrhythmias\n', '\n', '   In postmarketing safety surveillance, isolated, idiosyncratic cases of  oselabeledaefromdruguse   oselabeledaefromdruguse  and/or  oselabeledaefromdruguse have been reported in patients with  notaecandidatepreexistingconditionorriskfactor  in which a causal relationship to Sensipar could not be completely excluded and which may be mediated by  nonoseaeaeonlyasinstruction [see Adverse Reactions       (     6.2     )].    ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
123,sensipar,123,3670,3714,"\n', '\n', '    5.4             Adynamic Bone Disease\n', '\n', '   nonoseaeaeonlyasinstruction may develop if  nonoseaeaeonlyasinstruction  One clinical study evaluated bone histomorphometry in patients treated with Sensipar for 1 year.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,sensipar,124,3714,3734,Three patients with mild  notaecandidatepreexistingconditionorriskfactor at the beginning of the study developed  oselabeledaefromdruguse during treatment with Sensipar.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
125,sensipar,125,3734,3749,Two of these patients had  oselabeledaefromdruguse at multiple time points during the study.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,sensipar,126,3749,3783,"In three 6-month, phase 3 studies conducted in patients with  notaecandidatepreexistingconditionorriskfactor on dialysis, 11% of patients treated with Sensipar had mean  oselabeledaefromdruguse during the efficacy-assessment phase.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
127,sensipar,127,3783,3788,If  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,anoro,0,0,39,"['    6 ADVERSE REACTIONS\n', '\n', '  LABA, such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of  oselabeledaeclasseffect related  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
1,anoro,1,39,65,ANORO ELLIPTA is not indicated for the treatment of  notaecandidatepreexistingconditionorriskfactor   [See Boxed Warning and Warnings and Precautions (5.1).]  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
2,anoro,2,65,138,"\n', '\n', '\n', '\n', ' The following adverse reactions are described in greater detail in other sections:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.5)]  \n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.7)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,anoro,3,138,158,"\n', ' *    Worsening of  oselabeledaefromdruguse [see Warnings and Precautions (5.9)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,anoro,4,158,178,"\n', ' *    Worsening of  oselabeledaefromdruguse [see Warnings and Precautions (5.10)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,anoro,5,178,179,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,anoro,6,179,230,"', '      EXCERPT:   Most common adverse reactions (incidence >=1% and more common than placebo) include pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, and chest pain.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,anoro,7,230,235,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,anoro,8,235,276,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or  http://www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,anoro,9,276,313,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,anoro,10,313,407,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The clinical program for ANORO ELLIPTA included 8,138 subjects with  notaecandidateindication in four 6-month lung function trials, one 12-month long-term safety study, and 9 other trials of shorter duration.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
11,anoro,11,407,448,"A total of 1,124 subjects have received at least 1 dose of ANORO ELLIPTA (umeclidinium/vilanterol 62.5 mcg/25 mcg), and 1,330 subjects have received a higher dose of umeclidinium/vilanterol (125 mcg/25 mcg).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,anoro,12,448,465,The safety data described below are based on the four 6-month and the one 12-month trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,anoro,13,465,501,"Adverse reactions observed in the other trials were similar to those observed in the confirmatory trials.\n', '\n', '\n', '\n', '   6-Month Trials:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,anoro,14,501,564,"The incidence of adverse reactions associated with ANORO ELLIPTA in Table 1 is based on four 6-month trials: 2 placebo-controlled trials (Trials 1 and 2; n = 1,532 and n = 1,489, respectively) and 2 active-controlled trials (Trials 3 and 4; n = 843 and n = 869, respectively).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,anoro,15,564,579,"Of the 4,733 subjects, 68% were male and 84% were Caucasian.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,anoro,16,579,606,"They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,anoro,17,606,746,"At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV1) was 48% (range: 13% to 76%), the mean post-bronchodilator FEV1/forced vital capacity (FVC) ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -45% to 109%).\n', '\n', '\n', '\n', ' Subjects received 1 dose once daily of the following: ANORO ELLIPTA, umeclidinium/vilanterol 125 mcg/25 mcg, umeclidinium 62.5 mcg, umeclidinium 125 mcg, vilanterol 25 mcg, active control, or placebo.\n', '\n', '\n', '\n', '   Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,anoro,18,746,753,Adverse Reactions With ANORO ELLIPTA With >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,anoro,19,753,760,=1% Incidence and More Common,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,anoro,20,760,771,Than With Placebo in Subjects With Chronic Obstructive Pulmonary Disease  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,anoro,21,771,805,"\n', '\n', '\n', '\n', '\n', '  Adverse Reaction                               Placebo  (n = 555)  %    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,anoro,22,805,816,ANORO ELLIPTA  (n = 842)  %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,anoro,23,816,827,Umeclidinium  62.5 mcg  (n = 418)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,anoro,24,827,831,%    Vilanterol  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,anoro,25,831,834,25 mcg  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,anoro,26,834,842,"(n = 1,034)  %    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,anoro,27,842,858,"\n', '   nonoseaegeneralterm and infestations                                                                                   \n', '                                                 oselabeledaefromdruguse                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,anoro,28,858,901,"\n', '                                                                                                <1          2                    1                2            \n', '                                                 oselabeledaefromdruguse                                     \n', '                                                                                                <1          1                    <1               1            \n', '                                                 oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,anoro,29,901,917,"\n', '                                                                                                <1          1                    <1               <1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,anoro,30,917,936,"\n', '   nonoseaegeneralterm                                                                                    \n', '                                                 oselabeledaefromdruguse                                  \n', '                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,anoro,31,936,954,"<1          1                    <1               <1           \n', '                                                 oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,anoro,32,954,961,"\n', '                                                                                                1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,anoro,33,961,963,2                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,anoro,34,963,980,"<1               2            \n', '   nonoseaegeneralterm and connective tissue  nonoseaegeneralterm                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,anoro,35,980,994,"\n', '                                                 oselabeledaefromdruguse                             \n', '                                                                                                1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,anoro,36,994,996,2                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,anoro,37,996,1031,"<1               2            \n', '                                                 oselabeledaefromdruguse                                 \n', '                                                                                                <1          1                    <1               <1           \n', '                                                 oselabeledaefromdruguse                                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,anoro,38,1031,1047,"\n', '                                                                                                <1          1                    <1               <1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,anoro,39,1047,1058,"\n', '   nonoseaegeneralterm and administration site conditions                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,anoro,40,1058,1078,"\n', '                                                 oselabeledaefromdruguse                                    \n', '                                                                                                <1          1                    <1               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,anoro,41,1078,1188,"<1           \n', '           Other adverse reactions with ANORO ELLIPTA observed with an incidence less than 1% but more common than with placebo included the following:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', ' \n', '\n', '   12-Month Trial:  In a long-term safety trial, 335 subjects were treated for up to 12 months with umeclidinium/vilanterol 125 mcg/25 mcg or placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,anoro,42,1188,1214,The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo-controlled efficacy trials described above.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,anoro,43,1214,1277,Adverse reactions that occurred with a frequency of greater than or equal to 1% in the group receiving umeclidinium/vilanterol 125 mcg/25 mcg that exceeded that in placebo in this trial were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,anoro,44,1277,1278,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,anoro,45,1278,1289,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,anoro,46,1289,1303,"WARNING: ASTHMA-RELATED DEATH\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,anoro,47,1303,1305,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,anoro,48,1305,1376,"ASTHMA-RELATED DEATH\n', '\n', '    Long-acting beta2-adrenergic agonists (LABA) increase the risk of  nonoseaeaeforanotherdruginclass related  nonoseaegeneralterm  Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual  notaecandidatepreexistingconditionorriskfactor therapy showed an increase in  nonoseaeaeforanotherdruginclass related  nonoseaegeneralterm in subjects receiving salmeterol.",0,1,1,0,0,0,0,0,0,0,0,0,1,0,0
49,anoro,49,1376,1417,"This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients in ANOROTM ELLIPTA  (r)     [see Warnings and Precautions (5.1)]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,anoro,50,1417,1451,"\n', '\n', '\n', '\n', '   The safety and efficacy of ANORO ELLIPTA in patients with  notaecandidatepreexistingconditionorriskfactor have not been established.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
51,anoro,51,1451,1486,"ANORO ELLIPTA is not indicated for the treatment of  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
52,anoro,52,1486,1498,*    LABA increase the risk of asthma-related death.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,anoro,53,1498,1503,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,anoro,54,1503,1522,"\n', ' *    Do not initiate in acutely deteriorating COPD or to treat acute symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,anoro,55,1522,1527,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,anoro,56,1527,1550,"\n', ' *    Do not use in combination with an additional medicine containing LABA because of risk of overdose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,anoro,57,1550,1576,"(  5.3  ) \n', ' *    If paradoxical bronchospasm occurs, discontinue ANORO ELLIPTA and institute alternative therapy. (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,anoro,58,1576,1579,5.5  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,anoro,59,1579,1595,"\n', ' *    Use with caution in patients with cardiovascular disorders (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,anoro,60,1595,1598,5.7  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,anoro,61,1598,1621,"\n', ' *    Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,anoro,62,1621,1641,"(  5.8  ) \n', ' *    Worsening of narrow-angle glaucoma may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,anoro,63,1641,1663,Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a physician immediately if symptoms occur.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,anoro,64,1663,1681,"(  5.9  ) \n', ' *    Worsening of urinary retention may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,anoro,65,1681,1706,Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a physician immediately if symptoms occur.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,anoro,66,1706,1724,"(  5.10  ) \n', ' *    Be alert to hypokalemia and hyperglycemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,anoro,67,1724,1729,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,anoro,68,1729,1819,"\n', '    \n', ' \n', '\n', '   5.1 Asthma-Related Death\n', '\n', '\n', '\n', '    *    Data from a large placebo-controlled trial in subjects with  notaecandidatepreexistingconditionorriskfactor showed that LABA may increase the risk of  nonoseaeaeonlyasinstruction related  nonoseaegeneralterm  Data are not available to determine whether the rate of  nonoseaegeneralterm in patients with  notaecandidateindication is increased by LABA.",1,1,1,1,0,0,0,0,0,0,0,0,0,0,0
69,anoro,69,1819,1896,"\n', ' *    A 28-week, placebo-controlled, US trial comparing the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in  nonoseaeaeforanotherdruginclass related  nonoseaegeneralterm in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol vs. 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]).",0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
70,anoro,70,1896,1925,"The increased risk of  oselabeledaeclasseffect related  nonoseaegeneralterm is considered a class effect of LABA, including vilanterol, one of the active ingredients in ANORO ELLIPTA.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,anoro,71,1925,1931,"\n', ' *    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,anoro,72,1931,1957,No trial adequate to determine whether the rate of  nonoseaeaeonlyasinstruction related  nonoseaegeneralterm is increased in subjects treated with ANORO ELLIPTA has been conducted.,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
73,anoro,73,1957,1974,The safety and efficacy of ANORO ELLIPTA in patients with  notaecandidatepreexistingconditionorriskfactor have not been established.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
74,anoro,74,1974,2122,"ANORO ELLIPTA is not indicated for the treatment of  notaecandidatepreexistingconditionorriskfactor  \n', '       5.2 Deterioration of Disease and Acute Episodes\n', ' \n', '\n', '  ANORO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of  notaecandidatepreexistingconditionorriskfactor  ANORO ELLIPTA has not been studied in subjects with acutely deteriorating  notaecandidatepreexistingconditionorriskfactor  The initiation of ANORO ELLIPTA in this setting is not appropriate.\n', '\n', '\n', '\n', ' ANORO ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of  notaecandidatepreexistingconditionorriskfactor  ANORO ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
75,anoro,75,2122,2234,"Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.\n', '\n', '\n', '\n', ' When beginning treatment with ANORO ELLIPTA, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and to use them only for symptomatic relief of  nonoseaeaeonlyasinstruction  When prescribing ANORO ELLIPTA, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient on how it should be used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,anoro,76,2234,2288,"Increasing inhaled, short-acting beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated.\n', '\n', '\n', '\n', ""  notaecandidateindication may deteriorate acutely over a period of hours or chronically over several days or longer.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
77,anoro,77,2288,2333,"If ANORO ELLIPTA no longer controls symptoms of  nonoseaeaeonlyasinstruction  the patient's inhaled, short-acting beta2-agonist becomes less effective; or the patient needs more short-acting beta2-agonist than usual, these may be markers of deterioration of disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,anoro,78,2333,2355,In this setting a re-evaluation of the patient and the  notaecandidateindication treatment regimen should be undertaken at once.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
79,anoro,79,2355,2451,"Increasing the daily dose of ANORO ELLIPTA beyond the recommended dose is not appropriate in this situation.\n"", '\n', '\n', '\n', '    5.3 Excessive Use of ANORO ELLIPTA and Use With Other Long-Acting Beta2-Agonists\n', '\n', '\n', '\n', '  ANORO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an  nonoseaeodorwithdrawal may result.",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
80,anoro,80,2451,2470,Clinically significant  nonoseaeodorwithdrawal and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
81,anoro,81,2470,2669,"Patients using ANORO ELLIPTA should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.\n', '\n', '\n', '\n', '    5.4 Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors\n', '\n', '\n', '\n', '  Caution should be exercised when considering the coadministration of ANORO ELLIPTA with long-term ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased  nonoseaeaefromdruginteraction may occur [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]  .\n', '\n', '\n', '\n', '    5.5 Paradoxical Bronchospasm\n', '\n', '\n', '\n', '  As with other inhaled medicines, ANORO ELLIPTA can produce  oselabeledaefromdruguse  which may be life threatening.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
82,anoro,82,2669,2751,"If  nonoseaeaeonlyasinstruction occurs following dosing with ANORO ELLIPTA, it should be treated immediately with an inhaled, short-acting bronchodilator; ANORO ELLIPTA should be discontinued immediately; and alternative therapy should be instituted.\n', '\n', '\n', '\n', '    5.6 Hypersensitivity Reactions\n', '\n', '\n', '\n', '   oselabeledaefromdruguse reactions may occur after administration of ANORO ELLIPTA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,anoro,83,2751,2885,"There have been reports of  oselabeledaefromdruguse in patients with severe  notaecandidatepreexistingconditionorriskfactor after inhalation of other powder products containing lactose; therefore, patients with severe  notaecandidateindication should not use ANORO ELLIPTA [see Contraindications (4)]  .\n', '\n', '\n', '\n', '    5.7 Cardiovascular Effects\n', '\n', '\n', '\n', '  Vilanterol, like other beta2-agonists, can produce a clinically significant  oselabeledaefromdruguse in some patients as measured by  oselabeledaefromdruguse  oselabeledaefromdruguse in pulse rate,  oselabeledaefromdruguse or diastolic  oselabeledaefromdruguse  oselabeledaefromdruguse in pulse rate, systolic or  oselabeledaefromdruguse  or symptoms [see Clinical Pharmacology (12.2)]  .",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
84,anoro,84,2885,2898,"If such effects occur, ANORO ELLIPTA may need to be discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,anoro,85,2898,3045,"In addition, beta-agonists have been reported to produce  oselabeledaeclasseffect  such as  oselabeledaeclasseffect e T  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  although the clinical significance of these findings is unknown.\n', '\n', '\n', '\n', ' Therefore, ANORO ELLIPTA should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor  especially  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.8 Coexisting Conditions\n', '\n', '\n', '\n', '  ANORO ELLIPTA, like all medicines containing sympathomimetic amines, should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor and in those who are unusually responsive to sympathomimetic amines.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
86,anoro,86,3045,3159,"Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting  nonoseaeaeforanotherdruginclass and  nonoseaeaeforanotherdruginclass \n', '\n', '\n', '\n', '    5.9 Worsening of  oselabeledaefromdruguse \n', '\n', '\n', '  ANORO ELLIPTA should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor  Prescribers and patients should be alert for signs and symptoms of  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction halos or  nonoseaeaeonlyasinstruction in association with  nonoseaeaeonlyasinstruction from  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction .",1,0,1,0,0,0,0,0,0,0,0,0,1,0,0
87,anoro,87,3159,3269,"Instruct patients to consult a physician immediately if any of these signs or symptoms develops.\n', '\n', '\n', '\n', '    5.10 Worsening of  oselabeledaefromdruguse \n', '\n', '\n', '  ANORO ELLIPTA should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor  Prescribers and patients should be alert for signs and symptoms of  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction , especially in patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  Instruct patients to consult a physician immediately if any of these signs or symptoms develops .  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
88,anoro,88,3269,3306,"\n', '\n', '\n', '\n', '    5.11 Hypokalemia and Hyperglycemia\n', '\n', '\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,anoro,89,3306,3346,"Beta-adrenergic agonist medicines may produce significant  oselabeledaeclasseffect in some patients, possibly through intracellular shunting, which has the potential to produce adverse  nonoseaemanifestationorcomplication  The  oselabeledaeclasseffect is usually transient, not requiring supplementation.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
90,anoro,90,3346,3359,Beta-agonist medicines may produce transient  oselabeledaeclasseffect in some patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,anoro,91,3359,3376,In 4 clinical trials of 6-month duration evaluating ANORO ELLIPTA in subjects with  notaecandidateindication '],0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
0,lioresal,0,0,107,"['  ADVERSE REACTIONS\n', '\n', '  Spasticity of Spinal Cord Origin\n', '\n', '  Clinical Studies\n', '\n', '  Commonly Observed in Patients with Spasticity of Spinal Origin\n', '\n', '  In pre- and post- marketing clinical trials, the most commonly observed adverse events associated with use of LIORESAL INTRATHECAL (baclofen injection) which were not seen at an equivalent incidence among placebo-treated patients were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,lioresal,1,107,159,"\n', '\n', '   Associated with Discontinuation of Treatment\n', '\n', '  8/474 patients with  notaecandidateindication receiving long term infusion of LIORESAL INTRATHECAL in pre- and post- marketing clinical studies in the U. S. discontinued treatment due to adverse events.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
2,lioresal,2,159,199,"These include:  oselabeledaefromdruguse (3),  oselabeledaefromdruguse (2),  oselabeledaefromdruguse (1),  oselabeledaefromdruguse (1) and  oselabeledaefromdrugcomponent (1) with unknown, if any, sequela.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,lioresal,3,199,242,"Eleven patients who developed  nonoseaeodorwithdrawal secondary to  nonoseaeodorwithdrawal had their treatment temporarily suspended, but all were subsequently re-started and were not, therefore, considered to be true discontinuations.\n', '\n', '    nonoseaegeneralterm",0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
4,lioresal,4,242,253,"\n', '    See  Warnings  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,lioresal,5,253,329,"\n', '\n', '   Incidence in Controlled Trials\n', '\n', '  Experience with LIORESAL INTRATHECAL (baclofen injection) obtained in parallel, placebo-controlled, randomized studies provides only a limited basis for estimating the incidence of adverse events because the studies were of very brief duration (up to three days of infusion) and involved only a total of 63 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,lioresal,6,329,377,"The following events occurred among the 31 patients receiving LIORESAL INTRATHECAL (baclofen injection) in two randomized, placebo-controlled trials:  oselabeledaefromdruguse (2),  oselabeledaefromdruguse (2),  oselabeledaefromdruguse (2),  oselabeledaefromdruguse (1).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,lioresal,7,377,393,"No adverse events were reported among the 32 patients receiving placebo in these studies.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,lioresal,8,393,442,"'\n', '   Events Observed during the Pre- and Post-marketing Evaluation of LIORESAL INTRATHECAL\n', '\n', '  Adverse events associated with the use of LIORESAL INTRATHECAL reflect experience gained with 576 patients followed prospectively in the United States.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,lioresal,9,442,466,They received LIORESAL INTRATHECAL for periods of one day (screening) (N = 576) to over eight years (maintenance),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,lioresal,10,466,472,(N = 10).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,lioresal,11,472,490,The usual screening bolus dose administered prior to pump implantation in these studies was typically 50 mcg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,lioresal,12,490,503,The maintenance dose ranged from 12 mcg to 2003 mcg per day.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,lioresal,13,503,554,"Because of the open, uncontrolled nature of the experience, a causal linkage between events observed and the administration of LIORESAL INTRATHECAL cannot be reliably assessed in many cases and many of the adverse events reported are known to occur in association with the underlying conditions being treated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,lioresal,14,554,610,"Nonetheless, many of the more commonly reported reactions-  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse and  oselabeledaefromdruguse appear clearly drug-related.\n', '\n', ' Adverse experiences reported during all U.S. studies (both controlled and uncontrolled) are shown in the following table.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,lioresal,15,610,658,"Eight of 474 patients who received chronic infusion via implanted pumps had adverse experiences which led to a discontinuation of long term treatment in the pre- and post-marketing studies.\n', '\n', ' INCIDENCE OF MOST FREQUENT (>=1%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,lioresal,16,658,672,ADVERSE EVENTS IN PATIENTS WITH SPASTICITY OF SPINAL ORIGIN IN PROSPECTIVELY MONITORED CLINICAL TRIALS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,lioresal,17,672,694,"\n', '                                                             Percent of Patients Reporting Events   \n', '                                                             N = 576Screening [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,lioresal,18,694,705,Following administration of test bolus] Percent  N = 474Titration,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,lioresal,19,705,708,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,lioresal,20,708,713,Two month period following implant,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,lioresal,21,713,719,] Percent  N = 430Maintenance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,lioresal,22,719,722,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,lioresal,23,722,737,"Beyond two months following implant] Percent   \n', ' Adverse Event                                                                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,lioresal,24,737,754,"\n', '  \n', ' N= total number of patients  entering  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,lioresal,25,754,757,each period           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,lioresal,26,757,786,"\n', ' %=% of patients evaluated                                    \n', '  \n', '  oselabeledaefromdruguse                                                   5.4             13.5                 25.3        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,lioresal,27,786,791,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,lioresal,28,791,797,oselabeledaefromdruguse                                                  5.7             5.9                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,lioresal,29,797,799,20.9        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,lioresal,30,799,808,"\n', '  oselabeledaefromdruguse                                                   1.7             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,lioresal,31,808,810,1.9                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,lioresal,32,810,812,7.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,lioresal,33,812,819,"\n', '  oselabeledaefromdruguse                                                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,lioresal,34,819,823,2.4             2.1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,lioresal,35,823,825,6.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,lioresal,36,825,835,"\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,lioresal,37,835,841,1.6             2.3                  5.6         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,lioresal,38,841,846,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,lioresal,39,846,850,oselabeledaefromdruguse                                                    1.6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,lioresal,40,850,854,2.5                  5.1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,lioresal,41,854,859,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,lioresal,42,859,863,oselabeledaefromdruguse                                                0.2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,lioresal,43,863,867,1.5                  5.1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,lioresal,44,867,878,"\n', '  oselabeledaefromdruguse                                                  0.5             1.3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,lioresal,45,878,880,4.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,lioresal,46,880,889,"\n', '  oselabeledaefromdruguse                                           0.7             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,lioresal,47,889,891,1.7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,lioresal,48,891,893,1.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,lioresal,49,893,898,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,lioresal,50,898,902,oselabeledaefromdruguse                                                   0.2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,lioresal,51,902,904,0.4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,lioresal,52,904,906,3.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,lioresal,53,906,915,"\n', '  oselabeledaefromdruguse                                           0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,lioresal,54,915,917,0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,lioresal,55,917,919,3.5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,lioresal,56,919,930,"\n', '  oselabeledaefromdruguse                                                    0.7             1.3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,lioresal,57,930,932,1.4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,lioresal,58,932,941,"\n', '  oselabeledaefromdruguse                                                   0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,lioresal,59,941,943,0.6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,lioresal,60,943,945,2.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,lioresal,61,945,954,"\n', '  nonoseaegeneralterm                                                       0.2             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,lioresal,62,954,958,0.4                  3.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,lioresal,63,958,965,"\n', '  oselabeledaefromdruguse                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,lioresal,64,965,969,0.0             0.6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,lioresal,65,969,971,3.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,lioresal,66,971,980,"\n', '  oselabeledaefromdruguse                                             0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,lioresal,67,980,982,0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,lioresal,68,982,984,3.5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,lioresal,69,984,991,"\n', '  oselabeledaefromdruguse                                                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,lioresal,70,991,995,1.0             0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,lioresal,71,995,997,1.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,lioresal,72,997,1006,"\n', '  oselabeledaefromdruguse                                                   0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,lioresal,73,1006,1008,0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,lioresal,74,1008,1010,2.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,lioresal,75,1010,1017,"\n', '  oselabeledaefromdruguse                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,lioresal,76,1017,1021,0.0             0.8                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,lioresal,77,1021,1023,2.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,lioresal,78,1023,1030,"\n', '  oselabeledaefromdruguse                                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,lioresal,79,1030,1034,0.2             0.8                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,lioresal,80,1034,1036,2.1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,lioresal,81,1036,1043,"\n', '  oselabeledaefromdruguse                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,lioresal,82,1043,1047,0.0             1.5                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,lioresal,83,1047,1049,0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,lioresal,84,1049,1054,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,lioresal,85,1054,1058,oselabeledaefromdruguse                                                   0.2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,lioresal,86,1058,1060,0.4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,lioresal,87,1060,1062,1.6         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,lioresal,88,1062,1071,"\n', '  oselabeledaefromdruguse                                            0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,lioresal,89,1071,1073,0.0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,lioresal,90,1073,1075,2.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,lioresal,91,1075,1084,"\n', '  oselabeledaefromdruguse                                        0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,lioresal,92,1084,1088,0.8                  1.4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,lioresal,93,1088,1099,"\n', '  oselabeledaefromdruguse                                                    0.0             0.4                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,lioresal,94,1099,1101,1.6         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,lioresal,95,1101,1110,"\n', '  oselabeledaefromdruguse                                                     0.2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,lioresal,96,1110,1112,0.4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,lioresal,97,1112,1114,0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,lioresal,98,1114,1123,"\n', '  oselabeledaefromdruguse                                                  0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,lioresal,99,1123,1125,0.0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,lioresal,100,1125,1127,1.6         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,lioresal,101,1127,1149,"\n', '  oselabeledaefromdruguse                                                     0.3             0.0                  1.2         \n', '  oselabeledaefromdruguse                                                       0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,lioresal,102,1149,1151,0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,lioresal,103,1151,1153,0.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,lioresal,104,1153,1164,"\n', '  oselabeledaefromdruguse                                                   0.2             0.2                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,lioresal,105,1164,1166,1.2         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,lioresal,106,1166,1171,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,lioresal,107,1171,1177,oselabeledaefromdruguse                                           0.0             0.6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,lioresal,108,1177,1179,0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,lioresal,109,1179,1184,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,lioresal,110,1184,1190,oselabeledaefromdruguse                                                   0.2             0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,lioresal,111,1190,1192,1.2         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,lioresal,112,1192,1199,"\n', '  oselabeledaefromdruguse                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,lioresal,113,1199,1203,0.0             0.4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,lioresal,114,1203,1205,0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,lioresal,115,1205,1212,"\n', '  oselabeledaefromdruguse                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,lioresal,116,1212,1216,0.0             0.4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,lioresal,117,1216,1218,0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,lioresal,118,1218,1225,"\n', '  oselabeledaefromdruguse                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,lioresal,119,1225,1229,0.2             0.2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,lioresal,120,1229,1231,0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,lioresal,121,1231,1240,"\n', '  oselabeledaefromdruguse                                              0.3             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,lioresal,122,1240,1242,0.4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,lioresal,123,1242,1244,0.5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,lioresal,124,1244,1251,"\n', '  oselabeledaefromdruguse                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,lioresal,125,1251,1255,0.2             0.6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,lioresal,126,1255,1257,0.5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,lioresal,127,1257,1262,"\n', '          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,lioresal,128,1262,1313,"In addition to the more common (1% or more) adverse events reported in the prospectively followed 576 domestic patients in pre- and post-marketing studies, experience from an additional 194 patients exposed to LIORESAL INTRATHECAL (baclofen injection) from foreign studies has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,lioresal,129,1313,1392,"The following adverse events, not described in the table, and arranged in decreasing order of frequency, and classified by body system, were reported:\n', ' \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,lioresal,130,1392,1463,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
131,lioresal,131,1463,1533,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
132,lioresal,132,1533,1564,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
133,lioresal,133,1564,1576,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
134,lioresal,134,1576,1607,"\n', '\n', '   Spasticity of Cerebral Origin\n', '\n', '  Clinical Studies\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,lioresal,135,1607,1670,"Commonly Observed\n', '\n', '  In pre-marketing clinical trials, the most commonly observed adverse events associated with use of LIORESAL INTRATHECAL (baclofen injection) which were not seen at an equivalent incidence among placebo-treated patients included:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,lioresal,136,1670,1805,"\n', '\n', '   Associated with Discontinuation of Treatment\n', '\n', '  Nine of 211 patients receiving LIORESAL INTRATHECAL in pre-marketing clinical studies in the U.S. discontinued long term infusion due to adverse events associated with intrathecal therapy.\n', '\n', ' The nine adverse events leading to discontinuation were:  oselabeledaefromdruguse (3),  oselabeledaefromdruguse (2),  oselabeledaefromdruguse (2),  oselabeledaefromdruguse (1), and  oselabeledaefromdruguse (1).\n', '\n', '    nonoseaegeneralterm \n', '  Three  nonoseaegeneralterm  none of which were attributed to LIORESAL INTRATHECAL, were reported in patients in clinical trials involving patients with  notaecandidateindication  ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
137,lioresal,137,1805,1807,See  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,lioresal,138,1807,1819,Warnings on other  nonoseaegeneralterm reported in  notaecandidateindication patients.  ,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
139,lioresal,139,1819,1888,"\n', '\n', '   Incidence in Controlled Trials\n', '\n', '  Experience with LIORESAL INTRATHECAL (baclofen injection) obtained in parallel, placebo-controlled, randomized studies provides only a limited basis for estimating the incidence of adverse events because the studies involved a total of 62 patients exposed to a single 50 mcg intrathecal bolus.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,lioresal,140,1888,1940,"The following events occurred among the 62 patients receiving LIORESAL INTRATHECAL in two randomized, placebo-controlled trials involving  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor patients, respectively:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
141,lioresal,141,1940,2005,"', '\n', '   Events Observed during the Pre-marketing Evaluation of LIORESAL INTRATHECAL\n', '\n', '  Adverse events associated with the use of LIORESAL INTRATHECAL reflect experience gained with a total of 211 U. S. patients with  notaecandidateindication  of whom 112 were pediatric patients (under age 16 at enrollment).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
142,lioresal,142,2005,2032,They received LIORESAL INTRATHECAL for periods of one day (screening) (N= 211) to 84 months (maintenance) (N= 1).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,lioresal,143,2032,2051,The usual screening bolus dose administered prior to pump implantation in these studies was 50-75 mcg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,lioresal,144,2051,2064,The maintenance dose ranged from 22 mcg to 1400 mcg per day.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,lioresal,145,2064,2125,"Doses used in this patient population for long term infusion are generally lower than those required for patients with  notaecandidateindication \n', '\n', ' Because of the open, uncontrolled nature of the experience, a causal linkage between events observed and the administration of LIORESAL INTRATHECAL cannot be reliably assessed in many cases.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
146,lioresal,146,2125,2184,"Nonetheless, many of the more commonly reported reactions-  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse appear clearly drug-related.\n', '\n', ' The most frequent (>=1%) adverse events reported during all clinical trials are shown in the following table.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,lioresal,147,2184,2211,"Nine patients discontinued long term treatment due to adverse events.\n', '\n', ' INCIDENCE OF MOST FREQUENT (>= 1%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,lioresal,148,2211,2225,ADVERSE EVENTS IN PATIENTS WITH SPASTICITY OF CEREBRAL ORIGIN IN PROSPECTIVELY MONITORED CLINICAL TRIALS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,lioresal,149,2225,2247,"\n', '                                                             Percent of Patients Reporting Events   \n', '                                                             N = 211Screening [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,lioresal,150,2247,2261,Following administration of test bolus] Percent  N = 153Titration [note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,lioresal,151,2261,2266,Two month period following implant,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,lioresal,152,2266,2272,] Percent  N = 150Maintenance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,lioresal,153,2272,2275,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,lioresal,154,2275,2290,"Beyond two months following implant] Percent   \n', ' Adverse Event                                                                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,lioresal,155,2290,2310,"\n', '  \n', ' N= Total number of patients  entering  each period.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,lioresal,156,2310,2325,211 patients received drug; (1 of 212) received placebo only.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,lioresal,157,2325,2339,"\n', '  \n', '  oselabeledaefromdruguse                                                        2.4             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,lioresal,158,2339,2341,14.4            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,lioresal,159,2341,2343,34.7        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,lioresal,160,2343,2350,"\n', '  oselabeledaefromdruguse                                                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,lioresal,161,2350,2354,7.6             10.5            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,lioresal,162,2354,2356,18.7        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,lioresal,163,2356,2365,"\n', '  oselabeledaefromdruguse                                                         6.6             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,lioresal,164,2365,2367,7.8             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,lioresal,165,2367,2369,10.7        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,lioresal,166,2369,2379,"\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,lioresal,167,2379,2385,6.6             10.5            4.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,lioresal,168,2385,2394,"\n', '  oselabeledaefromdruguse                                                         6.2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,lioresal,169,2394,2396,8.5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,lioresal,170,2396,2398,4.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,lioresal,171,2398,2407,"\n', '  oselabeledaefromdruguse                                                0.9             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,lioresal,172,2407,2411,6.5             8.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,lioresal,173,2411,2431,"\n', '  oselabeledaefromdruguse                                                       0.9             3.3             10.0        \n', '  oselabeledaefromdruguse                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,lioresal,174,2431,2435,2.4             2.6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,lioresal,175,2435,2437,8.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,lioresal,176,2437,2446,"\n', '  oselabeledaefromdruguse                                                           1.4             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,lioresal,177,2446,2450,3.3             7.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,lioresal,178,2450,2457,"\n', '  oselabeledaefromdruguse                                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,lioresal,179,2457,2459,1.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,lioresal,180,2459,2461,1.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,lioresal,181,2461,2463,4.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,lioresal,182,2463,2470,"\n', '  oselabeledaefromdruguse                                                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,lioresal,183,2470,2474,0.0             0.7             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,lioresal,184,2474,2476,6.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,lioresal,185,2476,2481,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,lioresal,186,2481,2485,oselabeledaefromdruguse                                                      1.9             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,lioresal,187,2485,2489,0.7             3.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,lioresal,188,2489,2498,"\n', '  oselabeledaefromdruguse                                                      1.9             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,lioresal,189,2498,2502,0.7             2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,lioresal,190,2502,2511,"\n', '  oselabeledaefromdruguse                                             0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,lioresal,191,2511,2515,2.6             2.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,lioresal,192,2515,2524,"\n', '  oselabeledaefromdruguse                                                        0.9             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,lioresal,193,2524,2528,0.7             2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,lioresal,194,2528,2537,"\n', '  oselabeledaefromdruguse                                                     0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,lioresal,195,2537,2539,1.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,lioresal,196,2539,2541,2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,lioresal,197,2541,2552,"\n', '  oselabeledaefromdruguse                                                             0.0             0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,lioresal,198,2552,2554,4.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,lioresal,199,2554,2561,"\n', '  oselabeledaefromdruguse                                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,lioresal,200,2561,2565,0.0             0.0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,lioresal,201,2565,2567,4.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,lioresal,202,2567,2576,"\n', '  oselabeledaefromdruguse                                                         0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,lioresal,203,2576,2580,0.7             2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,lioresal,204,2580,2589,"\n', '  oselabeledaefromdruguse                                                 0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,lioresal,205,2589,2593,0.0             3.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,lioresal,206,2593,2600,"\n', '  oselabeledaefromdruguse                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,lioresal,207,2600,2604,0.5             1.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,lioresal,208,2604,2606,0.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,lioresal,209,2606,2615,"\n', '  oselabeledaefromdruguse                                                        0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,lioresal,210,2615,2619,0.0             1.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,lioresal,211,2619,2626,"\n', '  oselabeledaefromdruguse                                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,lioresal,212,2626,2630,0.0             0.0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,lioresal,213,2630,2632,2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,lioresal,214,2632,2641,"\n', '  oselabeledaefromdruguse                                                           0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,lioresal,215,2641,2645,0.0             1.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,lioresal,216,2645,2654,"\n', '  oselabeledaefromdruguse                                                             0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,lioresal,217,2654,2658,0.0             1.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,lioresal,218,2658,2667,"\n', '  oselabeledaefromdruguse                                                        0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,lioresal,219,2667,2671,0.0             1.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,lioresal,220,2671,2678,"\n', '  oselabeledaefromdruguse                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,lioresal,221,2678,2682,0.0             0.0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,lioresal,222,2682,2684,2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,lioresal,223,2684,2693,"\n', '  oselabeledaefromdruguse                                                  0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,lioresal,224,2693,2695,0.7             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,lioresal,225,2695,2697,0.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,lioresal,226,2697,2706,"\n', '  oselabeledaefromdruguse                                                           0.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,lioresal,227,2706,2710,0.0             1.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,lioresal,228,2710,2719,"\n', '  oselabeledaefromdruguse                                             0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,lioresal,229,2719,2723,0.0             2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,lioresal,230,2723,2732,"\n', '  oselabeledaefromdruguse                                               0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,lioresal,231,2732,2736,0.0             2.0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,lioresal,232,2736,2771,"\n', '          The more common (1% or more) adverse events reported in the prospectively followed 211 patients exposed to LIORESAL INTRATHECAL (baclofen injection) have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,lioresal,233,2771,2846,"In the total cohort, the following adverse events, not described in the table, and arranged in decreasing order of frequency, and classified by body system, were reported:\n', ' \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
234,lioresal,234,2846,2877,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
235,lioresal,235,2877,2896,"\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
236,lioresal,236,2896,2917,"\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
237,lioresal,237,2917,2938,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
238,lioresal,238,2938,2950,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
239,lioresal,239,2950,2993,"\n', '\n', '    nonoseaegeneralterm    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
240,lioresal,240,2993,3023,"', '   Postmarketing Experience\n', '\n', '  The following adverse events have been reported during post-approval use of LIORESAL INTRATHECAL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,lioresal,241,3023,3108,"Because these events are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency.\n', '\n', '   Musculoskeletal\n', '\n', '  The onset of  oselabeledaefromdruguse or  oselabeledaefromdruguse has been reported.\n', '\n', '   Urogenital\n', '\n', '   oselabeledaefromdruguse in men and women, including  oselabeledaefromdruguse and  oselabeledaefromdruguse  have been reported.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,lioresal,242,3108,3117,oselabeledaefromdruguse in men has also been reported.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,lioresal,243,3117,3137,"nonoseaeodorwithdrawal has been reported following baclofen  nonoseaeaeonlyasinstruction \n', '\n', '    BOXED WARNING:",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
244,lioresal,244,3137,3221,"\n', '\n', '   oselabeledaefromdruguse  regardless of the cause, has resulted in sequelae that include  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  that in rare cases has advanced to  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal and  nonoseaegeneralterm  \n', '\n', ' Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms.",0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
245,lioresal,245,3221,3269,Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of  nonoseaeaeonlyasinstruction  Special attention should be given to patients at apparent risk (e.g.  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  history of  notaecandidatepreexistingconditionorriskfactor    ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
246,lioresal,246,3269,3294,"PRECAUTIONS\n', '\n', ""  Children should be of sufficient body mass to accommodate the implantable pump for chronic infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,lioresal,247,3294,3424,"Please consult pump manufacturer's manual for specific recommendations.\n"", '\n', ' Safety and effectiveness in pediatric patients below the age of 4 have not been established.\n', '\n', '    Screening\n', '\n', ""  Patients should be  notaecandidatepreexistingconditionorriskfactor free prior to the screening trial with LIORESAL INTRATHECAL (baclofen injection) because the presence of a systemic  nonoseaeaeonlyasinstruction may interfere with an assessment of the patient's response to bolus LIORESAL INTRATHECAL.\n"", '\n', '    Pump Implantation\n', '\n', '  Patients should be  notaecandidatepreexistingconditionorriskfactor free prior to pump implantation because the presence of  nonoseaeaeonlyasinstruction may increase the risk of surgical complications.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
248,lioresal,248,3424,3521,"Moreover, a systemic  nonoseaeaeonlyasinstruction may complicate dosing.\n', '\n', '    Pump Dose Adjustment and Titration\n', '\n', '  In most patients, it will be necessary to increase the dose gradually over time to maintain effectiveness; a sudden requirement for substantial dose escalation typically indicates a catheter complication (i. e., catheter kink or dislodgement).\n', '\n', ' Reservoir refilling must be performed by fully trained and qualified personnel following the directions provided by the pump manufacturer.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,lioresal,249,3521,3534,oselabeledaemedicationerror can occur if the reservoir refill septum is not properly accessed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,lioresal,250,3534,3552,Subcutaneous injection may result in symptoms of a systemic  nonoseaeodorwithdrawal or early depletion of the reservoir.,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
251,lioresal,251,3552,3606,"Refill intervals should be carefully calculated to prevent depletion of the reservoir, as this would result in the return of severe  nonoseaeaeonlyasinstruction and possibly symptoms of  nonoseaeaeonlyasinstruction \n', '\n', ' Strict aseptic technique in filling is required to avoid bacterial contamination and serious  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,lioresal,252,3606,3660,"A period of observation appropriate to the clinical situation should follow each refill or manipulation of the drug reservoir.\n', '\n', '  Extreme caution must be used when filling an FDA approved implantable pump equipped with an injection port that allows direct access to the intrathecal catheter.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,lioresal,253,3660,3823,"oselabeledaemedicationerror through the catheter access port may cause a life-threatening  nonoseaeodorwithdrawal   \n', '\n', '    Additional considerations pertaining to dosage adjustment\n', '\n', '  It may be important to titrate the dose to maintain some degree of muscle tone and allow occasional  nonoseaeaeonlyasinstruction to: 1) help support circulatory function, 2) possibly prevent the formation of  nonoseaeaeonlyasinstruction  3) optimize activities of daily living and ease of care.\n', '\n', ' Except in  nonoseaeaeonlyasinstruction related emergencies, the dose of LIORESAL INTRATHECAL should ordinarily be reduced slowly if the drug is discontinued for any reason.\n', '\n', ' An attempt should be made to discontinue concomitant oral antispasticity medication to avoid possible  nonoseaeaeonlyasinstruction or adverse drug interactions, either prior to screening or following implant and initiation of chronic LIORESAL INTRATHECAL infusion.",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
254,lioresal,254,3823,3843,Reduction and discontinuation of oral anti-spasmotics should be done slowly and with careful monitoring by the physician.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,lioresal,255,3843,3880,"Abrupt reduction or discontinuation of concomitant antispastics should be avoided.\n', '\n', '    Drowsiness\n', '\n', '   oselabeledaefromdruguse has been reported in patients on LIORESAL INTRATHECAL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,lioresal,256,3880,3930,"Patients should be  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction automobiles or other  nonoseaeaeonlyasinstruction  and activities made hazardous by  nonoseaeaeonlyasinstruction  Patients should also be cautioned that the  nonoseaeaeonlyasinstruction of LIORESAL INTRATHECAL (baclofen injection) may be additive to those of alcohol and other CNS depressants.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,lioresal,257,3930,3946,"'\n', '    Intrathecal mass\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,lioresal,258,3946,3963,"Cases of  oselabeledaefromdrugcomponent have been reported, most of them involving pharmacy compounded analgesic admixtures.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,lioresal,259,3963,4018,"The most frequent symptoms associated with  nonoseaeaeonlyasinstruction are: 1)  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication when previously well controlled,  nonoseaemanifestationorcomplication  poor response to escalating doses, or frequent or large dosage increases), 2)  nonoseaemanifestationorcomplication  3)  nonoseaemanifestationorcomplication deficit/ nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication dysfunction.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
260,lioresal,260,4018,4032,Clinicians should monitor patients on intraspinal therapy carefully for any new  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,lioresal,261,4032,4075,"In patients with new neurological signs or symptoms suggestive of an  nonoseaeaeonlyasinstruction  consider a neurosurgical consultation, since many of the symptoms of  nonoseaeaeonlyasinstruction are not unlike the symptoms experienced by patients with severe  notaecandidateindication from their disease.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
262,lioresal,262,4075,4353,"In some cases, performance of an imaging procedure may be appropriate to confirm or rule-out the diagnosis of an  nonoseaeaeonlyasinstruction \n', '\n', '    Precautions in special patient populations\n', '\n', '  Careful dose titration of LIORESAL INTRATHECAL is needed when  nonoseaeaeonlyasinstruction is necessary to sustain upright posture and balance in locomotion or whenever  nonoseaeaeonlyasinstruction is used to obtain optimal function and care.\n', '\n', ' Patients suffering from  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor should be treated cautiously with LIORESAL INTRATHECAL and kept under careful surveillance, because exacerbations of these conditions have been observed with oral administration.\n', '\n', ' LIORESAL INTRATHECAL should be used with caution in patients with a history of  notaecandidatepreexistingconditionorriskfactor  The presence of nociceptive stimuli or abrupt  nonoseaeaeonlyasinstruction of LIORESAL INTRATHECAL (baclofen injection) may cause an  nonoseaeodorwithdrawal \n', '\n', ' Because LIORESAL is primarily excreted unchanged by the kidneys, it should be given with caution in patients with  notaecandidatepreexistingconditionorriskfactor and it may be necessary to reduce the dosage.\n', '\n', '    LABORATORY TESTS\n', '\n', '  No specific laboratory tests are deemed essential for the management of patients on LIORESAL INTRATHECAL.\n', '\n', '    DRUG INTERACTIONS\n', '\n', '  There is inadequate systematic experience with the use of LIORESAL INTRATHECAL in combination with other medications to predict specific drug-drug interactions.",1,0,1,0,0,0,0,0,0,1,0,0,0,0,0
263,lioresal,263,4353,4412,"Interactions attributed to the combined use of LIORESAL INTRATHECAL and epidural morphine include  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction \n', '\n', '    CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY\n', '\n', '  No increase in  nonoseaeaeanimal was seen in rats receiving baclofen orally for two years.",0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
264,lioresal,264,4412,4439,"Adequate  nonoseaegeneralterm assays of baclofen have not been performed.\n', '\n', '    PREGNANCY\n', '\n', '  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
265,lioresal,265,4439,4453,There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
266,lioresal,266,4453,4472,"In animal studies, baclofen had adverse effects on  nonoseaeaeanimal when administered orally to  nonoseaeaeanimal rats.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
267,lioresal,267,4472,4514,"LIORESAL INTRATHECAL should be used during  notaecandidatepreexistingconditionorriskfactor only if the potential benefit justifies the potential  oselabeledaefromdruguse \n', '\n', ' Baclofen given orally increased the incidence of  nonoseaeaeanimal ( nonoseaeaeanimal  in rats.  ",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
268,lioresal,268,4514,4525,nonoseaeaeanimal and  nonoseaeaeanimal were observed in the dams.  ,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
269,lioresal,269,4525,4573,"nonoseaeaeanimal were not observed in mice or rabbits\n', '\n', '    NURSING MOTHERS\n', '\n', '  In mothers treated with oral LIORESAL (baclofen USP) in therapeutic doses, the active substance passes into the milk.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
270,lioresal,270,4573,4593,It is not known whether detectable levels of drug are present in milk of nursing mothers receiving LIORESAL INTRATHECAL.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,lioresal,271,4593,4655,"As a general rule, nursing should be undertaken while a patient is receiving LIORESAL INTRATHECAL only if the potential benefit justifies the potential risks to the infant.\n', '\n', '    PEDIATRIC USE\n', '\n', ""  Children should be of sufficient body mass to accommodate the implantable pump for chronic infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,lioresal,272,4655,4734,"Please consult pump manufacturer's manual for specific recommendations.\n"", '\n', ' Safety and effectiveness in pediatric patients below the age of 4 have not been established.\n', '\n', '    Considerations based on experience with oral LIORESAL (baclofen USP)\n', '\n', '  A dose-related increase in incidence of  nonoseaeaeanimal was observed in female rats treated chronically with oral LIORESAL.  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
273,lioresal,273,4734,4761,oselabeledaefromdruguse have been found by palpation in about 4% of the  notaecandidatepreexistingconditionorriskfactor patients who were treated with oral LIORESAL for up to one year.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
274,lioresal,274,4761,4777,In most cases these cysts disappeared spontaneously while patients continued to receive the drug.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,lioresal,275,4777,4779,nonoseaeaeonlyasinstruction    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,lioresal,276,4779,4830,"WARNINGS\n', '\n', '  LIORESAL INTRATHECAL is for use in single bolus intrathecal injections (via a catheter placed in the lumbar intrathecal space or injection by lumbar puncture) and in implantable pumps approved by the FDA specifically for the intrathecal administration of baclofen.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,lioresal,277,4830,4888,"Because of the possibility of potentially life-threatening  oselabeledaefromdruguse   oselabeledaefromdruguse  and/or  oselabeledaefromdruguse  physicians must be adequately trained and educated in chronic intrathecal infusion therapy.\n', '\n', "" The pump system should not be implanted until the patient's response to bolus LIORESAL INTRATHECAL injection is adequately evaluated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,lioresal,278,4888,4920,Evaluation (consisting of a screening procedure: see  Dosage and Administration  ) requires that LIORESAL INTRATHECAL be administered into the intrathecal space via a catheter or lumbar puncture.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,lioresal,279,4920,4976,"Because of the risks associated with the screening procedure and the adjustment of dosage following pump implantation, these phases must be conducted in a medically supervised and adequately equipped environment following the instructions outlined in the Dosage and Administration section.\n"", '\n', '  Resuscitative equipment should be available.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,lioresal,280,4976,5115,"\n', '\n', "" Following surgical implantation of the pump, particularly during the initial phases of pump use, the patient should be monitored closely until it is certain that the patient's response to the infusion is acceptable and reasonably stable.\n"", '\n', "" On each occasion that the dosing rate of the pump and/or the concentration of LIORESAL INTRATHECAL (baclofen injection) in the reservoir is adjusted, close medical monitoring is required until it is certain that the patient's response to the infusion is acceptable and reasonably stable.\n"", '\n', ' It is mandatory that the patient, all patient caregivers, and the physicians responsible for the patient receive adequate information regarding the risks of this mode of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,lioresal,281,5115,5147,All medical personnel and caregivers should be instructed in 1) the signs and symptoms of  nonoseaeaeonlyasinstruction  2) procedures to be followed in the event of  nonoseaeaeonlyasinstruction and,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,lioresal,282,5147,5185,"3) proper home care of the pump and insertion site.\n', '\n', '    Overdose\n', '\n', '  Signs of  oselabeledaefromdruguse may appear suddenly or insidiously.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,lioresal,283,5185,5259,"Acute massive  oselabeledaefromdruguse may present as  nonoseaeodorwithdrawal  Less sudden and/or less severe forms of  oselabeledaefromdruguse may present with signs of  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  rostral progression of  nonoseaeodorwithdrawal and  nonoseaeodorwithdrawal progressing to  nonoseaeodorwithdrawal  Should  nonoseaeaeonlyasinstruction appear likely, the patient should be taken immediately to a hospital for assessment and emptying of the pump reservoir.",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
284,lioresal,284,5259,5293,"In cases reported to date,  nonoseaeaeonlyasinstruction has generally been related to  nonoseaemanifestationorcomplication   oselabeledaemedicationerror  or  oselabeledaemedicationerror  (See   nonoseaeaeonlyasinstruction Symptoms  and  Treatment.  )",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
285,lioresal,285,5293,5314,"\n', '\n', ' Extreme caution must be used when filling an FDA approved implantable pump.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,lioresal,286,5314,5327,Such pumps should only be refilled through the reservoir refill septum.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,lioresal,287,5327,5340,oselabeledaemedicationerror can occur if the reservoir refill septum is not properly accessed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,lioresal,288,5340,5360,Some pumps are also equipped with a catheter access port that allows direct access to the intrathecal catheter.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,lioresal,289,5360,5437,"oselabeledaemedicationerror this  oselabeledaemedicationerror or  oselabeledaemedicationerror may cause a life-threatening  nonoseaeodorwithdrawal \n', '\n', '    Withdrawal\n', '\n', '  Abrupt  oselabeledaefromdruguse of intrathecal baclofen, regardless of the cause, has resulted in sequelae that included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  exaggerated  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication that in rare cases progressed to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm  ",0,1,0,0,1,0,0,0,0,1,0,0,0,0,0
290,lioresal,290,5437,5469,"In the first 9 years of post-marketing experience, 27 cases of  oselabeledaefromdruguse temporally related to the cessation of baclofen therapy were reported; six patients  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
291,lioresal,291,5469,5490,"In most cases, symptoms of  oselabeledaefromdruguse appeared within hours to a few days following interruption of baclofen therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,lioresal,292,5490,5530,"Common reasons for abrupt interruption of intrathecal baclofen therapy included  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction (especially  nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  human error may have played a causal or contributing role in some cases.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,lioresal,293,5530,5594,"Cases of  oselabeledaefromdrugcomponent leading to  nonoseaeodorwithdrawal symptoms have also been reported, most of them involving pharmacy compounded analgesic admixtures (see  PRECAUTIONS  ).\n', '\n', ' Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms.",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
294,lioresal,294,5594,5675,"Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of  nonoseaeodorwithdrawal \n', '\n', ' All patients receiving intrathecal baclofen therapy are potentially at risk for  oselabeledaefromdruguse  Early symptoms of  oselabeledaefromdruguse may include return of baseline  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal may develop or recur if treatment with intrathecal baclofen is interrupted.",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
295,lioresal,295,5675,5754,"Some clinical characteristics of the advanced  nonoseaeaeonlyasinstruction may resemble  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or other conditions associated with a  nonoseaeaeonlyasinstruction or widespread  nonoseaeaeonlyasinstruction \n', '\n', ' Rapid, accurate diagnosis and treatment in an emergency-room or intensive-care setting are important in order to prevent the potentially life-threatening  nonoseaeaeonlyasinstruction and systemic  nonoseaeaeonlyasinstruction of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,lioresal,296,5754,5778,The suggested treatment for  nonoseaeaeonlyasinstruction is the restoration of intrathecal baclofen at or near the same dosage as before therapy was interrupted.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,lioresal,297,5778,5817,"However, if restoration of intrathecal delivery is delayed, treatment with GABA-ergic agonist drugs such as oral or enteral baclofen, or oral, enteral, or intravenous benzodiazepines may prevent potentially  nonoseaegeneralterm sequelae.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
298,lioresal,298,5817,5943,"Oral or enteral baclofen alone should not be relied upon to halt the progression of  nonoseaeaeonlyasinstruction \n', '\n', '  nonoseaeodorwithdrawal have been reported  nonoseaeodorwithdrawal overdose and with  nonoseaeodorwithdrawal  nonoseaeodorwithdrawal  oselabeledaefromdruguse have been reported during  nonoseaeodorwithdrawal and with withdrawal from LIORESAL INTRATHECAL as well as in patients maintained on therapeutic doses of LIORESAL INTRATHECAL.\n', '\n', '    Fatalities\n', '\n', '   Spasticity of Spinal Cord Origin\n', '\n', '  There were 16  nonoseaegeneralterm reported among the 576 U.S. patients treated with LIORESAL INTRATHECAL (baclofen injection) in pre- and post- marketing studies evaluated as of December 1992.",1,1,0,0,0,0,0,0,0,1,0,0,0,0,0
299,lioresal,299,5943,6044,"Because these patients were treated under uncontrolled clinical settings, it is impossible to determine definitively what role, if any, LIORESAL INTRATHECAL played in their  nonoseaegeneralterm \n', '\n', ' As a group, the patients who  nonoseaegeneralterm were relatively young (mean age was 47 with a range from 25 to 63), but the majority suffered from severe  notaecandidateindication of many years duration, were nonambulatory, had various medical complications such as  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  and/or had received multiple concomitant medications.",0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
300,lioresal,300,6044,6140,"A case-by-case review of the clinical course of the 16 patients who  nonoseaegeneralterm failed to reveal any unique signs, symptoms, or laboratory results that would suggest that treatment with LIORESAL INTRATHECAL caused their  nonoseaegeneralterm  Two patients, however, did suffer  nonoseaegeneralterm within 2 weeks of pump implantation and one patient  nonoseaegeneralterm unexpectedly after screening.\n', '\n', ' One patient, a 44 year old male with  notaecandidatepreexistingconditionorriskfactor   nonoseaegeneralterm in hospital on the second day following pump implantation.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
301,lioresal,301,6140,6188,"An autopsy demonstrated severe  nonoseaeaeonlyasinstruction  A second patient, a 52 year old woman with  notaecandidatepreexistingconditionorriskfactor and a history of an  notaecandidatepreexistingconditionorriskfactor  was found dead in bed 12 days after pump implantation, 2 hours after having had documented normal vital signs.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
302,lioresal,302,6188,6197,An autopsy revealed  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,lioresal,303,6197,6211,It is impossible to determine whether LIORESAL INTRATHECAL contributed to these  nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
304,lioresal,304,6211,6220,The third patient underwent three baclofen screening trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,lioresal,305,6220,6281,"His medical history included  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  severe  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  Twelve days after screening (he was not implanted), he again experienced  nonoseaeaeonlyasinstruction with subsequent significant  nonoseaeaeonlyasinstruction  Based upon prior instruction, extraordinary resuscitative measures were not pursued and the patient  nonoseaegeneralterm",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
306,lioresal,306,6281,6298,"\n', '\n', '    Spasticity of Cerebral Origin\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,lioresal,307,6298,6325,"', '  There were three  nonoseaegeneralterm occurring among the 211 patients treated with LIORESAL INTRATHECAL in pre- marketing studies as of March 1996.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
308,lioresal,308,6325,6330,These  nonoseaegeneralterm '],0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
0,vyvanse,0,0,98,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *  Known  oselabeledaefromdruguse to amphetamine products or other ingredients of VYVANSE [see  Contraindications (4)  ]  \n', ' *   nonoseaeaefromdruginteraction When Used Concomitantly with Monoamine Oxidase Inhibitors [see  Contraindications (4)  and  Drug Interactions (7.1)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
1,vyvanse,1,98,140,"[see  Boxed Warning  ,  Warnings and Precautions (5.1)  , and  Drug Abuse and Dependence (9.2  ,  9.3)  ]  \n', ' *  Serious  oselabeledaeclasseffect [",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,vyvanse,2,140,142,see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,vyvanse,3,142,328,"Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse and Heart Rate  oselabeledaefromdruguse  oselabeledaeclasseffect [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaeclasseffect [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse  including  oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]  \n', ' *   nonoseaeaefromdruginteraction [see  Warnings and Precautions (5.7)  ]  \n', '      EXCERPT:   Most common adverse reactions (incidence >=5% and at a rate at least twice placebo) in children, adolescents, and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting (  6.1  )",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
4,vyvanse,4,328,388,"\n', ' \n', '\n', ' Most common adverse reactions (incidence >= 5% and at a rate at least twice placebo) in adults with BED were dry mouth, insomnia, decreased appetite, increased heart rate, constipation, feeling jittery, and anxiety (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,vyvanse,5,388,629,"\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Shire US Inc. at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '      notaecandidateindication  \n', '\n', ' The safety data in this section is based on data from the 4-week parallel-group controlled clinical studies of VYVANSE in pediatric and adult patients with  notaecandidateindication  [see  Clinical Studies (14.1)  ]  .\n', '\n', '     Adverse Reactions Associated with Discontinuation of Treatment in ADHD Clinical Trials  \n', '\n', ' In the controlled trial in patients ages 6 to 12 years (Study 1), 8% (18/218) of VYVANSE-treated patients discontinued due to adverse reactions compared to 0% (0/72) of placebo-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
6,vyvanse,6,629,679,"The most frequently reported adverse reactions (1% or more and twice rate of placebo) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse [2 instances for each adverse reaction, i.e., 2/218 (1%)].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,vyvanse,7,679,717,Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,vyvanse,8,717,769,"\n', '\n', ' In the controlled trial in patients ages 13 to 17 years (Study 4), 3% (7/233) of VYVANSE-treated patients discontinued due to adverse reactions compared to 1% (1/77) of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,vyvanse,9,769,805,The most frequently reported adverse reactions (1% or more and twice rate of placebo) were  oselabeledaefromdruguse (2/233; 1%) and  oselabeledaefromdruguse (2/233; 1%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,vyvanse,10,805,834,Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,vyvanse,11,834,880,"\n', '\n', ' In the controlled adult trial (Study 7), 6% (21/358) of VYVANSE-treated patients discontinued due to adverse reactions compared to 2% (1/62) of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,vyvanse,12,880,962,"The most frequently reported adverse reactions (1% or more and twice rate of placebo) were  oselabeledaefromdruguse (8/358; 2%),  oselabeledaefromdruguse (3/358; 1%),  oselabeledaefromdruguse (2/358; 1%),  oselabeledaefromdruguse (4/358; 1%),  oselabeledaefromdruguse (2/358; 1%),  oselabeledaefromdruguse (2/358; 1%), and  oselabeledaefromdruguse (3/358; 1%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,vyvanse,13,962,1000,Less frequently reported adverse reactions (less than 1% or less than twice rate of placebo) included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,vyvanse,14,1000,1024,"\n', '\n', '     Adverse Reactions Occurring at an Incidence of >=5% or More Among VYVANSE",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,vyvanse,15,1024,1117,"Treated Patients with ADHD in Clinical Trials  \n', '\n', ' The most common adverse reactions (incidence >=5% and at a rate at least twice placebo) reported in children, adolescents, and/or adults were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '     Adverse Reactions Occurring at an Incidence of 2% or More Among VYVANSE",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,vyvanse,16,1117,1152,"Treated Patients with ADHD in Clinical Trials  \n', '\n', ' Adverse reactions reported in the controlled trials in pediatric patients ages 6 to 12 years (Study 1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,vyvanse,17,1152,1237,", adolescent patients ages 13 to 17 years (Study 4), and adult patients (Study 7) treated with VYVANSE or placebo are presented in Tables 1, 2, and 3 below.\n', '\n', ' Table 1 Adverse Reactions Reported by 2% or More of Children (Ages 6 to 12 Years) with ADHD Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,vyvanse,18,1237,1243,"\n', '                                                     VYVANSE(n=218",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,vyvanse,19,1243,1292,")                  Placebo(n=72)          \n', '  \n', '  oselabeledaefromdruguse                                  39%                             4%                     \n', '  oselabeledaefromdruguse                                            22%                             3%                     \n', '  oselabeledaefromdruguse                                12%                             6%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,vyvanse,20,1292,1331,"\n', '  oselabeledaefromdruguse                                        10%                             0%                     \n', '  oselabeledaefromdruguse                                            9%                              4%                     \n', '  oselabeledaefromdruguse                                    9%                              1%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,vyvanse,21,1331,1465,"\n', '  oselabeledaefromdruguse                                              6%                              3%                     \n', '  oselabeledaefromdruguse                                           5%                              0%                     \n', '  oselabeledaefromdruguse                                           5%                              0%                     \n', '  oselabeledaefromdruguse                                     3%                              0%                     \n', '  oselabeledaefromdruguse                                                3%                              0%                     \n', '  oselabeledaefromdruguse                                             2%                              1%                     \n', '  oselabeledaefromdruguse                                          2%                              1%                     \n', '  oselabeledaefromdruguse                                                 2%                              0%                     \n', '  oselabeledaefromdruguse                                            2%                              0%                     \n', '        Table 2 Adverse Reactions Reported by 2% or More of Adolescent",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,vyvanse,22,1465,1472,(Ages 13 to 17 Years),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,vyvanse,23,1472,1496,Patients with ADHD Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 4),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,vyvanse,24,1496,1507,"\n', '                                                     VYVANSE(n=233)                  Placebo(n=77)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,vyvanse,25,1507,1551,"\n', '  \n', '  oselabeledaefromdruguse                                  34%                             3%                     \n', '  oselabeledaefromdruguse                                            13%                             4%                     \n', '  oselabeledaefromdruguse                                    9%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,vyvanse,26,1551,1590,"\n', '  oselabeledaefromdruguse                                           4%                              1%                     \n', '  oselabeledaefromdruguse                                        2%                              1%                     \n', '  oselabeledaefromdruguse                                            2%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,vyvanse,27,1590,1644,"\n', '  oselabeledaefromdruguse                                              2%                              0%                     \n', '        Table 3 Adverse Reactions Reported by 2% or More of Adult Patients with ADHD Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in a 4-Week Clinical Trial (Study 7)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,vyvanse,28,1644,1645,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,vyvanse,29,1645,1655,"', '                                                     VYVANSE(n=358)                  Placebo(n=62)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,vyvanse,30,1655,1678,"\n', '  \n', '  oselabeledaefromdruguse                                  27%                             2%                     \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,vyvanse,31,1678,1725,"oselabeledaefromdruguse                                            27%                             8%                     \n', '  oselabeledaefromdruguse                                           26%                             3%                     \n', '  oselabeledaefromdruguse                                            7%                              0%                     \n', '  oselabeledaefromdruguse                                              7%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,vyvanse,32,1725,1738,"\n', '  oselabeledaefromdruguse                                             6%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,vyvanse,33,1738,1751,"\n', '  oselabeledaefromdruguse                                            5%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,vyvanse,34,1751,1842,"\n', '  oselabeledaefromdruguse                                     4%                              0%                     \n', '  oselabeledaefromdruguse                                           3%                              0%                     \n', '  oselabeledaefromdruguse                            3%                              0%                     \n', '  oselabeledaefromdruguse                                       3%                              0%                     \n', '  oselabeledaefromdruguse                                        3%                              0%                     \n', '  oselabeledaefromdruguse                                    3%                              0%                     \n', '  oselabeledaefromdruguse                                             2%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,vyvanse,35,1842,1881,"\n', '  oselabeledaefromdruguse                                2%                              0%                     \n', '  oselabeledaefromdruguse                                              2%                              0%                     \n', '  oselabeledaefromdruguse                                        2%                              0%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,vyvanse,36,1881,1950,"\n', '         In addition, in the adult population  oselabeledaefromdruguse was observed in 2.6% of males on VYVANSE and 0% on placebo;  oselabeledaefromdruguse was observed in 1.4% of subjects on VYVANSE and 0% on placebo.\n', ' \n', '\n', '     Weight Loss and Slowing Growth Rate in Pediatric Patients with ADHD  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,vyvanse,37,1950,1955,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,vyvanse,38,1955,2024,"', ' In a controlled trial of VYVANSE in children ages 6 to 12 years (Study 1), mean  oselabeledaefromdruguse from baseline after 4 weeks of therapy was -0.9, -1.9, and -2.5 pounds, respectively, for patients receiving 30 mg, 50 mg, and 70 mg of VYVANSE, compared to a 1 pound  nonoseaeaeonlyasinstruction for patients receiving placebo.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,vyvanse,39,2024,2038,Higher doses were associated with greater  oselabeledaefromdruguse with 4 weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,vyvanse,40,2038,2120,"Careful follow-up for weight in children ages 6 to 12 years who received VYVANSE over 12 months suggests that consistently medicated children (i.e. treatment for 7 days per week throughout the year) have a  oselabeledaefromdruguse  measured by body weight as demonstrated by an age- and sex-normalized mean change from baseline in percentile, of -13.4 over 1 year (average percentiles at baseline and 12 months were 60.9 and 47.2, respectively).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,vyvanse,41,2120,2151,"In a 4-week controlled trial of VYVANSE in adolescents ages 13 to 17 years, mean  oselabeledaefromdruguse from baseline to endpoint was -2.7, -4.3, and -4.8 lbs.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,vyvanse,42,2151,2300,", respectively, for patients receiving 30 mg, 50 mg, and 70 mg of VYVANSE, compared to a 2.0 pound  nonoseaeaeonlyasinstruction for patients receiving placebo.\n', '\n', ' Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e. treatment for 7 days per week throughout the year) have a temporary  oselabeledaefromdruguse (on average, a total of about  oselabeledaefromdruguse and  oselabeledaefromdruguse over 3 years), without evidence of growth rebound during this period of development.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,vyvanse,43,2300,2351,"In a controlled trial of amphetamine (d- to l-enantiomer ratio of 3:1) in adolescents, mean  oselabeledaefromdruguse from baseline within the initial 4 weeks of therapy was -1.1 pounds and -2.8 pounds, respectively, for patients receiving 10 mg and 20 mg of amphetamine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,vyvanse,44,2351,2524,"Higher doses were associated with greater  oselabeledaefromdruguse within the initial 4 weeks of treatment  [see  Warnings and Precautions (5.5)  ]  .\n', '\n', '     Weight Loss in Adults with ADHD  \n', '\n', ' In the controlled adult trial (Study 7), mean  oselabeledaefromdruguse after 4 weeks of therapy was 2.8 pounds, 3.1 pounds, and 4.3 pounds, for patients receiving final doses of 30 mg, 50 mg, and 70 mg of VYVANSE, respectively, compared to a mean  nonoseaeaeonlyasinstruction of 0.5 pounds for patients receiving placebo.\n', '\n', '      notaecandidateindication  \n', '\n', ' The safety data in this section is based on data from two 12 week parallel group, flexible-dose, placebo-controlled studies in adults with  notaecandidateindication  [see  Clinical Studies 14.2  ]  .",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
45,vyvanse,45,2524,2604,"Patients with cardiovascular risk factors other than  notaecandidatepreexistingconditionorriskfactor and smoking were excluded.\n', '\n', '     Adverse Reactions Associated with Discontinuation of Treatment in BED Clinical Trials  \n', '\n', ' In controlled trials of patients ages 18 to 55 years, 5.1% (19/373) of VYVANSE-treated patients discontinued due to adverse reactions compared to 2.4% (9/372) of placebo-treated patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
46,vyvanse,46,2604,2622,No single adverse reaction led to discontinuation in 1% or more of VYVANSE-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,vyvanse,47,2622,2660,Less commonly reported adverse reactions (less than 1% or less than twice rate of placebo) included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,vyvanse,48,2660,2697,"\n', '\n', ' The most common adverse reactions (incidence >=5% and at a rate at least twice placebo) reported in adults were  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,vyvanse,49,2697,2703,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,vyvanse,50,2703,2708,oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,vyvanse,51,2708,2788,"\n', '\n', ' Adverse reactions reported in the pooled controlled trials in adult patients (Study 11 and 12) treated with VYVANSE or placebo are presented in Table 4 below.\n', '\n', ' Table 4 Adverse Reactions Reported by 2% or More of Adult Patients with BED Taking VYVANSE and at least Twice the Incidence in Patients Taking Placebo in 12-Week Clinical Trials (Study 11 and 12)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,vyvanse,52,2788,2799,"\n', '                                                             VYVANSE(N=373)             Placebo(N=372)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,vyvanse,53,2799,2817,"\n', '  \n', '  oselabeledaefromdruguse                                                        36%                         7%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,vyvanse,54,2817,2826,"\n', '  oselabeledaefromdruguse [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,vyvanse,55,2826,2857,"Includes all preferred terms containing the word  oselabeledaefromdruguse ""]                20%                         8%            \n', '  oselabeledaefromdruguse                                                8%                         2%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,vyvanse,56,2857,2866,"\n', '  oselabeledaefromdruguse [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,vyvanse,57,2866,2879,"Includes the preferred terms "" oselabeledaefromdruguse  and "" oselabeledaefromdruguse ""]                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,vyvanse,58,2879,2885,7%                         1%            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,vyvanse,59,2885,2898,"\n', '  oselabeledaefromdruguse                                                   6%                         1%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,vyvanse,60,2898,2911,"\n', '  oselabeledaefromdruguse                                                      6%                         1%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,vyvanse,61,2911,2924,"\n', '  oselabeledaefromdruguse                                                           5%                         1%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,vyvanse,62,2924,2950,"\n', '  oselabeledaefromdruguse                                                          4%                         2%            \n', '  oselabeledaefromdruguse                                                  4%                         0%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,vyvanse,63,2950,2976,"\n', '  oselabeledaefromdruguse                                                     4%                         0%            \n', '  oselabeledaefromdruguse                                                          2%                         1%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,vyvanse,64,2976,2989,"\n', '  oselabeledaefromdruguse                                                   2%                         1%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,vyvanse,65,2989,3002,"\n', '  oselabeledaefromdruguse                                                       2%                         1%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,vyvanse,66,3002,3028,"\n', '  oselabeledaefromdruguse                                                          2%                         1%            \n', '  oselabeledaefromdruguse                                              2%                         0%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,vyvanse,67,3028,3054,"\n', '  oselabeledaefromdruguse                                                  2%                         0%            \n', '  oselabeledaefromdruguse                                           2%                         0%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,vyvanse,68,3054,3080,"\n', '  oselabeledaefromdruguse                                                         2%                         0%            \n', '  oselabeledaefromdruguse                                                      2%                         0%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,vyvanse,69,3080,3093,"\n', '  oselabeledaefromdruguse                                                2%                         0%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,vyvanse,70,3093,3119,"\n', '           6.2 Postmarketing Experience\n', '   The following adverse reactions have been identified during post approval use of VYVANSE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,vyvanse,71,3119,3150,"Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,vyvanse,72,3150,3214,These events are as follows:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse or prolonged  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,vyvanse,73,3214,3215,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,vyvanse,74,3215,3226,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,vyvanse,75,3226,3243,"WARNING:  ABUSE AND DEPENDENCE\n', '\n', '    WARNING:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,vyvanse,76,3243,3279,"ABUSE AND DEPENDENCE  \n', '\n', '    CNS stimulants (amphetamines and methylphenidate-containing products), including VYVANSE, have a high potential for  oselabeledaefromdruguse and  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,vyvanse,77,3279,3304,oselabeledaefromdruguse   Assess the risk of  nonoseaeaeonlyasinstruction prior to prescribing and monitor for signs of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction while on therapy     ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,vyvanse,78,3304,3311,[see   Warnings and Precautions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,vyvanse,79,3311,3326,"5.1  ,   5.2)  , and    nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,vyvanse,80,3326,3347,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Serious Cardiovascular Reactions:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,vyvanse,81,3347,3374,Sudden death has been reported in association with CNS stimulant treatment at recommended doses in pediatric patients with structural cardiac abnormalities or other serious heart problems.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,vyvanse,82,3374,3389,"In adults, sudden death, stroke, and myocardial infarction have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,vyvanse,83,3389,3414,"Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, or coronary artery disease (  5.2  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,vyvanse,84,3414,3427,"\n', ' *   Blood Pressure and Heart Rate Increases:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,vyvanse,85,3427,3433,Monitor blood pressure and pulse.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,vyvanse,86,3433,3454,Consider benefits and risks before use in patients for whom blood pressure increases may be problematic (  5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,vyvanse,87,3454,3458,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,vyvanse,88,3458,3489,"*   Psychiatric Adverse Reactions: May cause psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychosis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,vyvanse,89,3489,3502,Evaluate for bipolar disorder prior to stimulant use (  5.4  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,vyvanse,90,3502,3506,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,vyvanse,91,3506,3526,*   Suppression of Growth: Monitor height and weight in pediatric patients during treatment (  5.5  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,vyvanse,92,3526,3540,"\n', "" *   Peripheral Vasculopathy, including Raynaud's phenomenon:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,vyvanse,93,3540,3552,"Stimulants are associated with peripheral vasculopathy, including Raynaud's phenomenon.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,vyvanse,94,3552,3602,"Careful observation for digital changes is necessary during treatment with stimulants (  5.6  ) \n"", ' *   Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,vyvanse,95,3602,3626,"If it occurs, discontinue VYVANSE and initiate supportive treatment (  4  ,  5.7  ,  10  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,vyvanse,96,3626,3761,"\n', '    \n', ' \n', '\n', '   5.1 Potential for Abuse and Dependence\n', '\n', '  CNS stimulants (amphetamines and methylphenidate-containing products), including VYVANSE, have a high potential for  oselabeledaefromdruguse and  oselabeledaefromdruguse  Assess the risk of  nonoseaeaeonlyasinstruction prior to prescribing, and monitor for signs of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction while on therapy [see   nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction (9.2  ,  9.3)  ]  .\n', '\n', '    5.2 Serious  oselabeledaeclasseffect \n', '   oselabeledaeclasseffect   oselabeledaeclasseffect and  oselabeledaeclasseffect have been reported in adults with CNS stimulant treatment at recommended doses.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,vyvanse,97,3761,3787,oselabeledaeclasseffect has been reported in children and adolescents with  notaecandidatepreexistingconditionorriskfactor and other serious  notaecandidatepreexistingconditionorriskfactor taking CNS stimulants at recommended doses for  notaecandidateindication  ,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
98,vyvanse,98,3787,3810,Avoid use in patients with known  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  serious  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and other serious  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
99,vyvanse,99,3810,3883,"Further evaluate patients who develop  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication during VYVANSE treatment.\n', '\n', '    5.3 Blood Pressure and Heart Rate Increases\n', '\n', '  CNS stimulants cause an  oselabeledaeclasseffect  oselabeledaefromdruguse in blood pressure (mean increase about 2-4 mm Hg) and  oselabeledaefromdruguse (mean increase about 3-6 bpm).",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
100,vyvanse,100,3883,3912,"Monitor all patients for potential  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication \n', '\n', '    5.4  oselabeledaeclasseffect \n', '    oselabeledaeclasseffect  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
101,vyvanse,101,3912,3961,"\n', '\n', ' CNS stimulants may  oselabeledaefromdruguse  oselabeledaeclasseffect behavior disturbance and  oselabeledaeclasseffect in patients with a pre-existing  notaecandidatepreexistingconditionorriskfactor \n', '\n', '     Induction of a Manic Episode in Patients with Bipolar Disorder    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
102,vyvanse,102,3961,3983,"\n', '\n', '  CNS stimulants may induce a  oselabeledaefromdruguse manic  oselabeledaefromdruguse  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,vyvanse,103,3983,4022,"Prior to initiating treatment, screen patients for risk factors for developing a  nonoseaeaeonlyasinstruction (e.g., comorbid or history of  notaecandidatepreexistingconditionorriskfactor or a family history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor .  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,vyvanse,104,4022,4063,"\n', '\n', '    New Psychotic or Manic Symptoms  \n', '\n', ' CNS stimulants, at recommended doses, may cause  oselabeledaeclasseffect or manic  oselabeledaeclasseffect  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,vyvanse,105,4063,4087,e.g.  oselabeledaeclasseffect   oselabeledaeclasseffect  or  oselabeledaeclasseffect in children and adolescents without a prior history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
106,vyvanse,106,4087,4096,"If such symptoms occur, consider discontinuing VYVANSE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,vyvanse,107,4096,4172,"In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants,  oselabeledaeclasseffect or manic  oselabeledaeclasseffect  oselabeledaeclasseffect occurred in 0.1% of CNS stimulant-treated patients compared to 0% in placebo-treated patients.\n', '\n', '    5.5  oselabeledaefromdruguse \n', '  CNS stimulants have been associated with  oselabeledaeclasseffect and  oselabeledaeclasseffect in pediatric patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,vyvanse,108,4172,4191,"Closely monitor growth (weight and height) in pediatric patients treated with CNS stimulants, including VYVANSE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,vyvanse,109,4191,4234,"In a 4-week, placebo-controlled trial of VYVANSE in patients ages 6 to 12 years old with  notaecandidateindication  there was a dose-related  oselabeledaefromdruguse in the VYVANSE groups compared to  nonoseaeaeonlyasinstruction in the placebo group.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
110,vyvanse,110,4234,4297,"Additionally, in studies of another stimulant, there was  nonoseaeaeforanotherdruginclass [see  Adverse Reactions (6.1)  ]  .\n', '\n', ""    5.6 Peripheral Vasculopathy, including Raynaud's Phenomenon\n"", '\n', '  Stimulants, including VYVANSE, are associated with  oselabeledaefromdruguse  including  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
111,vyvanse,111,4297,4351,"Signs and symptoms are usually intermittent and mild; however, very rare sequelae include  nonoseaemanifestationorcomplication and/or  nonoseaemanifestationorcomplication  Effects of  oselabeledaefromdruguse  including  oselabeledaefromdruguse  were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
112,vyvanse,112,4351,4365,Signs and symptoms generally improve after reduction in dose or discontinuation of drug.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,vyvanse,113,4365,4377,Careful observation for  nonoseaeaeonlyasinstruction is necessary during treatment with stimulants.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,vyvanse,114,4377,4494,"Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.\n', '\n', '    5.7 Serotonin Syndrome\n', '\n', ""    nonoseaeaefromdruginteraction  a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort [see  Drug Interactions (7.1)  ]  .",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
115,vyvanse,115,4494,4532,"Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism [see  Clinical Pharmacology 12.3  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,vyvanse,116,4532,4565,The potential for a pharmacokinetic interaction exists with the co-administration of CYP2D6 inhibitors which may increase the risk with increased exposure to the active metabolite of VYVANSE (dextroamphetamine).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,vyvanse,117,4565,4598,"In these situations, consider an alternative non-serotonergic drug or an alternative drug that does not inhibit CYP2D6 [see  Drug Interactions (7.1)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,vyvanse,118,4598,4669,"nonoseaeaeonlyasinstruction symptoms may include  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaemanifestationorcomplication   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction  and/or  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction .  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
119,vyvanse,119,4669,4699,"\n"", '\n', '  Concomitant use of VYVANSE with MAOI drugs is contraindicated [see  Contraindications (4)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,vyvanse,120,4699,4731,"\n', '\n', '  Discontinue treatment with VYVANSE and any concomitant serotonergic agents immediately if symptoms of  nonoseaeaeonlyasinstruction occur, and initiate supportive symptomatic treatment.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,vyvanse,121,4731,4755,Concomitant use of VYVANSE with other serotonergic drugs or CYP2D6 inhibitors should be used only if the potential benefit justifies the potential risk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,vyvanse,122,4755,4792,"If clinically warranted, consider initiating VYVANSE with lower doses, monitoring patients for the emergence of  nonoseaeaeonlyasinstruction during drug initiation or titration, and informing patients of the increased risk for  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,xarelto,0,0,129,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are also discussed in other sections of the labeling:\n', '\n', ' *  Increased risk of  nonoseaeodorwithdrawal after discontinuation in  notaecandidateindication [see  Boxed Warning  and  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse risk [see  Warnings and Precautions (5.2  ,  5.4  ,  5.5  ,  5.6  ,  5.7)  ]  \n', ' *   oselabeledaefromdruguse epidural  oselabeledaefromdruguse  oselabeledaefromdruguse [see  Boxed Warning  and  Warnings and Precautions (5.3)  ]  \n",0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
1,xarelto,1,129,136,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,xarelto,2,136,149,The most common adverse reaction (>5%) was bleeding.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,xarelto,3,149,154,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,xarelto,4,154,197,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,xarelto,5,197,226,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,xarelto,6,226,293,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' During clinical development for the approved indications, 18560 patients were exposed to XARELTO.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,xarelto,7,293,375,These included 7111 patients who received XARELTO 15 mg or 20 mg orally once daily for a mean of 19 months (5558 for 12 months and 2512 for 24 months) to reduce the risk of  notaecandidateindication and  notaecandidateindication in  notaecandidateindication (ROCKET AF); 6962 patients who received XARELTO 15 mg orally twice daily for three weeks followed by 20 mg orally once daily to treat  notaecandidateindication or  notaecandidateindication (EINSTEIN  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,xarelto,8,375,377,EINSTEIN  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,xarelto,9,377,403,"notaecandidateindication , 10 mg or 20 mg orally once daily (EINSTEIN Extension, EINSTEIN CHOICE) to reduce the risk of recurrence of  notaecandidateindication",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
10,xarelto,10,403,461,"and/or  notaecandidateindication  and 4487 patients who received XARELTO 10 mg orally once daily for prophylaxis of  notaecandidateindication following hip or knee replacement surgery (RECORD 1-3).\n', '\n', '    oselabeledaefromdruguse \n', ' The most common adverse reactions with XARELTO were  oselabeledaefromdruguse  [see  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
11,xarelto,11,461,525,"Warnings and Precautions (5.2)  ]  .\n', '\n', '      notaecandidateindication  \n', '\n', ' In the ROCKET  notaecandidateindication trial, the most frequent adverse reactions associated with permanent drug discontinuation were  oselabeledaefromdruguse events, with incidence rates of 4.3% for XARELTO vs. 3.1% for warfarin.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,xarelto,12,525,601,"The incidence of discontinuations for  nonoseaegeneralterm was similar in both treatment groups.\n', '\n', ' Table 1 shows the number of patients experiencing various types of  nonoseaeaeonlyasinstruction events in the ROCKET  notaecandidateindication trial.\n', '\n', ' Table 1: Bleeding Events in ROCKET AFMajor bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories.",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
13,xarelto,13,601,630,"These events occurred during treatment or within 2 days of stopping treatment.- On Treatment Plus 2 Days \n', ' Parameter                       XARELTON=7111n (%/year)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,xarelto,14,630,643,WarfarinN=7125n (%/year)  XARELTO vs. WarfarinHR(95% CI)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,xarelto,15,643,666,"\n', '  \n', ' Abbreviations: HR = Hazard Ratio, CI = Confidence interval, CRNM =",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,xarelto,16,666,673,Clinically Relevant Non-Major.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,xarelto,17,673,738,"\n', '  \n', ' Major  oselabeledaefromdruguse [note: Defined as clinically overt  oselabeledaefromdruguse associated with a  oselabeledaefromdruguse of >=2 g/dL, a transfusion of >=2 units of packed red blood cells or whole blood,  oselabeledaefromdruguse at a critical site, or with a fatal outcome.]          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,xarelto,18,738,755,"395 (3.6)                386 (3.5)            1.04 (0.90, 1.20)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,xarelto,19,755,802,"\n', '    oselabeledaefromdruguse  [note:  oselabeledaefromdruguse  oselabeledaefromdruguse events included  oselabeledaefromdruguse  oselabeledaefromdruguse events included intraparenchymal,  oselabeledaefromdruguse  oselabeledaefromdruguse events included intraparenchymal, intraventricular,  oselabeledaefromdruguse   oselabeledaefromdruguse and/or epidural  oselabeledaefromdruguse  oselabeledaefromdruguse ]          55",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,xarelto,20,802,818,"(0.5)                 84 (0.7)             0.67 (0.47, 0.93)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,xarelto,21,818,856,"\n', '      oselabeledaefromdruguse [note:  oselabeledaefromdruguse in this table specifically refers to non-traumatic  oselabeledaefromdruguse and/or intraventricular  oselabeledaefromdruguse  oselabeledaefromdruguse in patients on treatment plus 2 days.]          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,xarelto,22,856,873,"36 (0.3)                 58 (0.5)             0.63 (0.42, 0.96)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,xarelto,23,873,899,"\n', '     Other  oselabeledaefromdruguse                          19 (0.2)                 26 (0.2)             0.74 (0.41, 1.34)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,xarelto,24,899,934,"\n', '    oselabeledaefromdruguse  [note:  oselabeledaefromdruguse events included  oselabeledaefromdruguse  lower GI, and rectal  oselabeledaefromdruguse  oselabeledaefromdruguse  and rectal  oselabeledaefromdruguse  oselabeledaefromdruguse ]          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,xarelto,25,934,961,"221 (2.0)                140 (1.2)            1.61 (1.30, 1.99)       \n', '   Fatal  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,xarelto,26,961,980,[note: Fatal bleeding is adjudicated death with the primary cause of death from bleeding.]          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,xarelto,27,980,997,"27 (0.2)                 55 (0.5)             0.50 (0.31, 0.79)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,xarelto,28,997,1044,"\n', '     ICH                                24 (0.2)                 42 (0.4)             0.58 (0.35, 0.96)       \n', '      oselabeledaefromdruguse  oselabeledaefromdruguse is adjudicated death with the primary cause of death from  oselabeledaefromdruguse ]          27",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,xarelto,29,1044,1060,"(0.2)                 55 (0.5)             0.50 (0.31, 0.79)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,xarelto,30,1060,1067,"\n', '      oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,xarelto,31,1067,1084,"24 (0.2)                 42 (0.4)             0.58 (0.35, 0.96)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,xarelto,32,1084,1110,"\n', '     Non-intracranial                    3 (0.0)                 13 (0.1)             0.23 (0.07, 0.82)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,xarelto,33,1110,1166,"\n', '          Figure 1 shows the risk of major  nonoseaeaeonlyasinstruction events across major subgroups.\n', ' \n', '\n', '   Figure 1: Risk of Major Bleeding Events by Baseline Characteristics in ROCKET AF - On Treatment Plus 2 Days  \n', '\n",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,xarelto,34,1166,1194,"', ' \n', '\n', ' Note: The figure above presents effects in various subgroups all of which are baseline characteristics and",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,xarelto,35,1194,1223,"all of which were pre-specified ( nonoseaeaeonlyasinstruction status was not pre-specified in the subgroup, but was a criterion for the CHADS2 score).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,xarelto,36,1223,1259,"The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,xarelto,37,1259,1290,"Apparent homogeneity or heterogeneity among groups should not be over-interpreted.\n', '\n', '  Figure 1     Treatment of Deep Vein Thrombosis (DVT)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,xarelto,38,1290,1374,"and/or Pulmonary Embolism (PE)  \n', '\n', '   EINSTEIN  notaecandidateindication and EINSTEIN  notaecandidateindication Studies\n', '\n', ' In the pooled analysis of the EINSTEIN  notaecandidateindication and EINSTEIN  notaecandidateindication clinical studies, the most frequent adverse reactions leading to permanent drug discontinuation were  oselabeledaefromdruguse events, with XARELTO vs. enoxaparin/Vitamin K antagonist (VKA) incidence rates of 1.7% vs. 1.5%, respectively.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
39,xarelto,39,1374,1459,"The mean duration of treatment was 208 days for XARELTO-treated patients and 204 days for enoxaparin/VKA-treated patients.\n', '\n', ' Table 2 shows the number of patients experiencing major  nonoseaeaeonlyasinstruction events in the pooled analysis of the EINSTEIN  notaecandidateindication and EINSTEIN  notaecandidateindication studies.\n', '\n', ' Table 2: Bleeding EventsBleeding event occurred after randomization and up to 2 days after the last dose of study drug.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
40,xarelto,40,1459,1480,"Although a patient may have had 2 or more events, the patient is counted only once in a category.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,xarelto,41,1480,1503,"in the Pooled Analysis of EINSTEIN  notaecandidateindication and EINSTEIN  notaecandidateindication Studies \n', ' Parameter                                                     XARELTO [note:",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
42,xarelto,42,1503,1569,"Treatment schedule in EINSTEIN  notaecandidateindication and EINSTEIN  notaecandidateindication studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0-3.0)]] N=4130n (%)  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
43,xarelto,43,1569,1576,Enoxaparin/VKAN=4116n (%)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,xarelto,44,1576,1596,"\n', '  \n', ' Major  oselabeledaefromdruguse event                                                40 (1.0)              72",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,xarelto,45,1596,1641,"(1.7)         \n', '   Fatal  oselabeledaefromdruguse  oselabeledaefromdruguse                                                    3 (<0.1)              8 (0.2)          \n', '      oselabeledaefromdruguse                                                    2 (<0.1)              4 (<0.1)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,xarelto,46,1641,1673,"\n', '   Non-fatal critical organ  oselabeledaefromdruguse                                 10 (0.2)              29 (0.7)         \n', '      oselabeledaefromdruguse [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,xarelto,47,1673,1680,Treatment-emergent major  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,xarelto,48,1680,1828,"oselabeledaefromdruguse events with at least >2 subjects in any pooled treatment group]         3 (<0.1)              10 (0.2)         \n', '     Retroperitoneal                                                 1 (<0.1)              8 (0.2)          \n', '      oselabeledaefromdruguse  oselabeledaefromdruguse events with at least >2 subjects in any pooled treatment group]         3 (<0.1)              10 (0.2)         \n', '      oselabeledaefromdruguse  oselabeledaefromdruguse events with at least >2 subjects in any pooled treatment group]         3 (<0.1)              10 (0.2)         \n', '     Retroperitoneal                                                 1 (<0.1)              8 (0.2)          \n', '      oselabeledaefromdruguse cular                                                     3 (<0.1)              2 (<0.1)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,xarelto,49,1828,1838,"\n', '     Intra oselabeledaefromdruguse                                                    0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,xarelto,50,1838,1844,4 (<0.1)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,xarelto,51,1844,1907,"\n', '   Non-fatal non-critical organ  oselabeledaefromdruguse [note: Major  oselabeledaefromdruguse which is not fatal or in a critical organ, but resulting in a  oselabeledaefromdruguse and/or transfusion of >=2 units of whole blood or packed red blood cells]         27 (0.7)              37 (0.9)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,xarelto,52,1907,1932,"\n', '    oselabeledaefromdruguse                                          28 (0.7)              42 (1.0)         \n', '   Transfusion of >",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,xarelto,53,1932,1950,=2 units of whole blood or packed red blood cells        18 (0.4)              25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,xarelto,54,1950,1966,"(0.6)         \n', ' Clinically relevant non-major  oselabeledaefromdruguse                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,xarelto,55,1966,1969,357 (8.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,xarelto,56,1969,1985,")             357 (8.7)         \n', ' Any  oselabeledaefromdruguse                                                      1169",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,xarelto,57,1985,1994,(28.3)           1153 (28.0)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,xarelto,58,1994,2085,"\n', '             Reduction in the Risk of Recurrence of DVT and/or PE  \n', ' \n', '\n', '   EINSTEIN CHOICE Study\n', '\n', ' In the EINSTEIN CHOICE clinical study, the most frequent adverse reactions associated with permanent drug discontinuation were  oselabeledaefromdruguse events, with incidence rates of 1% for XARELTO 10 mg, 2% for XARELTO 20 mg, and 1% for acetylsalicylic acid (aspirin) 100 mg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,xarelto,59,2085,2164,"The mean duration of treatment was 293 days for XARELTO 10 mg-treated patients and 286 days for aspirin 100 mg-treated patients.\n', '\n', ' Table 3 shows the number of patients experiencing  nonoseaeaeonlyasinstruction events in the EINSTEIN CHOICE study.\n', '\n', ' Table 3: Bleeding EventsBleeding event occurred after the first dose and up to 2 days after the last dose of study drug.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,xarelto,60,2164,2185,"Although a patient may have had 2 or more events, the patient is counted only once in a category.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,xarelto,61,2185,2188,in EINSTEIN CHOICE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,xarelto,62,2188,2198,"\n', ' Parameter                                 XARELTO [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,xarelto,63,2198,2214,Treatment schedule: XARELTO 10 mg once daily or aspirin 100 mg once daily.],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,xarelto,64,2214,2220,10 mgN=1127n (%)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,xarelto,65,2220,2224,Acetylsalicylic Acid (aspirin)100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,xarelto,66,2224,2225,mgN=1131n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,xarelto,67,2225,2229,(%)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,xarelto,68,2229,2248,"\n', '  \n', ' Major  oselabeledaefromdruguse event                                 5 (0.4)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,xarelto,69,2248,2253,3 (0.3)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,xarelto,70,2253,2264,"\n', '   Fatal  oselabeledaefromdruguse                                        0                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,xarelto,71,2264,2270,1 (<0.1)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,xarelto,72,2270,2294,"\n', '   Non-fatal critical organ  oselabeledaefromdruguse                  2 (0.2)                         1 (<0.1)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,xarelto,73,2294,2348,"\n', '   Non-fatal non-critical organ  oselabeledaefromdruguse [note: Major  oselabeledaefromdruguse which is not fatal or in a critical organ, but resulting in a  oselabeledaefromdruguse and/or transfusion of >= 2 units of whole blood or packed red blood cells.]              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,xarelto,74,2348,2359,3 (0.3)                         1 (<0.1)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,xarelto,75,2359,2422,"\n', ' Clinically relevant non-major (CRNM)  oselabeledaefromdruguse [note:  oselabeledaefromdruguse which was clinically overt, did not meet the criteria for major  nonoseaeaeonlyasinstruction  but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or  nonoseaemanifestationorcomplication ]              22",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
76,xarelto,76,2422,2431,(2.0)                        20 (1.8)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,xarelto,77,2431,2631,"\n', ' Any  oselabeledaefromdruguse                                        151 (13.4)                      138 (12.2)             \n', '         In the EINSTEIN CHOICE study, there was an increased incidence of  oselabeledaefromdruguse  including major and CRNM  oselabeledaefromdruguse in the XARELTO 20 mg group compared to the XARELTO 10 mg or aspirin 100 mg groups.\n', ' \n', '\n', '     Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery  \n', '\n', ' In the RECORD clinical trials, the overall incidence rate of adverse reactions leading to permanent treatment discontinuation was 3.7% with XARELTO.\n', '\n', ' The rates of major  nonoseaeaeonlyasinstruction events and any  nonoseaeaeonlyasinstruction events observed in patients in the RECORD clinical trials are shown in Table 4.\n', '\n', ' Table 4: Bleeding EventsBleeding events occurring any time following the first dose of double-blind study medication (which may have been prior to administration of active drug) until two days after the last dose of double-blind study medication.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,xarelto,78,2631,2639,Patients may have more than one event.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,xarelto,79,2639,2647,in Patients Undergoing Hip or Knee Replacement Surgeries,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,xarelto,80,2647,2653,(RECORD 1-3),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,xarelto,81,2653,2666,"\n', '                                                   XARELTO 10 mg           Enoxaparin [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,xarelto,82,2666,2691,"Includes the placebo-controlled period for RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1-3)]    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,xarelto,83,2691,2715,"\n', '  \n', '   Total treated patients                           N=4487n (%)                     N=4524n (%)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,xarelto,84,2715,2726,"\n', '   Major  oselabeledaefromdruguse event                               14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,xarelto,85,2726,2735,(0.3)                        9 (0.2)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,xarelto,86,2735,2744,"\n', '     Fatal  oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,xarelto,87,2744,2752,1 (<0.1)                           0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,xarelto,88,2752,2796,"\n', '      oselabeledaefromdruguse into a critical organ                   2 (<0.1)                        3 (0.1)               \n', '      oselabeledaefromdruguse that required re-operation              7 (0.2)                         5 (0.1)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,xarelto,89,2796,2831,"\n', '     Extra-surgical site  oselabeledaefromdruguse requiring transfusion of >2 units of whole blood or packed cells             4 (0.1)                         1 (<0.1)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,xarelto,90,2831,2850,"\n', '   Any  oselabeledaefromdruguse event [note: Includes major  oselabeledaefromdruguse events]             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,xarelto,91,2850,2855,261 (5.8)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,xarelto,92,2855,2860,251 (5.6)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,xarelto,93,2860,2916,"\n', '   Hip Surgery Studies                              N=3281n (%)                     N=3298n (%)             \n', '   Major  oselabeledaefromdruguse event                               7 (0.2)                         3 (0.1)               \n', '     Fatal  oselabeledaefromdruguse                                   1 (<0.1)                           0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,xarelto,94,2916,2956,"\n', '      oselabeledaefromdruguse into a critical organ                   1 (<0.1)                        1 (<0.1)              \n', '      oselabeledaefromdruguse that required re-operation              2 (0.1)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,xarelto,95,2956,2962,1 (<0.1)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,xarelto,96,2962,3008,"\n', '     Extra-surgical site  oselabeledaefromdruguse requiring transfusion of >2 units of whole blood or packed cells             3 (0.1)                         1 (<0.1)              \n', '   Any  oselabeledaefromdruguse event                                201",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,xarelto,97,3008,3036,"(6.1)                       191 (5.8)              \n', '   Knee Surgery Study                               N=1206n (%)                     N=1226n (%)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,xarelto,98,3036,3051,"\n', '   Major  oselabeledaefromdruguse event                               7 (0.6)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,xarelto,99,3051,3056,6 (0.5)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,xarelto,100,3056,3067,"\n', '     Fatal  oselabeledaefromdruguse                                      0                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,xarelto,101,3067,3069,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,xarelto,102,3069,3090,"\n', '      oselabeledaefromdruguse into a critical organ                   1 (0.1)                         2 (0.2)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,xarelto,103,3090,3107,"\n', '      oselabeledaefromdruguse that required re-operation              5 (0.4)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,xarelto,104,3107,3112,4 (0.3)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,xarelto,105,3112,3143,"\n', '     Extra-surgical site  oselabeledaefromdruguse requiring transfusion of >2 units of whole blood or packed cells             1 (0.1)                            0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,xarelto,106,3143,3241,"\n', '   Any  oselabeledaefromdruguse event                                 60 (5.0)                        60 (4.9)              \n', '         Following XARELTO treatment, the majority of major  oselabeledaefromdruguse complications (>=60%) occurred during the first week after surgery.\n', ' \n', '\n', '   Other Adverse Reactions\n', '\n', '  nonoseaegeneralterm reported in >=1% of XARELTO-treated patients in the EINSTEIN  notaecandidateindication and EINSTEIN  notaecandidateindication studies are shown in Table",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
107,xarelto,107,3241,3313,"5.\n', '\n', ' Table 5: Other Adverse ReactionsAdverse reaction with Relative Risk >1.5 for XARELTO versus comparator Reported by >=1% of XARELTO-Treated Patients in EINSTEIN DVT and EINSTEIN PE Studies \n', ' Body SystemAdverse Reaction                                                                                \n', '  \n', '   EINSTEIN  notaecandidateindication Study                                            XARELTO 20 mgN=1718n (%)      ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
108,xarelto,108,3313,3320,Enoxaparin/VKAN=1711n (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,xarelto,109,3320,3358,"\n', '    nonoseaegeneralterm                                                                               \n', '    oselabeledaefromdruguse                                                    46 (2.7)              25 (1.5)         \n', '    nonoseaegeneralterm                                                     \n', '    oselabeledaefromdruguse                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,xarelto,110,3358,3373,"24 (1.4)              15 (0.9)         \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,xarelto,111,3373,3375,nonoseaegeneralterm                                                          ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
112,xarelto,112,3375,3405,"\n', '    oselabeledaefromdruguse                                                         50 (2.9)              31 (1.8)         \n', '    oselabeledaefromdruguse                                                      23 (1.3)              13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,xarelto,113,3405,3416,"(0.8)         \n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,xarelto,114,3416,3462,"\n', '    oselabeledaefromdruguse                                                         38 (2.2)              22 (1.3)         \n', '    nonoseaegeneralterm                                                                                    \n', '    oselabeledaefromdruguse                                                           24 (1.4)              11 (0.6)         \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
115,xarelto,115,3462,3474,oselabeledaefromdruguse                                                        20 (1.2)              10 (0.6)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,xarelto,116,3474,3499,"\n', '    oselabeledaefromdruguse                                                          28 (1.6)              18 (1.1)         \n', '   EINSTEIN  notaecandidateindication",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
117,xarelto,117,3499,3508,Study                                             XARELTO 20 mgN=2412n (%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,xarelto,118,3508,3515,Enoxaparin/VKAN=2405n (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,xarelto,119,3515,3518,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,xarelto,120,3518,3566,"'    nonoseaegeneralterm                                                                   \n', '    oselabeledaefromdruguse                                                          53 (2.2)              27 (1.1)         \n', '          nonoseaegeneralterm reported in >=1% of XARELTO-treated patients in RECORD 1-3 studies are shown in Table",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,xarelto,121,3566,3569,"6.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,xarelto,122,3569,3581,"' \n', '\n', ' Table 6:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,xarelto,123,3581,3675,"Other Adverse Drug ReactionsAdverse reaction occurring any time following the first dose of double-blind medication, which may have been prior to administration of active drug, until two days after the last dose of double-blind study medication Reported by >=1% of XARELTO-Treated Patients in RECORD 1-3 Studies \n', ' Body SystemAdverse Reaction                                   XARELTO10 mgN=4487n (%)  Enoxaparin [note: Includes the placebo-controlled period of RECORD 2, enoxaparin dosing was 40 mg once daily",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,xarelto,124,3675,3687,(RECORD 1-3)] N=4524n (%)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,xarelto,125,3687,3699,"\n', '  \n', '    nonoseaegeneralterm                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
126,xarelto,126,3699,3712,"\n', '    oselabeledaefromdruguse                                                  125 (2.8)              89",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,xarelto,127,3712,3723,"(2.0)         \n', '    nonoseaegeneralterm                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
128,xarelto,128,3723,3753,"\n', '    oselabeledaefromdruguse                                                 74 (1.7)              55 (1.2)         \n', '    oselabeledaefromdruguse                                                      52 (1.2)              32",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,xarelto,129,3753,3764,"(0.7)         \n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,xarelto,130,3764,3777,"\n', '    oselabeledaefromdruguse                                                           55 (1.2)              32",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,xarelto,131,3777,3812,"(0.7)         \n', '    nonoseaegeneralterm                                                                   \n', '    oselabeledaefromdruguse                                                          96 (2.1)              79 (1.8)         \n', '    oselabeledaefromdruguse                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
132,xarelto,132,3812,3822,63 (1.4)              40 (0.9)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,xarelto,133,3822,3833,"\n', '             Other clinical trial experience:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,xarelto,134,3833,3900,"In an investigational study of acute medically ill patients being treated with XARELTO 10 mg tablets, cases of  oselabeledaefromdruguse and  oselabeledaefromdruguse with  oselabeledaefromdruguse were observed.\n', ' \n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of XARELTO.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,xarelto,135,3900,3968,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,xarelto,136,3968,3986,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
137,xarelto,137,3986,4000,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,xarelto,138,4000,4008,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,xarelto,139,4008,4009,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,xarelto,140,4009,4020,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,xarelto,141,4020,4023,WARNING: (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,xarelto,142,4023,4046,"A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,xarelto,143,4046,4053,"\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,xarelto,144,4053,4075,"(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,xarelto,145,4075,4087,"\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,xarelto,146,4087,4096,WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,xarelto,147,4096,4114,"INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,xarelto,148,4114,4177,"', '   See full prescribing information for complete boxed warning  \n', '\n', '   (A)  Premature discontinuation of XARELTO increases the risk of thrombotic events  \n', '\n', '   Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,xarelto,149,4177,4224,"To reduce this risk, consider coverage with another anticoagulant if XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy (  2.3  ,   2.8  ,   5.1  ,   14.1  ).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,xarelto,150,4224,4229,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,xarelto,151,4229,4242,"', '   (B)  Spinal/epidural hematoma  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,xarelto,152,4242,4247,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,xarelto,153,4247,4272,"', '   Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,xarelto,154,4272,4298,"These hematomas may result in long-term or permanent paralysis (  5.2  ,   5.3  ,   6.2  ).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,xarelto,155,4298,4324,"\n', '\n', '   Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,xarelto,156,4324,4349,Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated (  5.3  ).  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,xarelto,157,4349,4404,"\n', '\n', ' \n', '\n', '    A. Premature discontinuation of XARELTO increases the risk of  nonoseaeodorwithdrawal  \n', '\n', '   Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of  nonoseaeodorwithdrawal  ",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
158,xarelto,158,4404,4430,"If anticoagulation with XARELTO is discontinued for a reason other than pathological  nonoseaeaeonlyasinstruction or completion of a course of therapy, consider coverage with another",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,xarelto,159,4430,4468,"anticoagulant   [see   Dosage and Administration (2.3  ,   2.8)  ,   Warnings and Precautions (5.1)  , and   Clinical Studies (14.1)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,xarelto,160,4468,4516,"\n', '\n', '     B. Spinal/epidural hematoma  \n', '\n', '    oselabeledaefromdruguse or spinal  oselabeledaefromdruguse  oselabeledaefromdruguse have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,xarelto,161,4516,4540,These  nonoseaeaeonlyasinstruction may result in long-term or permanent  nonoseaemanifestationorcomplication  Consider these risks when scheduling patients for spinal procedures.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
162,xarelto,162,4540,4689,"Factors that can increase the risk of developing  nonoseaeaeonlyasinstruction or spinal  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction in these patients include:  \n', '\n', ' *  use of indwelling epidural catheters \n', ' *  concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants \n', ' *  a history of traumatic or repeated epidural or spinal punctures \n', ' *  a history of spinal deformity or spinal surgery \n', ' *  optimal timing between the administration of XARELTO and neuraxial procedures is not known \n', '      [see   Warnings and Precautions (5.2  ,   5.3)   and   Adverse Reactions (6.2)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,xarelto,163,4689,4738,"\n', ' \n', '\n', '   Monitor patients frequently for signs and symptoms of  nonoseaemanifestationorcomplication  If  nonoseaeaeonlyasinstruction is noted, urgent treatment is necessary   [see   Warnings and Precautions (5.3)  ]  .  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
164,xarelto,164,4738,4743,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,xarelto,165,4743,4781,"', '   Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for  notaecandidateindication    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
166,xarelto,166,4781,4795,*  Risk of bleeding: XARELTO can cause serious and fatal bleeding.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,xarelto,167,4795,4804,Promptly evaluate signs and symptoms of blood loss.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,xarelto,168,4804,4809,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,xarelto,169,4809,4838,"\n', ' *  Pregnancy-related hemorrhage: Use XARELTO with caution in pregnant women due to the potential for obstetric hemorrhage and/or emergent delivery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,xarelto,170,4838,4847,Promptly evaluate signs and symptoms of blood loss.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,xarelto,171,4847,4871,"(  5.7  ) \n', ' *  Prosthetic heart valves: XARELTO use not recommended (  5.8  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,xarelto,172,4871,4877,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,xarelto,173,4877,4953,"', ' \n', '\n', '   5.1 Increased Risk of Thrombotic Events after Premature Discontinuation\n', '\n', '  Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of  nonoseaeodorwithdrawal  An increased rate of  nonoseaeodorwithdrawal was observed during the transition from XARELTO to warfarin in clinical trials in  notaecandidateindication patients.",0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
174,xarelto,174,4953,5094,"If XARELTO is discontinued for a reason other than pathological  nonoseaeaeonlyasinstruction or completion of a course of therapy, consider coverage with another anticoagulant [see  Dosage and Administration (2.3  ,  2.8)  and  Clinical Studies (14.1)  ]  .\n', '\n', '    5.2 Risk of Bleeding\n', '\n', '  XARELTO increases the risk of  oselabeledaefromdruguse and can cause serious or  nonoseaegeneralterm  oselabeledaefromdruguse  In deciding whether to prescribe XARELTO to patients at increased risk of  nonoseaeaeonlyasinstruction  the risk of  nonoseaeaeonlyasinstruction should be weighed against the risk of  nonoseaeaeonlyasinstruction \n', '\n', ' Promptly evaluate any signs or symptoms of  nonoseaeaeonlyasinstruction and consider the need for blood replacement.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
175,xarelto,175,5094,5104,Discontinue XARELTO in patients with active pathological  notaecandidatecontraindication  ,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
176,xarelto,176,5104,5147,"The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.\n', '\n', ' Concomitant use of other drugs that  nonoseaeaeonlyasinstruction increases the risk of  nonoseaeaefromdruginteraction  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
177,xarelto,177,5147,5231,"These include aspirin, P2Y12platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) [see  Drug Interactions (7.4)  ]  , selective serotonin reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors.\n', '\n', ' Concomitant use of drugs that are known combined P-gp and strong CYP3A4 inhibitors increases rivaroxaban exposure and may increase  nonoseaeaefromdruginteraction risk [see  Drug Interactions (7.2",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
178,xarelto,178,5231,5266,")  ]  .\n', '\n', '    Reversal of Anticoagulant Effect  \n', '\n', ' A specific antidote for rivaroxaban is not available.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,xarelto,179,5266,5292,"Because of high plasma protein binding, rivaroxaban is not expected to be dialyzable [see  Clinical Pharmacology (12.3)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,xarelto,180,5292,5308,Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,xarelto,181,5308,5330,Partial reversal of prothrombin time prolongation has been seen after administration of prothrombin complex concentrates (PCCs) in healthy volunteers.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,xarelto,182,5330,5501,"The use of other procoagulant reversal agents like activated prothrombin complex concentrate (APCC) or recombinant factor VIIa (rFVIIa) has not been evaluated.\n', '\n', '    5.3 Spinal/Epidural Anesthesia or Puncture\n', '\n', '  When  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor epidural  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or spinal puncture is employed, patients treated with anticoagulant agents for  notaecandidateindication are at risk of developing an  oselabeledaefromdruguse or spinal  oselabeledaefromdruguse  oselabeledaefromdruguse which can result in long-term or permanent  nonoseaemanifestationorcomplication [see  Boxed Warning  ]  .\n', '\n', ' To reduce the potential risk of  nonoseaeaeonlyasinstruction associated with the concurrent use of XARELTO and  nonoseaeaeonlyasinstruction or spinal anesthesia/ nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or spinal  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction anesthesia/ nonoseaeaeonlyasinstruction or spinal puncture, consider the pharmacokinetic profile of XARELTO [see  Clinical Pharmacology (12.3)  ]  .",1,0,1,1,1,0,0,0,0,0,0,0,0,0,0
183,xarelto,183,5501,5611,"Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of XARELTO is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.\n', '\n', ' An indwelling epidural or intrathecal catheter should not be removed before at least 2 half-lives have elapsed (i.e., 18 hours in young patients aged 20 to 45 years and 26 hours in elderly patients aged 60 to 76 years), after the last administration of XARELTO [see  Clinical Pharmacology (12.3)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,xarelto,184,5611,5630,The next XARELTO dose should not be administered earlier than 6 hours after the removal of the catheter.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,xarelto,185,5630,5741,"If traumatic puncture occurs, delay the administration of XARELTO for 24 hours.\n', '\n', ' Should the physician decide to administer anticoagulation in the context of  nonoseaeaeonlyasinstruction or spinal  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or spinal anesthesia/ nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction anesthesia/ nonoseaeaeonlyasinstruction or lumbar puncture, monitor frequently to detect any signs or symptoms of  nonoseaemanifestationorcomplication  such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and motor  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction ,  nonoseaemanifestationorcomplication and/or bladder  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  Instruct patients to immediately report if they experience any of the above signs or symptoms.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
186,xarelto,186,5741,5844,"If signs or symptoms of  nonoseaeaeonlyasinstruction are suspected, initiate urgent diagnosis and treatment including consideration for  nonoseaeaeonlyasinstruction even though such treatment may not prevent or reverse  nonoseaeaeonlyasinstruction \n', '\n', '    5.4 Use in Patients with Renal Impairment\n', '\n', '   Nonvalvular Atrial Fibrillation  \n', '\n', ' Periodically assess renal function as clinically indicated (i.e., more frequently in situations in which  nonoseaeaeonlyasinstruction  and adjust therapy accordingly [see  Dosage and Administration (2.4)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,xarelto,187,5844,5874,Consider dose adjustment or discontinuation of XARELTO in patients who develop  nonoseaeaeonlyasinstruction while on XARELTO [see  Use in Specific Populations (8.6)  ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,xarelto,188,5874,5912,"\n', '\n', '    Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE  \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,xarelto,189,5912,5960,"', '\n', ' Avoid the use of XARELTO in patients with  notaecandidatepreexistingconditionorriskfactor due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population [see  Use in Specific Populations (8.6)  ]  .\n',",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
190,xarelto,190,5960,6012,"'\n', '    Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery  \n', '\n', ' Avoid the use of XARELTO in patients with  notaecandidatepreexistingconditionorriskfactor due to an expected increase in rivaroxaban exposure and pharmacodynamic effects in this patient population.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
191,xarelto,191,6012,6056,Observe closely and promptly evaluate any signs or symptoms of  nonoseaemanifestationorcomplication in patients with  notaecandidatepreexistingconditionorriskfactor  Patients who develop  nonoseaeaeonlyasinstruction while on XARELTO should discontinue the treatment [see  Use in Specific Populations (8.6)  ].  ,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
192,xarelto,192,6056,6057,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,xarelto,193,6057,6080,"', '\n', '    5.5 Use in Patients with Hepatic Impairment\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,xarelto,194,6080,6139,"No clinical data are available for patients with severe  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Avoid use of XARELTO in patients with moderate ( notaecandidatepreexistingconditionorriskfactor  and severe ( notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or with any  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor associated with coagulopathy since drug exposure and  nonoseaeaeonlyasinstruction risk may be increased [see  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
195,xarelto,195,6139,6147,Use in Specific Populations (8.7)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,xarelto,196,6147,6151,]  .\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,xarelto,197,6151,6295,", '\n', '    5.6 Use with P-gp and Strong CYP3A4 Inhibitors or Inducers\n', '\n', '  Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A4 inhibitors [see  Drug Interactions (7.2)  ]  .\n', '\n', ' Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A4 inducers [see  Drug Interactions (7.3)  ]  .\n', '\n', '    5.7 Risk of  oselabeledaefromdruguse \n', '  In  notaecandidatepreexistingconditionorriskfactor women, XARELTO should be used only if the potential benefit justifies the potential  nonoseaeaeonlyasinstruction the mother and  nonoseaeaeonlyasinstruction  XARELTO dosing in  notaecandidatepreexistingconditionorriskfactor has not been studied.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
198,xarelto,198,6295,6312,The anticoagulant effect of XARELTO cannot be monitored with standard laboratory testing nor readily reversed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,xarelto,199,6312,6382,"Promptly evaluate any signs or symptoms suggesting  nonoseaemanifestationorcomplication (e.g., a  nonoseaemanifestationorcomplication hemoglobin and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or hematocrit,  nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication .\n', '\n', '    5.8 Patients with Prosthetic Heart Valves\n', '\n', '  The safety and efficacy of XARELTO have not been studied in patients with prosthetic heart valves.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
200,xarelto,200,6382,6410,"Therefore, use of XARELTO is not recommended in these patients.\n', '\n', '    5.9 Acute PE in Hemodynamically Unstable Patients or Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,xarelto,201,6410,6455,"Who Require Thrombolysis or Pulmonary Embolectomy\n', '\n', '  Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with  notaecandidatepreexistingconditionorriskfactor who present with  notaecandidatepreexistingconditionorriskfactor or who may receive  notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,benlysta,0,0,55,"['  6 ADVERSE REACTIONS\n', '\n', '  The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:\n', '\n', ' *      nonoseaegeneralterm  [ see Warnings and Precautions (  5.1  )]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
1,benlysta,1,55,59,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,benlysta,2,59,70,*     Serious  oselabeledaefromdruguse  [ see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,benlysta,3,70,77,(  5.2  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,benlysta,4,77,81,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,benlysta,5,81,94,*      oselabeledaefromdruguse  including  oselabeledaefromdruguse  [ see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,benlysta,6,94,101,(  5.3  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,benlysta,7,101,121,"\n', ' *      oselabeledaefromdruguse  [see Warnings and Precautions (  5.4  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,benlysta,8,121,125,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,benlysta,9,125,134,*      oselabeledaefromdruguse  [ see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,benlysta,10,134,141,(  5.5  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,benlysta,11,141,145,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,benlysta,12,145,154,*      oselabeledaefromdruguse  [ see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,benlysta,13,154,161,(  5.6  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,benlysta,14,161,166,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,benlysta,15,166,225,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', ' \n', '\n', '    EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,benlysta,16,225,268,"*    Common adverse reactions (>=5%): nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, and injection site reactions (subcutaneous administration).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,benlysta,17,268,277,"(  6.1  ,  6.2  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,benlysta,18,277,308,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-877-423-6597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,benlysta,19,308,371,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience with Intravenous Administration\n', '\n', '  The data described below reflect exposure to BENLYSTA administered intravenously plus standard therapy compared with placebo plus standard therapy in 2,133 patients in 3 controlled trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,benlysta,20,371,444,"Patients received BENLYSTA plus standard therapy at doses of 1 mg/kg (n = 673), 4 mg/kg (n = 111; Trial 1 only), or 10 mg/kg (n = 674), or placebo plus standard therapy (n = 675) intravenously over a 1-hour period on Days 0, 14, 28, and then every 28 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,benlysta,21,444,492,"In 2 of the trials (Trial 1 and Trial 3), treatment was given for 48 weeks, while in the other trial (Trial 2) treatment was given for 72 weeks  [see Clinical Studies (  14.1  )]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,benlysta,22,492,584,"Because there was no apparent dose-related increase in the majority of adverse events observed with BENLYSTA, the safety data summarized below are presented for the 3 intravenous doses pooled, unless otherwise indicated; the adverse reaction table displays the results for the recommended intravenous dose of 10 mg/kg compared with placebo.\n', '\n', ' The population had a mean age of 39 years (range: 18 to 75), 94% were female, and 52% were white.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,benlysta,23,584,668,"In these trials, 93% of patients treated with BENLYSTA plus standard therapy reported an adverse event compared with 92% treated with placebo plus standard therapy.\n', '\n', ' The most common serious adverse events were serious  oselabeledaefromdruguse (6.0% and 5.2% in the groups receiving BENLYSTA and placebo plus standard therapy, respectively), some of which were  nonoseaegeneralterm  [see Warnings and Precautions (  5.2  )]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,benlysta,24,668,670,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,benlysta,25,670,763,", '\n', ' The most commonly reported adverse events, occurring in >=5% of patients in clinical trials were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', ' The proportion of patients who discontinued treatment due to any adverse reaction during the controlled clinical trials was 6.2% for patients receiving BENLYSTA plus standard therapy and 7.1% for patients receiving placebo plus standard therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,benlysta,26,763,893,"The most common adverse reactions resulting in discontinuation of treatment (>=1% of patients receiving BENLYSTA or placebo) were  oselabeledaefromdruguse (1.6% BENLYSTA and 0.9% placebo),  nonoseaeaeratelteqplacebo (0.7% BENLYSTA and 1.2% placebo), and  nonoseaeaeratelteqplacebo (0.7% BENLYSTA and 1.0% placebo).\n', '\n', '   Table 1  lists adverse reactions, regardless of causality, occurring in at least 3% of patients with  notaecandidateindication who received BENLYSTA 10 mg/kg plus standard therapy and at an incidence at least 1% greater than that observed with placebo plus standard therapy in the 3 controlled studies.\n', '\n', ' Table 1.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
27,benlysta,27,893,949,"Incidence of Adverse Reactions Occurring in at Least 3% of Patients Treated with BENLYSTA 10 mg/kg plus Standard Therapy and at Least 1% More Frequently than in Patients Receiving Placebo plus Standard Therapy \n', '  Preferred Term                               BENLYSTA  10 mg/kg +  Standard Therapy(n =",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,benlysta,28,949,951,674)%    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,benlysta,29,951,956,Placebo +  Standard Therapy(n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,benlysta,30,956,959,= 675)%    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,benlysta,31,959,970,"\n', '   oselabeledaefromdruguse                                       15                             12                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,benlysta,32,970,988,"\n', '   oselabeledaefromdruguse                                     12                             9                            \n', '   oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,benlysta,33,988,990,10                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,benlysta,34,990,992,8                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,benlysta,35,992,1003,"\n', '   oselabeledaefromdruguse                              9                              7                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,benlysta,36,1003,1014,"\n', '   oselabeledaefromdruguse                                   9                              5                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,benlysta,37,1014,1025,"\n', '   oselabeledaefromdruguse                                     7                              5                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,benlysta,38,1025,1036,"\n', '   oselabeledaefromdruguse                            6                              4                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,benlysta,39,1036,1058,"\n', '   oselabeledaefromdruguse                                   5                              4                            \n', '   oselabeledaefromdruguse                                     5                              4                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,benlysta,40,1058,1059,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,benlysta,41,1059,1069,"', '   oselabeledaefromdruguse                                  5                              3                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,benlysta,42,1069,1080,"\n', '   oselabeledaefromdruguse                                     4                              3                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,benlysta,43,1080,1089,"\n', '   oselabeledaefromdruguse                                   4                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,benlysta,44,1089,1091,2                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,benlysta,45,1091,1100,"\n', '   oselabeledaefromdruguse                        3                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,benlysta,46,1100,1102,1                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,benlysta,47,1102,1149,"\n', '           6.2 Clinical Trials Experience with Subcutaneous Administration\n', '   The data described below reflect exposure to BENLYSTA administered subcutaneously plus standard therapy compared with placebo plus standard therapy in 836 patients in a controlled trial (Trial 4).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,benlysta,48,1149,1195,"In addition to standard therapy, patients received BENLYSTA 200 mg (n = 556) or placebo (n = 280) (2:1 randomization) once weekly for up to 52 weeks  [see Clinical Studies (  14.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,benlysta,49,1195,1232,".\n', '\n', ' The overall population had a mean age of 39 years (range: 18 to 77), 94% were female, and 60% were white.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,benlysta,50,1232,1261,"In the trial, 81% of patients treated with BENLYSTA plus standard therapy reported an adverse event compared with 84% treated with placebo plus standard therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,benlysta,51,1261,1343,"The proportion of patients who discontinued treatment due to any adverse reaction during the controlled clinical trial was 7.2% of patients receiving BENLYSTA plus standard therapy and 8.9% of patients receiving placebo plus standard therapy.\n', '\n', ' The safety profile observed for BENLYSTA administered subcutaneously plus standard therapy was consistent with the known safety profile of BENLYSTA administered intravenously plus standard therapy, with the exception of local  nonoseaenegation \n', '\n",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
52,benlysta,52,1343,1351,"', '   Injection Site Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,benlysta,53,1351,1400,"\n', '\n', ' In the clinical study for BENLYSTA administered subcutaneously, the frequency of  oselabeledaefromdruguse was 6.1% (34/556) for patients receiving BENLYSTA plus standard therapy and 2.5% (7/280) for patients receiving placebo plus standard therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,benlysta,54,1400,1472,"These  oselabeledaefromdruguse  oselabeledaefromdruguse reactions (most commonly pain,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions (most commonly pain, erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions (most commonly pain, erythema, hematoma,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions (most commonly  oselabeledaefromdruguse  oselabeledaefromdruguse reactions (most commonly pain, erythema, hematoma, pruritus, and  oselabeledaefromdruguse  were mild to moderate in severity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,benlysta,55,1472,1516,"The majority (94%) did not necessitate discontinuation of treatment.\n', '\n', '   6.3 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during postapproval use of BENLYSTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,benlysta,56,1516,1571,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' *     nonoseaegeneralterm  oselabeledaefromdruguse [see Warnings and Precautions (  5.3  )] .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,benlysta,57,1571,1582,"\n', '      6.4 Immunogenicity\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,benlysta,58,1582,1595,"As with all therapeutic proteins, there is potential for  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,benlysta,59,1595,1612,The detection of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,benlysta,60,1612,1659,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,benlysta,61,1659,1731,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction in other studies or to other products may be misleading.\n', '\n', ' In Trials 2 and 3 (intravenous dosing),  oselabeledaefromdruguse were detected in 4 of 563 (0.7%) patients receiving BENLYSTA 10 mg/kg and in 27 of 559 (4.8%)",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,benlysta,62,1731,1739,patients receiving BENLYSTA 1 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,benlysta,63,1739,1769,The reported frequency for the group receiving 10 mg/kg may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentrations.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,benlysta,64,1769,1783,oselabeledaefromdruguse were  oselabeledaefromdruguse in 3 patients receiving BENLYSTA 1 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,benlysta,65,1783,1817,Three patients with  oselabeledaefromdruguse experienced mild  oselabeledaefromdruguse of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  none of the reactions was life-threatening.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,benlysta,66,1817,1847,"In Trial 4 (subcutaneous dosing), there was no formation of  nonoseaenegation in 556 patients receiving BENLYSTA 200 mg during the 52-week placebo-controlled period.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
67,benlysta,67,1847,1880,"The clinical relevance of the presence of  nonoseaeaeonlyasinstruction is not known.\n', '\n', ' The data reflect the percentage of patients whose test results were  nonoseaeaeonlyasinstruction    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,benlysta,68,1880,1895,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,benlysta,69,1895,1917,*    Mortality: There were more deaths reported with BENLYSTA than with placebo during the controlled period of clinical trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,benlysta,70,1917,1931,"(  5.1  ) \n', ' *    Serious Infections:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,benlysta,71,1931,1948,"Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents, including BENLYSTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,benlysta,72,1948,1959,Use with caution in patients with severe or chronic infections.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,benlysta,73,1959,1975,Consider interrupting therapy with BENLYSTA if patients develop a new infection during treatment with BENLYSTA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,benlysta,74,1975,1980,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,benlysta,75,1980,1993,"\n', ' *    Progressive Multifocal Leukoencephalopathy (PML):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,benlysta,76,1993,2015,Patients presenting with new-onset or deteriorating neurological signs and symptoms should be evaluated for PML by an appropriate specialist.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,benlysta,77,2015,2029,"If PML is confirmed, consider discontinuation of immunosuppressant therapy, including BENLYSTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,benlysta,78,2029,2034,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,benlysta,79,2034,2046,"\n', ' *    Hypersensitivity Reactions, including Anaphylaxis:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,benlysta,80,2046,2054,Serious and fatal reactions have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,benlysta,81,2054,2069,BENLYSTA for intravenous use should be administered by healthcare providers prepared to manage anaphylaxis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,benlysta,82,2069,2085,Monitor patients during and for an appropriate period of time after intravenous administration of BENLYSTA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,benlysta,83,2085,2094,"(  2.1  ,  5.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,benlysta,84,2094,2113,"\n', ' *    Depression: Depression and suicidality have been reported in trials with BENLYSTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,benlysta,85,2113,2138,"Patients should be instructed to contact their healthcare provider if they experience new or worsening depression, suicidal thoughts, or other mood changes.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,benlysta,86,2138,2161,"(  5.5  ) \n', ' *    Immunization: Live vaccines should not be given concurrently with BENLYSTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,benlysta,87,2161,2215,"(  5.7  ) \n', '    \n', ' \n', '\n', '   5.1 Mortality\n', '\n', '  There were more  nonoseaegeneralterm reported with BENLYSTA than with placebo during the controlled period of the intravenous clinical trials.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
88,benlysta,88,2215,2296,"Out of 2,133 patients in 3 clinical trials, a total of 14  nonoseaegeneralterm occurred during the placebo-controlled, double-blind treatment periods: 3/675 (0.4%), 5/673 (0.7%), 0/111 (0%), and 6/674 (0.9%)  nonoseaegeneralterm in the groups receiving placebo, BENLYSTA 1 mg/kg, BENLYSTA 4 mg/kg, and BENLYSTA 10 mg/kg, respectively.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,benlysta,89,2296,2304,No single cause of  nonoseaegeneralterm predominated.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,benlysta,90,2304,2378,"Etiologies included  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction \n', '\n', '  In the controlled trial of BENLYSTA administered subcutaneously (N = 836), a total of 5  nonoseaegeneralterm occurred during the placebo-controlled, double-blind treatment period (0.7% [2/280] of patients receiving placebo and 0.5% [3/556] of patients receiving BENLYSTA).  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
91,benlysta,91,2378,2427,"nonoseaeaeonlyasinstruction was the most common cause of  nonoseaegeneralterm   \n', '\n', '    5.2 Serious Infections\n', '\n', '  Serious and sometimes  nonoseaegeneralterm  oselabeledaefromdruguse have been reported in patients receiving  nonoseaeaeonlyasinstruction  including BENLYSTA.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
92,benlysta,92,2427,2510,"Physicians should exercise caution when considering the use of BENLYSTA in patients with severe or chronic  notaecandidatepreexistingconditionorriskfactor  Consider interrupting therapy with BENLYSTA in patients who develop a new  nonoseaeaeonlyasinstruction while undergoing treatment with BENLYSTA and monitor these patients closely.\n', '\n', ' In the controlled clinical trials of BENLYSTA administered intravenously, the overall incidence of  oselabeledaefromdruguse was 71% in patients treated with BENLYSTA compared with 67% in patients who received placebo.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
93,benlysta,93,2510,2562,The most frequent  oselabeledaefromdruguse (>5% of patients receiving BENLYSTA) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  Serious  oselabeledaefromdruguse occurred in 6.0% of patients treated with BENLYSTA and in 5.2% of patients who received placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,benlysta,94,2562,2603,The most frequent serious  oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   nonoseaeaeratelteqplacebo leading to discontinuation of treatment occurred in 0.7% of patients receiving BENLYSTA and 1.0% of patients receiving placebo.  ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
95,benlysta,95,2603,2692,"oselabeledaefromdruguse resulting in  nonoseaegeneralterm occurred in 0.3% (4/1,458) of patients treated with BENLYSTA and in 0.1% (1/675) of patients receiving placebo.\n', '\n', '  In the controlled trial of BENLYSTA administered subcutaneously (N = 836), the overall incidence of  nonoseaeaeratelteqplacebo was 55% in patients treated with BENLYSTA compared with 57% in patients who received placebo (serious  nonoseaeaeratelteqplacebo  4.1% with BENLYSTA and 5.4% with placebo).",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
96,benlysta,96,2692,2713,The most commonly reported  nonoseaeaeonlyasinstruction with BENLYSTA administered subcutaneously were similar to those reported with BENLYSTA administered intravenously.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,benlysta,97,2713,2763,"\n', '\n', '   oselabeledaefromdruguse   \n', '\n', ' Cases of  oselabeledaefromdruguse  oselabeledaefromdruguse resulting in  nonoseaemanifestationorcomplication  including  nonoseaegeneralterm cases, have been reported in patients with  notaecandidateindication receiving  nonoseaeaeonlyasinstruction  including BENLYSTA.",1,1,0,1,1,0,0,0,0,0,0,0,0,0,0
98,benlysta,98,2763,2810,Risk factors for  nonoseaeaeonlyasinstruction include treatment with  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  Consider the diagnosis of  nonoseaeaeonlyasinstruction in any patient presenting with new-onset or deteriorating  nonoseaemanifestationorcomplication and symptoms and consult with a neurologist or other appropriate specialist as clinically indicated.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
99,benlysta,99,2810,2865,"In patients with confirmed  nonoseaeaeonlyasinstruction  consider stopping  nonoseaeaeonlyasinstruction  including BENLYSTA.\n', '\n', '    5.3 Hypersensitivity Reactions, including Anaphylaxis\n', '\n', '  Acute  oselabeledaefromdruguse  including  oselabeledaefromdruguse and  nonoseaegeneralterm  have been reported in association with BENLYSTA.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,benlysta,100,2865,2882,"These events generally occurred within hours of the infusion; however, they may occur later.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,benlysta,101,2882,2920,Non-acute  oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  have been reported and typically occurred up to a week following the most recent infusion.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,benlysta,102,2920,2938,"oselabeledaefromdruguse  including serious reactions, has occurred in patients who have previously tolerated infusions of BENLYSTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,benlysta,103,2938,3011,"Limited data suggest that patients with a history of multiple  notaecandidatepreexistingconditionorriskfactor or significant  notaecandidatepreexistingconditionorriskfactor may be at increased risk.\n', '\n', ' In the controlled clinical trials of BENLYSTA administered intravenously,  oselabeledaefromdruguse (occurring on the same day of infusion) were reported in 13% (191/1,458) of patients receiving BENLYSTA and 11% (76/675) of patients receiving placebo.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,benlysta,104,3011,3035,"oselabeledaefromdruguse was observed in 0.6% (9/1,458) of patients receiving BENLYSTA and 0.4% (3/675) of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,benlysta,105,3035,3088,"Manifestations included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or other  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Due to overlap in signs and symptoms, it was not possible to distinguish between  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction in all cases [see Warnings and Precautions (5.4)]  .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
106,benlysta,106,3088,3150,"Some patients (13%) received premedication, which may have mitigated or masked a  nonoseaeaeonlyasinstruction response; however, there is insufficient evidence to determine whether premedication diminishes the frequency or severity of  nonoseaeaeonlyasinstruction \n', '\n', ' BENLYSTA for intravenous use should be administered by healthcare providers prepared to manage  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,benlysta,107,3150,3171,"In the event of a serious reaction, administration of BENLYSTA must be discontinued immediately and appropriate medical therapy administered.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,benlysta,108,3171,3225,"Patients should be monitored during and for an appropriate period of time after intravenous administration of BENLYSTA.\n', '\n', '  In the controlled trial of BENLYSTA administered subcutaneously (N = 836), systemic  nonoseaeaeonlyasinstruction were similar to those observed in the intravenous clinical trials.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,benlysta,109,3225,3278,"\n', '\n', ' Patients receiving BENLYSTA should be informed of the signs and symptoms of  nonoseaeaeonlyasinstruction and be instructed to seek immediate medical care should a reaction occur.\n', '\n', '    5.4 Infusion Reactions\n', '\n', '  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,benlysta,110,3278,3323,"In the controlled clinical trials of BENLYSTA administered intravenously,  oselabeledaefromdruguse (occurring on the same day of the infusion) were reported in 17% (251/1,458) of patients receiving BENLYSTA and 15% (99/675) of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,benlysta,111,3323,3364,Serious  oselabeledaefromdruguse (excluding  nonoseaenegation  were reported in 0.5% of patients receiving BENLYSTA and 0.4% of patients receiving placebo and included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
112,benlysta,112,3364,3388,The most common  oselabeledaefromdruguse (>=3% of patients receiving BENLYSTA) were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,benlysta,113,3388,3422,"Due to overlap in signs and symptoms, it was not possible to distinguish between  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction in all cases [see Warnings and Precautions (5.3)]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,benlysta,114,3422,3468,"Some patients (13%) received premedication, which may have mitigated or masked an  nonoseaeaeonlyasinstruction  however, there is insufficient evidence to determine whether premedication diminishes the frequency or severity of  nonoseaeaeonlyasinstruction [see Adverse Reactions (6.1)]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,benlysta,115,3468,3492,".\n', '\n', ' BENLYSTA for intravenous use should be administered by healthcare providers prepared to manage  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,benlysta,116,3492,3619,"The infusion rate may be slowed or interrupted if the patient develops an  nonoseaeaeonlyasinstruction  Healthcare providers should be aware of the risk of  nonoseaeaeonlyasinstruction  which may present as  nonoseaeaeonlyasinstruction  and monitor patients closely.\n', '\n', '    5.5 Depression\n', '\n', '  In the controlled clinical trials of BENLYSTA administered intravenously,  oselabeledaefromdruguse were reported more frequently with BENLYSTA (16%) than with placebo (12%), related primarily to  oselabeledaefromdruguse (6.3% BENLYSTA and 4.7% placebo),  oselabeledaefromdruguse (6.0% BENLYSTA and 5.3% placebo), and  oselabeledaefromdruguse (3.9% BENLYSTA and 2.8% placebo).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,benlysta,117,3619,3655,"Serious  oselabeledaefromdruguse were reported in 0.8% of patients receiving BENLYSTA (0.6% and 1.2% with 1 and 10 mg/kg, respectively) and 0.4% of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,benlysta,118,3655,3681,"Serious  oselabeledaefromdruguse was reported in 0.4% (6/1,458) of patients receiving BENLYSTA and 0.1% (1/675) of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,benlysta,119,3681,3739,"Two  oselabeledaefromdruguse (0.1%) were reported in patients receiving BENLYSTA.\n', '\n', '  In the controlled trial of BENLYSTA administered subcutaneously (N = 836),  nonoseaeaeratelteqplacebo were reported in 6% of patients treated with BENLYSTA and in 11% of patients who received placebo.  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
120,benlysta,120,3739,3757,nonoseaeaeratelteqplacebo were reported in 2.7% of patients receiving BENLYSTA and 3.6% of patients receiving placebo.,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
121,benlysta,121,3757,3776,Serious  oselabeledaefromdruguse were reported in 0.2% of patients receiving BENLYSTA and in no patients receiving placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,benlysta,122,3776,3791,There were no serious  nonoseaenegation or  nonoseaenegation reported in either group.  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
123,benlysta,123,3791,3829,"\n', '\n', ' The majority of patients who reported serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction had a history of  notaecandidatepreexistingconditionorriskfactor or other serious  notaecandidatepreexistingconditionorriskfactor and most were receiving psychoactive medications.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
124,benlysta,124,3829,3953,"It is unknown if treatment with BENLYSTA is associated with increased risk for these events.\n', '\n', ' Patients receiving BENLYSTA should be instructed to contact their healthcare provider if they experience new or worsening  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or other  nonoseaeaeonlyasinstruction \n', '\n', '    5.6 Malignancy\n', '\n', '  The impact of treatment with BENLYSTA on the development of  nonoseaeaeonlyasinstruction is not known.\n', '\n', '  In the controlled clinical trials of BENLYSTA administered intravenously,  nonoseaeaeratelteqplacebo (including  nonoseaeaeratelteqplacebo  were reported in 0.4% of patients receiving BENLYSTA and 0.4% of patients receiving placebo.",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
125,benlysta,125,3953,3990,"In the intravenous controlled clinical trials,  nonoseaeaeratelteqplacebo  excluding  nonoseaeother  were observed in 0.2% (3/1,458) and 0.3% (2/675) of patients receiving BENLYSTA and placebo, respectively.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,1
126,benlysta,126,3990,4010,"In the controlled clinical trial of BENLYSTA administered subcutaneously (N = 836), the data were similar.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,benlysta,127,4010,4068,"The mechanism of action of BENLYSTA could increase the risk for the development of  oselabeledaefromdruguse   \n', '\n', '    5.7 Immunization\n', '\n', '  Live vaccines should not be given for 30 days before or concurrently with BENLYSTA as clinical safety has not been established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,benlysta,128,4068,4094,No data are available on the  nonoseaenegation from persons receiving live vaccines to patients receiving BENLYSTA or the effect of BENLYSTA on new immunizations.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
129,benlysta,129,4094,4107,"Because of its mechanism of action, BENLYSTA may  oselabeledaefromdruguse ']",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,furosemide,0,0,65,"['  ADVERSE REACTIONS\n', '\n', '  Adverse reactions are categorized below by organ system and listed by decreasing severity.\n', '\n', '    nonoseaegeneralterm  \n', '\n', ' *  1.   oselabeledaefromdruguse in patients with  notaecandidatepreexistingconditionorriskfactor \n', ' *  2.   oselabeledaefromdruguse",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
1,furosemide,1,65,74,"\n', ' *  3.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,furosemide,2,74,87,"oselabeledaefromdruguse ( oselabeledaefromdruguse  \n', ' *  4.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,furosemide,3,87,88,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,furosemide,4,88,97,"\n', ' *  5.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,furosemide,5,97,98,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,furosemide,6,98,114,"\n', ' *  6.   oselabeledaefromdruguse and gastric  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,furosemide,7,114,123,"\n', ' *  7.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,furosemide,8,123,124,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,furosemide,9,124,133,"\n', ' *  8.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,furosemide,10,133,134,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,furosemide,11,134,143,"\n', ' *  9.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,furosemide,12,143,144,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,furosemide,13,144,153,"\n', ' *  10.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,furosemide,14,153,154,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,furosemide,15,154,163,"\n', ' *  11.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,furosemide,16,163,164,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,furosemide,17,164,169,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,furosemide,18,169,171,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,furosemide,19,171,200,"\n', ' \n', '\n', ' *  1.  severe  oselabeledaefromdruguse or  oselabeledaefromdruguse (e.g. with  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,furosemide,20,200,209,"\n', ' *  2.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,furosemide,21,209,210,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,furosemide,22,210,219,"\n', ' *  3.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,furosemide,23,219,220,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,furosemide,24,220,229,"\n', ' *  4.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,furosemide,25,229,230,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,furosemide,26,230,235,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,furosemide,27,235,237,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,furosemide,28,237,267,"\n', ' \n', '\n', ' *  1.   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', ' *  2.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,furosemide,29,267,268,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,furosemide,30,268,277,"\n', ' *  3.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,furosemide,31,277,278,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,furosemide,32,278,287,"\n', ' *  4.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,furosemide,33,287,288,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,furosemide,34,288,297,"\n', ' *  5.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,furosemide,35,297,298,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,furosemide,36,298,307,"\n', ' *  6.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,furosemide,37,307,308,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,furosemide,38,308,317,"\n', ' *  7.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,furosemide,39,317,318,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,furosemide,40,318,323,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,furosemide,41,323,325,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,furosemide,42,325,352,"\n', ' \n', '\n', ' *  1.   oselabeledaefromdruguse \n', ' *  2.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,furosemide,43,352,353,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,furosemide,44,353,362,"\n', ' *  3.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,furosemide,45,362,363,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,furosemide,46,363,372,"\n', ' *  4.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,furosemide,47,372,373,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,furosemide,48,373,382,"\n', ' *  5.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,furosemide,49,382,383,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,furosemide,50,383,392,"\n', ' *  6.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,furosemide,51,392,393,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,furosemide,52,393,402,"\n', ' *  7.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,furosemide,53,402,403,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,furosemide,54,403,408,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,furosemide,55,408,410,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,furosemide,56,410,437,"\n', ' \n', '\n', ' *  1.   oselabeledaefromdruguse \n', ' *  2.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,furosemide,57,437,438,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,furosemide,58,438,447,"\n', ' *  3.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,furosemide,59,447,448,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,furosemide,60,448,457,"\n', ' *  4.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,furosemide,61,457,458,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,furosemide,62,458,467,"\n', ' *  5.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,furosemide,63,467,468,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,furosemide,64,468,477,"\n', ' *  6.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,furosemide,65,477,478,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,furosemide,66,478,487,"\n', ' *  7.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,furosemide,67,487,488,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,furosemide,68,488,497,"\n', ' *  8.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,furosemide,69,497,498,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,furosemide,70,498,507,"\n', ' *  9.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,furosemide,71,507,508,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,furosemide,72,508,517,"\n', ' *  10.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,furosemide,73,517,518,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,furosemide,74,518,527,"\n', ' *  11.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,furosemide,75,527,528,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,furosemide,76,528,537,"\n', ' *  12.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,furosemide,77,537,538,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,furosemide,78,538,543,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,furosemide,79,543,545,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
80,furosemide,80,545,575,"\n', ' \n', '\n', ' *  1.   oselabeledaefromdruguse may occur and be aggravated by alcohol, barbiturates or narcotics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,furosemide,81,575,584,"\n', ' *  2.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,furosemide,82,584,592,oselabeledaefromdruguse  oselabeledaefromdruguse cholesterol and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,furosemide,83,592,597,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,furosemide,84,597,599,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,furosemide,85,599,626,"\n', ' \n', '\n', ' *  1.   oselabeledaefromdruguse \n', ' *  2.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,furosemide,86,626,627,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,furosemide,87,627,636,"\n', ' *  3.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,furosemide,88,636,637,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,furosemide,89,637,646,"\n', ' *  4.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,furosemide,90,646,647,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,furosemide,91,647,656,"\n', ' *  5.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,furosemide,92,656,657,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,furosemide,93,657,666,"\n', ' *  6.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,furosemide,94,666,667,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,furosemide,95,667,676,"\n', ' *  7.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,furosemide,96,676,677,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,furosemide,97,677,686,"\n', ' *  8.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,furosemide,98,686,687,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,furosemide,99,687,696,"\n', ' *  9.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,furosemide,100,696,698,oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,furosemide,101,698,745,"PRECAUTIONS\n', '\n', '   General\n', '\n', '  Excessive  nonoseaeaeonlyasinstruction may cause  oselabeledaefromdruguse and  oselabeledaefromdruguse with  oselabeledaefromdruguse and possibly  oselabeledaefromdruguse  oselabeledaefromdruguse thrombosis and  oselabeledaefromdruguse  particularly in elderly patients.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,furosemide,102,745,772,"As with any effective  nonoseaeaeonlyasinstruction   oselabeledaefromdruguse may occur during furosemide therapy, especially in patients receiving higher doses and a restricted salt intake.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,furosemide,103,772,815,"oselabeledaefromdruguse may develop with furosemide, especially with brisk  nonoseaeaeonlyasinstruction  inadequate oral electrolyte intake, when  notaecandidatepreexistingconditionorriskfactor is present, or during concomitant use of corticosteroids, ACTH, licorice in large amounts, or prolonged use of laxatives.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,furosemide,104,815,828,Digitalis therapy may exaggerate metabolic effects of  nonoseaeaefromdruginteraction  especially  nonoseaeaefromdruginteraction,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
105,furosemide,105,828,871,"\n', '\n', ' All patients receiving furosemide therapy should be observed for these signs or symptoms of  nonoseaeaeonlyasinstruction or electrolyte  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ( nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication :  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
106,furosemide,106,871,891,nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaeaeonlyasinstruction pains or  nonoseaeaeonlyasinstruction   ,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
107,furosemide,107,891,903,nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
108,furosemide,108,903,1115,"nonoseaemanifestationorcomplication such as  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication   oselabeledaefromdruguse and  oselabeledaefromdruguse (with  oselabeledaefromdruguse and 2-hour postprandial  oselabeledaefromdruguse  oselabeledaefromdruguse the fasting and  oselabeledaefromdruguse  have been observed, and rarely, precipitation of  oselabeledaefromdruguse has been reported.\n', '\n', ' In patients with severe symptoms of  notaecandidatepreexistingconditionorriskfactor (because of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor , the administration of furosemide can cause  oselabeledaefromdruguse related to  nonoseaeaeonlyasinstruction and retention  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction production and  nonoseaeaeonlyasinstruction  Thus, these patients require careful monitoring, especially during the initial stages of treatment.\n', '\n', ' In patients at high risk for  notaecandidatepreexistingconditionorriskfactor furosemide can lead to a higher incidence of  nonoseaeaefromdruginteraction after receiving radiocontrast compared to high-risk patients who received only intravenous hydration prior to receiving radiocontrast.\n', '\n', ' In patients with  notaecandidatepreexistingconditionorriskfactor (e.g., associated with  notaecandidatepreexistingconditionorriskfactor  the effect of furosemide may be weakened and its  oselabeledaefromdruguse potentiated.\n', '\n', ' Asymptomatic  oselabeledaefromdruguse can occur and  oselabeledaefromdruguse may rarely be precipitated.\n', '\n', ' Patients  oselabeledaefromdruguse  ",1,0,1,0,1,1,0,0,0,0,0,0,0,0,0
109,furosemide,109,1115,1206,"The possibility exists of exacerbation or activation of  oselabeledaefromdruguse \n', '\n', ' As with many other drugs, patients should be observed regularly for the possible occurrence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction or kidney  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  or other  nonoseaeaeonlyasinstruction \n', '\n', '    Information for Patients\n', '\n', '  Patients receiving furosemide should be advised that they may experience symptoms from excessive  nonoseaeaeonlyasinstruction and/or electrolyte  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,furosemide,110,1206,1221,The  nonoseaeaeonlyasinstruction that sometimes occurs can usually be managed by getting up slowly.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,furosemide,111,1221,1262,"Potassium supplements and/or dietary measures may be needed to control or avoid  nonoseaeaeonlyasinstruction \n', '\n', ' Patients with  notaecandidatepreexistingconditionorriskfactor should be told that furosemide may  nonoseaeaeonlyasinstruction and thereby affect urine glucose tests.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
112,furosemide,112,1262,1346,"The  nonoseaeaeonlyasinstruction while taking furosemide.\n', '\n', '  notaecandidatepreexistingconditionorriskfactor patients should avoid medications that may  nonoseaeaeonlyasinstruction  including over-the-counter products for  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    Laboratory Tests\n', '\n', '  Serum electrolytes (particularly potassium), CO2, creatinine and BUN should be determined frequently during the first few months of furosemide therapy and periodically thereafter.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
113,furosemide,113,1346,1366,Serum and urine electrolyte determinations are particularly important when the patient is  nonoseaeaeonlyasinstruction profusely or receiving parenteral fluids.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,furosemide,114,1366,1376,Abnormalities should be corrected or the drug temporarily withdrawn.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,furosemide,115,1376,1479,"Other medications may also influence serum electrolytes.\n', '\n', ' Reversible  oselabeledaefromdruguse may occur and are associated with  oselabeledaefromdruguse  which should be avoided, particularly in patients with  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Urine and blood glucose should be checked periodically in  notaecandidatepreexistingconditionorriskfactor receiving furosemide, even in those suspected of latent  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Furosemide may  oselabeledaefromdruguse  oselabeledaefromdruguse calcium (rarely cases of tetany have been reported) and  oselabeledaefromdruguse  oselabeledaefromdruguse have been reported) and magnesium.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
116,furosemide,116,1479,1519,"Accordingly, serum levels of these electrolytes should be determined periodically.\n', '\n', ' In  notaecandidatepreexistingconditionorriskfactor furosemide may precipitate  oselabeledaefromdruguse  oselabeledaefromdruguse  therefore renal function must be monitored and renal ultrasonography performed.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
117,furosemide,117,1519,1524,(See   PRECAUTIONS:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,furosemide,118,1524,1528,Pediatric Use    ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,furosemide,119,1528,1651,"\n', '\n', '    Drug Interactions\n', '\n', '  Furosemide may increase the  nonoseaeaefromdruginteraction potential of aminoglycoside antibiotics, especially in the presence of  notaecandidatepreexistingconditionorriskfactor  Except in life-threatening situations, avoid this combination.\n', '\n', ' Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of  nonoseaeaefromdruginteraction  Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience  nonoseaeaefromdruginteraction at lower doses because of competitive renal excretory sites.\n', '\n', ' There is a risk of  nonoseaeaefromdruginteraction effects if cisplatin and furosemide are given concomitantly.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
120,furosemide,120,1651,1779,"In addition,  nonoseaeaefromdruginteraction of  nonoseaeaeonlyasinstruction such as cisplatin may be enhanced if furosemide is not given in lower doses and with  nonoseaeaeonlyasinstruction when used to achieve forced  nonoseaeaeonlyasinstruction during cisplatin treatment.\n', '\n', ' Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.\n', '\n', "" Lithium generally should not be given with  nonoseaeaeonlyasinstruction because they reduce lithium's renal clearance and add a high risk of  nonoseaeaefromdruginteraction \n"", '\n', ' Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
121,furosemide,121,1779,1831,"An interruption or reduction in the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary.\n', '\n', ' Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.\n', '\n', ' Furosemide may  nonoseaeaefromdruginteraction to norepinephrine.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
122,furosemide,122,1831,1866,"However, norepinephrine may still be used effectively.\n', '\n', ' Simultaneous administration of sucralfate and furosemide tablets may  nonoseaeaefromdruginteraction  nonoseaeaeonlyasinstruction the natriuretic and  nonoseaeaeonlyasinstruction of furosemide.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
123,furosemide,123,1866,1881,Patients receiving both drugs should be observed closely to determine if the desired  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,furosemide,124,1881,1889,and/or  nonoseaeaeonlyasinstruction of furosemide is achieved.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,furosemide,125,1889,1971,"The intake of furosemide and sucralfate should be separated by at least two hours.\n', '\n', ' In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  Use of furosemide concomitantly with chloral hydrate is, therefore, not recommended.\n', '\n', ' Phenytoin interferes directly with renal action of furosemide.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
126,furosemide,126,1971,2022,"There is evidence that treatment with phenytoin leads to decrease intestinal absorption of furosemide, and consequently to lower peak serum furosemide concentrations.\n', '\n', ' Methotrexate and other drugs that , like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,furosemide,127,2022,2037,"Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,furosemide,128,2037,2069,"High-dose treatment of both furosemide and these other drugs, may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the  nonoseaeaeonlyasinstruction",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,furosemide,129,2069,2199,"\n', '\n', ' Furosemide can increase the risk of  nonoseaeaefromdruginteraction even in the setting of minor or transient  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Concomitant use of cyclosporine and furosemide is associated with increased risk of  nonoseaeaefromdruginteraction secondary to furosemide-induced  oselabeledaefromdruguse and cyclosporine  nonoseaeaefromdruginteraction \n', '\n', ' High doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient  oselabeledaefromdruguse  followed by an overall  nonoseaemanifestationorcomplication \n', '\n', ' One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily  nonoseaeaefromdruginteraction in patients with  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,1,1,0,0,0,0,0,0,0,0,0
130,furosemide,130,2199,2280,"There are case reports of patients who developed  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction BUN,  nonoseaeaefromdruginteraction creatinine and serum  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction BUN,  nonoseaeaefromdruginteraction and serum potassium levels, and  nonoseaeaefromdruginteraction when furosemide was used in conjunction with NSAIDs.\n', '\n', ' Literature reports indicate that coadministration of indomethacin may  nonoseaeaefromdruginteraction and antihypertensive  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction the natriuretic and  nonoseaeaefromdruginteraction of furosemide in some patients by inhibiting prostaglandin synthesis.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
131,furosemide,131,2280,2296,"Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,furosemide,132,2296,2313,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,furosemide,133,2313,2363,"and/or  nonoseaeaeonlyasinstruction of furosemide is achieved.\n', '\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility\n', '\n', '  Furosemide was tested for  nonoseaeaeonlyasinstruction by oral administration in one strain of mice and one strain of rats.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,furosemide,134,2363,2389,A small but significantly increased incidence of  nonoseaeaeanimal occurred in female mice at a dose 17.5 times the maximum human dose of 600 mg.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
135,furosemide,135,2389,2472,"There were marginal increases in uncommon  nonoseaeaeanimal in male rats at a dose of 15 mg/kg (slightly greater than the maximum human dose) but not at 30 mg/kg.\n', '\n', ' Furosemide was devoid of  nonoseaeaeanimal activity in various strains of Salmonella typhimurium  when tested in the presence or absence of an in vitro  metabolic activation system, and questionably  nonoseaeaeanimal S9 at the highest dose tested.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
136,furosemide,136,2472,2501,"Furosemide did not induce  nonoseaeaeanimal in human cells in vitro,  but other studies on  nonoseaeaeonlyasinstruction in human cells in vitro  gave conflicting results.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
137,furosemide,137,2501,2529,In Chinese hamster cells it induced  nonoseaeaeanimal but was questionably  nonoseaeaeonlyasinstruction  Studies on the induction by furosemide of  nonoseaeaeonlyasinstruction in mice were inconclusive.,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
138,furosemide,138,2529,2568,"The urine of rats treated with this drug did not  nonoseaeaeanimal   \n', '\n', ' Furosemide produced  nonoseaeaeanimal in male or female rats, at 100 mg/kg/day (",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
139,furosemide,139,2568,2644,"the maximum effective  nonoseaeaeonlyasinstruction dose in the rat and 8 times the maximal human dose of 600 mg/day).\n', '\n', '    Pregnancy\n', '\n', '   Pregnancy Category C\n', '\n', '  Furosemide has been shown to cause unexplained  nonoseaeaeanimal and  nonoseaeaeanimal in rabbits at 2, 4 and 8 times the maximal recommended human dose.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
140,furosemide,140,2644,2658,There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
141,furosemide,141,2658,2771,"Furosemide should be used during  notaecandidatepreexistingconditionorriskfactor only if the potential benefit justifies the potential  nonoseaeaeonlyasinstruction \n', '\n', ' Treatment during  notaecandidatepreexistingconditionorriskfactor requires monitoring of fetal growth because of the potential for  oselabeledaefromdruguse \n', '\n', ' The effects of furosemide on embryonic and fetal development and on  nonoseaeaeanimal dams were studied in mice, rats and rabbits.\n', '\n', ' Furosemide caused unexplained  nonoseaeaeanimal and  nonoseaeaeanimal in the rabbit at the lowest dose of 25 mg/kg (2 times the maximal recommended human dose of 600 mg/day).",1,0,1,0,0,0,0,0,1,0,0,0,0,0,0
142,furosemide,142,2771,2815,"In another study, a dose of 50 mg/kg (4 times the maximal recommended human dose of 600 mg/day) also caused  nonoseaeaeanimal and  nonoseaeaeanimal when administered to rabbits between Days 12 and 17 of gestation.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
143,furosemide,143,2815,2835,"In a third study, none of the  nonoseaeaeanimal rabbits survived a dose of 100 mg/kg.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
144,furosemide,144,2835,3015,"Data from the above studies indicate  nonoseaeaeanimal that can precede  nonoseaeaeanimal \n', '\n', ' The results of the mouse study and one of the three rabbit studies also showed an increased incidence and severity of  nonoseaeaeanimal (distention of the renal pelvis and,  nonoseaeaeanimal some cases, of the ureters) in  nonoseaeaeanimal  nonoseaeaeanimal and,  nonoseaeaeanimal some cases, of the ureters) in  nonoseaeaeanimal  nonoseaeaeanimal the renal pelvis and, in some cases, of the  nonoseaeaeanimal   nonoseaeaeanimal derived from the treated dams as compared with the incidence in fetuses from the control group.\n', '\n', '    Nursing Mothers\n', '\n', '  Because it appears in breast milk, caution should be exercised when furosemide is administered to a nursing mother.\n', '\n', ' Furosemide may  oselabeledaefromdruguse \n', '\n', '    Pediatric Use\n', '\n', '  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
145,furosemide,145,3015,3025,In  notaecandidatepreexistingconditionorriskfactor furosemide may precipitate  oselabeledaefromdruguse  oselabeledaefromdruguse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
146,furosemide,146,3025,3062,"\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse has also been observed in children under 4 years of age with no history of  notaecandidatepreexistingconditionorriskfactor who have been treated chronically with furosemide.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
147,furosemide,147,3062,3082,"Monitor renal function, and renal ultrasonography should be considered, in pediatric patients receiving furosemide.\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,furosemide,148,3082,3109,"', ' If furosemide is administered to  notaecandidatepreexistingconditionorriskfactor during the first weeks of life, it may increase the risk of persistence of  oselabeledaefromdruguse",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
149,furosemide,149,3109,3121,"\n', '\n', '    Geriatric Use\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,furosemide,150,3121,3154,", '\n', '  Controlled clinical studies of furosemide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,furosemide,151,3154,3171,Other reported clinical experience has not identified differences in responses between the elderly and younger patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,furosemide,152,3171,3311,"In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of  notaecandidatepreexistingconditionorriskfactor  renal or cardiac  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  hepatic,  notaecandidatepreexistingconditionorriskfactor or cardiac  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor hepatic, renal or  notaecandidatepreexistingconditionorriskfactor  and of concomitant disease or other drug therapy.\n', '\n', ' This drug is known to be substantially excreted by the kidney, and the risk of  nonoseaeaeonlyasinstruction to this drug may be greater in patients with  notaecandidatepreexistingconditionorriskfactor  Because elderly patients are more likely to have  notaecandidatepreexistingconditionorriskfactor    WARNINGS\n', '\n', '  In patients with  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor  furosemide therapy is best initiated in the hospital.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
153,furosemide,153,3311,3333,In  notaecandidatepreexistingconditionorriskfactor and in states of  notaecandidatepreexistingconditionorriskfactor  therapy should not be instituted until the basic condition is improved.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
154,furosemide,154,3333,3440,"Sudden  nonoseaeaeonlyasinstruction and electrolyte  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction fluid and  nonoseaeaeonlyasinstruction in patients with  notaecandidatepreexistingconditionorriskfactor may precipitate  nonoseaeaeonlyasinstruction  therefore, strict observation is necessary during the period of  nonoseaeaeonlyasinstruction  Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication \n', '\n', ' If increasing  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction occur during treatment of severe progressive  notaecandidatepreexistingconditionorriskfactor  furosemide should be discontinued.\n', '\n', ' Cases of  oselabeledaefromdruguse and reversible or  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
155,furosemide,155,3440,3484,"Reports usually indicate that furosemide  oselabeledaefromdruguse is associated with rapid injection, severe  notaecandidatepreexistingconditionorriskfactor  the use of higher than recommended doses,  notaecandidatepreexistingconditionorriskfactor  or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other  nonoseaeaeonlyasinstruction ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,janumet,0,0,58,"['  6 ADVERSE REACTIONS\n', '\n', '   EXCERPT:    *  The most common adverse reactions reported in >=5% of patients simultaneously started on sitagliptin and metformin and more commonly than in patients treated with placebo were diarrhea, upper respiratory tract infection, and headache.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,janumet,1,58,63,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,janumet,2,63,108,"\n', ' *  Adverse reactions reported in >=5% of patients treated with sitagliptin in combination with sulfonylurea and metformin and more commonly than in patients treated with placebo in combination with sulfonylurea and metformin were hypoglycemia and headache.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,janumet,3,108,113,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,janumet,4,113,158,"\n', ' *  Hypoglycemia was the only adverse reaction reported in >=5% of patients treated with sitagliptin in combination with insulin and metformin and more commonly than in patients treated with placebo in combination with insulin and metformin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,janumet,5,158,163,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,janumet,6,163,208,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,janumet,7,208,241,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,janumet,8,241,395,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '     Sitagliptin and Metformin Coadministration in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise  \n', '\n', ' Table 1 summarizes the most common (>=5% of patients) adverse reactions reported (regardless of investigator assessment of causality) in a 24-week placebo-controlled factorial study in which sitagliptin and metformin were coadministered to patients with  notaecandidateindication inadequately controlled on diet and exercise.\n', '\n', ' Table 1: Sitagliptin and Metformin Coadministered to Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
9,janumet,9,395,400,: Adverse Reactions Reported (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,janumet,10,400,431,Regardless of Investigator Assessment of Causality) in >=5% of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Placebo)Intent-to-treat population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,janumet,11,431,458,"\n', '                               Number of Patients (%)   \n', '                                   Placebo      Sitagliptin 100 mg once daily  Metformin 500",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,janumet,12,458,459,mg/,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,janumet,13,459,483,Metformin 1000 mg twice daily [note: Data pooled for the patients given the lower and higher doses of metformin.]   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,janumet,14,483,489,Sitagliptin 50 mg twice daily +,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,janumet,15,489,492,Metformin 500 mg/,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,janumet,16,492,499,Metformin 1000 mg twice daily   \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,janumet,17,499,509,"', '                                   N = 176          N =",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,janumet,18,509,605,"179             N = 364                N = 372          \n', '  \n', '  oselabeledaefromdruguse                          7 (4.0)          5 (2.8)            28 (7.7)               28 (7.5)          \n', '  oselabeledaefromdruguse      9 (5.1)          8 (4.5)            19 (5.2)               23 (6.2)          \n', '  oselabeledaefromdruguse                          5 (2.8)          2 (1.1)            14 (3.8)               22 (5.9)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,janumet,19,605,639,"\n', '               Sitagliptin Add-on Therapy in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Alone  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,janumet,20,639,689,"In a 24-week placebo-controlled trial of sitagliptin 100 mg administered once daily added to a twice daily metformin regimen, there were no adverse reactions reported regardless of investigator assessment of causality in >=5% of patients and more commonly than in patients given placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,janumet,21,689,764,"Discontinuation of therapy due to clinical adverse reactions was similar to the placebo treatment group (sitagliptin and metformin, 1.9%; placebo and metformin, 2.5%).\n', '\n', '     Gastrointestinal Adverse Reactions  \n', '\n', ' The incidences of pre-selected  oselabeledaefromdruguse in patients treated with sitagliptin and metformin were similar to those reported for patients treated with metformin alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,janumet,22,764,787,"See  Table 2  .\n', '\n', ' Table 2: Pre-selected Gastrointestinal Adverse Reactions (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,janumet,23,787,794,Regardless of Investigator Assessment of Causality),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,janumet,24,794,863,"Reported in Patients with Type 2 Diabetes Receiving Sitagliptin and Metformin \n', '               Number of Patients (%)   \n', '               Study of Sitagliptin and Metformin in Patients Inadequately Controlled on Diet and Exercise  Study of Sitagliptin Add-on in Patients Inadequately Controlled on Metformin Alone   \n', '                 Placebo    Sitagliptin 100 mg once daily   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,janumet,25,863,865,Metformin 500,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,janumet,26,865,866,mg/,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,janumet,27,866,890,Metformin 1000 mg twice daily [note: Data pooled for the patients given the lower and higher doses of metformin.]   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,janumet,28,890,896,Sitagliptin 50 mg twice daily +,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,janumet,29,896,899,Metformin 500 mg/,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,janumet,30,899,909,Metformin 1000 mg twice daily  Placebo and Metformin >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,janumet,31,909,956,"=1500 mg daily  Sitagliptin 100 mg once daily and Metformin >=1500 mg daily   \n', '                N = 176      N = 179        N = 364            N = 372            N = 237           N = 464         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,janumet,32,956,1006,"\n', '  \n', '  oselabeledaefromdruguse       7 (4.0)      5 (2.8)        28 (7.7)          28 (7.5)            6 (2.5)           11 (2.4)        \n', '  oselabeledaefromdruguse         2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,janumet,33,1006,1026,(1.1)      2 (1.1)        20 (5.5)          18 (4.8)            2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,janumet,34,1026,1078,"(0.8)           6 (1.3)         \n', '  oselabeledaefromdruguse       1 (0.6)      0 (0.0)        2 (0.5)            8 (2.2)            2 (0.8)           5 (1.1)         \n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,janumet,35,1078,1100,[note:  oselabeledaefromdruguse was included in the analysis of  oselabeledaefromdruguse in the study of initial therapy.]    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,janumet,36,1100,1105,4 (2.3)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,janumet,37,1105,1110,6 (3.4)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,janumet,38,1110,1135,"14 (3.8)          11 (3.0)            9 (3.8)           10 (2.2)        \n', '                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,janumet,39,1135,1355,"Sitagliptin in Combination with Metformin and Glimepiride  \n', ' \n', '\n', ' In a 24-week placebo-controlled study of sitagliptin 100 mg as add-on therapy in patients with  notaecandidateindication inadequately controlled on metformin and glimepiride (sitagliptin, N=116; placebo, N=113), the adverse reactions reported regardless of investigator assessment of causality in >=5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were:  oselabeledaefromdruguse (Table 3) and  oselabeledaefromdruguse (6.9%, 2.7%).\n', '\n', '     Sitagliptin in Combination with Metformin and Rosiglitazone  \n', '\n', ' In a placebo-controlled study of sitagliptin 100 mg as add-on therapy in patients with  notaecandidateindication inadequately controlled on metformin and rosiglitazone (sitagliptin, N=181; placebo, N=97), the adverse reactions reported regardless of investigator assessment of causality through Week 18 in >=5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were:  oselabeledaefromdruguse (sitagliptin, 5.5%; placebo, 5.2%) and  oselabeledaefromdruguse (6.1%, 4.1%).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
40,janumet,40,1355,1527,"Through Week 54, the adverse reactions reported regardless of investigator assessment of causality in >=5% of patients treated with sitagliptin and more commonly than in patients treated with placebo were:  oselabeledaefromdruguse (sitagliptin, 15.5%; placebo, 6.2%),  oselabeledaefromdruguse (11.0%, 9.3%),  oselabeledaefromdruguse (8.3%, 5.2%), and  oselabeledaefromdruguse (5.5%, 4.1%).\n', '\n', '     Sitagliptin in Combination with Metformin and Insulin  \n', '\n', ' In a 24-week placebo-controlled study of sitagliptin 100 mg as add-on therapy in patients with  notaecandidateindication inadequately controlled on metformin and insulin (sitagliptin, N=229; placebo, N=233), the only adverse reaction reported regardless of investigator assessment of causality in >=5% of patients treated with sitagliptin and more commonly than in patients treated with placebo was  oselabeledaefromdruguse (",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
41,janumet,41,1527,1539,"Table 3).\n', '\n', '     Hypoglycemia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,janumet,42,1539,1593,"\n', '\n', ' In all (N=5) studies, adverse reactions of  nonoseaeaeonlyasinstruction were based on all reports of symptomatic  nonoseaeaeonlyasinstruction  a concurrent glucose measurement was not required although most (77%) reports of  oselabeledaefromdruguse were accompanied by a  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,janumet,43,1593,1639,"When the combination of sitagliptin and metformin was coadministered with a sulfonylurea or with insulin, the percentage of patients reporting at least one adverse reaction of  nonoseaeaefromdruginteraction was higher than that observed with placebo and metformin coadministered with a sulfonylurea or with insulin (",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
44,janumet,44,1639,1687,"Table 3).\n', '\n', ' Table 3: Incidence and Rate of  oselabeledaefromdruguse dverse reactions of  nonoseaeaeonlyasinstruction were based on all reports of symptomatic  oselabeledaefromdruguse  a concurrent glucose measurement was not required: Intent-to-treat population.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,janumet,45,1687,1730,"(Regardless of Investigator Assessment of Causality) in Placebo-Controlled Clinical Studies of Sitagliptin in Combination with Metformin Coadministered with Glimepiride or Insulin \n', '   Add-On to Glimepiride + Metformin  (24 weeks)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,janumet,46,1730,1757,"Sitagliptin 100 mg + Metformin + Glimepiride      Placebo + Metformin + Glimepiride     \n', '                                                   N = 116                           N = 113                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,janumet,47,1757,1790,"\n', '   Overall (%)                                    19 (16.4)                          1 (0.9)                \n', '   Rate (episodes/patient-year)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,janumet,48,1790,1814,"[note: Based on total number of events (i.e., a single patient may have had multiple events).]                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,janumet,49,1814,1818,0.82                              0.02                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,janumet,50,1818,1855,"\n', '   Severe (%) [note: Severe events of  nonoseaegeneralterm were defined as those events requiring medical assistance or exhibiting  oselabeledaefromdruguse  oselabeledaefromdruguse or  oselabeledaefromdruguse ]               0",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,janumet,51,1855,1864,(0.0)                           0 (0.0)                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,janumet,52,1864,1929,"\n', '   Add-On to Insulin + Metformin  (24 weeks)    Sitagliptin 100 mg + Metformin + Insulin      Placebo + Metformin + Insulin     \n', '                                                   N = 229                           N = 233                \n', '   Overall (%)                                    35 (15.3)                          19 (8.2)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,janumet,53,1929,1958,"\n', '   Rate (episodes/patient-year)                      0.98                              0.61                 \n', '   Severe (%)                                      1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,janumet,54,1958,1962,(0.4)                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,janumet,55,1962,1963,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,janumet,56,1963,1967,(0.4)                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,janumet,57,1967,2029,"\n', '         The overall incidence of reported adverse reactions of  oselabeledaefromdruguse in patients with  notaecandidateindication inadequately controlled on diet and exercise was 0.6% in patients given placebo, 0.6% in patients given sitagliptin alone, 0.8% in patients given metformin alone, and 1.6% in patients given sitagliptin in combination with metformin.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
58,janumet,58,2029,2126,"In patients with  notaecandidateindication inadequately controlled on metformin alone, the overall incidence of adverse reactions of  nonoseaeaeratelteqplacebo was 1.3% in patients given add-on sitagliptin and 2.1% in patients given add-on placebo.\n', ' \n', '\n', ' In the study of sitagliptin and add-on combination therapy with metformin and rosiglitazone, the overall incidence of  oselabeledaefromdruguse was 2.2% in patients given add-on sitagliptin and 0.0% in patients given add-on placebo through Week 18.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
59,janumet,59,2126,2315,"Through Week 54, the overall incidence of  oselabeledaefromdruguse was 3.9% in patients given add-on sitagliptin and 1.0% in patients given add-on placebo.\n', '\n', '     Vital Signs and Electrocardiograms  \n', '\n', ' With the combination of sitagliptin and metformin, no clinically meaningful  nonoseaenegation  nonoseaenegation vital signs or in  nonoseaenegation  nonoseaenegation vital signs or in ECG (including in  nonoseaenegation  were observed.\n', '\n', '     Pancreatitis  \n', '\n', ' In a pooled analysis of 19 double-blind clinical trials that included data from 10,246 patients randomized to receive sitagliptin 100 mg/day (N=5429) or corresponding (active or placebo) control (N=4817), the incidence of  oselabeledaefromdruguse was 0.1 per 100 patient-years in each group (4 patients with an event in 4708 patient-years for sitagliptin and 4 patients with an event in 3942 patient-years for control).  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
60,janumet,60,2315,2328,[See  Warnings and Precautions (5.2)  .]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,janumet,61,2328,2344,"\n', '\n', '     Sitagliptin  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,janumet,62,2344,2380,"', ' The most common adverse experience in sitagliptin monotherapy reported regardless of investigator assessment of causality in >=5% of patients and more commonly than in patients given placebo was  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,janumet,63,2380,2392,"\n', '\n', '     Metformin hydrochloride  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,janumet,64,2392,2425,"\n', '\n', ' The most common (>5%) established adverse reactions due to initiation of metformin therapy are  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,janumet,65,2425,2431,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,janumet,66,2431,2436,oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,janumet,67,2436,2448,"\n', '\n', '     Laboratory Tests  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,janumet,68,2448,2464,"\n', '\n', '     Sitagliptin  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,janumet,69,2464,2498,"', ' The incidence of  nonoseaegeneralterm was similar in patients treated with sitagliptin and metformin (7.6%) compared to patients treated with placebo and metformin (8.7%).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,janumet,70,2498,2539,"In most but not all studies, a small  oselabeledaefromdruguse (approximately 200 cells/microL difference in WBC vs placebo; mean baseline WBC approximately 6600 cells/microL) was observed due to a small  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,janumet,71,2539,2605,"This change in laboratory parameters is not considered to be clinically relevant.\n', '\n', '     Metformin hydrochloride  \n', '\n', ' In controlled clinical trials of metformin of 29 weeks duration, a  oselabeledaefromdruguse levels of previously normal serum  oselabeledaefromdruguse  without clinical manifestations, was observed in approximately 7% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,janumet,72,2605,2644,"Such decrease, possibly due to  nonoseaeaeonlyasinstruction from the B12-intrinsic factor complex, is, however, very rarely associated with  nonoseaemanifestationorcomplication and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12supplementation.  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
73,janumet,73,2644,2657,[See  Warnings and Precautions (5.5)  .]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,janumet,74,2657,2694,"\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  Additional adverse reactions have been identified during postapproval use of JANUMET, sitagliptin, or metformin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,janumet,75,2694,2756,"Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '  oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse including  oselabeledaefromdruguse  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,janumet,76,2756,2824,Warnings and Precautions (5.9)  ];   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  including  nonoseaegeneralterm and non-fatal  oselabeledaefromdruguse and necrotizing  oselabeledaefromdruguse  oselabeledaefromdruguse  [see  Indications and Usage (1)  ;  Warnings and Precautions (5.2)  ];   oselabeledaefromdruguse  including  oselabeledaefromdruguse (sometimes requiring dialysis)  [see  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,janumet,77,2824,2859,Warnings and Precautions (5.4)  ]  ; severe and disabling  oselabeledaefromdruguse  [see  Warnings and Precautions (5.10)  ]  ;  oselabeledaefromdruguse  [see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,janumet,78,2859,2903,"Warnings and Precautions (5.11)  ]  ;  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  hepatocellular, and mixed hepatocellular  oselabeledaefromdruguse  oselabeledaefromdruguse  and mixed hepatocellular liver  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,janumet,79,2903,2907,oselabeledaefromdruguse hepatocellular  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,janumet,80,2907,2908,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,janumet,81,2908,2919,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,janumet,82,2919,2925,"WARNING: LACTIC ACIDOSIS\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,janumet,83,2925,2933,"'\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,janumet,84,2933,2968,"LACTIC ACIDOSIS  \n', '\n', '      Postmarketing cases of metformin-associated  oselabeledaefromdruguse have resulted in  nonoseaegeneralterm   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and resistant  nonoseaemanifestationorcomplication  ",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
85,janumet,85,2968,3030,"The onset of metformin-associated  nonoseaeaeonlyasinstruction is often subtle, accompanied only by nonspecific symptoms such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Metformin-associated  oselabeledaefromdruguse was characterized by  oselabeledaefromdruguse (>5 mmol/Liter),  oselabeledaefromdruguse (without evidence of  nonoseaenegation or  nonoseaenegation ,",1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
86,janumet,86,3030,3059,an  oselabeledaefromdruguse  and metformin plasma levels generally >5 mcg/mL   [see   Warnings and Precautions (5.1)  ]  .    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,janumet,87,3059,3219,"\n', '\n', '     Risk factors for metformin-associated  nonoseaeaeonlyasinstruction include  notaecandidatepreexistingconditionorriskfactor  concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures,  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor , excessive alcohol intake, and  notaecandidatepreexistingconditionorriskfactor     \n', '\n', '     Steps to reduce the risk of and manage metformin-associated  nonoseaeaeonlyasinstruction in these high risk groups are provided in the full prescribing information   [see   Dosage and Administration (2.2)  ,   Contraindications (4)  ,   Warnings and Precautions (5.1)  ,   Drug Interactions (7)  , and   Use in Specific Populations (8.6  ,   8.7  )]  .     ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
88,janumet,88,3219,3228,"\n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,janumet,89,3228,3241,"If metformin-associated  nonoseaeaeonlyasinstruction    5 WARNINGS AND PRECAUTIONS\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,janumet,90,3241,3261,"'\n', '   EXCERPT:    *  Lactic acidosis: See  boxed warning  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,janumet,91,3261,3292,"(  5.1  ) \n', ' *  There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,janumet,92,3292,3301,"If pancreatitis is suspected, promptly discontinue JANUMET.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,janumet,93,3301,3306,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,janumet,94,3306,3327,"\n', ' *  Heart failure has been observed with two other members of the DPP-4 inhibitor class.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,janumet,95,3327,3344,Consider risks and benefits of JANUMET in patients who have known risk factors for heart failure.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,janumet,96,3344,3351,Monitor patients for signs and symptoms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,janumet,97,3351,3376,"(  5.3  ) \n', ' *  There have been postmarketing reports of acute renal failure, sometimes requiring dialysis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,janumet,98,3376,3389,"Before initiating JANUMET and at least annually thereafter, assess renal function.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,janumet,99,3389,3409,"(  5.4  ) \n', ' *  Vitamin B12deficiency: Metformin may lower Vitamin B12levels.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,janumet,100,3409,3414,Measure hematologic parameters annually.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,janumet,101,3414,3459,"(  5.5  ) \n', ' *  When used with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,janumet,102,3459,3511,"(  5.7  ) \n', ' *  There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with sitagliptin (one of the components of JANUMET), such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,janumet,103,3511,3538,"In such cases, promptly stop JANUMET, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,janumet,104,3538,3562,"(  5.9  ) \n', ' *  Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,janumet,105,3562,3577,Consider as a possible cause for severe joint pain and discontinue drug if appropriate.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,janumet,106,3577,3604,"(  5.10  ) \n', ' *  There have been postmarketing reports of bullous pemphigoid requiring hospitalization in patients taking DPP-4 inhibitors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,janumet,107,3604,3614,Tell patients to report development of blisters or erosions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,janumet,108,3614,3623,"If bullous pemphigoid is suspected, discontinue JANUMET.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,janumet,109,3623,3628,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,janumet,110,3628,3632,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,janumet,111,3632,3634,*  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,janumet,112,3634,3657,There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JANUMET or any other anti-diabetic drug.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,janumet,113,3657,3680,"(  5.12  ) \n', '    \n', ' \n', '\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,janumet,114,3680,3694,"5.1 Lactic Acidosis\n', '\n', '    Metformin hydrochloride    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,janumet,115,3694,3720,"\n', '\n', '  There have been postmarketing cases of metformin-associated  oselabeledaefromdruguse  including  nonoseaegeneralterm cases.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,janumet,116,3720,3833,"These cases had a subtle onset and were accompanied by nonspecific symptoms such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication  however,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and resistant  nonoseaemanifestationorcomplication have occurred with severe  nonoseaeaeonlyasinstruction  Metformin-associated  oselabeledaefromdruguse was characterized by  oselabeledaefromdruguse (>5 mmol/Liter),  oselabeledaefromdruguse (without evidence of  nonoseaenegation or  nonoseaenegation , and an  oselabeledaefromdruguse  metformin plasma levels were generally >5 mcg/mL. Metformin decreases liver uptake of lactate  oselabeledaefromdruguse which may increase the risk of  oselabeledaefromdruguse  especially in patients at risk.  ",1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
117,janumet,117,3833,3870,"\n', '\n', '  If metformin-associated  nonoseaeaeonlyasinstruction is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of JANUMET.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,janumet,118,3870,3920,"In JANUMET-treated patients with a diagnosis or strong suspicion of  nonoseaeaeonlyasinstruction  prompt hemodialysis is recommended to correct the  nonoseaeaeonlyasinstruction and remove accumulated metformin (metformin hydrochloride is dialyzable, with a clearance of up to 170 mL/min under good hemodynamic conditions).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,janumet,119,3920,3932,Hemodialysis has often resulted in reversal of symptoms and recovery.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,janumet,120,3932,3973,"\n', '\n', '  Educate patients and their families about the symptoms of  nonoseaeaeonlyasinstruction and if these symptoms occur instruct them to discontinue JANUMET and report these symptoms to their health care provider.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,janumet,121,3973,4016,"\n', '\n', '  For each of the known and possible risk factors for metformin-associated  nonoseaeaeonlyasinstruction  recommendations to reduce the risk of and manage metformin-associated  nonoseaeaeonlyasinstruction are provided below:  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,janumet,122,4016,4028,"\n', '\n', '     Renal Impairment    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,janumet,123,4028,4081,"\n', '\n', ""  The postmarketing metformin-associated  oselabeledaefromdruguse cases primarily occurred in patients with significant  notaecandidatepreexistingconditionorriskfactor  The risk of metformin accumulation and metformin-associated  nonoseaeaeonlyasinstruction increases with the severity of  notaecandidatepreexistingconditionorriskfactor because metformin is substantially excreted by the kidney.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
124,janumet,124,4081,4105,"Clinical recommendations based upon the patient's renal function include [see  Dosage and Administration (2.2)  ,  Clinical Pharmacology",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,janumet,125,4105,4113,(12.3)  ]  :  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,janumet,126,4113,4123,"\n"", '\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,janumet,127,4123,4138,"Before initiating JANUMET, obtain an estimated glomerular filtration rate (eGFR).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,janumet,128,4138,4165,"\n', ' *   JANUMET is contraindicated in patients with an  notaecandidatecontraindication   [see  Contraindications (4)  ] .  ",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
129,janumet,129,4165,4203,"\n', ' *   JANUMET is not recommended in patients with an  notaecandidatepreexistingconditionorriskfactor  because these patients require a lower dosage of sitagliptin than what is available in the fixed combination JANUMET product.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
130,janumet,130,4203,4221,"\n', ' *   Obtain an eGFR at least annually in all patients taking JANUMET.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,janumet,131,4221,4248,"In patients at increased risk for the development of  notaecandidatepreexistingconditionorriskfactor (e.g., the elderly), renal function should be assessed more frequently.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
132,janumet,132,4248,4256,"\n', '        Drug Interactions    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,janumet,133,4256,4316,"\n', ' \n', '\n', '  The concomitant use of JANUMET with specific drugs may increase the risk of metformin-associated  nonoseaeaefromdruginteraction  those that  nonoseaeaeonlyasinstruction  result in significant  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction or increase metformin accumulation [see  Drug Interactions (7)  ]  .",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
134,janumet,134,4316,4326,"Therefore, consider more frequent monitoring of patients.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,janumet,135,4326,4394,"\n', '\n', '     Age 65 or Greater    \n', '\n', ""  The risk of metformin-associated  oselabeledaefromdruguse increases with the patient's age because elderly patients have a greater likelihood of having  notaecandidatepreexistingconditionorriskfactor  renal, or cardiac  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or cardiac  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor than younger patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
136,janumet,136,4394,4416,Assess renal function more frequently in elderly patients [ see  Use in Specific Populations (8.5)  ].    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,janumet,137,4416,4430,"\n"", '\n', '     Radiological Studies with Contrast    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,janumet,138,4430,4516,"\n', '\n', '  Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute  nonoseaeaefromdruginteraction and the occurrence of  nonoseaeaefromdruginteraction  Stop JANUMET at the time of, or prior to, an iodinated contrast imaging procedure in patients with an  notaecandidatepreexistingconditionorriskfactor  ; in patients with a history of  notaecandidatepreexistingconditionorriskfactor  alcoholism, or  notaecandidatepreexistingconditionorriskfactor  or in patients who will be administered intra-arterial iodinated contrast.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
139,janumet,139,4516,4530,"Re-evaluate eGFR 48 hours after the imaging procedure, and restart JANUMET",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,janumet,140,4530,4537,if renal function is stable.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,janumet,141,4537,4598,"\n', '\n', '     Surgery and Other Procedures    \n', '\n', '  Withholding of food and fluids during surgical or other procedures may increase the risk for  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  JANUMET should be temporarily discontinued while patients have restricted food and fluid intake.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,janumet,142,4598,4610,"\n', '\n', '     Hypoxic States    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,janumet,143,4610,4649,"\n', '\n', '  Several of the postmarketing cases of metformin-associated  oselabeledaefromdruguse occurred in the setting of  notaecandidatepreexistingconditionorriskfactor (particularly when accompanied by  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor .  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
144,janumet,144,4649,4678,"notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor ,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and other conditions associated with  notaecandidatepreexistingconditionorriskfactor have been associated with  nonoseaeaeonlyasinstruction and may also cause  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
145,janumet,145,4678,4687,"When such events occur, discontinue JANUMET.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,janumet,146,4687,4700,"\n', '\n', '     Excessive Alcohol Intake    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,janumet,147,4700,4742,"\n', '\n', '  Alcohol potentiates the effect of metformin on lactate metabolism and this may increase the risk of metformin-associated  nonoseaeaefromdruginteraction  Warn patients against excessive alcohol intake while receiving JANUMET.  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
148,janumet,148,4742,4754,"\n', '\n', '     Hepatic Impairment    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,janumet,149,4754,4778,"\n', '\n', '  Patients with  notaecandidatepreexistingconditionorriskfactor have developed with cases of metformin-associated  oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
150,janumet,150,4778,4857,"This may be due to impaired lactate clearance resulting in  nonoseaeaeonlyasinstruction  Therefore, avoid use of JANUMET in patients with clinical or laboratory evidence of  notaecandidatepreexistingconditionorriskfactor   \n', '\n', '    5.2 Pancreatitis\n', '\n', '  There have been postmarketing reports of  oselabeledaefromdruguse  including  nonoseaegeneralterm and non-fatal  oselabeledaefromdruguse or necrotizing  oselabeledaefromdruguse  oselabeledaefromdruguse  in patients taking JANUMET.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
151,janumet,151,4857,4875,"After initiation of JANUMET, patients should be observed carefully for signs and symptoms of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,janumet,152,4875,4893,"If  nonoseaeaeonlyasinstruction is suspected, JANUMET should promptly be discontinued and appropriate management should be initiated.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,janumet,153,4893,4966,"It is unknown whether patients with a history of  notaecandidatepreexistingconditionorriskfactor are at increased risk for the development of  nonoseaeaeonlyasinstruction while using JANUMET.\n', '\n', '    5.3 Heart Failure\n', '\n', '   An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and  nonoseaeaeforanotherdruginclass has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class.",1,0,1,0,0,0,0,0,0,0,0,0,1,0,0
154,janumet,154,4966,5036,"These trials evaluated patients with  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor   \n', '\n', '  Consider the risks and benefits of JANUMET prior to initiating treatment in patients at risk for  nonoseaeaeonlyasinstruction  such as those with a prior history of  notaecandidatepreexistingconditionorriskfactor and a history of  notaecandidatepreexistingconditionorriskfactor  and observe these patients for signs and symptoms of  nonoseaeaeonlyasinstruction during therapy.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
155,janumet,155,5036,5052,Advise patients of the characteristic symptoms of  nonoseaeaeonlyasinstruction and to immediately report such symptoms.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,janumet,156,5052,5073,"If  nonoseaeaeonlyasinstruction develops, evaluate and manage according to current standards of care and consider discontinuation of JANUMET.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,janumet,157,5073,5091,"\n', '\n', '    5.4 Assessment of Renal Function\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,janumet,158,5091,5109,"', '   Metformin and sitagliptin are known to be substantially excreted by the kidney.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,janumet,159,5109,5121,"\n', '\n', '     Metformin hydrochloride    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,janumet,160,5121,5160,"\n', '\n', '  JANUMET is contraindicated in patients with severe  notaecandidatecontraindication [see  Contraindications (4)  and  Warnings and Precautions (5.1)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
161,janumet,161,5160,5197,"\n', '\n', '     Sitagliptin    \n', '\n', '  There have been postmarketing reports of  oselabeledaefromdruguse  including  oselabeledaefromdruguse  sometimes requiring dialysis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,janumet,162,5197,5215,"Before initiation of therapy with JANUMET and at least annually thereafter, renal function should be assessed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,janumet,163,5215,5250,"In patients in whom development of  nonoseaeaeonlyasinstruction is anticipated, particularly in elderly patients, renal function should be assessed more frequently and JANUMET discontinued if evidence of  nonoseaeaeonlyasinstruction is present.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,janumet,164,5250,5305,"\n', '\n', '    5.5 Vitamin B12Levels\n', '\n', '  In controlled clinical trials of metformin of 29 weeks duration, a  oselabeledaefromdruguse levels of previously normal serum  oselabeledaefromdruguse  without clinical manifestations, was observed in approximately 7% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,janumet,165,5305,5343,"Such decrease, possibly due to  nonoseaeaeonlyasinstruction from the B12-intrinsic factor complex, is, however, very rarely associated with  nonoseaemanifestationorcomplication and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12supplementation.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
166,janumet,166,5343,5368,Measurement of hematologic parameters on an annual basis is advised in patients on JANUMET and any apparent abnormalities should be appropriately investigated and managed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,janumet,167,5368,5380,[See  Adverse Reactions (6.1)  .]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,janumet,168,5380,5532,"\n', '\n', ' Certain individuals (those with  notaecandidatepreexistingconditionorriskfactor r calcium intake or  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor Vitamin B12or  notaecandidatepreexistingconditionorriskfactor intake or  notaecandidatepreexistingconditionorriskfactor  appear to be predisposed to developing  nonoseaeaeonlyasinstruction  In these patients, routine serum Vitamin B12measurements at two- to three-year intervals may be useful.\n', '\n', '    5.6 Change in Clinical Status of Patients with Previously Controlled Type 2 Diabetes\n', '\n', '  A patient with  notaecandidateindication previously well controlled on JANUMET who develops  nonoseaegeneralterm or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate, and metformin levels.",1,1,1,1,0,0,0,0,0,0,0,0,0,0,0
169,janumet,169,5532,5637,"If  nonoseaeaeonlyasinstruction of either form occurs, JANUMET must be stopped immediately and other appropriate corrective measures initiated.\n', '\n', '    5.7 Use with Medications Known to Cause Hypoglycemia\n', '\n', '   Sitagliptin  \n', '\n', ' When sitagliptin was used in combination with a sulfonylurea or with insulin, medications known to cause  nonoseaeaeonlyasinstruction  the incidence of  nonoseaeaefromdruginteraction was increased over that of placebo used in combination with a sulfonylurea or with insulin [see  Adverse Reactions (6)  ].  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
170,janumet,170,5637,5756,"Therefore, patients also receiving an insulin secretagogue (e.g., sulfonylurea) or insulin may require a lower dose of the insulin secretagogue or insulin to reduce the risk of  nonoseaeaeonlyasinstruction [see  Drug Interactions (7.4)  ]  .\n', '\n', '    Metformin hydrochloride  \n', '\n', '  nonoseaeaeonlyasinstruction does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,janumet,171,5756,5861,"Elderly,  notaecandidatepreexistingconditionorriskfactor  or malnourished patients, and those with  notaecandidatepreexistingconditionorriskfactor or pituitary  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor are particularly susceptible to  oselabeledaefromdruguse   nonoseaeaeonlyasinstruction may be difficult to recognize in the elderly, and in people who are taking beta-adrenergic blocking drugs.\n', '\n', '    5.8 Loss of Control of Blood Glucose\n', '\n', '  When a patient stabilized on any diabetic regimen is exposed to stress such as  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or surgery, a temporary  nonoseaeaeonlyasinstruction may occur.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
172,janumet,172,5861,5877,"At such times, it may be necessary to withhold JANUMET and temporarily administer insulin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,janumet,173,5877,5928,"JANUMET may be reinstituted after the acute episode is resolved.\n', '\n', '    5.9 Hypersensitivity Reactions\n', '\n', '  There have been postmarketing reports of serious  oselabeledaefromdruguse in patients treated with sitagliptin, one of the components of JANUMET.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,janumet,174,5928,5943,These reactions include  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse including  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,janumet,175,5943,5969,"Onset of these reactions occurred within the first 3 months after initiation of treatment with sitagliptin, with some reports occurring after the first dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,janumet,176,5969,6008,"If a  nonoseaeaeonlyasinstruction is suspected, discontinue JANUMET, assess for other potential causes for the event, and institute alternative treatment for  notaecandidateindication  [See  Adverse Reactions (6.2)  .]  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
177,janumet,177,6008,6027,"\n', '\n', '  nonoseaeaeforanotherdruginclass has also been reported with other DPP-4 inhibitors.",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
178,janumet,178,6027,6095,"Use caution in a patient with a history of  notaecandidatepreexistingconditionorriskfactor with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to  nonoseaeaeonlyasinstruction with JANUMET.\n', '\n', '    5.10 Severe and Disabling Arthralgia\n', '\n', '  There have been postmarketing reports of severe and disabling  oselabeledaeclasseffect in patients taking DPP-4 inhibitors.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
179,janumet,179,6095,6113,The time to onset of symptoms following initiation of drug therapy varied from one day to years.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,janumet,180,6113,6124,Patients experienced relief of symptoms upon discontinuation of the medication.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,janumet,181,6124,6144,A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,janumet,182,6144,6194,"Consider DPP-4 inhibitors as a possible cause for severe  nonoseaeaeonlyasinstruction and discontinue drug if appropriate.\n', '\n', '    5.11 Bullous Pemphigoid\n', '\n', '   Postmarketing cases of  oselabeledaeclasseffect requiring hospitalization have been reported with DPP-4 inhibitor use.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,janumet,183,6194,6214,"In reported cases, patients typically recovered with topical or systemic  nonoseaeaeonlyasinstruction and discontinuation of the DPP-4 inhibitor.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,janumet,184,6214,6229,Tell patients to report development of  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication while receiving JANUMET.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
185,janumet,185,6229,6254,"If  nonoseaeaeonlyasinstruction is suspected, JANUMET should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,janumet,186,6254,6288,"\n', '\n', '    5.12 Macrovascular Outcomes\n', '\n', '  There have been no clinical studies establishing conclusive evidence of  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,xofigo,0,0,60,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in another section of the label:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (  5.1  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,xofigo,1,60,61,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,xofigo,2,61,68,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,xofigo,3,68,182,"The most common adverse drug reactions (>= 10%) in patients receiving Xofigo were nausea, diarrhea, vomiting, and peripheral edema.\n', ' \n', '\n', ' The most common hematologic laboratory abnormalities (>= 10%) were anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia (  6.1  ).\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact    Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937    or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,xofigo,4,182,219,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,xofigo,5,219,335,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In the randomized clinical trial in patients with  notaecandidateindication with  notaecandidateindication  600 patients received intravenous injections of 50 kBq/kg (1.35 microcurie/kg) of Xofigo and best standard of care and 301 patients received placebo and best standard of care once every 4 weeks for up to 6 injections.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
6,xofigo,6,335,358,"Prior to randomization, 58% and 57% of patients had received docetaxel in the Xofigo and placebo arms, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,xofigo,7,358,422,"The median duration of treatment was 20 weeks (6 cycles) for Xofigo and 18 weeks (5 cycles) for placebo.\n', '\n', '\n', '\n', ' The most common adverse reactions (>= 10%) in patients receiving Xofigo were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,xofigo,8,422,427,(Table 3).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,xofigo,9,427,452,Grade 3 and 4 adverse events were reported among 57% of Xofigo-treated patients and 63% of placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,xofigo,10,452,474,The most common  oselabeledaefromdruguse in Xofigo-treated patients (>= 10%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,xofigo,11,474,482,oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,xofigo,12,482,523,"Table 4).\n', '\n', '\n', '\n', ' Treatment discontinuations due to adverse events occurred in 17% of patients who received Xofigo and 21% of patients who received placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,xofigo,13,523,621,"The most common  oselabeledaefromdruguse leading to discontinuation for Xofigo were  oselabeledaefromdruguse (2%) and  oselabeledaefromdruguse (2%).\n', '\n', '\n', '\n', ' Table 3 shows adverse reactions occurring in >= 2% of patients and for which the incidence for Xofigo exceeds the incidence for placebo.\n', '\n', '\n', '\n', ' Table 3: Adverse Reactions in the Randomized Trial \n', '  System/Organ ClassPreferred Term    Xofigo",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,xofigo,14,621,641,"(n=600)           Placebo (n=301)          \n', '  Grades 1-4%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,xofigo,15,641,659,Grades 3-4%              Grades 1-4%              Grades 3-4%              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,xofigo,16,659,666,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,xofigo,17,666,671,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,xofigo,18,671,675,oselabeledaefromdruguse             2                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,xofigo,19,675,679,1                        0                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,xofigo,20,679,681,0                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,xofigo,21,681,688,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,xofigo,22,688,699,"\n', '   oselabeledaefromdruguse                   36                       2                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,xofigo,23,699,710,"35                       2                        \n', '   oselabeledaefromdruguse                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,xofigo,24,710,712,25                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,xofigo,25,712,714,2                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,xofigo,26,714,718,15                       2                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,xofigo,27,718,729,"\n', '   oselabeledaefromdruguse                 19                       2                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,xofigo,28,729,733,14                       2                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,xofigo,29,733,740,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,xofigo,30,740,751,"\n', '   oselabeledaefromdruguse         13                       2                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,xofigo,31,751,762,"10                       1                        \n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,xofigo,32,762,775,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse failure and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,xofigo,33,775,779,3                        1                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,xofigo,34,779,783,1                        1                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,xofigo,35,783,901,"\n', '             Laboratory Abnormalities\n', '   Table 4 shows  nonoseaegeneralterm occurring in  >  10% of patients and for which the incidence for Xofigo exceeds the incidence for placebo.\n', '\n', '\n', '\n', '   Table 4: Hematologic Laboratory Abnormalities  \n', '\n', '\n', '\n', '\n', '  Hematologic Laboratory Abnormalities    Xofigo (n=600)           Placebo (n=301)          \n', '  Grades 1-4%              Grades 3-4%              Grades 1-4%              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,xofigo,36,901,907,Grades 3-4%              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,xofigo,37,907,916,"\n', '   oselabeledaefromdruguse                   93                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,xofigo,38,916,918,6                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,xofigo,39,918,931,"88                       6                        \n', '   oselabeledaefromdruguse          72                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,xofigo,40,931,933,20                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,xofigo,41,933,935,53                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,xofigo,42,935,937,7                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,xofigo,43,937,944,"\n', '   oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,xofigo,44,944,948,35                       3                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,xofigo,45,948,950,10                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,xofigo,46,950,964,"<1                       \n', '   oselabeledaefromdruguse         31                       3                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,xofigo,47,964,966,22                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,xofigo,48,966,1004,"<1                       \n', '   oselabeledaefromdruguse              18                       2                        5                        <1                       \n', '  Laboratory values were obtained at baseline and prior to each 4-week cycle.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,xofigo,49,1004,1038,"\n', '           As an adverse reaction, grade 3-4  oselabeledaefromdruguse was reported in 6% of patients on Xofigo and in 2% of patients on placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,xofigo,50,1038,1073,"Among patients who received Xofigo, the  nonoseaegeneralterm grade 3-4  oselabeledaefromdruguse occurred in 1% of docetaxel naive patients and in 4% of patients who had received prior docetaxel.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,xofigo,51,1073,1137,"Grade 3-4  oselabeledaefromdruguse occurred in 1% of docetaxel naive patients and in 3% of patients who have received prior docetaxel.\n', ' \n', '\n', '   Fluid Status\n', '\n', ""   oselabeledaefromdruguse occurred in 3% of patients on Xofigo and 1% of patients on placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,xofigo,52,1137,1214,"Xofigo increases adverse reactions such as  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse which may result in  nonoseaemanifestationorcomplication  Monitor patients' oral intake and fluid status carefully and promptly treat patients who display signs or symptoms of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction \n"", '\n', '\n', '\n', '    oselabeledaefromdruguse \n', '   oselabeledaefromdruguse  pain, and edema  oselabeledaefromdruguse  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
53,xofigo,53,1214,1272,"oselabeledaefromdruguse  and edema  oselabeledaefromdruguse  oselabeledaefromdruguse were reported in 1% of patients on Xofigo.\n', '\n', '\n', '\n', '   Secondary Malignant Neoplasms\n', '\n', ""  Xofigo contributes to a patient's overall long-term cumulative radiation exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,xofigo,54,1272,1336,"Long-term cumulative radiation exposure may be associated with an  oselabeledaefromdruguse and  oselabeledaefromdruguse  Due to its mechanism of action and  nonoseaeaeanimal  including  nonoseaeaeanimal  in rats following administration of radium-223 dichloride, Xofigo may increase the risk of  oselabeledaefromdruguse or other  oselabeledaefromdruguse  [see Nonclinical Toxicology (  13.1  )]  .",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
55,xofigo,55,1336,1450,"However, the overall incidence of new  nonoseaeaeratelteqplacebo in the randomized trial was lower on the Xofigo arm compared to placebo (<1% vs. 2%; respectively), but the expected latency period for the development of  nonoseaeaeonlyasinstruction exceeds the duration of follow up for patients on the trial.\n"", '\n', '\n', '\n', '   Subsequent Treatment with Cytotoxic Chemotherapy\n', '\n', '  In the randomized clinical trial, 16% patients in the Xofigo group and 18% patients in the placebo group received  nonoseaeaeonlyasinstruction after completion of study treatments.",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
56,xofigo,56,1450,1513,"Adequate safety monitoring and laboratory testing was not performed to assess how patients treated with Xofigo will tolerate subsequent  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '  EXCERPT:   Bone Marrow Suppression: Measure blood counts prior to treatment initiation and before every dose of Xofigo.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,xofigo,57,1513,1529,Discontinue Xofigo if hematologic values do not recover within 6 to 8 weeks after treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,xofigo,58,1529,1538,Monitor patients with compromised bone marrow reserve closely.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,xofigo,59,1538,1553,Discontinue Xofigo in patients who experience life-threatening complications despite supportive care measures.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,xofigo,60,1553,1639,"(  5.1  )\n', '\n', '\n', '\n', ' \n', '\n', '\n', '\n', '   5.1 Bone Marrow Suppression\n', '\n', '\n', '\n', '  In the randomized trial, 2% of patients on the Xofigo arm experienced  oselabeledaefromdruguse or ongoing  oselabeledaefromdruguse compared to no patients treated with placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,xofigo,61,1639,1684,"There were two  nonoseaegeneralterm due to  nonoseaeaeonlyasinstruction and for 7 of 13 patients treated with Xofigo,  nonoseaeaeonlyasinstruction was ongoing at the time of  nonoseaegeneralterm  Among the 13 patients who experienced  nonoseaeaeonlyasinstruction  54% required blood transfusions.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,xofigo,62,1684,1762,"Four percent (4%) of patients on the Xofigo arm and 2% on the placebo arm permanently discontinued therapy due to  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' In the randomized trial,  nonoseaegeneralterm related to  nonoseaeaeonlyasinstruction in association with  nonoseaeaeonlyasinstruction were observed in 1% of Xofigo-treated patients compared to 0.3% of patients treated with placebo.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,xofigo,63,1762,1801,"The incidence of  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo (2%), serious  nonoseaeaeratelteqplacebo (10%), and  nonoseaeaeratelteqplacebo (<1%) were similar for patients treated with Xofigo and placebo.  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
64,xofigo,64,1801,1824,oselabeledaefromdruguse  notably  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  has been reported in patients treated with Xofigo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,xofigo,65,1824,1857,"In the randomized trial, complete blood counts (CBCs) were obtained every 4 weeks prior to each dose and the nadir CBCs and times of recovery were not well characterized.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,xofigo,66,1857,1951,"In a separate single-dose phase 1 study of Xofigo, neutrophil and platelet count nadirs occurred 2 to 3 weeks after Xofigo administration at doses that were up to 1 to 5 times the recommended dose, and most patients recovered approximately 6 to 8 weeks after administration [see Adverse Reactions (  6  )]  .\n', '\n', '\n', '\n', ' Hematologic evaluation of patients must be performed at baseline and prior to every dose of Xofigo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,xofigo,67,1951,1985,"Before the first administration of Xofigo, the  nonoseaeaeonlyasinstruction  /L, the  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  Before subsequent administrations of Xofigo, the  nonoseaeaeonlyasinstruction and the  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,xofigo,68,1985,2018,"If there is no recovery to these values within 6 to 8 weeks after the last administration of Xofigo, despite receiving supportive care, further treatment with Xofigo should be discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,xofigo,69,2018,2038,Patients with evidence of  nonoseaeaeonlyasinstruction should be monitored closely and provided with supportive care measures when clinically indicated.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,xofigo,70,2038,2084,"Discontinue Xofigo in patients who experience life-threatening complications despite supportive care for  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' The safety and efficacy of concomitant chemotherapy with Xofigo have not been established.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,xofigo,71,2084,2107,"Outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive  nonoseaeaefromdruginteraction ']",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
0,lipitor,0,0,78,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse  [see  Warnings and Precautions (5.1)  ]  \n', '\n', '  oselabeledaefromdruguse  [see  Warnings and Precautions (5.2)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,lipitor,1,78,177,"\n', '\n', '   EXCERPT:   The most commonly reported adverse reactions (incidence >= 2%) in patients treated with LIPITOR in placebo-controlled trials regardless of causality were: nasopharyngitis, arthralgia, diarrhea, pain in extremity, and urinary tract infection (  6.1  ).\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (1-800-438-1985 and www.pfizer.com) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  .    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,lipitor,2,177,206,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,lipitor,3,206,337,"Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' In the LIPITOR placebo-controlled clinical trial database of 16,066 patients (8755 LIPITOR vs. 7311 placebo; age range 10-93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on LIPITOR and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,lipitor,4,337,524,"The five most common adverse reactions in patients treated with LIPITOR that led to treatment discontinuation and occurred at a rate greater than placebo were:  oselabeledaefromdruguse (0.7%),  oselabeledaefromdruguse (0.5%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%), and  oselabeledaefromdruguse (0.4%).\n', '\n', ' The most commonly reported adverse reactions (incidence >= 2% and greater than placebo) regardless of causality, in patients treated with LIPITOR in placebo controlled trials (n=8755) were:  oselabeledaefromdruguse (8.3%),  oselabeledaefromdruguse (6.9%),  oselabeledaefromdruguse (6.8%),  oselabeledaefromdruguse (6.0%), and  oselabeledaefromdruguse (5.7%).\n', '\n', ' Table 3 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in >= 2% and at a rate greater than placebo in patients treated with LIPITOR (n=8755), from seventeen placebo-controlled trials.\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,lipitor,5,524,530,"', ' Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,lipitor,6,530,563,Clinical adverse reactions occurring in >= 2% in patients treated with any dose of LIPITOR and at an incidence greater than placebo regardless of causality (% of patients).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,lipitor,7,563,586,"\n', ' Adverse Reaction [note: Adverse Reaction >= 2% in any dose greater than placebo]   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,lipitor,8,586,589,Any doseN=8755  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,lipitor,9,589,592,10 mgN=3908    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,lipitor,10,592,595,20 mgN=188   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,lipitor,11,595,603,40 mgN=604   80 mgN=4055  PlaceboN=7311   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,lipitor,12,603,613,"\n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,lipitor,13,613,619,oselabeledaefromdruguse                 8.3            12.9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,lipitor,14,619,625,5.3          7.0          4.2          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,lipitor,15,625,646,"8.2           \n', '  oselabeledaefromdruguse                      6.9            8.9            11.7         10.6         4.3          6.5           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,lipitor,16,646,653,"\n', '  oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,lipitor,17,653,672,"6.8            7.3            6.4          14.1         5.2          6.3           \n', '  oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,lipitor,18,672,680,6.0            8.5            3.7          9.3          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,lipitor,19,680,684,3.1          5.9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,lipitor,20,684,727,"\n', '  oselabeledaefromdruguse         5.7            6.9            6.4          8.0          4.1          5.6           \n', '  oselabeledaefromdruguse                       4.7            5.9            3.2          6.0          3.3          4.3           \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,lipitor,21,727,756,"oselabeledaefromdruguse                          4.0            3.7            3.7          7.1          3.8          3.5           \n', '  oselabeledaefromdruguse            3.8            5.2            3.2          5.1          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,lipitor,22,756,779,"2.3          3.6           \n', '  oselabeledaefromdruguse                   3.6            4.6            4.8          5.1          2.4          3.0           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,lipitor,23,779,788,"\n', '  oselabeledaefromdruguse                         3.5            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,lipitor,24,788,796,3.6            5.9          8.4          2.7          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,lipitor,25,796,798,3.1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,lipitor,26,798,807,"\n', '  oselabeledaefromdruguse                        3.0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,lipitor,27,807,813,2.8            1.1          5.3          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,lipitor,28,813,817,2.8          2.9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,lipitor,29,817,836,"\n', '  oselabeledaefromdruguse          2.3            3.9            1.6          2.8          0.7          2.1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,lipitor,30,836,871,"\n', '             Other adverse reactions reported in placebo-controlled studies include:\n', ' \n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,lipitor,31,871,881,nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,lipitor,32,881,883,oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,lipitor,33,883,895,nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,lipitor,34,895,903,nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,lipitor,35,903,909,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,lipitor,36,909,915,nonoseaegeneralterm  :  oselabeledaefromdruguse    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,lipitor,37,915,919,nonoseaegeneralterm    oselabeledaefromdruguse    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,lipitor,38,919,925,nonoseaegeneralterm  :  oselabeledaefromdruguse    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,lipitor,39,925,933,nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,lipitor,40,933,936,nonoseaegeneralterm    oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,lipitor,41,936,955,"\n', '\n', '     Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,lipitor,42,955,960,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,lipitor,43,960,969,"', ' In ASCOT  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,lipitor,44,969,977,Clinical Studies (14.1)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,lipitor,45,977,1073,"involving 10,305 participants (age range 40-80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with LIPITOR 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with LIPITOR was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.\n', '\n', '     Collaborative Atorvastatin Diabetes Study (CARDS)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,lipitor,46,1073,1078,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,lipitor,47,1078,1087,"', ' In CARDS  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,lipitor,48,1087,1135,"Clinical Studies (14.1)  ]  involving 2,838 subjects (age range 39-77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with  notaecandidateindication treated with LIPITOR",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
49,lipitor,49,1135,1176,"10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,lipitor,50,1176,1196,"No cases of  nonoseaenegation were reported.\n', '\n', '     Treating to New Targets Study",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
51,lipitor,51,1196,1200,(TNT)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,lipitor,52,1200,1214,"\n', '\n', ' In TNT  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,lipitor,53,1214,1275,"Clinical Studies (14.1)  ]  involving 10,001 subjects (age range 29-78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident  notaecandidateindication treated with LIPITOR 10 mg daily (n=5006) or LIPITOR 80 mg daily (n=4995)",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
54,lipitor,54,1275,1339,", there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,lipitor,55,1339,1342,Persistent  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,lipitor,56,1342,1380,(>=3 * ULN twice within 4-10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,lipitor,57,1380,1546,"oselabeledaefromdruguse (>= 10 * ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).\n', '\n', '     Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL)  \n', '\n', ' In IDEAL  [see  Clinical Studies (14.1)  ]  involving 8,888 subjects (age range 26-80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with LIPITOR 80 mg/day (n=4439) or simvastatin 20-40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,lipitor,58,1546,1564,"'\n', '     Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,lipitor,59,1564,1569,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,lipitor,60,1569,1688,"', ' In SPARCL involving 4731 subjects (age range 21-92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident  notaecandidatepreexistingconditionorriskfactor but with a  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor (TIA) within the previous 6 months treated with LIPITOR 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent  oselabeledaefromdruguse (>= 3 * ULN twice within 4-10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%).  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
61,lipitor,61,1688,1718,"oselabeledaefromdruguse (>10 * ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,lipitor,62,1718,1817,"oselabeledaefromdruguse was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group  [see  Warnings and Precautions (5.5)  ]  .\n', '\n', ' In a post-hoc analysis, LIPITOR 80 mg reduced the incidence of  notaecandidateindication (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of  oselabeledaefromdruguse (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
63,lipitor,63,1817,1836,The incidence of  nonoseaegeneralterm  nonoseaeaeratelteqplacebo was similar between groups (17 LIPITOR vs. 18 placebo).,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
64,lipitor,64,1836,1873,The incidence of non-fatal  oselabeledaefromdruguse was significantly greater in the atorvastatin group (38 non-fatal  oselabeledaefromdruguse  as compared to the placebo group (16 non-fatal  nonoseaeaeonlyasinstruction .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,lipitor,65,1873,1897,Subjects who entered the study with a  notaecandidatepreexistingconditionorriskfactor appeared to be at increased risk for  oselabeledaefromdruguse [7 (16%),0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
66,lipitor,66,1897,1904,LIPITOR vs. 2 (4%),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,lipitor,67,1904,1928,"placebo].\n', '\n', ' There were no significant differences between the treatment groups for all-cause  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,lipitor,68,1928,1952,216 (9.1%) in the LIPITOR 80 mg/day group vs. 211 (8.9%) in the placebo group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,lipitor,69,1952,1983,The proportions of subjects who experienced  nonoseaeaeratelteqplacebo were numerically smaller in the LIPITOR 80 mg group (3.3%) than in the placebo group (4.1%).,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
70,lipitor,70,1983,2137,"The proportions of subjects who experienced non-cardiovascular  nonoseaegeneralterm were numerically larger in the LIPITOR 80 mg group (5.0%) than in the placebo group (4.0%).\n', '\n', '     Adverse Reactions from Clinical Studies of LIPITOR in Pediatric Patients  \n', '\n', ' In a 26-week controlled study in boys and postmenarchal girls with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of LIPITOR 10 to 20 mg daily, as an adjunct to diet to  notaecandidateindication  notaecandidateindication total cholesterol,  notaecandidateindication  notaecandidateindication total cholesterol, LDL-C, and  notaecandidateindication  was generally similar to that of placebo  [see  ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
71,lipitor,71,2137,2150,Use in Special Populations (8.4)  and  Clinical Studies (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,lipitor,72,2150,2190,"14.6)  ]  .\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of LIPITOR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,lipitor,73,2190,2298,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' Adverse reactions associated with LIPITOR therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm and non-fatal  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,lipitor,74,2298,2322,"\n', '\n', ' There have been rare reports of  oselabeledaeclasseffect associated with statin use  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,lipitor,75,2322,2329,Warnings and Precautions (5.1)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,lipitor,76,2329,2367,"]  .\n', '\n', ' There have been rare postmarketing reports of  oselabeledaeclasseffect (e.g.,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  associated with statin use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,lipitor,77,2367,2425,"These  oselabeledaefromdruguse    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,lipitor,78,2425,2442,"Predisposing factors include advanced age (> 65), uncontrolled hypothyroidism, and renal impairment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,lipitor,79,2442,2457,Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,lipitor,80,2457,2476,"Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,lipitor,81,2476,2497,"LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected (  5.1  ,  8.5  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,lipitor,82,2497,2515,"\n', ' *  Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,lipitor,83,2515,2533,Check liver enzyme tests before initiating therapy and as clinically indicated thereafter (  5.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,lipitor,84,2533,2575,"\n', ' *  A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs. placebo (  5.5  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,lipitor,85,2575,2630,"\n', '    \n', ' \n', '\n', '   5.1 Skeletal Muscle\n', '\n', '   Rare cases of  oselabeledaefromdruguse with  nonoseaemanifestationorcomplication secondary to  oselabeledaefromdruguse have been reported with LIPITOR and with other drugs in this class.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
86,lipitor,86,2630,2693,"A history of  notaecandidatepreexistingconditionorriskfactor may be a risk factor for the development of  nonoseaeaeonlyasinstruction  Such patients merit closer monitoring for skeletal muscle effects.\n', '\n', ' Atorvastatin, like other statins, occasionally causes  oselabeledaefromdruguse  defined as  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication in conjunction with  nonoseaemanifestationorcomplication  values >10 times ULN.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
87,lipitor,87,2693,2758,"The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction \n', '\n', ' There have been rare reports of  oselabeledaeclasseffect , an  oselabeledaeclasseffect  associated with statin use.  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
88,lipitor,88,2758,2871,"nonoseaeaeonlyasinstruction is characterized by:  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  which persist despite discontinuation of statin treatment; muscle biopsy showing  nonoseaemanifestationorcomplication without significant  nonoseaenegation  improvement with  nonoseaeaeonlyasinstruction \n', '\n', '  nonoseaeaeonlyasinstruction should be considered in any patient with diffuse  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication tenderness or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or weakness, and/or marked  nonoseaemanifestationorcomplication  Patients should be advised to report promptly unexplained  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication pain,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication pain, tenderness, or  nonoseaemanifestationorcomplication  particularly if accompanied by  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication or if  nonoseaeaeonlyasinstruction persist after discontinuing LIPITOR.",1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
89,lipitor,89,2871,2966,"LIPITOR therapy should be discontinued if markedly  nonoseaemanifestationorcomplication occur or  nonoseaeaeonlyasinstruction is diagnosed or suspected.\n', '\n', ' The risk of  nonoseaeaefromdruginteraction during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals.",1,0,0,0,1,1,0,0,0,0,0,0,0,0,0
90,lipitor,90,2966,3060,"Physicians considering combined therapy with LIPITOR and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  or  nonoseaeaefromdruginteraction  particularly during the initial months of therapy and during any periods of upward dosage titration of either drug.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
91,lipitor,91,3060,3089,Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [see  Drug Interactions (7)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,lipitor,92,3089,3177,"Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe  nonoseaeaeonlyasinstruction \n', '\n', ' Prescribing recommendations for interacting agents are summarized in Table 2 [see  Dosage and Administration (2.6)  ,  Drug Interactions (7)  , and  Clinical Pharmacology (12.3)  ]  .\n', '\n', ' Table 2.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,lipitor,93,3177,3179,Drug Interactions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,lipitor,94,3179,3249,"Associated with Increased Risk of Myopathy/Rhabdomyolysis \n', ' Interacting Agents                                       Prescribing Recommendations                     \n', '  \n', ' Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir)  Avoid atorvastatin                              \n', ' HIV protease inhibitor (lopinavir plus ritonavir)        Use with caution and lowest dose necessary      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,lipitor,95,3249,3292,"\n', ' Clarithromycin, itraconazole,HIV protease inhibitors (saquinavir plus ritonavir [note: Use with caution and with the lowest dose necessary (12.3)] , darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,lipitor,96,3292,3300,Do not exceed 20 mg atorvastatin daily          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,lipitor,97,3300,3458,"\n', ' HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir)  Do not exceed 40 mg atorvastatin daily          \n', '        Cases of  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction  have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see  Drug Interactions (7.11)  ]  .\n', ' \n', '\n', '  LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a  nonoseaeaeonlyasinstruction or having a risk factor predisposing to the development of  nonoseaeaeonlyasinstruction secondary to  nonoseaeaeonlyasinstruction (e.g., severe  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  major surgery, trauma, severe  notaecandidatepreexistingconditionorriskfactor  endocrine and electrolyte  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor and electrolyte  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor .  ",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
98,lipitor,98,3458,3533,"\n', '\n', '    5.2  oselabeledaefromdruguse \n', '  Statins, like some other lipid-lowering therapies, have been associated with biochemical  oselabeledaeclasseffect  Persistent  oselabeledaefromdruguse (>3 times the upper limit of normal [ULN] occurr oselabeledaefromdruguse  on 2 or more occasions) in  oselabeledaefromdruguse occurred in 0.7% of patients who received LIPITOR in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,lipitor,99,3533,3565,"The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,lipitor,100,3565,3602,"\n', '\n', ' One patient in clinical trials developed  oselabeledaefromdruguse   oselabeledaefromdruguse (LFT) in other patients were not associated with  nonoseaenegation or other clinical signs or symptoms.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
101,lipitor,101,3602,3623,"Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,lipitor,102,3623,3666,"Eighteen of 30 patients with  nonoseaeaeonlyasinstruction continued treatment with a reduced dose of LIPITOR.\n', '\n', ' It is recommended that liver enzyme tests be obtained prior to initiating therapy with LIPITOR and repeated as clinically indicated.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,lipitor,103,3666,3689,"There have been rare postmarketing reports of  nonoseaegeneralterm and non-fatal  oselabeledaefromdruguse in patients taking statins, including atorvastatin.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,lipitor,104,3689,3712,"If serious  nonoseaeaeonlyasinstruction with clinical symptoms and/or  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication occurs during treatment with LIPITOR, promptly interrupt therapy.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
105,lipitor,105,3712,3836,"If an alternate etiology is not found, do not restart LIPITOR.\n', '\n', ' LIPITOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatecontraindication or  notaecandidatecontraindication are contraindications to the use of LIPITOR [see  Contraindications (4)  ]  .\n', '\n', '    5.3 Endocrine Function\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse HbA1c and  oselabeledaefromdruguse levels have been reported with HMG-CoA reductase inhibitors, including LIPITOR.\n', '\n', ' Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.",0,0,1,0,0,0,0,0,0,0,0,1,0,0,0
106,lipitor,106,3836,3850,Clinical studies have shown that LIPITOR does not  nonoseaenegation or  nonoseaenegation  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
107,lipitor,107,3850,3867,The effects of statins on male fertility have not been studied in adequate numbers of patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,lipitor,108,3867,3885,"The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,lipitor,109,3885,3949,"Caution should be exercised if a statin is administered concomitantly with drugs that may  nonoseaeaeonlyasinstruction  such as ketoconazole, spironolactone, and cimetidine.\n', '\n', '    5.4 CNS Toxicity\n', '\n', '   nonoseaeaeanimal was seen in a female dog treated for 3 months at 120 mg/kg/day.  ",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
110,lipitor,110,3949,3980,nonoseaeaeanimal and  nonoseaeaeanimal were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
111,lipitor,111,3980,4024,"The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0-24 hours) based on the maximum human dose of 80 mg/day.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,lipitor,112,4024,4061,A single  nonoseaeaeanimal was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
113,lipitor,113,4061,4101,No  nonoseaeaeanimal have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
114,lipitor,114,4101,4119,These doses were 6 to 11 times (mouse) and 8 to 16 times (rat),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,lipitor,115,4119,4173,"the human AUC (0-24) based on the maximum recommended human dose of 80 mg/day.\n', '\n', '  nonoseaeaeanimal  characterized by  nonoseaeaeanimal   nonoseaeaeanimal  and  nonoseaeaeanimal  have been observed in dogs treated with other members of this class.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
116,lipitor,116,4173,4339,"A chemically similar drug in this class produced  nonoseaeaeanimal ( nonoseaeaeanimal  in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.\n', '\n', '    5.5 Use in Patients with Recent Stroke or TIA\n', '\n', '  In a post-hoc analysis of the  nonoseaeaeonlyasinstruction Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where LIPITOR 80 mg vs. placebo was administered in 4,731 subjects without  nonoseaenegation who had a  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor within the preceding 6 months, a higher incidence of  oselabeledaefromdruguse was seen in the LIPITOR 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168).",1,0,1,0,0,0,0,1,1,0,0,0,0,0,0
117,lipitor,117,4339,4365,"The incidence of  nonoseaegeneralterm  nonoseaeaeratelteqplacebo was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively).",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
118,lipitor,118,4365,4397,"The incidence of nonfatal  oselabeledaefromdruguse was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,lipitor,119,4397,4425,"Some baseline characteristics, including  notaecandidatepreexistingconditionorriskfactor and lacunar  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor on study entry, were associated with a higher incidence of  oselabeledaefromdruguse ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,arcalyst,0,0,28,"['    6 ADVERSE REACTIONS\n', '\n', '  Six serious adverse reactions were reported by four patients during the clinical program.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,arcalyst,1,28,104,"These serious adverse reactions were   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  and   oselabeledaefromdruguse [  see Adverse Reactions (  6.3  )  ].\n', '\n', '\n', '\n', ' The most commonly reported adverse reaction associated with ARCALYST was  oselabeledaefromdruguse (ISR) [  see Adverse Reactions (  6.2    )].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,arcalyst,2,104,116,The next most commonly reported adverse reaction was  oselabeledaefromdruguse [  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,arcalyst,3,116,126,see Adverse Reactions (  6.3  )  ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,arcalyst,4,126,230,".\n', '\n', '\n', '\n', ' Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The data described herein reflect exposure to ARCALYST in 600 patients, including 85 exposed for at least 6 months and 65 exposed for at least one year.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,arcalyst,5,230,246,"These included patients with  notaecandidateindication  patients with other diseases, and healthy volunteers.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
6,arcalyst,6,246,262,Approximately 60 patients with  notaecandidateindication have been treated weekly with 160 mg of ARCALYST.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,arcalyst,7,262,273,The pivotal trial population included 47 patients with  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,arcalyst,8,273,290,These patients were between the ages of 22 and 78 years (average 51 years).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,arcalyst,9,290,301,Thirty-one patients were female and 16 were male.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,arcalyst,10,301,310,All of the patients were White/Caucasian.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,arcalyst,11,310,372,"Six pediatric patients (12-17 years) were enrolled directly into the open-label extension phase.\n', '\n', '\n', '\n', '   EXCERPT:   The most common adverse reactions reported by patients with CAPS treated with ARCALYST are injection-site reactions and upper respiratory tract infections.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,arcalyst,12,372,429,"(  6.2  ,  6.3  )\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-877-REGN-777 (1-877-734-6777) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,arcalyst,13,429,487,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  Part A of the clinical trial was conducted in patients with  notaecandidatepreexistingconditionorriskfactor who were naive to treatment with ARCALYST.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
14,arcalyst,14,487,526,"Part A of the study was a randomized, double-blind, placebo-controlled, six-week study comparing ARCALYST to placebo [  see Clinical Studies (  14  )  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,arcalyst,15,526,830,"Table 1  reflects the frequency of adverse events reported by at least two patients during Part A.\n', '\n', '\n', '\n', ' Table 1: Most Frequent Adverse Reactions (Part A, Reported by at Least Two Patients) \n', '   Adverse Event                                        ARCALYST160 mg(n = 23)      Placebo(n= 24)           \n', ' Any AE                                               17 (74%)                  13 (54%)                   \n', '  oselabeledaefromdruguse                             11 (48%)                  3 (13%)                    \n', '  oselabeledaefromdruguse                    6 (26%)                   1 (4%)                     \n', '  nonoseaeaeratelteqplacebo                                               1 (4%)                    3 (13%)                    \n', '  nonoseaeaeratelteqplacebo                                             1 (4%)                    3 (13%)                    \n', '  oselabeledaefromdruguse                                            2 (9%)                    1 (4%)                     \n', '  nonoseaeaeratelteqplacebo                                 0                         2 (8%)                     \n', '  oselabeledaefromdruguse                                                2 (9%)                    0                          \n', '  oselabeledaefromdruguse                                         2 (9%)                    0                          \n', '  nonoseaeaeratelteqplacebo                                   1 (4%)                    1 (4%)                     \n', '  nonoseaeaeratelteqplacebo                              1 (4%)                    1 (4%)                     \n', '           6.2 Injection-Site Reactions\n', '   In patients with  notaecandidateindication  the most common and consistently reported adverse event associated with ARCALYST was  oselabeledaefromdruguse (ISR).",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
16,arcalyst,16,830,1096,"The  oselabeledaefromdruguse  oselabeledaefromdruguse included  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema, dermatitis,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema, dermatitis, discomfort,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles,  oselabeledaefromdruguse  oselabeledaefromdruguse included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth and  oselabeledaefromdruguse  Most  oselabeledaefromdruguse lasted for one to two days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,arcalyst,17,1096,1169,"No  nonoseaeaeonlyasinstruction were assessed as severe, and no patient discontinued study participation due to an  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '   6.3 Infections\n', '\n', '  During Part A, the incidence of patients reporting  oselabeledaefromdruguse was greater with ARCALYST (48%) than with placebo (17%).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,arcalyst,18,1169,1199,"In Part B, randomized withdrawal, the incidence of  nonoseaeaeratelteqplacebo were similar in the ARCALYST (18%) and the placebo patients (22%).",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
19,arcalyst,19,1199,1236,"Part A of the trial was initiated in the winter months, while Part B was predominantly performed in the summer months.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,arcalyst,20,1236,1328,"In placebo-controlled studies across a variety of patient populations encompassing 360 patients treated with rilonacept and 179 treated with placebo, the incidence of  oselabeledaefromdruguse was 34% and 27% (2.15 per patient-exposure year and 1.81 per patient-exposure year), respectively, for rilonacept and placebo.\n', '\n', '\n', '\n', ' Serious  nonoseaeother  One patient receiving ARCALYST for an unapproved indication in another study developed an  nonoseaeaefromofflabel  .",0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
21,arcalyst,21,1328,1336,The patient was on chronic glucocorticoid treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,arcalyst,22,1336,1359,The  nonoseaeaefromofflabel occurred after an intraarticular glucocorticoid injection into the bursa with subsequent local exposure to a suspected source of mycobacteria.,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
23,arcalyst,23,1359,1371,The patient recovered after the administration of the appropriate antimicrobial therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,arcalyst,24,1371,1389,One patient treated for another unapproved indication developed  nonoseaeaefromofflabel  nonoseaeaefromofflabel  which resulted in hospitalization.,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
25,arcalyst,25,1389,1435,"One patient  nonoseaegeneralterm in an open-label study of  notaecandidateindication from   nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '   6.4 Malignancies\n', '\n', '  [s  ",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
26,arcalyst,26,1435,1439,ee Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,arcalyst,27,1439,1445,(  5.2  )],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,arcalyst,28,1445,1447,.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,arcalyst,29,1447,1504,"\n', '\n', '\n', '\n', '   6.5 Hematologic Events\n', '\n', '  One patient in a study in an unapproved indication developed transient  nonoseaeaefromofflabel ( nonoseaeaeonlyasinstruction  after receiving a large dose (2000 mg intravenously) of ARCALYST.",1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
30,arcalyst,30,1504,1566,"The patient did not experience any  nonoseaenegation \n', '\n', '\n', '\n', '   6.6 Immunogenicity\n', '\n', '   oselabeledaefromdruguse directed  oselabeledaefromdruguse the receptor domains of  oselabeledaefromdruguse were  oselabeledaefromdruguse by an ELISA assay in patients with  notaecandidateindication after treatment with ARCALYST.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
31,arcalyst,31,1566,1594,Nineteen of 55 patients (35%) who had received ARCALYST for at least 6 weeks tested positive for  oselabeledaefromdruguse on at least one occasion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,arcalyst,32,1594,1634,"Of the 19, seven tested positive at the last assessment (Week 18 or 24 of the open-label extension period), and five patients tested  oselabeledaefromdruguse for  oselabeledaefromdruguse on at least one occasion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,arcalyst,33,1634,1697,"There was no correlation of antibody activity and either clinical effectiveness or safety.\n', '\n', '\n', '\n', ' The data reflect the percentage of patients whose test results were  nonoseaeaeonlyasinstruction to the rilonacept receptor domains in specific assays, and are highly dependent on the sensitivity and specificity of the assays.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,arcalyst,34,1697,1747,"The observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction in an assay is highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,arcalyst,35,1747,1867,"For these reasons, comparison of the incidence of antibodies to rilonacept with the incidence of antibodies to other products may be misleading.\n', '\n', '\n', '\n', '   6.7 Lipid profiles\n', '\n', '   notaecandidatepreexistingconditionorriskfactor and lipid levels  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor in patients with  notaecandidatepreexistingconditionorriskfactor  Patients with  notaecandidateindication treated with ARCALYST experienced  oselabeledaefromdruguse in their mean  oselabeledaefromdruguse  oselabeledaefromdruguse in their mean total cholesterol,  oselabeledaefromdruguse  oselabeledaefromdruguse in their mean total cholesterol, HDL cholesterol,  oselabeledaefromdruguse  oselabeledaefromdruguse in their mean total cholesterol, HDL cholesterol, LDL cholesterol, and  oselabeledaefromdruguse  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
36,arcalyst,36,1867,1898,"The mean  oselabeledaefromdruguse from baseline for  oselabeledaefromdruguse  oselabeledaefromdruguse from baseline for total cholesterol,  oselabeledaefromdruguse  oselabeledaefromdruguse from baseline for total cholesterol, HDL cholesterol,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,arcalyst,37,1898,1940,"oselabeledaefromdruguse  oselabeledaefromdruguse from baseline for total cholesterol, HDL cholesterol, LDL cholesterol, and  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,arcalyst,38,1940,1952,*  Interleukin-1 blockade may interfere with immune response to infections.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,arcalyst,39,1952,1966,"Serious, life-threatening infections have been reported in patients taking ARCALYST.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,arcalyst,40,1966,1978,Discontinue treatment with ARCALYST if a patient develops a serious infection.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,arcalyst,41,1978,1992,Do not initiate treatment with ARCALYST in patients with active or chronic infections.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,arcalyst,42,1992,2013,"(  5.1  ) \n', ' *  Hypersensitivity reactions associated with ARCALYST administration have been rare.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,arcalyst,43,2013,2028,"If a hypersensitivity reaction occurs, discontinue administration of ARCALYST and initiate appropriate therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,arcalyst,44,2028,2049,"(  5.5  ) \n', ' *  Live vaccines should not be given concurrently with ARCALYST.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,arcalyst,45,2049,2064,"Prior to initiation of therapy with ARCALYST, patients should receive all recommended vaccinations.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,arcalyst,46,2064,2166,"(  5.3  ) \n', '    \n', ' \n', '\n', '   5.1 Infections\n', '\n', '\n', '\n', '  Interleukin -1 (IL-1) blockade may interfere with the immune response to  oselabeledaeclasseffect  Treatment with another medication that works through inhibition of IL-1 has been associated with an increased risk of serious  nonoseaeaeforanotherdruginclass  and serious  oselabeledaefromdruguse have been reported in patients taking ARCALYST [ see Clinical Studies (  14  )  ].",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
47,arcalyst,47,2166,2182,There was a greater incidence of  oselabeledaefromdruguse in patients on ARCALYST compared with placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,arcalyst,48,2182,2250,"In the controlled portion of the study, one  oselabeledaefromdruguse was reported as severe, which was  oselabeledaefromdruguse in a patient on ARCALYST.\n', '\n', '\n', '\n', ' In an open-label extension study, one patient developed  oselabeledaefromdruguse and  nonoseaegeneralterm [ see Adverse Reactions (  6.3  )  ].",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,arcalyst,49,2250,2314,"ARCALYST should be discontinued if a patient develops a serious  nonoseaeaeonlyasinstruction  Treatment with ARCALYST should not be initiated in patients with an active or chronic  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In clinical studies, ARCALYST has not been administered concomitantly with tumor necrosis factor (TNF) inhibitors.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,arcalyst,50,2314,2336,An increased incidence of serious  nonoseaeaefromdruginteraction has been associated with administration of an IL-1 blocker in combination with TNF inhibitors.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
51,arcalyst,51,2336,2380,"Taking ARCALYST with TNF inhibitors is not recommended because this may increase the risk of serious  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', ' Drugs that affect the immune system by blocking TNF",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,arcalyst,52,2380,2391,have been associated with an increased risk of  nonoseaeaeonlyasinstruction .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,arcalyst,53,2391,2508,"It is possible that taking drugs such as ARCALYST that block IL-1 increases the risk of  nonoseaeaeonlyasinstruction or other atypical or  nonoseaeaeonlyasinstruction  Healthcare providers should follow current CDC guidelines both to evaluate for and to treat possible  notaecandidatepreexistingconditionorriskfactor before initiating therapy with ARCALYST.\n', '\n', '\n', '\n', '    5.2 Immunosuppression\n', '\n', '\n', '\n', '  The impact of treatment with ARCALYST on  notaecandidatepreexistingconditionorriskfactor and/or chronic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor and the development of  nonoseaeother is not known [ see Adverse Reactions (  6.3  )]  .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,1
54,arcalyst,54,2508,2600,"However, treatment with immunosuppressants, including ARCALYST, may result in an increase in the risk of  oselabeledaeclasseffect \n', '\n', '\n', '\n', '    5.3 Immunizations\n', '\n', '\n', '\n', '  Since no data are available on either the efficacy of live vaccines or on the risks of  nonoseaeaeonlyasinstruction by live vaccines in patients receiving ARCALYST, live vaccines should not be given concurrently with ARCALYST.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,arcalyst,55,2600,2619,"In addition, because ARCALYST may  nonoseaeaeonlyasinstruction  vaccinations may not be effective in patients receiving ARCALYST.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,arcalyst,56,2619,2691,"No data are available on the effectiveness of vaccination with inactivated (killed) antigens in patients receiving ARCALYST.\n', '\n', '\n', '\n', ' Because IL-1 blockade may  nonoseaeaeonlyasinstruction  it is recommended that prior to initiation of therapy with ARCALYST adult and pediatric patients receive all recommended vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,arcalyst,57,2691,2707,(See current Recommended Immunizations schedules at the website of the Centers for Disease Control.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,arcalyst,58,2707,2769,"http://www.cdc.gov/vaccines/recs/schedules/).\n', '\n', '\n', '\n', '    5.4 Lipid Profile Changes\n', '\n', '\n', '\n', '  Patients should be monitored for  nonoseaeaeonlyasinstruction and provided with medical treatment if warranted [see Adverse Reactions (  6.7  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,arcalyst,59,2769,2817,".\n', '\n', '\n', '\n', '    5.5 Hypersensitivity\n', '\n', '\n', '\n', '   oselabeledaefromdruguse reactions associated with ARCALYST administration in the clinical studies were rare.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,arcalyst,60,2817,2823,If a  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,gattex,0,0,53,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions (>= 10%) across all studies with GATTEX are abdominal pain, injection site reactions, nausea, headaches, abdominal distension, upper respiratory tract infection.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,gattex,1,53,78,"In addition, vomiting and fluid overload were reported in the SBS studies (1 and 3) at rates >= 10%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,gattex,2,78,83,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,gattex,3,83,135,"\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact NPS Pharmaceuticals at 1-855-5GATTEX (1-855-542-8839) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,gattex,4,135,172,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,gattex,5,172,256,"Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' Across all clinical studies, 566 subjects were exposed to at least one dose of GATTEX (190 patient-years of exposure; mean duration of exposure was 17 weeks).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,gattex,6,256,439,"Of the 566 subjects, 173 subjects were treated in Phase 3  notaecandidateindication studies (134/173 [77%] at the dose of 0.05 mg/kg/day and 39/173 [23%] at the dose of 0.10 mg/kg/day).\n', '\n', '\n', '\n', ' The most commonly reported (>= 10%) adverse reactions in patients treated with GATTEX across all clinical studies (n = 566) were:  oselabeledaefromdruguse (30.0%);  oselabeledaefromdruguse (22.4%);  oselabeledaefromdruguse (18.2%);  oselabeledaefromdruguse (15.9%);  oselabeledaefromdruguse (13.8%);  oselabeledaefromdruguse (11.8%).\n', '\n', '\n', '\n', ' The rates of adverse reactions in subjects with  notaecandidateindication participating in two randomized, placebo-controlled, 24-week, double-blind clinical studies (Study 1 and Study 3) are summarized in Table 1.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,gattex,7,439,467,"Only those reactions with a rate of at least 5% in the GATTEX group, and greater than placebo group, are summarized in Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,gattex,8,467,477,The majority of these reactions were mild or moderate.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,gattex,9,477,514,"Of subjects receiving GATTEX at the recommended dose of 0.05 mg/kg/day, 88.3% (N=68/77) experienced an adverse reaction, as compared to 83.1% (49/59) for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,gattex,10,514,623,"Many of these adverse reactions have been reported in association with the underlying disease and/or parenteral nutrition.\n', '\n', '\n', '\n', ' Table 1: Adverse reactions in >=5% of GATTEX-treated SBS subjects and more frequent than placebo: Studies 1 and 3 \n', ' Adverse Reaction                                               Placebo(N=59)n (%)   GATTEX0.05mg/kg/day(N=77)n (%)   \n', '  \n', '  oselabeledaefromdruguse                                                     16 ( 27.1)            29 ( 37.7)        \n', '  oselabeledaefromdruguse                                  8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,gattex,11,623,632,( 13.6)             20 ( 26.0)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,gattex,12,632,678,"\n', '  oselabeledaefromdruguse                                                             12 ( 20.3)            19 ( 24.7)        \n', '  oselabeledaefromdruguse                                                1 ( 1.7)             15 ( 19.5)        \n', '  oselabeledaefromdruguse                                                           6 ( 10.2)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,gattex,13,678,708,"9 ( 11.7)         \n', '  oselabeledaefromdruguse                                                      4 ( 6.8)             9 ( 11.7)         \n', '  oselabeledaefromdruguse                                                          4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,gattex,14,708,760,"( 6.8)              7 ( 9.1)         \n', '  oselabeledaefromdruguse                                                    3 ( 5.1)              6 ( 7.8)         \n', '  oselabeledaefromdruguse                                                  2 ( 3.4)              5 ( 6.5)         \n', '  oselabeledaefromdruguse                                                     0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,gattex,15,760,763,4 ( 5.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,gattex,16,763,774,")         \n', '  oselabeledaefromdruguse                                                                  0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,gattex,17,774,777,4 ( 5.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,gattex,18,777,796,")         \n', '  oselabeledaefromdruguse                                                     1 ( 1.7)              4 ( 5.2)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,gattex,19,796,823,"\n', '   Subjects with  notaecandidatepreexistingconditionorriskfactor  oselabeledaefromdruguse                                 3 (13.6)             13 (41.9)         \n', '         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
20,gattex,20,823,869,"In placebo-controlled Studies 1 and 3, 12% of patients in each of the placebo and GATTEX study groups experienced an  nonoseaeaeratelteqplacebo \n', ' \n', '\n', '     Adverse Reactions of Special Interest  \n",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
21,gattex,21,869,888,"', '\n', '\n', '\n', '      nonoseaegeneralterm  .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,gattex,22,888,919,"Three subjects were diagnosed with  oselabeledaefromdruguse in the clinical studies, all of whom were male and had received GATTEX 0.05 mg/kg/day in Study 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,gattex,23,919,961,"One subject had a history of abdominal radiation for  notaecandidatepreexistingconditionorriskfactor two decades prior to receiving GATTEX and prior  notaecandidatepreexistingconditionorriskfactor on CT scan, and was diagnosed with  oselabeledaefromdruguse of unconfirmed origin after 11 months of exposure to GATTEX.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
24,gattex,24,961,1020,"Two subjects had extensive smoking histories, and were diagnosed with  oselabeledaefromdruguse ( oselabeledaefromdruguse and non-small  oselabeledaefromdruguse  oselabeledaefromdruguse (squamous and  oselabeledaefromdruguse  after 12 months and 3 months of GATTEX exposure, respectively.\n', '\n', '\n', '\n', '      oselabeledaefromdruguse  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,gattex,25,1020,1038,"In the clinical studies, 6 subjects were diagnosed with  oselabeledaefromdruguse after initiation of study treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,gattex,26,1038,1094,"In the  notaecandidateindication placebo-controlled studies, 1/59 (1.7%) of subjects on placebo and 1/109 (0.9%) of subjects on GATTEX 0.05 mg/kg/day were diagnosed with  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo (inflammatory stomal and  nonoseaeaeratelteqplacebo after 3 and 5 months, respectively).",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
27,gattex,27,1094,1190,"The remaining 4  nonoseaeaeonlyasinstruction cases occurred in the extension studies - two  oselabeledaefromdruguse (onset at 6 and 7 months in GATTEX 0.10 and 0.05 mg/kg/day dose groups, respectively), one  oselabeledaefromdruguse (onset 6 months in GATTEX 0.10 mg/kg/day dose group), and one small  oselabeledaefromdruguse (onset at 3 months in GATTEX 0.05 mg/kg/day dose group).\n', '\n', '\n', '\n', '      oselabeledaefromdruguse  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,gattex,28,1190,1222,"Overall, 12 subjects experienced one or more episodes of  oselabeledaefromdruguse  oselabeledaefromdruguse obstruction/ oselabeledaefromdruguse  6 in  notaecandidateindication placebo-controlled studies and 6 in the extension studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,gattex,29,1222,1264,The 6 subjects in the placebo-controlled trials were all on GATTEX: 3/77 (3.9%) on GATTEX 0.05 mg/kg/day and 3/32 (9.4%) on GATTEX 0.10 mg/kg/day.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,gattex,30,1264,1275,No cases of  nonoseaeaeonlyasinstruction occurred in the placebo group.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,gattex,31,1275,1284,Onsets ranged from 1 day to 6 months.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,gattex,32,1284,1323,"In the extension studies, 6 additional subjects (all on GATTEX 0.05 mg/kg/day) were diagnosed with  oselabeledaefromdruguse obstruction/ oselabeledaefromdruguse  oselabeledaefromdruguse stenosis with onsets ranging from 6 days to 7 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,gattex,33,1323,1343,Two of the 6 subjects from the placebo-controlled trials experienced recurrence of obstruction in the extension studies.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,gattex,34,1343,1406,"Of all 8 subjects with an episode of  oselabeledaefromdruguse obstruction/ oselabeledaefromdruguse  oselabeledaefromdruguse stenosis in these extension studies, 1 subject required endoscopic dilation and none required surgical intervention.\n', '\n', '\n', '\n', '      nonoseaegeneralterm  Biliary and Pancreatic  nonoseaegeneralterm  nonoseaegeneralterm and Pancreatic  nonoseaegeneralterm  nonoseaegeneralterm  .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,gattex,35,1406,1454,"For  nonoseaeaeonlyasinstruction and biliary  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction in the placebo-controlled studies, 3 subjects were diagnosed with  oselabeledaefromdruguse  all of whom had a prior history of  notaecandidatepreexistingconditionorriskfactor and were in the GATTEX 0.05 mg/kg/day dose group.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
36,gattex,36,1454,1463,No cases were reported in the placebo group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,gattex,37,1463,1478,One of these 3 cases had  oselabeledaefromdruguse and underwent cholecystectomy the next day.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,gattex,38,1478,1490,The remaining 2 cases underwent elective cholecystectomy at a later date.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,gattex,39,1490,1559,"In the extension studies, 3 subjects had an episode of  oselabeledaefromdruguse  2 subjects had new-onset  oselabeledaefromdruguse  and 1 subject experienced  nonoseaeaeonlyasinstruction secondary to an  notaecandidatepreexistingconditionorriskfactor  For  nonoseaeaeonlyasinstruction in the placebo-controlled studies, 1 subject (GATTEX 0.05 mg/kg/day dose group) had a  oselabeledaefromdruguse diagnosed after 4 months of GATTEX.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
40,gattex,40,1559,1600,"In the extension studies, 1 subject was diagnosed with  oselabeledaefromdruguse  and 1 subject was diagnosed with  oselabeledaefromdruguse \n', '\n', '\n', '\n', '      nonoseaegeneralterm  .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,gattex,41,1600,1637,"In the placebo-controlled trials,  oselabeledaefromdruguse was reported in 4/59 (6.8%) of subjects on placebo and 9/77 (11.7%) subjects on GATTEX 0.05 mg/kg/day.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,gattex,42,1637,1675,"Of the 9 cases in the GATTEX group, there were 2 cases of  oselabeledaefromdruguse (CHF), 1 of whom was reported as a serious adverse event and the other as non-serious.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,gattex,43,1675,1718,"The serious case had onset at 6 months, and was possibly associated with previously undiagnosed  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '     Concomitant Oral Medication  .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
44,gattex,44,1718,1734,GATTEX can increase the absorption of concomitant oral medications such as benzodiazepines and psychotropic agents.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,gattex,45,1734,1761,"In the placebo-controlled trials, an analysis of episodes of  nonoseaeaeonlyasinstruction and attention  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction was performed for subjects on benzodiazepines.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,gattex,46,1761,1795,One of the subjects in the GATTEX 0.05 mg/kg/day group (on prazepam) experienced dramatic  nonoseaeaefromdruginteraction progressing to  nonoseaeaefromdruginteraction during her first week of GATTEX therapy.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
47,gattex,47,1795,1941,"She was admitted to the ICU where her benzodiazepine level was >300 mcg/L. GATTEX and prazepam were discontinued, and  nonoseaeaefromdruginteraction resolved 5 days later.\n', '\n', '\n', '\n', '   6.2 Immunogenicity\n', '\n', '  Consistent with the potentially  nonoseaeaeonlyasinstruction properties of medicinal products containing peptides, administration of GATTEX may trigger the  oselabeledaefromdruguse  In a randomized, double-blind, placebo-controlled, parallel-group, multi-national, multi-center, clinical trial (Study 1) in adults with SBS, the incidence of  oselabeledaefromdruguse was 0% (0/16) at Week 12 and 18% (6/34) at Week 24 in subjects who received subcutaneous administration of 0.05 mg/kg",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
48,gattex,48,1941,1945,GATTEX once daily.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,gattex,49,1945,2013,"The  oselabeledaefromdruguse were cross-reactive to native glucagon-like peptide (GLP-2) in five of the six subjects (83%) who had  oselabeledaefromdruguse  In the extension study (Study 2), the  oselabeledaefromdruguse incidence rate increased over time to 27% (14/51) at 12 months and 38% (13/34) at 18 months.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,gattex,50,2013,2167,"nonoseaeaeonlyasinstruction appear to have no impact on short term (up to 1.5 years) efficacy and safety although the long-term impact is unknown.\n', '\n', '\n', '\n', ' A total of 40 subjects were tested for  nonoseaeaeonlyasinstruction - 20 of these subjects had no  nonoseaenegation  and the remaining 20 subjects had no detectable  nonoseaenegation although, the presence of teduglutide at low levels in these study samples could have resulted in false negatives (no  nonoseaeaeonlyasinstruction although present).\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction assay results are highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medication, and underlying diseases.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
51,gattex,51,2167,2213,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Neoplastic growth.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,gattex,52,2213,2223,There is a risk for acceleration of neoplastic growth.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,gattex,53,2223,2247,Colonoscopy of the entire colon with removal of polyps should be done before initiating treatment with GATTEX and is recommended after 1 year.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,gattex,54,2247,2264,"Subsequent colonoscopies should be done as needed, but no less frequently than every 5 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,gattex,55,2264,2272,In case of intestinal malignancy discontinue GATTEX.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,gattex,56,2272,2295,The clinical decision to continue GATTEX in patients with non-gastrointestinal malignancy should be made based on risk and benefit considerations.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,gattex,57,2295,2309,"(  5.1  ) \n', ' *  Intestinal obstruction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,gattex,58,2309,2327,"In patients who develop obstruction, GATTEX should be temporarily discontinued pending further clinical evaluation and management.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,gattex,59,2327,2332,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,gattex,60,2332,2343,"\n', ' *  Biliary and pancreatic disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,gattex,61,2343,2362,"Patients should undergo laboratory assessment (bilirubin, alkaline phosphatase, lipase, amylase) before starting GATTEX.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,gattex,62,2362,2372,Subsequent laboratory tests should be done every 6 months.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,gattex,63,2372,2395,"If clinically meaningful changes are seen, further evaluation is recommended including imaging, and continued treatment with GATTEX should be reassessed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,gattex,64,2395,2409,"(  5.3  ) \n', ' *  Fluid overload.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,gattex,65,2409,2420,There is a potential for fluid overload while on GATTEX.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,gattex,66,2420,2444,"If fluid overload occurs, especially in patients with cardiovascular disease, parenteral support should be appropriately adjusted, and GATTEX treatment reassessed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,gattex,67,2444,2510,"(  5.4  ) \n', '    \n', ' \n', '\n', '   5.1 Acceleration of Neoplastic Growth\n', '\n', '\n', '\n', '  Based on the pharmacologic activity and findings in animals, GATTEX has the potential to cause  oselabeledaefromdruguse including  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,gattex,68,2510,2536,In patients at increased risk for  nonoseaeaeonlyasinstruction  the clinical decision to use GATTEX should be considered only if the benefits outweigh the risks.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,gattex,69,2536,2569,"In patients with active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor (GI tract,  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor (GI tract, hepatobiliary,  notaecandidatepreexistingconditionorriskfactor , GATTEX therapy should be discontinued.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
70,gattex,70,2569,2592,In patients with active  nonoseaeaeonlyasinstruction  the clinical decision to continue GATTEX should be made based on risk-benefit considerations.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,gattex,71,2592,2605,[see  Clinical Pharmacology (12.1)  and  Nonclinical Toxicology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,gattex,72,2605,2634,"(13.1)  ]  \n', '\n', '\n', '\n', '    Colorectal Polyps  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,gattex,73,2634,2656,"'\n', '\n', '\n', '  oselabeledaefromdruguse were identified during the clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,gattex,74,2656,2679,Colonoscopy of the entire colon with removal of  nonoseaeaeonlyasinstruction should be done within 6 months prior to starting treatment with GATTEX.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,gattex,75,2679,2700,A follow-up colonoscopy (or alternate imaging) is recommended at the end of 1 year of GATTEX.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,gattex,76,2700,2714,Subsequent colonoscopies should be done every 5 years or more often as needed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,gattex,77,2714,2733,"If a  nonoseaeaeonlyasinstruction is found, adherence to current  nonoseaeaeonlyasinstruction follow-up guidelines is recommended.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,gattex,78,2733,2747,In case of diagnosis of  nonoseaeaeonlyasinstruction  GATTEX therapy should be discontinued .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,gattex,79,2747,2814,"[see  Adverse Reactions (6.1)  ]  \n', '\n', '\n', '\n', '     oselabeledaefromdruguse  \n', '\n', '\n', '\n', ' Based on  nonoseaeaeanimal findings in the rat  nonoseaeaeonlyasinstruction study, patients should be monitored clinically for  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
80,gattex,80,2814,2826,"If a  nonoseaeaeonlyasinstruction is found, it should be removed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,gattex,81,2826,2838,In case of  nonoseaeaeonlyasinstruction  GATTEX therapy should be discontinued.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,gattex,82,2838,2843,[see  Nonclinical Toxicology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,gattex,83,2843,2893,"(13.1)  ]  \n', '\n', '\n', '\n', '    5.2 Intestinal Obstruction\n', '\n', '\n', '\n', '   oselabeledaefromdruguse has been reported in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,gattex,84,2893,2918,In patients who develop  nonoseaeaeonlyasinstruction or stomal  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  GATTEX should be temporarily discontinued while the patient is clinically managed.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,gattex,85,2918,2932,"GATTEX may be restarted when the obstructive presentation resolves, if clinically indicated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,gattex,86,2932,3019,"[see  Adverse Reactions (6.1)  ]  \n', '\n', '\n', '\n', '    5.3 Biliary and Pancreatic Disease\n', '\n', '\n', '\n', '   Gallbladder and Biliary Tract Disease  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  have been reported in clinical studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,gattex,87,3019,3035,For identification of the onset or worsening of  nonoseaeaeonlyasinstruction biliary  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,gattex,88,3035,3069,"patients should undergo laboratory assessment of bilirubin and alkaline phosphatase within 6 months prior to starting GATTEX, and at least every 6 months while on GATTEX; or more frequently if needed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,gattex,89,3069,3100,"If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder and/or biliary tract is recommended; and the need for continued GATTEX treatment should be reassessed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,gattex,90,3100,3156,"[see  Adverse Reactions (6.1)  ]  \n', '\n', '\n', '\n', '    Pancreatic Disease  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse has been reported in clinical studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,gattex,91,3156,3199,"For identification of onset or worsening of  nonoseaeaeonlyasinstruction  patients should undergo laboratory assessment of lipase and amylase within 6 months prior to starting GATTEX, and at least every 6 months while on GATTEX; or more frequently if needed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,gattex,92,3199,3228,"If clinically meaningful changes are seen, further evaluation such as imaging of the pancreas is recommended; and the need for continued GATTEX treatment should be reassessed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,gattex,93,3228,3308,"[see  Adverse Reactions (6.1)  and  Nonclinical Toxicology (13.1)  ]  \n', '\n', '\n', '\n', '    5.4 Fluid Overload\n', '\n', '\n', '\n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse have been observed in clinical trials, which were felt to be related to enhanced fluid absorption associated with GATTEX.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,gattex,94,3308,3333,"If  nonoseaeaeonlyasinstruction occurs, parenteral support should be adjusted and GATTEX treatment should be reassessed, especially in patients with underlying  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
95,gattex,95,3333,3352,"If significant  nonoseaeaeonlyasinstruction develops while on GATTEX, the need for continued GATTEX treatment should be reassessed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,gattex,96,3352,3406,"[ see  Adverse Reactions (6.1)  ]  \n', '\n', '\n', '\n', '    5.5 Increased Absorption of Concomitant Oral Medication\n', '\n', '\n', '\n', '   nonoseaeaefromdruginteraction ']",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
0,kit,0,0,36,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions (incidence < 1%) are injection site irritation and/or pain.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,kit,1,36,41,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,kit,2,41,185,"\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Navidea Biopharmaceuticals, Inc.  at 1-800-476-5270 or www.lymphoseek.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,kit,3,185,229,"In open label, single arm clinical trials, 553 patients with either  notaecandidateindication   notaecandidateindication  or  notaecandidateindication  notaecandidatepreexistingconditionorriskfactor the oral cavity,  notaecandidatepreexistingconditionorriskfactor  notaecandidateindication the oral cavity, skin, and  notaecandidateindication received Lymphoseek.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
4,kit,4,229,237,No patients experienced serious adverse reactions.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,kit,5,237,294,"oselabeledaefromdruguse  oselabeledaefromdruguse irritation (4 patients; 0.7%) and  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '  EXCERPT:    Hypersensitivity: Ask patients about prior reactions to drugs, especially dextran or modified forms of dextran.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,kit,6,294,305,Observe for hypersensitivity signs and symptoms following Lymphoseek injection.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,kit,7,305,314,Have resuscitation equipment and trained personnel immediately available.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,kit,8,314,394,"(  5.1  )  \n', '\n', '\n', '\n', ' \n', '\n', '\n', '\n', '   5.1 Hypersensitivity Reactions\n', '\n', '\n', '\n', '   Lymphoseek may pose a risk of  oselabeledaefromdruguse to dextran [see  Description (11)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,kit,9,394,416,Serious  nonoseaeaeforanotherdruginclass have been associated with dextran and modified forms of dextran (such as iron dextran drugs).  ,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
10,kit,10,416,421,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,kit,11,421,521,"', '\n', '\n', ' Before administering Lymphoseek, ask patients about prior  nonoseaeaeonlyasinstruction to drugs, especially to dextran and modified forms of dextran.  Have resuscitation equipment and trained personnel immediately available at the time of Lymphoseek administration.\n', '\n', '\n', '\n', '    5.2 Radiation Risks\n', '\n', '\n', '\n', '   Any radiation-emitting product may increase the  nonoseaeaeonlyasinstruction  especially in pediatric patients.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,kit,12,521,540,Adhere to the dose recommendations and ensure safe handling to minimize the risk for excessive  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,androgel,0,0,43,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse reactions (incidence >= 5%) are acne, application site reaction, abnormal lab tests, and prostatic disorders.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,androgel,1,43,49,(  6.1  )  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,androgel,2,49,78,"To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or      www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,androgel,3,78,107,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,androgel,4,107,228,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '       Clinical Trials in Hypogonadal Men    \n', '\n', '   Table 1  shows the incidence of all adverse events judged by the investigator to be at least possibly related to treatment with AndroGel 1% and reported by >1% of patients in a 180 Day, Phase 3 study.\n', '\n', ' Table 1: Adverse Events",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,androgel,5,228,293,"Possibly, Probably or Definitely Related to Use of AndroGel 1% in the 180-Day Controlled Clinical Trial \n', '  * nonoseaegeneralterm occurred in nine patients with one or more of the following events reported:  oselabeledaefromdruguse hemoglobin or  oselabeledaefromdruguse  oselabeledaefromdruguse or hematocrit,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
6,androgel,6,293,298,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,androgel,7,298,299,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,androgel,8,299,321,* oselabeledaefromdruguse included five patients with  oselabeledaefromdruguse  one with  oselabeledaefromdruguse  and one with  oselabeledaefromdruguse results.    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,androgel,9,321,326,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,androgel,10,326,327,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,androgel,11,327,366,"** oselabeledaefromdruguse were reported in two patients: one with  oselabeledaefromdruguse and one with slight  oselabeledaefromdruguse     \n', '  \n', '   Adverse Event                               Dose of AndroGel 1%     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,androgel,12,366,378,"\n', '   50 mg                                       75 mg              100",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,androgel,13,378,380,mg               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,androgel,14,380,393,"\n', '                                               N = 77             N = 40                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,androgel,15,393,397,N = 78               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,androgel,16,397,429,"\n', '  oselabeledaefromdruguse                                        1%                 3%                    8%                     \n', '  oselabeledaefromdruguse                                    1%                 0%                    1%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,androgel,17,429,445,"\n', '  oselabeledaefromdruguse                   5%                 3%                    4%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,androgel,18,445,557,"\n', '  oselabeledaefromdruguse                                    0%                 3%                    1%                     \n', '  oselabeledaefromdruguse                                  1%                 0%                    1%                     \n', '  oselabeledaefromdruguse                          0%                 3%                    3%                     \n', '  oselabeledaefromdruguse                                1%                 0%                    3%                     \n', '  oselabeledaefromdruguse                                    4%                 3%                    0%                     \n', '  oselabeledaefromdruguse                                3%                 0%                    3%                     \n', '  nonoseaegeneralterm                           6%                 5%                    3%                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,androgel,19,557,627,"\n', '  oselabeledaefromdruguse                            0%                 3%                    1%                     \n', '  oselabeledaefromdruguse                                 0%                 3%                    1%                     \n', '  oselabeledaefromdruguse                                 1%                 3%                    1%                     \n', '  oselabeledaefromdruguse                         3%                 3%                    5%                     \n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,androgel,20,627,628,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,androgel,21,628,756,"*                          3%                 0%                    0%                     \n', '          Other less common adverse reactions, reported in fewer than 1% of patients included:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', ' \n', '\n', ' In this 180 day clinical trial,  oselabeledaefromdruguse were reported with AndroGel 1%, but none was severe enough to require treatment or discontinuation of drug.\n', '\n', ' Six patients (4%) in this trial had adverse events that led to discontinuation of AndroGel 1%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,androgel,22,756,791,"These events included:  nonoseaenegation   nonoseaenegation (neither of which were considered related to AndroGel 1% administration),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
23,androgel,23,791,916,"No AndroGel 1% patient discontinued due to  nonoseaenegation \n', '\n', ' In a separate uncontrolled pharmacokinetic study of 10 patients, two had adverse events associated with AndroGel 1%; these were  oselabeledaefromdruguse and  oselabeledaefromdruguse in one patient and  oselabeledaefromdruguse and  oselabeledaefromdruguse in the other.\n', '\n', ' In a 3 year, flexible dose, extension study, the incidence of all adverse events judged by the investigator to be at least possibly related to treatment with AndroGel 1% and reported by > 1% of patients is shown in  Table 2  .\n', '\n', ' Table 2: Adverse Events",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
24,androgel,24,916,950,"Possibly, Probably or Definitely Related to Use of AndroGel 1% in the 3 Year, Flexible Dose, Extension Study \n', '   Adverse Event                                           Percent of Subjects                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,androgel,25,950,961,"\n', '                                                         (N = 162)                                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,androgel,26,961,1020,"\n', '  \n', '  + nonoseaegeneralterm occurred in 15 patients with one or more of the following events reported:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse hemoglobin or  oselabeledaefromdruguse  oselabeledaefromdruguse or hematocrit,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     \n', '  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
27,androgel,27,1020,1042,"* oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse     \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,androgel,28,1042,1043,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,androgel,29,1043,1049,* oselabeledaefromdruguse included three patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,androgel,30,1049,1104,"There were two with a  oselabeledaefromdruguse and one with slight  oselabeledaefromdruguse     \n', '  \n', '  nonoseaegeneralterm                                       9.3                                             \n', '  oselabeledaefromdruguse                                                1.9                                             \n', '  oselabeledaefromdruguse                               5.6                                             \n', '  oselabeledaefromdruguse                                                    3.1                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,androgel,31,1104,1111,"\n', '  oselabeledaefromdruguse                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,androgel,32,1111,1122,"1.9                                             \n', '  oselabeledaefromdruguse                                       11.7                                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,androgel,33,1122,1129,"\n', '  oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,androgel,34,1129,1140,"1.2                                             \n', '  oselabeledaefromdruguse                                        3.7                                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,androgel,35,1140,1148,"\n', '  oselabeledaefromdruguse *                                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,androgel,36,1148,1171,"1.9                                             \n', '  oselabeledaefromdruguse                                            2.5                                             \n', '  oselabeledaefromdruguse                                                  2.5                                             \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,androgel,37,1171,1329,"'        Two patients reported serious adverse events considered possibly related to treatment:  oselabeledaefromdruguse  and  oselabeledaefromdruguse requiring a transurethral resection of the prostate (TURP).\n', ' \n', '\n', ' Discontinuation for adverse events in this study included: two patients with  oselabeledaefromdruguse  one with  oselabeledaefromdruguse  and five with  oselabeledaefromdruguse (including  oselabeledaefromdruguse in 4 patients, and  oselabeledaefromdruguse with  oselabeledaefromdruguse in a fifth patient).\n', '\n', '       Increases in Serum PSA Observed in Clinical Trials of Hypogonadal Men    \n', '\n', ' During the initial 6-month study, the mean change in  oselabeledaefromdruguse had a statistically significant  oselabeledaefromdruguse of 0.26 ng/mL. Serum PSA was measured every 6 months thereafter in the 162  notaecandidateindication men on AndroGel 1% in the 3-year extension study.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
38,androgel,38,1329,1349,There was no additional statistically significant  nonoseaenegation observed in mean  nonoseaenegation from 6 months through 36 months.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
39,androgel,39,1349,1364,"However, there were  oselabeledaefromdruguse observed in approximately 18% of individual patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,androgel,40,1364,1443,"The overall mean change from baseline in serum PSA values for the entire group from month 6 to 36 was 0.11 ng/mL.\n', '\n', ' Twenty-nine patients (18%) met the per-protocol criterion for  oselabeledaefromdruguse  defined as >2X the baseline or any single serum  oselabeledaefromdruguse  Most of these (25/29) met this criterion by at least  oselabeledaefromdruguse from baseline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,androgel,41,1443,1465,"In most cases where  oselabeledaefromdruguse (22/25), the maximum serum PSA value was still <2 ng/mL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,androgel,42,1465,1549,"The first occurrence of a pre-specified, post-baseline  oselabeledaefromdruguse was seen at or prior to Month 12 in most of the patients who met this criterion (23 of 29; 79%).\n', '\n', "" Four patients met this criterion by having a serum  oselabeledaefromdruguse and in these, maximum serum PSA values were 6.2 ng/mL, 6.6 ng/mL, 6.7 ng/mL, and 10.7 ng/mL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,androgel,43,1549,1562,"In two of these patients,  oselabeledaefromdruguse was detected on biopsy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,androgel,44,1562,1587,"The first patient's PSA levels were 4.7 ng/mL and 6.2 ng/mL at baseline and at Month 6/Final, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,androgel,45,1587,1662,"The second patient's PSA levels were 4.2 ng/mL, 5.2 ng/mL, 5.8 ng/mL, and 6.6 ng/mL at baseline, Month 6, Month 12, and Final, respectively.\n"", '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post approval use of AndroGel 1%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,androgel,46,1662,1727,"Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure (Table 3).\n', '\n', '     Table 3: Adverse Drug Reactions from Postmarketing Experience of AndroGel 1% by MedDRA System Organ Class \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,androgel,47,1727,1737,"nonoseaegeneralterm            oselabeledaefromdruguse  oselabeledaefromdruguse Hgb,  oselabeledaefromdruguse (",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,androgel,48,1737,1739,oselabeledaefromdruguse                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,androgel,49,1739,1759,"\n', '  nonoseaegeneralterm                            oselabeledaefromdruguse   oselabeledaefromdruguse                        \n', '  nonoseaegeneralterm                                 oselabeledaefromdruguse                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,androgel,50,1759,1766,"\n', '  nonoseaegeneralterm                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,androgel,51,1766,1768,oselabeledaefromdruguse                                               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,androgel,52,1768,1779,"\n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,androgel,53,1779,1781,oselabeledaefromdruguse                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,androgel,54,1781,1786,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,androgel,55,1786,1790,nonoseaegeneralterm                             oselabeledaefromdruguse                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,androgel,56,1790,1900,"\n', '  nonoseaegeneralterm                             oselabeledaefromdruguse  oselabeledaefromdruguse liver function tests (e.g.  oselabeledaefromdruguse   oselabeledaefromdruguse GGTP,  oselabeledaefromdruguse  oselabeledaefromdruguse  bilirubin)   \n', '  nonoseaegeneralterm                                      oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse (nitrogen,  oselabeledaefromdruguse  oselabeledaefromdruguse (nitrogen, calcium,  oselabeledaefromdruguse  oselabeledaefromdruguse (nitrogen, calcium, potassium,  oselabeledaefromdruguse  oselabeledaefromdruguse (nitrogen, calcium, potassium, phosphorus,  oselabeledaefromdruguse ,  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '  nonoseaegeneralterm :   oselabeledaefromdruguse                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,androgel,57,1900,1913,"\n', '  nonoseaegeneralterm                                      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,androgel,58,1913,1915,oselabeledaefromdruguse           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,androgel,59,1915,1960,"\n', '  nonoseaegeneralterm                               oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '  nonoseaegeneralterm            oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (frequent or  oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,androgel,60,1960,1969,"\n', '  nonoseaegeneralterm                               oselabeledaefromdruguse                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,androgel,61,1969,1980,"\n', '  nonoseaegeneralterm              oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,androgel,62,1980,1997,"oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,androgel,63,1997,2013,"\n', '  nonoseaegeneralterm                                  oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse ,  oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,androgel,64,2013,2048,"\n', '            Secondary Exposure to Testosterone in Children    Cases of  oselabeledaemedicationerror to testosterone resulting in virilization of  oselabeledaemedicationerror  oselabeledaemedicationerror of children have been reported in postmarket surveillance.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,androgel,65,2048,2088,Signs and symptoms of these reported cases have included  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication clitoris (with surgical intervention) or the  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication erections and  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
66,androgel,66,2088,2113,"In most cases with a reported outcome, these signs and symptoms were reported to have regressed with removal of the testosterone gel exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,androgel,67,2113,2147,"In a few cases, however,  nonoseaemanifestationorcomplication did not fully return to age appropriate normal size, and  nonoseaemanifestationorcomplication \n', '\n', '    BOXED WARNING:",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
68,androgel,68,2147,2149,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,androgel,69,2149,2151,SECONDARY EXPOSURE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,androgel,70,2151,2163,"TO TESTOSTERONE\n', '\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,androgel,71,2163,2165,SECONDARY EXPOSURE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,androgel,72,2165,2185,"TO TESTOSTERONE\n', '\n', '    *   oselabeledaefromdruguse has been reported in  oselabeledaemedicationerror    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,androgel,73,2185,2220,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,androgel,74,2220,2243,"(  5.1  ) \n', ' *  Avoid unintentional exposure of women or children to AndroGel 1%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,androgel,75,2243,2253,Secondary exposure to testosterone can produce signs of virilization.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,androgel,76,2253,2267,AndroGel 1% should be discontinued until the cause of virilization is identified.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,androgel,77,2267,2306,"(  5.2  ) \n', ' *  Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,androgel,78,2306,2318,Evaluate patients with signs or symptoms consistent with DVT or PE.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,androgel,79,2318,2350,"(  5.4  ) \n', ' *  Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with use of testosterone replacement therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,androgel,80,2350,2370,"(  5.5  ) \n', ' *  Exogenous administration of androgens may lead to azoospermia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,androgel,81,2370,2409,"(  5.8  ) \n', ' *  Edema, with or without congestive heart failure (CHF), may be a complication in patients with preexisting cardiac, renal, or hepatic disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,androgel,82,2409,2434,"(  5.10  ,  6.2  ) \n', ' *  Sleep apnea may occur in those with risk factors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,androgel,83,2434,2469,"(  5.12  ) \n', ' *  Monitor serum testosterone, prostate specific antigen (PSA), hemoglobin, hematocrit, liver function tests, and lipid concentrations periodically.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,androgel,84,2469,2486,"(  5.1  ,  5.3  ,  5.9  ,  5.13  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,androgel,85,2486,2500,"\n', ' *  AndroGel 1% is flammable until dry.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,androgel,86,2500,2582,"(  5.16  ) \n', '    \n', ' \n', '\n', '   5.1 Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer\n', '\n', '    *  Patients with  notaecandidatepreexistingconditionorriskfactor treated with androgens are at an increased risk for  oselabeledaeclasseffect of signs and symptoms of  oselabeledaeclasseffect  Monitor patients with  notaecandidatepreexistingconditionorriskfactor for worsening signs and symptoms.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
87,androgel,87,2582,2640,"\n', ' *  Patients treated with androgens may be at increased risk for  oselabeledaeclasseffect  Evaluate patients for  nonoseaeaeonlyasinstruction prior to initiating and during treatment with androgens [see Contraindications (  4  ), Adverse Reactions (  6.1  ) and Nonclinical Toxicology (  13.1  )] .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,androgel,88,2640,2685,"\n', '       5.2 Potential for Secondary Exposure to Testosterone\n', ' \n', '\n', '  Cases of  oselabeledaemedicationerror resulting in virilization of  oselabeledaemedicationerror  oselabeledaemedicationerror of children have been reported in postmarketing surveillance.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,androgel,89,2685,2719,"Signs and symptoms have included  nonoseaemanifestationorcomplication the penis or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or clitoris,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication erections and  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
90,androgel,90,2719,2737,"In most cases, these signs and symptoms regressed with removal of the exposure to testosterone gel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,androgel,91,2737,2764,"In a few cases, however,  nonoseaemanifestationorcomplication did not fully return to age-appropriate normal size, and  nonoseaemanifestationorcomplication than chronological age.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
92,androgel,92,2764,2790,The risk of transfer was increased in some of these cases by not adhering to precautions for the appropriate use of the topical testosterone product.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,androgel,93,2790,2839,"Children and women should avoid contact with unwashed or unclothed application sites in men using AndroGel 1% [see Dosage and Administration (  2.2  ), Use in Specific Populations (  8.1  )  and Clinical Pharmacology (  12.3  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,androgel,94,2839,2913,".\n', '\n', ' Inappropriate  nonoseaeaefromofflabel or development of pubic hair or libido  nonoseaeaefromofflabel  nonoseaeaefromofflabel  nonoseaeaefromofflabel or libido  nonoseaeaefromofflabel  or  nonoseaemanifestationorcomplication  significant increase in  nonoseaemanifestationorcomplication  or other signs of  nonoseaemanifestationorcomplication in adult women should be brought to the attention of a physician and the possibility of  nonoseaeaeonlyasinstruction should also be brought to the attention of a physician.",1,0,0,0,1,0,0,0,0,0,1,0,0,0,0
95,androgel,95,2913,2939,"Testosterone gel should be promptly discontinued until the cause of  nonoseaeaeonlyasinstruction has been identified.\n', '\n', '    5.3  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,androgel,96,2939,2959,"\n', '   oselabeledaefromdruguse  reflective of  oselabeledaefromdruguse  may require lowering or discontinuation of testosterone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,androgel,97,2959,2966,Check hematocrit prior to initiating treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,androgel,98,2966,2989,"It would also be appropriate to re-evaluate the hematocrit 3 to 6 months after starting treatment, and then annually.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,androgel,99,2989,3003,If  nonoseaeaeonlyasinstruction  stop therapy until  nonoseaeaeonlyasinstruction to an acceptable concentration.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,androgel,100,3003,3061,"An  nonoseaeaeonlyasinstruction may increase the risk of  nonoseaemanifestationorcomplication \n', '\n', '    5.4 Venous Thromboembolism\n', '\n', '  There have been postmarketing reports of  oselabeledaefromdruguse  including  oselabeledaefromdruguse  and  oselabeledaefromdruguse , in patients using testosterone products such as AndroGel 1%.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
101,androgel,101,3061,3111,"Evaluate patients who report symptoms of  nonoseaemanifestationorcomplication  edema, warmth and erythema  nonoseaemanifestationorcomplication the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  warmth and erythema  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and erythema  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication for  nonoseaeaeonlyasinstruction and those who present with acute  nonoseaemanifestationorcomplication for  nonoseaeaeonlyasinstruction  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
102,androgel,102,3111,3141,"If a  nonoseaeaeonlyasinstruction is suspected, discontinue treatment with AndroGel 1% and initiate appropriate workup and management [see Adverse Reactions (  6.2  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,androgel,103,3141,3182,".\n', '\n', '    5.5 Cardiovascular Risk\n', '\n', '  Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,androgel,104,3182,3231,"To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of  nonoseaeaeonlyasinstruction , such as non-fatal  nonoseaeaeonlyasinstruction  non-fatal  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  with the use of testosterone compared to non-use.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,androgel,105,3231,3336,"Some studies, but not all, have reported an increased risk of  oselabeledaeclasseffect in association with use of testosterone replacement therapy in men.\n', '\n', ' Patients should be informed of this possible risk when deciding whether to use or to continue to use AndroGel 1%.\n', '\n', '    5.6 Abuse of Testosterone and Monitoring of Serum Testosterone Concentrations\n', '\n', '   Testosterone has been subject to  oselabeledaeother  typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,androgel,106,3336,3368,Anabolic androgenic steroid  nonoseaeaefromofflabel can lead to serious  nonoseaeaefromofflabel and psychiatric  nonoseaeaefromofflabel  nonoseaeaefromofflabel [see Drug Abuse and Dependence (  9  )]  .  ,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
107,androgel,107,3368,3396,"\n', '\n', '  If testosterone  nonoseaeaeonlyasinstruction is suspected, check serum testosterone concentrations to ensure they are within therapeutic range.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,androgel,108,3396,3415,"However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,androgel,109,3415,3433,Counsel patients concerning the serious adverse reactions associated with  nonoseaeaeonlyasinstruction of testosterone and anabolic androgenic steroids.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,androgel,110,3433,3532,"Conversely, consider the possibility of testosterone and anabolic androgenic steroid  nonoseaeaeonlyasinstruction in suspected patients who present with serious  nonoseaeaeonlyasinstruction or psychiatric  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   \n', '\n', '    5.7 Use in Women\n', '\n', '  Due to lack of controlled evaluations in women and potential  nonoseaeaefromofflabel  AndroGel 1% is not indicated for use in women [see Contraindications (  4  )  and Use in Specific Populations (  8.1  ,  8.3  )].  ",1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
111,androgel,111,3532,3536,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,androgel,112,3536,3646,"\n', '    5.8 Potential for Adverse Effects on Spermatogenesis\n', '\n', '  With large doses of exogenous androgens, including AndroGel 1%,  oselabeledaeclasseffect through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to  oselabeledaeclasseffect \n', '\n', '    5.9 Hepatic Adverse Effects\n', '\n', '  Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious  nonoseaeaeforanotherdruginclass ( nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass  and  nonoseaeaeforanotherdruginclass .  ",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
113,androgel,113,3646,3657,nonoseaeaeforanotherdruginclass can be a life-threatening or fatal complication.,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
114,androgel,114,3657,3671,Long-term therapy with intramuscular testosterone enanthate has produced multiple  nonoseaeaeforanotherdruginclass  ,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
115,androgel,115,3671,3698,"AndroGel 1% is not known to cause these adverse effects.\n', '\n', '    5.10 Edema\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,androgel,116,3698,3721,"'  Androgens, including AndroGel 1%, may promote  oselabeledaefromdruguse sodium and  oselabeledaefromdruguse  oselabeledaefromdruguse and water.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,androgel,117,3721,3768,"oselabeledaefromdruguse  with or without  oselabeledaefromdruguse  may be a serious complication in patients with preexisting  notaecandidatepreexistingconditionorriskfactor  renal, or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor [see Adverse Reactions (  6.2  )].  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
118,androgel,118,3768,3866,"\n', '\n', '    5.11 Gynecomastia\n', '\n', '   oselabeledaefromdruguse may develop and persist in patients being treated with androgens, including AndroGel 1%, for  notaecandidateindication \n', '\n', '    5.12 Sleep Apnea\n', '\n', '  The treatment of  notaecandidateindication men with testosterone may potentiate  oselabeledaeclasseffect in some patients, especially those with risk factors such as  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor [see Adverse Reactions (  6.2  )]  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
119,androgel,119,3866,3906,".\n', '\n', '    5.13 Lipids\n', '\n', '   oselabeledaefromdruguse may require dose adjustment or discontinuation of testosterone therapy.\n', '\n', '    5.14  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,androgel,120,3906,3937,"\n', '  Androgens, including AndroGel 1%, should be used with caution in  notaecandidatepreexistingconditionorriskfactor at risk of  notaecandidatepreexistingconditionorriskfactor (and associated  notaecandidatepreexistingconditionorriskfactor .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
121,androgel,121,3937,3997,"Regular monitoring of  nonoseaeaeonlyasinstruction concentrations is recommended in these patients.\n', '\n', '    5.15 Decreased Thyroxine-binding Globulin\n', '\n', '  Androgens, including AndroGel 1%, may  oselabeledaefromdruguse  resulting in  oselabeledaefromdruguse and  oselabeledaefromdruguse T3 and  oselabeledaefromdruguse  oselabeledaefromdruguse and T4.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,androgel,122,3997,4017,"Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of  nonoseaenegation ']",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
0,savella,0,0,17,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,savella,1,17,96,"The most frequently occurring adverse reactions (>= 5% and greater than placebo) were nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, heart rate increased, dry mouth, and hypertension (  6.1  ).\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, LLC.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,savella,2,96,114,", at (800) 678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,savella,3,114,151,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,savella,4,151,312,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '     Patient Exposure  \n', '\n', '\n', '\n', ' Savella was evaluated in three double-blind placebo-controlled trials involving 2209  notaecandidateindication patients (1557 patients treated with Savella and 652 patients treated with placebo) for a treatment period up to 29 weeks.\n', '\n', '\n', '\n', ' The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
5,savella,5,312,355,"A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.\n', '\n', '\n', '\n', '     Adverse Reactions Leading to Discontinuation  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,savella,6,355,437,"\n', '\n', '\n', '\n', ' In placebo-controlled trials in patients with  notaecandidateindication  23% of patients treated with Savella\n', '\n', '\n', '\n', ' 100 mg/day, 26% of patients treated with Savella 200 mg/day discontinued prematurely due to adverse reactions, compared to 12% of patients treated with placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,savella,7,437,568,"The adverse reactions that led to  nonoseaeaeonlyasinstruction in >= 1% of patients in the Savella treatment group and with an incidence rate greater than that in the placebo treatment group were  oselabeledaefromdruguse (milnacipran 6%, placebo 1%),  oselabeledaefromdruguse (milnacipran 3%, placebo 1%),  oselabeledaefromdruguse (milnacipran 2%, placebo 0%),  oselabeledaefromdruguse (milnacipran 1%, placebo 0%),  oselabeledaefromdruguse (milnacipran 1%, placebo 0%),  oselabeledaefromdruguse (milnacipran 1%, placebo 0%),  oselabeledaefromdruguse (milnacipran 1%, placebo 0%), and  oselabeledaefromdruguse (milnacipran 1% and placebo 0.5%).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,savella,8,568,656,"Discontinuation due to adverse reactions was generally more common among patients treated with Savella 200 mg/day compared to Savella 100 mg/day.\n', '\n', '\n', '\n', '     Most Common Adverse Reactions in Placebo Controlled Trials  \n', '\n', '\n', '\n', ' In the placebo-controlled fibromyalgia patient trials, the most frequently occurring adverse reaction in clinical trials was  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,savella,9,656,779,"The most common adverse reactions (incidence >= 5% and twice placebo) in patients treated with Savella were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '     Table 4    lists all adverse reactions that occurred in at least 2% of patients treated with Savella at either 100 or 200 mg/day and at an incidence greater than that of placebo.\n', '\n', '\n', '\n', ' Table 4: Treatment-Emergent Adverse Reaction Incidence in Placebo Controlled Trials in Fibromyalgia Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,savella,10,779,802,(Events Occurring in at Least 2% of All Savella-Treated Patients and Occurring More Frequently in Either Savella Treatment Group,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,savella,11,802,809,Than in the Placebo Treatment Group),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,savella,12,809,830,"\n', '  System Organ Class-Preferred Term    Savella100 mg/day(n = 623) %    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,savella,13,830,837,Savella200 mg/day(n = 934),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,savella,14,837,839,%    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,savella,15,839,846,All Savella(n = 1557) %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,savella,16,846,852,Placebo(n = 652) %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,savella,17,852,859,"\n', '   nonoseaegeneralterm                                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,savella,18,859,868,"\n', '     oselabeledaefromdruguse                     8                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,savella,19,868,870,7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,savella,20,870,872,7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,savella,21,872,874,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,savella,22,874,883,"\n', '     oselabeledaefromdruguse                      3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,savella,23,883,885,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,savella,24,885,887,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,savella,25,887,889,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,savella,26,889,896,"\n', '   nonoseaegeneralterm                                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
27,savella,27,896,905,"\n', '     oselabeledaefromdruguse                   1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,savella,28,905,907,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,savella,29,907,909,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,savella,30,909,911,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,savella,31,911,925,"\n', '   nonoseaegeneralterm                                                                                     \n', '     oselabeledaefromdruguse                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,savella,32,925,927,35                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,savella,33,927,931,39                 37                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,savella,34,931,933,20                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,savella,35,933,942,"\n', '     oselabeledaefromdruguse                     16                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,savella,36,942,946,15                 16                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,savella,37,946,948,4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,savella,38,948,955,"\n', '     oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,savella,39,955,957,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,savella,40,957,959,7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,savella,41,959,961,7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,savella,42,961,963,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,savella,43,963,970,"\n', '     oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,savella,44,970,974,5                  5                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,savella,45,974,976,5                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,savella,46,976,978,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,savella,47,978,987,"\n', '     oselabeledaefromdruguse                   3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,savella,48,987,989,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,savella,49,989,991,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,savella,50,991,993,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,savella,51,993,1009,"\n', '   nonoseaegeneralterm                                                                                              \n', '     oselabeledaefromdruguse                       3                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,savella,52,1009,1011,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,savella,53,1011,1013,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,savella,54,1013,1015,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,savella,55,1015,1024,"\n', '     oselabeledaefromdruguse                           1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,savella,56,1024,1026,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,savella,57,1026,1028,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,savella,58,1028,1030,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,savella,59,1030,1041,"\n', '     oselabeledaefromdruguse                 2                  1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,savella,60,1041,1043,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,savella,61,1043,1045,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,savella,62,1045,1052,"\n', '   nonoseaegeneralterm                                                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,savella,63,1052,1059,"\n', '     oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,savella,64,1059,1061,7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,savella,65,1061,1063,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,savella,66,1063,1065,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,savella,67,1065,1067,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,savella,68,1067,1083,"\n', '   nonoseaegeneralterm                                                                                                 \n', '     oselabeledaefromdruguse             5                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,savella,69,1083,1085,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,savella,70,1085,1087,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,savella,71,1087,1089,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,savella,72,1089,1100,"\n', '     oselabeledaefromdruguse         3                  3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,savella,73,1100,1102,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,savella,74,1102,1104,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,savella,75,1104,1120,"\n', '   nonoseaegeneralterm                                                                                \n', '     oselabeledaefromdruguse               1                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,savella,76,1120,1122,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,savella,77,1122,1124,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,savella,78,1124,1126,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,savella,79,1126,1140,"\n', '   nonoseaegeneralterm                                                                                       \n', '     oselabeledaefromdruguse                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
80,savella,80,1140,1148,19                 17                 18                 14                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,savella,81,1148,1153,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,savella,82,1153,1157,oselabeledaefromdruguse                        11                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,savella,83,1157,1161,10                 10                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,savella,84,1161,1163,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,savella,85,1163,1170,"\n', '     oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,savella,86,1170,1174,6                  4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,savella,87,1174,1176,5                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,savella,88,1176,1178,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,savella,89,1178,1183,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,savella,90,1183,1189,oselabeledaefromdruguse                      2                  3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,savella,91,1189,1191,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,savella,92,1191,1193,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,savella,93,1193,1200,"\n', '     oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,savella,94,1200,1202,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,savella,95,1202,1204,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,savella,96,1204,1206,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,savella,97,1206,1208,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,savella,98,1208,1217,"\n', '     oselabeledaefromdruguse                     1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,savella,99,1217,1219,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,savella,100,1219,1221,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,savella,101,1221,1223,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,savella,102,1223,1234,"\n', '     oselabeledaefromdruguse                 2                  1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,savella,103,1234,1236,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,savella,104,1236,1238,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,savella,105,1238,1269,"\n', '   nonoseaegeneralterm                                                                                          \n', '     oselabeledaefromdruguse                         12                 12                 12                 10                 \n', '     oselabeledaefromdruguse                          5                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
106,savella,106,1269,1271,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,savella,107,1271,1273,4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,savella,108,1273,1275,4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,savella,109,1275,1291,"\n', '   nonoseaegeneralterm                                                                                          \n', '   oselabeledaefromdruguse                            2                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,savella,110,1291,1293,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,savella,111,1293,1295,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,savella,112,1295,1297,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,savella,113,1297,1315,"\n', '   nonoseaegeneralterm                                                                                                 \n', '     oselabeledaefromdruguse                    8                  9                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,savella,114,1315,1317,9                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,savella,115,1317,1319,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,savella,116,1319,1330,"\n', '     oselabeledaefromdruguse                             3                  4                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,savella,117,1330,1332,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,savella,118,1332,1334,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,savella,119,1334,1343,"\n', '     oselabeledaefromdruguse                         3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,savella,120,1343,1345,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,savella,121,1345,1347,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,savella,122,1347,1349,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,savella,123,1349,1356,"\n', '   nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,savella,124,1356,1369,"\n', '     oselabeledaefromdruguse                        11                 12                 12                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,savella,125,1369,1371,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,savella,126,1371,1382,"\n', '     oselabeledaefromdruguse                     7                  4                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,savella,127,1382,1384,5                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,savella,128,1384,1386,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,savella,129,1386,1397,"\n', '     oselabeledaefromdruguse                         2                  3                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,savella,130,1397,1399,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,savella,131,1399,1401,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,savella,132,1401,1408,"\n', '                oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,savella,133,1408,1517,"\n', ' \n', '\n', ' In placebo-controlled fibromyalgia clinical trials, patients treated with Savella for up to 3 months experienced a mean  oselabeledaefromdruguse of approximately 0.8 kg in both the Savella 100 mg/day and the Savella 200 mg/day treatment groups, compared with a mean  nonoseaeaeonlyasinstruction of approximately 0.2 kg in placebo-treated patients.\n', '\n', '\n', '\n', '     Genitourinary Adverse Reactions in Males  \n', '\n', '\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,savella,134,1517,1680,"In the placebo-controlled  notaecandidateindication studies, the following treatment-emergent adverse reactions related to the genitourinary system were observed in at least 2% of male patients treated with Savella, and occurred at a rate greater than in placebo-treated male patients:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '     Other Adverse Reactions Observed During Clinical Trials of Savella in Fibromyalgia  \n', '\n', '\n', '\n', ' Following is a list of frequent (those occurring on one or more occasions in at least 1/100 patients) treatment-emergent adverse reactions reported from 1824  notaecandidateindication patients treated with Savella for periods up to 68 weeks.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
135,savella,135,1680,1764,"The listing does not include those events already listed in    Table 4    , those events for which a drug cause was remote, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life threatening.\n', '\n', '\n', '\n', ' Adverse reactions are categorized by body system and listed in order of decreasing frequency.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,savella,136,1764,2010,"Adverse reactions of major clinical importance are described in the  Warnings and Precautions section (  5  )  .\n', '\n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse  oselabeledaefromdruguse decreased or  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following additional adverse reactions have been identified from spontaneous reports of Savella received worldwide.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
137,savella,137,2010,2036,"These adverse reactions have been chosen for inclusion because of a combination of seriousness, frequency of reporting, or potential causal connection to Savella.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,savella,138,2036,2071,"However, because these adverse reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,savella,139,2071,2255,"These events include:\n', '\n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse  oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
140,savella,140,2255,2328,"\n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
141,savella,141,2328,2337,"'\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,savella,142,2337,2343,WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,savella,143,2343,2397,"\n', '\n', '  WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS \n', '\n', '    Savella is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of  notaecandidatepreexistingconditionorriskfactor and other  notaecandidatepreexistingconditionorriskfactor  Antidepressants",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
144,savella,144,2397,2413,increased the risk compared to placebo of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,savella,145,2413,2437,"oselabeledaeclasseffect  in children, adolescents, and young adults in short-term studies of  notaecandidatepreexistingconditionorriskfactor  and other  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
146,savella,146,2437,2462,"Anyone considering the use of such drugs in a child, adolescent, or young adult must balance this risk with the clinical need.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,savella,147,2462,2507,Short-term studies did not show an increase in the risk of  nonoseaeaeonlyasinstruction with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,savella,148,2507,2570,"notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor are themselves associated with increases in the risk of  nonoseaeaeonlyasinstruction  Patients of all ages who are started on Savella should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  Families and caregivers should be advised of the need for close observation and communication with the prescriber.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
149,savella,149,2570,2606,"Savella is not approved for use in the treatment of  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
150,savella,150,2606,2625,*    Suicidality: Monitor for worsening of depressive symptoms and suicide risk (  5.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,savella,151,2625,2634,"\n', "" *    Serotonin Syndrome:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,savella,152,2634,2685,"Serotonin syndrome has been reported with SSRIs and SNRIs, including Savella, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St. John's Wort).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,savella,153,2685,2697,"If such symptoms occur, discontinue Savella and initiate supportive treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,savella,154,2697,2736,"If concomitant use of Savella with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment and dose increases (  5.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,savella,155,2736,2758,"\n"", ' *    Elevated blood pressure and heart rate: Savella may increase blood pressure and heart rate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,savella,156,2758,2792,"In an ambulatory blood pressure monitoring study, a substantially higher proportion of Savella-treated patients experienced clinically significant blood pressure and heart rate elevations as compared with placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,savella,157,2792,2819,"Measure blood pressure and heart rate prior to initiating treatment with Savella and monitor periodically throughout treatment (  5.3  ,  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,savella,158,2819,2835,"\n', ' *    Seizures: Cases have been reported with Savella therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,savella,159,2835,2853,Prescribe Savella with care in patients with a history of seizure disorder (  5.5  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,savella,160,2853,2877,"\n', ' *    Hepatotoxicity: More patients treated with Savella than with placebo experienced mild elevations of ALT and AST.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,savella,161,2877,2890,"Rarely, fulminant hepatitis has been reported in patients treated with Savella.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,savella,162,2890,2911,Avoid concomitant use of Savella in patients with substantial alcohol use or chronic liver disease (  5.6  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,savella,163,2911,2932,"\n', ' *    Discontinuation: Withdrawal symptoms have been reported in patients when discontinuing treatment with Savella.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,savella,164,2932,2944,A gradual dose reduction is recommended (  5.7  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,savella,165,2944,2962,"\n', ' *    Abnormal Bleeding: Savella may increase the risk of bleeding events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,savella,166,2962,2993,"Caution patients about the risk of bleeding associated with the concomitant use of Savella and NSAIDs, aspirin, or other drugs that affect coagulation (  5.9  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,savella,167,2993,3021,"\n', ' *    Male patients with a history of obstructive uropathies may experience higher rates of genitourinary adverse events (  5.11  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,savella,168,3021,3122,"\n', '    \n', ' \n', '\n', '   5.1 Suicide Risk\n', '\n', '\n', '\n', '  Savella is a selective serotonin and norepinephrine re-uptake inhibitor (SNRI), similar to some drugs used for the treatment of  notaecandidatepreexistingconditionorriskfactor and other  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', ' Patients, both adult and pediatric, with  notaecandidatepreexistingconditionorriskfactor or other  notaecandidatepreexistingconditionorriskfactor may experience  nonoseaeaeonlyasinstruction",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
169,savella,169,3122,3161,"and/or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking these medications, and this risk may persist until significant remission occurs.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,savella,170,3161,3187,nonoseaeaeonlyasinstruction is a known risk of  notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
171,savella,171,3187,3316,"There has been a long-standing concern, however, that antidepressants, including drugs that inhibit the reuptake of norepinephrine and/or serotonin, may have a role in inducing  oselabeledaeclasseffect and the emergence of  oselabeledaeclasseffect in certain patients during the early phases of treatment.\n', '\n', '\n', '\n', ' In the placebo-controlled clinical trials of adults with  notaecandidateindication  among the patients who had a history of  notaecandidatepreexistingconditionorriskfactor at treatment initiation, the incidence of  oselabeledaefromdruguse was 0.5% in patients treated with placebo, 0% in patients treated with Savella 100 mg/day, and 1.3% in patients treated with Savella 200 mg/day.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
172,savella,172,3316,3522,"No  nonoseaenegation occurred in the short-term or longer-term (up to 1 year)  notaecandidateindication trials.\n', '\n', '\n', '\n', ' Pooled analyses of short-term placebo-controlled trials of drugs used to treat  notaecandidatepreexistingconditionorriskfactor (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect ( oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidatepreexistingconditionorriskfactor  and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an increase in the risk of  nonoseaeaeonlyasinstruction with these drugs compared to placebo in adults beyond age 24; there was a reduction in  nonoseaeaeonlyasinstruction risk with antidepressants compared to placebo in adults age 65 and older.\n', '\n', '\n', '\n', ' The pooled analyses of placebo-controlled trials in children and adolescents with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term trials of 9 drugs used to treat  notaecandidatepreexistingconditionorriskfactor in over 4400 patients.",1,0,1,1,0,0,0,1,0,0,0,0,0,0,0
173,savella,173,3522,3606,"The pooled analyses of placebo-controlled trials in adults with  notaecandidatepreexistingconditionorriskfactor or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.\n', '\n', '\n', '\n', ' There was considerable variation in risk of  oselabeledaeclasseffect among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
174,savella,174,3606,3628,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across the different indications, with the highest incidence in  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
175,savella,175,3628,3650,"The risk of differences (drug versus placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,savella,176,3650,3784,"These risk differences (drug-placebo difference in the number of cases of  nonoseaeaeonlyasinstruction per 1000 patients treated) are provided in   Table 1    .\n', '\n', '\n', '\n', ' Table 1: Risk Differences (Drug - Placebo) in the number of Cases of  oselabeledaeclasseffect  per 1000 patients treated \n', '  Age Range         Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated    \n', '  < 18              14 additional cases                                                                   \n', '  18-24             5 additional cases                                                                    \n', '                    Decreases Compared to Placebo                                                         \n', '  25-64             ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,savella,177,3784,3788,1 fewer case                                                                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,savella,178,3788,3817,"\n', '  >= 65             6 fewer cases                                                                         \n', '        No  nonoseaenegation occurred in any of the pediatric trials.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
179,savella,179,3817,3889,"There were  nonoseaeaeonlyasinstruction in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction risk extends to longer-term use, i.e., beyond several months.\n', '\n', '\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,savella,180,3889,4075,"However, there is substantial evidence from placebo-controlled maintenance trials in adults with  notaecandidatepreexistingconditionorriskfactor that the use of antidepressants can delay the recurrence of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '  All patients being treated with drugs inhibiting the reuptake of norepinephrine and/or serotonin for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases  .\n', '\n', '\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect   oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with drugs inhibiting the reuptake of norepinephrine and/or serotonin for  notaecandidatepreexistingconditionorriskfactor as well as for other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
181,savella,181,4075,4370,"Although a causal link between the emergence of such symptoms and either the  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who may experience worsening  nonoseaeaeonlyasinstruction  or who are experiencing emergent  nonoseaeaeonlyasinstruction or symptoms that might be precursors to worsening  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe or abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', '\n', '\n', ' If the decision has been made to discontinue treatment due to worsening  nonoseaeaeonlyasinstruction or emergent  nonoseaeaeonlyasinstruction  medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can produce  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.1  ,  2.4  ), and Warnings and Precautions (  5.7  )]  .\n', '\n', '\n', '\n', '  Families and caregivers of patients being treated with drugs inhibiting the reuptake of norepinephrine and/or serotonin for  notaecandidatepreexistingconditionorriskfactor or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to health care providers.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
182,savella,182,4370,4381,Such monitoring should include daily observation by families and caregivers.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,savella,183,4381,4616,"Prescriptions for Savella should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '    5.2 Serotonin Syndrome\n', '\n', '\n', '\n', ""  The development of a potentially life-threatening  oselabeledaefromdruguse has been reported with SNRIs and SSRIs, including Savella, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat  notaecandidatepreexistingconditionorriskfactor and also others, such as linezolid and intravenous methylene blue).\n"", '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaegeneralterm (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication  and/or  nonoseaegeneralterm (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",1,1,1,0,1,0,0,0,0,0,0,0,0,0,0
184,savella,184,4616,4657,"Patients should be monitored for the emergence of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' The concomitant use of Savella with MAOIs intended to treat  notaecandidatepreexistingconditionorriskfactor is contraindicated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
185,savella,185,4657,4680,Savella should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,savella,186,4680,4711,All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,savella,187,4711,4737,No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,savella,188,4737,4764,There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Savella.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,savella,189,4764,4798,"Savella should be discontinued before initiating treatment with the MAOI [see Contraindications (  4.1  ), Dosage and Administration (  2.5  ,  2.6  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,savella,190,4798,4932,"\n', '\n', '\n', '\n', "" If concomitant use of Savella with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for  nonoseaeaefromdruginteraction  particularly during treatment initiation and dose increases.\n"", '\n', '\n', '\n', ' Treatment with Savella and any concomitant serotonergic agents should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated.\n', '\n', '\n', '\n', '    5.3 Elevated Blood Pressure\n', '\n",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
191,savella,191,4932,4985,"', '\n', '\n', '  A double-blind, placebo-controlled ambulatory blood pressure monitoring (ABPM) study was conducted to evaluate the effects of milnacipran (up to 200 mg/day) on blood pressure in 321  notaecandidateindication patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
192,savella,192,4985,5085,"Among  notaecandidateindication patients who were normotensive at baseline, an analysis of the blood pressure findings demonstrated a substantially higher proportion of Savella-treated patients had a  oselabeledaefromdruguse measurement at the Week 4, 50 mg BID steady state visit (17.7% [n=21/119]) and the Week 7, 100 mg BID steady state visit (14.3% [n=15/105]) as compared to placebo-treated patients (3.7% [n=2/54] and 0% [0/49] at the Week 4 and Week 7 visits, respectively).  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
193,savella,193,5085,5118,nonoseaeaeonlyasinstruction was defined as  nonoseaeaeonlyasinstruction (SBP)  nonoseaeaeonlyasinstruction and  nonoseaegeneralterm or  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction for the 12-hour period post AM study drug measurement at that visit.,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
194,savella,194,5118,5194,"Furthermore, 1.9% (4/210) of Savella-treated and 0.9% (1/111) of placebo patients discontinued treatment for  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' The  oselabeledaefromdruguse measurements in the  oselabeledaefromdruguse range in Savella-treated patients is supported by substantial  oselabeledaefromdruguse  oselabeledaefromdruguse mean SBP and  oselabeledaefromdruguse measurements observed in the ABPM study.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,savella,195,5194,5233,"Table 2    shows that, following treatment with Savella 50 mg BID for three weeks in patients who were normotensive at baseline, the  oselabeledaefromdruguse  oselabeledaefromdruguse systolic blood pressure (SBP) and  oselabeledaefromdruguse .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,savella,196,5233,5260,"After further treatment with Savella 100 mg BID for two weeks, the  oselabeledaefromdruguse SBP and  oselabeledaefromdruguse  oselabeledaefromdruguse and DBP was 6 mmHg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,savella,197,5260,5390,"Similar elevations occurred in Savella-treated patients who were  notaecandidatepreexistingconditionorriskfactor at baseline.\n', '\n', '\n', '\n', ' Table 2:  oselabeledaefromdruguse (Standard Error)  oselabeledaefromdruguse from Baseline in Mean 24-hour  oselabeledaefromdruguse and Diastolic  oselabeledaefromdruguse  oselabeledaefromdruguse (Standard Error)  oselabeledaefromdruguse from Baseline in Mean 24-hour Systolic and  oselabeledaefromdruguse (mmHg) of Milnacipran or Placebo following 4 Weeks of Treatment (50mg BID) and a Subsequent 2 Weeks of Treatment (100mg BID) \n', '           *Blood pressure measurements made after 3 weeks of milnacipran 50mg BID   \n', '           ^Blood pressure measurements made after 2 weeks of milnacipran",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
198,savella,198,5390,5394,100mg BID   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,savella,199,5394,5408,"\n', '  \n', '                            Normotensive     notaecandidatepreexistingconditionorriskfactor    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
200,savella,200,5408,5409,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,savella,201,5409,5415,"', '                            n            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,savella,202,5415,5445,"Systolic       Diastolic      n             Systolic       Diastolic      \n', '  Placebo                   39           0(2)           -1(1)          50            0(2)           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,savella,203,5445,5448,0(2)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,savella,204,5448,5463,"\n', '  50 mg BID*                92           5(1)           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,savella,205,5463,5469,5(1)           84            5(2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,savella,206,5469,5474,)           4(1)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,savella,207,5474,5502,"\n', '                                                                                                                   \n', '  Placebo                   37           0(2)           -1(1)          47            -1(2)          0(1)           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,savella,208,5502,5516,"\n', '  100 mg BID^               82           6(1)           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,savella,209,5516,5522,6(1)           80            5(2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,savella,210,5522,5527,)           4(1)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,savella,211,5527,5617,"\n', '             Similar patterns of treatment-emergent  oselabeledaefromdruguse were observed in Phase 3 and clinical pharmacology studies as manifested by an increased risk of new onset  oselabeledaefromdruguse or substantial  oselabeledaefromdruguse end of study  oselabeledaefromdruguse measurements in patients with  notaecandidatepreexistingconditionorriskfactor at baseline (   Table 3    ).\n', ' \n', '\n', ' Table 3: Blood pressure changes in Phase 3 randomized controlled trials \n', '                                            Milnacipran50 mg BID    Milnacipran100",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
212,savella,212,5617,5620,mg BID    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,savella,213,5620,5622,Placebo               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,savella,214,5622,5653,"\n', '   notaecandidateindication patients normotensive at baseline who became  oselabeledaefromdruguse (defined as  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction on three consecutive post-baseline visits)    ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
215,savella,215,5653,5677,"20%                   17%                   7%                    \n', '   notaecandidateindication patients with sustained  oselabeledaefromdruguse (increase of >",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
216,savella,216,5677,5689,= 15 mmHg on three consecutive post-baseline visits)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,savella,217,5689,5698,9%                    6%                    2%                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,savella,218,5698,5725,"\n', '   notaecandidateindication patients with sustained  oselabeledaefromdruguse (increase of >= 10 mmHg on three consecutive post-baseline visits)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
219,savella,219,5725,5734,13%                   10 %                  4%                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,savella,220,5734,5755,"\n', '                                            \n', '   notaecandidateindication patients  notaecandidatepreexistingconditionorriskfactor at baseline who had  oselabeledaefromdruguse >",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
221,savella,221,5755,5818,"= 15 mmHg at end of study    10%                   7%                    4%                    \n', '   notaecandidateindication patients  notaecandidatepreexistingconditionorriskfactor at baseline who had  oselabeledaefromdruguse >= 10 mmHg at end of study    8%                    6%                    3%                    \n', '          Sustained  nonoseaeaeonlyasinstruction may have adverse consequences.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
222,savella,222,5818,5911,"Cases of  oselabeledaefromdruguse requiring immediate treatment have been reported.\n', ' \n', '\n', ' Concomitant use of Savella with drugs that  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction has not been evaluated and such combinations should be used with caution [see Drug Interactions (  7  )]  .\n', '\n', '\n', '\n', ' Effects of Savella on blood pressure in patients with significant  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor have not been systematically evaluated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
223,savella,223,5911,5951,"Savella should be used with caution in these patients.\n', '\n', '\n', '\n', ' Measure blood pressure prior to initiating treatment and periodically monitor blood pressure throughout Savella treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,savella,224,5951,5966,Treat pre-existing  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor before starting therapy with Savella.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
225,savella,225,5966,6073,"For patients who experience a sustained  nonoseaeaeonlyasinstruction while receiving Savella, either reduce the dose or discontinue treatment with Savella if clinically warranted.\n', '\n', '\n', '\n', '    5.4 Elevated Heart Rate\n', '\n', '\n', '\n', '  A double-blind, placebo-controlled ABPM study was conducted to evaluate the effects of milnacipran (up to 200 mg/day) on blood pressure in 321  notaecandidateindication patients [see Warnings and Precautions (  5.3  )]  .",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
226,savella,226,6073,6081,Information on heart rate was also collected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,savella,227,6081,6115,"Following treatment with Savella 50mg BID for three weeks in patients who were normotensive at baseline, the mean  oselabeledaefromdruguse mean 24-hour  oselabeledaefromdruguse from baseline was 13 beats per minute.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,savella,228,6115,6304,"After further treatment with Savella 100 mg BID for two weeks, the mean  oselabeledaefromdruguse was 13 beats per minute.\n', '\n', '\n', '\n', ' Similar trends were observed in the clinical trials where Savella treatment was associated with mean  oselabeledaefromdruguse of approximately 7 to 8 beats per minute [see Adverse Reactions (  6.1  ]  .\n', '\n', '\n', '\n', '  oselabeledaefromdruguse >= 20 beats per minute occurred more frequently in Savella-treated patients when compared to placebo (8% in the Savella 50 mg BID and 100 mg BID treatment arms versus 0.3% in the placebo arm).\n', '\n', '\n', '\n', ' Savella has not been systematically evaluated in patients with a  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', ' Measure heart rate prior to initiating treatment and periodically monitor the heart rate throughout Savella treatment.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
229,savella,229,6304,6320,Treat pre-existing  notaecandidatepreexistingconditionorriskfactor and other  notaecandidatepreexistingconditionorriskfactor before starting therapy with Savella.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
230,savella,230,6320,6391,"For patients who experience a sustained  oselabeledaefromdruguse while receiving Savella, either reduce the dose or discontinue treatment with Savella if clinically warranted.\n', '\n', '\n', '\n', '    5.5 Seizures\n', '\n', '\n', '\n', '  Savella has not been systematically evaluated in patients with a  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
231,savella,231,6391,6410,In clinical trials evaluating Savella in patients with  notaecandidateindication   nonoseaenegation  nonoseaenegation have not been reported.,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
232,savella,232,6410,6525,"However,  nonoseaeaefromofflabel have been reported infrequently in patients treated with Savella for disorders other than  notaecandidateindication  Savella should be prescribed with care in patients with a history of a  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.6 Hepatotoxicity\n', '\n', '\n', '\n', '  In the placebo-controlled  notaecandidateindication trials, increases in the number of patients treated with Savella with mild  oselabeledaefromdruguse  oselabeledaefromdruguse ALT or  oselabeledaefromdruguse (1-3 times the upper limit of normal, ULN) were observed.  ",0,0,1,1,0,0,0,0,0,0,1,0,0,0,0
233,savella,233,6525,6567,"oselabeledaefromdruguse were more frequently observed in the patients treated with Savella 100 mg/day (6%) and Savella 200 mg/day (7%), compared to the patients treated with placebo (3%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,savella,234,6567,6605,One patient receiving Savella 100 mg/day (0.2%) had an  oselabeledaefromdruguse greater than 5 times the upper limit of normal but did not exceed 10 times the upper limit of normal.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,savella,235,6605,6701,"oselabeledaefromdruguse were more frequently observed in the patients treated with Savella 100 mg/day (3%) and Savella 200 mg/day (5%) compared to the patients treated with placebo (2%).\n', '\n', '\n', '\n', ' The  nonoseaeaeonlyasinstruction observed in the  notaecandidateindication clinical trials were not clinically significant.\n', '\n', '\n', '\n', ' No case met the criteria of  nonoseaenegation and associated with an  nonoseaenegation",1,0,0,1,0,0,0,1,0,0,0,0,0,0,0
236,savella,236,6701,6743,">= 2x ULN.\n', '\n', '\n', '\n', ' There have been cases of  oselabeledaefromdruguse and reports of  oselabeledaefromdruguse  including  oselabeledaefromdruguse with milnacipran from foreign postmarketing experience.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,savella,237,6743,6764,In the cases of  oselabeledaefromdruguse  there were significant underlying clinical conditions and/or the use of multiple concomitant medications.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,savella,238,6764,6971,"Because of underreporting, it is impossible to provide an accurate estimate of the true incidence of these reactions.\n', '\n', '\n', '\n', ' Savella should be discontinued in patients who develop  nonoseaemanifestationorcomplication or other evidence of  nonoseaemanifestationorcomplication  Treatment with Savella should not be resumed unless another cause can be established.\n', '\n', '\n', '\n', ' Savella should ordinarily not be prescribed to patients with substantial alcohol use or evidence of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.7 Discontinuation of Treatment with Savella\n', '\n', '\n', '\n', '   oselabeledaefromdruguse have been observed in clinical trials following discontinuation of milnacipran, as with other SNRIs and SSRIs.\n', '\n', '\n', '\n', ' During marketing of milnacipran, and other SNRIs and SSRIs, there have been spontaneous reports of adverse events indicative of  oselabeledaefromdruguse and  oselabeledaefromdruguse occurring upon discontinuation of these drugs, particularly when discontinuation is abrupt.",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
239,savella,239,6971,7019,"The adverse events include the following:  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal (e.g.,  nonoseaeodorwithdrawal such as  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  ",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
240,savella,240,7019,7061,"Although these events are generally self-limiting, some have been reported to be severe.\n', '\n', '\n', '\n', ' Patients should be monitored for these  nonoseaeaeonlyasinstruction with Savella.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,savella,241,7061,7073,Savella should be tapered and not abruptly discontinued after extended use.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,savella,242,7073,7088,If intolerable  nonoseaeaeonlyasinstruction  then resuming the previously prescribed dose may be considered.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,savella,243,7088,7115,"Subsequently, the physician may continue decreasing the dose but at a more gradual rate [see Dosage and Administration (  2.4  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,savella,244,7115,7166,".\n', '\n', '\n', '\n', '    5.8 Hyponatremia\n', '\n', '\n', '\n', '   oselabeledaefromdruguse may occur as a result of treatment with SSRIs and SNRIs, including Savella.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,savella,245,7166,7186,"In many cases, this  oselabeledaefromdruguse appears to be the result of the  oselabeledaefromdruguse (SIADH).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,savella,246,7186,7194,Cases with  oselabeledaefromdruguse have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,savella,247,7194,7213,"Elderly patients may be at greater risk of developing  oselabeledaefromdruguse with SNRIs, SSRIs, or Savella.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,savella,248,7213,7231,"Also, patients taking diuretics or who are otherwise  notaecandidatepreexistingconditionorriskfactor may be at greater risk [see",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
249,savella,249,7231,7241,Geriatric Use (  8.5  )]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,savella,250,7241,7336,"Discontinuation of Savella should be considered in patients with symptomatic  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Signs and symptoms of  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  which may lead to  nonoseaemanifestationorcomplication  Signs and symptoms associated with more severe and/or acute cases have included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm \n', '\n', '\n', '",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
251,savella,251,7336,7348,"\n', '    5.9 Abnormal Bleeding\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,savella,252,7348,7402,"', '\n', '\n', '  SSRIs and SNRIs, including Savella, may increase the risk of  oselabeledaefromdruguse  Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anti-coagulants may add to this risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,savella,253,7402,7566,"Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of  oselabeledaeclasseffect   oselabeledaeclasseffect events related to SSRIs and SNRIs use have ranged from  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect to life-threatening  oselabeledaeclasseffect \n', '\n', '\n', '\n', ' Patients should be cautioned about the risk of  nonoseaeaefromdruginteraction associated with the concomitant use of Savella and NSAIDs, aspirin, or other drugs that affect coagulation.\n', '\n', '\n', '\n', '    5.10 Activation of Mania\n', '\n', '\n', '\n', '  No activation of  nonoseaenegation or  nonoseaenegation was reported in the clinical trials evaluating effects of Savella in patients with  notaecandidateindication  ",0,0,0,1,0,1,0,1,0,0,0,0,0,0,0
254,savella,254,7566,7683,"However those clinical trials excluded patients with current  notaecandidatepreexistingconditionorriskfactor  Activation of  nonoseaeaeforanotherdruginclass and  nonoseaeaeforanotherdruginclass have been reported in patients with  notaecandidatepreexistingconditionorriskfactor who were treated with other similar drugs for  notaecandidatepreexistingconditionorriskfactor  As with these other agents, Savella should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.11 Patients with a History of Dysuria\n', '\n', '\n', '\n', '  Because of their noradrenergic effect, SNRIs including Savella, can affect  oselabeledaefromdruguse  oselabeledaefromdruguse resistance and  oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,0,0,0,0,1,0,0
255,savella,255,7683,7715,"In the controlled  notaecandidateindication trials,  oselabeledaefromdruguse occurred more frequently in patients treated with Savella (1%) than in placebo-treated patients (0.5%).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
256,savella,256,7715,7746,Caution is advised in use of Savella in patients with a history of  notaecandidatepreexistingconditionorriskfactor  notably in male patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and other  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
257,savella,257,7746,7906,"Male patients are more prone to  nonoseaeaeonlyasinstruction  such as  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  and may experience  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication \n', '\n', '\n', '\n', '    5.12 Angle Closure Glaucoma\n', '\n', '\n', '\n', '  The  oselabeledaefromdruguse that occurs following use of SNRI drugs including Savella may trigger an  oselabeledaefromdruguse in a patient with anatomically narrow angles who does not have a patent iridectomy.\n', '\n', '\n', '\n', '    5.13 Concomitant Use with Alcohol\n', '\n', '\n', '\n', '  In clinical trials, more patients treated with Savella developed  oselabeledaefromdruguse than did placebo treated patients [see Warnings and Precautions (  5.6  )]  .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
258,savella,258,7906,7934,Because it is possible that milnacipran may  oselabeledaefromdruguse  Savella should not be prescribed to patients with substantial alcohol use or evidence of  notaecandidatepreexistingconditionorriskfactor '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,xeloda,0,0,103,"['  6 ADVERSE REACTIONS\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '   EXCERPT:   Most common adverse reactions (>=30%) were diarrhea, hand-and-foot syndrome, nausea, vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,xeloda,1,103,116,"Other adverse reactions, including serious adverse reactions, have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,xeloda,2,116,156,"(  6  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,xeloda,3,156,227,"\n', '\n', ' \n', '\n', '  6.1 Adjuvant Colon Cancer\n', '\n', '      Table 4    shows the adverse reactions occurring in >=5% of patients from one phase 3 trial in patients with  notaecandidateindication who received at least one dose of study medication and had at least one safety assessment.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,xeloda,4,227,285,"A total of 995 patients were treated with 1250 mg/m  2  twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 974 patients were administered 5-FU and leucovorin (20 mg/m  2  leucovorin IV followed by 425 mg/m  2  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,xeloda,5,285,298,IV bolus 5-FU on days 1-5 every 28 days).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,xeloda,6,298,322,The median duration of treatment was 164 days for capecitabine-treated patients and 145 days for 5-FU/LV-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,xeloda,7,322,354,"A total of 112 (11%) and 73 (7%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,xeloda,8,354,487,"A total of 18  nonoseaegeneralterm due to all causes occurred either on study or within 28 days of receiving study drug: 8 (0.8%) patients randomized to XELODA and 10 (1.0%) randomized to 5-FU/LV.\n', '\n', '     Table 5    shows grade 3/4  nonoseaegeneralterm occurring in >=1% of patients from one phase 3 trial in patients with  notaecandidateindication who received at least one dose of study medication and had at least one safety assessment.\n', '\n', ' Table 4 Percent Incidence of Adverse Reactions Reported in >=5% of Patients Treated With XELODA or 5-FU/LV for Colon Cancer in the Adjuvant Setting (Safety Population)",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
9,xeloda,9,487,497,"\n', '                                   Adjuvant Treatment for Colon Cancer",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,xeloda,10,497,511,"(N=1969)   \n', '                                     XELODA(N=995)     5-FU/",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,xeloda,11,511,530,"LV(N=974)     \n', ' Body System/Adverse Event            All Grades          Grade 3/4         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,xeloda,12,530,536,All Grades          Grade 3/4       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,xeloda,13,536,546,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,xeloda,14,546,548,nonoseaegeneralterm                                                                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
15,xeloda,15,548,559,"\n', '    oselabeledaefromdruguse                               47                 12                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,xeloda,16,559,561,65                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,xeloda,17,561,563,14           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,xeloda,18,563,572,"\n', '    oselabeledaefromdruguse                                 34                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,xeloda,19,572,576,2                 47                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,xeloda,20,576,578,2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,xeloda,21,578,587,"\n', '    oselabeledaefromdruguse                             22                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,xeloda,22,587,589,2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,xeloda,23,589,591,60                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,xeloda,24,591,593,14           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,xeloda,25,593,606,"\n', '    oselabeledaefromdruguse                               15                  2                 21                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,xeloda,26,606,608,2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,xeloda,27,608,617,"\n', '    oselabeledaefromdruguse                         14                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,xeloda,28,617,619,3                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,xeloda,29,619,621,16                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,xeloda,30,621,623,2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,xeloda,31,623,630,"\n', '    oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,xeloda,32,630,636,9                  -                 11                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,xeloda,33,636,646,"<1           \n', '    oselabeledaefromdruguse                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,xeloda,34,646,651,7                 <1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,xeloda,35,651,656,7                 <1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,xeloda,36,656,665,"\n', '    oselabeledaefromdruguse                               6                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,xeloda,37,665,686,"<1                  5                  -           \n', '    nonoseaegeneralterm                                                                                 \n', '    oselabeledaefromdruguse                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,xeloda,38,686,690,60                 17                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,xeloda,39,690,692,9                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,xeloda,40,692,702,"<1           \n', '    oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,xeloda,41,702,704,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,xeloda,42,704,708,-                 22                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,xeloda,43,708,735,"<1           \n', '    oselabeledaefromdruguse                                    7                  -                  8                  -           \n', '    oselabeledaefromdruguse                                6                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,xeloda,44,735,749,"1                  5                 <1           \n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,xeloda,45,749,758,"\n', '    oselabeledaefromdruguse                                16                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,xeloda,46,758,779,"<1                 16                  1           \n', '    oselabeledaefromdruguse                                 7                 <1                  9                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,xeloda,47,779,822,"<1           \n', '    oselabeledaefromdruguse                               10                 <1                 10                  1           \n', '    oselabeledaefromdruguse                               10                 <1                  9                 <1           \n', '    nonoseaegeneralterm                                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,xeloda,48,822,901,"\n', '    oselabeledaefromdruguse                               6                 <1                  6                  -           \n', '    oselabeledaefromdruguse                                5                 <1                  6                 <1           \n', '    oselabeledaefromdruguse                               6                  -                  9                  -           \n', '    nonoseaegeneralterm                                                                                 \n', '    oselabeledaefromdruguse                                9                 <1                 11                 <1           \n', '    nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,xeloda,49,901,910,"\n', '    oselabeledaefromdruguse                          5                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,xeloda,50,910,915,<1                  6                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,xeloda,51,915,925,"<1           \n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,xeloda,52,925,932,"\n', '    oselabeledaefromdruguse                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,xeloda,53,932,934,2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,xeloda,54,934,937,<1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,xeloda,55,937,941,8                  5           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,xeloda,56,941,948,"\n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,xeloda,57,948,957,"\n', '    oselabeledaefromdruguse                               2                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,xeloda,58,957,998,"-                  5                  -           \n', '          Table 5 Percent Incidence of Grade 3/4 Laboratory Abnormalities Reported in >=1% of Patients Receiving XELODA Monotherapy for Adjuvant Treatment of Colon Cancer (Safety Population)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,xeloda,59,998,1010,"\n', ' Adverse Event                                                 XELODA(n=995)Grade 3/4 %  IV",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,xeloda,60,1010,1016,5-FU/LV(n=974)Grade 3/4 %   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,xeloda,61,1016,1054,"\n', '  \n', '    oselabeledaefromdruguse                                                1.6                   0.6            \n', '    oselabeledaefromdruguse                                                   1.1                   0.7            \n', '    oselabeledaefromdruguse                                                   2.3                   2.2            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,xeloda,62,1054,1074,"\n', '    oselabeledaefromdruguse                                                1.0                   1.2            \n', '    oselabeledaefromdruguse                                               13.0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,xeloda,63,1074,1076,13.0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,xeloda,64,1076,1112,"\n', '    oselabeledaefromdruguse [note: The incidence of grade 3/4  oselabeledaefromdruguse was 1.3% in the XELODA arm and 4.9% in the IV 5-FU/LV arm.]           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,xeloda,65,1112,1114,2.2                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,xeloda,66,1114,1116,26.2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,xeloda,67,1116,1127,"\n', '    oselabeledaefromdruguse  oselabeledaefromdruguse neutrophils/ oselabeledaefromdruguse                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,xeloda,68,1127,1136,"2.4                   26.4           \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,xeloda,69,1136,1170,"oselabeledaefromdruguse                                                 1.0                   0.7            \n', '    oselabeledaefromdruguse [note: It should be noted that grading was according to NCIC CTC Version 1 (May, 1994).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,xeloda,70,1170,1198,"In the NCIC-CTC Version 1,  nonoseaeaeonlyasinstruction grade 3 indicates a  nonoseaeaeonlyasinstruction  and grade 4 a value of > 3.0 * ULN.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,xeloda,71,1198,1223,The NCI CTC Version 2 and above define a grade 3  nonoseaeaeonlyasinstruction  and grade 4 values >10.0 * ULN.]            ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,xeloda,72,1223,1344,"20                   6.3            \n', '           6.2 Metastatic Colorectal Cancer\n', '     Monotherapy  \n', '\n', '     Table 6    shows the adverse reactions occurring in >=5% of patients from pooling the two phase 3 trials in first line  notaecandidateindication  A total of 596 patients with  notaecandidateindication were treated with 1250 mg/m  2  twice a day of XELODA administered for 2 weeks followed by a 1-week rest period, and 593 patients were administered 5-FU and leucovorin in the Mayo regimen (20 mg/m  2  leucovorin IV followed by 425 mg/m  2  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
73,xeloda,73,1344,1359,"IV bolus 5-FU, on days 1-5, every 28 days).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,xeloda,74,1359,1388,In the pooled colorectal database the median duration of treatment was 139 days for capecitabine-treated patients and 140 days for 5-FU/LV-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,xeloda,75,1388,1423,"A total of 78 (13%) and 63 (11%) capecitabine and 5-FU/LV-treated patients, respectively, discontinued treatment because of adverse reactions/intercurrent illness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,xeloda,76,1423,1504,"A total of 82  nonoseaegeneralterm due to all causes occurred either on study or within 28 days of receiving study drug: 50 (8.4%) patients randomized to XELODA and 32 (5.4%) randomized to 5-FU/LV.\n', '\n', ' Table 6 Pooled Phase 3 Colorectal Trials: Percent Incidence of Adverse Reactions in >=5% of Patients \n', ' Adverse Event                             XELODA(n=596)  5-FU",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,xeloda,77,1504,1508,/LV(n=593)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,xeloda,78,1508,1509,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,xeloda,79,1509,1542,"', '                                             Total%     Grade 3%    Grade 4%     Total%     Grade 3%    Grade 4%    \n', '  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,xeloda,80,1542,1568,"- Not observed                             \n', ' NA = Not Applicable                        \n', '  \n', '   Number of Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,xeloda,81,1568,1570,With >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,xeloda,82,1570,1574,One Adverse Event        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,xeloda,83,1574,1578,96          52          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,xeloda,84,1578,1580,9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,xeloda,85,1580,1597,"94          45          9        \n', '   Body System/Adverse Event                                                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,xeloda,86,1597,1613,"\n', '    nonoseaegeneralterm                                                                                                               \n', '    oselabeledaefromdruguse                                    55          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,xeloda,87,1613,1615,13          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,xeloda,88,1615,1617,2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,xeloda,89,1617,1628,"61          10          2        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,xeloda,90,1628,1632,oselabeledaefromdruguse                                      43          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,xeloda,91,1632,1640,4           -           51          3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,xeloda,92,1640,1654,"<1       \n', '    oselabeledaefromdruguse                                    27          4           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,xeloda,93,1654,1661,<1          30          4           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,xeloda,94,1661,1897,"<1       \n', '    oselabeledaefromdruguse                                  25          2           <1          62          14          1        \n', '    oselabeledaefromdruguse                              35          9           <1          31          5           -        \n', '    oselabeledaefromdruguse          10          <1          -           7           <1          -        \n', '    oselabeledaefromdruguse                                14          1           <1          17          1           -        \n', '    oselabeledaefromdruguse                             10          -           -           10          -           -        \n', '    oselabeledaefromdruguse             8           <1          -           10          1           -        \n', '    oselabeledaefromdruguse                 6           1           <1          3           1           -        \n', '    oselabeledaefromdruguse                                       6           4           1           5           2           1        \n', '    nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse                      54          17          NA          6           1           NA       \n', '    oselabeledaefromdruguse                                  27          1           -           26          1           -        \n', '    oselabeledaefromdruguse                          7           <1          -           5           -           -        \n', '    oselabeledaefromdruguse                                    6           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
95,xeloda,95,1897,1924,"-           -           21          <1          -        \n', '    nonoseaegeneralterm                                                                                                          \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,xeloda,96,1924,2002,"42          4           -           46          4           -        \n', '    oselabeledaefromdruguse                                     18          1           -           21          2           -        \n', '    oselabeledaefromdruguse                                       15          1           -           9           1           -        \n', '    oselabeledaefromdruguse                                        12          1           -           10          1           -        \n', '    oselabeledaefromdruguse                                  6           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,xeloda,97,2002,2010,1           -           6           1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,xeloda,98,2010,2020,"<1       \n', '    nonoseaegeneralterm                                                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
99,xeloda,99,2020,2027,"\n', '    oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,xeloda,100,2027,2050,"10          -           -           4           -           -        \n', '    oselabeledaefromdruguse                                    10          1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,xeloda,101,2050,2067,"-           7           -           -        \n', '    oselabeledaefromdruguse [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,xeloda,102,2067,2071,Excluding  nonoseaenegation          ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
103,xeloda,103,2071,2073,8           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,xeloda,104,2073,2080,<1          -           8           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,xeloda,105,2080,2111,"<1          -        \n', '    oselabeledaefromdruguse                                    7           -           -           7           -           -        \n', '    oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,xeloda,106,2111,2113,6           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,xeloda,107,2113,2119,1           -           11          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,xeloda,108,2119,2140,"<1          1        \n', '    nonoseaegeneralterm                                                                                                       \n', '    oselabeledaefromdruguse                          26          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,xeloda,109,2140,2142,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,xeloda,110,2142,2149,<1          31          2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,xeloda,111,2149,2163,"<1       \n', '    oselabeledaefromdruguse                                 7           2           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,xeloda,112,2163,2223,"<1          8           3           1        \n', '    nonoseaegeneralterm                                                                                                              \n', '    oselabeledaefromdruguse                              13          -           -           10          <1          -        \n', '    oselabeledaefromdruguse                             5           -           -           2           -           -        \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,xeloda,113,2223,2230,"nonoseaegeneralterm                                                                                                      \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,xeloda,114,2230,2240,oselabeledaefromdruguse                                     14          1           -           10          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,xeloda,115,2240,2272,"<1          1        \n', '    oselabeledaefromdruguse                                       7           <1          1           8           -           -        \n', '    oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,xeloda,116,2272,2291,"5           -           -           5           -           -        \n', '    oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,xeloda,117,2291,2293,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,xeloda,118,2293,2337,"<1          -           6           -           -        \n', '    oselabeledaefromdruguse                                 2           -           -           6           -           -        \n', '    nonoseaegeneralterm                                                                                                  \n', '    oselabeledaefromdruguse                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
119,xeloda,119,2337,2339,10          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,xeloda,120,2339,2345,2           -           9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,xeloda,121,2345,2374,"<1          -        \n', '    oselabeledaefromdruguse                                  8           1           -           6           1           -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,xeloda,122,2374,2385,"nonoseaegeneralterm                                                                                                         \n', '    oselabeledaefromdruguse                           8           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,xeloda,123,2385,2438,"3           <1          6           2           -        \n', '    nonoseaegeneralterm                                                                                                      \n', '    oselabeledaefromdruguse                             5           -           -           6           <1          -        \n', '    oselabeledaefromdruguse                                  5           -           -           4           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,xeloda,124,2438,2452,"<1          -        \n', '    nonoseaegeneralterm  oselabeledaefromdruguse                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
125,xeloda,125,2452,2454,5           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,xeloda,126,2454,2471,"<1          -           5           <1          -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,xeloda,127,2471,2473,nonoseaegeneralterm                                                                                              ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
128,xeloda,128,2473,2491,"\n', '    oselabeledaefromdruguse                                      80          2           <1          79          1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,xeloda,129,2491,2507,"<1       \n', '    oselabeledaefromdruguse                                 13          1           2           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,xeloda,130,2507,2520,"46          8           13       \n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
131,xeloda,131,2520,2529,"\n', '    oselabeledaefromdruguse                          48          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,xeloda,132,2529,2533,18          5           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,xeloda,133,2533,2593,"17          3           3        \n', '               6.3 Breast Cancer\n', '     In Combination with Docetaxel  \n', '\n', ' The following data are shown for the combination study with XELODA and docetaxel in patients with  notaecandidateindication in    Table 7    and    Table 8    .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
134,xeloda,134,2593,2668,In the XELODA and docetaxel combination arm the treatment was XELODA administered orally 1250 mg/m  2  twice daily as intermittent therapy (2 weeks of treatment followed by 1 week without treatment) for at least 6 weeks and docetaxel administered as a 1-hour intravenous infusion at a dose of 75 mg/m  2  on the first day of each 3-week cycle for at least 6 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,xeloda,135,2668,2705,In the monotherapy arm docetaxel was administered as a 1-hour intravenous infusion at a dose of 100 mg/m  2  on the first day of each 3-week cycle for at least 6 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,xeloda,136,2705,2725,The mean duration of treatment was 129 days in the combination arm and 98 days in the monotherapy arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,xeloda,137,2725,2757,A total of 66 patients (26%) in the combination arm and 49 (19%) in the monotherapy arm withdrew from the study because of adverse reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,xeloda,138,2757,2783,The percentage of patients requiring dose reductions due to adverse reactions was 65% in the combination arm and 36% in the monotherapy arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,xeloda,139,2783,2802,The percentage of patients requiring treatment interruptions due to adverse reactions in the combination arm was 79%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,xeloda,140,2802,2878,"Treatment interruptions were part of the dose modification scheme for the combination therapy arm but not for the docetaxel monotherapy-treated patients.\n', '\n', ' Table 7 Percent Incidence of Adverse Events Considered Related or Unrelated to Treatment in >=5% of Patients Participating in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy Study \n', ' Adverse Event                             XELODA 1250 mg/m  2  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,xeloda,141,2878,2879,/bid,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,xeloda,142,2879,2887,With Docetaxel75 mg/m  2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,xeloda,143,2887,2888,/3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,xeloda,144,2888,2890,weeks  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,xeloda,145,2890,2897,Docetaxel100 mg/m  2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,xeloda,146,2897,2898,/3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,xeloda,147,2898,2900,weeks   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,xeloda,148,2900,2918,"\n', '                                            (n=251)     (n=255)     \n', '                                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,xeloda,149,2918,2938,Total%     Grade 3%    Grade 4%     Total%     Grade 3%    Grade 4%    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,xeloda,150,2938,2952,"\n', '  \n', ' - Not observed                             \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,xeloda,151,2952,2960,"', ' NA = Not Applicable                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,xeloda,152,2960,2980,"\n', '  \n', '   Number of Patients With at Least One Adverse Event        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,xeloda,153,2980,2988,99         76.5        29.1         97         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,xeloda,154,2988,2990,57.6        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,xeloda,155,2990,2992,31.8      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,xeloda,156,2992,3003,"\n', '   Body System/Adverse Event                                                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,xeloda,157,3003,3036,"\n', '    nonoseaegeneralterm                                                                                                               \n', '    oselabeledaefromdruguse                                    67          14          <1          48          5           <1       \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
158,xeloda,158,3036,3040,oselabeledaefromdruguse                                  67          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,xeloda,159,3040,3056,"17          <1          43          5           -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,xeloda,160,3056,3075,"oselabeledaefromdruguse                                      45          7           -           36          2           -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,xeloda,161,3075,3079,oselabeledaefromdruguse                                    35          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,xeloda,162,3079,3083,4           1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,xeloda,163,3083,3098,"24          2           -        \n', '    oselabeledaefromdruguse                                20          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,xeloda,164,3098,3117,"2           -           18          -           -        \n', '    oselabeledaefromdruguse                              30          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,xeloda,165,3117,3154,"<3          <1          24          2           -        \n', '    oselabeledaefromdruguse                                   14          -           -           8           1           -        \n', '    oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,xeloda,166,3154,3156,6           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,xeloda,167,3156,3174,"<1          -           5           -           -        \n', '    nonoseaegeneralterm                                                                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,xeloda,168,3174,3179,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,xeloda,169,3179,3183,oselabeledaefromdruguse                      63          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,xeloda,170,3183,3185,24          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,xeloda,171,3185,3202,"NA          8           1           NA       \n', '    oselabeledaefromdruguse                                    41          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,xeloda,172,3202,3221,"6           -           42          7           -        \n', '    oselabeledaefromdruguse                               14          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,xeloda,173,3221,3246,"2           -           15          -           -        \n', '    oselabeledaefromdruguse                                  8           -           -           11          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,xeloda,174,3246,3257,"1           -        \n', '    oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,xeloda,175,3257,3259,9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,xeloda,176,3259,3285,"<1          -           5           -           -        \n', '    oselabeledaefromdruguse                          6           -           -           4           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,xeloda,177,3285,3419,"<1          -        \n', '    oselabeledaefromdruguse                                 5           1           -           5           1           -        \n', '    oselabeledaefromdruguse                                    4           -           -           5           -           -        \n', '    nonoseaegeneralterm                                                                                                          \n', '    oselabeledaefromdruguse                                     28          2           -           34          2           -        \n', '    oselabeledaefromdruguse                                    26          4           <1          25          6           -        \n', '    oselabeledaefromdruguse                                     22          4           -           27          6           -        \n', '    oselabeledaefromdruguse                                    16          2           -           11          2           -        \n', '    oselabeledaefromdruguse                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,xeloda,178,3419,3421,13          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,xeloda,179,3421,3439,"<1          -           13          2           -        \n', '    oselabeledaefromdruguse                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,xeloda,180,3439,3460,"7           -           -           6           2           -        \n', '    oselabeledaefromdruguse                                        7           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,xeloda,181,3460,3517,"<1          -           5           1           -        \n', '    oselabeledaefromdruguse                     4           <1          -           6           2           -        \n', '    oselabeledaefromdruguse                      5           -           -           5           -           -        \n', '    nonoseaegeneralterm                                                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
182,xeloda,182,3517,3524,"\n', '    oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,xeloda,183,3524,3526,16          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,xeloda,184,3526,3566,"<1          -           14          <1          -        \n', '    oselabeledaefromdruguse                                    15          3           -           15          2           -        \n', '    oselabeledaefromdruguse                                 12          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,xeloda,185,3566,3602,"<1          -           16          1           -        \n', '    oselabeledaefromdruguse                                   12          -           -           8           <1          -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,xeloda,186,3602,3641,"oselabeledaefromdruguse                                    8           -           -           10          <1          -        \n', '    oselabeledaefromdruguse                       6           -           -           10          1           -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,xeloda,187,3641,3652,oselabeledaefromdruguse                               4           <1          -           8           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,xeloda,188,3652,3673,"<1          -        \n', '    nonoseaegeneralterm                                                                                                       \n', '    oselabeledaefromdruguse                                    13          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
189,xeloda,189,3673,3710,"1           -           11          <1          -        \n', '    oselabeledaefromdruguse                          10          -           -           5           -           -        \n', '    oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,xeloda,190,3710,3733,"7           -           -           5           -           -        \n', '    oselabeledaefromdruguse                                 10          2           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,xeloda,191,3733,3737,-           7           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,xeloda,192,3737,3824,"<1          <1       \n', '    nonoseaegeneralterm                                                                                                              \n', '    oselabeledaefromdruguse                       12          -           -           7           <1          -        \n', '    oselabeledaefromdruguse                              5           -           -           4           -           -        \n', '    oselabeledaefromdruguse                              5           -           -           1           -           -        \n', '    nonoseaegeneralterm                                                                                                  \n', '    oselabeledaefromdruguse                                  15          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
193,xeloda,193,3824,3860,"2           -           24          3           -        \n', '    oselabeledaefromdruguse                                     15          2           -           25          2           -        \n', '    oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,xeloda,194,3860,3862,12          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,xeloda,195,3862,3882,"<1          -           11          3           -        \n', '    oselabeledaefromdruguse                                   8           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,xeloda,196,3882,3905,"<1          -           10          2           -        \n', '    nonoseaegeneralterm                                                                                                          \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
197,xeloda,197,3905,3909,oselabeledaefromdruguse                                       33          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,xeloda,198,3909,3920,<2          -           34          <3          1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,xeloda,199,3920,3936,"\n', '    nonoseaegeneralterm                                                                                                            \n', '    oselabeledaefromdruguse                           16          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
200,xeloda,200,3936,3938,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,xeloda,201,3938,3951,"13          21          5           16       \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,xeloda,202,3951,3988,"nonoseaegeneralterm                                                                                                      \n', '    oselabeledaefromdruguse                                     14          2           <1          16          2           -        \n', '    oselabeledaefromdruguse                                       13          1           -           22          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
203,xeloda,203,3988,4022,"<1          -        \n', '    oselabeledaefromdruguse                                 12          2           -           11          <1          -        \n', '    oselabeledaefromdruguse                                   7           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,xeloda,204,4022,4059,"<1          -           6           -           -        \n', '    oselabeledaefromdruguse                                  5           -           -           3           -           -        \n', '    oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,xeloda,205,4059,4085,"2           1           -           7           4           -        \n', '    nonoseaegeneralterm                                                                                                        \n', '    oselabeledaefromdruguse                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
206,xeloda,206,4085,4143,"7           <1          -           8           <1          -        \n', '    oselabeledaefromdruguse                     6           <1          -           4           -           -        \n', '    oselabeledaefromdruguse                     4           -           -           5           1           -        \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,xeloda,207,4143,4173,"nonoseaegeneralterm                                                                                                         \n', '    oselabeledaefromdruguse                                    5           -           -           5           -           -        \n', '    oselabeledaefromdruguse                                 3           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
208,xeloda,208,4173,4234,"<1          -           5           1           -        \n', '    nonoseaegeneralterm                                                                                                      \n', '    oselabeledaefromdruguse                                  5           -           -           5           1           -        \n', '            Table 8 Percent of Patients With Laboratory Abnormalities Participating in the XELODA and Docetaxel Combination vs Docetaxel Monotherapy Study",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
209,xeloda,209,4234,4250,"\n', ' Adverse Event                             XELODA 1250 mg/m  2  /bid",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,xeloda,210,4250,4258,With Docetaxel75 mg/m  2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,xeloda,211,4258,4259,/3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,xeloda,212,4259,4261,weeks  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,xeloda,213,4261,4268,Docetaxel100 mg/m  2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,xeloda,214,4268,4269,/3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,xeloda,215,4269,4271,weeks   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,xeloda,216,4271,4294,"\n', '                                            (n=251)     (n=255)     \n', ' Body System/Adverse Event                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,xeloda,217,4294,4314,Total%     Grade 3%    Grade 4%     Total%     Grade 3%    Grade 4%    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,xeloda,218,4314,4337,"\n', '  \n', '    nonoseaegeneralterm                                                                                                      \n', '    oselabeledaefromdruguse                                  91          37          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
219,xeloda,219,4337,4341,24          88          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,xeloda,220,4341,4354,"42          33       \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,xeloda,221,4354,4358,86          20          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,xeloda,222,4358,4362,49          87          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,xeloda,223,4362,4373,"10          66       \n', '    oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,xeloda,224,4373,4392,"41          2           1           23          1           2        \n', '    oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,xeloda,225,4392,4431,"80          7           3           83          5           <1       \n', '    oselabeledaefromdruguse                             99          48          41          98          44          40       \n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
226,xeloda,226,4431,4440,"\n', '    oselabeledaefromdruguse                          20          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,xeloda,227,4440,4448,7           2           6           2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,xeloda,228,4448,4450,2        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,xeloda,229,4450,4457,"\n', '                 Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,xeloda,230,4457,4487,"\n', ' \n', '\n', ' The following data are shown for the study in  notaecandidateindication patients who received a dose of 1250",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
231,xeloda,231,4487,4493,mg/m  2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,xeloda,232,4493,4506,administered twice daily for 2 weeks followed by a 1-week rest period.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,xeloda,233,4506,4515,The mean duration of treatment was 114 days.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,xeloda,234,4515,4606,"A total of 13 out of 162 patients (8%) discontinued treatment because of adverse reactions/intercurrent  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Table 9 Percent Incidence of Adverse Reactions Considered Remotely, Possibly or Probably Related to Treatment in >=5% of Patients Participating in the Single Arm Trial in Stage IV Breast Cancer \n', ' Adverse Event                                   Phase 2 Trial in Stage IV Breast Cancer(n=162)   \n', ' Body System/Adverse Event                             ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
235,xeloda,235,4606,4608,Total%             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,xeloda,236,4608,4616,Grade 3%            Grade 4%        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,xeloda,237,4616,4629,"\n', '  \n', ' - Not observed                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,xeloda,238,4629,4630,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,xeloda,239,4630,4638,"', ' NA = Not Applicable                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,xeloda,240,4638,4645,"\n', '  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,xeloda,241,4645,4650,", '    nonoseaegeneralterm                                                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
242,xeloda,242,4650,4655,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,xeloda,243,4655,4659,oselabeledaefromdruguse                                                57                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,xeloda,244,4659,4663,12                  3            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,xeloda,245,4663,4672,"\n', '  oselabeledaefromdruguse                                                  53                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,xeloda,246,4672,4696,"4                   -            \n', '  oselabeledaefromdruguse                                                37                  4                   -            \n', '  oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,xeloda,247,4696,4748,"24                  7                   -            \n', '  oselabeledaefromdruguse                                          20                  4                   -            \n', '  oselabeledaefromdruguse                                            15                  1                   -            \n', '  oselabeledaefromdruguse                                               8                   -                   -            \n', '    nonoseaegeneralterm                                                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
248,xeloda,248,4748,4759,"\n', '  oselabeledaefromdruguse                                  57                  11                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,xeloda,249,4759,4761,NA           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,xeloda,250,4761,4770,"\n', '  oselabeledaefromdruguse                                              37                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,xeloda,251,4770,4827,"1                   -            \n', '  oselabeledaefromdruguse                                           7                   -                   -            \n', '    nonoseaegeneralterm                                                                                                    \n', '  oselabeledaefromdruguse                                                 41                  8                   -            \n', '  oselabeledaefromdruguse                                                 12                  1                   -            \n', '  oselabeledaefromdruguse                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
252,xeloda,252,4827,4840,"6                   1                   -            \n', '    nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
253,xeloda,253,4840,4849,"\n', '  oselabeledaefromdruguse                                             21                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,xeloda,254,4849,4873,"1                   -            \n', '  oselabeledaefromdruguse                                                9                   1                   -            \n', '  oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,xeloda,255,4873,4972,"8                   -                   -            \n', '  oselabeledaefromdruguse                                                8                   -                   -            \n', '    nonoseaegeneralterm                                                                                                 \n', '  oselabeledaefromdruguse                                                23                  3                   -            \n', '  oselabeledaefromdruguse                                             7                   4                   1            \n', '    nonoseaegeneralterm                                                                                                        \n', '  oselabeledaefromdruguse                                          15                  -                   -            \n', '    nonoseaegeneralterm                                                                                            \n', '  oselabeledaefromdruguse                                                 9                   -                   -            \n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
256,xeloda,256,4972,4981,"\n', '  oselabeledaefromdruguse                                                   9                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,xeloda,257,4981,5001,"1                   -            \n', '    nonoseaegeneralterm                                                                                                      \n', '  oselabeledaefromdruguse                                             26                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
258,xeloda,258,5001,5005,2                   2            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,xeloda,259,5005,5012,"\n', '  oselabeledaefromdruguse                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,xeloda,260,5012,5027,"24                  3                   1            \n', '  oselabeledaefromdruguse                                                  72                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,xeloda,261,5027,5031,3                   1            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,xeloda,262,5031,5042,"\n', '  oselabeledaefromdruguse                                             94                  44                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,xeloda,263,5042,5044,15           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,xeloda,264,5044,5049,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,xeloda,265,5049,5051,nonoseaegeneralterm                                                                                              ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
266,xeloda,266,5051,5058,"\n', '  oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,xeloda,267,5058,5060,22                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,xeloda,268,5060,5064,9                   2            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,xeloda,269,5064,5155,"\n', '            6.4 Clinically Relevant Adverse Events in <5% of Patients\n', '   Clinically relevant adverse events reported in <5% of patients treated with XELODA either as monotherapy or in combination with docetaxel that were considered at least remotely related to treatment are shown below; occurrences of each grade 3 and 4 adverse event are provided in parentheses.\n', '\n', '     Monotherapy (Metastatic Colorectal Cancer, Adjuvant Colorectal Cancer, Metastatic Breast Cancer)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,xeloda,270,5155,5244,"\n', '\n', '\n', '    nonoseaegeneralterm      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.3%),  oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%)   \n', '    nonoseaegeneralterm :     oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.2%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
271,xeloda,271,5244,5370,"\n', '    nonoseaegeneralterm              oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '    nonoseaegeneralterm         oselabeledaefromdruguse   oselabeledaefromdruguse (0.5%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse   \n', '    nonoseaegeneralterm           oselabeledaefromdruguse   oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '    nonoseaegeneralterm                  oselabeledaefromdruguse                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
272,xeloda,272,5370,5520,"\n', '    nonoseaegeneralterm          oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   \n', '    nonoseaegeneralterm              oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   \n', '    nonoseaegeneralterm           oselabeledaefromdruguse (1.0%),  oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse   oselabeledaefromdruguse (0.3%),  oselabeledaefromdruguse (including  oselabeledaefromdruguse  (0.2%)   \n', '    nonoseaegeneralterm      oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
273,xeloda,273,5520,5561,"\n', '    nonoseaegeneralterm      oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (1.0%),  oselabeledaefromdruguse (0.1%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
274,xeloda,274,5561,5566,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,xeloda,275,5566,5602,"nonoseaegeneralterm             oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse (0.1%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
276,xeloda,276,5602,5617,"\n', '    nonoseaegeneralterm          oselabeledaefromdruguse   oselabeledaefromdruguse (0.1%)                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
277,xeloda,277,5617,5639,"\n', '    nonoseaegeneralterm                oselabeledaefromdruguse (0.6%)                                                            \n', '    nonoseaegeneralterm                  oselabeledaefromdruguse                                                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
278,xeloda,278,5639,5682,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse (0.1%),  oselabeledaefromdruguse   \n', '    nonoseaegeneralterm        oselabeledaefromdruguse (0.1%)                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
279,xeloda,279,5682,5683,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,xeloda,280,5683,5701,"', '   Postmarketing:       oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaemanifestationorcomplication secondary to  oselabeledaefromdruguse including  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
281,xeloda,281,5701,5782,"nonoseaegeneralterm outcome  [see  Warnings and Precautions (5.5)  ]  ,  oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse  severe  oselabeledaefromdruguse such as  oselabeledaefromdruguse and  oselabeledaefromdruguse   [see  Warnings and Precautions (5.7)  ]    ,  persistent or severe  oselabeledaefromdruguse can eventually lead to  nonoseaemanifestationorcomplication [  see  Warnings and Precautions (5.7)    ]   \n', '            XELODA",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
282,xeloda,282,5782,5838,"In Combination With Docetaxel (Metastatic Breast Cancer)  \n', ' \n', '\n', '\n', '    nonoseaegeneralterm      oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.8%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
283,xeloda,283,5838,5878,"\n', '    nonoseaegeneralterm         oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (1.2%),  oselabeledaefromdruguse (0.8%),  oselabeledaefromdruguse (0.4%), migraine (0.4%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
284,xeloda,284,5878,5891,"\n', '    nonoseaegeneralterm              oselabeledaefromdruguse (0.4%)                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
285,xeloda,285,5891,5918,"\n', '    nonoseaegeneralterm            oselabeledaefromdruguse (2.4%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%)                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
286,xeloda,286,5918,5938,"\n', '    nonoseaegeneralterm      oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%)                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
287,xeloda,287,5938,5968,"\n', '    nonoseaegeneralterm             oselabeledaefromdruguse (1.2%),  oselabeledaefromdruguse and  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.8%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
288,xeloda,288,5968,5973,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,xeloda,289,5973,5981,nonoseaegeneralterm                oselabeledaefromdruguse (0.4%)                                                               ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
290,xeloda,290,5981,6022,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdrugcomponent (0.4%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
291,xeloda,291,6022,6030,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
292,xeloda,292,6030,6031,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,xeloda,293,6031,6042,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,xeloda,294,6042,6052,"WARNING: XELODA-WARFARIN INTERACTION\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,xeloda,295,6052,6058,"', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,xeloda,296,6058,6063,XELODA-WARFARIN INTERACTION  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,xeloda,297,6063,6064,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,xeloda,298,6064,6076,"', '\n', '    XELODA Warfarin Interaction:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,xeloda,299,6076,6109,Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,xeloda,300,6109,6147,A clinically important XELODA-Warfarin drug interaction was demonstrated in a clinical pharmacology trial   [see   Warnings and Precautions (5.2)   and   Drug Interactions (7.1)  ]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,xeloda,301,6147,6175,nonoseaeaefromdruginteraction and/or  nonoseaeaefromdruginteraction  including  nonoseaegeneralterm  have been reported in patients taking XELODA concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
302,xeloda,302,6175,6208,Postmarketing reports have shown clinically significant  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction in prothrombin time (PT) and  nonoseaeaefromdruginteraction in patients who were stabilized on anticoagulants at the time XELODA was introduced.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
303,xeloda,303,6208,6237,"These events occurred within several days and up to several months after initiating XELODA therapy and, in a few cases, within 1 month after stopping XELODA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,xeloda,304,6237,6269,These events occurred in patients with and without  notaecandidatepreexistingconditionorriskfactor  Age greater than 60 and a diagnosis of  notaecandidatepreexistingconditionorriskfactor independently predispose patients to an increased risk of  nonoseaeaeonlyasinstruction    ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
305,xeloda,305,6269,6295,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Coagulopathy : May result in bleeding, death.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,xeloda,306,6295,6309,"Monitor anticoagulant response (e.g., INR) and adjust anticoagulant dose accordingly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,xeloda,307,6309,6314,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,xeloda,308,6314,6318,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,xeloda,309,6318,6326,*   Diarrhea : May be severe.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,xeloda,310,6326,6339,Interrupt XELODA treatment immediately until diarrhea resolves or decreases to grade 1.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,xeloda,311,6339,6344,Recommend standard antidiarrheal treatments.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,xeloda,312,6344,6369,"(  5.2  ) \n', ' *   Cardiotoxicity : Common in patients with a prior history of coronary artery disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,xeloda,313,6369,6401,"(  5.3  ) \n', ' *   Increased Risk of Severe or Fatal Adverse Reactions in Patients with Low or Absent Dihydropyrimidine Dehydrogenase (DPD) Activity:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,xeloda,314,6401,6432,"Withhold or permanently discontinue XELODA in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,xeloda,315,6432,6446,No XELODA dose has been proven safe in patients with absent DPD activity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,xeloda,316,6446,6470,"(  5.4  ) \n', ' *   Dehydration and Renal Failure : Interrupt XELODA treatment until dehydration is corrected.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,xeloda,317,6470,6480,Potential risk of acute renal failure secondary to dehydration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,xeloda,318,6480,6485,Monitor and correct dehydration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,xeloda,319,6485,6491,(  5.5  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,xeloda,320,6491,6507,"\n', ' *   Embryo-Fetal Toxicity : Can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,xeloda,321,6507,6525,Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,xeloda,322,6525,6538,"(  5.6  ,  8.1  ,  8.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,xeloda,323,6538,6572,"\n', ' *   Mucocutaneous and Dermatologic Toxicity : Severe mucocutaneous reactions, Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,xeloda,324,6572,6588,XELODA should be permanently discontinued in patients who experience a severe mucocutaneous reaction during treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,xeloda,325,6588,6598,XELODA may induce hand-and-foot syndrome.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,xeloda,326,6598,6619,Persistent or severe hand-and-foot syndrome can lead to loss of fingerprints which could impact patient identification.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,xeloda,327,6619,6637,Interrupt XELODA treatment until the hand-and-foot syndrome event resolves or decreases in intensity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
328,xeloda,328,6637,6663,"(  5.7  ) \n', ' *   Hyperbilirubinemia : Interrupt XELODA treatment immediately until the hyperbilirubinemia resolves or decreases in intensity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,xeloda,329,6663,6672,"(  5.8  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,xeloda,330,6672,6702,*   Hematologic : Do not treat patients with neutrophil counts <1.5 * 10  9  /L or thrombocyte counts <100 * 10  9  /L.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,xeloda,331,6702,6718,"If grade 3-4 neutropenia or thrombocytopenia occurs, stop therapy until condition resolves.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
332,xeloda,332,6718,6801,"(  5.9  ) \n', '    \n', ' \n', '\n', '   5.1  nonoseaeaefromdruginteraction \n', '  Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response (INR or prothrombin time) monitored closely with great frequency and the anticoagulant dose should be adjusted accordingly [see  Boxed Warning  and  Drug Interactions (7.1)  ].  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
333,xeloda,333,6801,6813,"\n', '\n', '    5.2 Diarrhea\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,xeloda,334,6813,6829,", '\n', '  XELODA can induce  oselabeledaefromdruguse  sometimes severe.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,xeloda,335,6829,6849,Patients with severe  nonoseaeaeonlyasinstruction should be carefully monitored and given fluid and electrolyte replacement if they become dehydrated.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,xeloda,336,6849,6893,"In 875 patients with either metastatic  notaecandidateindication or colorectal  notaecandidateindication  notaecandidateindication who received XELODA monotherapy, the median time to first occurrence of grade 2 to 4  oselabeledaefromdruguse was 34 days (range from 1 to 369 days).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
337,xeloda,337,6893,6907,The median duration of grade 3 to 4  oselabeledaefromdruguse was 5 days.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
338,xeloda,338,6907,6960,National Cancer Institute of Canada (NCIC) grade 2  nonoseaeaeonlyasinstruction is defined as an  nonoseaeaeonlyasinstruction  grade 3  nonoseaeaeonlyasinstruction as an  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  and grade 4  nonoseaeaeonlyasinstruction as an  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction or the need for parenteral support.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
339,xeloda,339,6960,7003,"If grade 2, 3 or 4  nonoseaeaeonlyasinstruction occurs, administration of XELODA should be immediately interrupted until the  nonoseaeaeonlyasinstruction resolves or decreases in intensity to grade 1 [see  Dosage and Administration (2.3)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,xeloda,340,7003,7078,"Standard antidiarrheal treatments (e.g., loperamide) are recommended.\n', '\n', '  oselabeledaefromdruguse ( oselabeledaefromdruguse  has been reported.\n', '\n', '    5.3 Cardiotoxicity\n', '\n', '  The  oselabeledaefromdruguse observed with XELODA includes  oselabeledaefromdruguse infarction/ oselabeledaefromdruguse  oselabeledaefromdruguse ischemia,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,xeloda,341,7078,7182,"These adverse reactions may be more common in patients with a prior history of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.4 Dihydropyrimidine Dehydrogenase Deficiency\n', '\n', '  Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the DPD gene that result in complete or near complete  notaecandidatepreexistingconditionorriskfactor are at increased risk for acute early-onset of toxicity and severe, life-threatening, or  nonoseaegeneralterm adverse reactions caused by XELODA (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse .",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
342,xeloda,342,7182,7260,"Patients with partial DPD activity may also have increased risk of severe, life-threatening, or  nonoseaegeneralterm adverse reactions caused by XELODA.\n', '\n', ' Withhold or permanently discontinue XELODA based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
343,xeloda,343,7260,7276,No XELODA dose has been proven safe for patients with complete absence of DPD activity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,xeloda,344,7276,7355,"There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.\n', '\n', '    5.5 Dehydration and Renal Failure\n', '\n', '   oselabeledaefromdruguse has been observed and may cause  nonoseaemanifestationorcomplication which can be  nonoseaegeneralterm  Patients with pre-existing  notaecandidatepreexistingconditionorriskfactor or who are receiving concomitant XELODA with known  nonoseaeaeonlyasinstruction are at higher risk.",1,1,1,0,1,0,0,0,0,0,0,0,0,0,0
345,xeloda,345,7355,7374,Patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor may rapidly become  nonoseaeaeonlyasinstruction  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
346,xeloda,346,7374,7390,Monitor patients when XELODA is administered to prevent and correct  nonoseaeaeonlyasinstruction at the onset.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,xeloda,347,7390,7413,"If grade 2 (or higher)  nonoseaeaeonlyasinstruction occurs, XELODA treatment should be immediately interrupted and the  nonoseaeaeonlyasinstruction corrected.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,xeloda,348,7413,7433,Treatment should not be restarted until the patient is rehydrated and any precipitating causes have been corrected or controlled.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,xeloda,349,7433,7452,Dose modifications should be applied for the precipitating adverse event as necessary [ see  Dosage and Administration (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,xeloda,350,7452,7456,2.3)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,xeloda,351,7456,7487,".\n', '\n', ' Patients with moderate  notaecandidatepreexistingconditionorriskfactor at baseline require dose reduction [see  Dosage and Administration (2.4)  ]  .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
352,xeloda,352,7487,7504,Patients with mild and moderate  notaecandidatepreexistingconditionorriskfactor at baseline should be carefully monitored for adverse reactions.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
353,xeloda,353,7504,7575,"Prompt interruption of therapy with subsequent dose adjustments is recommended if a patient develops a grade 2 to 4 adverse event as outlined in   Table 2     [see  Dosage and Administration (2.3)  ,  Use in Specific Populations (8.7)  , and  Clinical Pharmacology (12.3)  ]  .\n', '\n', '    5.6  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
354,xeloda,354,7575,7617,"\n', '   Based on findings from animal reproduction studies and its mechanism of action, XELODA may cause  oselabeledaefromdruguse when given to a  notaecandidatepreexistingconditionorriskfactor woman [see  Clinical Pharmacology (12.1)  ]  .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
355,xeloda,355,7617,7633,Limited available data are not sufficient to inform use of XELODA in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
356,xeloda,356,7633,7694,"In animal reproduction studies, administration of capecitabine to  nonoseaeaeanimal animals during the period of organogenesis caused  nonoseaeaeanimal and  nonoseaeaeanimal in mice and  nonoseaeaeanimal in monkeys at 0.2 and 0.6 times the exposure (AUC) in patients receiving the recommended dose respectively [see  Use in Specific Populations (8.1)  ]  .",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
357,xeloda,357,7694,7740,Apprise  notaecandidatepreexistingconditionorriskfactor women of the potential  oselabeledaefromdruguse  Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of XELODA [see  Use in Specific Populations (8.3)  ]  .  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
358,xeloda,358,7740,7757,"\n', '\n', '    5.7  oselabeledaefromdruguse and Dermatologic  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,xeloda,359,7757,7758,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,xeloda,360,7758,7770,"\n', '   Severe  oselabeledaefromdruguse  some with  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,xeloda,361,7770,7799,"nonoseaegeneralterm outcome, such as  oselabeledaefromdruguse and  oselabeledaefromdruguse  can occur in patients treated with XELODA [ see  Adverse Reactions (6.4)    ].",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
362,xeloda,362,7799,7819,XELODA should be permanently discontinued in patients who experience a severe  nonoseaeaeonlyasinstruction possibly attributable to XELODA treatment.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,xeloda,363,7819,7840,"\n', '\n', ""  oselabeledaefromdruguse ( oselabeledaefromdruguse or  oselabeledaefromdruguse  is a  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,xeloda,364,7840,7874,Median time to onset was 79 days (range from 11 to 360 days) with a severity range of grades 1 to 3 for patients receiving XELODA monotherapy in the metastatic setting.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,xeloda,365,7874,7885,Grade 1 is characterized by any of the following:  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,xeloda,366,7885,7905,nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or erythema  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or erythema of the hands,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
367,xeloda,367,7905,7911,and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
368,xeloda,368,7911,7927,nonoseaemanifestationorcomplication of the hands and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or feet and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
369,xeloda,369,7927,7937,and/or  nonoseaemanifestationorcomplication which does not disrupt normal activities.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
370,xeloda,370,7937,7991,Grade 2  nonoseaeaeonlyasinstruction is defined as  nonoseaemanifestationorcomplication and swelling  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and swelling of the hands and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication of the hands and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or feet and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or  nonoseaemanifestationorcomplication affecting the patient's activities of daily living.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
371,xeloda,371,7991,8038,"Grade 3  nonoseaeaeonlyasinstruction is defined as  nonoseaeaeonlyasinstruction  ulceration, blistering or severe pain of the  nonoseaeaeonlyasinstruction  nonoseaemanifestationorcomplication  ulceration, blistering or severe pain of the hands and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  blistering or severe pain of the  nonoseaemanifestationorcomplication  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
372,xeloda,372,8038,8067,nonoseaemanifestationorcomplication  blistering or severe pain of the hands and/or  nonoseaemanifestationorcomplication  nonoseaeaeonlyasinstruction or severe pain of the  nonoseaeaeonlyasinstruction  nonoseaemanifestationorcomplication or severe pain of the hands,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
373,xeloda,373,8067,8073,and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
374,xeloda,374,8073,8126,nonoseaemanifestationorcomplication of the hands and/or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or feet and/or severe  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or severe  nonoseaemanifestationorcomplication that causes the patient to be  nonoseaemanifestationorcomplication  Persistent or severe  nonoseaeaeonlyasinstruction (grade 2 and above) can eventually lead to  nonoseaemanifestationorcomplication which could impact patient identification.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
375,xeloda,375,8126,8153,"If grade 2 or 3  nonoseaeaeonlyasinstruction occurs, administration of XELODA should be interrupted until the event resolves or decreases in intensity to grade 1.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,xeloda,376,8153,8281,"Following grade 3  nonoseaeaeonlyasinstruction  subsequent doses of XELODA should be decreased [see  Dosage and Administration (2.3)  ]  .\n"", '\n', '    5.8 Hyperbilirubinemia\n', '\n', '  In 875 patients with either metastatic  notaecandidateindication or colorectal  notaecandidateindication  notaecandidateindication who received at least one dose of XELODA 1250 mg/m  2  twice daily as monotherapy for 2 weeks followed by a 1-week rest period, grade 3 (1.5-3 * ULN)  oselabeledaefromdruguse occurred in 15.2% (n=133) of patients and grade 4 (>3 * ULN)  oselabeledaefromdruguse occurred in 3.9% (n=34) of patients.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
377,xeloda,377,8281,8315,"Of 566 patients who had  notaecandidatepreexistingconditionorriskfactor at baseline and 309 patients without  nonoseaenegation at baseline, grade 3 or 4  oselabeledaefromdruguse occurred in 22.8% and 12.3%, respectively.",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
378,xeloda,378,8315,8370,"Of the 167 patients with grade 3 or 4  oselabeledaefromdruguse  18.6% (n=31) also had postbaseline  oselabeledaefromdruguse (grades 1 to 4, without elevations at baseline) in  oselabeledaefromdruguse and 27.5% (n=46) had postbaseline  oselabeledaefromdruguse at any time (not necessarily concurrent).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,xeloda,379,8370,8394,"The majority of these patients, 64.5% (n=20) and 71.7% (n=33), had  notaecandidatepreexistingconditionorriskfactor at baseline.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
380,xeloda,380,8394,8453,"In addition, 57.5% (n=96) and 35.3% (n=59) of the 167 patients had  oselabeledaefromdruguse (grades 1 to 4) at both prebaseline and postbaseline in alkaline phosphatase or  oselabeledaefromdruguse  oselabeledaefromdruguse (grades 1 to 4) at both prebaseline and postbaseline in  oselabeledaefromdruguse or transaminases, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
381,xeloda,381,8453,8527,"Only 7.8% (n=13) and 3.0% (n=5) had grade 3 or 4  oselabeledaefromdruguse alkaline phosphatase or  oselabeledaefromdruguse  oselabeledaefromdruguse or transaminases.\n', '\n', ' In the 596 patients treated with XELODA as first-line therapy for metastatic  notaecandidateindication  the incidence of grade 3 or 4  oselabeledaefromdruguse was similar to the overall clinical trial safety database of XELODA monotherapy.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
382,xeloda,382,8527,8568,The median time to onset for grade 3 or 4  oselabeledaefromdruguse in the  notaecandidateindication population was 64 days and median  oselabeledaefromdruguse from 8 um/L at baseline to 13 um/L during treatment with XELODA.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
383,xeloda,383,8568,8662,"Of the 136  notaecandidateindication patients with grade 3 or 4  oselabeledaefromdruguse  49 patients had grade 3 or 4  oselabeledaefromdruguse as their last measured value, of which 46 had  notaecandidatepreexistingconditionorriskfactor at baseline.\n', '\n', ' In 251 patients with metastatic  notaecandidateindication who received a combination of XELODA and docetaxel, grade 3 (1.5 to 3 * ULN)  oselabeledaefromdruguse occurred in 7% (n=17) and grade 4 (>3 * ULN)  oselabeledaefromdruguse occurred in 2% (",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
384,xeloda,384,8662,8802,"n=5).\n', '\n', ' If drug-related grade 3 to 4  nonoseaeaeonlyasinstruction occur, administration of XELODA should be immediately interrupted until the  nonoseaeaeonlyasinstruction to <=3.0 * ULN [  see recommended dose modifications under   Dosage and Administration (2.3)  ]  .\n', '\n', '    5.9 Hematologic\n', '\n', '  In 875 patients with either metastatic  notaecandidateindication or colorectal  notaecandidateindication  notaecandidateindication who received a dose of 1250 mg/m  2  administered twice daily as monotherapy for 2 weeks followed by a 1-week rest period, 3.2%, 1.7%, and 2.4% of patients had grade 3 or 4  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse  respectively.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
385,xeloda,385,8802,8850,"In 251 patients with metastatic  notaecandidateindication who received a dose of XELODA in combination with docetaxel, 68% had grade 3 or 4  oselabeledaefromdruguse  2.8% had grade 3 or 4  oselabeledaefromdruguse  and 9.6% had grade 3 or 4  oselabeledaefromdruguse",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
386,xeloda,386,8850,8873,"\n', '\n', ' Patients with baseline  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor should not be treated with XELODA.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
387,xeloda,387,8873,8933,"If unscheduled laboratory assessments during a treatment cycle show grade 3 or 4  nonoseaeaeonlyasinstruction  treatment with XELODA should be interrupted.\n', '\n', '    5.10 Geriatric Patients\n', '\n', '  Patients >=80 years old may experience a greater incidence of grade 3 or 4 adverse reactions.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,xeloda,388,8933,9017,"In 875 patients with either metastatic  notaecandidateindication or colorectal  notaecandidateindication  notaecandidateindication who received XELODA monotherapy, 62% of the 21 patients >=80 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event:  oselabeledaefromdruguse in 6 (28.6%),  oselabeledaefromdruguse in 3 (14.3%),  oselabeledaefromdruguse in 3 (14.3%), and  oselabeledaefromdruguse in 2 (9.5%) patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
389,xeloda,389,9017,9075,"Among the 10 patients 70 years of age and greater (no patients were >80 years of age) treated with XELODA in combination with docetaxel, 30% (3 out of 10) of patients experienced grade 3 or 4  oselabeledaefromdruguse and  oselabeledaefromdruguse  and 40% (4 out of 10)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,xeloda,390,9075,9080,experienced grade 3  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,xeloda,391,9080,9088,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
392,xeloda,392,9088,9265,"Among the 67 patients >=60 years of age receiving XELODA in combination with docetaxel, the incidence of grade 3 or 4 treatment-related adverse reactions, treatment-related serious adverse reactions, withdrawals due to adverse reactions, treatment discontinuations due to adverse reactions and treatment discontinuations within the first two treatment cycles was higher than in the <60 years of age patient group.\n', '\n', ' In 995 patients receiving XELODA as adjuvant therapy for  notaecandidateindication after  notaecandidateindication  41% of the 398 patients >=65 years of age treated with XELODA experienced a treatment-related grade 3 or 4 adverse event:  oselabeledaefromdruguse in 75 (18.8%),  oselabeledaefromdruguse in 52 (13.1%),  oselabeledaefromdruguse in 12 (3.0%),  oselabeledaefromdruguse  oselabeledaefromdruguse in 11 (2.8%),  oselabeledaefromdruguse in 6 (1.5%), and  oselabeledaefromdruguse in 5 (1.3%) patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
393,xeloda,393,9265,9375,"In patients >=65 years of age (all randomized population; capecitabine 188 patients, 5-FU/LV 208 patients) treated for  notaecandidateindication after  notaecandidateindication  the hazard ratios for disease-free survival and overall survival for XELODA compared to 5-FU/LV were 1.01 (95% C.I. 0.80 - 1.27) and 1.04 (95% C.I. 0.79 - 1.37), respectively.\n', '\n', '    5.11 Hepatic Insufficiency\n', '\n', '  Patients with mild to moderate  notaecandidatepreexistingconditionorriskfactor due to  notaecandidatepreexistingconditionorriskfactor should be carefully monitored when XELODA is administered.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
394,xeloda,394,9375,9383,The effect of severe  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,gazyva,0,0,122,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,gazyva,1,122,178,"oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.7)  ]  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,gazyva,2,178,209,The most common adverse reactions (incidence >= 10%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,gazyva,3,209,256,"\n', ' \n', '\n', '   EXCERPT:   The most common adverse reactions (incidence >= 10%) were infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough, nausea, and diarrhea.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,gazyva,4,256,262,(  6  )  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,gazyva,5,262,288,"To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,gazyva,6,288,325,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,gazyva,7,325,428,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The data described in Tables 3-6 below are based on a safety population of 773 previously untreated patients with  notaecandidateindication  Patients were treated with chlorambucil alone, GAZYVA in combination with chlorambucil, or rituximab in combination with chlorambucil.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,gazyva,8,428,458,"The Stage 1 analysis compared GAZYVA in combination with chlorambucil vs. chlorambucil alone, and Stage 2 compared GAZYVA in combination with chlorambucil vs. rituximab in combination with chlorambucil.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,gazyva,9,458,500,Patients received three 1000 mg doses of GAZYVA on the first cycle and a single dose of 1000 mg once every 28 days for 5 additional cycles in combination with chlorambucil (6 cycles of 28 days each in total).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,gazyva,10,500,542,"In the last 140 patients enrolled, the first dose of GAZYVA was split between day 1 (100 mg) and day 2 (900 mg)  [see  Dosage and Administration (2.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,gazyva,11,542,608,"In total, 81% of patients received all 6 cycles (of 28 days each) of GAZYVA-based therapy.\n', '\n', '\n', '\n', ' Table 3 Summary of Adverse Reactions Reported in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,gazyva,12,608,620,"\n', ' Adverse Reactions(MedDRA)System Organ Class  GAZYVA + Chlorambuciln",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,gazyva,13,620,627,= 241  Chlorambuciln = 116   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,gazyva,14,627,632,"\n', '                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,gazyva,15,632,636,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,gazyva,16,636,642,Grades 3-4 %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,gazyva,17,642,646,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,gazyva,18,646,664,"Grades 3-4 %     \n', '  \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,gazyva,19,664,679,"\n', '  oselabeledaefromdruguse                           69                21                0                 0           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,gazyva,20,679,686,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,gazyva,21,686,714,"\n', '  oselabeledaefromdruguse                                  41                35                18                16          \n', '  oselabeledaefromdruguse                             15                11                8                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,gazyva,22,714,716,4           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,gazyva,23,716,738,"\n', '  oselabeledaefromdruguse                                       12                5                 10                4           \n', '  oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,gazyva,24,738,746,7                 5                 0                 0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,gazyva,25,746,753,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,gazyva,26,753,760,"\n', '  oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,gazyva,27,760,762,10               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,gazyva,28,762,872,"< 1                7                 0           \n', '    nonoseaegeneralterm     \n', '  oselabeledaefromdruguse                                        10                0                 7                < 1          \n', '    nonoseaegeneralterm          \n', '  oselabeledaefromdruguse                      6                 2                 3                < 1          \n', '    nonoseaegeneralterm     \n', '  oselabeledaefromdruguse                                    5                < 1                2                 0           \n', '          Table 4 Summary of Adverse Reactions Reported in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 2)",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,gazyva,29,872,898,"\n', ' Adverse Reactions(MedDRA)System Organ Class  GAZYVA + Chlorambuciln = 336  Rituximab + Chlorambuciln = 321   \n', '                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,gazyva,30,898,902,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,gazyva,31,902,908,Grades 3-4 %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,gazyva,32,908,912,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,gazyva,33,912,930,"Grades 3-4 %     \n', '  \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,gazyva,34,930,945,"\n', '  oselabeledaefromdruguse                           66                20                38                4           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,gazyva,35,945,980,"\n', '    nonoseaegeneralterm     \n', '  oselabeledaefromdruguse                                  38                33                32                28          \n', '  oselabeledaefromdruguse                             14                10                7                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,gazyva,36,980,982,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,gazyva,37,982,989,"\n', '  oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,gazyva,38,989,1005,"6                 4                 2                < 1          \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,gazyva,39,1005,1012,"\n', '  oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,gazyva,40,1012,1056,"9                < 1                7                < 1          \n', '    nonoseaegeneralterm           \n', '  oselabeledaefromdruguse                                     10                2                 8                < 1          \n', '  oselabeledaefromdruguse                                 8                 0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,gazyva,41,1056,1060,5                 0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,gazyva,42,1060,1074,"\n', '    nonoseaegeneralterm          \n', '  oselabeledaefromdruguse                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,gazyva,43,1074,1076,6                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,gazyva,44,1076,1136,"< 1                3                 0           \n', '  oselabeledaefromdruguse                      5                 1                 2                < 1          \n', '          Table 5 Post-Baseline Laboratory Abnormalities by CTCAE Grade in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,gazyva,45,1136,1145,"\n', ' Investigations                        GAZYVA + Chlorambuciln",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,gazyva,46,1145,1152,= 241  Chlorambuciln = 116   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,gazyva,47,1152,1157,"\n', '                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,gazyva,48,1157,1161,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,gazyva,49,1161,1167,Grades 3-4 %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,gazyva,50,1167,1171,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,gazyva,51,1171,1189,"Grades 3-4 %     \n', '  \n', '    nonoseaegeneralterm                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,gazyva,52,1189,1204,"\n', '    oselabeledaefromdruguse                                78                48                53                27          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,gazyva,53,1204,1213,"\n', '    oselabeledaefromdruguse                                80                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,gazyva,54,1213,1215,40                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,gazyva,55,1215,1217,9                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,gazyva,56,1217,1219,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,gazyva,57,1219,1232,"\n', '    oselabeledaefromdruguse                                 84                37                12               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,gazyva,58,1232,1242,"< 1          \n', '    nonoseaegeneralterm                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,gazyva,59,1242,1247,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,gazyva,60,1247,1251,oselabeledaefromdruguse                               38                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,gazyva,61,1251,1272,"3                 33                2           \n', '    oselabeledaefromdruguse                               33                5                 18                3           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,gazyva,62,1272,1296,"\n', '    oselabeledaefromdruguse                               30                8                 12                3           \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,gazyva,63,1296,1302,29                1                 16                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,gazyva,64,1302,1304,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,gazyva,65,1304,1318,"\n', '    oselabeledaefromdruguse                       30                <1                20                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,gazyva,66,1318,1329,"2           \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,gazyva,67,1329,1337,27                2                 16                0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,gazyva,68,1337,1344,"\n', '    oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,gazyva,69,1344,1351,23                <1                15                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,gazyva,70,1351,1369,"<1          \n', '    oselabeledaefromdruguse             18                0                 11                0           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,gazyva,71,1369,1376,"\n', '    oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,gazyva,72,1376,1378,15                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,gazyva,73,1378,1382,1                 5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,gazyva,74,1382,1422,"<1          \n', '          Table 6 Post-Baseline Laboratory Abnormalities by CTCAE Grade in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 2)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,gazyva,75,1422,1437,"\n', ' Investigations                        GAZYVA + Chlorambuciln = 336  Rituximab + Chlorambuciln",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,gazyva,76,1437,1445,"= 321   \n', '                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,gazyva,77,1445,1449,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,gazyva,78,1449,1455,Grades 3-4 %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,gazyva,79,1455,1459,All Grades %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,gazyva,80,1459,1477,"Grades 3-4 %     \n', '  \n', '    nonoseaegeneralterm                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,gazyva,81,1477,1490,"\n', '    oselabeledaefromdruguse                                76                46                69                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,gazyva,82,1490,1492,41          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,gazyva,83,1492,1522,"\n', '    oselabeledaefromdruguse                                80                39                50                16          \n', '    oselabeledaefromdruguse                                 84                35                62                16          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,gazyva,84,1522,1559,"\n', '    oselabeledaefromdruguse                           48                13                40                8           \n', '    oselabeledaefromdruguse                                     39                10                37                10          \n', '    nonoseaegeneralterm                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,gazyva,85,1559,1619,"\n', '    oselabeledaefromdruguse                               37                3                 32                <1          \n', '    oselabeledaefromdruguse                               14                1                 10                <1          \n', '    oselabeledaefromdruguse                               26                7                 18                2           \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse                        27                2                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,gazyva,86,1619,1621,21                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,gazyva,87,1621,1641,"<1          \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse                        28                2                 21                1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,gazyva,88,1641,1663,"\n', '    oselabeledaefromdruguse                            23                <1                16                <1          \n', '                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,gazyva,89,1663,1680,nonoseaegeneralterm   The incidence of  oselabeledaefromdruguse was 65% with the first infusion of GAZYVA.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,gazyva,90,1680,1700,The incidence of Grade 3 or 4  oselabeledaefromdruguse was 20% with 7% of patients discontinuing therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,gazyva,91,1700,1721,The incidence of reactions with subsequent infusions was 3% with the second 1000 mg and < 1% thereafter.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,gazyva,92,1721,1768,"No Grade 3 or 4  nonoseaenegation were reported beyond the first 1000 mg infused.\n', ' \n', '\n', ' Of the first 53 patients receiving GAZYVA on the trial, 47 (89%) experienced an  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
93,gazyva,93,1768,1791,"After this experience, study protocol modifications were made to require pre-medication with a corticosteroid, antihistamine, and acetaminophen.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,gazyva,94,1791,1814,The first dose was also divided into two infusions (100 mg on day 1 and 900 mg on day 2).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,gazyva,95,1814,1948,"For the 140 patients for whom these mitigation measures were implemented, 74 patients (53%) experienced a reaction with the first 1000 mg (64 patients on day 1, 3 patients on day 2, and 7 patients on both days) and < 3% thereafter  [see  Dosage and Administration (2)  ]  .\n', '\n', '\n', '\n', '      nonoseaegeneralterm  : The incidence of  oselabeledaefromdruguse reported as an adverse reaction was 38% in the GAZYVA treated arm and 32% in the rituximab treated arm, with the incidence of serious adverse events being 1% and < 1%, respectively (  Table 4  ).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,gazyva,96,1948,1997,"Cases of  oselabeledaefromdruguse (occurring 28 days after completion of treatment or later) were 16% in the GAZYVA treated arm and 12% in the rituximab treated arm.\n', '\n', '\n', '\n', '      nonoseaegeneralterm   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
97,gazyva,97,1997,2011,The incidence of  oselabeledaefromdruguse was similar between GAZYVA and rituximab treated arms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,gazyva,98,2011,2050,"Thirty-eight percent of patients in the GAZYVA treated arm and 37% in the rituximab treated arm experienced an  oselabeledaefromdruguse  with Grade 3-4 rates being 11% and 13%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,gazyva,99,2050,2138,"Fatal events were reported in 1% of patients in both arms.\n', '\n', '\n', '\n', '      nonoseaegeneralterm  : The overall incidence of  oselabeledaefromdruguse reported as an adverse reaction was higher in the GAZYVA treated arm (14%) compared to the rituximab treated arm (7%), with the incidence of Grade 3-4 events being 10% and 3%, respectively (  Table 4  ).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,gazyva,100,2138,2156,The difference in incidences between the treatment arms is driven by events occurring during the first cycle.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,gazyva,101,2156,2199,"The incidence of  oselabeledaefromdruguse (all grades) in the first cycle were 11% in the GAZYVA and 3% in the rituximab treated arms, with Grade 3-4 rates being 8% and 2%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,gazyva,102,2199,2269,"Four percent of patients in the GAZYVA treated arm experienced acute  oselabeledaefromdruguse (occurring within 24 hours after the GAZYVA infusion).\n', '\n', '\n', '\n', ' The overall incidence of  oselabeledaefromdruguse and the number of fatal  oselabeledaefromdruguse were similar between the treatment arms, with 3 in the rituximab and 4 in the GAZYVA treated arms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,gazyva,103,2269,2302,"However, all fatal  oselabeledaefromdruguse in patients treated with GAZYVA occurred in Cycle 1.\n', '\n', '\n', '\n', '      nonoseaegeneralterm   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,gazyva,104,2302,2434,"The incidence of Grade 3 or 4  oselabeledaefromdruguse was 2% in the GAZYVA treated arm versus 0% in the rituximab treated arm.\n', '\n', '\n', '\n', '      nonoseaegeneralterm   Adverse events related to  oselabeledaefromdruguse (all events from the System Organ Class), including  oselabeledaefromdruguse  have been reported in the GAZYVA treated arm with higher incidence than in the rituximab treated arm (18% vs. 15%).\n', '\n', '\n', '\n', '      nonoseaegeneralterm  :  oselabeledaefromdruguse have occurred in patients who received GAZYVA in clinical trials and had normal baseline hepatic enzyme levels (AST, ALT, and ALP).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,gazyva,105,2434,2449,The events occurred most frequently within 24-48 hours of the first infusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,gazyva,106,2449,2468,"In some patients,  oselabeledaefromdruguse in  oselabeledaefromdruguse were observed concurrently with  oselabeledaefromdruguse or  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,gazyva,107,2468,2500,"In the pivotal study, there was no clinically meaningful difference in overall  oselabeledaefromdruguse adverse events between all arms (4% of patients in the GAZYVA treated arm).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,gazyva,108,2500,2520,"Medications commonly used to prevent  nonoseaeaeonlyasinstruction (e.g., acetaminophen) may also be implicated in these events.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,gazyva,109,2520,2533,"Monitor liver function tests during treatment, especially during the first cycle.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,gazyva,110,2533,2609,"Consider treatment interruption or discontinuation for  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '   6.2 Immunogenicity\n', '\n', '  Serum samples from patients with previously untreated  notaecandidateindication were tested during and after treatment for  nonoseaeaeonlyasinstruction  Of the GAZYVA treated patients, 7% (18/271) tested  oselabeledaefromdruguse at one or more time points.  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
111,gazyva,111,2609,2645,"nonoseaeaeonlyasinstruction has not been assessed.\n', '\n', '\n', '\n', ' Immunogenicity data are highly dependent on the sensitivity and specificity of the test methods used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,gazyva,112,2645,2685,"Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication, and the underlying disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,gazyva,113,2685,2704,"Therefore, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction may be misleading.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,gazyva,114,2704,2748,"Clinical significance of  nonoseaeaeonlyasinstruction is not known.\n', '\n', '\n', '\n', '   6.3 Additional Clinical Trial Experience\n', '\n', '     nonoseaegeneralterm  :  nonoseaegeneralterm  oselabeledaefromdruguse",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
115,gazyva,115,2748,2749,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,gazyva,116,2749,2760,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,gazyva,117,2760,2774,"WARNING: HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,gazyva,118,2774,2780,"', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,gazyva,119,2780,2789,HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,gazyva,120,2789,2798,"\n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,gazyva,121,2798,2833,"*   oselabeledaeclasseffect (HBV)  oselabeledaeclasseffect  in some cases resulting in  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm  can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA.",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
122,gazyva,122,2833,2843,Screen all patients for  notaecandidatepreexistingconditionorriskfactor before treatment initiation.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
123,gazyva,123,2843,2853,Monitor  notaecandidatepreexistingconditionorriskfactor during and after treatment with GAZYVA.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
124,gazyva,124,2853,2874,Discontinue GAZYVA and concomitant medications in the event of  nonoseaeaeonlyasinstruction [see Warnings and Precautions (5.1)].,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,gazyva,125,2874,2927,"\n', ' *   oselabeledaefromdruguse  including fatal  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Infusion reactions: Premedicate patients with glucocorticoid, acetaminophen, and anti-histamine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,gazyva,126,2927,2933,Monitor patients closely during infusions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,gazyva,127,2933,2940,Interrupt or discontinue infusion for reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,gazyva,128,2940,2953,"(  2.2  ,  5.3  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,gazyva,129,2953,2985,*  Tumor Lysis Syndrome: Anticipate tumor lysis syndrome; premedicate with anti-hyperuricemics and adequate hydration especially for patients with high tumor burden and/or high circulating lymphocyte count.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,gazyva,130,2985,3001,"Correct electrolyte abnormalities, provide supportive care, and monitor renal function and fluid balance.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,gazyva,131,3001,3018,"(  5.4  ) \n', ' *  Neutropenia: Monitor for infection.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,gazyva,132,3018,3031,"(  5.6  ) \n', ' *  Thrombocytopenia:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,gazyva,133,3031,3038,Monitor platelet counts and for bleeding.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,gazyva,134,3038,3047,Management of hemorrhage may require blood product support.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,gazyva,135,3047,3060,"(  5.7  ) \n', ' *  Immunization:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,gazyva,136,3060,3073,Do not administer live virus vaccines prior to or during GAZYVA treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,gazyva,137,3073,3148,"(  5.8  ) \n', '    \n', ' \n', '\n', '   5.1 Hepatitis B Virus Reactivation\n', '\n', '\n', '\n', '   oselabeledaeclasseffect  in some cases resulting in  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm  can occur in patients treated with anti-CD20 antibodies such as GAZYVA.  ",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
138,gazyva,138,3148,3311,"oselabeledaeclasseffect has been reported in patients who are  notaecandidatepreexistingconditionorriskfactor and also in patients who are HBsAg negative but are  notaecandidatepreexistingconditionorriskfactor  Reactivation has also occurred in patients who appear to have resolved  notaecandidatepreexistingconditionorriskfactor (i.e.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor .\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor   nonoseaeaeonlyasinstruction is often followed by  nonoseaeaeonlyasinstruction  i.e.,  nonoseaeaeonlyasinstruction and, in severe cases,  nonoseaeaeonlyasinstruction levels,  nonoseaeaeonlyasinstruction  and  nonoseaegeneralterm \n', '\n', '\n', '\n', ' Screen all patients for  notaecandidatepreexistingconditionorriskfactor by measuring HBsAg and anti-HBc before initiating treatment with GAZYVA.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
139,gazyva,139,3311,3397,"For patients who show evidence of  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor [regardless of antibody status] or  notaecandidatepreexistingconditionorriskfactor but  notaecandidatepreexistingconditionorriskfactor , consult physicians with expertise in managing  nonoseaeaeonlyasinstruction regarding monitoring and consideration for HBV antiviral therapy.\n', '\n', '\n', '\n', ' Monitor patients with evidence of current or prior  notaecandidatepreexistingconditionorriskfactor for clinical and laboratory signs of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction during and for several months following treatment with GAZYVA.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
140,gazyva,140,3397,3447,"oselabeledaeclasseffect has been reported for other CD20-directed cytolytic antibodies following completion of therapy.\n', '\n', '\n', '\n', ' In patients who develop  oselabeledaefromdruguse while receiving GAZYVA, immediately discontinue GAZYVA and any concomitant chemotherapy and institute appropriate treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,gazyva,141,3447,3542,"Resumption of GAZYVA in patients whose  nonoseaeaeonlyasinstruction resolves should be discussed with physicians with expertise in managing  nonoseaeaeonlyasinstruction  Insufficient data exist regarding the safety of resuming GAZYVA in patients who develop  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.2 Progressive Multifocal Leukoencephalopathy\n', '\n', '\n', '\n', '   oselabeledaefromdruguse resulting in  oselabeledaefromdruguse (PML), which can be fatal, was observed in patients treated with GAZYVA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,gazyva,142,3542,3583,"Consider the diagnosis of  nonoseaeaeonlyasinstruction in any patient presenting with new onset or  nonoseaeaeonlyasinstruction  Evaluation of  nonoseaeaeonlyasinstruction includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,gazyva,143,3583,3668,"Discontinue GAZYVA therapy and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.3 Infusion Reactions\n', '\n', '\n', '\n', '  GAZYVA can cause severe and life-threatening  oselabeledaefromdruguse  Two thirds of patients experienced a reaction to the first 1000 mg infused of GAZYVA.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,gazyva,144,3668,3676,oselabeledaefromdruguse can also occur with subsequent infusions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,gazyva,145,3676,3707,"Symptoms may include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and throat  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
146,gazyva,146,3707,3768,"Other common symptoms include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication [see  Adverse Reactions (6.1)  ]  .\n', '\n', '\n', '\n', ' Premedicate patients with acetaminophen, antihistamine, and a glucocorticoid .  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
147,gazyva,147,3768,3789,"Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, and/or oxygen) for  nonoseaeaeonlyasinstruction as needed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,gazyva,148,3789,3798,Closely monitor patients during the entire infusion.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,gazyva,149,3798,3869,"nonoseaeaeonlyasinstruction within 24 hours of receiving GAZYVA have occurred [see  Dosage and Administration (2)  ]  .\n', '\n', '\n', '\n', ' For patients with any Grade 4  nonoseaeaeonlyasinstruction  including but not limited to  nonoseaeaeonlyasinstruction  acute  nonoseaeaeonlyasinstruction  or other life-threatening  nonoseaeaeonlyasinstruction  Stop the GAZYVA infusion.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,gazyva,150,3869,3912,"Permanently discontinue GAZYVA therapy.\n', '\n', '\n', '\n', ' For patients with Grade 1, 2, or 3  nonoseaeaeonlyasinstruction  Interrupt GAZYVA for Grade 3 reactions until resolution of symptoms.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,gazyva,151,3912,3994,"Interrupt or reduce the rate of the infusion for Grade 1 or 2 reactions and manage symptoms [see  Dosage and Administration (2)  ]  .\n', '\n', '\n', '\n', '  For patients with preexisting  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  monitor more frequently throughout the infusion and the post-infusion period since they may be at greater risk of experiencing more severe reactions.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
152,gazyva,152,3994,4033,"nonoseaemanifestationorcomplication may occur as part of the GAZYVA  oselabeledaefromdruguse  Consider withholding antihypertensive treatments for 12 hours prior to, during each GAZYVA infusion, and for the first hour after administration until blood pressure is stable.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
153,gazyva,153,4033,4059,For patients at increased risk of  notaecandidatepreexistingconditionorriskfactor  consider the benefits versus the risks of withholding their antihypertensive medication as is suggested here.  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
154,gazyva,154,4059,4125,"\n', '\n', '\n', '\n', '    5.4 Tumor Lysis Syndrome\n', '\n', '\n', '\n', '   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication from  oselabeledaefromdruguse (TLS) can occur within 12-24 hours after the first infusion.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
155,gazyva,155,4125,4129,Patients with  notaecandidatepreexistingconditionorriskfactor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
156,gazyva,156,4129,4194,"and/or  notaecandidatepreexistingconditionorriskfactor circulating  notaecandidatepreexistingconditionorriskfactor (> 25 * 10  9  /L) are at greater risk for  nonoseaeaeonlyasinstruction and should receive appropriate tumor lysis prophylaxis with anti-hyperuricemics (e.g., allopurinol) and hydration beginning 12-24 hours prior to the infusion of GAZYVA [see  Dosage and Administration (2.2)  ].  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
157,gazyva,157,4194,4293,"For treatment of  nonoseaeaeonlyasinstruction  correct  nonoseaeaeonlyasinstruction  monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.\n', '\n', '\n', '\n', '    5.5 Infections\n', '\n', '\n', '\n', '   Serious  oselabeledaefromdruguse  fungal, and new or reactivated viral  oselabeledaefromdruguse  oselabeledaefromdruguse  and new or reactivated viral  oselabeledaefromdruguse  oselabeledaefromdruguse or reactivated  oselabeledaefromdruguse  oselabeledaefromdruguse can occur during and following GAZYVA therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,gazyva,158,4293,4302,Fatal  oselabeledaefromdruguse have been reported with GAZYVA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,gazyva,159,4302,4387,"Do not administer GAZYVA to patients with an  notaecandidatepreexistingconditionorriskfactor  Patients with a history of recurring or  notaecandidatepreexistingconditionorriskfactor may be at increased risk of  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '    5.6 Neutropenia\n', '\n', '\n', '\n', '   GAZYVA in combination with chlorambucil caused Grade 3 or 4  oselabeledaefromdruguse in 33% of patients in the trial.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
160,gazyva,160,4387,4406,Patients with Grade 3 to 4  nonoseaeaeonlyasinstruction should be monitored frequently with regular laboratory tests until resolution.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,gazyva,161,4406,4495,"Anticipate, evaluate, and treat any symptoms or signs of developing  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '  oselabeledaefromdruguse can also be of late onset (occurring more than 28 days after completion of treatment) and/or prolonged (lasting longer than 28 days).\n', '\n', '\n', '\n', ' Patients with  nonoseaeaeonlyasinstruction are strongly recommended to receive antimicrobial prophylaxis throughout the treatment period.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,gazyva,162,4495,4557,"Antiviral and antifungal prophylaxis should be considered.\n', '\n', '\n', '\n', '    5.7 Thrombocytopenia\n', '\n', '\n', '\n', '   GAZYVA in combination with chlorambucil caused Grade 3 or 4  oselabeledaefromdruguse in 10% of patients in the trial.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,gazyva,163,4557,4577,"In 4% of patients, GAZYVA caused acute  oselabeledaefromdruguse occurring within 24 hours after the GAZYVA infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,gazyva,164,4577,4594,Fatal  oselabeledaefromdruguse during Cycle 1 have also been reported in patients treated with GAZYVA.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,gazyva,165,4594,4627,"\n', '\n', '\n', '\n', ' Monitor all patients frequently for  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  especially during the first cycle.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,gazyva,166,4627,4659,In patients with Grade 3 or 4  nonoseaeaeonlyasinstruction  monitor platelet counts more frequently until resolution and consider subsequent dose delays of GAZYVA and chlorambucil or dose reductions of chlorambucil.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,gazyva,167,4659,4673,"Transfusion of blood products (i.e., platelet transfusion) may be necessary.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,gazyva,168,4673,4683,Consider withholding concomitant medications which may  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,aubagio,0,0,163,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are described elsewhere in the prescribing information:\n', '\n', '\n', '\n', ' *   oselabeledaeclasseffect [see  Contraindications (4.1)  and  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse  oselabeledaeclasseffect Potential/ oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.7)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.8)  ]  \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,aubagio,1,163,206,"', '      EXCERPT:   Most common adverse reactions (>=10% and >=2% greater than placebo): headache, diarrhea, nausea, alopecia, increase in ALT (  6  )  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,aubagio,2,206,234,"To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-745-4447 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,aubagio,3,234,267,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,aubagio,4,267,373,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' A total of 2047 patients receiving AUBAGIO (7 mg or 14 mg once daily) constituted the safety population in the pooled analysis of placebo controlled studies in patients with  notaecandidateindication forms of  notaecandidateindication  of these, 71% were female.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
5,aubagio,5,373,428,"The average age was 37 years.\n', '\n', '\n', '\n', ' Table 1 lists adverse reactions in placebo-controlled trials with rates that were at least 2% for AUBAGIO patients and also at least 2% above the rate in placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,aubagio,6,428,433,The most common were  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,aubagio,7,433,447,oselabeledaefromdruguse  an  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,aubagio,8,447,506,"The adverse reaction most commonly associated with discontinuation was an  oselabeledaefromdruguse (3.3%, 2.6%, and 2.3% of all patients in the AUBAGIO 7 mg, AUBAGIO 14 mg, and placebo treatment arms, respectively).\n', '\n', '\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,aubagio,9,506,522,Adverse Reactions in Pooled Placebo-Controlled Studies in Patients with Relapsing Forms of Multiple Sclerosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,aubagio,10,522,543,"\n', '   Adverse Reaction                        AUBAGIO 7 mg(N=1045)  AUBAGIO 14 mg(N=1002)     Placebo(N=997)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,aubagio,11,543,564,"\n', '  \n', '  oselabeledaefromdruguse                                          18%                   16%                   15%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,aubagio,12,564,580,"\n', '  oselabeledaefromdruguse              13%                   15%                    9%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,aubagio,13,580,596,"\n', '  oselabeledaefromdruguse                                          13%                   14%                    8%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,aubagio,14,596,628,"\n', '  oselabeledaefromdruguse                                          10%                   13%                    5%            \n', '  oselabeledaefromdruguse                                             8%                   11%                    7%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,aubagio,15,628,649,"\n', '  oselabeledaefromdruguse                                        8%                    9%                    7%            \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,aubagio,16,649,660,oselabeledaefromdruguse                                         8%                    6%                    5%            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,aubagio,17,660,676,"\n', '  oselabeledaefromdruguse                                        4%                    6%                    2%            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,aubagio,18,676,700,"\n', '  oselabeledaefromdruguse                                       3%                    4%                    2%            \n', '              Cardiovascular deaths  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,aubagio,19,700,753,"\n', ' \n', '\n', ' Four  nonoseaeaeonlyasinstruction  nonoseaegeneralterm  including three  nonoseaeaeonlyasinstruction  and one  nonoseaeaeonlyasinstruction in a patient with a history of  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor were reported among approximately 2600 patients exposed to AUBAGIO in the premarketing database.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
20,aubagio,20,753,773,"These  nonoseaeaeonlyasinstruction  nonoseaegeneralterm occurred during uncontrolled extension studies, one to nine years after initiation of treatment.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,aubagio,21,773,874,"A relationship between AUBAGIO and  nonoseaeaeonlyasinstruction  nonoseaegeneralterm has not been established.\n', '\n', '\n', '\n', '     Acute Renal Failure  \n', '\n', '\n', '\n', ' In placebo-controlled studies,  oselabeledaefromdruguse more than 100% over baseline in 8/1045 (0.8%) patients in the 7 mg AUBAGIO group and 6/1002 (0.6%) patients in the 14 mg AUBAGIO group versus 4/997 (0.4%) patients in the placebo group.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,aubagio,22,874,879,These elevations were transient.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,aubagio,23,879,987,"Some elevations were accompanied by  oselabeledaefromdruguse  AUBAGIO may cause  oselabeledaefromdruguse with transient  oselabeledaefromdruguse because AUBAGIO  oselabeledaefromdruguse \n', '\n', '\n', '\n', '     Hypophosphatemia  \n', '\n', '\n', '\n', ' In clinical trials, 18% of AUBAGIO-treated patients had  oselabeledaefromdruguse with  oselabeledaefromdruguse  compared to 7% of placebo-treated patients; 4% of AUBAGIO-treated patients had  oselabeledaefromdruguse with  oselabeledaefromdruguse  compared to 0.8% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,aubagio,24,987,997,No patient in any treatment group had a  nonoseaenegation,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
25,aubagio,25,997,1009,"\n', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,aubagio,26,1009,1044,"WARNING:   oselabeledaefromdruguse and RISK OF TERATOGENICITY\n', '\n', '  WARNING:  HEPATOTOXICITY and RISK OF TERATOGENICITY\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,aubagio,27,1044,1136,"WARNING:  HEPATOTOXICITY and RISK OF TERATOGENICITY\n', '\n', '\n', '\n', '   See full prescribing information for complete boxed warning  \n', '\n', '\n', '\n', '   Hepatotoxicity  \n', '\n', '\n', '\n', '   Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,aubagio,28,1136,1162,A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,aubagio,29,1162,1190,Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO and monitor ALT levels at least monthly for six months (  5.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,aubagio,30,1190,1212,"If drug induced liver injury is suspected, discontinue AUBAGIO and start accelerated elimination procedure (  5.3  ).   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,aubagio,31,1212,1266,"\n', '\n', '\n', '\n', '   Risk of Teratogenicity  \n', '\n', '\n', '\n', '   Based on animal data, AUBAGIO may cause major birth defects if used during pregnancy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,aubagio,32,1266,1284,AUBAGIO is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,aubagio,33,1284,1292,Pregnancy must be avoided during AUBAGIO treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,aubagio,34,1292,1302,"(  4.2  ,   5.2  )  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,aubagio,35,1302,1393,"\n', '\n', '\n', '\n', ' \n', '\n', '\n', '\n', '  Hepatotoxicity\n', '\n', '    Severe  oselabeledaeclasseffect including fatal  oselabeledaeclasseffect has been reported in patients treated with leflunomide, which is indicated for  notaecandidatepreexistingconditionorriskfactor  A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
36,aubagio,36,1393,1426,Concomitant use of AUBAGIO with other potentially  nonoseaeaeonlyasinstruction drugs may increase the risk of severe  nonoseaeaefromdruginteraction  Obtain transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy.,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
37,aubagio,37,1426,1452,Monitor ALT levels at least monthly for six months after starting AUBAGIO   [see   Warnings and Precautions (5.1)  ].   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,aubagio,38,1452,1474,"If  nonoseaeaeonlyasinstruction is suspected, discontinue AUBAGIO and start an accelerated elimination procedure with cholestyramine or charcoal   [see   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,aubagio,39,1474,1484,Warnings and Precautions (5.3)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,aubagio,40,1484,1505,AUBAGIO is contraindicated in patients with severe  notaecandidatecontraindication   [see   Contraindications (4.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
41,aubagio,41,1505,1526,Patients with pre-existing  notaecandidatepreexistingconditionorriskfactor may be at increased risk of developing  oselabeledaefromdruguse when taking AUBAGIO.   ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
42,aubagio,42,1526,1547,"\n', '\n', '\n', '\n', '   Risk of  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,aubagio,43,1547,1557,"\n', '    Based on animal data,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,aubagio,44,1557,1576,AUBAGIO  oselabeledaefromdruguse  nonoseaeaeanimal if used during  notaecandidatepreexistingconditionorriskfactor   nonoseaeaeonlyasinstruction must be excluded before starting AUBAGIO.,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0
45,aubagio,45,1576,1595,AUBAGIO is contraindicated in  notaecandidatecontraindication or women of childbearing potential who are not using reliable contraception.  ,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
46,aubagio,46,1595,1597,nonoseaeaeonlyasinstruction     ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,aubagio,47,1597,1640,"5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Elimination of AUBAGIO can be accelerated by administration of cholestyramine or activated charcoal for 11 days (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,aubagio,48,1640,1643,5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,aubagio,49,1643,1654,"\n', ' *  AUBAGIO may decrease WBC.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,aubagio,50,1654,1664,A recent CBC should be available before starting AUBAGIO.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,aubagio,51,1664,1672,Monitor for signs and symptoms of infection.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,aubagio,52,1672,1683,Consider suspending treatment with AUBAGIO in case of serious infection.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,aubagio,53,1683,1723,"Do not start AUBAGIO in patients with active infections (  5.4  ) \n', ' *  If patient develops symptoms consistent with peripheral neuropathy, evaluate patient and consider discontinuing AUBAGIO (  5.5  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,aubagio,54,1723,1747,"\n', ' *  Stop AUBAGIO if patient develops Stevens-Johnson syndrome or toxic epidermal necrolysis (  5.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,aubagio,55,1747,1759,"\n', ' *  AUBAGIO may increase blood pressure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,aubagio,56,1759,1773,Measure blood pressure at treatment initiation and monitor blood pressure during treatment (  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,aubagio,57,1773,1776,5.7  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,aubagio,58,1776,1782,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,aubagio,59,1782,1868,"', ' \n', '\n', '   5.1 Hepatotoxicity\n', '\n', '\n', '\n', '  Severe  oselabeledaeclasseffect including fatal  oselabeledaeclasseffect  oselabeledaeclasseffect failure and  oselabeledaeclasseffect has been reported in some patients treated with leflunomide, which is indicated for  notaecandidatepreexistingconditionorriskfactor  A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
60,aubagio,60,1868,1888,Patients with pre-existing  notaecandidatepreexistingconditionorriskfactor may be at increased risk of developing  oselabeledaefromdruguse when taking AUBAGIO.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
61,aubagio,61,1888,1914,"Patients with pre-existing  notaecandidatepreexistingconditionorriskfactor  or those with  notaecandidatepreexistingconditionorriskfactor  before initiating treatment, should not normally be treated with AUBAGIO.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
62,aubagio,62,1914,1999,"AUBAGIO is contraindicated in patients with severe  notaecandidatecontraindication [see  Contraindications (4.1)  ]  .\n', '\n', '\n', '\n', '  In placebo-controlled trials,  oselabeledaefromdruguse occurred in 61/1045 (5.8%) and 62/1002 (6.2%) of patients receiving AUBAGIO 7 mg and 14 mg, respectively, and 38/997 (3.8%) of patients receiving placebo, during the treatment period.",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
63,aubagio,63,1999,2010,These elevations occurred mostly within the first year of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,aubagio,64,2010,2021,Half of the cases returned to normal without drug discontinuation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,aubagio,65,2021,2063,"In clinical trials, if  nonoseaeaeonlyasinstruction was greater than three times the ULN on two consecutive tests, AUBAGIO was discontinued and patients underwent an accelerated elimination procedure [see  Warnings and Precautions (5.3)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,aubagio,66,2063,2089,"Of the patients who underwent discontinuation and accelerated elimination in controlled trials, half returned to normal or near normal values within 2 months.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,aubagio,67,2089,2127,"\n', '\n', '\n', '\n', ' One patient in the controlled trials developed  oselabeledaefromdruguse and  oselabeledaefromdruguse 5 months after initiation of AUBAGIO 14 mg treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,aubagio,68,2127,2145,The patient was hospitalized for 5 weeks and recovered after plasmapheresis and cholestyramine accelerated elimination procedure.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,aubagio,69,2145,2184,"nonoseaeaeonlyasinstruction in this patient could not be ruled out.\n', '\n', '\n', '\n', ' Obtain serum transaminase and bilirubin levels within 6 months before initiation of AUBAGIO therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,aubagio,70,2184,2197,Monitor ALT levels at least monthly for six months after starting AUBAGIO.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,aubagio,71,2197,2228,Consider additional monitoring when AUBAGIO is given with other potentially  nonoseaeaeonlyasinstruction  Consider discontinuing AUBAGIO if serum  nonoseaeaeonlyasinstruction (greater than three times the ULN) is confirmed.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,aubagio,72,2228,2265,"Monitor serum transaminase and bilirubin on AUBAGIO therapy, particularly in patients who develop symptoms suggestive of  nonoseaeaeonlyasinstruction  such as unexplained  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
73,aubagio,73,2265,2308,"and/or  nonoseaemanifestationorcomplication  If  nonoseaeaeonlyasinstruction is suspected to be AUBAGIO-induced, discontinue AUBAGIO and start an accelerated elimination procedure [see  Warnings and Precautions (5.3)  ]  and monitor liver tests weekly until normalized.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
74,aubagio,74,2308,2330,"If  nonoseaeaeonlyasinstruction is unlikely because some other probable cause has been found, resumption of AUBAGIO therapy may be considered.\n'",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,aubagio,75,2330,2384,", '\n', '\n', '\n', '    5.2 Use in Women of Childbearing Potential\n', '\n', '\n', '\n', '  There are no adequate and well-controlled studies evaluating AUBAGIO in  notaecandidatepreexistingconditionorriskfactor women.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
76,aubagio,76,2384,2396,"However, based on animal studies, teriflunomide may  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,aubagio,77,2396,2460,"nonoseaeaeanimal or  nonoseaeaeanimal when administered to a  notaecandidatepreexistingconditionorriskfactor woman [see  Contraindications (4.2)  ]  .\n', '\n', '\n', '\n', ' Women of childbearing potential must not be started on AUBAGIO until  notaecandidatecontraindication is excluded and it has been confirmed that they are using reliable contraception.",0,0,1,0,0,0,0,0,1,0,0,1,0,0,0
78,aubagio,78,2460,2481,"Before starting treatment with AUBAGIO, patients must be fully counseled on the potential for serious risk to the fetus.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,aubagio,79,2481,2531,"The patient must be advised that if there is any delay in onset of menses or any other reason to suspect  nonoseaeaeonlyasinstruction  they must notify the physician immediately for pregnancy testing and, if positive, the physician and patient must discuss the risk to the fetus.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,aubagio,80,2531,2604,"It is possible that rapidly lowering the plasma concentration of teriflunomide by instituting an accelerated elimination procedure may decrease the risk to the fetus from AUBAGIO [see  Warnings and Precautions (5.3)  ]  .\n', '\n', '\n', '\n', ' Upon discontinuing AUBAGIO, it is recommended that all women of childbearing potential undergo an accelerated elimination procedure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,aubagio,81,2604,2644,"Women receiving AUBAGIO treatment who wish to become  nonoseaeaeonlyasinstruction must discontinue AUBAGIO and undergo an accelerated elimination procedure, which includes verification of teriflunomide plasma concentrations less than 0.02 mg/L (0.02 mcg/mL).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,aubagio,82,2644,2699,"Human plasma concentrations of teriflunomide less than 0.02 mg/L (0.02 mcg/mL) are expected to have minimal risk [see  Contraindications (4.2)  ,  Warnings and Precautions (5.3)  and  Use in Specific Populations (8.1)  ]  .\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,aubagio,83,2699,2744,"'\n', '\n', '\n', '    5.3 Procedure for Accelerated Elimination of Teriflunomide\n', '\n', '\n', '\n', '  Teriflunomide is eliminated slowly from the plasma.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,aubagio,84,2744,2784,"Without an accelerated elimination procedure, it takes on average 8 months to reach plasma concentrations less than 0.02 mg/L, although because of individual variations in drug clearance it may take as long as 2 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,aubagio,85,2784,2799,An accelerated elimination procedure could be used at any time after discontinuation of AUBAGIO.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,aubagio,86,2799,2838,"Elimination can be accelerated by either of the following procedures:\n', '\n', '\n', '\n', ' *  Administration of cholestyramine 8 g every 8 hours for 11 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,aubagio,87,2838,2862,"If cholestyramine 8 g three times a day is not well tolerated, cholestyramine 4 g three times a day can be used.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,aubagio,88,2862,2883,"\n', ' *  Administration of 50 g oral activated charcoal powder every 12 hours for 11 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,aubagio,89,2883,3056,"\n', '    If either elimination procedure is poorly tolerated, treatment days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration rapidly.\n', ' \n', '\n', ' At the end of 11 days, both regimens successfully accelerated teriflunomide elimination, leading to more than 98% decrease in teriflunomide plasma concentrations.\n', '\n', '\n', '\n', ' Use of the accelerated elimination procedure may potentially result in return of disease activity if the patient had been responding to AUBAGIO treatment.\n', '\n', '\n', '\n', '    5.4 Bone Marrow Effects/Immunosuppression Potential/Infections\n', '\n', '\n', '\n', '   White Blood Cell (WBC) count decrease  \n', '\n', '\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,aubagio,90,3056,3066,A mean  oselabeledaefromdruguse  oselabeledaefromdruguse in white blood cell,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,aubagio,91,3066,3090,(WBC) count of approximately 15% (mainly neutrophils and lymphocytes) and in  oselabeledaefromdruguse  oselabeledaefromdruguse in white blood cell,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,aubagio,92,3090,3108,(WBC) count of approximately 15% (mainly  oselabeledaefromdruguse  oselabeledaefromdruguse in white blood cell,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,aubagio,93,3108,3117,(WBC) count of approximately 15% (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,aubagio,94,3117,3150,mainly neutrophils and  oselabeledaefromdruguse  and in platelet count of approximately 10% was observed in placebo-controlled trials with 7 mg and 14 mg of AUBAGIO compared to baseline.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,aubagio,95,3150,3167,The  oselabeledaefromdruguse occurred during the first 6 weeks and WBC count remained low during treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,aubagio,96,3167,3235,"In placebo-controlled studies,  oselabeledaefromdruguse was observed in 12% and 16% of patients receiving AUBAGIO 7 mg and 14 mg, respectively, compared with 7% of patients receiving placebo;  oselabeledaefromdruguse was observed in 10% and 12% of patients receiving AUBAGIO 7 mg and 14 mg, respectively, compared with 6% of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,aubagio,97,3235,3271,No cases of serious  nonoseaenegation were reported in premarketing clinical trials of AUBAGIO but rare cases of  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported in the postmarketing setting with leflunomide.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
98,aubagio,98,3271,3284,A similar risk would be expected for AUBAGIO [see  Clinical Pharmacology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,aubagio,99,3284,3291,(12.3)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,aubagio,100,3291,3311,Obtain a complete blood cell count (CBC) within 6 months before the initiation of treatment with AUBAGIO.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,aubagio,101,3311,3387,"Further monitoring should be based on signs and symptoms suggestive of  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '    Risk of Infection / Tuberculosis Screening  \n', '\n', '\n', '\n', ' Patients with active  notaecandidatepreexistingconditionorriskfactor or chronic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor should not start treatment until the infection(s) is resolved.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
102,aubagio,102,3387,3407,If a patient develops a serious  nonoseaeaeonlyasinstruction consider suspending treatment with AUBAGIO and using an accelerated elimination procedure.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,aubagio,103,3407,3418,Reassess the benefits and risks prior to resumption of therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,aubagio,104,3418,3545,"Instruct patients receiving AUBAGIO to report symptoms of  nonoseaeaeonlyasinstruction to a physician.\n', '\n', '\n', '\n', ' AUBAGIO is not recommended for patients with severe  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or severe, uncontrolled  notaecandidatepreexistingconditionorriskfactor  Medications like AUBAGIO that have  oselabeledaeclasseffect potential may cause patients to be  nonoseaemanifestationorcomplication  including  nonoseaemanifestationorcomplication \n', '\n', '\n', '\n', '  In placebo-controlled studies of AUBAGIO, no overall increase in the risk of serious  nonoseaeaeratelteqplacebo was observed with AUBAGIO 7 mg (2.2%) or 14 mg (2.7%) compared to placebo (2.2%).",1,0,1,0,1,0,1,0,0,0,0,0,0,0,0
105,aubagio,105,3545,3565,"However, one fatal case of  oselabeledaefromdruguse occurred in a patient taking AUBAGIO 14 mg for 1.7 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,aubagio,106,3565,3589,"Fatal  oselabeledaeclasseffect have been reported in the post-marketing setting in patients receiving leflunomide, especially  oselabeledaeclasseffect and  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,aubagio,107,3589,3617,"Most of the reports were confounded by concomitant immunosuppressant therapy and/or comorbid illness which, in addition to  notaecandidateother  may predispose patients to  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
108,aubagio,108,3617,3630,"In clinical studies with AUBAGIO,  oselabeledaefromdruguse has been observed.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,aubagio,109,3630,3661,"\n', '\n', '\n', '\n', '  In clinical studies with AUBAGIO, cases of  oselabeledaefromdruguse have been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,aubagio,110,3661,3710,"Prior to initiating AUBAGIO, screen patients for  notaecandidatepreexistingconditionorriskfactor with a tuberculin skin test or with a blood test for  notaecandidatepreexistingconditionorriskfactor  AUBAGIO has not been studied in patients with a  notaecandidatepreexistingconditionorriskfactor  and the safety of AUBAGIO in individuals with  notaecandidatepreexistingconditionorriskfactor is unknown.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
111,aubagio,111,3710,3727,For patients  notaecandidatepreexistingconditionorriskfactor  treat by standard medical practice prior to therapy with AUBAGIO.  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
112,aubagio,112,3727,3780,"\n', '\n', '\n', '\n', '    Vaccination  \n', '\n', '\n', '\n', ' No clinical data are available on the efficacy and safety of live vaccinations in patients taking AUBAGIO.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,aubagio,113,3780,3788,Vaccination with live vaccines is not recommended.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,aubagio,114,3788,3863,"The long half-life of AUBAGIO should be considered when contemplating administration of a live vaccine after stopping AUBAGIO.\n', '\n', '\n', '\n', '    Malignancy  \n', '\n', '\n', '\n', ' The risk of  oselabeledaeclasseffect  particularly  oselabeledaeclasseffect  is increased with the use of some  nonoseaeaeonlyasinstruction medications.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,aubagio,115,3863,3873,There is a potential for  oselabeledaefromdruguse with AUBAGIO.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,aubagio,116,3873,3989,"No apparent increase in the incidence of  nonoseaenegation and  nonoseaenegation was reported in the AUBAGIO clinical trials, but larger and longer-term studies would be needed to determine whether there is an increased risk of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction with AUBAGIO.\n', '\n', '\n', '\n', '    5.5 Peripheral Neuropathy\n', '\n', '\n', '\n', '   In placebo-controlled studies,  oselabeledaefromdruguse  including both  oselabeledaefromdruguse and  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse , occurred more frequently in patients taking AUBAGIO than in patients taking placebo.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
117,aubagio,117,3989,4037,"The incidence of  oselabeledaefromdruguse confirmed by nerve conduction studies was 1.4% (13 patients) and 1.9% (17 patients) of patients receiving 7 mg and 14 mg of AUBAGIO, respectively, compared with 0.4% receiving placebo (4 patients).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,aubagio,118,4037,4067,Treatment was discontinued in 0.7% (8 patients) with confirmed  oselabeledaefromdruguse (3 patients receiving AUBAGIO 7 mg and 5 patients receiving AUBAGIO 14 mg).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,aubagio,119,4067,4075,Five of them recovered following treatment discontinuation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,aubagio,120,4075,4087,Not all cases of  oselabeledaefromdruguse resolved with continued treatment.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,aubagio,121,4087,4096,oselabeledaeclasseffect also occurred in patients receiving leflunomide.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,aubagio,122,4096,4134,"\n', '\n', '\n', '\n', ' Age older than 60 years, concomitant  nonoseaeaeonlyasinstruction  and  notaecandidatepreexistingconditionorriskfactor may increase the risk for  nonoseaeaeonlyasinstruction .  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
123,aubagio,123,4134,4258,"If a patient taking AUBAGIO develops symptoms consistent with  nonoseaeaeonlyasinstruction  such as  nonoseaemanifestationorcomplication or tingling  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication numbness or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or tingling  nonoseaemanifestationorcomplication hands or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication numbness or  nonoseaemanifestationorcomplication hands or  nonoseaemanifestationorcomplication  consider discontinuing AUBAGIO therapy and performing an accelerated elimination procedure [see  Warnings and Precautions (5.3)  ]  .\n', '\n', '\n', '\n', '    5.6 Skin Reactions\n', '\n', '\n', '\n', '  Rare cases of  oselabeledaeclasseffect and  oselabeledaeclasseffect have been reported in patients with  notaecandidatepreexistingconditionorriskfactor receiving leflunomide.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
124,aubagio,124,4258,4271,A similar risk would be expected for AUBAGIO [see  Clinical Pharmacology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,aubagio,125,4271,4278,(12.3)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,aubagio,126,4278,4392,"If a patient taking AUBAGIO develops any of these conditions, stop AUBAGIO therapy and perform an accelerated elimination procedure [see  Warnings and Precautions (5.3)  ]  .\n', '\n', '\n', '\n', '    5.7 Increased Blood Pressure\n', '\n', '\n', '\n', '   In placebo-controlled studies, the  oselabeledaefromdruguse from basel oselabeledaefromdruguse  to the end of study in  oselabeledaefromdruguse was +2.3 mmHg and +2.7 mmHg for AUBAGIO 7 mg and 14 mg, respectively, and -0.6 mmHg for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,aubagio,127,4392,4406,The  oselabeledaefromdruguse from basel oselabeledaefromdruguse  in  oselabeledaefromdruguse was +1.4 mmHg,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,aubagio,128,4406,4427,"and +1.9 mmHg for AUBAGIO 7 mg and 14 mg, respectively, and -0.3 mmHg for placebo.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,aubagio,129,4427,4456,oselabeledaefromdruguse was an adverse reaction in 3.1% and 4.3% of patients treated with 7 mg or 14 mg of AUBAGIO compared with 1.8% for placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,aubagio,130,4456,4469,Check blood pressure before start of AUBAGIO treatment and periodically thereafter.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,aubagio,131,4469,4480,nonoseaeaeonlyasinstruction should be appropriately managed during treatment with AUBAGIO.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,aubagio,132,4480,4525,"\n', '\n', '\n', '\n', '    5.8  oselabeledaefromdruguse \n', '\n', '\n', '   oselabeledaeclasseffect and  oselabeledaeclasseffect have been reported during treatment with leflunomide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,aubagio,133,4525,4538,A similar risk would be expected for AUBAGIO [see  Clinical Pharmacology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,aubagio,134,4538,4552,(12.3)  ]  .  nonoseaeaeonlyasinstruction may be fatal.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,aubagio,135,4552,4568,oselabeledaeclasseffect may occur acutely at any time during therapy and has a variable clinical presentation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,aubagio,136,4568,4607,New onset or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  such as  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  with or without associated  nonoseaemanifestationorcomplication  may be a reason for discontinuation of the therapy and for further investigation as appropriate.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
137,aubagio,137,4607,4695,"If discontinuation of the drug is necessary, consider initiation of an accelerated elimination procedure [see  Warnings and Precautions (5.3)  ]  .\n', '\n', '\n', '\n', '    5.9 Concomitant Use with Immunosuppressive or Immunomodulating Therapies\n', '\n', '\n', '\n', '  Co-administration with antineoplastic, or immunosuppressive therapies used for treatment of  notaecandidateindication has not been evaluated.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
138,aubagio,138,4695,4728,"Safety studies in which AUBAGIO was concomitantly administered with other immune modulating therapies for up to one year (interferon beta, glatiramer acetate) did not reveal any specific safety concerns.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,aubagio,139,4728,4795,"The long term safety of these combinations in the treatment of  notaecandidateindication has not been established.\n', '\n', '\n', '\n', ' In any situation in which the decision is made to switch from AUBAGIO to another agent with a known potential for  nonoseaeaeonlyasinstruction  it would be prudent to monitor for  nonoseaeaeonlyasinstruction ']",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
0,harvoni,0,0,64,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with HARVONI for 8, 12, or 24 weeks are fatigue and headache (  6.1  )\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,harvoni,1,64,99,"'\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,harvoni,2,99,136,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,harvoni,3,136,254,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The safety assessment of HARVONI was based on pooled data from three Phase 3 clinical trials of subjects with  notaecandidateindication  with  notaecandidatepreexistingconditionorriskfactor  including 215, 539, and 326 subjects who received HARVONI for 8, 12 and 24 weeks, respectively  [see  Clinical Studies (14)  ].  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
4,harvoni,4,254,409,"\n', '\n', '\n', '\n', ' The proportion of subjects who permanently discontinued treatment due to adverse events was 0%, <1%, and 1% for subjects receiving HARVONI for 8, 12, and 24 weeks, respectively.\n', '\n', '\n', '\n', ' The most common adverse reactions (>=10%) were  oselabeledaefromdruguse and  oselabeledaefromdruguse in subjects treated with 8, 12, or 24 weeks of HARVONI.\n', '\n', '\n', '\n', ' Table 2 lists adverse reactions (adverse events assessed as causally related by the investigator, all grades) observed in >=5% of subjects receiving 8, 12, or 24 weeks treatment with HARVONI in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,harvoni,5,409,425,The majority of adverse reactions presented in Table 2 occurred at severity of grade 1.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,harvoni,6,425,507,"The side-by-side tabulation is to simplify presentation; direct comparison across trials should not be made due to differing trial designs.\n', '\n', '\n', '\n', ' Table 2 Adverse Reactions (All Grades) Reported in >=5% of Subjects Receiving 8, 12, or 24 Weeks of Treatment with HARVONI \n', '                                 HARVONI8 weeks             HARVONI12 weeks            HARVONI24 weeks        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,harvoni,7,507,516,"\n', '                                      N=215                      N=539                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,harvoni,8,516,518,N=326             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,harvoni,9,518,539,"\n', '  \n', '  oselabeledaefromdruguse                               16%                        13%                        18%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,harvoni,10,539,549,"\n', '  oselabeledaefromdruguse                              11%                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,harvoni,11,549,555,14%                        17%              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,harvoni,12,555,571,"\n', '  oselabeledaefromdruguse                                6%                         7%                         9%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,harvoni,13,571,587,"\n', '  oselabeledaefromdruguse                              4%                         3%                         7%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,harvoni,14,587,603,"\n', '  oselabeledaefromdruguse                              3%                         5%                         6%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,harvoni,15,603,611,"\n', '              Laboratory Abnormalities  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,harvoni,16,611,675,"\n', ' \n', '\n', '      nonoseaegeneralterm    oselabeledaefromdruguse of greater than 1.5*ULN were observed in 3%, <1%, and 2% of subjects treated with HARVONI for 8, 12, and 24 weeks, respectively.\n', '\n', '\n', '\n', '      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,harvoni,17,675,743,"nonoseaegeneralterm   Transient, asymptomatic  oselabeledaefromdruguse of greater than 3*ULN were observed in <1%, 2%, and 3% of subjects treated with HARVONI for 8, 12, and 24 weeks, respectively.\n', '\n', '\n', '\n', '      nonoseaegeneralterm    nonoseaeaeonlyasinstruction was not assessed in Phase 3 trials of HARVONI.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,harvoni,18,743,816,"Isolated, asymptomatic  nonoseaeaefromdruginteraction (Grade 3 or 4) have been previously reported in subjects treated with sofosbuvir in combination with ribavirin or peginterferon/ribavirin in other clinical trials.\n', '\n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post approval use of HARVONI.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
19,harvoni,19,816,945,"Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '      nonoseaegeneralterm  \n', '\n', '\n', '\n', ' Serious symptomatic  nonoseaeaefromdruginteraction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Bradycardia with amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking amiodarone, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease.",0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
20,harvoni,20,945,954,Coadministration of amiodarone with HARVONI is not recommended.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,harvoni,21,954,968,"In patients without alternative, viable treatment options, cardiac monitoring is recommended.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,harvoni,22,968,1002,"(  5.1  ,  6.2  ,  7.2  ) \n', ' *  Use with other drugs containing sofosbuvir, including SOVALDI, is not recommended (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,harvoni,23,1002,1005,5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,harvoni,24,1005,1027,"\n', '    \n', ' \n', '\n', '   5.1 Serious Symptomatic Bradycardia",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,harvoni,25,1027,1077,"When Coadministered with Amiodarone\n', '\n', '\n', '\n', '   Postmarketing cases of symptomatic  nonoseaeaefromdruginteraction  as well as fatal  nonoseaeaefromdruginteraction and cases requiring pacemaker intervention, have been reported when amiodarone is coadministered with HARVONI.  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
26,harvoni,26,1077,1101,"nonoseaeaefromdruginteraction has generally occurred within hours to days, but cases have been observed up to 2 weeks after initiating  notaecandidateindication treatment.",0,0,0,1,0,1,0,0,0,0,0,0,0,0,0
27,harvoni,27,1101,1131,"Patients also taking beta blockers, or those with underlying  notaecandidatepreexistingconditionorriskfactor and/or advanced  notaecandidatepreexistingconditionorriskfactor may be at increased risk for  nonoseaeaefromdruginteraction with coadministration of amiodarone.  ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
28,harvoni,28,1131,1141,nonoseaeaefromdruginteraction generally resolved after discontinuation of  notaecandidateindication treatment.,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0
29,harvoni,29,1141,1150,The mechanism for this effect is unknown.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,harvoni,30,1150,1176,"\n', '\n', '\n', '\n', '  Coadministration of amiodarone with HARVONI is not recommended.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,harvoni,31,1176,1278,"For patients taking amiodarone who have no other alternative, viable treatment options and who will be coadministered HARVONI:  \n', '\n', '\n', '\n', ' *   Counsel patients about the risk of serious symptomatic  nonoseaeaeonlyasinstruction  \n', ' *   Cardiac monitoring in an in-patient setting for the first 48 hours of coadministration is recommended, after which outpatient or self-monitoring of the heart rate should occur on a daily basis through at least the first 2 weeks of treatment.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,harvoni,32,1278,1313,"\n', '     Patients who are taking HARVONI who need to start amiodarone therapy due to no other alternative, viable treatment options should undergo similar cardiac monitoring as outlined above.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,harvoni,33,1313,1354,"\n', ' \n', '\n', ""  Due to amiodarone's long half-life, patients discontinuing amiodarone just prior to starting HARVONI should also undergo similar cardiac monitoring as outlined above.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,harvoni,34,1354,1386,"\n"", '\n', '\n', '\n', '  Patients who develop signs or symptoms of  nonoseaeaeonlyasinstruction should seek medical evaluation immediately.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,harvoni,35,1386,1416,Symptoms may include  nonoseaeaefromdruginteraction or  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction or  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction or  nonoseaeaefromdruginteraction '],0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
0,ella,0,0,70,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions (>= 5%) in the clinical trials were headache (18%), abdominal pain (12%), nausea (12%), dysmenorrhea (9%), fatigue (6%) and dizziness (5%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,ella,1,70,76,(  6  )  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,ella,2,76,105,"To report SUSPECTED ADVERSE REACTIONS, contact Afaxys, Inc. at 1-855-888-2467 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,ella,3,105,142,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,ella,4,142,241,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', '   ella  was studied in an open-label multicenter trial (Open-Label Study) and in a comparative, randomized, single-blind, multicenter trial (Single-Blind Comparative Study).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,ella,5,241,269,"In these studies, a total of 2,637 (1,533 + 1,104) women in the 30 mg ulipristal acetate groups were included in the safety analysis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,ella,6,269,293,The mean age of women who received ulipristal acetate was 24.5 years and the mean body mass index (BMI) was 25.3.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,ella,7,293,320,"The racial demographics of those enrolled were 67% Caucasian, 20% Black or African American, 2% Asian, and 12% other.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,ella,8,320,389,"\n', '\n', '\n', '\n', ' The most common adverse reactions (>= 10%) in the clinical trials for women receiving  ella  were  oselabeledaefromdruguse (18% overall) and  oselabeledaefromdruguse (12% overall) and  oselabeledaefromdruguse and upper abdominal  oselabeledaefromdruguse  oselabeledaefromdruguse (12% overall).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,ella,9,389,457,"Table 1 lists those adverse reactions that were reported in >= 5% of subjects in the clinical studies (  14  ).\n', '\n', '\n', '\n', ' Table 1: Adverse Reactions in >= 5% of Women (%) Receiving a Single Dose of ella (30 mg Ulipristal Acetate)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,ella,10,457,467,"\n', '   Most Common Adverse Reactions      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,ella,11,467,478,Open-Label Study                                                                                                                                        Single-Blind Comparative Study                                                                                                                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,ella,12,478,479,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,ella,13,479,491,"', '    N = 1,533        N = 1,104                                                                                                                                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,ella,14,491,500,"\n', '    oselabeledaefromdruguse        18                                                                                                                                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,ella,15,500,529,"19                                                                                                                                                      \n', '    oselabeledaefromdruguse          12                                                                                                                                                      13                                                                                                                                                      \n', '    oselabeledaefromdruguse and upper abdominal  oselabeledaefromdruguse  oselabeledaefromdruguse     15                                                                                                                                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,ella,16,529,540,"8                                                                                                                                                       \n', '     oselabeledaefromdruguse     7                                                                                                                                                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,ella,17,540,547,"13                                                                                                                                                      \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,ella,18,547,551,oselabeledaefromdruguse         6                                                                                                                                                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,ella,19,551,562,"6                                                                                                                                                       \n', '    oselabeledaefromdruguse       5                                                                                                                                                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,ella,20,562,564,5                                                                                                                                                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,ella,21,564,565,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,ella,22,565,620,"', '           6.2 Postmarketing Experience\n', '   The following adverse reactions have been identified during post-approval use of  ella:           nonoseaegeneralterm   oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,ella,23,620,633,*   ella is not indicated for termination of an existing pregnancy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,ella,24,633,638,Exclude pregnancy before administering.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,ella,25,638,643,(  5.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,ella,26,643,672,"\n', ' *  Ectopic pregnancy: Women who become pregnant or complain of lower abdominal pain after taking ella should be evaluated for ectopic pregnancy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,ella,27,672,677,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,ella,28,677,681,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,ella,29,681,696,*  Effect on menstrual cycle: ella may alter the next expected menses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,ella,30,696,710,"If menses is delayed beyond 1 week, pregnancy should be ruled out.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,ella,31,710,730,"(  5.5  ) \n', ' *   ella does not protect against STI/HIV.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,ella,32,730,794,"(  5.6  ) \n', '    \n', ' \n', '\n', '   5.1 Existing Pregnancy\n', '\n', '\n', '\n', '   ella  is not indicated for termination of an existing  notaecandidatecontraindication   notaecandidatepreexistingconditionorriskfactor should be excluded before prescribing ella.  ",0,0,1,0,0,0,0,0,0,0,0,1,0,0,0
33,ella,33,794,816,"If  notaecandidatepreexistingconditionorriskfactor cannot be excluded on the basis of history and/or physical examination,  nonoseaeaeonlyasinstruction should be performed.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
34,ella,34,816,900,"A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or  nonoseaeaeonlyasinstruction status of any woman after taking ella  .\n', '\n', '\n', '\n', '    5.2 Ectopic Pregnancy\n', '\n', '\n', '\n', '  A history of  notaecandidatepreexistingconditionorriskfactor is not a contraindication to use of this emergency contraceptive method.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
35,ella,35,900,929,"Healthcare providers, however, should consider the possibility of  nonoseaeaeonlyasinstruction in women who become  nonoseaeaeonlyasinstruction or complain of  nonoseaeaeonlyasinstruction after taking ella  .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,ella,36,929,1016,"A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or  nonoseaeaeonlyasinstruction status of any woman after taking ella  .\n', '\n', '\n', '\n', '    5.3 Repeated Use\n', '\n', '\n', '\n', '   ella  is for occasional use as an  notaecandidateindication  It should not replace a regular method of contraception.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
37,ella,37,1016,1094,"Repeated use of ella  within the same menstrual cycle is not recommended, as safety and efficacy of repeat use within the same cycle has not been evaluated.\n', '\n', '\n', '\n', '    5.4 CYP3A4 Inducers\n', '\n', '\n', '\n', '  A CYP3A4 inducer, rifampin, decreases the plasma concentration of ella significantly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,ella,38,1094,1121,Ella  should not be administered with CYP3A4 inducers [see Drug interactions (  7.1  ) and Pharmacokinetics (  12.3  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,ella,39,1121,1241,".\n', '\n', '\n', '\n', '    5.5 Fertility Following Use\n', '\n', '\n', '\n', '  A rapid return of fertility is likely following treatment with ella  for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of ella  to ensure ongoing prevention of  nonoseaeaeonlyasinstruction  While there are no data about use of ella  with regular hormonal contraceptives, due to its high affinity binding to the progesterone receptor, use of ella  may reduce the contraceptive action of regular hormonal contraceptive methods.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,ella,40,1241,1340,"Therefore, after use of ella  , a reliable barrier method of contraception should be used with subsequent acts of intercourse that occur in that same menstrual cycle.\n', '\n', '\n', '\n', '    5.6 Effect on Menstrual Cycle\n', '\n', '\n', '\n', '  After ella  intake,  oselabeledaefromdruguse sometimes  oselabeledaefromdruguse earlier or  oselabeledaefromdruguse  oselabeledaefromdruguse sometimes  oselabeledaefromdruguse  oselabeledaefromdruguse sometimes occur earlier or later than expected by a few days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,ella,41,1340,1361,"In clinical trials,  oselabeledaefromdruguse by a mean of 2.5 days but returned to normal in the subsequent cycle.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,ella,42,1361,1399,"Seven percent of subjects reported  oselabeledaefromdruguse occurring more than 7 days  oselabeledaefromdruguse  oselabeledaefromdruguse occurring more than 7 days earlier than expected, and 19% reported a  oselabeledaefromdruguse of more than 7 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,ella,43,1399,1450,"If there is a  nonoseaeaeonlyasinstruction in the onset of expected  nonoseaeaeonlyasinstruction beyond 1 week, rule out  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', ' Nine percent of women studied reported  oselabeledaefromdruguse after use of ella.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
44,ella,44,1450,1504,"\n', '\n', '\n', '\n', '    5.7 Sexually Transmitted Infections/HIV\n', '\n', '\n', '\n', '   ella  does not protect against  notaecandidatepreexistingconditionorriskfactor  or other  notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,surfaxin,0,0,105,"['    6 ADVERSE REACTIONS\n', '\n', '  Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '   EXCERPT:   Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,surfaxin,1,105,120,"(6.1)  \n', '\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,surfaxin,2,120,151,"'\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Discovery Laboratories, Inc. at 1-877-SURFAXN or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,surfaxin,3,151,199,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '      Studies in Premature Infants at Risk for Respiratory Distress Syndrome    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,surfaxin,4,199,299,"\n', '\n', '\n', '\n', ' The safety data described below reflect exposure to SURFAXIN at a dose of 5.8 mL per kg (up to 4 doses) administered in either 4 aliquots (Study 1) or 2 aliquots (Study 2) in 643 infants 32 weeks gestational age or less in 2 randomized double-blind, active-controlled clinical studies in which infants could receive up to 4 doses of surfactant intratracheally [  see Clinical Studies  (14)    ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,surfaxin,5,299,327,Study 1 was conducted in 1294  notaecandidateindication who weighed between 600 g and 1250 g at birth and were 32 weeks or less in gestational age.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
6,surfaxin,6,327,357,"Infants received 1 of 3 surfactants, SURFAXIN (N = 524), colfosceril palmitate (N = 506), or beractant (N = 258).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,surfaxin,7,357,383,Study 2 was conducted in 252  notaecandidateindication who weighed between 600 g and 1250 g and were less than 29 weeks in gestational age.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,surfaxin,8,383,461,"Infants received SURFAXIN (N = 119) or poractant alfa (N = 124).\n', '\n', '\n', '\n', ' Comparator surfactants colfosceril palmitate and beractant were administered at the recommended doses (5.0 and 4.0 mL per kg, respectively) while the first dose of poractant alfa administered (2.2 mL per kg) was less than the recommended dose of 2.5 mL per kg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,surfaxin,9,461,515,"Any subsequent doses of poractant alfa were at the recommended 1.25 mL per kg dose.\n', '\n', '\n', '\n', '  nonoseaegeneralterm ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and need for dose interruption) were assessed in both SURFAXIN controlled clinical studies.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
10,surfaxin,10,515,562,"Overall, the incidence of  nonoseaegeneralterm was higher in infants who received SURFAXIN compared to other surfactants (Table 2) and resulted in a greater proportion of infants treated with SURFAXIN who experienced  oselabeledaefromdruguse oxygen desaturation and  oselabeledaefromdruguse  oselabeledaefromdruguse and bradycardia.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
11,surfaxin,11,562,607,"For Study 1,  oselabeledaefromdruguse was reported in 17%, 9%, and 13% and  oselabeledaefromdruguse for 5%, 2%, and 3% of infants treated with SURFAXIN, colfosceril palmitate, and beractant, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,surfaxin,12,607,641,"For Study 2,  oselabeledaefromdruguse was reported in 8% and 2% and  oselabeledaefromdruguse in 3% and 2% of infants treated with SURFAXIN and poractant alfa, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,surfaxin,13,641,686,"These adverse reactions did not appear to be associated with an increased incidence of serious complications or mortality relative to the comparator surfactants (Table 3).\n', '\n', '\n', '\n', '   Table 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,surfaxin,14,686,697,Administration-Related Adverse Reactions in SURFAXIN Controlled Clinical Studies  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,surfaxin,15,697,732,"a    \n', '\n', '\n', '\n', '\n', '   a  Table includes only infants who received study treatment.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,surfaxin,16,732,750,"\n', '   b  In Study 1 doses were administered in 4 aliquots.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,surfaxin,17,750,757,"\n', '   c  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,surfaxin,18,757,768,In Study 2 doses were administered in 2 aliquots.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,surfaxin,19,768,788,"\n', '  \n', '                              Study 1  b                 Study 2  c                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,surfaxin,20,788,819,"\n', '                              SURFAXIN(N = 524)          Colfoscerilpalmitate(N = 506)      Beractant(N = 258)         SURFAXIN(N = 119)          Poractant alfa(N = 124)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,surfaxin,21,819,826,"\n', ' Total DosesAdministered    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,surfaxin,22,826,836,994                        1038                       444                        174                        160                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,surfaxin,23,836,837,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,surfaxin,24,837,852,"', '                              Total Number of Events (Events per 100 Doses)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,surfaxin,25,852,857,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,surfaxin,26,857,879,oselabeledaefromdruguse                 183 (18)                   161 (16)                   67 (15)                    47 (27)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,surfaxin,27,879,880,31,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,surfaxin,28,880,975,"(19)                     \n', '  oselabeledaefromdruguse                     88 (9)                     46 (4)                     38 (9)                     18 (10)                    7 (4)                       \n', '  oselabeledaefromdruguse          87 (9)                     46 (4)                     30 (7)                     7 (4)                      2 (1)                       \n', '  oselabeledaefromdruguse            55 (6)                     21 (2)                     19 (4)                     27 (16)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,surfaxin,29,975,976,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,surfaxin,30,976,988,"(1)                       \n', '        Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,surfaxin,31,988,991,Common Serious Complications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,surfaxin,32,991,1051,"Associated with Prematurity and RDS in SURFAXIN Controlled Clinical Studies Through 36-Weeks Post-Conceptual Age (PCA)  \n', ' \n', '\n', '\n', '                              Study 1                    Study 2                   \n', '                              SURFAXIN(N = 527)%         Colfoscerilpalmitate(N = 509)%      Beractant(N = 258)%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,surfaxin,33,1051,1055,SURFAXIN(N = 119)%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,surfaxin,34,1055,1059,Poractantalfa(N = 124)%     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,surfaxin,35,1059,1068,"\n', '  notaecandidatepreexistingconditionorriskfactor                      52                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
36,surfaxin,36,1068,1070,52                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,surfaxin,37,1070,1074,46                         66                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,surfaxin,38,1074,1076,75                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,surfaxin,39,1076,1086,"\n', '  notaecandidatepreexistingconditionorriskfactor  all grades  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
40,surfaxin,40,1086,1088,52                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,surfaxin,41,1088,1090,57                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,surfaxin,42,1090,1092,54                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,surfaxin,43,1092,1094,39                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,surfaxin,44,1094,1097,38                          \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,surfaxin,45,1097,1105,"', '        - Grade 3/4         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,surfaxin,46,1105,1109,19                         18                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,surfaxin,47,1109,1113,21                         13                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,surfaxin,48,1113,1115,8                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,surfaxin,49,1115,1124,"\n', '  notaecandidatepreexistingconditionorriskfactor  10                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
50,surfaxin,50,1124,1126,10                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,surfaxin,51,1126,1130,12                         4                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,surfaxin,52,1130,1132,9                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,surfaxin,53,1132,1142,"\n', ' Acquired  notaecandidatepreexistingconditionorriskfactor            44                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
54,surfaxin,54,1142,1144,44                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,surfaxin,55,1144,1146,44                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,surfaxin,56,1146,1148,45                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,surfaxin,57,1148,1150,52                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,surfaxin,58,1150,1153,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,surfaxin,59,1153,1163,'  notaecandidatepreexistingconditionorriskfactor   37                         35                         37                         ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
60,surfaxin,60,1163,1165,43                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,surfaxin,61,1165,1179,"44                          \n', '  notaecandidatepreexistingconditionorriskfactor  all grades  27                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
62,surfaxin,62,1179,1181,26                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,surfaxin,63,1181,1183,25                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,surfaxin,64,1183,1185,32                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,surfaxin,65,1185,1187,31                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,surfaxin,66,1187,1192,"\n', '        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,surfaxin,67,1192,1197,-Grade 3/4          6                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,surfaxin,68,1197,1201,7                          6                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,surfaxin,69,1201,1203,5                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,surfaxin,70,1203,1205,9                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,surfaxin,71,1205,1210,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,surfaxin,72,1210,1215,notaecandidatepreexistingconditionorriskfactor  all grades  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
73,surfaxin,73,1215,1217,17                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,surfaxin,74,1217,1219,17                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,surfaxin,75,1219,1223,19                         13                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,surfaxin,76,1223,1225,15                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,surfaxin,77,1225,1228,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,surfaxin,78,1228,1233,'        -Grade 2/3          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,surfaxin,79,1233,1237,6                          8                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,surfaxin,80,1237,1239,14                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,surfaxin,81,1239,1243,8                          8                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,surfaxin,82,1243,1262,"\n', '  notaecandidatepreexistingconditionorriskfactor through Day 7, all types  15                         17                         14                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
83,surfaxin,83,1262,1266,9                          7                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,surfaxin,84,1266,1278,"\n', '        - notaecandidatepreexistingconditionorriskfactor    9                          10                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
85,surfaxin,85,1278,1282,10                         3                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,surfaxin,86,1282,1284,5                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,surfaxin,87,1284,1292,"\n', '        - notaecandidatepreexistingconditionorriskfactor       ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
88,surfaxin,88,1292,1296,3                          4                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,surfaxin,89,1296,1298,2                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,surfaxin,90,1298,1300,4                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,surfaxin,91,1300,1302,1                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,surfaxin,92,1302,1313,"\n', '  notaecandidatepreexistingconditionorriskfactor       10                         12                         ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
93,surfaxin,93,1313,1315,14                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,surfaxin,94,1315,1319,6                          9                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,surfaxin,95,1319,1394,"\n', '      All-cause mortality through 36-weeks PCA was similar regardless of which exogenous surfactant was administered.\n', ' \n', '\n', ' Adverse reactions reported in the controlled clinical studies through 36-weeks PCA occurring in at least 10% of infants were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,surfaxin,96,1394,1419,"These reactions occurred at rates similar to the comparator surfactants.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,surfaxin,97,1419,1541,"No assessments for immunogenicity to SURFAXIN were performed in these clinical studies.\n', '\n', '\n', '\n', '   Follow-up Evaluations  \n', '\n', '\n', '\n', ' Twelve-month corrected-age follow-up of 1546 infants enrolled in the 2 controlled clinical studies demonstrated no significant differences in mortality or gross neurologic findings between infants treated with SURFAXIN and those treated with the comparator surfactants (colfosceril palmitate, beractant, or poractant alfa).\n', '\n', '\n', '\n', '     Clinical Study in Adults with ARDS    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,surfaxin,98,1541,1594,"\n', '\n', '\n', '\n', ' The safety and efficacy of lucinactant administered in 2 doses separated by 48 hours via segmental bronchoscopic lavage in adults with  notaecandidatepreexistingconditionorriskfactor was evaluated in a two-part clinical trial in 124 adult patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
99,surfaxin,99,1594,1629,Twenty-two patients were studied in the initial open-label portion of the trial (Part A) and 102 patients participated in a subsequent randomized controlled portion (Part B).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,surfaxin,100,1629,1690,"Compared to standard of care, patients who received treatment with lucinactant via segmental bronchoscopic lavage at doses up to 50 mL per lung segment had an increased incidence of  nonoseaegeneralterm   nonoseaeaefromofflabel   nonoseaeaefromofflabel   nonoseaeaefromofflabel   nonoseaeaefromofflabel   nonoseaeaefromofflabel  nonoseaeaefromofflabel   nonoseaeaefromofflabel   nonoseaeaefromofflabel  and  nonoseaeaefromofflabel compared to those patients receiving standard of care.",0,1,0,0,0,0,0,0,0,0,1,0,0,0,0
101,surfaxin,101,1690,1760,"SURFAXIN is not indicated for use in the treatment of  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Acute Changes in Lung Compliance: Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
102,surfaxin,102,1760,1764,(5.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,surfaxin,103,1764,1776,"\n', "" *  Administration-Related Adverse Reactions:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,surfaxin,104,1776,1821,"If adverse reactions including bradycardia, oxygen desaturation, reflux of SURFAXIN into the endotracheal tube (ETT), and airway/ETT obstruction occur during administration of SURFAXIN, dosing should be interrupted and the infant's clinical condition assessed and stabilized.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,surfaxin,105,1821,1839,Suctioning of the ETT or reintubation may be required if airway obstruction persists or is severe.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,surfaxin,106,1839,1843,(5.2)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,surfaxin,107,1843,1864,"\n"", ' *  Increased Serious Adverse Reactions in Adults with Acute Respiratory Distress Syndrome (ARDS):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,surfaxin,108,1864,1904,"Adults with ARDS who received lucinactant via segmental bronchoscopic lavage had an increased incidence of death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia, pneumothorax, hypotension, and pulmonary embolism.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,surfaxin,109,1904,1914,SURFAXIN is not indicated for use in ARDS.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,surfaxin,110,1914,1918,(5.3)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,surfaxin,111,1918,1930,"\n', '    \n', ' \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,surfaxin,112,1930,1974,"'\n', '   5.1 Acute Changes in Lung Compliance\n', '\n', '\n', '\n', '  Administration of exogenous surfactants, including SURFAXIN, can rapidly affect lung compliance and oxygenation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,surfaxin,113,1974,2012,"SURFAXIN should be administered only by clinicians trained and experienced in the resuscitation, intubation, stabilization, and ventilatory management of  notaecandidateindication in a clinical setting with the capacity to care for critically ill neonates.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
114,surfaxin,114,2012,2098,"Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.\n', '\n', '\n', '\n', '    5.2  nonoseaegeneralterm \n', '\n', '\n', ""  Frequently occurring adverse reactions related to the administration of SURFAXIN include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (ETT), and  oselabeledaefromdruguse ETT  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
115,surfaxin,115,2098,2121,"If any of these events occur, dosing with SURFAXIN should be interrupted and the infant's clinical condition assessed and stabilized.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,surfaxin,116,2121,2138,Suctioning of the ETT or reintubation may be required if  nonoseaeaeonlyasinstruction persists or is severe.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,surfaxin,117,2138,2225,"After the patient is stable, dosing may proceed with appropriate monitoring.\n"", '\n', '\n', '\n', '    5.3 Increased Serious Adverse Reactions in Adults with ARDS\n', '\n', '\n', '\n', '  In a two-part clinical trial in adult patients with  notaecandidatepreexistingconditionorriskfactor  compared to standard of care, patients who received lucinactant via segmental bronchoscopic lavage had an increased incidence of  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
118,surfaxin,118,2225,2231,nonoseaegeneralterm   nonoseaeaefromofflabel   nonoseaeaefromofflabel   ,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0
119,surfaxin,119,2231,2235,nonoseaeaefromofflabel   nonoseaeaefromofflabel   ,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
120,surfaxin,120,2235,2239,nonoseaeaefromofflabel   nonoseaeaefromofflabel   ,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
121,surfaxin,121,2239,2246,nonoseaeaefromofflabel  and  nonoseaeaefromofflabel '],0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
0,rituxan,0,0,51,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.1)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,rituxan,1,51,69,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,rituxan,2,69,90,"\n', ' *   oselabeledaefromdruguse with  oselabeledaefromdruguse [ see  Warnings and Precautions (5.3)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,rituxan,3,90,108,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.4)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,rituxan,4,108,126,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.5)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,rituxan,5,126,144,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.6)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,rituxan,6,144,162,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.7)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,rituxan,7,162,180,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.8)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,rituxan,8,180,206,"\n', ' *   oselabeledaefromdruguse obstruction and  oselabeledaefromdruguse  oselabeledaefromdruguse and perforation [ see  Warnings and Precautions (5.9)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,rituxan,9,206,249,"\n', '    The most common adverse reactions of Rituxan (incidence >= 25%) observed in clinical trials of patients with  notaecandidateindication were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
10,rituxan,10,249,346,"\n', ' \n', '\n', ' The most common adverse reactions of Rituxan (incidence >= 25%) observed in clinical trials of patients with  notaecandidateindication were:  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '   EXCERPT:   Most common adverse reactions in clinical trials were:\n', '\n', ' *  NHL (>= 25%): infusion reactions, fever, lymphopenia, chills, infection and asthenia (  6.1  ).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
11,rituxan,11,346,370,"\n', ' *  CLL (>= 25%): infusion reactions and neutropenia (  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,rituxan,12,370,419,"\n', ' *  RA (>= 10%): upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis (other important adverse reactions include infusion reactions, serious infections, and cardiovascular events) (  6.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,rituxan,13,419,464,"\n', ' *  GPA and MPA (>=15 %): infections, nausea, diarrhea, headache, muscle spasms, anemia, peripheral edema (other important adverse reactions include infusion reactions) (  6.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,rituxan,14,464,497,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,rituxan,15,497,533,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience in Lymphoid Malignancies\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,rituxan,16,533,609,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' The data described below reflect exposure to Rituxan in 2783 patients, with exposures ranging from a single infusion up to 2 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,rituxan,17,609,626,Rituxan was studied in both single-arm and controlled trials (n=356 and n=2427).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,rituxan,18,626,651,The population included 1180 patients with low grade or  notaecandidateindication  927 patients with  notaecandidateindication  and 676 patients with  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
19,rituxan,19,651,703,"Most  notaecandidateindication patients received Rituxan as an infusion of 375 mg/m  2  per infusion, given as a single agent weekly for up to 8 doses, in combination with chemotherapy for up to 8 doses, or following chemotherapy for up to 16 doses.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
20,rituxan,20,703,740,"notaecandidateindication patients received Rituxan 375 mg/m  2  as an initial infusion followed by 500 mg/m  2  for up to 5 doses, in combination with fludarabine and cyclophosphamide.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
21,rituxan,21,740,835,"Seventy-one percent of  notaecandidateindication patients received 6 cycles and 90% received at least 3 cycles of Rituxan-based therapy.\n', '\n', '     Infusion Reactions  \n', '\n', ' In the majority of patients with  notaecandidateindication   oselabeledaefromdruguse consisting of  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication occurred during the first Rituxan infusion.  ",0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
22,rituxan,22,835,872,"oselabeledaefromdruguse typically occurred within 30 to 120 minutes of beginning the first infusion and resolved with slowing or interruption of the Rituxan infusion and with supportive care (diphenhydramine, acetaminophen, and intravenous saline).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,rituxan,23,872,894,The incidence of  oselabeledaefromdruguse was highest during the first infusion (77%) and decreased with each subsequent infusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,rituxan,24,894,912,"[  See  Boxed Warning  ,  Warnings and Precautions (5.1)    ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,rituxan,25,912,986,"In patients with previously untreated follicular  notaecandidateindication or previously untreated  notaecandidateindication  who did not experience a Grade 3 or 4  nonoseaenegation in Cycle 1 and received a 90-minute infusion of Rituxan at Cycle 2, the incidence of Grade 3-4  oselabeledaefromdruguse on the day of, or day after the infusion was 1.1% (95% CI [0.3%, 2.8%]).",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
26,rituxan,26,986,1028,"For Cycles 2-8, the incidence of Grade 3-4  oselabeledaefromdruguse on the day of or day after the 90-minute infusion, was 2.8% (95% CI [1.3%, 5.0%]).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,rituxan,27,1028,1099,"[  See  Warnings and Precautions (5.1)  ,  Clinical Studies (14.4)    ].\n', '\n', '   Infections\n', '\n', ' Serious  oselabeledaefromdruguse (NCI CTCAE Grade 3 or 4), including  oselabeledaefromdruguse  occurred in less than 5% of patients with  notaecandidateindication in the single-arm studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
28,rituxan,28,1099,1147,"The overall incidence of  oselabeledaefromdruguse was 31% ( oselabeledaefromdruguse  oselabeledaefromdruguse was 31% (bacterial 19%,  oselabeledaefromdruguse  oselabeledaefromdruguse was 31% (bacterial 19%, viral 10%, unknown 6%, and  oselabeledaefromdruguse 1%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,rituxan,29,1147,1215,"[  See  Warnings and Precautions (5.4)  ,  (5.5)  ,  (5.6)    ].\n', '\n', ' In randomized, controlled studies where Rituxan was administered following chemotherapy for the treatment of follicular or low-grade  notaecandidateindication  the rate of  oselabeledaefromdruguse was higher among patients who received Rituxan.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
30,rituxan,30,1215,1276,"In  notaecandidateindication patients,  oselabeledaefromdruguse occurred more frequently in those who received Rituxan.\n', '\n', '     Cytopenias and hypogammaglobulinemia  \n', '\n', ' In patients with  notaecandidateindication receiving rituximab monotherapy, NCI-CTC Grade 3 and 4  oselabeledaefromdruguse were reported in 48% of patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
31,rituxan,31,1276,1314,"These included  oselabeledaefromdruguse (40%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%), and  oselabeledaefromdruguse (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,rituxan,32,1314,1347,"The median duration of  oselabeledaefromdruguse was 14 days (range, 1-588 days) and of  oselabeledaefromdruguse was 13 days (range, 2-116 days).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,rituxan,33,1347,1461,"A single occurrence of transient  oselabeledaefromdruguse ( oselabeledaefromdruguse  and two occurrences of  oselabeledaefromdruguse following Rituxan therapy occurred during the single-arm studies.\n', '\n', ' In studies of monotherapy, Rituxan-induced  nonoseaeaeonlyasinstruction occurred in 70% to 80% of patients with  notaecandidateindication   oselabeledaefromdruguse IgM and  oselabeledaefromdruguse  oselabeledaefromdruguse and IgG serum levels occurred in 14% of these patients.\n', '\n', ' In  notaecandidateindication trials, the frequency of prolonged  oselabeledaefromdruguse and late-onset  oselabeledaefromdruguse was higher in patients treated with R-FC compared to patients treated with FC.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
34,rituxan,34,1461,1490,Prolonged  nonoseaeaeonlyasinstruction is defined as Grade 3-4  nonoseaeaeonlyasinstruction that has not resolved between 24 and 42 days after the last dose of study treatment.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,rituxan,35,1490,1560,"Late-onset  nonoseaeaeonlyasinstruction is defined as Grade 3-4  nonoseaeaeonlyasinstruction starting at least 42 days after the last treatment dose.\n', '\n', ' In patients with previously untreated  notaecandidateindication  the frequency of prolonged  oselabeledaefromdruguse was 8.5% for patients who received R-FC (n=402) and 5.8% for patients who received FC (n=398).",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
36,rituxan,36,1560,1644,"In patients who did not have prolonged  nonoseaenegation  the frequency of late-onset  oselabeledaefromdruguse was 14.8% of 209 patients who received R-FC and 4.3% of 230 patients who received FC.\n', '\n', ' For patients with previously treated  notaecandidateindication  the frequency of prolonged  oselabeledaefromdruguse was 24.8% for patients who received R-FC (n=274) and 19.1% for patients who received FC (n=274).",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
37,rituxan,37,1644,1749,"In patients who did not have prolonged  nonoseaenegation  the frequency of late-onset  oselabeledaefromdruguse was 38.7% in 160 patients who received R-FC and 13.6% of 147 patients who received FC.\n', '\n', '     Relapsed or Refractory, Low-Grade NHL  \n', '\n', ' Adverse reactions in  Table 1  occurred in 356 patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell  notaecandidateindication treated in single-arm studies of Rituxan administered as a single agent",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
38,rituxan,38,1749,1761,[  See  Clinical Studies (14.1)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,rituxan,39,1761,1833,"Most patients received Rituxan 375 mg/m  2  weekly for 4 doses.\n', '\n', ' Table 1 Incidence of Adverse Reactions in >= 5% of Patients with Relapsed or Refractory, Low-Grade or Follicular NHL, Receiving Single-agent Rituxan (N=356)Adverse reactions observed up to 12 months following Rituxan.,Adverse reactions graded for severity by NCI-CTC criteria.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,rituxan,40,1833,1891,"\n', '                                                   All Grades (%)                Grade 3 and 4 (%)          \n', '  \n', ' Any Adverse Reactions                                   99                              57                 \n', '    nonoseaegeneralterm                                       86                              10                 \n', '    oselabeledaefromdruguse                                                 53                              1                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,rituxan,41,1891,1900,"\n', '    oselabeledaefromdruguse                                                33                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,rituxan,42,1900,1902,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,rituxan,43,1902,1913,"\n', '    oselabeledaefromdruguse                                             31                              4                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,rituxan,44,1913,1922,"\n', '    oselabeledaefromdruguse                                              26                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,rituxan,45,1922,1924,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,rituxan,46,1924,1931,"\n', '    oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,rituxan,47,1931,1935,19                              1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,rituxan,48,1935,1944,"\n', '    oselabeledaefromdruguse                                        14                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,rituxan,49,1944,1946,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,rituxan,50,1946,1957,"\n', '    oselabeledaefromdruguse                                                  12                              1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,rituxan,51,1957,1966,"\n', '    oselabeledaefromdruguse                                             10                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,rituxan,52,1966,1968,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,rituxan,53,1968,1973,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,rituxan,54,1973,1979,oselabeledaefromdruguse                                     9                               0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,rituxan,55,1979,1990,"\n', '    oselabeledaefromdruguse                                              5                               0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,rituxan,56,1990,2010,"\n', '    nonoseaegeneralterm                             67                              48                 \n', '    oselabeledaefromdruguse                                           48                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,rituxan,57,2010,2012,40                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,rituxan,58,2012,2021,"\n', '    oselabeledaefromdruguse                                            14                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,rituxan,59,2021,2023,4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,rituxan,60,2023,2032,"\n', '    oselabeledaefromdruguse                                           14                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,rituxan,61,2032,2034,6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,rituxan,62,2034,2043,"\n', '    oselabeledaefromdruguse                                      12                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,rituxan,63,2043,2045,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,rituxan,64,2045,2054,"\n', '    oselabeledaefromdruguse                                                8                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,rituxan,65,2054,2056,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,rituxan,66,2056,2076,"\n', '    nonoseaegeneralterm                                   44                              2                  \n', '    oselabeledaefromdruguse                                          15                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,rituxan,67,2076,2078,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,rituxan,68,2078,2085,"\n', '    oselabeledaefromdruguse                                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,rituxan,69,2085,2087,15                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,rituxan,70,2087,2089,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,rituxan,71,2089,2098,"\n', '    oselabeledaefromdruguse                                              14                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,rituxan,72,2098,2100,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,rituxan,73,2100,2122,"\n', '    oselabeledaefromdruguse                                             8                               1                  \n', '    nonoseaegeneralterm                                    38                              4                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,rituxan,74,2122,2131,"\n', '    oselabeledaefromdruguse                                       13                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,rituxan,75,2131,2133,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,rituxan,76,2133,2142,"\n', '    oselabeledaefromdruguse                                              12                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,rituxan,77,2142,2144,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,rituxan,78,2144,2153,"\n', '    oselabeledaefromdruguse                                          8                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,rituxan,79,2153,2155,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,rituxan,80,2155,2171,"\n', '    oselabeledaefromdruguse                                               7                               1                  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,rituxan,81,2171,2177,oselabeledaefromdruguse                                             6                               0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,rituxan,82,2177,2186,"\n', '    nonoseaegeneralterm                   38                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
83,rituxan,83,2186,2188,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,rituxan,84,2188,2197,"\n', '    oselabeledaefromdruguse                                            11                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,rituxan,85,2197,2199,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,rituxan,86,2199,2208,"\n', '    oselabeledaefromdruguse                                         9                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,rituxan,87,2208,2210,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,rituxan,88,2210,2221,"\n', '    oselabeledaefromdruguse                                      8                               0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,rituxan,89,2221,2232,"\n', '    oselabeledaefromdruguse                                          7                               0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,rituxan,90,2232,2241,"\n', '    nonoseaegeneralterm                                      37                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
91,rituxan,91,2241,2243,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,rituxan,92,2243,2252,"\n', '    oselabeledaefromdruguse                                                23                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,rituxan,93,2252,2254,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,rituxan,94,2254,2263,"\n', '    oselabeledaefromdruguse                                              10                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,rituxan,95,2263,2265,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,rituxan,96,2265,2274,"\n', '    oselabeledaefromdruguse                                              10                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,rituxan,97,2274,2276,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,rituxan,98,2276,2285,"\n', '    nonoseaegeneralterm                                        32                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
99,rituxan,99,2285,2287,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,rituxan,100,2287,2296,"\n', '    oselabeledaefromdruguse                                             10                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,rituxan,101,2296,2298,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,rituxan,102,2298,2307,"\n', '    oselabeledaefromdruguse                                               5                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,rituxan,103,2307,2309,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,rituxan,104,2309,2318,"\n', '    nonoseaegeneralterm                                26                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,rituxan,105,2318,2320,3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,rituxan,106,2320,2329,"\n', '    oselabeledaefromdruguse                                               10                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,rituxan,107,2329,2331,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,rituxan,108,2331,2340,"\n', '    oselabeledaefromdruguse                                            10                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,rituxan,109,2340,2342,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,rituxan,110,2342,2353,"\n', '    nonoseaegeneralterm                                 25                              3                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,rituxan,111,2353,2364,"\n', '    oselabeledaefromdruguse                                           10                              1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,rituxan,112,2364,2373,"\n', '    oselabeledaefromdruguse                                          6                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,rituxan,113,2373,2375,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,rituxan,114,2375,2460,"\n', '         In these single-arm Rituxan studies,  oselabeledaefromdruguse occurred during and up to 6 months after Rituxan infusion.\n', ' \n', '\n', '     Previously Untreated, Low-Grade or Follicular, NHL  \n', '\n', ' In Study 4, patients in the R-CVP arm experienced a higher incidence of  oselabeledaefromdruguse and  oselabeledaefromdruguse compared to patients in the CVP arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,rituxan,115,2460,2555,"The following adverse reactions occurred more frequently ( >= 5%) in patients receiving R-CVP compared to CVP alone:  oselabeledaefromdruguse (17% vs. 5%),  oselabeledaefromdruguse (15% vs. 6%),  oselabeledaefromdruguse (14% vs. 3%),  oselabeledaefromdruguse (10% vs. 2%),  oselabeledaefromdruguse (10% vs. 1%),  oselabeledaefromdruguse (8% vs. 3%), and  oselabeledaefromdruguse (7% vs. 1%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,rituxan,116,2555,2604,"[  See  Clinical Studies (14.2)    ].\n', '\n', ' In Study 5, detailed safety data collection was limited to serious adverse reactions, Grade >= 2  nonoseaeaeonlyasinstruction  and Grade >= 3 adverse reactions.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,rituxan,117,2604,2638,"In patients receiving Rituxan as single-agent maintenance therapy following Rituxan plus chemotherapy,  oselabeledaefromdruguse were reported more frequently compared to the observation arm (37% vs. 22%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,rituxan,118,2638,2780,"Grade 3-4 adverse reactions occurring at a higher incidence (>= 2%) in the Rituxan group were  oselabeledaefromdruguse (4% vs. 1%) and  oselabeledaefromdruguse (4% vs. <1%).\n', '\n', ' In Study 6, the following adverse reactions were reported more frequently ( >= 5%) in patients receiving Rituxan following CVP compared to patients who received no further therapy:  oselabeledaefromdruguse (39% vs. 14%),  oselabeledaefromdruguse (35% vs. 20%),  oselabeledaefromdruguse (30% vs. 18%),  oselabeledaefromdruguse (19% vs. 9%),  oselabeledaefromdruguse (18% vs. 10%),  oselabeledaefromdruguse (17% vs. 7%),  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,rituxan,119,2780,2813,"and/or  oselabeledaefromdruguse (17% vs. 5%),  oselabeledaefromdruguse (12% vs. 3%), and  oselabeledaefromdruguse (11% vs. 4%).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,rituxan,120,2813,2853,oselabeledaefromdruguse was the only Grade 3 or 4 adverse reaction that occurred more frequently ( >= 2%) in the Rituxan arm compared with those who received no further therapy (4% vs. 1%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,rituxan,121,2853,2978,"[  See  Clinical Studies (14.3)    ].\n', '\n', '     DLBCL  \n', '\n', ' In Studies 7 and 8, [  see  Clinical Studies (14.3)    ], the following adverse reactions, regardless of severity, were reported more frequently ( >= 5%) in patients age >= 60 years receiving R-CHOP as compared to CHOP alone:  oselabeledaefromdruguse (56% vs. 46%),  oselabeledaefromdruguse (31% vs. 24%),  oselabeledaefromdruguse (29% vs. 21%), and  oselabeledaefromdruguse (13% vs. 4%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,rituxan,122,2978,3097,"Detailed safety data collection in these studies was primarily limited to Grade 3 and 4 adverse reactions and serious adverse reactions.\n', '\n', ' In Study 8, a review of  nonoseaeaeonlyasinstruction determined that  oselabeledaefromdruguse or  oselabeledaefromdruguse accounted for most of the difference in  oselabeledaefromdruguse (4.5% for R-CHOP vs. 1.0% for CHOP).\n', '\n', ' The following Grade 3 or 4 adverse reactions occurred more frequently among patients in the R-CHOP arm compared with those in the CHOP arm:  oselabeledaefromdruguse (9% vs. 7%) and  oselabeledaefromdruguse (6% vs. 3%).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,rituxan,123,3097,3123,"Other Grade 3 or 4 adverse reactions occurring more frequently among patients receiving R-CHOP were  oselabeledaefromdruguse (Study 8),  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,rituxan,124,3123,3133,"Studies 8 and 9), and  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,rituxan,125,3133,3178,"Study 9).\n', '\n', '     CLL  \n', '\n', ' The data below reflect exposure to Rituxan in combination with fludarabine and cyclophosphamide in 676 patients with  notaecandidateindication in Study 11 or Study 12",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,rituxan,126,3178,3190,[  See  Clinical Studies (14.5)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,rituxan,127,3190,3204,The age range was 30-83 years and 71% were men.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,rituxan,128,3204,3455,"Detailed safety data collection in Study 11 was limited to Grade 3 and 4 adverse reactions and serious adverse reactions.\n', '\n', '  nonoseaeaeonlyasinstruction were defined by any of the following adverse events occurring during or within 24 hours of the start of infusion:  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction \n', '\n', ' In Study 11, the following Grade 3 and 4 adverse reactions occurred more frequently in R-FC-treated patients compared to FC-treated patients:  oselabeledaefromdruguse (9% in R-FC arm),  oselabeledaefromdruguse (30% vs. 19%),  oselabeledaefromdruguse (9% vs. 6%),  oselabeledaefromdruguse (23% vs. 12%), and  oselabeledaefromdruguse (3% vs. 1%).\n', '\n', ' In Study 12, the following Grade 3 or 4 adverse reactions occurred more frequently in R-FC-treated patients compared to FC-treated patients:  oselabeledaefromdruguse (7% in R-FC arm),  oselabeledaefromdruguse (49% vs. 44%),  oselabeledaefromdruguse (15% vs. 12%),  oselabeledaefromdruguse (11% vs. 9%),  oselabeledaefromdruguse (2% vs. 0%), and  oselabeledaefromdruguse (2% vs. < 1%).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,rituxan,129,3455,3654,"Fifty-nine percent of R-FC-treated patients experienced an  oselabeledaefromdruguse of any severity.\n', '\n', '   6.2 Clinical Trials Experience in Rheumatoid Arthritis\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' The data presented below reflect the experience in 2578  notaecandidateindication patients treated with Rituxan in controlled and long-term studies with a total exposure of 5014 patient-years.\n', '\n', ' Among all exposed patients, adverse reactions reported in greater than 10% of patients include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', ' In placebo-controlled studies, patients received 2 * 500 mg or 2 * 1000 mg intravenous infusions of Rituxan or placebo, in combination with methotrexate, during a 24-week period.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
130,rituxan,130,3654,3682,"From these studies, 938 patients treated with Rituxan (2 * 1000 mg) or placebo have been pooled (see  Table 2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,rituxan,131,3682,3714,Adverse reactions reported in >= 5% of patients were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse (see  Table 2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,rituxan,132,3714,3782,"The rates and types of adverse reactions in patients who received Rituxan 2 * 500 mg were similar to those observed in patients who received Rituxan 2 * 1000 mg.\n', '\n', ' Table 2These data are based on 938 patients treated in Phase 2 and 3 studies of Rituxan (2 * 1000 mg) or placebo administered in combination with methotrexate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,rituxan,133,3782,3790,Incidence of All Adverse ReactionsCoded using MedDRA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,rituxan,134,3790,3852,"Occurring in >= 2% and at Least 1% Greater than Placebo Among Rheumatoid Arthritis Patients in Clinical Studies Up to Week 24 (Pooled) \n', ' Preferred Term                               Placebo + MTXN=398n (%)         Rituxan + MTXN=540n (%)       \n', '  \n', '  oselabeledaefromdruguse                                          21",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,rituxan,135,3852,3857,(5)                          43,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,rituxan,136,3857,3873,"(8)               \n', '  oselabeledaefromdruguse                                                19 (5)                          41",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,rituxan,137,3873,3893,"(8)               \n', '  oselabeledaefromdruguse                     23 (6)                          37 (7)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,rituxan,138,3893,3901,"\n', '  oselabeledaefromdruguse                                            14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,rituxan,139,3901,3910,(4)                          31 (6)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,rituxan,140,3910,3918,"\n', '  oselabeledaefromdruguse                                               8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,rituxan,141,3918,3927,(2)                           27 (5)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,rituxan,142,3927,3935,"\n', '  oselabeledaefromdruguse                                              5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,rituxan,143,3935,3956,"(1)                           26 (5)               \n', '  oselabeledaefromdruguse                                                9 (2)                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,rituxan,144,3956,3957,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,rituxan,145,3957,3974,"(3)               \n', '  oselabeledaefromdruguse                                            3 ( < 1)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,rituxan,146,3974,3975,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,rituxan,147,3975,3987,"(3)               \n', '  oselabeledaefromdruguse                                              6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,rituxan,148,3987,3996,(2)                           14 (3)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,rituxan,149,3996,4003,"\n', '  oselabeledaefromdruguse                                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,rituxan,150,4003,4028,"3 ( < 1)                         12 (2)               \n', '  oselabeledaefromdruguse                                            3 ( < 1)                         12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,rituxan,151,4028,4045,"(2)               \n', '  oselabeledaefromdruguse                                  4 (1)                           11",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,rituxan,152,4045,4057,"(2)               \n', '  oselabeledaefromdruguse                                     0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,rituxan,153,4057,4066,(0)                           11 (2)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,rituxan,154,4066,4074,"\n', '  oselabeledaefromdruguse                                               5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,rituxan,155,4074,4097,"(1)                           9 (2)                \n', '  oselabeledaefromdruguse                                             2 ( < 1)                         9",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,rituxan,156,4097,4120,"(2)                \n', '  oselabeledaefromdruguse                                             1 ( < 1)                         9 (2)                \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,rituxan,157,4120,4127,"', '             Infusion Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,rituxan,158,4127,4136,"\n', ' \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,rituxan,159,4136,4185,"', ' In the Rituxan  notaecandidateindication pooled placebo-controlled studies, 32% of Rituxan-treated patients experienced an adverse reaction during or within 24 hours following their first infusion, compared to 23% of placebo-treated patients receiving their first infusion.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
160,rituxan,160,4185,4213,"The incidence of adverse reactions during the 24-hour period following the second infusion, Rituxan or placebo, decreased to 11% and 13%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,rituxan,161,4213,4228,Acute  oselabeledaefromdruguse (manifested by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
162,rituxan,162,4228,4284,"nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication  with or without associated  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication  were experienced by 27% of Rituxan-treated patients following their first infusion, compared to 19% of placebo-treated patients receiving their first placebo infusion.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
163,rituxan,163,4284,4309,"The incidence of these acute  oselabeledaefromdruguse following the second infusion of Rituxan or placebo decreased to 9% and 11%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,rituxan,164,4309,4326,Serious acute  oselabeledaefromdruguse were experienced by < 1% of patients in either treatment group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,rituxan,165,4326,4363,"Acute  oselabeledaefromdruguse required dose modification (stopping, slowing, or interruption of the infusion) in 10% and 2% of patients receiving rituximab or placebo, respectively, after the first course.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,rituxan,166,4363,4378,The proportion of patients experiencing acute  oselabeledaefromdruguse decreased with subsequent courses of Rituxan.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,rituxan,167,4378,4440,"The administration of intravenous glucocorticoids prior to Rituxan infusions reduced the incidence and severity of such reactions, however, there was no clear benefit from the administration of oral glucocorticoids for the prevention of acute  nonoseaeaeonlyasinstruction  Patients in clinical studies also received antihistamines and acetaminophen prior to Rituxan infusions.\n', '\n', '     Infections  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,rituxan,168,4440,4445,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,rituxan,169,4445,4483,"', ' In the pooled, placebo-controlled studies, 39% of patients in the Rituxan group experienced an  oselabeledaefromdruguse of any type compared to 34% of patients in the placebo group.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,rituxan,170,4483,4501,The most common  oselabeledaefromdruguse were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,rituxan,171,4501,4509,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,rituxan,172,4509,4562,"The incidence of serious  oselabeledaefromdruguse was 2% in the Rituxan-treated patients and 1% in the placebo group.\n', '\n', ' In the experience with Rituxan in 2578  notaecandidateindication patients, the rate of serious  oselabeledaefromdruguse was 4.31 per 100 patient years.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
173,rituxan,173,4562,4592,The most common serious  oselabeledaefromdruguse ( >= 0.5%) were  oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   nonoseaegeneralterm serious  oselabeledaefromdruguse included  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
174,rituxan,174,4592,4599,oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,rituxan,175,4599,4612,Rates of serious  nonoseaeaeonlyasinstruction remained stable in patients receiving subsequent courses.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,rituxan,176,4612,4651,"In 185 Rituxan-treated  notaecandidateindication patients with active disease, subsequent treatment with a biologic DMARD, the majority of which were TNF antagonists, did not appear to increase the rate of serious  nonoseaenegation  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
177,rituxan,177,4651,4700,"Thirteen serious  oselabeledaefromdruguse were observed in 186.1 patient years (6.99 per 100 patient years) prior to exposure and 10 were observed in 182.3 patient years (5.49 per 100 patient years) after exposure.\n', '\n', '     Cardiac Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,rituxan,178,4700,4741,"\n', '\n', ' In the pooled, placebo-controlled studies, the proportion of patients with serious  oselabeledaefromdruguse was 1.7% and 1.3% in the Rituxan and placebo treatment groups, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,rituxan,179,4741,4809,"Three cardiovascular  nonoseaegeneralterm occurred during the double-blind period of the  notaecandidateindication studies including all rituximab regimens (3/769 = 0.4%) as compared to none in the placebo treatment group (0/389).\n', '\n', ' In the experience with Rituxan in 2578  notaecandidateindication patients, the rate of serious  oselabeledaefromdruguse was 1.93 per 100 patient years.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
180,rituxan,180,4809,4843,"The rate of  oselabeledaefromdruguse  was 0.56 per 100 patient years (28 events in 26 patients), which is consistent with  nonoseaeaeonlyasinstruction rates in the general  notaecandidateindication population.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
181,rituxan,181,4843,4971,"These rates did not increase over three courses of Rituxan.\n', '\n', ' Since patients with  notaecandidatepreexistingconditionorriskfactor are at increased risk for  nonoseaeaeonlyasinstruction compared with the general population, patients with  notaecandidateindication should be monitored throughout the infusion and Rituxan should be discontinued in the event of a serious or life-threatening  nonoseaeaeonlyasinstruction \n', '\n', '     Hypophosphatemia and hyperuricemia  \n', '\n', ' In the pooled, placebo-controlled studies, newly-occurring  oselabeledaefromdruguse ( < 2.0 mg/dl) was observed in 12% (67/540) of patients on Rituxan versus 10% (39/398) of patients on placebo.  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
182,rituxan,182,4971,4981,oselabeledaefromdruguse was more common in patients who received corticosteroids.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,rituxan,183,4981,5064,"Newly-occurring  oselabeledaefromdruguse (>10 mg/dl) was observed in 1.5% (8/540) of patients on Rituxan versus 0.3% (1/398) of patients on placebo.\n', '\n', ' In the experience with Rituxan in  notaecandidateindication patients, newly-occurring  oselabeledaefromdruguse was observed in 21% (528/2570) of patients and newly-occurring  oselabeledaefromdruguse was observed in 2% (56/2570) of patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
184,rituxan,184,5064,5157,"The majority of the observed  oselabeledaefromdruguse occurred at the time of the infusions and was transient.\n', '\n', '     Retreatment in Patients with RA  \n', '\n', ' In the experience with Rituxan in  notaecandidateindication patients, 2578 patients have been exposed to Rituxan and have received up to 10 courses of Rituxan in  notaecandidateindication clinical trials, with 1890, 1043, and 425 patients having received at least two, three, and four courses, respectively.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
185,rituxan,185,5157,5184,Most of the patients who received additional courses did so 24 weeks or more after the previous course and none were retreated sooner than 16 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,rituxan,186,5184,5419,"The rates and types of adverse reactions reported for subsequent courses of Rituxan were similar to rates and types seen for a single course of Rituxan.\n', '\n', ' In RA Study 2, where all patients initially received Rituxan, the safety profile of patients who were retreated with Rituxan was similar to those who were retreated with placebo [  See  Clinical Studies (14.6)  , and  Dosage and Administration (2.5)    ].\n', '\n', ""   6.3 Clinical Trials Experience in Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)\n"", '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' The data presented below reflect the experience in 197 patients with  notaecandidateindication and  notaecandidateindication treated with Rituxan or cyclophosphamide in a single controlled study, which was conducted in two phases: a 6 month randomized, double-blind, double-dummy, active-controlled remission induction phase and an additional 12 month remission maintenance phase.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
187,rituxan,187,5419,5441,"In the 6-month remission induction phase, 197 patients with  notaecandidateindication and  notaecandidateindication were randomized to either Rituxan 375 mg/",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
188,rituxan,188,5441,5445,m  2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,rituxan,189,5445,5482,"once weekly for 4 weeks plus glucocorticoids, or oral cyclophosphamide 2 mg/kg daily (adjusted for renal function, white blood cell count, and other factors) plus glucocorticoids to induce remission.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,rituxan,190,5482,5507,"Once remission was achieved or at the end of the 6 month remission induction period, the cyclophosphamide group received azathioprine to maintain remission.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,rituxan,191,5507,5519,The Rituxan group did not receive additional therapy to maintain remission.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,rituxan,192,5519,5580,"The primary analysis was at the end of the 6 month remission induction period and the safety results for this period are described below.\n', '\n', ' Adverse reactions presented below in  Table 3  were adverse events which occurred at a rate of greater than or equal to 10% in the Rituxan group.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,rituxan,193,5580,5629,"This table reflects experience in 99 GPA and  notaecandidateindication patients treated with Rituxan, with a total of 47.6 patient-years of observation and 98  notaecandidateindication and  notaecandidateindication patients treated with cyclophosphamide, with a total of 47.0 patient-years of observation.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
194,rituxan,194,5629,5715,"oselabeledaefromdruguse was the most common category of adverse events reported (47-62%) and is discussed below.\n', '\n', ' Table 3 Incidence of All Adverse Reactions Occurring in >= 10% of Rituxan-treated GPA and MPA Patients in the Clinical Study Up to Month 6The study design allowed for crossover or treatment by best medical judgment, and 13 patients in each treatment group received a second therapy during the 6 month study period.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,rituxan,195,5715,5732,"\n', ' Preferred Term                                   RituxanN=99n (%)           CyclophosphamideN=98n (%)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,rituxan,196,5732,5744,"\n', '  \n', '  oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,rituxan,197,5744,5750,18 (18%)                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,rituxan,198,5750,5756,20 (20%)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,rituxan,199,5756,5775,"\n', '  oselabeledaefromdruguse                                             17 (17%)                        12 (12%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,rituxan,200,5775,5820,"\n', '  oselabeledaefromdruguse                                             17 (17%)                        19 (19%)              \n', '  oselabeledaefromdruguse                                        17 (17%)                        15 (15%)              \n', '  oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,rituxan,201,5820,5826,16 (16%)                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,rituxan,202,5826,5832,20 (20%)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,rituxan,203,5832,5845,"\n', '  oselabeledaefromdruguse                                     16 (16%)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,rituxan,204,5845,5851,6 (6%)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,rituxan,205,5851,5870,"\n', '  oselabeledaefromdruguse                                             14 (14%)                        12 (12%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,rituxan,206,5870,5889,"\n', '  oselabeledaefromdruguse                                           13 (13%)                         9 (9%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,rituxan,207,5889,5908,"\n', '  oselabeledaefromdruguse                                                13 (13%)                        11 (11%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,rituxan,208,5908,5927,"\n', '  oselabeledaefromdruguse                                              13 (13%)                        21 (21%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,rituxan,209,5927,5946,"\n', '  oselabeledaefromdruguse                                        13 (13%)                        15 (15%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,rituxan,210,5946,5965,"\n', '  oselabeledaefromdruguse                                         12 (12%)                         5 (5%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,rituxan,211,5965,5984,"\n', '  oselabeledaefromdruguse                                            11 (11%)                         6 (6%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,rituxan,212,5984,5997,"\n', '  oselabeledaefromdruguse                                              10 (10%)                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,rituxan,213,5997,6003,11 (11%)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,rituxan,214,6003,6022,"\n', '  oselabeledaefromdruguse                                           10 (10%)                        26 (27%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,rituxan,215,6022,6035,"\n', '  oselabeledaefromdruguse                                                 10 (10%)                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,rituxan,216,6035,6041,17 (17%)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,rituxan,217,6041,6096,"\n', '             Infusion Reactions  \n', ' \n', '\n', '  nonoseaeaeonlyasinstruction in the active-controlled, double-blind study were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion-related by investigators.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,rituxan,218,6096,6127,"Among the 99 patients treated with Rituxan, 12% experienced at least one  oselabeledaefromdruguse  compared with 11% of the 98 patients in the cyclophosphamide group.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,rituxan,219,6127,6140,oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,rituxan,220,6140,6180,"In the Rituxan group, the proportion of patients experiencing an  oselabeledaefromdruguse was 12%, 5%, 4%, and 1% following the first, second, third, and fourth infusions, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,rituxan,221,6180,6291,"Patients were pre-medicated with antihistamine and acetaminophen before each Rituxan infusion and were on background oral corticosteroids which may have mitigated or masked an  nonoseaeaeonlyasinstruction  however, there is insufficient evidence to determine whether premedication diminishes the frequency or severity of  nonoseaeaeonlyasinstruction \n', '\n', '     Infections  \n', '\n', ' In the active-controlled, double-blind study, 62% (61/99) of patients in the Rituxan group experienced an  oselabeledaefromdruguse of any type compared to 47% (46/98) patients in the cyclophosphamide group by Month 6.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,rituxan,222,6291,6309,The most common  oselabeledaefromdruguse in the Rituxan group were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,rituxan,223,6309,6317,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,rituxan,224,6317,6356,"The incidence of serious  oselabeledaefromdruguse was 11% in the Rituxan-treated patients and 10% in the cyclophosphamide treated patients, with rates of approximately 25 and 28 per 100 patient-years, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,rituxan,225,6356,6364,The most common serious infection was  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,rituxan,226,6364,6417,"\n', '\n', '     Hypogammaglobulinemia  \n', '\n', '  oselabeledaefromdruguse ( oselabeledaefromdruguse  IgG or IgM  oselabeledaefromdruguse  oselabeledaefromdruguse or IgM  oselabeledaefromdruguse  oselabeledaefromdruguse  has been observed in patients with  notaecandidateindication and  notaecandidateindication treated with Rituxan.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
227,rituxan,227,6417,6526,"At 6 months, in the Rituxan group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline, had  oselabeledaefromdruguse  oselabeledaefromdruguse IgA,  oselabeledaefromdruguse  oselabeledaefromdruguse IgA, IgG and  oselabeledaefromdruguse levels, respectively compared to 25%, 50% and 46% in the cyclophosphamide group.\n', '\n', '     Retreatment in Patients with GPA and MPA  \n', '\n', ' In the active-controlled, double-blind study, subsequent courses of Rituxan were allowed for patients experiencing a relapse of disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,rituxan,228,6526,6563,"The limited data preclude any conclusions regarding the safety of subsequent courses of Rituxan with  notaecandidateindication and  notaecandidateindication [  See  Dosage and Administration (2.6)  , and  Warnings and Precautions",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
229,rituxan,229,6563,6568,(5.14)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,rituxan,230,6568,6592,".\n', '\n', '   6.4 Immunogenicity\n', '\n', '  As with all therapeutic proteins",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,rituxan,231,6592,6601,", there is a potential for  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,rituxan,232,6601,6651,"The observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay is highly dependent on several factors including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,rituxan,233,6651,6711,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction may be misleading.\n', '\n', ' Using an ELISA assay,  oselabeledaefromdruguse  was detected in 4 of 356 (1.1%) patients with low-grade or follicular  notaecandidateindication receiving single-agent Rituxan.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
234,rituxan,234,6711,6751,"Three of the four patients had an objective clinical response.\n', '\n', ' A total of 273/2578 (11%) patients with  notaecandidateindication tested  oselabeledaefromdruguse at any time after receiving Rituxan.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
235,rituxan,235,6751,6765,nonoseaeaeonlyasinstruction positivity was not associated with increased  nonoseaeaeonlyasinstruction or other adverse reactions.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,rituxan,236,6765,6797,"Upon further treatment, the proportions of patients with  nonoseaeaeonlyasinstruction were similar between  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction positive and  nonoseaeaeonlyasinstruction patients, and most reactions were mild to moderate.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,rituxan,237,6797,6850,"Four  oselabeledaefromdruguse patients had serious  oselabeledaefromdruguse  and the temporal relationship between  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction was variable.\n', '\n', ' A total of 23/99 (23%) Rituxan-treated patients with  notaecandidateindication and  notaecandidateindication tested  oselabeledaefromdruguse by 18 months.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
238,rituxan,238,6850,6914,"The clinical relevance of  nonoseaeaeonlyasinstruction in Rituxan-treated patients is unclear.\n', '\n', '   6.5 Postmarketing Experience\n', '\n', '  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,rituxan,239,6914,6992,"Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Rituxan.\n', '\n', ' *   nonoseaegeneralterm  prolonged  oselabeledaefromdruguse   oselabeledaefromdruguse  Grade 3-4 prolonged or late-onset  oselabeledaefromdruguse   oselabeledaefromdruguse  prolonged  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
240,rituxan,240,6992,7004,[ See  Warnings and Precautions (5.6)   ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,rituxan,241,7004,7016,"\n', ' *   nonoseaegeneralterm   nonoseaegeneralterm  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
242,rituxan,242,7016,7093,"\n', ' *   nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse with  oselabeledaefromdruguse  \n', ' *   nonoseaegeneralterm   oselabeledaefromdruguse  including  oselabeledaefromdruguse , increase in  nonoseaegeneralterm  oselabeledaefromdruguse in  notaecandidatepreexistingconditionorriskfactor  and a reported increased incidence of Grade 3 and 4  oselabeledaefromdruguse [ See  Warnings and Precautions (5.6)   ].",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
243,rituxan,243,7093,7103,"\n', ' *   nonoseaegeneralterm   oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
244,rituxan,244,7103,7107,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,rituxan,245,7107,7109,*   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,rituxan,246,7109,7115,nonoseaegeneralterm  severe  oselabeledaefromdruguse  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
247,rituxan,247,7115,7135,"\n', ' *   nonoseaegeneralterm   oselabeledaefromdruguse  oselabeledaefromdruguse obstruction and  oselabeledaefromdruguse  \n', '",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
248,rituxan,248,7135,7152,"*   nonoseaegeneralterm   nonoseaegeneralterm  oselabeledaefromdruguse and  nonoseaegeneralterm  oselabeledaefromdruguse  \n', '",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
249,rituxan,249,7152,7154,*   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,rituxan,250,7154,7161,nonoseaegeneralterm   oselabeledaefromdruguse  /  oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
251,rituxan,251,7161,7162,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,rituxan,252,7162,7173,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,rituxan,253,7173,7175,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,rituxan,254,7175,7195,"FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,rituxan,255,7195,7201,"', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,rituxan,256,7201,7230,"FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY  \n', '\n', '    Infusion Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,rituxan,257,7230,7262,"\n', '\n', '   Rituxan administration can result in serious, including  nonoseaegeneralterm  oselabeledaefromdruguse   nonoseaegeneralterm within 24 hours of Rituxan infusion have occurred.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
258,rituxan,258,7262,7278,Approximately 80% of  nonoseaegeneralterm  oselabeledaefromdruguse occurred in association with the first infusion.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
259,rituxan,259,7278,7282,Monitor patients closely.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,rituxan,260,7282,7299,Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,rituxan,261,7299,7321,"[  see   Warnings and Precautions (5.1)  ,   Adverse Reactions (6.1)    ].          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,rituxan,262,7321,7378,"\n', '\n', '   Severe Mucocutaneous Reactions  \n', '\n', '   Severe, including  nonoseaegeneralterm   oselabeledaefromdruguse can occur in patients receiving Rituxan [  see   Warnings and Precautions (5.2)  ,   Adverse Reactions (6)    ].          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
263,rituxan,263,7378,7383,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,rituxan,264,7383,7395,"', '   Hepatitis B Virus (HBV) Reactivation  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,rituxan,265,7395,7428,"\n', '\n', '    oselabeledaefromdruguse can occur in patients treated with Rituxan, in some cases resulting in fulminant  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm  ",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
266,rituxan,266,7428,7448,"Screen all patients for  notaecandidatepreexistingconditionorriskfactor before treatment initiation, and monitor patients during and after treatment with Rituxan.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
267,rituxan,267,7448,7481,"Discontinue Rituxan and concomitant medications in the event of  nonoseaeaeonlyasinstruction [  see   Warnings and Precautions (5.3)  ,   Adverse Reactions (6)    ].          ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,rituxan,268,7481,7498,"\n', '\n', '    oselabeledaefromdruguse , including  nonoseaegeneralterm  oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
269,rituxan,269,7498,7538,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Tumor lysis syndrome: Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function (  5.5  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,rituxan,270,7538,7561,"\n', ' *  Infections: Withhold Rituxan and institute appropriate anti-infective therapy (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,rituxan,271,7561,7589,"\n', ' *  Cardiac arrhythmias and angina: Discontinue infusions in case of serious or life-threatening events (  5.7  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,rituxan,272,7589,7618,"\n', ' *  Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms (  5.9  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,rituxan,273,7618,7645,"\n', ' *  Live virus vaccines: Do not administer live virus vaccines prior to or during Rituxan (  5.10  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,rituxan,274,7645,7669,"\n', ' *  Cytopenias: Monitor blood counts at regular intervals (  5.11  ,  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,rituxan,275,7669,7728,"\n', '    \n', ' \n', '\n', '   5.1 Infusion Reactions\n', '\n', '  Rituxan can cause severe, including  nonoseaegeneralterm   oselabeledaefromdruguse  Severe reactions typically occurred during the first infusion with time to onset of 30-120 minutes.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
276,rituxan,276,7728,7777,"oselabeledaefromdruguse and sequelae include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaegeneralterm \n', '\n', ' Premedicate patients with an antihistamine and acetaminophen prior to dosing.",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
277,rituxan,277,7777,7798,"For  notaecandidateindication patients, methylprednisolone 100 mg intravenously or its equivalent is recommended 30 minutes prior to each infusion.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
278,rituxan,278,7798,7818,"Institute medical management (e.g. glucocorticoids, epinephrine, bronchodilators, or oxygen) for  nonoseaeaeonlyasinstruction as needed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,rituxan,279,7818,7837,"Depending on the severity of the  nonoseaeaeonlyasinstruction and the required interventions, temporarily or permanently discontinue Rituxan.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,rituxan,280,7837,7852,Resume infusion at a minimum 50% reduction in rate after symptoms have resolved.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,rituxan,281,7852,7887,Closely monitor the following patients: those with pre-existing  notaecandidatepreexistingconditionorriskfactor or pulmonary  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  those who experienced prior  notaecandidatepreexistingconditionorriskfactor  and those with  notaecandidatepreexistingconditionorriskfactor  ).,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
282,rituxan,282,7887,7934,"[ See  Boxed Warning  ,  Warnings and Precautions (5.7)  ,  Adverse Reactions (6.1)    ].\n', '\n', '    5.2 Severe Mucocutaneous Reactions\n', '\n', '   oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,rituxan,283,7934,7948,"some with  nonoseaegeneralterm outcome, can occur in patients treated with Rituxan.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
284,rituxan,284,7948,7964,These reactions include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,rituxan,285,7964,7985,The onset of these reactions has been variable and includes reports with onset on the first day of Rituxan exposure.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,rituxan,286,7985,8013,Discontinue Rituxan in patients who experience a severe  nonoseaeaeonlyasinstruction  The safety of readministration of Rituxan to patients with severe  nonoseaeaeonlyasinstruction has not been determined.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,rituxan,287,8013,8082,"[ See  Boxed Warning  ,  Adverse Reactions (6  )  ].\n', '\n', '    5.3 Hepatitis B Virus Reactivation\n', '\n', '   oselabeledaeclasseffect  in some cases resulting in fulminant  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaegeneralterm  can occur in patients treated with drugs classified as  nonoseaeaeonlyasinstruction  including Rituxan.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
288,rituxan,288,8082,8174,"Cases have been reported in patients who are  notaecandidatepreexistingconditionorriskfactor and also in patients who are  notaecandidatepreexistingconditionorriskfactor but are  notaecandidatepreexistingconditionorriskfactor  Reactivation also has occurred in patients who appear to have resolved  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor .\n', '\n', '  nonoseaeaeonlyasinstruction is defined as an abrupt  nonoseaemanifestationorcomplication manifesting as a rapid  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication in a person who was previously  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor   nonoseaeaeonlyasinstruction is often followed by  nonoseaemanifestationorcomplication  i.e.,  nonoseaemanifestationorcomplication  ",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
289,rituxan,289,8174,8213,"In severe cases  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm can occur.\n', '\n', ' Screen all patients for  notaecandidatepreexistingconditionorriskfactor by measuring HBsAg and anti-HBc before initiating treatment with Rituxan.",0,1,1,0,1,0,0,0,0,0,0,0,0,0,0
290,rituxan,290,8213,8299,"For patients who show evidence of prior  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor [regardless of  nonoseaeaeonlyasinstruction status] or  notaecandidatepreexistingconditionorriskfactor but  notaecandidatepreexistingconditionorriskfactor , consult with physicians with expertise in managing  nonoseaeaeonlyasinstruction regarding monitoring and consideration for  nonoseaeaeonlyasinstruction antiviral therapy before and/or during Rituxan treatment.\n', '\n', ' Monitor patients with evidence of current or prior  notaecandidatepreexistingconditionorriskfactor for clinical and laboratory signs of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction during and for several months following Rituxan therapy.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
291,rituxan,291,8299,8342,"oselabeledaefromdruguse has been reported up to 24 months following completion of Rituxan therapy.\n', '\n', ' In patients who develop  nonoseaeaeonlyasinstruction while on Rituxan, immediately discontinue Rituxan and any concomitant chemotherapy, and institute appropriate treatment.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,rituxan,292,8342,8378,Insufficient data exist regarding the safety of resuming Rituxan in patients who develop  nonoseaeaeonlyasinstruction  Resumption of Rituxan in patients whose  nonoseaeaeonlyasinstruction resolves should be discussed with physicians with expertise in managing hepatitis B.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,rituxan,293,8378,8389,"[ See  Boxed Warning  ,  Adverse Reactions (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,rituxan,294,8389,8393,6)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,rituxan,295,8393,8437,"\n', '\n', '    5.4  oselabeledaefromdruguse \n', '\n', '   oselabeledaefromdruguse resulting in  oselabeledaefromdruguse and  nonoseaegeneralterm can occur in Rituxan-treated patients with  notaecandidatepreexistingconditionorriskfactor or with  notaecandidatepreexistingconditionorriskfactor  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
296,rituxan,296,8437,8464,The majority of patients with  notaecandidatepreexistingconditionorriskfactor diagnosed with  oselabeledaefromdruguse received Rituxan in combination with chemotherapy or as part of a hematopoietic stem cell transplant.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
297,rituxan,297,8464,8476,The patients with  notaecandidatepreexistingconditionorriskfactor had prior or concurrent immunosuppressive therapy.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
298,rituxan,298,8476,8516,"Most cases of  oselabeledaefromdruguse were diagnosed within 12 months of their last infusion of Rituxan.\n', '\n', ' Consider the diagnosis of  nonoseaeaeonlyasinstruction in any patient presenting with new-onset neurologic manifestations.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,rituxan,299,8516,8540,"Evaluation of  nonoseaeaeonlyasinstruction includes, but is not limited to, consultation with a neurologist, brain MRI, and lumbar puncture.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,rituxan,300,8540,8561,Discontinue Rituxan and consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,rituxan,301,8561,8588,"[ See  Boxed Warning  ,  Adverse Reactions (6)    ].\n', '\n', '    5.5  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,rituxan,302,8588,8635,"\n', '\n', '   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication from  oselabeledaefromdruguse  some  nonoseaegeneralterm  can occur within 12-24 hours after the first infusion of Rituxan in patients with  notaecandidateindication  ",0,1,0,1,1,0,0,0,0,0,0,0,0,0,0
303,rituxan,303,8635,8677,"A  notaecandidatepreexistingconditionorriskfactor  ) or high  notaecandidatepreexistingconditionorriskfactor burden, confers a greater risk of  nonoseaeaeonlyasinstruction \n', '\n', ' Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
304,rituxan,304,8677,8700,"nonoseaeaeonlyasinstruction  Correct  notaecandidatepreexistingconditionorriskfactor  monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
305,rituxan,305,8700,8781,"[ See  Warnings and Precautions (5.8)  ,  Adverse Reactions (6)    ].\n', '\n', '    5.6 Infections\n', '\n', '  Serious, including  nonoseaegeneralterm   oselabeledaefromdruguse  fungal, and new or reactivated viral  oselabeledaefromdruguse  oselabeledaefromdruguse  and new or reactivated viral  oselabeledaefromdruguse  oselabeledaefromdruguse can occur during and following the completion of Rituxan-based therapy.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
306,rituxan,306,8781,8797,oselabeledaefromdruguse have been reported in some patients with prolonged  nonoseaeaeonlyasinstruction (defined as  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,rituxan,307,8797,8805,>11 months after rituximab exposure).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,rituxan,308,8805,8846,New or reactivated  oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  oselabeledaefromdruguse B and  oselabeledaefromdruguse  Discontinue Rituxan for serious  nonoseaeaeonlyasinstruction and institute appropriate anti-infective therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,rituxan,309,8846,8873,"[ See  Adverse Reactions (6  ,  6.1)    ].\n', '\n', '    5.7  oselabeledaefromdruguse \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,rituxan,310,8873,8919,"', '  Discontinue infusions for serious or life-threatening  nonoseaeaeonlyasinstruction  Perform cardiac monitoring during and after all infusions of Rituxan for patients who develop clinically significant  nonoseaeaeonlyasinstruction  or who have a history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
311,rituxan,311,8919,8989,"[ See  Adverse Reactions (6)    ].\n', '\n', '    5.8 Renal\n', '\n', '  Severe, including  nonoseaegeneralterm   oselabeledaefromdruguse can occur after Rituxan administration in patients with  notaecandidateindication   oselabeledaefromdruguse has occurred in patients who experience  nonoseaeaeonlyasinstruction and in patients with  notaecandidateindication administered concomitant cisplatin therapy during clinical trials.",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
312,rituxan,312,8989,9002,The combination of cisplatin and Rituxan is not an approved treatment regimen.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,rituxan,313,9002,9022,Monitor closely for signs of  nonoseaeaeonlyasinstruction and discontinue Rituxan in patients with a  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication  ,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
314,rituxan,314,9022,9028,[ See  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,rituxan,315,9028,9033,(5.5)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,rituxan,316,9033,9035,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,rituxan,317,9035,9084,", '\n', '    5.9 Bowel Obstruction and Perforation\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse obstruction and  oselabeledaefromdruguse  in some cases leading to  nonoseaegeneralterm  can occur in patients receiving Rituxan in combination with chemotherapy.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
318,rituxan,318,9084,9110,"In postmarketing reports, the mean time to documented  nonoseaemanifestationorcomplication perforation was 6 (range 1-77) days in patients with NHL.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
319,rituxan,319,9110,9133,Evaluate if symptoms of  nonoseaemanifestationorcomplication  oselabeledaefromdruguse was 6 (range 1-77) days in patients with  notaecandidateindication  ,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
320,rituxan,320,9133,9148,Evaluate if symptoms of obstruction such as  nonoseaemanifestationorcomplication or repeated  nonoseaemanifestationorcomplication occur.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
321,rituxan,321,9148,9326,"[ See  Adverse Reactions (6)    ].\n', '\n', '    5.10 Immunization\n', '\n', '  The safety of immunization with live viral vaccines following Rituxan therapy has not been studied and vaccination with live virus vaccines is not recommended.\n', '\n', ' For  notaecandidateindication patients, physicians should follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of Rituxan.\n', '\n', ' The effect of Rituxan on immune responses was assessed in a randomized, controlled study in patients with  notaecandidateindication treated with Rituxan and methotrexate (MTX) compared to patients treated with MTX alone.\n', '\n', ' A response to pneumococcal vaccination (a T-cell independent antigen) as measured by an  oselabeledaefromdruguse in patients treated with Rituxan plus MTX as compared to patients treated with MTX alone (19% vs. 61%).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
322,rituxan,322,9326,9388,"A  oselabeledaefromdruguse compared to patients on MTX alone (47% vs. 93%).\n', '\n', ' A positive response to tetanus toxoid vaccine (a T-cell dependent antigen with existing immunity) was similar in patients treated with Rituxan plus MTX compared to patients on MTX alone (39% vs. 42%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,rituxan,323,9388,9448,"The proportion of patients maintaining a  nonoseaeaeonlyasinstruction (to evaluate delayed type  nonoseaeaeonlyasinstruction  was also similar (77% of patients on Rituxan plus MTX vs. 70% of patients on MTX alone).\n', '\n', ' Most patients in the Rituxan-treated group had  nonoseaeaeonlyasinstruction at the time of immunization.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,rituxan,324,9448,9504,"The clinical implications of these findings are not known.\n', '\n', '    5.11 Laboratory Monitoring\n', '\n', '  In patients with  notaecandidatepreexistingconditionorriskfactor  during treatment with Rituxan monotherapy, obtain complete blood counts (CBC) and platelet counts prior to each Rituxan course.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
325,rituxan,325,9504,9542,"During treatment with Rituxan and chemotherapy, obtain CBC and platelet counts at weekly to monthly intervals and more frequently in patients who develop  nonoseaeaeonlyasinstruction [ See  Adverse Reactions (6.1)    ] .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,rituxan,326,9542,9568,In patients with  notaecandidateindication   notaecandidateindication or  notaecandidateindication  obtain CBC and platelet counts at two to four month intervals during Rituxan therapy.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
327,rituxan,327,9568,9647,"The duration of  nonoseaeaeonlyasinstruction caused by Rituxan can extend months beyond the treatment period.\n', '\n', '    5.12 Concomitant Use with Biologic Agents and DMARDS other than Methotrexate in RA, GPA and MPA\n', '\n', '  Limited data are available on the safety of the use of biologic agents or DMARDs other than methotrexate in  notaecandidateindication patients exhibiting peripheral  nonoseaeaeonlyasinstruction following treatment with rituximab.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
328,rituxan,328,9647,9664,Observe patients closely for signs of  nonoseaeaeonlyasinstruction if biologic agents and/or DMARDs are used concomitantly.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,rituxan,329,9664,9703,"Use of concomitant immunosuppressants other than corticosteroids has not been studied in  notaecandidateindication or  notaecandidateindication patients exhibiting peripheral  nonoseaeaeonlyasinstruction following treatment with Rituxan.\n', '\n', '    5.13 Use in RA Patients",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
330,rituxan,330,9703,9777,"Who Have Not Had Prior Inadequate Response to Tumor Necrosis Factor (TNF) Antagonists\n', '\n', '  While the efficacy of Rituxan was supported in four controlled trials in patients with  notaecandidateindication with prior inadequate responses to non-biologic DMARDs, and in a controlled trial in MTX-naive patients, a favorable risk-benefit relationship has not been established in these populations.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
331,rituxan,331,9777,9874,"The use of Rituxan in patients with  notaecandidateindication who have not had prior inadequate response to one or more TNF antagonists is not recommended [ See  Clinical Studies (14.6)    ].\n', '\n', ""    5.14 Retreatment in Patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)\n"", '\n', '  Limited data are available on the safety and efficacy of subsequent courses of Rituxan in patients with  notaecandidateindication and  notaecandidateindication ']",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
0,thalomid,0,0,48,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are described in detail in other labeling sections:\n', '\n', ' *   oselabeledaefromdruguse [see  Boxed Warning  ,  Warnings and Precautions (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,thalomid,1,48,79,"5.1  ,  5.2)  , and  Patient Counseling Information (17)  ]  \n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,thalomid,2,79,116,"Boxed Warning  ,  Warnings and Precautions (5.3)  , and  Patient Counseling Information (17)  ]  \n', ' *  Increased  nonoseaegeneralterm in Patients with MM",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
3,thalomid,3,116,211,"When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.7)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,thalomid,4,211,239,"Warnings and Precautions (5.8)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.9)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,thalomid,5,239,246,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,thalomid,6,246,290,"[see  Warnings and Precautions (5.10)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.11)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,thalomid,7,290,303,"Warnings and Precautions (5.12)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,thalomid,8,303,382,"*   oselabeledaefromdruguse [see  Warnings and Precautions (5.13)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.14)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.16)  ]  \n', '   *   notaecandidateindication  The most common adverse reactions (>= 20%) are  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
9,thalomid,9,382,437,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,thalomid,10,437,443,"\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,thalomid,11,443,445,notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,thalomid,12,445,471,The most common adverse reactions (>= 10%) are  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,thalomid,13,471,479,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,thalomid,14,479,511,To report SUSPECTED ADVERSE REACTIONS or embryo-fetal exposure: contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,thalomid,15,511,544,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,thalomid,16,544,638,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' Most patients taking thalidomide can be expected to experience adverse reactions.\n', '\n', '   Teratogenicity:  \n', '\n', ' The most serious toxicity associated with thalidomide is its documented  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,thalomid,17,638,689,"The risk of severe  oselabeledaefromdruguse  primarily  oselabeledaefromdruguse or  oselabeledaefromdruguse  is extremely high during the critical period of  notaecandidatepreexistingconditionorriskfactor  The critical period is estimated, depending on the source of information, to range from 35 to 50 days after the last menstrual period.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
18,thalomid,18,689,709,"The risk of other potentially severe  nonoseaeaeonlyasinstruction outside this critical period is unknown, but may be significant.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,thalomid,19,709,890,"Based on present knowledge, thalidomide must not be used at any time during  notaecandidatecontraindication \n', '\n', ' Because thalidomide is present in the semen of patients receiving the drug, males receiving thalidomide must always use a latex or synthetic condom during any sexual contact with females of reproductive potential, even if he has undergone a successful vasectomy.\n', '\n', '   Venous and  oselabeledaefromdruguse   \n', '\n', ' An increased risk of  oselabeledaefromdruguse (such as  oselabeledaefromdruguse and  oselabeledaefromdruguse ,  oselabeledaefromdruguse (including  oselabeledaefromdruguse , and  oselabeledaefromdruguse have been reported in patients with  notaecandidateindication treated with thalidomide  [see  Warnings and Precautions (5.3)  ]  .\n', '\n', '   Peripheral Neuropathy:  \n', '\n', '  oselabeledaefromdruguse is a very common, potentially severe, adverse reaction of treatment with thalidomide that may result in irreversible damage.   ",0,0,0,1,0,0,0,0,0,0,0,1,0,0,0
20,thalomid,20,890,902,oselabeledaefromdruguse generally occurs following chronic use over a period of months.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,thalomid,21,902,914,"However, reports following relatively short-term use also exist.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,thalomid,22,914,937,"Incidence of  oselabeledaefromdruguse events leading to discontinuation, dose reduction or interruption increases with cumulative dose and duration of therapy.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,thalomid,23,937,985,"Symptoms may occur some time after thalidomide treatment has been stopped and may resolve slowly or not at all.\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse are the most commonly observed adverse reactions associated with the use of thalidomide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,thalomid,24,985,1042,"Adverse event profiles from clinical trials are summarized in the sections that follow.\n', '\n', '   Adverse Reactions in Multiple Myeloma Controlled Clinical Trials  \n', '\n', ' The safety analyses were conducted in two controlled clinical studies (Study 1 and Study 2).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,thalomid,25,1042,1058,The safety analysis in Study 1 was conducted on 204 patients who received treatment.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,thalomid,26,1058,1075,Table 1  lists the most common adverse drug reactions (>= 10%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,thalomid,27,1075,1134,The most frequently reported adverse reactions were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,thalomid,28,1134,1207,"\n', '\n', ' Twenty-three percent of patients (47/204) discontinued due to adverse reactions; 30% (31/102) from the THALOMID/dexamethasone arm and 16% (16/102) from the dexamethasone alone arm.\n', '\n', ' Table 1: Adverse Drug Reactions Reported in >=10% of Patients in the THALOMID/Dexamethasone Arm (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,thalomid,29,1207,1215,Study 1 - Safety Population; N=204),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,thalomid,30,1215,1261,"\n', ' *Treatment-emergent adverse reactions reported in >=10% of  patients in THALOMID/dexamethasone arm and with a >=1% difference in the THALOMID/dexamethasone arm compared to the dexamethasone alone arm.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,thalomid,31,1261,1275,"\n', '  \n', '   Body SystemAdverse Reaction      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,thalomid,32,1275,1283,Thal + Dex *(N=102)                                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,thalomid,33,1283,1287,Dex Alone*(N=102)                                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,thalomid,34,1287,1304,"\n', '   All Gradesn (%)            Grade 3/4n (%)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,thalomid,35,1304,1324,"All Gradesn (%)            Grade 3/4n (%)            \n', '    nonoseaegeneralterm     97",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,thalomid,36,1324,1343,(95)                    33 (32)                    96 (94)                    30 (29)                     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,thalomid,37,1343,1351,"\n', '        oselabeledaefromdruguse         73",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,thalomid,38,1351,1370,(72)                    11 (11)                    60 (59)                    5 (5)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,thalomid,39,1370,1378,"\n', '    nonoseaegeneralterm                92",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,thalomid,40,1378,1460,"(90)                    30 (29)                    76 (74)                    18 (18)                     \n', '        oselabeledaefromdruguse   55 (54)                    4 (4)                      28 (28)                    1 (1)                       \n', '        oselabeledaefromdruguse            29 (28)                    9 (9)                      12 (12)                    3 (3)                       \n', '        oselabeledaefromdruguse  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,thalomid,41,1460,1465,26 (26)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,thalomid,42,1465,1470,1 (1)                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,thalomid,43,1470,1471,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,thalomid,44,1471,1481,(14)                    3 (3)                       \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,thalomid,45,1481,1488,"', '        oselabeledaefromdruguse               26",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,thalomid,46,1488,1492,(26)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,thalomid,47,1492,1507,1 (1)                      6 (6)                      0 (0)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,thalomid,48,1507,1515,"\n', '        oselabeledaefromdruguse     22",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,thalomid,49,1515,1520,(22)                    8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,thalomid,50,1520,1533,(8)                      16 (16)                    5 (5)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,thalomid,51,1533,1543,"\n', '        oselabeledaefromdruguse        oselabeledaefromdruguse  20",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,thalomid,52,1543,1562,(20)                    1 (1)                      14 (14)                    0 (0)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,thalomid,53,1562,1565,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,thalomid,54,1565,1570,'        oselabeledaefromdruguse  16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,thalomid,55,1570,1574,(16)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,thalomid,56,1574,1589,3 (3)                      3 (3)                      3 (3)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,thalomid,57,1589,1678,"\n', '    nonoseaegeneralterm    91 (89)                    19 (19)                    84 (82)                    16 (16)                     \n', '        oselabeledaefromdruguse              81 (79)                    17 (17)                    72 (71)                    13 (13)                     \n', '        oselabeledaefromdruguse                24 (24)                    1 (1)                      20 (20)                    3 (3)                       \n', '        oselabeledaefromdruguse          23",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,thalomid,58,1678,1697,(23)                    1 (1)                      21 (21)                    2 (2)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,thalomid,59,1697,1698,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,thalomid,60,1698,1724,"', '        oselabeledaefromdruguse          22 (22)                    1 (1)                      13 (13)                    0 (0)                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,thalomid,61,1724,1831,"\n', '    nonoseaegeneralterm        88 (86)                    29 (29)                    96 (94)                    19 (19)                     \n', '        oselabeledaefromdruguse   36 (35)                    6 (6)                      30 (29)                    3 (3)                       \n', '        oselabeledaefromdruguse   32 (31)                    10 (10)                    24 (24)                    10 (10)                     \n', '    nonoseaegeneralterm         83 (81)                    22 (22)                    70 (69)                    8 (8)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,thalomid,62,1831,1852,"\n', '        oselabeledaefromdruguse         56 (55)                    8 (8)                      29 (28)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,thalomid,63,1852,1853,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,thalomid,64,1853,1860,"(1)                       \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,thalomid,65,1860,1884,'        oselabeledaefromdruguse             29 (28)                    4 (4)                      25 (24)                    2 (2)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,thalomid,66,1884,1885,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,thalomid,67,1885,1907,"', '        oselabeledaefromdruguse               29 (28)                    5 (5)                      23 (22)                    1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,thalomid,68,1907,1938,"(1)                       \n', '        oselabeledaefromdruguse        12 (12)                    1 (1)                      6 (6)                      0 (0)                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,thalomid,69,1938,1992,"\n', '    nonoseaegeneralterm           70 (69)                    37 (36)                    60 (59)                    21 (21)                     \n', '        oselabeledaefromdruguse                58 (56)                    6 (6)                      47 (46)                    4 (4)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,thalomid,70,1992,2002,"\n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,thalomid,71,2002,2021,(22)                    21 (21)                    5 (5)                      5 (5)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,thalomid,72,2021,2065,"\n', '    oselabeledaefromdruguse                     64 (63)                    10 (10)                    66 (65)                    15 (15)                     \n', '        oselabeledaefromdruguse              17 (17)                    0 (0)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,thalomid,73,2065,2070,14 (14)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,thalomid,74,2070,2071,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,thalomid,75,2071,2076,(1)                       \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,thalomid,76,2076,2102,"', '        oselabeledaefromdruguse           13 (13)                    0 (0)                      10 (10)                    2 (2)                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,thalomid,77,2102,2164,"\n', '    nonoseaegeneralterm                52 (51)                    19 (19)                    51 (50)                    20 (20)                     \n', '        oselabeledaefromdruguse              43 (42)                    13 (13)                    32 (31)                    15 (15)                     \n', '    nonoseaegeneralterm         48",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
78,thalomid,78,2164,2173,(47)                    5 (5)                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,thalomid,79,2173,2183,35 (34)                    2 (2)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,thalomid,80,2183,2192,"\n', '        oselabeledaefromdruguse  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,thalomid,81,2192,2212,31 (30)                    4 (4)                      18 (18)                    2 (2)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,thalomid,82,2212,2235,"\n', '        oselabeledaefromdruguse             21 (21)                    0 (0)                      11 (11)                    0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,thalomid,83,2235,2293,"(0)                       \n', '    nonoseaegeneralterm                  47 (46)                    7 (7)                      45 (44)                    4 (4)                       \n', '        oselabeledaefromdruguse            14 (14)                    2 (2)                      10 (10)                    2 (2)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
84,thalomid,84,2293,2305,"\n', '    nonoseaegeneralterm          42 (41)                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,thalomid,85,2305,2310,9 (9)                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,thalomid,86,2310,2311,41,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,thalomid,87,2311,2328,"(40)                    14 (14)                     \n', '        oselabeledaefromdruguse      41",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,thalomid,88,2328,2352,"(40)                    6 (6)                      38 (37)                    13 (13)                     \n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,thalomid,89,2352,2368,The safety analysis in Study 2 was conducted on 466 patients who received treatment.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,thalomid,90,2368,2389,Table 2  lists the most common adverse drug reactions (>= 10%) that were observed.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,thalomid,91,2389,2412,Table 3  lists the most common Grade 3/4 adverse drug reactions (occurring at > 2%) that were observed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,thalomid,92,2412,2550,"The adverse reactions most often reported by patients treated with THALOMID/dexamethasone were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  Adverse reactions with a frequency at least 2-fold higher in the THALOMID/dexamethasone group than in the placebo/dexamethasone group include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', ' \n', '\n', ' Twenty-six percent of patients (121/466) discontinued due to adverse events; 37% (86/234) from the THALOMID/dexamethasone arm and 15% (35/232) from the placebo/dexamethasone arm.\n', '\n', ' Table 2: Adverse Drug Reactions Reported in >=10% of Patients in the THALOMID/Dexamethasone Arm (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,thalomid,93,2550,2558,Study 2 - Safety Population; N=466),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,thalomid,94,2558,2564,"\n', '  *",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,thalomid,95,2564,2607,All adverse reactions reported in >=10% of patients in THALOMID/dexamethasone arm and with a >=1% difference in proportion of patients between the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,thalomid,96,2607,2614,NOS = not otherwise specified.    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,thalomid,97,2614,2628,"\n', '  \n', '   Body SystemAdverse Reaction      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,thalomid,98,2628,2630,Thal/,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,thalomid,99,2630,2646,Dex (N=234)*n (%)      Placebo/Dex (N=232)*n (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,thalomid,100,2646,2659,"\n', '   Patients with at least 1 Adverse Reaction      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,thalomid,101,2659,2669,233 (99)                   230 (99)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,thalomid,102,2669,2681,"\n', '    nonoseaegeneralterm      176 (75)                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
103,thalomid,103,2681,2686,149 (64)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,thalomid,104,2686,2694,"\n', '        oselabeledaefromdruguse     80",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,thalomid,105,2694,2699,(34)                    57,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,thalomid,106,2699,2711,"(25)                     \n', '        oselabeledaefromdruguse             56",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,thalomid,107,2711,2720,(24)                    47 (20)                     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,thalomid,108,2720,2766,"\n', '        oselabeledaefromdruguse              50 (21)                    36 (16)                     \n', '        oselabeledaefromdruguse NOS            31 (13)                    19 (8)                      \n', '    nonoseaegeneralterm    162 (69)                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,thalomid,109,2766,2771,149 (64)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,thalomid,110,2771,2813,"\n', '        oselabeledaefromdruguse         116 (50)                   49 (21)                     \n', '        oselabeledaefromdruguse               30 (13)                    27 (12)                     \n', '        oselabeledaefromdruguse            27",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,thalomid,111,2813,2835,"(11)                    21 (9)                      \n', '    nonoseaegeneralterm    161 (69)                   138",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
112,thalomid,112,2835,2914,"(60)                    \n', '        oselabeledaefromdruguse               62 (26)                    29 (12)                     \n', '        oselabeledaefromdruguse            51 (23)                    32 (14)                     \n', '        oselabeledaefromdruguse          27 (12)                    15 (6)                      \n', '        oselabeledaefromdruguse  24 (10)                    12 (5)                      \n', '    nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,thalomid,113,2914,2919,139 (59)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,thalomid,114,2919,2922,138 (60,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,thalomid,115,2922,3088,")                    \n', '        oselabeledaefromdruguse NOS        35 (15)                    28 (12)                     \n', '    nonoseaegeneralterm    90 (38)                    97 (42)                     \n', '        oselabeledaefromdruguse              27 (12)                    22 (10)                     \n', '        oselabeledaefromdruguse           24 (10)                    19 (8)                      \n', '    nonoseaegeneralterm    96 (41)                    89 (38)                     \n', '        oselabeledaefromdruguse NOS    36 (15)                    32 (14)                     \n', '    nonoseaegeneralterm       92 (39)                    53 (23)                     \n', '        oselabeledaefromdruguse  30 (13)                    4 (2)                       \n', '     Table 3: Grade 3/4 Adverse Drug Reactions Reported in >2% of Patients in the THALOMID/Dexamethasone Arm (",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,thalomid,116,3088,3096,Study 2 - Safety Population; N=466),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,thalomid,117,3096,3138,"\n', '  *All Grade 3/4 adverse reactions with >2% of patients in THALOMID/dexamethasone arm and with a higher frequency in the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,thalomid,118,3138,3145,NOS = not otherwise specified.    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,thalomid,119,3145,3177,"\n', '  \n', '   Body SystemAdverse Reaction      THALOMID/Dex (N=234)*n (%)      Placebo/Dex (N=232)*n (%)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,thalomid,120,3177,3306,"\n', '    nonoseaegeneralterm      50 (21)                    36 (16)                   \n', '        oselabeledaefromdruguse NOS        17 (7)                     14 (6)                      \n', '        oselabeledaefromdruguse NOS  7 (3)                      3 (1)                       \n', '    nonoseaegeneralterm      44 (19)                    26 (11)                   \n', '        oselabeledaefromdruguse             11 (5)                     4 (2)                       \n', '    nonoseaegeneralterm      33 (14)                    34 (15)                   \n', '        oselabeledaefromdruguse          7 (3)                      3 (1)                       \n', '    nonoseaegeneralterm      47",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,thalomid,121,3306,3311,(20)                    20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,thalomid,122,3311,3351,"(9)                    \n', '        oselabeledaefromdruguse              8 (3)                      1 (<1)                      \n', '        oselabeledaefromdruguse NOS  8 (3)                      0 (0)                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,thalomid,123,3351,3354,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,thalomid,124,3354,3369,'        oselabeledaefromdruguse  6 (3)                      1 (<1)                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,thalomid,125,3369,3374,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,thalomid,126,3374,3403,"nonoseaegeneralterm          35 (15)                    27 (11)                   \n', '        oselabeledaefromdruguse  11 (5)                     8 (3)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,thalomid,127,3403,3406,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,thalomid,128,3406,3420,'        oselabeledaefromdruguse  6 (3)                      2 (1)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,thalomid,129,3420,3454,"\n', '    nonoseaegeneralterm         42 (18)                    14 (6)                    \n', '        oselabeledaefromdruguse  27 (12)                    4 (2)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,thalomid,130,3454,3467,"\n', '    nonoseaegeneralterm      26 (11)                    22",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
131,thalomid,131,3467,3471,(10)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,thalomid,132,3471,3522,"\n', '        oselabeledaefromdruguse         7 (3)                      2 (1)                       \n', '    nonoseaegeneralterm             21 (9)                     21 (9)                    \n', '        oselabeledaefromdruguse     8 (3)                      4 (2)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
133,thalomid,133,3522,3534,"\n', '    nonoseaegeneralterm      24 (10)                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
134,thalomid,134,3534,3552,"17 (7)                    \n', '        oselabeledaefromdruguse          8 (3)                      6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,thalomid,135,3552,3561,"(3)                       \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,thalomid,136,3561,3590,"nonoseaegeneralterm      27 (12)                    13 (6)                    \n', '        oselabeledaefromdruguse   16 (7)                     4 (2)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
137,thalomid,137,3590,3640,"\n', '    nonoseaegeneralterm      19 (8)                     8 (3)                     \n', '        oselabeledaefromdruguse              5 (2)                      3 (1)                       \n', '        oselabeledaefromdruguse    5 (2)                      2 (1)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,thalomid,138,3640,3674,"\n', '    nonoseaegeneralterm      6 (3)                      0 (0)                     \n', '        oselabeledaefromdruguse              5 (2)                      0 (0)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,thalomid,139,3674,3691,"\n', '        Less Common Adverse Drug Reactions in Multiple Myeloma Controlled Clinical Trials  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,thalomid,140,3691,3703,"\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,thalomid,141,3703,3763,"In Study 2, THALOMID in combination with dexamethasone in patients with  notaecandidateindication  the following adverse drug reactions not described above were reported*:\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse NOS,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse NOS,  oselabeledaefromdruguse",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
142,thalomid,142,3763,3809,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse NOS\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse NOS\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse NOS,  oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse NOS\n'",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,thalomid,143,3809,3819,", '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
144,thalomid,144,3819,3864,"\n', ' * All adverse reactions with >=3% of patients in THALOMID/dexamethasone arm and with a >=1% difference in proportion of patients between the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,thalomid,145,3864,3905,All grade 3/4 and serious adverse reactions reported >2 patients in THALOMID/dexamethasone arm and with a percentage higher in the THALOMID/dexamethasone arm compared to the placebo/dexamethasone arm have been considered for possible inclusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,thalomid,146,3905,3935,"In any cases medical judgment has been applied for consideration of causality assessment.\n', '\n', '   Adverse Reactions in Erythema Nodosum Leprosum (ENL)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,thalomid,147,3935,3938,Clinical Trials  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,thalomid,148,3938,3971,"\n', '\n', '   Table 4  lists treatment-emergent signs and symptoms that occurred in THALOMID-treated patients in clinical trials in  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
149,thalomid,149,3971,4005,The most common adverse reactions (>=10%) reported in patients with ENL were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  Doses ranged from 50 to 300 mg/day.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,thalomid,150,4005,4037,"All adverse reactions were mild to moderate in severity, and none resulted in discontinuation.\n', '\n', ' Table 4: Summary of Adverse Events (AEs)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,thalomid,151,4037,4056,"Reported in Celgene-sponsored Controlled Clinical Trials \n', '   Body System/Adverse Event      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,thalomid,152,4056,4064,All AEs Reportedin Patients with ENL      AEs,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,thalomid,153,4064,4095,"Reported in >=3 HIV-seropositive Patients     \n', '                                                         Thalidomide                Placebo                   \n', '                              50 to 300 mg/day(N=24)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,thalomid,154,4095,4107,100 mg/day(N=36)           200 mg/day(N=32)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,thalomid,155,4107,4120,"(N=35)                    \n', '  nonoseaegeneralterm          0                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
156,thalomid,156,4120,4126,8 (22.2%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,thalomid,157,4126,4138,13 (40.6%)                 10 (28.6%)                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,thalomid,158,4138,4147,"\n', '         oselabeledaefromdruguse              0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,thalomid,159,4147,4165,2 (5.6%)                   4 (12.5%)                  3 (8.6%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,thalomid,160,4165,4174,"\n', '         oselabeledaefromdruguse          0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,thalomid,161,4174,4186,6 (16.7%)                  8 (25.0%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,thalomid,162,4186,4192,3 (8.6%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,thalomid,163,4192,4201,"\n', '         oselabeledaefromdruguse     0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,thalomid,164,4201,4219,2 (5.6%)                   4 (12.5%)                  3 (8.6%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,thalomid,165,4219,4250,"\n', '    nonoseaegeneralterm            16 (66.7%)                 18 (50.0%)                 19 (59.4%)                 13 (37.1%)                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
166,thalomid,166,4250,4281,"\n', '         nonoseaeaeratelteqplacebo      1 (4.2%)                   1 (2.8%)                   1 (3.1%)                   4 (11.4%)                   ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
167,thalomid,167,4281,4302,"\n', '         oselabeledaefromdruguse   1 (4.2%)                   2 (5.6%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,thalomid,168,4302,4308,1 (2.9%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,thalomid,169,4308,4321,"\n', '         oselabeledaefromdruguse            2 (8.3%)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,thalomid,170,4321,4333,2 (5.6%)                   7 (21.9%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,thalomid,171,4333,4339,1 (2.9%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,thalomid,172,4339,4352,"\n', '         oselabeledaefromdruguse           1 (4.2%)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,thalomid,173,4352,4362,2 (5.6%)                   0                          0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,thalomid,174,4362,4377,"\n', '         nonoseaeaeratelteqplacebo              1 (4.2%)                   0                          ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
175,thalomid,175,4377,4384,3 (9.4%)                   4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,thalomid,176,4384,4389,(11.4%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,thalomid,177,4389,4406,"\n', '         oselabeledaefromdruguse        1 (4.2%)                   0                          0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,thalomid,178,4406,4408,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,thalomid,179,4408,4417,"\n', '         oselabeledaefromdruguse               0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,thalomid,180,4417,4429,7 (19.4%)                  7 (21.9%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,thalomid,181,4429,4435,6 (17.1%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,thalomid,182,4435,4469,"\n', '         oselabeledaefromdruguse            3 (12.5%)                  6 (16.7%)                  6 (18.7%)                  4 (11.4%)                   \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,thalomid,183,4469,4475,'         oselabeledaefromdruguse           0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,thalomid,184,4475,4481,3 (8.3%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,thalomid,185,4481,4487,2 (6.3%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,thalomid,186,4487,4493,1 (2.9%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,thalomid,187,4493,4508,"\n', '         oselabeledaefromdruguse             2 (8.3%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,thalomid,188,4508,4510,0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,thalomid,189,4510,4512,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,thalomid,190,4512,4531,"\n', '         oselabeledaefromdruguse           1 (4.2%)                   0                          0                          0                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,thalomid,191,4531,4565,"\n', '         oselabeledaefromdruguse       1 (4.2%)                   0                          0                          0                           \n', '         oselabeledaefromdruguse                2 (8.3%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,thalomid,192,4565,4577,1 (3.1%)                   2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,thalomid,193,4577,4590,"\n', '    nonoseaegeneralterm           5 (20.8%)                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
194,thalomid,194,4590,4602,16 (44.4%)                 16 (50.0%)                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,thalomid,195,4602,4608,15 (42.9%)                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,thalomid,196,4608,4617,"\n', '         oselabeledaefromdruguse            0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,thalomid,197,4617,4623,1 (2.8%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,thalomid,198,4623,4624,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,thalomid,199,4624,4635,(9.4%)                   2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,thalomid,200,4635,4662,"\n', '         oselabeledaefromdruguse        1 (4.2%)                   1 (2.8%)                   3 (9.4%)                   0                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,thalomid,201,4662,4681,"\n', '         nonoseaeaeratelteqplacebo            1 (4.2%)                   4 (11.1%)                  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
202,thalomid,202,4681,4687,6 (18.7%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,thalomid,203,4687,4693,6 (17.1%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,thalomid,204,4693,4696,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,thalomid,205,4696,4702,'         oselabeledaefromdruguse           0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,thalomid,206,4702,4708,3 (8.3%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,thalomid,207,4708,4709,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,thalomid,208,4709,4720,(9.4%)                   2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,thalomid,209,4720,4729,"\n', '         oselabeledaefromdruguse          0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,thalomid,210,4729,4737,3 (8.3%)                   0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,thalomid,211,4737,4743,2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,thalomid,212,4743,4752,"\n', '         oselabeledaefromdruguse  0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,thalomid,213,4752,4754,0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,thalomid,214,4754,4762,3 (9.4%)                   0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,thalomid,215,4762,4777,"\n', '         oselabeledaefromdruguse              1 (4.2%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,thalomid,216,4777,4783,4 (12.5%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,thalomid,217,4783,4789,1 (2.9%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,thalomid,218,4789,4816,"\n', '         oselabeledaefromdruguse     1 (4.2%)                   4 (11.1%)                  2 (6.3%)                   0                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,thalomid,219,4816,4831,"\n', '         oselabeledaefromdruguse          1 (4.2%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,thalomid,220,4831,4833,0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,thalomid,221,4833,4835,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,thalomid,222,4835,4873,"\n', '    nonoseaegeneralterm      1 (4.2%)                   8 (22.2%)                  12 (37.5%)                 8 (22.9%)                 \n', '         oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
223,thalomid,223,4873,4879,1 (4.2%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,thalomid,224,4879,4885,3 (8.3%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,thalomid,225,4885,4886,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,thalomid,226,4886,4893,(3.1%)                   0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,thalomid,227,4893,4902,"\n', '         oselabeledaefromdruguse        0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,thalomid,228,4902,4920,2 (5.6%)                   3 (9.4%)                   1 (2.9%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,thalomid,229,4920,4929,"\n', '         oselabeledaefromdruguse      0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,thalomid,230,4929,4935,1 (2.8%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,thalomid,231,4935,4947,4 (12.5%)                  2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,thalomid,232,4947,4978,"\n', '    nonoseaegeneralterm             13 (54.2%)                 19 (52.8%)                 18 (56.3%)                 12 (34.3%)                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
233,thalomid,233,4978,4989,"\n', '         oselabeledaefromdruguse           0                          0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,thalomid,234,4989,4997,3 (9.4%)                   0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,thalomid,235,4997,5024,"\n', '         oselabeledaefromdruguse           1 (4.2%)                   7 (19.4%)                  6 (18.7%)                  0                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,thalomid,236,5024,5035,"\n', '         oselabeledaefromdruguse            0                          0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,thalomid,237,5035,5047,3 (9.4%)                   2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,thalomid,238,5047,5056,"\n', '         oselabeledaefromdruguse         0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,thalomid,239,5056,5062,1 (2.8%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,thalomid,240,5062,5063,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,thalomid,241,5063,5070,(9.4%)                   0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,thalomid,242,5070,5079,"\n', '         oselabeledaefromdruguse          0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,thalomid,243,5079,5087,3 (8.3%)                   0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,thalomid,244,5087,5089,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,thalomid,245,5089,5098,"\n', '         oselabeledaefromdruguse         0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,thalomid,246,5098,5116,2 (5.6%)                   5 (15.6%)                  4 (11.4%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,thalomid,247,5116,5147,"\n', '         oselabeledaefromdruguse          9 (37.5%)                  13 (36.1%)                 12 (37.5%)                 4 (11.4%)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,thalomid,248,5147,5162,"\n', '         oselabeledaefromdruguse              1 (4.2%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,thalomid,249,5162,5164,0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,thalomid,250,5164,5166,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,thalomid,251,5166,5181,"\n', '         oselabeledaefromdruguse             2 (8.3%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,thalomid,252,5181,5183,0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,thalomid,253,5183,5185,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,thalomid,254,5185,5187,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,thalomid,255,5187,5216,", '    nonoseaegeneralterm         3 (12.5%)                  9 (25.0%)                  6 (18.7%)                  9 (25.7%)                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
256,thalomid,256,5216,5247,"\n', '         oselabeledaefromdruguse         1 (4.2%)                   3 (8.3%)                   2 (6.3%)                   2 (5.7%)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,thalomid,257,5247,5262,"\n', '         nonoseaeaeratelteqplacebo            1 (4.2%)                   0                          ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
258,thalomid,258,5262,5264,0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,thalomid,259,5264,5270,4 (11.4%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,thalomid,260,5270,5283,"\n', '         oselabeledaefromdruguse           1 (4.2%)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,thalomid,261,5283,5289,3 (8.3%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,thalomid,262,5289,5290,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,thalomid,263,5290,5301,(3.1%)                   2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,thalomid,264,5301,5332,"\n', '    nonoseaegeneralterm        10 (41.7%)                 17 (47.2%)                 18 (56.3%)                 19 (54.3%)                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
265,thalomid,265,5332,5341,"\n', '         oselabeledaefromdruguse                0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,thalomid,266,5341,5347,4 (11.1%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,thalomid,267,5347,5355,1 (3.1%)                   0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,thalomid,268,5355,5382,"\n', '         oselabeledaefromdruguse   1 (4.2%)                   2 (5.6%)                   3 (9.4%)                   0                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,thalomid,269,5382,5397,"\n', '         oselabeledaefromdruguse       1 (4.2%)                   0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,thalomid,270,5397,5405,1 (3.1%)                   0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,thalomid,271,5405,5436,"\n', '         nonoseaeaeratelteqplacebo            2 (8.3%)                   1 (2.8%)                   2 (6.3%)                   2 (5.7%)                    ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
272,thalomid,272,5436,5467,"\n', '         nonoseaeaeratelteqplacebo                5 (20.8%)                  9 (25.0%)                  8 (25.0%)                  11 (31.4%)                  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
273,thalomid,273,5467,5486,"\n', '         oselabeledaefromdruguse  1 (4.2%)                   6 (16.7%)                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,thalomid,274,5486,5498,6 (18.7%)                  2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,thalomid,275,5498,5509,"\n', '         nonoseaeaeratelteqplacebo            0                          0                          ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
276,thalomid,276,5509,5516,4 (12.5%)                  4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,thalomid,277,5516,5521,(11.4%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,thalomid,278,5521,5526,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,thalomid,279,5526,5552,nonoseaegeneralterm          2 (8.3%)                   6 (16.7%)                  2 (6.3%)                   4 (11.4%)                 ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
280,thalomid,280,5552,5561,"\n', '         oselabeledaefromdruguse         0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,thalomid,281,5561,5567,3 (8.3%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,thalomid,282,5567,5568,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,thalomid,283,5568,5579,(3.1%)                   2 (5.7%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,thalomid,284,5579,5588,"\n', '         oselabeledaefromdruguse           0                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,thalomid,285,5588,5596,4 (11.1%)                  0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,thalomid,286,5596,5602,1 (2.9%)                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,thalomid,287,5602,5615,"\n', '         oselabeledaefromdruguse           2 (8.3%)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,thalomid,288,5615,5623,1 (2.8%)                   0                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,thalomid,289,5623,5625,0                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,thalomid,290,5625,5638,"\n', '        Other Adverse Events Observed in ENL Patients  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,thalomid,291,5638,5678,"\n', ' \n', '\n', ' THALOMID in doses up to 400 mg/day has been administered investigationally in the United States over a 19-year period in 1465 patients with  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
292,thalomid,292,5678,5690,The published literature describes the treatment of an additional 1678 patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,thalomid,293,5690,5726,"To provide a meaningful estimate of the proportion of the individuals having adverse events, similar types of events were grouped into a smaller number of standardized categories using a modified COSTART dictionary/terminology.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,thalomid,294,5726,5735,These categories are used in the listing below.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,thalomid,295,5735,5749,All reported events are included except those already listed in the previous table.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,thalomid,296,5749,5770,"Due to the fact that these data were collected from uncontrolled studies, the incidence rate cannot be determined.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,thalomid,297,5770,5786,No causal relationship between THALOMID and these events can be conclusively determined at this time.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,thalomid,298,5786,5835,"These are reports of all adverse events noted by investigators in patients to whom they had administered thalidomide.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
299,thalomid,299,5835,5853,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
300,thalomid,300,5853,5875,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
301,thalomid,301,5875,5907,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
302,thalomid,302,5907,5951,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
303,thalomid,303,5951,5977,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
304,thalomid,304,5977,6023,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
305,thalomid,305,6023,6047,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
306,thalomid,306,6047,6081,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
307,thalomid,307,6081,6101,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
308,thalomid,308,6101,6123,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
309,thalomid,309,6123,6168,"\n', '\n', '   Other Adverse Events Observed in HIV-seropositive Patients  \n', '\n', ' In addition to controlled clinical trials, THALOMID has been used in uncontrolled studies in 145 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,thalomid,310,6168,6209,Less frequent adverse events that have been reported in these  notaecandidatepreexistingconditionorriskfactor patients treated with THALOMID were grouped into a smaller number of standardized categories using modified COSTART dictionary/terminology and these categories are used in the listing below.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
311,thalomid,311,6209,6251,"Adverse events that have already been included in the tables and narrative above, or that are too general to be informative are not listed.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
312,thalomid,312,6251,6298,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
313,thalomid,313,6298,6352,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
314,thalomid,314,6352,6396,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
315,thalomid,315,6396,6424,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
316,thalomid,316,6424,6480,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
317,thalomid,317,6480,6507,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
318,thalomid,318,6507,6526,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
319,thalomid,319,6526,6530,incomplete  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,thalomid,320,6530,6536,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,thalomid,321,6536,6538,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,thalomid,322,6538,6559,"oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
323,thalomid,323,6559,6615,"\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following additional adverse reactions have been identified during post approval use of THALOMID and are not already included in Clinical Trials Experience  [see  Adverse Reactions (6.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,thalomid,324,6615,6691,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
325,thalomid,325,6691,6697,nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
326,thalomid,326,6697,6720,"oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
327,thalomid,327,6720,6732,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
328,thalomid,328,6732,6744,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
329,thalomid,329,6744,6846,"\n', '\n', '    nonoseaegeneralterm   Severe  oselabeledaefromdruguse (e.g.,  nonoseaegeneralterm  oselabeledaefromdruguse including  oselabeledaefromdruguse  and  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse .\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse  oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
330,thalomid,330,6846,6857,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,thalomid,331,6857,6875,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
332,thalomid,332,6875,6895,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
333,thalomid,333,6895,6929,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
334,thalomid,334,6929,6944,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
335,thalomid,335,6944,6955,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,thalomid,336,6955,6985,"\n', '\n', '    WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM  \n', '\n', '    oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,thalomid,337,6985,7034,"\n', '\n', '   If thalidomide is taken during  notaecandidatepreexistingconditionorriskfactor  it can cause severe  oselabeledaefromdruguse or  oselabeledaefromdruguse  Thalidomide should never be used by females who are  notaecandidatecontraindication or who could become  nonoseaeaeonlyasinstruction while taking the drug.",1,0,1,0,0,0,0,0,0,0,0,1,0,0,0
338,thalomid,338,7034,7139,"Even a single dose [1 capsule (regardless of strength)] taken by a  notaecandidatepreexistingconditionorriskfactor woman during her  notaecandidatepreexistingconditionorriskfactor can cause severe  oselabeledaefromdruguse   \n', '\n', '   Because of this toxicity and in an effort to make the chance of  nonoseaeaeonlyasinstruction  (r)   (thalidomide) as negligible as possible, THALOMID  (r)   (thalidomide) is approved for marketing only through a special restricted distribution program: THALOMID REMS  (r)   program, approved by the Food and Drug Administration.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
339,thalomid,339,7139,7184,"\n', '\n', ""   You can get the information about THALOMID and the THALOMID REMS program on the Internet at www.celgeneriskmanagement.com or by calling the manufacturer's toll-free number 1-888-423-5436.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,thalomid,340,7184,7237,"\n"", '\n', '   VENOUS THROMBOEMBOLISM  \n', '\n', '   The use of THALOMID  (r)   (thalidomide) in  notaecandidateindication results in an increased risk of  oselabeledaefromdruguse  such as  oselabeledaefromdruguse and  oselabeledaefromdruguse   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
341,thalomid,341,7237,7254,This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
342,thalomid,342,7254,7290,"In one controlled trial, the rate of  oselabeledaefromdruguse was 22.5% in patients receiving thalidomide in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,thalomid,343,7290,7374,"Patients and physicians are advised to be observant for the signs and symptoms of  nonoseaeaeonlyasinstruction  Instruct patients to seek medical care if they develop symptoms such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication or leg  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Ischemic heart disease (including myocardial infarction) and stroke have been observed in patients treated with THALOMID in combination with dexamethasone.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
344,thalomid,344,7374,7388,"(  5.3  ) \n', ' *  Increased Mortality:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,thalomid,345,7388,7404,Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,thalomid,346,7404,7441,"(  5.4  ) \n', ' *  Drowsiness and Somnolence: Instruct patients to avoid situations where drowsiness may be a problem and not to take other medications that may cause drowsiness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,thalomid,347,7441,7479,"(  5.5  ) \n', ' *  Peripheral Neuropathy: Examine patients at monthly intervals for the first 3 months of thalidomide therapy and periodically thereafter for signs or symptoms of peripheral neuropathy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,thalomid,348,7479,7510,"Consider electrophysiological testing, consisting of measurement of sensory nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an effort to detect asymptomatic neuropathy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,thalomid,349,7510,7544,"(  5.6  ) \n', ' *  Dizziness and Orthostatic Hypotension: Advise patients to sit upright for a few minutes prior to standing up from a recumbent position.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,thalomid,350,7544,7566,"(  5.7  ) \n', ' *  Neutropenia: Patients may require dose interruption and/or dose reduction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,thalomid,351,7566,7575,"(  5.8  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
352,thalomid,352,7575,7588,*  Thrombocytopenia: Patients may require dose interruption and/or dose reduction.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
353,thalomid,353,7588,7621,"(  5.9  ) \n', ' *  Increased HIV Viral Load: Measure viral load after the first and third months of treatment and every 3 months thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
354,thalomid,354,7621,7642,"(  5.10  ) \n', ' *  Bradycardia: Monitor patients for bradycardia and possible syncope.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
355,thalomid,355,7642,7650,Dose reduction or discontinuation may be required.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,thalomid,356,7650,7655,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,thalomid,357,7655,7670,"\n', ' *  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,thalomid,358,7670,7680,Do not resume THALOMID following discontinuation for these reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,thalomid,359,7680,7719,"(  5.12  ) \n', ' *  Seizures: Monitor patients with a history of seizures or at risk for the development of seizures closely for clinical changes that could precipitate acute seizure activity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,thalomid,360,7719,7728,"(  5.13  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,thalomid,361,7728,7755,"*  Tumor Lysis Syndrome: Monitor patients at risk (e.g., those with high tumor burden prior to treatment) and take appropriate precautions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,thalomid,362,7755,7768,"(  5.14  ) \n', ' *  Hypersensitivity:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,thalomid,363,7768,7780,Monitor patients for potential hypersensitivity to the drug and its components.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,thalomid,364,7780,7843,"(  5.16  ) \n', '    \n', ' \n', '\n', '   5.1 Embryo-Fetal Toxicity\n', '\n', '  Thalidomide is a powerful  oselabeledaefromdruguse that induces a high frequency of severe and life-threatening  oselabeledaefromdruguse  even after a single dose.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,thalomid,365,7843,7859,nonoseaegeneralterm at or shortly after birth has been reported in about 40% of infants.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
366,thalomid,366,7859,7886,"When there is no satisfactory alternative treatment, females of reproductive potential may be treated with thalidomide provided adequate precautions are taken to avoid  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,thalomid,367,7886,7943,"THALOMID  (r)  (thalidomide) is only available through the THALOMID REMS program [see  Warnings and Precautions (5.2)  ]  .\n', '\n', ' Oral ingestion is the only type of maternal thalidomide exposure known to result in drug-associated  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
368,thalomid,368,7943,7983,"There are no specific data available regarding the reproductive risks of cutaneous absorption or inhalation of thalidomide; however, females of reproductive potential should avoid contact with THALOMID  (r)  (thalidomide) Capsules.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,thalomid,369,7983,7994,THALOMID Capsules should be stored in blister packs until ingestion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,thalomid,370,7994,8057,"If there is contact with non-intact thalidomide capsules or the powder contents, the exposed area should be washed with soap and water.\n', '\n', ' If healthcare providers or other care givers are exposed to body fluids from patients receiving THALOMID (thalidomide) the exposed area should be washed with soap and water.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
371,thalomid,371,8057,8197,"Appropriate precautions should be utilized, such as wearing gloves to prevent the potential cutaneous exposure to THALOMID.\n', '\n', '   Females of Reproductive Potential    Females of reproductive potential must avoid  nonoseaeaeonlyasinstruction for at least 4 weeks before beginning THALOMID therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy.\n', ' \n', '\n', ' Females must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control, beginning 4 weeks prior to initiating treatment with THALOMID, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of THALOMID therapy.\n', '\n', ' Two  nonoseaeaeonlyasinstruction must be obtained prior to initiating therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,thalomid,372,8197,8272,"The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing THALOMID therapy and then weekly during the first month, then monthly thereafter in females with regular menstrual cycles or every 2 weeks in females with  notaecandidatepreexistingconditionorriskfactor [see  Use in Specific Populations (8.3)  ]  .\n', '\n', '   Males     nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
373,thalomid,373,8272,8315,"Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking THALOMID and for up to 4 weeks after discontinuing THALOMID, even if they have undergone a successful vasectomy.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,thalomid,374,8315,8418,"Male patients taking THALOMID must not donate sperm [see  Use in Specific Populations (8.3)  ]  .\n', ' \n', '\n', '   Blood Donation    Patients must not donate blood during treatment with THALOMID and for 4 weeks following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to THALOMID.\n', ' \n', '\n', '    5.2 THALOMID REMS Program\n', '\n', '  Because of the  nonoseaeaeonlyasinstruction",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,thalomid,375,8418,8430,[see  Warnings and Precautions (5.1)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,thalomid,376,8430,8500,", THALOMID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), the THALOMID REMS  program.\n', '\n', ' Required components of the THALOMID REMS  program include the following:\n', '\n', ' *  Prescribers must be certified with the THALOMID REMS program by enrolling and complying with the REMS requirements.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,thalomid,377,8500,8522,"\n', ' *  Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,thalomid,378,8522,8577,"In particular, female patients of reproductive potential who are not  nonoseaeaeonlyasinstruction must comply with the  nonoseaeaeonlyasinstruction testing and contraception requirements [see  Use in Specific Populations (8.3)  ] and males must comply with contraception requirements [see  Use in Specific Populations (8.3)  ] .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,thalomid,379,8577,8610,"\n', ' *  Pharmacies must be certified with the THALOMID REMS program, must only dispense to patients who are authorized to receive THALOMID and comply with REMS requirements.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,thalomid,380,8610,8689,"\n', '    Further information about the THALOMID REMS  program is available at www.celgeneriskmanagement.com or by telephone at 1-888-423-5436.\n', ' \n', '\n', '    5.3 Venous and Arterial Thromboembolism\n', '\n', '  The use of THALOMID in patients with  notaecandidateindication results in an increased risk of  oselabeledaefromdruguse  such as  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
381,thalomid,381,8689,8706,This risk increases significantly when thalidomide is used in combination with standard chemotherapeutic agents including dexamethasone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
382,thalomid,382,8706,8841,"In one controlled trial, the rate of  oselabeledaefromdruguse was 22.5% in patients receiving thalidomide in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002).\n', '\n', '  oselabeledaefromdruguse (11.1%), including  oselabeledaefromdruguse (1.3%), and  oselabeledaefromdruguse ( oselabeledaefromdruguse  2.6%) have also occurred in patients with previously untreated  notaecandidateindication treated with THALOMID and dexamethasone compared to placebo and dexamethasone (4.7%, 1.7%, and 0.9%, respectively) in one clinical trial [see  Adverse Reactions (6.1)  ]  .\n', '\n', "" Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
383,thalomid,383,8841,8892,Patients and physicians should be observant for the signs and symptoms of  nonoseaeaeonlyasinstruction  Advise patients to seek immediate medical care if they develop symptoms such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication or leg  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication [see  Boxed Warning  ]  .,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
384,thalomid,384,8892,8938,"Agents that also may increase the risk of  nonoseaeaeonlyasinstruction should be used with caution in patients receiving THALOMID [see  Drug Interactions (7.7)  ]  .\n"", '\n', '     5.4 Increased Mortality in Patients with MM",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
385,thalomid,385,8938,9034,"When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone  \n', '\n', '   In two randomized clinical trials in patients with  notaecandidateindication  the addition of pembrolizumab to a thalidomide analogue plus dexamethasone, a use for which no PD-1 or PD-L1 blocking antibody is indicated, resulted in increased  nonoseaegeneralterm  Treatment of patients with  notaecandidateindication with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.  ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
386,thalomid,386,9034,9105,"\n', '\n', '    5.5 Drowsiness and Somnolence\n', '\n', '  Thalidomide frequently causes  oselabeledaefromdruguse and  oselabeledaefromdruguse  Patients should be instructed to avoid situations where  nonoseaegeneralterm may be a problem and not to take other medications that may cause  nonoseaeaeonlyasinstruction without adequate medical advice [see  Drug Interactions (7.1)  ].   ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
387,thalomid,387,9105,9196,"Advise patients as to the possible  nonoseaemanifestationorcomplication of mental and/or physical abilities required for the performance of hazardous tasks, such as  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication mental and/or physical abilities required for the performance of hazardous tasks, such as driving a car or  nonoseaemanifestationorcomplication other complex or dangerous  nonoseaemanifestationorcomplication  Dose reductions may be required.\n', '\n', '    5.6 Peripheral Neuropathy\n', '\n', '  Thalidomide is known to cause  oselabeledaefromdruguse that may be permanent.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
388,thalomid,388,9196,9221,oselabeledaefromdruguse is a common (>=10%) and potentially severe adverse reaction of treatment with thalidomide that may be irreversible.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,thalomid,389,9221,9247,"oselabeledaefromdruguse generally occurs following chronic use over a period of months; however,  oselabeledaefromdruguse following relatively short-term use has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,thalomid,390,9247,9255,The correlation with cumulative dose is unclear.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,thalomid,391,9255,9301,"Symptoms may occur some time after thalidomide treatment has been stopped and may resolve slowly or not at all.\n', '\n', ' Few reports of  oselabeledaefromdruguse have arisen in the treatment of  notaecandidateindication despite long-term thalidomide treatment.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
392,thalomid,392,9301,9437,"However, the inability clinically to differentiate  nonoseaeaeonlyasinstruction from the  nonoseaeaeonlyasinstruction often seen in  notaecandidatepreexistingconditionorriskfactor makes it difficult to determine accurately the incidence of  nonoseaeaeonlyasinstruction in  notaecandidateindication patients treated with thalidomide.\n', '\n', ' Patients should be examined at monthly intervals for the first 3 months of thalidomide therapy to enable the clinician to detect early signs of  nonoseaeaeonlyasinstruction  which include  nonoseaemanifestationorcomplication  tingling or pain in the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  tingling or pain in the hands and  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or pain in the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or pain in the hands and  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication in the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication in the hands and  nonoseaemanifestationorcomplication  Patients should be evaluated periodically thereafter during treatment.",1,0,1,1,1,0,0,0,0,0,0,0,0,0,0
393,thalomid,393,9437,9490,"Patients should be regularly counseled, questioned, and evaluated for signs or symptoms of  nonoseaeaeonlyasinstruction  Consideration should be given to electrophysiological testing, consisting of measurement of sensory nerve action potential (SNAP) amplitudes at baseline and thereafter every 6 months in an effort to detect asymptomatic neuropathy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,thalomid,394,9490,9511,"If symptoms of  nonoseaeaeonlyasinstruction develop, thalidomide should be discontinued immediately to limit further damage, if clinically appropriate.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,thalomid,395,9511,9656,"Usually, treatment with thalidomide should only be reinitiated if the  nonoseaeaeonlyasinstruction returns to baseline status.\n', '\n', ' Medications known to be associated with  nonoseaeaeonlyasinstruction should be used with caution in patients receiving thalidomide [see  Drug Interactions (7.3)  ]  .\n', '\n', '    5.7 Dizziness and Orthostatic Hypotension\n', '\n', '  Patients should also be advised that thalidomide may cause  oselabeledaefromdruguse and  oselabeledaefromdruguse and that, therefore, they should sit upright for a few minutes prior to standing up from a recumbent position.\n', '\n', '    5.8 Neutropenia\n', '\n', ""   oselabeledaefromdruguse  including  oselabeledaefromdruguse  have been reported in association with the clinical use of thalidomide.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
396,thalomid,396,9656,9667,Treatment should not be initiated with an  notaecandidatepreexistingconditionorriskfactor  .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
397,thalomid,397,9667,9701,"White blood cell count and differential should be monitored on an ongoing basis, especially in patients who may be more prone to  notaecandidatepreexistingconditionorriskfactor  such as patients who are  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
398,thalomid,398,9701,9776,"If  nonoseaeaeonlyasinstruction  while on treatment, the patient's medication regimen should be re-evaluated and, if the  nonoseaeaeonlyasinstruction persists, consideration should be given to withholding thalidomide if clinically appropriate.\n"", '\n', '    5.9 Thrombocytopenia\n', '\n', '   oselabeledaefromdruguse  including Grade 3 or 4 occurrences, has been reported in association with the clinical use of thalidomide.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,thalomid,399,9776,9784,"Monitor blood counts, including platelet counts.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
400,thalomid,400,9784,9795,"Dose reduction, delay, or discontinuation may be required.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
401,thalomid,401,9795,9840,"Monitor for signs and symptoms of  nonoseaeaeonlyasinstruction including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  especially if concomitant medication may increase the risk of  nonoseaeaeonlyasinstruction \n', '\n', '    5.10 Increased HIV Viral Load\n',",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
402,thalomid,402,9840,9875,"'\n', '  In a randomized, placebo-controlled trial of thalidomide in an  notaecandidatepreexistingconditionorriskfactor patient population,  oselabeledaefromdruguse were found to  oselabeledaefromdruguse (median change = 0.42",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
403,thalomid,403,9875,9876,log10copies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
404,thalomid,404,9876,9889,"HIV RNA/mL, p = 0.04 compared to placebo).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
405,thalomid,405,9889,9908,"A similar trend was observed in a second, unpublished study conducted in patients who were  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
406,thalomid,406,9908,9917,The clinical significance of this increase is unknown.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
407,thalomid,407,9917,9930,Both studies were conducted prior to availability of highly active antiretroviral therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,thalomid,408,9930,9992,"Until the clinical significance of this finding is further understood, in  notaecandidatepreexistingconditionorriskfactor patients, viral load should be measured after the first and third months of treatment and every 3 months thereafter.\n', '\n', '    5.11 Bradycardia\n', '\n', '   oselabeledaefromdruguse in association with thalidomide use has been reported.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
409,thalomid,409,9992,10005,"Cases of  oselabeledaefromdruguse have been reported, some required medical interventions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
410,thalomid,410,10005,10027,The clinical significance and underlying etiology of the  nonoseaeaeonlyasinstruction noted in some thalidomide-treated patients are presently unknown.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
411,thalomid,411,10027,10121,"Monitor patients for  nonoseaeaeonlyasinstruction and  nonoseaemanifestationorcomplication  Dose reduction or discontinuation may be required.\n', '\n', ' Medications known to  nonoseaeaeonlyasinstruction should be used with caution in patients receiving thalidomide [see  Drug Interactions (7.2)  ]  .\n', '\n', '    5.12 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis\n', '\n', '  Serious  oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse  which may be  nonoseaegeneralterm  have been reported.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
412,thalomid,412,10121,10138,THALOMID should be discontinued if a  nonoseaeaeonlyasinstruction occurs and only resumed following appropriate clinical evaluation.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
413,thalomid,413,10138,10234,"If the  nonoseaeaeonlyasinstruction is exfoliative, purpuric, or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction is exfoliative,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction is  nonoseaeaeonlyasinstruction  purpuric, or bullous or if  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction is suspected, use of THALOMID should not be resumed.\n', '\n', '    5.13 Seizures\n', '\n', '  Although not reported from pre-marketing controlled clinical trials,  oselabeledaefromdruguse  including  oselabeledaefromdruguse  have been reported during post-approval use of THALOMID in clinical practice.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,thalomid,414,10234,10255,"Because these events are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
415,thalomid,415,10255,10283,"Most patients had disorders that may have predisposed them to  nonoseaeaeonlyasinstruction activity, and it is not currently known whether thalidomide has any  nonoseaeaeonlyasinstruction influence.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,thalomid,416,10283,10402,"During therapy with thalidomide, patients with a history of  notaecandidatepreexistingconditionorriskfactor or with other risk factors for the development of  nonoseaeaeonlyasinstruction should be monitored closely for clinical changes that could precipitate acute  nonoseaeaeonlyasinstruction activity.\n', '\n', '    5.14  oselabeledaefromdruguse \n', '  Monitor patients at risk of  nonoseaeaeonlyasinstruction (e.g., patients with high  notaecandidatepreexistingconditionorriskfactor burden prior to treatment) and take appropriate precautions.\n', '\n', '    5.15 Contraceptive Risks\n', '\n', '  Some contraceptive methods may pose a higher risk of adverse effects or may be medically contraindicated in some patients treated with THALOMID.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
417,thalomid,417,10402,10450,"Because some patients may develop sudden, severe  nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction  use of an intrauterine device (IUD) or implantable contraception in these patients may carry an increased risk for  nonoseaeaefromdruginteraction or  nonoseaeaefromdruginteraction either at insertion, removal or during use.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
418,thalomid,418,10450,10479,"Treatment with THALOMID, the presence of an underlying  notaecandidatepreexistingconditionorriskfactor  and/or use of an estrogen-containing contraceptive can each increase the risk of  oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
419,thalomid,419,10479,10492,It is not known if these risks of  nonoseaeaeonlyasinstruction are additive.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
420,thalomid,420,10492,10529,"However, they should be taken into consideration when choosing contraceptive methods.\n', '\n', '    5.16 Hypersensitivity\n', '\n', '   oselabeledaefromdruguse to THALOMID has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
421,thalomid,421,10529,10553,Signs and symptoms have included the occurrence of  nonoseaemanifestationorcomplication  possibly associated with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication '],0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,seroquel,0,0,159,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in more detail in other sections of the labeling:\n', '\n', ' *    Increased  nonoseaegeneralterm in elderly patients with  notaecandidatepreexistingconditionorriskfactor [see  Warnings and Precautions (5.1)  ]  \n', ' *     oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect  oselabeledaeclasseffect and behaviors in adolescents and young adults [see  Warnings and Precautions (5.2)  ]  \n', ' *     nonoseaeaefromofflabel  including  nonoseaeaefromofflabel in elderly patients with  notaecandidatepreexistingconditionorriskfactor [see  Warnings and Precautions 5.3  ]  \n', ' *     oselabeledaeclasseffect  [see  Warnings and Precautions 5.4  ]  \n', ' *     oselabeledaeclasseffect ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  [see  Warnings and Precautions 5.  ",0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
1,seroquel,1,159,162,5]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,seroquel,2,162,179,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions 5.6  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,seroquel,3,179,189,"\n', ' *     oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,seroquel,4,189,213,"Warnings and Precautions 5.7  ]  \n', ' *     nonoseaemanifestationorcomplication [see  Warnings and Precautions 5.8  ]  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
5,seroquel,5,213,225,"\n', ' *     oselabeledaefromdruguse (children and adolescents)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,seroquel,6,225,235,[see  Warnings and Precautions 5.9  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,seroquel,7,235,250,"\n', ' *     oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,seroquel,8,250,274,"Warnings and Precautions 5.10    ]  \n', ' *     nonoseaeaeanimal [see  Warnings and Precautions 5.11  ]  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
9,seroquel,9,274,291,"\n', ' *     nonoseaeodorwithdrawal [see  Warnings and Precautions 5.12  ]  ",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
10,seroquel,10,291,301,"\n', ' *     oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,seroquel,11,301,325,"Warnings and Precautions 5.13  ]  \n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions 5.14  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,seroquel,12,325,335,"\n', ' *     oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,seroquel,13,335,346,"Warnings and Precautions 5.15  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,seroquel,14,346,378,"*    Potential for  oselabeledaefromdruguse and motor  oselabeledaefromdruguse  oselabeledaefromdruguse [see  Warnings and Precautions 5.16  ]  \n', ' *     nonoseaeaeforanotherdruginclass [see  ",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
15,seroquel,15,378,402,"Warnings and Precautions 5.17  ]  \n', ' *     oselabeledaeclasseffect [see  Warnings and Precautions 5.18  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,seroquel,16,402,412,"\n', ' *     oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,seroquel,17,412,523,"Warnings and Precautions 5.19  ]  \n', '      EXCERPT:   Most common adverse reactions (incidence >=5% and twice placebo):\n', ' \n', '\n', ' Adults: somnolence, dry mouth, dizziness, constipation, asthenia, abdominal pain, postural hypotension, pharyngitis, weight gain, lethargy, ALT increased, dyspepsia (  6.1  )\n', '\n', ' Children and Adolescents: somnolence, dizziness, fatigue, increased appetite, nausea, vomiting, dry mouth, tachycardia, weight increased (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,seroquel,18,523,559,"\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,seroquel,19,559,588,"\n', '\n', ' \n', '\n', '  6.1 Clinical Study Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,seroquel,20,588,669,"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n', '\n', '   Adults:  \n', '\n', ' The information below is derived from a clinical trial database for SEROQUEL consisting of over 4300 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,seroquel,21,669,804,"This database includes 698 patients exposed to SEROQUEL for the treatment of  notaecandidateindication  405 patients exposed to SEROQUEL for the treatment of acute  notaecandidateindication (monotherapy and adjunct therapy), 646 patients exposed to SEROQUEL for the maintenance treatment of  notaecandidateindication as adjunct therapy, and approximately 2600 patients and/or normal subjects exposed to 1 or more doses of SEROQUEL for the treatment of  notaecandidateindication \n', '\n', ' Of these approximately 4300 subjects, approximately 4000 (2300 in  notaecandidateindication  405 in acute  notaecandidateindication  698 in  notaecandidateindication  and 646 for the maintenance treatment of  notaecandidateindication  were patients who participated in multiple dose effectiveness trials, and their experience corresponded to approximately 2400 patient-years.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
22,seroquel,22,804,855,"The conditions and duration of treatment with SEROQUEL varied greatly and included (in overlapping categories) open-label and double-blind phases of studies, inpatients and outpatients, fixed-dose and dose-titration studies, and short-term or longer-term exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,seroquel,23,855,952,"Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, ECGs, and results of ophthalmologic examinations.\n', '\n', ' The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed.\n', '\n', ' Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials\n', '\n', '    notaecandidateindication   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,seroquel,24,952,985,"Overall, there was little difference in the incidence of discontinuation due to adverse reactions (4% for SEROQUEL vs. 3% for placebo) in a pool of controlled trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,seroquel,25,985,1004,"However, discontinuations due to  oselabeledaefromdruguse (0.8% SEROQUEL vs. 0% placebo) and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,seroquel,26,1004,1037,(0.4% SEROQUEL vs. 0% placebo) were considered to be drug related  [see Warnings and Precautions (  5.7  and  5.19  )].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,seroquel,27,1037,1353,"\n', '\n', '    notaecandidateindication   \n', '\n', '    notaecandidateindication   Overall, discontinuations due to adverse reactions were 5.7% for SEROQUEL vs. 5.1% for placebo in monotherapy and 3.6% for SEROQUEL vs. 5.9% for placebo in adjunct therapy.\n', '\n', '    notaecandidateindication   Overall, discontinuations due to adverse reactions were 12.3% for SEROQUEL 300 mg vs. 19.0% for SEROQUEL 600 mg and 5.2% for placebo.\n', '\n', '   Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials:  \n', '\n', ' In the acute therapy of  notaecandidateindication (up to 6 weeks) and bipolar mania (up to 12 weeks) trials, the most commonly observed adverse reactions associated with the use of SEROQUEL monotherapy (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that of placebo were  oselabeledaefromdruguse (18%),  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (5%), and  oselabeledaefromdruguse (5%).\n', '\n', '   Adverse Reactions Occurring at an Incidence of 2% or More Among SEROQUEL Treated Patients in Short-Term, Placebo-Controlled Trials:  \n', '\n', ' The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
28,seroquel,28,1353,1378,"Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,seroquel,29,1378,1525,"The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence in the population studied.\n', '\n', ' Table 9 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred during acute therapy of  notaecandidateindication (up to 6 weeks) and  notaecandidateindication (up to 12 weeks) in 2% or more of patients treated with SEROQUEL (doses ranging from 75 to 800 mg/day) where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients.\n', '\n', ' Table 9: Adverse Reaction Incidence in 3- to 12-Week Placebo-Controlled Clinical Trials for the Treatment of Schizophrenia and Bipolar Mania",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
30,seroquel,30,1525,1528,(Monotherapy),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,seroquel,31,1528,1546,"\n', '  Preferred Term          SEROQUEL (n=719)         PLACEBO (n=404)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,seroquel,32,1546,1969,"\n', '   oselabeledaefromdruguse                21%                      14%                     \n', '   oselabeledaefromdruguse               20%                      17%                     \n', '   oselabeledaefromdruguse              18%                      8%                      \n', '   oselabeledaefromdruguse               11%                      5%                      \n', '   oselabeledaefromdruguse               9%                       3%                      \n', '   oselabeledaefromdruguse            8%                       3%                      \n', '   oselabeledaefromdruguse                    7%                       5%                      \n', '   oselabeledaefromdruguse             6%                       4%                      \n', '   oselabeledaefromdruguse                6%                       5%                      \n', '   oselabeledaefromdruguse                5%                       3%                      \n', '   oselabeledaefromdruguse               5%                       1%                      \n', '   oselabeledaefromdruguse             5%                       1%                      \n', '   oselabeledaefromdruguse           5%                       1%                      \n', '   oselabeledaefromdruguse                 4%                       3%                      \n', '   oselabeledaefromdruguse             4%                       3%                      \n', '   oselabeledaefromdruguse                    4%                       2%                      \n', '   oselabeledaefromdruguse          4%                       1%                      \n', '   oselabeledaefromdruguse    4%                       1%                      \n', '   oselabeledaefromdruguse               3%                       1%                      \n', '   oselabeledaefromdruguse           3%                       1%                      \n', '   oselabeledaefromdruguse                3%                       1%                      \n', '   oselabeledaefromdruguse                   2%                       1%                      \n', '   oselabeledaefromdruguse         2%                       0%                      \n', '   oselabeledaefromdruguse               2%                       1%                      \n', '         In the acute adjunct therapy of  notaecandidateindication (up to 3 weeks) studies, the most commonly observed adverse reactions associated with the use of SEROQUEL (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that of placebo were  oselabeledaefromdruguse (34%),  oselabeledaefromdruguse (19%),  oselabeledaefromdruguse (10%),  oselabeledaefromdruguse (10%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (6%), and  oselabeledaefromdruguse (6%).\n',",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
33,seroquel,33,1969,2099,"' \n', '\n', ' Table 10 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred during therapy (up to 3 weeks) of  notaecandidateindication in 2% or more of patients treated with SEROQUEL (doses ranging from 100 to 800 mg/day) used as adjunct therapy to lithium and divalproex where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients.\n', '\n', ' Table 10: Adverse Reaction Incidence in 3-Week Placebo-Controlled Clinical Trials for the Treatment of Bipolar Mania (Adjunct Therapy) \n', '  Preferred Term            SEROQUEL  (n=196)    PLACEBO  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
34,seroquel,34,2099,2116,"(n=203)    \n', '   oselabeledaefromdruguse                34%              9%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,seroquel,35,2116,2136,"\n', '   oselabeledaefromdruguse                 19%              3%             \n', '   oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,seroquel,36,2136,2142,17%              13%            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,seroquel,37,2142,2155,"\n', '   oselabeledaefromdruguse                  10%              4%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,seroquel,38,2155,2168,"\n', '   oselabeledaefromdruguse              10%              5%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,seroquel,39,2168,2207,"\n', '   oselabeledaefromdruguse                 9%               6%             \n', '   oselabeledaefromdruguse                    8%               7%             \n', '   oselabeledaefromdruguse            7%               3%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,seroquel,40,2207,2285,"\n', '   oselabeledaefromdruguse      7%               2%             \n', '   oselabeledaefromdruguse                 6%               4%             \n', '   oselabeledaefromdruguse               6%               3%             \n', '   oselabeledaefromdruguse               6%               3%             \n', '   oselabeledaefromdruguse                 5%               3%             \n', '   oselabeledaefromdruguse                4%               3%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,seroquel,41,2285,2350,"\n', '   oselabeledaefromdruguse                  4%               2%             \n', '   oselabeledaefromdruguse          4%               2%             \n', '   oselabeledaefromdruguse                 4%               1%             \n', '   oselabeledaefromdruguse                 4%               3%             \n', '   oselabeledaefromdruguse                3%               2%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,seroquel,42,2350,2402,"\n', '   oselabeledaefromdruguse                 3%               2%             \n', '   oselabeledaefromdruguse           3%               1%             \n', '   oselabeledaefromdruguse               3%               1%             \n', '   oselabeledaefromdruguse     3%               0%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,seroquel,43,2402,2441,"\n', '   oselabeledaefromdruguse                 2%               1%             \n', '   oselabeledaefromdruguse                 2%               1%             \n', '   oselabeledaefromdruguse                     2%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,seroquel,44,2441,2480,"\n', '   oselabeledaefromdruguse              2%               1%             \n', '   oselabeledaefromdruguse               2%               1%             \n', '   oselabeledaefromdruguse        2%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,seroquel,45,2480,2493,"\n', '   oselabeledaefromdruguse            2%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,seroquel,46,2493,2506,"\n', '   oselabeledaefromdruguse            2%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,seroquel,47,2506,2519,"\n', '   oselabeledaefromdruguse         2%               0%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,seroquel,48,2519,2532,"\n', '   oselabeledaefromdruguse                   2%               0%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,seroquel,49,2532,2545,"\n', '   oselabeledaefromdruguse                    2%               0%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,seroquel,50,2545,2571,"\n', '   oselabeledaefromdruguse                 2%               1%             \n', '   oselabeledaefromdruguse                  2%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,seroquel,51,2571,2589,"\n', '   oselabeledaefromdruguse    2%               1%             \n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,seroquel,52,2589,2780,"In  notaecandidateindication studies (up to 8 weeks), the most commonly observed treatment emergent adverse reactions associated with the use of SEROQUEL (incidence of 5% or greater) and observed at a rate on SEROQUEL at least twice that of placebo were  oselabeledaefromdruguse (57%),  oselabeledaefromdruguse (44%),  oselabeledaefromdruguse (18%),  oselabeledaefromdruguse (10%), and  oselabeledaefromdruguse (5%).\n', ' \n', '\n', ' Table 11 enumerates the incidence, rounded to the nearest percent, of adverse reactions that occurred during therapy (up to 8 weeks) of  notaecandidateindication in 2% or more of patients treated with SEROQUEL (doses of 300 and 600 mg/day) where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients.\n', '\n', ' Table 11: Adverse Reaction Incidence in 8-Week Placebo-Controlled Clinical Trials for the Treatment of Bipolar Depression \n', '                                     Preferred Term                   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
53,seroquel,53,2780,2787,"\n', '                                                                        SEROQUEL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,seroquel,54,2787,2795,(n=698)    PLACEBO  (n=347,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,seroquel,55,2795,2848,")    \n', '   oselabeledaefromdruguse  oselabeledaefromdruguse omnolence combines adverse reaction terms  oselabeledaefromdruguse and  oselabeledaefromdruguse    57%              15%            \n', '   oselabeledaefromdruguse                          44%              13%            \n', '   oselabeledaefromdruguse                          18%              7%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,seroquel,56,2848,2874,"\n', '   oselabeledaefromdruguse                       10%              4%             \n', '   oselabeledaefromdruguse                            10%              8%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,seroquel,57,2874,2952,"\n', '   oselabeledaefromdruguse                          7%               4%             \n', '   oselabeledaefromdruguse                           5%               4%             \n', '   oselabeledaefromdruguse                 5%               3%             \n', '   oselabeledaefromdruguse                           5%               2%             \n', '   oselabeledaefromdruguse                   5%               3%             \n', '   oselabeledaefromdruguse            4%               3%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,seroquel,58,2952,2991,"\n', '   oselabeledaefromdruguse                          4%               1%             \n', '   oselabeledaefromdruguse                       4%               1%             \n', '   oselabeledaefromdruguse                     4%               2%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,seroquel,59,2991,3009,"\n', '   oselabeledaefromdruguse                   4%               1%             \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,seroquel,60,3009,3011,oselabeledaefromdruguse                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,seroquel,61,3011,3017,3%               2%             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,seroquel,62,3017,3043,"\n', '   oselabeledaefromdruguse                       3%               2%             \n', '   oselabeledaefromdruguse                              3%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,seroquel,63,3043,3056,"\n', '   oselabeledaefromdruguse            3%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,seroquel,64,3056,3076,"\n', '   oselabeledaefromdruguse                       3%               1%             \n', '   oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,seroquel,65,3076,3082,3%               0%             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,seroquel,66,3082,3154,"\n', '   oselabeledaefromdruguse                        3%               0%             \n', '   oselabeledaefromdruguse                   2%               1%             \n', '   oselabeledaefromdruguse                    2%               1%             \n', '   oselabeledaefromdruguse                             2%               1%             \n', '   oselabeledaefromdruguse    2%               1%             \n', '   oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,seroquel,67,3154,3160,2%               1%             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,seroquel,68,3160,3173,"\n', '   oselabeledaefromdruguse                           2%               1%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,seroquel,69,3173,3212,"\n', '   oselabeledaefromdruguse                   2%               1%             \n', '   oselabeledaefromdruguse                       2%               1%             \n', '   oselabeledaefromdruguse                          2%               0%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,seroquel,70,3212,3225,"\n', '   oselabeledaefromdruguse             2%               0%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,seroquel,71,3225,3273,"\n', '         Explorations for interactions on the basis of gender, age, and race did not reveal any clinically meaningful differences in the adverse reaction occurrence on the basis of these demographic factors.\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,seroquel,72,3273,3350,"Dose Dependency of Adverse Reactions in Short-Term, Placebo-Controlled Trials\n', '\n', '   Dose-related Adverse Reactions:  Spontaneously elicited adverse reaction data from a study of  notaecandidateindication comparing five fixed doses of SEROQUEL (75 mg, 150 mg, 300 mg, 600 mg, and 750 mg/day) to placebo were explored for dose-relatedness of adverse reactions.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
73,seroquel,73,3350,3529,"Logistic regression analyses revealed a positive dose response (p<0.05) for the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', ' Adverse Reactions in clinical trials with quetiapine and not listed elsewhere in the label:\n', '\n', ' The following adverse reactions have also been reported with quetiapine:  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse (not associated with  nonoseaenegation ,  oselabeledaefromdruguse   oselabeledaefromdruguse (which may occur at or near initiation of treatment and be associated with  oselabeledaefromdruguse and/ or  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse (and other related events),  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '  oselabeledaeclasseffect :\n', '\n', '   Dystonia  \n', '\n', '   Class Effect:  Symptoms of  oselabeledaeclasseffect   oselabeledaefromdruguse  may occur in susceptible individuals during the first few days of treatment.  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
74,seroquel,74,3529,3579,"nonoseaeaeonlyasinstruction include:  nonoseaemanifestationorcomplication  sometimes progressing to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication  While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
75,seroquel,75,3579,3631,"An elevated risk of  nonoseaeaeonlyasinstruction is observed in males and younger age groups.\n', '\n', ' Four methods were used to measure  nonoseaeaeonlyasinstruction  (1) Simpson-Angus total score (mean change from baseline) which evaluates  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,seroquel,76,3631,3642,(2) Barnes  nonoseaeaeonlyasinstruction Rating Scale (BARS),1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,seroquel,77,3642,3753,"Global Assessment Score, (3) incidence of spontaneous complaints of  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction , and (4) use of anticholinergic medications to treat emergent  nonoseaeaeonlyasinstruction \n', '\n', '   Adults:  Data from one 6-week clinical trial of  notaecandidateindication comparing five fixed doses of SEROQUEL (75, 150, 300, 600, 750 mg/day) provided evidence for the lack of treatment-emergent  nonoseaenegation  and dose-relatedness for  nonoseaenegation associated with SEROQUEL treatment.",1,0,0,1,0,0,0,1,0,0,0,0,0,0,0
78,seroquel,78,3753,3980,"Three methods were used to measure  nonoseaeaeonlyasinstruction  (1) Simpson-Angus total score (mean change from baseline) which evaluates  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  (2) incidence of spontaneous complaints of  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction , and (3) use of anticholinergic medications to treat emergent  nonoseaeaeonlyasinstruction \n', '\n', ' In Table 12,  nonoseaeaeratelteqplacebo included  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo included  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo included  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo included  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and other  nonoseaeaeratelteqplacebo included  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo \n', '\n', ' Table 12: Adverse Reactions Associated with EPS in a Short-Term, Placebo-Controlled Multiple Fixed-Dose Phase III Schizophrenia Trial (6 weeks duration) \n', '  Preferred Term            SEROQUEL  75 mg/day  (N=53)    SEROQUEL  150 mg/day  (N=48)    SEROQUEL  300 mg/day  (N=52)    SEROQUEL  600 mg/day  (N=51)    ",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
79,seroquel,79,3980,3991,SEROQUEL  750 mg/day  (N=54)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,seroquel,80,3991,3997,Placebo  (N=51)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,seroquel,81,3997,4026,"\n', '                            n      %         n      %         n      %         n      %         n      %         n     %      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,seroquel,82,4026,4057,"\n', '   nonoseaeaeratelteqplacebo            2      3.8       2      4.2       0      0.0       2      3.9       3      5.6       4     7.8    ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
83,seroquel,83,4057,4097,"\n', '   nonoseaeaeratelteqplacebo              2      3.8       0      0.0       1      1.9       1      2.0       1      1.9       4     7.8    \n', '   nonoseaeaeratelteqplacebo                 1      ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
84,seroquel,84,4097,4159,"1.9       1      2.1       0      0.0       0      0.0       1      1.9       4     7.8    \n', '   nonoseaeaeratelteqplacebo          2      3.8       0      0.0       0      0.0       1      2.0       0      0.0       0     0.0    \n', '  Other  nonoseaeaeratelteqplacebo    ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
85,seroquel,85,4159,4184,2      3.8       0      0.0       3      5.8       3      5.9       1      1.9       4     7.8    \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,seroquel,86,4184,4223,"', '                    nonoseaeaeonlyasinstruction incidence rates as measured by the Simpson-Angus total score for placebo and the five fixed doses (75, 150, 300, 600, 750 mg/day) were:",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,seroquel,87,4223,4235,"-0.6; -1.0, -1.2; -1.6; -1.8 and -1.8.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,seroquel,88,4235,4406,"The rate of anticholinergic medication use to treat emergent  nonoseaeaeonlyasinstruction for placebo and the five fixed doses was: 14%; 11%; 10%; 8%; 12% and 11%.\n', ' \n', '\n', ' In six additional placebo-controlled clinical trials (3 in acute  notaecandidateindication and 3 in  notaecandidateindication  using variable doses of SEROQUEL, there were no differences between the SEROQUEL and placebo treatment groups in the incidence of  nonoseaeaeratelteqplacebo  as assessed by Simpson-Angus total scores, spontaneous complaints of  nonoseaeaeonlyasinstruction and the use of concomitant anticholinergic medications to treat  nonoseaeaeonlyasinstruction \n', '\n', ' In two placebo-controlled clinical trials for the treatment of  notaecandidateindication using 300 mg and 600 mg of SEROQUEL, the incidence of adverse reactions potentially related to  oselabeledaefromdruguse was 12% in both dose groups and 6% in the placebo group.",1,0,0,1,0,0,1,0,0,0,0,0,0,0,0
89,seroquel,89,4406,4481,"In these studies, the incidence of the individual adverse reactions ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  were generally low and did not exceed 4% in any treatment group.\n', '\n', ' The 3 treatment groups were similar in mean change in SAS total score and BARS Global Assessment score at the end of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,seroquel,90,4481,4535,"The use of concomitant anticholinergic medications was infrequent and similar across the three treatment groups.\n', '\n', '   Children and Adolescents  \n', '\n', ' The information below is derived from a clinical trial database for SEROQUEL consisting of over 1000 pediatric patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,seroquel,91,4535,4605,"This database includes 677 patients exposed to SEROQUEL for the treatment of  notaecandidateindication and 393 children and adolescents (10-17 years old) exposed to SEROQUEL for the treatment of acute  notaecandidateindication \n', '\n', ' Adverse Reactions Associated with Discontinuation of Treatment in Short-Term, Placebo-Controlled Trials\n', '\n', '  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
92,seroquel,92,4605,4631,"The incidence of discontinuation due to adverse reactions for quetiapine-treated and placebo-treated patients was 8.2% and 2.7%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,seroquel,93,4631,4674,"The adverse event leading to discontinuation in 1% or more of patients on SEROQUEL and at a greater incidence than placebo was  oselabeledaefromdruguse (2.7% and 0% for placebo).\n', '\n', '  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
94,seroquel,94,4674,4700,"The incidence of discontinuation due to adverse reactions for quetiapine-treated and placebo-treated patients was 11.4% and 4.4%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,seroquel,95,4700,4819,"The adverse reactions leading to discontinuation in 2% or more of patients on SEROQUEL and at a greater incidence than placebo were  oselabeledaefromdruguse (4.1% vs. 1.1%) and  oselabeledaefromdruguse (2.1% vs. 0).\n', '\n', ' Commonly Observed Adverse Reactions in Short-Term, Placebo-Controlled Trials\n', '\n', ' In therapy for  notaecandidateindication (up to 6 weeks), the most commonly observed adverse reactions associated with the use of quetiapine in adolescents (incidence of 5% or greater and quetiapine incidence at least twice that for placebo) were  oselabeledaefromdruguse (34%),  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
96,seroquel,96,4819,5024,"oselabeledaefromdruguse (12%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (7%).\n', '\n', ' In  notaecandidateindication therapy (up to 3 weeks) the most commonly observed adverse reactions associated with the use of quetiapine in children and adolescents (incidence of 5% or greater and quetiapine incidence at least twice that for placebo) were  oselabeledaefromdruguse (53%),  oselabeledaefromdruguse (18%),  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (7%), and  oselabeledaefromdruguse (6%).\n', '\n', ' In an acute (8-week) SEROQUEL XR trial in children and adolescents (10-17 years of age) with  notaecandidateindication  in which efficacy was not established, the most commonly observed adverse reactions associated with the use of SEROQUEL XR (incidence of 5% or greater and at least twice that for placebo) were  oselabeledaefromdruguse (7%),  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
97,seroquel,97,5024,5131,"oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (5%) and  oselabeledaefromdruguse (5%).\n', '\n', '   Adverse Reactions Occurring at an Incidence of >= 2% among SEROQUEL Treated Patients in Short-Term, Placebo-Controlled Trials  \n', '\n', '    notaecandidateindication (Adolescents, 13- 17 years old)  \n', '\n', ' The following findings were based on a 6-week placebo-controlled trial in which quetiapine was administered in either doses of 400 or 800 mg/day.\n', '",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
98,seroquel,98,5131,5265,"\n', ' Table 13 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during therapy (up to 6 weeks) of  notaecandidateindication in 2% or more of patients treated with SEROQUEL (doses of 400 or 800 mg/day) where the incidence in patients treated with SEROQUEL was at least twice the incidence in placebo-treated patients.\n', '\n', ' Adverse events that were potentially dose-related with higher frequency in the 800 mg group compared to the 400 mg group included  oselabeledaefromdruguse (8% vs. 15%),  oselabeledaefromdruguse (4% vs. 10%), and  oselabeledaefromdruguse (6% vs. 11%).\n',",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
99,seroquel,99,5265,5300,"'\n', ' Table 13: Adverse Reaction Incidence in a 6-Week Placebo-Controlled Clinical Trial for the Treatment of Schizophrenia in Adolescent Patients \n', '  Preferred Term      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,seroquel,100,5300,5308,SEROQUEL 400 mg  (n=73)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,seroquel,101,5308,5321,SEROQUEL800 mg  (n=74)    Placebo  (n=75)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,seroquel,102,5321,5365,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse omnolence combines adverse reaction terms  oselabeledaefromdruguse and  oselabeledaefromdruguse     33%                      35%              11%         \n', '   oselabeledaefromdruguse           8%                       15%              5%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,seroquel,103,5365,5381,"\n', '   oselabeledaefromdruguse           4%                       10%              1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,seroquel,104,5381,5409,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse achycardia combines adverse reaction terms  oselabeledaefromdruguse and  oselabeledaefromdruguse     6%                       11%              0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,seroquel,105,5409,5425,"\n', '   oselabeledaefromdruguse        3%                       5%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,seroquel,106,5425,5457,"\n', '   oselabeledaefromdruguse          1%                       3%               0%          \n', '   oselabeledaefromdruguse            1%                       3%               1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,seroquel,107,5457,5473,"\n', '   oselabeledaefromdruguse           1%                       3%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,seroquel,108,5473,5489,"\n', '   oselabeledaefromdruguse             0%                       3%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,seroquel,109,5489,5505,"\n', '   oselabeledaefromdruguse      3%                       1%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,seroquel,110,5505,5521,"\n', '   oselabeledaefromdruguse            3%                       1%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,seroquel,111,5521,5553,"\n', '   oselabeledaefromdruguse       3%                       1%               0%          \n', '   oselabeledaefromdruguse          3%                       0%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,seroquel,112,5553,5569,"\n', '   oselabeledaefromdruguse           3%                       0%               1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,seroquel,113,5569,5585,"\n', '   oselabeledaefromdruguse     3%                       0%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,seroquel,114,5585,5616,"\n', '            Bipolar I Mania (Children and Adolescents 10 to 17 years old)  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,seroquel,115,5616,5962,"The following findings were based on a 3-week placebo-controlled trial in which quetiapine was administered in either doses of 400 or 600 mg/day.\n', '\n', ' Commonly Observed Adverse Reactions\n', '\n', ' In  notaecandidateindication therapy (up to 3 weeks) the most commonly observed adverse reactions associated with the use of quetiapine in children and adolescents (incidence of 5% or greater and quetiapine incidence at least twice that for placebo) were  oselabeledaefromdruguse (53%),  oselabeledaefromdruguse (18%),  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (7%), and  oselabeledaefromdruguse (6%).\n', '\n', ' Table 14 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during therapy (up to 3 weeks) of  notaecandidateindication in 2% or more of patients treated with SEROQUEL (doses of 400 or 600 mg/day) where the incidence in patients treated with SEROQUEL was greater than the incidence in placebo-treated patients.\n', '\n', ' Adverse events that were potentially dose-related with higher frequency in the 600 mg group compared to the 400 mg group included  oselabeledaefromdruguse (50% vs. 57%),  oselabeledaefromdruguse (6% vs. 10%) and  oselabeledaefromdruguse (6% vs. 9%).\n', '\n', ' Table 14: Adverse Reactions in a 3-Week Placebo-Controlled Clinical Trial for the Treatment of Bipolar Mania in Children and Adolescent Patients \n', '  Preferred Term              SEROQUEL  400 mg  (n=95)    SEROQUEL  600 mg  (n=98)    Placebo  (n=90)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
116,seroquel,116,5962,6082,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse omnolence combines adverse reactions terms  oselabeledaefromdruguse and  oselabeledaefromdruguse     50%              57%              14%         \n', '   oselabeledaefromdruguse                   19%              17%              2%          \n', '   oselabeledaefromdruguse                      6%               10%              4%          \n', '   oselabeledaefromdruguse                     14%              9%               4%          \n', '   oselabeledaefromdruguse          10%              9%               1%          \n', '   oselabeledaefromdruguse  oselabeledaefromdruguse achycardia combines adverse reaction terms  oselabeledaefromdruguse and  oselabeledaefromdruguse     6%               9%               1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,seroquel,117,6082,6130,"\n', '   oselabeledaefromdruguse                   7%               7%               0%          \n', '   oselabeledaefromdruguse                    8%               7%               3%          \n', '   oselabeledaefromdruguse            3%               6%               2%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,seroquel,118,6130,6146,"\n', '   oselabeledaefromdruguse            6%               6%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,seroquel,119,6146,6162,"\n', '   oselabeledaefromdruguse                3%               5%               1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,seroquel,120,6162,6178,"\n', '   oselabeledaefromdruguse                     1%               4%               1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,seroquel,121,6178,6194,"\n', '   oselabeledaefromdruguse                  1%               3%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,seroquel,122,6194,6226,"\n', '   oselabeledaefromdruguse    1%               3%               1%          \n', '   oselabeledaefromdruguse         0%               2%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,seroquel,123,6226,6242,"\n', '   oselabeledaefromdruguse                        3%               2%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,seroquel,124,6242,6258,"\n', '   oselabeledaefromdruguse                  4%               2%               1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,seroquel,125,6258,6274,"\n', '   oselabeledaefromdruguse                    2%               2%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,seroquel,126,6274,6290,"\n', '   oselabeledaefromdruguse                      1%               2%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,seroquel,127,6290,6322,"\n', '   oselabeledaefromdruguse          4%               2%               1%          \n', '   oselabeledaefromdruguse                     2%               2%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,seroquel,128,6322,6354,"\n', '   oselabeledaefromdruguse              3%               2%               0%          \n', '   oselabeledaefromdruguse                4%               2%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,seroquel,129,6354,6370,"\n', '   oselabeledaefromdruguse                    2%               0%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,seroquel,130,6370,6386,"\n', '   oselabeledaefromdruguse                 2%               0%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,seroquel,131,6386,6402,"\n', '   oselabeledaefromdruguse            3%               0%               0%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,seroquel,132,6402,6436,"\n', '   oselabeledaefromdruguse                      2%               0%               0%          \n', '            Extrapyramidal Symptoms:  \n', ' \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,seroquel,133,6436,6518,"', ' In a short-term placebo-controlled monotherapy trial in adolescent patients with  notaecandidateindication (6-week duration), the aggregated incidence of  oselabeledaefromdruguse was 12.9% (19/147) for SEROQUEL and 5.3% (4/75) for placebo, though the incidence of the individual adverse events ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  did not exceed 4.1% in any treatment group.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
134,seroquel,134,6518,6725,"In a short-term placebo-controlled monotherapy trial in children and adolescent patients with  notaecandidateindication (3-week duration), the aggregated incidence of  oselabeledaefromdruguse was 3.6% (7/193) or SEROQUEL and 1.1% (1/90) for placebo.\n', '\n', ' Table 15 presents a listing of patients with adverse reactions potentially associated with  oselabeledaefromdruguse in the short-term placebo-controlled monotherapy trial in adolescent patients with  notaecandidateindication (6-week duration).\n', '\n', ' In Tables 15 - 16  oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   oselabeledaefromdruguse included  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse included  oselabeledaefromdruguse only  oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  and other  oselabeledaefromdruguse included  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', ' Table 15: Adverse Reactions Associated with Extrapyramidal Symptoms in the Placebo-Controlled Trial in Adolescent Patients with Schizophrenia (6-week duration) \n', '  Preferred Term                SEROQUEL  400 mg/day  (N=73)    SEROQUEL  800 mg/day  (N=74)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
135,seroquel,135,6725,6739,All  SEROQUEL  (N=147)    Placebo  (N=75)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,seroquel,136,6739,6740,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,seroquel,137,6740,6746,"', '                                n       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,seroquel,138,6746,6760,%          n       %          n       %          n     %       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,seroquel,139,6760,6769,"\n', '   oselabeledaefromdruguse                2       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,seroquel,140,6769,6773,2.7        0       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,seroquel,141,6773,6842,"0.0        2       1.4        0     0.0     \n', '   oselabeledaefromdruguse                  4       5.5        4       5.4        8       5.4        2     2.7     \n', '   oselabeledaefromdruguse                     3       4.1        4       5.4        7       4.8        3     4.0     \n', '   oselabeledaefromdruguse              2       2.7        0       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,seroquel,142,6842,6850,0.0        2       1.4        0     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,seroquel,143,6850,6867,"0.0     \n', '  Other  oselabeledaefromdruguse    2       2.7        2       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,seroquel,144,6867,6875,2.7        4       2.7        0     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,seroquel,145,6875,6927,"0.0     \n', '               Table 16 presents a listing of patients with adverse reactions associated with  nonoseaeaeonlyasinstruction in a short-term placebo-controlled monotherapy trial in children and adolescent patients with  notaecandidateindication (3-week duration).\n', ' \n', '\n',",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
146,seroquel,146,6927,6961,"' Table 16: Adverse Reactions Associated with Extrapyramidal Symptoms in a Placebo-Controlled Trial in Children and Adolescent Patients with Bipolar I Mania (3-week duration) \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,seroquel,147,6961,7000,Preferred TermThere were no adverse experiences with the preferred term of  nonoseaenegation or  nonoseaenegation     SEROQUEL  400 mg/day  (N=95)    SEROQUEL  600 mg/day  (N=98)    ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
148,seroquel,148,7000,7013,All SEROQUEL  (N=193)    Placebo  (N=90)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,seroquel,149,7013,7053,"\n', '                       n       %          n       %          n         %            n     %       \n', '   oselabeledaefromdruguse         2       2.1        1       1.0        3         1.6          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,seroquel,150,7053,7055,1     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,seroquel,151,7055,7078,"1.1     \n', '   oselabeledaefromdruguse            1       1.0        1       1.0        2         1.0          0     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,seroquel,152,7078,7089,"0.0     \n', '  Other   oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,seroquel,153,7089,7099,1       1.1        1       1.0        2         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,seroquel,154,7099,7103,1.0          0     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,seroquel,155,7103,7110,"0.0     \n', '                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,seroquel,156,7110,7123,Other Adverse Reactions Observed During the Pre-Marketing Evaluation of SEROQUEL  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,seroquel,157,7123,7194,"\n', ' \n', '\n', ' Following is a list of COSTART terms that reflect treatment-emergent adverse reactions as defined in the introduction to the ADVERSE REACTIONS section reported by patients treated with SEROQUEL at multiple doses  >  75 mg/day during any phase of a trial within the premarketing database of approximately 2200 patients treated for  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
158,seroquel,158,7194,7234,"All reported reactions are included except those already listed in the tables or elsewhere in labeling, those reactions for which a drug cause was remote, and those reaction terms which were so general as to be uninformative.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,seroquel,159,7234,7423,"It is important to emphasize that, although the reactions reported occurred during treatment with SEROQUEL, they were not necessarily caused by it.\n', '\n', ' Reactions are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse reactions are those occurring in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse reactions are those occurring in 1/100 to 1/1000 patients; rare reactions are those occurring in fewer than 1/1000 patients.\n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
160,seroquel,160,7423,7458,"\n', '\n', '    nonoseaegeneralterm   Frequent:     oselabeledaefromdruguse     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
161,seroquel,161,7458,7462,Rare:     oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,seroquel,162,7462,7517,"\n', '\n', '    nonoseaegeneralterm   Frequent:     oselabeledaefromdruguse     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
163,seroquel,163,7517,7526,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,seroquel,164,7526,7528,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,seroquel,165,7528,7565,"oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
166,seroquel,166,7565,7585,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,seroquel,167,7585,7612,"\n', '\n', '    nonoseaegeneralterm   Frequent:     oselabeledaefromdruguse   oselabeledaefromdruguse     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,seroquel,168,7612,7618,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,seroquel,169,7618,7648,"\n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
170,seroquel,170,7648,7657,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,seroquel,171,7657,7659,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,seroquel,172,7659,7688,"oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
173,seroquel,173,7688,7695,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,seroquel,174,7695,7711,"oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
175,seroquel,175,7711,7714,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,seroquel,176,7714,7758,"Adjusted for gender.] ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,seroquel,177,7758,7786,"\n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,seroquel,178,7786,7793,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,seroquel,179,7793,7821,"oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
180,seroquel,180,7821,7849,"\n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
181,seroquel,181,7849,7855,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,seroquel,182,7855,7873,"\n', '\n', '    nonoseaegeneralterm   Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
183,seroquel,183,7873,7877,Rare:     oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,seroquel,184,7877,7878,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,seroquel,185,7878,7928,"', '\n', '   Laboratory, ECG and vital sign changes observed in clinical studies  \n', '\n', ' Laboratory Changes:\n', '\n', ' Neutrophil Counts\n', '\n', '   Adults  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,seroquel,186,7928,8002,"In placebo-controlled monotherapy clinical trials involving 3368 patients on quetiapine fumarate and 1515 on placebo, the incidence of at least one occurrence of  oselabeledaefromdruguse among patients with a normal baseline neutrophil count and at least one available follow up laboratory measurement was 0.3% (10/2967) in patients treated with quetiapine fumarate, compared to 0.1% (2/1349) in patients treated with placebo  [see      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,seroquel,187,8002,8012,Warnings and Precautions (5.10)      ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,seroquel,188,8012,8033,"\n', '\n', ' Transaminase Elevations\n', '\n', '   Adults  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,seroquel,189,8033,8057,"Asymptomatic, transient and reversible  oselabeledaefromdruguse in serum transaminases (primarily  oselabeledaefromdruguse  oselabeledaefromdruguse (primarily ALT) have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,seroquel,190,8057,8113,"In  notaecandidateindication trials in adults, the proportions of patients with  oselabeledaefromdruguse of > 3 times the upper limits of the normal reference range in a pool of 3- to 6-week placebo-controlled trials were approximately 6% (29/483) for SEROQUEL compared to 1% (3/194) for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
191,seroquel,191,8113,8167,"In acute  notaecandidateindication trials in adults, the proportions of patients with  nonoseaeaeratelteqplacebo of > 3 times the upper limits of the normal reference range in a pool of 3- to 12-week placebo-controlled trials were approximately 1% for both SEROQUEL (3/560) and placebo (3/294).",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
192,seroquel,192,8167,8194,These  oselabeledaefromdruguse usually occurred within the first 3 weeks of drug treatment and promptly returned to pre-study levels with ongoing treatment with SEROQUEL.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,seroquel,193,8194,8261,"In  notaecandidateindication trials, the proportions of patients with  nonoseaeaeratelteqplacebo of > 3 times the upper limits of the normal reference range in two 8-week placebo-controlled trials was 1% (5/698) for SEROQUEL and 2% (6/347) for placebo.\n', '\n', ' Decreased Hemoglobin\n', '\n', '   Adults  :",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
194,seroquel,194,8261,8318,"In short-term placebo-controlled trials,  oselabeledaefromdruguse to <= 13 g/dL males, <= 12 g/dL females on at least one occasion occurred in 8.3% (594/7155) of quetiapine-treated patients compared to 6.2% (219/3536) of patients treated with placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,seroquel,195,8318,8402,"In a database of controlled and uncontrolled clinical trials,  oselabeledaefromdruguse to <= 13 g/dL males, <= 12 g/dL females on at least one occasion occurred in 11% (2277/20729) of quetiapine-treated patients.\n', '\n', ' Interference with Urine Drug Screens\n', '\n', ' There have been literature reports suggesting  oselabeledaefromdruguse for methadone and tricyclic antidepressants in patients who have taken quetiapine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,seroquel,196,8402,8511,"Caution should be exercised in the interpretation of  oselabeledaefromdruguse for these drugs, and confirmation by alternative analytical technique (e.g., chromatographic methods) should be considered.\n', '\n', ' ECG Changes\n', '\n', ""   Adults:  Between-group comparisons for pooled placebo-controlled trials revealed no statistically significant SEROQUEL/placebo differences in the proportions of patients experiencing potentially important  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo ECG parameters, including  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo ECG parameters, including QT,  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo ECG parameters, including QT, QTc, and  nonoseaeaeratelteqplacebo  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
197,seroquel,197,8511,8562,"However, the proportions of patients meeting the criteria for  oselabeledaefromdruguse were compared in four 3- to 6-week placebo-controlled clinical trials for the treatment of  notaecandidateindication revealing a 1% (4/399) incidence for SEROQUEL compared to 0.6% (1/156) incidence for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
198,seroquel,198,8562,8599,In acute (monotherapy)  notaecandidateindication trials the proportions of patients meeting the criteria for  oselabeledaefromdruguse was 0.5% (1/192) for SEROQUEL compared to 0% (0/178) incidence for placebo.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
199,seroquel,199,8599,8634,In acute  notaecandidateindication (adjunct) trials the proportions of patients meeting the same criteria was 0.6% (1/166) for SEROQUEL compared to 0% (0/171) incidence for placebo.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
200,seroquel,200,8634,8651,"In  notaecandidateindication trials, no patients had  nonoseaenegation to > 120 beats per minute.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
201,seroquel,201,8651,8684,"SEROQUEL use was associated with a mean  oselabeledaefromdruguse  assessed by ECG, of 7 beats per minute compared to a mean increase of 1 beat per minute among placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,seroquel,202,8684,8717,This slight tendency to  nonoseaeaeonlyasinstruction in adults may be related to SEROQUEL's potential for inducing  oselabeledaefromdruguse  [see      Warnings and Precautions (5.7)      ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,seroquel,203,8717,8731,"\n"", '\n', '   Children and Adolescents:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,seroquel,204,8731,8788,"In the acute (6 week)  notaecandidateindication trial in adolescents,  oselabeledaefromdruguse (> 110 bpm) occurred in 5.2% (3/73) of patients receiving SEROQUEL 400 mg and 8.5% (5/74) of patients receiving SEROQUEL 800 mg compared to 0% (0/75) of patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
205,seroquel,205,8788,8833,"Mean  oselabeledaefromdruguse were 3.8 bpm and 11.2 bpm for SEROQUEL 400 mg and 800 mg groups, respectively, compared to a decrease of 3.3 bpm in the placebo group  [see      Warnings and Precautions (5.7)      ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,seroquel,206,8833,8838,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,seroquel,207,8838,8900,"', ' In the acute (3 week)  notaecandidateindication trial in children and adolescents,  oselabeledaefromdruguse (> 110 bpm) occurred in 1.1% (1/89) of patients receiving SEROQUEL 400 mg and 4.7% (4/85) of patients receiving SEROQUEL 600 mg compared to 0% (0/98) of patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
208,seroquel,208,8900,8945,"Mean  oselabeledaefromdruguse were 12.8 bpm and 13.4 bpm for SEROQUEL 400 mg and 600 mg groups, respectively, compared to a decrease of 1.7 bpm in the placebo group  [see      Warnings and Precautions (5.7)      ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,seroquel,209,8945,9018,"\n', '\n', ' In an acute (8-week) SEROQUEL XR trial in children and adolescents (10-17 years of age) with  notaecandidateindication  in which efficacy was not established,  oselabeledaefromdruguse (> 110 bpm 10-12 years and 13-17 years) occurred in 0% of patients receiving SEROQUEL XR and 1.2% of patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
210,seroquel,210,9018,9020,Mean  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,seroquel,211,9020,9040,"oselabeledaefromdruguse were 3.4 bpm for SEROQUEL XR, compared to 0.3 bpm in the placebo group  [see      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,seroquel,212,9040,9050,Warnings and Precautions (5.7)      ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,seroquel,213,9050,9082,"\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions were identified during post approval of SEROQUEL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,seroquel,214,9082,9162,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' Adverse reactions reported since market introduction which were temporally related to quetiapine therapy include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse , and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,seroquel,215,9162,9163,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,seroquel,216,9163,9174,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,seroquel,217,9174,9239,"WARNING:  INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '  WARNING:  INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '      Increased Mortality in Elderly Patients with Dementia-Related Psychosis    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,seroquel,218,9239,9279,"\n', '\n', '   Elderly patients with  notaecandidatepreexistingconditionorriskfactor treated with antipsychotic drugs are at an increased risk of  nonoseaegeneralterm   [see   Warnings and Precautions (5.1)  ].   ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
219,seroquel,219,9279,9304,SEROQUEL is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor [see   Warnings and Precautions (5.1)  ].  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
220,seroquel,220,9304,9356,"\n', '\n', '     Suicidal Thoughts and Behaviors    \n', '\n', '   Antidepressants increased the risk of  oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior in children, adolescents, and young adults in short-term studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,seroquel,221,9356,9415,These studies did not show an increase in the risk of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older   [see   Warnings and Precautions (5.2)  ].     ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,seroquel,222,9415,9454,"\n', '\n', '   In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,seroquel,223,9454,9542,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *     Cerebrovascular Adverse Reactions: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) has been seen in elderly patients with dementia-related psychoses treated with atypical antipsychotic drugs  (5.3)   \n', ' *     Neuroleptic Malignant Syndrome (NMS): Manage with immediate discontinuation and close monitoring  (5.4)   \n', ' *    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,seroquel,224,9542,9551,*    Hyperglycemia and Diabetes Mellitus:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,seroquel,225,9551,9567,"Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,seroquel,226,9567,9589,"Monitor glucose regularly in patients with diabetes or at risk for diabetes \n', ' *    Dyslipidemia:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,seroquel,227,9589,9601,Undesirable alterations have been observed in patients treated with atypical antipsychotics.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,seroquel,228,9601,9664,"Appropriate clinical monitoring is recommended, including fasting blood lipid testing at the beginning of, and periodically, during treatment \n', ' *    Weight Gain: Gain in body weight has been observed; clinical monitoring of weight is recommended \n', '    Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,seroquel,229,9664,9844,"These metabolic changes include hyperglycemia, dyslipidemia, and weight gain  (5.5)   \n', ' *     Tardive Dyskinesia: Discontinue if clinically appropriate  (5.6)   \n', ' *     Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease  (5.7)   \n', ' *     Increased Blood Pressure in Children and Adolescents: Monitor blood pressure at the beginning of, and periodically during treatment in children and adolescents  (5.9)   \n', ' *     Leukopenia, Neutropenia and Agranulocytosis: Monitor complete blood count frequently during the first few months of treatment in patients with a pre-existing low white cell count or a history of leukopenia/neutropenia and discontinue SEROQUEL at the first sign of a decline in WBC in absence of other causative factors  (5.10)   \n', ' *     Cataracts: Lens changes have been observed in patients during long-term quetiapine treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,seroquel,230,9844,9969,"Lens examination is recommended when starting treatment and at 6-month intervals during chronic treatment  (5.11)   \n', '    \n', ' \n', '\n', '   5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis\n', '\n', '  Elderly patients with  notaecandidatepreexistingconditionorriskfactor treated with antipsychotic drugs are at an increased risk of  nonoseaegeneralterm  Analysis of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of  nonoseaegeneralterm in drug-treated patients of between 1.6 to 1.7 times the risk of  nonoseaegeneralterm in placebo-treated patients.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
231,seroquel,231,9969,10007,"Over the course of a typical 10-week controlled trial, the rate of  nonoseaegeneralterm in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
232,seroquel,232,10007,10054,"Although the causes of  nonoseaegeneralterm were varied, most of the  nonoseaeaefromofflabel appeared to be either  nonoseaeaefromofflabel  nonoseaegeneralterm appeared to be either cardiovascular (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction  in nature.",1,1,0,0,0,0,0,0,0,0,1,0,0,0,0
233,seroquel,233,10054,10108,"Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase  nonoseaegeneralterm  The extent to which the findings of increased  nonoseaegeneralterm in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
234,seroquel,234,10108,10206,"SEROQUEL is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor [ see Boxed Warning  ].\n', '\n', '    5.2 Suicidal Thoughts and Behaviors in Adolescents and Young Adults\n', '\n', '  Patients with  notaecandidateindication , both adult and pediatric, may experience  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
235,seroquel,235,10206,10232,nonoseaeaeonlyasinstruction is a known risk of  nonoseaeaeonlyasinstruction and certain other  nonoseaeaeonlyasinstruction  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,seroquel,236,10232,10269,"There has been a long-standing concern, however, that antidepressants may have a role in inducing  nonoseaeaeonlyasinstruction and the emergence of  nonoseaeaeonlyasinstruction in certain patients during the early phases of treatment.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,seroquel,237,10269,10419,"Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior ( oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an increase in the risk of  nonoseaeaeonlyasinstruction with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.\n', '\n', ' The pooled analyses of placebo-controlled trials in children and adolescents with  notaecandidateindication   notaecandidatepreexistingconditionorriskfactor , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
238,seroquel,238,10419,10461,"The pooled analyses of placebo-controlled trials in adults with  notaecandidateindication or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
239,seroquel,239,10461,10492,"There was considerable variation in risk of  nonoseaeaeonlyasinstruction  oselabeledaefromdruguse among drugs, but a tendency toward an  oselabeledaefromdruguse in the younger patients for almost all drugs studied.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,seroquel,240,10492,10514,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across the different indications, with the highest incidence in  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
241,seroquel,241,10514,10535,"The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,seroquel,242,10535,10560,These risk differences (drug-placebo difference in the number of cases of  nonoseaeaeonlyasinstruction per 1000 patients treated) are provided in Table,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,seroquel,243,10560,10561,2.\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,seroquel,244,10561,10607,"', '\n', ' Table 2: Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated \n', '  Age Range      Drug-Placebo Difference in Number of Cases of  oselabeledaeclasseffect per 1000 Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,seroquel,245,10607,10631,"Treated     \n', '                  oselabeledaeclasseffect Compared to Placebo                                                           \n', '  <18            14 additional cases                                                                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,seroquel,246,10631,10644,"\n', '  18-24          5 additional cases                                                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,seroquel,247,10644,10645,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,seroquel,248,10645,10654,"', '                 Decreases Compared to Placebo                                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,seroquel,249,10654,10667,"\n', '  25-64          1 fewer case                                                                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,seroquel,250,10667,10680,"\n', '  >=65           6 fewer cases                                                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,seroquel,251,10680,10696,"\n', '        No  nonoseaenegation occurred in any of the pediatric trials.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
252,seroquel,252,10696,10754,"There were  nonoseaeaeonlyasinstruction in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction risk extends to longer-term use, i.e., beyond several months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,seroquel,253,10754,10845,"However, there is substantial evidence from placebo-controlled maintenance trials in adults with  notaecandidateindication that the use of antidepressants can delay the recurrence of  nonoseaeaeonlyasinstruction \n', '\n', '  All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
254,seroquel,254,10845,10912,"\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with antidepressants for  notaecandidateindication as well as for other indications, both psychiatric and nonpsychiatric.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
255,seroquel,255,10912,11097,"Although a causal link between the emergence of such symptoms and either the  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose  nonoseaeaeonlyasinstruction  or who are experiencing emergent  nonoseaeaeonlyasinstruction or symptoms that might be precursors to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', '  Families and caregivers of patients being treated with antidepressants for  notaecandidateindication or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to healthcare providers.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
256,seroquel,256,11097,11109,Such monitoring should include daily observation by families and caregivers.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,seroquel,257,11109,11151,"Prescriptions for SEROQUEL should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of  nonoseaeaeonlyasinstruction \n', '\n', '  Screening Patients for  nonoseaeaeonlyasinstruction   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,seroquel,258,11151,11206,A  nonoseaeaeonlyasinstruction may be the initial presentation of  nonoseaeaeonlyasinstruction  It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of  nonoseaeaeonlyasinstruction  Whether any of the symptoms described above represent such a conversion is unknown.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,seroquel,259,11206,11336,"However, prior to initiating treatment with an antidepressant, including SEROQUEL, patients with  notaecandidatepreexistingconditionorriskfactor should be adequately screened to determine if they are at risk for  nonoseaeaeonlyasinstruction  such screening should include a detailed psychiatric history, including a family history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.3 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis\n', '\n', '  In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with  notaecandidatepreexistingconditionorriskfactor  there was a higher incidence of  nonoseaeaefromofflabel ( nonoseaeaefromofflabel and  nonoseaeaefromofflabel  including  nonoseaegeneralterm compared to placebo-treated subjects.",1,1,1,0,0,0,0,0,0,0,1,0,0,0,0
260,seroquel,260,11336,11365,SEROQUEL is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor [see also Boxed Warning and  Warnings and Precautions (5.1)  ].  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
261,seroquel,261,11365,11388,"\n', '\n', '    5.4 Neuroleptic Malignant Syndrome (NMS)\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,seroquel,262,11388,11415,"A potentially  nonoseaegeneralterm symptom complex sometimes referred to as  oselabeledaefromdruguse  has been reported in association with administration of antipsychotic drugs, including SEROQUEL.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
263,seroquel,263,11415,11426,Rare cases of  oselabeledaefromdruguse have been reported with SEROQUEL.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,seroquel,264,11426,11465,"Clinical manifestations of  nonoseaeaeonlyasinstruction are  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and evidence of  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication pulse or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or blood pressure,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
265,seroquel,265,11465,11498,"Additional signs may include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication \n', '\n', ' The diagnostic evaluation of patients with this syndrome is complicated.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
266,seroquel,266,11498,11538,"In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  etc.) and untreated or inadequately treated  nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,seroquel,267,11538,11613,"Other important considerations in the differential diagnosis include  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction \n', '\n', ' The management of  nonoseaeaeonlyasinstruction should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,seroquel,268,11613,11658,"There is no general agreement about specific pharmacological treatment regimens for  nonoseaeaeonlyasinstruction \n', '\n', ' If a patient requires antipsychotic drug treatment after recovery from  nonoseaeaeonlyasinstruction  the potential reintroduction of drug therapy should be carefully considered.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,seroquel,269,11658,11739,"The patient should be carefully monitored since recurrences of  nonoseaeaeonlyasinstruction have been reported.\n', '\n', '    5.5 Metabolic Changes\n', '\n', '  Atypical antipsychotic drugs have been associated with  oselabeledaeclasseffect that include  oselabeledaeclasseffect  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  While all of the drugs in the class have been shown to produce some  oselabeledaeclasseffect  each drug has its own specific risk profile.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,seroquel,270,11739,11797,"In some patients, a  nonoseaeaeonlyasinstruction more than one of the metabolic parameters of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction of more than one of the metabolic parameters of weight,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction of more than one of the metabolic parameters of weight, blood glucose, and  nonoseaeaeonlyasinstruction was observed in clinical studies.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,seroquel,271,11797,11858,"nonoseaeaeonlyasinstruction profiles should be managed as clinically appropriate.\n', '\n', '  Hyperglycemia and Diabetes Mellitus  \n', '\n', '  oselabeledaefromdruguse  in some cases extreme and associated with  oselabeledaefromdruguse or  oselabeledaefromdruguse or  nonoseaegeneralterm  has been reported in patients treated with atypical antipsychotics, including quetiapine.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
272,seroquel,272,11858,11899,Assessment of the relationship between atypical antipsychotic use and  nonoseaeaeonlyasinstruction is complicated by the possibility of an increased background risk of  notaecandidatepreexistingconditionorriskfactor in patients with  notaecandidateindication and the increasing incidence of  notaecandidatepreexistingconditionorriskfactor in the general population.,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
273,seroquel,273,11899,11917,"Given these confounders, the relationship between atypical antipsychotic use and  nonoseaeaeonlyasinstruction is not completely understood.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,seroquel,274,11917,11939,"However, epidemiological studies suggest an increased risk of treatment-emergent  oselabeledaeclasseffect in patients treated with the atypical antipsychotics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,seroquel,275,11939,12021,"Precise risk estimates for  nonoseaeaeonlyasinstruction in patients treated with atypical antipsychotics are not available.\n', '\n', ' Patients with an established diagnosis of  notaecandidatepreexistingconditionorriskfactor who are started on atypical antipsychotics should be monitored regularly for  nonoseaeaeonlyasinstruction  Patients with risk factors for  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidateother  who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.",1,0,1,0,0,0,0,0,0,0,0,0,0,1,0
276,seroquel,276,12021,12066,Any patient treated with atypical antipsychotics should be monitored for symptoms of  nonoseaeaeonlyasinstruction including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Patients who develop symptoms of  nonoseaeaeonlyasinstruction during treatment with atypical antipsychotics should undergo fasting blood glucose testing.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
277,seroquel,277,12066,12144,"In some cases,  nonoseaeaeonlyasinstruction has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.\n', '\n', '  Adults:  \n', '\n', ' Table 3: Fasting Glucose - Proportion of Patients Shifting to >=126 mg/dL in Short-Term (<=12 weeks)",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,seroquel,278,12144,12154,Placebo-Controlled StudiesIncludes SEROQUEL and SEROQUEL XR data.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,seroquel,279,12154,12184,"\n', '  Laboratory Analyte    Category Change (At Least Once) from Baseline    Treatment Arm     N       Patients  n (%)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,seroquel,280,12184,12211,"\n', '   nonoseaeaeratelteqplacebo      Normal to High  (<100 mg/dL to  >=126 mg/dL)    ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
281,seroquel,281,12211,12215,Quetiapine        2907    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,seroquel,282,12215,12221,71 (2.4%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,seroquel,283,12221,12236,"\n', '  Placebo               1346                                            19 (1.4%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,seroquel,284,12236,12245,"\n', '   nonoseaeaeratelteqplacebo  oselabeledaefromdruguse      ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
285,seroquel,285,12245,12251,Normal to  oselabeledaefromdruguse  (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,seroquel,286,12251,12266,<100 mg/dL to  >=126 mg/dL)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,seroquel,287,12266,12270,Quetiapine        2907    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,seroquel,288,12270,12276,71 (2.4%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,seroquel,289,12276,12291,"\n', '  Placebo               1346                                            19 (1.4%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,seroquel,290,12291,12323,"\n', '  Borderline to High  (>= 100 mg/dL and <126 mg/dL to  >=126 mg/dL)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,seroquel,291,12323,12325,Quetiapine                                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,seroquel,292,12325,12333,572               67 (11.7%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,seroquel,293,12333,12348,"\n', '  Placebo               279                                             33 (11.8%)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,seroquel,294,12348,12417,"\n', '           In a 24-week trial (active-controlled, 115 patients treated with SEROQUEL) designed to evaluate glycemic status with oral glucose tolerance testing of all patients, at week 24 the incidence of a treatment-emergent post-glucose challenge  oselabeledaefromdruguse was 1.7% and the incidence of a  oselabeledaefromdruguse treatment-emergent  oselabeledaefromdruguse was 2.6%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,seroquel,295,12417,12504,"The  oselabeledaefromdruguse was 3.2 mg/dL and mean  oselabeledaefromdruguse was -1.8 mg/dL for quetiapine.\n', ' \n', '\n', ' In 2 long-term placebo-controlled randomized withdrawal clinical trials for  notaecandidateindication maintenance, mean exposure of 213 days for SEROQUEL (646 patients) and 152 days for placebo (680 patients), the  oselabeledaefromdruguse was +5.0 mg/dL for SEROQUEL and -0.05 mg/dL for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
296,seroquel,296,12504,12563,"The exposure-adjusted rate of any  oselabeledaefromdruguse (>= 126 mg/dL) for patients more than 8 hours since a meal (however, some patients may not have been precluded from calorie intake from fluids during fasting period) was 18.0 per 100 patient years for SEROQUEL (10.7% of patients;",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,seroquel,297,12563,12645,"n=556) and 9.5 for placebo per 100 patient years (4.6% of patients; n=581).\n', '\n', '  Children and Adolescents:  \n', '\n', ' In a placebo-controlled SEROQUEL monotherapy study of adolescent patients (13-17 years of age) with  notaecandidateindication (6 weeks duration), the mean  nonoseaeaeratelteqplacebo for SEROQUEL (n=138) compared to placebo (n=67) was",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
298,seroquel,298,12645,12725,"-0.75 mg/dL versus -1.70 mg/dL. In a placebo-controlled SEROQUEL monotherapy study of children and adolescent patients (10-17 years of age) with  notaecandidateindication (3 weeks duration), the  oselabeledaefromdruguse for SEROQUEL (n=170) compared to placebo (n=81) was 3.62 mg/dL versus -1.17 mg/dL. No patient in either study with a baseline  notaecandidatepreexistingconditionorriskfactor  or a baseline  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
299,seroquel,299,12725,12740,"had a treatment-emergent  nonoseaenegation \n', '\n', '",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
300,seroquel,300,12740,12844,"In a placebo-controlled SEROQUEL XR monotherapy study (8 weeks duration) of children and adolescent patients (10 - 17 years of age) with  notaecandidateindication  in which efficacy was not established, the  oselabeledaefromdruguse for SEROQUEL XR (n = 60) compared to placebo (n = 62) was 1.8 mg/dL versus 1.6 mg/dL. In this study, there were no patients in the SEROQUEL XR or placebo-treated groups with a baseline normal fasting glucose level (< 100 mg/dL) that had an  nonoseaenegation  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
301,seroquel,301,12844,12889,"There was one patient in the SEROQUEL XR group with a baseline  notaecandidatepreexistingconditionorriskfactor  who had an  oselabeledaefromdruguse level of > 126 mg/dL compared to zero patients in the placebo group.\n', '\n', '   oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
302,seroquel,302,12889,13017,"\n', '\n', '  Adults:  \n', '\n', ' Table 4 shows the percentage of adult patients with  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total cholesterol,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total cholesterol, triglycerides,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total cholesterol, triglycerides, LDL-cholesterol and  nonoseaeaeonlyasinstruction from baseline by indication in clinical trials with SEROQUEL.\n', '\n', ' Table 4: Percentage of Adult Patients with Shifts in Total Cholesterol, Triglycerides, LDL-Cholesterol and HDL-Cholesterol from Baseline to Clinically Significant Levels by Indication \n', '  Laboratory Analyte              Indication        Treatment Arm       N       Patients  n (%)    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,seroquel,303,13017,13026,"\n', '   oselabeledaefromdruguse     notaecandidateindication weeks",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
304,seroquel,304,13026,13032,duration    SEROQUEL            137     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,seroquel,305,13032,13038,24 (18%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,seroquel,306,13038,13053,"\n', '  Placebo                         92                6 (7%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,seroquel,307,13053,13062,"\n', '   notaecandidateindication weeks duration    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
308,seroquel,308,13062,13072,SEROQUEL          463                 41 (9%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,seroquel,309,13072,13079,"\n', '  Placebo                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,seroquel,310,13079,13087,250               15 (6%)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,seroquel,311,13087,13098,"\n', '   oselabeledaefromdruguse        notaecandidateindication     SEROQUEL            ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
312,seroquel,312,13098,13106,120     26 (22%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,seroquel,313,13106,13121,"\n', '  Placebo                         70                11 (16%)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,seroquel,314,13121,13132,"\n', '   notaecandidateindication             SEROQUEL          436                 ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
315,seroquel,315,13132,13138,59 (14%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,seroquel,316,13138,13153,"\n', '  Placebo                         232               20 (9%)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,seroquel,317,13153,13164,"\n', '   oselabeledaefromdruguse     notaecandidateindication     SEROQUEL            ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
318,seroquel,318,13164,13176,naParameters not measured in the SEROQUEL registration studies for  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
319,seroquel,319,13176,13190,Lipid parameters also were not measured in the  notaecandidateindication registration studies.    ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
320,seroquel,320,13190,13192,na           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,seroquel,321,13192,13201,"\n', '  Placebo                         na                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,seroquel,322,13201,13203,na                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,seroquel,323,13203,13210,"\n', '   notaecandidateindication             ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
324,seroquel,324,13210,13220,SEROQUEL          465                 29 (6%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,seroquel,325,13220,13227,"\n', '  Placebo                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,seroquel,326,13227,13235,256               12 (5%)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,seroquel,327,13235,13244,"\n', '   oselabeledaefromdruguse     notaecandidateindication     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
328,seroquel,328,13244,13250,SEROQUEL            na      na           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,seroquel,329,13250,13259,"\n', '  Placebo                         na                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,seroquel,330,13259,13261,na                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,seroquel,331,13261,13278,"\n', '   notaecandidateindication             SEROQUEL          393                 56 (14%)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
332,seroquel,332,13278,13285,"\n', '  Placebo                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
333,seroquel,333,13285,13293,214               29 (14%)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,seroquel,334,13293,13303,"\n', '            Children and Adolescents:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,seroquel,335,13303,13365,"\n', ' \n', '\n', ' Table 5 shows the percentage of children and adolescents with  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total cholesterol,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total cholesterol, triglycerides,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total cholesterol, triglycerides, LDL-cholesterol and  nonoseaeaeonlyasinstruction from baseline in clinical trials with SEROQUEL.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,seroquel,336,13365,13422,"'\n', ' Table 5: Percentage of Children and Adolescents with Shifts in Total Cholesterol, Triglycerides, LDL-Cholesterol and HDL-Cholesterol from Baseline to Clinically Significant Levels \n', '  Laboratory  Analyte              Indication        Treatment Arm       N       Patients  n (%)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,seroquel,337,13422,13432,"\n', '   oselabeledaefromdruguse     notaecandidateindication years,",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
338,seroquel,338,13432,13461,"6 weeks duration    SEROQUEL            107     13 (12%)     \n', '  Placebo                          56                1 (2%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
339,seroquel,339,13461,13475,"\n', '   notaecandidateindication years, 3 weeks duration    SEROQUEL          ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
340,seroquel,340,13475,13483,159                 16 (10%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,seroquel,341,13483,13517,"\n', '  Placebo                          66                2 (3%)              \n', '   oselabeledaefromdruguse        notaecandidateindication     SEROQUEL            103     17 (17%)     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
342,seroquel,342,13517,13549,"\n', '  Placebo                          51                4 (8%)              \n', '   notaecandidateindication                    SEROQUEL          149                 32 (22%)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
343,seroquel,343,13549,13565,"\n', '  Placebo                          60                8 (13%)             \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,seroquel,344,13565,13575,"', '   oselabeledaefromdruguse      notaecandidateindication     SEROQUEL            ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
345,seroquel,345,13575,13583,112     4 (4%)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,seroquel,346,13583,13598,"\n', '  Placebo                          60                1 (2%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,seroquel,347,13598,13605,"\n', '   notaecandidateindication                    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
348,seroquel,348,13605,13615,SEROQUEL          169                 13 (8%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,seroquel,349,13615,13649,"\n', '  Placebo                          74                4 (5%)              \n', '   oselabeledaefromdruguse       notaecandidateindication     SEROQUEL            104     16 (15%)     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
350,seroquel,350,13649,13673,"\n', '  Placebo                          54                10 (19%)            \n', '   notaecandidateindication                    SEROQUEL          ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
351,seroquel,351,13673,13681,154                 16 (10%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
352,seroquel,352,13681,13696,"\n', '  Placebo                          61                4 (7%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
353,seroquel,353,13696,13924,"\n', '           In a placebo-controlled SEROQUEL XR monotherapy study (8 weeks duration) of children and adolescent patients (10-17 years of age) with  notaecandidatepreexistingconditionorriskfactor  in which efficacy was not established, the percentage of children and adolescents with shifts in  nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction   nonoseaeaeratelteqplacebo were: total cholesterol 8% (7/83) for SEROQUEL XR vs. 6% (5/84) for placebo; triglycerides 28% (22/80) for SEROQUEL XR vs. 9% (7/82) for placebo;  nonoseaeaeratelteqplacebo  oselabeledaefromdruguse  oselabeledaefromdruguse were: total cholesterol 8% (7/83) for SEROQUEL XR vs. 6% (5/84) for placebo;  oselabeledaefromdruguse  oselabeledaefromdruguse were: total cholesterol 8% (7/83) for SEROQUEL XR vs. 6% (5/84) for placebo; triglycerides 28% (22/80) for SEROQUEL XR vs. 9% (7/82) for placebo; LDL-cholesterol 2% (2/86) for SEROQUEL XR vs. 4% (3/85) for placebo and  oselabeledaefromdruguse 20% (13/65) for SEROQUEL XR vs. 15% (11/74) for placebo.\n', ' \n', '\n', '  Weight Gain  ",1,0,1,0,0,0,1,0,0,0,0,0,0,0,0
354,seroquel,354,13924,13941,"\n', '\n', '  oselabeledaefromdruguse have been observed in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
355,seroquel,355,13941,13961,"Patients receiving quetiapine should receive regular monitoring of weight.\n', '\n', '  Adults  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,seroquel,356,13961,14007,"\n', '\n', ' In clinical trials with SEROQUEL the following  oselabeledaefromdruguse have been reported.\n', '\n', ' Table 6: Proportion of Patients with Weight Gain >=7% of Body Weight (Adults)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,seroquel,357,14007,14020,"\n', '  Vital Sign                           Indication                        Treatment Arm      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,seroquel,358,14020,14029,N       Patients  n (%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,seroquel,359,14029,14037,"\n', '   oselabeledaefromdruguse >=",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,seroquel,360,14037,14047,7% of Body Weight       notaecandidateindication to 6 weeks,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
361,seroquel,361,14047,14049,duration    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,seroquel,362,14049,14059,SEROQUEL           391     89 (23%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,seroquel,363,14059,14074,"\n', '  Placebo                              206                               11 (6%)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,seroquel,364,14074,14075,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,seroquel,365,14075,14097,"', '   notaecandidateindication (monotherapy)up to 12 weeks duration    SEROQUEL                          209                44 (21%)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
366,seroquel,366,14097,14112,"\n', '  Placebo                              198                               13 (7%)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,seroquel,367,14112,14130,"\n', '   notaecandidateindication (adjunct therapy)up to 3 weeks duration    SEROQUEL                          196                ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
368,seroquel,368,14130,14136,25 (13%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,seroquel,369,14136,14151,"\n', '  Placebo                              203                               8 (4%)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,seroquel,370,14151,14162,"\n', '   notaecandidateindication to 8 weeks duration    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
371,seroquel,371,14162,14172,SEROQUEL                          554                47 (8%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,seroquel,372,14172,14188,"\n', '  Placebo                              295                               7 (2%)             \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
373,seroquel,373,14188,14209,"', '            Children and Adolescents:  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,seroquel,374,14209,14284,"In two clinical trials with SEROQUEL, one in  notaecandidateindication and one in  notaecandidateindication  reported  oselabeledaefromdruguse are included in table 7.\n', '\n', ' Table 7: Proportion of Patients with Weight Gain >=7% of Body Weight (Children and Adolescents) \n', '  Vital Sign                            Indication        Treatment Arm       N       Patients  n (%)    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
375,seroquel,375,14284,14292,"\n', '   oselabeledaefromdruguse >=",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,seroquel,376,14292,14303,7% of Body Weight        notaecandidateindication  weeks duration    ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
377,seroquel,377,14303,14313,SEROQUEL            111     23 (21%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,seroquel,378,14313,14340,"\n', '  Placebo                               44                3 (7%)              \n', '   notaecandidateindication  weeks duration         SEROQUEL          ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
379,seroquel,379,14340,14348,157                 18 (12%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,seroquel,380,14348,14363,"\n', '  Placebo                               68                0 (0%)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
381,seroquel,381,14363,14454,"\n', '           The  oselabeledaefromdruguse in the  notaecandidateindication trial was 2.0 kg in the SEROQUEL group and -0.4 kg in the placebo group and in the  notaecandidateindication trial, it was 1.7 kg in the SEROQUEL group and 0.4 kg in the placebo group.\n', ' \n', '\n', ' In an open-label study that enrolled patients from the above two pediatric trials, 63% of patients (241/380) completed 26 weeks of therapy with SEROQUEL.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
382,seroquel,382,14454,14468,"After 26 weeks of treatment, the mean  oselabeledaefromdruguse was 4.4 kg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
383,seroquel,383,14468,14484,Forty-five percent of the patients  oselabeledaefromdruguse  not adjusted for normal growth.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
384,seroquel,384,14484,14603,"In order to adjust for normal growth over 26 weeks an increase of at least 0.5 standard deviation from baseline in BMI was used as a measure of a clinically significant change; 18.3% of patients on SEROQUEL met this criterion after 26 weeks of treatment.\n', '\n', ' In a clinical trial for SEROQUEL XR in children and adolescents (10-17 years of age) with  notaecandidateindication  in which efficacy was not established, the percentage of patients with  oselabeledaefromdruguse >=7% of body weight at any time was 15% (14/92) for SEROQUEL XR vs. 10% (10/100) for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
385,seroquel,385,14603,14684,"The  oselabeledaefromdruguse in the SEROQUEL XR group vs. 0.6 kg in the placebo group.\n', '\n', ' When treating pediatric patients with SEROQUEL for any indication,  nonoseaeaeonlyasinstruction should be assessed against that expected for normal growth.\n', '\n', '    5.6  oselabeledaefromdruguse \n', '  A syndrome of potentially irreversible, involuntary,  oselabeledaefromdruguse may develop in patients treated with antipsychotic drugs, including quetiapine.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
386,seroquel,386,14684,14729,"Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
387,seroquel,387,14729,14787,"Whether antipsychotic drug products differ in their potential to cause  nonoseaeaeonlyasinstruction is unknown.\n', '\n', ' The risk of developing  nonoseaeaeonlyasinstruction and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,seroquel,388,14787,14850,"However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.\n', '\n', ' There is no known treatment for established cases of  nonoseaeaeonlyasinstruction  although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,seroquel,389,14850,14880,"Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,seroquel,390,14880,14978,"The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.\n', '\n', ' Given these considerations, SEROQUEL should be prescribed in a manner that is most likely to minimize the occurrence of  nonoseaeaeonlyasinstruction  Chronic antipsychotic treatment should generally be reserved for patients who appear to suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,seroquel,391,14978,15004,"In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
392,seroquel,392,15004,15040,"The need for continued treatment should be reassessed periodically.\n', '\n', ' If signs and symptoms of  nonoseaeaeonlyasinstruction appear in a patient on SEROQUEL, drug discontinuation should be considered.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
393,seroquel,393,15040,15110,"However, some patients may require treatment with SEROQUEL despite the presence of the syndrome.\n', '\n', '    5.7 Hypotension\n', '\n', '  Quetiapine may induce  oselabeledaefromdruguse associated with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and, in some patients,  nonoseaemanifestationorcomplication  especially during the initial dose-titration period, probably reflecting its alpha1-adrenergic antagonist properties.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
394,seroquel,394,15110,15148,"oselabeledaefromdruguse was reported in 1% (28/3265) of the patients treated with SEROQUEL, compared with 0.2% (2/954) on placebo and about 0.4% (2/527) on active control drugs.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,seroquel,395,15148,15216,"nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction may lead to  nonoseaemanifestationorcomplication \n', '\n', ' SEROQUEL should be used with particular caution in patients with known  notaecandidatepreexistingconditionorriskfactor (history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor ,  notaecandidatepreexistingconditionorriskfactor or conditions which would predispose patients to  nonoseaeaeonlyasinstruction ( notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor and treatment with  nonoseaeaeonlyasinstruction .",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
396,seroquel,396,15216,15250,The risk of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction may be minimized by limiting the initial dose to 25 mg twice daily [see  Dosage and Administration (2.2)  ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
397,seroquel,397,15250,15331,"If  nonoseaeaeonlyasinstruction occurs during titration to the target dose, a return to the previous dose in the titration schedule is appropriate.\n', '\n', '     5.8 Falls  \n', '\n', '   Atypical antipsychotic drugs, including SEROQUEL, may cause  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and sensory  oselabeledaefromdruguse  oselabeledaefromdruguse  which may lead to  nonoseaemanifestationorcomplication and, consequently,  nonoseaemanifestationorcomplication or other injuries.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
398,seroquel,398,15331,15367,"For patients with diseases, conditions, or medications that could exacerbate these effects, complete  nonoseaeaeonlyasinstruction risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,seroquel,399,15367,15483,"\n', '\n', '    5.9 Increases in Blood Pressure (Children and Adolescents)\n', '\n', '  In placebo-controlled trials in children and adolescents with  notaecandidateindication (6-week duration) or  notaecandidateindication (3-week duration), the incidence of  oselabeledaefromdruguse at any time  oselabeledaefromdruguse (>=20 mmHg) was 15.2% (51/335) for SEROQUEL and 5.5% (9/163) for placebo; the incidence of  oselabeledaefromdruguse at any time  oselabeledaefromdruguse (>=10 mmHg) was 40.6% (136/335) for SEROQUEL and 24.5% (40/163) for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
400,seroquel,400,15483,15684,"In the 26-week open-label clinical trial, one child with a reported history of  notaecandidatepreexistingconditionorriskfactor experienced a  oselabeledaefromdruguse  Blood pressure in children and adolescents should be measured at the beginning of, and periodically during treatment.\n', '\n', ' In a placebo-controlled SEROQUEL XR clinical trial (8 weeks duration) in children and adolescents (10-17 years of age) with  notaecandidateindication  in which efficacy was not established, the incidence of  oselabeledaefromdruguse at any time  oselabeledaefromdruguse (>=20 mmHg) was 6.5% (6/92) for SEROQUEL XR and 6.0% (6/100) for placebo; the incidence of  oselabeledaefromdruguse at any time  oselabeledaefromdruguse (>=10 mmHg) was 46.7% (43/92) for SEROQUEL XR and 36.0% (36/100) for placebo.\n', '\n', '    5.10 Leukopenia, Neutropenia and Agranulocytosis\n', '\n', '  In clinical trial and postmarketing experience, events of  oselabeledaefromdruguse  oselabeledaefromdruguse have been reported temporally related to atypical antipsychotic agents, including SEROQUEL.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
401,seroquel,401,15684,15728,"oselabeledaefromdruguse (including  nonoseaegeneralterm cases) has also been reported.\n', '\n', ' Possible risk factors for  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction include pre-existing  notaecandidatepreexistingconditionorriskfactor  and history of  notaecandidatepreexistingconditionorriskfactor leukopenia/ notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor neutropenia.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
402,seroquel,402,15728,15818,"Patients with a pre-existing  notaecandidatepreexistingconditionorriskfactor or a history of  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor leukopenia/ notaecandidatepreexistingconditionorriskfactor should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue SEROQUEL at the first sign of a  nonoseaeaeonlyasinstruction in absence of other causative factors.\n', '\n', ' Patients with  nonoseaeaeonlyasinstruction should be carefully monitored for  nonoseaeaeonlyasinstruction or other symptoms or signs of  nonoseaeaeonlyasinstruction and treated promptly if such symptoms or signs occur.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
403,seroquel,403,15818,15883,"Patients with severe  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  ) should discontinue SEROQUEL and have their WBC followed until recovery.\n', '\n', '    5.11 Cataracts\n', '\n', '  The development of  nonoseaeaeanimal was observed in association with quetiapine treatment in chronic dog studies [see  Nonclinical Toxicology (13.2)  ].   ",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
404,seroquel,404,15883,15913,"oselabeledaefromdruguse have also been observed in adults, children and adolescents during long-term SEROQUEL treatment, but a causal relationship to SEROQUEL use has not been established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
405,seroquel,405,15913,15928,"Nevertheless, the possibility of  nonoseaeaeonlyasinstruction cannot be excluded at this time.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
406,seroquel,406,15928,16003,"Therefore, examination of the lens by methods adequate to detect  nonoseaeaeonlyasinstruction  such as slit lamp exam or other appropriately sensitive methods, is recommended at initiation of treatment or shortly thereafter, and at 6-month intervals during chronic treatment.\n', '\n', '    5.12 QT Prolongation\n', '\n', '  In clinical trials, quetiapine was not associated with a persistent  nonoseaenegation  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
407,seroquel,407,16003,16018,"However, the QT effect was not systematically evaluated in a thorough QT study.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,seroquel,408,16018,16073,"In post marketing experience, there were cases reported of  nonoseaeodorwithdrawal in patients who overdosed on quetiapine [see  Overdosage (10.1)  ],  in patients with concomitant illness, and in patients taking medicines known to cause  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor [see  Drug Interactions (7.1",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
409,seroquel,409,16073,16190,")  ]  .\n', '\n', ' The use of quetiapine should be avoided in combination with other drugs that are known to  nonoseaeaeonlyasinstruction including Class 1A antiarrythmics (e.g., quinidine, procainamide) or Class III antiarrythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to  nonoseaeaeonlyasinstruction (e.g., pentamidine, levomethadyl acetate, methadone).\n', '\n', ' Quetiapine should also be avoided in circumstances that may increase the risk of occurrence of  nonoseaeaeonlyasinstruction",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
410,seroquel,410,16190,16338,"and/or  nonoseaeaeonlyasinstruction including (1) a history of  notaecandidatepreexistingconditionorriskfactor such as  notaecandidatepreexistingconditionorriskfactor  (2)  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  (3) concomitant use of other drugs that  nonoseaeaeonlyasinstruction  and (4) presence of  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Caution should also be exercised when quetiapine is prescribed in patients with increased risk of  nonoseaeaeonlyasinstruction (e.g.,  notaecandidatepreexistingconditionorriskfactor  family history of  notaecandidatepreexistingconditionorriskfactor  the elderly,  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor .\n', '\n', '    5.13 Seizures\n', '\n', '  During clinical trials,  oselabeledaefromdruguse occurred in 0.5% (20/3490) of patients treated with SEROQUEL compared to 0.2% (2/954) on placebo and 0.7% (4/527) on active control drugs.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
411,seroquel,411,16338,16403,"As with other antipsychotics, SEROQUEL should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor or with conditions that potentially  nonoseaeaeonlyasinstruction  e.g.,  notaecandidatepreexistingconditionorriskfactor  Conditions that  nonoseaeaeonlyasinstruction may be more prevalent in a population of 65 years or older.\n', '\n', '    5.14  oselabeledaefromdruguse \n', ""  Adults:",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
412,seroquel,412,16403,16462,Clinical trials with quetiapine demonstrated dose-related  oselabeledaefromdruguse  The  oselabeledaefromdruguse in total and  oselabeledaefromdruguse  oselabeledaefromdruguse and free  oselabeledaefromdruguse  of approximately 20% at the higher end of the therapeutic dose range was maximal in the first six weeks of treatment and maintained without adaptation or progression during more chronic therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
413,seroquel,413,16462,16492,"In nearly all cases, cessation of quetiapine treatment was associated with a reversal of the effects on total and free T4, irrespective of the duration of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,seroquel,414,16492,16504,The mechanism by which quetiapine effects the thyroid axis is unclear.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
415,seroquel,415,16504,16530,"If there is an effect on the hypothalamic-pituitary axis, measurement of TSH alone may not accurately reflect a patient's thyroid status.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,seroquel,416,16530,16644,"Therefore, both TSH and free T4, in addition to clinical assessment, should be measured at baseline and at follow-up.\n"", '\n', ' In the  notaecandidateindication adjunct studies, where SEROQUEL was added to lithium or divalproex, 12% (24/196) of SEROQUEL treated patients compared to 7% (15/203) of placebo-treated patients had  oselabeledaefromdruguse  Of the SEROQUEL treated patients with  oselabeledaefromdruguse  3 had simultaneous  oselabeledaefromdruguse (free T4<0.8 LLN).\n', '\n', ' About 0.7% (26/3489) of SEROQUEL patients did experience  oselabeledaefromdruguse in monotherapy studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
417,seroquel,417,16644,16701,"Some patients with  oselabeledaefromdruguse needed replacement thyroid treatment.\n', '\n', ' In all quetiapine trials, the incidence of significant  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thyroid hormones and  nonoseaeaeonlyasinstruction were [note: Based on shifts from normal baseline to potentially clinically important value at any time post-baseline.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
418,seroquel,418,16701,16731,"nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total T4,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction T4, free T4, total  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total T4,  nonoseaeaeonlyasinstruction T4, total  nonoseaeaeonlyasinstruction",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
419,seroquel,419,16731,16758,nd free T3are defined as M0.8 x LLN (pmol/L) and  nonoseaeaeonlyasinstruction is > 5 mlU/L at any time.],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
420,seroquel,420,16758,16809,":  oselabeledaefromdruguse free T4<0.8 LLN), 2.0% (357/17513);  oselabeledaefromdruguse  4.0% (75/1861);  oselabeledaefromdruguse  0.4% (53/13766);  oselabeledaefromdruguse  2.0% (26/1312), and  oselabeledaefromdruguse  4.9% (956/19412).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
421,seroquel,421,16809,16893,"In eight patients, where TBG was measured, levels of TBG were unchanged.\n', '\n', ' Table 8 shows the incidence of these shifts in short-term placebo-controlled clinical trials.\n', '\n', ' Table 8: Incidence of  oselabeledaefromdruguse in Thyroid Hormone Levels and TSH in Short-Term Placebo-Controlled Clinical TrialsBased on shifts from normal baseline to potentially clinically important value at any time post-baseline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
422,seroquel,422,16893,16930,Shifts in  oselabeledaefromdruguse  oselabeledaefromdruguse Thyroid Hormone Levels and TSH in Short-Term Placebo-Controlled Clinical TrialsBased on shifts from normal baseline to potentially clinically important value at any time post-baseline.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
423,seroquel,423,16930,16970,"Shifts in total T4,  oselabeledaefromdruguse  oselabeledaefromdruguse Thyroid Hormone Levels and TSH in Short-Term Placebo-Controlled Clinical TrialsBased on shifts from normal baseline to potentially clinically important value at any time post-baseline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
424,seroquel,424,16970,17015,"Shifts in  oselabeledaefromdruguse T4, free T4, total  oselabeledaefromdruguse  oselabeledaefromdruguse Thyroid Hormone Levels and TSH in Short-Term Placebo-Controlled Clinical TrialsBased on shifts from normal baseline to potentially clinically important value at any time post-baseline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
425,seroquel,425,17015,17062,"Shifts in total T4,  oselabeledaefromdruguse T4, total  oselabeledaefromdruguse  oselabeledaefromdruguse Thyroid Hormone Levels and  oselabeledaefromdruguse in Short-Term Placebo-Controlled Clinical TrialsBased on shifts from normal baseline to potentially clinically important value at any time post-baseline.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
426,seroquel,426,17062,17121,"nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total T4,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction T4, free T4, total  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction total T4,  nonoseaeaeonlyasinstruction T4, total  nonoseaeaeonlyasinstruction and free T3 are defined as <0.8 x LLN (pmol/L) and  nonoseaeaeonlyasinstruction is >5 mlU/L at any time.,",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
427,seroquel,427,17121,17128,Includes SEROQUEL and SEROQUEL XR data.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
428,seroquel,428,17128,17139,"\n', '  Total T4     Free T4    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
429,seroquel,429,17139,17142,Total T3     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
430,seroquel,430,17142,17145,Free T3    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
431,seroquel,431,17145,17170,"TSH          \n', '  Quetiapine    Placebo    Quetiapine    Placebo    Quetiapine    Placebo    Quetiapine    Placebo    Quetiapine    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
432,seroquel,432,17170,17172,Placebo      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
433,seroquel,433,17172,17247,"\n', '  3.4 %  (37/1097)    0.6%  (4/651)    0.7%  (52/7218)    0.1%  (4/3668)    0.5%  (2/369)    0.0%  (0/113)    0.2%  (11/5673)    0.0%  (1/2679)    3.2%  (240/7587)    2.7%  (105/3912)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
434,seroquel,434,17247,17252,"\n', '                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
435,seroquel,435,17252,17414,"In short-term placebo-controlled monotherapy trials, the incidence of reciprocal, shifts in T3and TSH was 0.0 % for both quetiapine (1/4800) and placebo (0/2190) and for T4and TSH the shifts were 0.1% (7/6154) for quetiapine versus 0.0% (1/3007) for placebo.\n', ' \n', '\n', '  Children and Adolescents:  \n', '\n', ' In acute placebo-controlled trials in children and adolescent patients with  notaecandidateindication (6-week duration) or  notaecandidateindication (3-week duration), the incidence of shifts for thyroid function values at any time for SEROQUEL treated patients and placebo-treated patients for  oselabeledaefromdruguse was 2.9% (8/280) vs. 0.7% (1/138), respectively and for  oselabeledaefromdruguse was 2.8% (8/289) vs. 0% (0/145, respectively).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
436,seroquel,436,17414,17453,"Of the SEROQUEL treated patients with  oselabeledaefromdruguse levels, 1 had simultaneous  oselabeledaefromdruguse evel at end of treatment.\n', '\n', '    5.15  oselabeledaefromdruguse \n', '   Adults  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
437,seroquel,437,17453,17618,"During clinical trials with quetiapine, the incidence of  oselabeledaefromdruguse occurred in 3.6% (158/4416) of patients treated with quetiapine compared to 2.6% (51/1968) on placebo.\n', '\n', '  Children and Adolescents:  \n', '\n', ' In acute placebo-controlled trials in children and adolescent patients with  notaecandidateindication (3-week duration) or  notaecandidateindication (6-week duration), the incidence of  oselabeledaefromdruguse males; > 26 ug/L females at any time) was 13.4% (18/134) for SEROQUEL compared to 4% (3/75) for placebo in males and 8.7% (9/104) for SEROQUEL compared to 0% (0/39) for placebo in females.\n', '\n', ' Like other drugs that antagonize dopamine D2receptors, SEROQUEL  oselabeledaefromdruguse in some patients and the elevation may persist during chronic administration.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
438,seroquel,438,17618,17633,"nonoseaeaeonlyasinstruction  regardless of etiology, may  nonoseaemanifestationorcomplication  resulting in  nonoseaemanifestationorcomplication  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
439,seroquel,439,17633,17652,"This, in turn, may  nonoseaemanifestationorcomplication by  nonoseaemanifestationorcomplication in both female and male patients.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
440,seroquel,440,17652,17656,oselabeledaeclasseffect   oselabeledaeclasseffect   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
441,seroquel,441,17656,17671,oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported in patients receiving  nonoseaeaeonlyasinstruction compounds.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
442,seroquel,442,17671,17693,Long-standing  nonoseaeaeonlyasinstruction when associated with  nonoseaeaeonlyasinstruction may lead to  nonoseaemanifestationorcomplication in both female and male subjects.\n',1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
443,seroquel,443,17693,17741,", '\n', ' Tissue culture experiments indicate that approximately one-third of human  nonoseaeaeonlyasinstruction are prolactin dependent in vitro  , a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
444,seroquel,444,17741,17752,"As is common with compounds which  nonoseaeaeonlyasinstruction release,  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
445,seroquel,445,17752,17785,nonoseaeaeanimal  and pancreatic islet cell  nonoseaeaeanimal  nonoseaeaeanimal ( nonoseaeaeanimal   nonoseaeaeanimal and pancreatic  nonoseaeaeanimal  nonoseaeaeanimal  was observed in  nonoseaeaeonlyasinstruction studies conducted in mice and rats.,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
446,seroquel,446,17785,17834,"Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and  nonoseaeaeonlyasinstruction in humans, but the available evidence is too limited to be conclusive [see  Nonclinical Toxicology (13.1)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
447,seroquel,447,17834,17884,"\n', '\n', '    5.16 Potential for  oselabeledaefromdruguse and Motor  oselabeledaefromdruguse \n', '   oselabeledaefromdruguse was a commonly reported adverse event reported in patients treated with SEROQUEL especially during the 3-5 day period of initial dose-titration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
448,seroquel,448,17884,17914,"In  notaecandidateindication trials,  oselabeledaefromdruguse was reported in 18% (89/510) of patients on SEROQUEL compared to 11% (22/206) of placebo patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
449,seroquel,449,17914,17946,"In acute  notaecandidateindication trials using SEROQUEL as monotherapy,  oselabeledaefromdruguse was reported in 16% (34/209) of patients on SEROQUEL compared to 4% of placebo patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
450,seroquel,450,17946,17982,"In acute  notaecandidateindication trials using SEROQUEL as adjunct therapy,  oselabeledaefromdruguse was reported in 34% (66/196) of patients on SEROQUEL compared to 9% (19/203) of placebo patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
451,seroquel,451,17982,18012,"In  notaecandidateindication trials,  oselabeledaefromdruguse was reported in 57% (398/698) of patients on SEROQUEL compared to 15% (51/347) of placebo patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
452,seroquel,452,18012,18082,"Since SEROQUEL has the potential to  oselabeledaefromdruguse judgment, thinking, or  oselabeledaefromdruguse  oselabeledaefromdruguse judgment,  oselabeledaefromdruguse  oselabeledaefromdruguse  thinking, or motor skills, patients should be cautioned about performing activities requiring mental alertness, such as operating a motor vehicle (including automobiles) or operating hazardous machinery until they are reasonably certain that SEROQUEL therapy does not affect them adversely.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
453,seroquel,453,18082,18109,"oselabeledaefromdruguse may lead to  nonoseaemanifestationorcomplication \n', '\n', '    5.17 Body Temperature Regulation\n', '\n', '  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
454,seroquel,454,18109,18124,"Although not reported with SEROQUEL,  nonoseaeaeforanotherdruginclass has been attributed to antipsychotic agents.",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
455,seroquel,455,18124,18199,"Appropriate care is advised when prescribing SEROQUEL for patients who will be experiencing conditions which may contribute to an  nonoseaeaeonlyasinstruction  e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to  nonoseaeaeonlyasinstruction \n', '\n', '    5.18  oselabeledaeclasseffect \n', '   oselabeledaeclasseffect and  oselabeledaeclasseffect have been associated with antipsychotic drug use.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
456,seroquel,456,18199,18283,"nonoseaeaeonlyasinstruction is a common cause of morbidity and  nonoseaegeneralterm in elderly patients, in particular those with advanced  notaecandidatepreexistingconditionorriskfactor  SEROQUEL and other antipsychotic drugs should be used cautiously in patients at risk for  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.19 Discontinuation Syndrome\n', '\n', '   oselabeledaefromdruguse  such as  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal have been described after abrupt cessation of atypical antipsychotic drugs, including SEROQUEL.",1,1,1,0,0,0,0,0,0,1,0,0,0,0,0
457,seroquel,457,18283,18339,"In short-term placebo-controlled, monotherapy clinical trials with SEROQUEL XR that included a discontinuation phase which evaluated  nonoseaeaeonlyasinstruction  the aggregated incidence of patients experiencing one or more  oselabeledaefromdruguse after abrupt cessation was 12.1% (241/1993) for SEROQUEL XR and 6.7% (71/1065) for placebo.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
458,seroquel,458,18339,18366,"The incidence of the individual adverse events (i.e.,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal and  nonoseaeodorwithdrawal ']",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
0,prograf,0,0,66,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:\n', '\n', ' *     oselabeledaefromdruguse and Other  oselabeledaefromdruguse [see  Boxed Warning  ,  Warnings and Precautions  (  5.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,prograf,1,66,94,"\n', ' *    Serious  oselabeledaefromdruguse [see  Boxed Warning  ,  Warnings and Precautions  (  5.3  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,prograf,2,94,120,"\n', ' *     oselabeledaefromdruguse [see  Boxed Warning  ,  Warnings and Precautions  (  5.4  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,prograf,3,120,146,"\n', ' *     oselabeledaefromdruguse [see  Boxed Warning  ,  Warnings and Precautions  (  5.5  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,prograf,4,146,156,"\n', ' *    New Onset  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,prograf,5,156,172,After Transplant [see  Warnings and Precautions  (  5.6  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,prograf,6,172,193,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions  (  5.7  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,prograf,7,193,203,"\n', ' *     oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,prograf,8,203,214,Warnings and Precautions  (  5.8  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,prograf,9,214,224,"\n', ' *     oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,prograf,10,224,235,Warnings and Precautions  (  5.9  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,prograf,11,235,256,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions  (  5.10  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,prograf,12,256,257,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,prograf,13,257,280,"', ' *     oselabeledaefromdruguse with Prograf Injection [see  Warnings and Precautions  (  5.11  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,prograf,14,280,301,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions  (  5.15  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,prograf,15,301,322,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions  (  5.17  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,prograf,16,322,343,"\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions  (  5.18  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,prograf,17,343,365,"\n', '   *     notaecandidateindication  The most common adverse reactions ( >= 30%) were  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
18,prograf,18,365,407,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,prograf,19,407,411,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,prograf,20,411,413,*     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,prograf,21,413,415,notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
22,prograf,22,415,466,The most common adverse reactions (>= 40%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,prograf,23,466,470,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,prograf,24,470,472,*     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,prograf,25,472,474,notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
26,prograf,26,474,518,The most common adverse reactions ( >= 15%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,prograf,27,518,526,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,prograf,28,526,558,"To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc at 1-800-727-7003 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,prograf,29,558,591,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Studies Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,prograf,30,591,636,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,prograf,31,636,671,"In addition, the clinical trials were not designed to establish comparative differences across study arms with regards to the adverse reactions discussed below.\n', '\n', '   Kidney Transplant  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,prograf,32,671,693,"\n', '\n', ' The incidence of adverse reactions was determined in three randomized  notaecandidateindication trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
33,prograf,33,693,722,One of the trials used azathioprine (AZA) and corticosteroids and two of the trials used mycophenolate mofetil (MMF) and corticosteroids concomitantly for maintenance  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,prograf,34,722,825,"\n', '\n', ' Prograf-based  nonoseaeaeonlyasinstruction in conjunction with azathioprine and corticosteroids following  notaecandidateindication was assessed in trial where 205 patients received Prograf based  nonoseaeaeonlyasinstruction and 207 patients received cyclosporine based  nonoseaeaeonlyasinstruction  The trial population had a mean age of 43 years (mean+/-sd was 43+/-13 years on Prograf and 44+/-12 years on cyclosporine arm), the distribution was 61% male, and the composition was White (58%), Black (25%), Hispanic (12%) and Other (5%).",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
35,prograf,35,825,945,"The 12 month  nonoseaeaeonlyasinstruction information from this trial is presented below.\n', '\n', ' The most common adverse reactions ( >= 30%) observed in Prograf-treated  notaecandidateindication patients are:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', ' Adverse reactions that occurred in >= 15% of  notaecandidateindication patients treated with Prograf in conjunction with azathioprine are presented below:\n', '\n', ' Table 4.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
36,prograf,36,945,958,Kidney Transplantation: Adverse Reactions Occurring in >= 15% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,prograf,37,958,968,Treated with Prograf in Conjunction with Azathioprine (AZA),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,prograf,38,968,989,"\n', '                                                         Prograf/AZA  (N=205)    Cyclosporine/AZA(N=207)     \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,prograf,39,989,993,'   nonoseaegeneralterm                                                                                            ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,prograf,40,993,1014,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     54%  44%  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,prograf,41,1014,1029,32%  23%  19%    34%  38%  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,prograf,42,1029,1038,30%  16%  16%     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,prograf,43,1038,1058,"\n', '   nonoseaegeneralterm                                                                                          \n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,prograf,44,1058,1060,oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,prograf,45,1060,1090,44%  38%  35%  29%  28%    41%  36%  43%  23%  20%     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,prograf,46,1090,1097,"\n', '   nonoseaegeneralterm                                                                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
47,prograf,47,1097,1125,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse                               50%  19%               52%  13%                    \n', '   nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,prograf,48,1125,1222,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse          45%  34%               42%  35%                    \n', '   nonoseaegeneralterm                                                                                 \n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    49%  34%  31%  31%  24%  22%  22%  18%    53%  17%  38%  32%  9%  25%  16%  19%    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,prograf,49,1222,1250,"\n', '   nonoseaegeneralterm                                                                                       \n', '   oselabeledaefromdruguse   oselabeledaefromdruguse                                     30%  15%               24%  17%                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,prograf,50,1250,1257,"\n', '   nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,prograf,51,1257,1318,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    45%  36%  34%  33%  32%  29%  24%    49%  48%  30%  31%  30%  29%  20%    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,prograf,52,1318,1325,"\n', '   nonoseaegeneralterm                                                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,prograf,53,1325,1353,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse                               22%  18%               18%  15%                    \n', '   nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,prograf,54,1353,1366,"\n', '   oselabeledaefromdruguse                                             25%                    24%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,prograf,55,1366,1416,"\n', '   nonoseaegeneralterm                                                                                                      \n', '   oselabeledaefromdruguse   oselabeledaefromdruguse                                         17%  15%               12%  7%                     \n', '         Two trials were conducted for Prograf-based  nonoseaeaeonlyasinstruction in conjunction with MMF and corticosteroids.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,prograf,56,1416,1495,"In the non-US trial (Study 1), the incidence of adverse reactions was based on 1195  notaecandidateindication patients that received Prograf (Group C, n=403), or one of two cyclosporine (CsA) regimens (Group A, n=384 and Group B, n=408) in combination with MMF and corticosteroids; all patients, except those in one of the two cyclosporine groups, also received induction with daclizumab.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
57,prograf,57,1495,1527,"The trial population had a mean age of 46 years (range 17 to 76), the distribution was 65% male, and the composition was 93% Caucasian.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,prograf,58,1527,1574,"The 12 month post-transplant information from this trial is presented below.\n', ' \n', '\n', ' Adverse reactions that occurred in >= 10% of  notaecandidateindication patients treated with Prograf in conjunction with MMF in Study 1",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
59,prograf,59,1574,1588,[Note: This trial was conducted entirely outside of the United States.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,prograf,60,1588,1617,"Such trials often report a lower incidence of adverse reactions in comparison to U.S. trials] are presented below:\n', '\n', ' Table 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,prograf,61,1617,1630,Kidney Transplantation: Adverse Reactions Occurring in >= 10% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,prograf,62,1630,1641,Treated with Prograf in Conjunction with MMF (Study 1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,prograf,63,1641,1642,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,prograf,64,1642,1689,"', ' Key: Group A = CsA/MMF/CS, B = CsA/MMF/CS/Daclizumab, C= Tac/MMF/CS/DaclizumabCsA= Cyclosporine, CS = Corticosteroids, Tac = Tacrolimus, MMF = mycophenolate mofetil   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,prograf,65,1689,1703,"\n', '  \n', '                                                            Prograf(Group C)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,prograf,66,1703,1711,Cyclosporine(Group A)    Cyclosporine(Group B)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,prograf,67,1711,1712,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,prograf,68,1712,1733,"', '                                                            (N=403)       (N=384)            (N=408)          \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,prograf,69,1733,1744,oselabeledaefromdruguse                                                  25%           16%                13%              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,prograf,70,1744,1760,"\n', '   oselabeledaefromdruguse                                   24%           28%                24%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,prograf,71,1760,1776,"\n', '   oselabeledaefromdruguse                                                    17%           19%                17%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,prograf,72,1776,1792,"\n', '   oselabeledaefromdruguse                                              13%           14%                12%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,prograf,73,1792,1824,"\n', '   oselabeledaefromdruguse                                                13%           10%                10%              \n', '   oselabeledaefromdruguse                                          11%           12%                13%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,prograf,74,1824,1840,"\n', '   oselabeledaefromdruguse                                            10%           15%                13%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,prograf,75,1840,1845,"\n', '          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,prograf,76,1845,1895,"In the U.S. trial (Study 2) with Prograf-based  nonoseaeaeonlyasinstruction in conjunction with MMF and corticosteroids, 424  notaecandidateindication patients received Prograf (n=212) or cyclosporine (n=212) in combination with MMF 1 gram twice daily, basiliximab induction, and corticosteroids.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
77,prograf,77,1895,1947,"The trial population had a mean age of 48 years (range 17 to 77), the distribution was 63% male, and the composition was White (74%), Black (20%), Asian (3%) and other (3%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,prograf,78,1947,2006,"The 12 month  nonoseaeaeonlyasinstruction information from this trial is presented below.\n', ' \n', '\n', ' Adverse reactions that occurred in >=15% of  notaecandidateindication patients treated with Prograf in conjunction with MMF in Study 2 are presented below:\n', '\n', ' Table 6.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
79,prograf,79,2006,2019,Kidney Transplantation: Adverse Reactions Occurring in >= 15% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,prograf,80,2019,2030,Treated with Prograf in Conjunction with MMF (Study 2),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,prograf,81,2030,2043,"\n', '                                                                Prograf/MMF         Cyclosporine/MMF        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,prograf,82,2043,2140,"\n', '                                                                (N=212)             (N=212)                 \n', '   nonoseaegeneralterm                                                                                \n', '   oselabeledaefromdruguse                                                      44%                 26%                     \n', '   oselabeledaefromdruguse                                                        39%                 47%                     \n', '   oselabeledaefromdruguse                                                  36%                 41%                     \n', '   oselabeledaefromdruguse                                                      26%                 25%                     \n', '   oselabeledaefromdruguse                                                     18%                 15%                     \n', '                                                                                                            \n', '   nonoseaegeneralterm                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
83,prograf,83,2140,2145,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,prograf,84,2145,2153,oselabeledaefromdruguse                                          29%                 27%                     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,prograf,85,2153,2191,"\n', '   oselabeledaefromdruguse                                    28%                 23%                     \n', '   oselabeledaefromdruguse                                             24%                 18%                     \n', '                                                                                                            \n', '   nonoseaegeneralterm                                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
86,prograf,86,2191,2281,"\n', '   oselabeledaefromdruguse                                                28%                 22%                     \n', '   oselabeledaefromdruguse                                              28%                 21%                     \n', '   oselabeledaefromdruguse                                                  26%                 19%                     \n', '   oselabeledaefromdruguse                                                 21%                 15%                     \n', '   oselabeledaefromdruguse                                                18%                 25%                     \n', '   oselabeledaefromdruguse                                                   16%                 18%                     \n', '                                                                                                            \n', '   nonoseaegeneralterm                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,prograf,87,2281,2294,"\n', '   oselabeledaefromdruguse                                                        34%                 20%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,prograf,88,2294,2319,"\n', '   oselabeledaefromdruguse                                                      24%                 25%                     \n', '                                                                                                            \n', '   nonoseaegeneralterm                                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,prograf,89,2319,2332,"\n', '   oselabeledaefromdruguse                                                        30%                 28%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,prograf,90,2332,2357,"\n', '   oselabeledaefromdruguse                                                    16%                 12%                     \n', '                                                                                                            \n', '   nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
91,prograf,91,2357,2364,"\n', '   oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,prograf,92,2364,2409,"35%                 46%                     \n', '   oselabeledaefromdruguse                                                  32%                 35%                     \n', '   oselabeledaefromdruguse                                                      30%                 21%                     \n', '   oselabeledaefromdruguse                                       26%                 22%                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,prograf,93,2409,2446,"\n', '   oselabeledaefromdruguse                                    23%                 23%                     \n', '         Less frequently observed adverse reactions in both  notaecandidateindication and  notaecandidateindication patients are described under the subsection  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
94,prograf,94,2446,2454,Less Frequently Reported Adverse Reactions  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,prograf,95,2454,2478,"Liver Transplantation  \n', ' \n', '\n', ' There were two randomized comparative  notaecandidateindication trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
96,prograf,96,2478,2507,"In the U.S. trial, 263 adult and pediatric patients received tacrolimus and steroids and 266 patients received cyclosporine-based immunosuppressive regimen (CsA/AZA).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,prograf,97,2507,2564,"The trial population had a mean age of 44 years (range 0.4 to70), the distribution was 52% male, and the composition was White (78%), Black (5%), Asian (2%), Hispanic (13%) and Other (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,prograf,98,2564,2583,"In the European trial, 270 patients received tacrolimus and steroids and 275 patients received CsA/AZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,prograf,99,2583,2639,"The trial population had a mean age of 46 years (range 15 to 68), the distribution was 59% male, and the composition was White (95.4%), Black (1%), Asian (2%) and Other (2%).\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,prograf,100,2639,2665,The proportion of patients reporting more than one adverse event was > 99% in both the tacrolimus group and the CsA/AZA group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,prograf,101,2665,2687,Precautions must be taken when comparing the incidence of adverse reactions in the U.S. trial to that in the European trial.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,prograf,102,2687,2706,The 12-month post-transplant information from the U.S. trial and from the European trial is presented below.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,prograf,103,2706,2725,The two trials also included different patient populations and patients were treated with immunosuppressive regimens of differing intensities.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,prograf,104,2725,2816,"Adverse reactions reported in >=15% in tacrolimus patients (combined trial results) are presented below for the two controlled trials in  notaecandidateindication \n', '\n', ' The most common adverse reactions (>= 40%) observed in Prograf-treated  notaecandidateindication patients are:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
105,prograf,105,2816,2848,"These all occur with oral and IV administration of Prograf and some may respond to a reduction in dosing (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,prograf,106,2848,2874,"oselabeledaefromdruguse was sometimes associated with other  oselabeledaefromdruguse such as  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', ' Table 7.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,prograf,107,2874,2887,Liver Transplantation: Adverse Reactions Occurring in >= 15% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,prograf,108,2887,2901,"Treated with Prograf \n', '                        U.S. TRIAL            EUROPEAN TRIAL        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,prograf,109,2901,2919,"\n', '  Prograf  (N=250)      Cyclosporine/AZA(N=250)    Prograf  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,prograf,110,2919,2928,(N=264)      Cyclosporine/AZA(N=265)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,prograf,111,2928,2935,"\n', '   nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
112,prograf,112,2935,2996,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    64%  64%  56%  40%    60%  68%  46%  30%    37%  32%  48%  17%    26%  23%  32%  17%    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,prograf,113,2996,3003,"\n', '   nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,prograf,114,3003,3092,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    72%  46%  36%  34%  27%  24%    47%  37%  30%  24%  15%  27%    37%  32%  6%  7%  14%  23%    27%  27%  5%  5%  11%  21%    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,prograf,115,3092,3099,"\n', '   nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,prograf,116,3099,3104,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,prograf,117,3104,3125,"oselabeledaefromdruguse          47%                   56%                   38%                  43%                   \n', '   nonoseaegeneralterm                                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
118,prograf,118,3125,3182,"\n', '   oselabeledaefromdruguse    40%                   27%                   36%                  23%                   \n', '   oselabeledaefromdruguse    39%                   25%                   24%                  19%                   \n', '   oselabeledaefromdruguse         30%                   22%                   12%                  9%                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,prograf,119,3182,3288,"\n', '   oselabeledaefromdruguse              18%                   15%                   19%                  12%                   \n', '   oselabeledaefromdruguse    16%                   18%                   21%                  19%                   \n', '   nonoseaegeneralterm                                                                                           \n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    48%  47%  45%  29%    45%  38%  26%  34%    16%  33%  13%  13%    9%  22%  9%  16%      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,prograf,120,3288,3295,"\n', '   nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,prograf,121,3295,3349,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    47%  32%  24%         38%  26%  20%         5%  8%  14%          1%  8%  19%           \n', '   nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
122,prograf,122,3349,3452,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    63%  59%  52%  48%  30%  27%  26%    57%  54%  48%  56%  29%  22%  26%    24%  29%  11%  19%  17%  7%  12%    22%  22%  7%  22%  17%  8%  14%    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,prograf,123,3452,3459,"\n', '   nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,prograf,124,3459,3513,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    30%  29%  28%         32%  23%  30%         36%  5%  5%          35%  4%  4%           \n', '   nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
125,prograf,125,3513,3570,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse        36%  24%              20%  19%              15%  10%             7%  4%                \n', '           Less frequently observed adverse reactions in both  notaecandidateindication and  notaecandidateindication patients are described under the subsection  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,prograf,126,3570,3578,Less Frequently Reported Adverse Reactions  .   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,prograf,127,3578,3580,notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
128,prograf,128,3580,3609,"\n', ' \n', '\n', ' The incidence of adverse reactions was determined based on two trials in primary orthotopic  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
129,prograf,129,3609,3647,"In a trial conducted in Europe, 314 patients received a regimen of antibody induction, corticosteroids and azathioprine (AZA) in combination with Prograf (n=157) or cyclosporine (n=157) for 18 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,prograf,130,3647,3776,"The trial population had a mean age of 51 years (range 18 to 65), the distribution was 82% male, and the composition was White (96%), Black (3%) and other (1%).\n', '\n', ' The most common adverse reactions ( >= 15%) observed in Prograf-treated  notaecandidateindication patients are:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', ' Adverse reactions in  notaecandidateindication patients in the European trial are presented below:\n', '\n', ' Table 8.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
131,prograf,131,3776,3789,Heart Transplantation: Adverse Reactions Occurring in >= 15% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,prograf,132,3789,3820,"Treated with Prograf in Conjunction with Azathioprine (AZA) \n', '                                                           Prograf/AZA  (n=157)     Cyclosporine/AZA   (n=157)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,prograf,133,3820,3840,"\n', '   nonoseaegeneralterm                                    \n', '   oselabeledaefromdruguse                                             62%                  69%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
134,prograf,134,3840,3853,"\n', '   oselabeledaefromdruguse                                     15%                  14%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,prograf,135,3853,3873,"\n', '   nonoseaegeneralterm                                          \n', '   oselabeledaefromdruguse                                            32%                  30%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,prograf,136,3873,3886,"\n', '   oselabeledaefromdruguse                                                24%                  21%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,prograf,137,3886,3911,"\n', '   nonoseaegeneralterm                      \n', '                                                                                                            \n', '   oselabeledaefromdruguse                                        26%                  16%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,prograf,138,3911,3924,"\n', '   oselabeledaefromdruguse                                            23%                  17%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,prograf,139,3924,3937,"\n', '   oselabeledaefromdruguse                                             18%                  27%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,prograf,140,3937,3957,"\n', '   nonoseaegeneralterm                               \n', '   oselabeledaefromdruguse                                                   50%                  36%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
141,prograf,141,3957,3970,"\n', '   oselabeledaefromdruguse                                               48%                  39%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,prograf,142,3970,3995,"\n', '                                                                                                            \n', '   nonoseaegeneralterm                                        \n', '   oselabeledaefromdruguse                                 56%                  57%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,prograf,143,3995,4008,"\n', '   oselabeledaefromdruguse                                  16%                  12%                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,prograf,144,4008,4028,"\n', '   nonoseaegeneralterm                                       \n', '   oselabeledaefromdruguse                                               17%                  18%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
145,prograf,145,4028,4048,"\n', '   nonoseaegeneralterm                                           \n', '   oselabeledaefromdruguse                                                   15%                  6%                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
146,prograf,146,4048,4134,"\n', '         In the European trial, the cyclosporine trough concentrations were above the pre-defined target range (i.e., 100 to 200 ng/mL) at Day 122 and beyond in 32 to 68% of the patients in the cyclosporine treatment arm, whereas the tacrolimus trough concentrations were within the pre-defined target range (i.e., 5 to 15 ng/mL) in 74 to 86% of the patients in the tacrolimus treatment",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,prograf,147,4134,4198,"arm.\n', ' \n', '\n', ' In a U.S. trial, the incidence of adverse reactions was based on 331  notaecandidateindication patients that received corticosteroids and Prograf in combination with sirolimus (n=109), Prograf in combination with MMF (n=107) or cyclosporine modified in combination with MMF (n=115) for 1 year.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
148,prograf,148,4198,4265,"The trial population had a mean age of 53 years (range 18 to 75), the distribution was 78% male, and the composition was White (83%), Black (13%) and other (4%).\n', '\n', ' Only selected targeted treatment-emergent adverse reactions were collected in the U.S.  notaecandidateindication trial.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
149,prograf,149,4265,4477,"Those reactions that were reported at a rate of 15% or greater in patients treated with Prograf and MMF include the following: any target adverse reactions (99%),  oselabeledaefromdruguse (89%),  oselabeledaefromdruguse requiring antihyperglycemic therapy (70%)  ,   oselabeledaefromdruguse (65%),  oselabeledaefromdruguse ( oselabeledaefromdruguse  (65%),  oselabeledaefromdruguse (on two separate occasions) (61%),  oselabeledaefromdruguse (57%),  oselabeledaefromdruguse (34%),  oselabeledaefromdruguse (34%), serious  oselabeledaefromdruguse (30%),  oselabeledaefromdruguse (24%),  oselabeledaefromdruguse (19%), and other  oselabeledaefromdruguse (15%).\n', '\n', ' Other targeted treatment-emergent adverse reactions in Prograf-treated patients occurred at a rate of less than 15%, and include the following:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '  \n', '\n', '   New Onset Diabetes After Transplant  \n', '\n', '   Kidney Transplant  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,prograf,150,4477,4510,"\n', '\n', '  nonoseaeaeonlyasinstruction  is defined as a composite of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  insulin use >= 30 days or oral  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,prograf,151,4510,4561,"In a trial in  notaecandidateindication patients (Study 2),  oselabeledaefromdruguse was observed in 75% in the Prograf-treated and 61% in the Neoral-treated patients without pre-transplant history of  notaecandidateother (  Table 9  )  [see  ",0,0,0,1,0,0,0,0,0,0,0,0,0,1,0
152,prograf,152,4561,4571,Clinical Studies  (  14.1  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,prograf,153,4571,4573,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,prograf,154,4573,4582,", '\n', ' Table 9.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,prograf,155,4582,4587,Incidence of New Onset Diabetes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,prograf,156,4587,4605,After Transplant at 1 year in Kidney Transplant Recipients in a Phase 3 Trial (Study 2),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,prograf,157,4605,4615,"\n', '  Parameter                          Treatment Group                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,prograf,158,4615,4630,"\n', '  Prograf/MMF  (n = 212)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,prograf,159,4630,4634,Neoral/MMF  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,prograf,160,4634,4640,(n = 212)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,prograf,161,4640,4653,"\n', '   oselabeledaefromdruguse                              112/150 (75%)                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,prograf,162,4653,4659,93/152 (61%)                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,prograf,163,4659,4672,"\n', '       oselabeledaefromdruguse    96/150 (64%)                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,prograf,164,4672,4678,80/152 (53%)                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,prograf,165,4678,4691,"\n', '       oselabeledaefromdruguse                    59/150 (39%)                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,prograf,166,4691,4697,28/152 (18%)                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,prograf,167,4697,4742,"\n', '      Insulin Use >= 30 days         9/150 (6%)                          4/152 (3%)                          \n', '      Oral  nonoseaeaeonlyasinstruction          15/150 (10%)                        5/152 (3%)                          ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,prograf,168,4742,4747,"\n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,prograf,169,4747,4803,"In early trials of Prograf,  nonoseaeaeonlyasinstruction  was evaluated with a more limited criteria of ""use of insulin for 30 or more consecutive days with < 5 day gap"" in patients without a prior history of  nonoseaenegation or  nonoseaenegation  Data are presented in Tables 10 to 13.  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
170,prograf,170,4803,4838,oselabeledaefromdruguse was reported in 20% of Prograf/Azathioprine (AZA)-treated  notaecandidateindication patients without pre-transplant history of  notaecandidateother in a Phase 3 trial (  Table 10  ).,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0
171,prograf,171,4838,4850,The median time to onset of  oselabeledaefromdruguse was 68 days.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,prograf,172,4850,4912,"Insulin dependence was reversible in 15% of these  oselabeledaefromdruguse patients at one year and in 50% at 2 years  nonoseaeaeonlyasinstruction  Black and Hispanic  notaecandidateindication patients were at an increased risk of development of  oselabeledaefromdruguse (  Table 11  ).\n', ' \n', '\n', ' Table 10.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
173,prograf,173,4912,4979,"Incidence of Post-Transplant Diabetes Mellitus and Insulin Use at 2 Years in Kidney Transplant Recipients in a Phase 3 Trial using Azathioprine (AZA) \n', '  Status of  nonoseaeaeonlyasinstruction se of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of  notaecandidateother or  notaecandidateother     Prograf/AZA            ",1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
174,prograf,174,4979,4983,CsA/AZA               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,prograf,175,4983,5000,"\n', '  Patients without pre-transplant history of  notaecandidatepreexistingconditionorriskfactor    151                    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
176,prograf,176,5000,5012,"151                   \n', '  New onset  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,prograf,177,5012,5021,1st Year                                     30/151 (20%)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,prograf,178,5021,5027,6/151 (4%)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,prograf,179,5027,5047,"\n', '  Still  oselabeledaefromdruguse at one year in those without prior history of  notaecandidateother    ",0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
180,prograf,180,5047,5059,25/151 (17%)           5/151 (3%)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,prograf,181,5059,5090,"\n', '  New onset  oselabeledaefromdruguse post 1 year                                   1                      0                     \n', '  Patients with  oselabeledaefromdruguse at 2 years                                16/151",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,prograf,182,5090,5101,(11%)           5/151 (3%)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,prograf,183,5101,5109,"\n', '        Table 11.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,prograf,184,5109,5124,Development of Post-Transplant Diabetes Mellitus by Race or Ethnicity and by Treatment Group,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,prograf,185,5124,5144,"During First Year Post Kidney Transplantation in a Phase 3 Trial \n', '  Patient Race                  Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,prograf,186,5144,5182,"Who Developed  nonoseaeaeonlyasinstruction se of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of  notaecandidateother or  notaecandidateother     \n', '  Prograf                       ",1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
187,prograf,187,5182,5184,Cyclosporine                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,prograf,188,5184,5197,"\n', '  Black                         15/41 (37%)                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,prograf,189,5197,5203,3 (8%)                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,prograf,190,5203,5216,"\n', '  Hispanic                      5/17 (29%)                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,prograf,191,5216,5222,1 (6%)                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,prograf,192,5222,5235,"\n', '  Caucasian                     10/82 (12%)                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,prograf,193,5235,5241,1 (1%)                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,prograf,194,5241,5254,"\n', '  Other                         0/11 (0%)                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,prograf,195,5254,5255,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,prograf,196,5255,5260,(10%)                               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,prograf,197,5260,5273,"\n', '  Total                         30/151 (20%)                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,prograf,198,5273,5279,6 (4%)                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,prograf,199,5279,5352,"\n', '           Liver Transplant  \n', ' \n', '\n', '  oselabeledaefromdruguse was reported in 18% and 11% of Prograf-treated  notaecandidateindication patients and was reversible in 45% and 31% of these patients at 1 year  nonoseaeaeonlyasinstruction  in the U.S. and European randomized trials, respectively, (  Table 12  ).  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
200,prograf,200,5352,5398,"oselabeledaefromdruguse was associated with the use of Prograf in 47% and 33% of  notaecandidateindication recipients in the U.S. and European randomized trials, respectively, and may require treatment  [see  Adverse Reactions  (  6.1  )]  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
201,prograf,201,5398,5400,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,prograf,202,5400,5409,", '\n', ' Table 12.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,prograf,203,5409,5468,"Incidence of Post-Transplant Diabetes Mellitus and Insulin Use at 1 Year in Liver Transplant Recipients \n', '  Status of  nonoseaeaeonlyasinstruction se of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of  notaecandidateother or  notaecandidateother     US Trial              European Trial        ",1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
204,prograf,204,5468,5490,"\n', '  Prograf               Cyclosporine          Prograf               Cyclosporine          \n', '  Patients at riskPatients without",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,prograf,205,5490,5498,pre-transplant history of  notaecandidateother     ,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
206,prograf,206,5498,5504,239                   236                   239                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,prograf,207,5504,5540,"249                   \n', '  New Onset  oselabeledaefromdruguse        42 (18%)              30 (13%)              26 (11%)              12 (5%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,prograf,208,5540,5577,"\n', '  Patients still on insulin at 1 year    23 (10%)              19 (8%)               18 (8%)               6 (2%)                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,prograf,209,5577,5585,"\n', '             Heart Transplant  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,prograf,210,5585,5660,"\n', ' \n', '\n', '  oselabeledaefromdruguse was reported in 13% and 22% of Prograf-treated  notaecandidateindication patients receiving mycophenolate mofetil (MMF) or azathioprine (AZA) and was reversible in 30% and 17% of these patients at one year  nonoseaeaeonlyasinstruction  in the U.S. and European randomized trials, respectively (  Table 13  ).   ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
211,prograf,211,5660,5715,"oselabeledaefromdruguse defined as two  oselabeledaefromdruguse was reported with the use of Prograf plus MMF or AZA in 32% and 35% of  notaecandidateindication recipients in the U.S. and European randomized trials, respectively, and may require treatment  [see  Adverse Reactions  (  6.1  )]  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
212,prograf,212,5715,5717,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,prograf,213,5717,5726,", '\n', ' Table 13.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,prograf,214,5726,5772,"Incidence of Post-Transplant Diabetes Mellitus and Insulin Use at 1 Year in Heart Transplant Recipients \n', '  Status of  nonoseaeaeonlyasinstruction se of insulin for 30 or more consecutive days without a prior history of  notaecandidateother or  notaecandidateother     ",1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
215,prograf,215,5772,5775,US Trial            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,prograf,216,5775,5795,"European Trial          \n', '  Prograf/MMF     Cyclosporine/MMF    Prograf/AZA             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,prograf,217,5795,5799,Cyclosporine/AZA        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,prograf,218,5799,5880,"\n', '  Patients at riskPatients without pre-transplant history of  notaecandidateother     75                  83                      132                     138                        \n', '  New Onset  oselabeledaefromdruguse     10 (13%)            6 (7%)                  29 (22%)                5 (4%)                     \n', '  Patients still on insulin at 1 year 7-12 months for the U.S. trial.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
219,prograf,219,5880,5926,"7 (9%)              1 (1%)                  24 (18%)                4 (3%)                     \n', '             Less Frequently Reported Adverse Reactions (>3% and <15%)  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,prograf,220,5926,5973,", ' \n', '\n', ' The following adverse reactions were reported in either  notaecandidateindication  kidney, and/or heart  notaecandidateindication  notaecandidateindication  and/or heart  notaecandidateindication  notaecandidateindication recipients who were treated with tacrolimus in clinical trials.   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
221,prograf,221,5973,5975,nonoseaegeneralterm    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
222,prograf,222,5975,5978,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,prograf,223,5978,5989,Warnings and Precautions  (  5.8  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,prograf,224,5989,6222,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse  [see  Warnings and Precautions  (  5.7  )]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
225,prograf,225,6222,6228,",  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,prograf,226,6228,6258,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,prograf,227,6258,6260,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
228,prograf,228,6260,6315,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
229,prograf,229,6315,6402,"\n', '\n', '  oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
230,prograf,230,6402,6429,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
231,prograf,231,6429,6466,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
232,prograf,232,6466,6498,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,prograf,233,6498,6529,"\n', '   6.2 Postmarketing Adverse Reactions\n', '\n', '  The following adverse reactions have been reported from worldwide marketing experience with Prograf.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,prograf,234,6529,6560,Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,prograf,235,6560,6757,"Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of the reporting, or (3) strength of causal connection to the drug.\n', '\n', ' Other reactions include:   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  [see  Warnings and Precautions  (  5.15  )]  .   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  [see  Warnings and Precautions  (  5.17  )]     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
236,prograf,236,6757,6759,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
237,prograf,237,6759,6797,"\n', '\n', ' Cases of  oselabeledaefromdruguse , sometimes  nonoseaegeneralterm  - oselabeledaefromdruguse  including  oselabeledaefromdruguse  [see  Warnings and Precautions  (  5.4  )]     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
238,prograf,238,6797,6799,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
239,prograf,239,6799,6819,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
240,prograf,240,6819,6872,"\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse hot and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
241,prograf,241,6872,6909,"Warnings and Precautions  (  5.8  )]  ,  oselabeledaefromdruguse   [see  Warnings and Precautions  (  5.4  )]  ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,prograf,242,6909,6911,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
243,prograf,243,6911,6969,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
244,prograf,244,6969,6990,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,prograf,245,6990,6997,"', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,prograf,246,6997,7005,BOXED WARNING - MALIGNANCIES AND SERIOUS  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,prograf,247,7005,7018,"\n', '  BOXED WARNING - MALIGNANCIES AND SERIOUS INFECTIONS\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,prograf,248,7018,7066,", '\n', '    *  Increased risk of development of  oselabeledaefromdruguse and other  oselabeledaefromdruguse  particularly of the  oselabeledaefromdruguse  oselabeledaefromdruguse  particularly of the skin, due to  nonoseaeaeonlyasinstruction [see Warnings and Precautions (5.2)].",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,prograf,249,7066,7098,"\n', ' *   oselabeledaefromdruguse to  oselabeledaefromdruguse  viral, fungal, and protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  fungal, and protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  and",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,prograf,250,7098,7120,"protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse [see Warnings and Precautions (5.3, 5.4, 5.5)]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,prograf,251,7120,7121,.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,prograf,252,7121,7139,"\n', ' *  Only physicians experienced in  nonoseaeaeonlyasinstruction and management of  notaecandidateindication    ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
253,prograf,253,7139,7183,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *    Lymphoma and Other Malignancies: Risk of lymphomas, including post transplant lymphoproliferative disorder (PLTD); appears related to intensity and duration of use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,prograf,254,7183,7196,Avoid prolonged exposure to UV light and sunlight (  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,prograf,255,7196,7243,"\n', ' *    Serious infections: Increased risk of bacterial, viral, fungal and protozoal infections, including opportunistic infections: combination immunosuppression should be used with caution (  5.3  ) \n', ' *    Polyoma Virus Infections:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,prograf,256,7243,7325,"Serious, sometimes fatal outcomes, including polyoma virus-associated nephropathy (PVAN), mostly due to BK virus, and JC virus-associated progressive multifocal leukoencephalopathy (PML); consider reducing immunosuppression (  5.4  ) \n', ' *    Cytomegalovirus (CMV) Infections: Increased risk of CMV viremia and disease; consider reducing immunosuppression (  5.5  ) \n', ' *    New Onset Diabetes After Transplant:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,prograf,257,7325,7333,Monitor blood glucose (  5.6  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,prograf,258,7333,7360,"\n', ' *    Nephrotoxicity: Acute and/or chronic; reduce the dose; use caution with other nephrotoxic drugs (  5.7  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,prograf,259,7360,7405,"\n', ' *    Neurotoxicity: Risk of Posterior Reversible Encephalopathy Syndrome, monitor for neurologic abnormalities; reduce or discontinue Prograf and other immunosuppressants (  5.8  ) \n', ' *    Hyperkalemia: Monitor serum potassium levels.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,prograf,260,7405,7425,Careful consideration should be given prior to use of other agents also associated with hyperkalemia (  5.9  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,prograf,261,7425,7438,"\n', ' *    Hypertension: May require antihypertensive therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,prograf,262,7438,7449,Monitor relevant drug-drug interactions (  5.10  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,prograf,263,7449,7478,"\n', ' *    Anaphylactic Reactions with IV formulation: Observe patients receiving Prograf injection for signs and symptoms of anaphylaxis (  5.11  ) \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,prograf,264,7478,7487,"', ' *    Use with Sirolimus:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,prograf,265,7487,7546,"Not recommended in liver and heart transplant due to increased risk of serious adverse reactions (  5.12  ) \n', ' *    Myocardial Hypertrophy: Consider dosage reduction or discontinuation (  5.15  ) \n', ' *    Immunizations: Use of live vaccines should be avoided (  5.16  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,prograf,266,7546,7566,"\n', ' *    Pure Red Cell Aplasia: Discontinuation should be considered (  5.17  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,prograf,267,7566,7612,"\n', '    \n', ' \n', '\n', '   5.1 Management of Immunosuppression\n', '\n', '  Only physicians experienced in  nonoseaeaeonlyasinstruction and management of  notaecandidateindication patients should use Prograf.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
268,prograf,268,7612,7632,Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,prograf,269,7632,7721,"The physicians responsible for maintenance therapy should have complete information requisite for the follow up of the patient [see  Boxed Warning  ]  .\n', '\n', '    5.2 Lymphoma and Other Malignancies\n', '\n', '  Patients receiving immunosuppressants, including Prograf, are at increased risk of developing  oselabeledaefromdruguse and other  oselabeledaefromdruguse  particularly of the  oselabeledaefromdruguse  oselabeledaefromdruguse  particularly of the skin [see  Boxed Warning  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,prograf,270,7721,7804,"The risk appears to be related to the intensity and duration of  nonoseaeaeonlyasinstruction rather than to the use of any specific agent.\n', '\n', ' As usual for patients with increased risk for  nonoseaeaeonlyasinstruction  exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.\n', '\n', '  oselabeledaeclasseffect  has been reported in  notaecandidatepreexistingconditionorriskfactor  notaecandidateindication recipients.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
271,prograf,271,7804,7816,The majority of  oselabeledaeclasseffect events appear related to  oselabeledaeclasseffect  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,prograf,272,7816,7927,"The risk of  nonoseaeaeonlyasinstruction appears greatest in those individuals who are  notaecandidatepreexistingconditionorriskfactor  a population which includes many young children.\n', '\n', '    5.3 Serious Infections\n', '\n', '  Patients receiving immunosuppressants, including Prograf, are at increased risk of developing  oselabeledaefromdruguse  viral, fungal, and protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  fungal, and protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  and protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse [see  Boxed Warning  and  Warnings and Precautions  (  5.4  ,  5.5  )]  .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
273,prograf,273,7927,7941,"These  oselabeledaefromdruguse may lead to serious, including  nonoseaegeneralterm  outcomes.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
274,prograf,274,7941,8017,"Because of the danger of  nonoseaeaeonlyasinstruction which can increase  nonoseaeaeonlyasinstruction  combination  nonoseaeaeonlyasinstruction should be used with caution.\n', '\n', '    5.4 Polyoma Virus Infections\n', '\n', '  Patients receiving immunosuppressants, including Prograf, are at increased risk for  oselabeledaefromdruguse  including  oselabeledaefromdruguse   nonoseaeaeonlyasinstruction in  notaecandidateindication patients may have serious, and sometimes  nonoseaegeneralterm  outcomes.",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
275,prograf,275,8017,8053,"These include  oselabeledaefromdruguse , mostly due to  oselabeledaefromdruguse  and  oselabeledaefromdruguse  which have been observed in patients receiving tacrolimus [see  Adverse Reactions  (  6.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,prograf,276,8053,8089,".\n', '\n', '  nonoseaeaeonlyasinstruction is associated with serious outcomes, including  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication [see  Adverse Reactions  (  6.2  )]  .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
277,prograf,277,8089,8122,"Patient monitoring may help detect patients at risk for  nonoseaeaeonlyasinstruction \n', '\n', ' Cases of  oselabeledaefromdruguse have been reported in patients treated with Prograf.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,prograf,278,8122,8136,nonoseaeaeonlyasinstruction  which is sometimes  nonoseaegeneralterm  commonly presents with  nonoseaemanifestationorcomplication   ,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
279,prograf,279,8136,8232,"nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  Risk factors for  nonoseaeaeonlyasinstruction include treatment with  nonoseaeaeonlyasinstruction and  notaecandidatepreexistingconditionorriskfactor  In  notaecandidatepreexistingconditionorriskfactor patients, physicians should consider  nonoseaeaeonlyasinstruction in the differential diagnosis in patients reporting  nonoseaemanifestationorcomplication and consultation with a neurologist should be considered as clinically indicated.\n', '\n', ' Reductions in  nonoseaeaeonlyasinstruction should be considered for patients who develop evidence of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  Physicians should also consider the risk that reduced  nonoseaeaeonlyasinstruction represents to the functioning allograft.\n',",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
280,prograf,280,8232,8271,"'\n', '    5.5 Cytomegalovirus (CMV) Infections\n', '\n', '  Patients receiving immunosuppressants, including Prograf, are at increased risk of developing  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,prograf,281,8271,8311,The risk of  oselabeledaefromdruguse is highest among  notaecandidateindication recipients  notaecandidatepreexistingconditionorriskfactor at time of  nonoseaeaeonlyasinstruction who receive a graft from a  notaecandidatepreexistingconditionorriskfactor  Therapeutic approaches to limiting  nonoseaeaeonlyasinstruction exist and should be routinely provided.,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
282,prograf,282,8311,8356,"Patient monitoring may help detect patients at risk for  nonoseaeaeonlyasinstruction  Consideration should be given to reducing the amount of  nonoseaeaeonlyasinstruction in patients who develop  nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction \n', '\n', '    5.6 New Onset Diabetes",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,prograf,283,8356,8398,"After Transplant\n', '\n', '  Prograf was shown to cause new onset  oselabeledaefromdruguse in clinical trials of  notaecandidateindication  liver, and heart  notaecandidateindication  notaecandidateindication  and heart  notaecandidateindication  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
284,prograf,284,8398,8412,New onset  oselabeledaefromdruguse after  notaecandidateindication may be reversible in some patients.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
285,prograf,285,8412,8424,Black and Hispanic  notaecandidateindication patients are at an increased risk.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
286,prograf,286,8424,8448,Blood glucose concentrations should be monitored closely in patients using Prograf [see  Adverse Reactions  (  6.1  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,prograf,287,8448,8450,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,prograf,288,8450,8490,", '\n', '    5.7 Nephrotoxicity\n', '\n', '  Prograf, like other calcineurin-inhibitors, can cause acute or chronic  oselabeledaefromdruguse  particularly when used in high doses.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,prograf,289,8490,8519,Acute  oselabeledaefromdruguse is most often related to  nonoseaeaeonlyasinstruction  is characterized by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or a  nonoseaemanifestationorcomplication  and is typically reversible.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
290,prograf,290,8519,8547,Chronic  oselabeledaefromdruguse is associated with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and characteristic histologic  nonoseaemanifestationorcomplication  the changes associated with chronic  oselabeledaefromdruguse are typically progressive.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
291,prograf,291,8547,8566,Patients with  notaecandidatepreexistingconditionorriskfactor should be monitored closely as the dosage of Prograf may need to be reduced.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
292,prograf,292,8566,8669,"In patients with persistent  notaecandidatepreexistingconditionorriskfactor who are unresponsive to dosage adjustments, consideration should be given to changing to another  nonoseaeaeonlyasinstruction \n', '\n', ' Based on reported adverse reactions terms related to  oselabeledaefromdruguse   oselabeledaefromdruguse was reported in approximately 52% of  notaecandidateindication patients and in 40% and 36% of  notaecandidateindication patients receiving Prograf in the U.S. and European randomized trials, respectively, and in 59% of  notaecandidateindication patients in a European randomized trial [see  Adverse Reactions  (  6.1  )].  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
293,prograf,293,8669,8705,"\n', '\n', ' Due to the potential for additive or synergistic  nonoseaeaefromdruginteraction  care should be taken when administering Prograf with drugs that may be associated with  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
294,prograf,294,8705,8743,"These include, but are not limited to, aminoglycosides, ganciclovir, amphotericin B, cisplatin, nucleotide reverse transcriptase inhibitors (e.g., tenofovir) and protease inhibitors (e.g., ritonavir, indinavir).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,prograf,295,8743,8827,"Similarly, care should be exercised when administering with CYP3A4 inhibitors such as antifungal drugs (e.g., ketoconazole), calcium channel blockers (e.g., diltiazem, verapamil), and macrolide antibiotics (e.g., clarithromycin, erythromycin, troleandomycin) which will result in increased tacrolimus whole blood concentrations due to inhibition of tacrolimus metabolism [see  Drug Interactions  (  7.3  ,  7.4  ,  7.5  ,  7.6  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,prograf,296,8827,8862,".\n', '\n', '    5.8 Neurotoxicity\n', '\n', '   Prograf may cause a spectrum of  oselabeledaefromdruguse  particularly when used in high doses.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,prograf,297,8862,8915,"The most severe  oselabeledaefromdruguse include  oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse  Patients treated with tacrolimus have been reported to develop  oselabeledaefromdruguse  Symptoms indicating  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  Diagnosis may be confirmed by radiological procedure.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
298,prograf,298,8915,8938,"If  nonoseaeaeonlyasinstruction is suspected or diagnosed, blood pressure control should be maintained and immediate reduction of  nonoseaeaeonlyasinstruction is advised.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,prograf,299,8938,8991,"This syndrome is characterized by reversal of symptoms upon reduction or discontinuation of  nonoseaeaeonlyasinstruction   \n', ' \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse  in the absence of  nonoseaenegation  have also been associated with high plasma concentrations of tacrolimus.  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
300,prograf,300,8991,9014,oselabeledaefromdruguse have occurred in adult and pediatric patients receiving Prograf [see  Adverse Reactions  (  6.1  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,prograf,301,9014,9057,".\n', '\n', ' Less severe  oselabeledaefromdruguse  include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and other  oselabeledaefromdruguse  oselabeledaefromdruguse motor function,  oselabeledaefromdruguse  oselabeledaefromdruguse motor function, mental status, and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,prograf,302,9057,9071,[see  Adverse Reactions  (  6.1  )].   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,prograf,303,9071,9118,"oselabeledaefromdruguse and  oselabeledaefromdruguse have been associated with high whole-blood concentrations of tacrolimus and may respond to dosage adjustment.\n', '\n', '    5.9 Hyperkalemia\n', '\n', '   oselabeledaefromdruguse has been reported with Prograf use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,prograf,304,9118,9125,Serum potassium levels should be monitored.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,prograf,305,9125,9172,"Careful consideration should be given prior to use of other agents also associated with  nonoseaeaeonlyasinstruction (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during Prograf therapy [see  Adverse Reactions  (  6.1  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,prograf,306,9172,9187,".\n', '\n', '    5.10 Hypertension\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,prograf,307,9187,9219,"', '   oselabeledaefromdruguse is a common adverse effect of Prograf therapy and may require antihypertensive therapy [see  Adverse Reactions  (  6.1  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,prograf,308,9219,9281,"The control of blood pressure can be accomplished with any of the common antihypertensive agents, though careful consideration should be given prior to use of antihypertensive agents associated with  nonoseaeaeonlyasinstruction (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) [see  Warnings and Precautions  (  5.9  )]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,prograf,309,9281,9312,Calcium-channel blocking agents may increase tacrolimus blood concentrations and therefore require dosage reduction of Prograf [see  Drug Interactions  (  7.5  )].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,prograf,310,9312,9359,"\n', '\n', '    5.11 Anaphylactic Reactions with Prograf Injection\n', '\n', '   oselabeledaefromdruguse have occurred with injectables containing castor oil derivatives, including Prograf, in a small percentage of patients (0.6%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,prograf,311,9359,9369,The exact cause of these reactions is not known.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,prograf,312,9369,9397,Prograf injection should be reserved for patients who are unable to take Prograf capsules [see  Indications and Usage  (  1.4  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,prograf,313,9397,9433,".\n', '\n', ' Patients receiving Prograf injection should be under continuous observation for at least the first 30 minutes following the start of the infusion and at frequent intervals thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,prograf,314,9433,9448,"If signs or symptoms of  nonoseaeaeonlyasinstruction occur, the infusion should be stopped.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,prograf,315,9448,9468,"An aqueous solution of epinephrine should be available at the bedside as well as a source of oxygen.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,prograf,316,9468,9554,"'\n', '    5.12 Use with Sirolimus\n', '\n', '  The safety and efficacy of Prograf with sirolimus has not been established in  notaecandidateindication patients.\n', '\n', ' Use of sirolimus with Prograf in studies of de novo   notaecandidateindication patients was associated with an excess  nonoseaegeneralterm   nonoseaeaefromdruginteraction  and  nonoseaeaefromdruginteraction  and is not recommended [see  Indications and Usage  (  1.4  )]  ",0,1,0,1,0,1,0,0,0,0,0,0,0,0,0
317,prograf,317,9554,9613,".\n', '\n', ' Use of sirolimus (2 mg per day) with Prograf in  notaecandidateindication patients in a U.S. trial was associated with increased risk of  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  and  nonoseaeaefromdruginteraction  and is not recommended [see  Clinical Studies  (  14.3  )]  ",0,0,0,1,0,1,0,0,0,0,0,0,0,0,0
318,prograf,318,9613,9637,".\n', '\n', '    5.13 Use with CYP3A4 Inhibitors and Inducers\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,prograf,319,9637,9709,"When coadministering Prograf with strong CYP3A4-inhibitors (e.g., telaprevir, boceprevir, ritonavir, ketoconazole, itraconazole, voriconazole, clarithromycin) and strong inducers (e.g., rifampin, rifabutin) adjustments in the dosing regimen of Prograf and subsequent frequent monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions are recommended [see  Drug Interactions  (  7  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,prograf,320,9709,9747,"\n', '\n', '    5.14 QT Prolongation\n', '\n', '  Prograf may  oselabeledaefromdruguse and may cause  oselabeledaefromdruguse  Avoid Prograf in patients with  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
321,prograf,321,9747,9850,"In patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  those taking certain antiarrhythmic medications or other medicinal products that lead to  nonoseaeaeonlyasinstruction  and those with  notaecandidatepreexistingconditionorriskfactor such as  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor  consider obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.\n', '\n', ' When coadministering Prograf with other substrates and/or inhibitors of CYP3A4 that also have the potential to  nonoseaeaeonlyasinstruction  a reduction in Prograf dose, frequent monitoring of tacrolimus whole blood concentrations, and monitoring for  nonoseaeaeonlyasinstruction is recommended.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
322,prograf,322,9850,9886,Use of Prograf with amiodarone has been reported to result in increased tacrolimus whole blood concentrations with or without concurrent  nonoseaeaefromdruginteraction [see  Drug Interactions  (  7  )].  ,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
323,prograf,323,9886,9903,"\n', '\n', '    5.15 Myocardial Hypertrophy\n', '\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,prograf,324,9903,9944,", '   oselabeledaefromdruguse has been reported in infants, children, and adults, particularly those with high tacrolimus trough concentrations, and is generally manifested by echocardiographically demonstrated concentric  oselabeledaefromdruguse and interventricular septum  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,prograf,325,9944,9959,This condition appears reversible in most cases following dose reduction or discontinuance of therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,prograf,326,9959,9982,"In patients who develop  oselabeledaefromdruguse or clinical manifestations of  oselabeledaefromdruguse while receiving Prograf therapy, echocardiographic evaluation should be considered.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,prograf,327,9982,10010,"If  nonoseaeaeonlyasinstruction is diagnosed, dosage reduction or discontinuation of Prograf should be considered [see  Adverse Reactions  (  6.2  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
328,prograf,328,10010,10022,".\n', '\n', '    5.16 Immunizations\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,prograf,329,10022,10110,", '\n', '  The use of live vaccines should be avoided during treatment with tacrolimus; examples include (not limited to) the following: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.\n', '\n', '    5.17 Pure Red Cell Aplasia\n', '\n', '  Cases of  oselabeledaefromdruguse  have been reported in patients treated with tacrolimus.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,prograf,330,10110,10120,A mechanism for  oselabeledaefromdruguse has not been elucidated.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,prograf,331,10120,10144,"All patients reported risk factors for  nonoseaeaeonlyasinstruction such as  notaecandidatepreexistingconditionorriskfactor  underlying disease, or concomitant medications associated with  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
332,prograf,332,10144,10169,"If  nonoseaeaeonlyasinstruction is diagnosed, discontinuation of Prograf should be considered [see  Adverse Reactions  (  6.2  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
333,prograf,333,10169,10229,".\n', '\n', '    5.18 Gastrointestinal Perforation\n', '\n', '   oselabeledaefromdruguse has been reported in patients treated with Prograf; all reported cases were considered to be a complication of  notaecandidateindication surgery or accompanied by  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor  As  nonoseaeaeonlyasinstruction ']",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
0,inlyta,0,0,89,"['  6 ADVERSE REACTIONS\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' The safety of INLYTA has been evaluated in 715 patients in monotherapy studies, which included 537 patients with advanced  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
1,inlyta,1,89,215,"The data described  [see  Adverse Reactions (6.1)  ]  reflect exposure to INLYTA in 359 patients with advanced  notaecandidateindication who participated in a randomized clinical study versus sorafenib  [see  Clinical Studies (14)  ]  .\n', '\n', ' The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [see  Warnings and Precautions (5.1-5.13)  ]  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse perforation and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
2,inlyta,2,215,273,"\n', '\n', '   EXCERPT:   The most common (>=20%) adverse reactions are diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,inlyta,3,273,315,"(  6.1  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,inlyta,4,315,378,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  The median duration of treatment was 6.4 months (range 0.03 to 22.0) for patients who received INLYTA and 5.0 months (range 0.03 to 20.1) for patients who received sorafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,inlyta,5,378,410,Dose modifications or temporary delay of treatment due to an adverse reaction occurred in 199/359 patients (55%) receiving INLYTA and 220/355 patients (62%) receiving sorafenib.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,inlyta,6,410,512,"Permanent discontinuation due to an adverse reaction occurred in 34/359 patients (9%) receiving INLYTA and 46/355 patients (13%) receiving sorafenib.\n', '\n', ' The most common (>=20%) adverse reactions observed following treatment with INLYTA were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  Table 1 presents adverse reactions reported in >=10% patients who received INLYTA or sorafenib.\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,inlyta,7,512,522,Adverse Reactions Occurring in >=10% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,inlyta,8,522,590,"Who Received INLYTA or Sorafenib \n', ' Adverse Reaction [note: Percentages are treatment-emergent, all-causality events]       INLYTA          Sorafenib      \n', ' (N=359)                                       (N=355)       \n', ' All Grades [note: National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0]      Grade 3/4       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,inlyta,9,590,596,All Grades        Grade 3/4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,inlyta,10,596,606,"\n', ' %                                                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,inlyta,11,606,637,"%          \n', '  \n', '  oselabeledaefromdruguse                                        55               11               53                7          \n', '  oselabeledaefromdruguse                                    40               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,inlyta,12,637,639,16               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,inlyta,13,639,643,29               11          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,inlyta,14,643,652,"\n', '  oselabeledaefromdruguse                                         39               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,inlyta,15,652,663,"11               32                5          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,inlyta,16,663,682,"oselabeledaefromdruguse                              34                5               29                4          \n', '  oselabeledaefromdruguse                                          32                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,inlyta,17,682,699,"3               22                1          \n', '  oselabeledaefromdruguse                                       31                0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,inlyta,18,699,703,14                0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,inlyta,19,703,712,"\n', '  oselabeledaefromdruguse        27                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,inlyta,20,712,716,5               51               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,inlyta,21,716,718,16          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,inlyta,22,718,725,"\n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,inlyta,23,725,727,25                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,inlyta,24,727,814,"2               21                1          \n', '  oselabeledaefromdruguse                                        24                3               17                1          \n', '  oselabeledaefromdruguse                                        21                5               14                3          \n', '  oselabeledaefromdruguse                                    20                1               20                1          \n', '  oselabeledaefromdruguse                                  19               <1                8                0          \n', '  oselabeledaefromdruguse                                           15                1               17                1          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,inlyta,25,814,829,"oselabeledaefromdruguse                            15                1               12                1          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,inlyta,26,829,835,oselabeledaefromdruguse                                      15                2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,inlyta,27,835,837,11                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,inlyta,28,837,839,1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,inlyta,29,839,846,"\n', '  oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,inlyta,30,846,848,15                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,inlyta,31,848,850,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,inlyta,32,850,852,12               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,inlyta,33,852,862,"<1          \n', '  oselabeledaefromdruguse                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,inlyta,34,862,866,15                3               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,inlyta,35,866,868,12                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,inlyta,36,868,900,"3          \n', '  oselabeledaefromdruguse                                  14                2               11                1          \n', '  oselabeledaefromdruguse                                        14                1               11                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,inlyta,37,900,1032,"\n', '  oselabeledaefromdruguse                               13                1               14                1          \n', '  oselabeledaefromdruguse                                            13               <1               32                4          \n', '  oselabeledaefromdruguse                                     11                3                7                2          \n', '  oselabeledaefromdruguse                                       11                0                8                0          \n', '  oselabeledaefromdruguse                                        10                0               11                0          \n', '  oselabeledaefromdruguse                                       10                0                2                0          \n', '  oselabeledaefromdruguse                                         7                0               12                0          \n', '  oselabeledaefromdruguse                                         4                0               32                0          \n', '  oselabeledaefromdruguse                                         2                0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,inlyta,38,1032,1034,10               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,inlyta,39,1034,1171,"<1          \n', '           Selected adverse reactions (all grades) that were reported in <10% of patients treated with INLYTA included  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,inlyta,40,1171,1193,"occlusion/ oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (1%).\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,inlyta,41,1193,1231,"\n', '\n', ' Table 2 presents the most common  nonoseaegeneralterm reported in >=10% patients who received INLYTA or sorafenib.\n', '\n', ' Table 2.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,inlyta,42,1231,1241,Laboratory Abnormalities Occurring in >=10% of Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,inlyta,43,1241,1257,"Who Received INLYTA or Sorafenib \n', ' Laboratory Abnormality                        N         INLYTA        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,inlyta,44,1257,1261,N       Sorafenib    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,inlyta,45,1261,1287,"\n', ' All Grades [note: National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0]   Grade 3/4   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,inlyta,46,1287,1290,All Grades  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,inlyta,47,1290,1293,Grade 3/4    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,inlyta,48,1293,1305,"\n', ' %                                             %           %           %        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,inlyta,49,1305,1348,"\n', '  \n', ' ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase   \n', '  \n', '   Hematology                                                                                                       \n', '  oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,inlyta,50,1348,1350,320          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,inlyta,51,1350,1352,35          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,inlyta,52,1352,1355,<1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,inlyta,53,1355,1361,316          52          4        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,inlyta,54,1361,1368,"\n', '  oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,inlyta,55,1368,1380,317          33          3          309          36          4        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,inlyta,56,1380,1387,"\n', '  oselabeledaefromdruguse                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,inlyta,57,1387,1400,312          15          <1         310          14          0        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,inlyta,58,1400,1407,"\n', '  oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,inlyta,59,1407,1411,320          11          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,inlyta,60,1411,1413,0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,inlyta,61,1413,1415,315          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,inlyta,62,1415,1417,16          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,inlyta,63,1417,1434,"<1       \n', '    nonoseaegeneralterm                                                                                                        \n', '  oselabeledaefromdruguse                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,inlyta,64,1434,1440,336          55          0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,inlyta,65,1440,1442,318          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,inlyta,66,1442,1456,"41          <1       \n', '  oselabeledaefromdruguse                        314          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,inlyta,67,1456,1458,44          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,inlyta,68,1458,1461,<1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,inlyta,69,1461,1467,291          43          0        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,inlyta,70,1467,1495,"\n', '  oselabeledaefromdruguse                                 336          39          1          319          59          2        \n', '  oselabeledaefromdruguse                                336          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,inlyta,71,1495,1499,30          1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,inlyta,72,1499,1503,319          34          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,inlyta,73,1503,1505,1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,inlyta,74,1505,1543,"\n', '  oselabeledaefromdruguse                                336          28          2          319          23          2        \n', '  oselabeledaefromdruguse                             338          27          5          319          46          15       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,inlyta,75,1543,1552,"\n', '  oselabeledaefromdruguse                            338          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,inlyta,76,1552,1556,25          2          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,inlyta,77,1556,1562,319          33          2        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,inlyta,78,1562,1569,"\n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,inlyta,79,1569,1571,331          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,inlyta,80,1571,1576,22          <1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,inlyta,81,1576,1580,313          22          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,inlyta,82,1580,1582,2        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,inlyta,83,1582,1587,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,inlyta,84,1587,1591,oselabeledaefromdruguse                                331          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,inlyta,85,1591,1593,20          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,inlyta,86,1593,1596,<1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,inlyta,87,1596,1598,311          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,inlyta,88,1598,1600,25          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,inlyta,89,1600,1602,1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,inlyta,90,1602,1609,"\n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,inlyta,91,1609,1619,338          17          1          319          13          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,inlyta,92,1619,1621,1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,inlyta,93,1621,1626,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,inlyta,94,1626,1641,oselabeledaefromdruguse                              337          15          <1         319          18          1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,inlyta,95,1641,1652,"\n', '  oselabeledaefromdruguse                                 333          15          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,inlyta,96,1652,1654,3          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,inlyta,97,1654,1656,314          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,inlyta,98,1656,1658,10          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,inlyta,99,1658,1660,3        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,inlyta,100,1660,1671,"\n', '  oselabeledaefromdruguse                                 336          11          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,inlyta,101,1671,1674,<1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,inlyta,102,1674,1678,319          8           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,inlyta,103,1678,1711,"<1       \n', '  oselabeledaefromdruguse                                 338          13          4          319          11          2        \n', '  oselabeledaefromdruguse                             336          13          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,inlyta,104,1711,1715,2          318          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,inlyta,105,1715,1719,49          16       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,inlyta,106,1719,1769,"\n', '             Selected  nonoseaegeneralterm (all grades) that were reported in <10% of patients treated with INLYTA included  oselabeledaefromdruguse (above the upper limit of normal) (9% for INLYTA versus 1% for sorafenib) and  oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,inlyta,107,1769,1794,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Hypertension including hypertensive crisis has been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,inlyta,108,1794,1806,Blood pressure should be well-controlled prior to initiating INLYTA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,inlyta,109,1806,1814,Monitor for hypertension and treat as needed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,inlyta,110,1814,1830,"For persistent hypertension despite use of anti-hypertensive medications, reduce the INLYTA dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,inlyta,111,1830,1835,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,inlyta,112,1835,1854,"\n', ' *  Arterial and venous thrombotic events have been observed and can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,inlyta,113,1854,1868,Use with caution in patients who are at increased risk for these events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,inlyta,114,1868,1877,"(  5.2  ,  5.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,inlyta,115,1877,1894,"\n', ' *  Hemorrhagic events, including fatal events, have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,inlyta,116,1894,1921,INLYTA has not been studied in patients with evidence of untreated brain metastasis or recent active gastrointestinal bleeding and should not be used in those patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,inlyta,117,1921,1942,"(  5.4  ) \n', ' *  Cardiac failure has been observed and can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,inlyta,118,1942,1955,Monitor for signs or symptoms of cardiac failure throughout treatment with INLYTA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,inlyta,119,1955,1977,"(  5.5  ) \n', ' *  Gastrointestinal perforation and fistula, including death, have occurred.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,inlyta,120,1977,1990,Use with caution in patients at risk for gastrointestinal perforation or fistula.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,inlyta,121,1990,2010,"(  5.6  ) \n', ' *  Hypothyroidism requiring thyroid hormone replacement has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,inlyta,122,2010,2025,"Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,inlyta,123,2025,2031,(  5.7  ) \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,inlyta,124,2031,2047,"', ' *  Stop INLYTA at least 24 hours prior to scheduled surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,inlyta,125,2047,2069,"(  5.8  ) \n', ' *  Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,inlyta,126,2069,2080,Permanently discontinue INLYTA if signs or symptoms of RPLS occur.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,inlyta,127,2080,2106,"(  5.9  ) \n', ' *  Monitor for proteinuria before initiation of, and periodically throughout, treatment with INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,inlyta,128,2106,2122,"For moderate to severe proteinuria, reduce the dose or temporarily interrupt treatment with INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,inlyta,129,2122,2144,"(  5.10  ) \n', ' *  Liver enzyme elevation has been observed during treatment with INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,inlyta,130,2144,2162,"Monitor ALT, AST and bilirubin before initiation of, and periodically throughout, treatment with INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,inlyta,131,2162,2167,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,inlyta,132,2167,2173,"\n', ' *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,inlyta,133,2173,2190,The starting dose of INLYTA should be decreased if used in patients with moderate hepatic impairment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,inlyta,134,2190,2202,INLYTA has not been studied in patients with severe hepatic impairment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,inlyta,135,2202,2235,"(  2.2  ,  5.12  ) \n', ' *  INLYTA can cause fetal harm when administered to a pregnant woman based on its mechanism of action.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,inlyta,136,2235,2258,Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant while receiving INLYTA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,inlyta,137,2258,2264,"(  5.13  ,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,inlyta,138,2264,2267,8.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,inlyta,139,2267,2336,"\n', '    \n', ' \n', '\n', '   5.1 Hypertension and Hypertensive Crisis\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse was reported in 145/359 patients (40%) receiving INLYTA and 103/355 patients (29%) receiving sorafenib.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
140,inlyta,140,2336,2362,Grade 3/4  oselabeledaefromdruguse was observed in 56/359 patients (16%) receiving INLYTA and 39/355 patients (11%) receiving sorafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,inlyta,141,2362,2383,oselabeledaefromdruguse was reported in 2/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,inlyta,142,2383,2423,The median onset time for  oselabeledaefromdruguse ( oselabeledaefromdruguse or  oselabeledaefromdruguse  was within the first month of the start of INLYTA treatment and  oselabeledaefromdruguse have been observed as early as 4 days after starting INLYTA.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,inlyta,143,2423,2431,nonoseaeaeonlyasinstruction was managed with standard antihypertensive therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,inlyta,144,2431,2469,Discontinuation of INLYTA treatment due to  oselabeledaefromdruguse occurred in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see  Adverse Reactions (6.1)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,inlyta,145,2469,2489,"\n', '\n', ' Blood pressure should be well-controlled prior to initiating INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,inlyta,146,2489,2505,Patients should be monitored for  nonoseaeaeonlyasinstruction and treated as needed with standard  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,inlyta,147,2505,2523,In the case of persistent  nonoseaeaeonlyasinstruction despite use of  nonoseaeaeonlyasinstruction  reduce the INLYTA dose.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,inlyta,148,2523,2582,"Discontinue INLYTA if  nonoseaeaeonlyasinstruction is severe and persistent despite  nonoseaeaeonlyasinstruction and dose reduction of INLYTA, and discontinuation should be considered if there is evidence of  nonoseaeaeonlyasinstruction  If INLYTA is interrupted, patients receiving antihypertensive medications should be monitored for  nonoseaeaeonlyasinstruction [see  Dosage and Administration (2.2)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,inlyta,149,2582,2617,"\n', '\n', '    5.2 Arterial Thromboembolic Events\n', '\n', '  In clinical trials,  oselabeledaefromdruguse have been reported, including  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
150,inlyta,150,2617,2659,In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication  Grade 3/4  oselabeledaefromdruguse were reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib.  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
151,inlyta,151,2659,2739,"nonoseaegeneralterm  oselabeledaefromdruguse was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see  Adverse Reactions (6.1)  ]  .\n', '\n', ' In clinical trials with INLYTA,  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  were reported in 17/715 patients (2%), with two  nonoseaegeneralterm secondary to  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
152,inlyta,152,2739,2769,"\n', '\n', ' Use INLYTA with caution in patients who are at risk for, or who have a history of, these events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,inlyta,153,2769,2820,"INLYTA has not been studied in patients who had an  notaecandidatepreexistingconditionorriskfactor within the previous 12 months.\n', '\n', '    5.3 Venous Thromboembolic Events\n', '\n', '  In clinical trials,  oselabeledaefromdruguse have been reported, including  nonoseaegeneralterm  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
154,inlyta,154,2820,2858,In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse were reported in 11/359 patients (3%) receiving INLYTA and 2/355 patients (1%) receiving sorafenib.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
155,inlyta,155,2858,2896,Grade 3/4  oselabeledaefromdruguse were reported in 9/359 patients (3%) receiving INLYTA (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  and 2/355 patients (1%) receiving sorafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,inlyta,156,2896,2919,nonoseaegeneralterm  oselabeledaefromdruguse was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
157,inlyta,157,2919,2945,"In clinical trials with INLYTA,  oselabeledaefromdruguse were reported in 22/715 patients (3%), with two  nonoseaegeneralterm secondary to  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
158,inlyta,158,2945,2975,"\n', '\n', ' Use INLYTA with caution in patients who are at risk for, or who have a history of, these events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,inlyta,159,2975,3048,"INLYTA has not been studied in patients who had a  notaecandidatepreexistingconditionorriskfactor within the previous 6 months.\n', '\n', '    5.4 Hemorrhage\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse were reported in 58/359 patients (16%) receiving INLYTA and 64/355 patients (18%) receiving sorafenib.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
160,inlyta,160,3048,3089,Grade 3/4  oselabeledaefromdruguse were reported in 5/359 (1%) patients receiving INLYTA (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  and 11/355 (3%) patients receiving sorafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,inlyta,161,3089,3150,"nonoseaegeneralterm  oselabeledaefromdruguse was reported in 1/359 patients (<1%) receiving INLYTA ( oselabeledaefromdruguse  and 3/355 patients (1%) receiving sorafenib.\n', '\n', ' INLYTA has not been studied in patients who have evidence of untreated  notaecandidatepreexistingconditionorriskfactor or recent  notaecandidatepreexistingconditionorriskfactor and should not be used in those patients.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
162,inlyta,162,3150,3220,"If any  nonoseaeaeonlyasinstruction requires medical intervention, temporarily interrupt the INLYTA dose.\n', '\n', '    5.5 Cardiac Failure\n', '\n', '   In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse was reported in 6/359 patients (2%) receiving INLYTA and 3/355 patients (1%) receiving sorafenib.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
163,inlyta,163,3220,3247,Grade 3/4  oselabeledaefromdruguse was observed in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,inlyta,164,3247,3272,nonoseaegeneralterm  oselabeledaefromdruguse was reported in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
165,inlyta,165,3272,3285,Monitor for signs or symptoms of  nonoseaeaeonlyasinstruction throughout treatment with INLYTA.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,inlyta,166,3285,3297,Management of  nonoseaeaeonlyasinstruction may require permanent discontinuation of INLYTA.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,inlyta,167,3297,3357,"\n', '\n', '    5.6 Gastrointestinal Perforation and Fistula Formation\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with RCC,  oselabeledaefromdruguse was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,inlyta,168,3357,3380,"In clinical trials with INLYTA,  oselabeledaefromdruguse was reported in 5/715 patients (1%), including one  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
169,inlyta,169,3380,3482,"In addition to cases of  oselabeledaefromdruguse  oselabeledaefromdruguse perforation,  oselabeledaefromdruguse were reported in 4/715 patients (1%).\n', '\n', ' Monitor for symptoms of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction perforation or  nonoseaeaeonlyasinstruction periodically throughout treatment with INLYTA.\n', '\n', '    5.7 Thyroid Dysfunction\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse was reported in 69/359 patients (19%) receiving INLYTA and 29/355 patients (8%) receiving sorafenib.  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
170,inlyta,170,3482,3504,oselabeledaefromdruguse was reported in 4/359 patients (1%) receiving INLYTA and 4/355 patients (1%) receiving sorafenib.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,inlyta,171,3504,3553,"In patients who had  notaecandidatepreexistingconditionorriskfactor before treatment,  oselabeledaefromdruguse to >=10 muU/mL occurred in 79/245 patients (32%) receiving INLYTA and 25/232 patients (11%) receiving sorafenib [see  Adverse Reactions (6.1)  ].  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
172,inlyta,172,3553,3576,"\n', '\n', ' Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,inlyta,173,3576,3645,"Treat  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction according to standard medical practice to maintain euthyroid state.\n', '\n', '    5.8 Wound Healing Complications\n', '\n', '  No formal studies of the effect of INLYTA on  notaecandidatepreexistingconditionorriskfactor have been conducted.\n', '\n', ' Stop treatment with INLYTA at least 24 hours prior to scheduled surgery.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
174,inlyta,174,3645,3733,"The decision to resume INLYTA therapy after surgery should be based on clinical judgment of adequate wound healing.\n', '\n', '    5.9 Reversible Posterior Leukoencephalopathy Syndrome\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse  was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see  Adverse Reactions (6.1)  ]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
175,inlyta,175,3733,3794,"There were two additional reports of  oselabeledaefromdruguse in other clinical trials with INLYTA.\n', '\n', '  nonoseaeaeonlyasinstruction is a neurological disorder which can present with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and other  nonoseaemanifestationorcomplication and neurologic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  Mild to severe  nonoseaeaeonlyasinstruction may be present.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
176,inlyta,176,3794,3815,Magnetic resonance imaging is necessary to confirm the diagnosis of  nonoseaeaeonlyasinstruction  Discontinue INLYTA in patients developing  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,inlyta,177,3815,3886,"The safety of reinitiating INLYTA therapy in patients previously experiencing  notaecandidatepreexistingconditionorriskfactor is not known.\n', '\n', '    5.10 Proteinuria\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse was reported in 39/359 patients (11%) receiving INLYTA and 26/355 patients (7%) receiving sorafenib.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
178,inlyta,178,3886,3922,Grade 3  oselabeledaefromdruguse was reported in 11/359 patients (3%) receiving INLYTA and 6/355 patients (2%) receiving sorafenib [see  Adverse Reactions (6.1)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,inlyta,179,3922,3948,"\n', '\n', ' Monitoring for  nonoseaeaeonlyasinstruction before initiation of, and periodically throughout, treatment with INLYTA is recommended.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,inlyta,180,3948,4109,"For patients who develop moderate to severe  nonoseaeaeonlyasinstruction  reduce the dose or temporarily interrupt INLYTA treatment.\n', '\n', '    5.11 Elevation of Liver Enzymes\n', '\n', '  In a controlled clinical study with INLYTA for the treatment of patients with  notaecandidateindication   oselabeledaefromdruguse of all grades occurred in 22% of patients on both arms, with Grade 3/4 events in <1% of patients on the INLYTA arm and 2% of patients on the sorafenib arm.\n', '\n', ' Monitor ALT, aspartate aminotransferase (AST) and bilirubin before initiation of and periodically throughout treatment with INLYTA.\n', '\n', '    5.12 Hepatic Impairment\n', '\n', '  The systemic exposure to axitinib was higher in subjects with moderate  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor  compared to subjects with normal hepatic function.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
181,inlyta,181,4109,4126,A dose decrease is recommended when administering INLYTA to patients with moderate  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
182,inlyta,182,4126,4172,"INLYTA has not been studied in patients with severe  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor  [see  Dosage and Administration (2.2)  ,  Use in Specific Populations (8.6)  , and  Clinical Pharmacology (12.3)  ].  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
183,inlyta,183,4172,4187,"\n', '\n', '    5.13 Pregnancy\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,inlyta,184,4187,4210,"', '  INLYTA can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman based on its mechanism of action.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
185,inlyta,185,4210,4226,There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women using INLYTA.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
186,inlyta,186,4226,4279,"In  nonoseaeaeonlyasinstruction studies in mice, axitinib was  nonoseaeaeanimal   nonoseaeaeanimal and  nonoseaeaeanimal at maternal exposures that were lower than human exposures at the recommended clinical dose.\n', '\n', ' Women of childbearing potential should be advised to avoid becoming  nonoseaeaeonlyasinstruction while receiving INLYTA.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
187,inlyta,187,4279,4312,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if a patient becomes  nonoseaeaeonlyasinstruction while receiving this drug, the patient should be apprised of the potential  oselabeledaefromdruguse ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,lumason,0,0,77,"['    6  ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed elsewhere in the labeling:\n', '\n', '\n', '\n', ' *  Severe  oselabeledaefromdruguse [see Warnings and Precautions (  5.1  )]  \n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,lumason,1,77,78,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,lumason,2,78,96,"', '      EXCERPT:   Most common adverse reactions (incidence >= 0.5%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,lumason,3,96,278,"are headache and nausea (  6.1  ).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Bracco Diagnostics Inc at 1-800-257-5181 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', '\n', '\n', '\n', ' \n', '\n', '  6.1  Clinical Trials Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In completed clinical trials, a total of 6307 adult subjects (128 healthy volunteers and 6179 patients) received Lumason at cumulative doses ranging from 0.2 to 161 mL (mean 10.5 mL).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,lumason,4,278,296,"Lumason was administered mainly as single or multiple injections; however, some subjects received infusion dosing.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,lumason,5,296,315,The majority (73%) of subjects received Lumason at cumulative doses of 10 mL or less.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,lumason,6,315,340,"There were 65% men and 35% women, with an average age of 59 years (range 17 to 99 years).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,lumason,7,340,409,"A total of 4993 (79%) subjects were Caucasian; 192 (3%) were Black; 1053 (17%) were Asian; 33 (< 1%) were Hispanic; and 36 (<1%) were in other racial groups or race was not reported.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,lumason,8,409,484,"In the clinical trials, serious adverse reactions were observed in 2 subjects; one who experienced a  oselabeledaefromdruguse and  oselabeledaefromdruguse symptoms and another who experienced  oselabeledaefromdruguse shortly following Lumason administration.\n', '\n', '\n', '\n', ' The most commonly reported adverse reactions among patients (occurring among at least 0.2% of patients) are listed below (Table 1).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,lumason,9,484,540,"Most adverse reactions were mild to moderate in intensity and resolved spontaneously.\n', '\n', '\n', '\n', '\n', '   *  occurring in at least 0.2% of patients   \n', '  \n', '   Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,lumason,10,540,545,Adverse Reactions in Patients*n =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,lumason,11,545,547,6179     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,lumason,12,547,561,"\n', ' Number (%) of Patients with Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,lumason,13,561,567,302 (4.9%)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,lumason,14,567,580,"\n', '  oselabeledaefromdruguse         56 (0.9%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,lumason,15,580,593,"\n', '  oselabeledaefromdruguse           34 (0.6%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,lumason,16,593,606,"\n', '  oselabeledaefromdruguse        19 (0.3%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,lumason,17,606,619,"\n', '  oselabeledaefromdruguse  18 (0.3%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,lumason,18,619,632,"\n', '  oselabeledaefromdruguse  16 (0.3%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,lumason,19,632,645,"\n', '  oselabeledaefromdruguse      16 (0.3%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,lumason,20,645,658,"\n', '  oselabeledaefromdruguse       11 (0.2%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,lumason,21,658,671,"\n', '  oselabeledaefromdruguse  11 (0.2%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,lumason,22,671,672,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,lumason,23,672,684,"', '        6.2  Postmarketing Experience\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,lumason,24,684,709,"In the international postmarketing clinical experience and on-going clinical trials, serious adverse reactions have uncommonly been reported following administration of Lumason.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,lumason,25,709,741,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,lumason,26,741,764,"The serious adverse reactions include fatalities, especially in a pattern of symptoms suggestive of  oselabeledaefromdruguse hypersensitivity  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,lumason,27,764,774,Other serious reactions included  oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,lumason,28,774,846,"These reactions typically occurred within 30 minutes of Lumason administration.\n', '\n', '\n', '\n', ' The risk for serious  oselabeledaefromdruguse may be increased among patients with unstable  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor artery  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or unstable  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or serious  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    BOXED WARNING:",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
29,lumason,29,846,848,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,lumason,30,848,861,"SERIOUS CARDIOPULMONARY REACTIONS\n', '\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,lumason,31,861,910,"SERIOUS CARDIOPULMONARY REACTIONS\n', '\n', '    Serious  oselabeledaefromdruguse  including\n', '\n', ' nonoseaegeneralterm     5  WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,lumason,32,910,918,"*  Cardiopulmonary reactions, including fatalities.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,lumason,33,918,932,Always have resuscitation equipment and trained personnel readily available (  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,lumason,34,932,945,"\n', ' *  Anaphylactoid reactions (  5.2  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,lumason,35,945,1006,"\n', '    \n', ' \n', '\n', '   5.1  Cardiopulmonary Reactions\n', '\n', '\n', '\n', '  Serious  oselabeledaefromdruguse  including  nonoseaegeneralterm have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including Lumason.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,lumason,36,1006,1016,These reactions typically occurred within 30 minutes of administration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,lumason,37,1016,1051,The risk for these reactions may be increased among patients with unstable  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor artery  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or unstable  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or serious  notaecandidatepreexistingconditionorriskfactor .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
38,lumason,38,1051,1218,"Always have cardiopulmonary resuscitation personnel and equipment readily available prior to Lumason administration and monitor all patients for acute reactions.\n', '\n', '\n', '\n', ' The reported reactions that may follow the administration of ultrasound contrast agents include: fatal  oselabeledaeclasseffect or respiratory  oselabeledaeclasseffect  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect ,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect \n', '\n', '\n', '\n', '    5.2  Anaphylactoid Reactions\n', '\n', '\n', '\n', '   oselabeledaefromdruguse such as  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse have uncommonly been observed following the injection of Lumason.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,lumason,39,1218,1324,"These reactions may occur in patients with no history of prior exposure to sulfur hexafluoride lipid containing microspheres.\n', '\n', '\n', '\n', '    5.3   oselabeledaefromdruguse \n', '\n', '\n', '  In patients with  notaecandidatepreexistingconditionorriskfactor  bi-directional, or transient right-to-left  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or transient right-to-left  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  some intravenously injected sulfur hexafluoride lipid containing microspheres may bypass filtering by the lung and directly enter the arterial circulation.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
40,lumason,40,1324,1415,"oselabeledaefromdruguse by these microspheres may result in  nonoseaemanifestationorcomplication  Lumason is only for intravenous administration; do not administer Lumason by intra-arterial injection.\n', '\n', '\n', '\n', '    5.4  High Mechanical Index\n', '\n', '\n', '\n', '  High  nonoseaeaeonlyasinstruction and lead to  oselabeledaefromdruguse  Additionally, end-systolic triggering with high mechanical indices has been reported to cause  nonoseaeaeonlyasinstruction ']",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,xtandi,0,0,51,"['  6 ADVERSE REACTIONS\n', '\n', '  The following is discussed in more detail in other sections of the labeling:\n', '\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions  (  5.1  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,xtandi,1,51,73,"\n', ' *     oselabeledaefromdruguse  [see  Warnings and Precautions  (  5.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,xtandi,2,73,74,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,xtandi,3,74,81,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,xtandi,4,81,137,"The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,xtandi,5,137,142,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,xtandi,6,142,187,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,xtandi,7,187,216,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,xtandi,8,216,327,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' Three randomized clinical trials enrolled patients with  notaecandidateindication that has progressed on androgen deprivation therapy (GnRH therapy or bilateral orchiectomy), a disease setting that is also defined as  notaecandidateindication  Two trials were placebo-controlled (Studies 1 and 2), and one trial was bicalutamide-controlled (Study 3).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
9,xtandi,9,327,344,"In Studies 1 and 2, patients received XTANDI 160 mg or placebo orally once daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,xtandi,10,344,361,"In Study 3, patients received XTANDI 160 mg or bicalutamide 50 mg orally once daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,xtandi,11,361,368,All patients continued androgen deprivation therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,xtandi,12,368,461,"Patients were allowed, but not required, to take glucocorticoids.\n', '\n', ' The most common adverse reactions (>= 10%) that occurred more commonly (>= 2% over placebo) in the XTANDI-treated patients from the two randomized placebo-controlled clinical trials were  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,xtandi,13,461,479,"\n', '\n', '   Study 1: XTANDI versus Placebo in Metastatic CRPC",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,xtandi,14,479,482,Following Chemotherapy  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,xtandi,15,482,504,"\n', '\n', ' Study 1 enrolled 1199 patients with  notaecandidateindication who had previously received docetaxel.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
16,xtandi,16,504,520,The median duration of treatment was 8.3 months with XTANDI and 3.0 months with placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,xtandi,17,520,575,"During the trial, 48% of patients on the XTANDI arm and 46% of patients on the placebo arm received glucocorticoids.\n', '\n', ' Grade 3 and higher adverse reactions were reported among 47% of XTANDI-treated patients and 53% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,xtandi,18,575,599,Discontinuations due to adverse events were reported for 16% of XTANDI-treated patients and 18% of placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,xtandi,19,599,638,The most common adverse reaction leading to treatment discontinuation was  oselabeledaefromdruguse  which occurred in 0.9% of the XTANDI-treated patients compared to none (0%) of the placebo-treated patients.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,xtandi,20,638,677,"Table 1  shows adverse reactions reported in Study 1 that occurred at a >= 2% higher frequency in the XTANDI arm compared to the placebo arm.\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,xtandi,21,677,682,Adverse Reactions in Study 1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,xtandi,22,682,713,"\n', '                                             XTANDI  N = 800    Placebo  N = 399    \n', '  Grade 1-4a  (%)                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,xtandi,23,713,740,Grade 3-4  (%)    Grade 1-4  (%)    Grade 3-4  (%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,xtandi,24,740,747,"\n', '   nonoseaegeneralterm                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,xtandi,25,747,758,"\n', '       oselabeledaefromdruguse                    50.6             9.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,xtandi,26,758,760,44.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,xtandi,27,760,762,9.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,xtandi,28,762,777,"\n', '       oselabeledaefromdruguse                       15.4             1.0              13.3             0.8              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,xtandi,29,777,784,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,xtandi,30,784,793,"\n', '       oselabeledaefromdruguse                              26.4             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,xtandi,31,793,797,5.3              24.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,xtandi,32,797,808,"4.0              \n', '       oselabeledaefromdruguse                             20.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,xtandi,33,808,814,2.5              17.3             1.8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,xtandi,34,814,834,"\n', '       oselabeledaefromdruguse                   15.0             1.3              11.5             0.3              \n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,xtandi,35,834,844,oselabeledaefromdruguse                      9.8              1.5              6.8              1.8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,xtandi,36,844,859,"\n', '       oselabeledaefromdruguse              2.6              0.3              0.3              0.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,xtandi,37,859,888,"\n', '   nonoseaegeneralterm                 \n', '       oselabeledaefromdruguse                               21.8             1.1              17.5             0.3              \n', '   nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,xtandi,38,888,899,"\n', '       oselabeledaefromdruguse                              20.3             0.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,xtandi,39,899,918,"10.3             0.0              \n', '       oselabeledaefromdruguse                           6.4              2.1              2.8              1.3              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,xtandi,40,918,925,"\n', '   nonoseaegeneralterm                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,xtandi,41,925,940,"\n', '       oselabeledaefromdruguse                               12.1             0.9              5.5              0.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,xtandi,42,940,966,"\n', '       oselabeledaefromdruguse                              9.5              0.5              7.5              0.5              \n', '       oselabeledaefromdruguse     and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,xtandi,43,966,981,"7.4              6.6              4.5              3.8              \n', '       oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,xtandi,44,981,1026,"6.6              0.0              4.5              0.0              \n', '       oselabeledaefromdruguse           4.3              0.3              1.8              0.0              \n', '       oselabeledaefromdruguse                           4.0              0.3              1.8              0.0              \n', '   nonoseaegeneralterm                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,xtandi,45,1026,1047,"\n', '       oselabeledaefromdruguse     10.9             0.0              6.5              0.3              \n', '       oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,xtandi,46,1047,1059,And     Lung  oselabeledaefromdruguse  oselabeledaefromdruguse     8.5              2.4              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,xtandi,47,1059,1092,"4.8              1.3              \n', '   nonoseaegeneralterm                      \n', '       oselabeledaefromdruguse                               8.8              0.0              6.0              0.5              \n', '       oselabeledaefromdruguse                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,xtandi,48,1092,1107,"6.5              0.3              4.0              0.0              \n', '   nonoseaegeneralterm                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,xtandi,49,1107,1129,"\n', '       oselabeledaefromdruguse                              6.9              1.8              4.5              1.0              \n', '       oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,xtandi,50,1129,1144,"4.8              0.0              2.5              0.0              \n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,xtandi,51,1144,1166,"\n', '       oselabeledaefromdruguse                                   4.6              0.3              1.3              0.0              \n', '       oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,xtandi,52,1166,1174,4.0              1.4              0.8              0.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,xtandi,53,1174,1181,"\n', '   nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,xtandi,54,1181,1211,"\n', '       oselabeledaefromdruguse                               3.8              0.0              1.3              0.0              \n', '       oselabeledaefromdruguse                               3.5              0.0              1.3              0.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,xtandi,55,1211,1238,"\n', '   nonoseaegeneralterm                      \n', '       oselabeledaefromdruguse                              3.3              0.1              1.3              0.3              \n', '  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,xtandi,56,1238,1243,a    CTCAE v4  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,xtandi,57,1243,1254,b    Includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   c    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,xtandi,58,1254,1256,Includes  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,xtandi,59,1256,1263,oselabeledaefromdruguse and  oselabeledaefromdruguse   d    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,xtandi,60,1263,1269,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,xtandi,61,1269,1275,oselabeledaefromdruguse  and  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,xtandi,62,1275,1295,e    Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   f    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,xtandi,63,1295,1301,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,xtandi,64,1301,1307,oselabeledaefromdruguse  and  oselabeledaefromdruguse     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,xtandi,65,1307,1365,"\n', '             Study 2: XTANDI versus Placebo in Chemotherapy-naive Metastatic CRPC  \n', ' \n', '\n', ' Study 2 enrolled 1717 patients with  notaecandidateindication who had not received prior  nonoseaeaeonlyasinstruction  of whom 1715 received at least one dose of study drug.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
66,xtandi,66,1365,1381,The median duration of treatment was 17.5 months with XTANDI and 4.6 months with placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,xtandi,67,1381,1406,Grade 3-4 adverse reactions were reported in 44% of XTANDI-treated patients and 37% of placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,xtandi,68,1406,1430,Discontinuations due to adverse events were reported for 6% of XTANDI-treated patients and 6% of placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,xtandi,69,1430,1458,The most common adverse reaction leading to treatment discontinuation was  oselabeledaefromdruguse  oselabeledaefromdruguse  which occurred in 1% of patients on each treatment arm.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,xtandi,70,1458,1497,"Table 2  includes adverse reactions reported in Study 2 that occurred at a >= 2% higher frequency in the XTANDI arm compared to the placebo arm.\n', '\n', ' Table 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,xtandi,71,1497,1502,Adverse Reactions in Study 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,xtandi,72,1502,1515,"\n', '                                              XTANDI    N = 871      Placebo    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,xtandi,73,1515,1519,N = 844     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,xtandi,74,1519,1574,"\n', '   Grade 1-4  a      (%)                      Grade 3-4    (%)      Grade 1-4    (%)      Grade 3-4    (%)     \n', '  \n', '   nonoseaegeneralterm                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
75,xtandi,75,1574,1579,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,xtandi,76,1579,1583,oselabeledaefromdruguse                    46.9             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,xtandi,77,1583,1585,3.4              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,xtandi,78,1585,1587,33.0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,xtandi,79,1587,1589,2.8             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,xtandi,80,1589,1611,"\n', '       oselabeledaefromdruguse                       11.5             0.2              8.2              0.4             \n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,xtandi,81,1611,1620,"\n', '       oselabeledaefromdruguse                              28.6             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,xtandi,82,1620,1622,2.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,xtandi,83,1622,1624,22.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,xtandi,84,1624,1626,3.0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,xtandi,85,1626,1631,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,xtandi,86,1631,1639,oselabeledaefromdruguse                             21.4             1.6              16.1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,xtandi,87,1639,1641,1.1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,xtandi,88,1641,1659,"\n', '   nonoseaegeneralterm                 \n', '       oselabeledaefromdruguse                           23.2             0.7              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,xtandi,89,1659,1661,17.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,xtandi,90,1661,1663,0.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,xtandi,91,1663,1676,"\n', '       oselabeledaefromdruguse                               16.8             0.3              14.3             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,xtandi,92,1676,1678,0.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,xtandi,93,1678,1685,"\n', '   nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
94,xtandi,94,1685,1692,"\n', '       oselabeledaefromdruguse                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,xtandi,95,1692,1696,18.0             0.1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,xtandi,96,1696,1698,7.8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,xtandi,97,1698,1711,"0.0             \n', '       oselabeledaefromdruguse                           14.2             7.2              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,xtandi,98,1711,1722,"4.1              2.3             \n', '   nonoseaegeneralterm                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
99,xtandi,99,1722,1737,"\n', '       oselabeledaefromdruguse                              11.3             0.3              7.1              0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,xtandi,100,1737,1742,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,xtandi,101,1742,1748,oselabeledaefromdruguse                               11.0             0.2              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,xtandi,102,1748,1752,7.0              0.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,xtandi,103,1752,1767,"\n', '       oselabeledaefromdruguse                              7.6              0.1              3.7              0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,xtandi,104,1767,1782,"\n', '       oselabeledaefromdruguse           5.7              0.0              1.3              0.1             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,xtandi,105,1782,1797,"\n', '       oselabeledaefromdruguse                 2.1              0.1              0.4              0.0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,xtandi,106,1797,1804,"\n', '   nonoseaegeneralterm                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,xtandi,107,1804,1819,"\n', '       oselabeledaefromdruguse                               11.0             0.6              8.5              0.6             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,xtandi,108,1819,1826,"\n', '   nonoseaegeneralterm                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,xtandi,109,1826,1835,"\n', '       oselabeledaefromdruguse     16.4             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,xtandi,110,1835,1837,0.0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,xtandi,111,1837,1863,"10.5             0.0             \n', '       oselabeledaefromdruguse And     Lung  oselabeledaefromdruguse  oselabeledaefromdruguse     7.9              1.5              4.7              1.1             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,xtandi,112,1863,1870,"\n', '   nonoseaegeneralterm                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,xtandi,113,1870,1892,"\n', '       oselabeledaefromdruguse                               8.2              0.1              5.7              0.0             \n', '   nonoseaegeneralterm                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,xtandi,114,1892,1899,"\n', '       oselabeledaefromdruguse                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,xtandi,115,1899,1905,8.8              1.3              5.8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,xtandi,116,1905,1907,1.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,xtandi,117,1907,1914,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
118,xtandi,118,1914,1923,"\n', '       oselabeledaefromdruguse                                   12.7             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,xtandi,119,1923,1927,1.6              5.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,xtandi,120,1927,1944,"0.7             \n', '       oselabeledaefromdruguse              8.8              2.1              3.0              1.1             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,xtandi,121,1944,1951,"\n', '   nonoseaegeneralterm         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
122,xtandi,122,1951,1958,"\n', '       oselabeledaefromdruguse                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,xtandi,123,1958,1962,18.9             0.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,xtandi,124,1962,1964,16.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,xtandi,125,1964,1966,0.7             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,xtandi,126,1966,1988,"\n', '   nonoseaegeneralterm                             \n', '       oselabeledaefromdruguse                       12.4             0.8              8.5              0.2             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,xtandi,127,1988,1995,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
128,xtandi,128,1995,2013,"\n', '       oselabeledaefromdruguse                           3.4              0.0              1.4              0.0             \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,xtandi,129,2013,2020,'  a    CTCAE v4  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,xtandi,130,2020,2031,b    Includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   c    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,xtandi,131,2031,2033,Includes  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,xtandi,132,2033,2040,oselabeledaefromdruguse and  oselabeledaefromdruguse   d    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,xtandi,133,2040,2046,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,xtandi,134,2046,2052,oselabeledaefromdruguse  and  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,xtandi,135,2052,2066,e    Includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   f    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,xtandi,136,2066,2084,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   g    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,xtandi,137,2084,2090,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,xtandi,138,2090,2096,oselabeledaefromdruguse  and  oselabeledaefromdruguse     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,xtandi,139,2096,2155,"\n', '             Study 3: XTANDI versus Bicalutamide in Chemotherapy-naive Metastatic CRPC  \n', ' \n', '\n', ' Study 3 enrolled 375 patients with  notaecandidateindication who had not received prior  nonoseaeaeonlyasinstruction  of whom 372 received at least one dose of study drug.  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
140,xtandi,140,2155,2171,The median duration of treatment was 11.6 months with XTANDI and 5.8 months with bicalutamide.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,xtandi,141,2171,2199,Discontinuations with an adverse event as the primary reason were reported for 7.6% of XTANDI-treated patients and 6.3% of bicalutamide-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,xtandi,142,2199,2244,"The most common adverse reactions leading to treatment discontinuation were  oselabeledaefromdruguse and  oselabeledaefromdruguse  which occurred in 3.8% of XTANDI-treated patients for each event and in 2.1% and 1.6% of bicalutamide-treated patients, respectively.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,xtandi,143,2244,2274,"Table 3  shows overall and common adverse reactions (>= 10%) in XTANDI-treated patients.\n', '\n', ' Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,xtandi,144,2274,2279,Adverse Reactions in Study 3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,xtandi,145,2279,2286,"\n', '                                              XTANDI    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,xtandi,146,2286,2296,(N=183)      Bicalutamide    (N=189)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,xtandi,147,2296,2359,"\n', '   Grade 1-4  a      (%)                      Grade 3-4    (%)      Grade 1-4  a      (%)      Grade 3-4    (%)     \n', '  \n', '  Overall                                    94.0             38.8             94.2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,xtandi,148,2359,2361,37.6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,xtandi,149,2361,2368,"\n', '   nonoseaegeneralterm                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
150,xtandi,150,2368,2379,"\n', '       oselabeledaefromdruguse                    31.7             1.6              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,xtandi,151,2379,2381,22.8             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,xtandi,152,2381,2383,1.1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,xtandi,153,2383,2390,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
154,xtandi,154,2390,2401,"\n', '       oselabeledaefromdruguse                              19.1             2.7              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,xtandi,155,2401,2410,"18.0             1.6              \n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,xtandi,156,2410,2414,oselabeledaefromdruguse                   16.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,xtandi,157,2414,2420,1.1              14.3             0.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,xtandi,158,2420,2427,"\n', '   nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
159,xtandi,159,2427,2449,"\n', '       oselabeledaefromdruguse                              14.8             0                11.1             0                \n', '       oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,xtandi,160,2449,2457,14.2             7.1              7.4              4.2              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,xtandi,161,2457,2486,"\n', '   nonoseaegeneralterm                 \n', '       oselabeledaefromdruguse                                 14.2             0                17.5             0                \n', '       oselabeledaefromdruguse                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
162,xtandi,162,2486,2490,12.6             1.1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,xtandi,163,2490,2494,13.2             0.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,xtandi,164,2494,2509,"\n', '       oselabeledaefromdruguse                               11.5             0                9.0              1.1              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,xtandi,165,2509,2516,"\n', '   nonoseaegeneralterm                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
166,xtandi,166,2516,2538,"\n', '       oselabeledaefromdruguse      12.0             0                6.3              0.5              \n', '   nonoseaegeneralterm                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
167,xtandi,167,2538,2549,"\n', '       oselabeledaefromdruguse                            10.9             0.5              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,xtandi,168,2549,2564,"7.9              0.5              \n', '  a    CTCAE v 4b    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,xtandi,169,2564,2570,Including  oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,xtandi,170,2570,2580,c    Including  oselabeledaefromdruguse and  oselabeledaefromdruguse d    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,xtandi,171,2580,2584,Including  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,xtandi,172,2584,2596,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,xtandi,173,2596,2604,"\n', '             Laboratory Abnormalities  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,xtandi,174,2604,2667,"\n', ' \n', '\n', ' In the two randomized placebo-controlled clinical trials, Grade 1-4  oselabeledaefromdruguse occurred in 15% of patients treated with XTANDI (1% Grade 3-4) and in 6% of patients treated with placebo (0.5% Grade 3-4).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,xtandi,175,2667,2709,The incidence of Grade 1-4  oselabeledaefromdruguse was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,xtandi,176,2709,2749,Grade 1-4  nonoseaeaeratelteqplacebo occurred in 10% of patients treated with XTANDI (0.2% Grade 3-4) and 16% of patients treated with placebo (0.2% Grade 3-4).,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
177,xtandi,177,2749,2833,"Grade 1-4  oselabeledaefromdruguse occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).\n', '\n', '   Infections  \n', '\n', ' In Study 1, 1% of patients treated with XTANDI compared to 0.3% of patients treated with placebo  nonoseaegeneralterm from  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,xtandi,178,2833,2915,"In Study 2, 1 patient in each treatment group (0.1%) had an  nonoseaeaeonlyasinstruction resulting in  nonoseaegeneralterm \n', '\n', '   Falls and Fall-related Injuries  \n', '\n', ' In the two randomized placebo-controlled clinical trials,  oselabeledaefromdruguse including  oselabeledaefromdruguse  occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo.  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
179,xtandi,179,2915,3035,"nonoseaeaeonlyasinstruction were not associated with  nonoseaenegation or  nonoseaenegation   oselabeledaefromdruguse  oselabeledaefromdruguse injuries were more severe in patients treated with XTANDI and included  oselabeledaefromdruguse  oselabeledaefromdruguse injuries were more severe in patients treated with XTANDI and included non-pathologic fractures, joint injuries, and  oselabeledaefromdruguse  oselabeledaefromdruguse injuries were more severe in patients treated with XTANDI and included non-pathologic fractures,  oselabeledaefromdruguse  and hematomas.\n', '\n', '   Hypertension  \n', '\n', ' In the two randomized placebo-controlled trials,  oselabeledaefromdruguse was reported in 11% of patients receiving XTANDI and 4% of patients receiving placebo.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
180,xtandi,180,3035,3052,No patients experienced  nonoseaenegation  Medical history of  notaecandidatepreexistingconditionorriskfactor was balanced between arms.  ,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
181,xtandi,181,3052,3102,"oselabeledaefromdruguse led to study discontinuation in < 1% of patients in each arm.\n', '\n', '   6.2 Post-Marketing Experience\n', '\n', '  The following additional adverse reactions have been identified during post approval use of XTANDI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,xtandi,182,3102,3147,"Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse ( oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
183,xtandi,183,3147,3152,oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,xtandi,184,3152,3164,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
185,xtandi,185,3164,3172,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
186,xtandi,186,3172,3185,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
187,xtandi,187,3185,3200,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,xtandi,188,3200,3212,*    Seizure occurred in 0.5% of patients receiving XTANDI.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,xtandi,189,3212,3227,"In patients with predisposing factors, seizures were reported in 2.2% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,xtandi,190,3227,3239,Permanently discontinue XTANDI in patients who develop a seizure during treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,xtandi,191,3239,3261,"(  5.1  ) \n', ' *    Posterior reversible encephalopathy syndrome (PRES): Discontinue XTANDI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,xtandi,192,3261,3266,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,xtandi,193,3266,3272,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,xtandi,194,3272,3309,"', ' \n', '\n', '    5.1 Seizure  \n', '\n', '    oselabeledaefromdruguse occurred in 0.5% of patients receiving XTANDI in clinical studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,xtandi,195,3309,3324,In these trials patients with predisposing factors for  nonoseaeaeonlyasinstruction were generally excluded.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,xtandi,196,3324,3336,oselabeledaefromdruguse occurred from 31 to 603 days after initiation of XTANDI.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,xtandi,197,3336,3353,Patients experiencing  nonoseaeaeonlyasinstruction were permanently discontinued from therapy and all  nonoseaeaeonlyasinstruction events resolved.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,xtandi,198,3353,3403,"\n', '\n', '  In a single-arm trial designed to assess the risk of  nonoseaeaeonlyasinstruction in patients with pre-disposing factors for  nonoseaeaeonlyasinstruction  8 of 366 (2.2%) XTANDI-treated patients experienced a  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,xtandi,199,3403,3425,Three of the 8 patients experienced a second  oselabeledaefromdruguse during continued treatment with XTANDI after their first  nonoseaeaeonlyasinstruction resolved.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,xtandi,200,3425,3440,It is unknown whether anti-epileptic medications will prevent  nonoseaeaeonlyasinstruction with XTANDI.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,xtandi,201,3440,3544,"Patients in the study had one or more of the following pre-disposing factors: the use of medications that may  nonoseaeaeonlyasinstruction (~ 54%), history of  notaecandidatepreexistingconditionorriskfactor (~ 28%), history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor (~ 24%), and  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor from  notaecandidateindication  unexplained  notaecandidatepreexistingconditionorriskfactor within the last 12 months, past history of  notaecandidatepreexistingconditionorriskfactor  presence of a  notaecandidatepreexistingconditionorriskfactor  history of  notaecandidatepreexistingconditionorriskfactor  or history of  notaecandidatepreexistingconditionorriskfactor (all < 5%).",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
202,xtandi,202,3544,3557,Approximately 17% of patients had more than one risk factor.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,xtandi,203,3557,3599,"\n', '\n', '  Advise patients of the risk of developing a  nonoseaeaeonlyasinstruction while receiving XTANDI and of engaging in any activity where sudden  nonoseaeaeonlyasinstruction could cause serious harm to themselves or others.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,xtandi,204,3599,3608,"\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,xtandi,205,3608,3622,Permanently discontinue XTANDI in patients who develop a  nonoseaeaeonlyasinstruction during treatment.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,xtandi,206,3622,3627,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,xtandi,207,3627,3673,"', '    5.2 Posterior Reversible Encephalopathy Syndrome (PRES)\n', '\n', '  There have been reports of  oselabeledaefromdruguse  in patients receiving XTANDI [see  Adverse Reactions  (  6.2  )]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,xtandi,208,3673,3715,nonoseaeaeonlyasinstruction is a  nonoseaeaeonlyasinstruction which can present with rapidly evolving symptoms including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and other  nonoseaemanifestationorcomplication and neurological  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  with or without associated  nonoseaemanifestationorcomplication  ,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
209,xtandi,209,3715,3734,"A diagnosis of  nonoseaeaeonlyasinstruction requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,xtandi,210,3734,3744,Discontinue XTANDI in patients who develop  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,sabril,0,0,80,"['      6         ADVERSE REACTIONS  \n', '\n', '  The following adverse reactions are discussed in more detail in other sections of the prescribing information:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see    BOXED WARNING     and     Warnings and Precautions (5.1)    ]  \n', ' *   oselabeledaefromdruguse in Infants [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,sabril,1,80,83,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,sabril,2,83,99,"(5.3)    ]  \n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,sabril,3,99,124,"Warnings and Precautions (5.4)    ]  \n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse Behavior and  oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,sabril,4,124,149,"Warnings and Precautions (5.5)    ]  \n', ' *   nonoseaeaeonlyasinstruction of Antiepileptic Drugs (AEDs) [see    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,sabril,5,149,162,"Warnings and Precautions (5.6)    ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,sabril,6,162,165,*   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,sabril,7,165,168,[see    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,sabril,8,168,171,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,sabril,9,171,190,"(5.7)    ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,sabril,10,190,193,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,sabril,11,193,209,"(5.8)    ]  \n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,sabril,12,209,228,"Warnings and Precautions (5.9)    ]  \n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,sabril,13,228,247,"Warnings and Precautions (5.10)    ]  \n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,sabril,14,247,257,Warnings and Precautions (5.11)    ]  \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,sabril,15,257,282,"', '      EXCERPT:     Refractory    Complex Partial Seizures  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,sabril,16,282,359,"Most common adverse reactions in controlled studies include:\n', '\n', '\n', '\n', ' *  Adults >16 years of age (change of >=5% over placebo): in addition to permanent vision loss, fatigue, somnolence, nystagmus, tremor, vision blurred, memory impairment, weight gain, arthralgia, abnormal coordination, and confusional state  (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,sabril,17,359,362,6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,sabril,18,362,413,"\n', ' *  Pediatrics 10 to 16 years of age (change of >=5% over placebo): increased weight, upper respiratory tract infection, tremor, fatigue, aggression and diplopia   (  6.1  )  \n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,sabril,19,413,453,"Infantile Spasms         (incidence >5%)  \n', ' \n', '\n', ' *  Somnolence, bronchitis, ear infection, and otitis media acute (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,sabril,20,453,484,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact Lundbeck at 1-800-455-1141 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,sabril,21,484,485,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,sabril,22,485,512,"', ' \n', '\n', ' \n', '\n', '    6.1          Clinical Trial    Experience  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,sabril,23,512,521,"\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,sabril,24,521,590,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '     Adverse    Reactions    in U    .    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,sabril,25,590,594,S    .    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,sabril,26,594,602,and Primary Non-U    .    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,sabril,27,602,606,S    .    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,sabril,28,606,609,Clinical Studies    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,sabril,29,609,653,"In U.S. and primary non-U.S. clinical studies of 4,079 SABRIL treated patients, the most commonly observed (>=5%) adverse reactions associated with the use of SABRIL in combination with other AEDs were  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,sabril,30,653,698,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,sabril,31,698,740,"\n', '\n', '\n', '\n', ' The adverse reactions most commonly associated with SABRIL treatment discontinuation in >=1% of patients were  oselabeledaefromdruguse and  oselabeledaefromdruguse \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,sabril,32,740,753,"'\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,sabril,33,753,795,In patients with  notaecandidateindication  the adverse reactions most commonly associated with SABRIL treatment discontinuation in >=1% of patients were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
34,sabril,34,795,824,"\n', '\n', '\n', '\n', '     Most Common        Adverse        Reactions        in Controlled Clinical Trials    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,sabril,35,824,892,"\n', '\n', '\n', '\n', '      notaecandidateindication      Adults       Table 5 lists the treatment emergent adverse reactions that occurred in >=2% and more than one patient per SABRIL treated group and that occurred more frequently than in placebo patients from 2 U.S. add-on clinical studies of  notaecandidateindication in adults.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
36,sabril,36,892,916,"\n', '\n', '\n', '\n', '\n', '   Table 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,sabril,37,916,976,"Treatment Emergent Adverse Reactions Occurring in >=2% and More than One Patient per SABRIL-Treated Group and More Frequently than in Placebo Patients (Studies 024 and 025)     \n', '                     SABRIL dosage(mg/day)                    \n', '    Body System         Adverse Reaction     3000[N=134]%     6000[N=43]%      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,sabril,38,976,978,Placebo[N=135]%   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,sabril,39,978,996,"\n', '       nonoseaegeneralterm                                                        \n', '         oselabeledaefromdruguse      2                0                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,sabril,40,996,998,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,sabril,41,998,1029,"\n', '         oselabeledaefromdruguse       2                5                1             \n', '       nonoseaegeneralterm                                                        \n', '         oselabeledaefromdruguse     13               16                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,sabril,42,1029,1031,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,sabril,43,1031,1066,"\n', '         oselabeledaefromdruguse      7               16                3             \n', '         oselabeledaefromdruguse      2                 2               0             \n', '         oselabeledaefromdruguse      0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,sabril,44,1066,1070,5               0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,sabril,45,1070,1077,"\n', '       nonoseaegeneralterm                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
46,sabril,46,1077,1086,"\n', '         oselabeledaefromdruguse     10               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,sabril,47,1086,1088,16                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,sabril,48,1088,1112,"7             \n', '         oselabeledaefromdruguse       10                 2               8             \n', '         oselabeledaefromdruguse      7                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,sabril,49,1112,1114,9               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,sabril,50,1114,1116,6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,sabril,51,1116,1125,"\n', '         oselabeledaefromdruguse      8                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,sabril,52,1125,1127,5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,sabril,53,1127,1129,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,sabril,54,1129,1138,"\n', '         oselabeledaefromdruguse      5                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,sabril,55,1138,1142,5               1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,sabril,56,1142,1151,"\n', '         oselabeledaefromdruguse      4                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,sabril,57,1151,1153,5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,sabril,58,1153,1155,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,sabril,59,1155,1158,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,sabril,60,1158,1164,'         oselabeledaefromdruguse      4                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,sabril,61,1164,1166,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,sabril,62,1166,1168,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,sabril,63,1168,1177,"\n', '         oselabeledaefromdruguse      3                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,sabril,64,1177,1179,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,sabril,65,1179,1181,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,sabril,66,1181,1190,"\n', '         oselabeledaefromdruguse      2                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,sabril,67,1190,1205,"5               2             \n', '         oselabeledaefromdruguse      2                 0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,sabril,68,1205,1207,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,sabril,69,1207,1221,"\n', '       nonoseaegeneralterm                                                        \n', '         oselabeledaefromdruguse      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,sabril,70,1221,1223,23               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,sabril,71,1223,1227,40               16             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,sabril,72,1227,1290,"\n', '         oselabeledaefromdruguse     6                12                7             \n', '         oselabeledaefromdruguse     5                 7                1             \n', '         oselabeledaefromdruguse     5                 7                1             \n', '         oselabeledaefromdruguse        4                 7                3             \n', '         oselabeledaefromdruguse     1                 5                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,sabril,73,1290,1292,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,sabril,74,1292,1314,"\n', '         oselabeledaefromdruguse       2                 0                0             \n', '         oselabeledaefromdruguse      0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,sabril,75,1314,1318,5                0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,sabril,76,1318,1325,"\n', '       nonoseaegeneralterm                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,sabril,77,1325,1334,"\n', '         oselabeledaefromdruguse     14                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,sabril,78,1334,1336,9               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,sabril,79,1336,1338,10             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,sabril,80,1338,1349,"\n', '         oselabeledaefromdruguse     7                 9                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,sabril,81,1349,1356,"6             \n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,sabril,82,1356,1377,"oselabeledaefromdruguse     5                 7                4             \n', '         oselabeledaefromdruguse     4                 5                0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,sabril,83,1377,1386,"\n', '         oselabeledaefromdruguse     0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,sabril,84,1386,1388,5                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,sabril,85,1388,1390,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,sabril,86,1390,1397,"\n', '       nonoseaegeneralterm                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,sabril,87,1397,1445,"\n', '         oselabeledaefromdruguse     3                 5                2             \n', '         oselabeledaefromdruguse     1                 2                1             \n', '         oselabeledaefromdruguse     1                 2                1             \n', '         oselabeledaefromdruguse     0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,sabril,88,1445,1449,2                0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,sabril,89,1449,1456,"\n', '       nonoseaegeneralterm                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,sabril,90,1456,1469,"\n', '         oselabeledaefromdruguse     1                  5              1              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,sabril,91,1469,1489,"\n', '         oselabeledaefromdruguse     6                14               3              \n', '       nonoseaegeneralterm                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
92,sabril,92,1489,1502,"\n', '         oselabeledaefromdruguse     10                5               3              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,sabril,93,1502,1518,"\n', '         oselabeledaefromdruguse      4                7               2              \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,sabril,94,1518,1524,'         oselabeledaefromdruguse      6                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,sabril,95,1524,1583,"2               4              \n', '         oselabeledaefromdruguse       3                5               1              \n', '         oselabeledaefromdruguse      1                9               1              \n', '         oselabeledaefromdruguse      3                0               1              \n', '       nonoseaegeneralterm                                                        \n', '         oselabeledaefromdruguse     33               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,sabril,96,1583,1587,26               31             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,sabril,97,1587,1596,"\n', '         oselabeledaefromdruguse     22               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,sabril,98,1596,1600,26               13             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,sabril,99,1600,1611,"\n', '         oselabeledaefromdruguse     24               26               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,sabril,100,1611,1613,17             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,sabril,101,1613,1622,"\n', '         oselabeledaefromdruguse     13               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,sabril,102,1622,1624,19                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,sabril,103,1624,1702,"9             \n', '         oselabeledaefromdruguse       15               16                8             \n', '         oselabeledaefromdruguse      7               16                3             \n', '         oselabeledaefromdruguse      7               16                2             \n', '         oselabeledaefromdruguse      9                0                1             \n', '         oselabeledaefromdruguse      4                7                2             \n', '         oselabeledaefromdruguse      4                5                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,sabril,104,1702,1704,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,sabril,105,1704,1741,"\n', '         oselabeledaefromdruguse      7                2                1             \n', '         oselabeledaefromdruguse      4                7                2             \n', '         oselabeledaefromdruguse      4                2                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,sabril,106,1741,1743,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,sabril,107,1743,1754,"\n', '         oselabeledaefromdruguse      4                5                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,sabril,108,1754,1756,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,sabril,109,1756,1769,"\n', '         oselabeledaefromdruguse      4                0                0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,sabril,110,1769,1793,"\n', '         oselabeledaefromdruguse      2                5                0             \n', '         oselabeledaefromdruguse      2                2                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,sabril,111,1793,1795,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,sabril,112,1795,1806,"\n', '         oselabeledaefromdruguse      2                0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,sabril,113,1806,1808,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,sabril,114,1808,1844,"\n', '         oselabeledaefromdruguse      0                5                0             \n', '       nonoseaegeneralterm                                                        \n', '         oselabeledaefromdruguse      7               23                7             \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
115,sabril,115,1844,1848,'         oselabeledaefromdruguse      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,sabril,116,1848,1852,6               14                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,sabril,117,1852,1854,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,sabril,118,1854,1861,"\n', '         oselabeledaefromdruguse      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,sabril,119,1861,1865,4               14                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,sabril,120,1865,1867,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,sabril,121,1867,1906,"\n', '         oselabeledaefromdruguse       4                0                3             \n', '         oselabeledaefromdruguse      5                0                1             \n', '         oselabeledaefromdruguse      3                7                0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,sabril,122,1906,1911,"\n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,sabril,123,1911,1917,oselabeledaefromdruguse      3                5                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,sabril,124,1917,1919,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,sabril,125,1919,2001,"\n', '         oselabeledaefromdruguse      1                7                1             \n', '         oselabeledaefromdruguse      2                5                2             \n', '         oselabeledaefromdruguse      1                5                1             \n', '       nonoseaegeneralterm                                                        \n', '         oselabeledaefromdruguse     9                 5                3             \n', '         oselabeledaefromdruguse     0                 5                0             \n', '       nonoseaegeneralterm                                                        \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
126,sabril,126,2001,2014,"'         oselabeledaefromdruguse      7               14               5              \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,sabril,127,2014,2020,'         oselabeledaefromdruguse         2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,sabril,128,2020,2037,"14               7              \n', '         oselabeledaefromdruguse      0                5               1              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,sabril,129,2037,2057,"\n', '         oselabeledaefromdruguse      6                2               1              \n', '       nonoseaegeneralterm                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,sabril,130,2057,2066,"\n', '         oselabeledaefromdruguse          4                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,sabril,131,2066,2130,"5               4              \n', '              Pediatrics 10 to 16 years of age    Table 6 lists adverse reactions from controlled clinical studies of pediatric patients receiving SABRIL or placebo as add-on therapy for refractory  notaecandidateindication   Adverse reactions that are listed occurred in at least 2% of SABRIL treated patients and more frequently than placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
132,sabril,132,2130,2169,"The median SABRIL dose was 49.4 mg/kg, (range of 8.0 - 105.9 mg/kg).\n', ' \n', '\n', '\n', '   Table 6.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,sabril,133,2169,2213,"Treatment-Emergent Adverse Reactions Reported  by >=2% of Pediatric CPS Patients (10 to 16 years of age)  Treated with SABRIL and Higher than Placebo     \n', '   Body System       Adverse Reaction  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,sabril,134,2213,2216,All SABRIL[N=109]%  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,sabril,135,2216,2218,Placebo[N=46]%    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,sabril,136,2218,2223,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,sabril,137,2223,2247,"nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse     5                0                \n', '       oselabeledaefromdruguse   3                0                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,sabril,138,2247,2305,"\n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse    6                2                \n', '       oselabeledaefromdruguse   3                0                \n', '       oselabeledaefromdruguse   3                2                \n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse      9                4                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,sabril,139,2305,2323,"\n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   10               4                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
140,sabril,140,2323,2334,"\n', '       oselabeledaefromdruguse    6                2                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,sabril,141,2334,2363,"\n', '       oselabeledaefromdruguse   6                2                \n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   17               2                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
142,sabril,142,2363,2454,"\n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   6                2                \n', '       oselabeledaefromdruguse       6                0                \n', '       oselabeledaefromdruguse    5                2                \n', '       oselabeledaefromdruguse   4                2                \n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   6                2                \n', '       oselabeledaefromdruguse   5                0                \n', '       oselabeledaefromdruguse  4                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,sabril,143,2454,2459,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,sabril,144,2459,2472,"nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   3               0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
145,sabril,145,2472,2490,"\n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse         3               0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
146,sabril,146,2490,2497,"\n', '              notaecandidateindication    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
147,sabril,147,2497,2654,"In a randomized, placebo-controlled IS study with a 5 day double-blind treatment phase (n=40), the adverse events reported by >5% of patients receiving SABRIL and that occurred more frequently than in placebo patients, were  oselabeledaefromdruguse (SABRIL 45%,   placebo  30%),  oselabeledaefromdruguse (SABRIL 30%,  placebo  15%),  oselabeledaefromdruguse (SABRIL 10%,   placebo  5%), and  oselabeledaefromdruguse SABRIL 10%,   placebo  0%).\n', ' \n', '\n', ' In a dose response study of low-dose (18-36 mg/kg/day) versus high-dose (100-148 mg/kg/day) vigabatrin, no clear correlation between dose and incidence of adverse events was observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,sabril,148,2654,2698,"The treatment emergent adverse reactions (>=5% in either dose group) are summarized in Table 7.\n', '\n', '\n', '\n', '\n', '    Table 7.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,sabril,149,2698,2741,"Treatment Emergent Adverse Reactions Occurring in >=5% of Infantile Spasms Patients     \n', '  \n', '                   SABRILLow Dose   SABRIL High Dose   \n', '    Body System       Adverse Reaction   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,sabril,150,2741,2800,"[N=114]%         [N=108]%         \n', '     nonoseaegeneralterm (other than field or acuity changes)                                       \n', '       oselabeledaefromdruguse   5                5                \n', '       oselabeledaefromdruguse   5                2                \n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse     14               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
151,sabril,151,2800,2802,20               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,sabril,152,2802,2811,"\n', '       oselabeledaefromdruguse   14               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,sabril,153,2811,2813,12               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,sabril,154,2813,2822,"\n', '       oselabeledaefromdruguse     13               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,sabril,155,2822,2824,12               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,sabril,156,2824,2829,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,sabril,157,2829,2842,"nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse        29               19               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
158,sabril,158,2842,2869,"\n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   51               46               \n', '       oselabeledaefromdruguse   44               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
159,sabril,159,2869,2871,30               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,sabril,160,2871,2882,"\n', '       oselabeledaefromdruguse   20               19               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,sabril,161,2882,2893,"\n', '       oselabeledaefromdruguse    13               11               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,sabril,162,2893,3006,"\n', '       oselabeledaefromdruguse   8                3                \n', '       oselabeledaefromdruguse   7                14               \n', '       oselabeledaefromdruguse   6                5                \n', '       oselabeledaefromdruguse    5                9                \n', '       oselabeledaefromdruguse   5                6                \n', '       oselabeledaefromdruguse    5                3                \n', '       oselabeledaefromdruguse   5                1                \n', '      nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   9                7                \n', '      nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse     19               17               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
163,sabril,163,3006,3017,"\n', '       oselabeledaefromdruguse   17               19               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,sabril,164,3017,3039,"\n', '       oselabeledaefromdruguse   6                4                \n', '       oselabeledaefromdruguse     5                7                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,sabril,165,3039,3077,"\n', '       oselabeledaefromdruguse   4                7                \n', '       oselabeledaefromdruguse    4                6                \n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   16               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
166,sabril,166,3077,3079,23               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,sabril,167,3079,3088,"\n', '       oselabeledaefromdruguse     10               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,sabril,168,3088,3090,12               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,sabril,169,3090,3095,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,sabril,170,3095,3108,"nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse   13               4                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
171,sabril,171,3108,3135,"\n', '       oselabeledaefromdruguse        3                8                \n', '     nonoseaegeneralterm                                       \n', '       oselabeledaefromdruguse         8                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
172,sabril,172,3135,3137,11               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,sabril,173,3137,3148,"\n', '             6.2       Post Marketing Experience  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,sabril,174,3148,3168,"\n', '   The following adverse reactions have been reported during post approval use of SABRIL worldwide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,sabril,175,3168,3206,"All adverse reactions that are not listed above as adverse reactions reported in clinical trials, that are not relatively common in the population and are not too vague to be useful are listed in this section.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,sabril,176,3206,3237,"These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,sabril,177,3237,3717,"Adverse reactions are categorized by system organ class.\n', '\n', '\n', '\n', '      nonoseaegeneralterm        :          oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia,  oselabeledaefromdruguse malformation, limb  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome,  oselabeledaefromdruguse  oselabeledaefromdruguse vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas,  oselabeledaefromdruguse  limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipes\n', '\n', '\n', '\n', '      nonoseaegeneralterm        :     oselabeledaefromdruguse \n', '\n', '\n', '      nonoseaegeneralterm        :          oselabeledaefromdruguse \n', '\n', '\n', '      nonoseaegeneralterm        :     oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '      nonoseaegeneralterm        :      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '      nonoseaegeneralterm        :      oselabeledaefromdruguse \n', '\n', '\n', '      nonoseaegeneralterm        :      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,sabril,178,3717,3745,"\n', '\n', '\n', '      nonoseaegeneralterm        :          oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
179,sabril,179,3745,3821,"\n', '\n', '\n', '      nonoseaegeneralterm      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '      nonoseaegeneralterm      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (SJS),  oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:  WARNING:  VISION LOSS\n', '\n', '     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
180,sabril,180,3821,3827,WARNING:  VISION LOSS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,sabril,181,3827,3874,"\n', '\n', '    *  SABRIL causes  oselabeledaefromdruguse bilateral concentric  oselabeledaefromdruguse  oselabeledaefromdruguse  Because assessing vision may be difficult in infants and children, the frequency and extent of  nonoseaeaeonlyasinstruction is poorly characterized in these patients.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,sabril,182,3874,3890,"For this reason, the risk described below is primarily based on the adult experience.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,sabril,183,3890,3932,"\n', ' *  Based upon adult studies, 30 percent or more of patients can be affected, ranging in severity from mild to severe, including  oselabeledaefromdruguse to  oselabeledaefromdruguse  and can result in disability.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,sabril,184,3932,3952,"In some cases, SABRIL also can  oselabeledaefromdruguse and may  oselabeledaefromdruguse  \n', ' *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,sabril,185,3952,3987,"The onset of  oselabeledaefromdruguse from SABRIL is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,sabril,186,3987,4015,"\n', ' *  Symptoms of  nonoseaeaeonlyasinstruction from SABRIL are unlikely to be recognized by patients or caregivers before  nonoseaeaeonlyasinstruction is severe.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,sabril,187,4015,4035,"nonoseaeaeonlyasinstruction of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,sabril,188,4035,4123,"\n', ' *  The risk of  nonoseaeaeonlyasinstruction increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of  nonoseaeaeonlyasinstruction  \n', ' *  Unless a patient is formally exempted from periodic ophthalmologic assessment as documented in the SHARE program, vision should be assessed to the extent possible at baseline (no later than 4 weeks after starting SABRIL) and at least every 3 months during therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,sabril,189,4123,4140,Vision assessment is also required about 3 to 6 months after the discontinuation of SABRIL therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,sabril,190,4140,4158,"\n', ' *  Once detected,  oselabeledaefromdruguse due to SABRIL is not reversible.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,sabril,191,4158,4199,"It is expected that, even with frequent monitoring, some patients will develop severe  nonoseaeaeonlyasinstruction  \n', ' *  Drug discontinuation should be considered, balancing benefit and risk, if  nonoseaeaeonlyasinstruction is documented.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,sabril,192,4199,4218,"\n', ' *  It is possible that  nonoseaeaeonlyasinstruction can worsen despite discontinuation of SABRIL.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,sabril,193,4218,4222,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,sabril,194,4222,4224,*  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,sabril,195,4224,4276,Because of the risk of  nonoseaeaeonlyasinstruction  SABRIL should be withdrawn from patients with refractory  notaecandidateindication who fail to show substantial clinical benefit within 3 months of initiation and within 2-4 weeks of initiation for patients with  notaecandidateindication  or sooner if treatment failure becomes obvious.,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
196,sabril,196,4276,4289,Patient response to and continued need for SABRIL should be periodically reassessed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,sabril,197,4289,4325,"\n', ' *  SABRIL should not be used in patients with, or at high risk of, other types of  notaecandidatepreexistingconditionorriskfactor unless the benefits of treatment clearly outweigh the risks.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
198,sabril,198,4325,4350,"The interaction of other types of  notaecandidatepreexistingconditionorriskfactor with  nonoseaeaeonlyasinstruction from SABRIL has not been well-characterized, but is likely adverse.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
199,sabril,199,4350,4384,"\n', ' *  SABRIL should not be used with other drugs associated with serious  nonoseaeaeonlyasinstruction such as  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction unless the benefits clearly outweigh the risks.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,sabril,200,4384,4422,"\n', ' *  The possibility that  nonoseaeaeonlyasinstruction from SABRIL may be more common, more severe or have more severe functional consequences in infants and children than in adults cannot be excluded.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,sabril,201,4422,4444,"\n', ' *  The lowest dose and shortest exposure to SABRIL consistent with clinical objectives should be used.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,sabril,202,4444,4449,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,sabril,203,4449,4459,Because of the risk of  nonoseaeaeonlyasinstruction      5        ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,sabril,204,4459,4498,"WARNINGS AND PRECAUTIONS  \n', '\n', '\n', '\n', '   EXCERPT:    *  Permanent vision loss: Baseline and periodic vision assessment is required (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,sabril,205,4498,4501,5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,sabril,206,4501,4505,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,sabril,207,4505,4704,"*  Abnormal MRI signal changes have been reported in some infants with IS receiving SABRIL (  5.3  ) \n', ' *  Suicidal behavior and ideation: Antiepileptic drugs, including SABRIL increase the risk of suicidal thoughts and behavior (  5.5  ) \n', ' *  Withdrawal of AEDs: Dose should be tapered gradually to avoid withdrawal seizures (  5.6  ) \n', ' *  Anemia: Monitor for symptoms of anemia (  5.7  ) \n', ' *  Somnolence and fatigue: Advise patients not to drive or operate machinery until they have gained sufficient experience on SABRIL (  5.8  ) \n', '    \n', ' \n', '\n', '    5.1        Vision Loss  \n', '\n', '\n', '\n', '   Because of the risk of  oselabeledaefromdruguse  and because, when it is effective, SABRIL provides an observable symptomatic benefit, patient response and continued need for treatment should be periodically assessed.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,sabril,208,4704,4747,"\n', '\n', '\n', '\n', '  In patients with refractory  notaecandidateindication  SABRIL should be withdrawn if a substantial clinical benefit is not observed within 3 months of initiating treatment.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
209,sabril,209,4747,4777,"If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 3 months, treatment should be discontinued at that time.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,sabril,210,4777,4818,"\n', '\n', '\n', '\n', '  In patients with  notaecandidateindication  SABRIL should be withdrawn if a substantial clinical benefit is not observed within 2 to 4 weeks.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
211,sabril,211,4818,4857,"If, in the clinical judgment of the prescriber, evidence of treatment failure becomes obvious earlier than 2 to 4 weeks, treatment should be discontinued at that time [see  BOXED WARNING  ].    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,sabril,212,4857,4878,"\n', '\n', '\n', '\n', '   Monitoring of Vision    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,sabril,213,4878,4938,"\n', '\n', '\n', '\n', ' Monitoring of vision by an ophthalmic professional with expertise in visual field interpretation and the ability to perform dilated indirect ophthalmoscopy of the retina is required, unless a patient is formally exempted from periodic ophthalmologic assessment as documented in the Support, Help",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,sabril,214,4938,4960,And Resources for  nonoseaeaeonlyasinstruction (SHARE) program [see  Warnings and Precautions (5.2)  ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,sabril,215,4960,4979,"Because vision testing in infants is difficult,  nonoseaeaeonlyasinstruction may not be detected until it is severe.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,sabril,216,4979,5054,"For patients receiving SABRIL who are not exempted, vision assessment is required at baseline (no later than 4 weeks after starting SABRIL) and at least every 3 months while on therapy and about 3-6 months after the discontinuation of therapy.\n', '\n', '\n', '\n', '  The diagnostic approach should be individualized for the patient and clinical situation.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,sabril,217,5054,5075,"For all patients, attempts to monitor vision periodically and/or formal exemptions must be documented under the SHARE program.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,sabril,218,5075,5095,"In adults and cooperative pediatric patients, perimetry is recommended, preferably by automated threshold visual field testing.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,sabril,219,5095,5139,"Additional testing may also include electrophysiology (e.g., electroretinography [ERG]), retinal imaging (e.g., optical coherence tomography [OCT]), and/or other methods appropriate for the patient, but this additional testing is not required.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,sabril,220,5139,5170,"In patients exempted from vision testing, treatment may continue according to clinical judgment, with appropriate patient counseling and with documentation in the SHARE program of the exemption.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,sabril,221,5170,5197,"Because of variability, results from ophthalmic monitoring must be interpreted with caution, and repeat assessment is recommended if results are abnormal or uninterpretable.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,sabril,222,5197,5272,"Repeat assessment in the first few weeks of treatment is recommended to establish if, and to what degree, reproducible results can be obtained, and to guide selection of appropriate ongoing monitoring for the patient.\n', '\n', '\n', '\n', ' The onset and progression of  oselabeledaefromdruguse from SABRIL is unpredictable, and it may occur or worsen precipitously between assessments.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,sabril,223,5272,5284,"Once detected,  oselabeledaefromdruguse due to SABRIL is not reversible.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,sabril,224,5284,5437,"It is expected that even with frequent monitoring, some SABRIL patients will develop severe  oselabeledaefromdruguse  Drug discontinuation should be considered, balancing benefit and risk, if  nonoseaeaeonlyasinstruction is documented.\n', '\n', '\n', '\n', '     5.2        SABRIL SHARE Program  \n', '\n', '\n', '\n', '  SABRIL is available only through a restricted distribution program called the SHARE program, because of the risk of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Notable requirements components of the SHARE Program include the following:\n', '\n', '\n', '\n', ' *  *  Assess vision prior to initiating therapy and then every 3 months during therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,sabril,225,5437,5491,"\n', ' *  Remove patients from SABRIL therapy if the patients do not experience a meaningful reduction in  notaecandidateindication  \n', ' *  *  The patient is  notaecandidatepreexistingconditionorriskfactor (subsequent Ophthalmologic Assessment Forms do not need to be submitted to the REMS coordinating center)",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
226,sabril,226,5491,5527,"\n', "" *  The patient's general  notaecandidatepreexistingconditionorriskfactor permanently precludes the need for visual assessment (subsequent Ophthalmologic Assessment Forms do not need to be submitted to the REMS coordinating center)",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
227,sabril,227,5527,5549,"\n"", "" *  The patient's general  notaecandidatepreexistingconditionorriskfactor temporarily precludes the ability to assess visual function.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
228,sabril,228,5549,5565,"The evaluation, however, may be performed at a later time as clinically appropriate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,sabril,229,5565,5676,"\n"", "" *  The patient's medical condition prevents visual assessment being performed safely \n"", ' *  For other reasons specified by the prescriber \n', '   The prescriber may, with appropriate documentation and caregiver counseling, exempt certain patients from vision assessment, using the Ophthalmologic Assessment Form, if: \n', '   Prescribers must be certified with the program by enrolling and reviewing educational materials and comply with the following: \n', ' *  Patient/parent/legal guardian must understand the risks and benefits and sign a Patient-Prescriber Agreement.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,sabril,230,5676,5699,"\n', ' *  Pharmacies that dispense SABRIL must be certified and agree to comply with the REMS requirements.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,sabril,231,5699,5714,Certified pharmacies must only dispense SABRIL to patients who are enrolled in the program.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,sabril,232,5714,5793,"\n', '        5.3        Magnetic Resonance Imaging (MRI) Abnormalities in Infants  \n', ' \n', '\n', '   oselabeledaefromdruguse characterized by  oselabeledaefromdruguse and  oselabeledaefromdruguse a symmetric pattern involving the thalamus, basal ganglia, brain stem, and  oselabeledaefromdruguse  oselabeledaefromdruguse a symmetric pattern involving the thalamus, basal ganglia,  oselabeledaefromdruguse  oselabeledaefromdruguse a symmetric pattern involving the  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,sabril,233,5793,5857,"a symmetric pattern involving the thalamus,  oselabeledaefromdruguse  brain stem, and cerebellum have been observed in some infants treated with vigabatrin for  notaecandidateindication  In a retrospective epidemiologic study in infants with  notaecandidateindication (N=205), the prevalence of these changes was 22% in vigabatrin treated patients versus 4% in patients treated with other therapies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
234,sabril,234,5857,5873,"\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,sabril,235,5873,5898,"In the study above, in post marketing experience, and in published literature reports, these changes generally resolved with discontinuation of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,sabril,236,5898,5911,"In a few patients, the lesion resolved despite continued use.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,sabril,237,5911,5990,"It has been reported that some infants exhibited coincident  nonoseaeaeonlyasinstruction  but no causal relationship has been established and the potential for long-term clinical sequelae has not been adequately studied.\n', '\n', '\n', '\n', '  nonoseaeaeanimal ( nonoseaeaeanimal and neurobehavioral  nonoseaeaeanimal  nonoseaeaeanimal  was observed in rats exposed to vigabatrin during late gestation and the neonatal and juvenile periods of development.  ",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
238,sabril,238,5990,6255,"The relationship between these findings and the  nonoseaeaeonlyasinstruction in infants treated with vigabatrin for  notaecandidateindication is unknown [see   Warnings and Precautions (5.4)  and  Use in Specific Populations (8.1)  ]  .\n', '\n', '\n', '\n', ' The specific pattern of signal changes observed in  notaecandidateindication patients was not observed in older pediatric and adult patients treated with vigabatrin for  notaecandidateindication  In a blinded review of MRI images obtained in prospective clinical trials in patients with  notaecandidateindication 3 years and older (N=656), no difference was observed in anatomic distribution or prevalence of  nonoseaeaeratelteqplacebo between vigabatrin treated and placebo treated patients.\n', '\n', '\n', '\n', ' For adults treated with SABRIL, routine MRI surveillance is unnecessary as there is no evidence that vigabatrin causes  nonoseaenegation in this population.\n', '\n', '\n', '\n', '     5.4        Neurotoxicity  \n', '\n', '\n', '\n', '   nonoseaeaeanimal  characterized by fluid accumulation and separation  nonoseaeaeanimal  has been observed  nonoseaeaeanimal  nonoseaeaeanimal and separation of the outer layers of myel nonoseaeaeanimal  has been observed in  nonoseaeaeanimal  nonoseaeaeanimal  has been observed  nonoseaeaeanimal in adult and juvenile rats and adult mice, dogs, and possibly monkeys following administration of vigabatrin.",1,0,0,1,0,0,1,1,1,0,0,0,0,0,0
239,sabril,239,6255,6279,"This lesion, referred to as  nonoseaeaeanimal (IME), was seen in animals at doses within the human therapeutic range.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
240,sabril,240,6279,6292,A no-effect dose was not established in rodents or dogs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,sabril,241,6292,6376,"In the rat and dog,  nonoseaeaeanimal was reversible following discontinuation of vigabatrin treatment, but, in the rat, pathologic changes consisting of  nonoseaeaeanimal or degenerating  nonoseaeaeanimal  m nonoseaeaeanimal ralization, and gliosis were seen in  nonoseaeaeanimal  nonoseaeaeanimal  m nonoseaeaeanimal ralization, and gliosis were seen in  nonoseaeaeanimal  nonoseaeaeanimal  and gliosis were seen  nonoseaeaeanimal  nonoseaeaeanimal were seen  nonoseaeaeanimal areas in which  nonoseaeaeanimal had been previously observed.   ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
242,sabril,242,6376,6563,"nonoseaeaeanimal in adult animals was correlated with  nonoseaeaeanimal and  nonoseaeaeanimal in visual and  nonoseaeaeanimal  nonoseaeaeanimal and somatosensory  nonoseaeaeanimal (EP).\n', '\n', '\n', '\n', ' Administration of vigabatrin to rats during the neonatal and juvenile periods of development produced  nonoseaeaeanimal the brain gray matter (areas including the thalamus, midbrain, deep cerebellar nuclei, substantia nigra, hippocampus, and  nonoseaeaeanimal  nonoseaeaeanimal the brain gray matter (areas including the thalamus, midbrain, deep cerebellar nuclei, substantia nigra,  nonoseaeaeanimal  nonoseaeaeanimal the brain gray matter (areas including the thalamus, midbrain,  nonoseaeaeanimal  nonoseaeaeanimal the brain gray matter (areas including the thalamus,  nonoseaeaeanimal  nonoseaeaeanimal brain gray matter (areas including the  nonoseaeaeanimal  nonoseaeaeanimal  nonoseaeaeanimal the brain gray matter (areas including the thalamus, midbrain, deep cerebellar nuclei,  nonoseaeaeanimal  hippocampus, and forebrain) which are considered distinct from the IME observed in vigabatrin treated adult animals.  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
243,sabril,243,6563,6594,nonoseaeaeanimal and evidence of oligodendrocyte  nonoseaeaeanimal ury were additional findings in  nonoseaeaeanimal  nonoseaeaeanimal were additional f nonoseaeaeanimal ings in  nonoseaeaeanimal of vigabatrin-treated rats.  ,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
244,sabril,244,6594,6615,An  nonoseaeaeanimal was seen  nonoseaeaeanimal some  nonoseaeaeanimal regions following vigabatrin exposure during the early postnatal period.   ,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
245,sabril,245,6615,6637,Long-term  nonoseaeaeanimal ( nonoseaeaeanimal   nonoseaeaeanimal   nonoseaeaeanimal  were also observed following vigabatrin treatment of young rats.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
246,sabril,246,6637,6856,"These effects in young animals occurred at doses lower than those producing  nonoseaeaeanimal in adult animals and were associated with plasma vigabatrin levels substantially lower than those achieved clinically in infants and children [see  Use in Specific Populations (8.1)  ]  .\n', '\n', '\n', '\n', ' In a published study, vigabatrin (200, 400 mg/kg/day) induced  nonoseaeaeanimal of young rats when administered by intraperitoneal injection on postnatal days 5-7.\n', '\n', '\n', '\n', ' Administration of vigabatrin to female rats during  nonoseaeaeanimal and lactation at doses below those used clinically resulted in  nonoseaeaeanimal and convulsions  nonoseaeaeanimal the mature  nonoseaeaeanimal  nonoseaeaeanimal the mature  nonoseaeaeanimal \n', '\n', '\n', '\n', '  oselabeledaefromdruguse changes characterized by  oselabeledaefromdruguse reased T2 signal and restricted diffusion in a symmetric pattern involving the  oselabeledaefromdruguse  oselabeledaefromdruguse changes characterized by  oselabeledaefromdruguse reased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia, brain stem, and  oselabeledaefromdruguse  oselabeledaefromdruguse changes characterized by  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
247,sabril,247,6856,6882,"oselabeledaefromdruguse reased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus, basal ganglia,  oselabeledaefromdruguse  oselabeledaefromdruguse changes characterized by  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,sabril,248,6882,7016,"oselabeledaefromdruguse reased T2 signal and restricted diffusion in a symmetric pattern involving the thalamus,  oselabeledaefromdruguse  oselabeledaefromdruguse and restricted diffusion  oselabeledaefromdruguse a symmetric pattern involving the thalamus, basal ganglia, brain stem, and  oselabeledaefromdruguse  oselabeledaefromdruguse and restricted diffusion  oselabeledaefromdruguse a symmetric pattern involving the thalamus, basal ganglia,  oselabeledaefromdruguse  oselabeledaefromdruguse and restricted diffusion  oselabeledaefromdruguse a symmetric pattern involving the thalamus,  oselabeledaefromdruguse  oselabeledaefromdruguse and restricted diffusion  oselabeledaefromdruguse a symmetric pattern involving the  oselabeledaefromdruguse  oselabeledaefromdruguse a symmetric pattern involving the thalamus, basal ganglia, brain stem, and  oselabeledaefromdruguse  oselabeledaefromdruguse a symmetric pattern involving the thalamus, basal ganglia,  oselabeledaefromdruguse  oselabeledaefromdruguse a symmetric pattern involving the thalamus,  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,sabril,249,7016,7046,"a symmetric pattern involving the  oselabeledaefromdruguse  basal ganglia, brain stem, and cerebellum have been observed in some infants treated for  notaecandidateindication with vigabatrin.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
250,sabril,250,7046,7151,"Studies of the effects of vigabatrin on MRI and EP in adult  notaecandidateindication patients have demonstrated no clear-cut abnormalities [see  Warnings and Precautions (5.3)  ]  .\n', '\n', '\n', '\n', '     5.5        Suicidal Behavior and Ideation  \n', '\n', '\n', '\n', '  Antiepileptic drugs (AEDs), including SABRIL, increase the risk of  oselabeledaefromdruguse  oselabeledaefromdruguse thoughts or  oselabeledaefromdruguse in patients taking these drugs for any indication.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
251,sabril,251,7151,7274,"Patients treated with any AED for any indication should be monitored for the emergence or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction depression,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction  and/or any  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction mood or  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI: 1.2, 2.7) of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking or  oselabeledaeclasseffect compared to patients randomized to placebo.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,sabril,252,7274,7342,"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of  oselabeledaeclasseffect  oselabeledaeclasseffect behavior or  oselabeledaeclasseffect among 27,863 AED treated patients was 0.43%, compared to 0.24% among 16,029 placebo treated patients, representing an increase of approximately one case of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking or  oselabeledaeclasseffect for every 530 patients treated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,sabril,253,7342,7429,"There were four  oselabeledaeclasseffect in drug treated patients in the trials and none in placebo treated patients, but the number is too small to allow any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' The increased risk of  oselabeledaeclasseffect  oselabeledaeclasseffect thoughts or  oselabeledaeclasseffect with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,sabril,254,7429,7501,"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or behavior beyond 24 weeks could not be assessed.\n', '\n', '\n', '\n', ' The risk of  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or behavior was generally consistent among drugs in the data analyzed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,sabril,255,7501,7532,The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,sabril,256,7532,7552,The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,sabril,257,7552,7583,"Table 4 shows absolute and relative risk by indication for all evaluated AEDs.\n', '\n', '\n', '\n', ' Table 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,sabril,258,7583,7593,Risk by Indication for Antiepileptic Drugs in the Pooled Analysis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,sabril,259,7593,7632,"\n', '   Indication       Placebo Patients with Events per 1000 Patients    Drug Patients with Events per 1000 Patients     Relative Risk: Incidence of Drug Events in Drug Patients/Incidence in Placebo Patients      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,sabril,260,7632,7644,Risk Difference: Additional Drug Patients with Events per 1000 Patients    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,sabril,261,7644,7709,"\n', '   notaecandidateindication         1.0              3.4              3.5              2.4              \n', '   notaecandidatepreexistingconditionorriskfactor      5.7              8.5              1.5              2.9              \n', '  Other            1.0              1.8              1.9              0.9              \n', '  Total            2.4              4.3              1.8              1.9              \n', '           ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
262,sabril,262,7709,7794,"The relative risk for  oselabeledaeclasseffect  oselabeledaeclasseffect thoughts or  oselabeledaeclasseffect was higher in clinical trials for  notaecandidateindication than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor indications.\n', ' \n', '\n', ' Anyone considering prescribing SABRIL or any other AED must balance the risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction with the risk of untreated illness.  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
263,sabril,263,7794,8009,"notaecandidateindication and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and  nonoseaegeneralterm and an increased risk of  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor thoughts and  notaecandidatepreexistingconditionorriskfactor  Should  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.\n', '\n', '\n', '\n', ' Patients, their caregivers, and families should be informed that AEDs increase the risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction and should be advised of the need to be alert for the emergence or  nonoseaeaeonlyasinstruction  any  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction mood or  nonoseaeaeonlyasinstruction  or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts,  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  Behaviors of concern should be reported immediately to healthcare providers.\n', '\n', '\n', '\n', '     5.6        Withdrawal of Antiepileptic Drugs (AEDs)  \n', '\n', '\n', '\n', '  As with all AEDs, SABRIL should be withdrawn gradually.",1,1,1,1,0,0,0,0,0,0,0,0,0,0,0
264,sabril,264,8009,8168,"Patients and caregivers should be told not to suddenly discontinue SABRIL therapy.\n', '\n', '\n', '\n', ' In controlled clinical studies in adults with  notaecandidateindication  SABRIL was tapered by decreasing the daily dose 1000 mg/day on a weekly basis until discontinued.\n', '\n', '\n', '\n', ' In a controlled study in pediatric patients with  notaecandidateindication  SABRIL was tapered by decreasing the daily dose by one third every week for three weeks.\n', '\n', '\n', '\n', ' In a controlled clinical study in patients with  notaecandidateindication  SABRIL was tapered by decreasing the daily dose at a rate of 25-50 mg/kg every 3-4 days [see  Dosage and Administration (2.1)  ].  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
265,sabril,265,8168,8273,"\n', '\n', '\n', '\n', '     5.7        Anemia  \n', '\n', '\n', '\n', '  In North American controlled trials in adults, 6% of patients (16/280) receiving SABRIL and 2% of patients (3/188) receiving placebo had adverse events of  oselabeledaefromdruguse and/or met criteria for potentially clinically important  oselabeledaefromdruguse  oselabeledaefromdruguse involving  oselabeledaefromdruguse  oselabeledaefromdruguse involving hemoglobin,  oselabeledaefromdruguse  oselabeledaefromdruguse involving hemoglobin, hematocrit, and/or  oselabeledaefromdruguse indices.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,sabril,266,8273,8385,"Across U.S. controlled trials, there were mean  oselabeledaefromdruguse of about 3% and 0% in SABRIL and placebo treated patients, respectively, and a mean  oselabeledaefromdruguse of about 1% in SABRIL treated patients compared to a mean gain of about 1% in patients treated with placebo.\n', '\n', '\n', '\n', ' In controlled and open label  notaecandidateindication trials in adults and pediatric patients, 3 SABRIL patients (0.06%, 3/4855) discontinued for  oselabeledaefromdruguse and 2 SABRIL patients experienced unexplained  oselabeledaefromdruguse  oselabeledaefromdruguse hemoglobin to below 8 g/dL",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
267,sabril,267,8385,8515,"and/or  oselabeledaefromdruguse below 24%.\n', '\n', '\n', '\n', '     5.8        Somnolence and Fatigue  \n', '\n', '\n', '\n', '  SABRIL causes  oselabeledaefromdruguse and  oselabeledaefromdruguse  Patients should be advised not to drive a car or operate other complex machinery until they are familiar with the effects of SABRIL on their ability to perform such activities.\n', '\n', '\n', '\n', ' Pooled data from two SABRIL controlled trials in adults demonstrated that 24% (54/222) of SABRIL patients experienced  oselabeledaefromdruguse compared to 10% (14/135) of placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,sabril,268,8515,8539,"In those same studies, 28% of SABRIL patients experienced  oselabeledaefromdruguse compared to 15% (20/135) of placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,sabril,269,8539,8611,"Almost 1% of SABRIL patients discontinued from clinical trials for  oselabeledaefromdruguse and almost 1% discontinued for  oselabeledaefromdruguse \n', '\n', '\n', '\n', '  Pooled data from three SABRIL controlled trials in pediatric patients demonstrated that 6% (10/165) of SABRIL patients experienced  oselabeledaefromdruguse compared to 5% (5/104) of placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,sabril,270,8611,8638,"In those same studies, 10% (17/165) of SABRIL patients experienced  oselabeledaefromdruguse compared to 7% (7/104) of placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,sabril,271,8638,8701,"No SABRIL patients discontinued from clinical trials due to  nonoseaenegation or  nonoseaenegation   \n', '\n', '\n', '\n', '     5.9        Peripheral Neuropathy  \n', '\n', '\n', '\n', '  SABRIL causes symptoms of  oselabeledaefromdruguse in adults.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
272,sabril,272,8701,8737,Pediatric clinical trials were not designed to assess symptoms of  nonoseaeaeonlyasinstruction  but observed incidence of symptoms based on pooled data from controlled pediatric studies appeared similar for pediatric patients on vigabatrin and placebo.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,sabril,273,8737,8766,"In a pool of North American controlled and uncontrolled  notaecandidateindication studies, 4.2% (19/457) of SABRIL patients developed signs and/or symptoms of  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
274,sabril,274,8766,8867,"In the subset of North American placebo-controlled epilepsy trials, 1.4% (4/280) of SABRIL treated patients and no (0/188) placebo patients developed signs and/or symptoms of  oselabeledaefromdruguse  Initial manifestations of  oselabeledaefromdruguse in these trials included, in some combination, symptoms of  nonoseaemanifestationorcomplication or tingling in the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or tingling in the toes or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication in the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication in the toes or  nonoseaemanifestationorcomplication  signs of  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication  starting at the ankles.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
275,sabril,275,8867,8899,"Clinical studies in the development program were not designed to investigate  nonoseaeaeonlyasinstruction systematically and did not include nerve conduction studies, quantitative sensory testing, or skin or nerve biopsy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,sabril,276,8899,9156,"There is insufficient evidence to determine if development of these signs and symptoms were related to duration of SABRIL treatment, cumulative dose, or if the findings of  nonoseaeaeonlyasinstruction were completely reversible upon discontinuation of SABRIL.\n', '\n', '\n', '\n', '     5.10        Weight Gain  \n', '\n', '\n', '\n', '  SABRIL causes  oselabeledaefromdruguse in adult and pediatric patients.\n', '\n', '\n', '\n', ' Data pooled from randomized controlled trials in adults found that 17% (77/443) of SABRIL patients versus 8% (22/275) of placebo patients  oselabeledaefromdruguse >=7% of baseline body  oselabeledaefromdruguse  In these same trials, the mean weight change among SABRIL patients was 3.5 kg compared to 1.6 kg for placebo patients.\n', '\n', '\n', '\n', '  Data pooled from randomized controlled trials in pediatric patients with refractory  notaecandidateindication found that 47% (77/163) of SABRIL patients versus 19% (19/102) of placebo patients  oselabeledaefromdruguse >=7% of baseline body  oselabeledaefromdruguse   \n', '\n', '\n', '\n', '  In all  notaecandidateindication trials, 0.6% (31/4855) of SABRIL patients discontinued for  oselabeledaefromdruguse  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
277,sabril,277,9156,9170,The long term effects of SABRIL related  nonoseaeaeonlyasinstruction are not known.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,sabril,278,9170,9227,"nonoseaeaeonlyasinstruction was not related to the occurrence of  nonoseaenegation   \n', '\n', '\n', '\n', '     5.11        Edema  \n', '\n', '\n', '\n', '  SABRIL causes  oselabeledaefromdruguse in adults.  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
279,sabril,279,9227,9316,"Pediatric clinical trials were not designed to assess  nonoseaeaeonlyasinstruction  but observed incidence of  nonoseaeaeratelteqplacebo based pooled data from controlled pediatric studies appeared similar for pediatric patients on vigabatrin and placebo.\n', '\n', '\n', '\n', ' Pooled data from controlled trials demonstrated increased risk among SABRIL patients compared to placebo patients for  oselabeledaefromdruguse (SABRIL 2%, placebo 1%), and  oselabeledaefromdruguse (SABRIL 1%, placebo 0%).",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
280,sabril,280,9316,9334,"In these studies, one SABRIL and no placebo patients discontinued for an  oselabeledaefromdruguse related AE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,sabril,281,9334,9379,"In adults, there was no apparent association between  nonoseaeaeonlyasinstruction and  nonoseaegeneralterm such as  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction was not associated with  nonoseaeaeonlyasinstruction suggestive of  nonoseaeaeonlyasinstruction renal or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or hepatic  nonoseaeaeonlyasinstruction ']",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
0,invokana,0,0,64,"['  6 ADVERSE REACTIONS\n', '\n', '  The following important adverse reactions are described below and elsewhere in the labeling:\n', '\n', ' *   oselabeledaefromdruguse [see  Boxed Warning  and  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,invokana,1,64,77,"Warnings and Precautions (5.2)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,invokana,2,77,124,"*   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,invokana,3,124,155,"Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,invokana,4,155,173,"\n', ' *   nonoseaeaefromdruginteraction with Concomitant Use with Insulin and Insulin Secretagogues [see  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
5,invokana,5,173,186,"Warnings and Precautions (5.7)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,invokana,6,186,254,"*   oselabeledaefromdruguse [see  Warnings and Precautions (5.8)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.9)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.10)  ]  \n', ' *   oselabeledaefromdruguse (LDL-C) [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,invokana,7,254,263,Warnings and Precautions (5.11)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,invokana,8,263,286,"\n', '   *  Most common adverse reactions associated with INVOKANA (5% or greater incidence):  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,invokana,9,286,298,oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,invokana,10,298,306,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,invokana,11,306,336,"To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,invokana,12,336,369,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Studies Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,invokana,13,369,453,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '     Pool of Placebo-Controlled Trials  \n', '\n', ' The data in Table 1 is derived from four 26-week placebo-controlled trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,invokana,14,453,486,In one trial INVOKANA was used as monotherapy and in three trials INVOKANA was used as add-on therapy  [see  Clinical Studies (14)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,invokana,15,486,507,These data reflect exposure of 1667 patients to INVOKANA and a mean duration of exposure to INVOKANA of 24 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,invokana,16,507,530,"Patients received INVOKANA 100 mg (N=833), INVOKANA 300 mg (N=834) or placebo (N=646) once daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,invokana,17,530,550,The mean age of the population was 56 years and 2% were older than 75 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,invokana,18,550,581,"Fifty percent (50%) of the population was male and 72% were Caucasian, 12% were Asian, and 5% were Black or African American.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,invokana,19,581,609,"At baseline the population had  notaecandidateindication for an average of 7.3 years, had a mean HbA1Cof 8.0% and 20% had established  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
20,invokana,20,609,644,"Baseline  notaecandidatepreexistingconditionorriskfactor was normal or  notaecandidatepreexistingconditionorriskfactor (mean  notaecandidatepreexistingconditionorriskfactor  ).\n', '\n', ' Table 1 shows common adverse reactions associated with the use of INVOKANA.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
21,invokana,21,644,741,"These adverse reactions were not present at baseline, occurred more commonly on INVOKANA than on placebo, and occurred in at least 2% of patients treated with either INVOKANA 100 mg or INVOKANA 300 mg.\n', '\n', ' Table 1: Adverse Reactions From Pool of Four 26-Week Placebo-Controlled Studies Reported in >= 2% of INVOKANA-Treated PatientsThe four placebo-controlled trials included one monotherapy trial and three add-on combination trials with metformin, metformin and sulfonylurea, or metformin and pioglitazone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,invokana,22,741,753,"\n', ' Note: Percentages were weighted by studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,invokana,23,753,769,Study weights were proportional to the harmonic mean of the three treatment sample sizes.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,invokana,24,769,788,"\n', '  \n', '   Adverse Reaction                            PlaceboN=646        INVOKANA 100 mgN=833      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,invokana,25,788,798,"INVOKANA 300 mgN=834     \n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,invokana,26,798,830,[note:  oselabeledaefromdruguse include the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ]           3.8%                  5.9%                  4.4%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,invokana,27,830,870,"\n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ]           0.7%                  5.1%                  4.6%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,invokana,28,870,905,"\n', '  oselabeledaefromdruguse [note: Thirst includes the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ]           0.1%                  2.8%                  2.4%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,invokana,29,905,921,"\n', '  oselabeledaefromdruguse                                      0.9%                  1.8%                  2.4%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,invokana,30,921,937,"\n', '  oselabeledaefromdruguse                                            1.6%                  2.1%                  2.3%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,invokana,31,937,946,"\n', '                                                  N=312                 N=425                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,invokana,32,946,948,N=430           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,invokana,33,948,981,"\n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse include the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ]           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,invokana,34,981,990,2.8%                 10.6%                 11.6%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,invokana,35,990,1006,"\n', '  oselabeledaefromdruguse                             0.0%                  1.6%                  3.2%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,invokana,36,1006,1013,"\n', '                                                  N=334                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,invokana,37,1013,1017,N=408                 N=404           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,invokana,38,1017,1057,"\n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse  include the following adverse reactions:  oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ]           0.7%                  4.2%                  3.8%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,invokana,39,1057,1121,"\n', '           oselabeledaefromdruguse was also more commonly reported in patients taking INVOKANA 100 mg (1.8%), 300 mg (1.7%) than in patients taking placebo (0.8%).\n', ' \n', '\n', '     Pool of Placebo- and Active-Controlled Trials  \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,invokana,40,1121,1178,"The occurrence of adverse reactions for canagliflozin was evaluated in a larger pool of patients participating in placebo- and active-controlled trials.\n', '\n', ' The data combined eight clinical trials  [see  Clinical Studies (14)  ]  and reflect exposure of 6177 patients to INVOKANA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,invokana,41,1178,1200,The mean duration of exposure to INVOKANA was 38 weeks with 1832 individuals exposed to INVOKANA for greater than 50 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,invokana,42,1200,1223,"Patients received INVOKANA 100 mg (N=3092), INVOKANA 300 mg (N=3085) or comparator (N=3262) once daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,invokana,43,1223,1243,The mean age of the population was 60 years and 5% were older than 75 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,invokana,44,1243,1276,"Fifty-eight percent (58%) of the population was male and 73% were Caucasian, 16% were Asian, and 4% were Black or African American.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,invokana,45,1276,1347,"At baseline, the population had  notaecandidateindication for an average of 11 years, had a mean HbA1Cof 8.0% and 33% had established  notaecandidatepreexistingconditionorriskfactor  Baseline  notaecandidatepreexistingconditionorriskfactor (mean  notaecandidatepreexistingconditionorriskfactor  ).\n', '\n', ' The types and frequency of common adverse reactions observed in the pool of eight clinical trials were consistent with those listed in Table 1.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
46,invokana,46,1347,1353,Percentages were weighted by studies.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,invokana,47,1353,1368,Study weights were proportional to the harmonic mean of the three treatment sample sizes.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,invokana,48,1368,1440,"In this pool, INVOKANA was also associated with the adverse reactions of  oselabeledaefromdruguse (1.8% with comparator, 2.2% with INVOKANA 100 mg, and 2.0% with INVOKANA 300 mg) and  oselabeledaefromdruguse (i.e.,  oselabeledaefromdruguse  (0.6% with comparator, 0.7% with INVOKANA 100 mg, and 1.1% with INVOKANA 300 mg).\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,invokana,49,1440,1496,"In the pool of eight clinical trials, the incidence rate of  oselabeledaefromdruguse (acute or  oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse or chronic) was 0.1%, 0.2%, and 0.1% receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,invokana,50,1496,1548,"In the pool of eight clinical trials,  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,invokana,51,1548,1585,"Five patients experienced serious adverse reactions of  oselabeledaefromdruguse with INVOKANA, which included 4 patients with  oselabeledaefromdruguse and 1 patient with a  oselabeledaefromdruguse and  oselabeledaefromdruguse occurring within hours of exposure to INVOKANA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,invokana,52,1585,1594,"Among these patients, 2 patients discontinued INVOKANA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,invokana,53,1594,1761,"One patient with  oselabeledaefromdruguse had recurrence when INVOKANA was re-initiated.\n', '\n', '  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.\n', '\n', ' Other adverse reactions occurring more frequently on INVOKANA than on comparator were:\n', '\n', '     Lower Limb Amputation  \n', '\n', ' An approximately 2-fold increased risk of  oselabeledaefromdruguse associated with INVOKANA use was observed in CANVAS and CANVAS-R, two large, randomized, placebo-controlled trials evaluating patients with  notaecandidateindication who had either established  notaecandidatepreexistingconditionorriskfactor or were at risk for  nonoseaeaeonlyasinstruction  Patients in CANVAS and CANVAS-R were followed for an average of 5.7 and 2.1 years, respectively.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
54,invokana,54,1761,1794,"The  nonoseaeaeonlyasinstruction data for CANVAS and CANVAS-R are shown in Tables 2 and 3, respectively  [see  Warnings and Precautions (5.1)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,invokana,55,1794,1814,"\n', '\n', ' Table 2: CANVAS Amputations \n', '                                  PlaceboN=1441    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,invokana,56,1814,1818,INVOKANA 100 mgN=1445  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,invokana,57,1818,1824,INVOKANA 300 mgN=1441  INVOKANA (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,invokana,58,1824,1862,"Pooled)N=2886   \n', '  \n', "" Note: Incidence is based on the number of patients with at least one  nonoseaeaeonlyasinstruction  and not the total number of  nonoseaeaeonlyasinstruction events.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,invokana,59,1862,1881,A patient's follow-up is calculated from Day 1 to the first  nonoseaeaeonlyasinstruction event date.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,invokana,60,1881,1890,Some patients had more than one  nonoseaeaeonlyasinstruction    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,invokana,61,1890,1898,"\n"", '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,invokana,62,1898,1934,"' Patients with an  oselabeledaefromdruguse  n (%)      22 (1.5)           50 (3.5)            45 (3.1)            95 (3.3)        \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,invokana,63,1934,1940,Total  oselabeledaefromdruguse                      33                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,invokana,64,1940,1942,83                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,invokana,65,1942,1944,79                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,invokana,66,1944,1946,162           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,invokana,67,1946,1960,"\n', '  oselabeledaefromdruguse incidence rate(per 1000 patient-years)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,invokana,68,1960,1962,2.8                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,invokana,69,1962,1966,6.2                 5.5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,invokana,70,1966,1968,5.9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,invokana,71,1968,2003,"\n', ' Hazard Ratio (95% CI)                  --         2.24 (1.36, 3.69)   2.01 (1.20, 3.34)   2.12 (1.34, 3.38)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,invokana,72,2003,2022,"\n', '          Table 3: CANVAS-R Amputations \n', '                                                   PlaceboN=2903           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,invokana,73,2022,2041,"INVOKANA 100 mg (with up-titration to 300 mg)N=2904   \n', '  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,invokana,74,2041,2069,", "" Note: Incidence is based on the number of patients with at least one  nonoseaeaeonlyasinstruction  and not the total number of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,invokana,75,2069,2088,A patient's follow-up is calculated from Day 1 to the first  nonoseaeaeonlyasinstruction event date.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,invokana,76,2088,2097,Some patients had more than one  nonoseaeaeonlyasinstruction    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,invokana,77,2097,2105,"\n"", '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,invokana,78,2105,2146,"' Patients with an  oselabeledaefromdruguse  n (%)                   25 (0.9)                        45 (1.5)              \n', ' Total  oselabeledaefromdruguse                                       36                              59                 \n', '  oselabeledaefromdruguse incidence",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,invokana,79,2146,2157,rate(per 1000 patient-years)               4.2                             7.5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,invokana,80,2157,2190,"\n', ' Hazard Ratio (95% CI)                                   --                      1.80 (1.10, 2.93)          \n', '             Volume Depletion-Related Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,invokana,81,2190,2216,"\n', ' \n', '\n', ' INVOKANA results in an osmotic diuresis, which may lead to  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,invokana,82,2216,2253,"In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,invokana,83,2253,2266,An increased incidence was observed in patients on the 300 mg dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,invokana,84,2266,2370,"The three factors associated with the largest increase in  nonoseaeaeonlyasinstruction were the use of loop diuretics,  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor  ), and age 75 years and older (Table 4)  [see  Dosage and Administration (2.2)  ,  Warnings and Precautions (5.2)  , and  Use in Specific Populations (8.5  and  8.6)  ]  .\n', '\n', ' Table 4: Proportion of Patients With at Least One  oselabeledaefromdruguse (Pooled Results from 8 Clinical Trials) \n', '",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
85,invokana,85,2370,2388,Baseline Characteristic                   Comparator Group [note: Includes placebo and active-comparator groups] %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,invokana,86,2388,2392,INVOKANA 100 mg%      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,invokana,87,2392,2452,"INVOKANA 300 mg%     \n', '  \n', ' Overall population                                1.5%                  2.3%                  3.4%           \n', ' 75 years of age and older [note: Patients could have more than 1 of the listed risk factors]           2.6%                  4.9%                  8.7%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,invokana,88,2452,2468,"\n', '  notaecandidatepreexistingconditionorriskfactor                2.5%                  4.7%                  8.1%           ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
89,invokana,89,2468,2487,"\n', ' Use of loop diuretic                              4.7%                  3.2%                  8.8%           \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,invokana,90,2487,2493,"', '              Falls  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,invokana,91,2493,2498,"\n', ' \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,invokana,92,2498,2555,"', '\n', ' In a pool of nine clinical trials with mean duration of exposure to INVOKANA of 85 weeks, the proportion of patients who experienced  oselabeledaefromdruguse was 1.3%, 1.5%, and 2.1% with comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,invokana,93,2555,2616,"The higher risk of  oselabeledaefromdruguse for patients treated with INVOKANA was observed within the first few weeks of treatment.\n', '\n', '     Impairment in Renal Function  \n', '\n', ' INVOKANA is associated with a dose-dependent  oselabeledaefromdruguse and a concomitant  oselabeledaefromdruguse (Table 5).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,invokana,94,2616,2724,"Patients with moderate  notaecandidatepreexistingconditionorriskfactor at baseline had larger mean changes.\n', '\n', ' Table 5:  oselabeledaefromdruguse Serum Creatinine and  oselabeledaefromdruguse  oselabeledaefromdruguse and eGFR Associated with INVOKANA in the Pool of Four Placebo-Controlled Trials and Moderate Renal Impairment Trial \n', '                        PlaceboN=646       INVOKANA 100 mgN=833      INVOKANA 300 mgN=834     \n', ' Pool of Four Placebo-Controlled Trials  Baseline           Creatinine (mg/dL)          0.84           0.82             0.82         \n', ' eGFR (mL/min/1.73 m  2  )  87.0               ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
95,invokana,95,2724,2726,88.3                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,invokana,96,2726,2745,"88.8       \n', ' Week 6 Change        Creatinine (mg/dL)  0.01                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,invokana,97,2745,2766,"0.03           0.05         \n', ' eGFR (mL/min/1.73 m  2  )  -1.6               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,invokana,98,2766,2800,"-3.8                        -5.0       \n', ' End of Treatment Change [note: Week 26 in mITT LOCF population]   Creatinine (mg/dL)  0.01                        0.02           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,invokana,99,2800,2817,"0.03         \n', ' eGFR (mL/min/1.73 m  2  )  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,invokana,100,2817,2821,-1.6               -2.3                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,invokana,101,2821,2823,-3.4       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,invokana,102,2823,2830,"\n', '                        PlaceboN=90        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,invokana,103,2830,2834,INVOKANA 100 mgN=90      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,invokana,104,2834,2855,"INVOKANA 300 mgN=89     \n', '  notaecandidatepreexistingconditionorriskfactor Trial  Baseline           Creatinine (mg/dL)          ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
105,invokana,105,2855,2861,1.61           1.62             1.63         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,invokana,106,2861,2878,"\n', ' eGFR (mL/min/1.73 m  2  )  40.1               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,invokana,107,2878,2903,"39.7                        38.5       \n', ' Week 3 Change        Creatinine (mg/dL)  0.03                        0.18           0.28         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,invokana,108,2903,2922,"\n', ' eGFR (mL/min/1.73 m  2  )  -0.7               -4.6                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,invokana,109,2922,2924,-6.2       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,invokana,110,2924,2942,"\n', ' End of Treatment Change  Creatinine (mg/dL)  0.07                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,invokana,111,2942,3039,"0.16           0.18         \n', ' eGFR (mL/min/1.73 m  2  )  -1.5               -3.6                        -4.0       \n', '            In the pool of four placebo-controlled trials where patients had normal or mildly  notaecandidatepreexistingconditionorriskfactor  the proportion of patients who experienced at least one event of significant  oselabeledaefromdruguse  defined as an  nonoseaeaeonlyasinstruction  and 30% lower than baseline, was 2.1% with placebo, 2.0% with INVOKANA 100 mg, and 4.1% with INVOKANA 300 mg.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
112,invokana,112,3039,3160,"At the end of treatment, 0.5% with placebo, 0.7% with INVOKANA 100 mg, and 1.4% with INVOKANA 300 mg had a significant  oselabeledaefromdruguse \n', ' \n', '\n', ' In a trial carried out in patients with moderate  notaecandidatepreexistingconditionorriskfactor with a baseline  notaecandidatepreexistingconditionorriskfactor  (mean baseline  notaecandidatepreexistingconditionorriskfactor  )  [see  Clinical Studies (14.3)  ]  , the proportion of patients who experienced at least one event of significant  oselabeledaefromdruguse  defined as an  oselabeledaefromdruguse  was 6.9% with placebo, 18% with INVOKANA 100 mg, and 22.5% with INVOKANA 300 mg.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
113,invokana,113,3160,3344,"At the end of treatment, 4.6% with placebo, 3.4% with INVOKANA 100 mg, and 2.2% with INVOKANA 300 mg had a significant  oselabeledaefromdruguse \n', '\n', ' In a pooled population of patients with moderate  notaecandidatepreexistingconditionorriskfactor (N=1085) with baseline  notaecandidatepreexistingconditionorriskfactor  2  (mean baseline  notaecandidatepreexistingconditionorriskfactor  ), the overall incidence of these events was lower than in the dedicated trial but a dose-dependent increase in incident episodes of significant  oselabeledaefromdruguse compared to placebo was still observed.\n', '\n', ' Use of INVOKANA has been associated with an increased incidence of  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse , particularly in patients with moderate  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' In the pooled analysis of patients with moderate  notaecandidatepreexistingconditionorriskfactor  the incidence of  oselabeledaefromdruguse was 3.7% with placebo, 8.9% with INVOKANA 100 mg, and 9.3% with INVOKANA 300 mg.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
114,invokana,114,3344,3396,"Discontinuations due to  oselabeledaefromdruguse occurred in 1.0% with placebo, 1.2% with INVOKANA 100 mg, and 1.6% with INVOKANA 300 mg  [see  Warnings and Precautions (5.4)  ]  .\n', '\n', '     Genital Mycotic Infections  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,invokana,115,3396,3401,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,invokana,116,3401,3457,"', ' In the pool of four placebo-controlled clinical trials,  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred in 2.8%, 10.6%, and 11.6% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,invokana,117,3457,3475,Patients with a history of  notaecandidatepreexistingconditionorriskfactor were more likely to develop  oselabeledaefromdruguse on INVOKANA.  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
118,invokana,118,3475,3504,nonoseaeaeonlyasinstruction patients who developed  nonoseaeaeonlyasinstruction on INVOKANA were more likely to experience recurrence and require treatment with oral or topical antifungal agents and anti-microbial agents.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,invokana,119,3504,3600,"In  oselabeledaefromdruguse  discontinuation due to  oselabeledaefromdruguse occurred in 0% and 0.7% of patients treated with placebo and INVOKANA, respectively  [see  Warnings and Precautions (5.8)  ]  .\n', '\n', ' In the pool of four placebo-controlled clinical trials,  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse  occurred in 0.7%, 4.2%, and 3.8% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,invokana,120,3600,3669,"oselabeledaefromdruguse occurred more commonly in uncircumcised males and in males with a prior history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  Male patients who developed  nonoseaeaeonlyasinstruction  oselabeledaefromdruguse infections on INVOKANA were more likely to experience  oselabeledaefromdruguse (22% on INVOKANA versus none on placebo), and require treatment with oral or topical antifungal agents and anti-microbial agents than patients on comparators.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
121,invokana,121,3669,3694,"In males, discontinuations due to  oselabeledaefromdruguse occurred in 0% and 0.5% of patients treated with placebo and INVOKANA, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,invokana,122,3694,3751,"In the pooled analysis of 8 controlled trials,  oselabeledaefromdruguse was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the  oselabeledaefromdruguse  [see  Warnings and Precautions (5.8)  ]  .\n', '\n', '     Hypoglycemia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,invokana,123,3751,3786,"\n', '\n', ' In all clinical trials,  nonoseaeaeonlyasinstruction was defined as any event regardless of symptoms, where biochemical  nonoseaeaeonlyasinstruction was documented (any  nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,invokana,124,3786,3832,"Severe  nonoseaeaeonlyasinstruction was defined as an event consistent with  nonoseaeaeonlyasinstruction where the patient required the assistance of another person to recover,  nonoseaeaeonlyasinstruction  or experienced a  nonoseaeaeonlyasinstruction (regardless of whether biochemical documentation of a  nonoseaeaeonlyasinstruction was obtained).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,invokana,125,3832,3868,"In individual clinical trials  [see  Clinical Studies (14)  ]  , episodes of  nonoseaeaefromdruginteraction occurred at a higher rate when INVOKANA was co-administered with insulin or sulfonylureas",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
126,invokana,126,3868,3950,"(Table 6)  [see  Warnings and Precautions (5.7)  ]  .\n', '\n', ' Table 6: Incidence of  oselabeledaefromdruguse umber of patients experiencing at least one event of  oselabeledaefromdruguse based on either biochemically documented episodes or severe  oselabeledaefromdruguse in the intent-to-treat population in Controlled Clinical Studies \n', '   Monotherapy(26 weeks)            Placebo(N=192)       INVOKANA 100 mg(N=195)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,invokana,127,3950,3955,INVOKANA 300 mg(N=197)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,invokana,128,3955,3967,"\n', ' Overall [N (%)]                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,invokana,129,3967,3972,5 (2.6)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,invokana,130,3972,3982,7 (3.6)                    6 (3.0)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,invokana,131,3982,3994,"\n', '   In Combination with Metformin(26 weeks)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,invokana,132,3994,3999,Placebo + Metformin(N=183)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,invokana,133,3999,4006,INVOKANA 100 mg + Metformin(N=368)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,invokana,134,4006,4025,"INVOKANA 300 mg + Metformin(N=367)     \n', ' Overall [N (%)]                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,invokana,135,4025,4051,"3 (1.6)                 16 (4.3)                   17 (4.6)            \n', ' Severe [N (%)]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,invokana,136,4051,4099,"[note: Severe episodes of  nonoseaeaeonlyasinstruction were defined as those where the patient required the assistance of another person to recover, lost consciousness, or experienced a seizure (regardless of whether biochemical documentation of a low glucose value was obtained)]          0",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,invokana,137,4099,4113,(0)                   1 (0.3)                    1 (0.3)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,invokana,138,4113,4125,"\n', '   In Combination with Metformin(52 weeks)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,invokana,139,4125,4137,Glimepiride + Metformin(N=482)      INVOKANA 100 mg + Metformin(N=483)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,invokana,140,4137,4144,INVOKANA 300 mg + Metformin(N=485)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,invokana,141,4144,4157,"\n', ' Overall [N (%)]                      165",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,invokana,142,4157,4166,(34.2)               27 (5.6)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,invokana,143,4166,4171,24 (4.9)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,invokana,144,4171,4183,"\n', ' Severe [N (%)]                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,invokana,145,4183,4189,15 (3.1)                 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,invokana,146,4189,4194,(0.4)                    3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,invokana,147,4194,4203,"(0.6)            \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,invokana,148,4203,4210,In Combination with Sulfonylurea(18 weeks)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,invokana,149,4210,4215,Placebo + Sulfonylurea(N=69)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,invokana,150,4215,4222,INVOKANA 100 mg + Sulfonylurea(N=74)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,invokana,151,4222,4241,"INVOKANA 300 mg + Sulfonylurea(N=72)     \n', ' Overall [N (%)]                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,invokana,152,4241,4246,4 (5.8)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,invokana,153,4246,4256,3 (4.1)                   9 (12.5)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,invokana,154,4256,4270,"\n', '   In Combination with Metformin + Sulfonylurea(26 weeks)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,invokana,155,4270,4286,Placebo + Metformin + Sulfonylurea(N=156)      INVOKANA 100 mg + Metformin + Sulfonylurea(N=157)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,invokana,156,4286,4334,"INVOKANA 300 mg + Metformin + Sulfonylurea(N=156)     \n', ' Overall [N (%)]                      24 (15.4)                43 (27.4)                  47 (30.1)           \n', ' Severe [N (%)]                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,invokana,157,4334,4335,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,invokana,158,4335,4339,(0.6)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,invokana,159,4339,4346,1 (0.6)                       0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,invokana,160,4346,4360,"\n', '   In Combination with Metformin + Sulfonylurea(52 weeks)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,invokana,161,4360,4388,"Sitagliptin + Metformin + Sulfonylurea(N=378)                                 INVOKANA 300 mg + Metformin + Sulfonylurea(N=377)     \n', ' Overall [N (%)]                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,invokana,162,4388,4393,154 (40.7)                                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,invokana,163,4393,4394,163,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,invokana,164,4394,4410,"(43.2)           \n', ' Severe [N (%)]                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,invokana,165,4410,4418,13 (3.4)                                           15 (4.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,invokana,166,4418,4434,")            \n', '   In Combination with Metformin + Pioglitazone(26 weeks)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,invokana,167,4434,4450,Placebo + Metformin + Pioglitazone(N=115)      INVOKANA 100 mg + Metformin + Pioglitazone(N=113)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,invokana,168,4450,4471,"INVOKANA 300 mg + Metformin + Pioglitazone(N=114)     \n', ' Overall [N (%)]                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,invokana,169,4471,4476,3 (2.6)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,invokana,170,4476,4498,"3 (2.7)                    6 (5.3)            \n', '   In Combination with Insulin(18 weeks)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,invokana,171,4498,4501,Placebo(N=565)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,invokana,172,4501,4506,INVOKANA 100 mg(N=566)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,invokana,173,4506,4511,INVOKANA 300 mg(N=587)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,invokana,174,4511,4524,"\n', ' Overall [N (%)]                      208",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,invokana,175,4524,4550,"(36.8)              279 (49.3)                 285 (48.6)           \n', ' Severe [N (%)]                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,invokana,176,4550,4568,"14 (2.5)                10 (1.8)                   16 (2.7)            \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,invokana,177,4568,4573,'              Bone Fracture  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,invokana,178,4573,4611,"\n', ' \n', '\n', ' The occurrence of  nonoseaeaeonlyasinstruction was evaluated in a pool of nine clinical trials with a mean duration of exposure to INVOKANA of 85 weeks.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,invokana,179,4611,4649,"The incidence rates of adjudicated  oselabeledaefromdruguse were 1.1, 1.4, and 1.5 per 100 patient-years of exposure in the comparator, INVOKANA 100 mg, and INVOKANA 300 mg groups, respectively.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,invokana,180,4649,4670,oselabeledaefromdruguse  oselabeledaefromdruguse were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,invokana,181,4670,4813,"(e.g., fall from no more than standing height), and affect the  oselabeledaefromdruguse  nonoseaeaeonlyasinstruction from no more than standing height), and affect the upper extremities  [see  Warnings and Precautions (5.10)  ]  .\n', '\n', '     Laboratory and Imaging Tests  \n', '\n', '     Increases in Serum Potassium  \n', '\n', ' In a pooled population of patients (N=723) with moderate  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor  ),  oselabeledaefromdruguse  oselabeledaefromdruguse to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 8.8% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
182,invokana,182,4813,4862,"Severe  oselabeledaefromdruguse (greater than or equal to 6.5 mEq/L) occurred in 0.4% of patients treated with placebo, no patients treated with INVOKANA 100 mg, and 1.3% of patients treated with INVOKANA 300 mg.\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,invokana,183,4862,4880,"In these patients,  nonoseaeaeonlyasinstruction were more commonly seen in those with  notaecandidatepreexistingconditionorriskfactor at baseline.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
184,invokana,184,4880,4990,"Among patients with moderate  notaecandidatepreexistingconditionorriskfactor  approximately 84% were taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, angiotensin-converting-enzyme inhibitors, and angiotensin-receptor blockers  [see  Warnings and Precautions (5.4  and  5.5)  and  Use in Specific Populations (8.6)  ]  .\n', '\n', '     Increases in Serum Magnesium  \n', '\n', ' Dose-related  oselabeledaefromdruguse were observed early after initiation of INVOKANA (within 6 weeks) and remained elevated throughout treatment.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
185,invokana,185,4990,5027,"In the pool of four placebo-controlled trials, the  oselabeledaefromdruguse was 8.1% and 9.3% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to -0.6% with placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,invokana,186,5027,5106,"In a trial of patients with moderate  notaecandidatepreexistingconditionorriskfactor  [see  Clinical Studies (14.3)  ]  ,  oselabeledaefromdruguse by 0.2%, 9.2%, and 14.8% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.\n', '\n', '     Increases in Serum Phosphate  \n', '\n', ' Dose-related  oselabeledaefromdruguse levels were observed with INVOKANA.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
187,invokana,187,5106,5144,"In the pool of four placebo controlled trials, the mean percent  oselabeledaefromdruguse were 3.6% and 5.1% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to 1.5% with placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,invokana,188,5144,5197,"In a trial of patients with moderate  notaecandidatepreexistingconditionorriskfactor  [see  Clinical Studies (14.3)  ]  , the mean  oselabeledaefromdruguse by 1.2%, 5.0%, and 9.3% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.\n', '\n",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
189,invokana,189,5197,5229,"', '     Increases in Low-Density Lipoprotein Cholesterol (LDL-C) and non-High-Density Lipoprotein Cholesterol (non-HDL-C)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,invokana,190,5229,5258,"\n', '\n', ' In the pool of four placebo-controlled trials, dose-related  oselabeledaefromdruguse with INVOKANA were observed.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,invokana,191,5258,5291,"oselabeledaefromdruguse relative to placebo were 4.4 mg/dL (4.5%) and 8.2 mg/dL (8.0%) with INVOKANA 100 mg and INVOKANA 300 mg, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,invokana,192,5291,5339,"The mean baseline LDL-C levels were 104 to 110 mg/dL across treatment groups  [see  Warnings and Precautions (5.11)  ]  .\n', '\n', ' Dose-related  oselabeledaefromdruguse with INVOKANA were observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,invokana,193,5339,5373,"Mean  oselabeledaefromdruguse relative to placebo were 2.1 mg/dL (1.5%) and 5.1 mg/dL (3.6%) with INVOKANA 100 mg and 300 mg, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,invokana,194,5373,5464,"The mean baseline non-HDL-C levels were 140 to 147 mg/dL across treatment groups.\n', '\n', '     Increases in Hemoglobin  \n', '\n', ' In the pool of four placebo-controlled trials, mean  oselabeledaefromdruguse were -0.18 g/dL (-1.1%) with placebo, 0.47 g/dL (3.5%) with INVOKANA 100 mg, and 0.51 g/dL (3.8%) with INVOKANA 300 mg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,invokana,195,5464,5479,The mean baseline hemoglobin value was approximately 14.1 g/dL across treatment groups.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,invokana,196,5479,5580,"At the end of treatment, 0.8%, 4.0%, and 2.7% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively, had  oselabeledaefromdruguse \n', '\n', '     Decreases in Bone Mineral Density  \n', '\n', ' Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry in a clinical trial of 714 older adults (mean age 64 years)  [see  Clinical Studies (14.3)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,invokana,197,5580,5642,"At 2 years, patients randomized to INVOKANA 100 mg and INVOKANA 300 mg had placebo-corrected  oselabeledaefromdruguse the total hip of 0.9% and 1.2%, respectively, and at the  oselabeledaefromdruguse  oselabeledaefromdruguse of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,invokana,198,5642,5693,"Additionally, placebo-adjusted  oselabeledaefromdruguse were 0.1%  oselabeledaefromdruguse femoral neck for both INVOKANA doses and 0.4% at the  oselabeledaefromdruguse  oselabeledaefromdruguse were 0.1%  oselabeledaefromdruguse for both INVOKANA doses and 0.4% at the distal forearm for patients randomized to INVOKANA 300 mg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,invokana,199,5693,5742,"The placebo-adjusted change at the distal forearm for patients randomized to INVOKANA 100 mg was 0%.\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  Additional adverse reactions have been identified during postapproval use of INVOKANA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,invokana,200,5742,5812,"Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '  oselabeledaefromdruguse  [see  Warnings and Precautions (5.3)  ]  \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,invokana,201,5812,5846,"Warnings and Precautions (5.4)  ]  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse  [see  Warnings and Precautions (5.9)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,invokana,202,5846,5860,"\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,invokana,203,5860,5871,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,invokana,204,5871,5975,"WARNING: LOWER LIMB AMPUTATION\n', '\n', '    WARNING: LOWER LIMB AMPUTATION  \n', '\n', '    *  An approximately 2-fold increased risk of  oselabeledaefromdruguse associated with INVOKANA use was observed in CANVAS and CANVAS-R, two large, randomized, placebo-controlled trials in patients with  notaecandidateindication who had established  notaecandidatepreexistingconditionorriskfactor  or were at risk for  notaecandidatepreexistingconditionorriskfactor  \n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse toe and  oselabeledaefromdruguse were most frequent; however,  oselabeledaefromdruguse were also observed.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
205,invokana,205,5975,6131,"Some patients had multiple  oselabeledaefromdruguse  oselabeledaefromdruguse  some involving  oselabeledaefromdruguse  \n', ' *  Before initiating, consider factors that may increase the risk of  nonoseaeaeonlyasinstruction  such as a history of prior  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  \n', ' *  Monitor patients receiving INVOKANA for  nonoseaemanifestationorcomplication  new  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or ulcers  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Lower limb amputation : See  boxed warning  (  5.1  ) \n', ' *   Hypotension : Before initiating INVOKANA, assess volume status and correct hypovolemia in patients with renal impairment, the elderly, in patients with low systolic blood pressure, or if on diuretics, ACEi, or ARB.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
206,invokana,206,6131,6143,Monitor for signs and symptoms during therapy (  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,invokana,207,6143,6171,"\n', ' *   Ketoacidosis : Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,invokana,208,6171,6182,"If suspected, discontinue INVOKANA, evaluate and treat promptly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,invokana,209,6182,6192,"Before initiating INVOKANA, consider risk factors for ketoacidosis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,invokana,210,6192,6216,Patients on INVOKANA may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis (  5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,invokana,211,6216,6244,"\n', ' *   Acute kidney injury and impairment in renal function : Consider temporarily discontinuing in settings of reduced oral intake or fluid losses.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,invokana,212,6244,6255,"If acute kidney injury occurs, discontinue and promptly treat.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,invokana,213,6255,6265,Monitor renal function during therapy (  5.4  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,invokana,214,6265,6269,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,invokana,215,6269,6273,*   Hyperkalemia :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,invokana,216,6273,6305,"Monitor potassium levels in patients with impaired renal function and in patients predisposed to hyperkalemia (  2.2  ,  5.5  ,  6.1  ,  8.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,invokana,217,6305,6315,"\n', ' *   Urosepsis and pyelonephritis :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,invokana,218,6315,6371,"Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated (  5.6  ) \n', ' *   Hypoglycemia : Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA (  5.7  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,invokana,219,6371,6391,"\n', ' *   Genital mycotic infections : Monitor and treat if indicated (  5.8  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,invokana,220,6391,6414,"\n', ' *   Hypersensitivity reactions : Discontinue INVOKANA and monitor until signs and symptoms resolve (  5.9  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,invokana,221,6414,6423,"\n', ' *   Bone fracture :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,invokana,222,6423,6438,Consider factors that contribute to fracture risk before initiating INVOKANA (  5.10  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,invokana,223,6438,6542,"\n', ' *   Increased LDL-C : Monitor LDL-C and treat if appropriate (  5.11  ) \n', '    \n', ' \n', '\n', '   5.1 Lower Limb Amputation\n', '\n', '   An approximately 2-fold increased risk of  oselabeledaefromdruguse associated with INVOKANA use was observed in CANVAS and CANVAS-R, two large, randomized, placebo-controlled trials evaluating patients with type 2 diabetes who had either established  notaecandidatepreexistingconditionorriskfactor or were at risk for  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
224,invokana,224,6542,6568,"In CANVAS, INVOKANA-treated patients and placebo-treated patients had 5.9 and 2.8  oselabeledaefromdruguse per 1000 patients per year, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,invokana,225,6568,6596,"In CANVAS-R, INVOKANA-treated patients and placebo-treated patients had 7.5 and 4.2  oselabeledaefromdruguse per 1000 patients per year, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,invokana,226,6596,6616,The risk of  oselabeledaefromdruguse was observed at both the 100 mg and 300 mg once daily dosage regimens.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,invokana,227,6616,6647,"The  nonoseaeaeonlyasinstruction data for CANVAS and CANVAS-R are shown in Tables 2 and 3, respectively [see  Adverse Reactions (6.1)  ].    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,invokana,228,6647,6735,"\n', '\n', '   oselabeledaefromdruguse the toe and  oselabeledaefromdruguse  oselabeledaefromdruguse and midfoot (99 out of 140 patients with  oselabeledaefromdruguse receiving INVOKANA in the two trials) were the most frequent; however,  oselabeledaefromdruguse  oselabeledaefromdruguse involving the leg,  oselabeledaefromdruguse and above the  oselabeledaefromdruguse  oselabeledaefromdruguse involving the leg, below and  oselabeledaefromdruguse  were also observed (41 out of 140 patients with  oselabeledaefromdruguse receiving INVOKANA in the two trials).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,invokana,229,6735,6861,"Some patients had multiple  oselabeledaefromdruguse  oselabeledaefromdruguse  some involving  oselabeledaefromdruguse   \n', '\n', '   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction were the most common precipitating medical events leading to the need for an  nonoseaeaeonlyasinstruction  The risk of  nonoseaeaeonlyasinstruction was highest in patients with a baseline history of prior  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor   \n', '\n', '  Before initiating INVOKANA, consider factors in the patient history that may predispose to the need for  nonoseaeaeonlyasinstruction  such as a history of prior  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor  Counsel patients about the importance of routine preventative foot care.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
230,invokana,230,6861,6924,"Monitor patients receiving INVOKANA for signs and symptoms of  nonoseaeaeonlyasinstruction (including  nonoseaemanifestationorcomplication , new  nonoseaemanifestationorcomplication or tenderness, sores or ulcers involving the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  sores or ulcers involving the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication or ulcers involving the  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication involving the  nonoseaemanifestationorcomplication  and discontinue INVOKANA if these complications occur.  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
231,invokana,231,6924,6940,"\n', '\n', '    5.2 Hypotension\n', '\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,invokana,232,6940,6948,", '  INVOKANA causes  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,invokana,233,6948,7045,"Symptomatic  oselabeledaefromdruguse can occur after initiating INVOKANA [see  Adverse Reactions (6.1)  ]  particularly in patients with  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor  ), elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system (e.g., angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or patients with  notaecandidatepreexistingconditionorriskfactor  Before initiating INVOKANA in patients with one or more of these characteristics, volume status should be assessed and corrected.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
234,invokana,234,7045,7076,"Monitor for signs and symptoms after initiating therapy.\n', '\n', '    5.3 Ketoacidosis\n', '\n', '  Reports of  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,invokana,235,7076,7118,"a serious life-threatening condition requiring urgent hospitalization have been identified in postmarketing surveillance in patients with  notaecandidatepreexistingconditionorriskfactor and type 2  notaecandidatepreexistingconditionorriskfactor  notaecandidateindication receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including INVOKANA.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
236,invokana,236,7118,7131,nonoseaegeneralterm cases of  oselabeledaefromdruguse have been reported in patients taking INVOKANA.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
237,invokana,237,7131,7205,"INVOKANA is not indicated for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor [see  Indications and Usage (1)  ]  .\n', '\n', ' Patients treated with INVOKANA who present with signs and symptoms consistent with severe  nonoseaemanifestationorcomplication should be assessed for  nonoseaeaeonlyasinstruction regardless of presenting blood glucose levels, as  oselabeledaefromdruguse associated with INVOKANA may be present even if  nonoseaeaeonlyasinstruction  ",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
238,invokana,238,7205,7228,"If  nonoseaeaeonlyasinstruction is suspected, INVOKANA should be discontinued, patient should be evaluated, and prompt treatment should be instituted.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,invokana,239,7228,7297,"Treatment of  nonoseaeaeonlyasinstruction may require insulin, fluid and carbohydrate replacement.\n', '\n', ' In many of the postmarketing reports, and particularly in patients with  notaecandidatepreexistingconditionorriskfactor  the presence of  nonoseaeaeonlyasinstruction was not immediately recognized and institution of treatment was delayed because presenting  nonoseaeaeonlyasinstruction those typically expected for  nonoseaeaeonlyasinstruction (often less than 250 mg/dL).",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
240,invokana,240,7297,7326,Signs and symptoms at presentation were consistent with  nonoseaemanifestationorcomplication and severe  nonoseaemanifestationorcomplication and included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
241,invokana,241,7326,7418,"In some but not all cases, factors predisposing to  nonoseaeaeonlyasinstruction such as insulin dose reduction,  notaecandidatepreexistingconditionorriskfactor  reduced caloric intake due to illness or surgery,  notaecandidatepreexistingconditionorriskfactor suggesting  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor  history of  notaecandidatepreexistingconditionorriskfactor or pancreatic surgery), and alcohol abuse were identified.\n', '\n', ' Before initiating INVOKANA, consider factors in the patient history that may predispose to  nonoseaeaeonlyasinstruction including  notaecandidatepreexistingconditionorriskfactor from any cause, caloric restriction, and alcohol abuse.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
242,invokana,242,7418,7510,"In patients treated with INVOKANA consider monitoring for  nonoseaeaeonlyasinstruction and temporarily discontinuing INVOKANA in clinical situations known to predispose to  nonoseaeaeonlyasinstruction (e.g., prolonged fasting due to  nonoseaeaeonlyasinstruction or surgery).\n', '\n', '    5.4 Acute Kidney Injury and Impairment in Renal Function\n', '\n', '  INVOKANA causes  oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  and can cause  oselabeledaefromdruguse [see  Adverse Reactions (6.1)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,invokana,243,7510,7582,"There have been postmarketing reports of  oselabeledaefromdruguse  some requiring hospitalization and  nonoseaemanifestationorcomplication  in patients receiving INVOKANA; some reports involved patients younger than 65 years of age.\n', '\n', ' Before initiating INVOKANA, consider factors that may predispose patients to  nonoseaeaeonlyasinstruction including  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor and concomitant medications (diuretics, ACE inhibitors, ARBs, NSAIDs).",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
244,invokana,244,7582,7625,Consider temporarily discontinuing INVOKANA in any setting of reduced oral intake (such as  nonoseaeaeonlyasinstruction or fasting) or  nonoseaeaeonlyasinstruction (such as  nonoseaeaeonlyasinstruction or excessive heat exposure); monitor patients for signs and symptoms of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,invokana,245,7625,7663,"If  nonoseaeaeonlyasinstruction occurs, discontinue INVOKANA promptly and institute treatment.\n', '\n', ' INVOKANA  oselabeledaefromdruguse and  oselabeledaefromdruguse  Patients with  notaecandidatepreexistingconditionorriskfactor may be more susceptible to these changes.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
246,invokana,246,7663,7681,oselabeledaefromdruguse can occur after initiating INVOKANA [see  Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,invokana,247,7681,7696,Renal function should be evaluated prior to initiation of INVOKANA and monitored periodically thereafter.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,invokana,248,7696,7715,Dosage adjustment and more frequent renal function monitoring are recommended in patients with  notaecandidatepreexistingconditionorriskfactor  2  .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
249,invokana,249,7715,7933,"Use of INVOKANA is not recommended when  notaecandidatepreexistingconditionorriskfactor  and is contraindicated in patients with an  notaecandidatecontraindication    [see  Dosage and Administration (2.2)  ,  Contraindications (4)  and  Use in Specific Populations (8.6)  ]  .\n', '\n', '    5.5 Hyperkalemia\n', '\n', '  INVOKANA can lead to  oselabeledaefromdruguse  Patients with  notaecandidatepreexistingconditionorriskfactor who are taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, or medications that interfere with the renin-angiotensin-aldosterone system are at an increased risk of developing  oselabeledaefromdruguse [see  Dosage and Administration (2.2)  and  Adverse Reactions (6.1)  ]  .\n', '\n', ' Monitor serum potassium levels periodically after initiating INVOKANA in patients with  notaecandidatepreexistingconditionorriskfactor and in patients predisposed to  nonoseaeaeonlyasinstruction due to medications or other medical conditions.\n', '\n', '    5.6 Urosepsis and Pyelonephritis\n', '\n', '  There have been postmarketing reports of serious  oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse requiring hospitalization in patients receiving SGLT2 inhibitors, including INVOKANA.",1,0,1,0,0,0,0,0,0,0,0,1,0,0,0
250,invokana,250,7933,8036,"Treatment with SGLT2 inhibitors increases the risk for  oselabeledaefromdruguse  Evaluate patients for signs and symptoms of  nonoseaeaeonlyasinstruction and treat promptly, if indicated [see  Adverse Reactions (6)  ]  .\n', '\n', '    5.7 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues\n', '\n', '  Insulin and insulin secretagogues are known to cause  nonoseaeaeonlyasinstruction  INVOKANA can increase the risk of  nonoseaeaefromdruginteraction when combined with insulin or an insulin secretagogue [see  Adverse Reactions (6.1)  ]  .",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
251,invokana,251,8036,8119,"Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of  nonoseaeaeonlyasinstruction when used in combination with INVOKANA.\n', '\n', '    5.8 Genital Mycotic Infections\n', '\n', '  INVOKANA increases the risk of  oselabeledaefromdruguse  Patients with a history of  notaecandidatepreexistingconditionorriskfactor and uncircumcised males were more likely to develop  oselabeledaefromdruguse [see  Adverse Reactions (6.1)  ]  .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
252,invokana,252,8119,8157,"Monitor and treat appropriately.\n', '\n', '    5.9 Hypersensitivity Reactions\n', '\n', '   oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  have been reported with INVOKANA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,invokana,253,8157,8169,These reactions generally occurred within hours to days after initiating INVOKANA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,invokana,254,8169,8253,"If  nonoseaeaeonlyasinstruction occur, discontinue use of INVOKANA; treat and monitor until signs and symptoms resolve [see  Contraindications (4)  and  Adverse Reactions (6.1  ,  6.2)  ]  .\n', '\n', '    5.10 Bone Fracture\n', '\n', '  An increased risk of  oselabeledaefromdruguse  occurring as early as 12 weeks after treatment initiation, was observed in patients using INVOKANA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,invokana,255,8253,8323,"Consider factors that contribute to fracture risk prior to initiating INVOKANA [see  Adverse Reactions (6.1)  ]  .\n', '\n', '    5.11 Increases in Low-Density Lipoprotein (LDL-C)\n', '\n', '  Dose-related  oselabeledaefromdruguse occur with INVOKANA [see  Adverse Reactions (6.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,invokana,256,8323,8367,"Monitor LDL-C and treat if appropriate after initiating INVOKANA.\n', '\n', '    5.12 Macrovascular Outcomes\n', '\n', '  There have been no clinical studies establishing conclusive evidence of  nonoseaenegation ']",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
0,daytrana,0,0,61,"['  6 ADVERSE REACTIONS\n', '\n', '  Detailed information on serious and adverse reactions of particular importance is provided in the  Boxed Warning  and  Warnings and Precautions  (  5  ) sections:\n', '\n', ' *   oselabeledaefromdruguse [   see Boxed Warning   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,daytrana,1,61,103,"\n', ' *   notaecandidatecontraindication to Methylphenidate [   see Contraindications (4.1)   ] \n', ' *  Marked  notaecandidatecontraindication   notaecandidatecontraindication  or  notaecandidatecontraindication [   see Contraindications (4.2)   ]",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
2,daytrana,2,103,318,"\n', ' *   notaecandidatecontraindication [   see Contraindications (4.3)   ] \n', ' *   notaecandidatecontraindication or a family history of  notaecandidatecontraindication [   see Contraindications (4.4)   ] \n', ' *  Monoamine Oxidase Inhibitors [   see Contraindications (4.5)   and   Drug Interactions (7.1)   ] \n', ' *  Serious  oselabeledaeclasseffect [   see Warnings and Precautions (5.1)   ] \n', ' *   oselabeledaeclasseffect [   see Warnings and Precautions (5.1)   ] \n', ' *   oselabeledaeclasseffect [   see Warnings and Precautions (5.2)   ] \n', ' *   oselabeledaeclasseffect [   see Warnings and Precautions (5.3)   ] \n', ' *   oselabeledaeclasseffect [   see Warnings and Precautions (5.4)   ] \n', ' *   oselabeledaefromdruguse [   see Warnings and Precautions (5.5)   ] \n', ' *  Long-Term  oselabeledaeclasseffect [   see Warnings and Precautions (5.6)   ] \n', ' *   oselabeledaefromdruguse [   see Warnings and Precautions (5.7)   ]",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
3,daytrana,3,318,336,"\n', ' *   oselabeledaefromdruguse [   see Warnings and Precautions (5.8)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,daytrana,4,336,354,"\n', ' *   oselabeledaeclasseffect [   see Warnings and Precautions (5.9)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,daytrana,5,354,445,"\n', ' *   nonoseaeaeonlyasinstruction [   see Warnings and Precautions (5.10)   ] \n', ' *   nonoseaeaeonlyasinstruction Monitoring [   see Warnings and Precautions (5.11)   ] \n', '    The most commonly reported (frequency >= 5% and twice the rate of placebo) adverse reactions in a controlled trial in children aged 6-12 included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,daytrana,6,445,543,"The most commonly reported (frequency >= 5% and twice the rate of placebo) adverse reactions in a controlled trial in adolescents aged 13-17 were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [    see Adverse Reactions (6.1)  ]  .\n', ' \n', '\n', ' The most common (>= 2% of subjects) adverse reaction associated with discontinuations in double-blind clinical trials in children or adolescents was  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,daytrana,7,543,600,"[    see Adverse Reactions (6.1)  ]  .\n', '\n', ' The overall Daytrana development program included exposure to Daytrana in a total of 2,152 participants in clinical trials, including 1,529 children aged 6-12, 223 adolescents aged 13-17, and 400 adults.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,daytrana,8,600,632,"The 1,752 child and adolescent subjects aged 6-17 years were evaluated in 10 controlled clinical studies, 7 open-label clinical studies, and 5 clinical pharmacology studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,daytrana,9,632,679,"In a combined studies pool of children using Daytrana with a wear time of 9 hours, 212 subjects were exposed for >= 6 months and 115 were exposed for >= 1 year; 85 adolescents have been exposed for >= 6 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,daytrana,10,679,763,"Most patients studied were exposed to Daytrana patch sizes of 12.5 cm  2  , 18.75 cm  2  , 25 cm  2  or 37.5 cm  2  , with a wear time of 9 hours.\n', '\n', ' In the data presented below, the adverse reactions reported during exposure were obtained primarily by general inquiry at each visit, and were recorded by the clinical investigators using terminology of their own choosing.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,daytrana,11,763,835,"Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of events into a smaller number of standardized event categories.\n', '\n', ' Throughout this section adverse reactions reported are events that were considered to be reasonably associated with the use of Daytrana based on comprehensive assessment of the available adverse event information.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,daytrana,12,835,850,A causal association for Daytrana often cannot be reliably established in individual cases.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,daytrana,13,850,907,"Further, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '    EXCERPT:    *  Children (ages 6-12):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,daytrana,14,907,963,"The most commonly (>=5% and twice the rate of placebo) reported adverse reactions in a placebo-controlled trial in children aged 6-12 included appetite decreased, insomnia, nausea, vomiting, weight decreased, tic, affect lability, and anorexia (  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,daytrana,15,963,1026,"\n', ' *  Adolescents (ages 13-17): The most commonly (>=5% and twice the rate of placebo) reported adverse reactions in a placebo-controlled trial in adolescents aged 13-17 included appetite decreased, nausea, insomnia, weight decreased, dizziness, abdominal pain, and anorexia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,daytrana,16,1026,1045,The majority of subjects in these trials had erythema at the application site (  6.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,daytrana,17,1045,1085,"\n', ' *  The most common (>=2% of subjects) adverse reaction associated with discontinuations in controlled clinical trials in children or adolescents was application site reactions (  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,daytrana,18,1085,1121,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact Noven Therapeutics, LLC at 1-877-567-7857 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,daytrana,19,1121,1219,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Adverse Reactions Associated With Discontinuation of Treatment\n', '\n', ' In a 7-week double-blind, parallel-group, placebo-controlled study in children with  notaecandidateindication conducted in the outpatient setting, 7.1% (7/98) of patients treated with Daytrana discontinued due to adverse events compared with 1.2% (1/85) receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
20,daytrana,20,1219,1253,"The most commonly reported (>= 1% and twice the rate of placebo) adverse reactions leading to discontinuation in the Daytrana group were  oselabeledaefromdruguse (2%),  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,daytrana,21,1253,1270,"oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,daytrana,22,1270,1329,"1%).\n', '\n', ' In a 7-week double-blind, parallel-group, placebo-controlled study in adolescents with  notaecandidateindication conducted in the outpatient setting, 5.5% (8/145) of patients treated with Daytrana discontinued due to adverse reactions compared with 2.8% (2/72) receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
23,daytrana,23,1329,1363,"The most commonly reported adverse reactions leading to discontinuation in the Daytrana group were  oselabeledaefromdruguse (2%) and  oselabeledaefromdruguse  oselabeledaefromdruguse (1.4%).\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,daytrana,24,1363,1403,"Commonly Observed Adverse Reactions in Double-Blind, Placebo-Controlled Trials\n', '\n', '    oselabeledaefromdruguse and  oselabeledaefromdruguse  \n', '\n', ' Daytrana is a  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,daytrana,25,1403,1431,"In addition to the most commonly reported adverse reactions presented in Table 2, the majority of subjects in those studies had minimal to definite  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,daytrana,26,1431,1455,This  nonoseaeaeonlyasinstruction generally caused no or minimal discomfort and did not usually interfere with therapy or result in discontinuation from treatment.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,daytrana,27,1455,1466,nonoseaeaeonlyasinstruction is not by itself a manifestation of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,daytrana,28,1466,1597,"However,  nonoseaeaeonlyasinstruction should be suspected if  nonoseaeaeonlyasinstruction is accompanied by evidence of a more intense  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication (edema,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication (edema, papules,  nonoseaemanifestationorcomplication  that does not significantly improve within 48 hours or spreads beyond the patch site [    see Warnings and Precautions (5.8)    ].\n', '\n', '   Most Commonly Reported Adverse Reactions  \n', '\n', ' Table 2 lists treatment-emergent adverse reactions reported in >= 1% Daytrana-treated children or adolescents with ADHD in two 7 week double-blind, parallel-group, placebo-controlled studies conducted in the outpatient setting.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
29,daytrana,29,1597,1657,"Overall, in these studies, 75.5% of children and 78.6% of adolescents experienced at least 1 adverse event.\n', '\n', '\n', '  * Six subjects had  oselabeledaefromdruguse  all judged as mild and described as  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,daytrana,30,1657,1711,"\n', '  \n', '   Table 2      Number (%) of Subjects with Commonly Reported Adverse Reactions (>= 1% in the Daytrana Group) in 7-Week Placebo-controlled Studies in Either Children or Adolescents - Safety Population     \n', '                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,daytrana,31,1711,1715,Adolescents         Children       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,daytrana,32,1715,1739,"\n', ' System Organ Class   Preferred term    PlaceboN = 72    DaytranaN = 145    PlaceboN = 85     DaytranaN",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,daytrana,33,1739,1742,= 98    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,daytrana,34,1742,1749,"\n', '  nonoseaegeneralterm                                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,daytrana,35,1749,1761,"\n', '     oselabeledaefromdruguse                             0 (0)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,daytrana,36,1761,1767,1 (0.7)            0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,daytrana,37,1767,1772,(0)            1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,daytrana,38,1772,1810,"(1.0)        \n', '  nonoseaegeneralterm                                                                                     \n', '     oselabeledaefromdruguse                          0 (0)            7 (4.8)           5 (5.9)           7 (7.1)        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,daytrana,39,1810,1864,"\n', '     oselabeledaefromdruguse                                 2 (2.8)           14 (9.7)          2 (2.4)          12 (12.2)       \n', '     oselabeledaefromdruguse                               1 (1.4)           5 (3.4)           4 (4.7)          10 (10.2)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,daytrana,40,1864,1894,"\n', '  nonoseaegeneralterm                                                                                                 \n', '     oselabeledaefromdruguse                       1 (1.4)           8 (5.5)            0 (0)            9",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,daytrana,41,1894,1905,"(9.2)        \n', '  nonoseaegeneralterm                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,daytrana,42,1905,1932,"\n', '     oselabeledaefromdruguse                               1 (1.4)           7 (4.8)           1 (1.2)           5 (5.1)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,daytrana,43,1932,2034,"\n', '     oselabeledaefromdruguse                     1 (1.4)          37 (25.5)          4 (4.7)          25 (25.5)       \n', '  nonoseaegeneralterm                                                                                       \n', '     oselabeledaefromdruguse                              1 (1.4)           8 (5.5)           1 (1.2)            0 (0)         \n', '     oselabeledaefromdruguse                               9 (12.5)         18 (12.4)         10 (11.8)         15 (15.3)       \n', '  nonoseaegeneralterm                                                                                          \n', '     oselabeledaefromdruguse                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,daytrana,44,2034,2050,1 (1.4)            0 (0)             0 (0)            6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,daytrana,45,2050,2055,(6.1)*       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,daytrana,46,2055,2089,"\n', '     oselabeledaefromdruguse                               2 (2.8)           9 (6.2)           4 (4.7)          13 (13.3)       \n', '     oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,daytrana,47,2089,2109,5 (6.9)           16 (11)           4 (4.7)           7 (7.1)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,daytrana,48,2109,2117,"\n', '     oselabeledaefromdruguse                                     0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,daytrana,49,2117,2207,"(0)             0 (0)             0 (0)            7 (7.1)        \n', '           Adverse Reactions With the Long-Term Use of Daytrana\n', ' \n', '\n', ' In a long-term open-label study of up to 12 months duration in 326 children wearing Daytrana 9 hours daily, the most common (>= 10%) adverse reactions were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,daytrana,50,2207,2322,"A total of 30 subjects (9.2%) were withdrawn from the study due to adverse events and 22 additional subjects (6.7%) discontinued treatment as the result of an  oselabeledaefromdruguse  Other than  oselabeledaefromdruguse   oselabeledaefromdruguse (5 subjects, 1.5%) was the only additional adverse reaction leading to discontinuation reported with a frequency of greater than 1%.\n', '\n', ' In a long-term open-label study of up to 6 months duration in 162 adolescents wearing Daytrana 9 hours daily, the most common (>= 10%) adverse reactions were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,daytrana,51,2322,2421,"A total of 9 subjects (5.5%) were withdrawn from the study due to adverse events and 3 additional subjects (1.9%) discontinued treatment as the result of an  oselabeledaefromdruguse  Other adverse reactions leading to discontinuation that occurred with a frequency of greater than 1% included affect lability and irritability (2 subjects each, 1.2%).\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  In addition, the following adverse reactions have been identified during the postapproval use of Daytrana.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,daytrana,52,2421,2473,"Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to Daytrana exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,daytrana,53,2473,2475,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,daytrana,54,2475,2476,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,daytrana,55,2476,3796,"\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse such as  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling, ulcer,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling, ulcer, urticaria,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling, ulcer, urticaria, vesicles, and  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration, discomfort, dryness, eczema, edema,  oselabeledaefromdruguse  oselabeledaefromdruguse such as bleeding, bruising, burn, burning, dermatitis, discharge, discoloration,  oselabeledaefromdruguse  dryness, eczema, edema, erosion, erythema, excoriation, exfoliation, fissure, hyperpigmentation, hypopigmentation, induration, infection, inflammation, irritation, pain, papules, paresthesia, pruritus, rash, scab, swelling, ulcer, urticaria, vesicles, and warmth.\n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,daytrana,56,3796,3820,"'\n', '    nonoseaegeneralterm    oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,daytrana,57,3820,3827,"', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,daytrana,58,3827,3880,"\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaeaefromdruginteraction in combination with serotonergic drugs\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse \n",0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
59,daytrana,59,3880,3915,"', '   6.3 Adverse Reactions With Oral Methylphenidate Products\n', '\n', '   oselabeledaeclasseffect and  oselabeledaeclasseffect are the most common adverse reactions reported with other methylphenidate products.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,daytrana,60,3915,4052,"In children,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect during prolonged therapy,  oselabeledaeclasseffect  and  oselabeledaeclasseffect may occur more frequently; however, any of the other adverse reactions listed below may also occur.\n', '\n', ' Other reactions include:\n', '\n', '    nonoseaegeneralterm    oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  oselabeledaeclasseffect or decreased\n', '\n', '    nonoseaegeneralterm    oselabeledaeclasseffect including  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect with histopathological findings of  oselabeledaeclasseffect  and  oselabeledaeclasseffect \n', '    nonoseaegeneralterm    oselabeledaeclasseffect   oselabeledaeclasseffect during prolonged therapy\n', '\n', '    nonoseaegeneralterm    oselabeledaeclasseffect  rare reports of  oselabeledaeclasseffect   oselabeledaeclasseffect \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,daytrana,61,4052,4134,"nonoseaegeneralterm    oselabeledaeclasseffect increased or  oselabeledaeclasseffect  oselabeledaeclasseffect or decreased,  oselabeledaeclasseffect  oselabeledaeclasseffect arteritis and/or  oselabeledaeclasseffect \n', ' Although a definite causal relationship has not been established, the following have been reported in patients taking methylphenidate:\n', '\n', '    nonoseaegeneralterm    oselabeledaeclasseffect and/or  oselabeledaeclasseffect \n', '    nonoseaegeneralterm    oselabeledaeclasseffect  ranging from  oselabeledaeclasseffect to severe  oselabeledaeclasseffect \n', '    nonoseaegeneralterm    oselabeledaeclasseffect",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,daytrana,62,4134,4142,"\n', '    nonoseaegeneralterm    oselabeledaeclasseffect",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,daytrana,63,4142,4213,"\n', '    oselabeledaeclasseffect   Very rare reports of  oselabeledaeclasseffect  have been received, and, in most of these, patients were concurrently receiving therapies associated with  nonoseaeaeonlyasinstruction  In a single report, a ten-year-old boy who had been taking methylphenidate for approximately 18 months experienced an  oselabeledaeclasseffect within 45 minutes of ingesting his first dose of venlafaxine.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,daytrana,64,4213,4309,"It is uncertain whether this case represented a drug-drug interaction, a response to either drug alone, or some other cause.\n', '\n', '    nonoseaegeneralterm    oselabeledaeclasseffect \n', '\n', '    BOXED WARNING: \n', '\n', '  \n', '\n', '    WARNING:  oselabeledaefromdruguse  \n', '\n', '   Daytrana should be given cautiously to patients with a history of  notaecandidatepreexistingconditionorriskfactor or alcoholism.  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
65,daytrana,65,4309,4328,Chronic  oselabeledaefromdruguse can lead to marked  nonoseaeodorwithdrawal and  nonoseaeodorwithdrawal with varying degrees of  nonoseaeodorwithdrawal   ,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
66,daytrana,66,4328,4340,"Frank  nonoseaeodorwithdrawal can occur, especially with parenteral  nonoseaeaeonlyasinstruction   ",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
67,daytrana,67,4340,4376,"Careful supervision is required during withdrawal from  nonoseaeaeonlyasinstruction  since severe  nonoseaeodorwithdrawal    5 WARNINGS AND PRECAUTIONS\n', '\n', '     EXCERPT:    *  Serious Cardiovascular Events:",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
68,daytrana,68,4376,4404,Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,daytrana,69,4404,4426,"Sudden death, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,daytrana,70,4426,4458,"Stimulant products generally should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,daytrana,71,4458,4509,"(  5.1  ) \n', ' *  Increase in Blood Pressure: Monitor patients for changes in heart rate and blood pressure and use with caution in patients for whom an increase in blood pressure or heart rate would be problematic. (  5.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,daytrana,72,4509,4513,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,daytrana,73,4513,4519,*  Psychiatric Adverse Events:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,daytrana,74,4519,4551,"Use of stimulants may cause treatment-emergent psychotic or manic symptoms in patients with no prior history, or exacerbation of symptoms in patients with pre-existing psychiatric illness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,daytrana,75,4551,4563,Clinical evaluation for Bipolar Disorder is recommended prior to stimulant use.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,daytrana,76,4563,4568,Monitor for aggressive behavior.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,daytrana,77,4568,4573,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,daytrana,78,4573,4577,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,daytrana,79,4577,4588,*  Seizures: Stimulants may lower the convulsive threshold.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,daytrana,80,4588,4595,Discontinue in the presence of seizures.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,daytrana,81,4595,4608,"(  5.3  ) \n', ' *  Priapism:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,daytrana,82,4608,4624,Cases of painful and prolonged penile erections and priapism have been reported with methylphenidate products.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,daytrana,83,4624,4647,Immediate medical attention should be sought if signs or symptoms of prolonged penile erections or priapism are observed (  5.4  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,daytrana,84,4647,4661,"\n', "" *  Peripheral Vasculopathy, including Raynaud's phenomenon:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,daytrana,85,4661,4677,"Stimulants used to treat ADHD are associated with peripheral vasculopathy, including Raynaud's phenomenon.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,daytrana,86,4677,4690,Careful observation for digital changes is necessary during treatment with ADHD stimulants.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,daytrana,87,4690,4719,"(  5.5  ) \n"", ' *  Long-Term Suppression of Growth: Monitor height and weight at appropriate intervals in pediatric patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,daytrana,88,4719,4751,"(  5.6  ) \n', ' *  Chemical Leukoderma: Daytrana use may result in a persistent loss of skin pigmentation at and around the application site.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,daytrana,89,4751,4771,"Loss of pigmentation, in some cases, has been reported at other sites distant from the application site.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,daytrana,90,4771,4778,Monitor for signs of skin depigmentation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,daytrana,91,4778,4784,Discontinue Daytrana if it occurs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,daytrana,92,4784,4807,"(  5.7  ) \n', ' *  Contact Sensitization: Use of Daytrana may lead to contact sensitization.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,daytrana,93,4807,4817,Treatment should be discontinued if contact sensitization is suspected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,daytrana,94,4817,4835,Erythema is commonly seen with use of Daytrana and is not by itself an indication of sensitization.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,daytrana,95,4835,4876,"However, contact sensitization should be suspected if erythema is accompanied by evidence of a more intense local reaction (edema, papules, vesicles) that does not significantly improve within 48 hours or spreads beyond the patch site.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,daytrana,96,4876,4904,"(  5.8  ) \n', ' *  Visual Disturbance: Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,daytrana,97,4904,4918,"(  5.9  ) \n', ' *  External Heat:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,daytrana,98,4918,4935,Patients should be advised to avoid exposing the Daytrana application site to direct external heat sources.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,daytrana,99,4935,4956,"When heat is applied to Daytrana after patch application, both the rate and extent of absorption are significantly increased.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,daytrana,100,4956,4984,"(  5.10  ) \n', ' *  Hematologic monitoring: Periodic CBC, differential, and platelet counts are advised during prolonged therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,daytrana,101,4984,4989,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,daytrana,102,4989,5047,"\n', '    \n', ' \n', '\n', '   5.1 Serious Cardiovascular Events\n', '\n', '  Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems\n', '\n', '  Children and Adolescents  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,daytrana,103,5047,5080,", '\n', '  oselabeledaeclasseffect has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with  notaecandidatepreexistingconditionorriskfactor or other serious  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,daytrana,104,5080,5147,"Although some serious  notaecandidatepreexistingconditionorriskfactor alone carry an increased risk of  nonoseaeaeonlyasinstruction  stimulant products generally should not be used in children or adolescents with known serious  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  serious  notaecandidatepreexistingconditionorriskfactor  or other serious  notaecandidatepreexistingconditionorriskfactor that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.\n', '\n', '  Adults  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
105,daytrana,105,5147,5178,"\n', '\n', '  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported in adults taking stimulant drugs at usual doses for  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
106,daytrana,106,5178,5291,"Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  serious  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or other serious  notaecandidatepreexistingconditionorriskfactor  Adults with such abnormalities should also generally not be treated with stimulant drugs.\n', '\n', ' Hypertension and Other Cardiovascular Conditions\n', '\n', ' Stimulant medications cause a modest  oselabeledaeclasseffect average  oselabeledaeclasseffect  oselabeledaeclasseffect average blood pressure (about 2-4 mmHg) and average  oselabeledaeclasseffect (about 3-6 bpm), and individuals may have larger increases.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
107,daytrana,107,5291,5367,"While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction heart rate and  nonoseaeaeonlyasinstruction  Caution is indicated in treating patients whose underlying medical conditions might be compromised by  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction blood pressure or  nonoseaeaeonlyasinstruction  e.g., those with pre-existing  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  recent  notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
108,daytrana,108,5367,5468,"[  see Adverse Reactions (6.1)  ]  .\n', '\n', ' Assessing Cardiovascular Status in Patients Being Treated With Stimulant Medications\n', '\n', ' Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  and physical exam to assess for the presence of  notaecandidatepreexistingconditionorriskfactor  and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
109,daytrana,109,5468,5606,"Patients who develop symptoms such as  nonoseaeaeonlyasinstruction  unexplained  nonoseaeaeonlyasinstruction  or other symptoms suggestive of  nonoseaeaeonlyasinstruction during stimulant treatment should undergo a prompt cardiac evaluation.\n', '\n', '    5.2 Psychiatric Adverse Events\n', '\n', '  Pre-Existing Psychosis\n', '\n', ' Administration of stimulants may  oselabeledaeclasseffect behavior disturbance and  oselabeledaeclasseffect  oselabeledaeclasseffect and thought disorder in patients with a pre-existing  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Bipolar Illness\n', '\n', ' Particular care should be taken in using stimulants to treat  notaecandidateindication in patients with comorbid  notaecandidatepreexistingconditionorriskfactor because of concern for possible  oselabeledaeclasseffect mixed/ oselabeledaeclasseffect  oselabeledaefromdruguse manic  oselabeledaefromdruguse in such patients.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
110,daytrana,110,5606,5723,"Prior to initiating treatment with a stimulant, patients with comorbid  notaecandidatepreexistingconditionorriskfactor should be adequately screened to determine if they are at risk for  notaecandidatepreexistingconditionorriskfactor  such screening should include a detailed  nonoseaeaeonlyasinstruction history, including a family history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Emergence of New Psychotic or Manic Symptoms\n', '\n', ' Treatment emergent  oselabeledaeclasseffect or manic  oselabeledaeclasseffect  oselabeledaeclasseffect  e.g.,  oselabeledaeclasseffect   oselabeledaeclasseffect  or  oselabeledaeclasseffect in children and adolescents without a prior history of  nonoseaenegation or  nonoseaenegation can be caused by stimulants at usual doses.",1,0,1,0,0,0,0,1,0,0,0,0,0,0,0
111,daytrana,111,5723,5749,"If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,daytrana,112,5749,5856,"In a pooled analysis of multiple short term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3,482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to none in placebo-treated patients.\n', '\n', ' Aggression\n', '\n', '  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction is often observed in children and adolescents with  notaecandidatepreexistingconditionorriskfactor  and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of  notaecandidateindication  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
113,daytrana,113,5856,5907,"Although there is no systematic evidence that stimulants cause  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  patients beginning treatment for  notaecandidateindication should be monitored for the appearance of or  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction \n', '\n', '    5.3  oselabeledaeclasseffect \n', '  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
114,daytrana,114,5907,5960,"There is some clinical evidence that stimulants may  oselabeledaeclasseffect in patients with prior history of  notaecandidatepreexistingconditionorriskfactor  in patients with prior  notaecandidatepreexistingconditionorriskfactor in absence of  nonoseaenegation  and, very rarely, in patients without a history of  nonoseaenegation and no prior EEG evidence of  nonoseaenegation  ",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
115,daytrana,115,5960,6017,"In the presence of  nonoseaenegation  the drug should be discontinued.\n', '\n', '    5.4 Priapism\n', '\n', '   oselabeledaeclasseffect and painful  oselabeledaeclasseffect  oselabeledaeclasseffect  sometimes requiring surgical intervention, have been reported with methylphenidate products in both pediatric and adult patients.  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
116,daytrana,116,6017,6042,"oselabeledaeclasseffect was not reported with drug initiation but developed after some time on the drug, often subsequent to an increase in dose.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,daytrana,117,6042,6060,nonoseaeodorwithdrawal has also appeared during a period of drug withdrawal (drug holidays or during discontinuation).,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
118,daytrana,118,6060,6132,"Patients who develop  nonoseaeaeonlyasinstruction or frequent and painful  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction sustained or  nonoseaeaeonlyasinstruction and painful  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction should seek immediate medical attention.\n', '\n', ""    5.5 Peripheral Vasculopathy, including Raynaud's phenomenon\n"", '\n', '  Stimulants, including Daytrana, used to treat  notaecandidateindication are associated with  oselabeledaeclasseffect  including  oselabeledaeclasseffect  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
119,daytrana,119,6132,6186,"Signs and symptoms are usually intermittent and mild; however, very rare sequelae include  nonoseaemanifestationorcomplication and/or  nonoseaemanifestationorcomplication  Effects of  oselabeledaeclasseffect  including  oselabeledaeclasseffect  were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
120,daytrana,120,6186,6200,Signs and symptoms generally improve after reduction in dose or discontinuation of drug.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,daytrana,121,6200,6214,Careful observation for  nonoseaeaeonlyasinstruction is necessary during treatment with  notaecandidateindication stimulants.,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
122,daytrana,122,6214,6370,"Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients\n', '\n', '    5.6 Long-Term Suppression of Growth\n', '\n', '  Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary  oselabeledaeclasseffect (on average, a total of about 2 cm  oselabeledaeclasseffect and 2.7 kg  oselabeledaeclasseffect over 3 years), without evidence of growth rebound during this period of development.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,daytrana,123,6370,6402,"Published data are inadequate to determine whether chronic use of amphetamines may cause a similar  nonoseaeaeonlyasinstruction  however, it is anticipated that they likely have this effect as well.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,daytrana,124,6402,6489,"Therefore, growth should be monitored during treatment with stimulants, and patients who are  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction growing or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction growing or  nonoseaeaeonlyasinstruction height or  nonoseaeaeonlyasinstruction as expected may need to have their treatment interrupted.\n', '\n', '    5.7  oselabeledaefromdruguse \n', '  Daytrana use may result in a persistent  oselabeledaefromdruguse   oselabeledaefromdruguse  in some cases, has been reported at other sites distant from the application site.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,daytrana,125,6489,6525,nonoseaeaeonlyasinstruction can mimic the appearance of  nonoseaeaeonlyasinstruction  particularly when the  nonoseaeaeonlyasinstruction  Individuals with a history of  notaecandidatepreexistingconditionorriskfactor and/or a family history of  notaecandidatepreexistingconditionorriskfactor may be more at risk.  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
126,daytrana,126,6525,6535,nonoseaeaeonlyasinstruction may persist even after Daytrana use is discontinued.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,daytrana,127,6535,6556,Monitor for signs of  nonoseaeaeonlyasinstruction  and advise patients to immediately inform their healthcare provider if  nonoseaeaeonlyasinstruction occur.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,daytrana,128,6556,6631,"Discontinue the Daytrana patch in patients with  nonoseaeaeonlyasinstruction \n', '\n', '    5.8 Contact Sensitization\n', '\n', '  In an open-label study of 305 subjects conducted to characterize  nonoseaeaeonlyasinstruction in children with  notaecandidateindication treated with Daytrana using a 9-hour wear time, one subject (0.3%) was confirmed by patch testing to be  oselabeledaefromdruguse ( oselabeledaefromdruguse .",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
129,daytrana,129,6631,6641,This subject experienced  oselabeledaefromdruguse and edema  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,daytrana,130,6641,6656,oselabeledaefromdruguse concurrent  oselabeledaefromdruguse  oselabeledaefromdruguse abdomen and  oselabeledaefromdruguse resulting in treatment discontinuation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,daytrana,131,6656,6691,"This subject was not transitioned to oral methylphenidate.\n', '\n', ' Use of Daytrana may lead to  oselabeledaefromdruguse  Daytrana should be discontinued if  nonoseaeaeonlyasinstruction is suspected.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,daytrana,132,6691,6766,"oselabeledaefromdruguse is commonly seen with use of Daytrana and is not by itself an indication of  nonoseaeaeonlyasinstruction  However,  nonoseaeaeonlyasinstruction should be suspected if  nonoseaeaeonlyasinstruction is accompanied by evidence of a more intense  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication (edema,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication (edema, papules,  nonoseaemanifestationorcomplication  that does not significantly improve within 48 hours or spreads beyond the patch site.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
133,daytrana,133,6766,6824,"Confirmation of a diagnosis of  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  may require further diagnostic testing.\n', '\n', ' Patients  oselabeledaefromdruguse  as evidenced by development of an  oselabeledaefromdruguse  may develop  oselabeledaefromdruguse or other systemic reactions if methylphenidate-containing products are taken via other routes, e.g., orally.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,daytrana,134,6824,6850,Manifestations of  nonoseaeaeonlyasinstruction may include a  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication previous dermatitis or of  nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication in previously unaffected skin.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
135,daytrana,135,6850,6870,Other systemic reactions may include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
136,daytrana,136,6870,6914,"No cases of  nonoseaenegation have been observed in clinical trials of Daytrana.\n', '\n', ' Patients who develop  nonoseaeaeonlyasinstruction to Daytrana and require oral treatment with methylphenidate should be initiated on oral medication under close medical supervision.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
137,daytrana,137,6914,6999,"It is possible that some patients  nonoseaeaeonlyasinstruction by exposure to Daytrana may not be able to take methylphenidate in any form.\n', '\n', '    5.9  oselabeledaefromdruguse \n', '   oselabeledaeclasseffect and  oselabeledaeclasseffect have been reported with stimulant treatment.\n', '\n', '    5.10 Patients Using External Heat\n', '\n', '  Patients should be advised to avoid exposing the Daytrana application site to  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,viibryd,0,0,74,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', '\n', '\n', ' *   oselabeledaeclasseffect  oselabeledaeclasseffect Thoughts and  oselabeledaeclasseffect in Children, Adolescents, and Young Adults [see Warnings and Precautions (  5.1  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,viibryd,1,74,94,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.2  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,viibryd,2,94,118,"\n', ' *  Increased Risk of  oselabeledaefromdruguse [see Warnings and Precautions (  5.3  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,viibryd,3,118,144,"\n', ' *  Activation of  oselabeledaefromdruguse or  oselabeledaefromdruguse [see Warnings and Precautions (  5.4  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,viibryd,4,144,164,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.5  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,viibryd,5,164,183,"\n', ' *   nonoseaeaeonlyasinstruction [see Warnings and Precautions (  5.6  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,viibryd,6,183,190,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,viibryd,7,190,203,[see Warnings and Precautions (  5.7  )].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,viibryd,8,203,223,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.8  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,viibryd,9,223,224,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,viibryd,10,224,289,"', '      EXCERPT:   Most common adverse reactions (incidence >= 5% and at least twice the rate of placebo): diarrhea, nausea, vomiting, and insomnia (  6  ).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, LLC.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,viibryd,11,289,309,at 1-800-678-1605 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,viibryd,12,309,346,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,viibryd,13,346,528,"Because clinical trials are conducted under widely varying conditions and varying lengths of time, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice.\n', '\n', '\n', '\n', ' The most commonly observed adverse reactions in VIIBRYD-treated patients with  notaecandidateindication (MDD) in placebo-controlled studies (incidence >= 5% and at least twice the rate of placebo) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '     Patient Exposure  \n', '\n', '\n', '\n', ' The safety of VIIBRYD was evaluated in 3,007 patients (18-70 years of age) diagnosed with  notaecandidateindication who participated in clinical studies, representing 676 patient-years of exposure.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
14,viibryd,14,528,649,"In an open-label 52 week study at 40 mg daily, 599 patients were exposed to VIIBRYD for a total of 348 patient-years.\n', '\n', '\n', '\n', ' The adverse reaction information presented below was derived from studies of VIIBRYD 20 mg and 40 mg daily in patients with MDD including:\n', '\n', '\n', '\n', ' *  Four placebo-controlled 8 to 10-week studies in 2,233 patients, including 1,266 VIIBRYD-treated patients; and \n', ' *  An open-label 52-week study of 599 VIIBRYD-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,viibryd,15,649,685,"\n', '    These studies included a titration period of 10 mg daily for 7 days, followed by 20 mg daily for 7 days or to 40 mg daily over 2 weeks.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,viibryd,16,685,763,"In these clinical trials, VIIBRYD was administered with food.\n', ' \n', '\n', '     Adverse reactions reported as reasons for discontinuation of treatment  \n', '\n', '\n', '\n', ' In these studies, 7.3% of the VIIBRYD-treated patients discontinued treatment due to an adverse reaction, compared with 3.5% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,viibryd,17,763,871,"The most common adverse reaction leading to discontinuation in at least 1% of the VIIBRYD-treated patients in the placebo-controlled studies was  oselabeledaefromdruguse (1.4%).\n', '\n', '\n', '\n', '     Common adverse reactions in placebo-controlled MDD studies  \n', '\n', '\n', '\n', '   Table 2  shows the incidence of common adverse reactions occuring in >= 2% of VIIBRYD-treated patients and greater than the rate of placebo-treated patients in MDD Studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,viibryd,18,871,942,"There were no dose-related adverse reactions between 20 mg and 40 mg reported.\n', '\n', '\n', '\n', ' Table 2: Common Adverse Reactions Occurring in >= 2% of VIIBRYD-treated Patients and Greater than the Rate of Placebo-Treated Patients \n', '   System Organ Class    Preferred Term                 Placebo    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,viibryd,19,942,946,N=967      VIIBRYD    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,viibryd,20,946,951,20 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,viibryd,21,951,953,N=288      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,viibryd,22,953,960,VIIBRYD    40 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,viibryd,23,960,962,N=978     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,viibryd,24,962,983,"\n', '  \n', '  1 Includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,viibryd,25,983,996,"\n', '  2 Includes  oselabeledaefromdruguse and  oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,viibryd,26,996,1012,"\n', '  3 Includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,viibryd,27,1012,1070,"\n', '  Sexual adverse reactions are presented in Table 3    \n', '  \n', '    nonoseaegeneralterm                                                                              \n', '        oselabeledaefromdruguse                                       10%              26%               29%               \n', '        oselabeledaefromdruguse                                         7%               22%               24%               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,viibryd,28,1070,1086,"\n', '        oselabeledaefromdruguse                                      5%               8%                7%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,viibryd,29,1086,1189,"\n', '        oselabeledaefromdruguse                                       2%               4%                5%                \n', '        oselabeledaefromdruguse  1                              3%               7%                4%                \n', '        oselabeledaefromdruguse                                      2%               2%                3%                \n', '        oselabeledaefromdruguse                                     1%               3%                3%                \n', '        oselabeledaefromdruguse                                1%               1%                2%                \n', '        oselabeledaefromdruguse                           1%               2%                1%                \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,viibryd,30,1189,1191,nonoseaegeneralterm                                                                                ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,viibryd,31,1191,1198,"\n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,viibryd,32,1198,1209,2                                    14%              15%               14%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,viibryd,33,1209,1225,"\n', '        oselabeledaefromdruguse                                      5%               6%                8%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,viibryd,34,1225,1264,"\n', '        oselabeledaefromdruguse                                     2%               4%                5%                \n', '        oselabeledaefromdruguse                                    1%               1%                2%                \n', '    nonoseaegeneralterm                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,viibryd,35,1264,1280,"\n', '        oselabeledaefromdruguse                                       2%               7%                6%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,viibryd,36,1280,1314,"\n', '        oselabeledaefromdruguse                                2%               2%                3%                \n', '        oselabeledaefromdruguse  3                                1%               2%                3%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,viibryd,37,1314,1351,"\n', '    nonoseaegeneralterm                                                                                       \n', '        oselabeledaefromdruguse                                        3%               4%                3%                \n', '    nonoseaegeneralterm                                                                                       \n', '        oselabeledaefromdruguse                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,viibryd,38,1351,1430,"<1%              1%                2%                \n', '    nonoseaegeneralterm                                                                      \n', '        oselabeledaefromdruguse                             1%               1%                3%                \n', '    nonoseaegeneralterm                                                         \n', '        oselabeledaefromdruguse                                     1%               2%                1%                \n', '    nonoseaegeneralterm                                                                                          \n', '        oselabeledaefromdruguse                               1%               1%                2%                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,viibryd,39,1430,1473,"\n', '              Sexual adverse reactions  \n', ' \n', '\n', '   Table 3  displays the most common sexual adverse reactions in the placebo-controlled MDD studies.\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,viibryd,40,1473,1526,"', '\n', '\n', ' Table 3: Common Sexual Adverse Reactions Occurring in >= 2% of VIIBRYD-treated Patients and Greater than the Rate of Placebo-Treated Patients \n', '  - Not applicable*Includes  oselabeledaefromdruguse and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,viibryd,41,1526,1543,"\n', '  \n', '   Preferred Term               Males       Females      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,viibryd,42,1543,1552,"\n', '   Placebo    N=416             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,viibryd,43,1552,1562,VIIBRYD 20 mg/day    N=122      VIIBRYD    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,viibryd,44,1562,1567,40 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,viibryd,45,1567,1571,N=417      Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,viibryd,46,1571,1573,N=551      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,viibryd,47,1573,1579,VIIBRYD 20 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,viibryd,48,1579,1583,N=166      VIIBRYD    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,viibryd,49,1583,1588,40 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,viibryd,50,1588,1590,N=561     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,viibryd,51,1590,1597,"\n', '  oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,viibryd,52,1597,1907,"<1%         2%            2%            0%         1%            1%             \n', '  oselabeledaefromdruguse         1%          0%            3%            -          -             -              \n', '  oselabeledaefromdruguse             <1%         3%            4%            <1%        2%            2%             \n', '  oselabeledaefromdruguse         0%          1%            2%            -          -             -              \n', '                 Other adverse reactions observed in clinical studies  \n', ' \n', '\n', ' The following list does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.\n', '\n', '\n', '\n', ' Reactions are categorized by body system according to the following definitions:  frequent  adverse reactions are those occurring in at least 1/100 patients;  infrequent  adverse reactions are those occurring in 1/100 to 1/1000 patients;  rare  reactions are those occurring in fewer than 1/1000 patients:\n', '\n', '\n', '\n', ' *      nonoseaegeneralterm  infrequent :  oselabeledaefromdruguse \n', ' *      nonoseaegeneralterm  infrequent:  oselabeledaefromdruguse   oselabeledaefromdruguse  rare:  oselabeledaefromdruguse \n', ' *      nonoseaegeneralterm  frequent :  oselabeledaefromdruguse   oselabeledaefromdruguse  infrequent :  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,viibryd,53,1907,1908,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,viibryd,54,1908,1919,"', ' *      nonoseaegeneralterm  infrequent :  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
55,viibryd,55,1919,1962,"\n', ' *      nonoseaegeneralterm  infrequent :  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '      6.2 Post-marketing Experience\n', '   The following adverse reactions have been identified during post-approval use of VIIBRYD.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,viibryd,56,1962,1993,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,viibryd,57,1993,2090,"Reports of adverse reactions temporally associated with VIIBRYD that have been received since market introduction and that are not listed above include the following:\n', '\n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,viibryd,58,2090,2114,"WARNING: SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '\n', '\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,viibryd,59,2114,2162,"SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '\n', '\n', '    Antidepressants increased the risk of  oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect  oselabeledaeclasseffect and behaviors in patients aged 24 years and younger in short-term studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,viibryd,60,2162,2186,"Monitor closely for clinical worsening and for emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,viibryd,61,2186,2234,"'\n', '\n', '\n', '   EXCERPT:    *  Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,viibryd,62,2234,2292,"If it occurs, discontinue VIIBRYD and initiate supportive treatment (  5.2  ) \n', ' *  Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (  5.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,viibryd,63,2292,2296,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,viibryd,64,2296,2304,*  Activation of Mania/Hypomania:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,viibryd,65,2304,2315,Screen patients for bipolar disorder (  5.4  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,viibryd,66,2315,2328,"\n', ' *  Seizures: Can occur with treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,viibryd,67,2328,2343,Use with caution in patients with a seizure disorder (  5.6  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,viibryd,68,2343,2353,"\n', ' *  Angle Closure Glaucoma:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,viibryd,69,2353,2369,"Avoid use of antidepressants, including VIIBRYD, in patients with untreated anatomically narrow angles.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,viibryd,70,2369,2485,"(  5.7  ) \n', '    \n', ' \n', '\n', '   5.1 Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults\n', '\n', '\n', '\n', '  In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of  oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect  oselabeledaeclasseffect and behaviors in patients age 24 years and younger was greater in antidepressant-treated patients than in placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,viibryd,71,2485,2544,"The drug-placebo differences in the number of cases of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behaviors per 1000 patients treated are provided in  Table 1  .\n', '\n', '\n', '\n', ' No  nonoseaenegation occurred in any of the pediatric studies.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
72,viibryd,72,2544,2626,"There were  nonoseaeaeonlyasinstruction in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Table 1: Risk Differences of the Number of Patients with Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients \n', '  Age Range (years)     ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,viibryd,73,2626,2646,Drug-Placebo Difference in Number of Patients with  oselabeledaeclasseffect  oselabeledaeclasseffect Thoughts or  oselabeledaeclasseffect per 1000 Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,viibryd,74,2646,2691,"Treated     \n', '                      Increases Compared to Placebo                                                      \n', ' <18                 14 additional patients                                                              \n', ' 18-24               5 additional patients                                                               \n', '                      Decreases Compared to Placebo                                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,viibryd,75,2691,2692,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,viibryd,76,2692,2703,"', ' 25-64               1 fewer patient                                                                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,viibryd,77,2703,2711,"\n', ' >=65                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,viibryd,78,2711,2715,6 fewer patients                                                                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,viibryd,79,2715,2758,"\n', '        It is unknown whether the risk of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,viibryd,80,2758,2834,"However, there is substantial evidence from placebo-controlled maintenance studies in adults with  notaecandidateindication that antidepressants delay the recurrence of  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' Monitor all antidepressant-treated patients for clinical worsening and emergence of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behaviors, especially during the initial few months of drug therapy and at times of dosage changes.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
81,viibryd,81,2834,2854,Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,viibryd,82,2854,2943,"Consider changing the therapeutic regimen, including possibly discontinuing VIIBRYD, in patients whose  notaecandidateindication is persistently worse, or who are experiencing emergent  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or behaviors.\n', '\n', '\n', '\n', '       5.2 Serotonin Syndrome\n', '\n', '\n', '\n', ""     SNRIs and SSRIs, including VIIBRYD, can precipitate  oselabeledaefromdruguse  a potentially life-threatening condition.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
83,viibryd,83,2943,3008,"The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (  4  ) and Drug Interactions (  7  )].   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,viibryd,84,3008,3019,nonoseaeaeonlyasinstruction can also occur when these drugs are used alone.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,viibryd,85,3019,3153,"Symptoms of  oselabeledaefromdruguse were noted in 0.1% of  notaecandidateindication patients treated with VIIBRYD in premarketing clinical trials.\n"", '\n', '\n', '\n', '     nonoseaeaeonlyasinstruction signs and symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication  and  nonoseaegeneralterm (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .\n', '\n', '\n', '\n', '    The concomitant use of VIIBRYD with MAOIs is contraindicated.",1,1,0,1,1,0,0,0,0,0,0,0,0,0,0
86,viibryd,86,3153,3175,"In addition, do not initiate VIIBRYD in a patient being treated with MAOIs such as linezolid or intravenous methylene blue.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,viibryd,87,3175,3197,No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,viibryd,88,3197,3228,"If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking VIIBRYD, discontinue VIIBRYD before initiating treatment with the MAOI",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,viibryd,89,3228,3247,"[see Contraindications (  4  ), Drug Interactions (  7.1  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,viibryd,90,3247,3298,"\n', '\n', '\n', '\n', '    Monitor all patients taking VIIBRYD for the emergence of  nonoseaeaeonlyasinstruction  Discontinue treatment with VIIBRYD and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,viibryd,91,3298,3380,"If concomitant use of VIIBRYD with other serotonergic drugs is clinically warranted, inform patients of the increased risk for  nonoseaeaeonlyasinstruction and monitor for symptoms.\n', '\n', '\n', '\n', '    5.3 Increased Risk of Bleeding\n', '\n', '\n', '\n', '  Drugs that interfere with serotonin reuptake inhibition, including VIIBRYD, increase the risk of  oselabeledaefromdruguse events.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,viibryd,92,3380,3409,"Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,viibryd,93,3409,3508,"Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of  oselabeledaeclasseffect   oselabeledaeclasseffect events related to drugs that interfere with serotonin reuptake have ranged from  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect to life-threatening  oselabeledaeclasseffect \n', '\n', '\n', '\n', ' Inform patients about the risk of  nonoseaeaeonlyasinstruction associated with the concomitant use of VIIBRYD and antiplatelet agents or anticoagulants.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,viibryd,94,3508,3589,"For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing VIIBRYD.\n', '\n', '\n', '\n', '    5.4 Activation of Mania or Hypomania\n', '\n', '\n', '\n', '  In patients with  notaecandidatepreexistingconditionorriskfactor  treating a  notaecandidateindication with VIIBRYD or another antidepressant may precipitate a  oselabeledaefromdruguse manic  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
95,viibryd,95,3589,3622,"In controlled clinical trials, patients with  notaecandidatepreexistingconditionorriskfactor were excluded; however, symptoms of  oselabeledaefromdruguse or  oselabeledaefromdruguse were reported in 0.1% of undiagnosed patients treated with VIIBRYD.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
96,viibryd,96,3622,3658,"Prior to initiating treatment with VIIBRYD, screen patients for any personal or family history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor [see Dosage and Administration (  2.2  )]  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
97,viibryd,97,3658,3754,".\n', '\n', '\n', '\n', '    5.5 Discontinuation Syndrome\n', '\n', '\n', '\n', '   oselabeledaefromdruguse of serotonergic antidepressants, particularly after abrupt discontinuation, include:  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal (e.g.,  nonoseaeodorwithdrawal  such as  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  ",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
98,viibryd,98,3754,3767,A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,viibryd,99,3767,3779,[see Dosage and Administration (  2.5  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,viibryd,100,3779,3840,".\n', '\n', '\n', '\n', '    5.6 Seizures\n', '\n', '\n', '\n', '  VIIBRYD has not been systematically evaluated in patients with a  notaecandidatepreexistingconditionorriskfactor  Patients with a history of  notaecandidatepreexistingconditionorriskfactor were excluded from clinical studies.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
101,viibryd,101,3840,3922,"VIIBRYD should be prescribed with caution in patients with a  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '       5.7 Angle-Closure Glaucoma\n', '\n', '\n', '\n', '     The  oselabeledaefromdruguse that occurs following use of many antidepressant drugs including VIIBRYD may trigger an  oselabeledaefromdruguse in a patient with  notaecandidatepreexistingconditionorriskfactor who does not have a patent iridectomy.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
102,viibryd,102,3922,3987,"Avoid use of antidepressants, including VIIBRYD, in patients with untreated  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.8 Hyponatremia\n', '\n', '\n', '\n', '   oselabeledaefromdruguse may occur as a result of treatment with SNRIs and SSRIs, including VIIBRYD.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
103,viibryd,103,3987,3995,Cases of  oselabeledaefromdruguse have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,viibryd,104,3995,4051,Signs and symptoms of  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  which may lead to  nonoseaemanifestationorcomplication  Signs and symptoms associated with more severe and/or acute cases have included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm  ,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
105,viibryd,105,4051,4099,"In many cases, this  oselabeledaefromdruguse appears to be the result of the  oselabeledaefromdruguse (SIADH).\n', '\n', '\n', '\n', ' In patients with symptomatic  nonoseaeaeonlyasinstruction  discontinue VIIBRYD and institute appropriate medical intervention.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,viibryd,106,4099,4123,"Elderly patients, patients taking diuretics, and those who are  notaecandidatepreexistingconditionorriskfactor may be at greater risk of developing  nonoseaeaeonlyasinstruction ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,enbrel,0,0,8,['    6         ADVERSE REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,enbrel,1,8,54,"\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *  Serious  oselabeledaefromdruguse [see Boxed Warning and  Warnings and Precautions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,enbrel,2,54,61,(    5.1    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,enbrel,3,61,65,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,enbrel,4,65,68,*   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,enbrel,5,68,75,[  see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,enbrel,6,75,82,(    5.2    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,enbrel,7,82,86,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,enbrel,8,86,89,*   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,enbrel,9,89,99,[  see  Boxed Warning and Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,enbrel,10,99,105,(    5.3    ) ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,enbrel,11,105,118,"\n', ' *  Patients with  notaecandidatepreexistingconditionorriskfactor [see  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
12,enbrel,12,118,121,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,enbrel,13,121,128,(    5.4    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,enbrel,14,128,135,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,enbrel,15,135,141,[see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,enbrel,16,141,148,(    5.5    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,enbrel,17,148,155,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,enbrel,18,155,161,[see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,enbrel,19,161,168,(    5.6    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,enbrel,20,168,175,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,enbrel,21,175,181,[see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,enbrel,22,181,188,(    5.7    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,enbrel,23,188,195,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,enbrel,24,195,201,[see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,enbrel,25,201,208,(    5.9    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,enbrel,26,208,215,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,enbrel,27,215,221,[see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,enbrel,28,221,228,(    5.10    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,enbrel,29,228,229,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,enbrel,30,229,254,"', '      EXCERPT:   Most common adverse reactions (incidence > 5%):     infections and injection site reactions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,enbrel,31,254,306,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,enbrel,32,306,328,"\n', '\n', ' \n', '\n', '  6.1       Clinical Trials Experience",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,enbrel,33,328,363,"\n', '\n', '  Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,enbrel,34,363,376,[see Warnings and Precautions (      5      )]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,enbrel,35,376,388,The most common adverse reactions with Enbrel were  oselabeledaefromdruguse and  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,enbrel,36,388,389,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,enbrel,37,389,397,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,enbrel,38,397,456,"Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.\n', '\n', '   Adverse Reactions in Adult Patients    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,enbrel,39,456,463,w    ith R    heumatoid    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,enbrel,40,463,478,"A    rthritis    , Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,enbrel,41,478,625,"\n', '\n', ' The data described below reflect exposure to Enbrel in 2219 adult patients with  notaecandidateindication followed for up to 80 months, in 182 patients with  notaecandidateindication for up to 24 months, in 138 patients with  notaecandidateindication for up to 6 months, and in 1204 adult patients with  notaecandidateindication for up to 18 months.\n', '\n', ' In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.\n', '\n', '   Adverse Reactions in Pediatric Patients  \n', '\n', ' In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients  [see    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
42,enbrel,42,625,658,"Warnings and Precautions (      5      ),    Use in Specific Populations (      8.4      ), and Clinical Studies (      14.2      and      14.6      )    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,enbrel,43,658,660,]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,enbrel,44,660,725,".\n', '\n', ' In a 48-week clinical study in 211 children aged 4 to 17 years with pediatric  notaecandidateindication  the adverse reactions reported were similar to those seen in previous studies in adults with  notaecandidateindication   Long-term safety profile for up to 264 additional weeks was assessed in an open-label extension study and",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
45,enbrel,45,725,820,"no new safety signals were identified.\n', '\n', ' In open-label clinical studies of children with  notaecandidateindication  adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children.\n', '\n', '   Infections       \n', '\n', '  oselabeledaefromdruguse  including  oselabeledaefromdruguse  bacterial, and fungal  oselabeledaefromdruguse  oselabeledaefromdruguse  and fungal  oselabeledaefromdruguse  oselabeledaefromdruguse  have been observed in adult and pediatric patients.   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
46,enbrel,46,820,844,oselabeledaefromdruguse have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,enbrel,47,844,898,"\n', '\n', ' In controlled portions of trials, the types and severity of  oselabeledaefromdruguse were similar between Enbrel and the respective control group (placebo or MTX for  notaecandidateindication and  notaecandidateindication patients) in  notaecandidateindication   notaecandidateindication   notaecandidateindication and  notaecandidateindication patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
48,enbrel,48,898,922,"Rates of  nonoseaeaeonlyasinstruction in  notaecandidateindication and adult  notaecandidateindication patients are provided in Table 3 and Table 4, respectively.   ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
49,enbrel,49,922,933,oselabeledaefromdruguse consisted primarily of  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,enbrel,50,933,991,"\n', '\n', ' In controlled portions of trials in  notaecandidateindication   notaecandidateindication   notaecandidateindication and  notaecandidateindication  the rates of serious  oselabeledaefromdruguse were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups).  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
51,enbrel,51,991,1033,"In clinical trials in rheumatologic indications, serious  oselabeledaefromdruguse experienced by patients have included, but are not limited to,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,enbrel,52,1033,1069,"In clinical trials in adult  notaecandidateindication patients, serious  oselabeledaefromdruguse experienced by patients have included, but are not limited to,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
53,enbrel,53,1069,1102,The rate of serious  nonoseaeaeonlyasinstruction was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,enbrel,54,1102,1138,"\n', '\n', ' In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy),  oselabeledaefromdruguse was observed in approximately 0.02% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,enbrel,55,1138,1174,"In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the U.S. and Canada,  oselabeledaefromdruguse was observed in approximately 0.006% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,enbrel,56,1174,1188,These studies include reports of  oselabeledaefromdruguse and extrapulmonary  oselabeledaefromdruguse  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,enbrel,57,1188,1192,[    see    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,enbrel,58,1192,1205,Warnings and Precautions    (      5.1      )    ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,enbrel,59,1205,1243,"\n', '\n', ' The types of  oselabeledaefromdruguse reported in pediatric patients with  notaecandidateindication and  notaecandidateindication were generally mild and consistent with those commonly seen in the general pediatric population.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
60,enbrel,60,1243,1338,"Two  notaecandidateindication patients developed  oselabeledaefromdruguse and signs and symptoms of  oselabeledaefromdruguse  which resolved without sequelae.\n', '\n', '   Injection Site Reactions  \n', '\n', ' In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed  oselabeledaefromdruguse  In controlled trials in patients with  notaecandidateindication  15% of adult patients and 7% of pediatric patients treated with Enbrel developed  oselabeledaefromdruguse during the first 3 months of treatment.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
61,enbrel,61,1338,1452,"All  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were described as mild to moderate ( oselabeledaefromdruguse  oselabeledaefromdruguse reactions were described as mild to moderate (erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were described as mild to moderate (erythema, itching,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were described as mild to moderate (erythema, itching, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were described as mild to moderate (erythema, itching, pain, swelling,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding,  oselabeledaefromdruguse  and generally did not necessitate drug discontinuation.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,enbrel,62,1452,1465,oselabeledaefromdruguse generally occurred in the first month and subsequently decreased in frequency.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,enbrel,63,1465,1477,The mean duration of  oselabeledaefromdruguse was 3 to 5 days.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,enbrel,64,1477,1521,"Seven percent of patients experienced  oselabeledaefromdruguse when subsequent injections were given.\n', '\n', '   Other Adverse Reactions  \n', '\n', ' Table 3 summarizes adverse reactions reported in adult  notaecandidateindication patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
65,enbrel,65,1521,1567,"The types of adverse reactions seen in patients with  notaecandidateindication or  notaecandidateindication were similar to the types of adverse reactions seen in patients with  notaecandidateindication \n', '\n', '\n', '   Table 3    .    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
66,enbrel,66,1567,1580,Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,enbrel,67,1580,1607,"\n', '                    Placebo         Controlled      a      (Studies I, II, and a Phase 2    S    tudy)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,enbrel,68,1607,1610,Active Controlled      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,enbrel,69,1610,1612,b      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,enbrel,70,1612,1617,(Study III)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,enbrel,71,1617,1654,"\n', '                    Placebo  (N = 152)    E    nbrel      c    (N = 349)    MTX  (N = 217)    E    nbrel      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,enbrel,72,1654,1656,c    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,enbrel,73,1656,1662,(N = 415)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,enbrel,74,1662,1677,"\n', '        Reaction      Percent of Patients      Percent of Patients     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,enbrel,75,1677,1678,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,enbrel,76,1678,1687,"', '                                                                                       \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,enbrel,77,1687,1691,oselabeledaefromdruguse  d  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,enbrel,78,1691,1697,(total)  39               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,enbrel,79,1697,1703,50               86               81                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,enbrel,80,1703,1710,"\n', '   oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,enbrel,81,1710,1712,e    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,enbrel,82,1712,1735,"30               38               70               65                \n', '   oselabeledaefromdruguse  15               21               59               54                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,enbrel,83,1735,1742,"\n', '   oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,enbrel,84,1742,1744,11               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,enbrel,85,1744,1750,37               18               43                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,enbrel,86,1750,1765,"\n', '   oselabeledaefromdruguse        9                8                16               16                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,enbrel,87,1765,1838,"\n', '   oselabeledaefromdruguse            2                3                19               13                \n', '   oselabeledaefromdruguse        1                2                5                5                 \n', '   oselabeledaefromdruguse         -                3                4                2                 \n', '   oselabeledaefromdruguse       1                -                4                2                 \n', '   oselabeledaefromdruguse  -                -                1                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,enbrel,88,1838,1870,"1                 \n', '                                                                                       \n', '   a    Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,enbrel,89,1870,1872,b    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,enbrel,90,1872,1879,Study duration of 2 years.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,enbrel,91,1879,1881,c    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,enbrel,92,1881,1885,Any dose.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,enbrel,93,1885,1887,d    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,enbrel,94,1887,1905,Includes  oselabeledaefromdruguse  viral and fungal  oselabeledaefromdruguse  oselabeledaefromdruguse and fungal  oselabeledaefromdruguse  oselabeledaefromdruguse     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,enbrel,95,1905,1920,e    Most frequent  oselabeledaefromdruguse were  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,enbrel,96,1920,1991,"\n', '           In placebo-controlled adult  notaecandidateindication trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.\n', ' \n', '\n', ' Table 4 summarizes adverse reactions reported in adult  notaecandidateindication patients from Studies",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
97,enbrel,97,1991,2011,"I and II.\n', '\n', '\n', '   Table 4    .    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,enbrel,98,2011,2029,Percent of Adult PsO Patients Experiencing Adverse Reactions    in Placebo-Controlled Portions of Clinical Trials    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,enbrel,99,2029,2036,(Studies I & II)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,enbrel,100,2036,2049,"\n', '                                              Placebo  (N = 359)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,enbrel,101,2049,2070,"Enbrel      a    (N = 876)   \n', '   Reaction         Percent of Patients     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,enbrel,102,2070,2090,"\n', '                                                     \n', '  nonoseaeaeratelteqplacebo  b       (total)  28               ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
103,enbrel,103,2090,2092,27                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,enbrel,104,2092,2103,"\n', '  nonoseaeaeratelteqplacebo  14               12                ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
105,enbrel,105,2103,2112,"\n', '  nonoseaeaeratelteqplacebo  c    ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
106,enbrel,106,2112,2116,17               17                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,enbrel,107,2116,2125,"\n', '  oselabeledaefromdruguse  6                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,enbrel,108,2125,2127,15                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,enbrel,109,2127,2160,"\n', '  oselabeledaefromdruguse         2                3                 \n', '  nonoseaeaeratelteqplacebo             1                1                 \n', '  nonoseaeaeratelteqplacebo         2                1                 ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
110,enbrel,110,2160,2180,"\n', '  oselabeledaefromdruguse        -                1                 \n', '  oselabeledaefromdruguse  -                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,enbrel,111,2180,2240,"1                 \n', '  nonoseaeaeratelteqplacebo          1                -                 \n', '                                                     \n', '   a    Includes 25 mg subcutaneous (SC) once weekly (QW), 25 mg SC twice weekly (BIW), 50 mg SC QW, and 50 mg SC BIW doses.  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
112,enbrel,112,2240,2242,b    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,enbrel,113,2242,2244,Includes  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,enbrel,114,2244,2260,nonoseaeaeratelteqplacebo  viral and fungal  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo and fungal  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo   ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
115,enbrel,115,2260,2268,c    Most frequent  nonoseaeaeratelteqplacebo were  ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
116,enbrel,116,2268,2275,nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo and  nonoseaeaeratelteqplacebo    ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
117,enbrel,117,2275,2287,"\n', '           6.2       Immunogenicity\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,enbrel,118,2287,2300,"As with all therapeutic proteins, there is potential for  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,enbrel,119,2300,2317,The detection of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,enbrel,120,2317,2357,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,enbrel,121,2357,2455,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction in the studies described below with the incidence of  nonoseaeaeonlyasinstruction in other studies or  nonoseaeaeonlyasinstruction may be misleading.\n', '\n', '   Immunogenicity  \n', '\n', ' Patients with  notaecandidateindication   notaecandidateindication   notaecandidateindication or  notaecandidateindication were tested at multiple time points for  nonoseaeaeonlyasinstruction   oselabeledaefromdruguse drug product were detected at least once in sera of approximately 6% of adult patients with  notaecandidateindication   notaecandidateindication   notaecandidateindication or  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
122,enbrel,122,2455,2459,These  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,enbrel,123,2459,2558,"Results from  notaecandidateindication patients were similar to those seen in adult  notaecandidateindication patients treated with Enbrel.\n', '\n', ' In adult  notaecandidateindication studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients  oselabeledaefromdruguse at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%-8.7% and were all  oselabeledaefromdruguse  The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
124,enbrel,124,2558,2573,No apparent correlation of  nonoseaeaeonlyasinstruction to clinical response or adverse events was observed.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,enbrel,125,2573,2588,The  nonoseaeaeonlyasinstruction data of Enbrel beyond 120 weeks of exposure are unknown.     ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,enbrel,126,2588,2593,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,enbrel,127,2593,2619,"', ' In pediatric  notaecandidateindication studies, approximately 10% of subjects developed  oselabeledaefromdruguse by Week 48 and approximately 16% of subjects",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
128,enbrel,128,2619,2627,developed  oselabeledaefromdruguse by Week 264.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,enbrel,129,2627,2633,All of these  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,enbrel,130,2633,2706,"However, because of the limitations of the  nonoseaeaeonlyasinstruction assays, the incidence of binding and  nonoseaeaeonlyasinstruction may not have been reliably determined.\n', '\n', ' The data reflect the percentage of patients whose test results were considered  nonoseaeaeonlyasinstruction in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.\n', '\n', '   Autoantibodies  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,enbrel,131,2706,2730,"\n', '\n', ' Patients with  notaecandidateindication had serum samples tested for  nonoseaeaeonlyasinstruction at multiple time points.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
132,enbrel,132,2730,2733,In  notaecandidateindication,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
133,enbrel,133,2733,2779,"Studies I and II, the percentage of patients evaluated for  nonoseaeaeonlyasinstruction  who developed  oselabeledaefromdruguse (titer >= 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,enbrel,134,2779,2836,The percentage of patients who developed new  oselabeledaefromdruguse was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by  Crithidia luciliae  assay (3% of patients treated with Enbrel compared to none of placebo-treated patients).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,enbrel,135,2836,2857,The proportion of patients treated with Enbrel who developed  oselabeledaefromdruguse was similarly increased compared to placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,enbrel,136,2857,2892,"In  notaecandidateindication Study III, no pattern of increased  nonoseaenegation development was seen in Enbrel patients compared to MTX patients  [see Warnings and Precautions (      5.9      )]  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
137,enbrel,137,2892,2930,".\n', '\n', '   6.3       Postmarketing Experience\n', '\n', '  Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,enbrel,138,2930,2994,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.\n', '\n', ' Adverse reactions are listed by body system below:\n', '\n', '\n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,enbrel,139,2994,3002,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,enbrel,140,3002,3004,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,enbrel,141,3004,3006,[see,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,enbrel,142,3006,3018,Warnings    and Precautions    (      5.5      )]     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,enbrel,143,3018,3027,"\n', '  nonoseaegeneralterm    oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
144,enbrel,144,3027,3030,[see    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,enbrel,145,3030,3040,Warnings and Precautions (      5.4      )]     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,enbrel,146,3040,3074,"\n', '  nonoseaeaeonlyasinstruction    oselabeledaefromdruguse (IBD)   \n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
147,enbrel,147,3074,3098,"oselabeledaefromdruguse   \n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '  nonoseaegeneralterm    oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
148,enbrel,148,3098,3124,"\n', '  nonoseaegeneralterm    oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   [see Warnings and Precautions (      5.3      )]     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
149,enbrel,149,3124,3141,"\n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
150,enbrel,150,3141,3143,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,enbrel,151,3143,3145,[see,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,enbrel,152,3145,3152,Warning    s    and Precaution    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,enbrel,153,3152,3160,s (      5.2      )]     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,enbrel,154,3160,3171,"\n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
155,enbrel,155,3171,3212,"\n', '  nonoseaegeneralterm    oselabeledaefromdruguse   \n', '  nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  new or worsening  oselabeledaefromdruguse  oselabeledaefromdruguse (",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
156,enbrel,156,3212,3302,"all sub-types including  oselabeledaefromdruguse  oselabeledaefromdruguse (all sub-types including pustular and  oselabeledaefromdruguse    \n', '         oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and   oselabeledaefromdruguse  and  oselabeledaefromdruguse have also been reported in postmarketing use.\n', ' \n', '\n', ' Rare (< 0.1%) cases of  oselabeledaefromdruguse have been reported in  notaecandidateindication patients receiving Enbrel, which is not effective for the treatment of  notaecandidatepreexistingconditionorriskfactor \n",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
157,enbrel,157,3302,3313,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,enbrel,158,3313,3316,WARNING:  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,enbrel,159,3316,3322,"SERIOUS INFECTIONS and MALIGNANCIES\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,enbrel,160,3322,3331,"'\n', '    WARNING:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,enbrel,161,3331,3336,SERIOUS INFECTIONS and MALIGNANCIES  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,enbrel,162,3336,3348,"\n', '\n', '    SERIOUS INFECTIONS  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,enbrel,163,3348,3399,"\n', '\n', '   Patients treated with Enbrel are at increased risk for developing serious  oselabeledaefromdruguse that may lead to hospitalization or  nonoseaegeneralterm [see Warnings and Precautions (      5.1      ) and Adverse Reactions (      6      )].  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
164,enbrel,164,3399,3418,Most patients who developed these  nonoseaeaefromdruginteraction were taking concomitant  nonoseaeaeonlyasinstruction such as methotrexate or corticosteroids.  ,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
165,enbrel,165,3418,3498,"\n', '\n', '   Enbrel should be discontinued if a patient develops a serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   \n', '\n', '   Reported  oselabeledaefromdruguse include:  \n', '\n', ' *   oselabeledaefromdruguse  including  oselabeledaefromdruguse  Patients with  oselabeledaefromdruguse  oselabeledaefromdruguse have frequently presented with  oselabeledaefromdruguse  oselabeledaefromdruguse have frequently presented with disseminated or  oselabeledaefromdruguse disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,enbrel,166,3498,3512,Patients should be tested for  notaecandidatepreexistingconditionorriskfactor before Enbrel use and during therapy.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
167,enbrel,167,3512,3524,Treatment for  notaecandidatepreexistingconditionorriskfactor should be initiated prior to Enbrel use.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
168,enbrel,168,3524,3530,"\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,enbrel,169,3530,3548,oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,enbrel,170,3548,3578,"Patients with  oselabeledaefromdruguse  oselabeledaefromdruguse or other invasive fungal infections may present with  oselabeledaefromdruguse  oselabeledaefromdruguse may present with disseminated, rather than localized, disease.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,enbrel,171,3578,3617,nonoseaeaefromofflabel and antibody  nonoseaeaefromofflabel  nonoseaeaeonlyasinstruction may be negative in some patients with active  nonoseaeaeonlyasinstruction  Empiric anti-fungal therapy should be considered in patients at risk for  nonoseaeaeonlyasinstruction who develop severe systemic illness.,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
172,enbrel,172,3617,3647,"\n', ' *   oselabeledaefromdruguse  viral, and other  oselabeledaefromdruguse  oselabeledaefromdruguse  and other  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse and Listeria.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,enbrel,173,3647,3652,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,enbrel,174,3652,3767,"The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent  oselabeledaefromdruguse  oselabeledaefromdruguse  \n', '      The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent  oselabeledaefromdruguse  nonoseaeaeonlyasinstruction   \n', ' \n', '\n', '   Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with Enbrel, including the possible development of  nonoseaeaeonlyasinstruction in patients who tested negative for  notaecandidatepreexistingconditionorriskfactor prior to initiating therapy.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
175,enbrel,175,3767,3803,"\n', '\n', '   MALIGNANCIES  \n', '\n', '    oselabeledaefromdruguse and other  oselabeledaefromdruguse  some  nonoseaegeneralterm     5        WARNINGS AND PRECAUTIONS      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
176,enbrel,176,3803,3815,"\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,enbrel,177,3815,3826,*  Do not start Enbrel during an active infection.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,enbrel,178,3826,3841,"If an infection develops, monitor carefully and stop Enbrel if infection becomes serious.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,enbrel,179,3841,3846,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,enbrel,180,3846,3888,"\n', ' *  Consider empiric anti-fungal therapy for patients at risk for invasive fungal infections who develop a severe systemic illness on Enbrel (those who reside or travel to regions where mycoses are endemic).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,enbrel,181,3888,3910,"(  5.1  ) \n', ' *  Demyelinating disease, exacerbation or new onset, may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,enbrel,182,3910,3915,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,enbrel,183,3915,3919,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,enbrel,184,3919,3935,*  Cases of lymphoma have been observed in patients receiving TNF-blocking agents.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,enbrel,185,3935,3958,"(  5.3  ) \n', ' *  Congestive heart failure, worsening or new onset, may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,enbrel,186,3958,3990,"(  5.4  ) \n', ' *  Advise patients to seek immediate medical attention if symptoms of pancytopenia or aplastic anemia develop, and consider stopping Enbrel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,enbrel,187,3990,4018,"(  5.5  ) \n', ' *  Monitor patients previously infected with hepatitis B virus for reactivation during and several months after therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,enbrel,188,4018,4032,"If reactivation occurs, consider stopping Enbrel and beginning anti-viral therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,enbrel,189,4032,4051,"(  5.6  ) \n', ' *  Anaphylaxis or serious allergic reactions may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,enbrel,190,4051,4074,"(  5.7  ) \n', ' *  Stop Enbrel if lupus-like syndrome or autoimmune hepatitis develops.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,enbrel,191,4074,4231,"(  5.9  ) \n', '    \n', ' \n', '\n', '   5.1       Serious Infections\n', '\n', '  Patients treated with Enbrel are at increased risk for developing serious  oselabeledaefromdruguse involving various organ systems and sites that may lead to hospitalization or  nonoseaegeneralterm \n', '\n', '  oselabeledaefromdruguse  oselabeledaeclasseffect due to  oselabeledaeclasseffect  oselabeledaeclasseffect due to bacterial,  oselabeledaeclasseffect  oselabeledaefromdruguse due to bacterial, mycobacterial,  oselabeledaefromdruguse  oselabeledaeclasseffect due to bacterial, mycobacterial, invasive fungal,  oselabeledaeclasseffect  oselabeledaeclasseffect due to bacterial, mycobacterial, invasive fungal, viral,  oselabeledaeclasseffect  or other opportunistic pathogens including  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaefromdruguse   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported with TNF blockers.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
192,enbrel,192,4231,4331,"Patients have frequently presented with disseminated rather than localized disease.\n', '\n', ' Treatment with Enbrel should not be initiated in patients with an active  notaecandidatepreexistingconditionorriskfactor  including clinically important  notaecandidatepreexistingconditionorriskfactor  Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant  nonoseaeaeonlyasinstruction (such as corticosteroids or methotrexate), may be at greater risk of  nonoseaeaeonlyasinstruction  The risks and benefits of treatment should be considered prior to initiating therapy in patients:\n', '\n', ' *  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
193,enbrel,193,4331,4358,"With chronic or recurrent  notaecandidatepreexistingconditionorriskfactor  \n', ' *  Who have been exposed to  notaecandidatepreexistingconditionorriskfactor  \n', ' *  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
194,enbrel,194,4358,4433,"With a history of an  notaecandidatepreexistingconditionorriskfactor  \n', ' *  Who have resided or traveled in areas of endemic  nonoseaeaeonlyasinstruction or endemic  nonoseaeaeonlyasinstruction  such as  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  or \n', ' *  With underlying conditions that may  notaecandidatepreexistingconditionorriskfactor  such as advanced or poorly controlled  notaecandidatepreexistingconditionorriskfactor [see Adverse Reactions (    6.1    )] .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
195,enbrel,195,4433,4486,"\n', '    Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with Enbrel.\n', ' \n', '\n', ' Enbrel should be discontinued if a patient develops a serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,enbrel,196,4486,4582,"A patient who develops a new  oselabeledaefromdruguse during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an  nonoseaeaeonlyasinstruction patient, and appropriate antimicrobial therapy should be initiated.\n', '\n', '  Tuberculosis  \n', '\n', ' Cases of  oselabeledaefromdruguse or new  oselabeledaefromdruguse have been observed in patients receiving Enbrel, including patients who have previously received treatment for  nonoseaeaeonlyasinstruction or active  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  Data from clinical trials and preclinical studies",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,enbrel,197,4582,4601,suggest that the risk of  nonoseaeaeratelteqplacebo is lower with Enbrel than with TNF-blocking monoclonal antibodies.,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
198,enbrel,198,4601,4619,"Nonetheless, postmarketing cases of  oselabeledaefromdruguse have been reported for TNF blockers, including Enbrel.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,enbrel,199,4619,4634,oselabeledaefromdruguse has developed in patients who tested  notaecandidatepreexistingconditionorriskfactor prior to initiation of therapy.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
200,enbrel,200,4634,4658,Patients should be evaluated for  nonoseaeaeonlyasinstruction risk factors and tested for  notaecandidatepreexistingconditionorriskfactor prior to initiating Enbrel and periodically during therapy.   ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
201,enbrel,201,4658,4665,nonoseaeaeonlyasinstruction while on therapy with Enbrel.\n',1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,enbrel,202,4665,4697,", '\n', ' Treatment of  notaecandidatepreexistingconditionorriskfactor prior to therapy with TNF-blocking agents has been shown to reduce the risk of  nonoseaeaeonlyasinstruction during therapy.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
203,enbrel,203,4697,4880,"nonoseaeaeonlyasinstruction result when assessing if treatment for  nonoseaeaeonlyasinstruction is needed prior to initiating Enbrel, even for patients previously vaccinated with  nonoseaeaeonlyasinstruction .\n', '\n', '  nonoseaeaeonlyasinstruction should also be considered prior to initiation of Enbrel in patients with a past history of  notaecandidatepreexistingconditionorriskfactor or active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor in whom an adequate course of treatment cannot be confirmed, and for patients with a  notaecandidatepreexistingconditionorriskfactor but having risk factors for  notaecandidatepreexistingconditionorriskfactor  Consultation with a physician with expertise in the treatment of  nonoseaeaeonlyasinstruction is recommended to aid in the decision whether initiating  nonoseaeaeonlyasinstruction is appropriate for an individual patient.\n', '\n', '  nonoseaeaeonlyasinstruction should be strongly considered in patients who develop a new  nonoseaeaeonlyasinstruction during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of  nonoseaeaeonlyasinstruction  or who have had close contact with a person with  nonoseaeaeonlyasinstruction \n', '\n', '  Invasive Fungal Infections  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
204,enbrel,204,4880,4887,"\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,enbrel,205,4887,4912,"' Cases of serious and sometimes  nonoseaegeneralterm  oselabeledaefromdruguse  including  oselabeledaefromdruguse  have been reported with TNF blockers, including Enbrel.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
206,enbrel,206,4912,4957,"For patients who reside or travel in regions where  nonoseaeaeonlyasinstruction are endemic,  nonoseaeaeonlyasinstruction should be suspected if they develop a serious  nonoseaeaeonlyasinstruction  Appropriate empiric anti-fungal therapy should be considered while a diagnostic workup is being performed.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,enbrel,207,4957,4972,nonoseaeaeonlyasinstruction and antibody  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction in some patients with active  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,enbrel,208,4972,5027,"When feasible, the decision to administer empiric anti-fungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive  nonoseaeaeonlyasinstruction and should take into account both the risk for severe  nonoseaeaeonlyasinstruction and the risks of anti-fungal therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,enbrel,209,5027,5164,"In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no  nonoseaenegation were reported among patients treated with Enbrel.\n', '\n', '    5.2        oselabeledaefromdruguse \n', '  Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of  oselabeledaefromdruguse  some presenting with  oselabeledaefromdruguse and some associated with permanent disability, and with  oselabeledaefromdruguse  Cases of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  other  oselabeledaefromdruguse  and new onset or exacerbation of  oselabeledaefromdruguse have been reported in postmarketing experience with Enbrel therapy.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
210,enbrel,210,5164,5203,Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system  notaecandidatepreexistingconditionorriskfactor [   see   Adverse Reactions   (     6.2     )]  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
211,enbrel,211,5203,5265,".\n', '\n', '    5.3       Malignancies\n', '\n', '   Lymphomas  \n', '\n', ' In the controlled portions of clinical trials of TNF-blocking agents, more cases of  oselabeledaeclasseffect have been observed among patients receiving a TNF blocker compared to control patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,enbrel,212,5265,5368,"During the controlled portions of Enbrel trials in adult patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication  2  oselabeledaefromdruguse were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months).\n', '\n', ' Among 6543 adult rheumatology ( notaecandidateindication   notaecandidateindication   notaecandidateindication  patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of  oselabeledaefromdruguse was 0.10 cases per 100 patient-years.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
213,enbrel,213,5368,5400,"This was 3-fold higher than the rate of  nonoseaeaeonlyasinstruction expected in the general U.S. population based on the Surveillance, Epidemiology, and End Results (SEER) Database.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,enbrel,214,5400,5492,"An increased rate of  nonoseaeaeonlyasinstruction up to several-fold has been reported in the  notaecandidateindication patient population, and may be further increased in patients with more severe disease activity.\n', '\n', ' Among 4410 adult  notaecandidateindication patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of  nonoseaeaeonlyasinstruction was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
215,enbrel,215,5492,5556,"No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials.\n', '\n', '  Leukemia  \n', '\n', ' Cases of  oselabeledaeclasseffect and chronic  oselabeledaeclasseffect  oselabeledaeclasseffect have been reported in association with postmarketing TNF-blocker use in  notaecandidateindication and other indications.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
216,enbrel,216,5556,5623,"Even in the absence of TNF-blocker therapy, patients with  notaecandidatepreexistingconditionorriskfactor may be at higher risk (approximately 2-fold) than the general population for the development of  nonoseaeaeonlyasinstruction \n', '\n', ' During the controlled portions of Enbrel trials, 2 cases of  oselabeledaefromdruguse were observed among 5445 (0.06 cases per 100 patient-years)",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
217,enbrel,217,5623,5755,"Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months).\n', '\n', ' Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of  oselabeledaefromdruguse was 0.03 cases per 100 patient-years.\n', '\n', '  Other Malignancies  \n', '\n', ' Information is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies.\n', '\n', ' For  nonoseaeaeonlyasinstruction other than  nonoseaeaeonlyasinstruction and  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,enbrel,218,5755,5757,nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,enbrel,219,5757,5783,there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,enbrel,220,5783,5829,Analysis of the  nonoseaeaeonlyasinstruction rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general U.S. population based on the SEER database and suggests no increase in rates over time.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,enbrel,221,5829,5862,"Whether treatment with Enbrel might influence the development and course of  nonoseaeaeonlyasinstruction in adults is unknown.\n', '\n', '  Melanoma and   Non  - M   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,enbrel,222,5862,5868,elanoma   S   kin   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,enbrel,223,5868,5875,C   ancer (NMSC)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,enbrel,224,5875,6013,"\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse has been reported in patients treated with TNF antagonists including etanercept.\n', '\n', ' Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of  oselabeledaefromdruguse was 0.043 cases per 100 patient-years.\n', '\n', ' Among 3306 adult rheumatology ( notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of  oselabeledaefromdruguse was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
225,enbrel,225,6013,6136,"Among 1245 adult  notaecandidatepreexistingconditionorriskfactor patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of  oselabeledaefromdruguse was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years.\n', '\n', ' Postmarketing cases of  oselabeledaefromdruguse have been reported very infrequently in patients treated with Enbrel.\n', '\n', ' Periodic skin examinations should be considered for all patients at increased risk for  nonoseaeaeonlyasinstruction \n', '\n', '  Pediatric Patients  \n', '\n', ""  oselabeledaefromdruguse  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
226,enbrel,226,6136,6175,"some  nonoseaegeneralterm  have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at <= 18 years of age), including Enbrel.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
227,enbrel,227,6175,6196,Approximately half the cases were  oselabeledaefromdruguse  including  oselabeledaeclasseffect and non-Hodgkin's  oselabeledaeclasseffect  oselabeledaeclasseffect  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,enbrel,228,6196,6229,The other cases represented a variety of different  oselabeledaefromdruguse and included rare  oselabeledaefromdruguse usually associated with  nonoseaeaeonlyasinstruction and  oselabeledaefromdruguse that are not usually observed in children and adolescents.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,enbrel,229,6229,6249,The  oselabeledaefromdruguse occurred after a median of 30 months of therapy (range 1 to 84 months).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,enbrel,230,6249,6259,Most of the patients were receiving concomitant  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,enbrel,231,6259,6400,"These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.\n"", '\n', ' In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, no  nonoseaenegation  including  nonoseaenegation or  nonoseaenegation  have been reported.\n', '\n', '  Post   m   arketing Use  \n', '\n', ' In global postmarketing adult and pediatric use,  oselabeledaefromdruguse and other  oselabeledaefromdruguse have been reported.\n', '\n', '    5.4       Patients With Heart Failure\n', '\n', '  Two clinical trials evaluating the use of Enbrel in the treatment of  notaecandidatepreexistingconditionorriskfactor were terminated early due to lack of efficacy.",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
232,enbrel,232,6400,6419,One of these studies suggested higher  nonoseaegeneralterm in Enbrel-treated patients compared to placebo [see   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
233,enbrel,233,6419,6435,Adverse React   ion   s       (     6.2     )]  .     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,enbrel,234,6435,6456,"There have been postmarketing reports of  oselabeledaefromdruguse , with and without identifiable precipitating factors, in patients taking Enbrel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,enbrel,235,6456,6482,There have also been rare (< 0.1%) reports of  oselabeledaefromdruguse  including  oselabeledaefromdruguse in patients without known preexisting  notaecandidateother  ,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
236,enbrel,236,6482,6494,Some of these patients have been under 50 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,enbrel,237,6494,6569,"Physicians should exercise caution when using Enbrel in patients who also have  notaecandidatepreexistingconditionorriskfactor  and monitor patients carefully.\n', '\n', '    5.5        oselabeledaefromdruguse \n', '  Rare (< 0.1%) reports of  oselabeledaefromdruguse  including very rare (< 0.01%) reports of  oselabeledaefromdruguse  some with a  nonoseaegeneralterm outcome, have been reported in patients treated with Enbrel.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
238,enbrel,238,6569,6578,The causal relationship to Enbrel therapy remains unclear.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,enbrel,239,6578,6647,"Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant  notaecandidatepreexistingconditionorriskfactor  All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (eg,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  while on Enbrel.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
240,enbrel,240,6647,6685,"Discontinuation of Enbrel therapy should be considered in patients with confirmed significant  nonoseaeaeonlyasinstruction \n', '\n', ' Two percent of patients treated concurrently with Enbrel and anakinra developed  nonoseaeaefromdruginteraction ( nonoseaeaefromdruginteraction .",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
241,enbrel,241,6685,6754,"While  nonoseaeaefromdruginteraction  one patient developed  nonoseaeaefromdruginteraction that resolved with antibiotic therapy.\n', '\n', '    5.6       Hepatitis B Reactivation\n', '\n', '   oselabeledaefromdruguse in patients who were previously  notaecandidatepreexistingconditionorriskfactor  and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
242,enbrel,242,6754,6773,"In some instances,  oselabeledaefromdruguse occurring in conjunction with TNF-blocker therapy has been  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
243,enbrel,243,6773,6818,The majority of these reports have occurred in patients concomitantly receiving other  nonoseaeaeonlyasinstruction  which may also contribute to  nonoseaeaeonlyasinstruction  Patients at risk for  nonoseaeaeonlyasinstruction should be evaluated for prior evidence of  nonoseaeaeonlyasinstruction before initiating TNF-blocker therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,enbrel,244,6818,6834,Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
245,enbrel,245,6834,6870,Adequate data are not available on the safety or efficacy of treating patients who are carriers of  nonoseaeaeonlyasinstruction with anti-viral therapy in conjunction with TNF-blocker therapy to prevent  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,enbrel,246,6870,6904,Patients previously infected with  notaecandidatepreexistingconditionorriskfactor and requiring treatment with Enbrel should be closely monitored for clinical and laboratory signs of  nonoseaeaeonlyasinstruction throughout therapy and for several months following termination of therapy.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
247,enbrel,247,6904,6929,In patients who develop  oselabeledaefromdruguse  consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,enbrel,248,6929,6944,The safety of resuming Enbrel therapy after  nonoseaeaeonlyasinstruction is controlled is not known.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,enbrel,249,6944,7002,"Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.\n', '\n', '    5.7       Allergic Reactions  \n', '\n', '   oselabeledaefromdruguse associated with administration of Enbrel during clinical trials have been reported in < 2% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,enbrel,250,7002,7034,"If an  nonoseaeaeonlyasinstruction or other serious  nonoseaeaeonlyasinstruction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated.\n', '\n', ' Caution:  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,enbrel,251,7034,7123,"The following components contain dry natural rubber (a derivative of latex), which may cause  oselabeledaefromdrugcomponent in individuals sensitive to  oselabeledaefromdrugcomponent  the needle cover of the prefilled syringe, the needle cover within the white cap of the SureClick autoinjector, and the needle cover within the purple cap of the Enbrel Mini cartridge.\n', '\n', '    5.8       Immunizations\n', '\n', '  Live vaccines should not be given concurrently with Enbrel.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,enbrel,252,7123,7221,"It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [   see       Drug Interactions (     7.1     )       and   Use in   Specific Populations (     8.4     )   ]  .\n', '\n', '    5.9       Autoimmunity\n', '\n', '  Treatment with Enbrel may result in the  oselabeledaefromdruguse [see Adverse Reactions (     6.1     )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,enbrel,253,7221,7260,"and, rarely (< 0.1%), in the development of a  oselabeledaefromdruguse or  oselabeledaefromdruguse [see Adverse Reactions (     6.2     )]  , which may resolve following withdrawal of Enbrel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,enbrel,254,7260,7319,"If a patient develops symptoms and findings suggestive of a  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated.\n', '\n', '    5.10       Immunosuppression\n', '\n', '  TNF mediates  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction responses.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,enbrel,255,7319,7334,"TNF-blocking agents, including Enbrel, affect host defenses against  nonoseaeaeonlyasinstruction   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,enbrel,256,7334,7353,The effect of TNF inhibition on the development and course of  nonoseaeaeonlyasinstruction is not fully understood.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,enbrel,257,7353,7384,"In a study of 49 patients with  notaecandidatepreexistingconditionorriskfactor treated with Enbrel, there was no evidence of  nonoseaenegation   nonoseaenegation  or  nonoseaenegation  [   see   ",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
258,enbrel,258,7384,7415,"Warnings   and Precautions   (     5.1     ,     5.3     )       and   Adverse Reactions   (     6.1     )   ]  .\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,enbrel,259,7415,7437,"'\n', ""    5.11       Use in Wegener's Granulomatosis Patients\n"", '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,enbrel,260,7437,7453,The use of Enbrel in patients with  notaecandidatecontraindication receiving  nonoseaeaeonlyasinstruction is not recommended.,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0
261,enbrel,261,7453,7554,"In a study of patients with  notaecandidatepreexistingconditionorriskfactor  the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of  nonoseaeaefromdruginteraction and was not associated with improved clinical outcomes when compared with standard therapy alone [see   Drug Interactions (     7.3     )   ]  .\n', '\n', '    5.12       Use with Anakinra or Abatacept\n', '\n', '  Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions (     7.2     )]  ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
262,enbrel,262,7554,7582,".\n', '\n', '    5.13       Use in Patients with Moderate to Severe Alcoholic Hepatitis\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,enbrel,263,7582,7627,In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe  notaecandidatepreexistingconditionorriskfactor  the  nonoseaegeneralterm rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months.,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
264,enbrel,264,7627,7644,Physicians should use caution when using Enbrel in patients with moderate to severe  notaecandidatepreexistingconditionorriskfactor '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,belviq,0,0,58,"['    6 ADVERSE REACTIONS\n', '\n', '  The following important adverse reactions are described below and elsewhere in labeling:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse or  oselabeledaefromdruguse [ see Warnings and Precautions (  5.1  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,belviq,1,58,76,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.2  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,belviq,2,76,94,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.3  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,belviq,3,94,112,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.4  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,belviq,4,112,130,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.5  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,belviq,5,130,148,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.7  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,belviq,6,148,166,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.8  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,belviq,7,166,184,"\n', ' *   oselabeledaefromdruguse [ see Warnings and Precautions (  5.9  ) ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,belviq,8,184,239,"\n', '      EXCERPT:   Most common adverse reactions (greater than 5%) in non-diabetic patients are headache, dizziness, fatigue, nausea, dry mouth, and constipation, and in diabetic patients are hypoglycemia, headache, back pain, cough, and fatigue.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,belviq,9,239,459,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at 1-888-274-2378 or FDA at 1-800-FDA-1088 or at      www.fda.gov/medwatch    .\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  In the BELVIQ placebo-controlled clinical database of trials of at least one year in duration, of 6888 patients (3451 BELVIQ vs. 3437 placebo; age range 18-66 years, 79.3% women, 66.6% Caucasians, 19.2% Blacks, 11.8% Hispanics, 2.4% other, 7.4% type 2  notaecandidatepreexistingconditionorriskfactor , a total of 1969 patients were exposed to BELVIQ 10 mg twice daily for 1 year and 426 patients were exposed for 2 years.\n', '\n', '\n', '\n', ' In clinical trials of at least one year in duration, 8.6% of patients treated with BELVIQ prematurely discontinued treatment due to adverse reactions, compared with 6.7% of placebo-treated patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
10,belviq,10,459,642,"The most common adverse reactions leading to discontinuation more often among BELVIQ treated patients than placebo were  oselabeledaefromdruguse (1.3% vs. 0.8%),  oselabeledaefromdruguse (0.9% vs. 0.5%) and  oselabeledaefromdruguse (0.7% vs. 0.2%).\n', '\n', '\n', '\n', '       Most Common Adverse Reactions  \n', '\n', '\n', '\n', ' Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The most common adverse reactions for non-diabetic patients (greater than 5% and more commonly than placebo) treated with BELVIQ compared to placebo were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,belviq,11,642,730,"The most common adverse reactions for diabetic patients were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  Adverse reactions that were reported by greater than or equal to 2% of patients and were more frequently reported by patients taking BELVIQ compared to placebo are summarized in Table 2 (non-diabetic subjects) and Table 3 (subjects with type 2 diabetes mellitus).\n', '\n', '\n', '\n', ' Table 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,belviq,12,730,755,Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients without Diabetes Mellitus,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,belviq,13,755,777,"\n', '    Adverse Reaction                                              Number of patients (%)     \n', '    BELVIQ    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,belviq,14,777,781,10 mg BID    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,belviq,15,781,785,N=3195                                 Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,belviq,16,785,819,"N=3185     \n', '    nonoseaegeneralterm                                                                               \n', '        oselabeledaefromdruguse                                                    264 (8.3)             170 (5.3)            \n', '        oselabeledaefromdruguse                                                  207",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,belviq,17,819,828,(6.5)             179 (5.6)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,belviq,18,828,853,"\n', '        oselabeledaefromdruguse                                              186 (5.8)             125 (3.9)            \n', '        oselabeledaefromdruguse                                                 169",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,belviq,19,853,863,(5.3)             74 (2.3)             \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,belviq,20,863,879,"', '        oselabeledaefromdruguse                                                  122 (3.8)             83 (2.6)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,belviq,21,879,896,"\n', '    nonoseaegeneralterm                                                     \n', '        oselabeledaefromdruguse                                                   229 (7.2",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,belviq,22,896,954,")             114 (3.6)            \n', '    nonoseaegeneralterm And Infestations                                                                              \n', '        oselabeledaefromdruguse                         439 (13.7)            391 (12.3)           \n', '        oselabeledaefromdruguse                                           414 (13.0)            381 (12.0)           \n', '        oselabeledaefromdruguse                                   207",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,belviq,23,954,963,(6.5)             171 (5.4)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,belviq,24,963,975,"\n', '    nonoseaegeneralterm And Connective Tissue  nonoseaegeneralterm                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,belviq,25,975,992,"\n', '        oselabeledaefromdruguse                                                 201 (6.3)             178 (5.6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,belviq,26,992,999,"\n', '        oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,belviq,27,999,1009,65 (2.0)              43 (1.4)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,belviq,28,1009,1016,"\n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,belviq,29,1016,1029,"\n', '        oselabeledaefromdruguse                                                  537 (16.8)            321",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,belviq,30,1029,1050,"(10.1)           \n', '        oselabeledaefromdruguse                                                 270 (8.5)             122 (3.8)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,belviq,31,1050,1093,"\n', '    nonoseaegeneralterm  Thoracic And Mediastinal  nonoseaegeneralterm                                                          \n', '        oselabeledaefromdruguse                                                     136 (4.3)             109 (3.4)            \n', '        oselabeledaefromdruguse                                        111 (3.5)             80",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,belviq,32,1093,1119,"(2.5)             \n', '        oselabeledaefromdruguse                                          93 (2.9)              78 (2.4)             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,belviq,33,1119,1146,"nonoseaegeneralterm                                                                   \n', '        oselabeledaefromdruguse                                                      67 (2.1)              58 (1.8)             \n', '        Table 3.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,belviq,34,1146,1173,Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients with Type 2 Diabetes Mellitus,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,belviq,35,1173,1185,"\n', '                                                                  Number of patients (%)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,belviq,36,1185,1193,"\n', '    Adverse Reaction                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,belviq,37,1193,1195,BELVIQ    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,belviq,38,1195,1197,10 mg,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,belviq,39,1197,1201,BID    N=256       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,belviq,40,1201,1205,Placebo    N=252     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,belviq,41,1205,1229,"\n', '    nonoseaegeneralterm                                                                               \n', '        oselabeledaefromdruguse                                                    24 (9.4)              20 (7.9)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,belviq,42,1229,1243,"\n', '        oselabeledaefromdruguse                                                 7 (2.7)               0                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,belviq,43,1243,1317,"\n', '    nonoseaegeneralterm                                                     \n', '        oselabeledaefromdruguse                                                   19 (7.4)              10 (4.0)             \n', '        oselabeledaefromdruguse                                          12 (4.7)              6 (2.4)              \n', '    nonoseaegeneralterm                                                                                  \n', '        oselabeledaefromdruguse                                          8 (3.1)               2 (0.8)              \n', '    nonoseaegeneralterm And Infestations                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,belviq,44,1317,1334,"\n', '        oselabeledaefromdruguse                                           29 (11.3)             25 (9.9)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,belviq,45,1334,1375,"\n', '        oselabeledaefromdruguse                                   23 (9.0)              15 (6.0)             \n', '        oselabeledaefromdruguse                                           8 (3.1)               5 (2.0)              \n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
46,belviq,46,1375,1383,"\n', '        oselabeledaefromdruguse                                              75",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,belviq,47,1383,1421,"(29.3)             53 (21.0)            \n', '        oselabeledaefromdruguse                            7 (2.7)               2 (0.8)              \n', '        oselabeledaefromdruguse                                        6 (2.3)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,belviq,48,1421,1422,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,belviq,49,1422,1426,(0.4)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,belviq,50,1426,1438,"\n', '    nonoseaegeneralterm And Connective Tissue  nonoseaegeneralterm                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,belviq,51,1438,1455,"\n', '        oselabeledaefromdruguse                                                 30 (11.7)             20 (7.9)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,belviq,52,1455,1537,"\n', '        oselabeledaefromdruguse                                             12 (4.7)              9 (3.6)              \n', '    nonoseaegeneralterm                                                                                 \n', '        oselabeledaefromdruguse                                                  37 (14.5)             18 (7.1)             \n', '        oselabeledaefromdruguse                                                 18 (7.0)              16 (6.3)             \n', '    nonoseaegeneralterm                                                                                    \n', '        oselabeledaefromdruguse                                                   9 (3.5)               8 (3.2)              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,belviq,53,1537,1545,"\n', '        oselabeledaefromdruguse                                                  9",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,belviq,54,1545,1554,(3.5)               6 (2.4)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,belviq,55,1554,1583,"\n', '        oselabeledaefromdruguse                                                    7 (2.7)               3 (1.2)              \n', '        oselabeledaefromdruguse                                                6 (2.3)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,belviq,56,1583,1588,5 (2.0)              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,belviq,57,1588,1595,"\n', '    nonoseaegeneralterm                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,belviq,58,1595,1619,"\n', '        oselabeledaefromdruguse                                                     21 (8.2)              11 (4.4)             \n', '    nonoseaegeneralterm                                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,belviq,59,1619,1645,"\n', '        oselabeledaefromdruguse                                              13 (5.1)              8 (3.2)              \n', '               Other Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,belviq,60,1645,1698,"\n', ' \n', '\n', '   Serotonin-associated Adverse Reactions  \n', '\n', '\n', '\n', ' SSRIs, SNRIs, bupropion, tricyclic antidepressants, and MAOIs were excluded from the BELVIQ trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,belviq,61,1698,1741,"Triptans and dextromethorphan were permitted: 2% and 15%, respectively, of patients without diabetes and 1% and 12%, respectively, of patients with type 2 diabetes experienced concomitant use at some point during the trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,belviq,62,1741,1776,Two patients treated with BELVIQ in the clinical program experienced a constellation of symptoms and signs consistent with  oselabeledaefromdruguse  including one patient on concomitant dextromethorphan who reported an event of  nonoseaeaefromdruginteraction  ,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
63,belviq,63,1776,1811,Some symptoms of possible serotonergic etiology that are included in the criteria for  nonoseaeaeonlyasinstruction were reported by patients treated with BELVIQ and placebo during clinical trials of at least 1 year in duration.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,belviq,64,1811,1878,"In both groups,  oselabeledaefromdruguse were the most frequent of these events (1.0% vs. 0.2%, respectively), followed by  oselabeledaefromdruguse (0.3% vs. 0.2%),  oselabeledaefromdruguse (0.2% vs. less than 0.1%),  oselabeledaefromdruguse (0.1% vs. 0.1%) and  oselabeledaefromdruguse (0.1% vs. 0.2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,belviq,65,1878,2000,"Because  nonoseaeaeonlyasinstruction has a very low incidence, an association between BELVIQ and  nonoseaeaeonlyasinstruction cannot be excluded on the basis of clinical trial results [  see Warnings and Precautions (  5.1  )  ].\n', '\n', '\n', '\n', '   Hypoglycemia in Patients with Type 2 Diabetes  \n', '\n', '\n', '\n', ' In a clinical trial of patients with  notaecandidatepreexistingconditionorriskfactor   oselabeledaefromdruguse requiring the assistance of another person occurred in 4 (1.6%) of BELVIQ-treated patients and in 1 (0.4%) placebo-treated patient.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
66,belviq,66,2000,2021,"Of these 4 BELVIQ-treated patients, all were concomitantly using a sulfonylurea (with or without metformin).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,belviq,67,2021,2032,BELVIQ has not been studied in patients taking insulin.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,belviq,68,2032,2044,oselabeledaefromdruguse defined as  nonoseaeaeonlyasinstruction occurred in 19 (7.4%),1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,belviq,69,2044,2077,"BELVIQ-treated patients and 16 (6.3%) placebo-treated patients.\n', '\n', '\n', '\n', '   Cognitive Impairment  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,belviq,70,2077,2158,"\n', '\n', '\n', '\n', ' In clinical trials of at least 1-year duration, adverse reactions related to  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse  oselabeledaefromdruguse concentration/ oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred in 2.3% of patients taking BELVIQ and 0.7% of patients taking placebo.\n', '\n', '\n', '\n', '   Psychiatric Disorders  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,belviq,71,2158,2225,"\n', '\n', '\n', '\n', '  oselabeledaefromdruguse leading to hospitalization or drug withdrawal occurred more frequently in patients treated with BELVIQ (2.2%) as compared to placebo (1.1%) in non-diabetic patients.\n', '\n', '\n', '\n', '    oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,belviq,72,2225,2271,"In short-term studies with healthy individuals, the incidence of  nonoseaeaefromofflabel following supratherapeutic doses of BELVIQ (40 and 60 mg) was increased as compared to placebo [  see Drug Abuse and Dependence (  9.2  )  ].",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
73,belviq,73,2271,2321,"In clinical trials of at least 1-year duration in  notaecandidateindication patients,  oselabeledaefromdruguse was observed in 0.17% of patients taking BELVIQ and 0.03% taking placebo.\n', '\n', '\n', '\n', '    oselabeledaefromdruguse and  oselabeledaefromdruguse   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
74,belviq,74,2321,2368,"In trials of at least one year in duration, reports of  oselabeledaefromdruguse  oselabeledaefromdruguse occurred in 2.6% BELVIQ-treated vs. 2.4% placebo-treated and  oselabeledaefromdruguse occurred in 0.6% BELVIQ-treated vs. 0.4% placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,belviq,75,2368,2394,"1.3% of BELVIQ patients vs. 0.6% of placebo patients discontinued drug due to  oselabeledaefromdruguse ,  oselabeledaefromdruguse  or suicidal ideation- oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,belviq,76,2394,2439,"oselabeledaefromdruguse related events.\n', '\n', '\n', '\n', '   Laboratory Abnormalities  \n', '\n', '\n', '\n', '   Lymphocyte and Neutrophil Counts.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,belviq,77,2439,2468,"In clinical trials of at least 1-year duration,  oselabeledaefromdruguse were  oselabeledaefromdruguse in 12.2% of patients taking BELVIQ and 9.0% taking placebo, and  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,belviq,78,2468,2496,"oselabeledaefromdruguse in 5.6% and 4.3%, respectively.\n', '\n', '\n', '\n', '   Hemoglobin.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,belviq,79,2496,2544,"In clinical trials of at least 1-year duration, 10.4% of patients taking BELVIQ and 9.3% taking placebo had  oselabeledaefromdruguse at some point during the trials.\n', '\n', '\n', '\n', '   Prolactin.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,belviq,80,2544,2682,"In clinical trials,  oselabeledaefromdruguse greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal, occurred in 6.7%, 1.7%, and 0.1% of BELVIQ-treated patients and 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively.\n', '\n', '\n', '\n', '   Eye disorders  .\n', '\n', '\n', '\n', ' More patients on BELVIQ reported an  oselabeledaefromdruguse than patients on placebo in clinical trials of patients without  notaecandidateother (4.5% vs. 3.0%) and with  notaecandidatepreexistingconditionorriskfactor (6.3% vs. 1.6%).",0,0,1,0,0,0,0,0,0,0,0,0,0,1,0
81,belviq,81,2682,2714,In the population without  notaecandidateother  events of  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse occurred in BELVIQ-treated patients at an incidence greater than that of placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
82,belviq,82,2714,2827,"In the population with  notaecandidatepreexistingconditionorriskfactor   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse infections,  oselabeledaefromdruguse  oselabeledaefromdruguse infections, irritations, and  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse occurred in BELVIQ-treated patients at an incidence greater than placebo.\n', '\n', '\n', '\n', '       Echocardiographic Safety Assessments  \n', '\n', '\n', '\n', ' The possible occurrence of  nonoseaeaeonlyasinstruction was prospectively evaluated in 7794 patients in three clinical trials of at least one year in duration, 3451 of whom took BELVIQ 10 mg twice daily.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
83,belviq,83,2827,2859,The primary echocardiographic safety parameter was the proportion of patients who developed echocardiographic criteria of mild or greater  nonoseaeaeonlyasinstruction and/or moderate or greater  nonoseaeaeonlyasinstruction from baseline to 1 year.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,belviq,84,2859,2882,"At 1 year, 2.4% of patients who received BELVIQ and 2.0% of patients who received placebo developed  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,belviq,85,2882,2896,The relative risk for  oselabeledaefromdruguse with BELVIQ is summarized in Table 4.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,belviq,86,2896,2943,"BELVIQ was not studied in patients with  notaecandidatepreexistingconditionorriskfactor or hemodynamically-significant  notaecandidatepreexistingconditionorriskfactor [  see Warnings and Precautions (  5.2  )  ].\n', '\n', '\n', '\n', ' Table 4.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
87,belviq,87,2943,2955,Incidence of FDA-Defined Valvulopathy at Week 52 by Treatment Group1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,belviq,88,2955,3020,"\n', '    1  Patients without valvulopathy at baseline who received study medication and had a post-baseline echocardiogram; ITT-intention-to-treat; LOCF-last observation carried forward   \n', '  \n', '                                  Study 1       Study 2       Study 3     \n', '                                  BELVIQ    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,belviq,89,3020,3028,N=1278       Placebo    N=1191       BELVIQ    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,belviq,90,3028,3032,N=1208       Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,belviq,91,3032,3040,N=1153       BELVIQ    N=210       Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,belviq,92,3040,3103,"N=209     \n', '    FDA-defined  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions: The safety of coadministration with other serotonergic or antidopaminergic agents has not been established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,belviq,93,3103,3113,Manage with immediate BELVIQ discontinuation and provide supportive treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,belviq,94,3113,3128,"(  5.1  ) \n', ' *  Valvular heart disease:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,belviq,95,3128,3144,If signs or symptoms develop consider BELVIQ discontinuation and evaluate the patient for possible valvulopathy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,belviq,96,3144,3149,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,belviq,97,3149,3153,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,belviq,98,3153,3166,*  Cognitive Impairment: May cause disturbances in attention or memory.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,belviq,99,3166,3177,Caution with use of hazardous machinery when starting BELVIQ treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,belviq,100,3177,3196,"(  5.3  ) \n', ' *  Psychiatric Disorders, including euphoria and dissociation:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,belviq,101,3196,3207,Do not exceed recommended dose of 10 mg twice daily.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,belviq,102,3207,3225,"(  5.4  ) \n', ' *  Monitor for depression or suicidal thoughts.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,belviq,103,3225,3230,Discontinue if symptoms develop.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,belviq,104,3230,3252,"(  5.4  ) \n', ' *  Use of Antidiabetic Medications: weight loss may cause hypoglycemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,belviq,105,3252,3256,Monitor blood glucose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,belviq,106,3256,3266,BELVIQ has not been studied in patients taking insulin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,belviq,107,3266,3292,"(  5.5  ) \n', ' *  Priapism: Patients should seek emergency treatment if an erection lasts >4 hours.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,belviq,108,3292,3302,Use BELVIQ with caution in patients predisposed to priapism.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,belviq,109,3302,3357,"(  5.6  ) \n', '    \n', ' \n', '\n', '   5.1 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions\n', '\n', '\n', '\n', ""  BELVIQ is a serotonergic drug.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,belviq,110,3357,3541,"The development of a potentially life-threatening  oselabeledaeclasseffect or  oselabeledaeclasseffect (NMS)-like reactions have been reported during use of serotonergic drugs, including, but not limited to, selective serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, dietary supplements such as St. John's Wort and tryptophan, drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs]), dextromethorphan, lithium, tramadol, antipsychotics or other dopamine antagonists, particularly when used in combination [ see Drug Interactions (  7.1  )  ].\n"", '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaegeneralterm (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .  ",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
111,belviq,111,3541,3691,"nonoseaeaeonlyasinstruction  in its most severe form, can resemble  nonoseaeaeonlyasinstruction  which includes  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication with possible  nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Patients should be monitored for the emergence of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction signs and symptoms.\n', '\n', '\n', '\n', ' The safety of BELVIQ when coadministered with other serotonergic or antidopaminergic agents, including antipsychotics, or drugs that impair metabolism of serotonin, including MAOIs, has not been systematically evaluated and has not been established.\n', '\n', '\n', '\n', ' If concomitant administration of BELVIQ with an agent that affects the serotonergic neurotransmitter system is clinically warranted, extreme caution and careful observation of the patient is advised, particularly during treatment initiation and dose increases.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
112,belviq,112,3691,3810,"Treatment with BELVIQ and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated [ see Adverse Reactions (  6.1  ) and Drug Interactions (  7.1  )  ].\n', '\n', '\n', '\n', '    5.2 Valvular Heart Disease\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  oselabeledaeclasseffect primarily affecting the  oselabeledaeclasseffect  oselabeledaeclasseffect primarily affecting the mitral and/or  oselabeledaeclasseffect valves, has been reported in patients who took serotonergic drugs with 5-HT2Breceptor agonist activity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,belviq,113,3810,3828,The etiology of the  nonoseaeaeonlyasinstruction is thought to be activation of 5-HT2Breceptors on cardiac interstitial cells.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,belviq,114,3828,3842,"At therapeutic concentrations, BELVIQ is selective for 5-HT2Creceptors as compared to 5-HT2Breceptors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,belviq,115,3842,4069,"In clinical trials of 1-year duration, 2.4% of patients receiving BELVIQ and 2.0% of patients receiving placebo developed echocardiographic criteria for  oselabeledaefromdruguse at one year (mild or greater  oselabeledaefromdruguse and/or moderate or greater  oselabeledaefromdruguse : none of these patients was symptomatic [ see Adverse Reactions (  6.1  ) see Clinical Pharmacology (  12.1  )  ].\n', '\n', '\n', '\n', ' BELVIQ has not been studied in patients with  notaecandidatepreexistingconditionorriskfactor or hemodynamically-significant  notaecandidatepreexistingconditionorriskfactor  Preliminary data suggest that 5HT2Breceptors may be overexpressed in  nonoseaeaeonlyasinstruction  Therefore, BELVIQ should be used with caution in patients with  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' BELVIQ should not be used in combination with serotonergic and dopaminergic drugs that are potent 5-HT2Breceptor agonists and are known to increase the risk for  nonoseaeaeonlyasinstruction (e.g., cabergoline).\n', '\n', '\n', '\n', ' Patients who develop signs or symptoms of  nonoseaeaeonlyasinstruction  including  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or a new  nonoseaeaeonlyasinstruction while being treated with BELVIQ should be evaluated and discontinuation of BELVIQ should be considered.\n',",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
116,belviq,116,4069,4160,"'\n', '\n', '\n', '    5.3 Cognitive Impairment\n', '\n', '\n', '\n', '  In clinical trials of at least one year in duration,  oselabeledaefromdruguse  oselabeledaefromdruguse in attention and  oselabeledaefromdruguse were reported adverse reactions associated with 1.9% of patients treated with BELVIQ and 0.5% of patients treated with placebo, and led to discontinuation in 0.3% and 0.1% of these patients, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,belviq,117,4160,4337,"Other reported adverse reactions associated with BELVIQ in clinical trials included  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [ see Adverse Reactions (  6.1  )  ].\n', '\n', '\n', '\n', ' Since BELVIQ has the potential to  oselabeledaefromdruguse  patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that BELVIQ therapy does not affect them adversely [ see Patient Counseling Information (  17  )  ].\n', '\n', '\n', '\n', '    5.4  oselabeledaefromdruguse \n', '\n', '\n', '  Events of  nonoseaeaefromofflabel   nonoseaeaefromofflabel  and  nonoseaeaefromofflabel were seen with BELVIQ at supratherapeutic doses in short-term studies [ see Adverse Reactions (  6.1  ), Drug Abuse and Dependence (  9.2  ), and Overdosage (  10  )  ].",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
118,belviq,118,4337,4374,"In clinical trials of at least 1-year in duration, 6 patients (0.2%) treated with BELVIQ developed  oselabeledaefromdruguse  as compared with 1 patient (<0.1%) treated with placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,belviq,119,4374,4452,"Doses of BELVIQ should not exceed 10 mg twice a day.\n', '\n', '\n', '\n', ' Some drugs that target the central nervous system have been associated with  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  Patients treated with BELVIQ should be monitored for the emergence or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction  and/or any unusual  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction mood or  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,belviq,120,4452,4477,Discontinue BELVIQ in patients who experience  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction [ see Adverse Reactions (  6.1  )  ],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,belviq,121,4477,4562,".\n', '\n', '\n', '\n', '    5.5 Potential Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus on Anti-diabetic Therapy\n', '\n', '\n', '\n', '   nonoseaeaeonlyasinstruction may increase the risk of  nonoseaeaeonlyasinstruction in patients with  notaecandidatepreexistingconditionorriskfactor treated with insulin and/or insulin secretagogues (e.g., sulfonylureas);  oselabeledaefromdruguse was observed in clinical trials with BELVIQ.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
122,belviq,122,4562,4572,BELVIQ has not been studied in combination with insulin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,belviq,123,4572,4821,"Measurement of blood glucose levels prior to starting BELVIQ and during BELVIQ treatment is recommended in patients with  notaecandidatepreexistingconditionorriskfactor  Decreases in medication doses for anti-diabetic medications which are non-glucose-dependent should be considered to mitigate the risk of  nonoseaeaeonlyasinstruction  If a patient develops  nonoseaeaeonlyasinstruction after starting BELVIQ, appropriate changes should be made to the anti-diabetic drug regimen [ see Adverse Reactions (  6.1  )  ].\n', '\n', '\n', '\n', '    5.6 Priapism\n', '\n', '\n', '\n', '   oselabeledaeclasseffect ( oselabeledaeclasseffect  oselabeledaeclasseffect in duration) is a potential effect of 5-HT2Creceptor agonism.\n', '\n', '\n', '\n', ' If not treated promptly,  nonoseaeaeonlyasinstruction can result in irreversible  nonoseaeaeonlyasinstruction  Men who have an  nonoseaeaeonlyasinstruction  whether painful or not, should immediately discontinue the drug and seek emergency medical attention.\n', '\n', '\n', '\n', ' BELVIQ should be used with caution in men who have conditions that might predispose them to  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction , or in men with anatomical deformation of the  nonoseaeaefromdruginteraction (e.g.,  nonoseaeaefromdruginteraction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction .",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
124,belviq,124,4821,4845,"There is limited experience with the combination of BELVIQ and medication indicated for  nonoseaeaeonlyasinstruction (e.g., phosphodiesterase type 5 inhibitors).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,belviq,125,4845,4915,"Therefore, the combination of BELVIQ and these medications should be used with caution.\n', '\n', '\n', '\n', '    5.7 Heart Rate Decreases\n', '\n', '\n', '\n', '  In clinical trials of at least 1-year in duration, the  nonoseaeaeratelteqplacebo (HR) was  nonoseaeaeratelteqplacebo .",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
126,belviq,126,4915,4939,nonoseaeaeratelteqplacebo beats per minute (bpm) in BELVIQ and -0 nonoseaeaeratelteqplacebo  bpm in placebo-treated patients without diabetes and -2.,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
127,belviq,127,4939,4985,nonoseaeaeratelteqplacebo  oselabeledaefromdruguse (HR) was  oselabeledaefromdruguse (bpm) in BELVIQ and -0.4 bpm in placebo-treated patients without diabetes and -2.0 beats per minute (bpm) in BELVIQ and -0.4 bpm in placebo-treated patients with  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0
128,belviq,128,4985,5023,The incidence of  oselabeledaefromdruguse was 5.3% in BELVIQ and 3.2% in placebo-treated patients without diabetes and 3.6% in BELVIQ and 2.0% in placebo-treated patients with type 2 diabetes.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,belviq,129,5023,5048,"In the combined population, adverse reactions of  oselabeledaefromdruguse occurred in 0.3% of BELVIQ and 0.1% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,belviq,130,5048,5082,"Use with caution in patients with  nonoseaeaeonlyasinstruction or a history of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.8  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,belviq,131,5082,5145,"\n', '\n', '\n', '  In clinical trials of at least one year in duration, adverse reactions of  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  were reported in 0.4% of patients treated with BELVIQ as compared to 0.2% of patients treated with placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,belviq,132,5145,5194,Adverse reactions of  oselabeledaefromdruguse (including  oselabeledaefromdruguse and  oselabeledaefromdruguse  oselabeledaefromdruguse hemoglobin and  oselabeledaefromdruguse  were reported by 1.3% of patients treated with BELVIQ as compared to 1.2% treated with placebo [ see Adverse Reactions (  6.1  )  ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,belviq,133,5194,5245,"Consider periodic monitoring of complete blood count during treatment with BELVIQ.\n', '\n', '\n', '\n', '    5.9 Prolactin Elevation\n', '\n', '\n', '\n', '  Lorcaserin moderately  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,belviq,134,5245,5343,"In a subset of placebo-controlled clinical trials of at least one year in duration,  oselabeledaefromdruguse greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal, measured both before and 2 hours after dosing, occurred in 6.7%, 1.7%, and 0.1% of BELVIQ-treated patients and 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively [ see Adverse Reactions (  6.1  )  ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,belviq,135,5343,5364,"Prolactin should be measured when symptoms and signs of  nonoseaeaeonlyasinstruction are suspected (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,belviq,136,5364,5380,There was one patient treated with BELVIQ who developed a  oselabeledaefromdruguse during the trial.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,belviq,137,5380,5454,"The relationship of BELVIQ to the  nonoseaeaeonlyasinstruction in this patient is unknown.\n', '\n', '\n', '\n', '    5.10 Pulmonary Hypertension\n', '\n', '\n', '\n', '  Certain centrally-acting weight loss agents that act on the serotonin system have been associated with  oselabeledaeclasseffect  a rare but lethal disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,belviq,138,5454,5483,"Because of the low incidence of this disease, the clinical trial experience with BELVIQ is inadequate to determine if BELVIQ increases the risk for  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,onglyza,0,0,17,"['    6 ADVERSE REACTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,onglyza,1,17,55,"*    Adverse reactions reported in >=5% of patients treated with ONGLYZA and more commonly than in patients treated with placebo are upper respiratory tract infection, urinary tract infection, and headache.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,onglyza,2,55,59,(6.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,onglyza,3,59,98,"\n', ' *    Peripheral edema was reported more commonly in patients treated with the combination of ONGLYZA and a thiazolidinedione (TZD) than in patients treated with the combination of placebo and TZD.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,onglyza,4,98,102,(6.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,onglyza,5,102,135,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,onglyza,6,135,168,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,onglyza,7,168,277,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '     Adverse Reactions with Monotherapy and with Add-On Combination Therapy  \n', '\n', '  In two placebo-controlled monotherapy trials of 24-weeks duration, patients were treated with ONGLYZA 2.5 mg daily, ONGLYZA 5 mg daily, and placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,onglyza,8,277,313,"Three 24-week, placebo-controlled, add-on combination therapy trials were also conducted: one with metformin, one with a thiazolidinedione (pioglitazone or rosiglitazone), and one with glyburide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,onglyza,9,313,340,"In these three trials, patients were randomized to add-on therapy with ONGLYZA 2.5 mg daily, ONGLYZA 5 mg daily, or placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,onglyza,10,340,365,A saxagliptin 10 mg treatment arm was included in one of the monotherapy trials and in the add-on combination trial with metformin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,onglyza,11,365,472,"The 10 mg dosage is not an approved dosage.\n', '\n', '\n', '\n', ' In a prespecified pooled analysis of the 24-week data (regardless of glycemic rescue) from the two monotherapy trials, the add-on to metformin trial, the add-on to thiazolidinedione (TZD) trial, and the add-on to glyburide trial, the overall incidence of adverse events in patients treated with ONGLYZA 2.5 mg and ONGLYZA 5 mg was similar to placebo (72% and 72.2% versus 70.6%, respectively).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,onglyza,12,472,506,"Discontinuation of therapy due to adverse events occurred in 2.2%, 3.3%, and 1.8% of patients receiving ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,onglyza,13,506,596,"The most common adverse events (reported in at least 2 patients treated with ONGLYZA 2.5 mg or at least 2 patients treated with ONGLYZA 5 mg) associated with premature discontinuation of therapy included  oselabeledaefromdruguse (0.1% and 0.5% versus 0%, respectively),  oselabeledaefromdruguse (0.2% and 0.3% versus 0.3%),  oselabeledaefromdruguse (0.3% and 0% versus 0%), and  oselabeledaefromdruguse (0.1% and 0.2% versus 0%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,onglyza,14,596,694,"The adverse reactions in this pooled analysis reported (regardless of investigator assessment of causality) in >=5% of patients treated with ONGLYZA 5 mg, and more commonly than in patients treated with placebo are shown in Table 1.\n', '\n', '\n', '\n', ' Table 1: Adverse Reactions in Placebo-Controlled TrialsThe 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,onglyza,15,694,703,Table shows 24-week data regardless of glycemic rescue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,onglyza,16,703,786,"Reported in >=5% of Patients Treated with ONGLYZA 5 mg and More Commonly than in Patients Treated with Placebo \n', '                                                          Number (%) of Patients          \n', '                                                          ONGLYZA 5 mg    N=882            Placebo    N=799     \n', '  \n', '   oselabeledaefromdruguse                      68 (7.7)                         61 (7.6)          \n', '   oselabeledaefromdruguse                                60 (6.8)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,onglyza,17,786,787,49,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,onglyza,18,787,799,"(6.1)          \n', '   oselabeledaefromdruguse                                               57",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,onglyza,19,799,808,(6.5)                         47 (5.9)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,onglyza,20,808,997,"\n', '         In patients treated with ONGLYZA 2.5 mg,  oselabeledaefromdruguse (6.5%) was the only adverse reaction reported at a rate >=5% and more commonly than in patients treated with placebo.\n', ' \n', '\n', ' In this pooled analysis, adverse reactions that were reported in >=2% of patients treated with ONGLYZA 2.5 mg or ONGLYZA 5 mg and >=1% more frequently compared to placebo included:  oselabeledaefromdruguse (2.9% and 2.6% versus 1.6%, respectively),  oselabeledaefromdruguse (2.4% and 1.7% versus 0.5%),  oselabeledaefromdruguse (1.9% and 2.3% versus 0.9%), and  oselabeledaefromdruguse (2.2% and 2.3% versus 1.3%).\n', '\n', '\n', '\n', ' In the add-on to TZD trial, the incidence of  oselabeledaefromdruguse was higher for ONGLYZA 5 mg versus placebo (8.1% and 4.3%, respectively).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,onglyza,21,997,1010,The incidence of  oselabeledaefromdruguse for ONGLYZA 2.5 mg was 3.1%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,onglyza,22,1010,1025,None of the reported adverse reactions of  nonoseaeaeonlyasinstruction resulted in study drug discontinuation.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,onglyza,23,1025,1101,"Rates of  oselabeledaefromdruguse for ONGLYZA 2.5 mg and ONGLYZA 5 mg versus placebo were 3.6% and 2% versus 3% given as monotherapy, 2.1% and 2.1% versus 2.2% given as add-on therapy to metformin, and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,onglyza,24,1101,1138,"The incidence rate of  oselabeledaefromdruguse was 1.0 and 0.6 per 100 patient-years, respectively, for ONGLYZA (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,onglyza,25,1138,1148,The 10 mg dosage is not an approved dosage.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,onglyza,26,1148,1166,The incidence rate of  nonoseaeaeonlyasinstruction events in patients who received ONGLYZA did not increase over time.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,onglyza,27,1166,1219,"Causality has not been established and nonclinical studies have not demonstrated adverse effects of ONGLYZA on bone.\n', '\n', '\n', '\n', ' An event of  nonoseaeaeonlyasinstruction  consistent with a diagnosis of  nonoseaeaeonlyasinstruction  was observed in the clinical program.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,onglyza,28,1219,1291,"The relationship of this event to ONGLYZA is not known.\n', '\n', '\n', '\n', '     Adverse Reactions in Patients with Renal Impairment  \n', '\n', '  ONGLYZA 2.5 mg was compared to placebo in a 12-week trial in 170 patients with  notaecandidatepreexistingconditionorriskfactor and moderate or  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor (ESRD).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
29,onglyza,29,1291,1403,"The incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between ONGLYZA and placebo.\n', '\n', '\n', '\n', '     Adverse Reactions with Concomitant Use with Insulin  \n', '\n', '  In the add-on to insulin trial [  see  Clinical Studies (14.2)    ], the incidence of adverse events, including serious adverse events and discontinuations due to adverse events, was similar between ONGLYZA and placebo, except for confirmed  nonoseaeaefromdruginteraction [  see  Adverse Reactions (",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
30,onglyza,30,1403,1407,6.1)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,onglyza,31,1407,1441,".\n', '\n', '\n', '\n', '     Adverse Reactions with Concomitant Use with Metformin in Treatment-Naive Patients with Type 2 Diabetes  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,onglyza,32,1441,1556,"\n', '\n', '  Table 2 shows the adverse reactions reported (regardless of investigator assessment of causality) in >=5% of patients participating in an additional 24-week, active-controlled trial of coadministered ONGLYZA and metformin in treatment-naive patients.\n', '\n', '\n', '\n', ' Table 2: Initial Therapy with Combination of ONGLYZA and Metformin in Treatment-Naive Patients: Adverse Reactions Reported in >=5% of Patients Treated with Combination Therapy of ONGLYZA 5 mg Plus Metformin (and More Commonly than in Patients Treated with Metformin Alone)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,onglyza,33,1556,1568,"\n', '                                Number (%) of Patients                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,onglyza,34,1568,1583,"\n', '                                ONGLYZA 5 mg + Metformin    N=320                     Metformin    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,onglyza,35,1583,1585,N=328     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,onglyza,36,1585,1607,"\n', '  \n', '   oselabeledaefromdruguse                     24 (7.5)                                              17 (5.2)                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,onglyza,37,1607,1624,"\n', '   oselabeledaefromdruguse              22 (6.9)                                              13 (4.0)                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,onglyza,38,1624,1629,"\n', '             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,onglyza,39,1629,1650,"Hypoglycemia  \n', '   Adverse reactions of  nonoseaeaeonlyasinstruction were based on all reports of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,onglyza,40,1650,1664,A concurrent glucose measurement was not required or was normal in some patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,onglyza,41,1664,1737,"Therefore, it is not possible to conclusively determine that all these reports reflect true  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In the add-on to glyburide study, the overall incidence of reported  oselabeledaefromdruguse was higher for ONGLYZA 2.5 mg and ONGLYZA 5 mg (13.3% and 14.6%) versus placebo (10.1%).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,onglyza,42,1737,1783,"The incidence of confirmed  oselabeledaefromdruguse in this study, defined as symptoms of  nonoseaeaeonlyasinstruction accompanied by a fingerstick  nonoseaeaeonlyasinstruction  was 2.4% and 0.8% for ONGLYZA 2.5 mg and ONGLYZA 5 mg and 0.7% for placebo [  see  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,onglyza,43,1783,1792,Warnings and Precautions (5.2)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,onglyza,44,1792,1858,"The incidence of reported  oselabeledaefromdruguse for ONGLYZA 2.5 mg and ONGLYZA 5 mg versus placebo given as monotherapy was 4% and 5.6% versus 4.1%, respectively, 7.8% and 5.8% versus 5% given as add-on therapy to metformin, and 4.1% and 2.7% versus 3.8% given as add-on therapy to TZD.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,onglyza,45,1858,1959,"The incidence of reported  nonoseaeaeratelteqplacebo was 3.4% in treatment-naive patients given ONGLYZA 5 mg plus metformin and 4% in patients given metformin alone.\n', '\n', '\n', '\n', ' In the active-controlled trial comparing add-on therapy with ONGLYZA 5 mg to glipizide in patients inadequately controlled on metformin alone, the incidence of reported  nonoseaeaeratelteqplacebo was 3% (19 events in 13 patients) with ONGLYZA 5 mg versus 36.3% (750 events in 156 patients) with glipizide.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
46,onglyza,46,1959,2007,"Confirmed symptomatic  nonoseaenegation (accompanying fingerstick  nonoseaeaeonlyasinstruction  was reported in none of the ONGLYZA-treated patients and in 35 glipizide-treated patients (8.1%) (p<0.0001).\n', '\n', '\n', '\n', '",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
47,onglyza,47,2007,2049,During 12 weeks of treatment in patients with moderate or  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  the overall incidence of reported  nonoseaeaeratelteqplacebo was 20% among patients treated with ONGLYZA 2.5 mg and 22% among patients treated with placebo.,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0
48,onglyza,48,2049,2128,"Four ONGLYZA-treated patients (4.7%) and three placebo-treated patients (3.5%) reported at least one episode of confirmed symptomatic  oselabeledaefromdruguse (accompanying fingerstick  nonoseaeaeonlyasinstruction .\n', '\n', '\n', '\n', ' In the add-on to insulin trial, the overall incidence of reported  nonoseaeaeratelteqplacebo was 18.4% for ONGLYZA 5 mg and 19.9% for placebo.",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
49,onglyza,49,2128,2203,"However, the incidence of confirmed symptomatic  oselabeledaefromdruguse (accompanying fingerstick  nonoseaeaeonlyasinstruction  was higher with ONGLYZA 5 mg (5.3%) versus placebo (3.3%).\n', '\n', '\n', '\n', ' In the add-on to metformin plus sulfonylurea trial, the overall incidence of reported  nonoseaeaefromdruginteraction was 10.1% for ONGLYZA 5 mg and 6.3% for placebo.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
50,onglyza,50,2203,2238,Confirmed  oselabeledaefromdruguse was reported in 1.6% of the ONGLYZA-treated patients and in none of the placebo-treated patients [  see      Warnings and Precautions (5.2)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,onglyza,51,2238,2258,".\n', '\n', '\n', '\n', '     Hypersensitivity Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,onglyza,52,2258,2314,"\n', '\n', '   oselabeledaefromdruguse  such as  oselabeledaefromdruguse and  oselabeledaefromdruguse in the 5-study pooled analysis up to Week 24 were reported in 1.5%, 1.5%, and 0.4% of patients who received ONGLYZA 2.5 mg, ONGLYZA 5 mg, and placebo, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,onglyza,53,2314,2336,None of these events in patients who received ONGLYZA required hospitalization or were reported as life-threatening by the investigators.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,onglyza,54,2336,2437,"One ONGLYZA-treated patient in this pooled analysis discontinued due to  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '     Infections  \n', '\n', '  In the unblinded, controlled, clinical trial database for ONGLYZA to date, there have been 6 (0.12%) reports of  oselabeledaefromdruguse among the 4959 ONGLYZA-treated patients (1.1 per 1000 patient-years) compared to no reports of  nonoseaeaeonlyasinstruction among the 2868 comparator-treated patients.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,onglyza,55,2437,2448,Two of these six cases were confirmed with laboratory testing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,onglyza,56,2448,2477,The remaining cases had limited information or had presumptive diagnoses of  nonoseaeaeonlyasinstruction  None of the six cases occurred in the United States or in Western Europe.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,onglyza,57,2477,2494,One case occurred in Canada in a patient originally from Indonesia who had recently visited Indonesia.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,onglyza,58,2494,2512,The duration of treatment with ONGLYZA until report of  oselabeledaefromdruguse ranged from 144 to 929 days.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,onglyza,59,2512,2527,Post-treatment lymphocyte counts were consistently within the reference range for four cases.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,onglyza,60,2527,2544,One patient had  notaecandidatepreexistingconditionorriskfactor prior to initiation of ONGLYZA that remained stable throughout ONGLYZA treatment.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
61,onglyza,61,2544,2563,The final patient had an isolated  oselabeledaefromdruguse approximately four months prior to the report of  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,onglyza,62,2563,2577,There have been no spontaneous reports of  nonoseaenegation associated with ONGLYZA use.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
63,onglyza,63,2577,2657,"Causality has not been estimated and there are too few cases to date to determine whether  nonoseaeaeonlyasinstruction is related to ONGLYZA use.\n', '\n', '\n', '\n', ' There has been one case of a potential  oselabeledaefromdruguse in the unblinded, controlled clinical trial database to date in an ONGLYZA-treated patient who developed suspected foodborne  nonoseaegeneralterm  oselabeledaefromdruguse after approximately 600 days of ONGLYZA therapy.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,onglyza,64,2657,2689,"There have been no spontaneous reports of  nonoseaenegation associated with ONGLYZA use.\n', '\n', '\n', '\n', '     Vital Signs  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
65,onglyza,65,2689,2745,"\n', '\n', '  No clinically meaningful changes in vital signs have been observed in patients treated with ONGLYZA.\n', '\n', '\n', '\n', '     Laboratory Tests  \n', '\n', '    Absolute Lymphocyte Counts  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,onglyza,66,2745,2767,"\n', '\n', '  There was a dose-related mean  oselabeledaefromdruguse observed with ONGLYZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,onglyza,67,2767,2821,"From a baseline mean absolute  oselabeledaefromdruguse of approximately 2200 cells/microL,  oselabeledaefromdruguse of approximately 100 and 120 cells/microL with ONGLYZA 5 mg and 10 mg, respectively, relative to placebo were observed at 24 weeks in a pooled analysis of five placebo-controlled clinical studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,onglyza,68,2821,2841,Similar effects were observed when ONGLYZA 5 mg was given in initial combination with metformin compared to metformin alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,onglyza,69,2841,2854,There was no difference observed for ONGLYZA 2.5 mg relative to placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,onglyza,70,2854,2897,"The proportion of patients who were reported to have a  oselabeledaefromdruguse was 0.5%, 1.5%, 1.4%, and 0.4% in the ONGLYZA 2.5 mg, 5 mg, 10 mg, and placebo groups, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,onglyza,71,2897,2925,"In most patients, recurrence was not observed with repeated exposure to ONGLYZA although some patients had recurrent decreases upon rechallenge that led to discontinuation of ONGLYZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,onglyza,72,2925,2937,The  nonoseaeaeonlyasinstruction were not associated with clinically relevant adverse reactions.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,onglyza,73,2937,2975,"The 10 mg dosage is not an approved dosage.\n', '\n', '\n', '\n', ' The clinical significance of this  nonoseaeaeonlyasinstruction relative to placebo is not known.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,onglyza,74,2975,2996,"When clinically indicated, such as in settings of unusual or prolonged  nonoseaeaeonlyasinstruction  lymphocyte count should be measured.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,onglyza,75,2996,3055,"The effect of ONGLYZA on lymphocyte counts in patients with  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor  is unknown.\n', '\n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  Additional adverse reactions have been identified during postapproval use of ONGLYZA.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
76,onglyza,76,3055,3132,"Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [ see  Contraindications (4)  and  Warnings and Precautions (5.3)   ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,onglyza,77,3132,3160,"\n', ' *     oselabeledaefromdruguse [ see  Indications and Usage (1.2)  and  Warnings and Precautions (5.1)   ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,onglyza,78,3160,3195,"\n', ' *    Severe and disabling  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,onglyza,79,3195,3214,"*     Acute Pancreatitis (postmarketing reports): If pancreatitis is suspected, promptly discontinue ONGLYZA.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,onglyza,80,3214,3218,(5.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,onglyza,81,3218,3219,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,onglyza,82,3219,3226,"', ' *     Hypoglycemia:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,onglyza,83,3226,3263,"In add-on to sulfonylurea, add-on to insulin, and add-on to metformin plus sulfonylurea trials, confirmed hypoglycemia was more common in patients treated with ONGLYZA compared to placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,onglyza,84,3263,3297,"When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,onglyza,85,3297,3305,"(5.2  ,  6.1)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,onglyza,86,3305,3324,"\n', ' *     Hypersensitivity-Related Events (e.g., urticaria, facial edema):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,onglyza,87,3324,3356,"More common in patients treated with ONGLYZA than in patients treated with placebo; and postmarketing reports of serious hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,onglyza,88,3356,3380,"Promptly discontinue ONGLYZA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,onglyza,89,3380,3392,"(5.3  ,  6.1  ,  6.2)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,onglyza,90,3392,3400,"\n', ' *     Arthralgia:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,onglyza,91,3400,3413,Severe and disabling arthralgia has been reported in patients taking DPP4 inhibitors.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,onglyza,92,3413,3428,Consider as a possible cause for severe joint pain and discontinue drug if appropriate.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,onglyza,93,3428,3461,"(  5.4  ) \n', ' *    There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,onglyza,94,3461,3465,(5.5)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,onglyza,95,3465,3487,"\n', '    \n', ' \n', '\n', '   5.1 Pancreatitis\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,onglyza,96,3487,3514,"'\n', '\n', '\n', '  There have been postmarketing reports of  oselabeledaefromdruguse in patients taking ONGLYZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,onglyza,97,3514,3532,"After initiation of ONGLYZA, patients should be observed carefully for signs and symptoms of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,onglyza,98,3532,3550,"If  nonoseaeaeonlyasinstruction is suspected, ONGLYZA should promptly be discontinued and appropriate management should be initiated.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,onglyza,99,3550,3655,"It is unknown whether patients with a  notaecandidatepreexistingconditionorriskfactor are at increased risk for the development of  nonoseaeaeonlyasinstruction while using ONGLYZA.\n', '\n', '\n', '\n', '    5.2 Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin\n', '\n', '\n', '\n', '  When ONGLYZA was used in combination with a sulfonylurea or with insulin, medications known to cause  nonoseaeaeonlyasinstruction  the incidence of confirmed  nonoseaeaefromdruginteraction was increased over that of placebo used in combination with a sulfonylurea or with insulin.",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
100,onglyza,100,3655,3666,[ see  Adverse Reactions (6.1)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,onglyza,101,3666,3755,"Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of  nonoseaeaeonlyasinstruction when used in combination with ONGLYZA [ see  Dosage and Administration (2.4)    ].\n', '\n', '\n', '\n', '    5.3 Hypersensitivity Reactions\n', '\n', '\n', '\n', '  There have been postmarketing reports of serious  oselabeledaefromdruguse in patients treated with ONGLYZA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,onglyza,102,3755,3767,These reactions include  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,onglyza,103,3767,3793,"Onset of these reactions occurred within the first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,onglyza,104,3793,3934,"If a serious  nonoseaeaeonlyasinstruction is suspected, discontinue ONGLYZA, assess for other potential causes for the event, and institute alternative treatment for  notaecandidateindication [ see  Adverse Reactions (6.2)    ].\n', '\n', '\n', '\n', ' Use caution in a patient with a history of  notaecandidatepreexistingconditionorriskfactor to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is unknown whether such patients will be predisposed to  nonoseaeaeonlyasinstruction with ONGLYZA.\n', '\n', '\n', '\n', '    5.4 Severe and Disabling Arthralgia\n', '\n', '\n', '\n', '  There have been postmarketing reports of severe and disabling  oselabeledaeclasseffect in patients taking DPP4 inhibitors.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
105,onglyza,105,3934,3952,The time to onset of symptoms following initiation of drug therapy varied from one day to years.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,onglyza,106,3952,3963,Patients experienced relief of symptoms upon discontinuation of the medication.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,onglyza,107,3963,3983,A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP4 inhibitor.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,onglyza,108,3983,4048,"Consider DPP4 inhibitors as a possible cause for severe  nonoseaeaeonlyasinstruction and discontinue drug if appropriate.\n', '\n', '\n', '\n', '    5.5 Macrovascular Outcomes\n', '\n', '\n', '\n', '  There have been no clinical studies establishing conclusive evidence of  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,xeljanz,0,0,17,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,xeljanz,1,17,66,"The most commonly reported adverse reactions during the first 3 months in controlled clinical trials (occurring in greater than or equal to 2% of patients treated with XELJANZ monotherapy or in combination with DMARDs) were upper respiratory tract infections, headache, diarrhea and nasopharyngitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,xeljanz,2,66,72,(  6.1  )  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,xeljanz,3,72,100,"To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,xeljanz,4,100,137,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,xeljanz,5,137,254,"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.\n', '\n', '\n', '\n', ' Although other doses have been studied, the recommended dose of XELJANZ is 5 mg twice daily.\n', '\n', '\n', '\n', ' The following data includes two Phase 2 and five Phase 3 double-blind, controlled, multicenter trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,xeljanz,6,254,317,"In these trials, patients were randomized to doses of XELJANZ 5 mg twice daily (292 patients) and 10 mg twice daily (306 patients) monotherapy, XELJANZ 5 mg twice daily (1044 patients) and 10 mg twice daily (1043 patients) in combination with DMARDs (including methotrexate) and placebo (809 patients).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,xeljanz,7,317,367,"All seven protocols included provisions for patients taking placebo to receive treatment with XELJANZ at Month 3 or Month 6 either by patient response (based on uncontrolled disease activity) or by design, so that adverse events cannot always be unambiguously attributed to a given treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,xeljanz,8,367,399,Therefore some analyses that follow include patients who changed treatment by design or by patient response from placebo to XELJANZ in both the placebo and XELJANZ group of a given interval.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,xeljanz,9,399,491,"Comparisons between placebo and XELJANZ were based on the first 3 months of exposure, and comparisons between XELJANZ 5 mg twice daily and XELJANZ 10 mg twice daily were based on the first 12 months of exposure.\n', '\n', '\n', '\n', ' The long-term safety population includes all patients who participated in a double-blind, controlled trial (including earlier development phase studies) and then participated in one of two long-term safety studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,xeljanz,10,491,511,The design of the long-term safety studies allowed for modification of XELJANZ doses according to clinical judgment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,xeljanz,11,511,759,"This limits the interpretation of the long-term safety data with respect to dose.\n', '\n', '\n', '\n', ' The most common serious adverse reactions were serious  oselabeledaefromdruguse  [see  Warnings and Precautions (5.1)  ]  .\n', '\n', '\n', '\n', ' The proportion of patients who discontinued treatment due to any adverse reaction during the 0 to 3 months exposure in the double-blind, placebo-controlled trials was 4% for patients taking XELJANZ and 3% for placebo-treated patients.\n', '\n', '\n', '\n', '     Overall Infections  \n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 3 months exposure, the overall frequency of  oselabeledaefromdruguse was 20% and 22% in the 5 mg twice daily and 10 mg twice daily groups, respectively, and 18% in the placebo group.\n', '\n', '\n', '\n', ' The most commonly reported  oselabeledaefromdruguse with XELJANZ were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (4%, 3%, and 2% of patients, respectively).\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,xeljanz,12,759,772,"'\n', '\n', '     Serious Infections  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,xeljanz,13,772,788,"\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,xeljanz,14,788,845,"In the seven controlled trials, during the 0 to 3 months exposure, serious  oselabeledaefromdruguse were reported in 1 patient (0.5 events per 100 patient-years) who received placebo and 11 patients (1.7 events per 100 patient-years) who received XELJANZ 5 mg or 10 mg twice daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,xeljanz,15,845,964,"The rate difference between treatment groups (and the corresponding 95% confidence interval) was 1.1 (-0.4, 2.5) events per 100 patient-years for the combined 5 mg twice daily and 10 mg twice daily XELJANZ group minus placebo.\n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 12 months exposure, serious  oselabeledaefromdruguse were reported in 34 patients (2.7 events per 100 patient-years) who received 5 mg twice daily of XELJANZ and 33 patients (2.7 events per 100 patient-years) who received 10 mg twice daily of XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,xeljanz,16,964,984,"The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was -0.1 (-1.3,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,xeljanz,17,984,997,1.2) events per 100 patient-years for 10 mg twice daily,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,xeljanz,18,997,1188,"XELJANZ minus 5 mg twice daily XELJANZ.\n', '\n', '\n', '\n', ' The most common serious  oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see  Warnings and Precautions (5.1)  ]  .\n', '\n', '\n', '\n', '     Tuberculosis  \n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 3 months exposure,  nonoseaenegation was not reported in patients who received placebo, 5 mg twice daily of XELJANZ, or 10 mg twice daily of XELJANZ.\n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 12 months exposure,  oselabeledaefromdruguse was reported in 0 patients who received 5 mg twice daily of XELJANZ and 6 patients (0.5 events per 100 patient-years) who received 10 mg twice daily of XELJANZ.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
19,xeljanz,19,1188,1251,"The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was 0.5 (0.1, 0.9) events per 100 patient-years for 10 mg twice daily XELJANZ minus 5 mg twice daily XELJANZ.\n', '\n', '\n', '\n', ' Cases of  oselabeledaefromdruguse were also reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,xeljanz,20,1251,1286,The median XELJANZ exposure prior to diagnosis of  oselabeledaefromdruguse was 10 months (range from 152 to 960 days) [  see  Warnings and Precautions (5.1)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,xeljanz,21,1286,1326,"\n', '\n', '\n', '\n', '     Opportunistic Infections (excluding tuberculosis)  \n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,xeljanz,22,1326,1439,"In the seven controlled trials, during the 0 to 3 months exposure,  nonoseaenegation were not reported in patients who received placebo, 5 mg twice daily of XELJANZ, or 10 mg twice daily of XELJANZ.\n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 12 months exposure,  oselabeledaefromdruguse were reported in 4 patients (0.3 events per 100 patient-years) who received 5 mg twice daily of XELJANZ and 4 patients (0.3 events per 100 patient-years) who received 10 mg twice daily of XELJANZ.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
23,xeljanz,23,1439,1456,The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,xeljanz,24,1456,1472,"(-0.5, 0.5) events per 100 patient-years for 10 mg twice daily",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,xeljanz,25,1472,1520,"XELJANZ minus 5 mg twice daily XELJANZ.\n', '\n', '\n', '\n', ' The median XELJANZ exposure prior to diagnosis of an  oselabeledaefromdruguse was 8 months (range from 41 to 698 days)  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,xeljanz,26,1520,1530,Warnings and Precautions (5.1)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,xeljanz,27,1530,1616,"\n', '\n', '\n', '\n', '     Malignancy  \n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 3 months exposure,  oselabeledaefromdruguse excluding  nonoseaenegation were reported in 0 patients who received placebo and 2 patients (0.3 events per 100 patient-years) who received either XELJANZ 5 mg or 10 mg twice daily.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
28,xeljanz,28,1616,1735,"The rate difference between treatment groups (and the corresponding 95% confidence interval) was 0.3 (-0.1, 0.7) events per 100 patient-years for the combined 5 mg and 10 mg twice daily XELJANZ group minus placebo.\n', '\n', '\n', '\n', ' In the seven controlled trials, during the 0 to 12 months exposure,  oselabeledaefromdruguse excluding  nonoseaeother were reported in 5 patients (0.4 events per 100 patient-years) who received 5 mg twice daily of XELJANZ and 7 patients (0.6 events per 100 patient-years) who received 10 mg twice daily of XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
29,xeljanz,29,1735,1754,The rate difference between XELJANZ doses (and the corresponding 95% confidence interval) was 0.2 (-0.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,xeljanz,30,1754,1768,", 0.7) events per 100 patient-years for 10 mg twice daily",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,xeljanz,31,1768,1776,XELJANZ minus 5 mg twice daily XELJANZ.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,xeljanz,32,1776,1900,"One of these  oselabeledaefromdruguse was a case of  oselabeledaefromdruguse that occurred during the 0 to 12 month period in a patient treated with XELJANZ 10 mg twice daily.\n', '\n', '\n', '\n', ' The most common types of  oselabeledaefromdruguse  including  oselabeledaefromdruguse observed during the long-term extension, were  oselabeledaefromdruguse and breast  oselabeledaefromdruguse  oselabeledaefromdruguse  followed by  oselabeledaefromdruguse  colorectal, renal cell, prostate  oselabeledaefromdruguse  oselabeledaefromdruguse  renal cell, prostate  oselabeledaefromdruguse  oselabeledaefromdruguse  prostate  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see  Warnings and Precautions (5.2)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,xeljanz,33,1900,2044,"\n', '\n', '\n', '\n', '     Laboratory Abnormalities  \n', '\n', '\n', '\n', '      oselabeledaefromdruguse  \n', '\n', '\n', '\n', ' In the controlled clinical trials, confirmed  oselabeledaefromdruguse below 500 cells/mm  3  occurred in 0.04% of patients for the 5 mg twice daily and 10 mg twice daily XELJANZ groups combined during the first 3 months of exposure.\n', '\n', '\n', '\n', ' Confirmed  oselabeledaefromdruguse  were associated with an increased incidence of treated and serious  nonoseaemanifestationorcomplication  [see  Warnings and Precautions (5.4)  ].  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
34,xeljanz,34,2044,2234,"\n', '\n', '\n', '\n', '      oselabeledaefromdruguse  \n', '\n', '\n', '\n', ' In the controlled clinical trials, confirmed  oselabeledaefromdruguse  oselabeledaefromdruguse  occurred in 0.07% of patients for the 5 mg twice daily and 10 mg twice daily XELJANZ groups combined during the first 3 months of exposure.\n', '\n', '\n', '\n', ' There were no confirmed  nonoseaenegation  nonoseaenegation  observed in any treatment group.\n', '\n', '\n', '\n', ' There was no clear relationship between  nonoseaeaeonlyasinstruction and the occurrence of serious  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In the long-term safety population, the pattern and incidence of confirmed  nonoseaeaeonlyasinstruction remained consistent with what was seen in the controlled clinical trials  [see  Warnings and Precautions (5.4)  ].  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
35,xeljanz,35,2234,2296,"\n', '\n', '\n', '\n', '     Liver Enzyme Elevations  \n', '\n', '\n', '\n', ' Confirmed  oselabeledaefromdruguse greater than 3 times the upper limit of normal (3* ULN) were observed in patients treated with XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,xeljanz,36,2296,2428,"In patients experiencing  oselabeledaefromdruguse  modification of treatment regimen, such as reduction in the dose of concomitant DMARD, interruption of XELJANZ, or reduction in XELJANZ dose, resulted in  nonoseaeaeonlyasinstruction or normalization of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In the controlled monotherapy trials (0-3 months), no differences in the incidence of  nonoseaeaeratelteqplacebo or AST  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo were observed between the placebo, and XELJANZ 5 mg, and 10 mg twice daily groups.\n', '\n', '\n', '\n', ' In the controlled background DMARD trials (0-3 months),  oselabeledaefromdruguse greater than 3",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
37,xeljanz,37,2428,2457,"* ULN were observed in 1.0%, 1.3% and 1.2% of patients receiving placebo, 5 mg, and 10 mg twice daily, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,xeljanz,38,2457,2466,"In these trials,  nonoseaeaeratelteqplacebo greater than 3",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
39,xeljanz,39,2466,2531,"* ULN were observed in 0.6%, 0.5% and 0.4% of patients receiving placebo, 5 mg, and 10 mg twice daily, respectively.\n', '\n', '\n', '\n', ' One case of  oselabeledaefromdruguse was reported in a patient treated with XELJANZ 10 mg twice daily for approximately 2.5 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,xeljanz,40,2531,2550,The patient developed symptomatic  oselabeledaefromdruguse of  oselabeledaefromdruguse  oselabeledaefromdruguse of AST and  oselabeledaefromdruguse greater than 3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,xeljanz,41,2550,2587,"* ULN and  oselabeledaefromdruguse greater than 2* ULN, which required hospitalizations and a liver biopsy.\n', '\n', '\n', '\n', '     Lipid Elevations  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,xeljanz,42,2587,2674,"\n', '\n', '\n', '\n', ' In the controlled clinical trials, dose-related  oselabeledaefromdruguse  oselabeledaefromdruguse lipid parameters (total cholesterol, LDL cholesterol, HDL cholesterol,  oselabeledaefromdruguse  oselabeledaefromdruguse lipid parameters ( oselabeledaefromdruguse  oselabeledaefromdruguse lipid parameters (total cholesterol,  oselabeledaefromdruguse  oselabeledaefromdruguse lipid parameters (total cholesterol, LDL cholesterol,  oselabeledaefromdruguse  triglycerides) were observed at one month of exposure and remained stable thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,xeljanz,43,2674,2736,"Changes in lipid parameters during the first 3 months of exposure in the controlled clinical trials are summarized below:\n', '\n', '\n', '\n', ' *  Mean  oselabeledaefromdruguse by 15% in the XELJANZ 5 mg twice daily arm and 19% in the XELJANZ 10 mg twice daily arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,xeljanz,44,2736,2768,"\n', ' *  Mean  oselabeledaefromdruguse by 10% in the XELJANZ 5 mg twice daily arm and 12% in the XELJANZ 10 mg twice daily arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,xeljanz,45,2768,2788,"\n', ' *  Mean LDL/HDL ratios were essentially unchanged in XELJANZ-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,xeljanz,46,2788,2870,"\n', '    In a controlled clinical trial,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction LDL cholesterol and  nonoseaeaeonlyasinstruction decreased to pretreatment levels in response to statin therapy.\n', ' \n', '\n', ' In the long-term safety population,  oselabeledaefromdruguse parameters remained consistent with what was seen in the controlled clinical trials.\n', '\n', '\n', '\n', '     Serum Creatinine Elevations  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,xeljanz,47,2870,2906,"\n', '\n', '\n', '\n', ' In the controlled clinical trials, dose-related  oselabeledaefromdruguse in  oselabeledaefromdruguse were observed with XELJANZ treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,xeljanz,48,2906,2967,"The mean  oselabeledaefromdruguse was <0.1 mg/dL in the 12-month pooled safety analysis; however with increasing duration of exposure in the long-term extensions, up to 2% of patients were discontinued from XELJANZ treatment due to the protocol-specified discontinuation criterion of an  oselabeledaefromdruguse by more than 50% of baseline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,xeljanz,49,2967,3094,"The clinical significance of the observed  nonoseaeaeonlyasinstruction is unknown.\n', '\n', '\n', '\n', '     Other Adverse Reactions  \n', '\n', '\n', '\n', ' Adverse reactions occurring in 2% or more of patients on 5 mg twice daily or 10 mg twice daily XELJANZ and at least 1% greater than that observed in patients on placebo with or without DMARD are summarized in Table 4.\n', '\n', '\n', '\n', ' Table 4: Adverse Reactions Occurring in at Least 2% or More of Patients on 5 or 10 mg Twice Daily XELJANZ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,xeljanz,50,3094,3112,With or Without DMARD (0-3 months) and at Least 1% Greater Than That,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,xeljanz,51,3112,3128,"Observed in Patients on Placebo \n', '                                 XELJANZ5 mg Twice Daily  XELJANZ10",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,xeljanz,52,3128,3129,mg,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,xeljanz,53,3129,3134,Twice Daily             Placebo               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,xeljanz,54,3134,3151,"\n', ' Preferred Term                      N = 1336(%)           N = 1349(%)                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,xeljanz,55,3151,3156,N = 809(%)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,xeljanz,56,3156,3189,"\n', '  \n', ' N reflects randomized and treated patients from the seven clinical trials   \n', '  \n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,xeljanz,57,3189,3193,4.0                   2.9                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,xeljanz,58,3193,3195,2.3                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,xeljanz,59,3195,3202,"\n', '  oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,xeljanz,60,3202,3206,3.8                   2.8                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,xeljanz,61,3206,3228,"2.8                 \n', '  oselabeledaefromdruguse          4.5                   3.8                        3.3                 \n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,xeljanz,62,3228,3232,4.3                   3.4                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,xeljanz,63,3232,3245,"2.1                 \n', '  oselabeledaefromdruguse                            1.6                   2.3                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,xeljanz,64,3245,3304,"1.1                 \n', '          Other adverse reactions occurring in controlled and open-label extension studies included:\n', ' \n', '\n', '    nonoseaegeneralterm and lymphatic system  nonoseaegeneralterm    oselabeledaefromdruguse \n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,xeljanz,65,3304,3317,"'\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,xeljanz,66,3317,3333,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,xeljanz,67,3333,3349,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,xeljanz,68,3349,3370,"\n', '\n', '\n', '    nonoseaegeneralterm  thoracic and mediastinal  nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,xeljanz,69,3370,3374,oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,xeljanz,70,3374,3399,"oselabeledaefromdruguse \n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,xeljanz,71,3399,3415,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
72,xeljanz,72,3415,3457,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
73,xeljanz,73,3457,3475,"\n', '\n', '\n', '    nonoseaegeneralterm :   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,xeljanz,74,3475,3494,"', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
75,xeljanz,75,3494,3495,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,xeljanz,76,3495,3506,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,xeljanz,77,3506,3508,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,xeljanz,78,3508,3516,"SERIOUS INFECTIONS AND MALIGNANCY\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,xeljanz,79,3516,3522,"', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,xeljanz,80,3522,3527,SERIOUS INFECTIONS AND MALIGNANCY  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,xeljanz,81,3527,3539,"\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,xeljanz,82,3539,3541,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,xeljanz,83,3541,3571,"SERIOUS INFECTIONS AND MALIGNANCY\n', '\n', '\n', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,xeljanz,84,3571,3619,"\n', '\n', '\n', '\n', ' *  Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,xeljanz,85,3619,3622,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,xeljanz,86,3622,3626,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,xeljanz,87,3626,3628,*  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,xeljanz,88,3628,3642,"If a serious infection develops, interrupt XELJANZ until the infection is controlled.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,xeljanz,89,3642,3645,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,xeljanz,90,3645,3646,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,xeljanz,91,3646,3677,"', ' *  Prior to starting XELJANZ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,xeljanz,92,3677,3680,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,xeljanz,93,3680,3687,"\n', ' *  Monitor",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,xeljanz,94,3687,3705,"all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,xeljanz,95,3705,3708,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,xeljanz,96,3708,3727,"\n', ' *  Lymphoma and other malignancies have been observed in patients treated with XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,xeljanz,97,3727,3756,Epstein Barr Virus-associated post-transplant lymphoproliferative disorder has been observed at an increased rate in renal transplant patients treated with XELJANZ and concomitant immunosuppressive medications.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,xeljanz,98,3756,3759,(5.2),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,xeljanz,99,3759,3765,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,xeljanz,100,3765,3780,"', ' \n', '\n', '    SERIOUS INFECTIONS  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,xeljanz,101,3780,3840,"\n', '\n', '\n', '\n', '   Patients treated with XELJANZ are at increased risk for developing serious  oselabeledaefromdruguse that may lead to hospitalization or  nonoseaegeneralterm   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,xeljanz,102,3840,3859,Most patients who developed these  nonoseaeaefromdruginteraction were taking concomitant  nonoseaeaeonlyasinstruction such as methotrexate or corticosteroids.  ,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
103,xeljanz,103,3859,3893,"\n', '\n', '\n', '\n', '   If a serious  nonoseaeaeonlyasinstruction develops, interrupt XELJANZ until the  nonoseaeaeonlyasinstruction is controlled.   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,xeljanz,104,3893,3934,"\n', '\n', '\n', '\n', '   Reported  oselabeledaefromdruguse include:   \n', '\n', '\n', '\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,xeljanz,105,3934,3947,oselabeledaefromdruguse  which may present with  oselabeledaefromdruguse or extrapulmonary  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,xeljanz,106,3947,3949,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,xeljanz,107,3949,3963,Patients should be tested for  nonoseaeaeonlyasinstruction before XELJANZ use and during therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,xeljanz,108,3963,3975,Treatment for  notaecandidatepreexistingconditionorriskfactor should be initiated prior to XELJANZ use.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
109,xeljanz,109,3975,4005,"\n', ' *   oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  Patients with  oselabeledaefromdruguse may present with disseminated, rather than localized, disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,xeljanz,110,4005,4011,"\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,xeljanz,111,4011,4042,"oselabeledaefromdruguse  viral, and other  oselabeledaefromdruguse due to  oselabeledaefromdruguse  oselabeledaefromdruguse  and other  oselabeledaefromdruguse due to  oselabeledaefromdruguse  oselabeledaefromdruguse due to  oselabeledaefromdruguse pathogens.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,xeljanz,112,4042,4047,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,xeljanz,113,4047,4072,The risks and benefits of treatment with XELJANZ should be carefully considered prior to initiating therapy in patients with chronic or recurrent  notaecandidatepreexistingconditionorriskfactor    ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
114,xeljanz,114,4072,4130,"\n', ' \n', '\n', '   Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with XELJANZ, including the possible development of  nonoseaeaeonlyasinstruction in patients who  notaecandidatepreexistingconditionorriskfactor prior to initiating therapy   [see   Warnings and Precautions",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
115,xeljanz,115,4130,4138,(5.1)  ]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,xeljanz,116,4138,4189,"\n', '\n', '\n', '\n', '     MALIGNANCIES  \n', '\n', '\n', '\n', '    oselabeledaefromdruguse and other  oselabeledaefromdruguse have been observed in patients treated with XELJANZ.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,xeljanz,117,4189,4226,"nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction has been observed at an increased rate in  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
118,xeljanz,118,4226,4242,"*  Avoid use of XELJANZ during an active serious infection, including localized infections.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,xeljanz,119,4242,4268,"(  5.1  ) \n', ' *  Gastrointestinal Perforations - Use with caution in patients that may be at increased risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,xeljanz,120,4268,4298,"(  5.3  ) \n', ' *  Laboratory Monitoring -Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,xeljanz,121,4298,4319,"(  5.4  ) \n', ' *  Immunizations - Live vaccines: Avoid use with XELJANZ.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,xeljanz,122,4319,4465,"(  5.5  ) \n', '    \n', ' \n', '\n', '   5.1 Serious Infections\n', '\n', '\n', '\n', '   Serious and sometimes fatal  oselabeledaefromdruguse due to  oselabeledaefromdruguse  mycobacterial, invasive fungal, viral, or other  oselabeledaefromdruguse  oselabeledaefromdruguse due to bacterial, mycobacterial, invasive fungal,  oselabeledaefromdruguse  or other  oselabeledaefromdruguse  oselabeledaefromdruguse due to bacterial, mycobacterial, invasive  oselabeledaefromdruguse  viral, or other  oselabeledaefromdruguse  oselabeledaefromdruguse due to bacterial,  oselabeledaefromdruguse  invasive fungal, viral, or other  oselabeledaefromdruguse  oselabeledaefromdruguse due to bacterial, mycobacterial, invasive fungal, viral, or other  oselabeledaefromdruguse pathogens have been reported in  notaecandidateindication patients receiving XELJANZ.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
123,xeljanz,123,4465,4499,The most common serious  oselabeledaefromdruguse reported with XELJANZ included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [see  Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,xeljanz,124,4499,4509,Among  oselabeledaefromdruguse   oselabeledaefromdruguse and other  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,xeljanz,125,4509,4521,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,xeljanz,126,4521,4527,oselabeledaefromdruguse were reported with XELJANZ.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,xeljanz,127,4527,4552,"Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunomodulating agents such as methotrexate or corticosteroids.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,xeljanz,128,4552,4680,"\n', '\n', '\n', '\n', ' Other serious  nonoseaeaeonlyasinstruction that were not reported in clinical studies may also occur (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction .\n', '\n', '\n', '\n', ' Avoid use of XELJANZ in patients with an active, serious  notaecandidatepreexistingconditionorriskfactor  including  notaecandidatepreexistingconditionorriskfactor  The risks and benefits of treatment should be considered prior to initiating XELJANZ in patients:\n', '\n', '\n', '\n', ' *  with  notaecandidatepreexistingconditionorriskfactor or recurrent  notaecandidatepreexistingconditionorriskfactor \n', ' *  who have been  notaecandidatepreexistingconditionorriskfactor \n',",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
129,xeljanz,129,4680,4760,"' *  with a history of a serious or an  notaecandidatepreexistingconditionorriskfactor \n', ' *  who have resided or traveled in areas of endemic  notaecandidatepreexistingconditionorriskfactor or endemic  notaecandidatepreexistingconditionorriskfactor  or \n', ' *  with underlying conditions that may  notaecandidatepreexistingconditionorriskfactor them  notaecandidatepreexistingconditionorriskfactor  \n', '    Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with XELJANZ.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
130,xeljanz,130,4760,4781,XELJANZ should be interrupted if a patient develops a serious  nonoseaeaeonlyasinstruction  an  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,xeljanz,131,4781,5098,"A patient who develops a new  nonoseaeaeonlyasinstruction during treatment with XELJANZ should undergo prompt and complete diagnostic testing appropriate for an  notaecandidatepreexistingconditionorriskfactor  appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.\n', ' \n', '\n', '    Tuberculosis  \n', '\n', '\n', '\n', ' Patients should be evaluated and tested for latent or active  notaecandidatepreexistingconditionorriskfactor prior to administration of XELJANZ.\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction should also be considered prior to administration of XELJANZ in patients with a past history of  notaecandidatepreexistingconditionorriskfactor or active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for  nonoseaenegation but who have risk factors for  notaecandidatepreexistingconditionorriskfactor  Consultation with a physician with expertise in the treatment of  nonoseaeaeonlyasinstruction is recommended to aid in the decision about whether initiating  nonoseaeaeonlyasinstruction is appropriate for an individual patient.\n', '\n', '\n', '\n', ' Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction  including patients who tested negative for  nonoseaenegation prior to initiating therapy.\n', '\n', '\n', '\n', ' Patients with  notaecandidatepreexistingconditionorriskfactor should be treated with standard antimycobacterial therapy before administering XELJANZ.\n', '\n', '\n', '\n', '    Viral Reactivation  \n', '\n', '\n', '\n', '   oselabeledaefromdruguse  including cases of  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse , were observed in clinical studies with XELJANZ.",1,0,1,0,0,0,0,1,0,0,0,0,0,0,0
132,xeljanz,132,5098,5109,The impact of XELJANZ on chronic  nonoseaeaeonlyasinstruction is unknown.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,xeljanz,133,5109,5128,Patients who screened positive for  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor B or  notaecandidatepreexistingconditionorriskfactor were excluded from clinical trials.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
134,xeljanz,134,5128,5146,Screening for  nonoseaeaeonlyasinstruction should be performed in accordance with clinical guidelines before starting therapy with XELJANZ.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,xeljanz,135,5146,5172,The risk of  oselabeledaefromdruguse is increased in patients treated with XELJANZ and appears to be higher in patients treated with XELJANZ in Japan.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,xeljanz,136,5172,5258,"\n', '\n', '\n', '\n', '    5.2 Malignancy and Lymphoproliferative Disorders\n', '\n', '\n', '\n', '  Consider the risks and benefits of XELJANZ treatment prior to initiating therapy in patients with a known  notaecandidatepreexistingconditionorriskfactor other than a successfully treated  notaecandidatepreexistingconditionorriskfactor  or when considering continuing XELJANZ in patients who develop a  nonoseaeaeonlyasinstruction   oselabeledaefromdruguse were observed in clinical studies of XELJANZ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
137,xeljanz,137,5258,5270,[see  Adverse Reactions (6.1)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,xeljanz,138,5270,5286,"\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,xeljanz,139,5286,5343,"In the seven controlled  notaecandidateindication clinical studies, 11  oselabeledaefromdruguse and one  oselabeledaefromdruguse were diagnosed in 3328 patients receiving XELJANZ with or without DMARD, compared to 0  nonoseaenegation and 0  nonoseaeother in 809 patients in the placebo with or without DMARD group during the first 12 months of exposure.  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,1
140,xeljanz,140,5343,5380,"oselabeledaefromdruguse and  oselabeledaefromdruguse have also been observed in the long-term extension studies in  notaecandidateindication patients treated with XELJANZ.\n', '\n', '\n', '\n', '",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
141,xeljanz,141,5380,5498,"In Phase 2B, controlled dose-ranging trials in de-novo   notaecandidatepreexistingconditionorriskfactor patients, all of whom received induction therapy with basiliximab, high-dose corticosteroids, and mycophenolic acid products,  nonoseaeaefromdruginteraction post-transplant  nonoseaeaefromdruginteraction was observed in 5 out of 218 patients treated with XELJANZ (2.3%) compared to 0 out of 111 patients treated with cyclosporine.\n', '\n', '\n', '\n', '    Non-Melanoma Skin Cancer  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse  have been reported in patients treated with XELJANZ.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
142,xeljanz,142,5498,5621,"Periodic skin examination is recommended for patients who are at increased risk for  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.3 Gastrointestinal Perforations\n', '\n', '\n', '\n', '  Events of  oselabeledaefromdruguse have been reported in clinical studies with XELJANZ in  notaecandidateindication patients, although the role of  nonoseaeaeonlyasinstruction in these events is not known.\n', '\n', '\n', '\n', ' XELJANZ should be used with caution in patients who may be at increased risk for  notaecandidatepreexistingconditionorriskfactor (e.g., patients with a history of  notaecandidatepreexistingconditionorriskfactor .",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
143,xeljanz,143,5621,5650,Patients presenting with new onset  nonoseaeaeonlyasinstruction should be evaluated promptly for early identification of  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6.1)  ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,xeljanz,144,5650,5689,"\n', '\n', '\n', '\n', '    5.4 Laboratory Abnormalities\n', '\n', '\n', '\n', '   Lymphocyte Abnormalities  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,xeljanz,145,5689,5705,"\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,xeljanz,146,5705,5739,Treatment with XELJANZ was associated with initial  oselabeledaefromdruguse at one month of exposure followed by a gradual  oselabeledaefromdruguse below the baseline of approximately 10% during 12 months of therapy.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,xeljanz,147,5739,5794,"oselabeledaefromdruguse  were associated with an increased incidence of treated and serious  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' Avoid initiation of XELJANZ treatment in patients with a  notaecandidatepreexistingconditionorriskfactor (i.e., less than 500 cells/mm  3  ).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
148,xeljanz,148,5794,5835,"In patients who develop a confirmed  nonoseaeaeonlyasinstruction  treatment with XELJANZ is not recommended.\n', '\n', '\n', '\n', ' Monitor lymphocyte counts at baseline and every 3 months thereafter.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,xeljanz,149,5835,5939,"For recommended modifications based on lymphocyte counts see  Dosage and Administration (2.2)    .\n', '\n', '\n', '\n', '    Neutropenia  \n', '\n', '\n', '\n', ' Treatment with XELJANZ was associated with an increased incidence of  oselabeledaefromdruguse  oselabeledaefromdruguse  ) compared to placebo.\n', '\n', '\n', '\n', ' Avoid initiation of XELJANZ treatment in patients with a  notaecandidatepreexistingconditionorriskfactor (i.e.,  notaecandidatepreexistingconditionorriskfactor  ).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
150,xeljanz,150,5939,5967,"For patients who develop a  oselabeledaefromdruguse  , interrupt XELJANZ dosing until ANC is greater than or equal to 1000 cells/mm  3  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,xeljanz,151,5967,6018,"In patients who develop an  nonoseaeaeonlyasinstruction  3  , treatment with XELJANZ is not recommended.\n', '\n', '\n', '\n', ' Monitor neutrophil counts at baseline and after 4-8 weeks of treatment and every 3 months thereafter.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,xeljanz,152,6018,6090,"For recommended modifications based on ANC results see  Dosage and Administration (2.2)    .\n', '\n', '\n', '\n', '     oselabeledaefromdruguse  \n', '\n', '\n', '\n', ' Avoid initiation of XELJANZ treatment in patients with a  notaecandidatepreexistingconditionorriskfactor (i.e. less than 9 g/dL).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
153,xeljanz,153,6090,6147,"Treatment with XELJANZ should be interrupted in patients who develop  oselabeledaefromdruguse or whose  oselabeledaefromdruguse greater than 2 g/dL on treatment.\n', '\n', '\n', '\n', ' Monitor hemoglobin at baseline and after 4-8 weeks of treatment and every 3 months thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,xeljanz,154,6147,6216,"For recommended modifications based on hemoglobin results see  Dosage and Administration (2.2)    .\n', '\n', '\n', '\n', '    Liver Enzyme Elevations  \n', '\n', '\n', '\n', ' Treatment with XELJANZ was associated with an increased incidence of  oselabeledaefromdruguse compared to placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,xeljanz,155,6216,6270,"Most of these abnormalities occurred in studies with background DMARD (primarily methotrexate) therapy.\n', '\n', '\n', '\n', ' Routine monitoring of liver tests and prompt investigation of the causes of  nonoseaeaeonlyasinstruction is recommended to identify potential cases of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,xeljanz,156,6270,6393,"If  nonoseaeaeonlyasinstruction is suspected, the administration of XELJANZ should be interrupted until this diagnosis has been excluded.\n', '\n', '\n', '\n', '    Lipid Elevations  \n', '\n', '\n', '\n', ' Treatment with XELJANZ was associated with  oselabeledaefromdruguse in lipid parameters including total cholesterol, low-density lipoprotein (LDL) cholesterol, and  oselabeledaefromdruguse  oselabeledaefromdruguse lipid parameters including  oselabeledaefromdruguse  oselabeledaefromdruguse lipid parameters including total cholesterol,  oselabeledaefromdruguse  oselabeledaefromdruguse including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,xeljanz,157,6393,6402,Maximum effects were generally observed within 6 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,xeljanz,158,6402,6451,"The effect of these  nonoseaeaeonlyasinstruction on cardiovascular morbidity and  nonoseaegeneralterm has not been determined.\n', '\n', '\n', '\n', ' Assessment of lipid parameters should be performed approximately 4-8 weeks following initiation of XELJANZ therapy.\n'",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
159,xeljanz,159,6451,6488,", '\n', '\n', '\n', ' Manage patients according to clinical guidelines [e.g., National Cholesterol Educational Program (NCEP)] for the management of  nonoseaeaeonlyasinstruction",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,xeljanz,160,6488,6511,"\n', '\n', '\n', '\n', '    5.5 Vaccinations\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,xeljanz,161,6511,6539,"', '\n', '\n', '  No data are available on the response to vaccination or on the  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,tobi,0,0,6,['    ADVERSE REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,tobi,1,6,38,"\n', '\n', '  TOBI was generally well tolerated during two clinical studies in 258  notaecandidateindication patients ranging in age from 6 to 48 years.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
2,tobi,2,38,93,"Patients received TOBI in alternating periods of 28 days on and 28 days off drug in addition to their standard  notaecandidateindication therapy for a total of 24 weeks.\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse were the only adverse experiences reported by significantly more TOBI-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
3,tobi,3,93,119,Thirty-three patients (13%) treated with TOBI complained of  oselabeledaefromdruguse compared to 17 (7%) placebo patients.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,tobi,4,119,155,"oselabeledaefromdruguse was more common in the on-drug periods.\n', '\n', ' Eight patients from the TOBI group (3%) reported  oselabeledaefromdruguse compared to no placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,tobi,5,155,180,"All episodes were transient, resolved without discontinuation of the TOBI treatment regimen, and were not associated with  nonoseaenegation in audiograms.  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
6,tobi,6,180,206,nonoseaeaeonlyasinstruction is one of the sentinel symptoms of  nonoseaeaeonlyasinstruction  and patients with this symptom should be carefully monitored for high frequency  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,tobi,7,206,264,"The numbers of patients reporting  nonoseaeaeratelteqplacebo such as  nonoseaeaeratelteqplacebo were similar in the TOBI and placebo groups.\n', '\n', ' Nine (3%) patients in the TOBI group and nine (3%) patients in the placebo group had  nonoseaeaeratelteqplacebo of at least 50% over baseline.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
8,tobi,8,264,333,"In all nine patients in the TOBI group,  nonoseaeaeonlyasinstruction at the next visit.\n', '\n', ' Table 1 lists the percent of patients with treatment-emergent adverse experiences (spontaneously reported and solicited) that occurred in >5% of TOBI patients during the two Phase III studies.\n', '\n', ' Table 1: Percent of Patients",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,tobi,9,333,384,"With Treatment Emergent Adverse Experiences Occurring in >5% of TOBI Patients \n', '   1  Includes subjective complaints of  nonoseaeaeratelteqplacebo    \n', '   2  Includes reported  oselabeledaefromdruguse or  oselabeledaefromdruguse associated with intercurrent illness or study drug administration.   ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
10,tobi,10,384,405,"\n', '  \n', '   Adverse Event      TOBI    (n=258)    %      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,tobi,11,405,413,Placebo    (n=262)    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,tobi,12,413,418,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,tobi,13,418,424,nonoseaeaeratelteqplacebo  46.1             47.3              ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
14,tobi,14,424,431,"\n', '  nonoseaeaeratelteqplacebo      ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
15,tobi,15,431,440,"38.0             39.3              \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,tobi,16,440,444,nonoseaeaeratelteqplacebo  37.6             ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
17,tobi,17,444,451,"39.7              \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,tobi,18,451,455,nonoseaeaeratelteqplacebo         35.7             ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
19,tobi,19,455,468,"39.3              \n', '  oselabeledaefromdruguse         34.5             33.6              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,tobi,20,468,508,"\n', '  nonoseaeaeratelteqplacebo          33.7             38.5              \n', '  nonoseaeaeratelteqplacebo  1         32.9             43.5              \n', '  oselabeledaefromdruguse    31.4             31.3              \n', '  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
21,tobi,21,508,512,nonoseaeaeratelteqplacebo         26.7             ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
22,tobi,22,512,514,32.1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,tobi,23,514,534,"\n', '  nonoseaeaeratelteqplacebo       26.0             29.8              \n', '  oselabeledaefromdruguse  21.3             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
24,tobi,24,534,541,"19.8              \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,tobi,25,541,558,"nonoseaeaeratelteqplacebo       19.4             23.7              \n', '  nonoseaeaeratelteqplacebo         18.6             27.9              ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
26,tobi,26,558,567,"\n', '  oselabeledaefromdruguse  2    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,tobi,27,567,569,16.3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,tobi,28,569,571,15.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,tobi,29,571,593,"\n', '  nonoseaeaeratelteqplacebo           15.9             20.2              \n', '  nonoseaeaeratelteqplacebo         14.0             22.1              ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
30,tobi,30,593,613,"\n', '  nonoseaeaeratelteqplacebo   12.8             23.7              \n', '  oselabeledaefromdruguse  12.8             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
31,tobi,31,613,615,6.5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,tobi,32,615,624,"\n', '  nonoseaeaeratelteqplacebo           11.2             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
33,tobi,33,624,635,"16.0              \n', '  nonoseaeaeratelteqplacebo      10.1             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
34,tobi,34,635,637,15.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,tobi,35,637,655,"\n', '  nonoseaeaeratelteqplacebo             8.1              12.6              \n', '  nonoseaeaeratelteqplacebo        ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
36,tobi,36,655,659,8.1              9.2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,tobi,37,659,664,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,tobi,38,664,677,"nonoseaeaeratelteqplacebo         7.4              8.8               \n', '  nonoseaeaeratelteqplacebo        ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
39,tobi,39,677,679,7.0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,tobi,40,679,681,8.0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,tobi,41,681,690,"\n', '  oselabeledaefromdruguse        7.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,tobi,42,690,692,6.5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,tobi,43,692,699,"\n', '  nonoseaeaeratelteqplacebo  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
44,tobi,44,699,701,6.6              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,tobi,45,701,712,"6.9               \n', '  nonoseaeaeratelteqplacebo         6.2              ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
46,tobi,46,712,725,"10.3              \n', '  oselabeledaefromdruguse          6.2              5.3               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,tobi,47,725,734,"\n', '  nonoseaeaeratelteqplacebo  5.8              ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
48,tobi,48,734,743,"8.0               \n', '  nonoseaeaeratelteqplacebo        ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
49,tobi,49,743,754,"5.8              7.6               \n', '  nonoseaeaeratelteqplacebo  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
50,tobi,50,754,756,5.4              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,tobi,51,756,769,"9.9               \n', '  nonoseaeaeratelteqplacebo             5.4              6.1               ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
52,tobi,52,769,820,"\n', '         Adverse drug reactions (<5%) occurring more frequently with TOBI in the placebo-controlled studies and assessed as drug-related in >=1% of patients:\n', ' \n', '\n', '    nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,tobi,53,820,934,"\n', '\n', '  oselabeledaefromdruguse (3.1%, vs 0% for placebo)\n', '\n', '    nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse (4.7%, vs 2.7% for placebo)\n', '\n', '    nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse (4.3%, vs 3.1% for placebo)\n', '\n', '   Adverse drug reactions derived from spontaneous reports  \n', '\n', ' The following adverse reactions have been identified during postapproval use of TOBI.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,tobi,54,934,1016,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse (see WARNINGS - Ototoxicity)\n', '\n', '    nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
55,tobi,55,1016,1021,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,tobi,56,1021,1023,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,tobi,57,1023,1040,"\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,tobi,58,1040,1042,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,tobi,59,1042,1066,"\n', '\n', '  oselabeledaefromdruguse (see WARNINGS -  oselabeledaefromdruguse ,  oselabeledaefromdruguse \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,tobi,60,1066,1068,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,tobi,61,1068,1077,"\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,tobi,62,1077,1081,oselabeledaefromdruguse     PRECAUTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,tobi,63,1081,1099,"\n', '\n', '    Information for Patients  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,tobi,64,1099,1105,"', '   NOTE:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,tobi,65,1105,1130,"In addition to information provided below, a Patient Medication Guide providing instructions for proper use of TOBI is contained inside the package.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,tobi,66,1130,1193,"\n', '\n', '     Safety Information  \n', '\n', '  TOBI is in a class of antibiotics that have caused  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction were two symptoms that were seen in more patients taking TOBI than placebo in research studies.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,tobi,67,1193,1202,Patients with  notaecandidateindication can have many symptoms.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
68,tobi,68,1202,1213,Some of these symptoms may be related to your medications.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,tobi,69,1213,1236,"If you have new or worsening symptoms, you should tell your doctor.\n', '\n', '  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,tobi,70,1236,1253,You should tell your doctor if you have  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or any  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,tobi,71,1253,1275,"\n', '\n', '  nonoseaeaeonlyasinstruction  Inform your doctor if you have any history of  notaecandidatepreexistingconditionorriskfactor",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
72,tobi,72,1275,1317,"\n', '\n', '  nonoseaeaeonlyasinstruction  If you want to become  nonoseaeaeonlyasinstruction or are  nonoseaeaeonlyasinstruction while on TOBI, you should talk with your doctor about the possibility of TOBI causing any harm.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,tobi,73,1317,1379,"'\n', ' Nursing Mothers: If you are nursing a baby, you should talk with your doctor before using TOBI.\n', '\n', '     TOBI Packaging  \n', '\n', '  TOBI comes in a single dose, ready-to-use ampule containing 300 mg tobramycin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,tobi,74,1379,1428,"Each foil pouch contains 4 ampules, for 2 days of TOBI therapy.\n', '\n', '     Dosage  \n', '\n', '  The 300 mg dose of TOBI is the same for patients regardless of age or weight.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,tobi,75,1428,1441,TOBI has not been studied in patients less than 6 years old.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,tobi,76,1441,1508,"Doses should be inhaled as close to 12 hours apart as possible and not less than 6 hours apart.\n', '\n', ' You should not mix TOBI with dornase alfa (PULMOZYME  (r)  , Genentech) in the nebulizer.\n', '\n', ' If you are taking several medications the recommended order is as follows:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,tobi,77,1508,1564,"bronchodilator first, followed by chest physiotherapy, then other inhaled medications and, finally, TOBI.\n', '\n', '     Treatment Schedule  \n', '\n', '  You should take TOBI in repeated cycles of 28 days on drug followed by 28 days off drug.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,tobi,78,1564,1661,"You should take TOBI twice a day during the 28-day period on drug.\n', '\n', '     How To Administer TOBI  \n', '\n', '  THIS INFORMATION IS NOT INTENDED TO REPLACE CONSULTATION WITH YOUR PHYSICIAN AND CF CARE TEAM ABOUT PROPERLY TAKING MEDICATION OR USING INHALATION EQUIPMENT.\n', '\n', ' TOBI is specifically formulated for inhalation using a PARI LC PLUSTM Reusable Nebulizer and a DeVilbiss  (r)  Pulmo-Aide  (r)   air compressor.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,tobi,79,1661,1674,"TOBI can be taken at home, school, or at work.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,tobi,80,1674,1742,"The following are instructions on how to use the DeVilbiss Pulmo-Aide air compressor and PARI LC PLUS Reusable Nebulizer to administer TOBI.\n', '\n', ' You will need the following supplies:\n', '\n', ' *  TOBI plastic ampule (vial) \n', ' *  DeVilbiss Pulmo-Aide air compressor \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,tobi,81,1742,1749,*  PARI LC PLUS Reusable Nebulizer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,tobi,82,1749,1773,"\n', ' *  Tubing to connect the nebulizer and compressor \n', ' *  Clean paper or cloth towels",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,tobi,83,1773,1855,"\n', ' *  Nose clips (optional) \n', '    It is important that your nebulizer and compressor function properly before starting your TOBI therapy.\n', ' \n', '\n', "" Note: Please refer to the manufacturers' care and use instructions for important information.\n"", '\n', '     Preparing Your TOBI for Inhalation  \n', '\n', '  1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,tobi,84,1855,1872,"Wash your hands thoroughly with soap and water.\n', '\n', ' 2a.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,tobi,85,1872,1890,"TOBI is packaged with 4 ampules per foil pouch.\n', '\n', ' 2b.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,tobi,86,1890,1902,Separate one ampule by gently pulling apart at the bottom tabs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,tobi,87,1902,1920,"Store all remaining ampules in the refrigerator as directed.\n', '\n', ' 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,tobi,88,1920,1942,"Lay out the contents of a PARI LC PLUS Reusable Nebulizer package on a clean, dry paper or cloth towel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,tobi,89,1942,1965,"You should have the following parts:\n', '\n', ' *  Nebulizer Top and Bottom (Nebulizer Cup)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,tobi,90,1965,1966,Assembly,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,tobi,91,1966,1970,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,tobi,92,1970,1975,*  Inspiratory Valve Cap,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,tobi,93,1975,1988,"\n', ' *  Mouthpiece with Valve \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,tobi,94,1988,1998,"*  Tubing \n', '    4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,tobi,95,1998,2020,"Remove the Nebulizer Top from the Nebulizer Cup by twisting the Nebulizer Top counter-clockwise, and then lifting off.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,tobi,96,2020,2032,Place the Nebulizer Top on the clean paper or cloth towel.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,tobi,97,2032,2053,"Stand the Nebulizer Cup upright on the towel.\n', ' \n', '\n', ' 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,tobi,98,2053,2065,Connect one end of the tubing to the compressor air outlet.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,tobi,99,2065,2071,The tubing should fit snugly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,tobi,100,2071,2113,"Plug in your compressor to an electrical outlet.\n', '\n', ' 6. Open the TOBI ampule by holding the bottom tab with one hand and twisting off the top of the ampule with the other hand.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,tobi,101,2113,2162,"Be careful not to squeeze the ampule until you are ready to empty its contents into the Nebulizer Cup.\n', '\n', ' 7. Squeeze all  the contents of the ampule into the Nebulizer Cup.\n', '\n', ' 8.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,tobi,102,2162,2167,Replace the Nebulizer Top.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,tobi,103,2167,2169,Note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,tobi,104,2169,2207,"In order to insert the Nebulizer Top into the Nebulizer Cup, the semi-circle halfway down the stem of the Nebulizer Top should face the Nebulizer Outlet.\n', '\n', ' 9.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,tobi,105,2207,2215,Attach the Mouthpiece to the Nebulizer Outlet.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,tobi,106,2215,2229,Then firmly push the Inspiratory Valve Cap in place on the Nebulizer Top.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,tobi,107,2229,2247,"Note: The Inspiratory Valve Cap will fit snugly.\n', '\n', ' 10.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,tobi,108,2247,2276,"Connect the free end of the tubing from the compressor to the Air Intake on the bottom of the nebulizer, making sure to keep the nebulizer upright.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,tobi,109,2276,2306,"Press the tubing on the Air Intake firmly.\n', '\n', '     TOBI Treatment  \n', '\n', '  1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,tobi,110,2306,2319,"Turn on the compressor.\n', '\n', ' 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,tobi,111,2319,2328,Check for a steady mist from the Mouthpiece.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,tobi,112,2328,2355,"If there is no mist, check all tubing connections and confirm that the compressor is working properly.\n', '\n', ' 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,tobi,113,2355,2378,"Sit or stand in an upright position that will allow you to breathe normally.\n', '\n', ' 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,tobi,114,2378,2397,Place Mouthpiece between your teeth and on top of your tongue and breathe normally only through your mouth.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,tobi,115,2397,2412,Nose clips may help you breathe through your mouth and not through your nose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,tobi,116,2412,2428,"Do not block airflow with your tongue.\n', '\n', ' 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,tobi,117,2428,2447,"Continue treatment until all your TOBI is gone, and there is no longer any mist being produced.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,tobi,118,2447,2460,You may hear a sputtering sound when the Nebulizer Cup is empty.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,tobi,119,2460,2472,The entire TOBI treatment should take approximately 15 minutes to complete.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,tobi,120,2472,2498,"Note: If you are interrupted, need to cough or rest during your TOBI treatment, turn off the compressor to save your medication.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,tobi,121,2498,2579,"Turn the compressor back on when you are ready to resume your therapy.\n', '\n', ' 6. Follow the nebulizer cleaning and disinfecting instructions after completing therapy.\n', '\n', '     Cleaning Your Nebulizer  \n', '\n', '  To reduce the risk of infection, illness or injury from contamination, you must thoroughly clean all parts of the nebulizer as instructed after each treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,tobi,122,2579,2588,Never use a nebulizer with a clogged nozzle.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,tobi,123,2588,2609,"If the nozzle is clogged, no aerosol mist is produced, which will alter the effectiveness of the treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,tobi,124,2609,2624,"Replace the nebulizer if clogging occurs.\n', '\n', ' 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,tobi,125,2624,2641,"Remove tubing from nebulizer and disassemble nebulizer parts.\n', '\n', ' 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,tobi,126,2641,2682,"Wash all parts (except tubing) with warm water and liquid dish soap.\n', '\n', ' 3. Rinse thoroughly with warm water and shake out water.\n', '\n', ' 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,tobi,127,2682,2698,"Air dry or hand dry nebulizer parts on a clean, lint-free cloth.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,tobi,128,2698,2714,"Reassemble nebulizer when dry, and store.\n', '\n', ' 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,tobi,129,2714,2731,You can also wash all parts of the nebulizer in a dishwasher (except tubing).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,tobi,130,2731,2750,"Place the nebulizer parts in a dishwasher basket, then place on the top rack of the dishwasher.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,tobi,131,2750,2769,"Remove and dry the parts when the cycle is complete.\n', '\n', '     Disinfecting",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,tobi,132,2769,2772,Your Nebulizer  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,tobi,133,2772,2798,"\n', '\n', '  Your nebulizer is for your use only - Do not share your nebulizer with other people.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,tobi,134,2798,2805,You must regularly disinfect the nebulizer.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,tobi,135,2805,2831,"Failure to do so could lead to serious or  nonoseaegeneralterm illness.\n', '\n', ' Clean the nebulizer as described above.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,tobi,136,2831,2855,"Every other treatment day, disinfect the nebulizer parts (except tubing) by boiling them in water for a full 10 minutes.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,tobi,137,2855,2926,"Dry parts on a clean, lint-free cloth.\n', '\n', '     Care and Use of Your Pulmo-Aide Compressor  \n', '\n', ""  Follow the manufacturer's instructions for care and use of your compressor.\n"", '\n', '  Filter Change:  \n', '\n', ' 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,tobi,138,2926,2966,"DeVilbiss Compressor filters should be changed every six months or sooner if filter turns completely gray in color.\n', '\n', '  Compressor Cleaning:  \n', '\n', ' 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,tobi,139,2966,2991,"With power switch in the ""Off"" position, unplug power cord from wall outlet.\n', '\n', ' 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,tobi,140,2991,3011,"Wipe outside of the compressor cabinet with a clean, damp cloth every few days to keep dust free.\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,tobi,141,3011,3019,", '\n', ' Caution:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,tobi,142,3019,3075,"Do not submerge in water; doing so will result in compressor damage.\n', '\n', '     Storage Instructions  \n', '\n', ""  You should store TOBI ampules in a refrigerator (2 degrees C-8 degrees C or 36 degrees F -46 degrees F).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,tobi,143,3075,3212,"However, when you don't have a refrigerator available (e.g., transporting your TOBI), you may store the foil pouches (opened or unopened) at room temperature (up to 25 degrees C/77 degrees F) for up to 28 days.\n"", '\n', ' Avoid exposing TOBI ampules to intense light.\n', '\n', ' Unrefrigerated TOBI, which is normally slightly yellow, may darken with age; however, the color change does not indicate any change in the quality of the product.\n', '\n', ' You should not use TOBI if it is cloudy, if there are particles in the solution, or if it has been stored at room temperature for more than 28 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,tobi,144,3212,3285,"You should not use TOBI beyond the expiration date stamped on the ampule.\n', '\n', '     Additional Information  \n', '\n', '  Nebulizer: 1-800-327-8632\n', '\n', ' Compressor: 1-800-338-1988\n', '\n', ' TOBI: 1-888-NOW-NOVA (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,tobi,145,3285,3349,"1-888-669-6682)\n', '\n', '    \n', '\n', '  Laboratory Tests\n', '\n', '  Audiograms  \n', '\n', ' Clinical studies of TOBI did not identify  nonoseaenegation using audiometric tests which evaluated hearing up to 8000 Hz.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
146,tobi,146,3349,3404,"Physicians should consider an audiogram for patients who show any evidence of  nonoseaeaeonlyasinstruction  or who are at increased risk for  nonoseaeaeonlyasinstruction    nonoseaeaeonlyasinstruction may be a sentinel symptom of  nonoseaeaeonlyasinstruction  and therefore the onset of this symptom warrants caution.\n', '\n', '  Serum Concentrations  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,tobi,147,3404,3409,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,tobi,148,3409,3443,"', ' In patients with normal renal function treated with TOBI, serum tobramycin concentrations are approximately 1 mcg/mL 1 hour after dose administration and do not require routine monitoring.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,tobi,149,3443,3494,"Serum concentrations of tobramycin in patients with  notaecandidatepreexistingconditionorriskfactor or patients treated with concomitant parenteral tobramycin should be monitored at the discretion of the treating physician.\n', '\n', ' The serum concentration of tobramycin should only be monitored through venipuncture and not finger prick blood sampling.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
150,tobi,150,3494,3516,Contamination of the skin of the fingers with tobramycin may lead to falsely increased measurements of serum levels of the drug.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,tobi,151,3516,3585,"This contamination cannot be completely avoided by hand washing before testing.\n', '\n', '  Renal Function  \n', '\n', ' The clinical studies of TOBI did not reveal any imbalance in the percentage of patients in the TOBI and placebo groups who experienced at least a 50%  nonoseaeaeratelteqplacebo from baseline (see ADVERSE REACTIONS).",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
152,tobi,152,3585,3699,"Laboratory tests of urine and renal function should be conducted at the discretion of the treating physician.\n', '\n', '     Drug Interactions  \n', '\n', '  In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME, Genentech), beta-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n', '\n', ' Concurrent and/or sequential use of TOBI with other drugs with  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction potential should be avoided.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,tobi,153,3699,3714,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,tobi,154,3714,3732,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or intravenous mannitol.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,tobi,155,3732,3787,"The interaction between inhaled mannitol and TOBI has not been evaluated.\n', '\n', '     Carcinogenesis, Mutagenesis, Impairment of Fertility  \n', '\n', '  A two-year rat inhalation toxicology study to assess  nonoseaeaeonlyasinstruction potential of TOBI has been completed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,tobi,156,3787,3803,Rats were exposed to TOBI for up to 1.5 hours per day for 95 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,tobi,157,3803,3816,The clinical formulation of the drug was used for this carcinogenicity study.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,tobi,158,3816,3851,"Serum levels of tobramycin of up to 35 mcg/mL were measured in rats, in contrast to the average 1 mcg/mL levels observed in  notaecandidateindication patients in clinical trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
159,tobi,159,3851,3895,"There was no drug-related increase in the incidence of any variety of  nonoseaeaeanimal \n', '\n', ' Additionally, TOBI has been evaluated for  nonoseaeaeonlyasinstruction in a battery of in vitro and in vivo tests.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
160,tobi,160,3895,3923,"The Ames bacterial reversion test, conducted with 5 tester strains, failed to show a significant  nonoseaeaeanimal with or without metabolic activation in all strains.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
161,tobi,161,3923,4047,"Tobramycin was negative in the mouse  nonoseaeaeanimal forward mutation assay, did not induce  nonoseaeaeanimal in Chinese hamster ovary cells, and was negative in the mouse micronucleus test.\n', '\n', ' Subcutaneous administration of up to 100 mg/kg of tobramycin did not affect  nonoseaeaeanimal or cause  nonoseaeaeanimal in male or female rats.\n', '\n', '     Pregnancy  \n', '\n', '   \n', '\n', '  Teratogenic Effects - Pregnancy Category D\n', '\n', ' (See WARNINGS)\n', '\n', ' No reproduction toxicology studies have been conducted with TOBI.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
162,tobi,162,4047,4077,"However, subcutaneous administration of tobramycin at doses of 100 or 20 mg/kg/day during organogenesis was not  nonoseaeaeanimal in rats or rabbits, respectively.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
163,tobi,163,4077,4122,"Doses of tobramycin >=40 mg/kg/day were severely  nonoseaeaeanimal to rabbits and precluded the evaluation of  nonoseaeaeonlyasinstruction  Aminoglycosides can cause  oselabeledaeclasseffect (e.g.,  oselabeledaeclasseffect  when administered to a  notaecandidatepreexistingconditionorriskfactor woman.  ",1,0,1,0,0,0,0,0,1,0,0,0,0,0,0
164,tobi,164,4122,4136,nonoseaeaeonlyasinstruction was not evaluated in offspring during nonclinical  nonoseaeaeonlyasinstruction studies with tobramycin.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,tobi,165,4136,4208,"If TOBI is used during  nonoseaeaeonlyasinstruction  or if the patient becomes  nonoseaeaeonlyasinstruction while taking TOBI, the patient should be apprised of the potential  oselabeledaefromdruguse \n', '\n', '     Nursing Mothers  \n', '\n', '  It is not known if TOBI will reach sufficient concentrations after administration by inhalation to be excreted in human breast milk.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,tobi,166,4208,4305,"Because of the potential for  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction in infants, a decision should be made whether to terminate nursing or discontinue TOBI.\n', '\n', '     Pediatric Use  \n', '\n', '  The safety and efficacy of TOBI have not been studied in pediatric patients under 6 years of age.\n', '\n', '     Geriatric Use  \n', '\n', '  Clinical studies of TOBI did not include patients aged 65 years and over.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,tobi,167,4305,4431,"Tobramycin is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with  notaecandidatepreexistingconditionorriskfactor  Because elderly patients are more likely to have  notaecandidatepreexistingconditionorriskfactor     WARNINGS  \n', '\n', '  Caution should be exercised when prescribing TOBI to patients with known or suspected  notaecandidatepreexistingconditionorriskfactor  auditory, vestibular, or neuromuscular  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  vestibular, or neuromuscular  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or neuromuscular  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  Patients receiving concomitant parenteral aminoglycoside therapy should be monitored as clinically appropriate.\n', '\n', ' Aminoglycosides can cause  oselabeledaeclasseffect when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
168,tobi,168,4431,4524,"Aminoglycosides cross the placenta, and streptomycin has been associated with several reports of total, irreversible, bilateral  oselabeledaeclasseffect in pediatric  oselabeledaefromdruguse  Patients who use TOBI during  nonoseaeaeonlyasinstruction  or become  nonoseaeaeonlyasinstruction while taking TOBI should be apprised of the potential  oselabeledaefromdruguse \n', '\n', '     Ototoxicity  \n', '\n', '   nonoseaenegation  as measured by complaints of  nonoseaenegation or by audiometric evaluations, did not occur with TOBI therapy during clinical studies.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
169,tobi,169,4524,4546,"However, transient  oselabeledaefromdruguse occurred in eight TOBI-treated patients versus no placebo patients in the clinical studies.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,tobi,170,4546,4572,nonoseaeaeonlyasinstruction may be a sentinel symptom of  nonoseaeaeonlyasinstruction  and therefore the onset of this symptom warrants caution (see ADVERSE REACTIONS).  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,tobi,171,4572,4574,oselabeledaeclasseffect  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,tobi,172,4574,4594,manifested as both  oselabeledaeclasseffect and vestibular  oselabeledaeclasseffect  oselabeledaeclasseffect  has been reported with parenteral aminoglycosides.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,tobi,173,4594,4627,"oselabeledaeclasseffect may be manifested by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication \n', '\n', '  In postmarketing experience, patients receiving TOBI have reported  oselabeledaefromdruguse   ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
174,tobi,174,4627,4643,Some of these reports occurred in patients with previous or concomitant treatment with systemic aminoglycosides.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,tobi,175,4643,4689,"Patients with  oselabeledaefromdruguse frequently reported  oselabeledaefromdruguse \n', '\n', '     Nephrotoxicity  \n', '\n', '   oselabeledaeclasseffect was not seen during TOBI clinical studies but has been associated with aminoglycosides as a class.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,tobi,176,4689,4776,"If  nonoseaeaeonlyasinstruction occurs in a patient receiving TOBI, tobramycin therapy should be discontinued until serum concentrations fall below 2 mcg/mL.\n', '\n', '     Muscular Disorders  \n', '\n', '  TOBI should be used cautiously in patients with  notaecandidatepreexistingconditionorriskfactor  such as  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  since aminoglycosides may  oselabeledaefromdruguse because of a potential curare-like effect on neuromuscular function.\n', '\n', '     ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
177,tobi,177,4776,4796,"Bronchospasm  \n', '\n', '   oselabeledaefromdruguse has been reported with inhalation of TOBI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,tobi,178,4796,4819,"In clinical studies of TOBI,  nonoseaeaeratelteqplacebo measured after the inhaled dose were similar in the TOBI and placebo groups.  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
179,tobi,179,4819,4822,nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,zaltrap,0,0,59,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed elsewhere in the labeling:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [ see  Boxed Warning  ,  Warnings and Precautions (5.1)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,zaltrap,1,59,82,"\n', ' *   oselabeledaefromdruguse [ see  Boxed Warning  ,  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,zaltrap,2,82,105,"\n', ' *   oselabeledaefromdruguse [ see  Boxed Warning  ,  Warnings and Precautions (5.3)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,zaltrap,3,105,123,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.4)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,zaltrap,4,123,141,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.5)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,zaltrap,5,141,159,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.6)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,zaltrap,6,159,177,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.7)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,zaltrap,7,177,208,"\n', ' *   oselabeledaefromdruguse and  nonoseaemanifestationorcomplication [ see  Warnings and Precautions (5.8)   ] \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
8,zaltrap,8,208,211,[ see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,zaltrap,9,211,219,Warnings and Precautions (5.9)   ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,zaltrap,10,219,238,"\n', ' *   oselabeledaefromdruguse  [ see  Warnings and Precautions (5.10)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,zaltrap,11,238,316,"\n', '      EXCERPT:   Most common adverse reactions (all grades, >=20% incidence and at least 2% greater incidence for the ZALTRAP/FOLFIRI regimen) were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,zaltrap,12,316,321,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,zaltrap,13,321,363,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,zaltrap,14,363,400,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,zaltrap,15,400,528,"Because clinical trials are conducted under varying designs and in different patient populations, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.\n', '\n', '\n', '\n', ' The safety of ZALTRAP in combination with FOLFIRI was evaluated in 1216 previously treated patients with  notaecandidateindication (Study 1) who were treated with ZALTRAP 4 mg per kg intravenous (N=611) or placebo (N=605) every two weeks (one cycle) in a randomized (1:1), double-blind, placebo-controlled Phase 3 study.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
16,zaltrap,16,528,835,"Patients received a median of 9 cycles of ZALTRAP/FOLFIRI or 8 cycles of placebo/FOLFIRI.\n', '\n', '\n', '\n', ' The most common adverse reactions (all grades, >=20% incidence) reported at a higher incidence (2% or greater between-arm difference) in the ZALTRAP/FOLFIRI arm , in order of decreasing frequency, were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  fatigue,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (see  Table 1  ).\n', '\n', '\n', '\n', ' The most common Grade 3-4 adverse reactions (>=5%) reported at a higher incidence (2% or greater between-arm difference) in the ZALTRAP/FOLFIRI arm, in order of decreasing frequency, were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (see  Table 1  ).\n', '\n', '\n', '\n', ' The most frequent adverse reactions leading to permanent discontinuation in >=1% of patients treated with ZALTRAP/FOLFIRI regimen were  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' The ZALTRAP dose was reduced and/or omitted in 17% of patients compared to placebo-dose modification in 5% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,zaltrap,17,835,991,"Cycle delays >7 days occurred in 60% of patients treated with ZALTRAP/FOLFIRI compared with 43% of patients treated with placebo/FOLFIRI.\n', '\n', '\n', '\n', ' The most common adverse reactions and  nonoseaegeneralterm during study treatment in Study 1 where the incidence was >=5% (all grades) in patients receiving ZALTRAP in combination with FOLFIRI and which occurred at >=2% higher frequency in patients treated with ZALTRAP/FOLFIRI compared to placebo/FOLFIRI are shown in Table 1.\n', '\n', '\n', '\n', ' Table 1 - Selected Adverse Reactions and Laboratory Findings in Study 1: \n', ' Primary System Organ Class  Preferred Term (%)  Placebo/FOLFIRI(N=605)  ZALTRAP/FOLFIRI(N=611)   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,zaltrap,18,991,1019,"\n', ' All grades                                  Grades 3-4       All grades       Grades 3-4      \n', '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,zaltrap,19,1019,1076,"' Note: Adverse Reactions are reported using MedDRA version MEDDRA13.1 and graded using NCI CTC version 3.0   \n', '  \n', '  nonoseaegeneralterm                                                                                    \n', '    oselabeledaefromdruguse                       6%              0.8%              9%              0.8%         \n', '  nonoseaegeneralterm                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
20,zaltrap,20,1076,1133,"\n', '    oselabeledaefromdruguse                                    72%              12%              78%              16%         \n', '    oselabeledaefromdruguse                                   57%              30%              67%              37%         \n', '    oselabeledaefromdruguse                              35%              2%               48%              3%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,zaltrap,21,1133,1140,"\n', '  nonoseaegeneralterm                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,zaltrap,22,1140,1159,"\n', '    oselabeledaefromdruguse                            24%              2%               32%              3%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,zaltrap,23,1159,1183,"\n', '    oselabeledaefromdruguse                                   3%               1%               9%               4%          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,zaltrap,24,1183,1209,"nonoseaegeneralterm                                                                                       \n', '    oselabeledaefromdruguse                                      9%              0.3%              22%              2%          \n', '  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,zaltrap,25,1209,1211,nonoseaegeneralterm                                                                                             ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,zaltrap,26,1211,1230,"\n', '    oselabeledaefromdruguse                                  11%             1.5%              41%              19%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,zaltrap,27,1230,1237,"\n', '  nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,zaltrap,28,1237,1249,"\n', '    oselabeledaefromdruguse                                     7%                0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,zaltrap,29,1249,1255,28%             0.2%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,zaltrap,30,1255,1267,"\n', '    oselabeledaefromdruguse                                     3%                0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,zaltrap,31,1267,1273,25%             0.5%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,zaltrap,32,1273,1310,"\n', '    oselabeledaefromdruguse                                       9%              0.8%              12%             0.8%         \n', '    oselabeledaefromdruguse                            3%                0               8%              0.2%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,zaltrap,33,1310,1327,"\n', '    oselabeledaefromdruguse                                    2%                0               6%                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,zaltrap,34,1327,1353,"\n', '  nonoseaegeneralterm                                                                                     \n', '    oselabeledaefromdruguse                                      57%              8%               69%              19%         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,zaltrap,35,1353,1391,"\n', '    oselabeledaefromdruguse                                    33%              5%               50%              13%         \n', '    oselabeledaefromdruguse                                24%              2%               27%              4%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,zaltrap,36,1391,1410,"\n', '    oselabeledaefromdruguse                          8%               1%               11%              1%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,zaltrap,37,1410,1427,"\n', '    oselabeledaefromdruguse                                   2%                0               6%                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,zaltrap,38,1427,1451,"\n', '    oselabeledaefromdruguse                             2%              0.5%              5%              0.7%         \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,zaltrap,39,1451,1491,"oselabeledaefromdruguse                                    2%              0.3%              5%              0.3%         \n', '  nonoseaegeneralterm                                                                         \n', '    oselabeledaefromdruguse        4%              0.5%              11%              3%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,zaltrap,40,1491,1508,"\n', '    oselabeledaefromdruguse                        3%                0               8%                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,zaltrap,41,1508,1534,"\n', '  nonoseaegeneralterm                                                                                    \n', '    oselabeledaefromdruguse                                   41%              1%               62%              8%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,zaltrap,42,1534,1552,"\n', '    oselabeledaefromdruguse                    19%             0.5%              23%               0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,zaltrap,43,1552,1559,"\n', '  nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,zaltrap,44,1559,1578,"\n', '    oselabeledaefromdruguse                                       39%              8%               48%              13%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,zaltrap,45,1578,1597,"\n', '    oselabeledaefromdruguse                                      13%              3%               18%              5%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,zaltrap,46,1597,1623,"\n', '  nonoseaegeneralterm                                                                                                 \n', '    oselabeledaefromdruguse                                 54%              2%               62%              3%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
47,zaltrap,47,1623,1642,"\n', '    oselabeledaefromdruguse                                 39%              2%               50%              3%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,zaltrap,48,1642,1661,"\n', '    oselabeledaefromdruguse                              14%             0.8%              32%              3%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,zaltrap,49,1661,1823,"\n', '            oselabeledaefromdruguse occurred at a higher frequency in patients receiving ZALTRAP/FOLFIRI (46%, all grades; 12%, Grade 3-4) than in patients receiving placebo/FOLFIRI (33%, all grades; 7%, Grade 3-4), including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', ' \n', '\n', ' In patients with  notaecandidateindication  severe  oselabeledaefromdruguse have been reported with ZALTRAP/FOLFIRI (0.3%) and placebo/FOLFIRI (0.5%).\n', '\n', '\n', '\n', ' In patients with  notaecandidateindication   oselabeledaefromdruguse , consisting primarily of  oselabeledaefromdruguse and  oselabeledaefromdruguse  occurred in 9% of patients treated with ZALTRAP/FOLFIRI and 7% of patients treated with placebo/FOLFIRI.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
50,zaltrap,50,1823,1853,Grade 3-4  oselabeledaefromdruguse occurred in 8% of patients treated with ZALTRAP/FOLFIRI and in 6% of patients treated with placebo/FOLFIRI.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,zaltrap,51,1853,1915,"oselabeledaefromdruguse occurred in 5% of patients treated with ZALTRAP/FOLFIRI and 3.4% of patients treated with placebo/FOLFIRI.\n', '\n', '\n', '\n', '   6.2 Immunogenicity\n', '\n', '  As with all therapeutic proteins, there is a potential for  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,zaltrap,52,1915,1939,"In patients with various  notaecandidateindication across 15 studies, 1.4% (41/2862) of patients tested  nonoseaeaeonlyasinstruction  at baseline.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
53,zaltrap,53,1939,1968,The incidence of  oselabeledaefromdruguse was 3.1% (53/1687) in patients receiving intravenous ziv-aflibercept and 1.7% (19/1134) in patients receiving placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,zaltrap,54,1968,2038,"Among patients who tested  oselabeledaefromdruguse and had sufficient samples for further testing,  oselabeledaefromdruguse in 17 of 48 ziv-aflibercept-treated patients and in 2 of 40 patients receiving placebo.\n', '\n', '\n', '\n', ' The mean free ziv-aflibercept trough concentrations were lower in patients with  nonoseaeaeonlyasinstruction than in the overall population.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,zaltrap,55,2038,2086,"The impact of  nonoseaeaeonlyasinstruction on efficacy and safety could not be assessed based on limited available data.\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction data are highly dependent on the sensitivity and specificity of the assay.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,zaltrap,56,2086,2120,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction in an assay may be influenced by several factors, including sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,zaltrap,57,2120,2149,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction \n', '\n', '    BOXED WARNING:",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,zaltrap,58,2149,2151,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,zaltrap,59,2151,2161,"HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,zaltrap,60,2161,2169,"'\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,zaltrap,61,2169,2178,"HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,zaltrap,62,2178,2222,"\n', '\n', '     nonoseaegeneralterm   Severe and sometimes  nonoseaegeneralterm  oselabeledaefromdruguse  including  oselabeledaefromdruguse (GI)  oselabeledaefromdruguse  has been reported in the patients who have received ZALTRAP in combination with FOLFIRI.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,zaltrap,63,2222,2270,"Monitor patients for signs and symptoms of  nonoseaeaeonlyasinstruction and other severe  nonoseaeaeonlyasinstruction   Do not administer ZALTRAP to patients with severe  notaecandidatepreexistingconditionorriskfactor [  see   Dosage and Administration (2.2)  ,   Warnings and Precautions (5.1)    ].  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
64,zaltrap,64,2270,2303,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse including  nonoseaegeneralterm  oselabeledaefromdruguse can occur in patients receiving ZALTRAP.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,zaltrap,65,2303,2328,"Discontinue ZALTRAP therapy in patients who experience  nonoseaeaeonlyasinstruction [  see   Dosage and Administration (2.2)  ,   Warnings and Precautions",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,zaltrap,66,2328,2335,(5.2)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,zaltrap,67,2335,2367,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm   Severe  oselabeledaefromdruguse can occur in patients receiving ZALTRAP/FOLFIRI.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,zaltrap,68,2367,2375,Discontinue ZALTRAP in patients with  nonoseaeaeonlyasinstruction     ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,zaltrap,69,2375,2435,"5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '  EXCERPT:   Adverse reactions, sometimes severe and life-threatening or fatal, have been seen in clinical trials with ZALTRAP, including:\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,zaltrap,70,2435,2446,*  Fistula Formation: Discontinue ZALTRAP if fistula occurs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,zaltrap,71,2446,2455,"(  2.2  ,  5.4  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,zaltrap,72,2455,2470,"\n', ' *  Hypertension: Monitor blood pressure and treat hypertension.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,zaltrap,73,2470,2479,Temporarily suspend ZALTRAP if hypertension is not controlled.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,zaltrap,74,2479,2481,Discontinue ZALTRAP,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,zaltrap,75,2481,2486,if hypertensive crisis develops.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,zaltrap,76,2486,2521,"(  2.2  ,  5.5  ) \n', ' *  Arterial Thromboembolic Events (ATE) (e.g., transient ischemic attacks, cerebrovascular accident, angina pectoris):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,zaltrap,77,2521,2523,Discontinue ZALTRAP,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,zaltrap,78,2523,2527,if ATE develops.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,zaltrap,79,2527,2544,"(  5.6  ) \n', ' *  Proteinuria: Monitor urine protein.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,zaltrap,80,2544,2546,Suspend ZALTRAP,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,zaltrap,81,2546,2556,when proteinuria >= 2 grams per 24 hours.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,zaltrap,82,2556,2558,Discontinue ZALTRAP,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,zaltrap,83,2558,2569,if nephrotic syndrome or thrombotic microangiopathy (TMA) develops.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,zaltrap,84,2569,2630,"(  2.2  ,  5.7  ) \n', ' *  Neutropenia and Neutropenic Complications: Delay administration of ZALTRAP/FOLFIRI until neutrophil count is >= 1.5 * 10  9  /L. (5.8) \n', ' *  Diarrhea and Dehydration: Incidence of severe diarrhea and dehydration is increased.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,zaltrap,85,2630,2636,Monitor elderly patients more closely.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,zaltrap,86,2636,2645,"(  5.9  ,  8.5  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,zaltrap,87,2645,2662,"\n', ' *  Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue ZALTRAP.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,zaltrap,88,2662,2724,"(  5.10  ) \n', '    \n', ' \n', '\n', '   5.1 Hemorrhage\n', '\n', '\n', '\n', '  Patients treated with ZALTRAP have an increased risk of  oselabeledaefromdruguse  including severe and sometimes  nonoseaegeneralterm  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,zaltrap,89,2724,2761,In patients with  notaecandidateindication   oselabeledaefromdruguse  oselabeledaefromdruguse (all grades) were reported in 38% of patients treated with ZALTRAP/FOLFIRI compared to 19% of patients treated with placebo/FOLFIRI.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
90,zaltrap,90,2761,2800,Grade 3-4  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  were reported in 3% of patients receiving ZALTRAP/FOLFIRI compared with 1% of patients receiving placebo/FOLFIRI.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,zaltrap,91,2800,2924,"Severe  oselabeledaefromdruguse and  oselabeledaefromdruguse  oselabeledaefromdruguse including  nonoseaegeneralterm events have also occurred in patients receiving ZALTRAP.\n', '\n', '\n', '\n', ' Monitor patients for signs and symptoms of  nonoseaeaeonlyasinstruction  Do not initiate ZALTRAP in patients with severe  notaecandidatepreexistingconditionorriskfactor  Discontinue ZALTRAP in patients who develop severe  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ].\n', '\n', '\n', '\n', '    5.2 Gastrointestinal Perforation\n', '\n', '\n', '\n', '   oselabeledaefromdruguse including  nonoseaegeneralterm  oselabeledaefromdruguse can occur in patients receiving ZALTRAP.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
92,zaltrap,92,2924,2980,"Across three Phase 3 placebo-controlled clinical studies ( notaecandidateindication  pancreatic, and lung  notaecandidateindication  notaecandidatepreexistingconditionorriskfactor  and lung  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor populations), the incidence of  oselabeledaefromdruguse (all grades) was 0.8% for patients treated with ZALTRAP and 0.3% for patients treated with placebo.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
93,zaltrap,93,2980,3098,"Grade 3-4  oselabeledaefromdruguse events occurred in 0.8% of patients treated with ZALTRAP and 0.2% of patients treated with placebo.\n', '\n', '\n', '\n', ' Monitor patients for signs and symptoms of  nonoseaeaeonlyasinstruction  Discontinue ZALTRAP therapy in patients who experience  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ].\n', '\n', '\n', '\n', '    5.3 Compromised Wound Healing\n', '\n', '\n', '\n', '  ZALTRAP  nonoseaeaeanimal in animal models [ see  Nonclinical Toxicology (",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
94,zaltrap,94,3098,3102,13.2)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,zaltrap,95,3102,3176,".\n', '\n', '\n', '\n', ' Grade 3  oselabeledaefromdruguse was reported in 2 patients (0.3%) treated with ZALTRAP/FOLFIRI regimen and in none of the patients treated with placebo/FOLFIRI regimen.\n', '\n', '\n', '\n', ' Suspend ZALTRAP for at least 4 weeks prior to elective surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,zaltrap,96,3176,3197,Do not resume ZALTRAP for at least 4 weeks following major surgery and until the surgical wound is fully healed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,zaltrap,97,3197,3228,"For minor surgery such as central venous access port placement, biopsy, and tooth extraction, ZALTRAP may be initiated/resumed once the surgical wound is fully healed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,zaltrap,98,3228,3246,Discontinue ZALTRAP in patients with  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,zaltrap,99,3246,3268,".\n', '\n', '\n', '\n', '    5.4 Fistula Formation\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,zaltrap,100,3268,3305,"'\n', '\n', '\n', '   oselabeledaefromdruguse involving  oselabeledaefromdruguse  oselabeledaefromdruguse involving gastrointestinal and  oselabeledaefromdruguse sites occurs at a higher incidence in patients treated with ZALTRAP.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,zaltrap,101,3305,3387,"In patients with  notaecandidateindication   oselabeledaefromdruguse  oselabeledaefromdruguse (anal,  oselabeledaefromdruguse  oselabeledaefromdruguse (anal, enterovesical,  oselabeledaefromdruguse  oselabeledaefromdruguse (anal, enterovesical, enterocutaneous,  oselabeledaefromdruguse  oselabeledaefromdruguse (anal, enterovesical, enterocutaneous, colovaginal,  oselabeledaefromdruguse sites) were reported in 9 of 611 patients (1.5%) treated with ZALTRAP/FOLFIRI regimen and 3 of 605 patients (0.5%) treated with placebo/FOLFIRI regimen.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
102,zaltrap,102,3387,3494,"Grade 3  oselabeledaefromdruguse formation occurred in 2 patients treated with ZALTRAP (0.3%) and in 1 placebo-treated patient (0.2%).\n', '\n', '\n', '\n', ' Discontinue ZALTRAP therapy in patients who develop  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ].\n', '\n', '\n', '\n', '    5.5 Hypertension\n', '\n', '\n', '\n', '  ZALTRAP increases the risk of Grade 3-4  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,zaltrap,103,3494,3508,There is no clinical trial experience administering ZALTRAP to patients with  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,zaltrap,104,3508,3558,In patients with  notaecandidateindication  Grade 3  oselabeledaefromdruguse (defined as requiring adjustment in existing  nonoseaeaeonlyasinstruction or treatment with more than one drug) was reported in 1.5% of patients treated with placebo/FOLFIRI and 19% of patients treated with ZALTRAP/FOLFIRI.,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
105,zaltrap,105,3558,3580,Grade 4  oselabeledaefromdruguse ( oselabeledaefromdruguse  was reported in 1 patient (0.2%) treated with ZALTRAP/FOLFIRI.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,zaltrap,106,3580,3639,"Among those patients treated with ZALTRAP/FOLFIRI developing Grade 3-4  oselabeledaefromdruguse  54% had onset during the first two cycles of treatment.\n', '\n', '\n', '\n', ' Monitor blood pressure every two weeks or more frequently as clinically indicated during treatment with ZALTRAP.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,zaltrap,107,3639,3651,Treat with appropriate  nonoseaeaeonlyasinstruction and continue monitoring blood pressure regularly.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,zaltrap,108,3651,3676,"Temporarily suspend ZALTRAP in patients with  nonoseaeaeonlyasinstruction until controlled, and permanently reduce ZALTRAP dose to 2 mg per kg for subsequent cycles.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,zaltrap,109,3676,3697,Discontinue ZALTRAP in patients with  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,zaltrap,110,3697,3756,".\n', '\n', '\n', '\n', '    5.6 Arterial Thromboembolic Events\n', '\n', '\n', '\n', '   oselabeledaefromdruguse , including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred more frequently in patients who have received ZALTRAP.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,zaltrap,111,3756,3786,In patients with  notaecandidateindication   oselabeledaefromdruguse was reported in 2.6% of patients treated with ZALTRAP/FOLFIRI and 1.7% of patients treated with placebo/FOLFIRI.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
112,zaltrap,112,3786,3905,"Grade 3-4 events occurred in 11 patients (1.8%) treated with ZALTRAP/FOLFIRI and 4 patients (0.7%) treated with placebo/FOLFIRI.\n', '\n', '\n', '\n', ' Discontinue ZALTRAP in patients who experience an  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ].\n', '\n', '\n', '\n', '    5.7 Proteinuria\n', '\n', '\n', '\n', '  Severe  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred more frequently in patients treated with ZALTRAP.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,zaltrap,113,3905,3934,In patients with  notaecandidateindication   oselabeledaefromdruguse was reported in 62% patients treated with ZALTRAP/FOLFIRI compared to 41% patients treated with placebo/FOLFIRI.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
114,zaltrap,114,3934,3973,Grade 3-4  oselabeledaefromdruguse occurred in 8% of patients treated with ZALTRAP/FOLFIRI to 1% of patients treated with placebo/FOLFIRI [ see  Adverse Reactions (6.1)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,zaltrap,115,3973,4000,oselabeledaefromdruguse occurred in 2 patients (0.5%) treated with ZALTRAP/FOLFIRI compared to none of the patients treated with placebo/FOLFIRI.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,zaltrap,116,4000,4057,"oselabeledaefromdruguse was reported in 3 of 2258 patients with  notaecandidatepreexistingconditionorriskfactor enrolled across completed studies.\n', '\n', '\n', '\n', ' Monitor  nonoseaeaeonlyasinstruction by urine dipstick analysis and/or urinary protein creatinine ratio (UPCR) for the development or worsening of  nonoseaeaeonlyasinstruction during ZALTRAP therapy.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
117,zaltrap,117,4057,4123,"Patients with a dipstick of >=2+ for protein or a UPCR greater than 1 should undergo a 24-hour urine collection.\n', '\n', '\n', '\n', ' Suspend ZALTRAP administration for  nonoseaeaeonlyasinstruction 2 grams per 24 hours or more, and resume when  nonoseaeaeonlyasinstruction is less than 2 grams per 24 hours.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,zaltrap,118,4123,4151,"If recurrent, suspend until  nonoseaeaeonlyasinstruction is less than 2 grams per 24 hours and then permanently reduce the ZALTRAP dose to 2 mg per kg.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,zaltrap,119,4151,4173,Discontinue ZALTRAP in patients who develop  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction [ see  Dosage and Administration (2.2)    ],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,zaltrap,120,4173,4229,".\n', '\n', '\n', '\n', '    5.8 Neutropenia and Neutropenic Complications\n', '\n', '\n', '\n', '  A higher incidence of  oselabeledaefromdruguse ( oselabeledaefromdruguse and  oselabeledaefromdruguse  occurred in patients receiving ZALTRAP.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,zaltrap,121,4229,4273,In patients with  notaecandidateindication  Grade 3-4  oselabeledaefromdruguse occurred in 37% of patients treated with ZALTRAP/FOLFIRI compared to 30% patients treated with placebo/FOLFIRI [ see  Adverse Reactions (6.1)    ].,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
122,zaltrap,122,4273,4302,Grade 3-4  oselabeledaefromdruguse occurred in 4% of patients treated with ZALTRAP/FOLFIRI compared to 2% of patients treated with placebo/FOLFIRI.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,zaltrap,123,4302,4365,"Grade 3-4  oselabeledaefromdruguse  oselabeledaefromdruguse infection/ oselabeledaefromdruguse occurred in 1.5% of patients treated with ZALTRAP/FOLFIRI and 1.2% of patients treated with placebo/FOLFIRI.\n', '\n', '\n', '\n', ' Monitor CBC with differential count at baseline and prior to initiation of each cycle of ZALTRAP.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,zaltrap,124,4365,4435,"Delay ZALTRAP/FOLFIRI until neutrophil count is at or above 1.5 * 10  9  /L.\n', '\n', '\n', '\n', '    5.9 Diarrhea and Dehydration\n', '\n', '\n', '\n', '  The incidence of severe  oselabeledaefromdruguse is increased in patients treated with ZALTRAP/FOLFIRI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,zaltrap,125,4435,4471,In patients with  notaecandidateindication  Grade 3-4  oselabeledaefromdruguse was reported in 19% of patients treated with ZALTRAP/FOLFIRI compared to 8% of patients treated with placebo/FOLFIRI.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,zaltrap,126,4471,4500,Grade 3-4  oselabeledaefromdruguse was reported in 4% of patients treated with ZALTRAP/FOLFIRI compared to 1% of patients treated with placebo/FOLFIRI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,zaltrap,127,4500,4506,[ see  Adverse Reactions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,zaltrap,128,4506,4511,6.1)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,zaltrap,129,4511,4540,The incidence of  nonoseaeaeonlyasinstruction is increased in patients who are age 65 years or older as compared to patients younger than 65 years of age [ see  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,zaltrap,130,4540,4548,Geriatric Use (8.5)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,zaltrap,131,4548,4653,"Monitor elderly patients closely for  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS)\n', '\n', '\n', '\n', '   oselabeledaefromdruguse (also known as  oselabeledaefromdruguse  was reported in 0.5% of 3795 patients treated with ZALTRAP monotherapy or in combination with chemotherapy.\n', '\n', '\n', '\n', ' Confirm the diagnosis of  nonoseaeaeonlyasinstruction with MRI and discontinue ZALTRAP in patients who develop  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,zaltrap,132,4653,4674,"Symptoms usually resolve or improve within days, although some patients have experienced ongoing  nonoseaemanifestationorcomplication or  nonoseaegeneralterm ']",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
0,tradjenta,0,0,18,"['    6  ADVERSE REACTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,tradjenta,1,18,144,"*  Adverse reactions reported in >=5% of patients treated with TRADJENTA and more commonly than in patients treated with placebo included nasopharyngitis  (6.1)   \n', ' *  Hypoglycemia was more commonly reported in patients treated with the combination of TRADJENTA and sulfonylurea compared with those treated with the combination of placebo and sulfonylurea  (6.1)   \n', '    \n', ' \n', '\n', '     To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or 1-800-459-9906 TTY, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,tradjenta,2,144,182,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1  Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,tradjenta,3,182,307,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The safety evaluation of TRADJENTA 5 mg once daily in patients with  notaecandidateindication is based on 14 placebo-controlled trials, 1 active-controlled study, and one study in patients with severe  notaecandidatepreexistingconditionorriskfactor  In the 14 placebo-controlled studies, a total of 3625 patients were randomized and treated with TRADJENTA 5 mg daily and 2176 with placebo.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
4,tradjenta,4,307,321,The mean exposure in patients treated with TRADJENTA across studies was 29.6 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,tradjenta,5,321,380,"The maximum follow-up was 78 weeks.\n', '\n', '\n', '\n', "" TRADJENTA 5 mg once daily was studied as monotherapy in three placebo-controlled trials of 18 and 24 weeks' duration and in five additional placebo-controlled studies lasting <=18 weeks.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,tradjenta,6,380,523,"The use of TRADJENTA in combination with other antihyperglycemic agents was studied in six placebo-controlled trials: two with metformin (12 and 24 weeks' treatment duration); one with a sulfonylurea (18 weeks' treatment duration); one with metformin and sulfonylurea (24 weeks' treatment duration); one with pioglitazone (24 weeks' treatment duration); and one with insulin (primary endpoint at 24 weeks).\n"", '\n', '\n', '\n', ' In a pooled dataset of 14 placebo-controlled clinical trials, adverse reactions that occurred in >=2% of patients receiving TRADJENTA (n = 3625) and more commonly than in patients given placebo (n = 2176), are shown in Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,tradjenta,7,523,633,"The overall incidence of adverse events with TRADJENTA were similar to placebo.\n', '\n', '\n', '\n', ' Table 1 Adverse Reactions Reported in >=2% of Patients Treated with TRADJENTA and Greater than Placebo in Placebo-Controlled Clinical Studies of TRADJENTA Monotherapy or Combination Therapy \n', '                    Number (%) of Patients     \n', '   TRADJENTA 5 mgn = 3625      Placebon = 2176     \n', '  oselabeledaefromdruguse  254 (7.0)        132 (6.1)         \n', '  oselabeledaefromdruguse         119",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,tradjenta,8,633,638,(3.3)        65,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,tradjenta,9,638,654,"(3.0)          \n', '  oselabeledaefromdruguse            76 (2.1)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,tradjenta,10,654,659,30 (1.4)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,tradjenta,11,659,946,"\n', '      Rates for other adverse reactions for TRADJENTA 5 mg vs placebo when TRADJENTA was used in combination with specific anti-diabetic agents were:  oselabeledaefromdruguse (3.1% vs 0%) and  oselabeledaefromdruguse (2.4% vs 0%) when TRADJENTA was used as add-on to sulfonylurea;  oselabeledaefromdruguse (2.7% vs 0.8%) and  oselabeledaefromdruguse (2.3% vs 0.8%) when TRADJENTA was used as add-on to pioglitazone; and  oselabeledaefromdruguse (2.1% vs 1%) when TRADJENTA was used as add-on to basal insulin therapy.\n', ' \n', '\n', "" Following 104 weeks' treatment in a controlled study comparing TRADJENTA with glimepiride in which all patients were also receiving metformin, adverse reactions reported in >=5% of patients treated with TRADJENTA (n = 776) and more frequently than in patients treated with a sulfonylurea (n = 775) were  oselabeledaefromdruguse (9.1% vs 8.4%),  oselabeledaefromdruguse (8.1% vs 6.1%),  oselabeledaefromdruguse (8.0% vs 7.6%),  oselabeledaefromdruguse (6.4% vs 5.2%),  oselabeledaefromdruguse (6.1% vs 4.9%), and  oselabeledaefromdruguse (5.3% vs 3.9%).\n"", '\n', '\n', '\n', ' Other adverse reactions reported in clinical studies with treatment of TRADJENTA were  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse skin  oselabeledaefromdruguse  or  oselabeledaefromdruguse , and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,tradjenta,12,946,992,"In the clinical trial program,  oselabeledaefromdruguse was reported in 15.2 cases per 10,000 patient year exposure while being treated with TRADJENTA compared with 3.7 cases per 10,000 patient year exposure while being treated with comparator (placebo and active comparator, sulfonylurea).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,tradjenta,13,992,1034,"Three additional cases of  oselabeledaefromdruguse were reported following the last administered dose of linagliptin.\n', '\n', '\n', '\n', '   \n', '\n', '    Hypoglycemia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,tradjenta,14,1034,1074,"In the placebo-controlled studies, 199 (6.6%) of the total 2994 patients treated with TRADJENTA 5 mg reported  oselabeledaefromdruguse compared to 56 patients (3.6%) of 1546 placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,tradjenta,15,1074,1099,"The incidence of  nonoseaeaeratelteqplacebo was similar to placebo when TRADJENTA was administered as monotherapy or in combination with metformin, or with pioglitazone.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
16,tradjenta,16,1099,1142,"When TRADJENTA was administered in combination with metformin and a sulfonylurea, 181 of 792 (22.9%) patients reported  oselabeledaefromdruguse compared with 39 of 263 (14.8%) patients administered placebo in combination with metformin and a sulfonylurea.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,tradjenta,17,1142,1156,Adverse reactions of  nonoseaeaeonlyasinstruction were based on all reports of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,tradjenta,18,1156,1170,A concurrent glucose measurement was not required or was normal in some patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,tradjenta,19,1170,1275,"Therefore, it is not possible to conclusively determine that all these reports reflect true  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In the study of patients receiving TRADJENTA as add-on therapy to a stable dose of insulin for up to 52 weeks (n=1261), no significant difference in the incidence of investigator reported  nonoseaeaeratelteqplacebo  defined as all symptomatic or asymptomatic episodes with a self-measured  nonoseaeaeonlyasinstruction  was noted between the TRADJENTA- (31.4%) and placebo- (32.9%) treated groups.",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
20,tradjenta,20,1275,1327,"During the same time period, severe  oselabeledaefromdruguse  defined as requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions, were reported in 11 (1.7%) of TRADJENTA treated patients and 7 (1.1%) of placebo treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,tradjenta,21,1327,1407,"Events that were considered life-threatening or required hospitalization were reported in 3 (0.5%) patients on TRADJENTA and 1 (0.2%) on placebo.\n', '\n', '\n', '\n', '   Use in  nonoseaegeneralterm  TRADJENTA was compared to placebo as add-on to pre-existing antidiabetic therapy over 52 weeks in 133 patients with severe  notaecandidatepreexistingconditionorriskfactor (estimated  notaecandidatepreexistingconditionorriskfactor .",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
22,tradjenta,22,1407,1433,"For the initial 12 weeks of the study, background antidiabetic therapy was kept stable and included insulin, sulfonylurea, glinides, and pioglitazone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,tradjenta,23,1433,1485,"For the remainder of the trial, dose adjustments in antidiabetic background therapy were allowed.\n', '\n', '\n', '\n', ' In general, the incidence of adverse events including severe  oselabeledaefromdruguse was similar to those reported in other TRADJENTA trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,tradjenta,24,1485,1527,"The observed incidence of  oselabeledaefromdruguse was higher (TRADJENTA, 63% compared to placebo, 49%) due to an increase in asymptomatic  oselabeledaefromdruguse especially during the first 12 weeks when background glycemic therapies were kept stable.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,tradjenta,25,1527,1569,Ten TRADJENTA-treated patients (15%) and 11 placebo-treated patients (17%) reported at least one episode of confirmed symptomatic  nonoseaeaeratelteqplacebo (accompanying finger stick glucose <=54 mg/dL).,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
26,tradjenta,26,1569,1623,"During the same time period, severe  nonoseaeaeratelteqplacebo  defined as an event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions, were reported in 3 (4.4%) TRADJENTA-treated patients and 3 (4.6%) placebo-treated patients.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
27,tradjenta,27,1623,1693,"Events that were considered life-threatening or required hospitalization were reported in 2 (2.9%) patients on TRADJENTA and 1 (1.5%) patient on placebo.\n', '\n', '\n', '\n', "" Renal function as measured by mean eGFR and creatinine clearance did not change over 52 weeks' treatment compared to placebo.\n"", '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,tradjenta,28,1693,1708,"', '\n', '\n', '     Laboratory Tests  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,tradjenta,29,1708,1738,"\n', '\n', '  Changes in laboratory findings were similar in patients treated with TRADJENTA 5 mg compared to patients treated with placebo.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,tradjenta,30,1738,1794,"nonoseaeaeonlyasinstruction that occurred more frequently in the TRADJENTA group and  >  1% more than in the placebo group were  oselabeledaefromdruguse in  oselabeledaefromdruguse (1.3% in the placebo group, 2.7% in the TRADJENTA group).\n', '\n', '\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,tradjenta,31,1794,1848,"No clinically meaningful changes in vital signs were observed in patients treated with TRADJENTA.\n', '\n', '\n', '\n', '   6.2  Postmarketing Experience\n', '\n', '  Additional adverse reactions have been identified during postapproval use of TRADJENTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,tradjenta,32,1848,1903,"Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse  including  nonoseaegeneralterm  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,tradjenta,33,1903,1940,"[see Indications and Usage  (1.2)  and Warnings and Precautions  (5.1)  ]  \n', ' *   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,tradjenta,34,1940,1975,"[see Warnings and Precautions  (5.3)  ]  \n', ' *  Severe and disabling  oselabeledaefromdruguse [see Warnings and Precautions  (5.4)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,tradjenta,35,1975,1979,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,tradjenta,36,1979,1981,*   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,tradjenta,37,1981,1982,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,tradjenta,38,1982,1988,"\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,tradjenta,39,1988,2016,"oselabeledaefromdruguse   oselabeledaefromdruguse     5  WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,tradjenta,40,2016,2031,"*  There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,tradjenta,41,2031,2041,"If pancreatitis is suspected, promptly discontinue TRADJENTA.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,tradjenta,42,2041,2045,(5.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,tradjenta,43,2045,2116,"\n', ' *  When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia  (5.2)   \n', ' *  There have been postmarketing reports of serious hypersensitivity reactions in patients treated with TRADJENTA including anaphylaxis, angioedema, and exfoliative skin conditions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,tradjenta,44,2116,2144,"In such cases, promptly discontinue TRADJENTA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,tradjenta,45,2144,2148,(5.3)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,tradjenta,46,2148,2167,"\n', ' *  Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,tradjenta,47,2167,2183,Consider as a possible cause for severe joint pain and discontinue drug if appropriate.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,tradjenta,48,2183,2187,(5.4)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,tradjenta,49,2187,2275,"\n', ' *  There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with TRADJENTA or any other antidiabetic drug  (5.5)   \n', '    \n', ' \n', '\n', '   5.1  Pancreatitis\n', '\n', '\n', '\n', '  There have been postmarketing reports of  oselabeledaefromdruguse  including  nonoseaegeneralterm  oselabeledaefromdruguse  in patients taking TRADJENTA.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,tradjenta,50,2275,2287,Take careful notice of potential signs and symptoms of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,tradjenta,51,2287,2301,"If  nonoseaeaeonlyasinstruction is suspected, promptly discontinue TRADJENTA and initiate appropriate management.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,tradjenta,52,2301,2377,"It is unknown whether patients with a history of  notaecandidatepreexistingconditionorriskfactor are at increased risk for the development of  nonoseaeaeonlyasinstruction while using TRADJENTA.\n', '\n', '\n', '\n', '    5.2  Use with Medications Known to Cause Hypoglycemia\n', '\n', '\n', '\n', '  Insulin secretagogues and insulin are known to cause  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
53,tradjenta,53,2377,2420,"The use of TRADJENTA in combination with an insulin secretagogue (e.g., sulfonylurea) was associated with a higher rate of  nonoseaeaefromdruginteraction compared with placebo in a clinical trial [see Adverse Reactions (  6.1  )]  .",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
54,tradjenta,54,2420,2455,The use of TRADJENTA in combination with insulin in subjects with severe  notaecandidatepreexistingconditionorriskfactor was associated with a higher rate of  nonoseaeaefromdruginteraction [see Adverse Reactions (  6.1  )]  .,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
55,tradjenta,55,2455,2533,"Therefore, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of  nonoseaeaeonlyasinstruction when used in combination with TRADJENTA.\n', '\n', '\n', '\n', '    5.3  Hypersensitivity Reactions\n', '\n', '\n', '\n', '  There have been postmarketing reports of serious  oselabeledaefromdruguse in patients treated with TRADJENTA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,tradjenta,56,2533,2545,These reactions include  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,tradjenta,57,2545,2571,"Onset of these reactions occurred within the first 3 months after initiation of treatment with TRADJENTA, with some reports occurring after the first dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,tradjenta,58,2571,2629,"If a serious  nonoseaeaeonlyasinstruction is suspected, discontinue TRADJENTA, assess for other potential causes for the event, and institute alternative treatment for  notaecandidateindication \n', '\n', '\n', '\n', '  nonoseaeaeforanotherdruginclass has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors.",1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
59,tradjenta,59,2629,2714,"Use caution in a patient with a history of  notaecandidatepreexistingconditionorriskfactor to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to  nonoseaeaeonlyasinstruction with TRADJENTA.\n', '\n', '\n', '\n', '    5.4  Severe and Disabling Arthralgia\n', '\n', '\n', '\n', '   There have been postmarketing reports of severe and disabling  oselabeledaeclasseffect in patients taking DPP-4 inhibitors.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
60,tradjenta,60,2714,2732,The time to onset of symptoms following initiation of drug therapy varied from one day to years.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,tradjenta,61,2732,2743,Patients experienced relief of symptoms upon discontinuation of the medication.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,tradjenta,62,2743,2763,A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,tradjenta,63,2763,2781,Consider DPP-4 inhibitors as a possible cause for severe  nonoseaeaeonlyasinstruction and discontinue drug if appropriate.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,tradjenta,64,2781,2832,"\n', '\n', '\n', '\n', '    5.5  Macrovascular Outcomes\n', '\n', '\n', '\n', '  There have been no clinical studies establishing conclusive evidence of  nonoseaenegation ']",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
0,hetlioz,0,0,5,['    6.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,hetlioz,1,5,18,"ADVERSE REACTIONS\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,hetlioz,2,18,61,"The most common adverse reactions (incidence >5% and at least twice as high on HETLIOZ than on placebo) were headache, increased alanine aminotransferase, nightmares or unusual dreams, and upper respiratory or urinary tract infection (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,hetlioz,3,61,64,6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,hetlioz,4,64,149,"\n', '\n', '\n', '\n', ' To report SUSPECTED ADVERSE REACTIONS, contact Vanda Pharmaceuticals Inc. at 1-844-438-5469 or  www.hetlioz.com  or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,hetlioz,5,149,286,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' A total of 1346 subjects were treated with at least one dose of HETLIOZ, of which 139 were treated for > 26 weeks and 93 were treated for > 1 year.\n', '\n', '\n', '\n', ' A 26-week, parallel-arm placebo-controlled study (Study 1) evaluated HETLIOZ (n=42) compared to placebo (n=42) in patients with Non-24.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,hetlioz,6,286,437,"A randomized-withdrawal, placebo- controlled study of 8 weeks duration (Study 2) also evaluated HETLIOZ (n=10), compared to placebo (n=10), in patients with Non-24.\n', '\n', '\n', '\n', ' In placebo-controlled studies, 6% of patients exposed to HETLIOZ discontinued treatment due to an adverse event, compared with 4% of patients who received placebo.\n', '\n', '\n', '\n', '   Table 1  shows the incidence of adverse reactions from Study 1.\n', '\n', '\n', '\n', '\n', '  *Adverse reactions with an incidence > 5% and at least twice as high on HETLIOZ than on placebo are displayed.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,hetlioz,7,437,447,"\n', '  \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,hetlioz,8,447,456,Table 1: Adverse Reactions in Study 1            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,hetlioz,9,456,478,"\n', '                                                          HETLIOZN=42                 PlaceboN=42           \n', '  oselabeledaefromdruguse                                                     17 %                        7 %               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,hetlioz,10,478,491,"\n', '  oselabeledaefromdruguse                           10 %                        5 %               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,hetlioz,11,491,506,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse                                    10 %                        0 %               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,hetlioz,12,506,519,"\n', '  oselabeledaefromdruguse                            7 %                         0 %               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,hetlioz,13,519,528,"\n', '  oselabeledaefromdruguse     5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,hetlioz,14,528,533,"WARNINGS AND PRECAUTIONS\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,hetlioz,15,533,598,"'\n', '\n', '\n', '  EXCERPT:   May cause somnolence: After taking HETLIOZ, patients should limit their activity to preparing for going to bed, because HETLIOZ can impair the performance of activities requiring complete mental alertness (  5.1  )\n', '\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,hetlioz,16,598,623,"'\n', ' \n', '\n', '\n', '\n', '   5.1  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,hetlioz,17,623,652,"\n', '\n', '\n', '  After taking HETLIOZ, patients should limit their activity to preparing for going to bed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,hetlioz,18,652,659,HETLIOZ can potentially  oselabeledaefromdruguse '],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,opsumit,0,0,86,"['    6 ADVERSE REACTIONS\n', '\n', '  Clinically significant adverse reactions that appear in other sections of the labeling include:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,opsumit,1,86,142,"Warnings and Precautions (5.4)  ]  \n', '      EXCERPT:   Most common adverse reactions (more frequent than placebo by >=3%) are anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, and urinary tract infection (  6.1  ).\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,opsumit,2,142,178,"' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Actelion at 1-866-228-3546 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,opsumit,3,178,215,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,opsumit,4,215,311,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' Safety data for OPSUMIT were obtained primarily from one placebo-controlled clinical study in 742 patients with  notaecandidateindication (SERAPHIN study)  [see  Clinical Studies (14)  ]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
5,opsumit,5,311,351,The exposure to OPSUMIT in this trial was up to 3.6 years with a median exposure of about 2 years (N=542 for 1 year; N=429 for 2 years; and N=98 for more than 3 years).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,opsumit,6,351,429,"The overall incidence of treatment discontinuations because of adverse events was similar across OPSUMIT 10 mg and placebo treatment groups (approximately 11%).\n', '\n', '\n', '\n', ' Table 2 presents adverse reactions more frequent on OPSUMIT than on placebo by >=3%.\n', '\n', '\n', '\n', ' Table 2 Adverse Reactions \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,opsumit,7,429,433,Adverse Reaction                                   OPSUMIT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,opsumit,8,433,454,"10 mg(N=242)(%)       Placebo(N=249)(%)       \n', '  \n', '  oselabeledaefromdruguse                                                         13                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,opsumit,9,454,456,3               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,opsumit,10,456,467,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse                                    20                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,opsumit,11,467,469,13               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,opsumit,12,469,478,"\n', '  oselabeledaefromdruguse                                                     12                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,opsumit,13,478,480,6               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,opsumit,14,480,489,"\n', '  oselabeledaefromdruguse                                                       14                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,opsumit,15,489,491,9               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,opsumit,16,491,502,"\n', '  oselabeledaefromdruguse                                                       6                          2               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,opsumit,17,502,511,"\n', '  oselabeledaefromdruguse                                         9                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,opsumit,18,511,513,6               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,opsumit,19,513,514,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,opsumit,20,514,540,"', '           6.2 Postmarketing Experience\n', '   The following adverse reactions have been identified during post-approval use of OPSUMIT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,opsumit,21,540,593,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse (",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,opsumit,22,593,599,oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,opsumit,23,599,628,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm  thoracic and mediastinal  nonoseaegeneralterm  :  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,opsumit,24,628,639,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,opsumit,25,639,644,WARNING:   oselabeledaefromdruguse \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,opsumit,26,644,651,"', '    WARNING:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,opsumit,27,651,656,EMBRYO-FETAL TOXICITY  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,opsumit,28,656,705,"\n', '\n', '    *  Do not administer OPSUMIT to a  notaecandidatepreexistingconditionorriskfactor female because it may cause  oselabeledaefromdruguse [see Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1)].",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
29,opsumit,29,705,736,"\n', ' *  Females of reproductive potential: Exclude  notaecandidatepreexistingconditionorriskfactor before the start of treatment, monthly during treatment, and 1 month after stopping treatment.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
30,opsumit,30,736,763,"Prevent  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
31,opsumit,31,763,773,*  Other ERAs cause hepatotoxicity and liver failure.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,opsumit,32,773,788,Obtain baseline liver enzymes and monitor as clinically indicated (  5.3  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,opsumit,33,788,803,"\n', ' *  Decreases in hemoglobin (  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,opsumit,34,803,820,"\n', ' *  Pulmonary edema in patients with pulmonary veno-occlusive disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,opsumit,35,820,831,"If confirmed, discontinue treatment (  5.5  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,opsumit,36,831,854,"\n', ' *  Decreases in sperm count have been observed in patients taking ERAs (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,opsumit,37,854,910,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdruguse \n', '\n', '\n', '  OPSUMIT may cause  oselabeledaefromdruguse when administered during  notaecandidatepreexistingconditionorriskfactor and is contraindicated for use in females who are  notaecandidatecontraindication  ",0,0,1,0,0,0,0,0,0,0,0,1,0,0,0
38,opsumit,38,910,953,"In females of reproductive potential, exclude  notaecandidatepreexistingconditionorriskfactor prior to initiation of therapy, ensure use of acceptable contraceptive methods and obtain monthly pregnancy tests [see  Dosage and Administration (2.2)  and  Use in Specific Populations (",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
39,opsumit,39,953,960,"8.1  ,  8.6)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,opsumit,40,960,996,"]  .\n', '\n', '\n', '\n', ' OPSUMIT is available for females through the OPSUMIT REMS Program, a restricted distribution program [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,opsumit,41,996,1157,"Warnings and Precautions (5.2)  ]  .\n', '\n', '\n', '\n', '    5.2 OPSUMIT REMS Program\n', '\n', '\n', '\n', '  For all females, OPSUMIT is available only through a restricted program called the OPSUMIT REMS Program, because of the risk of  oselabeledaefromdruguse [see  Contraindications (4.1)  ,  Warnings and Precautions (5.1)  , and  Use in Specific Populations (8.1  ,  8.6)  ]  .\n', '\n', '\n', '\n', ' Notable requirements of the OPSUMIT REMS Program include the following:\n', '\n', '\n', '\n', ' *  Prescribers must be certified with the program by enrolling and completing training.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,opsumit,42,1157,1183,"\n', ' *  All females, regardless of reproductive potential, must enroll in the OPSUMIT REMS Program prior to initiating OPSUMIT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,opsumit,43,1183,1192,Male patients are not enrolled in the REMS.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,opsumit,44,1192,1224,"\n', ' *  Females of reproductive potential must comply with the pregnancy testing and contraception requirements [see  Use in Specific Populations (8.6)  ] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,opsumit,45,1224,1250,"\n', ' *  Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive OPSUMIT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,opsumit,46,1250,1262,"\n', '    Further information is available at www.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,opsumit,47,1262,1272,OPSUMITREMS.com or 1-866-228-3546.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,opsumit,48,1272,1336,"Information on OPSUMIT certified pharmacies or wholesale distributors is available through Actelion Pathways at 1-866-228-3546.\n', ' \n', '\n', '    5.3 Hepatotoxicity\n', '\n', '\n', '\n', '  Other ERAs have caused  nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass  and  nonoseaeaeforanotherdruginclass  ",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
49,opsumit,49,1336,1389,"The incidence of  nonoseaeaeonlyasinstruction in the study of OPSUMIT in  notaecandidateindication is shown in Table 1.\n', '\n', '\n', '\n', ' Table 1 Incidence of  oselabeledaefromdruguse in the SERAPHIN Study \n', '                                           OPSUMIT 10 mg(N=242)                  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
50,opsumit,50,1389,1392,Placebo(N=249)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,opsumit,51,1392,1402,"\n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,opsumit,52,1402,1413,oselabeledaefromdruguse  * ULN                                          3.4%                               4.5%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,opsumit,53,1413,1426,"\n', ' > oselabeledaefromdruguse                                          2.1%                               0.4%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,opsumit,54,1426,1459,"\n', '         In the placebo-controlled study of OPSUMIT, discontinuations for  oselabeledaefromdruguse were 3.3% in the OPSUMIT 10 mg group vs. 1.6% for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,opsumit,55,1459,1515,"Obtain liver enzyme tests prior to initiation of OPSUMIT and repeat during treatment as clinically indicated.\n', ' \n', '\n', ' Advise patients to report symptoms suggesting  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,opsumit,56,1515,1543,"If clinically relevant  nonoseaeaeonlyasinstruction occur, or if elevations are accompanied by an  nonoseaeaeonlyasinstruction  or by clinical symptoms of  nonoseaeaeonlyasinstruction  discontinue OPSUMIT.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,opsumit,57,1543,1625,"Consider re-initiation of OPSUMIT when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.4 Hemoglobin Decrease\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse hemoglobin concentration and  oselabeledaefromdruguse have occurred following administration of other ERAs and were observed in clinical studies with OPSUMIT.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,opsumit,58,1625,1633,These decreases occurred early and stabilized thereafter.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,opsumit,59,1633,1675,In the placebo-controlled study of OPSUMIT in  notaecandidateindication  OPSUMIT 10 mg caused a mean  oselabeledaefromdruguse from baseline to up to 18 months of about 1.0 g/dL compared to no change in the placebo group.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
60,opsumit,60,1675,1705,A  oselabeledaefromdruguse to below 10.0 g/dL was reported in 8.7% of the OPSUMIT 10 mg group and in 3.4% of the placebo group.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,opsumit,61,1705,1710,oselabeledaefromdruguse seldom require transfusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,opsumit,62,1710,1774,"Initiation of OPSUMIT is not recommended in patients with  notaecandidatepreexistingconditionorriskfactor  Measure hemoglobin prior to initiation of treatment and repeat during treatment as clinically indicated [see  Adverse Reactions (6.1)  ]  .\n', '\n', '\n', '\n', '    5.5 Pulmonary Edema with Pulmonary Veno-occlusive Disease (",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
63,opsumit,63,1774,1855,"PVOD)\n', '\n', '\n', '\n', '  Should signs of  nonoseaeaeonlyasinstruction occur, consider the possibility of associated  oselabeledaefromdruguse  If confirmed, discontinue OPSUMIT.\n', '\n', '\n', '\n', '    5.6 Decreased Sperm Counts\n', '\n', '\n', '\n', '  Other ERAs have caused  nonoseaeaeforanotherdruginclass ']",1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
0,egrifta,0,0,178,"['    6 ADVERSE REACTIONS\n', '\n', '  The most commonly reported adverse reactions are  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse  reactions due to the effect of GH (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus, pain, urticaria,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus, pain, urticaria, irritation,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus, pain, urticaria, irritation, swelling,  oselabeledaefromdruguse .\n', '\n', '\n', '\n', ' During the first 26 weeks of treatment (main phase), discontinuations as a result of adverse reactions occurred in 9.6% of patients receiving EGRIFTA  (r)  and 6.8% of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,egrifta,1,178,361,"Apart from patients with  oselabeledaefromdruguse identified during the studies and who were discontinued per protocol (2.2%), the most common reasons for discontinuation of EGRIFTA  (r)  treatment were adverse reactions due to the effect of GH (4.2%) and local  oselabeledaefromdruguse (4.6%).\n', '\n', '\n', '\n', ' During the following 26 weeks of treatment (extension phase), discontinuations as a result of adverse events occurred in 2.4% of patients in the T-T group (patients treated with tesamorelin for Week 0-26 and with tesamorelin for Week 26-52) and 5.2% of patients in the T-P group (patients treated with tesamorelin for Week 0-26 and with placebo for Week 26-52).\n', '\n', '\n', '\n', '   EXCERPT:   Most commonly reported adverse reactions (>5% and more frequent than placebo):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,egrifta,2,361,381,"Arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,egrifta,3,381,593,"(  6.1  )\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact    EGRIFTA ASSIST  TM  toll free at 1-844-EGRIFTA (1-844-347-4382) or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch  \n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' Seven hundred and forty  notaecandidateindication and  notaecandidateindication were exposed to EGRIFTA  (r)  in the Phase 3 clinical trials; of these 543 received EGRIFTA  (r)  during the initial 26-week placebo-controlled phase  [see Clinical Studies (  14  )].  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,egrifta,4,593,667,"\n', '\n', '\n', '\n', ' Adverse reactions that occurred more frequently with EGRIFTA  (r)  relative to placebo and had an incidence >=1% during the first 26 weeks across all studies are presented in  Table 1  .\n', '\n', '\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,egrifta,5,667,694,Adverse Reactions Reported in >= 1% and More Frequent in EGRIFTA(r) -treated than Placebo Patients during the 26-Week Main Phase (Combined Studies),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,egrifta,6,694,710,"\n', '                                              Incidence of patients (%) with adverse drug reactions   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,egrifta,7,710,715,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,egrifta,8,715,724,System Organ Class  Preferred Term         EGRIFTA  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,egrifta,9,724,735,(r)  (N=543)        Placebo(N=263)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,egrifta,10,735,742,"\n', '    nonoseaegeneralterm                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
11,egrifta,11,742,763,"\n', '       oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,egrifta,12,763,767,13.36.15.51.81.71.51.11.1    11.04.61.90.80.40.80.80.0       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,egrifta,13,767,774,"\n', '    nonoseaegeneralterm                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
14,egrifta,14,774,779,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,egrifta,15,779,805,oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse  8.57.66.14.12.91.71.71.71.51.31.11.1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,egrifta,16,805,807,2.70.82.33.01.11.10.40.40.40.80.80.0   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,egrifta,17,807,822,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse  4.84.21.5                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,egrifta,18,822,824,2.31.50.0                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,egrifta,19,824,835,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
20,egrifta,20,835,839,oselabeledaefromdruguse      oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,egrifta,21,839,841,4.42.61.71.1                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,egrifta,22,841,843,3.80.00.80.8                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,egrifta,23,843,869,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse       1.1                          0.4                             \n', '    nonoseaegeneralterm        oselabeledaefromdruguse     2.0                          1.5                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,egrifta,24,869,874,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,egrifta,25,874,887,"nonoseaegeneralterm                                                                  \n', '       oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,egrifta,26,887,889,3.72.41.1                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,egrifta,27,889,891,1.51.10.4                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,egrifta,28,891,902,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      1.3                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,egrifta,29,902,904,0.8                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,egrifta,30,904,911,"\n', '    nonoseaegeneralterm                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,egrifta,31,911,936,"\n', '       oselabeledaefromdruguse                           1.1                          0.0                             \n', '    nonoseaegeneralterm                                                                                          \n', '        oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,egrifta,32,936,940,1.5                          0.4                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,egrifta,33,940,987,"\n', '         Mean levels of fasting blood glucose and fasting insulin were not significantly different between EGRIFTA  (r)  -treated and placebo-treated patients after 26 weeks of treatment.\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,egrifta,34,987,1030,"In the EGRIFTA  (r)  Phase 3 clinical trials, mean baseline (Week 0) HbA1cwas 5.26% among patients in the EGRIFTA  (r)  group and 5.28% among those in the placebo group.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,egrifta,35,1030,1080,"At Week 26, mean  oselabeledaefromdruguse among patients treated with EGRIFTA  (r)  compared with placebo (5.39% vs. 5.28% for the EGRIFTA  (r)  and placebo groups, respectively, mean treatment difference of 0.12%, p=0.0004).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,egrifta,36,1080,1201,"Patients receiving EGRIFTA  (r)  had an increased risk of developing  oselabeledaefromdruguse ( oselabeledaefromdruguse  compared with placebo (4.5% vs. 1.3%), with a hazard ratio of 3.3 (CI 1.4, 9.6).\n', '\n', '\n', '\n', ' Adverse reactions observed during Week 26 to 52 of the Phase 3 clinical trials which had an incidence of >=1% and were seen more frequently with EGRIFTA  (r)  relative to placebo are presented in  Table 2  :\n', '\n', '\n', '\n', ' Table 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,egrifta,37,1201,1301,"Adverse Reactions Reported in >= 1% and More Frequent in EGRIFTA(r)-treated than Placebo Patients during the 26-Week Extension Phase of the Combined Studies (Week 26 to Week 52 of the studies) \n', '  1T-T = tesamorelin for Week 0-26 and tesamorelin for Week 26-52    \n', '  2T-P = tesamorelin for Week 0-26 and placebo for Week 26-52    \n', '  For patients who continued from Week 26-52, mean levels of  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,egrifta,38,1301,1323,nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo were not different between the T-T and T-P groups.    ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
39,egrifta,39,1323,1360,"\n', '  \n', '                                     Incidence of patients (%) with adverse drug reactions   \n', '   System Organ Class  Preferred Term  T-T  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,egrifta,40,1360,1362,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,egrifta,41,1362,1382,(Week 26-52)(N=246)              T-P  2  (Week 26-52)(N=135)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,egrifta,42,1382,1400,"\n', '    nonoseaegeneralterm                                                                         \n', '       oselabeledaefromdruguse      oselabeledaefromdruguse  3.31.2                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,egrifta,43,1400,1402,0.70.0                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,egrifta,44,1402,1422,"\n', '    nonoseaegeneralterm                                                                         \n', '       oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse  2.02.01.2                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,egrifta,45,1422,1424,0.00.00.0                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,egrifta,46,1424,1429,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,egrifta,47,1429,1437,nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,egrifta,48,1437,1439,1.61.61.6                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,egrifta,49,1439,1441,1.50.71.5                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,egrifta,50,1441,1446,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,egrifta,51,1446,1452,nonoseaegeneralterm        oselabeledaefromdruguse  2.0                                      ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,egrifta,52,1452,1454,0.7                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,egrifta,53,1454,1467,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse  1.61.2                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,egrifta,54,1467,1469,0.70.0                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,egrifta,55,1469,1489,"\n', '    nonoseaegeneralterm                                                                         \n', '       oselabeledaefromdruguse      oselabeledaefromdruguse      oselabeledaefromdruguse  1.21.21.2                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,egrifta,56,1489,1491,0.70.00.0                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,egrifta,57,1491,1504,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse  1.61.2                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,egrifta,58,1504,1506,1.50.7                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,egrifta,59,1506,1517,"\n', '           6.2 Immunogenicity\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,egrifta,60,1517,1535,"As with all therapeutic proteins and peptides, there is a potential for in vivo  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,egrifta,61,1535,1579,In the combined Phase 3 clinical trials  oselabeledaefromdruguse were detected in 49.5% of patients treated with EGRIFTA  (r)  for 26 weeks and 47.4% of patients who received EGRIFTA  (r)  for 52 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,egrifta,62,1579,1594,In the subset of patients with  oselabeledaefromdruguse   oselabeledaefromdruguse in 85.2%.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,egrifta,63,1594,1607,oselabeledaefromdruguse  was observed in approximately 60% of patients who developed  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,egrifta,64,1607,1642,oselabeledaefromdruguse  Patients with and without  nonoseaeaeonlyasinstruction had similar mean  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction suggesting that the  nonoseaeaeonlyasinstruction did not alter the efficacy of EGRIFTA  (r)  .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,egrifta,65,1642,1734,"In a group of patients who had  oselabeledaefromdruguse after 26 weeks of treatment (56%) and were re-assessed 6 months later, after stopping EGRIFTA  (r)  treatment, 18% were still  oselabeledaefromdruguse \n', '\n', '\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse tesamorelin and  oselabeledaefromdruguse were detected in vitro at Week 52 in 10% and 5% of EGRIFTA  (r)  -treated patients, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,egrifta,66,1734,1817,"They did not appear to have an impact on efficacy, as evidenced by comparable changes in VAT and IGF-1 level in patients with or without in vitro  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' The observed incidence of  nonoseaeaeonlyasinstruction in an assay is highly dependent on several factors including assay sensitivity and specificity, methodology, sample handling, timing of sample collection, concomitant medication and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,egrifta,67,1817,1876,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA  (r)  therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,egrifta,68,1876,1889,"(  5.1  ) \n', ' *  Elevated IGF-1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,egrifta,69,1889,1896,: Monitor regularly in all patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,egrifta,70,1896,1904,Consider discontinuation in patients with persistent elevations.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,egrifta,71,1904,1909,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,egrifta,72,1909,1929,"\n', ' *  Fluid retention: May include edema, arthralgia, and carpal tunnel syndrome.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,egrifta,73,1929,1954,"(  5.3  ) \n', ' *  Glucose intolerance: May develop with EGRIFTA  (r)  use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,egrifta,74,1954,1970,Evaluate glucose status prior to and during therapy with EGRIFTA  (r)  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,egrifta,75,1970,1991,"(  5.4  ) \n', ' *  Hypersensitivity reactions (e.g., rash, urticaria):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,egrifta,76,1991,2001,Advise patients to seek immediate medical attention if suspected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,egrifta,77,2001,2022,"(  5.5  ) \n', ' *  Injection site reactions: Advise patients to rotate sites.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,egrifta,78,2022,2040,"(  5.6  ) \n', ' *  Acute critical illness: Consider discontinuation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,egrifta,79,2040,2103,"(  5.7  ) \n', '    \n', ' \n', '\n', '   5.1 Neoplasms\n', '\n', '\n', '\n', '  EGRIFTA  (r)  induces the release of endogenous growth hormone (GH), a known growth factor.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,egrifta,80,2103,2131,"Thus, patients with active  notaecandidatecontraindication should not be treated with EGRIFTA  (r)   [see Contraindications (  4.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
81,egrifta,81,2131,2176,".\n', '\n', '\n', '\n', ' For patients with a history of  notaecandidatepreexistingconditionorriskfactor  EGRIFTA  (r)  therapy should be initiated after careful evaluation of the potential benefit of treatment.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
82,egrifta,82,2176,2311,"For patients with a history of treated and stable  notaecandidatepreexistingconditionorriskfactor  EGRIFTA  (r)  therapy should be initiated only after careful evaluation of the potential benefit of treatment relative to the risk of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In addition, the decision to start treatment with EGRIFTA  (r)  should be considered carefully based on the increased background risk of  notaecandidatepreexistingconditionorriskfactor in  notaecandidatepreexistingconditionorriskfactor patients.\n', '\n', '\n', '\n', '    5.2 Elevated IGF-1\n', '\n', '\n', '\n', '  EGRIFTA  (r)  stimulates GH production and  oselabeledaefromdruguse  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
83,egrifta,83,2311,2352,"Given that IGF-1 is a growth factor and the effect of prolonged  nonoseaeaeonlyasinstruction levels on the development or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction is unknown, IGF-1 levels should be monitored closely during EGRIFTA  (r)  therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,egrifta,84,2352,2429,"Careful consideration should be given to discontinuing EGRIFTA  (r)  in patients with  nonoseaeaeonlyasinstruction (e.g., >3 SDS), particularly if the efficacy response is not robust (e.g., based on visceral adipose tissue changes measured by waist circumference or CT scan).\n', '\n', '\n', '\n', ' During the clinical trials, patients were monitored every three months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,egrifta,85,2429,2477,"Among patients who received EGRIFTA  (r)  for 26 weeks, 47.4% had  oselabeledaefromdruguse  oselabeledaefromdruguse 2 standard deviation scores ( oselabeledaefromdruguse , and 35.6% had SDS  oselabeledaefromdruguse  with this effect seen as early as 13 weeks of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,egrifta,86,2477,2512,"Among those patients who remained on EGRIFTA  (r)  for a total of 52 weeks, at the end of treatment 33.7% had  oselabeledaefromdruguse and 22.6% had  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,egrifta,87,2512,2572,"\n', '\n', '\n', '\n', '    5.3 Fluid Retention\n', '\n', '\n', '\n', '   oselabeledaefromdruguse may occur during EGRIFTA  (r)  therapy and is thought to be related to the induction of GH secretion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,egrifta,88,2572,2698,"It manifests as  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication resulting in a variety of adverse reactions (e.g.  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  which are either transient or resolve with discontinuation of treatment.\n', '\n', '\n', '\n', '    5.4 Glucose Intolerance\n', '\n', '\n', '\n', '  EGRIFTA  (r)  treatment may result in  oselabeledaefromdruguse  During the Phase 3 clinical trials, the percentages of patients with  oselabeledaefromdruguse >= 6.5%) from baseline to Week 26 were 4.5% and 1.3% in the EGRIFTA  (r)  and placebo groups, respectively.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
89,egrifta,89,2698,2739,"An increased risk of developing  oselabeledaefromdruguse with EGRIFTA  (r)  ( oselabeledaefromdruguse  relative to placebo was observed [intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6)].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,egrifta,90,2739,2758,"Therefore, glucose status should be carefully evaluated prior to initiating EGRIFTA  (r)  treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,egrifta,91,2758,2987,"In addition, all patients treated with EGRIFTA  (r)  should be monitored periodically for changes in glucose metabolism to diagnose those who develop  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction is a known cardiovascular risk factor and patients who develop  nonoseaeaeonlyasinstruction have an elevated risk for developing  nonoseaeaeonlyasinstruction  Caution should be exercised in treating  notaecandidateindication with EGRIFTA  (r)  if they develop  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  and careful consideration should be given to discontinuing EGRIFTA  (r)  treatment in patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue by waist circumference or CT scan measurements.\n', '\n', '\n', '\n', ' Since EGRIFTA  (r)   oselabeledaefromdruguse  patients with  notaecandidatepreexistingconditionorriskfactor  nonoseaeaeonlyasinstruction who are receiving ongoing treatment with EGRIFTA  (r)  should be monitored at regular intervals for potential development or worsening of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.5 Hypersensitivity Reactions\n', '\n', '\n', '\n', '   oselabeledaefromdruguse may occur in patients treated with EGRIFTA  (r)  .  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
92,egrifta,92,2987,3012,oselabeledaefromdruguse occurred in 3.6% of patients with  notaecandidateindication treated with EGRIFTA  (r)  in the Phase 3 clinical trials.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
93,egrifta,93,3012,3029,These reactions included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and other  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,egrifta,94,3029,3147,"In cases of suspected  nonoseaeaeonlyasinstruction  patients should be advised to seek prompt medical attention and treatment with EGRIFTA  (r)  should be discontinued immediately.\n', '\n', '\n', '\n', '    5.6 Injection Site Reactions\n', '\n', '\n', '\n', '  EGRIFTA  (r)  treatment may cause  oselabeledaefromdruguse  including  oselabeledaefromdruguse  oselabeledaefromdruguse erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse erythema, pruritus, pain, irritation, and  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,egrifta,95,3147,3186,The incidence of  oselabeledaefromdruguse was 24.5% in EGRIFTA  (r)  -treated patients and 14.4% in placebo-treated patients during the first 26 weeks of treatment in the Phase 3 clinical trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,egrifta,96,3186,3211,"For patients who continued EGRIFTA  (r)  for an additional 26 weeks, the incidence of  oselabeledaefromdruguse was 6.1%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,egrifta,97,3211,3307,"In order to reduce the incidence of  nonoseaeaeonlyasinstruction  it is recommended to rotate the site of injection to different areas of the abdomen.\n', '\n', '\n', '\n', '    5.7 Acute Critical Illness\n', '\n', '\n', '\n', '   nonoseaegeneralterm in patients with  notaecandidatepreexistingconditionorriskfactor due to complications following  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  or those with  notaecandidatepreexistingconditionorriskfactor has been reported after treatment with pharmacologic amounts of growth hormone.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
98,egrifta,98,3307,3333,EGRIFTA  (r)  has not been studied in patients with  notaecandidatepreexistingconditionorriskfactor  Since EGRIFTA  (r)   nonoseaeaeonlyasinstruction '],1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,genotropin,0,0,130,"['  6 ADVERSE REACTIONS\n', '\n', '  The following important adverse reactions are also described elsewhere in the labeling:\n', '\n', ' *  Increased mortality in patients with acute critical illness [see  Warnings and Precautions (5.1)  ]  \n', ' *  Fatalities in children with  notaecandidateindication [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
1,genotropin,1,130,160,"Warnings and Precautions (5.5)  ]  \n', ' *  Severe  oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,genotropin,2,160,167,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,genotropin,3,167,205,"[see  Warnings and Precautions (5.7)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.8)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,genotropin,4,205,208,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,genotropin,5,208,217,Warnings and Precautions (5.9)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,genotropin,6,217,249,"\n', ' *   oselabeledaefromdruguse in pediatric patients [see  Warnings and Precautions (5.10)  ]  \n', ' *   oselabeledaefromdruguse in pediatric patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,genotropin,7,249,301,"[see  Warnings and Precautions (5.11)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse in patients with  notaecandidateindication [see  Warnings and Precautions (5.12)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,genotropin,8,301,307,(5.13)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,genotropin,9,307,314,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,genotropin,10,314,399,"[see  Warnings and Precautions (5.15)  ]  \n', '      EXCERPT:   Other common somatropin-related adverse reactions include injection site reactions/rashes and lipoatrophy (  6.1  ) and headaches (6.3).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,genotropin,11,399,428,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,genotropin,12,428,524,"Because clinical trials are conducted under varying conditions, adverse reaction rates observed during the clinical trials performed with one somatropin formulation cannot always be directly compared to the rates observed during the clinical trials performed with a second somatropin formulation, and may not reflect the adverse reaction rates observed in practice.\n', '\n', '     Clinical Trials in children with GHD  \n', '\n', ' In clinical studies with GENOTROPIN in pediatric  notaecandidateindication patients, the following events were reported infrequently:  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,genotropin,13,524,670,"oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including pain or burning associated with the injection,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including pain or burning associated with the injection, fibrosis,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including pain or burning associated with the injection, fibrosis, nodules,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including pain or burning associated with the injection, fibrosis, nodules, rash,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including pain or burning associated with the injection, fibrosis, nodules, rash, inflammation,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions, including pain or burning associated with the injection, fibrosis, nodules, rash, inflammation, pigmentation, or  oselabeledaefromdruguse  oselabeledaefromdruguse or burning associated  oselabeledaefromdruguse  oselabeledaefromdruguse  fibrosis, nodules, rash, inflammation, pigmentation, or bleeding;  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,genotropin,14,670,682,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and mild  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,genotropin,15,682,699,"\n', '\n', '     Clinical Trials in PWS  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,genotropin,16,699,901,"'\n', ' In two clinical studies with GENOTROPIN in pediatric patients with  notaecandidateindication  the following drug-related events were reported:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '     Clinical Trials in children with SGA  \n', '\n', ' In clinical studies of 273 pediatric patients born  notaecandidateindication treated with GENOTROPIN, the following clinically significant events were reported: mild transient  oselabeledaefromdruguse  one patient with  oselabeledaefromdruguse  two patients with  oselabeledaefromdruguse  two patients with  oselabeledaefromdruguse  and several patients with  oselabeledaefromdruguse   oselabeledaefromdruguse  and self-limited  oselabeledaefromdruguse   nonoseaenegation were not detected in any of the patients treated with GENOTROPIN.\n', '\n', '     Clinical Trials in children with Turner Syndrome  \n', '\n', ' In two clinical studies with GENOTROPIN in pediatric patients with  notaecandidateindication  the most frequently reported adverse events were  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
17,genotropin,17,901,918,The only treatment-related adverse event that occurred in more than 1 patient was  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,genotropin,18,918,992,"\n', '\n', '     Clinical Trials in children with Idiopathic Short Stature  \n', '\n', ' In two open-label clinical studies with GENOTROPIN in pediatric patients with  notaecandidateindication  the most commonly encountered adverse events include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
19,genotropin,19,992,1019,"In one of the two studies, during GENOTROPIN treatment, the mean IGF-1 standard deviation (SD) scores were maintained in the normal range.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,genotropin,20,1019,1031,IGF-1 SD scores above +2 SD were observed as follows:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,genotropin,21,1031,1058,"1 subject (3%), 10 subjects (30%) and 16 subjects (38%) in the untreated control, 0.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,genotropin,22,1058,1233,"23 and the 0.47 mg/kg/week groups, respectively, had at least one measurement; while 0 subjects (0%), 2 subjects (7%) and 6 subjects (14%) had two or more consecutive IGF-1 measurements above +2 SD.\n', '\n', '     Clinical Trials in adults with GHD  \n', '\n', ' In clinical trials with GENOTROPIN in 1,145  notaecandidateindication adults, the majority of the adverse events consisted of mild to moderate symptoms of  oselabeledaefromdruguse  including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  These events were reported early during therapy, and tended to be transient and/or responsive to dosage reduction.\n', '\n', ' Table 1 displays the adverse events reported by 5% or more of adult  notaecandidateindication patients in clinical trials after various durations of treatment with GENOTROPIN.",0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
23,genotropin,23,1233,1260,"Also presented are the corresponding incidence rates of these adverse events in placebo patients during the 6-month double-blind portion of the clinical trials.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,genotropin,24,1260,1302,"'\n', ' Table 1 Adverse Events Reported by >= 5% of 1,145 Adult GHD Patients During Clinical Trials of GENOTROPIN and Placebo, Grouped by Duration of Treatment \n', '                            Double Blind Phase  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,genotropin,25,1302,1306,Open Label PhaseGENOTROPIN   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,genotropin,26,1306,1316,"\n', ' Adverse Event              Placebo0-6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,genotropin,27,1316,1318,mo.n =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,genotropin,28,1318,1322,572% Patients  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,genotropin,29,1322,1327,GENOTROPIN0-6 mo.n =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,genotropin,30,1327,1336,573% Patients  6-12 mo.n =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,genotropin,31,1336,1354,504% Patients  12-18 mo.n = 63% Patients  18-24 mo.n =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,genotropin,32,1354,1358,60% Patients   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,genotropin,33,1358,1393,"\n', '  \n', '   n = number of patients receiving treatment during the indicated period.% = percentage of patients who reported the event during the indicated period.     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,genotropin,34,1393,1405,"\n', '  \n', ""  oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,genotropin,35,1405,1411,5.1          17.5 [note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,genotropin,36,1411,1431,"Increased significantly when compared to placebo, P<=.025: Fisher's Exact Test (one-sided)]           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,genotropin,37,1431,1435,5.6               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,genotropin,38,1435,1454,"1.7         \n"", '  oselabeledaefromdruguse                       4.2             17.3              6.9              6.3              3.3         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,genotropin,39,1454,1461,"\n', '  oselabeledaefromdruguse       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,genotropin,40,1461,1469,14.5             15.5             13.1             15.9             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,genotropin,41,1469,1471,13.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,genotropin,42,1471,1478,"\n', '  oselabeledaefromdruguse                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,genotropin,43,1478,1482,5.9             14.7              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,genotropin,44,1482,1499,"6.7              1.6              3.3         \n', '  oselabeledaefromdruguse                2.6             10.8              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,genotropin,45,1499,1522,"3.0               0                0          \n', '  oselabeledaefromdruguse                      1.9              9.6              2.2              3.2               0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,genotropin,46,1522,1544,"\n', '  oselabeledaefromdruguse                         7.7              9.9              6.2               0                0          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,genotropin,47,1544,1552,oselabeledaefromdruguse         1.6              7.9              2.4              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,genotropin,48,1552,1556,1.6               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,genotropin,49,1556,1573,"\n', '  oselabeledaefromdruguse                          3.8              5.8              4.6              6.3              1.7         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,genotropin,50,1573,1586,"\n', '  oselabeledaefromdruguse                          1.6              4.9              2.0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,genotropin,51,1586,1597,"4.8              6.7         \n', '  oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,genotropin,52,1597,1657,"4.4              2.8              3.4              4.8              5.0         \n', '                Post-Trial Extension Studies in Adults  \n', ' \n', '\n', ' In expanded post-trial extension studies,  oselabeledaefromdruguse developed in 12 of 3,031 patients (0.4%) during treatment with GENOTROPIN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,genotropin,53,1657,1678,"All 12 patients had predisposing factors, e.g.,  notaecandidatepreexistingconditionorriskfactor and/or marked  notaecandidatepreexistingconditionorriskfactor  prior to receiving GENOTROPIN.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
54,genotropin,54,1678,1713,"Of the 3,031 patients receiving GENOTROPIN, 61 (2%) developed symptoms of  oselabeledaefromdruguse  which lessened after dosage reduction or treatment interruption (52) or surgery (9).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,genotropin,55,1713,1761,"Other adverse events that have been reported include  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '     Anti-hGH Antibodies  \n', '\n', ' As with all therapeutic proteins, there is potential for  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,genotropin,56,1761,1778,The detection of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,genotropin,57,1778,1825,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,genotropin,58,1825,1846,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction may be misleading.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,genotropin,59,1846,1941,"In the case of growth hormone,  nonoseaeaeonlyasinstruction with binding capacities lower than 2 mg/mL have not been associated with  nonoseaenegation  In a very small number of patients treated with somatropin, when binding capacity was greater than 2 mg/mL,  nonoseaeaeonlyasinstruction was observed.\n', '\n', ' In 419 pediatric patients evaluated in clinical studies with GENOTROPIN lyophilized powder, 244 had been treated previously with GENOTROPIN or other growth hormone preparations and 175 had received no previous growth hormone therapy.  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
60,genotropin,60,1941,1942,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,genotropin,61,1942,1955,( oselabeledaefromdruguse  were present in six previously treated patients at baseline.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,genotropin,62,1955,1972,Three of the six became  oselabeledaefromdruguse during 6 to 12 months of treatment with GENOTROPIN.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,genotropin,63,1972,2004,"Of the remaining 413 patients, eight (1.9%) developed detectable  oselabeledaefromdruguse during treatment with GENOTROPIN; none had an  nonoseaeaeonlyasinstruction binding capacity > 2 mg/L.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,genotropin,64,2004,2061,"There was no evidence that the growth response to GENOTROPIN was affected in these  nonoseaeaeonlyasinstruction patients.\n', '\n', '     Periplasmic Escherichia coli Peptides  \n', '\n', ' Preparations of GENOTROPIN contain a small amount of periplasmic  Escherichia coli  peptides (PECP).  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,genotropin,65,2061,2085,"oselabeledaefromdruguse are found in a small number of patients treated with GENOTROPIN, but these appear to be of no clinical significance.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,genotropin,66,2085,2177,"'\n', '   6.2 Post-Marketing Experience\n', '\n', '  Because these adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' Serious  oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported with post-marketing use of somatropin products  [see  Warnings and Precautions (5.6)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,genotropin,67,2177,2213,"\n', '\n', '  nonoseaeaeonlyasinstruction has been reported in a small number of  notaecandidateindication children treated with somatropin, somatrem (methionylated rhGH) and GH of pituitary origin.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
68,genotropin,68,2213,2244,"It is uncertain whether these cases of  nonoseaeaeonlyasinstruction are related to GH therapy, the pathology of  notaecandidateindication itself, or other associated treatments such as radiation therapy.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
69,genotropin,69,2244,2274,"On the basis of current evidence, experts have not been able to conclude that GH therapy  per se  was responsible for these cases of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,genotropin,70,2274,2310,"The risk for children with  notaecandidateindication  if any, remains to be established  [see  Contraindications (4)  and  Warnings and Precautions (5.3)  ].  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
71,genotropin,71,2310,2347,"\n', '\n', ' The following serious adverse reactions have been observed with use of somatropin (including events observed in patients who received brands of somatropin other than GENOTROPIN):  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,genotropin,72,2347,2352,oselabeledaefromdruguse  [see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,genotropin,73,2352,2384,"Warnings and Precautions (5.1)  ]  ,  oselabeledaefromdruguse  [see  Warnings and Precautions (5.2)  ]  ,  oselabeledaefromdruguse  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,genotropin,74,2384,2420,"Warnings and Precautions (5.3)  ]  ,  oselabeledaefromdruguse  [see  Warnings and Precautions (5.9)  ]  ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,genotropin,75,2420,2476,"Warnings and Precautions (5.15)  ]  .\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse  occasionally associated with  oselabeledaefromdruguse  have been reported in children treated with growth hormone  [see  Warnings and Precautions (5.10)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,genotropin,76,2476,2485,Cases have been reported with GENOTROPIN  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,genotropin,77,2485,2525,"\n', '\n', ' The following additional adverse reactions have been observed during the appropriate use of somatropin:  oselabeledaefromdruguse (children and adults),  oselabeledaefromdruguse (children), and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,genotropin,78,2525,2618,"\n', '\n', ' New-onset  oselabeledaefromdruguse    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk (  5.1  ) \n', ' *  Prader-Willi syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatmentDiscontinue treatment if these signs occur (  5.2  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,genotropin,79,2618,2632,*  Neoplasm: Monitor patients with preexisting tumors for progression or recurrence.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,genotropin,80,2632,2665,Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin in particular meningiomas in patients treated with radiation to the head for their first neoplasm (  5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,genotropin,81,2665,2688,"\n', ' *  Impaired Glucose Tolerance and Diabetes Mellitus: May be unmaskedPeriodically monitor glucose levels in all patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,genotropin,82,2688,2716,"Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment (  5.4  ) \n', ' *  Intracranial Hypertension: Exclude preexisting papilledema.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,genotropin,83,2716,2746,"May develop and is usually reversible after discontinuation or dose reduction (  5.5  ) \n', ' *  Hypersensitivity: Serious hypersensitivity reactions may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,genotropin,84,2746,2763,"In the event of an allergic reaction, seek prompt medical attention (  5.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,genotropin,85,2763,2791,"\n', ' *  Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome - especially in adults): May occur frequently.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,genotropin,86,2791,2800,Reduce dose as necessary (  5.7  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,genotropin,87,2800,2804,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,genotropin,88,2804,2815,*  Hypoadrenalism: Monitor patients for reduced serum cortisol levels,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,genotropin,89,2815,2846,"and/or need for glucocorticoid dose increases in those with known hypoadrenalism (  5.8  ) \n', ' *  Hypothyroidism: May first become evident or worsen.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,genotropin,90,2846,2855,Monitor thyroid function periodically (  5.9  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,genotropin,91,2855,2859,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,genotropin,92,2859,2869,*  Slipped Capital Femoral Epiphysis: May develop.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,genotropin,93,2869,2913,"Evaluate children with the onset of a limp or hip/knee pain (  5.10  ) \n', ' *  Progression of Preexisting Scoliosis: Monitor any child with scoliosis for progression of the curve (  5.11  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,genotropin,94,2913,2917,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,genotropin,95,2917,3015,"*  Pancreatitis: Consider pancreatitis in patients with persistent severe abdominal pain (  5.15  ) \n', '    \n', ' \n', '\n', '   5.1 Acute Critical Illness\n', '\n', '   Increased  nonoseaegeneralterm in patients with  notaecandidatecontraindication due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with  notaecandidatepreexistingconditionorriskfactor has been reported after treatment with pharmacologic  amounts of somatropin [see  Contraindications (4)  ].  ",0,1,1,0,0,0,0,0,0,0,0,1,0,0,0
96,genotropin,96,3015,3070,Two placebo-controlled clinical trials in  notaecandidatepreexistingconditionorriskfactor adult patients (n=522) with these conditions in intensive care units revealed a significant increase in  nonoseaegeneralterm (42% vs. 19%) among somatropin-treated patients (doses 5.3-8 mg/day) compared to those receiving placebo.,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
97,genotropin,97,3070,3095,The safety of continuing somatropin treatment in patients receiving replacement  doses for approved indications who concurrently develop these illnesses has not been established.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,genotropin,98,3095,3119,"Therefore, the potential benefit of treatment continuation with somatropin in patients having  notaecandidatecontraindication should be weighed against the potential risk.  ",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
99,genotropin,99,3119,3139,"\n', '\n', '    5.2 Prader-Willi Syndrome in Children\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,genotropin,100,3139,3205,"', '  There have been reports of  nonoseaegeneralterm after initiating therapy with somatropin in pediatric patients with  notaecandidateindication who had one or more of the following risk factors:  notaecandidatecontraindication  history of  notaecandidatecontraindication or  notaecandidatepreexistingconditionorriskfactor  or unidentified  notaecandidatepreexistingconditionorriskfactor  Male patients with one or more of these factors may be at greater risk than females.",0,1,1,1,0,0,0,0,0,0,0,1,0,0,0
101,genotropin,101,3205,3227,Patients with  notaecandidateindication should be evaluated for signs of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction before initiation of treatment with somatropin.,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
102,genotropin,102,3227,3258,"If during treatment with somatropin, patients show signs of  nonoseaeaeonlyasinstruction (including onset of or  nonoseaeaeonlyasinstruction  and/or new onset  nonoseaeaeonlyasinstruction  treatment should be interrupted.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,genotropin,103,3258,3303,All patients with  notaecandidateindication treated with somatropin should also have effective weight control and be monitored for signs of  nonoseaeaeonlyasinstruction  which should be diagnosed as early as possible and treated aggressively [see  Contraindications (4)  ].  ,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
104,genotropin,104,3303,3354,"\n', '\n', '    5.3 Neoplasms\n', '\n', '  In childhood  notaecandidatecontraindication survivors who were treated with radiation to the brain/head for their first  notaecandidatepreexistingconditionorriskfactor and who developed subsequent  notaecandidateindication and were treated with somatropin,",0,0,1,1,0,0,0,0,0,0,0,1,0,0,0
105,genotropin,105,3354,3366,an increased risk of a  oselabeledaefromdruguse has been reported.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,genotropin,106,3366,3383,oselabeledaefromdruguse  in particular  oselabeledaefromdruguse  were the most common of these second  nonoseaeaefromofflabel  ,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
107,genotropin,107,3383,3412,"In adults, it is unknown whether there is any relationship between somatropin replacement therapy and  nonoseaeaeonlyasinstruction [see  Contraindications (4)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,genotropin,108,3412,3436,Monitor all patients with a history of  notaecandidatecontraindication secondary to an  notaecandidatepreexistingconditionorriskfactor routinely while on somatropin therapy for progression or  nonoseaeaeonlyasinstruction,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0
109,genotropin,109,3436,3444,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,genotropin,110,3444,3478,Because children with certain rare genetic causes of  notaecandidateindication have an increased risk of developing  nonoseaeaeonlyasinstruction  practitioners should thoroughly consider the risks and benefits of starting somatropin in these patients.,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
111,genotropin,111,3478,3563,"If treatment with somatropin is initiated, these patients should be carefully monitored for development of  nonoseaeaeonlyasinstruction \n', '\n', ' Monitor patients on somatropin therapy carefully for  nonoseaeaeonlyasinstruction  or potential malignant changes,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction \n', '\n', '    5.4  oselabeledaefromdruguse and Diabetes Mellitus\n', '\n', '  Treatment with somatropin may  oselabeledaefromdruguse  particularly at higher doses in susceptible patients.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,genotropin,112,3563,3583,"As a result, previously undiagnosed  notaecandidatepreexistingconditionorriskfactor and overt  notaecandidatepreexistingconditionorriskfactor may be unmasked during somatropin treatment.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
113,genotropin,113,3583,3588,oselabeledaeclasseffect has been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,genotropin,114,3588,3651,"Therefore, glucose levels should be monitored periodically in all patients treated with somatropin, especially in those with risk factors for  notaecandidatepreexistingconditionorriskfactor  such as  notaecandidatepreexistingconditionorriskfactor   notaecandidateindication  or a family history of  notaecandidatepreexistingconditionorriskfactor  Patients with preexisting  notaecandidatepreexistingconditionorriskfactor or type 2  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor should be monitored closely during somatropin therapy.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
115,genotropin,115,3651,3724,"The doses of antihyperglycemic drugs (i.e., insulin or oral/injectable agents) may require adjustment when somatropin therapy is instituted in these patients.\n', '\n', '    5.5 Intracranial Hypertension\n', '\n', '   oselabeledaefromdruguse  with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and/or  nonoseaemanifestationorcomplication has been reported in a small number of patients treated with somatropin products.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
116,genotropin,116,3724,3741,Symptoms usually occurred within the first eight (8) weeks after the initiation of somatropin therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,genotropin,117,3741,3765,"In all reported cases,  nonoseaeaeonlyasinstruction signs and symptoms rapidly resolved after cessation of therapy or a reduction of the somatropin dose.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,genotropin,118,3765,3790,"Funduscopic examination should be performed routinely before initiating treatment with somatropin to exclude preexisting papilledema, and periodically during the course of somatropin therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,genotropin,119,3790,3806,"If  nonoseaeaeonlyasinstruction is observed by funduscopy during somatropin treatment, treatment should be stopped.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,genotropin,120,3806,3831,"If  nonoseaeaeonlyasinstruction is diagnosed, treatment with somatropin can be restarted at a lower dose after  nonoseaeaeonlyasinstruction signs and symptoms have resolved.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,genotropin,121,3831,3890,"Patients with  notaecandidateindication and  notaecandidateindication may be at increased risk for the development of  oselabeledaefromdruguse \n', '\n', '    5.6 Severe Hypersensitivity\n', '\n', '   Serious  oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported with post-marketing use of somatropin products.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
122,genotropin,122,3890,3925,Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs [see  Contraindications (4)  ].    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,genotropin,123,3925,3955,"\n', '\n', '    5.7 Fluid Retention\n', '\n', '   oselabeledaefromdruguse during somatropin replacement therapy in adults may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,genotropin,124,3955,4072,"Clinical manifestations of  nonoseaeaeonlyasinstruction (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication including  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  are usually transient and dose dependent.\n', '\n', '    5.8 Hypoadrenalism\n', '\n', '   Patients receiving somatropin therapy who have or are at risk for  notaecandidatepreexistingconditionorriskfactor s) may be at risk for  oselabeledaefromdruguse and/or unmasking of  oselabeledaefromdruguse  In addition, patients treated with glucocorticoid replacement for previously diagnosed  notaecandidatepreexistingconditionorriskfactor may require an increase in their maintenance or  nonoseaeaeonlyasinstruction following initiation of somatropin treatment [see  Section 7.1, 11-beta Hydroxysteroid Dehydrogenase Type 1  ].    ",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
125,genotropin,125,4072,4073,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,genotropin,126,4073,4113,"', '\n', '    5.9 Hypothyroidism\n', '\n', '  Undiagnosed/untreated  notaecandidatepreexistingconditionorriskfactor may prevent an optimal response to somatropin, in particular, the growth response in children.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
127,genotropin,127,4113,4131,Patients with  notaecandidateindication have an inherently increased risk of developing  nonoseaeaeonlyasinstruction disease and  nonoseaeaeonlyasinstruction  ,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
128,genotropin,128,4131,4148,In patients with  notaecandidateindication   oselabeledaefromdruguse may first become evident or worsen during somatropin treatment.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
129,genotropin,129,4148,4222,"Therefore, patients treated with somatropin should have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or appropriately adjusted when indicated.\n', '\n', '    5.10 Slipped Capital Femoral Epiphyses in Pediatric Patients\n', '\n', '   oselabeledaefromdruguse may occur more frequently in patients with endocrine disorders (including  notaecandidateindication and  notaecandidateindication  or in patients undergoing  nonoseaeaeonlyasinstruction  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
130,genotropin,130,4222,4339,"Any pediatric patient with the onset of a  nonoseaemanifestationorcomplication or complaints of  nonoseaemanifestationorcomplication or knee  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication during somatropin therapy should be carefully evaluated.\n', '\n', '    5.11 Progression of Preexisting Scoliosis in Pediatric Patients\n', '\n', '   oselabeledaefromdruguse can occur in patients who experience  nonoseaeaeonlyasinstruction  Because somatropin  nonoseaeaeonlyasinstruction  patients with a history of  notaecandidatepreexistingconditionorriskfactor who are treated with somatropin should be monitored for progression of  nonoseaeaeonlyasinstruction  However, somatropin has not been shown to increase the occurrence of  nonoseaenegation   nonoseaeaeonlyasinstruction including  nonoseaeaeonlyasinstruction are commonly seen in untreated  notaecandidateindication patients.  ",1,0,1,1,1,0,0,1,0,0,0,0,0,0,0
131,genotropin,131,4339,4351,nonoseaeaeonlyasinstruction is also commonly seen in untreated patients with  notaecandidateindication  ,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
132,genotropin,132,4351,4437,"Physicians should be alert to these abnormalities, which may manifest during somatropin therapy.\n', '\n', '    5.12 Otitis Media and  oselabeledaefromdruguse in Turner Syndrome\n', '\n', '  Patients with  notaecandidateindication should be evaluated carefully for  nonoseaeaeonlyasinstruction and other  nonoseaeaeonlyasinstruction since these patients have an increased risk of  nonoseaeaeonlyasinstruction and hearing  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  Somatropin treatment may increase the occurrence of  oselabeledaefromdruguse in patients with  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
133,genotropin,133,4437,4514,"In addition, patients with  notaecandidateindication should be monitored closely for  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction aneurysm/ nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  as these patients are also at risk for these conditions.\n', '\n', '    5.13 Lipoatrophy\n', '\n', '  When somatropin is administered subcutaneously at the same site over a long period of time,  nonoseaeaefromofflabel may result.",1,0,0,1,0,0,0,0,0,0,1,0,0,0,0
134,genotropin,134,4514,4530,This can be avoided by rotating the injection site [see  Dosage and Administration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,genotropin,135,4530,4537,(2.3)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,genotropin,136,4537,4598,"\n', '\n', '    5.14 Laboratory Tests\n', '\n', '  Serum levels of  oselabeledaefromdruguse  alkaline phosphatase, parathyroid hormone (PTH) and IGF-I may  oselabeledaefromdruguse  oselabeledaefromdruguse  parathyroid hormone (PTH) and IGF-I may  oselabeledaefromdruguse  oselabeledaefromdruguse and IGF-",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,genotropin,137,4598,4657,"I may  oselabeledaefromdruguse  oselabeledaefromdruguse may  oselabeledaefromdruguse during somatropin therapy.\n', '\n', '    5.15 Pancreatitis\n', '\n', '  Cases of  oselabeledaefromdruguse have been reported rarely in children and adults receiving somatropin treatment, with some evidence supporting a greater risk in children compared with adults.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,genotropin,138,4657,4679,Published literature indicates that girls who have  notaecandidateindication may be at greater risk than other somatropin-treated children.  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
139,genotropin,139,4679,4702,"nonoseaeaeonlyasinstruction should be considered in any somatropin-treated patient, especially a child, who develops persistent severe  nonoseaemanifestationorcomplication ']",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,signifor,0,0,58,"['      6         ADVERSE REACTIONS  \n', '\n', '  Clinically significant adverse reactions that appear in other sections of the labeling include:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.1)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,signifor,1,58,59,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,signifor,2,59,79,"', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse  [see Warnings and Precautions (5.2)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,signifor,3,79,80,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,signifor,4,80,100,"', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse  [see Warnings and Precautions (5.3)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,signifor,5,100,117,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.4)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,signifor,6,117,135,"\n', ' *   oselabeledaefromdruguse  [see Warnings and Precautions (5.5)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,signifor,7,135,152,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.6)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,signifor,8,152,153,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,signifor,9,153,160,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,signifor,10,160,193,"Most common adverse reactions occurring in >= 20% of patients are diarrhea, nausea, hyperglycemia, cholelithiasis, headache, abdominal pain, fatigue, and diabetes mellitus (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,signifor,11,193,196,6  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,signifor,12,196,237,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,signifor,13,237,275,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1       Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,signifor,14,275,359,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' A total of 162  notaecandidateindication patients were exposed to SIGNIFOR in the Phase III study   [see Clinical Studies (14)]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,signifor,15,359,388,"At study entry, patients were randomized to receive twice a day (b.i.d.) doses of either 0.6 mg or 0.9 mg of SIGNIFOR given subcutaneously.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,signifor,16,388,409,The mean age of patients was approximately 40 years old with a predominance of female patients (78%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,signifor,17,409,443,The majority of the patients had persistent or recurrent  notaecandidateindication (83%) and few patients (<= 5%) in either treatment group had received previous pituitary irradiation.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
18,signifor,18,443,500,"The median exposure to the treatment was 10.4 months (0.03-37.8) with 68% of patients having at least six-months exposure.\n', '\n', '\n', '\n', ' In the Phase III trial, adverse reactions were reported in 98% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,signifor,19,500,535,The most common adverse reactions (frequency >= 20% in either group) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,signifor,20,535,543,There were no deaths during the study.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,signifor,21,543,554,Serious adverse events were reported in 25% of patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,signifor,22,554,604,"Adverse events leading to study discontinuation were reported in 17% of patients.\n', '\n', '\n', '\n', ' Adverse reactions with an overall frequency higher than 5% are presented in Table 1 by randomized dose group and overall.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,signifor,23,604,691,"Adverse reactions are ranked by frequency, with the most frequent reactions listed first.\n', '\n', '\n', '\n', "" Table 1 - Adverse reactions [n (%)] with an overall frequency of more than 5% in the combined dose group in the Phase III study in Cushing's disease patients \n"", '                  SIGNIFOR0.6 mg bidN=82  SIGNIFOR0.9 mg bidN=80  OverallN=162      \n', '  oselabeledaefromdruguse         48",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,signifor,24,691,722,"(59)          46 (58)          94 (58)           \n', '  oselabeledaefromdruguse           38 (46)          46 (58)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,signifor,25,722,727,84 (52)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,signifor,26,727,744,"\n', '  oselabeledaefromdruguse    31 (38)          34 (43)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,signifor,27,744,745,65,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,signifor,28,745,779,"(40)           \n', '  oselabeledaefromdruguse   25 (30)          24 (30)          49 (30)           \n', '  oselabeledaefromdruguse         23",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,signifor,29,779,789,(28)          23 (29)          46,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,signifor,30,789,913,"(28)           \n', '  oselabeledaefromdruguse   19 (23)          20 (25)          39 (24)           \n', '  oselabeledaefromdruguse          12 (15)          19(24)           31 (19)           \n', '  oselabeledaefromdruguse  13 (16)          16 (20)          29 (18)           \n', '  oselabeledaefromdruguse  14 (17)          14 (18)          28 (17)           \n', '  oselabeledaefromdruguse  10 (12)          11 (14)          21 (13)           \n', '  oselabeledaefromdruguse         10 (12)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,signifor,31,913,935,"10 (13)          20 (12)           \n', '  oselabeledaefromdruguse         13 (16)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,signifor,32,935,943,5 (6)            18 (11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,signifor,33,943,1017,")           \n', '  oselabeledaefromdruguse  10 (12)          8 (10)           18 (11)           \n', '  oselabeledaefromdruguse  11 (13)          6 (8)            17 (10)           \n', '  oselabeledaefromdruguse  10 (12)          7 (9)            17 (10)           \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,signifor,34,1017,1168,"9 (11)           8 (10)           17 (10)           \n', '  oselabeledaefromdruguse  10 (12)          6 (8)            16 (10)           \n', '  oselabeledaefromdruguse  7 (9)            9 (11)           16 (10)           \n', '  oselabeledaefromdruguse  7 (9)            9 (11)           16 (10)           \n', '  oselabeledaefromdruguse     8 (10)           8 (10)           16 (10)           \n', '  oselabeledaefromdruguse        8 (10)           7 (9)            15 (9)            \n', '  oselabeledaefromdruguse     12 (15)          3 (4)            15 (9)            \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,signifor,35,1168,1197,"oselabeledaefromdruguse  10 (12)          5 (6)            15 (9)            \n', '  oselabeledaefromdruguse          5 (6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,signifor,36,1197,1200,9 (11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,signifor,37,1200,1247,")           14 (9)            \n', '  oselabeledaefromdruguse        9 (11)           5 (6)            14 (9)            \n', '  oselabeledaefromdruguse         3 (4)            11 (14)          14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,signifor,38,1247,1435,"(9)            \n', '  oselabeledaefromdruguse          10 (12)          4 (5)            14 (9)            \n', '  oselabeledaefromdruguse       5 (6)            8 (10)           13 (8)            \n', '  oselabeledaefromdruguse         6 (7)            7 (9)            13 (8)            \n', '  oselabeledaefromdruguse  7 (9)            5 (6)            12 (7)            \n', '  oselabeledaefromdruguse     7 (9)            4 (5)            11 (7)            \n', '  oselabeledaefromdruguse      5 (6)            6 (8)            11 (7)            \n', '  oselabeledaefromdruguse         3 (4)            8 (10)           11 (7)            \n', '  oselabeledaefromdruguse        4 (5)            6 (8)            10 (6)            \n', '  oselabeledaefromdruguse         5 (6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,signifor,39,1435,1445,5 (6)            10 (6)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,signifor,40,1445,1453,"\n', '  oselabeledaefromdruguse  5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,signifor,41,1453,1474,"(6)            5 (6)            10 (6)            \n', '  oselabeledaefromdruguse      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,signifor,42,1474,1489,6 (7)            4 (5)            10 (6)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,signifor,43,1489,1511,"\n', '  oselabeledaefromdruguse  6 (7)            4 (5)            10 (6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,signifor,44,1511,1519,"\n', '  oselabeledaefromdruguse  8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,signifor,45,1519,1566,"(10)           2 (3)            10 (6)            \n', '  oselabeledaefromdruguse          4 (5)            6 (8)            10 (6)            \n', '  oselabeledaefromdruguse  4 (5)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,signifor,46,1566,1576,5 (6)            9 (6)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,signifor,47,1576,1588,"\n', '  oselabeledaefromdruguse  4 (5)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,signifor,48,1588,1598,5 (6)            9 (6)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,signifor,49,1598,1620,"\n', '  oselabeledaefromdruguse  6 (7)            3 (4)            9 (6)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,signifor,50,1620,1642,"\n', '  oselabeledaefromdruguse  6 (7)            3 (4)            9 (6)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,signifor,51,1642,1695,"\n', '          Other notable adverse reactions which occurred with a frequency less than 5% were:  oselabeledaefromdruguse (4%);  oselabeledaefromdruguse (2%) and  oselabeledaefromdruguse (2%).\n', ' \n', '\n', '   Gastrointestinal Disorders  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,signifor,52,1695,1738,"\n', '\n', '\n', '\n', '  nonoseaegeneralterm  predominantly  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse were reported frequently in the Phase III trial (see Table 1).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,signifor,53,1738,1803,"These events began to develop primarily during the first month of treatment with SIGNIFOR and required no intervention.\n', '\n', '\n', '\n', '   Hyperglycemia and Diabetes  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse were reported frequently in the Phase III trial.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,signifor,54,1803,1840,"For all patients, these terms included:  oselabeledaefromdruguse (40%),  oselabeledaefromdruguse (18%),  oselabeledaefromdruguse (11%), and  oselabeledaefromdruguse (9%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,signifor,55,1840,1874,"In general,  oselabeledaefromdruguse  oselabeledaefromdruguse fasting plasma glucose (FPG) and  oselabeledaefromdruguse (HbA1c) were seen soon after initiation of SIGNIFOR and were sustained during the treatment period.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,signifor,56,1874,1900,"In the SIGNIFOR 0.6 mg group, mean  oselabeledaefromdruguse from 98.6 mg/dL at baseline to 125.1 mg/dL at Month 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,signifor,57,1900,1926,"In the SIGNIFOR 0.9 mg group, mean  oselabeledaefromdruguse from 97.0 mg/dL at baseline to 128.0 mg/dL at Month 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,signifor,58,1926,1947,"In the SIGNIFOR 0.6 mg group,  oselabeledaefromdruguse from 5.8% at baseline to 7.2% at Month 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,signifor,59,1947,1978,"In the SIGNIFOR 0.9 mg group,  oselabeledaefromdruguse from 5.8% at baseline to 7.3% at Month 6  [see Warning and Precautions (5.2)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,signifor,60,1978,2021,".\n', '\n', '\n', '\n', ' At one-month follow-up visits following discontinuation of SIGNIFOR,  nonoseaeaeonlyasinstruction and HbA1c  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction but remained above baseline values.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,signifor,61,2021,2086,"Long-term follow-up data are not available.\n', '\n', '\n', '\n', '   Elevated Liver Tests  \n', '\n', '\n', '\n', ' In the Phase III trial, there were transient mean  oselabeledaefromdruguse values in patients treated with SIGNIFOR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,signifor,62,2086,2098,Mean values returned to baseline levels by Month 4 of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,signifor,63,2098,2155,"The elevations were not associated with clinical symptoms of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' In the clinical development program of SIGNIFOR, there were 4 patients with concurrent  oselabeledaefromdruguse  oselabeledaefromdruguse ALT greater than 3 x ULN and  oselabeledaefromdruguse greater than 2",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,signifor,64,2155,2179,x ULN: one patient with  notaecandidateindication and three healthy volunteers  [see Warnings and Precautions (5.4)]  .,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
65,signifor,65,2179,2196,"In all four cases, the elevations were noted within the first 10 days of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,signifor,66,2196,2214,"In all of these cases,  oselabeledaefromdruguse were seen either concomitantly or preceding the  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,signifor,67,2214,2223,The patient with  notaecandidateindication developed  oselabeledaefromdruguse  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
68,signifor,68,2223,2302,"All four cases had resolution of the  nonoseaegeneralterm with discontinuation of SIGNIFOR.\n', '\n', '\n', '\n', '   Hypocortisolism  \n', '\n', '\n', '\n', ' Cases of  oselabeledaefromdruguse were reported in the Phase III study in  notaecandidateindication patients  [see Adverse Reactions (6) and Clinical Studies (14)]  .",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
69,signifor,69,2302,2336,"The majority of cases were manageable by reducing the dose of SIGNIFOR and/or adding low-dose, short-term glucocorticoid therapy  [see Warnings and Precautions (5.1)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,signifor,70,2336,2392,".\n', '\n', '\n', '\n', '   Injection Site Reactions  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse were reported in 17% of patients enrolled in the Phase III trial in  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
71,signifor,71,2392,2448,"The events were most frequently reported as  oselabeledaefromdruguse pain,  oselabeledaefromdruguse  oselabeledaefromdruguse pain, erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse pain, erythema, hematoma,  oselabeledaefromdruguse  oselabeledaefromdruguse pain, erythema, hematoma, hemorrhage, and  oselabeledaefromdruguse  oselabeledaefromdruguse  erythema, hematoma, hemorrhage, and pruritus.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,signifor,72,2448,2601,"These events resolved spontaneously and required no intervention.\n', '\n', '\n', '\n', '   Thyroid Function  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse with the use of SIGNIFOR was reported for seven patients participating in the Phase III study in  notaecandidateindication  All seven patients presented with a  notaecandidatepreexistingconditionorriskfactor at study entry which precludes establishing a conclusive relationship between the adverse event and the use of SIGNIFOR.\n', '\n', '\n', '\n', '   Other Abnormal Laboratory Findings  \n', '\n', '\n', '\n', ' Asymptomatic and reversible  oselabeledaefromdruguse in  oselabeledaefromdruguse  oselabeledaefromdruguse lipase and  oselabeledaefromdruguse were observed in patients receiving SIGNIFOR in clinical studies.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
73,signifor,73,2601,2654,"oselabeledaeclasseffect is a potential adverse reaction associated with the use of somatostatin analogs due to the association between  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' For hemoglobin levels, mean decreases that remained within normal range were observed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,signifor,74,2654,2680,"Also, post-baseline  oselabeledaefromdruguse  oselabeledaefromdruguse PT and  oselabeledaefromdruguse were noted in 33% and 47% of patients, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,signifor,75,2680,2692,The  oselabeledaefromdruguse and PTT  oselabeledaefromdruguse  oselabeledaefromdruguse      5        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,signifor,76,2692,2736,"WARNINGS AND PRECAUTIONS  \n', '\n', '\n', '\n', '   EXCERPT:    *   Hypocortisolism:  Decreases in circulating levels of cortisol may occur resulting in biochemical and/or clinical hypocortisolism.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,signifor,77,2736,2741,SIGNIFOR dose reduction or interruption,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,signifor,78,2741,2759,and/or adding a low-dose short-term glucocorticoid may be necessary (  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,signifor,79,2759,2774,"\n', ' *   Hyperglycemia and Diabetes  (occurs with initiation)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,signifor,80,2774,2800,: Intensive glucose monitoring is recommended and may require initiation or adjustment of anti-diabetic treatment per standard of care (  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,signifor,81,2800,2886,"\n', ' *   Bradycardia and QT Prolongation:  Use with caution in at-risk patients; ECG testing prior to dosing and on treatment (  5.3  ,  7.1  ) \n', ' *   Liver Test Elevations:  Evaluate liver tests prior to and during treatment (  5.4  ) \n', ' *   Cholelithiasis:  Perform gallbladder ultrasounds before starting treatment and at 6-month intervals (  5.5  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,signifor,82,2886,2992,"\n', '    \n', ' \n', '\n', '   5.1       Hypocortisolism\n', '\n', '\n', '\n', '  Treatment with SIGNIFOR leads to  notaecandidateindication   notaecandidateindication may lead to a  oselabeledaefromdruguse and potentially  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' Monitor and instruct patients on the signs and symptoms associated with  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction .",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
83,signifor,83,2992,3068,"If  nonoseaeaeonlyasinstruction occurs, consider temporary dose reduction or interruption of treatment with SIGNIFOR, as well as temporary, exogenous glucocorticoid replacement therapy.\n', '\n', '\n', '\n', '    5.2        oselabeledaefromdruguse and Diabetes \n', '\n', '\n', '\n', '   oselabeledaefromdruguse have been seen in healthy volunteers and patients treated with SIGNIFOR.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,signifor,84,3068,3095,"In the Phase III trial, the development of  oselabeledaefromdruguse and  oselabeledaefromdruguse was observed  [see Clinical Studies (14)]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,signifor,85,3095,3130,"In this trial, nearly all patients-including those with normal glucose status at baseline,  notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor developed  oselabeledaefromdruguse in the first two weeks of treatment.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
86,signifor,86,3130,3168,"notaecandidateindication patients with  notaecandidatepreexistingconditionorriskfactor (as defined by  nonoseaeaeonlyasinstruction while receiving anti-diabetic therapy) may be at a higher risk of developing severe  nonoseaeaeonlyasinstruction and associated complications, e.g.,  nonoseaeaeonlyasinstruction  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
87,signifor,87,3168,3218,"\n', '\n', '\n', '\n', ' Because of this predictable adverse reaction, the glycemic status [fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c)] should be assessed prior to starting treatment with SIGNIFOR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,signifor,88,3218,3237,In patients with  notaecandidatepreexistingconditionorriskfactor intensive anti-diabetic therapy should be optimized prior to treatment with SIGNIFOR.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
89,signifor,89,3237,3281,"Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,signifor,90,3281,3302,"After treatment discontinuation, glycemic monitoring (e.g., FPG or HbA1c) should be done according to clinical practice.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,signifor,91,3302,3382,"Patients who were initiated on anti-diabetic therapy as a result of SIGNIFOR may require closer monitoring after discontinuation of SIGNIFOR, especially if the anti-diabetic therapy has a risk of causing  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' If  nonoseaeaeonlyasinstruction develops in a patient treated with SIGNIFOR, the initiation or adjustment of anti-diabetic treatment per standard of care is recommended.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,signifor,92,3382,3398,The optimal treatment for the management of SIGNIFOR-induced  nonoseaeaeonlyasinstruction is not known.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,signifor,93,3398,3495,"If uncontrolled  nonoseaeaeonlyasinstruction persists, despite appropriate medical management, the dose of SIGNIFOR should be reduced or discontinued.\n', '\n', '\n', '\n', '    5.3       Bradycardia and QT Prolongation\n', '\n', '\n', '\n', '   Bradycardia  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse has been reported with the use of SIGNIFOR  [see Adverse Reactions (6)]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,signifor,94,3495,3536,Patients with  notaecandidatepreexistingconditionorriskfactor and/or risk factors for  notaecandidatepreexistingconditionorriskfactor  such as history of clinically significant  notaecandidatepreexistingconditionorriskfactor  high-grade  notaecandidatepreexistingconditionorriskfactor  or concomitant use of drugs associated with  notaecandidatepreexistingconditionorriskfactor  should be carefully monitored.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
95,signifor,95,3536,3616,"Dose adjustments of beta-blockers, calcium channel blockers, or correction of  nonoseaeaeonlyasinstruction may be necessary.\n', '\n', '\n', '\n', '  QT Prolongation  \n', '\n', '\n', '\n', ' SIGNIFOR is associated with  oselabeledaefromdruguse  In two thorough QT studies with SIGNIFOR,  oselabeledaefromdruguse occurred at therapeutic and supra-therapeutic doses.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,signifor,96,3616,3748,"SIGNIFOR should be used with caution in patients who are at significant risk of developing  nonoseaeaeonlyasinstruction  such as those:\n', '\n', '\n', '\n', ' *  with  notaecandidatepreexistingconditionorriskfactor  \n', ' *  with uncontrolled or significant  notaecandidatepreexistingconditionorriskfactor including  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or clinically significant  notaecandidatepreexistingconditionorriskfactor  \n', ' *  on anti-arrhythmic therapy or other substances that are known to lead to  notaecandidatepreexistingconditionorriskfactor  \n', ' *  with  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor  \n', '    A baseline ECG is recommended prior to initiating therapy with SIGNIFOR and monitoring for an effect on the QTc interval is advisable.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
97,signifor,97,3748,3767,nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction must be corrected prior to SIGNIFOR administration and should be monitored periodically during therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,signifor,98,3767,3826,"\n', ' \n', '\n', '    5.4       Liver Test Elevations\n', '\n', '\n', '\n', ""  In the Phase III trial, 5% of patients had an  oselabeledaefromdruguse or AST level  oselabeledaefromdruguse  oselabeledaefromdruguse (ULN).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,signifor,99,3826,3870,"In the entire clinical development program of SIGNIFOR, there were 4 cases of concurrent  oselabeledaefromdruguse (alanine aminotransferase) greater than 3 x ULN and  oselabeledaefromdruguse than 2 x ULN: one patient with Cushing's disease and three healthy volunteers",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,signifor,100,3870,3881,[see Adverse Reactions (6   )]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,signifor,101,3881,3939,"In these cases,  oselabeledaefromdruguse were seen either concomitantly or preceding the  oselabeledaefromdruguse \n"", '\n', '\n', '\n', ' Monitoring of liver tests should be done after 1 to 2 weeks on treatment, then monthly for 3 months, and every 6 months thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,signifor,102,3939,3976,"If ALT is normal at baseline and  nonoseaeaeonlyasinstruction of 3-5 times the ULN are observed on treatment, repeat the test within a week or within 48 hours if exceeding 5 times ULN.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,signifor,103,3976,4011,"If  nonoseaeaeonlyasinstruction at baseline and  nonoseaeaeonlyasinstruction of 3-5 times the baseline values are observed on treatment, repeat the test within a week or sooner if exceeding 5 times ULN.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,signifor,104,4011,4026,Tests should be done in a laboratory that can provide same-day results.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,signifor,105,4026,4056,"If the values are confirmed or rising, interrupt SIGNIFOR treatment and investigate for probable cause of the findings, which may or may not be SIGNIFOR-related.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,signifor,106,4056,4105,"Serial measures of ALT, aspartate aminotransferase, alkaline phosphatase, and total bilirubin, should be done weekly, or more frequently, if any value exceeds 5 times the baseline value in case of abnormal baselines or 5 times the ULN in case of normal baselines.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,signifor,107,4105,4196,"If resolution of abnormalities to normal or near normal occurs, resuming treatment with SIGNIFOR may be done cautiously, with close observation, and only if some other likely cause has been found.\n', '\n', '\n', '\n', '    5.5       Cholelithiasis \n', '\n', '\n', '\n', '   oselabeledaefromdruguse has been frequently reported in clinical studies with SIGNIFOR  [see Adverse Reactions (6)]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,signifor,108,4196,4275,"Ultrasonic examination of the gallbladder before, and at 6- to 12-month intervals during SIGNIFOR therapy is recommended.\n', '\n', '\n', '\n', '    5.6       Monitoring for Deficiency of Pituitary Hormones\n', '\n', '\n', '\n', '  As the pharmacological activity of SIGNIFOR mimics that of somatostatin,  oselabeledaefromdruguse  other than ACTH, may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,signifor,109,4275,4311,"Monitoring of pituitary function (e.g., TSH/free T4, GH/IGF-1) should occur prior to initiation of therapy with SIGNIFOR and periodically during treatment should be considered as clinically appropriate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,signifor,110,4311,4333,Patients who have undergone  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor are particularly at increased risk for  nonoseaeaeonlyasinstruction of  nonoseaeaeonlyasinstruction '],1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,dexamethasone,0,0,65,"['  ADVERSE REACTIONS\n', '\n', '    (Listed alphabetically, under each subsection)  \n', '\n', ' The following adverse reactions have been reported with dexamethasone or other corticosteroids:\n', '\n', '   Allergic Reactions\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,dexamethasone,1,65,109,"\n', '\n', '   Cardiovascular\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse following recent  notaecandidatepreexistingconditionorriskfactor (see    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
2,dexamethasone,2,109,133,"WARNINGS  :  Cardio-Renal    ),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,dexamethasone,3,133,169,"\n', '\n', '   Dermatologic\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse scaly  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,dexamethasone,4,169,184,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,dexamethasone,5,184,255,"\n', '\n', '   Endocrine\n', '\n', '   oselabeledaefromdruguse and glucose  oselabeledaefromdruguse  oselabeledaefromdruguse carbohydrate and  oselabeledaefromdruguse  development of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse or oral hypoglycemic agents  oselabeledaefromdruguse  oselabeledaefromdruguse insulin or  oselabeledaefromdruguse  manifestations of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and pituitary  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,dexamethasone,6,255,279,"adrenocortical and  oselabeledaefromdruguse (particularly in times of  notaecandidatepreexistingconditionorriskfactor  as in trauma, surgery, or  notaecandidatepreexistingconditionorriskfactor ,  oselabeledaefromdruguse",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
7,dexamethasone,7,279,280,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,dexamethasone,8,280,313,"', '\n', '   Fluid and Electrolyte Disturbances\n', '\n', '   oselabeledaefromdruguse in susceptible patients,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,dexamethasone,9,313,388,"\n', '\n', '   Gastrointestinal\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse (usually reversible upon discontinuation),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse with possible  oselabeledaefromdruguse  oselabeledaefromdruguse with possible perforation and  oselabeledaefromdruguse   oselabeledaefromdruguse and large  oselabeledaefromdruguse  oselabeledaefromdruguse the small and  oselabeledaefromdruguse (particularly in patients with  notaecandidatepreexistingconditionorriskfactor ,  oselabeledaefromdruguse",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
10,dexamethasone,10,388,454,"\n', '\n', '   Metabolic\n', '\n', '   nonoseaemanifestationorcomplication due to  oselabeledaefromdruguse \n', '\n', '   Musculoskeletal\n', '\n', '   oselabeledaefromdruguse and humeral  oselabeledaefromdruguse  oselabeledaefromdruguse femoral and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
11,dexamethasone,11,454,513,"\n', '\n', '   Neurological/Psychiatric\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse with  oselabeledaefromdruguse ( oselabeledaefromdruguse  usually following discontinuation of treatment,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,dexamethasone,12,513,592,"\n', '\n', '   Ophthalmic\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '   Other\n', '\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse or decreased  oselabeledaefromdruguse and number  oselabeledaefromdruguse  oselabeledaefromdruguse or decreased motility and  oselabeledaefromdruguse  oselabeledaefromdruguse and number  oselabeledaefromdruguse  oselabeledaefromdruguse motility and  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,dexamethasone,13,592,596,oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,dexamethasone,14,596,598,oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,dexamethasone,15,598,632,"PRECAUTIONS\n', '\n', '   General\n', '\n', '  The lowest possible dose of corticosteroids should be used to control the condition under treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,dexamethasone,16,632,702,"When reduction in dosage is possible, the reduction should be gradual.\n', '\n', ' Since complications of treatment with corticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,dexamethasone,17,702,727,", '\n', '  oselabeledaeclasseffect has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,dexamethasone,18,727,813,"Discontinuation of corticosteroids may result in clinical improvement.\n', '\n', '    Cardio-Renal\n', '\n', '  As  oselabeledaefromdruguse with resultant  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication may occur in patients receiving corticosteroids, these agents should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor \n', '    Endocrine\n', '\n', '   oselabeledaefromdruguse may be minimized by gradual reduction of dosage.",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
19,dexamethasone,19,813,846,"This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of  notaecandidatepreexistingconditionorriskfactor occurring during that period, hormone therapy should be reinstituted.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
20,dexamethasone,20,846,1046,"Since  nonoseaemanifestationorcomplication may be  nonoseaemanifestationorcomplication  salt and/or a mineralocorticoid should be administered concurrently.\n', '\n', '    Gastrointestinal\n', '\n', '  Steroids should be used with caution in active or latent  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and nonspecific  notaecandidatepreexistingconditionorriskfactor  since they may increase the risk of a  nonoseaeaeonlyasinstruction \n', '\n', ' Signs of  nonoseaemanifestationorcomplication following  oselabeledaeclasseffect in patients receiving corticosteroids may be minimal or absent.\n', '\n', ' There is an enhanced effect due to decreased metabolism of corticosteroids in patients with  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    Musculoskeletal\n', '\n', '  Corticosteroids  oselabeledaeclasseffect and  oselabeledaeclasseffect both through their  oselabeledaeclasseffect  oselabeledaeclasseffect regulation (i.e.,  oselabeledaeclasseffect  oselabeledaeclasseffect regulation (i.e., decreasing absorption and  oselabeledaeclasseffect  and  oselabeledaeclasseffect  This, together with a  nonoseaemanifestationorcomplication secondary to an  oselabeledaeclasseffect  and  oselabeledaeclasseffect  may lead to  oselabeledaeclasseffect in pediatric patients and the development of  oselabeledaeclasseffect at any age.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
21,dexamethasone,21,1046,1124,"Special consideration should be given to patients at increased risk of  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor women) before initiating corticosteroid therapy.\n', '\n', '    Neuro-Psychiatric\n', '\n', '  Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of  notaecandidatepreexistingconditionorriskfactor  they do not show that they affect the ultimate outcome or natural history of the disease.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
22,dexamethasone,22,1124,1202,"The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see   DOSAGE AND ADMINISTRATION    ).\n', '\n', ' An  oselabeledaeclasseffect has been observed with the use of high doses of corticosteroids, most often occurring in patients with  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor , or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
23,dexamethasone,23,1202,1226,"This  nonoseaeaeonlyasinstruction is generalized, may involve ocular and respiratory muscles, and may result in  nonoseaemanifestationorcomplication   oselabeledaeclasseffect may occur.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
24,dexamethasone,24,1226,1320,"Clinical improvement or recovery after stopping corticosteroids may require weeks to years.\n', '\n', '  oselabeledaeclasseffect may appear when corticosteroids are used, ranging from  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  to frank  oselabeledaeclasseffect  Also, existing  oselabeledaeclasseffect or psychotic tendencies may be  oselabeledaeclasseffect  oselabeledaeclasseffect may be  oselabeledaeclasseffect by corticosteroids.\n', '\n', '    Ophthalmic\n', '\n', '   oselabeledaeclasseffect may become  oselabeledaeclasseffect in some individuals.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,dexamethasone,25,1320,1372,"If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.\n', '\n', '    Information for Patients\n', '\n', '  Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,dexamethasone,26,1372,1509,"As prolonged use may cause  nonoseaeaeonlyasinstruction and make patients  nonoseaeaeonlyasinstruction on corticosteroids, they should advise any medical attendants that they are taking corticosteroids and they should seek medical advice at once should they develop an  nonoseaeaeonlyasinstruction including  nonoseaeaeonlyasinstruction or other signs of  nonoseaeaeonlyasinstruction  Following prolonged therapy, withdrawal of corticosteroids may result in symptoms of the  nonoseaeodorwithdrawal including,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal \n', '\n', ' Persons who are on corticosteroids should be warned to avoid exposure to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  Patients should also be advised that if they are exposed, medical advice should be sought without delay.\n', '\n', '    Drug Interactions\n', '\n', '   ",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
27,dexamethasone,27,1509,1512,Aminoglutethimide  :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,dexamethasone,28,1512,1526,"Aminoglutethimide may  nonoseaeaefromdruginteraction by corticosteroids.\n', '\n', '  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
29,dexamethasone,29,1526,1536,Amphotericin B Injection and Potassium-depleting agents  :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,dexamethasone,30,1536,1566,"When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of  nonoseaeaefromdruginteraction  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
31,dexamethasone,31,1566,1603,"In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction \n', '\n', '  Antibiotics  :",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
32,dexamethasone,32,1603,1621,Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see Drug Interactions:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,dexamethasone,33,1621,1639,"Hepatic Enzyme Inducers, Inhibitors and Substrates).\n', '\n', '  Anticholinesterases  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,dexamethasone,34,1639,1656,Concomitant use of anticholinesterase agents and corticosteroids may produce  nonoseaeaefromdruginteraction in patients with  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
35,dexamethasone,35,1656,1709,"If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.\n', '\n', '  Anticoagulants, Oral  : Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,dexamethasone,36,1709,1761,"Therefore, coagulation indices should be monitored frequently to maintain the desired  nonoseaeaeonlyasinstruction \n', '\n', '  Antidiabetics  : Because corticosteroids may  oselabeledaeclasseffect  dosage adjustments of antidiabetic agents may be required.\n', '\n', '  Antitubercular Drugs  :",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,dexamethasone,37,1761,1814,"Serum concentrations of isoniazid may be decreased.\n', '\n', '  Cholestyramine  : Cholestyramine may increase the clearance of corticosteroids.\n', '\n', '  Cyclosporine  : Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,dexamethasone,38,1814,1851,"nonoseaeaefromdruginteraction have been reported with this concurrent use.\n', '\n', '  Dexamethasone Suppression Test (DST)  :  nonoseaeaefromdruginteraction  in patients being treated with indomethacin have been reported.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
39,dexamethasone,39,1851,1983,"Thus, results of the DST should be interpreted with caution in these patients.\n', '\n', '  Digitalis Glycosides  : Patients on digitalis glycosides may be at increased risk of  nonoseaeaefromdruginteraction due to  nonoseaeaefromdruginteraction \n', '\n', '  Ephedrine  : Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.\n', '\n', '  Estrogens, Including Oral Contraceptives  : Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.\n', '\n', '  Hepatic Enzyme Inducers, Inhibitors and Substrates  : Drugs which induce cytochrome P450 3A4",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
40,dexamethasone,40,1983,2018,"(CYP 3A4) enzyme activity ( e.g., barbiturates, phenytoin, carbamazepine, rifampin  ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,dexamethasone,41,2018,2047,"Drugs which inhibit CYP 3A4 ( e.g., ketoconazole, macrolide antibiotics such as erythromycin  ) have the potential to result in increased plasma concentrations of corticosteroids.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,dexamethasone,42,2047,2123,"Dexamethasone is a moderate inducer of CYP 3A4. Co-adminstration with other drugs that are metabolized by CYP 3A4 ( e.g., indinavir, erythromycin  ) may increase their clearance, resulting in decreased plasma concentration.\n', '\n', '  Ketoconazole  : Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,dexamethasone,43,2123,2190,"In addition, ketoconazole alone can  nonoseaeaeonlyasinstruction and may cause  nonoseaeaefromdruginteraction during corticosteroid withdrawal.\n', '\n', '  Nonsteroidal Anti-Inflammatory Agents (NSAIDS)  : Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of  nonoseaeaefromdruginteraction  Aspirin should be used cautiously in conjunction with corticosteroids in  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
44,dexamethasone,44,2190,2213,"The clearance of salicylates may be increased with concurrent use of corticosteroids.\n', '\n', '  Phenytoin  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,dexamethasone,45,2213,2246,"In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in  nonoseaeaefromdruginteraction control.\n',",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
46,dexamethasone,46,2246,2256,"'\n', '  Skin Tests  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,dexamethasone,47,2256,2299,"Corticosteroids may  nonoseaeaefromdruginteraction \n', '\n', '  Thalidomide  : Co-administration with thalidomide should be employed cautiously, as  nonoseaeaefromdruginteraction has been reported with concomitant use.\n', '\n', '  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
48,dexamethasone,48,2299,2301,Vaccines  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,dexamethasone,49,2301,2329,: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to  nonoseaeaefromdruginteraction  Corticosteroids may also  nonoseaeaefromdruginteraction  ,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
50,dexamethasone,50,2329,2352,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see   WARNINGS  :  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,dexamethasone,51,2352,2356,Infections  :  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,dexamethasone,52,2356,2359,Vaccination    ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,dexamethasone,53,2359,2361,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,dexamethasone,54,2361,2494,", '\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility\n', '\n', '  No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction \n', '\n', ' Steroids may  oselabeledaeclasseffect or decrease  oselabeledaeclasseffect and number  oselabeledaeclasseffect  oselabeledaeclasseffect or decrease motility and  oselabeledaeclasseffect  oselabeledaeclasseffect motility and  oselabeledaeclasseffect  oselabeledaeclasseffect motility and  oselabeledaeclasseffect in some patients.\n', '\n', '    Pregnancy\n', '\n', '   Teratogenic Effects:  nonoseaeaeonlyasinstruction Category C    : Corticosteroids have been shown to be  nonoseaeaeanimal in many species when given in doses equivalent to the human dose.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
55,dexamethasone,55,2494,2518,"Animal studies in which corticosteroids have been given to  nonoseaeaeanimal mice, rats, and rabbits have yielded an increased incidence of  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
56,dexamethasone,56,2518,2520,nonoseaeaeanimal  ,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
57,dexamethasone,57,2520,2534,There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
58,dexamethasone,58,2534,2622,"Corticosteroids should be used during  notaecandidatepreexistingconditionorriskfactor only if the potential benefit justifies the potential  oselabeledaefromdruguse   nonoseaeaeonlyasinstruction born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of  nonoseaeaeonlyasinstruction  notaecandidatepreexistingconditionorriskfactor should be carefully observed for signs of hypoadrenalism.\n', '\n', '    Nursing Mothers\n', '\n', '  Systemically administered corticosteroids appear in human milk and could  oselabeledaeclasseffect   oselabeledaeclasseffect  or cause other untoward effects.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
59,dexamethasone,59,2622,2707,"Because of the potential for serious  oselabeledaefromdruguse  a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.\n', '\n', '    Pediatric Use\n', '\n', '  The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,dexamethasone,60,2707,2749,"Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of  notaecandidateindication (patients >2 years of age), and aggressive  notaecandidateindication and  notaecandidateindication (patients >1 month of age).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
61,dexamethasone,61,2749,2829,"Other indications for pediatric use of corticosteroids, e.g., severe  notaecandidateindication and  notaecandidateindication  are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.\n', '\n', ' The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see   ADVERSE REACTIONS    ).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
62,dexamethasone,62,2829,2896,"Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a  oselabeledaeclasseffect  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,dexamethasone,63,2896,2932,"This  oselabeledaeclasseffect of corticosteroids  oselabeledaeclasseffect has been observed at low systemic doses and in the absence of laboratory evidence of  nonoseaenegation (i.e., cosyntropin stimulation and basal cortisol plasma levels).",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
64,dexamethasone,64,2932,2958,Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,dexamethasone,65,2958,2993,"The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential  nonoseaeaeonlyasinstruction of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,dexamethasone,66,2993,3056,"In order to minimize the potential  nonoseaeaeonlyasinstruction of corticosteroids, pediatric patients should be titrated  to the lowest effective dose.\n', '\n', '    Geriatric Use\n', '\n', '  Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,dexamethasone,67,3056,3073,Other reported clinical experience has not identified differences in responses between the elderly and younger patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,dexamethasone,68,3073,3141,"In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of  notaecandidatepreexistingconditionorriskfactor  renal, or cardiac  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor hepatic,  notaecandidatepreexistingconditionorriskfactor  or cardiac  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor hepatic, renal, or  notaecandidatepreexistingconditionorriskfactor  and of concomitant disease or other drug therapy.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
69,dexamethasone,69,3141,3272,"In particular, the increased risk of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction    WARNINGS\n', '\n', '   General\n', '\n', '  Rare instances of  oselabeledaeclasseffect have occurred in patients receiving corticosteroid therapy (see   ADVERSE REACTIONS    ).\n', '\n', ' Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual  notaecandidatepreexistingconditionorriskfactor before, during, and after the  notaecandidatepreexistingconditionorriskfactor situation.\n', '\n', '    Cardio-Renal\n', '\n', '  Average and large doses of corticosteroids can cause  oselabeledaeclasseffect   oselabeledaeclasseffect and water  oselabeledaeclasseffect  oselabeledaeclasseffect  and  oselabeledaeclasseffect  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
70,dexamethasone,70,3272,3290,These effects are less likely to occur with the synthetic derivatives except when used in large doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,dexamethasone,71,3290,3300,Dietary salt restriction and potassium supplementation may be necessary.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,dexamethasone,72,3300,3380,"All corticosteroids  oselabeledaeclasseffect \n', '\n', ' Literature reports suggest an apparent association between use of corticosteroids and  oselabeledaeclasseffect after a recent  notaecandidatepreexistingconditionorriskfactor  therefore, therapy with corticosteroids should be used with great caution in these patients.\n', '\n', '    Endocrine\n', '\n', '  Corticosteroids can produce reversible  oselabeledaeclasseffect with the potential for  nonoseaeodorwithdrawal after withdrawal of treatment.  ",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
73,dexamethasone,73,3380,3399,nonoseaeodorwithdrawal may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage.,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
74,dexamethasone,74,3399,3432,"This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of  notaecandidatepreexistingconditionorriskfactor occurring during that period, hormone therapy should be reinstituted.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
75,dexamethasone,75,3432,3471,"If the patient is receiving steroids already, dosage may have to be increased.\n', '\n', ' Metabolic clearance of corticosteroids is decreased in  notaecandidatepreexistingconditionorriskfactor patients and increased in  notaecandidatepreexistingconditionorriskfactor patients.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
76,dexamethasone,76,3471,3521,"nonoseaeaeonlyasinstruction of the patient may necessitate adjustment in dosage.\n', '\n', '    Infections\n', '\n', '   General  \n', '\n', ' Patients who are on corticosteroids are more  oselabeledaeclasseffect than are healthy individuals.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,dexamethasone,77,3521,3538,There may be decreased resistance and inability to localize  nonoseaeaeonlyasinstruction when corticosteroids are used.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,dexamethasone,78,3538,3631,"oselabeledaeclasseffect  oselabeledaeclasseffect with any pathogen ( oselabeledaeclasseffect  oselabeledaeclasseffect with any pathogen (viral,  oselabeledaeclasseffect  oselabeledaeclasseffect with any pathogen (viral, bacterial,  oselabeledaeclasseffect  oselabeledaeclasseffect with any pathogen (viral, bacterial, fungal,  oselabeledaeclasseffect  oselabeledaeclasseffect with any pathogen (viral, bacterial, fungal, protozoan or  oselabeledaeclasseffect  in any location of the body may be associated with the use of corticosteroids alone or in combination with other  nonoseaeaeonlyasinstruction  These  nonoseaeaeonlyasinstruction may be mild to severe.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,dexamethasone,79,3631,3694,"With increasing doses of corticosteroids, the rate of occurrence of  nonoseaeaeonlyasinstruction  Corticosteroids may also  oselabeledaeclasseffect some signs of current  oselabeledaeclasseffect \n', '\n', '   nonoseaegeneralterm  :Corticosteroids may  oselabeledaeclasseffect and therefore should not be used in the presence of such  nonoseaeaeonlyasinstruction unless they are needed to control  nonoseaeaeonlyasinstruction  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
80,dexamethasone,80,3694,4113,"There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction (see   PRECAUTIONS  :  Drug Interactions  :  Amphotericin B injection and potassium-depleting agents    ).\n', '\n', '  Special Pathogens  : Latent disease may be activated or there may be an exacerbation of intercurrent  oselabeledaeclasseffect due to pathogens, including those caused by  oselabeledaeclasseffect  oselabeledaeclasseffect due to pathogens, including those caused by Amoeba  ,  oselabeledaeclasseffect  oselabeledaeclasseffect  oselabeledaeclasseffect due to pathogens, including those caused by Amoeba  , Candida  ,  oselabeledaeclasseffect  oselabeledaeclasseffect due to pathogens, including those caused by Amoeba  , Candida  , Cryptococcus  ,  oselabeledaeclasseffect  oselabeledaeclasseffect due to pathogens, including those caused by Amoeba  , Candida  , Cryptococcus  , Mycobacterium  ,  oselabeledaeclasseffect  oselabeledaeclasseffect due to pathogens, including those caused by Amoeba  , Candida  , Cryptococcus  , Mycobacterium  , Nocardia  ,  oselabeledaeclasseffect  oselabeledaeclasseffect due to pathogens, including those caused by Amoeba  , Candida  , Cryptococcus  , Mycobacterium  , Nocardia  , Pneumocystis  ,  oselabeledaeclasseffect  .\n', '\n', ' It is recommended that  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or any patient with unexplained  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Similarly, corticosteroids should be used with great care in patients with known or suspected  notaecandidatepreexistingconditionorriskfactor  In such patients,  oselabeledaeclasseffect may lead to  oselabeledaeclasseffect and dissemination with widespread larval migration, often accompanied by severe  nonoseaemanifestationorcomplication and potentially  nonoseaegeneralterm  nonoseaemanifestationorcomplication \n', '\n', ' Corticosteroids should not be used in  notaecandidatepreexistingconditionorriskfactor \n', '\n', '   nonoseaegeneralterm  : The use of corticosteroids in  notaecandidateindication should be restricted to those cases of  notaecandidateindication or disseminated  notaecandidateindication  notaecandidateindication in which the corticosteroid is used for the management of the disease in conjunction with an appropriate  nonoseaeaeonlyasinstruction regimen.\n', '\n', ' If corticosteroids are indicated in patients with  notaecandidateindication or  notaecandidateindication  close observation is necessary as reactivation of the disease may occur.",1,1,1,1,1,1,0,0,0,0,0,0,0,0,0
81,dexamethasone,81,4113,4153,"During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.\n', '\n', '  Vaccination  : Administration of live or live, attenuated vaccines is contraindicated in patients receiving  nonoseaeaeonlyasinstruction doses of corticosteroids.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,dexamethasone,82,4153,4161,Killed or inactivated vaccines may be administered.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,dexamethasone,83,4161,4174,"However, the response to such vaccines cannot be predicted.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,dexamethasone,84,4174,4229,"Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for  notaecandidatepreexistingconditionorriskfactor \n', '\n', '   nonoseaegeneralterm  :  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction can have a more serious or even  nonoseaegeneralterm course in pediatric and adult patients on corticosteroids.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
85,dexamethasone,85,4229,4250,"In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,dexamethasone,86,4250,4268,The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,dexamethasone,87,4268,4283,If exposed to  nonoseaeaeonlyasinstruction  prophylaxis with  nonoseaeaeonlyasinstruction  may be indicated.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,dexamethasone,88,4283,4300,If exposed to  nonoseaeaeonlyasinstruction  prophylaxis with immune globulin (IG) may be indicated.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,dexamethasone,89,4300,4316,(See the respective package inserts for VZIG and IG for complete prescribing information.),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,dexamethasone,90,4316,4378,"If  nonoseaemanifestationorcomplication develops, treatment with antiviral agents should be considered.\n', '\n', '    Ophthalmic\n', '\n', '  Use of corticosteroids may produce  oselabeledaeclasseffect   oselabeledaeclasseffect with possible  nonoseaemanifestationorcomplication  and may enhance the establishment of secondary  oselabeledaeclasseffect  oselabeledaeclasseffect  oselabeledaeclasseffect  oselabeledaeclasseffect  or viruses.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
91,dexamethasone,91,4378,4405,The use of oral corticosteroids is not recommended in the treatment of  notaecandidatepreexistingconditionorriskfactor and may lead to an increase in the risk of new episodes.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
92,dexamethasone,92,4405,4416,Corticosteroids should not be used in active  notaecandidatepreexistingconditionorriskfactor '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,linzess,0,0,47,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse reactions (>=2%) reported in IBS-C or CIC patients are: diarrhea, abdominal pain, flatulence and abdominal distension.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,linzess,1,47,89,"(  6.1  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,linzess,2,89,118,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,linzess,3,118,243,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' Exposure in clinical development included approximately 2570, 2040, and 1220 patients with either IBS-C or CIC treated with LINZESS for 6 months or longer, 1 year or longer, and 18 months or longer, respectively (not mutually exclusive).\n', '\n', ' Demographic characteristics were comparable between treatment groups in all studies  [see Clinical Studies (  14  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,linzess,4,243,245,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,linzess,5,245,263,", '\n', '     Irritable Bowel Syndrome with Constipation (IBS-C)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,linzess,6,263,315,"\n', '\n', '     Most Common Adverse Reactions  \n', '\n', ' The data described below reflect exposure to LINZESS in the two placebo-controlled clinical trials involving 1605 adult patients with  notaecandidateindication (Trials 1 and 2).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,linzess,7,315,338,Patients were randomized to receive placebo or 290 mcg LINZESS once daily on an empty stomach for up to 26 weeks.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,linzess,8,338,376,Table 1  provides the incidence of adverse reactions reported in at least 2% of IBS-C patients in the LINZESS treatment group and at an incidence that was greater than in the placebo group.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,linzess,9,376,406,", '\n', ' Table 1: Most Common Adverse Reactionsa in Two Placebo-Controlled Trials (1 and 2) in Patients with IBS-C",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,linzess,10,406,479,"\n', '  a: Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo    \n', '  b: "" oselabeledaefromdruguse  term includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse     \n', '  \n', '   Adverse Reactions                               LINZESS    290 mcg    [N=807]    %      Placebo    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,linzess,11,479,485,[N=798]    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,linzess,12,485,496,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
13,linzess,13,496,504,b        oselabeledaefromdruguse      oselabeledaefromdruguse  20742                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,linzess,14,504,506,3521                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,linzess,15,506,515,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
16,linzess,16,515,519,3                             1                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,linzess,17,519,539,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse       4                             3                           \n', '             Diarrhea  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,linzess,18,539,577,"\n', ' \n', '\n', '  oselabeledaefromdruguse was the most commonly reported adverse reaction of the LINZESS-treated patients in the pooled  notaecandidateindication pivotal placebo-controlled trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
19,linzess,19,577,601,"In these trials, 20% of LINZESS-treated patients reported  oselabeledaefromdruguse compared to 3% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,linzess,20,601,651,"Severe  oselabeledaefromdruguse was reported in 2% of the LINZESS-treated patients versus less than 1% of the placebo-treated patients, and 5% of LINZESS-treated patients discontinued due to  oselabeledaefromdruguse vs less than 1% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,linzess,21,651,681,The majority of reported cases of  oselabeledaefromdruguse started within the first 2 weeks of LINZESS treatment  [see Warnings and Precautions (  5.2  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,linzess,22,681,696,".\n', '\n', '     Adverse Reactions Leading to Discontinuation  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,linzess,23,696,737,"\n', '\n', ' In placebo-controlled trials in patients with  notaecandidateindication  9% of patients treated with LINZESS and 3% of patients treated with placebo discontinued prematurely due to adverse reactions.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,linzess,24,737,768,"In the LINZESS treatment group, the most common reasons for discontinuation due to adverse reactions were  oselabeledaefromdruguse (5%) and  oselabeledaefromdruguse (1%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,linzess,25,768,789,"In comparison, less than 1% of patients in the placebo group withdrew due to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,linzess,26,789,805,"\n', '\n', '     Adverse Reactions Leading to Dose Reductions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,linzess,27,805,810,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,linzess,28,810,841,"', ' In the open-label, long-term trials, 2147 patients with  notaecandidateindication received 290 mcg of LINZESS daily for up to 18 months.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,linzess,29,841,871,"In these trials, 29% of patients had their dose reduced or suspended secondary to adverse reactions, the majority of which were  oselabeledaefromdruguse or other  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,linzess,30,871,942,"\n', '\n', '     Less Common Adverse Reactions  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were reported in <2% of patients in the LINZESS treatment group and at an incidence greater than in the placebo treatment group.\n', '\n', '     Chronic Idiopathic Constipation (CIC)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,linzess,31,942,997,"\n', '\n', '     Most Common Adverse Reactions  \n', '\n', ' The data described below reflect exposure to LINZESS in the two double-blind placebo-controlled clinical trials of 1275 adult patients with  notaecandidateindication (Trials 3 and 4).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
32,linzess,32,997,1006,Patients were randomized to receive placebo or 145 mcg,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,linzess,33,1006,1025,"LINZESS or 290 mcg LINZESS once daily on an empty stomach, for at least 12 weeks.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,linzess,34,1025,1155,"Table 2  provides the incidence of adverse reactions reported in at least 2% of CIC patients in the 145 mcg LINZESS treatment group and at an incidence that was greater than in the placebo treatment group.\n', '\n', ' Table 2: Most Common Adverse Reactionsa in the Two Placebo-controlled Trials (3 and 4) in Patients with CIC \n', '  a: Reported in at least 2% of LINZESS-treated patients and at an incidence greater than placebo    \n', '  b: "" oselabeledaefromdruguse  term includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse     \n', '  \n', '   Adverse Reactions                                             LINZESS    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,linzess,35,1155,1164,145 mcg    [N=430]    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,linzess,36,1164,1166,Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,linzess,37,1166,1172,[N=423]    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,linzess,38,1172,1183,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,linzess,39,1183,1191,b        oselabeledaefromdruguse      oselabeledaefromdruguse  16763                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,linzess,40,1191,1193,5652                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,linzess,41,1193,1206,"\n', '    nonoseaegeneralterm        oselabeledaefromdruguse      oselabeledaefromdruguse  53                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,linzess,42,1206,1208,42                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,linzess,43,1208,1335,"\n', '         The safety of a 72 mcg dose was evaluated in an additional placebo-controlled trial in which 1223 patients were randomized to LINZESS 72 mcg, 145 mcg, or placebo once daily for 12 weeks (Trial 5).\n', ' \n', '\n', ' In Trial 5, adverse reactions that occurred at a frequency of >= 2% in LINZESS-treated patients (n=411 in each LINZESS 72 mcg and 145 mcg group) and at a higher rate than placebo (n=401) were:\n', '\n', ' *   oselabeledaefromdruguse (LINZESS 72 mcg 19%; LINZESS 145 mcg 22%; placebo 7%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,linzess,44,1335,1360,"\n', ' *   oselabeledaefromdruguse (LINZESS 72 mcg 2%; LINZESS 145 mcg 1%; placebo < 1%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,linzess,45,1360,1367,"\n', '         oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,linzess,46,1367,1544,"\n', ' \n', '\n', ' This section summarizes information from Trials 3 and 4 (pooled) and Trial 5 regarding  oselabeledaefromdruguse  the most commonly reported adverse reaction reported in LINZESS-treated patients in  notaecandidateindication placebo-controlled studies.\n', '\n', ' In all trials, the majority of reported cases of  oselabeledaefromdruguse started within the first 2 weeks of LINZESS treatment.\n', '\n', ' Severe  oselabeledaefromdruguse was reported in less than 1% of the 72 mcg LINZESS-treated patients (Trial 5), in 2% of the 145 mcg LINZESS-treated patients (Trials 3 and 4; Trial 5), and less than 1% of the placebo-treated patients (Trials 3, 4, and 5)  [see Warnings and Precautions (  5.2  )]  .\n', '\n', '     Adverse Reactions Leading to Discontinuation  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
47,linzess,47,1544,1666,"\n', '\n', ' In placebo-controlled trials in patients with  notaecandidateindication  3% of patients treated with 72 mcg (Trial 5) and between 5% (Trial 5) and 8% (Trials 3 and 4) of patients treated with 145 mcg of LINZESS discontinued prematurely due to adverse reactions compared to between less than 1% (Trial 5) and 4% (Trials 3 and 4) of patients treated with placebo.\n', '\n', ' In patients treated with 72 mcg LINZESS the most common reason for discontinuation due to adverse reactions was  oselabeledaefromdruguse (2% in Trial 5) and",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
48,linzess,48,1666,1715,"in patients treated with 145 mcg LINZESS, the most common reasons for discontinuation due to adverse reactions were  oselabeledaefromdruguse (3% in Trial 5 and 5% in Trials 3 and 4) and  oselabeledaefromdruguse (1% in Trials 3 and 4).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,linzess,49,1715,1759,"In comparison, less than 1% of patients in the placebo group withdrew due to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (Trials 3 and 4; Trial 5).\n', '\n', '     Adverse Reactions Leading to Dose Reductions  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,linzess,50,1759,1764,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,linzess,51,1764,1795,"', ' In the open-label, long-term trials, 1129 patients with  notaecandidateindication received 290 mcg of LINZESS daily for up to 18 months.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
52,linzess,52,1795,1825,"In these trials, 27% of patients had their dose reduced or suspended secondary to adverse reactions, the majority of which were  oselabeledaefromdruguse or other  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,linzess,53,1825,1883,"\n', '\n', '     Less Common Adverse Reactions  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  were reported in less than 2% of patients in the LINZESS treatment group and at an incidence greater than placebo treatment group.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,linzess,54,1883,1914,"'\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post approval use of LINZESS.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,linzess,55,1914,1979,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,linzess,56,1979,1981,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,linzess,57,1981,1990,"RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,linzess,58,1990,1998,"'\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,linzess,59,1998,2087,"RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS\n', '\n', '\n', '\n', '    *  LINZESS is contraindicated in patients less than 6 years of age; in nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused  nonoseaegeneralterm due to  nonoseaeaeanimal    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Diarrhea: Patients may experience severe diarrhea.",0,1,0,0,0,0,0,0,1,0,0,0,0,0,0
60,linzess,60,2087,2099,"If severe diarrhea occurs,suspend dosing and rehydrate the patient.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,linzess,61,2099,2104,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,linzess,62,2104,2150,"\n', '    \n', ' \n', '\n', '   5.1 Risk of Serious Dehydration in Pediatric Patients\n', '\n', '  LINZESS is contraindicated in patients less than 6 years of age.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,linzess,63,2150,2169,The safety and effectiveness of LINZESS in patients less than 18 years of age have not been established.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,linzess,64,2169,2249,"In neonatal mice (human age equivalent of approximately 0 to 28 days), linaclotide  nonoseaeaeanimal as a consequence of GC-C agonism resulting in  nonoseaegeneralterm within the first 24 hours due to  nonoseaeaeanimal  Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than patients 6 years of age and older to develop severe  nonoseaeaeonlyasinstruction and its potentially serious consequences.\n'",1,1,0,0,0,0,0,0,1,0,0,0,0,0,0
65,linzess,65,2249,2272,", '\n', ' Avoid use of LINZESS in pediatric patients 6 years to less than 18 years of age.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,linzess,66,2272,2321,"Although there were no  nonoseaegeneralterm in older juvenile mice, given the  nonoseaegeneralterm in young juvenile mice and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of LINZESS in pediatric patients 6 years to less than 18 years of age",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,linzess,67,2321,2350,"[see Contraindications (  4  ), Warnings and Precautions (  5.2  ), Use in Specific Populations (  8.4  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,linzess,68,2350,2397,".\n', '\n', '    5.2 Diarrhea\n', '\n', '      oselabeledaefromdruguse was the most common adverse reaction of LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,linzess,69,2397,2413,The incidence of  oselabeledaefromdruguse was similar between the  notaecandidateindication and  notaecandidateindication populations.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
70,linzess,70,2413,2456,"Severe  oselabeledaefromdruguse was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients, and in <1% of 72 mcg LINZESS-treated CIC patients [see Adverse Reactions (  6.1  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,linzess,71,2456,2519,".\n', '\n', '    In post-marketing experience, severe  oselabeledaefromdruguse associated with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  requiring hospitalization or intravenous fluid administration have been reported in patients treated with LINZESS.\n', '\n', '    If severe  nonoseaeaeonlyasinstruction ']",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,kyprolis,0,0,8,['    6         ADVERSE REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,kyprolis,1,8,45,"\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *   oselabeledaefromdruguse [see   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,kyprolis,2,45,56,Warnings and Precautions  (    5.1    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,kyprolis,3,56,60,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,kyprolis,4,60,67,*   oselabeledaefromdruguse  [see   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,kyprolis,5,67,78,Warnings and Precautions  (    5.2    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,kyprolis,6,78,94,"\n', ' *   oselabeledaefromdruguse [see   Warnings and Precautions  (    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,kyprolis,7,94,99,5.3    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,kyprolis,8,99,120,"\n', ' *   oselabeledaefromdruguse [see   Warnings and Precautions  (    5.4    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,kyprolis,9,120,124,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,kyprolis,10,124,131,*   oselabeledaefromdruguse  [see   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,kyprolis,11,131,142,Warnings and Precautions  (    5.5    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,kyprolis,12,142,163,"\n', ' *   oselabeledaefromdruguse [see   Warnings and Precautions  (    5.6    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,kyprolis,13,163,179,"\n', ' *   oselabeledaefromdruguse [see   Warnings and Precautions  (    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,kyprolis,14,179,184,5.7    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,kyprolis,15,184,205,"\n', ' *   oselabeledaefromdruguse [see   Warnings and Precautions  (    5.8    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,kyprolis,16,205,226,"\n', ' *   oselabeledaefromdruguse [see   Warnings and Precautions  (    5.9    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,kyprolis,17,226,233,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,kyprolis,18,233,246,[see   Warnings and Precautions (    5.10    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,kyprolis,19,246,266,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions  (    5.11    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,kyprolis,20,266,290,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see   Warnings and Precautions  (    5.12    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,kyprolis,21,290,294,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,kyprolis,22,294,301,*   oselabeledaefromdruguse  [see   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,kyprolis,23,301,312,Warnings and Precautions  (    5.13    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,kyprolis,24,312,322,"\n', ' *   oselabeledaefromdruguse [see   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,kyprolis,25,322,328,Warnings and Precautions   (    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,kyprolis,26,328,333,5.14    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,kyprolis,27,333,364,"\n', ' *  Increased  nonoseaegeneralterm and Serious Toxicities in Combintaion with Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Patients [see   Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,kyprolis,28,364,371,(    5.15    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,kyprolis,29,371,372,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,kyprolis,30,372,379,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,kyprolis,31,379,421,"The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in monotherapy trials:  anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,kyprolis,32,421,497,"(  6  )\n', ' \n', '\n', '    \n', '\n', ' The most common adverse reactions occurring in at least 20% of patients treated with Kyprolis in the combination therapy trials: anemia, neutropenia, diarrhea, dyspnea, fatigue, thrombocytopenia, pyrexia, insomnia, muscle spasm, cough, upper respiratory tract infection, hypokalemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,kyprolis,33,497,546,"(  6  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,kyprolis,34,546,576,"\n', '\n', ' \n', '\n', '  6.1       Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,kyprolis,35,576,646,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug, and may not reflect the rates observed in medical practice.\n', '\n', '   Safety Experience with Kyprolis in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,kyprolis,36,646,695,"\n', '\n', ' The safety of Kyprolis in combination with lenalidomide and dexamethasone (KRd) was evaluated in an open-label randomized study in patients with relapsed  notaecandidateindication  Details of the study treatment are described in Section 14.1.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
37,kyprolis,37,695,777,"The median number of cycles initiated was 22 cycles for the KRd arm and 14 cycles for the Rd arm.\n', '\n', '  nonoseaegeneralterm due to adverse reactions within 30 days of the last dose of any therapy in the KRd arm occurred in 27/392 (7%) patients compared with 27/389 (7%) patients who  nonoseaegeneralterm due to adverse events within 30 days of the last dose of any Rd therapy.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,kyprolis,38,777,828,"The most common cause of  nonoseaegeneralterm occurring in patients (%) in the two arms (KRd  versus  Rd) included  nonoseaeaeonlyasinstruction 10 (3%)  versus  7 (2%),  nonoseaegeneralterm 9 (2%)  versu    ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,kyprolis,39,828,837,"s  10 (3%),  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,kyprolis,40,837,871,"nonoseaegeneralterm 0 (0%)  versus  1 (< 1%), and other adverse reactions 9 (2%)  versus  10 (3%).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,kyprolis,41,871,897,Serious adverse reactions were reported in 60% of the patients in the KRd arm and 54% of the patients in the Rd arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,kyprolis,42,897,964,"The most common serious adverse reactions reported in the KRd arm as compared with the Rd arm were  oselabeledaefromdruguse (14%  versus  11%),  oselabeledaefromdruguse (4%  versus  1.5%),  oselabeledaefromdruguse (4%  versus  2%), and  oselabeledaefromdruguse (3%  versus  2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,kyprolis,43,964,988,Discontinuation due to any adverse reaction occurred in 26% in the KRd arm  versus  25% in the Rd arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,kyprolis,44,988,1039,"Adverse reactions leading to discontinuation of Kyprolis occurred in 12% of patients and the most common reactions included  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (0.8%), and  oselabeledaefromdruguse (0.8%).\n', '\n', '   Common Adverse    Reactions    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,kyprolis,45,1039,1091,"(    >=         10%)  \n', '\n', ' The adverse reactions in the first 12 cycles of therapy that occurred at a rate of 10% or greater in the KRd arm are presented in Table 8.\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,kyprolis,46,1091,1179,"' Table 8:  Most Common Adverse Reactions (>= 10% in the KRd Arm)  Occurring in Cycles 1-12  (20/27 mg/m2 Regimen In Combination with Lenalidomide and Dexamethasone) \n', '                    KRd Arm    (N         =         392)    n (%)      Rd Arm    (N         =         389)    n (%)     \n', '               Adverse Reactions by Body System      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,kyprolis,47,1179,1199,Any Grade        >=         Grade         3      Any Grade        >=         Grade         3     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,kyprolis,48,1199,1206,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,kyprolis,49,1206,1214,"\n', '        oselabeledaefromdruguse     138",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,kyprolis,50,1214,1228,(35)         53 (14)          127 (33)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,kyprolis,51,1228,1229,47,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,kyprolis,52,1229,1292,"(12)           \n', '        oselabeledaefromdruguse  124 (32)         104 (27)         115 (30)         89 (23)           \n', '        oselabeledaefromdruguse  100 (26)         58 (15)          75 (19)          39 (10)           \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,kyprolis,53,1292,1294,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,kyprolis,54,1294,1321,"\n', '        oselabeledaefromdruguse   115 (29)         7 (2)            105 (27)         12 (3)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,kyprolis,55,1321,1335,"\n', '        oselabeledaefromdruguse  68 (17)          0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,kyprolis,56,1335,1336,53,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,kyprolis,57,1336,1345,(14)          1 (0)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,kyprolis,58,1345,1368,"\n', '        oselabeledaefromdruguse     60 (15)          1 (0)            39 (10)          3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,kyprolis,59,1368,1377,"(1)             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,kyprolis,60,1377,1379,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,kyprolis,61,1379,1406,"\n', '        oselabeledaefromdruguse    109 (28)         21 (5)           104 (27)         20 (5)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,kyprolis,62,1406,1433,"\n', '        oselabeledaefromdruguse    93 (24)          5 (1)            64 (17)          1 (0)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,kyprolis,63,1433,1441,"\n', '        oselabeledaefromdruguse  63",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,kyprolis,64,1441,1460,(16)          2 (1)            57 (15)          2 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,kyprolis,65,1460,1492,"\n', '        oselabeledaefromdruguse   53 (14)          11 (3)           46 (12)          7 (2)             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,kyprolis,66,1492,1494,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,kyprolis,67,1494,1521,"\n', '        oselabeledaefromdruguse  85 (22)          7 (2)            52 (13)          3 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,kyprolis,68,1521,1536,"\n', '        oselabeledaefromdruguse  63 (16)          0                43",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,kyprolis,69,1536,1542,(11)          0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,kyprolis,70,1542,1550,"\n', '        oselabeledaefromdruguse  54",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,kyprolis,71,1550,1555,(14)          5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,kyprolis,72,1555,1569,(1)            39 (10)          2 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,kyprolis,73,1569,1583,"\n', '        oselabeledaefromdruguse  a    54 (14)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,kyprolis,74,1583,1603,"35 (9)           43 (11)          27 (7)            \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,kyprolis,75,1603,1605,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,kyprolis,76,1605,1613,"\n', '        oselabeledaefromdruguse  78",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,kyprolis,77,1613,1618,(20)          22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,kyprolis,78,1618,1640,"(6)           35 (9)           12 (3)            \n', '        oselabeledaefromdruguse  55",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,kyprolis,79,1640,1662,"(14)          10 (3)           39 (10)          5 (1)             \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,kyprolis,80,1662,1686,'        oselabeledaefromdruguse  43 (11)          18 (5)           33 (9)           15 (4)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,kyprolis,81,1686,1701,"\n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  88",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
82,kyprolis,82,1701,1720,(22)          3 (1)            73 (19)          3 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,kyprolis,83,1720,1725,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,kyprolis,84,1725,1727,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,kyprolis,85,1727,1756,"\n', '        oselabeledaefromdruguse  b    43 (11)          7 (2)            37 (10)          4 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,kyprolis,86,1756,1790,"\n', '    nonoseaegeneralterm                                                                         \n', '        oselabeledaefromdruguse   63 (16)          6 (2)            50 (13)          8 (2)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,kyprolis,87,1790,1795,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,kyprolis,88,1795,1797,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,kyprolis,89,1797,1823,"\n', '        oselabeledaefromdruguse  c    91 (23)          2 (1)            52 (13)          0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,kyprolis,90,1823,1833,"\n', '        oselabeledaefromdruguse  d    70",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,kyprolis,91,1833,1847,(18)          9 (2)            58 (15)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,kyprolis,92,1847,1852,6 (2)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,kyprolis,93,1852,1857,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,kyprolis,94,1857,1859,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
95,kyprolis,95,1859,1928,"\n', '        oselabeledaefromdruguse       45 (12)          5 (1)            53 (14)          5 (1)             \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse and thrombotic  oselabeledaefromdruguse  oselabeledaefromdruguse  e    49 (13)          16 (4)           22 (6)           9 (2)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,kyprolis,96,1928,1942,"\n', '        oselabeledaefromdruguse  f    41 (11)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,kyprolis,97,1942,1957,12 (3)           15 (4)           4 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,kyprolis,98,1957,2009,"\n', ' KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone  a    oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   b    oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   c   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,kyprolis,99,2009,2027,d    oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   e    oselabeledaefromdruguse and thrombotic      oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,kyprolis,100,2027,2048,oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,kyprolis,101,2048,2057,f    oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,kyprolis,102,2057,2081,"\n', '           There were 274 (70%) patients in the KRd arm who received treatment beyond Cycle 12.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,kyprolis,103,2081,2374,"There were no new clinically relevant adverse reactions that emerged in the later treatment cycles.\n', ' \n', '\n', '   Adverse Reactions Occurring at a Frequency of <         10%  \n', '\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    Grade 3 and higher adverse reactions that occurred during Cycles 1-12 with a substantial difference (>= 2%) between the two arms were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,kyprolis,104,2374,2390,"\n', ' \n', '\n', '   Laboratory Abnormalities  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,kyprolis,105,2390,2413,"\n', '\n', ' Table 9 describes Grade 3-4  nonoseaegeneralterm reported at a rate of >",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
106,kyprolis,106,2413,2428,"= 10% in the KRd arm for patients who received combination therapy.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,kyprolis,107,2428,2457,"'\n', ' Table 9: Grade 3-4 Laboratory Abnormalities (>= 10% in the KRd Arm) in Cycles 1-12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,kyprolis,108,2457,2463,(20/27 mg/m2 Regimen,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,kyprolis,109,2463,2470,In Combination with Lenalidomide and Dexamethasone),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,kyprolis,110,2470,2479,"\n', '    nonoseaegeneralterm      KRd    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,kyprolis,111,2479,2492,(N         =         392)    n (%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,kyprolis,112,2492,2494,Rd    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,kyprolis,113,2494,2515,"(N         =         389)    n (%)     \n', '  oselabeledaefromdruguse  182",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,kyprolis,114,2515,2531,"(46)         119 (31)          \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,kyprolis,115,2531,2549,"152 (39)         140 (36)          \n', '  oselabeledaefromdruguse  122",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,kyprolis,116,2549,2565,"(31)         106 (27)          \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,kyprolis,117,2565,2583,"101 (26)         59 (15)           \n', '  oselabeledaefromdruguse  97",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,kyprolis,118,2583,2588,(25)          71,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,kyprolis,119,2588,2626,"(18)           \n', '  oselabeledaefromdruguse  58 (15)          68 (18)           \n', '  oselabeledaefromdruguse  41 (11)          23 (6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,kyprolis,120,2626,2666,"\n', ' KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone   \n', '           Safety Experience with Kyprolis    in Combination with Dexamethasone    in Patients with Multiple Myeloma  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,kyprolis,121,2666,2713,"\n', ' \n', '\n', ' The safety of Kyprolis in combination with dexamethasone was evaluated in an open-label, randomized trial of patients with relapsed  notaecandidateindication  The study treatment is described in Section 14.2.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
122,kyprolis,122,2713,2743,Patients received treatment for a median duration of 40 weeks in the Kyprolis/dexamethasone (Kd) arm and 27 weeks in the bortezomib/dexamethasone (Vd),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,kyprolis,123,2743,2788,"arm.\n', '\n', '  nonoseaegeneralterm due to adverse reactions within 30 days of last study treatment occurred in 22/463 (5%) patients in the Kd arm and 21/456 (5%) patients in the Vd arm.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,kyprolis,124,2788,2913,"The causes of  nonoseaegeneralterm occurring in patients (%) in the two arms (Kd  versus  Vd) included  nonoseaeaeonlyasinstruction 7 (2%)  versus  5 (1%),  nonoseaeaeonlyasinstruction 5 (1%)  versus  8 (2%), disease progression 6 (1%)  versus  4 (1%),  nonoseaeaeonlyasinstruction 3 (1%)  versus  2 (< 1%),  nonoseaeaeonlyasinstruction 1 (< 1%)  versus  0 (0%), and other adverse events 2 (< 1%)  versus  2 (< 1%).",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
125,kyprolis,125,2913,2939,Serious adverse reactions were reported in 48% of the patients in the Kd arm and 36% of the patients in the Vd arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,kyprolis,126,2939,2964,"In both treatment arms,  oselabeledaefromdruguse was the most commonly reported serious adverse reaction (6%  versus  9%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,kyprolis,127,2964,2988,Discontinuation due to any adverse reaction occurred in 20% in the Kd arm  versus  21% in the Vd arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,kyprolis,128,2988,3012,"The most common reaction leading to discontinuation was  oselabeledaefromdruguse in the Kd arm (n = 6, 1.3%) and  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,kyprolis,129,3012,3036,"oselabeledaefromdruguse in the Vd arm (n = 19, 4.2%).\n', '\n', '   Common Adverse    Reactions         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,kyprolis,130,3036,3045,(    >=         10%)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,kyprolis,131,3045,3117,"\n', '\n', ' Adverse reactions in the first 6 months of therapy that occurred at a rate of 10% or greater in the Kd arm are presented in Table 10.\n', '\n', ' Table 10: Most Common Adverse Reactions (>= 10% in the Kd Arm) Occurring in Months 1-6 (20/56 mg/m2 Regimen",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,kyprolis,132,3117,3122,In Combination with Dexamethasone),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,kyprolis,133,3122,3127,"\n', '                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,kyprolis,134,3127,3137,Kd    (N         =         463)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,kyprolis,135,3137,3142,n (%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,kyprolis,136,3142,3168,"Vd    (N         =         456)    n (%)     \n', '   Adverse Reaction by Body System      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,kyprolis,137,3168,3188,Any Grade        >=         Grade         3      Any Grade        >=         Grade         3     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,kyprolis,138,3188,3195,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,kyprolis,139,3195,3207,"\n', '       oselabeledaefromdruguse      160 (35)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,kyprolis,140,3207,3222,57 (12)          112 (25)         43 (9)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,kyprolis,141,3222,3229,"\n', '       oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,kyprolis,142,3229,3258,"a    127 (27)         46 (10)          112 (25)         65 (14)           \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,kyprolis,143,3258,3285,"\n', '       oselabeledaefromdruguse    111 (24)         14 (3)           150 (33)         26 (6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,kyprolis,144,3285,3293,"\n', '       oselabeledaefromdruguse      69",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,kyprolis,145,3293,3312,(15)          4 (1)            66 (15)          3 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,kyprolis,146,3312,3329,"\n', '       oselabeledaefromdruguse  58 (13)          1 (0)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,kyprolis,147,3329,3339,109 (24)         6 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,kyprolis,148,3339,3371,"\n', '       oselabeledaefromdruguse    45 (10)          5 (1)            32 (7)           3 (1)             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,kyprolis,149,3371,3373,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
150,kyprolis,150,3373,3422,"\n', '       oselabeledaefromdruguse     112 (24)         13 (3)           124 (27)         25 (6)            \n', '       oselabeledaefromdruguse     102 (22)         9 (2)            52 (11)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,kyprolis,151,3422,3427,3 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,kyprolis,152,3427,3435,"\n', '       oselabeledaefromdruguse  75",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,kyprolis,153,3435,3445,(16)          3 (1)            73,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,kyprolis,154,3445,3454,(16)          3 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,kyprolis,155,3454,3466,"\n', '       oselabeledaefromdruguse    71 (15)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,kyprolis,156,3466,3481,9 (2)            66 (14)          13 (3)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,kyprolis,157,3481,3515,"\n', '    nonoseaegeneralterm     \n', '       oselabeledaefromdruguse  66 (14)          4 (1)            54 (12)          3 (1)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
158,kyprolis,158,3515,3528,"\n', '       oselabeledaefromdruguse  54 (12)          5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,kyprolis,159,3528,3542,(1)            26 (6)           2 (0)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,kyprolis,160,3542,3569,"\n', '       oselabeledaefromdruguse  45 (10)          0 (0)            42 (9)           1 (0)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,kyprolis,161,3569,3574,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,kyprolis,162,3574,3576,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
163,kyprolis,163,3576,3584,"\n', '       oselabeledaefromdruguse  66",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,kyprolis,164,3584,3603,(14)          1 (0)            22 (5)           3 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,kyprolis,165,3603,3630,"\n', '       oselabeledaefromdruguse   58 (13)          7 (2)            60 (13)          8 (2)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,kyprolis,166,3630,3635,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,kyprolis,167,3635,3637,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,kyprolis,168,3637,3659,"\n', '       oselabeledaefromdruguse    68 (15)          4 (1)            38 (8)           2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,kyprolis,169,3659,3668,"(0)             \n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,kyprolis,170,3668,3695,"oselabeledaefromdruguse  b    ,c    54 (12)          7 (2)            167 (37)         23 (5)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,kyprolis,171,3695,3765,"\n', '    nonoseaegeneralterm     \n', '       oselabeledaefromdruguse    103 (22)         5 (1)            113 (25)         10 (2)            \n', '    nonoseaegeneralterm     \n', '       oselabeledaefromdruguse  d    123 (27)         23 (5)           66 (15)          8 (2)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
172,kyprolis,172,3765,3770,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,kyprolis,173,3770,3794,oselabeledaefromdruguse  e    91 (20)          0 (0)            61 (13)          2 (0)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,kyprolis,174,3794,3799,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,kyprolis,175,3799,3801,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
176,kyprolis,176,3801,3806,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,kyprolis,177,3806,3810,oselabeledaefromdruguse  f    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,kyprolis,178,3810,3834,"80 (17)          29 (6)           33 (7)           12 (3)            \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,kyprolis,179,3834,3871,Kd = Kyprolis and dexamethasone; Vd = bortezomib and dexamethasone  a    oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   b    oselabeledaefromdruguse include  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   c  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,kyprolis,180,3871,3879,See Clinical Studies (14.2).  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,kyprolis,181,3879,3899,d    oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   e   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,kyprolis,182,3899,3912,f    oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,kyprolis,183,3912,4012,"\n', '            The event rate of >= Grade 2  oselabeledaefromdruguse in the Kd arm was 6% (95% CI:  4, 8)  versus  32% (95% CI:  28, 36) in the Vd arm.\n', ' \n', '\n', '   Adverse Reactions Occurring at a Frequency of <         10%  \n', '\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
184,kyprolis,184,4012,4032,' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
185,kyprolis,185,4032,4043,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
186,kyprolis,186,4043,4060,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
187,kyprolis,187,4060,4108,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ,  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
188,kyprolis,188,4108,4131,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
189,kyprolis,189,4131,4160,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
190,kyprolis,190,4160,4175,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
191,kyprolis,191,4175,4192,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
192,kyprolis,192,4192,4201,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
193,kyprolis,193,4201,4214,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
194,kyprolis,194,4214,4241,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
195,kyprolis,195,4241,4256,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
196,kyprolis,196,4256,4269,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
197,kyprolis,197,4269,4277,"\n', '      Laboratory Abnormalities  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,kyprolis,198,4277,4344,"\n', ' \n', '\n', ' Table 11 describes Grades 3-4  nonoseaegeneralterm reported at a rate of >= 10% in the Kd arm.\n', '\n', ' Table 11: Grades 3-4 Laboratory Abnormalities (>= 10%) in Months 1-6 (20/56 mg/m2 Regimen",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
199,kyprolis,199,4344,4349,In Combination with Dexamethasone),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,kyprolis,200,4349,4356,"\n', '    nonoseaegeneralterm      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
201,kyprolis,201,4356,4366,Kd    (N         =         463)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,kyprolis,202,4366,4371,n (%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,kyprolis,203,4371,4394,"Vd    (N         =         456)    n (%)     \n', '  oselabeledaefromdruguse  248",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,kyprolis,204,4394,4398,(54)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,kyprolis,205,4398,4403,180 (40)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,kyprolis,206,4403,4428,"\n', '  oselabeledaefromdruguse  243 (53)         198 (43)          \n', '  oselabeledaefromdruguse  79",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,kyprolis,207,4428,4445,"(17)          68 (15)           \n', '  oselabeledaefromdruguse  85",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,kyprolis,208,4445,4450,(18)          77,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,kyprolis,209,4450,4466,"(17)           \n', '  oselabeledaefromdruguse  73 (16)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,kyprolis,210,4466,4467,61,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,kyprolis,211,4467,4507,"(13)           \n', '  oselabeledaefromdruguse  a    65 (14)          49 (11)           \n', '  oselabeledaefromdruguse  55 (12)          21 (5)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,kyprolis,212,4507,4534,"\n', ' Kd = Kyprolis and dexamethasone; Vd = bortezomib and dexamethasone  a  Calculated using the Cockcroft-Gault formula.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,kyprolis,213,4534,4564,"\n', '           Safety Experience with Kyprolis in Patients with Multiple Myeloma who Received Monotherapy  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,kyprolis,214,4564,4642,"The safety of Kyprolis, dosed at 20/27 mg/m  2  by up to 10-minute infusion, was evaluated in clinical trials in which 598 patients with relapsed and/or refractory  notaecandidateindication received Kyprolis monotherapy starting with the 20 mg/m  2  dose in Cycle 1, Day 1 and escalating to 27 mg/m  2  on Cycle 1, Day 8 or Cycle 2, Day 1.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
215,kyprolis,215,4642,4662,Premedication with dexamethasone 4 mg was required before each dose in Cycle 1 and was optional for subsequent cycles.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,kyprolis,216,4662,4682,"The median age was 64 years (range 32-87), and approximately 57% were male.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,kyprolis,217,4682,4698,The patients received a median of 5 (range 1-20) prior regimens.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,kyprolis,218,4698,4706,The median number of cycles initiated was 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,kyprolis,219,4706,4746,"(range 1-35).\n', '\n', ' Serious adverse reactions, regardless of causality, were reported in 50% of patients in the pooled Kyprolis monotherapy studies (N = 598).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,kyprolis,220,4746,4818,"The most common serious adverse reactions were:  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (2%), and  oselabeledaefromdruguse (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,kyprolis,221,4818,4859,"In patients treated with Kyprolis, the incidence of serious adverse reactions was higher in those >= 65 years old and those >= 75 years old  [see Geriatric Use         (      8.5      )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,kyprolis,222,4859,4894,".\n', '\n', '  nonoseaegeneralterm due to adverse reactions within 30 days of the last dose of Kyprolis occurred in 30/598 (5%) patients receiving Kyprolis monotherapy.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
223,kyprolis,223,4894,4944,"These adverse reactions were related to  oselabeledaefromdruguse in 10 (2%) patients,  oselabeledaefromdruguse in 8 (1%) patients,  oselabeledaefromdruguse in 4 (< 1%) patients, and other adverse reactions in 8 (1%) patients.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,kyprolis,224,4944,4999,In a randomized trial comparing Kyprolis as a single agent  versus  corticosteroids with optional oral cyclophosphamide for patients with relapsed and refractory  notaecandidateindication   nonoseaegeneralterm was higher in the patients treated with Kyprolis in comparison to the control arm in the subgroup of 48 patients >= 75 years of age.,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
225,kyprolis,225,4999,5066,"The most common cause of discontinuation due to an adverse reaction was  oselabeledaefromdruguse (2%).\n', '\n', ' Safety of Kyprolis monotherapy dosed at 20/56 mg/m  2  by 30-minute infusion was evaluated in a multicenter, open-label study in patients with relapsed and/or refractory  notaecandidateindication   The study treatment is described in Section 14.3.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
226,kyprolis,226,5066,5144,"The patients received a median of 4 (range 1-10) prior regimens.\n', '\n', ' The common adverse reactions occurring at a rate of 20% or greater with Kyprolis monotherapy are presented in Table 12.\n', '\n', ' Table 12: Most Common Adverse Reactions (>= 20%) with Kyprolis Monotherapy  \n', '                    20/56         mg/m      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,kyprolis,227,5144,5159,2      by 30  -  minute infusion    (N         =         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,kyprolis,228,5159,5162,24)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,kyprolis,229,5162,5168,20/27         mg/m      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,kyprolis,230,5168,5172,2      by    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,kyprolis,231,5172,5192,2  -  to 10  -  minute infusion    (N         =         598)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,kyprolis,232,5192,5221,"\n', '   Adverse Reaction      Any Grade    n (%)      Grades         3         -         5    n (%)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,kyprolis,233,5221,5242,Any Grade    n (%)      Grades         3         -         5    n (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,kyprolis,234,5242,5296,"\n', '  oselabeledaefromdruguse          14 (58)          2 (8)            238 (40)         25 (4)            \n', '  oselabeledaefromdruguse  a       14 (58)          2 (8)            202 (34)         21 (4)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,kyprolis,235,5296,5310,"\n', '  oselabeledaefromdruguse          14 (58)          0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,kyprolis,236,5310,5320,177 (30)         11 (2)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,kyprolis,237,5320,5328,"\n', '  oselabeledaefromdruguse  13",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,kyprolis,238,5328,5333,(54)          13,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,kyprolis,239,5333,5343,(54)          220 (37)         152,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,kyprolis,240,5343,5347,(25)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,kyprolis,241,5347,5362,"\n', '  oselabeledaefromdruguse           13 (54)          0                211",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,kyprolis,242,5362,5412,"(35)         7 (1)             \n', '  oselabeledaefromdruguse           10 (42)          7 (29)           291 (49)         141 (24)          \n', '  oselabeledaefromdruguse  b    10 (42)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,kyprolis,243,5412,5476,"3 (13)           90 (15)          22 (4)            \n', '  oselabeledaefromdruguse           9 (38)           0                73 (12)          1 (< 1)           \n', '  oselabeledaefromdruguse         8 (33)           0                141 (24)         7 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,kyprolis,244,5476,5481,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,kyprolis,245,5481,5527,"oselabeledaefromdruguse  c         8 (33)           0                134 (22)         2 (< 1)           \n', '  oselabeledaefromdruguse         8 (33)           0                104 (17)         4 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,kyprolis,246,5527,5535,"\n', '  oselabeledaefromdruguse      8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,kyprolis,247,5535,5559,"(33)           8 (33)           85 (14)          73 (12)           \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,kyprolis,248,5559,5568,oselabeledaefromdruguse         7 (29)           0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,kyprolis,249,5568,5575,75 (13)          0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,kyprolis,250,5575,5599,"\n', '  oselabeledaefromdruguse        7 (29)           0                64 (11)          5 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,kyprolis,251,5599,5634,"\n', '  oselabeledaefromdruguse         6 (25)           1 (4)            160 (27)         8 (1)             \n', '  oselabeledaefromdruguse  6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,kyprolis,252,5634,5667,"(25)           1 (4)            103 (17)         15 (3)            \n', '  oselabeledaefromdruguse  5 (21)           0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,kyprolis,253,5667,5713,"118 (20)         1 (< 1)           \n', '  oselabeledaefromdruguse        5 (21)           1 (4)            115 (19)         19 (3)            \n', '  oselabeledaefromdruguse  5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,kyprolis,254,5713,5732,(21)           1 (4)            112 (19)         15 (3)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,kyprolis,255,5732,5740,"\n', '  oselabeledaefromdruguse  5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,kyprolis,256,5740,5764,"(21)           0                89 (15)          2 (< 1)           \n', '  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,kyprolis,257,5764,5810,"5 (21)           0                62 (10)          2 (< 1)           \n', '  oselabeledaefromdruguse       5 (21)           0                20 (3)           1 (< 1)           \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,kyprolis,258,5810,5848,'   a   oselabeledaefromdruguse includes preferred terms of  oselabeledaefromdruguse and  oselabeledaefromdruguse   b   oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   c   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,kyprolis,259,5848,5904,"\n', '             Adverse Reactions Occurring at a Frequency of <     20    %  \n', ' \n', '\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
260,kyprolis,260,5904,5915,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
261,kyprolis,261,5915,5934,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
262,kyprolis,262,5934,5949,"\n', ' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
263,kyprolis,263,5949,5958,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
264,kyprolis,264,5958,5985,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
265,kyprolis,265,5985,6014,"\n', ' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
266,kyprolis,266,6014,6031,"\n', ' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
267,kyprolis,267,6031,6050,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
268,kyprolis,268,6050,6051,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,kyprolis,269,6051,6060,"', ' *    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
270,kyprolis,270,6060,6061,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,kyprolis,271,6061,6074,"\n', ' *    nonoseaegeneralterm     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
272,kyprolis,272,6074,6091,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
273,kyprolis,273,6091,6106,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
274,kyprolis,274,6106,6282,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse and thrombotic  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse and  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    Grade 3 and higher adverse reactions occurring at an incidence of > 1% include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', ' \n', '\n', '   Laboratory Abnormalities  \n', '\n', ' Table 13 describes Grade 3-4 laboratory abnormalities reported at a rate of > 10% for patients who received Kyprolis monotherapy.\n', '\n', ' Table 13: Grade 3-4 Laboratory Abnormalities (> 10%) with Kyprolis Monotherapy \n', '    nonoseaegeneralterm      Kyprolis    20/56 mg/m      2      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
275,kyprolis,275,6282,6297,(N = 24)      Kyprolis    20/27 mg/m      2      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,kyprolis,276,6297,6303,(N = 598)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,kyprolis,277,6303,6315,"\n', '  oselabeledaefromdruguse  15 (63)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,kyprolis,278,6315,6332,"151 (25)          \n', '  oselabeledaefromdruguse  11 (46)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,kyprolis,279,6332,6337,184 (31)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,kyprolis,280,6337,6362,"\n', '  oselabeledaefromdruguse  7 (29)           132 (22)          \n', '  oselabeledaefromdruguse  3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,kyprolis,281,6362,6416,"(13)           71 (12)           \n', '  oselabeledaefromdruguse  2 (8)            69 (12)           \n', '  oselabeledaefromdruguse  2 (8)            67 (11)           \n', '           6.2       Postmarketing Experience\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,kyprolis,282,6416,6430,The following additional adverse reactions were reported in the postmarketing experience with Kyprolis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,kyprolis,283,6430,6472,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse     5        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,kyprolis,284,6472,6505,"WARNINGS AND PRECAUTIONS  \n', '\n', '   EXCERPT:    *  Cardiac Toxicities:  Monitor for signs and symptoms of cardiac failure or ischemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,kyprolis,285,6505,6511,Withhold Kyprolis and evaluate promptly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,kyprolis,286,6511,6516,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,kyprolis,287,6516,6520,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,kyprolis,288,6520,6526,*  Acute Renal Failure:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,kyprolis,289,6526,6531,Monitor serum creatinine regularly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,kyprolis,290,6531,6536,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,kyprolis,291,6536,6549,"\n', ' *  Tumor Lysis Syndrome (TLS):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,kyprolis,292,6549,6555,Administer pre-treatment hydration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,kyprolis,293,6555,6572,"(  2.1  ) Monitor for TLS, including uric acid levels and treat promptly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,kyprolis,294,6572,6610,"(  5.3  ) \n', ' *  Pulmonary Toxicity, including Acute Respiratory Distress Syndrome, Acute Respiratory Failure, and Acute Diffuse Infiltrative Pulmonary Disease:  Withhold Kyprolis and evaluate promptly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,kyprolis,295,6610,6629,"(  5.4  ) \n', ' *  Pulmonary Hypertension: Withhold Kyprolis and evaluate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,kyprolis,296,6629,6642,"(  5.5  ) \n', ' *  Dyspnea:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,kyprolis,297,6642,6654,"For severe or life threatening dyspnea, withhold Kyprolis and evaluate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,kyprolis,298,6654,6677,"(  5.6  ) \n', ' *  Hypertension Including Hypertensive Crisis:  Monitor blood pressure regularly.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,kyprolis,299,6677,6689,"If hypertension cannot be controlled, interrupt treatment with Kyprolis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,kyprolis,300,6689,6704,"(  5.7  ) \n', ' *  Venous Thrombosis:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,kyprolis,301,6704,6708,Thromboprophylaxis is recommended.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,kyprolis,302,6708,6726,"(  5.8  ) \n', ' *  Infusion Reactions: Premedicate with dexamethasone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,kyprolis,303,6726,6735,"(  2.1  ,  5.9  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,kyprolis,304,6735,6739,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,kyprolis,305,6739,6743,*  Hemorrhage:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,kyprolis,306,6743,6761,"Fatal or serious cases of hemorrhage may occur, including gastrointestinal, pulmonary, and intracranial hemorrhage.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,kyprolis,307,6761,6770,Promptly evaluate signs and symptoms of blood loss.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,kyprolis,308,6770,6796,"(  5.10  ) \n', ' *  Thrombocytopenia: Monitor platelet counts; interrupt or reduce Kyprolis dosing as clinically indicated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,kyprolis,309,6796,6823,"(  2.3  ,   5.11  ) \n', ' *  Hepatic Toxicity and Hepatic Failure: Monitor liver enzymes regularly.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,kyprolis,310,6823,6828,Withhold Kyprolis if suspected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,kyprolis,311,6828,6848,"(  5.12  ) \n', ' *  Thrombotic Microangiopathy: Monitor for signs and symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,kyprolis,312,6848,6853,Discontinue Kyprolis if suspected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,kyprolis,313,6853,6893,"(  5.13  ) \n', ' *  Posterior Reversible Encephalopathy Syndrome (PRES): Consider neuro-radiological imaging (MRI) for onset of visual or neurological symptoms; discontinue Kyprolis if suspected.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,kyprolis,314,6893,6927,"(  5.14  ) \n', ' *  Increased Fatal and Serious Toxicites in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Patients (  5.15  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,kyprolis,315,6927,6928,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,kyprolis,316,6928,6944,"', ' *  Embryo-Fetal Toxicity: Kyprolis can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,kyprolis,317,6944,6956,Females of reproductive potential should avoid becoming pregnant while being treated.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,kyprolis,318,6956,6965,"(  5.16  ,   8.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,kyprolis,319,6965,7018,"\n', '    \n', ' \n', '\n', '   5.1        oselabeledaefromdruguse \n', '  New onset or worsening of pre-existing  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse  and  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,kyprolis,320,7018,7030,oselabeledaefromdruguse including  nonoseaegeneralterm have occurred following administration of Kyprolis.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
321,kyprolis,321,7030,7042,Some events occurred in patients with normal baseline ventricular function.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,kyprolis,322,7042,7059,"In clinical studies with Kyprolis, these events occurred throughout the course of Kyprolis therapy.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,kyprolis,323,7059,7074,nonoseaegeneralterm due to  oselabeledaefromdruguse has occurred within one day of Kyprolis administration.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
324,kyprolis,324,7074,7126,"In a randomized, open-label, multicenter trial evaluating Kyprolis in combination with lenalidomide and dexamethasone (KRd) versus  lenalidomide/dexamethasone (Rd), the incidence of  oselabeledaefromdruguse was 6% in the KRd arm versus  4% in the Rd arm.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,kyprolis,325,7126,7202,"In a randomized, open-label, multicenter trial of Kyprolis plus dexamethasone (Kd) versus  bortezomib plus dexamethasone (Vd), the incidence of  oselabeledaefromdruguse was 8% in the Kd arm versus  3% in the Vd arm.\n', '\n', ' Monitor patients for clinical signs or symptoms of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   Evaluate promptly if  nonoseaeaeonlyasinstruction is suspected.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,kyprolis,326,7202,7232,"Withhold Kyprolis for Grade 3 or 4  nonoseaeaeonlyasinstruction until recovery, and consider whether to restart Kyprolis at 1 dose level reduction based on a benefit/risk assessment",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,kyprolis,327,7232,7357,"[see    Dosage and Administration    (     2.3     )   ]  .\n', '\n', ' While adequate hydration is required prior to each dose in Cycle 1, all patients should also be monitored for evidence of  nonoseaeaeonlyasinstruction  especially patients at risk for  nonoseaeaeonlyasinstruction  Adjust total fluid intake as clinically appropriate in patients with baseline  notaecandidatepreexistingconditionorriskfactor or who are at risk for  nonoseaeaeonlyasinstruction [see Dosage and Administration    (     2.1     )   ]  .\n', '\n', '  In patients >= 75 years of age, the risk of  nonoseaeaeonlyasinstruction is increased compared to patients  75 years of age.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
328,kyprolis,328,7357,7394,Patients with  notaecandidatepreexistingconditionorriskfactor and IV  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor III and  notaecandidatepreexistingconditionorriskfactor  recent  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor uncontrolled by medications were not eligible for the clinical trials.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
329,kyprolis,329,7394,7449,These patients may be at greater risk for  nonoseaeaeonlyasinstruction and should have a comprehensive medical assessment (including blood pressure and fluid management) prior to starting treatment with Kyprolis and remain under close follow-up  [see Use in Specific Populations   (     8.5     )]  .  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,kyprolis,330,7449,7483,"\n', '\n', '    5.2       Acute Renal Failure\n', '\n', '  Cases of  oselabeledaefromdruguse have occurred in patients receiving Kyprolis.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,kyprolis,331,7483,7504,oselabeledaefromdruguse adverse events (including  oselabeledaefromdruguse  have occurred in approximately 10% of patients treated with Kyprolis.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
332,kyprolis,332,7504,7523,oselabeledaefromdruguse was reported more frequently in patients with advanced relapsed and refractory  notaecandidateindication who received Kyprolis monotherapy.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
333,kyprolis,333,7523,7543,This risk was greater in patients with a baseline  notaecandidatepreexistingconditionorriskfactor (calculated using Cockcroft and Gault equation).,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
334,kyprolis,334,7543,7558,Monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,kyprolis,335,7558,7577,Reduce or withhold dose as appropriate [see Dosage and Administration    (     2.3     )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,kyprolis,336,7577,7579,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,kyprolis,337,7579,7618,", '\n', '    5.3       Tumor Lysis Syndrome\n', '\n', '  Cases of  oselabeledaefromdruguse , including  nonoseaegeneralterm outcomes, have been reported in patients who received Kyprolis.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
338,kyprolis,338,7618,7674,"Patients with  notaecandidateindication and a high  notaecandidatepreexistingconditionorriskfactor should be considered to be at greater risk for  oselabeledaefromdruguse  Ensure that patients are well hydrated before administration of Kyprolis in Cycle 1, and in subsequent cycles as needed [see    Dosage and Administration   (     2.1     )]  .",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
339,kyprolis,339,7674,7720,"Consider uric acid-lowering drugs in patients at risk for  nonoseaeaeonlyasinstruction  Monitor for evidence of TLS during treatment and manage promptly, including interruption of Kyprolis until TLS is resolved [see Dosage and Administration   (     2.1     )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,kyprolis,340,7720,7768,".\n', '\n', '    5.4       Pulmonary Toxicity\n', '\n', '   oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse such as  oselabeledaefromdruguse and  oselabeledaefromdruguse have occurred in less than 1% of patients receiving Kyprolis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,kyprolis,341,7768,7775,Some events have been  nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
342,kyprolis,342,7775,7801,In the event of drug-induced  nonoseaeaeonlyasinstruction  discontinue Kyprolis [see    Dosage and Administration    (     2.3     )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,kyprolis,343,7801,7848,".\n', '\n', '    5.5       Pulmonary Hypertension\n', '\n', '   oselabeledaefromdruguse was reported in approximately 1% of patients treated with Kyprolis and was Grade 3 or greater in less than 1% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,kyprolis,344,7848,7859,Evaluate with cardiac imaging and/or other tests as indicated.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,kyprolis,345,7859,7884,"Withhold Kyprolis for  nonoseaeaeonlyasinstruction until resolved or returned to baseline, and consider whether to restart Kyprolis based on a benefit/risk assessment",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,kyprolis,346,7884,7899,[see   Dosage and Administration   (     2.3     )   ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,kyprolis,347,7899,7901,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,kyprolis,348,7901,7942,", '\n', '    5.6       Dyspnea\n', '\n', '   oselabeledaefromdruguse was reported in 28% of patients treated with Kyprolis and was Grade 3 or greater in 4% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,kyprolis,349,7942,7973,Evaluate  nonoseaeaeonlyasinstruction to exclude  nonoseaeaeonlyasinstruction including  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction   Stop Kyprolis for Grade 3 or 4  nonoseaeaeonlyasinstruction until resolved or returned to baseline.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,kyprolis,350,7973,8027,"Consider whether to restart Kyprolis based on a benefit/risk assessment  [see Dosage and Administration   (     2.3     )   ,       Warnings and Precautions   (     5.1      and     5.4     )   ,   and Adverse Reactions   (     6.1     )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,kyprolis,351,8027,8063,".\n', '\n', '    5.7       Hypertension\n', '\n', '   oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  has been observed with Kyprolis.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
352,kyprolis,352,8063,8106,"In a randomized, open-label, multicenter trial evaluating Kyprolis in combination with KRd versus  Rd, the incidence of  oselabeledaefromdruguse events was 16% in the KRd arm versus  8% in the Rd arm.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
353,kyprolis,353,8106,8144,"In a randomized, open-label, multicenter trial of Kd versus  Vd, the incidence of  oselabeledaefromdruguse events was 26% in the Kd arm versus  10% in the Vd arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
354,kyprolis,354,8144,8161,Some of these events have been  nonoseaegeneralterm  Monitor blood pressure regularly in all patients.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
355,kyprolis,355,8161,8175,"If  nonoseaeaeonlyasinstruction cannot be adequately controlled, withhold Kyprolis and evaluate.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,kyprolis,356,8175,8200,Consider whether to restart Kyprolis based on a benefit/risk assessment [see Dosage and Administration   (     2     )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,kyprolis,357,8200,8202,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,kyprolis,358,8202,8236,", '\n', '    5.8       Venous Thrombosis\n', '\n', '    oselabeledaefromdruguse (including  oselabeledaefromdruguse and  oselabeledaefromdruguse  have been observed with Kyprolis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,kyprolis,359,8236,8286,"In a randomized, open-label, multicenter trial evaluating KRd versus  Rd (with thromboprophylaxis used in both arms), the incidence of  oselabeledaefromdruguse in the first 12 cycles was 13% in the KRd arm versus  6% in the Rd arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,kyprolis,360,8286,8328,"In a randomized, open-label, multicenter trial of Kd versus  Vd, the incidence of  oselabeledaefromdruguse in months 1-6 was 9% in the Kd arm versus  2% in the Vd arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,kyprolis,361,8328,8342,"With Kyprolis monotherapy, the incidence of  oselabeledaefromdruguse was 2%.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,kyprolis,362,8342,8372,"\n', '\n', ""  Thromboprophylaxis is recommended for patients being treated with the combination of Kyprolis with dexamethasone or with lenalidomide plus dexamethasone.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,kyprolis,363,8372,8389,The thromboprophylaxis regimen should be based on an assessment of the patient's underlying risks.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,kyprolis,364,8389,8451,"\n"", '\n', '  Patients using oral contraceptives or a hormonal method of contraception associated with a risk of  nonoseaeaeonlyasinstruction should consider an alternative method of effective contraception during treatment with Kyprolis in combination with dexamethasone or lenalidomide plus dexamethasone  [see Use in Specific Population (     8.3     )]   .    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,kyprolis,365,8451,8487,"\n', '\n', '    5.9       Infusion Reactions\n', '\n', '   oselabeledaefromdruguse  including life-threatening reactions, have occurred in patients receiving Kyprolis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,kyprolis,366,8487,8534,Symptoms include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication  These reactions can occur immediately following or up to 24 hours after administration of Kyprolis.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
367,kyprolis,367,8534,8562,Administer dexamethasone prior to Kyprolis to reduce the incidence and severity of  nonoseaeaeonlyasinstruction [see Dosage and Administration   (     2     )]  .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
368,kyprolis,368,8562,8619,"Inform patients of the risk and of symptoms and to contact a physician immediately if symptoms of an  nonoseaeaeonlyasinstruction occur.\n', '\n', '    5.10       Hemorrhage\n', '\n', '    nonoseaegeneralterm or serious cases of  oselabeledaefromdruguse have been reported in patients treated with Kyprolis.  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
369,kyprolis,369,8619,8644,"oselabeledaefromdruguse have included  oselabeledaefromdruguse  pulmonary, and intracranial  oselabeledaefromdruguse  oselabeledaefromdruguse  and intracranial  oselabeledaefromdruguse  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,kyprolis,370,8644,8660,"The  oselabeledaefromdruguse can be spontaneous, and  oselabeledaefromdruguse has occurred without trauma.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
371,kyprolis,371,8660,8691,oselabeledaefromdruguse has been reported in patients having either  notaecandidatepreexistingconditionorriskfactor or normal  notaecandidatepreexistingconditionorriskfactor   oselabeledaefromdruguse has also been reported in patients who were not on antiplatelet therapy or anticoagulation.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
372,kyprolis,372,8691,8729,Promptly evaluate signs and symptoms of  nonoseaeaeonlyasinstruction  Reduce or withhold dose as appropriate [   see Dosage and Administration (     2.3     )   and Adverse Reactions (     6.1     )].    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
373,kyprolis,373,8729,8796,"\n', '\n', '    5.11       Thrombocytopenia\n', '\n', '   Kyprolis causes  oselabeledaefromdruguse with platelet nadirs observed between Day 8 and Day 15 of each 28-day cycle, with recovery to baseline platelet count usually by the start of the next cycle [see Adverse Reactions   (     6.1     )]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,kyprolis,374,8796,8811,oselabeledaefromdruguse was reported in approximately 40% of patients in clinical trials with Kyprolis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,kyprolis,375,8811,8820,Monitor platelet counts frequently during treatment with Kyprolis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,kyprolis,376,8820,8841,Reduce or withhold dose as appropriate [see Dosage and Administration    (     2.3     )]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,kyprolis,377,8841,8867,oselabeledaefromdruguse may occur [see   Adverse Reactions (     6.1     ) and Warnings and Precautions (     5.10     )   ].    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,kyprolis,378,8867,8914,"\n', '\n', '    5.12       Hepatic Toxicity and Hepatic Failure\n', '\n', '  Cases of  oselabeledaefromdruguse  including  nonoseaegeneralterm cases, have been reported (< 1%) during treatment with Kyprolis.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
379,kyprolis,379,8914,8930,"Kyprolis can cause  oselabeledaefromdruguse  Monitor liver enzymes regularly, regardless of baseline values.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,kyprolis,380,8930,8959,Reduce or withhold dose as appropriate [see Dosage and Administration   (     2.3     )   and Adverse Reactions   (     6.1     )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
381,kyprolis,381,8959,8961,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
382,kyprolis,382,8961,9005,", '\n', '    5.13       Thrombotic Microangiopathy\n', '\n', '   Cases of  oselabeledaefromdruguse  including  oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse , have been reported in patients who received Kyprolis.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
383,kyprolis,383,9005,9012,Some of these events have been  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
384,kyprolis,384,9012,9025,nonoseaegeneralterm  Monitor for signs and symptoms of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  ,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
385,kyprolis,385,9025,9036,"If the diagnosis is suspected, stop Kyprolis and evaluate.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
386,kyprolis,386,9036,9052,"If the diagnosis of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction is excluded, Kyprolis may be restarted.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
387,kyprolis,387,9052,9085,The safety of reinitiating Kyprolis therapy in patients previously experiencing  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction is not known  [see Dosage and Administration (     2.3     )   ]  .  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,kyprolis,388,9085,9122,"\n', '\n', '    5.14       Posterior Reversible Encephalopathy Syndrome\n', '\n', '  Cases of  oselabeledaefromdruguse  have been reported in patients receiving Kyprolis.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,kyprolis,389,9122,9167,"nonoseaeaeonlyasinstruction  formerly termed  nonoseaeaeonlyasinstruction , is a  nonoseaeaeonlyasinstruction which can present with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and other  nonoseaemanifestationorcomplication and neurological  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  along with  nonoseaemanifestationorcomplication  and",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
390,kyprolis,390,9167,9180,the diagnosis is confirmed by neuro-radiological imaging (MRI).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,kyprolis,391,9180,9190,Discontinue Kyprolis if  nonoseaeaeonlyasinstruction is suspected and evaluate.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
392,kyprolis,392,9190,9342,"The safety of reinitiating Kyprolis therapy in patients previously experiencing  nonoseaeaeonlyasinstruction is not known.\n', '\n', '    5.15       Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Patients\n', '\n', '   In a clinical trial of 955 transplant-ineligible patients with newly diagnosed  notaecandidateindication randomized to Kyprolis (20/36 mg/m  2  by 30-minute infusion twice weekly for four of each six-week cycle), melphalan and prednisone (KMP) or bortezomib, melphalan and prednisone (VMP), a higher incidence of  nonoseaegeneralterm adverse reactions (7% versus  4%) and serious adverse reactions (50% versus  42%) were observed in the KMP arm compared to patients in the VMP arm, respectively.",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
393,kyprolis,393,9342,9405,"Patients in the KMP arm were observed to have a higher incidence of any grade adverse reactions involving  oselabeledaefromdruguse (11% versus  4%),  oselabeledaefromdruguse (25% versus  8%),  oselabeledaefromdruguse (14% versus  6%), and  oselabeledaefromdruguse (18% versus  9%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,kyprolis,394,9405,9426,This study did not meet its primary outcome measure of superiority in progression-free survival for the KMP arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,kyprolis,395,9426,9459,"Kyprolis in combination with melphalan and prednisone is not indicated for transplant-ineligible patients with newly diagnosed  notaecandidateindication   \n', '\n', '    5.16        oselabeledaefromdruguse",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
396,kyprolis,396,9459,9487,"\n', '  Kyprolis can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman based on its mechanism of action and findings in animals.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
397,kyprolis,397,9487,9526,"There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women using Kyprolis.\n', '\n', ' Advise females of reproductive potential to avoid becoming  nonoseaeaeonlyasinstruction while being treated with Kyprolis.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
398,kyprolis,398,9526,9543,Advise males of reproductive potential to avoid fathering a child while being treated with Kyprolis.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,kyprolis,399,9543,9566,Advise women who use Kyprolis during  notaecandidatepreexistingconditionorriskfactor or become  notaecandidatepreexistingconditionorriskfactor during treatment with Kyprolis of the potential  oselabeledaefromdruguse '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,renvela,0,0,32,"['  6 ADVERSE REACTIONS\n', '\n', '   EXCERPT:    *  Most of the safety experience is with sevelamer tablets and sevelamer hydrochloride.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,renvela,1,32,102,"In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting (22%), nausea (20%), diarrhea (19%), dyspepsia (16%), abdominal pain (9%), flatulence (8%), and constipation (8%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,renvela,2,102,107,(  6.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,renvela,3,107,139,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-800-847-0069 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,renvela,4,139,172,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,renvela,5,172,235,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' There are limited clinical trial data on the safety of Renvela.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,renvela,6,235,263,"However, because it contains the same active ingredient as the hydrochloride salt, the adverse event profiles of the two salts are expected to be similar.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,renvela,7,263,367,"In a cross-over study in hemodialysis patients with treatment durations of eight weeks each and no washout, and another cross-over study in hemodialysis patients with treatment durations of four weeks each and no washout between treatment periods, the adverse reactions on sevelamer carbonate powder were similar to those reported for sevelamer hydrochloride.\n', '\n', ' In a parallel design study of sevelamer hydrochloride with treatment duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride (n=99) were similar to those reported for the active-comparator group (n=101).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,renvela,8,367,435,"Overall adverse reactions among those treated with sevelamer hydrochloride occurring in >5% of patients included:  oselabeledaeclasseffect (22%),  oselabeledaeclasseffect (20%),  oselabeledaeclasseffect (19%),  oselabeledaeclasseffect (16%),  oselabeledaeclasseffect (9%),  oselabeledaeclasseffect (8%), and  oselabeledaeclasseffect (8%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,renvela,9,435,494,"A total of 27 patients treated with sevelamer and 10 patients treated with comparator withdrew from the study due to adverse reactions.\n', '\n', ' Based on studies of 8-52 weeks, the most common reason for withdrawal from sevelamer hydrochloride was  oselabeledaeclasseffect (3%-16%).\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,renvela,10,494,521,"In 143 peritoneal dialysis patients studied for 12 weeks using sevelamer hydrochloride, most common adverse reactions were similar to adverse reactions observed in hemodialysis patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,renvela,11,521,562,The most frequently occurring treatment emergent serious adverse reaction was  oselabeledaeclasseffect (8 reactions in 8 patients [8%] in the sevelamer group and 2 reactions in 2 patients [4%] on active control).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,renvela,12,562,591,"Thirteen patients (14%) in the sevelamer group and 9 patients (20%) in the active-control group discontinued, mostly for  oselabeledaeclasseffect",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,renvela,13,591,685,"\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.\n', '\n', ' The following adverse reactions have been identified during postapproval use of sevelamer hydrochloride or sevelamer carbonate:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and uncommon cases of  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,renvela,14,685,711,oselabeledaefromdruguse  and  oselabeledaefromdruguse  Appropriate medical management should be given to patients who develop  nonoseaeaeonlyasinstruction or have worsening of existing  nonoseaeaeonlyasinstruction    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,renvela,15,711,751,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Serious cases of dysphagia, bowel obstruction, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,renvela,16,751,756,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,renvela,17,756,809,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdruguse \n', '  Cases of  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in association with use of the tablet formulation of sevelamer, some requiring hospitalization and intervention.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,renvela,18,809,996,"Consider using sevelamer suspension in patients with a history of  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Cases of  oselabeledaefromdruguse obstruction and  oselabeledaefromdruguse  oselabeledaefromdruguse and perforation have also been reported with sevelamer use.\n', '\n', ' Patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  severe  notaecandidatepreexistingconditionorriskfactor  including severe  notaecandidatepreexistingconditionorriskfactor  or major GI tract surgery were not included in the Renvela clinical studies.\n', '\n', '    5.2 Reductions in Vitamins D, E, K (clotting factors) and Folic Acid Levels\n', '\n', '  In preclinical studies in rats and dogs, sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate,  nonoseaeaeanimal vitamins D, E, and K (coagulation parameters) and  nonoseaeaeanimal  nonoseaeaeanimal D, E, and  nonoseaeaeanimal  nonoseaeaeanimal D,  nonoseaeaeanimal  nonoseaeaeanimal  E, and K (coagulation parameters) and folic acid levels at doses of 6-10 times the recommended human dose.",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
19,renvela,19,996,1037,"In short-term clinical trials, there was no evidence of  nonoseaenegation  However, in a one-year clinical trial,  oselabeledaefromdruguse (normal range 10 to 55 ng/mL)  oselabeledaefromdruguse ']",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
0,afinitor,0,0,43,"['  6     ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in another section of the label  [see Warnings and Precautions (5)]  :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,afinitor,1,43,64,"\n', '\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.1)] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,afinitor,2,64,81,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.2)] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,afinitor,3,81,104,"\n', ' *   nonoseaeaefromdruginteraction with concomitant use of ACE inhibitors [see Warnings and Precautions (5.3)] .",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
4,afinitor,4,104,121,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.4)] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,afinitor,5,121,138,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.5)] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,afinitor,6,138,155,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (5.6)] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,afinitor,7,155,260,"\n', '    Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.\n', ' \n', '\n', '   EXCERPT:   Advanced HR+ BC, advanced NET, advanced RCC: Most common adverse reactions (incidence >=30%) include stomatitis, infections, rash, fatigue, diarrhea, edema, abdominal pain, nausea, fever, asthenia, cough, headache and decreased appetite.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,afinitor,8,260,273,"(  6.1  ,  6.2  ,  6.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,afinitor,9,273,286,"\n', '\n', ' Renal angiomyolipoma with TSC:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,afinitor,10,286,300,Most common adverse reaction (incidence >= 30%) is stomatitis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,afinitor,11,300,335,"(  6.4  )\n', '\n', ' SEGA with TSC: Most common adverse reactions (incidence >= 30%) are stomatitis and respiratory tract infection.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,afinitor,12,335,379,"(  6.5  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,afinitor,13,379,452,"\n', '\n', ' \n', '\n', '  6.1     Clinical Study Experience in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer\n', '\n', '  The efficacy and safety of AFINITOR (10 mg/day) plus exemestane (25 mg/day) (n=485) versus placebo plus exemestane (25 mg/day)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,afinitor,14,452,472,"(n=239) was evaluated in a randomized, controlled trial (BOLERO-2) in patients with  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,afinitor,15,472,494,"The median age of patients was 61 years (range 28-93 years), and 75% were Caucasian.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,afinitor,16,494,543,"Safety results are based on a median follow-up of approximately 13 months.\n', '\n', ' The most common adverse reactions (incidence >=30%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,afinitor,17,543,575,The most common Grade 3/4 adverse reactions (incidence >=2%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,afinitor,18,575,610,"The most common laboratory abnormalities (incidence >=50%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse , and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,afinitor,19,610,641,The most common Grade 3/4 laboratory abnormalities (incidence >= 3%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,afinitor,20,641,681,"\n', '\n', '  nonoseaegeneralterm adverse reactions occurred more frequently in patients who received AFINITOR plus exemestane (2%) compared to patients on the placebo plus exemestane arm (0.4%).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,afinitor,21,681,713,"The rates of treatment-emergent adverse events resulting in permanent discontinuation were 24% and 5% for the AFINITOR plus exemestane and placebo plus exemestane treatment groups, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,afinitor,22,713,846,"Dose adjustments (interruptions or reductions) were more frequent among patients in the AFINITOR plus exemestane arm than in the placebo plus exemestane arm (63% versus 14%).\n', '\n', ' Table 2 compares the incidence of treatment-emergent adverse reactions reported with an incidence of >=10% for patients receiving AFINITOR 10 mg daily versus placebo.\n', '\n', ' Table 2: Adverse Reactions Reported >=10% of Patients with Advanced HR+ BC* \n', ' Grading according to CTCAE Version 3.0  *  160 patients (33.2%) were exposed to AFINITOR therapy for a period of >= 32 weeks  a  Exemestane (25 mg/day)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,afinitor,23,846,865,b  Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,afinitor,24,865,962,"c  Includes all preferred terms within the  nonoseaegeneralterm system organ class, the most common being  oselabeledaefromdruguse (10%),  oselabeledaefromdruguse (10%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%), and also including  oselabeledaefromdruguse (<1%), and  oselabeledaefromdruguse (<1%), and  oselabeledaefromdruguse (<1%).  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,afinitor,25,962,964,d  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,afinitor,26,964,970,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,afinitor,27,970,976,oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,afinitor,28,976,984,e  Exposure to AFINITOR or placebo   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,afinitor,29,984,1009,"\n', '  \n', '                    AFINITOR (10 mg/day)    + exemestane  a      N=482      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,afinitor,30,1009,1016,Placebo    + exemestane  a      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,afinitor,31,1016,1018,N=238     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,afinitor,32,1018,1026,"\n', '                    All Grades       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,afinitor,33,1026,1032,Grade 3          Grade 4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,afinitor,34,1032,1041,All Grades       Grade 3          Grade 4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,afinitor,35,1041,1056,"\n', '                    %                %                %                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,afinitor,36,1056,1058,%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,afinitor,37,1058,1299,"\n', '   Any adverse reaction      100              41               9                90               22               5               \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  b    67               8                0                11               0.8              0                 \n', '        oselabeledaefromdruguse   33               2                0.2              18               0.8              0                 \n', '        oselabeledaefromdruguse     29               0.2              0.2              28               1                0                 \n', '        oselabeledaefromdruguse   17               0.8              0.2              12               0.8              0                 \n', '        oselabeledaefromdruguse  14               0.4              0                13               0.4              0                 \n', '        oselabeledaefromdruguse  11               0                0                7                0                0                 \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse    36               4                0.4              27               1                0                 \n', '        oselabeledaefromdruguse  19               1                0                6                0.4              0                 \n', '        oselabeledaefromdruguse    15               0.2              0                7                0.4              0                 \n', '        oselabeledaefromdruguse   13               2                0.2              4                0                0                 \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,afinitor,38,1299,1301,c    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,afinitor,39,1301,1313,50               4                1                25               2                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,afinitor,40,1313,1320,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,afinitor,41,1320,1374,"\n', '        oselabeledaefromdruguse  25               1                0                6                0                0                 \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  30               1                0                12               0.4              0                 \n', '        oselabeledaefromdruguse  14               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,afinitor,42,1374,1384,5                0.4              2                0.4              0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,afinitor,43,1384,1391,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,afinitor,44,1391,1410,"\n', '        oselabeledaefromdruguse  20               0.8              0                17               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,afinitor,45,1410,1429,"\n', '        oselabeledaefromdruguse  14               0.2              0                10               0.8              0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,afinitor,46,1429,1448,"\n', '        oselabeledaefromdruguse  9                0.4              0                11               2                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,afinitor,47,1448,1455,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,afinitor,48,1455,1498,"\n', '        oselabeledaefromdruguse  22               0.2              0                6                0                0                 \n', '        oselabeledaefromdruguse   21               0.4              0                14               0                0                 \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,afinitor,49,1498,1519,"nonoseaegeneralterm     \n', '        oselabeledaefromdruguse   13               0.2              0                8                0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,afinitor,50,1519,1526,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,afinitor,51,1526,1552,"\n', '        oselabeledaefromdruguse      24               0.6              0                12               0                0                 \n', '        oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,afinitor,52,1552,1562,21               4                0.2              11               0.8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,afinitor,53,1562,1564,0.4               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,afinitor,54,1564,1584,"\n', '        oselabeledaefromdruguse  17               0                0                1                0                0                 \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,afinitor,55,1584,1592,"', '        oselabeledaefromdruguse  d    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,afinitor,56,1592,1611,"19               4                0.2              0.4              0                0                 \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,afinitor,57,1611,1694,"\n', '        oselabeledaefromdruguse       39               1                0                6                0                0                 \n', '        oselabeledaefromdruguse   13               0.2              0                5                0                0                 \n', '        oselabeledaefromdruguse   10               0                0                5                0                0                 \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  6                0                0                14               0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,afinitor,58,1694,1712,"\n', '   Median duration of treatment  e        23.9 weeks       13.4 weeks      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,afinitor,59,1712,1778,"\n', '             Key observed  nonoseaegeneralterm are presented in Table 3.\n', ' \n', '\n', ' Table 3: Key Laboratory Abnormalities Reported in >=10% of Patients with Advanced HR+ BC \n', ' Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,afinitor,60,1778,1810,"Reflects corresponding adverse drug reaction reports of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (collectively as  oselabeledaefromdruguse , which occurred at lower frequency.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,afinitor,61,1810,1823,"\n', '  \n', '   Laboratory parameter      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,afinitor,62,1823,1838,AFINITOR (10 mg/day)    + exemestane  a      N=482      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,afinitor,63,1838,1845,Placebo    + exemestane  a      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,afinitor,64,1845,1847,N=238     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,afinitor,65,1847,1855,"\n', '                    All Grades       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,afinitor,66,1855,1861,Grade 3          Grade 4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,afinitor,67,1861,1870,All Grades       Grade 3          Grade 4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,afinitor,68,1870,1885,"\n', '                    %                %                %                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,afinitor,69,1885,1887,%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,afinitor,70,1887,1922,"\n', '    nonoseaegeneralterm  b       \n', '  oselabeledaefromdruguse  68               6                0.6              40               0.8              0.4               \n', '  oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,afinitor,71,1922,1934,58               1                0                28               5                0.8               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,afinitor,72,1934,1979,"\n', '  oselabeledaefromdruguse  54               3                0.2              5                0                0.4               \n', '  oselabeledaefromdruguse  54               11               0.6              37               5                0.8               \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,afinitor,73,1979,1989,31               2                0                11               0.8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,afinitor,74,1989,1991,0.8               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,afinitor,75,1991,1998,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,afinitor,76,1998,2005,"\n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,afinitor,77,2005,2017,69               9                0.4              44               0.8              0.4               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,afinitor,78,2017,2030,"\n', '  oselabeledaefromdruguse  70               0.6              0.2              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,afinitor,79,2030,2043,"38               0.8              0.8               \n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,afinitor,80,2043,2055,69               4                0.2              45               3                0.4               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,afinitor,81,2055,2087,"\n', '  oselabeledaefromdruguse  51               4                0.2              29               5                0                 \n', '  oselabeledaefromdruguse  50               0.8              0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,afinitor,82,2087,2093,26               0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,afinitor,83,2093,2106,"\n', '  oselabeledaefromdruguse  33               0.8              0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,afinitor,84,2106,2112,16               0.8              0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,afinitor,85,2112,2123,"\n', '  oselabeledaefromdruguse  29               4                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,afinitor,86,2123,2131,0.2              7                1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,afinitor,87,2131,2136,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,afinitor,88,2136,2144,oselabeledaefromdruguse  24               2                0.2              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,afinitor,89,2144,2148,13               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,afinitor,90,2148,2150,0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,afinitor,91,2150,2172,"\n', '               Topical Prophylaxis for Stomatitis  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,afinitor,92,2172,2237,"In a single arm study (SWISH; N=92) in  notaecandidatepreexistingconditionorriskfactor women with  notaecandidateindication beginning AFINITOR (10 mg/day) plus exemestane (25 mg/day), patients started dexamethasone 0.5mg/5mL alcohol-free mouthwash (10 mL swished for 2 minutes and spat, 4 times daily for 8 weeks) concurrently with AFINITOR and exemestane.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
93,afinitor,93,2237,2258,No food or drink was to be consumed for at least 1 hour after swishing and spitting the dexamethasone mouthwash.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,afinitor,94,2258,2280,The primary objective of this study was to assess the incidence of Grade >= 2  nonoseaeaeonlyasinstruction within 8 weeks.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,afinitor,95,2280,2309,"The incidence of Grade >= 2  oselabeledaefromdruguse within 8 weeks was 2%, which was lower than the 33% reported in the BOLERO-2 trial.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,afinitor,96,2309,2320,The incidence of Grade 1  oselabeledaefromdruguse was 19%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,afinitor,97,2320,2333,No cases of Grade 3 or 4  nonoseaenegation were reported.  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
98,afinitor,98,2333,2443,"oselabeledaefromdruguse was reported in 2% of patients in this study compared to 0.2% in the BOLERO-2 trial.\n', '\n', '   6.2     Clinical Study Experience in Advanced Neuroendocrine Tumors\n', '\n', '    Advanced Pancreatic Neuroendocrine Tumors (PNET)  \n', '\n', ' In a randomized, controlled trial (RADIANT-3) of AFINITOR (n=204) versus placebo (n=203) in patients with  notaecandidateindication the median age of patients was 58 years (range 20-87), 79% were White, and 55% were male.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
99,afinitor,99,2443,2500,"Patients on the placebo arm could cross over to open-label AFINITOR upon disease progression.\n', '\n', ' The most common adverse reactions (incidence >= 30%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,afinitor,100,2500,2523,The most common Grade 3-4 adverse reactions (incidence >= 5%) were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,afinitor,101,2523,2551,The most common  nonoseaegeneralterm (incidence >= 50%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse .,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,afinitor,102,2551,2573,The most common Grade 3-4  nonoseaegeneralterm (incidence >= 3%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
103,afinitor,103,2573,2590,"oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,afinitor,104,2590,2618,nonoseaegeneralterm  nonoseaegeneralterm during double-blind treatment where an adverse event was the primary cause occurred in seven patients on AFINITOR and one patient on placebo.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,afinitor,105,2618,2659,"Causes of  nonoseaegeneralterm on the AFINITOR arm included one case of each of the following:  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaegeneralterm  nonoseaegeneralterm (cause unknown),  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
106,afinitor,106,2659,2673,There was one  nonoseaegeneralterm due to  nonoseaeaeonlyasinstruction on the placebo arm.,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,afinitor,107,2673,2722,"After cross-over to open-label AFINITOR, there were three additional  nonoseaegeneralterm  one due to  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction in a patient with  notaecandidatepreexistingconditionorriskfactor  one due to  nonoseaeaeonlyasinstruction with  nonoseaeaeonlyasinstruction  and the other due to  nonoseaeaeonlyasinstruction  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
108,afinitor,108,2722,2750,"The rates of treatment-emergent adverse events resulting in permanent discontinuation were 20% and 6% for the AFINITOR and placebo treatment groups, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,afinitor,109,2750,2769,Dose delay or reduction was necessary in 61% of everolimus patients and 29% of placebo patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,afinitor,110,2769,2792,Grade 3-4  oselabeledaefromdruguse occurred in six patients in the everolimus arm and three patients in the placebo arm.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,afinitor,111,2792,2864,"oselabeledaefromdruguse included five patients with  oselabeledaefromdruguse in the everolimus arm and one in the placebo arm as well as three patients with  oselabeledaefromdruguse in the everolimus arm and two in the placebo arm.\n', '\n', ' Table 4 compares the incidence of treatment-emergent adverse reactions reported with an incidence of >=10% for patients receiving AFINITOR 10 mg daily versus placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,afinitor,112,2864,2900,"\n', '\n', ' Table 4:  Adverse Reactions Reported >=10% of Patients with Advanced PNET  \n', ' Grading according to CTCAE Version 3.0  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,afinitor,113,2900,2902,a   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,afinitor,114,2902,2938,"Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse pain/swelling/ oselabeledaefromdruguse  oselabeledaefromdruguse pain/ oselabeledaefromdruguse ulceration,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   b   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,afinitor,115,2938,2954,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,afinitor,116,2954,2956,c  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,afinitor,117,2956,2967,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,afinitor,118,2967,2979,"\n', '  \n', '                    AFINITOR    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,afinitor,119,2979,2981,N=204      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,afinitor,120,2981,2999,"Placebo    N=203     \n', '                    All Grades       Grade 3          Grade 4          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,afinitor,121,2999,3025,"All Grades       Grade 3          Grade 4         \n', '                    %                %                %                %                %                %               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,afinitor,122,3025,3081,"\n', '   Any adverse reaction      100              49               13               98               32               8               \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  a    70               7                0                20               0                0                 \n', '        oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,afinitor,123,3081,3083,b    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,afinitor,124,3083,3095,50               5                0.5              25               3                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,afinitor,125,3095,3108,"\n', '        oselabeledaefromdruguse  36               4                0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,afinitor,126,3108,3152,"32               6                1                 \n', '        oselabeledaefromdruguse     32               2                0                33               2                0                 \n', '        oselabeledaefromdruguse   29               1                0                21               2                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,afinitor,127,3152,3163,"\n', '        oselabeledaefromdruguse  14               0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,afinitor,128,3163,3165,0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,afinitor,129,3165,3190,"13               0.5              0                 \n', '        oselabeledaefromdruguse  11               0                0                4                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,afinitor,130,3190,3197,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
131,afinitor,131,3197,3208,"\n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  45               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,afinitor,132,3208,3212,3                0.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,afinitor,133,3212,3237,"27               2                0.5               \n', '        oselabeledaefromdruguse (general and  oselabeledaefromdruguse  oselabeledaefromdruguse and peripheral)  39               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,afinitor,134,3237,3241,1                0.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,afinitor,135,3241,3247,12               1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,afinitor,136,3247,3285,"\n', '        oselabeledaefromdruguse      31               0.5              0.5              13               0.5              0                 \n', '        oselabeledaefromdruguse   19               3                0                20               3                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,afinitor,137,3285,3292,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,afinitor,138,3292,3303,"\n', '         oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,afinitor,139,3303,3307,25               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,afinitor,140,3307,3309,0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,afinitor,141,3309,3313,13               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,afinitor,142,3313,3315,0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,afinitor,143,3315,3322,"\n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,afinitor,144,3322,3326,16               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,afinitor,145,3326,3334,0                6                0.5              0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,afinitor,146,3334,3341,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
147,afinitor,147,3341,3360,"\n', '        oselabeledaefromdruguse  28               0.5              0                11               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,afinitor,148,3360,3367,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
149,afinitor,149,3367,3386,"\n', '        oselabeledaefromdruguse  30               1                0                18               1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,afinitor,150,3386,3410,"\n', '        oselabeledaefromdruguse  10               2                0                0.5              0                0                 \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,afinitor,151,3410,3412,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
152,afinitor,152,3412,3431,"\n', '        oselabeledaefromdruguse  15               1                0.5              7                0.5              0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,afinitor,153,3431,3450,"\n', '        oselabeledaefromdruguse  15               1                0                11               1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,afinitor,154,3450,3469,"\n', '        oselabeledaefromdruguse  14               0.5              0                6                1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,afinitor,155,3469,3488,"\n', '        oselabeledaefromdruguse  10               0                0                4                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,afinitor,156,3488,3495,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
157,afinitor,157,3495,3516,"\n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  30               0.5              0                15               1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,afinitor,158,3516,3535,"\n', '        oselabeledaefromdruguse  19               0                0                5                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,afinitor,159,3535,3554,"\n', '        oselabeledaefromdruguse  12               0.5              0                7                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,afinitor,160,3554,3561,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
161,afinitor,161,3561,3568,"\n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,afinitor,162,3568,3580,14               0                0                8                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,afinitor,163,3580,3587,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
164,afinitor,164,3587,3608,"\n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  25               0.5              0                13               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,afinitor,165,3608,3657,"\n', '        oselabeledaefromdruguse  22               0                0                1                0                0                 \n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  20               2                0.5              7                0.5              0                 \n', '        oselabeledaefromdruguse  c    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,afinitor,166,3657,3688,"17               3                0.5              0                0                0                 \n', '        oselabeledaefromdruguse  11               0                0                6                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,afinitor,167,3688,3695,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,afinitor,168,3695,3714,"\n', '        oselabeledaefromdruguse       59               0.5              0                19               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,afinitor,169,3714,3775,"\n', '        oselabeledaefromdruguse  22               0.5              0                2                0                0                 \n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  21               0                0                13               0                0                 \n', '        oselabeledaefromdruguse  oselabeledaefromdruguse  13               0                0                6                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,afinitor,170,3775,3782,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
171,afinitor,171,3782,3801,"\n', '        oselabeledaefromdruguse  13               1                0                6                1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,afinitor,172,3801,3816,"\n', '   Median duration of treatment (wks)      37               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,afinitor,173,3816,3818,16              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,afinitor,174,3818,3878,"\n', '             In female patients aged 18 to 55 years,  oselabeledaefromdruguse occurred in 5 of 46 (11%) AFINITOR-treated females and none of the 33 females in the placebo group.\n', ' \n', '\n', ' Key observed  nonoseaegeneralterm are presented in Table 5.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
175,afinitor,175,3878,3931,"\n', '\n', ' Table 5:  Key Laboratory Abnormalities Reported in >=10% of Patients with Advanced PNET  \n', ' Grading according to CTCAE Version 3.0   \n', '  \n', '   Laboratory parameter      AFINITOR    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,afinitor,176,3931,3935,N=204      Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,afinitor,177,3935,3950,"N=203     \n', '                    All Grades       Grade 3-4        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,afinitor,178,3950,3958,All Grades       Grade 3-4       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,afinitor,179,3958,3976,"\n', '                    %                %                %                %               \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,afinitor,180,3976,3978,nonoseaegeneralterm                                                                          ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
181,afinitor,181,3978,3987,"\n', '        oselabeledaefromdruguse  86               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,afinitor,182,3987,4002,"15               63               1                 \n', '        oselabeledaefromdruguse  45               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,afinitor,183,4002,4004,16               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,afinitor,184,4004,4006,22               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,afinitor,185,4006,4008,4                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,afinitor,186,4008,4023,"\n', '        oselabeledaefromdruguse  45               3                11               0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,afinitor,187,4023,4038,"\n', '        oselabeledaefromdruguse  43               2                13               0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,afinitor,188,4038,4053,"\n', '        oselabeledaefromdruguse  30               4                17               2                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,afinitor,189,4053,4054,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,afinitor,190,4054,4074,"', '                                                                                       \n', '    nonoseaegeneralterm                                                                         \n', '         oselabeledaefromdruguse  74               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
191,afinitor,191,4074,4076,8                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,afinitor,192,4076,4089,"66               8                 \n', '        oselabeledaefromdruguse  75               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,afinitor,193,4089,4091,17               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,afinitor,194,4091,4093,53               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,afinitor,195,4093,4095,6                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,afinitor,196,4095,4102,"\n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,afinitor,197,4102,4106,66               0.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,afinitor,198,4106,4110,22               0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,afinitor,199,4110,4121,"\n', '        oselabeledaefromdruguse  56               0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,afinitor,200,4121,4125,40               0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,afinitor,201,4125,4136,"\n', '        oselabeledaefromdruguse  56               4                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,afinitor,202,4136,4140,41               4                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,afinitor,203,4140,4149,"\n', '        oselabeledaefromdruguse  48               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,afinitor,204,4149,4151,2                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,afinitor,205,4151,4164,"35               2                 \n', '        oselabeledaefromdruguse  40               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,afinitor,206,4164,4168,10               14               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,afinitor,207,4168,4170,3                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,afinitor,208,4170,4181,"\n', '        oselabeledaefromdruguse  39               0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,afinitor,209,4181,4185,10               0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,afinitor,210,4185,4200,"\n', '        oselabeledaefromdruguse  37               0.5              12               0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,afinitor,211,4200,4215,"\n', '        oselabeledaefromdruguse  23               4                5                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,afinitor,212,4215,4237,"\n', '        oselabeledaefromdruguse  19               2                14               0                 \n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,afinitor,213,4237,4241,16               1                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,afinitor,214,4241,4245,16               1                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,afinitor,215,4245,4267,"\n', '        oselabeledaefromdruguse  13               1                8                0                 \n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,afinitor,216,4267,4273,10               1                14               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,afinitor,217,4273,4275,2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,afinitor,218,4275,4329,"\n', '        nonoseaeaeratelteqplacebo  7                0                10               0.5               \n', '             Unresectable, Locally Advanced or Metastatic, Well-Differentiated, Non-Functional Neuroendocrine Tumors of Gastrointestinal or Lung Origin  \n', ' \n', '\n', '",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
219,afinitor,219,4329,4387,"In a randomized, controlled trial (RADIANT-4) of AFINITOR (n=202 treated) versus placebo (n=98 treated) in patients with  notaecandidateindication of GI or lung origin, the median age of patients was 63 years (range 22-86), 76% were White, and 53% were female.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
220,afinitor,220,4387,4420,The median duration of exposure to AFINITOR was 9.3 months; 64% of patients were treated for >= 6 months and 39% were treated for >= 12 months.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,afinitor,221,4420,4601,"AFINITOR was discontinued for adverse reactions in 29% of patients, dose reduction or delay was required in 70% of AFINITOR-treated patients.\n', '\n', ' Serious adverse reactions occurred in 42% of AFINITOR-treated patients and included 3  nonoseaegeneralterm events ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction .\n', '\n', ' Table 6 and Table 7 summarize the incidence of adverse reactions of AFINITOR occurring at an incidence of >=10% and at >=5% absolute incidence over placebo (all Grades) or >=2% higher incidence over placebo (Grade 3 and 4).\n', '\n', ' Table 6: Adverse Reactions in >=10% of AFINITOR-Treated Patients with Non-Functional NET of Gastrointestinal or Lung Origin \n', '     Grading according to NCI CTCAE Version 4.03  a  Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
222,afinitor,222,4601,4613,b   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,afinitor,223,4613,4634,"oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   c  Includes  oselabeledaefromdruguse and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,afinitor,224,4634,4650,"\n', '  \n', '                    AFINITOR    N=202      Placebo    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,afinitor,225,4650,4652,N=98     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,afinitor,226,4652,4660,"\n', '                    All Grades       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,afinitor,227,4660,4666,Grade 3          Grade 4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,afinitor,228,4666,4675,All Grades       Grade 3          Grade 4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,afinitor,229,4675,4690,"\n', '                    %                %                %                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,afinitor,230,4690,4692,%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,afinitor,231,4692,4703,"\n', '   Any adverse reaction      99               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,afinitor,232,4703,4709,57               12               89               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,afinitor,233,4709,4720,"21               7               \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
234,afinitor,234,4720,4735,"\n', '        oselabeledaefromdruguse  a    63               9                0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,afinitor,235,4735,4741,22               0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,afinitor,236,4741,4748,"\n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,afinitor,237,4748,4760,41               8                1                31               2                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,afinitor,238,4760,4779,"\n', '        oselabeledaefromdruguse     26               3                1                17               1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,afinitor,239,4779,4805,"\n', '        oselabeledaefromdruguse   15               4                0                12               2                0                 \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
240,afinitor,240,4805,4831,"\n', '        oselabeledaefromdruguse  39               3                0                6                1                0                 \n', '        oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,afinitor,241,4831,4843,37               4                1                36               1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,afinitor,242,4843,4844,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,afinitor,243,4844,4850,"', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,afinitor,244,4850,4862,23               2                1                8                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,afinitor,245,4862,4869,"\n', '        oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,afinitor,246,4869,4881,23               1                1                8                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,afinitor,247,4881,4888,"\n', '    nonoseaegeneralterm      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
248,afinitor,248,4888,4889,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,afinitor,249,4889,4897,"', '        oselabeledaefromdruguse  b    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,afinitor,250,4897,4914,"58               8                3                29               1                1                 \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,afinitor,251,4914,4916,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
252,afinitor,252,4916,4935,"\n', '        oselabeledaefromdruguse  22               1                0                17               1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,afinitor,253,4935,4942,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
254,afinitor,254,4942,4961,"\n', '        oselabeledaefromdruguse  22               1                0                17               1                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,afinitor,255,4961,4968,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
256,afinitor,256,4968,4987,"\n', '        oselabeledaefromdruguse  18               1                0                4                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,afinitor,257,4987,4994,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
258,afinitor,258,4994,5020,"\n', '        oselabeledaefromdruguse      27               0                0                20               0                0                 \n', '        oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,afinitor,259,5020,5041,"20               3                0                11               1                1                 \n', '        oselabeledaefromdruguse  c    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,afinitor,260,5041,5053,16               2                0                2                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,afinitor,261,5053,5072,"\n', '        oselabeledaefromdruguse  13               1                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,afinitor,262,5072,5079,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
263,afinitor,263,5079,5117,"\n', '        oselabeledaefromdruguse       30               1                0                9                0                0                 \n', '        oselabeledaefromdruguse   17               1                0                9                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,afinitor,264,5117,5130,"\n', '            Table 7: Laboratory Abnormalities in >=",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,afinitor,265,5130,5160,"10% of AFINITOR-Treated Patients with Non-Functional NET of Gastrointestinal or Lung Origin \n', '     Grading according to NCI CTCAE Version 4.03   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,afinitor,266,5160,5176,"\n', '  \n', '                    AFINITOR    N=202      Placebo    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,afinitor,267,5176,5178,N=98     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,afinitor,268,5178,5186,"\n', '                    All Grades       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,afinitor,269,5186,5192,Grade 3          Grade 4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,afinitor,270,5192,5201,All Grades       Grade 3          Grade 4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,afinitor,271,5201,5216,"\n', '                    %                %                %                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,afinitor,272,5216,5218,%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,afinitor,273,5218,5225,"\n', '    nonoseaegeneralterm      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
274,afinitor,274,5225,5244,"\n', '        oselabeledaefromdruguse     81               5                0                41               2                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,afinitor,275,5244,5251,"\n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,afinitor,276,5251,5263,66               15               2                32               2                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,afinitor,277,5263,5327,"\n', '        oselabeledaefromdruguse  49               2                0                17               0                0                 \n', '        oselabeledaefromdruguse  33               2                1                11               0                0                 \n', '        oselabeledaefromdruguse  32               2                0                15               3                0                 \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
278,afinitor,278,5327,5346,"\n', '        oselabeledaefromdruguse  71               0                0                37               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,afinitor,279,5346,5353,"\n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,afinitor,280,5353,5365,57               1                1                34               2                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,afinitor,281,5365,5375,"\n', '        oselabeledaefromdruguse (fasting)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,afinitor,282,5375,5387,55               6                0                36               1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,afinitor,283,5387,5394,"\n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,afinitor,284,5394,5406,46               5                1                39               1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,afinitor,285,5406,5430,"\n', '        oselabeledaefromdruguse  43               4                0                15               2                0                 \n', '        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,afinitor,286,5430,5432,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,afinitor,287,5432,5444,30               3                1                8                1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,afinitor,288,5444,5482,"\n', '        oselabeledaefromdruguse  27               4                2                12               3                0                 \n', '        oselabeledaefromdruguse  18               0                0                8                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,afinitor,289,5482,5540,"\n', '               6.3     Clinical Study Experience in Advanced Renal Cell Carcinoma\n', '   The data described below reflect exposure to AFINITOR (n=274) and placebo (n=137) in a randomized, controlled trial (RECORD-1) in patients with  notaecandidateindication who received prior treatment with sunitinib and/or sorafenib.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
290,afinitor,290,5540,5566,"The median age of patients was 61 years (range 27-85), 88% were Caucasian, and 78% were male.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,afinitor,291,5566,5636,"The median duration of blinded study treatment was 141 days (range 19-451 days) for patients receiving AFINITOR and 60 days (range 21-295 days) for those receiving placebo.\n', '\n', ' The most common adverse reactions (incidence >=30%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,afinitor,292,5636,5671,The most common Grade 3-4 adverse reactions (incidence >=3%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,afinitor,293,5671,5699,The most common  nonoseaegeneralterm (incidence >=50%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
294,afinitor,294,5699,5765,"The most common Grade 3-4  nonoseaegeneralterm (incidence >=3%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   nonoseaegeneralterm due to  oselabeledaefromdruguse (0.7%),  oselabeledaefromdruguse (0.7%), and  oselabeledaefromdruguse (0.4%) were observed on the AFINITOR arm but none on the placebo arm.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
295,afinitor,295,5765,5798,"The rates of treatment-emergent adverse events (irrespective of causality) resulting in permanent discontinuation were 14% and 3% for the AFINITOR and placebo treatment groups, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,afinitor,296,5798,5838,The most common adverse reactions (irrespective of causality) leading to treatment discontinuation were  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were the most common reasons for treatment delay or dose reduction.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,afinitor,297,5838,5857,The most common medical interventions required during AFINITOR treatment were for  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,afinitor,298,5857,5895,"\n', '\n', ' Table 8 compares the incidence of treatment-emergent adverse reactions reported with an incidence of >=10% for patients receiving AFINITOR 10 mg daily versus placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,afinitor,299,5895,5975,"Within each MedDRA system organ class, the adverse reactions are presented in order of decreasing frequency.\n', '\n', ' Table 8: Adverse Reactions Reported in at Least 10% of Patients with RCC and at a Higher Rate in the AFINITOR Arm than in the Placebo Arm \n', ' Grading according to CTCAE Version 3.0  a   oselabeledaefromdruguse (including  oselabeledaefromdruguse , and  oselabeledaefromdruguse and tongue  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,afinitor,300,5975,5977,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,afinitor,301,5977,6060,"b  Includes all preferred terms within the  nonoseaegeneralterm system organ class, the most common being  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%), and  oselabeledaefromdruguse (3%), and also including  oselabeledaefromdruguse (<1%),  oselabeledaefromdruguse (<1%), and  oselabeledaefromdruguse (<1%).  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
302,afinitor,302,6060,6062,c  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,afinitor,303,6062,6078,Includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,afinitor,304,6078,6097,"\n', '  \n', '                    AFINITOR    10 mg/day    N=274      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,afinitor,305,6097,6101,Placebo    N=137     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,afinitor,306,6101,6109,"\n', '                    All Grades       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,afinitor,307,6109,6115,Grade 3          Grade 4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,afinitor,308,6115,6124,All Grades       Grade 3          Grade 4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,afinitor,309,6124,6139,"\n', '                    %                %                %                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,afinitor,310,6139,6141,%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,afinitor,311,6141,6156,"\n', '   Any    a    dverse    r    eaction    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,afinitor,312,6156,6158,97               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,afinitor,313,6158,6162,52               13               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,afinitor,314,6162,6164,93               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,afinitor,315,6164,6168,23               5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,afinitor,316,6168,6175,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
317,afinitor,317,6175,6184,"\n', '        oselabeledaefromdruguse  a    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,afinitor,318,6184,6188,44               4                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,afinitor,319,6188,6204,"<1               8                0                0                 \n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,afinitor,320,6204,6216,30               1                0                7                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,afinitor,321,6216,6235,"\n', '        oselabeledaefromdruguse     26               1                0                19               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,afinitor,322,6235,6242,"\n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,afinitor,323,6242,6254,20               2                0                12               0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,afinitor,324,6254,6255,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,afinitor,325,6255,6302,"', '    nonoseaegeneralterm      b      37               7                3                18               1                0                 \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse   33               3                <1               23               4                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
326,afinitor,326,6302,6322,"\n', '        oselabeledaefromdruguse    31               5                0                27               3                <1                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,afinitor,327,6322,6343,"\n', '        oselabeledaefromdruguse  25               <1               0                8                <1               0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
328,afinitor,328,6343,6350,"\n', '        oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,afinitor,329,6350,6363,20               <1               0                9                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,afinitor,330,6363,6382,"\n', '        oselabeledaefromdruguse  19               1                0                1                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,afinitor,331,6382,6389,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
332,afinitor,332,6389,6396,"\n', '        oselabeledaefromdruguse      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
333,afinitor,333,6396,6398,30               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,afinitor,334,6398,6403,<1               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,afinitor,335,6403,6409,16               0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,afinitor,336,6409,6416,"\n', '        oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,afinitor,337,6416,6447,"24               6                1                15               3                0                 \n', '        oselabeledaefromdruguse  18               0                0                0                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
338,afinitor,338,6447,6448,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
339,afinitor,339,6448,6456,"', '        oselabeledaefromdruguse  c    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,afinitor,340,6456,6468,14               4                0                0                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,afinitor,341,6468,6475,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
342,afinitor,342,6475,6514,"\n', '        oselabeledaefromdruguse       29               1                0                7                0                0                 \n', '        oselabeledaefromdruguse   14               <1               0                7                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,afinitor,343,6514,6539,"\n', '        oselabeledaefromdruguse   13               <1               0                5                0                0                 \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,afinitor,344,6539,6541,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
345,afinitor,345,6541,6566,"\n', '        oselabeledaefromdruguse   25               1                0                14               <1               0                 \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,afinitor,346,6566,6568,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
347,afinitor,347,6568,6577,"\n', '        oselabeledaefromdruguse   19               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,afinitor,348,6577,6635,"<1               <1               9                <1               0                 \n', '        oselabeledaefromdruguse  10               0                0                2                0                0                 \n', '    nonoseaegeneralterm     \n', '        oselabeledaefromdruguse  10               1                0                7                0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
349,afinitor,349,6635,6644,"\n', '   Medi    an    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,afinitor,350,6644,6660,d    uration of    t    reatment (d)      141              60              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,afinitor,351,6660,6873,"\n', '             Other notable adverse reactions occurring more frequently with AFINITOR than with placebo, but with an incidence of <10% include:\n', ' \n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (<1%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (reported as  oselabeledaefromdruguse  (5%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (<1%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (<1%)\n', '",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
352,afinitor,352,6873,7048,"\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (9%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (5%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (2%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (< 1%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (3%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (1%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (3%)\n', '\n', '        nonoseaegeneralterm   oselabeledaefromdruguse (3%)\n', '\n', ' Key  nonoseaegeneralterm are presented in Table 9.\n', '\n', ' Table 9: Key Laboratory Abnormalities Reported in Patients with RCC at a Higher Rate in the AFINITOR Arm than the Placebo Arm",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
353,afinitor,353,7048,7092,"\n', ' Grading according to CTCAE Version 3.0  a  Reflects corresponding adverse drug reaction reports of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (collectively  oselabeledaefromdruguse , which occurred at lower frequency.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
354,afinitor,354,7092,7104,"\n', '  \n', '   Laboratory    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
355,afinitor,355,7104,7108,p    arameter      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,afinitor,356,7108,7115,AFINITOR    10 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,afinitor,357,7115,7117,N=274      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,afinitor,358,7117,7121,Placebo    N=137     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,afinitor,359,7121,7129,"\n', '                    All Grades       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,afinitor,360,7129,7135,Grade 3          Grade 4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,afinitor,361,7135,7144,All Grades       Grade 3          Grade 4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,afinitor,362,7144,7159,"\n', '                    %                %                %                %                %                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,afinitor,363,7159,7161,%               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,afinitor,364,7161,7168,"\n', '    nonoseaegeneralterm      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
365,afinitor,365,7168,7179,"a                                                                                                             \n', '        oselabeledaefromdruguse  92               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,afinitor,366,7179,7254,"12               1                79               5                <1                \n', '        oselabeledaefromdruguse  51               16               2                28               5                0                 \n', '        oselabeledaefromdruguse  23               1                0                2                0                <1                \n', '        oselabeledaefromdruguse  14               0                <1               4                0                0                 \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,afinitor,367,7254,7278,"nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  77               4                0                35               0                0                 \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
368,afinitor,368,7278,7284,'        oselabeledaefromdruguse  73               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,afinitor,369,7284,7289,<1               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,afinitor,370,7289,7293,34               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
371,afinitor,371,7293,7295,0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,afinitor,372,7295,7302,"\n', '        oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
373,afinitor,373,7302,7304,57               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,afinitor,374,7304,7315,15               <1               25               1                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,afinitor,375,7315,7334,"\n', '        oselabeledaefromdruguse  50               1                0                34               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,afinitor,376,7334,7353,"\n', '        oselabeledaefromdruguse  37               6                0                8                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,afinitor,377,7353,7356,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,afinitor,378,7356,7362,'        oselabeledaefromdruguse  25               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,afinitor,379,7362,7402,"<1               <1               7                0                0                 \n', '        oselabeledaefromdruguse  21               1                0                4                0                0                 \n', '        oselabeledaefromdruguse  3                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,afinitor,380,7402,7477,"<1               <1               2                0                0                 \n', '               6.4     Clinical Study Experience in Renal Angiomyolipoma with Tuberous Sclerosis Complex\n', '   The data described below are based on a randomized (2:1), double-blind, placebo-controlled trial (EXIST-2) of AFINITOR in 118 patients with  notaecandidateindication (n=113) or  notaecandidatepreexistingconditionorriskfactor (n=5).",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
381,afinitor,381,7477,7504,"The median age of patients was 31 years (range 18 to 61 years), 89% were Caucasian, and 34% were male.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
382,afinitor,382,7504,7565,"The median duration of blinded study treatment was 48 weeks (range 2 to 115 weeks) for patients receiving AFINITOR and 45 weeks (range 9 to 115 weeks) for those receiving placebo.\n', '\n', ' The most common adverse reaction reported for AFINITOR (incidence >=30%) was  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
383,afinitor,383,7565,7588,The most common Grade 3-4 adverse reactions (incidence >=2%) were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
384,afinitor,384,7588,7610,The most common  nonoseaegeneralterm (incidence >=50%) were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
385,afinitor,385,7610,7628,The most common Grade 3-4  nonoseaegeneralterm (incidence >=3%) was  oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
386,afinitor,386,7628,7655,"\n', '\n', ' The rate of adverse reactions resulting in permanent discontinuation was 3.8% in the AFINITOR-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
387,afinitor,387,7655,7679,Adverse reactions leading to permanent discontinuation in the AFINITOR arm were  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,afinitor,388,7679,7700,Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 52% of AFINITOR-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,afinitor,389,7700,7713,The most common adverse reaction leading to AFINITOR dose adjustment was  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,afinitor,390,7713,7753,"\n', '\n', ' Table 10 compares the incidence of adverse reactions reported with an incidence of >=10% for patients receiving AFINITOR and occurring more frequently with AFINITOR than with placebo.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,afinitor,391,7753,7786,"nonoseaegeneralterm are described separately in Table 11.\n', '\n', ' Table 10: Adverse Reactions Reported in >=10% of AFINITOR-treated Patients with Renal Angiomyolipoma",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
392,afinitor,392,7786,7803,"\n', ' Grading according to CTCAE Version 3.0  a  Includes  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
393,afinitor,393,7803,7815,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,afinitor,394,7815,7829,"\n', '  \n', '                    AFINITOR         N=79      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,afinitor,395,7829,7833,Placebo         N=39     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
396,afinitor,396,7833,7838,"\n', '                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
397,afinitor,397,7838,7843,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
398,afinitor,398,7843,7848,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,afinitor,399,7848,7853,Grade 4    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
400,afinitor,400,7853,7858,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
401,afinitor,401,7858,7863,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
402,afinitor,402,7863,7868,Grade 4    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
403,afinitor,403,7868,7873,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
404,afinitor,404,7873,7901,"Any adverse reaction      100              25               5                97               8                5               \n', '    nonoseaegeneralterm                                                                                                           \n', '        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
405,afinitor,405,7901,7911,oselabeledaefromdruguse  a    78               6                0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
406,afinitor,406,7911,7936,"23               0                0                 \n', '        oselabeledaefromdruguse   15               0                0                5                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
407,afinitor,407,7936,7943,"\n', '        oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,afinitor,408,7943,7955,14               0                0                5                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
409,afinitor,409,7955,7981,"\n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  13               0                0                8                0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
410,afinitor,410,7981,8015,"\n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  11               0                0                5                0                0                 \n', '    nonoseaegeneralterm                                                                                                           \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
411,afinitor,411,8015,8025,"', '        oselabeledaefromdruguse  13               0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
412,afinitor,412,8025,8033,0                5                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
413,afinitor,413,8033,8035,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,afinitor,414,8035,8120,", '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse      20               0                0                13               0                0                 \n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse       22               0                0                5                0                0                 \n', '              oselabeledaefromdruguse occurred in 15% of AFINITOR-treated females (8 of 52) and 4% (1 of 26) of females in the placebo group.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
415,afinitor,415,8120,8261,"Other adverse reactions involving the female reproductive system were  oselabeledaefromdruguse (10%),  oselabeledaefromdruguse (10%), and  oselabeledaefromdruguse (8%).\n', ' \n', '\n', ' The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients:  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (1%).\n', '\n', ' Table 11:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,afinitor,416,8261,8273,Key Laboratory Abnormalities Reported in AFINITOR-treated Patients with Renal Angiomyolipoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
417,afinitor,417,8273,8298,"\n', ' Grading according to CTCAE Version 3.0   \n', '  \n', '                    AFINITOR         N=79      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
418,afinitor,418,8298,8302,Placebo         N=39     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
419,afinitor,419,8302,8307,"\n', '                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
420,afinitor,420,8307,8312,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
421,afinitor,421,8312,8317,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
422,afinitor,422,8317,8322,Grade 4    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
423,afinitor,423,8322,8327,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
424,afinitor,424,8327,8332,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
425,afinitor,425,8332,8337,Grade 4    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
426,afinitor,426,8337,8382,"\n', '    nonoseaegeneralterm                                                                                                            \n', '        oselabeledaefromdruguse     61               0                0                49               0                0                 \n', '        oselabeledaefromdruguse  37               0                0                21               0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
427,afinitor,427,8382,8393,"\n', '        nonoseaeaeratelteqplacebo  25               0                ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
428,afinitor,428,8393,8395,1                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
429,afinitor,429,8395,8401,26               0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
430,afinitor,430,8401,8420,"\n', '        oselabeledaefromdruguse  20               1                0                8                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
431,afinitor,431,8420,8439,"\n', '        oselabeledaefromdruguse  19               0                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
432,afinitor,432,8439,8489,"\n', '                                                                                                                         \n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  85               1                0                46               0                0                 \n', '        oselabeledaefromdruguse  52               0                0                10               0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
433,afinitor,433,8489,8570,"\n', '        oselabeledaefromdruguse  49               5                0                15               0                0                 \n', '        oselabeledaefromdruguse  32               1                0                10               0                0                 \n', '        oselabeledaefromdruguse   23               1                0                8                0                0                 \n', '        oselabeledaefromdruguse   20               1                0                15               0                0                 \n', '        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
434,afinitor,434,8570,8584,oselabeledaefromdruguse  14               0                0                8                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
435,afinitor,435,8584,8750,"\n', '             Updated safety information from 112 patients treated with AFINITOR for a median duration of 3.9 years identified the following additional adverse reactions and key  nonoseaegeneralterm   oselabeledaefromdruguse (63%),  oselabeledaefromdruguse (40%),  oselabeledaefromdruguse (38%),  oselabeledaefromdruguse (31%),  oselabeledaefromdruguse (18%),  oselabeledaefromdruguse (16%),  oselabeledaefromdruguse (12%),  oselabeledaefromdruguse (12%),  oselabeledaefromdruguse (11%), and  oselabeledaefromdruguse (10%).\n', ' \n', '\n', '   6.5     Clinical Study Experience in Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex\n', '\n', '  The data described below are based on a randomized (2:1), double-blind, placebo-controlled trial (EXIST-1) of AFINITOR in 117 patients with  notaecandidateindication .",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
436,afinitor,436,8750,8777,"The median age of patients was 9.5 years (range 0.8 to 26 years), 93% were Caucasian, and 57% were male.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
437,afinitor,437,8777,8841,"The median duration of blinded study treatment was 52 weeks (range 24 to 89 weeks) for patients receiving AFINITOR and 47 weeks (range 14 to 88 weeks) for those receiving placebo.\n', '\n', ' The most common adverse reactions reported for AFINITOR (incidence >= 30%) were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
438,afinitor,438,8841,8875,The most common Grade 3-4 adverse reactions (incidence >=2%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
439,afinitor,439,8875,8895,The most common key  nonoseaegeneralterm (incidence >=50%) were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
440,afinitor,440,8895,8913,The most common Grade 3-4  nonoseaegeneralterm (incidence >=3%) was  oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
441,afinitor,441,8913,8931,"\n', '\n', ' There were no adverse reactions resulting in permanent discontinuation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
442,afinitor,442,8931,8952,Dose adjustments (interruptions or reductions) due to adverse reactions occurred in 55% of AFINITOR-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
443,afinitor,443,8952,8965,The most common adverse reaction leading to AFINITOR dose adjustment was  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
444,afinitor,444,8965,9005,"\n', '\n', ' Table 12 compares the incidence of adverse reactions reported with an incidence of >=10% for patients receiving AFINITOR and occurring more frequently with AFINITOR than with placebo.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
445,afinitor,445,9005,9074,"nonoseaegeneralterm are described separately in Table 13.\n', '\n', ' Table 12: Adverse Reactions Reported in >= 10% of AFINITOR-treated Patients with SEGA in EXIST-1 \n', ' Grading according to CTCAE Version 3.0  a  Includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  b  Includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
446,afinitor,446,9074,9078,c  Includes  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
447,afinitor,447,9078,9088,oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  d  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
448,afinitor,448,9088,9090,Includes  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
449,afinitor,449,9090,9104,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
450,afinitor,450,9104,9108,e  Includes  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
451,afinitor,451,9108,9124,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
452,afinitor,452,9124,9138,"\n', '  \n', '                    AFINITOR    N=78      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
453,afinitor,453,9138,9142,Placebo    N=39     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
454,afinitor,454,9142,9147,"\n', '                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
455,afinitor,455,9147,9152,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
456,afinitor,456,9152,9157,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
457,afinitor,457,9157,9162,Grade 4    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
458,afinitor,458,9162,9167,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
459,afinitor,459,9167,9172,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
460,afinitor,460,9172,9177,Grade 4    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
461,afinitor,461,9177,9188,"\n', '    nonoseaegeneralterm      97               36               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
462,afinitor,462,9188,9190,3                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
463,afinitor,463,9190,9192,92               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
464,afinitor,464,9192,9196,23               3               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
465,afinitor,465,9196,9218,"\n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  a    62               9                0                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
466,afinitor,466,9218,9224,26               3                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
467,afinitor,467,9224,9243,"\n', '        oselabeledaefromdruguse   22               1                0                13               0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
468,afinitor,468,9243,9262,"\n', '        oselabeledaefromdruguse   17               0                0                5                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
469,afinitor,469,9262,9281,"\n', '        oselabeledaefromdruguse  10               0                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
470,afinitor,470,9281,9282,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
471,afinitor,471,9282,9297,"', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  b    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
472,afinitor,472,9297,9307,31               1                1                23               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
473,afinitor,473,9307,9309,0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
474,afinitor,474,9309,9310,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
475,afinitor,475,9310,9318,"', '        oselabeledaefromdruguse  c    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
476,afinitor,476,9318,9330,10               4                1                3                0                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
477,afinitor,477,9330,9349,"\n', '        oselabeledaefromdruguse  10               0                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
478,afinitor,478,9349,9363,"\n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
479,afinitor,479,9363,9375,23               6                0                18               3                0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
480,afinitor,480,9375,9394,"\n', '        oselabeledaefromdruguse    14               0                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
481,afinitor,481,9394,9395,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
482,afinitor,482,9395,9416,"', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse   oselabeledaefromdruguse or other  oselabeledaefromdruguse  d    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
483,afinitor,483,9416,9510,"21               5                0                3                0                0                 \n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  e    21               0                0                8                0                0                 \n', '        oselabeledaefromdruguse       10               0                0                5                0                0                 \n', '              oselabeledaefromdruguse occurred in 17% of AFINITOR-treated females aged 10 to 55 years (3 of 18) and none of the females in the placebo group.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
484,afinitor,484,9510,9636,"For this same group of AFINITOR-treated females, the following  oselabeledaefromdruguse were reported:  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%), and  oselabeledaefromdruguse (6%).\n', ' \n', '\n', ' The following additional adverse reactions occurred in less than 10% of AFINITOR-treated patients:  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (1%) and  oselabeledaefromdruguse (1%).\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
485,afinitor,485,9636,9644,"'\n', ' Table 13:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
486,afinitor,486,9644,9682,"Key Laboratory Abnormalities Reported in AFINITOR-treated Patients with SEGA in EXIST-1 \n', ' Grading according to CTCAE Version 3.0   \n', '  \n', '                    AFINITOR    N=78      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
487,afinitor,487,9682,9686,Placebo    N=39     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
488,afinitor,488,9686,9691,"\n', '                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
489,afinitor,489,9691,9696,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
490,afinitor,490,9696,9701,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
491,afinitor,491,9701,9706,Grade 4    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
492,afinitor,492,9706,9711,All Grades    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
493,afinitor,493,9711,9716,Grade 3    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
494,afinitor,494,9716,9721,Grade 4    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
495,afinitor,495,9721,9849,"\n', '    nonoseaegeneralterm                                                                                                            \n', '        oselabeledaefromdruguse  72               3                0                44               5                0                 \n', '        oselabeledaefromdruguse  46               9                0                41               3                0                 \n', '        oselabeledaefromdruguse     41               0                0                21               0                0                 \n', '    nonoseaegeneralterm                                                                                                           \n', '        oselabeledaefromdruguse  81               0                0                39               0                0                 \n', '        oselabeledaefromdruguse   33               0                0                0                0                0                 \n', '        oselabeledaefromdruguse  27               0                0                15               0                0                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
496,afinitor,496,9849,9868,"\n', '        oselabeledaefromdruguse   18               0                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
497,afinitor,497,9868,9887,"\n', '        oselabeledaefromdruguse  9                1                0                3                0                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
498,afinitor,498,9887,10025,"\n', '             Updated safety information from 111 patients treated with AFINITOR for a median duration of 47 months identified the following additional notable adverse reactions and key  nonoseaegeneralterm   oselabeledaefromdruguse (14%),  oselabeledaefromdruguse (13%),  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (5%), and  oselabeledaefromdruguse (1%).\n', ' \n', '\n', '   6.6     Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post approval use of AFINITOR.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
499,afinitor,499,10025,10057,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
500,afinitor,500,10057,10118,"oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse with some cases reported with  nonoseaemanifestationorcomplication (including  nonoseaemanifestationorcomplication    5     WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Non-infectious pneumonitis: Monitor for clinical symptoms or radiological changes; fatal cases have occurred.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
501,afinitor,501,10118,10134,"Manage by dose reduction or discontinuation until symptoms resolve, and consider use of corticosteroids.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
502,afinitor,502,10134,10139,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
503,afinitor,503,10139,10155,"\n', ' *  Infections: Increased risk of infections, some fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
504,afinitor,504,10155,10165,"Monitor for signs and symptoms, and treat promptly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
505,afinitor,505,10165,10170,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
506,afinitor,506,10170,10174,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
507,afinitor,507,10174,10178,*  Angioedema:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
508,afinitor,508,10178,10192,Patients taking concomitant ACE inhibitor therapy may be at increased risk for angioedema.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
509,afinitor,509,10192,10222,"(  5.3  ) \n', ' *  Stomatitis: Stomatitis, including mouth ulcers and oral mucositis, occurs in most patients treated with AFINITOR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
510,afinitor,510,10222,10240,Initiation of topical treatment with dexamethasone mouthwash when starting AFINITOR reduces the incidence and severity of stomatitis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
511,afinitor,511,10240,10279,"(  5.4  ,  6.1  ) \n', ' *  Renal failure: Cases of renal failure (including acute renal failure), some with a fatal outcome, have been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
512,afinitor,512,10279,10302,"(  5.5  ) \n', ' *  Impaired wound healing: Increased risk of wound-related complications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
513,afinitor,513,10302,10307,Monitor signs and symptoms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
514,afinitor,514,10307,10316,Exercise caution in the peri-surgical period.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
515,afinitor,515,10316,10347,"(  5.6  ) \n', ' *  Laboratory test alterations: Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
516,afinitor,516,10347,10359,"Decreases in hemoglobin, neutrophils, and platelets may also occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
517,afinitor,517,10359,10378,"Monitor renal function, blood glucose, lipids, and hematologic parameters prior to treatment and periodically thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
518,afinitor,518,10378,10405,"(  5.8  ) \n', ' *  Vaccinations: Avoid live vaccines and close contact with those who have received live vaccines.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
519,afinitor,519,10405,10410,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
520,afinitor,520,10410,10426,"\n', ' *  Embryo-Fetal Toxicity: Can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
521,afinitor,521,10426,10444,Advise patients of reproductive potential of the potential risk to a fetus and to use effective contraception.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
522,afinitor,522,10444,10457,"(  5.12  ,  8.1  ,  8.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
523,afinitor,523,10457,10502,"\n', '    \n', ' \n', '\n', '   5.1     Non-infectious Pneumonitis\n', '\n', '   oselabeledaefromdruguse is a class effect of rapamycin derivatives, including AFINITOR.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
524,afinitor,524,10502,10535,"oselabeledaefromdruguse was reported in up to 19% of patients treated with AFINITOR in clinical trials, some cases reported with  oselabeledaefromdruguse (including  oselabeledaefromdruguse  as a secondary event.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
525,afinitor,525,10535,10581,"The incidence of Common Terminology Criteria (CTC) Grade 3 and 4  oselabeledaefromdruguse was up to 4.0% and up to 0.2%, respectively [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
526,afinitor,526,10581,10644,"nonoseaegeneralterm outcomes have been observed.\n', '\n', ' Consider a diagnosis of  nonoseaeaeonlyasinstruction in patients presenting with non-specific respiratory signs and symptoms such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication  and in whom  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and other causes have been excluded by means of appropriate investigations.  ",1,1,1,0,1,0,0,0,0,0,0,0,0,0,0
527,afinitor,527,10644,10658,nonoseaeaeonlyasinstruction such as  nonoseaeaeonlyasinstruction  should be considered in the differential diagnosis.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
528,afinitor,528,10658,10699,"Advise patients to report promptly any new or  nonoseaeaeonlyasinstruction \n', '\n', ' Patients who develop radiological changes suggestive of  nonoseaeaeonlyasinstruction and have few or no symptoms may continue AFINITOR therapy without dose alteration.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
529,afinitor,529,10699,10729,"Imaging appears to overestimate the incidence of clinical  nonoseaeaeonlyasinstruction \n', '\n', ' If symptoms are moderate, consider interrupting therapy until symptoms improve.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
530,afinitor,530,10729,10737,The use of corticosteroids may be indicated.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
531,afinitor,531,10737,10767,AFINITOR may be reintroduced at a daily dose approximately 50% lower than the dose previously administered [see Table 1 in Dosage and Administration (2.2)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
532,afinitor,532,10767,10796,".\n', '\n', ' For cases of Grade 3  nonoseaeaeonlyasinstruction  interrupt AFINITOR until resolution to less than or equal to Grade 1.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
533,afinitor,533,10796,10832,AFINITOR may be re-introduced at a daily dose approximately 50% lower than the dose previously administered depending on the individual clinical circumstances [see Dosage and Administration (2.2)]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
534,afinitor,534,10832,10844,"If toxicity recurs at Grade 3, consider discontinuation of AFINITOR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
535,afinitor,535,10844,10855,For cases of Grade 4  nonoseaeaeonlyasinstruction  discontinue AFINITOR.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
536,afinitor,536,10855,10864,Corticosteroids may be indicated until clinical symptoms resolve.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
537,afinitor,537,10864,10885,For patients who require use of corticosteroids for treatment of  nonoseaeaeonlyasinstruction  prophylaxis for  nonoseaeaeonlyasinstruction may be considered.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
538,afinitor,538,10885,10930,"The development of  oselabeledaefromdruguse has been reported even at a reduced dose.\n', '\n', '    5.2     Infections\n', '\n', '  AFINITOR has  oselabeledaefromdruguse properties and may predispose patients to  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
539,afinitor,539,10930,10948,"fungal, viral, or protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  viral, or protozoal  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
540,afinitor,540,10948,10960,oselabeledaefromdruguse  or protozoal  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
541,afinitor,541,10960,10979,"[see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
542,afinitor,542,10979,11023,oselabeledaefromdruguse and systemic  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse  other  oselabeledaefromdruguse   oselabeledaefromdruguse  such as  oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse  and  oselabeledaefromdruguse including  oselabeledaefromdruguse have occurred in patients taking AFINITOR.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
543,afinitor,543,11023,11067,"Some of these  nonoseaeaeonlyasinstruction have been severe (e.g., leading to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or hepatic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  or  nonoseaegeneralterm  Physicians and patients should be aware of the increased risk of  nonoseaeaeonlyasinstruction with AFINITOR.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
544,afinitor,544,11067,11082,Complete treatment of pre-existing  notaecandidatepreexistingconditionorriskfactor prior to starting treatment with AFINITOR.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
545,afinitor,545,11082,11118,"While taking AFINITOR, be vigilant for signs and symptoms of  nonoseaeaeonlyasinstruction  if a diagnosis of an  nonoseaeaeonlyasinstruction is made, institute appropriate treatment promptly and consider interruption or discontinuation of AFINITOR.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
546,afinitor,546,11118,11161,"If a diagnosis of  nonoseaeaeonlyasinstruction is made, discontinue AFINITOR and treat with appropriate antifungal therapy.\n', '\n', '  oselabeledaefromdruguse  some with a  nonoseaegeneralterm outcome, has been reported in patients who received everolimus.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
547,afinitor,547,11161,11176,This may be associated with concomitant use of corticosteroids or other  nonoseaeaeonlyasinstruction agents.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
548,afinitor,548,11176,11260,"Prophylaxis for  nonoseaeaeonlyasinstruction should be considered when concomitant use of corticosteroids or other  nonoseaeaeonlyasinstruction agents are required.\n', '\n', '    5.3     Angioedema with Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors\n', '\n', '  Patients taking concomitant ACE inhibitor therapy may be at increased risk for  nonoseaeaefromdruginteraction (e.g.,  nonoseaeaefromdruginteraction airways or  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction or tongue, with or without  nonoseaeaefromdruginteraction .",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
549,afinitor,549,11260,11349,"In a pooled analysis of randomized double-blind oncology clinical trials, the incidence of  nonoseaeaefromdruginteraction in patients taking everolimus with an ACE inhibitor was 6.8% compared to 1.3% in the control arm with an ACE inhibitor.\n', '\n', '    5.4     Stomatitis\n', '\n', '    oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  has occurred in patients treated with AFINITOR at an incidence ranging from 44%-78% across the clinical trial experience.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
550,afinitor,550,11349,11381,"Grade 3 or 4  oselabeledaefromdruguse was reported in 4%-9% of patients [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
551,afinitor,551,11381,11393,oselabeledaefromdruguse most often occurs within the first 8 weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
552,afinitor,552,11393,11436,"When starting AFINITOR, initiating dexamethasone alcohol-free oral solution as a swish and spit mouthwash reduces the incidence and severity of  nonoseaeaeonlyasinstruction [see Adverse Reactions (6.1) and Use in Specific Populations (8.4)]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
553,afinitor,553,11436,11482,"If  nonoseaeaeonlyasinstruction does occur, mouthwashes and/or other topical treatments are recommended, but alcohol-, hydrogen peroxide-, iodine-, or thyme- containing products should be avoided as they may exacerbate the condition [see Dosage and Administration (2.2)]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
554,afinitor,554,11482,11505,Antifungal agents should not be used unless  nonoseaeaeonlyasinstruction has been diagnosed [see Drug Interactions (7.1)]  .  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
555,afinitor,555,11505,11561,"\n', '\n', '    5.5     Renal Failure\n', '\n', '  Cases of  oselabeledaefromdruguse (including  oselabeledaefromdruguse , some with a  nonoseaegeneralterm outcome, have been observed in patients treated with AFINITOR [see Laboratory Tests and Monitoring (5.8)]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
556,afinitor,556,11561,11607,".\n', '\n', '    5.6     Impaired Wound Healing\n', '\n', '  Everolimus  oselabeledaefromdruguse and increases the occurrence of  oselabeledaefromdruguse like  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
557,afinitor,557,11607,11615,These  nonoseaeaeonlyasinstruction may require surgical intervention.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
558,afinitor,558,11615,11682,"Exercise caution with the use of AFINITOR in the peri-surgical period.\n', '\n', '    5.7     Geriatric Patients\n', '\n', '  In the randomized advanced  notaecandidateindication study (BOLERO-2), the incidence of  nonoseaegeneralterm due to any cause within 28 days of the last AFINITOR dose was 6% in patients >",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
559,afinitor,559,11682,11699,= 65 years of age compared to 2% in patients < 65 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
560,afinitor,560,11699,11730,Adverse reactions leading to permanent treatment discontinuation occurred in 33% of patients >= 65 years of age compared to 17% in patients < 65 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
561,afinitor,561,11730,11759,"Careful monitoring and appropriate dose adjustments for adverse reactions are recommended [see Dosage and Administration (2.2), Use in Specific Populations (8.5)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
562,afinitor,562,11759,11761,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
563,afinitor,563,11761,11823,", '\n', '    5.8     Laboratory Tests and Monitoring\n', '\n', '   Renal Function  \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
564,afinitor,564,11823,11858,"Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of AFINITOR therapy and periodically thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
565,afinitor,565,11858,11877,Renal function of patients should be monitored particularly where patients have additional risk factors that may further  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
566,afinitor,566,11877,11932,"\n', '\n', '  Blood Glucose and Lipids  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
567,afinitor,567,11932,11961,Monitoring of fasting serum glucose and lipid profile is recommended prior to the start of AFINITOR therapy and periodically thereafter as well as management with appropriate medical therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
568,afinitor,568,11961,11981,More frequent monitoring is recommended when AFINITOR is co-administered with other drugs that may induce  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
569,afinitor,569,11981,12009,"When possible, optimal glucose and lipid control should be achieved before starting a patient on AFINITOR.\n', '\n', '  Hematologic Parameters  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
570,afinitor,570,12009,12051,"\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse hemoglobin,  oselabeledaefromdruguse  oselabeledaefromdruguse hemoglobin, lymphocytes,  oselabeledaefromdruguse  oselabeledaefromdruguse hemoglobin, lymphocytes, neutrophils, and  oselabeledaefromdruguse have been reported in patients taking AFINITOR",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
571,afinitor,571,12051,12069,"[see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
572,afinitor,572,12069,12323,"Monitoring of complete blood count is recommended prior to the start of AFINITOR therapy and periodically thereafter.\n', '\n', '    5.9     Drug-Drug Interactions\n', '\n', '  Due to significant increases in exposure of everolimus, co-administration with strong CYP3A4/PgP inhibitors should be avoided  [see Dosage and Administration (2.2, 2.5) and Drug Interactions (7.1)]  .\n', '\n', ' A reduction of the AFINITOR dose is recommended when co-administered with a moderate CYP3A4/PgP inhibitor [see Dosage and Administration (2.2, 2.5) and Drug Interactions (7.1)]  .\n', '\n', ' An increase in the AFINITOR dose is recommended when co-administered with a strong CYP3A4/PgP inducer [see Dosage and Administration (2.2, 2.5) and Drug Interactions (7.2)]  .\n', '\n', '    5.10     Hepatic Impairment\n', '\n', '  Exposure to everolimus was increased in patients with  notaecandidatepreexistingconditionorriskfactor  [see Clinical Pharmacology (12.3)]  .\n', '\n', ' For  notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication  notaecandidateindication patients with severe  notaecandidatepreexistingconditionorriskfactor (Child-Pugh class C), AFINITOR may be used at a reduced dose if the desired benefit outweighs the risk.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
573,afinitor,573,12323,12367,For patients with mild (Child-Pugh class A) or moderate (Child-Pugh class B)  notaecandidatepreexistingconditionorriskfactor  a dose reduction is recommended [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
574,afinitor,574,12367,12402,".\n', '\n', ' For patients with  notaecandidateindication and mild or moderate  notaecandidatepreexistingconditionorriskfactor  adjust the dose of AFINITOR Tablets or AFINITOR DISPERZ based on therapeutic drug monitoring.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
575,afinitor,575,12402,12447,"For patients with  notaecandidateindication and severe  notaecandidatepreexistingconditionorriskfactor  reduce the starting dose of AFINITOR Tablets or AFINITOR DISPERZ by approximately 50% and adjust subsequent doses based on therapeutic drug monitoring [see Dosage and Administration (2.4, 2.5)]  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
576,afinitor,576,12447,12614,".\n', '\n', '    5.11     Vaccinations\n', '\n', '  During AFINITOR treatment, avoid the use of live vaccines and avoid close contact with individuals who have received live vaccines (e.g.,  nonoseaeaeonlyasinstruction  measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  oral polio, BCG, yellow fever, varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  BCG, yellow fever, varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  yellow fever, varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  varicella, and TY21a typhoid  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
577,afinitor,577,12614,12625,nonoseaeaeonlyasinstruction  and TY21a typhoid  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction .\n',1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
578,afinitor,578,12625,12671,", '\n', ' For pediatric patients with  notaecandidateindication that do not require immediate treatment, complete the recommended childhood series of live virus vaccinations according to American Council on Immunization Practices (ACIP) guidelines prior to the start of therapy.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
579,afinitor,579,12671,12726,"An accelerated vaccination schedule may be appropriate.\n', '\n', '    5.12      oselabeledaefromdruguse \n', '   Based on animal studies and the mechanism of action [see Clinical Pharmacology (12.1)]  , AFINITOR can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
580,afinitor,580,12726,12761,"In animal studies, everolimus caused  nonoseaeaeanimal in rats when administered during the period of organogenesis at maternal exposures that were lower than human exposures at the clinical dose of 10 mg daily.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
581,afinitor,581,12761,12771,Advise  notaecandidatepreexistingconditionorriskfactor women of the potential  nonoseaeaeonlyasinstruction   ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
582,afinitor,582,12771,12793,"\n', '\n', '  Advise female patients of reproductive potential to avoid becoming  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,carac,0,0,51,"['  ADVERSE REACTIONS\n', '\n', '  The following were adverse events considered to be drug related and occurring with a frequency of >=1% with Carac:  oselabeledaefromdruguse (94.6%), and  oselabeledaefromdruguse (5.4%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,carac,1,51,78,"The signs and symptoms of  oselabeledaefromdruguse (i.e.,  oselabeledaefromdruguse  are presented below.\n', '\n', ' Summary of  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,carac,2,78,87,Irritation Signs and Symptoms - Pooled Phase 3 Studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,carac,3,87,118,"\n', '   Clinical Sign or Symptom      Active    1 Week    N=85      Active    2 Week    N=87      Active    4 Week    N=85      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,carac,4,118,124,ALL Active Treatments    N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,carac,5,124,127,Vehicle Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,carac,6,127,177,"N=127     \n', '                 n      (%)        n      (%)        n      (%)         n        (%)        n       (%)       \n', '  \n', '   oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,carac,7,177,186,Irritation Signs and Symptoms - Pooled Phase 3 Studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,carac,8,186,217,"\n', '   Clinical Sign or Symptom      Active    1 Week    N=85      Active    2 Week    N=87      Active    4 Week    N=85      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,carac,9,217,223,ALL Active Treatments    N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,carac,10,223,226,Vehicle Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,carac,11,226,277,"N=127     \n', '                 n      (%)        n      (%)        n      (%)         n        (%)        n       (%)       \n', '  \n', '  Erythema      76     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,carac,12,277,313,"(89.4)     82     (94.3)     82     (96.5)      240      (93.4)     76      (59.8)     \n', '   oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,carac,13,313,322,Irritation Signs and Symptoms - Pooled Phase 3 Studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,carac,14,322,353,"\n', '   Clinical Sign or Symptom      Active    1 Week    N=85      Active    2 Week    N=87      Active    4 Week    N=85      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,carac,15,353,359,ALL Active Treatments    N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,carac,16,359,362,Vehicle Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,carac,17,362,413,"N=127     \n', '                 n      (%)        n      (%)        n      (%)         n        (%)        n       (%)       \n', '  \n', '  Erythema      76     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,carac,18,413,468,"(89.4)     82     (94.3)     82     (96.5)      240      (93.4)     76      (59.8)     \n', '  Dryness       59     (69.4)     76     (87.4)     79     (92.9)      214      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,carac,19,468,478,(83.3)     60      (47.2)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,carac,20,478,486,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,carac,21,486,495,Irritation Signs and Symptoms - Pooled Phase 3 Studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,carac,22,495,526,"\n', '   Clinical Sign or Symptom      Active    1 Week    N=85      Active    2 Week    N=87      Active    4 Week    N=85      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,carac,23,526,532,ALL Active Treatments    N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,carac,24,532,535,Vehicle Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,carac,25,535,586,"N=127     \n', '                 n      (%)        n      (%)        n      (%)         n        (%)        n       (%)       \n', '  \n', '  Erythema      76     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,carac,26,586,641,"(89.4)     82     (94.3)     82     (96.5)      240      (93.4)     76      (59.8)     \n', '  Dryness       59     (69.4)     76     (87.4)     79     (92.9)      214      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,carac,27,641,651,(83.3)     60      (47.2)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,carac,28,651,676,"\n', '  Burning       51     (60.0)     70     (80.5)     71     (83.5)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,carac,29,676,684,192      (74.7)     28      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,carac,30,684,696,"(22.0)     \n', '   oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,carac,31,696,705,Irritation Signs and Symptoms - Pooled Phase 3 Studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,carac,32,705,736,"\n', '   Clinical Sign or Symptom      Active    1 Week    N=85      Active    2 Week    N=87      Active    4 Week    N=85      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,carac,33,736,742,ALL Active Treatments    N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,carac,34,742,745,Vehicle Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,carac,35,745,796,"N=127     \n', '                 n      (%)        n      (%)        n      (%)         n        (%)        n       (%)       \n', '  \n', '  Erythema      76     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,carac,36,796,851,"(89.4)     82     (94.3)     82     (96.5)      240      (93.4)     76      (59.8)     \n', '  Dryness       59     (69.4)     76     (87.4)     79     (92.9)      214      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,carac,37,851,861,(83.3)     60      (47.2)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,carac,38,861,886,"\n', '  Burning       51     (60.0)     70     (80.5)     71     (83.5)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,carac,39,886,894,192      (74.7)     28      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,carac,40,894,931,"(22.0)     \n', '  Erosion       21     (24.7)     38     (43.7)     54     (63.5)      113      (44.0)     17      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,carac,41,931,935,(13.4)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,carac,42,935,943,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,carac,43,943,952,Irritation Signs and Symptoms - Pooled Phase 3 Studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,carac,44,952,983,"\n', '   Clinical Sign or Symptom      Active    1 Week    N=85      Active    2 Week    N=87      Active    4 Week    N=85      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,carac,45,983,989,ALL Active Treatments    N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,carac,46,989,992,Vehicle Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,carac,47,992,1043,"N=127     \n', '                 n      (%)        n      (%)        n      (%)         n        (%)        n       (%)       \n', '  \n', '  Erythema      76     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,carac,48,1043,1098,"(89.4)     82     (94.3)     82     (96.5)      240      (93.4)     76      (59.8)     \n', '  Dryness       59     (69.4)     76     (87.4)     79     (92.9)      214      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,carac,49,1098,1108,(83.3)     60      (47.2)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,carac,50,1108,1133,"\n', '  Burning       51     (60.0)     70     (80.5)     71     (83.5)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,carac,51,1133,1141,192      (74.7)     28      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,carac,52,1141,1178,"(22.0)     \n', '  Erosion       21     (24.7)     38     (43.7)     54     (63.5)      113      (44.0)     17      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,carac,53,1178,1182,(13.4)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,carac,54,1182,1219,"\n', '  Pain          26     (30.6)     34     (39.1)     52     (61.2)      112      (43.6)     7       (5.5)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,carac,55,1219,1232,"\n', '   oselabeledaefromdruguse         12     (14.1)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,carac,56,1232,1240,28     (32.2)     51     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,carac,57,1240,1256,(60.0)      91       (35.4)     6       (4.7)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,carac,58,1256,1261,"\n', '                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,carac,59,1261,1280,"During clinical trials,  oselabeledaefromdruguse generally began on Day 4 and persisted for the remainder of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,carac,60,1280,1321,"Severity of  oselabeledaefromdruguse  oselabeledaefromdruguse at the last treatment visit was slightly below baseline for the vehicle group, mild to moderate for the 1-week active treatment group, and moderate for the 2- and 4-week active treatment groups.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,carac,61,1321,1390,"Mean severity declined rapidly for each active group after completion of treatment and was below baseline for each group at the Week 2 post-treatment follow-up visit.\n', ' \n', '\n', ' Thirty-one patients (12% of those treated with Carac in the Phase 3 clinical studies) discontinued study treatment early due to  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,carac,62,1390,1532,"Except for three patients, discontinuation of treatment occurred on or after Day 11 of treatment.\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse irritation adverse events, described as mild to moderate in intensity, were characterized as  oselabeledaefromdruguse  oselabeledaefromdruguse irritation adverse events, described as mild to moderate in intensity, were characterized as burning,  oselabeledaefromdruguse  oselabeledaefromdruguse irritation adverse events, described as mild to moderate in intensity, were characterized as burning, watering,  oselabeledaefromdruguse  oselabeledaefromdruguse irritation adverse events, described as mild to moderate in intensity, were characterized as burning, watering, sensitivity,  oselabeledaefromdruguse  oselabeledaefromdruguse irritation adverse events, described as mild to moderate in intensity, were characterized as burning, watering, sensitivity, stinging, and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,carac,63,1532,1589,"These adverse events occurred across all treatment arms in one of the two Phase 3 studies.\n', '\n', ' Summary of All Adverse Events Reported in >=1% of Patients in the Combined Active Treatment and Vehicle Groups - Pooled Phase 3 Studies \n', '   9721 and 9722",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,carac,64,1589,1605,"Combined     \n', '   Adverse    Event          Active    1 Week    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,carac,65,1605,1612,N= 85      Active    2Week    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,carac,66,1612,1615,N= 87      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,carac,67,1615,1617,Active    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,carac,68,1617,1619,4Week    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,carac,69,1619,1622,N= 85      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,carac,70,1622,1627,ALL Active    Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,carac,71,1627,1629,N=257      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,carac,72,1629,1633,Vehicle    Treatments    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,carac,73,1633,1712,"N=127     \n', '                                                                              \n', '                             n (%)      n (%)      n (%)      n (%)      n (%)     \n', '  \n', '   nonoseaegeneralterm           7         (8.2)     6         (6.9)     12        (14.1)    25        (9.7)     15        (11.8)    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,carac,74,1712,1713,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,carac,75,1713,1725,"', '   oselabeledaefromdruguse                  3         (3.5)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,carac,76,1725,1743,2         (2.3)     3         (3.5)     8         (3.1)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,carac,77,1743,1749,3         (2.4)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,carac,78,1749,1764,"\n', '   oselabeledaefromdruguse               4         (4.7)     0         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,carac,79,1764,1776,2         (2.4)     6         (2.3)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,carac,80,1776,1782,3         (2.4)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,carac,81,1782,1791,"\n', '   oselabeledaefromdruguse                   0         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,carac,82,1791,1797,2         (2.3)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,carac,83,1797,1815,1         (1.2)     3         (1.2)     2         (1.6)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,carac,84,1815,1824,"\n', '   oselabeledaefromdruguse    0         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,carac,85,1824,1826,0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,carac,86,1826,1828,0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,carac,87,1828,1830,0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,carac,88,1830,1836,2         (1.6)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,carac,89,1836,1845,"\n', '   nonoseaegeneralterm           1         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,carac,90,1845,1873,(1.2)     1         (1.1)     1         (1.2)     3         (1.2)     5         (3.9)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,carac,91,1873,1888,"\n', '   oselabeledaefromdruguse           0         0         0         0         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,carac,92,1888,1894,2         (1.6)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,carac,93,1894,1909,"\n', '   nonoseaegeneralterm               5         (5.9)     0         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
94,carac,94,1909,1911,1         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,carac,95,1911,1956,"(1.2)     6         (2.3)     6         (4.7)     \n', '   oselabeledaefromdruguse                 4         (4.7)     0         0         4         (1.6)     2         (1.6)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,carac,96,1956,1993,"\n', '   nonoseaegeneralterm         78        (91.8)    83        (95.4)    82        (96.5)    243       (94.6)    85        (66.9)    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
97,carac,97,1993,2006,"\n', '   oselabeledaefromdruguse    78        (91.8)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,carac,98,2006,2024,83        (95.4)    82        (96.5)    243       (94.6)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,carac,99,2024,2030,83        (65.4)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,carac,100,2030,2031,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,carac,101,2031,2045,"', '   oselabeledaefromdruguse           1         (1.2)     0         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,carac,102,2045,2047,2         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,carac,103,2047,2059,(2.4)     3         (1.2)     0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,carac,104,2059,2086,"\n', '   nonoseaegeneralterm            6         (7.1)     4         (4.6)     6         (7.1)     16        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,carac,105,2086,2096,(6.2)     6         (4.7)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,carac,106,2096,2115,"\n', '   oselabeledaefromdruguse            5         (5.9)     3         (3.4)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,carac,107,2115,2165,"6         (7.1)     14        (5.4)     3         (2.4)     \n', '                   Adverse Experiences Reported by Body System:\n', '   In the Phase 3 studies, no serious adverse event was considered related to study drug.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,carac,108,2165,2192,"A total of five patients, three in the active treatment groups and two in the vehicle group, experienced at least one serious adverse event.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,carac,109,2192,2235,"Three patients  nonoseaegeneralterm as a result of adverse event(s) considered unrelated to study drug ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction .\n', '\n', ' Post-treatment clinical laboratory tests other than  nonoseaeaeonlyasinstruction    ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,carac,110,2235,2247,"PRECAUTIONS\n', '\n', '   General:\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,carac,111,2247,2309,"'\n', '  There is a possibility of increased absorption through  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    Information for the Patient:\n', '\n', '  Patients using Carac should receive the following information and instructions:\n', '\n', ' *  1.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
112,carac,112,2309,2318,This medication is to be used as directed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,carac,113,2318,2327,"\n', ' *  2.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,carac,114,2327,2345,This medication should not be used for any disorder other than that for which it was prescribed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,carac,115,2345,2354,"\n', ' *  3.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,carac,116,2354,2361,It is for topical use only.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,carac,117,2361,2370,"\n', ' *  4.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,carac,118,2370,2383,"Avoid contact with the eyes, eyelids, nostrils, and mouth.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,carac,119,2383,2392,"\n', ' *  5.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,carac,120,2392,2403,Cleanse affected area and wait 10 minutes before applying Carac.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,carac,121,2403,2412,"\n', ' *  6.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,carac,122,2412,2419,Wash hands immediately after applying Carac.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,carac,123,2419,2428,"\n', ' *  7.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,carac,124,2428,2452,"Avoid prolonged exposure to sunlight or other forms of ultraviolet irradiation during treatment, as the intensity of the reaction may be increased.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,carac,125,2452,2461,"\n', ' *  8.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,carac,126,2461,2477,Most patients using Carac get  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction reactions where the medicine is used.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,carac,127,2477,2511,"These reactions include redness, dryness, burning, pain, erosion (loss of the upper layer of skin), and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction reactions where the medicine is used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,carac,128,2511,2533,"These reactions include redness, dryness, burning, pain,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction reactions where the medicine is used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,carac,129,2533,2553,"These reactions include redness, dryness, burning,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction reactions where the medicine is used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,carac,130,2553,2571,"These reactions include redness, dryness,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction reactions where the medicine is used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,carac,131,2571,2587,"These reactions include redness,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction reactions where the medicine is used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,carac,132,2587,2607,"These reactions include  nonoseaeaeonlyasinstruction  dryness, burning, pain, erosion ( nonoseaeaeonlyasinstruction , and swelling.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,carac,133,2607,2620,nonoseaeaeonlyasinstruction may persist for two or more weeks after therapy is discontinued.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,carac,134,2620,2630,Treated areas may be unsightly during and after therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,carac,135,2630,2639,"\n', ' *  9.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,carac,136,2639,2669,"If you develop  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication while on Carac therapy, stop the medication and contact your physician and/or pharmacist.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
137,carac,137,2669,2678,"\n', ' *  10.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,carac,138,2678,2688,Report any side effects to the physician and/or pharmacist.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,carac,139,2688,2778,"\n', '       Laboratory Tests:\n', ' \n', '\n', '  To rule out the presence of a frank  nonoseaeaeonlyasinstruction  a biopsy may be considered for those areas failing to respond to treatment or recurring after treatment.\n', '\n', '    Carcinogenesis, Mutagenesis, and Impairment of Fertility:\n', '\n', '  Adequate long-term studies in animals to evaluate  nonoseaeaeonlyasinstruction potential have not been conducted with fluorouracil.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,carac,140,2778,2835,"Studies with the active ingredient of Carac, fluorouracil, have shown positive effects in in vitro  and in vivo  tests for  nonoseaeaeanimal and on  nonoseaeaeanimal in in vivo  animal studies.\n', '\n', ' Fluorouracil produced morphological transformation of cells in in vitro  cell transformation assays.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
141,carac,141,2835,2867,"Morphological transformation was also produced in an in vitro  assay by a metabolite of fluorouracil, and the transformed cells produced  nonoseaeaeanimal when injected into  notaecandidatepreexistingconditionorriskfactor syngeneic mice.",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
142,carac,142,2867,2889,"Fluorouracil has been shown to exert  nonoseaeaeanimal activity in yeast cells, Bacillus subtilis  , and Drosophila  assays.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
143,carac,143,2889,2942,"In addition, fluorouracil has produced  nonoseaeaeanimal at concentrations of 1.0 and 2.0 mcg/mL in an in vitro  hamster fibroblast assay, was positive in a microwell mouse  nonoseaeaeanimal assay, and was positive in in vivo  micronucleus assays in rats and mice following intraperitoneal administration.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
144,carac,144,2942,2989,"Some patients receiving cumulative doses of 0.24 to 1.0 g of fluorouracil parenterally have shown an increase in numerical and structural  nonoseaeaeonlyasinstruction in peripheral blood lymphocytes.\n', '\n', ' Fluorouracil has been shown to  nonoseaeaeanimal after parenteral administration in rats.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
145,carac,145,2989,3014,Fluorouracil administered at intraperitoneal doses of 125 and 250 mg/kg has been shown to induce  nonoseaeaeanimal and  nonoseaeaeanimal in rats.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
146,carac,146,3014,3090,"In mice, single-dose intravenous and intraperitoneal injections of fluorouracil have been reported to  nonoseaeaeanimal and spermatocytes at a dose of 500 mg/kg and produce  nonoseaeaeanimal at 50 mg/kg.\n', '\n', '    Pediatric Use:\n', '\n', '   notaecandidatepreexistingconditionorriskfactor    WARNINGS\n', '\n', '  The potential for a  oselabeledaefromdruguse to fluorouracil exists.",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
147,carac,147,3090,3158,"Patch testing to prove  nonoseaeaeonlyasinstruction may be inconclusive.\n', '\n', ' Patients should discontinue therapy with Carac if symptoms of  nonoseaeaeonlyasinstruction develop.\n', '\n', ' Rarely, unexpected systemic toxicity (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  associated with parenteral administration of fluorouracil has been attributed to  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor activity.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
148,carac,148,3158,3231,"One case of life-threatening systemic toxicity has been reported with the topical use of 5% fluorouracil in a patient with a complete  notaecandidatepreexistingconditionorriskfactor  Symptoms included severe  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  Physical examination revealed  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction esophagus,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction esophagus, stomach, and  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
149,carac,149,3231,3301,"Although this case was observed with 5% fluorouracil cream, it is unknown whether patients with profound  notaecandidatepreexistingconditionorriskfactor would develop  nonoseaegeneralterm with lower concentrations of topically applied fluorouracil.\n', '\n', ' Applications to  nonoseaeaefromofflabel should be avoided due to the possibility of local  nonoseaeaefromofflabel  nonoseaeaefromofflabel should be avoided due to the possibility of local inflammation and  nonoseaeaefromofflabel ']",0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
0,cyramza,0,0,69,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse drug reactions are discussed in greater detail in other sections of the label:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.1  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,cyramza,1,69,97,"\n', ' *   oselabeledaefromdruguse [see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.2  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,cyramza,2,97,125,"\n', ' *   oselabeledaefromdruguse [see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.3  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,cyramza,3,125,153,"\n', ' *   oselabeledaefromdruguse [see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.4  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,cyramza,4,153,181,"\n', ' *   oselabeledaefromdruguse [see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.5  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,cyramza,5,181,209,"\n', ' *   oselabeledaefromdruguse [see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.6  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,cyramza,6,209,241,"\n', ' *  Patients with  notaecandidatepreexistingconditionorriskfactor or C  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor B or  notaecandidatepreexistingconditionorriskfactor [see Warnings and Precautions (  5.7  )] .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
7,cyramza,7,241,260,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.8  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,cyramza,8,260,282,"\n', ' *   oselabeledaefromdruguse Including  oselabeledaefromdruguse [see Warnings and Precautions (  5.9  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,cyramza,9,282,302,"\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.10  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,cyramza,10,302,348,"\n', '   *  The most common adverse reactions observed in single-agent CYRAMZA-treated patients at a rate of >=10% and >=2% higher than placebo were  oselabeledaefromdruguse and  oselabeledaefromdruguse  (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,cyramza,11,348,351,6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,cyramza,12,351,405,"\n', ' *  The most common adverse reactions observed in patients treated with CYRAMZA plus paclitaxel at a rate of >=30% and >=2% higher than placebo plus paclitaxel were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,cyramza,13,405,461,"\n', ' *  The most common adverse reactions observed in patients treated with CYRAMZA plus docetaxel at a rate of >=30% and >=2% higher than placebo plus docetaxel were  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse  and  oselabeledaefromdruguse  oselabeledaefromdruguse  (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,cyramza,14,461,465,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,cyramza,15,465,517,*  The most common adverse reactions observed in patients treated with CYRAMZA plus FOLFIRI at a rate of >=30% and >=2% higher than placebo plus FOLFIRI were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  (  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,cyramza,16,517,525,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,cyramza,17,525,559,"To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,cyramza,18,559,592,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,cyramza,19,592,689,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '   Gastric Cancer  \n', '\n', '\n', '\n', ' Safety data are presented from two randomized, placebo controlled clinical trials in which patients received CYRAMZA:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,cyramza,20,689,781,"Study 1, a randomized (2:1), double-blind, clinical trial in which 351 patients received either CYRAMZA 8 mg/kg intravenously every two weeks or placebo every two weeks and Study 2, a double-blind, randomized (1:1) clinical trial in which 656 patients received paclitaxel 80 mg/m  2  on days 1, 8, and 15 of each 28-day cycle plus either CYRAMZA 8 mg/kg intravenously every two weeks or placebo every two weeks.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,cyramza,21,781,827,"Both trials excluded patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or greater, uncontrolled  notaecandidatepreexistingconditionorriskfactor  major surgery within 28 days, or patients receiving chronic anti-platelet therapy other than once daily aspirin.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
22,cyramza,22,827,929,"Study 1 excluded patients with bilirubin >=1.5 mg/dL and Study 2 excluded patients with bilirubin >1.5 times the upper limit of normal.\n', '\n', '\n', '\n', '     CYRAMZA Administered as a Single Agent  \n', '\n', '\n', '\n', ' Among 236 patients who received CYRAMZA (safety population) in Study 1, median age was 60 years, 28% were women, 76% were White, and 16% were Asian.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,cyramza,23,929,1024,"Patients in Study 1 received a median of 4 doses of CYRAMZA; the median duration of exposure was 8 weeks, and 32 (14% of 236) patients received CYRAMZA for at least six months.\n', '\n', '\n', '\n', ' In Study 1, the most common adverse reactions (all grades) observed in CYRAMZA-treated patients at a rate of >=10% and >=2% higher than placebo were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,cyramza,24,1024,1047,The most common serious adverse events with CYRAMZA were  oselabeledaefromdruguse (3.8%) and  oselabeledaefromdruguse (2.1%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,cyramza,25,1047,1178,"Red blood cell transfusions were given to 11% of CYRAMZA-treated patients versus 8.7% of patients who received placebo.\n', '\n', '\n', '\n', '   Table 2  provides the frequency and severity of adverse reactions in Study 1.\n', '\n', '\n', '\n', ' Table 2: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA in Study 1 \n', '                                       \n', '  \n', '   Adverse Reactions (MedDRA)    System Organ Class      CYRAMZA (8 mg/kg)    N=236      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,cyramza,26,1178,1180,Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,cyramza,27,1180,1205,"N=115     \n', '   All Grades    (Frequency %)          Grade 3-4    (Frequency %)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,cyramza,28,1205,1223,All Grades    (Frequency %)      Grade 3-4    (Frequency %)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,cyramza,29,1223,1228,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,cyramza,30,1228,1243,"nonoseaegeneralterm          \n', '       oselabeledaefromdruguse                        14               1                9                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,cyramza,31,1243,1245,2                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,cyramza,32,1245,1276,"\n', '    nonoseaegeneralterm and Nutrition  nonoseaegeneralterm     \n', '       oselabeledaefromdruguse                    6                3                2                 1                   \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,cyramza,33,1276,1293,"nonoseaegeneralterm            \n', '       oselabeledaefromdruguse                        9                0                3                 0                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,cyramza,34,1293,1300,"\n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,cyramza,35,1300,1307,"\n', '       oselabeledaefromdruguse                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,cyramza,36,1307,1311,16               8                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,cyramza,37,1311,1313,8                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,cyramza,38,1313,1315,3                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,cyramza,39,1315,1406,"\n', '           Clinically relevant adverse reactions reported in >=1% and <5% of CYRAMZA-treated patients in Study 1 were:  oselabeledaefromdruguse (4.7% CYRAMZA versus 0.9% placebo),  oselabeledaefromdruguse (4.7% CYRAMZA versus 0.9% placebo),  oselabeledaefromdruguse (4.2% CYRAMZA versus 1.7% placebo),  oselabeledaefromdruguse (2.1% CYRAMZA versus 0% placebo), and  oselabeledaefromdruguse (1.7% CYRAMZA versus 0% placebo)  [",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,cyramza,40,1406,1430,"see Dosage and Administration (  2.3  ) and Warnings and Precautions (  5.1  ,  5.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,cyramza,41,1430,1442,".\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,cyramza,42,1442,1522,"Across clinical trials of CYRAMZA administered as a single agent, clinically relevant adverse reactions (including Grade >=3) reported in CYRAMZA-treated patients included  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' In Study 1, according to laboratory assessment, 8% of CYRAMZA-treated patients developed  oselabeledaefromdruguse versus 3% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,cyramza,43,1522,1657,"Two patients discontinued CYRAMZA due to  oselabeledaefromdruguse  The rate of  oselabeledaefromdruguse in Study 1 was 0.8% and the rate of  oselabeledaefromdruguse was 0.4%  [see Dosage and Administration (  2.2  ,  2.3  ) and Warnings and Precautions (  5.4  ,  5.5  )]  .\n', '\n', '\n', '\n', '     CYRAMZA Administered in Combination with Paclitaxel  \n', '\n', '\n', '\n', ' Among 327 patients who received CYRAMZA (safety population) in Study 2, median age was 61 years, 31% were women, 63% were White, and 33% were Asian.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,cyramza,44,1657,1761,"Patients in Study 2 received a median of 9 doses of CYRAMZA; the median duration of exposure was 18 weeks, and 93 (28% of 327) patients received CYRAMZA for at least six months.\n', '\n', '\n', '\n', ' In Study 2, the most common adverse reactions (all grades) observed in patients treated with CYRAMZA plus paclitaxel at a rate of >=30% and >=2% higher than placebo plus paclitaxel were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,cyramza,45,1761,1780,The most common serious adverse events with CYRAMZA plus paclitaxel were  oselabeledaefromdruguse (3.7%) and  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,cyramza,46,1780,1785,oselabeledaefromdruguse (2.4%),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,cyramza,47,1785,1802,; 19% of patients treated with CYRAMZA plus paclitaxel received granulocyte colony-stimulating factors.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,cyramza,48,1802,1923,"Adverse reactions resulting in discontinuation of any component of the CYRAMZA plus paclitaxel combination in 2% or more patients in Study 2 were  oselabeledaefromdruguse (4%) and  oselabeledaefromdruguse (3%).\n', '\n', '\n', '\n', '   Table 3  provides the frequency and severity of adverse reactions in Study 2.\n', '\n', '\n', '\n', ' Table 3: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA plus Paclitaxel in Study 2 \n', '   Adverse Reactions (MedDRA)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,cyramza,49,1923,1935,System Organ Class      CYRAMZA plus Paclitaxel    (N=327)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,cyramza,50,1935,1964,"Placebo plus Paclitaxel    (N=329)     \n', '   All Grades    (Frequency %)           Grade >=3 (Frequency %)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,cyramza,51,1964,1980,All Grades    (Frequency %)      Grade >=3 (Frequency %)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,cyramza,52,1980,1985,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,cyramza,53,1985,1990,nonoseaegeneralterm  nonoseaegeneralterm System  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,cyramza,54,1990,1992,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
55,cyramza,55,1992,2001,"\n', '       oselabeledaefromdruguse                      54               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,cyramza,56,2001,2005,41               31               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,cyramza,57,2005,2022,"19                 \n', '       oselabeledaefromdruguse                 13               2                6                2                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,cyramza,58,2022,2036,"\n', '    nonoseaegeneralterm           \n', '       oselabeledaefromdruguse                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,cyramza,59,2036,2042,32               4                23               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,cyramza,60,2042,2044,2                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,cyramza,61,2044,2097,"\n', '       oselabeledaefromdruguse events  10               4                6                2                  \n', '       oselabeledaefromdruguse                       20               1                7                1                  \n', '   General Disorders and  nonoseaegeneralterm     \n', '       oselabeledaefromdruguse  oselabeledaefromdruguse                 57               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,cyramza,62,2097,2099,12               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,cyramza,63,2099,2103,44               6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,cyramza,64,2103,2112,"\n', '       oselabeledaefromdruguse                 25               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,cyramza,65,2112,2114,2                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,cyramza,66,2114,2123,"14               1                  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,cyramza,67,2123,2125,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,cyramza,68,2125,2140,"\n', '       oselabeledaefromdruguse                  11               1                5                1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,cyramza,69,2140,2151,"\n', '    nonoseaegeneralterm and Urinary  nonoseaegeneralterm          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,cyramza,70,2151,2166,"\n', '       oselabeledaefromdruguse                      17               1                6                0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,cyramza,71,2166,2173,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
72,cyramza,72,2173,2188,"\n', '       oselabeledaefromdruguse                        31               0                7                0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,cyramza,73,2188,2195,"\n', '    nonoseaegeneralterm                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,cyramza,74,2195,2243,"\n', '       oselabeledaefromdruguse                     25               15               6                3                  \n', '           Clinically relevant adverse reactions reported in >=1% and <5% of the CYRAMZA plus paclitaxel treated patients in Study 2 were  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,cyramza,75,2243,2290,"3.1% CYRAMZA plus paclitaxel versus 1.8% placebo plus paclitaxel) and  oselabeledaefromdruguse (1.2% CYRAMZA plus paclitaxel versus 0.3% for placebo plus paclitaxel).\n', ' \n', '\n', '     Non-Small Cell Lung Cancer  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,cyramza,76,2290,2404,"\n', '\n', '\n', '\n', '     CYRAMZA Administered in Combination with Docetaxel  \n', '\n', '\n', '\n', ' Study 3 was a multinational, randomized, double-blind study conducted in patients with  notaecandidateindication with disease progression on or after one platinum-based therapy for locally advanced or  notaecandidateindication  Patients received either CYRAMZA 10 mg/kg intravenously plus docetaxel 75 mg/m  2  intravenously every 3 weeks or placebo plus docetaxel 75 mg/m  2  intravenously every 3 weeks.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
77,cyramza,77,2404,2561,"Due to an increased incidence of  oselabeledaefromdruguse and  oselabeledaefromdruguse in patients enrolled in East Asian sites, Study 3 was amended and 24 patients (11 CYRAMZA plus docetaxel, 13 placebo plus docetaxel) at East Asian sites received a starting dose of docetaxel at 60 mg/m  2  every 3 weeks.\n', '\n', '\n', '\n', ' Study 3 excluded patients with an ECOG PS of 2 or greater, bilirubin greater than the upper limit of normal (ULN), uncontrolled  notaecandidatepreexistingconditionorriskfactor  major surgery within 28 days, radiographic evidence of major  notaecandidatepreexistingconditionorriskfactor or blood vessel  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor by cancer, radiographic evidence of  notaecandidatepreexistingconditionorriskfactor  or gross  notaecandidatepreexistingconditionorriskfactor within the preceding 2 months, and patients receiving therapeutic anticoagulation or chronic anti-platelet therapy other than once daily aspirin.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
78,cyramza,78,2561,2627,"The study also excluded patients whose only prior treatment for advanced  notaecandidateindication was a tyrosine kinase (epidermal growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK]) inhibitor.\n', '\n', '\n', '\n', ' The data described below reflect exposure to CYRAMZA plus docetaxel in 627 patients in Study 3.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
79,cyramza,79,2627,2637,Demographics and baseline characteristics were similar between treatment arms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,cyramza,80,2637,2681,Median age was 62 years; 67% of patients were men; 84% were White and 12% were Asian; 33% had ECOG PS 0; 74% had non-squamous histology and 25% had squamous histology.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,cyramza,81,2681,2784,"Patients received a median of 4.5 doses of CYRAMZA; the median duration of exposure was 3.5 months, and 195 (31% of 627) patients received CYRAMZA for at least six months.\n', '\n', '\n', '\n', ' In Study 3, the most common adverse reactions (all grades) observed in CYRAMZA plus docetaxel-treated patients at a rate of >=30% and >=2% higher than placebo plus docetaxel were  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse  and  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,cyramza,82,2784,2817,Treatment discontinuation due to adverse reactions occurred more frequently in CYRAMZA plus docetaxel-treated patients (9%) than in placebo plus docetaxel-treated patients (5%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,cyramza,83,2817,2843,The most common adverse events leading to treatment discontinuation of CYRAMZA were  oselabeledaefromdruguse (0.5%) and  oselabeledaefromdruguse (0.3%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,cyramza,84,2843,2898,"For patients with non-squamous histology, the overall incidence of  oselabeledaefromdruguse was 7% and the incidence of >=Grade 3  nonoseaeaeratelteqplacebo was 1% for CYRAMZA plus docetaxel compared to 6% overall incidence and 1% for >=Grade 3  nonoseaeaeratelteqplacebo for placebo plus docetaxel.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
85,cyramza,85,2898,2941,"For patients with squamous histology, the overall incidence of  nonoseaeaeratelteqplacebo was 10% and the incidence of >=Grade 3  nonoseaeaeratelteqplacebo was 2% for CYRAMZA plus docetaxel compared to 12% overall incidence and 2% for >",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
86,cyramza,86,2941,2998,"=Grade 3  nonoseaeaeratelteqplacebo for placebo plus docetaxel.\n', '\n', '\n', '\n', ' The most common serious adverse events with CYRAMZA plus docetaxel were  oselabeledaefromdruguse (14%),  oselabeledaefromdruguse (6%), and  oselabeledaefromdruguse (5%).",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
87,cyramza,87,2998,3027,The use of granulocyte colony-stimulating factors was 42% in CYRAMZA plus docetaxel-treated patients versus 37% in patients who received placebo plus docetaxel.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,cyramza,88,3027,3068,"In patients >=65 years, there were 18 (8%)  nonoseaegeneralterm on treatment or within 30 days of discontinuation for CYRAMZA plus docetaxel and 9 (4%)  nonoseaegeneralterm for placebo plus docetaxel.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,cyramza,89,3068,3102,"In patients <65 years, there were 13 (3%)  nonoseaegeneralterm on treatment or within 30 days of discontinuation for CYRAMZA plus docetaxel and 26 (6%)  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,cyramza,90,3102,3136,"nonoseaegeneralterm for placebo plus docetaxel.\n', '\n', '\n', '\n', '   Table 4  provides the frequency and severity of adverse reactions in Study",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
91,cyramza,91,3136,3204,"3.\n', '\n', '\n', '\n', ' Table 4: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA in Study 3 \n', '   Adverse Reactions (MedDRA)    System Organ Class      CYRAMZA plus docetaxel    (N=627)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,cyramza,92,3204,3212,Placebo plus docetaxel    (N=618)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,cyramza,93,3212,3235,"\n', '   All Grades    (Frequency %)            Grade 3-4    (Frequency %)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,cyramza,94,3235,3253,All Grades    (Frequency %)      Grade 3-4    (Frequency %)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,cyramza,95,3253,3276,"\n', '    nonoseaegeneralterm and Lymphatic System  nonoseaegeneralterm  nonoseaegeneralterm     \n', '         oselabeledaefromdruguse             16               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,cyramza,96,3276,3278,16                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,cyramza,97,3278,3282,10                10                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,cyramza,98,3282,3344,"\n', '         oselabeledaefromdruguse                     55               49                46                40                \n', '         oselabeledaefromdruguse                13               3                 5                 <1                \n', '    nonoseaegeneralterm            \n', '         oselabeledaefromdruguse  oselabeledaefromdruguse  37               7                 19                2                 \n', '    nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
99,cyramza,99,3344,3353,"\n', '         oselabeledaefromdruguse           13               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,cyramza,100,3353,3382,"<1                5                 0                 \n', '   General Disorders and  nonoseaegeneralterm     \n', '         oselabeledaefromdruguse  oselabeledaefromdruguse                55               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
101,cyramza,101,3382,3384,14                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,cyramza,102,3384,3388,50                11                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,cyramza,103,3388,3397,"\n', '         oselabeledaefromdruguse                16               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,cyramza,104,3397,3399,0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,cyramza,105,3399,3409,"9                 <1                \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,cyramza,106,3409,3425,"nonoseaegeneralterm  nonoseaegeneralterm     \n', '         oselabeledaefromdruguse                       19               <1                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,cyramza,107,3425,3437,"7                 <1                \n', '    nonoseaegeneralterm                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
108,cyramza,108,3437,3444,"\n', '         oselabeledaefromdruguse                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,cyramza,109,3444,3446,11               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,cyramza,110,3446,3452,6                 5                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,cyramza,111,3452,3604,"\n', '           Clinically relevant adverse drug reactions reported in >=1% and <5% of the CYRAMZA plus docetaxel-treated patients in Study 3 were  oselabeledaefromdruguse (4.8% CYRAMZA plus docetaxel versus 2.4% for placebo plus docetaxel) and  oselabeledaefromdruguse (3.3% CYRAMZA plus docetaxel versus 0.8% placebo plus docetaxel).\n', ' \n', '\n', '     Colorectal Cancer  \n', '\n', '\n', '\n', '     CYRAMZA Administered in Combination with FOLFIRI  \n', '\n', '\n', '\n', ' Study 4 was a multinational, randomized, double-blind study conducted in patients with  notaecandidateindication with disease progression on or after therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
112,cyramza,112,3604,3751,"Patients received either CYRAMZA 8 mg/kg intravenously plus FOLFIRI intravenously every 2 weeks or placebo plus FOLFIRI intravenously every 2 weeks.\n', '\n', '\n', '\n', ' Study 4 excluded patients with an ECOG PS of 2 or greater, uncontrolled  notaecandidatepreexistingconditionorriskfactor  major surgery within 28 days, and those who experienced any of the following during first-line therapy with a bevacizumab-containing regimen: an  notaecandidatepreexistingconditionorriskfactor thromboembolic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor thrombotic/ notaecandidatepreexistingconditionorriskfactor  Grade 4  notaecandidatepreexistingconditionorriskfactor  Grade 3  notaecandidatepreexistingconditionorriskfactor  a Grade 3-4  notaecandidatepreexistingconditionorriskfactor event; or  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', ' Demographics and baseline characteristics for the treated population were similar between treatment arms (n=1057).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
113,cyramza,113,3751,3814,"Median age was 62 years; 57% of patients were men; 76% were White and 20% were Asian; 48% had ECOG PS 0.\n', '\n', '\n', '\n', ' The data described in this section reflect exposure to CYRAMZA plus FOLFIRI in 529 patients in Study 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,cyramza,114,3814,3856,"Patients received a median of 8 doses (range 1-68) of CYRAMZA; the median duration of exposure was 4.4 months, and 169 (32% of 529) patients received CYRAMZA for at least six months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,cyramza,115,3856,3905,The most common adverse reactions (all grades) observed in CYRAMZA plus FOLFIRI-treated patients at a rate of >=30% and >=2% higher than placebo plus FOLFIRI were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,cyramza,116,3905,3921,Twenty percent of patients treated with CYRAMZA plus FOLFIRI received granulocyte colony-stimulating factors.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,cyramza,117,3921,4013,"Treatment discontinuation of any study drug due to adverse reactions occurred more frequently in CYRAMZA plus FOLFIRI-treated patients (29%) than in placebo plus FOLFIRI-treated patients (13%).\n', '\n', '\n', '\n', ' The most common adverse reactions leading to discontinuation of any component of CYRAMZA plus FOLFIRI as compared to placebo plus FOLFIRI, were  oselabeledaefromdruguse (12.5% versus 5.3%) and  oselabeledaefromdruguse (4.2% versus 0.8%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,cyramza,118,4013,4176,"The most common adverse reactions leading to treatment discontinuation of CYRAMZA were  oselabeledaefromdruguse (1.5%) and  oselabeledaefromdruguse (1.7%).\n', '\n', '\n', '\n', ' The most common serious adverse events with CYRAMZA plus FOLFIRI were  oselabeledaefromdruguse (3.6%),  oselabeledaefromdruguse (3.0%), and  oselabeledaefromdruguse (2.8%).\n', '\n', '\n', '\n', '   Table 5  provides the frequency and severity of adverse reactions in Study 4.\n', '\n', '\n', '\n', ' Table 5: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA in Study 4 \n', '  a Includes 3 patients with  oselabeledaefromdruguse in the CYRAMZA plus FOLFIRI treatment group.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,cyramza,119,4176,4186,"\n', '  \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,cyramza,120,4186,4202,Adverse Reactions (MedDRA)    System Organ Class      CYRAMZA plus FOLFIRI    N=529      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,cyramza,121,4202,4206,Placebo plus FOLFIRI    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,cyramza,122,4206,4230,"N=528     \n', '   All Grades    (Frequency %)          Grade >=3    (Frequency %)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,cyramza,123,4230,4247,All Grades    (Frequency %)      Grade >=3    (Frequency %)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,cyramza,124,4247,4261,"\n', '    nonoseaegeneralterm and Lymphatic System  nonoseaegeneralterm  nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
125,cyramza,125,4261,4274,"\n', '       oselabeledaefromdruguse                     59               38               46                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,cyramza,126,4274,4276,23                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,cyramza,127,4276,4281,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,cyramza,128,4281,4292,oselabeledaefromdruguse                28               3                14                <1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,cyramza,129,4292,4314,"\n', '    nonoseaegeneralterm          \n', '       oselabeledaefromdruguse              37               2                27                2                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,cyramza,130,4314,4321,"\n', '       oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,cyramza,131,4321,4327,60               11               51                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,cyramza,132,4327,4329,10                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,cyramza,133,4329,4341,"\n', '       oselabeledaefromdruguse events  12               2                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,cyramza,134,4341,4360,"7                 1                   \n', '       oselabeledaefromdruguse                      31               4                21                2                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,cyramza,135,4360,4378,"\n', '   General Disorders and  nonoseaegeneralterm     \n', '       oselabeledaefromdruguse                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,cyramza,136,4378,4380,20               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,cyramza,137,4380,4394,"<1               9                 0                   \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,cyramza,138,4394,4422,"\n', '       oselabeledaefromdruguse                 6                1                2                 0                   \n', '    nonoseaegeneralterm and Urinary  nonoseaegeneralterm  nonoseaegeneralterm         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,cyramza,139,4422,4427,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,cyramza,140,4427,4429,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,cyramza,141,4429,4431,a                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,cyramza,142,4431,4435,17               3                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,cyramza,143,4435,4437,5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,cyramza,144,4437,4471,"<1                  \n', '    nonoseaegeneralterm  nonoseaegeneralterm     \n', '       oselabeledaefromdruguse                       33               0                15                0                   \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
145,cyramza,145,4471,4480,"\n', '       oselabeledaefromdruguse  13               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,cyramza,146,4480,4482,1                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,cyramza,147,4482,4484,5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,cyramza,148,4484,4494,"<1                  \n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
149,cyramza,149,4494,4501,"\n', '       oselabeledaefromdruguse                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,cyramza,150,4501,4505,26               11               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,cyramza,151,4505,4509,9                 3                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,cyramza,152,4509,4601,"\n', '           Clinically relevant adverse reactions reported in >=1% and <5% of CYRAMZA plus FOLFIRI-treated patients in Study 4 consisted of  oselabeledaefromdruguse (1.7% CYRAMZA plus FOLFIRI versus 0.6% for placebo plus FOLFIRI).\n', ' \n', '\n', ' Thyroid stimulating hormone (TSH) levels were evaluated in 224 patients (115 CYRAMZA plus FOLFIRI-treated patients and 109 placebo plus FOLFIRI-treated patients) with normal baseline TSH levels.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,cyramza,153,4601,4619,Patients underwent periodic TSH laboratory assessments until 30 days after the last dose of study treatment.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,cyramza,154,4619,4724,"oselabeledaefromdruguse levels were observed in 53 (46%) patients treated with CYRAMZA plus FOLFIRI compared with 4 (4%) patients treated with placebo plus FOLFIRI.\n', '\n', '\n', '\n', '   6.2 Immunogenicity\n', '\n', '  As with all therapeutic proteins, there is the potential for  oselabeledaeclasseffect  In 23 clinical trials, 86/2890 (3.0%) of CYRAMZA-treated patients tested  oselabeledaefromdruguse for treatment-emergent  oselabeledaefromdruguse by an enzyme-linked immunosorbent assay (ELISA).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,cyramza,155,4724,4776,"oselabeledaefromdruguse were  oselabeledaefromdruguse in 14 of the 86 patients who tested positive for treatment-emergent  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' The detection of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,cyramza,156,4776,4823,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,cyramza,157,4823,4851,"For these reasons, comparison of incidence of  nonoseaeaeonlyasinstruction with the incidences of  nonoseaeaeonlyasinstruction \n', '\n', '    BOXED WARNING:",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,cyramza,158,4851,4853,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,cyramza,159,4853,4861,"HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,cyramza,160,4861,4862,HEALING\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,cyramza,161,4862,4880,"', '\n', '\n', '\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,cyramza,162,4880,4888,"HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,cyramza,163,4888,4889,HEALING\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,cyramza,164,4889,4927,"', '\n', '\n', '\n', '     nonoseaegeneralterm  CYRAMZA increased the risk of  oselabeledaefromdruguse and  oselabeledaefromdruguse  including severe and sometimes  nonoseaegeneralterm  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
165,cyramza,165,4927,4967,"Permanently discontinue CYRAMZA in patients who experience severe  nonoseaeaeonlyasinstruction \n', '\n', '    [see Dosage and Administration (  2.3  ), Warnings and Precautions (  5.1  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,cyramza,166,4967,5009,".\n', '\n', '\n', '\n', '\n', '\n', '    nonoseaegeneralterm  CYRAMZA can increase the risk of  oselabeledaefromdruguse  a potentially  nonoseaegeneralterm event.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
167,cyramza,167,5009,5046,"Permanently discontinue CYRAMZA in patients who experience a  nonoseaeaeonlyasinstruction \n', '    [see Dosage and Administration (  2.3  ), Warnings and Precautions (  5.5  )].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,cyramza,168,5046,5075,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm   oselabeledaeclasseffect can occur with antibodies inhibiting the VEGF pathway.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
169,cyramza,169,5075,5143,"Discontinue CYRAMZA therapy in patients with  nonoseaeaeonlyasinstruction  Withhold CYRAMZA prior to surgery and discontinue CYRAMZA if a patient develops  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal ATEs have been reported in clinical trials.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,cyramza,170,5143,5149,Discontinue CYRAMZA for severe ATEs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,cyramza,171,5149,5154,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,cyramza,172,5154,5169,"\n', ' *  Hypertension: Monitor blood pressure and treat hypertension.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,cyramza,173,5169,5176,Temporarily suspend CYRAMZA for severe hypertension.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,cyramza,174,5176,5187,Discontinue CYRAMZA for hypertension that cannot be medically controlled.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,cyramza,175,5187,5211,"(  5.3  ) \n', ' *  Infusion-Related Reactions: Monitor for signs and symptoms during infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,cyramza,176,5211,5232,"(  5.4  ) \n', ' *  Impaired Wound Healing: Withhold CYRAMZA prior to surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,cyramza,177,5232,5274,"(  5.6  ) \n', ' *  Clinical Deterioration in Patients with Cirrhosis: New onset or worsening encephalopathy, ascites, or hepatorenal syndrome can occur in patients with Child-Pugh B or C cirrhosis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,cyramza,178,5274,5293,"(  5.7  ) \n', ' *  Reversible Posterior Leukoencephalopathy Syndrome: Discontinue CYRAMZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,cyramza,179,5293,5312,"(  5.8  ) \n', ' *  Proteinuria Including Nephrotic Syndrome: Monitor proteinuria.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,cyramza,180,5312,5324,Interrupt CYRAMZA for urine protein levels >=2 g/24 hours.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,cyramza,181,5324,5340,Permanently discontinue CYRAMZA for urine protein levels >3 g/24 hours or for nephrotic syndrome.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,cyramza,182,5340,5362,"(  5.9  ) \n', ' *  Thyroid Dysfunction: Monitor thyroid function during treatment with CYRAMZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,cyramza,183,5362,5381,"(  5.10  ) \n', ' *  Embryofetal Risk: Can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,cyramza,184,5381,5386,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,cyramza,185,5386,5408,"\n', '    \n', ' \n', '\n', '      5.1 Hemorrhage\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,cyramza,186,5408,5442,"'\n', '\n', '\n', '     CYRAMZA increased the risk of  oselabeledaefromdruguse and  oselabeledaefromdruguse  including severe and sometimes  nonoseaegeneralterm  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
187,cyramza,187,5442,5463,"In Study 1, the incidence of severe  oselabeledaefromdruguse was 3.4% for CYRAMZA and 2.6% for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,cyramza,188,5463,5586,"In Study 2, the incidence of severe  oselabeledaefromdruguse was 4.3% for CYRAMZA plus paclitaxel and 2.4% for placebo plus paclitaxel.\n', '\n', '\n', '\n', '    Patients with  notaecandidateindication receiving nonsteroidal anti-inflammatory drugs (NSAIDs) were excluded from enrollment in Studies 1 and 2; therefore, the risk of  nonoseaeaeonlyasinstruction in CYRAMZA-treated patients with  notaecandidatepreexistingconditionorriskfactor receiving NSAIDs is unknown.\n', '\n', '\n', '\n', '    In Study 3, the incidence of severe  oselabeledaefromdruguse was 2.4% for CYRAMZA plus docetaxel and 2.3% for placebo plus docetaxel.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
189,cyramza,189,5586,5802,"Patients with  notaecandidateindication receiving therapeutic anticoagulation or chronic therapy with NSAIDS or other anti-platelet therapy other than once daily aspirin or with radiographic evidence of  notaecandidatepreexistingconditionorriskfactor or blood vessel  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor were excluded from Study 3; therefore the risk of  nonoseaeaeonlyasinstruction in these groups of patients is unknown.\n', '\n', '\n', '\n', '    In Study 4, the incidence of severe  oselabeledaefromdruguse was 2.5% for CYRAMZA plus FOLFIRI and 1.7% for placebo plus FOLFIRI.\n', '\n', '\n', '\n', '    Permanently discontinue CYRAMZA in patients who experience severe  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.3  )]  .\n', '\n', '\n', '\n', '    5.2 Arterial Thromboembolic Events\n', '\n', '\n', '\n', '  Serious, sometimes  nonoseaegeneralterm   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse occurred in clinical trials including 1.7% of 236 patients who received CYRAMZA as a single agent for  notaecandidateindication in Study 1.",1,1,1,1,0,0,0,0,0,0,0,0,0,0,0
190,cyramza,190,5802,5825,Permanently discontinue CYRAMZA in patients who experience a severe  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.3  )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,cyramza,191,5825,5860,".\n', '\n', '\n', '\n', '       5.3 Hypertension\n', '\n', '\n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,cyramza,192,5860,5975,"An increased incidence of severe  oselabeledaefromdruguse occurred in patients receiving CYRAMZA as a single agent (8%) as compared to placebo (3%), in patients receiving CYRAMZA plus paclitaxel (15%) as compared to placebo plus paclitaxel (3%), in patients receiving CYRAMZA plus docetaxel (6%) as compared to placebo plus docetaxel (2%), and in patients receiving CYRAMZA plus FOLFIRI (11%) as compared to placebo plus FOLFIRI (3%).\n', '\n', '\n', '\n', ' Control  notaecandidatepreexistingconditionorriskfactor prior to initiating treatment with CYRAMZA.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
193,cyramza,193,5975,6014,"Monitor blood pressure every two weeks or more frequently as indicated during treatment.\n', '\n', '\n', '\n', ' Temporarily suspend CYRAMZA for severe  nonoseaeaeonlyasinstruction until medically controlled.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,cyramza,194,6014,6115,"Permanently discontinue CYRAMZA if medically significant  nonoseaeaeonlyasinstruction cannot be controlled with  nonoseaeaeonlyasinstruction or in patients with  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.3  )]  .\n', '\n', '\n', '\n', '    5.4  oselabeledaefromdruguse \n', '\n', '\n', '  Prior to the institution of premedication recommendations across clinical trials of CYRAMZA,  oselabeledaefromdruguse occurred in 6 out of 37 patients (16%), including two severe events.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,cyramza,195,6115,6133,The majority of  oselabeledaefromdruguse across trials occurred during or following a first or second CYRAMZA infusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,cyramza,196,6133,6173,Symptoms of  nonoseaeaeonlyasinstruction included  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication pain/ nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication pain and/or  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
197,cyramza,197,6173,6223,"In severe cases, symptoms included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication \n', '\n', '\n', '\n', ' Monitor patients during the infusion for signs and symptoms of  nonoseaeaeonlyasinstruction in a setting with available resuscitation equipment.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
198,cyramza,198,6223,6247,Immediately and permanently discontinue CYRAMZA for Grade 3 or 4  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.3  )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,cyramza,199,6247,6302,".\n', '\n', '\n', '\n', '       5.5 Gastrointestinal Perforations\n', '\n', '\n', '\n', '     CYRAMZA is an antiangiogenic therapy that can increase the risk of  oselabeledaefromdruguse  a potentially fatal event.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,cyramza,200,6302,6324,Four of 570 patients (0.7%) who received CYRAMZA as a single agent in clinical trials experienced  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,cyramza,201,6324,6360,"In Study 2, the incidence of  oselabeledaefromdruguse was also increased in patients that received CYRAMZA plus paclitaxel (1.2%) as compared to patients receiving placebo plus paclitaxel (0.3%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,cyramza,202,6360,6384,"In Study 3, the incidence of  oselabeledaefromdruguse was 1% for CYRAMZA plus docetaxel and 0.3% for placebo plus docetaxel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,cyramza,203,6384,6408,"In Study 4, the incidence of  oselabeledaefromdruguse was 1.7% for CYRAMZA plus FOLFIRI and 0.6% for placebo plus FOLFIRI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,cyramza,204,6408,6430,Permanently discontinue CYRAMZA in patients who experience a  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.3  )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,cyramza,205,6430,6477,".\n', '\n', '\n', '\n', '       5.6 Impaired Wound Healing\n', '\n', '\n', '\n', '      oselabeledaeclasseffect can occur with antibodies inhibiting the VEGF pathway.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,cyramza,206,6477,6492,CYRAMZA has not been studied in patients with serious or non-healing wounds.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,cyramza,207,6492,6536,"CYRAMZA, an antiangiogenic therapy, has the potential to  nonoseaeaeonlyasinstruction  Discontinue CYRAMZA therapy in patients with  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    Withhold CYRAMZA prior to surgery.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,cyramza,208,6536,6550,Resume following the surgical intervention based on clinical judgment of adequate wound healing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,cyramza,209,6550,6579,"If a patient develops  nonoseaeaeonlyasinstruction during therapy, discontinue CYRAMZA until the wound is fully healed [see Dosage and Administration (  2.3  )]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,cyramza,210,6579,6683,".\n', '\n', '\n', '\n', '    5.7 Clinical Deterioration in Patients with Child-Pugh B or C Cirrhosis\n', '\n', '\n', '\n', '  Clinical  oselabeledaefromdruguse  manifested by new onset or worsening encephalopathy, ascites, or hepatorenal syndrome was reported in patients with  oselabeledaefromdruguse or C  oselabeledaefromdruguse  oselabeledaefromdruguse  manifested by new onset or worsening encephalopathy, ascites, or hepatorenal syndrome was reported in patients with  oselabeledaefromdruguse or C  oselabeledaefromdruguse  nonoseaemanifestationorcomplication   ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
211,cyramza,211,6683,6707,nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication was reported in patients with Child-Pugh B or C cirrhosis who received single-agent CYRAMZA.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
212,cyramza,212,6707,6795,"Use CYRAMZA in patients with  notaecandidatepreexistingconditionorriskfactor or C  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor B or  notaecandidatepreexistingconditionorriskfactor only if the potential benefits of treatment are judged to outweigh the risks of clinical deterioration.\n', '\n', '\n', '\n', '    5.8 Reversible Posterior Leukoencephalopathy Syndrome\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  has been reported with a rate of <0.1% in clinical studies with CYRAMZA.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
213,cyramza,213,6795,6835,"Confirm the diagnosis of  nonoseaeaeonlyasinstruction with MRI and discontinue CYRAMZA in patients who develop  nonoseaeaeonlyasinstruction  Symptoms may resolve or improve within days, although some patients with  nonoseaeaeonlyasinstruction can experience ongoing  nonoseaemanifestationorcomplication or  nonoseaegeneralterm",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
214,cyramza,214,6835,6898,"\n', '\n', '\n', '\n', '       5.9 Proteinuria Including Nephrotic Syndrome\n', '\n', '\n', '\n', '     In Study 4, severe  oselabeledaefromdruguse occurred more frequently in patients treated with CYRAMZA plus FOLFIRI compared to patients receiving placebo plus FOLFIRI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,cyramza,215,6898,7006,"Severe  oselabeledaefromdruguse was reported in 3% of patients treated with CYRAMZA plus FOLFIRI (including 3 cases [0.6%] of  oselabeledaefromdruguse  compared to 0.2% of patients treated with placebo plus FOLFIRI.\n', '\n', '\n', '\n', '    Monitor  nonoseaeaeonlyasinstruction by urine dipstick and/or urinary protein creatinine ratio for the development of worsening of  nonoseaeaeonlyasinstruction during CYRAMZA therapy.\n', '\n', '\n', '\n', '    Withhold CYRAMZA for urine protein levels that are 2 or more grams over 24 hours.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,cyramza,216,7006,7027,Reinitiate CYRAMZA at a reduced dose once the urine protein level returns to less than 2 grams over 24 hours.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,cyramza,217,7027,7061,Permanently discontinue CYRAMZA for urine protein levels greater than 3 grams over 24 hours or in the setting of  nonoseaeaeonlyasinstruction [see Dosage and Administration (  2.3  )].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,cyramza,218,7061,7105,"\n', '\n', '\n', '\n', '       5.10 Thyroid Dysfunction\n', '\n', '\n', '\n', '     Monitor thyroid function during treatment with CYRAMZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,cyramza,219,7105,7158,"In Study 4, the incidence of  oselabeledaefromdruguse reported as an adverse event was 2.6% in the CYRAMZA plus FOLFIRI treated patients and 0.9% in the placebo plus FOLFIRI treated patients.\n', '\n', '\n', '\n', '       5.11  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,cyramza,220,7158,7190,"\n', '\n', '\n', '     Based on its mechanism of action, CYRAMZA can cause  oselabeledaefromdruguse when administered to  notaecandidatepreexistingconditionorriskfactor women.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
221,cyramza,221,7190,7217,"Animal models link angiogenesis, VEGF and VEGF Receptor 2 (VEGFR2) to critical aspects of female reproduction, embryofetal development, and postnatal development.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,cyramza,222,7217,7228,Advise  notaecandidatepreexistingconditionorriskfactor women of the potential  oselabeledaefromdruguse '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,luzu,0,0,41,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions observed in clinical trials were application site reactions, which occurred in less than 1% of subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,luzu,1,41,93,"(  6.1  ).\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,luzu,2,93,130,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,luzu,3,130,252,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In three Phase 3 clinical trials, 616 subjects were exposed to LUZU Cream, 1%: 305 with  notaecandidateindication and 311 subjects with  notaecandidateindication  Subjects with  notaecandidateindication or  notaecandidateindication applied LUZU Cream, 1% or vehicle cream once daily for 14 days or 7 days, respectively, to affected and adjacent areas.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,luzu,4,252,287,"During clinical trials with LUZU Cream, 1%, the most common adverse reactions were  oselabeledaefromdruguse which occurred in less than 1% of subjects in both the LUZU and vehicle arms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,luzu,5,287,347,"Most adverse reactions were mild in severity.\n', '\n', '\n', '\n', '   6.2 Post-Marketing Experience\n', '\n', '  The following adverse reactions have been identified during postmarketing use of luliconazole cream, 1%:  oselabeledaefromdruguse and  oselabeledaefromdruguse ']",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,avastin,0,0,58,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse Perforations and  oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,avastin,1,58,100,"\n', ' *  Surgery and  oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,avastin,2,100,120,"\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,avastin,3,120,140,"\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,avastin,4,140,160,"\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.6)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,avastin,5,160,170,"\n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,avastin,6,170,180,Warnings and Precautions (5.7)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,avastin,7,180,203,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.8)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,avastin,8,203,213,"\n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,avastin,9,213,223,Warnings and Precautions (5.9)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,avastin,10,223,243,"\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.11)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,avastin,11,243,253,"\n', ' *   nonoseaeaefromdruginteraction [see  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
12,avastin,12,253,262,Warnings and Precautions (5.12)   . ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,avastin,13,262,264,.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,avastin,14,264,265,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,avastin,15,265,283,"', '      EXCERPT:   Most common adverse reactions incidence (incidence > 10%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,avastin,16,283,312,"are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,avastin,17,312,358,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Genentech, Inc. at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,avastin,18,358,387,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,avastin,19,387,488,"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n', '\n', ' The most common adverse reactions observed in patients receiving Avastin as a single agent or in combination with chemotherapy at a rate > 10%, are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,avastin,20,488,629,"\n', '\n', ' The safety data below reflect exposure to Avastin in 2919 patients with  notaecandidateindication  non-squamous  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication  platinum-resistant or platinum-sensitive  notaecandidateindication  fallopian tube, or primary peritoneal  notaecandidateindication  notaecandidateindication  or primary peritoneal  notaecandidateindication  notaecandidateindication  including controlled studies (AVF2107g, E3200, E4599, EORTC 26101, BO17705, GOG-0240, MO22224, AVF4095, GOG-0213) at the recommended dose and schedule for a median of 6 to 23 doses.\n', '\n', ' Across clinical studies, Avastin was discontinued in 8% to 22% of patients because of adverse reactions  [see  Clinical Studies (14)  ].  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
21,avastin,21,629,655,"\n', '\n', '     Platinum  -  Resistant Recurrent Epithelia Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,avastin,22,655,747,"\n', '\n', ' The safety of Avastin was evaluated in 179 patients who received at least one dose of Avastin in a multicenter, open-label study (MO22224) in which patients were randomized (1:1) to Avastin with chemotherapy or chemotherapy alone in patients with platinum resistant,  notaecandidateindication  fallopian tube, or primary peritoneal  notaecandidateindication  notaecandidateindication  or primary peritoneal  notaecandidateindication  notaecandidateindication that recurred within < 6 months from the most recent platinum based therapy.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
23,avastin,23,747,771,Patients were randomized to receive Avastin (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,avastin,24,771,782,Patients had received no more than 2 prior chemotherapy regimens.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,avastin,25,782,817,The trial excluded patients with evidence of  notaecandidatepreexistingconditionorriskfactor by pelvic examination or  notaecandidatepreexistingconditionorriskfactor on CT scan or clinical symptoms of  notaecandidatepreexistingconditionorriskfactor  Patients were treated until disease progression or unacceptable toxicity.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
26,avastin,26,817,832,Forty percent of patients on the chemotherapy alone arm received Avastin alone upon progression.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,avastin,27,832,848,The demographics of the safety population were similar to the demographics of the efficacy population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,avastin,28,848,945,"Adverse reactions are presented in  Table 2  .\n', '\n', ' Table 2: Grade 2-4 Adverse Reactions Occurring at Higher Incidence (>= 5%) in Patients Receiving Avastin with Chemotherapy vs. Chemotherapy Alone in Study MO22224 \n', ' Adverse Reaction [note: NCI-CTC version 3]   Avastin with Chemotherapy(N=179)          Chemotherapy(N=181)          \n', '  \n', '    nonoseaegeneralterm     \n', '    oselabeledaefromdruguse                                      31%                                25%                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,avastin,29,945,952,"\n', '    oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,avastin,30,952,970,"\n', '    oselabeledaefromdruguse                             13%                                6%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,avastin,31,970,972,nonoseaegeneralterm                         ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,avastin,32,972,985,"\n', '    oselabeledaefromdruguse                                        11%                                4%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,avastin,33,985,990,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,avastin,34,990,1012,"nonoseaegeneralterm           \n', '     oselabeledaefromdruguse                   18%                                7%                   \n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,avastin,35,1012,1025,"\n', '    oselabeledaefromdruguse                                      12%                               0.6%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,avastin,36,1025,1032,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,avastin,37,1032,1050,"\n', '    oselabeledaefromdruguse                                        5%                                 0%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,avastin,38,1050,1052,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,avastin,39,1052,1077,"\n', '    oselabeledaefromdruguse                 11%                                5%                   \n', '    nonoseaegeneralterm                                                    \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,avastin,40,1077,1088,"oselabeledaefromdruguse                                     19%                                6%                   \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,avastin,41,1088,1226,"'         Grade 3-4 adverse reactions occurring at a higher incidence ( >= 2%) in 179 patients receiving Avastin with chemotherapy compared to 181 patients receiving chemotherapy alone were  oselabeledaefromdruguse (6.7% vs. 1.1%) and  oselabeledaefromdruguse (4.5% vs. 1.7%).\n', ' \n', '\n', '     Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer  \n', '\n', ' The safety of Avastin was evaluated in 247 patients who received at least one dose of Avastin in a double-blind study (AVF4095g) in patients with platinum sensitive  notaecandidateindication  fallopian tube or primary peritoneal  notaecandidateindication  notaecandidateindication or primary peritoneal  notaecandidateindication  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
42,avastin,42,1226,1268,Patients were randomized (1:1) to receive Avastin (15 mg/kg) or placebo every 3 weeks with carboplatin and gemcitabine for 6 to 10 cycles followed by Avastin or placebo alone until disease progression or unacceptable toxicity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,avastin,43,1268,1284,The demographics of the safety population were similar to the demographics of the efficacy population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,avastin,44,1284,1333,"Adverse reactions are presented in  Table 3  .\n', '\n', ' Table 3: Grade 1-5 Adverse Reactions Occurring at a Higher Incidence (>= 5%) in Patients Receiving Avastin with Chemotherapy vs. Placebo with Chemotherapy in Study",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,avastin,45,1333,1334,AVF4095,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,avastin,46,1334,1358,"g \n', ' Adverse Reaction [note: NCI-CTC version 3]   Avastin with Carboplatin and Gemcitabine(N=247)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,avastin,47,1358,1365,Placebo with Carboplatin and Gemcitabine(N=233)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,avastin,48,1365,1375,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,avastin,49,1375,1377,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,avastin,50,1377,1390,"\n', '    oselabeledaefromdruguse                                 58%                                51%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,avastin,51,1390,1410,"\n', '    nonoseaegeneralterm         \n', '    oselabeledaefromdruguse                                           72%                                66%                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,avastin,52,1410,1423,"\n', '    oselabeledaefromdruguse                                         38%                                29%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,avastin,53,1423,1469,"\n', '    oselabeledaefromdruguse                                       15%                                7%                   \n', '    oselabeledaefromdruguse                                      8%                                 3%                   \n', '    oselabeledaefromdruguse                                7%                                 0%                   \n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,avastin,54,1469,1482,"\n', '    oselabeledaefromdruguse                                          82%                                75%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,avastin,55,1482,1495,"\n', '    oselabeledaefromdruguse                             15%                                10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,avastin,56,1495,1502,"\n', '    nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,avastin,57,1502,1507,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,avastin,58,1507,1522,"oselabeledaefromdruguse                                        15%                                9%                   \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,avastin,59,1522,1535,"\n', '    oselabeledaefromdruguse                                        17%                                9%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,avastin,60,1535,1542,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,avastin,61,1542,1555,"\n', '    oselabeledaefromdruguse                                       28%                                19%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,avastin,62,1555,1568,"\n', '    oselabeledaefromdruguse                                        21%                                13%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,avastin,63,1568,1585,"\n', '    nonoseaegeneralterm           \n', '    oselabeledaefromdruguse                                         49%                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,avastin,64,1585,1588,30%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,avastin,65,1588,1601,"\n', '    oselabeledaefromdruguse                                        23%                                17%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,avastin,66,1601,1608,"\n', '    nonoseaegeneralterm              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,avastin,67,1608,1621,"\n', '    oselabeledaefromdruguse                                         21%                                15%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,avastin,68,1621,1628,"\n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,avastin,69,1628,1641,"\n', '    oselabeledaefromdruguse                                      20%                                3%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,avastin,70,1641,1648,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,avastin,71,1648,1661,"\n', '    oselabeledaefromdruguse                                        55%                                14%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,avastin,72,1661,1674,"\n', '    oselabeledaefromdruguse                                          30%                                24%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,avastin,73,1674,1687,"\n', '    oselabeledaefromdruguse                                            26%                                18%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,avastin,74,1687,1700,"\n', '    oselabeledaefromdruguse                               16%                                10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,avastin,75,1700,1713,"\n', '    oselabeledaefromdruguse                                        13%                                3%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,avastin,76,1713,1744,"\n', '    oselabeledaefromdruguse                                       10%                                4%                   \n', '    oselabeledaefromdruguse                                 8%                                 2%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,avastin,77,1744,1941,"nonoseaegeneralterm                 \n', '    oselabeledaefromdruguse                                     42%                                9%                   \n', '         Grade 3-4 adverse reactions occurring at a higher incidence (>= 2%) in patients receiving Avastin with chemotherapy compared to placebo with chemotherapy were:  oselabeledaefromdruguse (40% vs. 34%),  oselabeledaefromdruguse (4% vs. 1.3%),  oselabeledaefromdruguse (6% vs. 4%),  oselabeledaefromdruguse (4% vs. 0.9%),  oselabeledaefromdruguse (10% vs. 0.4%),  oselabeledaefromdruguse (4% vs. 1.7%),  oselabeledaefromdruguse (5% vs. 0.4%), and  oselabeledaefromdruguse (17% vs. 0.9%).\n', ' \n', '\n', ' The safety of Avastin was evaluated in an open-label, controlled study, GOG-0213, in 325 patients with platinum-sensitive  notaecandidateindication  fallopian tube, or primary peritoneal  notaecandidateindication  notaecandidateindication  or primary peritoneal  notaecandidateindication  notaecandidateindication  who have not received more than one previous regimen of chemotherapy.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
78,avastin,78,1941,1991,Patients were randomized (1:1) to receive carboplatin and paclitaxel for 6 to 8 cycles or Avastin (15 mg/kg every 3 weeks) with carboplatin and paclitaxel for 6 to 8 cycles followed by Avastin as a single agent until disease progression or unacceptable toxicity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,avastin,79,1991,2007,The demographics of the safety population were similar to the demographics of the efficacy population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,avastin,80,2007,2105,"Adverse reactions are presented in  Table 4  .\n', '\n', ' Table 4: Grade 1-5 Adverse Reactions Occurring at Higher Incidence (>= 5%) in Patients Receiving Avastin with Chemotherapy vs. Chemotherapy Alone in Study GOG-0213 \n', ' Adverse Reaction [note: NCI-CTC version 3]   Avastin with Carboplatin and Paclitaxel(N=325)  Carboplatin and Paclitaxel(N=332)   \n', '  \n', '    nonoseaegeneralterm         \n', '    oselabeledaefromdruguse                                         39%                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,avastin,81,2105,2108,32%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,avastin,82,2108,2121,"\n', '    oselabeledaefromdruguse                                   33%                                28%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,avastin,83,2121,2131,"\n', '    oselabeledaefromdruguse                                         33%                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,avastin,84,2131,2134,25%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,avastin,85,2134,2147,"\n', '    oselabeledaefromdruguse                                       33%                                16%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,avastin,86,2147,2154,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,avastin,87,2154,2167,"\n', '    oselabeledaefromdruguse                               35%                                25%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,avastin,88,2167,2180,"\n', '    oselabeledaefromdruguse                                    31%                                24%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,avastin,89,2180,2193,"\n', '    oselabeledaefromdruguse                                   27%                                17%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,avastin,90,2193,2219,"\n', '    oselabeledaefromdruguse                                     17%                                6%                   \n', '    oselabeledaefromdruguse                                 15%                                4%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,avastin,91,2219,2245,"\n', '    oselabeledaefromdruguse                                     12%                                5%                   \n', '    oselabeledaefromdruguse                                  11%                                6%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,avastin,92,2245,2263,"\n', '    oselabeledaefromdruguse                                     9%                                 3%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,avastin,93,2263,2265,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
94,avastin,94,2265,2278,"\n', '    oselabeledaefromdruguse                                       45%                                30%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,avastin,95,2278,2291,"\n', '    oselabeledaefromdruguse                                          29%                                18%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,avastin,96,2291,2304,"\n', '    oselabeledaefromdruguse                                25%                                14%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,avastin,97,2304,2317,"\n', '    oselabeledaefromdruguse                                        17%                                10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,avastin,98,2317,2330,"\n', '    oselabeledaefromdruguse                                13%                                8%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,avastin,99,2330,2348,"\n', '    oselabeledaefromdruguse                                        9%                                 0%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,avastin,100,2348,2350,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
101,avastin,101,2350,2363,"\n', '    oselabeledaefromdruguse                                        33%                                2%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,avastin,102,2363,2376,"\n', '    oselabeledaefromdruguse                                          30%                                25%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,avastin,103,2376,2389,"\n', '    oselabeledaefromdruguse                                            30%                                17%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,avastin,104,2389,2394,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,avastin,105,2394,2402,oselabeledaefromdruguse                                17%                                4%                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,avastin,106,2402,2415,"\n', '    oselabeledaefromdruguse                           14%                                3%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,avastin,107,2415,2435,"\n', '    nonoseaegeneralterm           \n', '    oselabeledaefromdruguse                                         38%                                20%                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
108,avastin,108,2435,2448,"\n', '    oselabeledaefromdruguse                                       14%                                2%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,avastin,109,2448,2461,"\n', '    oselabeledaefromdruguse                                        13%                                8%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,avastin,110,2461,2468,"\n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,avastin,111,2468,2486,"\n', '    oselabeledaefromdruguse                 15%                                9%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,avastin,112,2486,2488,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,avastin,113,2488,2498,"\n', '    oselabeledaefromdruguse                                 23%                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,avastin,114,2498,2501,16%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,avastin,115,2501,2532,"\n', '    oselabeledaefromdruguse                                    10%                                2%                   \n', '    oselabeledaefromdruguse                                         7%                                 2%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,avastin,116,2532,2554,"nonoseaegeneralterm                 \n', '    oselabeledaefromdruguse                                     42%                                3%                   \n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
117,avastin,117,2554,2567,"\n', '    oselabeledaefromdruguse                                      17%                                1%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,avastin,118,2567,2580,"\n', '    oselabeledaefromdruguse                       13%                                5%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,avastin,119,2580,2587,"\n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,avastin,120,2587,2592,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,avastin,121,2592,2752,"oselabeledaefromdruguse                                       8%                                 2%                   \n', '    nonoseaegeneralterm                                                            \n', '    oselabeledaefromdruguse                                        7%                                 2%                   \n', '         Grade 3-4 adverse reactions occurring at a higher incidence (>= 2%) in patients receiving Avastin with chemotherapy compared to chemotherapy alone were:  oselabeledaefromdruguse (11% vs. 0.6%),  oselabeledaefromdruguse (8% vs. 3%),  oselabeledaefromdruguse (6% vs. 3%),  oselabeledaefromdruguse (8% vs. 0%),  oselabeledaefromdruguse (6% vs. 0.9%),  oselabeledaefromdruguse (4% vs. 0.9%),  oselabeledaefromdruguse (3% vs. 0.9%), and  oselabeledaefromdruguse (3% vs. 0%).\n', ' \n', '\n', '     Metastatic Renal Cell Carcinoma (mRCC)  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
122,avastin,122,2752,2824,"\n', '\n', ' The safety of Avastin was evaluated in 337 patients who received at least one dose of Avastin in a multicenter, double-blind study (BO17705) in patients with  notaecandidateindication  Patients who had undergone a nephrectomy were randomized (1:1) to receive either Avastin (10 mg/kg every 2 weeks) or placebo with interferon alfa.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
123,avastin,123,2824,2834,Patients were treated until disease progression or unacceptable toxicity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,avastin,124,2834,2957,"The demographics of the safety population were similar to the demographics of the efficacy population.\n', '\n', ' Grade 3-5 adverse reactions occurring at a higher incidence ( >2%) were  oselabeledaefromdruguse (13% vs. 8%),  oselabeledaefromdruguse (10% vs. 7%),  oselabeledaefromdruguse (7% vs. 0%),  oselabeledaefromdruguse (6% vs. 1%; including  oselabeledaefromdruguse and  oselabeledaefromdruguse , and  oselabeledaefromdruguse (3% vs. 0.3%; including  oselabeledaefromdruguse  small  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  large  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,avastin,125,2957,3055,"Adverse reactions are presented in  Table 5  .\n', '\n', ' Table 5: Grades 1-5 Adverse Reactions Occurring at Higher Incidence (>= 5%) of Patients Receiving Avastin vs. Placebo with Interferon Alfa in Study BO17705 \n', ' Adverse Reaction [note: NCI-CTC version 3]   Avastin with Interferon Alfa(N=337)  Placebo with Interferon Alfa(N=304)   \n', '  \n', '    nonoseaegeneralterm         \n', '    oselabeledaefromdruguse                                         21%                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
126,avastin,126,3055,3058,16%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,avastin,127,3058,3065,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
128,avastin,128,3065,3078,"\n', '    oselabeledaefromdruguse                                          33%                                27%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,avastin,129,3078,3085,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,avastin,130,3085,3098,"\n', '    oselabeledaefromdruguse                               36%                                31%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,avastin,131,3098,3111,"\n', '    oselabeledaefromdruguse                                 20%                                15%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,avastin,132,3111,3118,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
133,avastin,133,3118,3131,"\n', '    oselabeledaefromdruguse                                          19%                                14%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,avastin,134,3131,3144,"\n', '    oselabeledaefromdruguse                                        12%                                6%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,avastin,135,3144,3161,"\n', '    nonoseaegeneralterm           \n', '    oselabeledaefromdruguse                                         24%                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,avastin,136,3161,3164,16%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,avastin,137,3164,3171,"\n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,avastin,138,3171,3184,"\n', '    oselabeledaefromdruguse                                      20%                                3%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,avastin,139,3184,3191,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
140,avastin,140,3191,3204,"\n', '    oselabeledaefromdruguse                                        27%                                4%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,avastin,141,3204,3218,"\n', '    oselabeledaefromdruguse                                        5%                                 0%                   \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,avastin,142,3218,3387,"', '    nonoseaegeneralterm                                                    \n', '    oselabeledaefromdruguse                                     28%                                9%                   \n', '         The following adverse reactions were reported at a 5-fold greater incidence in patients receiving Avastin with interferon-alfa compared to patients receiving placebo with interferon-alfa and not represented in Table 3:  oselabeledaefromdruguse (13 patients vs. 1 patient);  oselabeledaefromdruguse (9 vs. 0);  oselabeledaefromdruguse (8 vs. 0);  oselabeledaefromdruguse (8 vs. 1);  oselabeledaefromdruguse (8 vs. 1);  oselabeledaefromdruguse (7 vs. 1);  oselabeledaefromdruguse (7 vs. 0);  oselabeledaefromdruguse (6 vs. 0);  oselabeledaefromdruguse (5 vs. 0);  oselabeledaefromdruguse (5 vs. 0);  oselabeledaefromdruguse (5 vs. 0);  oselabeledaefromdruguse (5 vs. 0) and  oselabeledaefromdruguse (5 vs. 1).\n', ' \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,avastin,143,3387,3402,"'\n', '     Persistent, Recurrent, or Metastatic Cervical Cancer  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,avastin,144,3402,3440,"\n', '\n', ' The safety of Avastin was evaluated in 218 patients who received at least one dose of Avastin in a multicenter study (GOG-0240) in patients with persistent,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,avastin,145,3440,3451,notaecandidateindication  or metastatic  notaecandidateindication  notaecandidateindication  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
146,avastin,146,3451,3494,"Patients were randomized (1:1:1:1) to receive paclitaxel and cisplatin with or without Avastin (15 mg/kg every 3 weeks), or paclitaxel and topotecan with or without Avastin (15 mg/kg every 3 weeks).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,avastin,147,3494,3510,The demographics of the safety population were similar to the demographics of the efficacy population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,avastin,148,3510,3554,"Adverse reactions are presented in  Table 6  .\n', '\n', ' Table 6: Grades 1-4 Adverse Reactions Occurring at Higher Incidence (>= 5%) in Patients Receiving Avastin with Chemotherapy vs. Chemotherapy",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,avastin,149,3554,3558,Alone in Study GOG-0240,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,avastin,150,3558,3567,"\n', ' Adverse Reaction [note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,avastin,151,3567,3582,NCI-CTC version 3]   Avastin with Chemotherapy(N=218)          Chemotherapy(N=222)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,avastin,152,3582,3592,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,avastin,153,3592,3594,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
154,avastin,154,3594,3607,"\n', '    oselabeledaefromdruguse                               34%                                26%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,avastin,155,3607,3620,"\n', '    oselabeledaefromdruguse                                    26%                                19%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,avastin,156,3620,3633,"\n', '    oselabeledaefromdruguse                                   24%                                15%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,avastin,157,3633,3646,"\n', '    oselabeledaefromdruguse                                 21%                                7%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,avastin,158,3646,3659,"\n', '    oselabeledaefromdruguse                                     19%                                10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,avastin,159,3659,3672,"\n', '    oselabeledaefromdruguse                                  16%                                11%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,avastin,160,3672,3679,"\n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
161,avastin,161,3679,3692,"\n', '    oselabeledaefromdruguse                                          80%                                75%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,avastin,162,3692,3705,"\n', '    oselabeledaefromdruguse                                 15%                                22%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,avastin,163,3705,3712,"\n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
164,avastin,164,3712,3725,"\n', '    oselabeledaefromdruguse                          22%                                14%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,avastin,165,3725,3738,"\n', '    oselabeledaefromdruguse                                        10%                                5%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,avastin,166,3738,3791,"\n', '    nonoseaegeneralterm                 \n', '    oselabeledaefromdruguse                                     29%                                6%                   \n', '    oselabeledaefromdruguse                                       10%                                3%                   \n', '    nonoseaegeneralterm           \n', '    oselabeledaefromdruguse                                         22%                                13%                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
167,avastin,167,3791,3824,"\n', '    oselabeledaefromdruguse                                       8%                                 1%                   \n', '    nonoseaegeneralterm         \n', '    oselabeledaefromdruguse                                       15%                                10%                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,avastin,168,3824,3829,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,avastin,169,3829,3850,"oselabeledaefromdruguse                                       6%                                 1%                   \n', '    oselabeledaefromdruguse                                     6%                                0.0%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,avastin,170,3850,3857,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
171,avastin,171,3857,3870,"\n', '    oselabeledaefromdruguse                                      12%                                6%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,avastin,172,3870,3883,"\n', '    oselabeledaefromdruguse                                      12%                                5%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,avastin,173,3883,3888,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,avastin,174,3888,3890,nonoseaegeneralterm              ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
175,avastin,175,3890,3903,"\n', '    oselabeledaefromdruguse                                          17%                                10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,avastin,176,3903,3910,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
177,avastin,177,3910,3923,"\n', '    oselabeledaefromdruguse                                      14%                                8%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,avastin,178,3923,3930,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
179,avastin,179,3930,3943,"\n', '    oselabeledaefromdruguse                                        17%                                1%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,avastin,180,3943,3950,"\n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
181,avastin,181,3950,3963,"\n', '    oselabeledaefromdruguse                       16%                                10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,avastin,182,3963,3976,"\n', '    oselabeledaefromdruguse                                      10%                                3%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,avastin,183,3976,4024,"\n', '         Grade 3-4 adverse reactions occurring at a higher incidence (>= 2%) in 218 patients receiving Avastin with chemotherapy compared to 222 patients receiving chemotherapy alone were  oselabeledaefromdruguse (12% vs. 10%),  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,avastin,184,4024,4173,"oselabeledaefromdruguse (11% vs. 0.5%),  oselabeledaefromdruguse (8% vs. 3%),  oselabeledaefromdruguse (6% vs. 3%),  oselabeledaefromdruguse (4% vs. 0%),  oselabeledaefromdruguse (3% vs. 0%),  oselabeledaefromdruguse (8% vs. 6%),  oselabeledaefromdruguse (3% vs. 0.5%),  oselabeledaefromdruguse (14% vs. 10%),  oselabeledaefromdruguse (7% vs. 4%),  oselabeledaefromdruguse (4% vs. 1%),  oselabeledaefromdruguse (4% vs. 0.5%),  oselabeledaefromdruguse (8% vs. 4%),  oselabeledaefromdruguse (6% vs. 3%),  oselabeledaefromdruguse (6% vs. 3%), and  oselabeledaefromdruguse (6% vs. 1%).\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,avastin,185,4173,4256,"' \n', '\n', '     Metastatic Colorectal Cancer (mCRC)  \n', '\n', ' The safety of Avastin was evaluated in 392 patients who received at least one dose of Avastin in a double-blind, active-controlled study (AVF2107g), which compared Avastin (5 mg/kg every 2 weeks) with bolus-IFL to placebo with bolus IFL in patients with mCRC.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,avastin,186,4256,4281,"Patients were randomized (1:1:1) to placebo with bolus IFL, Avastin with bolus IFL, or Avastin with 5 fluorouracil and leucovorin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,avastin,187,4281,4336,"The demographics of the safety population were similar to the demographics of the efficacy population.\n', '\n', ' All Grade 3-4 adverse reactions and selected Grade 1-2 adverse reactions (i.e.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  were collected in the entire study population.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,avastin,188,4336,4381,"Adverse reactions are presented in  Table 7  .\n', '\n', ' Table 7: Grade 3-4 Adverse Reactions Occurring at Higher Incidence (>= 2%) in Patients Receiving Avastin vs. Placebo in Study AVF2107",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,avastin,189,4381,4408,"g \n', ' Adverse Reaction [note: NCI-CTC version 3]        Avastin with IFL(N=392)            Placebo with IFL(N=396)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,avastin,190,4408,4420,"\n', '  \n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
191,avastin,191,4420,4433,"\n', '    oselabeledaefromdruguse                                         10%                                7%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,avastin,192,4433,4451,"\n', '    oselabeledaefromdruguse                                             8%                                 5%                   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,avastin,193,4451,4522,"nonoseaegeneralterm                 \n', '    oselabeledaefromdruguse                                     12%                                2%                   \n', '    oselabeledaefromdruguse                             9%                                 5%                   \n', '    oselabeledaefromdruguse                       3%                                 1%                   \n', '    oselabeledaefromdruguse                                          3%                                 1%                   \n', '    nonoseaegeneralterm         \n', '    oselabeledaefromdruguse                                         34%                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
194,avastin,194,4522,4525,25%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,avastin,195,4525,4530,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,avastin,196,4530,4558,"oselabeledaefromdruguse                                   8%                                 5%                   \n', '    oselabeledaefromdruguse                                     4%                                 2%                   \n', '    nonoseaegeneralterm      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
197,avastin,197,4558,4571,"\n', '    oselabeledaefromdruguse                                       37%                                31%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,avastin,198,4571,4584,"\n', '    oselabeledaefromdruguse                                      21%                                14%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,avastin,199,4584,4612,"\n', '         The safety of Avastin was evaluated in 521 patients in an open-label, active-controlled study (E3200).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,avastin,200,4612,4669,"Patients who were previously treated with irinotecan and fluorouracil for initial therapy for  notaecandidatepreexistingconditionorriskfactor  Patients were randomized (1:1:1) to FOLFOX4, Avastin (10 mg/kg every 2 weeks prior to FOLFOX4 on Day 1) with FOLFOX4, or Avastin alone (10 mg/kg every 2 weeks).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
201,avastin,201,4669,4705,"Avastin was continued until disease progression or unacceptable toxicity.\n', ' \n', '\n', ' The demographics of the safety population were similar to the demographics of the efficacy population.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,avastin,202,4705,4868,"The most frequent adverse reactions (selected Grade 3-5 non-hematologic and Grade 4-5 hematologic) occurring at a higher incidence (>= 2%) in patients receiving Avastin with FOLFOX4 compared to FOLFOX4 alone were  oselabeledaefromdruguse (19% vs. 13%),  oselabeledaefromdruguse (18% vs. 13%),  oselabeledaefromdruguse (17% vs. 9%),  oselabeledaefromdruguse (12% vs. 5%),  oselabeledaefromdruguse (11% vs. 4%),  oselabeledaefromdruguse (10% vs. 5%),  oselabeledaefromdruguse (9% vs. 2%),  oselabeledaefromdruguse (8% vs. 5%),  oselabeledaefromdruguse (5% vs. 1%),  oselabeledaefromdruguse (5% vs. 3%),  oselabeledaefromdruguse (4% vs. 1%) and  oselabeledaefromdruguse (3% vs. 0%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,avastin,203,4868,4908,"These data are likely to under-estimate the true adverse event rates due to the reporting mechanisms.\n', '\n', '     First-Line Non Squamous Non Small Cell Lung Cancer (NSCLC)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,avastin,204,4908,4958,"\n', '\n', ' The safety of Avastin was evaluated as first-line treatment in 422 patients with unresectable  notaecandidateindication who received at least one dose of Avastin in an active-controlled, open-label, multicenter trial (E4599).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
205,avastin,205,4958,5002,"Chemotherapy naive patients with locally advanced, metastatic or recurrent non-squamous  notaecandidateindication were randomized (1:1) to receive six 21 day cycles of paclitaxel and carboplatin with or without Avastin (15 mg/kg every 3 weeks).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
206,avastin,206,5002,5028,"After completion or upon discontinuation of chemotherapy, patients randomized to receive Avastin continued to receive Avastin alone until disease progression or until unacceptable toxicity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,avastin,207,5028,5066,"The trial excluded patients with predominant squamous histology (mixed cell type tumors only),  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor (1/2 teaspoon or more of red blood),  notaecandidatepreexistingconditionorriskfactor  or receiving therapeutic anticoagulation.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
208,avastin,208,5066,5105,"The demographics of the safety population were similar to the demographics of the efficacy population.\n', '\n', ' Only Grade 3-5 non hematologic and Grade 4-5  nonoseaeaeonlyasinstruction were collected.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,avastin,209,5105,5272,"Grade 3-5  nonoseaegeneralterm and Grade 4-5 hematologic  nonoseaegeneralterm  oselabeledaefromdruguse occurring at a higher incidence (>= 2%) in patients receiving Avastin with paclitaxel and carboplatin compared with patients receiving chemotherapy alone were  oselabeledaefromdruguse (27% vs. 17%),  oselabeledaefromdruguse (16% vs. 13%),  oselabeledaefromdruguse (8% vs. 0.7%), infection without  oselabeledaefromdruguse (7% vs. 3%),  oselabeledaefromdruguse (5% vs. 3%),  oselabeledaefromdruguse (5% vs. 2%),  oselabeledaefromdruguse  oselabeledaefromdruguse (5% vs. 3%), infection with Grade 3 or 4  oselabeledaefromdruguse (4% vs. 2%),  oselabeledaefromdruguse (4% vs. 1%),  oselabeledaefromdruguse (3% vs. 1%) and  oselabeledaefromdruguse (3% vs. 0%).\n', '\n', '     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
210,avastin,210,5272,5275,Recurrent Glioblastoma  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,avastin,211,5275,5289,"\n', '\n', ' EORTC 26101 was a multicenter,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,avastin,212,5289,5321,"randomized, open-label study in patients with  notaecandidateindication following radiotherapy and temozolomide of whom 278 patients received at least one dose of Avastin and are considered safety evaluable.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
213,avastin,213,5321,5351,Patients were randomized (2:1) to receive Avastin (10 mg/kg every 2 weeks) with lomustine or lomustine alone until disease progression or unacceptable toxicity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,avastin,214,5351,5367,The demographics of the safety population were similar to the demographics of the efficacy population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,avastin,215,5367,5395,"In the Avastin with lomustine arm, 22% of patients discontinued treatment due to adverse reactions compared with 10% of patients in the lomustine arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,avastin,216,5395,5447,"In patients receiving Avastin with lomustine, the adverse reaction profile was similar to that observed in other approved indications.\n', '\n', '   6.2 Immunogenicity\n', '\n', '  As with all therapeutic proteins, there is a potential for  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,avastin,217,5447,5464,The detection of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,avastin,218,5464,5512,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,avastin,219,5512,5545,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction in the studies described below with the incidence of  nonoseaeaeonlyasinstruction in other studies or  nonoseaeaeonlyasinstruction may be misleading.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,avastin,220,5545,5588,"'\n', ' In clinical studies for adjuvant treatment of a solid  nonoseaeaeonlyasinstruction  0.6% (14/2323) of patients tested positive for treatment-emergent  oselabeledaefromdruguse as detected by an electrochemiluminescent (ECL) based assay.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,avastin,221,5588,5610,"Among these 14 patients, three tested  oselabeledaefromdruguse against bevacizumab using an enzyme-linked immunosorbent assay (ELISA).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,avastin,222,5610,5654,"The clinical significance of these  nonoseaeaeonlyasinstruction is not known.\n', '\n', '   6.3 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of Avastin.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,avastin,223,5654,5719,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
224,avastin,224,5719,5721,nonoseaegeneralterm    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
225,avastin,225,5721,5737,oselabeledaefromdruguse  Renal:   oselabeledaefromdruguse (manifested as severe  nonoseaemanifestationorcomplication    nonoseaegeneralterm    oselabeledaefromdruguse,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
226,avastin,226,5737,5738,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,avastin,227,5738,5749,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,avastin,228,5749,5751,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,avastin,229,5751,5762,"GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,avastin,230,5762,5772,"', '\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,avastin,231,5772,5796,"GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE  \n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,avastin,232,5796,5798,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,avastin,233,5798,5809,"GASTROINTESTINAL PERFORATIONS, SURGERY AND WOUND HEALING COMPLICATIONS, and HEMORRHAGE\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,avastin,234,5809,5827,"', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,avastin,235,5827,5845,"\n', '\n', ' *  Gastrointestinal Perforations: Discontinue for gastrointestinal perforation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,avastin,236,5845,5848,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,avastin,237,5848,5873,"\n', ' *  Surgery and Wound Healing Complications: Discontinue in patients who develop wound healing complications that require medical intervention.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,avastin,238,5873,5884,Withhold for at least 28 days prior to elective surgery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,avastin,239,5884,5903,Do not administer Avastin for at least 28 days after surgery and until the wound is fully healed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,avastin,240,5903,5906,(5.2),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,avastin,241,5906,5910,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,avastin,242,5910,5921,*  Hemorrhage: Severe or fatal hemorrhages have occurred.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,avastin,243,5921,5928,Do not administer for recent hemoptysis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,avastin,244,5928,5958,"Discontinue for Grade 3-4 hemorrhage (5.3) \n', '    \n', ' \n', '\n', '     oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,avastin,245,5958,5980,The incidence of  oselabeledaefromdruguse  some  nonoseaegeneralterm  in patients receiving Avastin ranges from 0.3% to 3%.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
246,avastin,246,5980,5995,Discontinue Avastin in patients who develop  oselabeledaefromdruguse   [see   Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,avastin,247,5995,6003,(5.1)  ]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,avastin,248,6003,6017,"\n', '\n', '     Surgery and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,avastin,249,6017,6043,"The incidence of  oselabeledaefromdruguse and surgical  oselabeledaefromdruguse  oselabeledaefromdruguse  including serious and  nonoseaegeneralterm complications, is increased in patients receiving Avastin.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
250,avastin,250,6043,6056,Discontinue Avastin in patients who develop  nonoseaeaeonlyasinstruction that require medical intervention.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,avastin,251,6056,6067,Withhold Avastin at least 28 days prior to elective surgery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,avastin,252,6067,6101,"Do not administer Avastin for at least 28 days after surgery, and until the wound is fully healed   [see   Warnings and Precautions (5.2)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,avastin,253,6101,6145,"\n', '\n', '      nonoseaegeneralterm  Severe or  nonoseaegeneralterm  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse occur up to 5-fold more frequently in patients receiving Avastin.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
254,avastin,254,6145,6171,Do not administer Avastin to patients with a recent history of  notaecandidatepreexistingconditionorriskfactor  Discontinue in patients who develop Grade 3-4  nonoseaeaeonlyasinstruction    ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
255,avastin,255,6171,6205,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Perforation or Fistula: Discontinue for tracheoesophageal fistula, grade 4 fistula, or necrotizing fasciitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,avastin,256,6205,6272,"(  5.1  ) \n', ' *  Arterial Thromboembolic Events (ATE): Discontinue for severe ATE. (  5.4  ) \n', ' *  Venous Thromboembolic Events (VTE): Discontinue for Grade 4 VTE. (  5.5  ) \n', ' *  Hypertension: Monitor blood pressure and treat hypertension.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,avastin,257,6272,6282,Withhold if not medically controlled; resume once controlled.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,avastin,258,6282,6290,Discontinue for hypertensive crisis or hypertensive encephalopathy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,avastin,259,6290,6311,"(  5.6  ) \n', ' *  Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,avastin,260,6311,6331,"(  5.7  ) \n', ' *  Renal Injury and Proteinuria: Monitor urine protein.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,avastin,261,6331,6336,Discontinue for nephrotic syndrome.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,avastin,262,6336,6347,Withhold until less than 2 grams of protein in urine.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,avastin,263,6347,6367,"(  5.8  ) \n', ' *  Infusion Reactions: Decrease rate for infusion reactions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,avastin,264,6367,6377,Discontinue for severe infusion reactions and administer medical therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,avastin,265,6377,6393,"(  5.9  ) \n', ' *  Embryo-fetal Toxicity:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,avastin,266,6393,6408,Advise females of potential risk to fetus and need for use of effective contraception.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,avastin,267,6408,6421,"(  5.10  ,  8.1  ,  8.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,avastin,268,6421,6425,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,avastin,269,6425,6430,*  Ovarian Failure:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,avastin,270,6430,6437,Advise females of the potential risk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,avastin,271,6437,6446,"(  5.11  ,  8.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,avastin,272,6446,6468,"\n', ' *  Congestive Heart Failure (CHF): Discontinue if CHF (  5.12  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,avastin,273,6468,6473,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,avastin,274,6473,6501,"\n', ' \n', '\n', '   5.1 Gastrointestinal Perforations and Fistulae\n', '\n', '  Serious and",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,avastin,275,6501,6524,sometimes  nonoseaegeneralterm  oselabeledaefromdruguse  oselabeledaefromdruguse perforation occur at a higher incidence in patients receiving Avastin compared to patients receiving chemotherapy.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
276,avastin,276,6524,6551,"The incidence ranged from 0.3% to 3% across clinical studies, with the highest incidence in patients with a history of prior pelvic radiation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,avastin,277,6551,6571,"Perforation can be complicated by intra-abdominal abscess, fistula formation, and the need for diverting ostomies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,avastin,278,6571,6588,The majority of  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse  and the need for diverting ostomies.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,avastin,279,6588,6709,"The majority of perforations occurred within 50 days of the first dose.\n', '\n', ' Serious  oselabeledaefromdruguse  oselabeledaefromdruguse (including, tracheoesophageal, bronchopleural, biliary, vaginal, renal and  oselabeledaefromdruguse  oselabeledaefromdruguse (including, tracheoesophageal, bronchopleural, biliary, vaginal,  oselabeledaefromdruguse  oselabeledaefromdruguse (including, tracheoesophageal, bronchopleural, biliary,  oselabeledaefromdruguse  oselabeledaefromdruguse (including, tracheoesophageal, bronchopleural,  oselabeledaefromdruguse  oselabeledaefromdruguse (including, tracheoesophageal,  oselabeledaefromdruguse  oselabeledaefromdruguse (including,  oselabeledaefromdruguse  bronchopleural, biliary, vaginal, renal and bladder sites) occur at a higher incidence in patients receiving Avastin compared to patients receiving chemotherapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,avastin,280,6709,6733,"The incidence ranged from < 1% to 1.8% across clinical studies, with the highest incidence in patients with  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
281,avastin,281,6733,6747,The majority of  oselabeledaefromdruguse occurred within 6 months of the first dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,avastin,282,6747,6840,"Patients who develop a  oselabeledaefromdruguse may also have a  nonoseaemanifestationorcomplication and require surgical intervention, as well as a diverting ostomy.\n', '\n', ' Avoid Avastin in patients with  notaecandidatepreexistingconditionorriskfactor who have evidence of  notaecandidatepreexistingconditionorriskfactor by pelvic examination or  notaecandidatepreexistingconditionorriskfactor on CT scan or clinical symptoms of  notaecandidatepreexistingconditionorriskfactor  Discontinue in patients who develop  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction or any Grade 4  nonoseaeaeonlyasinstruction  Discontinue in patients with  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6.1)  ].  ",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
283,avastin,283,6840,6856,"\n', '\n', '    5.2 Surgery and Wound Healing Complications\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,avastin,284,6856,6920,", '\n', '  In a controlled clinical study in which Avastin was not administered within 28 days of major surgical procedures, the incidence of  oselabeledaefromdruguse  including serious and  nonoseaegeneralterm complications, was 15% in patients with  notaecandidateindication who underwent surgery while receiving Avastin and 4% in patients who did not receive Avastin.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
285,avastin,285,6920,6969,In a controlled clinical study in patients with relapsed or recurrent  notaecandidateindication  the incidence of  oselabeledaefromdruguse was 5% in patients who received Avastin and 0.7% in patients who did not receive Avastin [see  Adverse Reactions (6.1)  ].  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
286,avastin,286,6969,6988,"\n', '\n', ' Discontinue Avastin in patients with  nonoseaeaeonlyasinstruction requiring medical intervention.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,avastin,287,6988,6999,Withhold for at least 28 days prior to elective surgery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,avastin,288,6999,7050,"Do not administer for at least 28 days following surgery and until the wound is fully healed.\n', '\n', '  oselabeledaefromdruguse including  nonoseaegeneralterm cases, has been reported in patients receiving Avastin, usually secondary to  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse formation.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
289,avastin,289,7050,7069,Discontinue in patients who develop  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6.3)  ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,avastin,290,7069,7084,"\n', '\n', '    5.3 Hemorrhage\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,avastin,291,7084,7162,"', '  Avastin can result in two distinct patterns of  oselabeledaefromdruguse  minor  oselabeledaefromdruguse  most commonly Grade 1  oselabeledaefromdruguse  and serious, and in some cases  nonoseaegeneralterm   oselabeledaefromdruguse  Severe or  nonoseaegeneralterm  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred up to 5-fold more frequently in patients receiving Avastin compared to patients receiving chemotherapy alone.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
292,avastin,292,7162,7199,"Across clinical studies, the incidence of Grades 3-5  oselabeledaefromdruguse events ranged from 0.4% to 7% in patients receiving Avastin [see  Adverse Reactions (6.1)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,avastin,293,7199,7275,"\n', '\n', ' Serious or  nonoseaegeneralterm  oselabeledaefromdruguse occurred in 31% of patients with squamous  notaecandidateindication and 4% of patients with non-squamous  notaecandidateindication receiving Avastin with chemotherapy compared to none of the patients receiving chemotherapy alone.\n', '\n', ' Do not administer Avastin to patients with recent history of  notaecandidatepreexistingconditionorriskfactor of 1/2 teaspoon or more of red blood.",0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
294,avastin,294,7275,7343,"Discontinue in patients who develop a Grade 3-4  nonoseaeaeonlyasinstruction \n', '\n', '    5.4 Arterial Thromboembolic Events\n', '\n', '  Serious, sometimes  nonoseaegeneralterm   oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurred at a higher incidence in patients receiving Avastin compared to patients receiving chemotherapy.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
295,avastin,295,7343,7386,"Across clinical studies, the incidence of Grades 3-5 ATE was 5% in patients receiving Avastin with chemotherapy compared to <= 2% in patients receiving chemotherapy alone; the highest incidence occurred in patients with  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
296,avastin,296,7386,7425,The risk of developing  nonoseaeaeonlyasinstruction was increased in patients with a history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or greater than 65 years old [see  Use in Specific Populations (8.5)  ].  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
297,avastin,297,7425,7490,"\n', '\n', ' Discontinue in patients who develop a severe  nonoseaeaeonlyasinstruction  The safety of reinitiating Avastin after an  nonoseaeaeonlyasinstruction is resolved is not known.\n', '\n', '    5.5 Venous Thromboembolic Events\n', '\n', '  An increased risk of  oselabeledaefromdruguse  was observed across clinical studies.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,avastin,298,7490,7521,"In Study GOG-0240, Grade 3-4  oselabeledaefromdruguse was reported in 11% of patients receiving Avastin with chemotherapy compared with 5% of patients receiving chemotherapy alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,avastin,299,7521,7585,"In EORTC 26101, the incidence of Grade 3-4  oselabeledaefromdruguse was 5% in patients receiving Avastin with chemotherapy compared to 2% in patients receiving chemotherapy alone.\n', '\n', ' Discontinue Avastin in patients with a Grade 4  nonoseaeaeonlyasinstruction  including  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6.1)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,avastin,300,7585,7604,"\n', '\n', '    5.6 Hypertension\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,avastin,301,7604,7624,The incidence of severe  oselabeledaefromdruguse is increased in patients receiving Avastin as compared to patients receiving chemotherapy alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,avastin,302,7624,7663,"Across clinical studies, the incidence of Grade 3-4  oselabeledaefromdruguse ranged from 5% to 18%.\n', '\n', ' Monitor blood pressure every two to three weeks during treatment with Avastin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,avastin,303,7663,7674,Treat with appropriate  nonoseaeaeonlyasinstruction and monitor blood pressure regularly.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,avastin,304,7674,7696,Continue to monitor blood pressure at regular intervals in patients with Avastin-induced or -exacerbated  nonoseaeaeonlyasinstruction after discontinuing Avastin.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,avastin,305,7696,7719,Withhold Avastin in patients with severe  nonoseaeaeonlyasinstruction that is not controlled with medical management; resume once controlled with medical management.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,avastin,306,7719,7729,Discontinue in patients who develop  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,avastin,307,7729,7743,"\n', '\n', '    5.7  oselabeledaefromdruguse \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,avastin,308,7743,7763,", '\n', '   oselabeledaefromdruguse was reported in < 0.5% of patients across clinical studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,avastin,309,7763,7780,The onset of symptoms occurred from 16 hours to 1 year after the first dose.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,avastin,310,7780,7819,nonoseaeaeonlyasinstruction is a  nonoseaeaeonlyasinstruction which can present with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and other  nonoseaemanifestationorcomplication and neurologic  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  Mild to severe  nonoseaemanifestationorcomplication may be present.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
311,avastin,311,7819,7848,"Magnetic resonance imaging is necessary to confirm the diagnosis of  nonoseaeaeonlyasinstruction \n', '\n', ' Discontinue Avastin in patients who develop  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,avastin,312,7848,7868,"Symptoms usually resolve or improve within days after discontinuing Avastin, although some patients have experienced ongoing  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,avastin,313,7868,7923,"The safety of reinitiating Avastin in patients who developed  nonoseaeaeonlyasinstruction is not known.\n', '\n', '    5.8  oselabeledaefromdruguse and Proteinuria\n', '\n', '  The incidence and severity of  oselabeledaefromdruguse is higher in patients receiving Avastin as compared to patients receiving chemotherapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,avastin,314,7923,7951,Grade 3 (defined as  oselabeledaefromdruguse  to Grade 4 (defined as  oselabeledaefromdruguse  ranged from 0.7% to 7% in clinical studies.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,avastin,315,7951,7977,"The overall incidence of  oselabeledaefromdruguse (all grades) was only adequately assessed in Study BO17705, in which the incidence was 20%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,avastin,316,7977,7996,Median onset of  oselabeledaefromdruguse was 5.6 months (15 days to 37 months) after initiating Avastin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,avastin,317,7996,8014,"Median time to resolution was 6.1 months (95% CI: 2.8, 11.3).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,avastin,318,8014,8092,"oselabeledaefromdruguse did not resolve in 40% of patients after median follow-up of 11.2 months and required discontinuation of Avastin in 30% of the patients who developed  oselabeledaefromdruguse \n', '\n', ' In an exploratory, pooled analysis of patients from seven randomized clinical studies, 5% of patients receiving Avastin with chemotherapy experienced Grades 2-4 (defined as  oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,avastin,319,8092,8105,Grades 2-4  oselabeledaefromdruguse resolved in 74% of patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,avastin,320,8105,8114,Avastin was reinitiated in 42% of patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,avastin,321,8114,8135,"Of the 113 patients who reinitiated Avastin, 48% experienced a second episode of Grade 2-4  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,avastin,322,8135,8166,"\n', '\n', '  oselabeledaefromdruguse occurred in < 1% of patients receiving Avastin across clinical studies, in some instances with  nonoseaegeneralterm outcome.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
323,avastin,323,8166,8229,"In a published case series, kidney biopsy of 6 patients with  oselabeledaefromdruguse showed findings consistent with  oselabeledaefromdruguse  Results of a retrospective analysis of 5805 patients who received Avastin with chemotherapy and 3713 patients who received chemotherapy alone, showed higher rates of  oselabeledaefromdruguse (between 1.5 to 1.9 times baseline levels) in patients who received Avastin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,avastin,324,8229,8276,"Serum creatinine levels did not return to baseline in approximately one-third of patients who received Avastin.\n', '\n', ' Monitor  nonoseaeaeonlyasinstruction by dipstick urine analysis for the development or worsening of  nonoseaegeneralterm with serial urinalyses during Avastin therapy.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
325,avastin,325,8276,8296,Patients with a 2+ or greater urine dipstick reading should undergo further assessment with a 24-hour urine collection.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,avastin,326,8296,8321,Withhold for  nonoseaeaeonlyasinstruction greater than or equal to 2 grams per 24 hours and resume when less than 2 grams per 24 hours.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,avastin,327,8321,8374,"Discontinue in patients who develop  nonoseaeaeonlyasinstruction \n', '\n', ' Data from a postmarketing safety study showed poor correlation between UPCR (Urine Protein/Creatinine Ratio) and 24-hour urine protein [Pearson Correlation 0.39 (95% CI: 0.17, 0.57)] .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
328,avastin,328,8374,8390,"\n', '\n', '    5.9 Infusion Reactions\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,avastin,329,8390,8433,"', '   oselabeledaefromdruguse reported across clinical studies and post-marketing experience include  oselabeledaefromdruguse   oselabeledaefromdruguse associated with  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  Grade 3  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,avastin,330,8433,8461,"In clinical studies,  oselabeledaefromdruguse with the first dose occurred in < 3% of patients and severe reactions occurred in 0.2% of patients.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,avastin,331,8461,8499,"'\n', ' Decrease the rate of infusion for mild, clinically insignificant  nonoseaeaeonlyasinstruction  Interrupt the infusion in patients with clinically significant  nonoseaegeneralterm and consider resuming at a slower rate following resolution.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
332,avastin,332,8499,8537,"Discontinue in patients who develop a severe  nonoseaegeneralterm and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen).\n', '\n', '    5.10  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
333,avastin,333,8537,8560,"\n', '  Avastin may cause  oselabeledaefromdruguse based on its mechanism of action and findings from animal studies.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,avastin,334,8560,8592,nonoseaeaeanimal were observed with the administration of bevacizumab to  nonoseaeaeanimal rabbits during organogenesis every 3 days at a dose as low as a clinical dose of 10 mg/kg.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
335,avastin,335,8592,8619,"Furthermore, animal models link angiogenesis and VEGF and VEGFR 2 to critical aspects of female reproduction, embryo-fetal development, and postnatal development.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,avastin,336,8619,8677,"Advise  notaecandidatepreexistingconditionorriskfactor women of the potential  oselabeledaefromdruguse  Advise females of reproductive potential to use effective contraception during treatment with and for 6 months after the last dose of Avastin [see  Use in Specific Populations (8.1  ,  8.3)  ,  Clinical Pharmacology (12.1)  ].  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
337,avastin,337,8677,8680,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
338,avastin,338,8680,8760,"'\n', '    5.11 Ovarian Failure\n', '\n', '  The incidence of  oselabeledaefromdruguse was 34% vs. 2% in  notaecandidatepreexistingconditionorriskfactor women receiving Avastin with chemotherapy as compared to those receiving chemotherapy alone for adjuvant treatment of a solid  notaecandidateindication  After discontinuing Avastin, recovery of ovarian function at all time points during the post-treatment period was demonstrated in 22% of women receiving Avastin.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
339,avastin,339,8760,8779,"Recovery of ovarian function is defined as resumption of menses, a  nonoseaeaeonlyasinstruction  or a FSH level",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,avastin,340,8779,8791,< 30 mIU/mL during the post-treatment period.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,avastin,341,8791,8802,Long-term effects of Avastin on fertility are unknown.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
342,avastin,342,8802,8839,"Inform females of reproductive potential of the risk of  nonoseaeaeonlyasinstruction prior to initiating Avastin [see  Adverse Reactions (6.1)  ,  Use in Specific Populations (8.3)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,avastin,343,8839,8874,"\n', '\n', '    5.12 Congestive Heart Failure (CHF)\n', '\n', '   Avastin is not indicated for use with anthracycline-based chemotherapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,avastin,344,8874,8900,The incidence of Grade >= 3  oselabeledaefromdruguse was 1% in patients receiving Avastin compared to 0.6% of patients receiving chemotherapy alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,avastin,345,8900,8934,"Among patients who received prior anthracycline treatment, the rate of  nonoseaeaefromofflabel was 4% for patients receiving Avastin with chemotherapy as compared to 0.6% for patients receiving chemotherapy alone.  ",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
346,avastin,346,8934,8983,"\n', '\n', '  In previously untreated patients with a  notaecandidatepreexistingconditionorriskfactor  the incidence of  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  were increased in patients receiving Avastin with anthracycline-based chemotherapy compared to patients receiving placebo with the same chemotherapy regimen.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
347,avastin,347,8983,9030,"The proportion of patients with a  nonoseaeaefromdruginteraction from baseline of >= 20% or a decline from baseline of 10% to < 50%, was 10% in patients receiving Avastin with chemotherapy compared to 5% in patients receiving chemotherapy alone.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
348,avastin,348,9030,9082,Time to onset of  nonoseaeaefromdruginteraction or  nonoseaeaefromdruginteraction was 1 to 6 months after the first dose in at least 85% of the patients and was resolved in 62% of the patients who developed  nonoseaeaefromdruginteraction in the Avastin arm compared to 82% in the placebo arm.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
349,avastin,349,9082,9092,Discontinue Avastin in patients who develop  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,remicade,0,0,99,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse reactions (>10%) - infections (e.g. upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain. (  6.1  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,remicade,1,99,128,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,remicade,2,128,261,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '     Adverse Reactions in Adults  \n', '\n', ' The data described herein reflect exposure to REMICADE in 4779 adult patients (1304 patients with  notaecandidatepreexistingconditionorriskfactor  1106 patients with  notaecandidatepreexistingconditionorriskfactor  202 with  notaecandidateindication  293 with  notaecandidateindication  484 with  notaecandidateindication  1373 with  notaecandidateindication  and 17 patients with other conditions), including 2625 patients exposed beyond 30 weeks and 374 exposed beyond 1 year.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
3,remicade,3,261,281,[For information on adverse reactions in pediatric patients see  Adverse Reactions (6.1)  .]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,remicade,4,281,312,"One of the most-common reasons for discontinuation of treatment was  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse .\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,remicade,5,312,321,"', '     Infusion-related Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,remicade,6,321,353,"\n', '\n', ' An infusion reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 hour after an infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,remicade,7,353,380,"In Phase 3 clinical studies, 18% of REMICADE-treated patients experienced an  oselabeledaefromdruguse compared to 5% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,remicade,8,380,406,"Of infliximab-treated patients who had an  oselabeledaefromdruguse during the induction period, 27% experienced an  oselabeledaefromdruguse during the maintenance period.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,remicade,9,406,523,"Of patients who did not have an infusion reaction during the induction period, 9% experienced an  oselabeledaefromdruguse during the maintenance period.\n', '\n', ' Among all REMICADE infusions, 3% were accompanied by nonspecific symptoms such as  oselabeledaefromdruguse or  oselabeledaefromdruguse  1% were accompanied by  oselabeledaefromdruguse (primarily  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse , and <1% were accompanied by  oselabeledaefromdruguse   oselabeledaefromdruguse  or the combined symptoms of  oselabeledaefromdruguse  oselabeledaefromdruguse and  oselabeledaefromdruguse  Serious  oselabeledaefromdruguse occurred in <1% of patients and included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,remicade,10,523,547,Approximately 3% of patients discontinued REMICADE because of  oselabeledaefromdruguse  and all patients recovered with treatment and/or discontinuation of the infusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,remicade,11,547,563,REMICADE infusions beyond the initial infusion were not associated with a higher incidence of reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,remicade,12,563,580,The  nonoseaeaeonlyasinstruction rates remained stable in  notaecandidateindication through 1 year in  notaecandidateindication Study I.,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,remicade,13,580,605,"In  notaecandidateindication Study II, the rates were variable over time and somewhat higher following the final infusion than after the initial infusion.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
14,remicade,14,605,696,"Across the 3  notaecandidateindication studies, the percent of total infusions resulting in  oselabeledaefromdruguse (i.e., an adverse event occurring within 1 hour) was 7% in the 3 mg/kg group, 4% in the 5 mg/kg group, and 1% in the placebo group.\n', '\n', ' Patients who became  oselabeledaefromdruguse were more likely (approximately two-to three-fold) to have an  oselabeledaefromdruguse than were those who were negative.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,remicade,15,696,825,"Use of concomitant  nonoseaeaeonlyasinstruction appeared to reduce the frequency of both  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  [see  Adverse Reactions (6.1)  and  Drug Interactions (7.4)  ]  .\n', '\n', '     Infusion Reactions Following Re-administration  \n', '\n', ' In a clinical trial of patients with moderate to severe  notaecandidateindication designed to assess the efficacy of long-term maintenance therapy versus re-treatment with an induction regimen of REMICADE following disease flare, 4% (8/219) of patients in the re-treatment therapy arm experienced serious  oselabeledaefromdruguse versus <1% (1/222) in the maintenance therapy arm.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
16,remicade,16,825,838,Patients enrolled in this trial did not receive any concomitant  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,remicade,17,838,857,"In this study, the majority of serious  oselabeledaefromdruguse occurred during the second infusion at Week 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,remicade,18,857,877,"Symptoms included, but were not limited to,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
19,remicade,19,877,961,"In all cases, REMICADE treatment was discontinued and/or other treatment instituted with complete resolution of signs and symptoms.\n', '\n', '     Delayed Reactions/Reactions Following Re-administration  \n', '\n', ' In  notaecandidateindication studies, approximately 1% of REMICADE-treated patients experienced a possible  oselabeledaefromdruguse  generally reported as  oselabeledaefromdruguse or a combination of  oselabeledaefromdruguse and/or  oselabeledaefromdruguse with  oselabeledaefromdruguse and/or  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
20,remicade,20,961,1037,"These reactions generally occurred within 2 weeks after repeat infusion.\n', '\n', '     Infections  \n', '\n', ' In REMICADE clinical studies, treated  oselabeledaefromdruguse were reported in 36% of REMICADE-treated patients (average of 51 weeks of follow-up) and in 25% of placebo-treated patients (average of 37 weeks of follow-up).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,remicade,21,1037,1061,The  oselabeledaefromdruguse most frequently reported were  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,remicade,22,1061,1086,"Among REMICADE-treated patients, serious  oselabeledaefromdruguse included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,remicade,23,1086,1167,"In clinical trials, 7  oselabeledaefromdruguse were reported; 2 cases each of  oselabeledaefromdruguse (1 case was  nonoseaegeneralterm  and  oselabeledaefromdruguse (1 case was  nonoseaegeneralterm , and 1 case each of  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse was reported in 14 patients, 4 of whom  nonoseaegeneralterm due to  oselabeledaefromdruguse  Other cases of  oselabeledaefromdruguse  including  oselabeledaefromdruguse  also have been reported post-marketing.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,remicade,24,1167,1205,Most of these cases of  oselabeledaefromdruguse occurred within the first 2 months after initiation of therapy with REMICADE and may reflect  nonoseaeaeonlyasinstruction  [see  Warnings and Precautions (5.1)  ]  .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,remicade,25,1205,1246,"In the 1-year placebo-controlled studies  notaecandidateindication I and  notaecandidateindication II, 5.3% of patients receiving REMICADE every 8 weeks with MTX developed serious  oselabeledaefromdruguse as compared to 3.4% of placebo patients receiving MTX.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
26,remicade,26,1246,1278,"Of 924 patients receiving REMICADE, 1.7% developed  oselabeledaefromdruguse and 0.4% developed  oselabeledaefromdruguse  when compared to 0.3% and 0.0% in the placebo arm respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,remicade,27,1278,1360,"In a shorter (22-week) placebo-controlled study of 1082  notaecandidateindication patients randomized to receive placebo, 3 mg/kg or 10 mg/kg REMICADE infusions at 0, 2, and 6 weeks, followed by every 8 weeks with MTX, serious  oselabeledaefromdruguse were more frequent in the 10 mg/kg REMICADE group (5.3%) than the 3 mg/kg or placebo groups (1.7% in both).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
28,remicade,28,1360,1441,"During the 54-week  notaecandidateindication II Study, 15% of patients with  notaecandidateindication developed a new  oselabeledaefromdruguse \n', '\n', ' In REMICADE clinical studies in patients with  notaecandidateindication   oselabeledaefromdruguse treated with antimicrobials were reported in 27% of REMICADE-treated patients (average of 41 weeks of follow-up) and in 18% of placebo-treated patients (average 32 weeks of follow-up).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,remicade,29,1441,1499,"The types of  nonoseaeaeonlyasinstruction  including serious  nonoseaeaeonlyasinstruction  reported in patients with  notaecandidatepreexistingconditionorriskfactor were similar to those reported in other clinical studies.\n', '\n', ' The onset of serious  nonoseaeaeonlyasinstruction may be preceded by constitutional symptoms such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
30,remicade,30,1499,1584,"The majority of serious  nonoseaeaeonlyasinstruction  however, may also be preceded by signs or symptoms localized to the site of the  nonoseaeaeonlyasinstruction \n', '\n', '     Autoantibodies/Lupus-like Syndrome  \n', '\n', ' Approximately half of REMICADE-treated patients in clinical trials who were  notaecandidatepreexistingconditionorriskfactor at baseline developed a  oselabeledaefromdruguse during the trial compared with approximately one-fifth of placebo-treated patients.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
31,remicade,31,1584,1608,oselabeledaefromdruguse were newly detected in approximately one-fifth of REMICADE-treated patients compared with 0% of placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,remicade,32,1608,1775,"Reports of  oselabeledaefromdruguse and  oselabeledaefromdruguse  however, remain uncommon.\n', '\n', '     Malignancies  \n', '\n', ' In controlled trials, more REMICADE-treated patients developed  oselabeledaefromdruguse than placebo-treated patients  [see  Warnings and Precautions (5.2)  ]  .\n', '\n', ' In a randomized controlled clinical trial exploring the use of REMICADE in patients with moderate to severe  notaecandidatepreexistingconditionorriskfactor who were either current smokers or ex-smokers, 157 patients were treated with REMICADE at doses similar to those used in  notaecandidateindication and  notaecandidateindication  Of these REMICADE-treated patients, 9 developed a  oselabeledaefromdruguse  including 1  oselabeledaefromdruguse  for a rate of 7.67 cases per 100 patient-years of follow-up (median duration of follow-up 0.8 years; 95% CI 3.51 - 14.56).",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
33,remicade,33,1775,1818,There was 1 reported  oselabeledaefromdruguse among 77 control patients for a rate of 1.63 cases per 100 patient-years of follow-up (median duration of follow-up 0.8 years; 95% CI 0.04 - 9.10).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,remicade,34,1818,1908,"The majority of the  oselabeledaefromdruguse  oselabeledaefromdruguse developed in the lung or  oselabeledaefromdruguse \n', '\n', '     Patients with Heart Failure  \n', '\n', ' In a randomized study evaluating REMICADE in moderate to severe  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor III/ notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor , 150 patients were randomized to receive treatment with 3 infusions of REMICADE 10 mg/kg, 5 mg/kg, or placebo, at 0, 2, and 6 weeks.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
35,remicade,35,1908,1932,Higher incidences of  nonoseaegeneralterm and hospitalization due to  oselabeledaefromdruguse were observed in patients receiving the 10 mg/kg REMICADE dose.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,remicade,36,1932,1967,"At 1 year, 8 patients in the 10 mg/kg REMICADE group had  nonoseaegeneralterm compared with 4  nonoseaegeneralterm each in the 5 mg/kg REMICADE and the placebo groups.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,remicade,37,1967,2001,"There were trends toward increased  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse in both the 10 mg/kg and 5 mg/kg REMICADE treatment groups, versus placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,remicade,38,2001,2068,"REMICADE has not been studied in patients with mild  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor I/ notaecandidatepreexistingconditionorriskfactor   [see  Contraindications (4)  and  Warnings and Precautions (5.5)  ]  .\n', '\n', '     Immunogenicity  \n', '\n', ' Treatment with REMICADE can be associated with the development of  oselabeledaefromdruguse  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
39,remicade,39,2068,2088,An enzyme immunoassay (EIA) method was originally used to measure  nonoseaeaeonlyasinstruction in clinical studies of REMICADE.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,remicade,40,2088,2134,"The EIA method is subject to interference by serum infliximab, possibly resulting in an underestimation of the rate of patient  nonoseaeaeonlyasinstruction  A separate, drug-tolerant electrochemiluminescence immunoassay (ECLIA) method for detecting  nonoseaeaeonlyasinstruction was subsequently developed and validated.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,remicade,41,2134,2145,This method is 60-fold more sensitive than the original EIA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,remicade,42,2145,2278,"With the ECLIA method, all clinical samples can be classified as either positive or negative for  nonoseaeaeonlyasinstruction without the need for the inconclusive category.\n', '\n', ' The incidence of  nonoseaeaeonlyasinstruction was based on the original EIA method in all clinical studies of REMICADE except for the Phase 3 study in pediatric patients with  notaecandidatepreexistingconditionorriskfactor where the incidence of  nonoseaeaeonlyasinstruction was detected using both the EIA and ECLIA methods  [see  Adverse Reactions, Pediatric  notaecandidateindication (6.1)  ]  .\n', '\n', ' The incidence of  oselabeledaefromdruguse in patients given a 3-dose induction regimen followed by maintenance dosing was approximately 10% as assessed through 1 to 2 years of REMICADE treatment.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
43,remicade,43,2278,2301,A higher incidence of  oselabeledaefromdruguse was observed in  notaecandidateindication patients receiving REMICADE after drug-free intervals >16 weeks.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
44,remicade,44,2301,2330,"In a study of  notaecandidateindication in which 191 patients received 5 mg/kg with or without MTX,  oselabeledaefromdruguse occurred in 15% of patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
45,remicade,45,2330,2340,The majority of  nonoseaeaeonlyasinstruction patients had low titers.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,remicade,46,2340,2474,"Patients who were  nonoseaeaeonlyasinstruction were more likely to have higher rates of clearance, reduced efficacy and to experience an  nonoseaeaeonlyasinstruction  [see  Adverse Reactions (6.1)  ]  than were patients who were  nonoseaeaeonlyasinstruction   oselabeledaefromdruguse development was lower among  notaecandidateindication and  notaecandidateindication patients receiving  nonoseaeaeonlyasinstruction such as 6-MP/AZA or MTX.\n', '\n', ' In the  notaecandidateindication Study II, which included both the 5 mg/kg and 3 mg/kg doses,  oselabeledaefromdruguse were observed in 36% of patients treated with 5 mg/kg every 8 weeks for 1 year, and in 51% of patients treated with 3 mg/kg every 8 weeks for 1 year.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
47,remicade,47,2474,2536,"In the  notaecandidateindication Study III, which also included both the 5 mg/kg and 3 mg/kg doses,  oselabeledaefromdruguse were observed in 20% of patients treated with 5 mg/kg induction (weeks 0, 2 and 6), and in 27% of patients treated with 3 mg/kg induction.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
48,remicade,48,2536,2605,"Despite the  nonoseaeaeonlyasinstruction formation, the  nonoseaeaeonlyasinstruction in Studies I and II in patients treated with 5 mg/kg induction followed by every 8 week maintenance for 1 year and in Study III in patients treated with 5 mg/kg induction (14.1%-23.0%) and serious  nonoseaeaeonlyasinstruction rates (<1%) were similar to those observed in other study populations.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,remicade,49,2605,2677,"The clinical significance of apparent increased  nonoseaeaeonlyasinstruction on efficacy and  nonoseaeaeonlyasinstruction in  notaecandidateindication patients as compared to patients with other diseases treated with REMICADE over the long term is not known.\n', '\n', ' The data reflect the percentage of patients whose test results were  nonoseaeaeonlyasinstruction in an immunoassay, and they are highly dependent on the sensitivity and specificity of the assay.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
50,remicade,50,2677,2710,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medication, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,remicade,51,2710,2783,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of antibodies to other products may be misleading.\n', '\n', '      oselabeledaefromdruguse  \n', '\n', ' Severe  oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  has been reported in patients receiving REMICADE  [see  Warnings and Precautions (5.4)  ]  .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,remicade,52,2783,2892,"oselabeledaefromdruguse  notaecandidatepreexistingconditionorriskfactor virus has occurred in patients receiving TNF-blocking agents, including REMICADE, who are  notaecandidatepreexistingconditionorriskfactor of this virus  [see  Warnings and Precautions (5.3)  ]  .\n', '\n', ' In clinical trials in  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication   oselabeledaefromdruguse were observed (ALT more common than AST) in a greater proportion of patients receiving REMICADE than in controls (Table 1), both when REMICADE was given as monotherapy and when it was used in combination with other  nonoseaeaeonlyasinstruction  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
53,remicade,53,2892,2971,"In general, patients who developed  oselabeledaefromdruguse and AST  oselabeledaefromdruguse  oselabeledaefromdruguse were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of REMICADE, or modification of concomitant medications.\n', '\n', ' Table 1: Proportion of patients with  oselabeledaefromdruguse in clinical trials \n', '                         Proportion of patients with  oselabeledaefromdruguse   \n', ' >1 to <3 * ULN            >",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,remicade,54,2971,2984,"=3 * ULN      >=5 * ULN     \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,remicade,55,2984,2989,' Placebo                   REMICADE        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,remicade,56,2989,2993,Placebo       REMICADE        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,remicade,57,2993,2997,Placebo       REMICADE      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,remicade,58,2997,3024,"\n', '  \n', '  notaecandidateindication [note: Placebo patients received methotrexate while REMICADE patients received both REMICADE and methotrexate.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
59,remicade,59,3024,3034,Median follow-up was 58 weeks.]        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,remicade,60,3034,3046,24%            34%            3%             4%             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,remicade,61,3046,3054,<1%            <1%        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,remicade,62,3054,3097,"\n', ""  notaecandidateindication [note: Placebo patients in the 2 Phase 3 trials in Crohn's disease received an initial dose of 5 mg/kg REMICADE at study start and were on placebo in the maintenance phase.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
63,remicade,63,3097,3123,Patients who were randomized to the placebo maintenance group and then later crossed over to REMICADE are included in the REMICADE group in ALT analysis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,remicade,64,3123,3133,Median follow-up was 54 weeks.]        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,remicade,65,3133,3151,34%            39%            4%             5%             0%             2%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,remicade,66,3151,3168,"\n"", '  notaecandidateindication [note: Median follow-up was 30 weeks.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
67,remicade,67,3168,3190,"Specifically, the median duration of follow-up was 30 weeks for placebo and 31 weeks for REMICADE.]        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,remicade,68,3190,3202,12%            17%            1%             2%             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,remicade,69,3202,3240,"<1%            <1%        \n', '  notaecandidateindication [note: Median follow-up was 24 weeks for the placebo group and 102 weeks for the REMICADE group.]        ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
70,remicade,70,3240,3258,15%            51%            0%             10%            0%             4%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,remicade,71,3258,3288,"\n', '  notaecandidateindication [note: Median follow-up was 39 weeks for the REMICADE group and 18 weeks for the placebo group.]        ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
72,remicade,72,3288,3306,16%            50%            0%             7%             0%             2%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,remicade,73,3306,3343,"\n', '  notaecandidateindication [note: ALT values are obtained in 2 Phase 3 psoriasis studies with median follow-up of 50 weeks for REMICADE and 16 weeks for placebo.]        ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
74,remicade,74,3343,3362,24%            49%            <1%            8%             0%             3%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,remicade,75,3362,3510,"\n', '                 Adverse Reactions in Psoriasis Studies  \n', ' \n', '\n', ' During the placebo-controlled portion across the 3 clinical trials up to Week 16, the proportion of patients who experienced at least 1 serious adverse reaction (SAE; defined as resulting in  nonoseaegeneralterm  life threatening, requires hospitalization, or persistent or significant disability/incapacity) was 0.5% in the 3 mg/kg REMICADE group, 1.9% in the placebo group, and 1.6% in the 5 mg/kg REMICADE group.\n', '\n', ' Among patients in the 2 Phase 3 studies, 12.4% of patients receiving REMICADE 5 mg/kg every 8 weeks through 1 year of maintenance treatment experienced at least 1 SAE in Study I.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,remicade,76,3510,3577,"In Study II, 4.1% and 4.7% of patients receiving REMICADE 3 mg/kg and 5 mg/kg every 8 weeks, respectively, through 1 year of maintenance treatment experienced at least 1 SAE.\n', '\n', ' One  nonoseaegeneralterm due to  nonoseaeaeonlyasinstruction occurred 25 days after the second infusion of 5 mg/kg REMICADE.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,remicade,77,3577,3588,Serious  oselabeledaefromdruguse included  oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,remicade,78,3588,3619,"In Study I, 2.7% of patients receiving REMICADE 5 mg/kg every 8 weeks through 1 year of maintenance treatment experienced at least 1 serious  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,remicade,79,3619,3709,"In Study II, 1.0% and 1.3% of patients receiving REMICADE 3 mg/kg and 5 mg/kg, respectively, through 1 year of treatment experienced at least 1 serious  oselabeledaefromdruguse  The most common serious  nonoseaeaeonlyasinstruction (requiring hospitalization) was  oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse (skin,  oselabeledaefromdruguse  oselabeledaefromdruguse (skin, throat, and  oselabeledaefromdruguse  reported by 5 (0.7%) patients in the 5 mg/kg REMICADE group.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,remicade,80,3709,3819,"Two active cases of  oselabeledaefromdruguse were reported: 6 weeks and 34 weeks after starting REMICADE.\n', '\n', ' In the placebo-controlled portion of the  notaecandidateindication studies, 7 of 1123 patients who received REMICADE at any dose were diagnosed with at least one  oselabeledaefromdruguse compared to 0 of 334 patients who received placebo.\n', '\n', ' In the  notaecandidateindication studies, 1% (15/1373) of patients experienced  oselabeledaefromdruguse or a combination of  oselabeledaefromdruguse and/or  oselabeledaefromdruguse with  oselabeledaefromdruguse  and/or  oselabeledaefromdruguse  usually early in the treatment course.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
81,remicade,81,3819,3855,"Of these patients, 6 required hospitalization due to  oselabeledaefromdruguse  severe  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '     Other Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,remicade,82,3855,3911,"\n', '\n', ' Safety data are available from 4779 REMICADE-treated adult patients, including 1304 with  notaecandidateindication  1106 with  notaecandidateindication  484 with  notaecandidateindication  202 with  notaecandidateindication  293 with  notaecandidateindication  1373 with  notaecandidateindication and 17 with other conditions.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
83,remicade,83,3911,3933,"[For information on other adverse reactions in pediatric patients,  see  Adverse Reactions (6.1)    ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,remicade,84,3933,3957,Adverse reactions reported in >=5% of all patients with  notaecandidateindication receiving 4 or more infusions are in Table 2.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
85,remicade,85,3957,4002,The types and frequencies of adverse reactions observed were similar in REMICADE-treated  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication and  notaecandidateindication patients except for  oselabeledaefromdruguse  which occurred in 26% of REMICADE-treated patients with  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
86,remicade,86,4002,4102,"In the  notaecandidateindication studies, there were insufficient numbers and duration of follow-up for patients who never received REMICADE to provide meaningful comparisons.\n', '\n', ' Table 2: Adverse reactions occurring in 5% or more of patients receiving 4 or more infusions for rheumatoid arthritis \n', '                                                                             Placebo         REMICADE       \n', '                                                                             (n=350)         (n=1129)       \n', '                                                                                                            \n', '  \n', '   Average weeks of follow-up                                                  59               ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
87,remicade,87,4102,4104,66          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,remicade,88,4104,4111,"\n', '    nonoseaegeneralterm                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,remicade,89,4111,4124,"\n', '    oselabeledaefromdruguse                                                                      20%              21%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,remicade,90,4124,4137,"\n', '    oselabeledaefromdruguse                                                              8%               12%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,remicade,91,4137,4150,"\n', '    nonoseaeaeratelteqplacebo                                                                    12%              12%         ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
92,remicade,92,4150,4163,"\n', '    oselabeledaefromdruguse                                                                   7%               10%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,remicade,93,4163,4177,"\n', '    nonoseaegeneralterm                                                            \n', '    oselabeledaefromdruguse                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
94,remicade,94,4177,4183,25%              32%         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,remicade,95,4183,4196,"\n', '    oselabeledaefromdruguse                                                                   8%               14%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,remicade,96,4196,4209,"\n', '    oselabeledaefromdruguse                                                                 8%               12%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,remicade,97,4209,4222,"\n', '    oselabeledaefromdruguse                                                                    8%               12%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,remicade,98,4222,4235,"\n', '    oselabeledaefromdruguse                                                                  9%               10%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,remicade,99,4235,4242,"\n', '    nonoseaegeneralterm                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,remicade,100,4242,4268,"\n', '    oselabeledaefromdruguse                                                                        5%               10%         \n', '    oselabeledaefromdruguse                                                                    2%               7%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,remicade,101,4268,4275,"\n', '    nonoseaegeneralterm                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,remicade,102,4275,4288,"\n', '    oselabeledaefromdruguse                                                                     7%               9%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,remicade,103,4288,4301,"\n', '    oselabeledaefromdruguse                                                                        7%               8%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,remicade,104,4301,4321,"\n', '    nonoseaegeneralterm                                         \n', '    oselabeledaefromdruguse                                                                       4%               7%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,remicade,105,4321,4334,"\n', '    oselabeledaefromdruguse                                                                  3%               5%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,remicade,106,4334,4341,"\n', '    nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,remicade,107,4341,4354,"\n', '    oselabeledaefromdruguse                                                                    14%              18%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,remicade,108,4354,4374,"\n', '    nonoseaegeneralterm                                       \n', '    oselabeledaefromdruguse                                                                  7%               8%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,remicade,109,4374,4394,"\n', '    nonoseaegeneralterm                                               \n', '    oselabeledaefromdruguse                                                     6%               8%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,remicade,110,4394,4401,"\n', '    nonoseaegeneralterm                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,remicade,111,4401,4415,"\n', '    oselabeledaefromdruguse                                                                5%               7%          \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,remicade,112,4415,4431,"', '         The most common serious adverse reactions observed in clinical trials were  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,remicade,113,4431,4433,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,remicade,114,4433,4445,[see  Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,remicade,115,4445,4606,"Other serious, medically relevant adverse reactions >=0.2% or clinically significant adverse reactions by body system were as follows:\n', ' \n', '\n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,remicade,116,4606,4624,"\n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
117,remicade,117,4624,4625,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,remicade,118,4625,4720,"\n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm  :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '        Adverse Reactions in Pediatric Patients  \n', ' \n', '\n', ""     Pediatric Crohn's Disease  \n"", '\n', ' There were some differences in the adverse reactions observed in the pediatric patients receiving REMICADE compared to those observed in adults with  notaecandidateindication  ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
119,remicade,119,4720,4861,"These differences are discussed in the following paragraphs.\n', '\n', ' The following adverse reactions were reported more commonly in 103 randomized pediatric  notaecandidateindication patients administered 5 mg/kg REMICADE through 54 weeks than in 385 adult  notaecandidateindication patients receiving a similar treatment regimen:  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (6%), and  oselabeledaefromdruguse (6%).\n', '\n', '  oselabeledaefromdruguse were reported in 56% of randomized pediatric patients in Study Peds  notaecandidateindication and in 50% of adult patients in Study  notaecandidateindication I.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
120,remicade,120,4861,4918,"In Study Peds  notaecandidateindication   oselabeledaefromdruguse were reported more frequently for patients who received every 8-week as opposed to every 12-week infusions (74% and 38%, respectively), while serious  oselabeledaefromdruguse were reported for 3 patients in the every 8-week and 4 patients in the every 12-week maintenance treatment group.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
121,remicade,121,4918,4968,"The most commonly reported  nonoseaeaeonlyasinstruction were  oselabeledaefromdruguse and  oselabeledaefromdruguse  and the most commonly reported serious  nonoseaeaeonlyasinstruction was  oselabeledaefromdruguse   oselabeledaefromdruguse was reported for 3 patients, (2 in the every 8-week and 1 in the every 12-week maintenance treatment groups).  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,remicade,122,4968,4988,"oselabeledaefromdruguse was reported for 2 patients in the every 8-week maintenance treatment group.\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,remicade,123,4988,5014,In Study Peds  notaecandidateindication  18% of randomized patients experienced 1 or more  nonoseaeaeratelteqplacebo  with no notable difference between treatment groups.,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
124,remicade,124,5014,5040,Of the 112 patients in Study Peds  notaecandidateindication  there were no serious  nonoseaenegation  and 2 patients had non-serious  oselabeledaefromdruguse,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
125,remicade,125,5040,5081,"\n', '\n', ' In Study Peds  notaecandidateindication  in which all patients received stable doses of 6-MP, AZA, or MTX, excluding inconclusive samples, 3 of 24 patients had  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,remicade,126,5081,5172,"Although 105 patients were tested for  nonoseaeaeonlyasinstruction  81 patients were classified as inconclusive because they could not be ruled as negative due to assay interference by the presence of infliximab in the sample.\n', '\n', '  oselabeledaefromdruguse up to 3 times the upper limit of normal (ULN) were seen in 18% of pediatric patients in  notaecandidateindication clinical trials; 4% had  oselabeledaefromdruguse >=3 * ULN, and 1% had elevations >=5 * ULN.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
127,remicade,127,5172,5230,"(Median follow-up was 53 weeks.)\n', '\n', '     Pediatric Ulcerative Colitis  \n', '\n', ' Overall, the adverse reactions reported in the pediatric  notaecandidateindication trial and adult  notaecandidateindication (Study UC I and Study UC II) studies were generally consistent.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
128,remicade,128,5230,5254,"In a pediatric UC trial, the most common adverse reactions were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,remicade,129,5254,5295,"\n', '\n', ""  oselabeledaefromdruguse were reported in 31 (52%) of 60 treated patients in the pediatric  notaecandidateindication trial and 22 (37%) required oral or parenteral antimicrobial treatment.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
130,remicade,130,5295,5348,The proportion of patients with  oselabeledaefromdruguse in the pediatric  notaecandidateindication trial was similar to that in the pediatric  notaecandidateindication study (Study Peds  notaecandidateindication  but higher than the proportion in the adults'  notaecandidateindication studies (Study  notaecandidateindication I and Study  notaecandidateindication II).,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
131,remicade,131,5348,5376,The overall incidence of  oselabeledaefromdruguse in the pediatric  notaecandidateindication trial was 13/22 (59%) in the every 8 week maintenance treatment group.  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
132,remicade,132,5376,5450,"oselabeledaefromdruguse (7/60 [12%]) and  oselabeledaefromdruguse (5/60 [8%]) were the most frequently reported  nonoseaeaeonlyasinstruction  Serious  oselabeledaefromdruguse were reported in 12% (7/60) of all treated patients.\n"", '\n', ' In the pediatric  notaecandidateindication trial, 58 patients were evaluated for  nonoseaeaeonlyasinstruction using the EIA as well as the drug-tolerant ECLIA.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
133,remicade,133,5450,5497,"With the EIA, 4 of 58 (7%) patients had  oselabeledaefromdruguse  With the ECLIA, 30 of 58 (52%) patients had  oselabeledaefromdruguse  [see  Adverse Reactions,  nonoseaeaeonlyasinstruction (6.1)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,remicade,134,5497,5520,The higher incidence of  nonoseaeaeonlyasinstruction by the ECLIA method was due to the 60-fold higher sensitivity compared to the EIA method.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,remicade,135,5520,5669,"While EIA-positive patients generally had undetectable trough infliximab concentrations, ECLIA-positive patients could have detectable trough concentrations of infliximab because the ECLIA assay is more sensitive and drug-tolerant.\n', '\n', '  oselabeledaefromdruguse up to 3 times the upper limit of normal (ULN) were seen in 17% (10/60) of pediatric patients in the pediatric  notaecandidateindication trial; 7% (4/60) had  oselabeledaefromdruguse >=3 * ULN, and 2% (1/60) had elevations >=5 * ULN (median follow-up was 49 weeks).\n', '\n', ' Overall, 8 of 60 (13%) treated patients experienced one or more  oselabeledaefromdruguse  including 4 of 22 (18%) patients in the every 8-week treatment maintenance group.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
136,remicade,136,5669,5711,"No serious  nonoseaenegation were reported.\n', '\n', ' In the pediatric  notaecandidateindication trial, 45 patients were in the 12 to 17 year age group and 15 in the 6 to 11 year age group.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
137,remicade,137,5711,5735,The numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,remicade,138,5735,5777,There were higher proportions of patients with serious adverse events (40% vs. 18%) and discontinuation due to adverse events (40% vs. 16%) in the younger age group than in the older age group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,remicade,139,5777,5839,"While the proportion of patients with  oselabeledaefromdruguse was also higher in the younger age group (60% vs. 49%), for serious  oselabeledaefromdruguse  the proportions were similar in the two age groups (13% in the 6 to 11 year age group vs. 11% in the 12 to 17 year age group).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,remicade,140,5839,5901,"Overall proportions of adverse reactions, including  oselabeledaefromdruguse  were similar between the 6 to 11 and 12 to 17 year age groups (13%).\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  Adverse reactions have been identified during post approval use of REMICADE in adult and pediatric patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,remicade,141,5901,6006,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' The following adverse reactions, some with  nonoseaegeneralterm outcome, have been reported during post-approval use of REMICADE:  oselabeledaefromdruguse  [see  Warnings and Precautions (5.6)  ]  ,  oselabeledaefromdruguse (including infants exposed  in utero  to infliximab),  oselabeledaefromdruguse (including  oselabeledaefromdruguse  oselabeledaefromdruguse and rapidly progressive disease),  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
142,remicade,142,6006,6085,"oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and cutaneous  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (such as  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse , new onset and  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse (all subtypes including  oselabeledaefromdruguse  oselabeledaefromdruguse (all subtypes including pustular, primarily  oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse (additional  oselabeledaefromdruguse have also been observed)  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,remicade,143,6085,6126,"Warnings and Precautions (5.9)  ]  ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see  Warnings and Precautions (5.4)  ]  , serious  oselabeledaefromdruguse  [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,remicade,144,6126,6271,"Warnings and Precautions (5.1)  ]  ,  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see  Warnings and Precautions (5.2)  ]  and  nonoseaeaefromdruginteraction including  nonoseaeaefromdruginteraction ( nonoseaeaefromdruginteraction  following vaccination in an  oselabeledaefromdruguse  [see  Warnings and Precautions (5.15)  ]  .\n', '\n', '     Infusion-related Reactions  \n', '\n', ' In post-marketing experience, cases of  oselabeledaefromdruguse  including  oselabeledaefromdruguse pharyngeal  oselabeledaefromdruguse  oselabeledaefromdruguse and severe  oselabeledaefromdruguse  and  oselabeledaefromdruguse have been associated with REMICADE administration.\n', '\n', ' Cases of  oselabeledaefromdruguse have been reported in association with REMICADE during or within 2 hours of infusion.  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
145,remicade,145,6271,6274,oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,remicade,146,6274,6327,"ischemia/ oselabeledaefromdruguse  oselabeledaefromdruguse infarction (some  nonoseaegeneralterm , and  oselabeledaefromdruguse occurring within 24 hours of initiation of infusion have also been reported  [see  Warnings and Precautions (5.8)  ]  .\n', '\n', '     Adverse Reactions in Pediatric Patients  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
147,remicade,147,6327,6437,"\n', '\n', ' The following serious adverse reactions have been reported in the post-marketing experience in children:  oselabeledaefromdruguse (some  nonoseaegeneralterm  including  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', ' Serious adverse reactions in the post-marketing experience with REMICADE in the pediatric population have also included  oselabeledaefromdruguse  including  oselabeledaefromdruguse  [see  Boxed Warning  and  Warnings and Precautions (5.2)  ]  , transient  oselabeledaefromdruguse   oselabeledaefromdruguse  and the development of  oselabeledaefromdruguse \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
148,remicade,148,6437,6446,"'\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,remicade,149,6446,6448,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,remicade,150,6448,6452,SERIOUS INFECTIONS and MALIGNANCY\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,remicade,151,6452,6462,"', '\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,remicade,152,6462,6467,SERIOUS INFECTIONS and MALIGNANCY  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,remicade,153,6467,6479,"\n', '\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,remicade,154,6479,6481,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,remicade,155,6481,6503,"SERIOUS INFECTIONS and MALIGNANCY\n', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,remicade,156,6503,6549,"\n', '\n', ' *  Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,remicade,157,6549,6565,"\n', ' *  Discontinue REMICADE if a patient develops a serious infection.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,remicade,158,6565,6589,"\n', ' *  Perform test for latent TB; if positive, start treatment for TB prior to starting REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,remicade,159,6589,6607,"Monitor all patients for active TB during treatment, even if initial latent TB test is negative.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,remicade,160,6607,6610,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,remicade,161,6610,6645,"\n', ' *  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,remicade,162,6645,6675,"\n', "" *  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,remicade,163,6675,6694,Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,remicade,164,6694,6721,"The majority of REMICADE cases were reported in patients with Crohn's disease or ulcerative colitis, most of whom were adolescent or young adult males.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,remicade,165,6721,6724,(5.2),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,remicade,166,6724,6730,"\n"", '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,remicade,167,6730,6745,"', ' \n', '\n', '    SERIOUS INFECTIONS  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,remicade,168,6745,6784,"\n', '\n', '   Patients treated with REMICADE  (r)   are at increased risk for developing serious  oselabeledaefromdruguse that may lead to hospitalization or  nonoseaegeneralterm   [see   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
169,remicade,169,6784,6802,Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,remicade,170,6802,6821,Most patients who developed these  nonoseaeaefromdruginteraction were taking concomitant  nonoseaeaeonlyasinstruction such as methotrexate or corticosteroids.    ,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
171,remicade,171,6821,6901,"\n', '\n', '   REMICADE should be discontinued if a patient develops a serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction     \n', '\n', '   Reported  oselabeledaefromdruguse include:  \n', '\n', ' *   oselabeledaefromdruguse  including  oselabeledaefromdruguse  Patients with  oselabeledaefromdruguse have frequently presented with disseminated or  oselabeledaefromdruguse  oselabeledaefromdruguse have frequently presented with  oselabeledaefromdruguse or extrapulmonary disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,remicade,172,6901,6926,"Patients should be tested for  nonoseaeaeonlyasinstruction before REMICADE use and during therapy.1,2 Treatment for  notaecandidatepreexistingconditionorriskfactor should be initiated prior to REMICADE use.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
173,remicade,173,6926,6955,"\n', ' *   oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  Patients with  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,remicade,174,6955,6980,"oselabeledaefromdruguse or other invasive fungal infections may present with  oselabeledaefromdruguse  oselabeledaefromdruguse may present with disseminated, rather than localized, disease.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,remicade,175,6980,6996,nonoseaeaeonlyasinstruction and antibody  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction in some patients with active  nonoseaeaeonlyasinstruction  Empiric,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,remicade,176,6996,7129,"anti-fungal therapy should be considered in patients at risk for  nonoseaeaeonlyasinstruction who develop severe systemic  nonoseaeaeonlyasinstruction  \n', ' *   oselabeledaefromdruguse  viral and other  oselabeledaefromdruguse  oselabeledaefromdruguse and other  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  \n', '      The risks and benefits of treatment with REMICADE should be carefully considered prior to initiating therapy in patients with chronic or recurrent  notaecandidatepreexistingconditionorriskfactor   \n', ' \n', '\n', '   Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with REMICADE, including the possible development of  nonoseaeaeonlyasinstruction in patients who  notaecandidatepreexistingconditionorriskfactor prior to initiating therapy.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
177,remicade,177,7129,7178,"\n', '\n', '     MALIGNANCY  \n', '\n', '    oselabeledaeclasseffect and other  oselabeledaeclasseffect  some  nonoseaegeneralterm  have been reported in children and adolescent patients treated with TNF blockers, including REMICADE   [see   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,remicade,178,7178,7189,Warnings and Precautions (5.2)  ]  .            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,remicade,179,7189,7223,"\n', '\n', '   Postmarketing cases of  oselabeledaefromdruguse , a rare type of  nonoseaeaeonlyasinstruction  have been reported in patients treated with TNF blockers including REMICADE.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,remicade,180,7223,7260,These cases have had a very aggressive disease course and have been  nonoseaegeneralterm  Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
181,remicade,181,7260,7306,"The majority of reported REMICADE cases have occurred in patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Serious infections - do not give REMICADE during an active infection.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
182,remicade,182,7306,7321,"If an infection develops, monitor carefully and stop REMICADE if infection becomes serious.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,remicade,183,7321,7326,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,remicade,184,7326,7397,"\n', ' *   Invasive fungal infections - for patients who develop a systemic illness on REMICADE, consider empiric antifungal therapy for those who reside or travel to regions where mycoses are endemic (  5.1  ) \n', "" *   Malignancies - the incidence of malignancies, including invasive cervical cancer and lymphoma, was greater in REMICADE treated patients than in controls.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,remicade,185,7397,7432,"Due to the risk of HSTCL carefully assess the risk/benefit especially if the patient has Crohn's disease or ulcerative colitis, is male, and is receiving azathioprine or 6-mercaptopurine treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,remicade,186,7432,7437,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,remicade,187,7437,7456,"\n"", ' *   Hepatitis B virus reactivation - test for HBV infection before starting REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,remicade,188,7456,7466,Monitor HBV carriers during and several months after therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,remicade,189,7466,7479,"If reactivation occurs, stop REMICADE and begin anti-viral therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,remicade,190,7479,7503,"(  5.3  ) \n', ' *   Hepatotoxicity - severe hepatic reactions, some fatal or necessitating liver transplantation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,remicade,191,7503,7515,Stop REMICADE in cases of jaundice and/or marked liver enzyme elevations.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,remicade,192,7515,7537,"(  5.4  ) \n', ' *   Heart failure - new onset or worsening symptoms may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,remicade,193,7537,7546,"(  4  ,  5.5  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,remicade,194,7546,7548,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,remicade,195,7548,7572,", ' *   Cytopenias - advise patients to seek immediate medical attention if signs and symptoms develop, and consider stopping REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,remicade,196,7572,7599,"(  5.6  ) \n', ' *   Hypersensitivity - serious infusion reactions including anaphylaxis or serum sickness-like reactions may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,remicade,197,7599,7641,"(  5.7  ) \n', ' *   Cardiovascular and Cerebrovascular Reactions - Cerebrovascular accidents, myocardial infarctions (some fatal), and arrhythmias have been reported during and within 24 hours of initiation of REMICADE infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,remicade,198,7641,7655,"Monitor patients during REMICADE infusion and if serious reaction occurs, discontinue infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,remicade,199,7655,7676,"(  5.8  ) \n', ' *   Demyelinating disease - exacerbation or new onset may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,remicade,200,7676,7698,"(  5.9  ) \n', ' *   Lupus-like syndrome - stop REMICADE if syndrome develops.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,remicade,201,7698,7723,"(  5.14  ) \n', ' *   Live vaccines or therapeutic infectious agents - should not be given with REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,remicade,202,7723,7737,Bring pediatric patients up to date with all vaccinations prior to initiating REMICADE.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,remicade,203,7737,7766,At least a six month waiting period following birth is recommended before the administration of live vaccines to infants exposed in utero to infliximab (  5.15  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,remicade,204,7766,7772,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,remicade,205,7772,7912,"', ' \n', '\n', '   5.1 Serious Infections\n', '\n', '  Patients treated with REMICADE are at increased risk for developing serious  oselabeledaefromdruguse involving various organ systems and sites that may lead to hospitalization or  nonoseaegeneralterm \n', '\n', '  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial, mycobacterial, invasive fungal, viral, or  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial, mycobacterial, invasive fungal,  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial, mycobacterial,  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial,  oselabeledaeclasseffect  oselabeledaeclasseffect  mycobacterial, invasive fungal, viral, or parasitic organisms including  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect and  oselabeledaeclasseffect have been reported with TNF-blockers.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
206,remicade,206,7912,8188,"Patients have frequently presented with disseminated rather than localized disease.\n', '\n', ' Treatment with REMICADE should not be initiated in patients with an active  notaecandidatepreexistingconditionorriskfactor  including clinically important  notaecandidatepreexistingconditionorriskfactor  Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of  nonoseaeaeonlyasinstruction  The risks and benefits of treatment should be considered prior to initiating therapy in patients:\n', '\n', ' *  with chronic or recurrent  notaecandidatepreexistingconditionorriskfactor  \n', ' *  who have been  notaecandidatepreexistingconditionorriskfactor  \n', ' *  with a history of an  notaecandidatepreexistingconditionorriskfactor  \n', ' *  who have resided or traveled in areas of endemic  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  such as  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  or \n', ' *  with underlying conditions that may  notaecandidatepreexistingconditionorriskfactor  \n', '       Tuberculosis  \n', ' \n', '\n', ' Cases of  oselabeledaefromdruguse or new  oselabeledaefromdruguse have been observed in patients receiving REMICADE, including patients who have previously received treatment for  notaecandidatepreexistingconditionorriskfactor or active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  Cases of  oselabeledaefromdruguse have also occurred in patients being treated with REMICADE during treatment for  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Patients should be evaluated for  nonoseaeaeonlyasinstruction risk factors and tested for  notaecandidatepreexistingconditionorriskfactor prior to initiating REMICADE and periodically during therapy.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
207,remicade,207,8188,8212,Treatment of  notaecandidatepreexistingconditionorriskfactor prior to therapy with TNF blocking agents has been shown to reduce the risk of  nonoseaeaeonlyasinstruction during therapy.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
208,remicade,208,8212,8457,"Induration of 5 mm or greater with  nonoseaeaeonlyasinstruction should be considered a  nonoseaeaeonlyasinstruction test result when assessing if treatment for  nonoseaeaeonlyasinstruction is needed prior to initiating REMICADE, even for patients previously vaccinated with  nonoseaeaeonlyasinstruction .\n', '\n', '  nonoseaeaeonlyasinstruction therapy should also be considered prior to initiation of REMICADE in patients with a past history of  notaecandidatepreexistingconditionorriskfactor or active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor in whom an adequate course of treatment cannot be confirmed, and for patients with a  notaecandidatepreexistingconditionorriskfactor but having risk factors for  nonoseaeaeonlyasinstruction  Consultation with a physician with expertise in the treatment of  nonoseaeaeonlyasinstruction is recommended to aid in the decision whether initiating  nonoseaeaeonlyasinstruction therapy is appropriate for an individual patient.\n', '\n', '  nonoseaeaeonlyasinstruction should be strongly considered in patients who develop a new  nonoseaeaeonlyasinstruction during REMICADE treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of  nonoseaeaeonlyasinstruction  or who have had close contact with a person with  nonoseaeaeonlyasinstruction \n', '\n', '    Monitoring  \n', '\n', ' Patients should be closely monitored for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with REMICADE, including the development of  nonoseaeaeonlyasinstruction in patients who  notaecandidatepreexistingconditionorriskfactor prior to initiating therapy.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
209,remicade,209,8457,8491,"nonoseaeaeonlyasinstruction may also be  nonoseaeaeonlyasinstruction while on therapy with REMICADE.\n', '\n', ' REMICADE should be discontinued if a patient develops a serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,remicade,210,8491,8541,"A patient who develops a new  nonoseaeaeonlyasinstruction during treatment with REMICADE should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an  notaecandidatepreexistingconditionorriskfactor patient, and appropriate antimicrobial therapy should be initiated.\n', '\n', '    Invasive Fungal Infections  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
211,remicade,211,8541,8577,"\n', '\n', ' For patients who reside or travel in regions where  nonoseaeaeonlyasinstruction are endemic,  nonoseaeaeonlyasinstruction should be suspected if they develop a serious systemic  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,remicade,212,8577,8593,Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,remicade,213,8593,8602,nonoseaeaeonlyasinstruction in some patients with active  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,remicade,214,8602,8709,"When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive  nonoseaeaeonlyasinstruction and should take into account both the risk for severe  nonoseaeaeonlyasinstruction and the risks of antifungal therapy.\n', '\n', '    5.2 Malignancies\n', '\n', ""   oselabeledaefromdruguse  some  nonoseaegeneralterm  have been reported among children, adolescents and young adults who received treatment with TNF-blocking agents (initiation of therapy <=18 years of age), including REMICADE.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
215,remicade,215,8709,8731,Approximately half of these cases were  oselabeledaefromdruguse  including  oselabeledaeclasseffect and non-Hodgkin's  oselabeledaeclasseffect  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,remicade,216,8731,8765,The other cases represented a variety of  oselabeledaeclasseffect  including rare  oselabeledaefromdruguse that are usually associated with  nonoseaeaeonlyasinstruction and  oselabeledaeclasseffect that are not usually observed in children and adolescents.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,remicade,217,8765,8791,The  oselabeledaefromdruguse occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF blocker therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,remicade,218,8791,8800,Most of the patients were receiving concomitant immunosuppressants.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,remicade,219,8800,8874,"These cases were reported post-marketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.\n"", '\n', '    Lymphomas  \n', '\n', ' In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of  oselabeledaeclasseffect have been observed among patients receiving a TNF blocker compared with control patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,remicade,220,8874,8927,"In the controlled and open-label portions of REMICADE clinical trials, 5 patients developed  oselabeledaefromdruguse among 5707 patients treated with REMICADE (median duration of follow-up 1.0 years) vs. 0  nonoseaeaeonlyasinstruction in 1600 control patients (median duration of follow-up 0.4 years).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,remicade,221,8927,8967,"In  notaecandidateindication patients, 2  oselabeledaefromdruguse were observed for a rate of 0.08 cases per 100 patient-years of follow-up, which is approximately three-fold higher than expected in the general population.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
222,remicade,222,8967,8991,In the combined clinical trial population for  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication  5  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
223,remicade,223,8991,9024,"oselabeledaefromdruguse were observed for a rate of 0.10 cases per 100 patient-years of follow-up, which is approximately four-fold higher than expected in the general population.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,remicade,224,9024,9080,Patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  particularly patients with highly active disease and/or chronic exposure to  nonoseaeaeonlyasinstruction  may be at a higher risk (up to several fold) than the general population for the development of  nonoseaeaeonlyasinstruction  even in the absence of TNF-blocking therapy.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
225,remicade,225,9080,9106,Cases of  oselabeledaeclasseffect and chronic  oselabeledaeclasseffect  oselabeledaeclasseffect have been reported with postmarketing TNF-blocker use in  notaecandidateindication and other indications.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
226,remicade,226,9106,9157,"Even in the absence of TNF blocker therapy, patients with  notaecandidatepreexistingconditionorriskfactor may be at a higher risk (approximately 2-fold) than the general population for the development of  nonoseaeaeonlyasinstruction \n', '\n', '    Hepatosplenic T-cell Lymphoma (HSTCL)  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
227,remicade,227,9157,9190,"\n', '\n', ' Postmarketing cases of  oselabeledaefromdruguse , a rare type of  nonoseaeaeonlyasinstruction  have been reported in patients treated with TNF blockers including REMICADE.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,remicade,228,9190,9229,These cases have had a very aggressive disease course and have been  nonoseaegeneralterm  Almost all patients had received treatment with the immunosuppressants azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
229,remicade,229,9229,9255,The majority of reported REMICADE cases have occurred in patients with  notaecandidateindication or  notaecandidateindication and most were in adolescent and young adult males.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
230,remicade,230,9255,9281,It is uncertain whether the occurrence of  nonoseaeaeonlyasinstruction is related to TNF-blockers or TNF-blockers in combination with these other immunosuppressants.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,remicade,231,9281,9409,"When treating patients, consideration of whether to use REMICADE alone or in combination with other immunosuppressants such as azathioprine or 6-mercaptopurine should take into account a possibility that there is a higher risk of  nonoseaeaeonlyasinstruction with combination therapy versus an observed increased risk of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction with REMICADE monotherapy from the clinical trial data [see  Warnings and Precautions (5.7)  and  Adverse Reactions (6.1)  ]  .\n', '\n', '     oselabeledaefromdruguse  \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in patients treated with TNF blocker therapy, including REMICADE [see  Adverse Reactions (6.2)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,remicade,232,9409,9438,"Periodic skin examination is recommended for all patients, particularly those with risk factors for  nonoseaeaeonlyasinstruction \n', '\n', '     Cervical Cancer    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,remicade,233,9438,9502,"\n', '\n', '  A population-based retrospective cohort study using data from Swedish national health registries found a 2 to 3 fold increase in the incidence of invasive  oselabeledaefromdruguse in women with  notaecandidateindication treated with infliximab compared to biologics-naive patients or the general population, particularly those over 60 years of age.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
234,remicade,234,9502,9515,A causal relationship between infliximab and  nonoseaeaeonlyasinstruction cannot be excluded.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,remicade,235,9515,9537,Periodic screening should continue in women treated with REMICADE [see  Adverse Reactions (6.2)  ]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,remicade,236,9537,9599,"\n', '\n', '    Other Malignancies  \n', '\n', ' In the controlled portions of clinical trials of some TNF-blocking agents including REMICADE, more  oselabeledaeclasseffect (excluding  nonoseaenegation and  nonoseaenegation ) have been observed in patients receiving those TNF-blockers compared with control patients.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
237,remicade,237,9599,9703,"During the controlled portions of REMICADE trials in patients with moderately to severely active  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication  14 patients were diagnosed with  oselabeledaeclasseffect (excluding  nonoseaenegation and  nonoseaenegation  among 4019 REMICADE-treated patients vs. 1 among 1597 control patients (at a rate of 0.52/100 patient-years among REMICADE-treated patients vs. a rate of 0.11/100 patient-years among control patients), with median duration of follow-up 0.5 years for REMICADE-treated patients and 0.4 years for control patients.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
238,remicade,238,9703,9821,"Of these, the most common  oselabeledaefromdruguse were  oselabeledaefromdruguse  oselabeledaefromdruguse were breast,  oselabeledaefromdruguse  oselabeledaefromdruguse were breast, colorectal, and  oselabeledaefromdruguse  The rate of  nonoseaeaeonlyasinstruction among REMICADE-treated patients was similar to that expected in the general population whereas the rate in control patients was lower than expected.\n', '\n', ' In a clinical trial exploring the use of REMICADE in patients with moderate to severe  notaecandidatepreexistingconditionorriskfactor , more  oselabeledaefromdruguse  oselabeledaefromdruguse  the majority of  oselabeledaefromdruguse  oselabeledaefromdruguse  the majority of lung or  oselabeledaefromdruguse origin, were reported in REMICADE-treated patients compared with control patients.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
239,remicade,239,9821,9841,All patients had a history of heavy smoking [see  Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,remicade,240,9841,9888,"Prescribers should exercise caution when considering the use of REMICADE in patients with moderate to severe  notaecandidatepreexistingconditionorriskfactor \n', '\n', '  notaecandidateindication patients should be monitored for  nonoseaeaeonlyasinstruction , particularly those patients who have had prior prolonged phototherapy treatment.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
241,remicade,241,9888,9956,"In the maintenance portion of clinical trials for REMICADE,  oselabeledaefromdruguse were more common in patients with previous phototherapy [see  Adverse Reactions (6.1)  ]  .\n', '\n', ' The potential role of TNF-blocking therapy in the development of  nonoseaeaeonlyasinstruction is not known [see  Adverse Reactions (6.1)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,remicade,242,9956,9988,Rates in clinical trials for REMICADE cannot be compared to rates in clinical trials of other TNF-blockers and may not predict rates observed in a broader patient population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,remicade,243,9988,10062,"Caution should be exercised in considering REMICADE treatment in patients with a history of  notaecandidatepreexistingconditionorriskfactor or in continuing treatment in patients who develop  nonoseaeaeonlyasinstruction while receiving REMICADE.\n', '\n', '    5.3 Hepatitis B Virus Reactivation\n', '\n', '  Use of TNF blockers, including REMICADE, has been associated with  oselabeledaeclasseffect  notaecandidatepreexistingconditionorriskfactor  in patients who are  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
244,remicade,244,10062,10080,"In some instances,  oselabeledaeclasseffect occurring in conjunction with TNF blocker therapy has been  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
245,remicade,245,10080,10119,"The majority of these reports have occurred in patients concomitantly receiving other  nonoseaeaeonlyasinstruction  which may also contribute to  nonoseaeaefromdruginteraction  Patients should be tested for  notaecandidatepreexistingconditionorriskfactor before initiating TNF blocker therapy, including REMICADE.",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
246,remicade,246,10119,10140,For patients who  notaecandidatepreexistingconditionorriskfactor  consultation with a physician with expertise in the treatment of  nonoseaeaeonlyasinstruction is recommended.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
247,remicade,247,10140,10208,Adequate data are not available on the safety or efficacy of treating patients who are  notaecandidatepreexistingconditionorriskfactor with anti-viral therapy in conjunction with TNF blocker therapy to prevent  nonoseaeaeonlyasinstruction  Patients who are  notaecandidatepreexistingconditionorriskfactor and require treatment with TNF blockers should be closely monitored for clinical and laboratory signs of active  nonoseaeaeonlyasinstruction throughout therapy and for several months following termination of therapy.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
248,remicade,248,10208,10231,In patients who develop  nonoseaeaeonlyasinstruction  TNF blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,remicade,249,10231,10247,The safety of resuming TNF blocker therapy after  nonoseaeaeonlyasinstruction is controlled is not known.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,remicade,250,10247,10310,"Therefore, prescribers should exercise caution when considering resumption of TNF blocker therapy in this situation and monitor patients closely.\n', '\n', '    5.4  oselabeledaefromdruguse \n', '  Severe  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  have been reported in postmarketing data in patients receiving REMICADE.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,remicade,251,10310,10320,oselabeledaefromdruguse has been diagnosed in some of these cases.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,remicade,252,10320,10355,Severe  oselabeledaefromdruguse occurred between 2 weeks to more than 1 year after initiation of REMICADE;  nonoseaenegation were not noted prior to discovery of the  oselabeledaefromdruguse in many of these cases.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
253,remicade,253,10355,10422,"Some of these cases were  nonoseaegeneralterm or necessitated  nonoseaemanifestationorcomplication  Patients with symptoms or signs of  nonoseaeaeonlyasinstruction should be evaluated for evidence of  nonoseaeaeonlyasinstruction  If  nonoseaemanifestationorcomplication and/or marked  nonoseaemanifestationorcomplication (e.g., >=5 times the upper limit of normal) develop, REMICADE should be discontinued, and a thorough investigation of the abnormality should be undertaken.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
254,remicade,254,10422,10515,"In clinical trials, mild or moderate  oselabeledaefromdruguse ALT and  oselabeledaefromdruguse  oselabeledaefromdruguse and AST have been observed in patients receiving REMICADE without progression to severe  nonoseaenegation [see  Adverse Reactions (6.1)  ]  .\n', '\n', '    5.5 Patients with Heart Failure\n', '\n', '  REMICADE has been associated with adverse outcomes in patients with  notaecandidatepreexistingconditionorriskfactor  and should be used in patients with  notaecandidatepreexistingconditionorriskfactor only after consideration of other treatment options.",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
255,remicade,255,10515,10569,"The results of a randomized study evaluating the use of REMICADE in patients with  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor III/ notaecandidatepreexistingconditionorriskfactor  suggested higher  nonoseaegeneralterm in patients who received 10 mg/kg REMICADE, and higher rates of  oselabeledaefromdruguse at doses of 5 mg/kg and 10 mg/kg.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
256,remicade,256,10569,10592,"There have been post-marketing reports of  oselabeledaefromdruguse  with and without identifiable precipitating factors, in patients taking REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,remicade,257,10592,10619,There have also been post-marketing reports of new onset  oselabeledaefromdruguse  including  oselabeledaefromdruguse in patients without known pre-existing  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
258,remicade,258,10619,10631,Some of these patients have been under 50 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,remicade,259,10631,10733,"If a decision is made to administer REMICADE to patients with  notaecandidatepreexistingconditionorriskfactor  they should be closely monitored during therapy, and REMICADE should be discontinued if new or worsening symptoms of  nonoseaeaeonlyasinstruction appear [see  Contraindications (4)  and  Adverse Reactions (6.1)  ]  .\n', '\n', '    5.6 Hematologic Reactions\n', '\n', '  Cases of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  some with a  nonoseaegeneralterm outcome, have been reported in patients receiving REMICADE.",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
260,remicade,260,10733,10742,The causal relationship to REMICADE therapy remains unclear.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,remicade,261,10742,10808,"Although no high-risk group(s) has been identified, caution should be exercised in patients being treated with REMICADE who have ongoing or a history of significant  notaecandidatepreexistingconditionorriskfactor  All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication (e.g., persistent  nonoseaemanifestationorcomplication  while on REMICADE.",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
262,remicade,262,10808,10862,"Discontinuation of REMICADE therapy should be considered in patients who develop significant  nonoseaeaeonlyasinstruction \n', '\n', '    5.7 Hypersensitivity\n', '\n', '  REMICADE has been associated with  oselabeledaefromdruguse that vary in their time of onset and required hospitalization in some cases.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,remicade,263,10862,10939,"Most  oselabeledaefromdruguse  which include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and/or  oselabeledaefromdruguse  have occurred during or within 2 hours of REMICADE infusion.\n', '\n', ' However, in some cases,  oselabeledaefromdruguse have been observed in patients after initial REMICADE therapy (i.e., as early as after the second dose), and when REMICADE therapy was reinstituted following an extended period without REMICADE treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,remicade,264,10939,11107,"Symptoms associated with these reactions include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and facial  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and/or  nonoseaemanifestationorcomplication  These reactions were associated with a marked increase in  oselabeledaefromdruguse  loss of detectable serum concentrations of infliximab, and possible loss of drug efficacy.\n', '\n', ' REMICADE should be discontinued for severe  nonoseaeaeonlyasinstruction  Medications for the treatment of  nonoseaeaeonlyasinstruction (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction [see  Adverse Reactions (6.1)  ]  .\n', '\n', ' In  notaecandidateindication   notaecandidateindication and  notaecandidateindication clinical trials, re-administration of REMICADE after a period of no treatment resulted in a higher incidence of  oselabeledaefromdruguse relative to regular maintenance treatment [see  Adverse Reactions (6.1)  ]  .",1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
265,remicade,265,11107,11149,"In general, the benefit-risk of re-administration of REMICADE after a period of no-treatment, especially as a re-induction regimen given at weeks 0, 2 and 6, should be carefully considered.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,remicade,266,11149,11236,"In the case where REMICADE maintenance therapy for  notaecandidateindication is interrupted, REMICADE should be reinitiated as a single dose followed by maintenance therapy.\n', '\n', '    5.8 Cardiovascular and Cerebrovascular Reactions During and After Infusion\n', '\n', '   Serious  oselabeledaefromdruguse   oselabeledaefromdruguse ischemia/ oselabeledaefromdruguse  oselabeledaefromdruguse infarction (some  nonoseaegeneralterm ,  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported during and within 24 hours of initiation of REMICADE infusion.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
267,remicade,267,11236,11255,Cases of  oselabeledaefromdruguse  oselabeledaefromdruguse have been reported during or within 2 hours of infusion of REMICADE.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,remicade,268,11255,11268,"Monitor patients during infusion and if serious reaction occurs, discontinue infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,remicade,269,11268,11292,Further management of reactions should be dictated by signs and symptoms [See  Adverse Reactions (6)  ]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,remicade,270,11292,11441,"\n', '\n', '    5.9 Neurologic Reactions\n', '\n', '  REMICADE and other agents that inhibit TNF have been associated with CNS manifestation of  oselabeledaeclasseffect   oselabeledaeclasseffect and new onset or exacerbation of clinical symptoms and/or radiographic evidence of  oselabeledaeclasseffect  including  oselabeledaeclasseffect and  oselabeledaefromdruguse  and  oselabeledaefromdruguse  including  oselabeledaefromdruguse  Prescribers should exercise caution in considering the use of REMICADE in patients with these  nonoseaeaeonlyasinstruction and should consider discontinuation of REMICADE if these disorders develop.\n', '\n', '    5.10 Use with Anakinra\n', '\n', '  Serious  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction were seen in clinical studies with concurrent use of anakinra and another TNFalpha-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
271,remicade,271,11441,11476,"Because of the nature of the adverse reactions seen with the combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNFalpha-blocking agents.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,remicade,272,11476,11548,"Therefore, the combination of REMICADE and anakinra is not recommended.\n', '\n', '    5.11 Use with Abatacept\n', '\n', '  In clinical studies, concurrent administration of TNF-blocking agents and abatacept have been associated with an increased risk of  nonoseaeaefromdruginteraction including serious  nonoseaeaefromdruginteraction compared with TNF -  blocking agents alone, without increased clinical benefit.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
273,remicade,273,11548,11573,"Therefore, the combination of REMICADE and abatacept is not recommended [see  Drug Interactions (7.1)  ]  .\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,remicade,274,11573,11617,"'\n', '    5.12 Concurrent Administration with Other Biological Therapeutics\n', '\n', '  There is insufficient information regarding the concomitant use of REMICADE with other biological therapeutics used to treat the same conditions as REMICADE.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,remicade,275,11617,11668,"The concomitant use of REMICADE with these biologics is not recommended because of the possibility of an increased risk of  nonoseaeaefromdruginteraction [see  Drug Interactions (7.3)  ]  .\n', '\n', '    5.13 Switching Between Biological Disease-Modifying Antirheumatic Drugs",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
276,remicade,276,11668,11819,"(DMARDs)\n', '\n', '  Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of  nonoseaeaefromdruginteraction \n', '\n', '    5.14 Autoimmunity\n', '\n', '  Treatment with REMICADE may result in the  oselabeledaefromdruguse and in the development of a  oselabeledaefromdruguse  If a patient develops symptoms suggestive of a  nonoseaeaeonlyasinstruction following treatment with REMICADE, treatment should be discontinued [see  Adverse Reactions (6.1)  ]  .\n', '\n', '    5.15 Live Vaccines/Therapeutic Infectious Agents\n', '\n', '  In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with live vaccines or on the  nonoseaeaefromdruginteraction  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
277,remicade,277,11819,11834,Use of live vaccines can result in clinical  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction  ,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
278,remicade,278,11834,11892,"The concurrent administration of live vaccines with REMICADE is not recommended.\n', '\n', '  nonoseaegeneralterm outcome due to  nonoseaeaefromdruginteraction has been reported in an infant who received a BCG vaccine after  oselabeledaefromdruguse  Infliximab is known to cross the placenta and has been detected up to 6 months following birth.",0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
279,remicade,279,11892,11960,"At least a six month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero  to infliximab.\n', '\n', ' Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of  notaecandidatepreexistingconditionorriskfactor  could result in clinical  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction  ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
280,remicade,280,11960,11968,It is recommended that  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,impavido,0,0,77,"['    6 ADVERSE REACTIONS\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '    EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,impavido,1,77,122,"*    Adverse reactions occurring in >=2% of patients include nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, and elevated creatinine (  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,impavido,2,122,158,"\n', '      To report SUSPECTED ADVERSE REACTIONS, contact    Paladin Therapeutics Inc. at 1-888-550-6060    or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,impavido,3,158,219,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '    Visceral Leishmaniasis  \n', '\n', '\n', '\n', ' One Phase 3 trial was conducted in patients >",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,impavido,4,219,227,= 12 years of age in India.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,impavido,5,227,290,Two-hundred and ninety-nine (299) patients (211 men and 88 women) received oral IMPAVIDO at a target dose of 2.5 mg/kg/day for 28 days (50 mg capsule once daily if weight was less than 25 kg and 50 mg capsule twice daily if weight was 25 kg or greater).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,impavido,6,290,300,Patients ranged between 12 and 64 years of age.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,impavido,7,300,325,Weight ranged between 15 and 67 kg (mean weight 38.6 kg) and BMI ranged between 8.2 and 24 (mean 16.1).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,impavido,8,325,350,Ninety-nine (99) patients received 1 mg/kg/day amphotericin B deoxycholate intravenously every other day for 15 doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,impavido,9,350,428,"A statistically significant higher percentage of men received IMPAVIDO compared to amphotericin B.\n', '\n', '\n', '\n', '  Less than 1% of patients who received IMPAVIDO  nonoseaegeneralterm (2/299) and no patient who received amphotericin B  nonoseaegeneralterm  Serious adverse reactions were reported in 2% of IMPAVIDO recipients (6/299) and 1% of amphotericin B recipients (1/99).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
10,impavido,10,428,445,Approximately 3% of patients discontinued treatment in each treatment arm due to an adverse reaction.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,impavido,11,445,489,Serious adverse reactions and adverse reactions leading to drug discontinuation that were thought to be related or possibly related to IMPAVIDO included  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  CTCAE (Common Terminology Criteria for Adverse Events),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,impavido,12,489,529,"Grade 4  oselabeledaefromdruguse (>=10 stools per day) and CTCAE Grade 4  oselabeledaefromdruguse (>=10x upper limit of normal ULN).\n', ' \n', '\n', ' Table 2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,impavido,13,529,544,: Treatment Emergent Adverse Reactions Occurring in >=2% of Visceral Leishmaniasis Patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,impavido,14,544,556,"Receiving IMPAVIDO \n', '  System Organ ClassPreferred Term                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,impavido,15,556,564,IMPAVIDON = 299               Amphotericin B DeoxycholateN =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,impavido,16,564,573,"99    \n', '   nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,impavido,17,573,592,"\n', '     oselabeledaefromdruguse                                             61 (20.4%)                    6 (6.1%)                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,impavido,18,592,611,"\n', '     oselabeledaefromdruguse                                             113 (37.8%)                   20 (20.0%)                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,impavido,19,611,637,"\n', '   nonoseaegeneralterm                                                                                                         \n', '     oselabeledaefromdruguse                                             19 (6.3%)                     4 (4.0%)                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
20,impavido,20,637,644,"\n', '   nonoseaegeneralterm                                                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,impavido,21,644,663,"\n', '     oselabeledaefromdruguse                                   69 (23.1%)                    22 (22.2%)                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,impavido,22,663,668,"\n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,impavido,23,668,707,"In this study,  oselabeledaefromdruguse (Cr)  oselabeledaefromdruguse >= 1.5 times above baseline occurred in approximately 10% of IMPAVIDO recipients and in 40% of amphotericin B recipients at the end of therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,impavido,24,707,729,Ten percent of subjects in each arm had  oselabeledaefromdruguse >=1.5 times above baseline at 6 months follow up.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,impavido,25,729,775,"No IMPAVIDO recipient discontinued therapy due to  nonoseaeaeonlyasinstruction \n', ' \n', '\n', '  oselabeledaefromdruguse of  oselabeledaefromdruguse during therapy occurred in up to half of IMPAVIDO recipients and up to a third of amphotericin B recipients.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,impavido,26,775,809,The elevations were mild (< 3x ULN) or moderate (3-5x ULN) in 94% and 6% respectively of IMPAVIDO-treated patients who experienced an elevation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,impavido,27,809,933,"No patient discontinued therapy due to  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' At the end of therapy, 62% and 2.4% of IMPAVIDO recipients and 54% and 2% of amphotericin B recipients had  oselabeledaefromdruguse  oselabeledaefromdruguse respectively.\n', '\n', '\n', '\n', '   Cutaneous Leishmaniasis  \n', '\n', '\n', '\n', ' The efficacy of IMPAVIDO in the treatment of  notaecandidateindication was evaluated in one placebo-controlled trial conducted in Colombia and Guatemala and in two comparative trials conducted in Bolivia and Brazil respectively.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
28,impavido,28,933,978,"In the placebo-controlled trial, eighty-nine (89) patients >=12 years of age received a target IMPAVIDO dose of 2.5 mg/kg/day for 28 days and forty-four (44) received placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,impavido,29,978,1132,"In the comparative trials, one hundred and twenty (120) patients >=12 years of age received a target IMPAVIDO dose of 2.5 mg/kg/day for 28 days and fifty eight (58) patients received 20 mg/kg/day pentavalent antimony (meglumine) parenterally for 20 days.\n', '\n', '\n', '\n', ' Table 3: Adverse Reactions Occurring in >=2% of IMPAVIDO-Treated Patients >=12 Years of Age with Cutaneous Leishmaniasis in the Placebo-Controlled Trial \n', '  System Organ ClassPreferred Term                           IMPAVIDON = 89                   PlaceboN = 44                 \n', '   nonoseaegeneralterm                                                                                               \n', '     oselabeledaefromdruguse                                          26 (29.2%)                       10 (22.7%)                    \n', '   nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,impavido,30,1132,1151,"\n', '     oselabeledaefromdruguse                                           10 (11.2%)                       3 (6.8%)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,impavido,31,1151,1170,"\n', '     oselabeledaefromdruguse                                                 7 (7.9%)                         2 (4.5%)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,impavido,32,1170,1189,"\n', '     oselabeledaefromdruguse                                                   32 (35.9%)                       5 (11.1%)                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,impavido,33,1189,1204,"\n', '     oselabeledaefromdruguse                                                 4 (4.5%)                         0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,impavido,34,1204,1211,"\n', '   nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,impavido,35,1211,1224,"\n', '     oselabeledaefromdruguse                                                  3 (3.4%)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,impavido,36,1224,1230,1 (2.3%)                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,impavido,37,1230,1243,"\n', '     oselabeledaefromdruguse                                                  5 (5.6%)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,impavido,38,1243,1249,2 (4.5%)                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,impavido,39,1249,1256,"\n', '   nonoseaegeneralterm                                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,impavido,40,1256,1271,"\n', '     oselabeledaefromdruguse                                                4 (4.5%)                         0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,impavido,41,1271,1305,"\n', '     oselabeledaefromdruguse                                                 25 (28.1%)                       10 (22.7%)                    \n', '     oselabeledaefromdruguse                                               3 (3.4%)                         0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,impavido,42,1305,1327,"\n', '   nonoseaegeneralterm                                                                                    \n', '     oselabeledaefromdruguse                                                 4 (4.5%)                         0                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,impavido,43,1327,1349,"\n', '        Table 4: Adverse Reactions Occurring in >=2% of IMPAVIDO-Treated Patients >",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,impavido,44,1349,1443,"= 12 Years of Age with Cutaneous Leishmaniasis in Two Comparative Trials \n', '  System Organ ClassPreferred Term                           IMPAVIDON = 120                  MeglumineN = 58               \n', '   nonoseaegeneralterm                                                                                                \n', '     oselabeledaefromdruguse                                           9 (7.5%)                         3 (5.2%)                      \n', '     oselabeledaefromdruguse                                                 18 (15.0%)                       3 (5.2%)                      \n', '     oselabeledaefromdruguse                                                   50 (41.7%)                       3 (5.2%)                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,impavido,45,1443,1458,"\n', '     oselabeledaefromdruguse                                                 33 (27.5%)                       0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,impavido,46,1458,1465,"\n', '   nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
47,impavido,47,1465,1470,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,impavido,48,1470,1480,oselabeledaefromdruguse                                             7 (5.8%)                         0                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,impavido,49,1480,1487,"\n', '   nonoseaegeneralterm                                                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,impavido,50,1487,1506,"\n', '     oselabeledaefromdruguse                                       13 (10.8%)                       4 (5.8%)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,impavido,51,1506,1513,"\n', '   nonoseaegeneralterm                                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,impavido,52,1513,1532,"\n', '     oselabeledaefromdruguse                                                15 (12.5%)                       4 (6.9%)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,impavido,53,1532,1554,"\n', '   nonoseaegeneralterm                                                                                    \n', '     oselabeledaefromdruguse                                                 7 (5.8%)                         0                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,impavido,54,1554,1570,"\n', '         In the placebo controlled trial, 12/89 (13.4%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,impavido,55,1570,1597,"IMPAVIDO subjects had  oselabeledaefromdruguse of 1.5-3 times above baseline, compared to 2/44 (4.5%) placebo subjects at end of therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,impavido,56,1597,1631,"In the comparative trial, a similar percentage of subjects who received IMPAVIDO or pentavalent antimony had  oselabeledaefromdruguse above baseline at 3 and 6 months after therapy (approximately 5%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,impavido,57,1631,1665,Approximately 25% of IMPAVIDO subjects and 11% of pentavalent antimony subjects had  oselabeledaefromdruguse 1.5-3 times above baseline at the end of therapy in the two active controlled trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,impavido,58,1665,1756,"The frequency of  nonoseaeaeratelteqplacebo and ALT  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo above upper limit of normal at end of therapy was similar in IMPAVIDO and placebo recipients (approximately 5%).\n', ' \n', '\n', ' Other adverse events seen at <2% incidence in the IMPAVIDO group included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
59,impavido,59,1756,1797,"\n', '\n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during use of IMPAVIDO worldwide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,impavido,60,1797,1872,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse \n',",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,impavido,61,1872,1889,"'\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,impavido,62,1889,1908,"\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,impavido,63,1908,1925,"', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,impavido,64,1925,1970,"\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,impavido,65,1970,1981,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,impavido,66,1981,1985,WARNING:  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,impavido,67,1985,1992,"\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,impavido,68,1992,2029,"EMBRYO-FETAL TOXICITY\n', '\n', '    IMPAVIDO may cause  oselabeledaefromdruguse   nonoseaeaeanimal and  nonoseaeaeanimal occurred in animals administered miltefosine at doses lower than the recommended human dose.  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
69,impavido,69,2029,2038,Do not administer IMPAVIDO to  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
70,impavido,70,2038,2052,"Obtain a serum or urine  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,impavido,71,2052,2076,"'\n', '\n', '\n', '   EXCERPT:    *    Embryo-Fetal Toxicity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,impavido,72,2076,2083,Do not use in pregnant women.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,impavido,73,2083,2096,Obtain a urine or serum pregnancy test prior to initiation of therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,impavido,74,2096,2121,"Advise use of effective contraception in females of reproductive potential (  Boxed Warning  ,  5.1  ,  8.1  ,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,impavido,75,2121,2129,"8.8  ,  13.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,impavido,76,2129,2138,"\n', ' *    Reproductive effects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,impavido,77,2138,2155,Miltefosine caused testicular atrophy and impaired fertility in male rats and impaired fertility in female rats.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,impavido,78,2155,2182,Advise patients of reproductive toxicities in animal studies and that the potential effects on human fertility have not been adequately evaluated (  13.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,impavido,79,2182,2191,"\n', ' *    Renal Effects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,impavido,80,2191,2214,"Monitor serum creatinine during therapy and for 4 weeks after end of therapy (  5.3  ,  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,impavido,81,2214,2223,"\n', ' *    Hepatic Effects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,impavido,82,2223,2239,"Monitor transaminases and bilirubin during therapy (  5.4  ,  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,impavido,83,2239,2248,"\n', ' *    Gastrointestinal Effects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,impavido,84,2248,2257,Encourage fluid intake (  5.5  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,impavido,85,2257,2265,"\n', ' *    Thrombocytopenia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,impavido,86,2265,2283,"Monitor platelet count during therapy for visceral leishmaniasis (  5.6  ,  6.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,impavido,87,2283,2294,"\n', ' *    Absorption of Oral Contraceptives.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,impavido,88,2294,2312,Advise use of alternative method of contraception if vomiting and/or diarrhea occur (  5.7  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,impavido,89,2312,2323,"\n', ' *    Stevens-Johnson syndrome.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,impavido,90,2323,2331,Discontinue IMPAVIDO (  5.8  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,impavido,91,2331,2414,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdruguse \n', '\n', '\n', '  Miltefosine may cause  oselabeledaefromdruguse   nonoseaeaeanimal  nonoseaeaeanimal toxicity, including  nonoseaeaeanimal and  nonoseaeaeanimal  was observed in animals administered miltefosine prior to mating, during early  nonoseaeaeonlyasinstruction  and during organogenesis at doses lower than the maximum recommended human dose (MRHD).",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
92,impavido,92,2414,2423,Do not use IMPAVIDO in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
93,impavido,93,2423,2441,Obtain a urine or serum  nonoseaeaeonlyasinstruction test prior to prescribing IMPAVIDO to females of reproductive potential.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,impavido,94,2441,2490,"Advise females of reproductive potential to use effective contraception during IMPAVIDO therapy and for 5 months after completion of therapy [see  Boxed Warning  , Contraindications (  4.1  ) and Use in Specific Populations (  8.1  ,  8.8  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,impavido,95,2490,2522,".\n', '\n', '\n', '\n', '    5.2 Reproductive Effects\n', '\n', '\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,impavido,96,2522,2528,"', '   Females  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,impavido,97,2528,2533,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,impavido,98,2533,2586,"', '\n', '\n', ' Miltefosine caused  nonoseaeaeanimal in rats and  nonoseaeaeanimal and  nonoseaeaeanimal in dogs at doses approximately 1.0 and 0.2 times respectively the MRHD based on body surface area comparisons [see Nonclinical Toxicology (  13.1  )]  .",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
99,impavido,99,2586,2649,"Effects on human female fertility have not been formally studied.\n', '\n', '\n', '\n', '  Males  \n', '\n', '\n', '\n', ' Miltefosine caused  nonoseaeaeanimal viable  nonoseaeaeanimal and  nonoseaeaeanimal in rats at doses approximately 0.4 times the MRHD",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
100,impavido,100,2649,2655,[see Nonclinical Toxicology (  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,impavido,101,2655,2660,13.1    ) ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,impavido,102,2660,2661,.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,impavido,103,2661,2736,"A higher dose in rats, approximately 1.0 times the MRHD, caused  nonoseaeaeanimal and  nonoseaeaeanimal that did not fully reverse 10 weeks after drug administration ended.\n', '\n', '\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse or absent  oselabeledaefromdruguse  oselabeledaefromdruguse during therapy have been reported during IMPAVIDO therapy [see Adverse Reactions (  6.2    ) ]  .",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
104,impavido,104,2736,2871,"The effects of IMPAVIDO on human male fertility have not been adequately studied.\n', '\n', '\n', '\n', ' Advise women and men of the animal fertility findings, and that the potential for  nonoseaeaeonlyasinstruction with IMPAVIDO therapy in humans has not been adequately evaluated.\n', '\n', '\n', '\n', '    5.3 Renal Effects\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  were noted in clinical trials evaluating IMPAVIDO in the treatment of  notaecandidateindication  Monitor renal function weekly in patients receiving IMPAVIDO during therapy and for 4 weeks after end of therapy [see Adverse Reactions (  6.1  )]  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
105,impavido,105,2871,2979,".\n', '\n', '\n', '\n', '    5.4 Hepatic Effects\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse in liver transaminases ( oselabeledaefromdruguse  oselabeledaefromdruguse in liver transaminases (ALT,  oselabeledaefromdruguse  oselabeledaefromdruguse in liver transaminases (ALT, AST) and  oselabeledaefromdruguse were noted in clinical trials evaluating IMPAVIDO in the treatment of  notaecandidateindication  Monitor liver transaminases (ALT, AST) and bilirubin during therapy in patients receiving IMPAVIDO [see Adverse Reactions (  6.1  )]  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
106,impavido,106,2979,3049,".\n', '\n', '\n', '\n', '    5.5 Gastrointestinal Effects\n', '\n', '\n', '\n', '   oselabeledaefromdruguse and/or  oselabeledaefromdruguse commonly occur during IMPAVIDO administration and may result in  nonoseaemanifestationorcomplication  Encourage fluid intake to avoid  nonoseaeaeonlyasinstruction [see Adverse Reactions (  6.1  )]  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
107,impavido,107,3049,3098,".\n', '\n', '\n', '\n', '    5.6 Thrombocytopenia\n', '\n', '\n', '\n', '   oselabeledaefromdruguse during therapy has been reported in patients treated for  notaecandidateindication  Monitor",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
108,impavido,108,3098,3120,"platelet count during therapy for  notaecandidateindication [see Adverse Reactions (  6.1  ,  6.2  )]  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
109,impavido,109,3120,3180,".\n', '\n', '\n', '\n', '    5.7 Absorption of Oral Contraceptives\n', '\n', '\n', '\n', '   nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction occurring during IMPAVIDO therapy may affect the absorption of oral contraceptives, and therefore compromise their efficacy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,impavido,110,3180,3251,"If  nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction occur during IMPAVIDO therapy, advise females to use additional non-hormonal or alternative method(s) of effective contraception.\n', '\n', '\n', '\n', '    5.8 Stevens-Johnson Syndrome\n', '\n', '\n', '\n', '   oselabeledaefromdruguse has been reported during IMPAVIDO therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,impavido,111,3251,3265,Discontinue IMPAVIDO if an  nonoseaeaeonlyasinstruction or bullous  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,effexor,0,0,81,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', ' *   oselabeledaefromdruguse [ see  Contraindications (4.1)   ] \n', ' *   oselabeledaeclasseffect Thoughts and  oselabeledaeclasseffect  oselabeledaeclasseffect and Behaviors in Children, Adolescents, and Adults [ see  Warnings and Precautions (5.1)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,effexor,1,81,99,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,effexor,2,99,117,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.3)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,effexor,3,117,135,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.4)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,effexor,4,135,153,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.5)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,effexor,5,153,176,"\n', ' *  Activation of  oselabeledaefromdruguse  oselabeledaefromdruguse [ see  Warnings and Precautions (5.6)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,effexor,6,176,194,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.7)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,effexor,7,194,212,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.8)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,effexor,8,212,230,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.9)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,effexor,9,230,246,"\n', ' *   oselabeledaefromdruguse and Height  oselabeledaefromdruguse  oselabeledaefromdruguse in Pediatric Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,effexor,10,246,257,[ see  Warnings and Precautions (5.10)   ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,effexor,11,257,261,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,effexor,12,261,278,*   oselabeledaefromdruguse in Pediatric Patients [ see  Warnings and Precautions (5.11)   ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,effexor,13,278,397,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [ see  Warnings and Precautions (5.12)  ]  \n', '      EXCERPT:   Most common adverse reactions (incidence >= 5% and at least twice the rate of placebo): nausea, somnolence, dry mouth, sweating, abnormal ejaculation, anorexia, constipation, erectile dysfunction, and libido decreased (  6.1  ).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Wyeth Pharmaceuticals Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,effexor,14,397,426,"\n', '\n', ' \n', '\n', '  6.1 Clinical Studies Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,effexor,15,426,483,"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n', '\n', '     Most Common Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,effexor,16,483,754,"\n', '\n', ' The most commonly observed adverse reactions in the clinical study database in Effexor XR treated patients in  notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication (incidence >= 5% and at least twice the rate of placebo) were:  oselabeledaefromdruguse (30.0%),  oselabeledaefromdruguse (15.3%),  oselabeledaefromdruguse (14.8%),  oselabeledaefromdruguse (11.4%),  oselabeledaefromdruguse (9.9%),  oselabeledaefromdruguse (9.8%),  oselabeledaefromdruguse (9.3%),  oselabeledaefromdruguse (5.3%) and  oselabeledaefromdruguse (5.1%).\n', '\n', '     Adverse Reactions Reported as Reasons for Discontinuation of Treatment  \n', '\n', ' Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received Effexor XR (37.5-225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.\n', '\n', ' The most common adverse reactions leading to discontinuation in >= 1% of the Effexor XR treated patients in the short-term studies (up to 12 weeks) across indications are shown in Table 7.\n', '\n', ' Table 7: Incidence (%) of Patients Reporting Adverse Reactions Leading to Discontinuation in Placebo-controlled Clinical Studies (up to 12 Weeks Duration)",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
17,effexor,17,754,794,"\n', ' Body SystemAdverse Reaction       Effexor XRn = 3,558                   Placebon = 2,197                   \n', '  \n', '  nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse                        1.7                                   0.5                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,effexor,18,794,803,"\n', '    oselabeledaefromdruguse                        1.5                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,effexor,19,803,805,0.8                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,effexor,20,805,812,"\n', '  nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,effexor,21,812,823,"\n', '    oselabeledaefromdruguse                          4.3                                   0.4                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,effexor,22,823,830,"\n', '  nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,effexor,23,830,841,"\n', '    oselabeledaefromdruguse                       2.2                                   0.8                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,effexor,24,841,852,"\n', '    oselabeledaefromdruguse                        2.1                                   0.6                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,effexor,25,852,874,"\n', '    oselabeledaefromdruguse                      1.7                                   0.3                                \n', '  nonoseaegeneralterm               1.5                                   0.6                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,effexor,26,874,883,"\n', '    oselabeledaefromdruguse                        1.0                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,effexor,27,883,885,0.2                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,effexor,28,885,935,"\n', '             Common Adverse Reactions in Placebo-controlled Studies  \n', ' \n', '\n', ' The number of patients receiving multiple doses of Effexor XR during the premarketing assessment for each approved indication is shown in Table 8.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,effexor,29,935,995,"The conditions and duration of exposure to venlafaxine in all development programs varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient (Effexor only) and outpatient studies, fixed-dose, and titration studies.\n', '\n', ' Table 8:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,effexor,30,995,1012,"Patients Receiving Effexor XR in Premarketing Clinical Studies \n', ' Indication                                          Effexor XR                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,effexor,31,1012,1025,"\n', '  \n', '  notaecandidateindication                                                 705",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
32,effexor,32,1025,1052,"[note: In addition, in the premarketing assessment of Effexor, multiple doses were administered to 2,897 patients in studies for  notaecandidateindication ]    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
33,effexor,33,1052,1061,"\n', '  notaecandidateindication                                                 1,381                                                ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
34,effexor,34,1061,1070,"\n', '  notaecandidateindication                                                 819                                                  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
35,effexor,35,1070,1077,"\n', '  notaecandidateindication                                                  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
36,effexor,36,1077,1079,"1,314                                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,effexor,37,1079,1302,"\n', '        The incidences of common adverse reactions (those that occurred in >= 2% of Effexor XR treated patients [357  notaecandidateindication patients, 1,381  notaecandidateindication patients, 819  notaecandidateindication patients, and 1,001  notaecandidateindication patients] and more frequently than placebo) in Effexor XR treated patients in short-term, placebo-controlled, fixed- and flexible-dose clinical studies (doses 37.5 to 225 mg per day) are shown in Table 9.\n', ' \n', '\n', ' The adverse reaction profile did not differ substantially between the different patient populations.\n', '\n', ' Table 9: Common Adverse Reactions: Percentage of Patients Reporting Adverse Reactions (>= 2% and > placebo) in Placebo-controlled Studies (up to 12 Weeks Duration) across All Indications \n', ' Body SystemAdverse Reaction                    Effexor XRn = 3,558        Placebon = 2,197                 \n', '  \n', '  nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse                                     12.6                       7.8                              \n', '  nonoseaegeneralterm                                                                                      \n', '    oselabeledaefromdruguse                                 3.4                        2.6                              \n', '    oselabeledaefromdruguse                                  2.2                        ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
38,effexor,38,1302,1304,2.0                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,effexor,39,1304,1313,"\n', '    oselabeledaefromdruguse                               3.7                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,effexor,40,1313,1315,1.9                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,effexor,41,1315,1322,"\n', '  nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,effexor,42,1322,1342,"\n', '    oselabeledaefromdruguse                                     9.8                        2.6                              \n', '    oselabeledaefromdruguse                                 9.3                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,effexor,43,1342,1344,3.4                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,effexor,44,1344,1364,"\n', '    oselabeledaefromdruguse                                     7.7                        7.2                              \n', '    oselabeledaefromdruguse                                    14.8                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,effexor,45,1364,1366,5.3                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,effexor,46,1366,1382,"\n', '    oselabeledaefromdruguse                                       30.0                       11.8                             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,effexor,47,1382,1404,"oselabeledaefromdruguse                                     4.3                        2.7                              \n', '  nonoseaegeneralterm                                                                                             \n', '    oselabeledaefromdruguse                              2.9                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,effexor,48,1404,1406,1.4                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,effexor,49,1406,1415,"\n', '    oselabeledaefromdruguse                                    15.8                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,effexor,50,1415,1437,"9.5                              \n', '    oselabeledaefromdruguse                                     17.8                       9.5                              \n', '    oselabeledaefromdruguse                             5.1                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,effexor,51,1437,1459,"1.6                              \n', '    oselabeledaefromdruguse                                  7.1                        5.0                              \n', '    oselabeledaefromdruguse                                  2.4                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,effexor,52,1459,1461,1.4                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,effexor,53,1461,1468,"\n', '    oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,effexor,54,1468,1472,15.3                       7.5                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,effexor,55,1472,1481,"\n', '    oselabeledaefromdruguse                                       4.7                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,effexor,56,1481,1490,"1.6                              \n', '  nonoseaegeneralterm                                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,effexor,57,1490,1499,"\n', '    oselabeledaefromdruguse                                         3.7                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,effexor,58,1499,1501,0.2                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,effexor,59,1501,1508,"\n', '  nonoseaegeneralterm                                                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,effexor,60,1508,1519,"\n', '    oselabeledaefromdruguse (including  oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,effexor,61,1519,1523,11.4                       2.9                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,effexor,62,1523,1530,"\n', '  nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,effexor,63,1530,1539,"\n', '    oselabeledaefromdruguse                              4.2                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,effexor,64,1539,1542,1.6                              \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,effexor,65,1542,1564,"', '  nonoseaegeneralterm                                                                                          \n', '    oselabeledaefromdruguse  oselabeledaefromdruguse ejaculation/ oselabeledaefromdruguse (men) [note:",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,effexor,66,1564,1587,"Percentages based on the number of men (Effexor XR, n = 1,440; placebo, n = 923)]   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,effexor,67,1587,1591,9.9                        0.5                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,effexor,68,1591,1603,"\n', '    oselabeledaefromdruguse (men)                             3.6                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,effexor,69,1603,1605,0.1                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,effexor,70,1605,1642,"\n', '    oselabeledaefromdruguse (women) [note: Percentages based on the number of women (Effexor XR, n = 2,118; placebo, n = 1,274)]   2.0                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,effexor,71,1642,1644,0.2                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,effexor,72,1644,1654,"\n', '   Impotence (men)                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,effexor,73,1654,1656,5.3                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,effexor,74,1656,1658,1.0                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,effexor,75,1658,1708,"\n', '             Other Adverse Reactions Observed in Clinical Studies  \n', ' \n', '\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,effexor,76,1708,1721,"', '    nonoseaegeneralterm  -  oselabeledaefromdruguse [  see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,effexor,77,1721,1732,"Warnings and Precautions (5.4)    ],  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,effexor,78,1732,1749,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse [  see  Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
79,effexor,79,1749,1754,(5.4)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,effexor,80,1754,1785,"\n', '\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse [  see  Warnings and Precautions (5.10)    ],  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,effexor,81,1785,1797,[  see  Warnings and Precautions (5.10)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,effexor,82,1797,1833,"\n', '\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse [  see  Warnings and Precautions (5.8)    ],  oselabeledaefromdruguse [  see  Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
83,effexor,83,1833,1855,"(5.6)    ],  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,effexor,84,1855,1871,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,effexor,85,1871,1887,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
86,effexor,86,1887,1929,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse disorders associated with  oselabeledaefromdruguse  oselabeledaefromdruguse disorders associated with  oselabeledaefromdruguse bleeding or increased  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,effexor,87,1929,1962,"\n', '\n', '   6.2 Vital Sign Changes\n', '\n', '  In placebo-controlled premarketing studies, there were  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,effexor,88,1962,1969,see  Table 10  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,effexor,89,1969,1998,"Across most indications, a dose-related  oselabeledaefromdruguse systolic and  oselabeledaefromdruguse  oselabeledaefromdruguse and diastolic blood pressure was evident in patients treated with Effexor XRs.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,effexor,90,1998,2050,"Across all clinical studies in  notaecandidateindication   notaecandidateindication   notaecandidateindication and  notaecandidateindication  1.4% of patients in the Effexor XR groups experienced an  oselabeledaefromdruguse of >=15 mm Hg along with a  oselabeledaefromdruguse Hg, compared to 0.9% of patients in the placebo groups.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
91,effexor,91,2050,2215,"Similarly, 1% of patients in the Effexor XR groups experienced an  oselabeledaefromdruguse of >= 20 mm Hg with a  oselabeledaefromdruguse  compared to 0.3% of patients in the placebo groups.\n', '\n', ' Table 10: Final On-therapy  oselabeledaefromdruguse  oselabeledaefromdruguse Supine Systolic (SSBP) and  oselabeledaefromdruguse  oselabeledaefromdruguse Supine Systolic (SSBP) and Diastolic (SDBP)  oselabeledaefromdruguse (mm Hg) in Placebo-controlled Studies \n', '                             Effexor XR     Placebo     \n', ' Indication                  <= 75 mg per day  > 75 mg per day                             \n', '   (Duration)                   SSBP         SDBP         SSBP         SDBP           SSBP             SDBP         \n', '  \n', '  notaecandidateindication                                                                                                                \n', '   (8-12 weeks)                 -0.28        0.37         2.93         ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
92,effexor,92,2215,2219,3.56           -1.08            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,effexor,93,2219,2221,-0.10        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,effexor,94,2221,2228,"\n', '  notaecandidateindication                                                                                                                ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
95,effexor,95,2228,2238,"\n', '   (8 weeks)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,effexor,96,2238,2248,-0.28        0.02         2.40         1.68           -1.26            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,effexor,97,2248,2260,"-0.92        \n', '   (6 months)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,effexor,98,2260,2264,1.27         -0.69        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,effexor,99,2264,2266,2.06         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,effexor,100,2266,2272,1.28           -1.29            -0.74        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,effexor,101,2272,2279,"\n', '  notaecandidateindication                                                                                                                ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
102,effexor,102,2279,2291,"\n', '   (12 weeks)                   -0.29        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,effexor,103,2291,2295,-1.26        1.18         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,effexor,104,2295,2301,1.34           -1.96            -1.22        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,effexor,105,2301,2313,"\n', '   (6 months)                   -0.98        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,effexor,106,2313,2315,-0.49        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,effexor,107,2315,2317,2.51         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,effexor,108,2317,2319,1.96           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,effexor,109,2319,2323,-1.84            -0.65        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,effexor,110,2323,2354,"\n', '  notaecandidateindication                                                                                                                 \n', '   (10-12 weeks)                -1.15        0.97         -0.36        0.16           -1.29            -0.99        ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
111,effexor,111,2354,2381,"\n', '             Effexor XR treatment was associated with sustained  oselabeledaefromdruguse (defined as treatment-emergent  nonoseaeaeonlyasinstruction and >= 10 mm",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,effexor,112,2381,2399,Hg above baseline for three consecutive on-therapy visits (see  Table 11  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,effexor,113,2399,2453,"An insufficient number of patients received mean doses of Effexor XR over 300 mg per day in clinical studies to fully evaluate the incidence of sustained  nonoseaeaeonlyasinstruction at these higher doses.\n', ' \n', '\n', ' Table 11: Sustained  oselabeledaefromdruguse in Effexor XR Premarketing Studies",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,effexor,114,2453,2472,"\n', ' Indication                        Dose Range (mg per day)               Incidence (%)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,effexor,115,2472,2488,"\n', '  \n', '  notaecandidateindication                               75-375                                ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
116,effexor,116,2488,2489,19/705,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,effexor,117,2489,2509,"(3)                         \n', '  notaecandidateindication                               37.5-225                              5/1011 (0.5)                       ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
118,effexor,118,2509,2521,"\n', '  notaecandidateindication                               75-225                                5/771",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
119,effexor,119,2521,2541,"(0.6)                        \n', '  notaecandidateindication                                75-225                                9/973 (0.9)                        ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
120,effexor,120,2541,2570,"\n', '         Effexor XR was associated with mean  oselabeledaefromdruguse compared with placebo in premarketing placebo-controlled studies (see  Table 12  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,effexor,121,2570,2622,"[  see  Warnings and Precautions (5.3  ,  5.4)    ].\n', ' \n', '\n', ' Table 12: Approximate Mean Final On-therapy  oselabeledaefromdruguse (beats/min) in Effexor XR Premarketing Placebo-controlled Studies",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,effexor,122,2622,2629,(up to 12 Weeks Duration),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,effexor,123,2629,2644,"\n', ' Indication  (Duration)            Effexor XR                            Placebo                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,effexor,124,2644,2663,"\n', '  \n', '  notaecandidateindication  (12 weeks)                   2                                     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
125,effexor,125,2663,2679,"1                                  \n', '  notaecandidateindication  (8 weeks)                    2                                     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,effexor,126,2679,2696,"< 1                                \n', '  notaecandidateindication  (12 weeks)                   3                                     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
127,effexor,127,2696,2710,"1                                  \n', '  notaecandidateindication  (12 weeks)                    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
128,effexor,128,2710,2715,1                                     < 1                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,effexor,129,2715,2735,"\n', '           6.3 Laboratory Changes\n', '     Serum Cholesterol  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,effexor,130,2735,2998,"', ' Effexor XR was associated with mean final  oselabeledaefromdruguse compared with mean final decreases for placebo in premarketing  notaecandidateindication   notaecandidateindication   notaecandidateindication and  notaecandidateindication clinical studies (Table 13).\n', '\n', ' Table 13:  oselabeledaefromdruguse Final On-therapy  oselabeledaefromdruguse Concentrations (mg/dL) in Effexor XR Premarketing Studies \n', ' Indication  (Duration)            Effexor XR                            Placebo                            \n', '  \n', '  notaecandidateindication                                                                                                        \n', '   (12 weeks)                      +1.5                                  -7.4                               \n', '  notaecandidateindication                                                                                                        \n', '   (8 weeks)                       +1.0                                  -4.9                               \n', '   (6 months)                      +2.3                                  -7.7                               \n', '  notaecandidateindication                                                                                                        \n', '   (12 weeks)                      +7.9                                  -2.9                               \n', '   (6 months)                      +5.6                                  -4.2                               \n', '  notaecandidateindication                                                                                                         \n', '   (12 weeks)                      5.8                                   -3.7                               \n', '         Effexor XR (venlafaxine hydrochloride) extended-release capsules treatment for up to 12 weeks in premarketing placebo-controlled trials for  notaecandidateindication was associated with a mean final on-therapy  oselabeledaefromdruguse concentration of approximately 1.5 mg/dL compared with a mean final decrease of 7.4 mg/dL for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
131,effexor,131,2998,3062,"Effexor XR treatment for up to 8 weeks and up to 6 months in premarketing placebo-controlled  notaecandidateindication trials was associated with mean final on-therapy  oselabeledaefromdruguse of approximately 1.0 mg/dL and 2.3 mg/dL, respectively while placebo subjects experienced mean final decreases of 4.9 mg/dL and 7.7 mg/dL, respectively.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
132,effexor,132,3062,3125,"Effexor XR treatment for up to 12 weeks and up to 6 months in premarketing placebo-controlled  notaecandidateindication trials was associated with mean final on-therapy  oselabeledaefromdruguse of approximately 7.9 mg/dL and 5.6 mg/dL, respectively, compared with mean final decreases of 2.9 and 4.2 mg/dL, respectively, for placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
133,effexor,133,3125,3230,"Effexor XR treatment for up to 12 weeks in premarketing placebo-controlled  notaecandidateindication trials was associated with mean final on-therapy  oselabeledaefromdruguse of approximately 5.8 mg/dL compared with a mean final decrease of 3.7 mg/dL for placebo.\n', ' \n', '\n', ' Patients treated with Effexor (immediate release) for at least 3 months in placebo-controlled 12-month extension trials had a mean final on-therapy  oselabeledaefromdruguse of 9.1 mg/dL compared with a decrease of 7.1 mg/dL among placebo-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
134,effexor,134,3230,3248,This increase was duration dependent over the study period and tended to be greater with higher doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,effexor,135,3248,3264,Clinically relevant  oselabeledaefromdruguse  defined as 1) a final on-therapy  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,effexor,136,3264,3341,">=50 mg/dL from baseline and to a value >=261 mg/dL, or 2) an average on-therapy  oselabeledaefromdruguse >=50 mg/dL from baseline and to a value >=261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients.\n', '\n', '     Serum Triglycerides  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,effexor,137,3341,3417,"\n', '\n', ' Effexor XR was associated with mean final on-therapy  oselabeledaefromdruguse compared with placebo in premarketing clinical studies of  notaecandidateindication and  notaecandidateindication up to 12 weeks (pooled data) and 6 months duration (Table 14).\n', '\n', ' Table 14: Mean Final On-therapy  oselabeledaefromdruguse Concentrations (mg/dL) in Effexor XR Premarketing Studies",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
138,effexor,138,3417,3430,"\n', ' Indication  (Duration)            Effexor XR                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,effexor,139,3430,3432,Placebo                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,effexor,140,3432,3449,"\n', '  \n', '  notaecandidateindication  (12 weeks)                   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
141,effexor,141,3449,3453,8.2                                   0.4                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,effexor,142,3453,3467,"\n', '  notaecandidateindication  (6 months)                   11.8                                  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
143,effexor,143,3467,3469,1.8                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,effexor,144,3469,3483,"\n', '  notaecandidateindication  (12 weeks)                    5.9                                   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
145,effexor,145,3483,3485,0.9                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,effexor,146,3485,3499,"\n', '  notaecandidateindication  (6 months)                    9.3                                   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
147,effexor,147,3499,3501,0.3                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,effexor,148,3501,3548,"\n', '           6.4 Pediatric Patients\n', '   In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical studies) in children and adolescents (ages 6 to 17) was similar to that seen for adults.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,effexor,149,3548,3669,"As with adults,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were observed [  see  Warnings and Precautions (5.3  ,  5.10  ,  5.11)  and  Use in Specific Populations (8.4)    ].\n', '\n', ' In pediatric clinical studies, the adverse reaction,  oselabeledaefromdruguse  was observed.\n', '\n', ' Particularly, the following adverse reactions were observed in pediatric patients:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '   6.5 Adverse Reactions Identified During Postapproval Use\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,effexor,150,3669,3687,"', '  The following adverse reactions have been identified during postapproval use of Effexor XR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,effexor,151,3687,3732,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:\n', '\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
152,effexor,152,3732,3754,"oselabeledaefromdruguse \n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
153,effexor,153,3754,3765,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
154,effexor,154,3765,3781,"', '    nonoseaegeneralterm  -  oselabeledaefromdruguse [  see  Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
155,effexor,155,3781,3804,"(5.4 )    ],  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse ,  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,effexor,156,3804,3805,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,effexor,157,3805,3848,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse [  see  Warnings and Precautions (5.9)    ],  oselabeledaefromdruguse [  see  Warnings and Precautions (5.9)    ],  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
158,effexor,158,3848,3849,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,effexor,159,3849,3860,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
160,effexor,160,3860,3877,"', '    nonoseaegeneralterm  -  oselabeledaefromdruguse  [  see  Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
161,effexor,161,3877,3884,"(5.2)    ],  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,effexor,162,3884,3892,oselabeledaefromdruguse [  see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,effexor,163,3892,3923,"(5.2)    ],  oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse and  oselabeledaefromdruguse ,  oselabeledaefromdruguse coordination and  oselabeledaefromdruguse  oselabeledaefromdruguse and balance,  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,effexor,164,3923,3944,"\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse [  see  Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
165,effexor,165,3944,3949,(5.12)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,effexor,166,3949,3977,"\n', '\n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm  -  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
167,effexor,167,3977,3978,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,effexor,168,3978,3989,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,effexor,169,3989,4010,"WARNING: SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '    WARNING: SUICIDAL THOUGHTS AND BEHAVIORS  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,effexor,170,4010,4048,"\n', '\n', '    Antidepressants increased the risk of  oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior in children, adolescents, and young adults in short-term studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,effexor,171,4048,4107,These studies did not show an increase in the risk of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [    see   Warnings and Precautions (5.1)  ].  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,effexor,172,4107,4144,"\n', '\n', '   In patients of all ages who are started on antidepressant therapy monitor closely for clinical worsening and emergence of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,effexor,173,4144,4180,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicide risk (  5.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,effexor,174,4180,4189,"\n', ' *   Serotonin Syndrome:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,effexor,175,4189,4199,Risk increases with concomitant use of other serotonergic drugs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,effexor,176,4199,4224,"Discontinue Effexor XR and initiate supportive treatment if serotonin syndrome occurs (  4.2  ,  5.2  ,  7.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,effexor,177,4224,4241,"\n', ' *   Elevations in Blood Pressure: Control hypertension before initiating treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,effexor,178,4241,4253,Monitor blood pressure regularly during treatment (  5.3  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,effexor,179,4253,4271,"\n', ' *   Abnormal Bleeding: Effexor XR may increase risk of bleeding events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,effexor,180,4271,4303,"Caution patients about the risk of bleeding associated with the concomitant use of Effexor XR and NSAIDs, aspirin, or other drugs that affect coagulation (  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,effexor,181,4303,4313,"\n', ' *   Angle Closure Glaucoma:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,effexor,182,4313,4329,Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,effexor,183,4329,4335,(  5.5  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,effexor,184,4335,4355,"\n', ' *   Activation of Mania/Hypomania: Use cautiously in patients with bipolar disorder.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,effexor,185,4355,4372,Caution patients about the risk of activation of mania/hypomania (  5.6  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,effexor,186,4372,4425,"\n', '    \n', ' \n', '\n', '   5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults\n', '\n', '  Patients with  notaecandidateindication , both adult and pediatric, may experience  nonoseaeaeonlyasinstruction",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
187,effexor,187,4425,4464,"and/or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,effexor,188,4464,4490,nonoseaeaeonlyasinstruction is a known risk of  nonoseaeaeonlyasinstruction and certain other  notaecandidatepreexistingconditionorriskfactor  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
189,effexor,189,4490,4527,"There has been a long-standing concern, however, that antidepressants may have a role in inducing  oselabeledaeclasseffect and the emergence of  oselabeledaeclasseffect in certain patients during the early phases of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,effexor,190,4527,4676,"Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior ( oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidateindication and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an increase in the risk of  nonoseaenegation with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.\n', '\n', ' The pooled analyses of placebo-controlled studies in children and adolescents with  notaecandidateindication   notaecandidateindication , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients.",0,0,1,1,0,0,0,1,0,0,0,0,0,0,0
191,effexor,191,4676,4718,"The pooled analyses of placebo-controlled studies in adults with  notaecandidateindication or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
192,effexor,192,4718,4746,"There was considerable variation in risk of  oselabeledaeclasseffect among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,effexor,193,4746,4768,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across the different indications, with the highest incidence in  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
194,effexor,194,4768,4789,"The risk differences (drug versus placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,effexor,195,4789,4930,"These risk differences (drug-placebo difference in the number of cases of  nonoseaeaeonlyasinstruction per 1,000 patients treated) are provided in Table 1.\n', '\n', ' Table 1: Difference in the Number of Cases of  oselabeledaeclasseffect per 1,000 Patients Treated versus Placebo \n', '                Age Range                                 Increases Compared to Placebo                   \n', '                   < 18                                        14 additional cases                        \n', '                  18-24                                         5 additional cases                        \n', '                                                          Decreases Compared to Placebo                   \n', '                  25-64                                            1 fewer case                           \n', '                  >= 65                                           6 fewer cases                           \n', '        No  nonoseaenegation occurred in any of the pediatric studies.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
196,effexor,196,4930,4987,"There were  nonoseaeaeonlyasinstruction in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeother \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction risk extends to longer term use, i.e., beyond several months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,1
197,effexor,197,4987,5142,"However, there is substantial evidence from placebo-controlled maintenance studies in adults with  notaecandidateindication that the use of antidepressants can delay the recurrence of  nonoseaeaeonlyasinstruction \n', '\n', ' All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with antidepressants for  notaecandidateindication  as well as for other indications, both psychiatric and nonpsychiatric.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
198,effexor,198,5142,5388,"Although a causal link between the emergence of such symptoms and either the worsening of  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose  notaecandidateindication is persistently worse, or who are experiencing emergent  nonoseaeaeonlyasinstruction or symptoms that might be precursors to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', ' If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt  nonoseaeaeonlyasinstruction [ see  Warnings and Precautions (5.7)  and  Dosage and Administration (2.8)    ].\n', '\n', ' Families and caregivers of patients being treated with antidepressants for  notaecandidateindication or other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to healthcare providers.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
199,effexor,199,5388,5400,Such monitoring should include daily observation by families and caregivers .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,effexor,200,5400,5463,"Prescriptions for Effexor XR should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of  nonoseaeaeonlyasinstruction \n', '\n', '    Screening Patients for Bipolar Disorder  \n', '\n', ' A  nonoseaeaeonlyasinstruction may be the initial presentation of  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
201,effexor,201,5463,5513,It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of  nonoseaeaeonlyasinstruction in patients at risk for  notaecandidatepreexistingconditionorriskfactor  Whether any of the symptoms described above represent such a conversion is unknown.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
202,effexor,202,5513,5563,"However, prior to initiating treatment with an antidepressant, patients with  notaecandidatepreexistingconditionorriskfactor should be adequately screened to determine if they are at risk for  notaecandidatepreexistingconditionorriskfactor  such screening should include a detailed  notaecandidatepreexistingconditionorriskfactor history, including a  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
203,effexor,203,5563,5762,"It should be noted that Effexor XR is not approved for use in treating  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.2 Serotonin Syndrome\n', '\n', ""  The development of a potentially life-threatening  oselabeledaefromdruguse has been reported with SNRIs and SSRIs, including Effexor XR alone, but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's wort) and with drugs that impair metabolism of serotonin in particular, MAOIs, both those intended to treat  notaecandidatepreexistingconditionorriskfactor and others, such as linezolid or intravenous methylene blue).\n"", '\n', '  nonoseaeaeonlyasinstruction symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ;  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
204,effexor,204,5762,5798,"Patients should be monitored for the emergence of  nonoseaeaeonlyasinstruction \n', '\n', ' The concomitant use of Effexor XR with MAOIs (intended to treat  notaecandidatepreexistingconditionorriskfactor  is contraindicated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
205,effexor,205,5798,5822,Effexor XR should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,effexor,206,5822,5853,All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,effexor,207,5853,5879,No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,effexor,208,5879,5907,There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking Effexor XR.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,effexor,209,5907,5941,"Effexor XR should be discontinued before initiating treatment with the MAOI [ see  Contraindications (4.2)  ,  Dosage and Administration (2.6)  , and  Drug Interactions (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,effexor,210,5941,5945,7.3)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,effexor,211,5945,6016,".\n', '\n', "" If concomitant use of Effexor XR with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, mirtazapine, fentanyl, lithium, tramadol, buspirone, amphetamines, tryptophan, or St. John's wort) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [ see  Drug Interactions (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,effexor,212,6016,6021,7.3)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,effexor,213,6021,6062,"Patients should be made aware of the potential risk of  nonoseaeaefromdruginteraction  Treatment with Effexor XR and any concomitant serotonergic agents should be discontinued immediately if the above events occur, and supportive symptomatic treatment should be initiated.\n"",",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
214,effexor,214,6062,6123,"'\n', '    5.3 Elevations in Blood Pressure\n', '\n', '  In controlled trials, there were dose-related  oselabeledaefromdruguse systolic and  oselabeledaefromdruguse  oselabeledaefromdruguse and diastolic  oselabeledaefromdruguse  as well as cases of sustained  oselabeledaefromdruguse [see  Adverse Reactions (6.2)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,effexor,215,6123,6145,"\n', '\n', ' Monitor blood pressure before initiating treatment with Effexor XR and regularly during treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,effexor,216,6145,6158,Control pre-existing  notaecandidatepreexistingconditionorriskfactor before initiating treatment with Effexor XR.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
217,effexor,217,6158,6195,Use caution in treating patients with pre-existing  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor or cerebrovascular  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor that might be compromised by  nonoseaeaeonlyasinstruction  Sustained  nonoseaeaeonlyasinstruction can lead to adverse outcomes.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
218,effexor,218,6195,6209,Cases of  oselabeledaefromdruguse requiring immediate treatment have been reported with Effexor XR.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,effexor,219,6209,6262,"Consider dose reduction or discontinuation of treatment for patients who experience a sustained  nonoseaeaeonlyasinstruction \n', '\n', ' Across all clinical studies with Effexor, 1.4% of patients in the Effexor XR treated groups experienced a >=15 mm Hg  oselabeledaefromdruguse (SDBP ) >",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,effexor,220,6262,6278,"= 105 mm Hg, compared to 0.9% of patients in the placebo groups.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,effexor,221,6278,6330,"Similarly, 1% of patients in the Effexor XR treated groups experienced a >= 20 mm Hg  oselabeledaefromdruguse (SSBP) with  oselabeledaefromdruguse  compared to 0.3% of patients in the placebo groups [ see  Table 10 in Adverse Reactions (6.2)    ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,effexor,222,6330,6351,Effexor XR treatment was associated with  oselabeledaefromdruguse (defined as treatment-emergent  nonoseaeaeonlyasinstruction and >= 10 mm,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,effexor,223,6351,6361,Hg above baseline for three consecutive on-therapy visits,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,effexor,224,6361,6375,[ see  Table 11 in Adverse Reactions (6.2)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,effexor,225,6375,6499,"An insufficient number of patients received mean doses of Effexor XR over 300 mg per day in clinical studies to fully evaluate the incidence of sustained  nonoseaeaeonlyasinstruction at these higher doses.\n', '\n', '    5.4 Abnormal Bleeding\n', '\n', '  SSRIs and SNRIs, including Effexor XR, may increase the risk of  oselabeledaefromdruguse events, ranging from  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse to life-threatening  oselabeledaefromdruguse  Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anti-coagulants or other drugs known to affect platelet function may add to this risk.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,effexor,226,6499,6667,"Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of  oselabeledaeclasseffect  Caution patients about the risk of  nonoseaeaefromdruginteraction associated with the concomitant use of Effexor XR and NSAIDs, aspirin, or other drugs that affect coagulation.\n', '\n', '    5.5 Angle-Closure Glaucoma\n', '\n', '  The  oselabeledaefromdruguse that occurs following use of many antidepressant drugs including Effexor XR may trigger an  oselabeledaefromdruguse in a patient with  notaecandidatepreexistingconditionorriskfactor who does not have a patent iridectomy.\n', '\n', '    5.6 Activation of Mania/Hypomania\n', '\n', '   oselabeledaefromdruguse or  oselabeledaefromdruguse was reported in Effexor XR treated patients in the premarketing studies in  notaecandidateindication   notaecandidateindication  and  notaecandidateindication (see  Table 2  ).  ",0,0,1,1,0,1,0,0,0,0,0,0,0,0,0
227,effexor,227,6667,6712,nonoseaeaeforanotherdruginclass  nonoseaeaeforanotherdruginclass has also been reported in a small proportion of patients with  notaecandidatepreexistingconditionorriskfactor who were treated with other marketed drugs to treat  notaecandidateindication  Effexor XR should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0
228,effexor,228,6712,6874,"\n', '\n', ' Table 2: Incidence (%) of  oselabeledaefromdruguse or  oselabeledaefromdruguse Reported in Effexor XR Treated Patients in the Premarketing Studies \n', ' Indication                          Effexor XR                         Placebo                             \n', '  \n', '  notaecandidateindication                                 0.3                                0.0                                 \n', '  notaecandidateindication                                 0.0                                0.2                                 \n', '  notaecandidateindication                                 0.2                                0.0                                 \n', '  notaecandidateindication                                  0.1                                0.0                                 \n', '            5.7 Discontinuation Syndrome\n', ' \n', '\n', '   nonoseaeaeonlyasinstruction have been systematically evaluated in patients taking venlafaxine, including prospective analyses of clinical studies in  notaecandidateindication and retrospective surveys of studies in  notaecandidateindication and  notaecandidateindication  Abrupt  oselabeledaefromdruguse  the frequency of which increased with increased dose level and with longer duration of treatment.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
229,effexor,229,6874,7062,"Reported symptoms include  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal coordination and  nonoseaeodorwithdrawal  nonoseaeodorwithdrawal and balance,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal (including  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal \n', '\n', ' During marketing of Effexor XR, other SNRIs, and SSRIs, there have been spontaneous reports of  oselabeledaefromdruguse of these drugs, particularly when abrupt, including the following:  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeaeonlyasinstruction (e.g.,  nonoseaeodorwithdrawal  such as  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  While these events are generally self-limiting, there have been reports of serious  oselabeledaefromdruguse \n', '\n', ' Patients should be monitored for these symptoms when discontinuing treatment with Effexor XR.",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
230,effexor,230,7062,7079,"A gradual reduction in the dose, rather than abrupt cessation, is recommended whenever possible.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,effexor,231,7079,7094,If intolerable  nonoseaeaeonlyasinstruction  then resuming the previously prescribed dose may be considered.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,effexor,232,7094,7147,"Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [ see  Dosage and Administration (2.8)    ].\n', '\n', '    5.8 Seizures\n', '\n', '   oselabeledaefromdruguse have occurred with venlafaxine therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,effexor,233,7147,7178,"Effexor XR, like many antidepressants, should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor and should be discontinued in any patient who develops  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
234,effexor,234,7178,7193,"[Must mitigate the risk: Risk factors, concomitant meds that  nonoseaeaeonlyasinstruction ]",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,effexor,235,7193,7229,"\n', '\n', '    5.9 Hyponatremia\n', '\n', '   oselabeledaefromdruguse can occur as a result of treatment with SSRIs and SNRIs, including Effexor XR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,effexor,236,7229,7248,"In many cases, the  oselabeledaefromdruguse appears to be the result of the  oselabeledaefromdruguse  secretion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,effexor,237,7248,7256,Cases with  oselabeledaefromdruguse have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,effexor,238,7256,7274,Elderly patients may be at greater risk of developing  oselabeledaeclasseffect with SSRIs and SNRIs [ see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,effexor,239,7274,7284,Use in Specific Populations (8.5)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,effexor,240,7284,7305,"Also, patients taking diuretics, or those who are otherwise volume-depleted, may be at greater risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,effexor,241,7305,7481,"Consider discontinuation of Effexor XR in patients with symptomatic  nonoseaeaeonlyasinstruction  and institute appropriate medical intervention.\n', '\n', ' Signs and symptoms of  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  which may lead to  nonoseaemanifestationorcomplication  Signs and symptoms associated with more severe and/or acute cases have included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm \n', '\n', '    5.10 Weight and  oselabeledaefromdruguse in Pediatric Patients\n', '\n', '   Weight Changes  \n', '\n', ' The average  oselabeledaefromdruguse and incidence of  oselabeledaefromdruguse (percentage of patients who lost 3.5% or more) in the placebo-controlled pediatric studies in  notaecandidateindication   notaecandidateindication  and  notaecandidateindication are shown in Tables 3 and 4.\n', '\n', ' Table 3: Average Change in Body Weight (kg)",1,1,0,1,1,0,0,0,0,0,0,0,0,0,0
242,effexor,242,7481,7500,"From Beginning of Treatment in Pediatric Patients in Double-blind, Placebo-controlled Studies of Effexor XR",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,effexor,243,7500,7513,"\n', ' Indication  (Duration)              Effexor XR                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,effexor,244,7513,7540,"Placebo                             \n', '  \n', '  notaecandidateindication and  notaecandidateindication  (4 pooled studies, 8 weeks)  -0.45",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
245,effexor,245,7540,7575,"(n = 333)                    +0.77 (n = 333)                     \n', '  notaecandidateindication  (16 weeks)                     -0.75 (n = 137)                    +0.76",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
246,effexor,246,7575,7582,(n = 148)                     \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,effexor,247,7582,7657,"', '        Table 4: Incidence (%) of Pediatric Patients Experiencing Weight Loss (3.5% or more) in Double-blind, Placebo-controlled Studies of Effexor XR \n', ' Indication  (Duration)              Effexor XR                         Placebo                             \n', '  \n', '  notaecandidateindication and  notaecandidateindication  (4 pooled studies, 8 weeks)  18",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
248,effexor,248,7657,7673,[note: p < 0.001 versus placebo] (n = 333)  3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,effexor,249,7673,7679,(n = 333)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,effexor,250,7679,7726,"\n', '  notaecandidateindication  (16 weeks)                     47(n = 137)                        14 (n = 148)                        \n', '          oselabeledaefromdruguse was not limited to patients with treatment-emergent  oselabeledaefromdruguse [ see  Warnings and Precautions",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
251,effexor,251,7726,7731,(5.11)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,effexor,252,7731,7776,".\n', ' \n', '\n', ' The risks associated with longer term Effexor XR use were assessed in an open-label  notaecandidateindication study of children and adolescents who received Effexor XR for up to six months.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
253,effexor,253,7776,7798,The children and adolescents in the study had  oselabeledaefromdruguse  based on data from age- and sex-matched peers.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,effexor,254,7798,7831,"The  oselabeledaefromdruguse was larger for children (< 12 years old) than for adolescents (>= 12 years old).\n', '\n', '    Height Changes  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,effexor,255,7831,7868,"\n', '\n', ' Table 5 shows the average  nonoseaeaeonlyasinstruction in pediatric patients in the short-term, placebo-controlled  notaecandidateindication   notaecandidateindication  and  notaecandidateindication studies.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
256,effexor,256,7868,7994,"The differences in height increases in  notaecandidateindication and  notaecandidateindication studies were most notable in patients younger than twelve.\n', '\n', ' Table 5: Average Height Increases (cm) in Pediatric Patients in Placebo-controlled Studies of Effexor XR \n', ' Indication  (Duration)              Effexor XR                         Placebo                             \n', '  \n', '  notaecandidateindication  (8 weeks)                      0.8 (n = 146)                      0.7 (n = 147)                       \n', '  notaecandidateindication  (8 weeks)                      0.3 [note: p = 0.041] (n = 122)    1.0 (n = 132)                       ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
257,effexor,257,7994,8013,"\n', '  notaecandidateindication  (16 weeks)                     1.0 (n = 109)                      ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
258,effexor,258,8013,8020,1.0 (n = 112)                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,effexor,259,8020,8060,"\n', '         In the six-month, open-label  notaecandidateindication study, children and adolescents had  oselabeledaefromdruguse that were  oselabeledaefromdruguse  based on data from age- and sex-matched peers.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
260,effexor,260,8060,8178,"The difference between observed and expected growth rates was larger for children (< 12 years old) than for adolescents (>= 12 years old).\n', ' \n', '\n', '    5.11  oselabeledaefromdruguse in Pediatric Patients\n', '\n', '   oselabeledaefromdruguse (reported as  oselabeledaefromdruguse  was more commonly observed in Effexor XR treated patients versus placebo-treated patients in the premarketing evaluation of Effexor XR for  notaecandidateindication   notaecandidateindication  and  notaecandidateindication (see  Table 6  ).\n', '\n', ' Table 6: Incidence (%) of Decreased Appetite and Associated Discontinuation",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
261,effexor,261,8178,8196,RatesThe discontinuation rates for weight loss were 0.7% for patients receiving either Effexor XR or placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,effexor,262,8196,8210,(%) in Pediatric Patients in Placebo-controlled Studies of Effexor XR,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,effexor,263,8210,8220,"\n', ' Indication  (Duration)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,effexor,264,8220,8231,Effexor XR Incidence  Discontinuation       Placebo Incidence     Discontinuation        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,effexor,265,8231,8275,"\n', '  \n', '  notaecandidateindication and  notaecandidateindication  (pooled, 8 weeks)  10                    0.0                   3                     -                      \n', '  notaecandidateindication  (16 weeks)       22                    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
266,effexor,266,8275,8318,"0.7                   3                     0.0                    \n', '              5.12 Interstitial Lung Disease and Eosinophilic Pneumonia\n', ' \n', '\n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse associated with venlafaxine therapy have been rarely reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,effexor,267,8318,8345,The possibility of these adverse events should be considered in venlafaxine-treated patients who present with progressive  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication '],0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,raxibacumab,0,0,43,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Common adverse reactions in healthy adult subjects (>=1.5%) were: rash, pain in extremity, pruritus, and somnolence.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,raxibacumab,1,43,48,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,raxibacumab,2,48,91,"\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,raxibacumab,3,91,128,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,raxibacumab,4,128,173,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,raxibacumab,5,173,185,The safety of raxibacumab has been studied only in healthy volunteers.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,raxibacumab,6,185,299,"It has not been studied in patients with inhalational anthrax.\n', '\n', '\n', '\n', ' The safety of raxibacumab has been evaluated in 326 healthy subjects treated with a dose of 40 mg/kg in 3 clinical trials: a drug interaction trial with ciprofloxacin (Study 1), a repeat-dose trial of 20 subjects with the second raxibacumab dose administered >=4 months after the first dose (Study 2), and a placebo-controlled trial evaluating single doses with a subset of subjects receiving 2 raxibacumab doses 14 days apart (Study 3).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,raxibacumab,7,299,310,Raxibacumab was administered to 86 healthy subjects in Study 1.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,raxibacumab,8,310,367,"In Study 3, 240 healthy subjects received raxibacumab (217 received 1 dose and 23 received 2 doses) and 80 subjects received placebo.\n', '\n', '\n', '\n', ' The overall safety of raxibacumab was evaluated as an integrated summary of these 3 clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,raxibacumab,9,367,396,"Of 326 raxibacumab subjects, 283 received single doses, 23 received 2 doses 14 days apart, and 20 received 2 doses more than 4 months apart.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,raxibacumab,10,396,531,"The subjects were 18 to 88 years of age, 53% female, 74% white, 17% black/African American, 6% Asian, and 15% Hispanic.\n', '\n', '\n', '\n', '   Adverse Reactions Leading to Discontinuation of Raxibacumab Infusion  \n', '\n', '\n', '\n', ' Four subjects (1.2%) had their infusion of raxibacumab discontinued for adverse reactions: 2 subjects (neither of whom received diphenhydramine premedication) due to  oselabeledaefromdruguse (mild), and 1 subject each discontinued for  oselabeledaefromdruguse (mild) and  oselabeledaefromdruguse (moderate).\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,raxibacumab,11,531,542,"\n', '   Most Frequently Reported Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,raxibacumab,12,542,575,"\n', '\n', '\n', '\n', ' The most frequently reported adverse reactions were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,raxibacumab,13,575,594,"\n', '\n', '\n', '\n', ' Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,raxibacumab,14,594,614,Adverse Reactions Reported in >=1.5% of Healthy Adult Subjects Exposed to Raxibacumab 40 mg/kg IV,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,raxibacumab,15,614,631,"\n', '  Preferred Term          Placebo  N = 80 (%)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,raxibacumab,16,631,639,Single-dose Raxibacumab  N = 283,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,raxibacumab,17,639,643,(%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,raxibacumab,18,643,649,Double-dose Raxibacumab  >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,raxibacumab,19,649,661,=4 Months Apart  N = 20 (%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,raxibacumab,20,661,666,Double-dose Raxibacumab  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,raxibacumab,21,666,670,2 Weeks Apart  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,raxibacumab,22,670,681,N = 23 (%)    Total Raxibacumab Subjects  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,raxibacumab,23,681,688,N = 326 (%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,raxibacumab,24,688,699,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,raxibacumab,25,699,711,1 (1.3)    9 (3.2)            0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,raxibacumab,26,711,713,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,raxibacumab,27,713,714,9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,raxibacumab,28,714,737,"(2.8)             \n', '   oselabeledaefromdruguse       1 (1.3)    7 (2.5)            0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,raxibacumab,29,737,739,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,raxibacumab,30,739,744,7 (2.1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,raxibacumab,31,744,758,"\n', '   oselabeledaefromdruguse                0          7 (2.5)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,raxibacumab,32,758,760,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,raxibacumab,33,760,762,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,raxibacumab,34,762,767,7 (2.1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,raxibacumab,35,767,793,"\n', '   oselabeledaefromdruguse              0          4 (1.4)            0                  1 (4.3)            5 (1.5)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,raxibacumab,36,793,844,"\n', '              Rashes  \n', ' \n', '\n', ' For all subjects exposed to raxibacumab in clinical trials, the rate of  oselabeledaefromdruguse was 2.8% (9/326) compared with 1.3% (1/80) of placebo subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,raxibacumab,37,844,891,Mild to moderate  oselabeledaefromdruguse were reported in 22.2% (6/27) of subjects who did not receive diphenhydramine premedication compared to 3.3% (2/61) of subjects who were premedicated with diphenhydramine in the ciprofloxacin/raxibacumab combination trial (Study 1).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,raxibacumab,38,891,1013,"In the placebo-controlled raxibacumab study where all subjects received diphenhydramine (Study 3), the rate of  nonoseaeaeratelteqplacebo was 2.5% in both placebo- and raxibacumab-treated subjects.\n', '\n', '\n', '\n', '   Less Common Adverse Reactions  \n', '\n', '\n', '\n', ' Clinically significant adverse reactions that were reported in <1.5% of subjects exposed to raxibacumab and at rates higher than in placebo subjects are listed below:\n', '\n', '\n', '\n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
39,raxibacumab,39,1013,1047,"\n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,raxibacumab,40,1047,1061,"\n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,raxibacumab,41,1061,1073,"\n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,raxibacumab,42,1073,1105,"\n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *      nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,raxibacumab,43,1105,1112,"\n', '      Immunogenicity  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,raxibacumab,44,1112,1124,"\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,raxibacumab,45,1124,1199,"The development of  oselabeledaefromdruguse was evaluated in all subjects receiving single and double doses of raxibacumab in Studies 1, 2, and 3.  nonoseaenegation in any raxibacumab-treated human subjects following single or repeat doses of raxibacumab.\n', '\n', '\n', '\n', ' The incidence of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the immunogenicity assay.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
46,raxibacumab,46,1199,1242,"Additionally, the observed incidence of any  nonoseaeaeonlyasinstruction in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,raxibacumab,47,1242,1282,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '  EXCERPT:   Infusion reactions may occur.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,raxibacumab,48,1282,1286,Premedicate with diphenhydramine.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,raxibacumab,49,1286,1300,Slow or interrupt infusion and administer treatment based on severity of the reaction.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,raxibacumab,50,1300,1379,"(  5.1  )\n', '\n', '\n', '\n', ' \n', '\n', '\n', '\n', '   5.1 Infusion Reactions\n', '\n', '\n', '\n', '   oselabeledaefromdruguse were reported during administration of raxibacumab in clinical trials including reports of  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,raxibacumab,51,1379,1433,"If these reactions occur, slow or interrupt raxibacumab infusion and administer appropriate treatment based on severity of the reaction.\n', '\n', '\n', '\n', ' Premedicate with diphenhydramine within 1 hour prior to administering raxibacumab to reduce the risk of  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,paxil,0,0,106,"['  ADVERSE REACTIONS\n', '\n', '  Associated With Discontinuation of Treatment:\n', '\n', '  Twenty percent (1,199/6,145) of patients treated with PAXIL in worldwide clinical trials in  notaecandidateindication and 16.1% (84/522), 11.8% (64/542), 9.4% (44/469), 10.7% (79/735), and 11.7% (79/676) of patients treated with PAXIL in worldwide trials in  notaecandidatepreexistingconditionorriskfactor   notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication  respectively, discontinued treatment due to an adverse event.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
1,paxil,1,106,170,"The most common events (>=1%) associated with discontinuation and considered to be drug related (i.e., those events associated with dropout at a rate approximately twice or greater for PAXIL compared to placebo) included the following:\n', '\n', '\n', '                 Major Depressive Disorder    OCD      Panic Disorder    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,paxil,2,170,174,Social Anxiety Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,paxil,3,174,178,Generalized Anxiety Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,paxil,4,178,180,PTSD     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,paxil,5,180,209,"\n', '  PAXIL          Placebo    PAXIL    Placebo    PAXIL    Placebo    PAXIL    Placebo    PAXIL    Placebo    PAXIL    Placebo    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,paxil,6,209,334,"\n', '   nonoseaegeneralterm                                                                                                                        \n', '   oselabeledaefromdruguse     2.3%     0.7%     -                 1.9%     0.3%     3.4%     0.3%     2.0%     0.2%     2.8%     0.6%     \n', '   oselabeledaefromdruguse       -        -        1.7%     0%       1.3%     0.3%     3.1%     0%                         -        -        \n', '   oselabeledaefromdruguse      1.1%     0.5%     -                                                                       -        -        \n', '   oselabeledaefromdruguse         1.1%     0.3%     -                                   1.7%     0%                         1.0%     0.2%     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
7,paxil,7,334,395,"\n', '   oselabeledaefromdruguse        -        -        -                                   1.1%     0%                         -        -        \n', '   oselabeledaefromdruguse      -        -        1.5%     0%                         1.9%     0%       1.0%     0.2%     -        -        \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,paxil,8,395,397,nonoseaegeneralterm                                                                                                                ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
9,paxil,9,397,459,"\n', '   oselabeledaefromdruguse    -                 1.1%     0%                                                             -        -        \n', '   oselabeledaefromdruguse         3.2%     1.1%     1.9%     0%       3.2%     1.2%     4.0%     0.3%     2.0%     0.2%     2.2%     0.6%     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,paxil,10,459,686,"\n', '   oselabeledaefromdruguse       1.0%     0.3%     -                                                                                         \n', '   oselabeledaefromdruguse      1.0%     0.3%     -                                                                       -        -        \n', '   oselabeledaefromdruguse       1.0%     0.3%     -                                   1.0%     0%                         -        -        \n', '   oselabeledaefromdruguse                                                           1.0%     0.3%                       -        -        \n', '  Other                                                                                                                      \n', '   oselabeledaefromdruguse       1.6%     0.4%     1.9%     0.4%                       2.5%     0.6%     1.8%     0.2%     1.6%     0.2%     \n', '   oselabeledaefromdruguse    1.6%     0%       2.1%     0%                         4.9%     0.6%     2.5%     0.5%     -        -        \n', '   oselabeledaefromdruguse       1.0%     0.3%     -                                   1.1%     0%       1.1%     0.2%     -        -        \n', '   oselabeledaefromdruguse     -                 1.5%     0%                                                             -        -        \n', '   oselabeledaefromdruguse                                                          1.0%     0%                         -        -        \n', '                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,paxil,11,686,745,"Where numbers are not provided the incidence of the adverse events in patients treated with PAXIL was not >1% or was not greater than or equal to 2 times the incidence of placebo.\n', ' \n', '\n', ' a. Incidence corrected for gender.\n', '\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,paxil,12,745,753,"Commonly Observed Adverse Events:\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,paxil,13,753,771,"', '    Major Depressive Disorder:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,paxil,14,771,915,"The most commonly observed adverse events associated with the use of paroxetine (incidence of 5% or greater and incidence for PAXIL at least twice that for placebo, derived from Table 2) were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and other  oselabeledaefromdruguse \n', '\n', '     Obsessive Compulsive Disorder:  \n', '\n', '  The most commonly observed adverse events associated with the use of paroxetine (incidence of 5% or greater and incidence for PAXIL at least twice that of placebo, derived from Table 3) were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,paxil,15,915,937,"\n', '\n', '     Panic Disorder:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,paxil,16,937,992,"The most commonly observed adverse events associated with the use of paroxetine (incidence of 5% or greater and incidence for PAXIL at least twice that for placebo, derived from Table 3) were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,paxil,17,992,1015,"\n', '\n', '     Social Anxiety Disorder:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,paxil,18,1015,1078,"The most commonly observed adverse events associated with the use of paroxetine (incidence of 5% or greater and incidence for PAXIL at least twice that for placebo, derived from Table 3) were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,paxil,19,1078,1101,"\n', '\n', '     Generalized Anxiety Disorder:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,paxil,20,1101,1162,"The most commonly observed adverse events associated with the use of paroxetine (incidence of 5% or greater and incidence for PAXIL at least twice that for placebo, derived from Table 4) were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,paxil,21,1162,1185,"\n', '\n', '     Posttraumatic Stress Disorder:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,paxil,22,1185,1246,"The most commonly observed adverse events associated with the use of paroxetine (incidence of 5% or greater and incidence for PAXIL at least twice that for placebo, derived from Table 4) were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,paxil,23,1246,1314,"\n', '\n', '   Incidence in Controlled Clinical Trials:\n', '\n', '  The prescriber should be aware that the figures in the tables following cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,paxil,24,1314,1339,"Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,paxil,25,1339,1375,"The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the populations studied.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,paxil,26,1375,1445,"'\n', '     Major Depressive Disorder:  \n', '\n', '  Table 2 enumerates adverse events that occurred at an incidence of 1% or more among paroxetine-treated patients who participated in short-term (6-week) placebo-controlled trials in which patients were dosed in a range of 20 mg to 50 mg/day.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,paxil,27,1445,1468,"Reported adverse events were classified using a standard COSTART-based Dictionary terminology.\n', '\n', ' Table 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,paxil,28,1468,1484,Treatment-Emergent Adverse Experience Incidence in Placebo-Controlled Clinical Trials for Major Depressive Disordera,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,paxil,29,1484,1492,"\n', '  Body System          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,paxil,30,1492,1511,Preferred Term                   PAXIL  (n = 421)    Placebo  (n = 421)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,paxil,31,1511,1526,"\n', '   nonoseaegeneralterm       oselabeledaefromdruguse                         18%          17%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,paxil,32,1526,1554,"\n', '                        oselabeledaefromdruguse                         15%          6%           \n', '   nonoseaegeneralterm        oselabeledaefromdruguse                      3%           1%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,paxil,33,1554,1567,"\n', '                        oselabeledaefromdruguse                     3%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,paxil,34,1567,1610,"\n', '   nonoseaegeneralterm          oselabeledaefromdruguse                         11%          2%           \n', '                        oselabeledaefromdruguse                             2%           1%           \n', '   nonoseaegeneralterm      oselabeledaefromdruguse                           26%          9%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,paxil,35,1610,1623,"\n', '                        oselabeledaefromdruguse                        18%          12%          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,paxil,36,1623,1636,"\n', '                        oselabeledaefromdruguse                     14%          9%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,paxil,37,1636,1701,"\n', '                        oselabeledaefromdruguse                         12%          8%           \n', '                        oselabeledaefromdruguse               6%           2%           \n', '                        oselabeledaefromdruguse                       4%           2%           \n', '                        oselabeledaefromdruguse             2%           0%           \n', '                        oselabeledaefromdruguse                        2%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,paxil,38,1701,1716,"\n', '   nonoseaegeneralterm       oselabeledaefromdruguse                         2%           1%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,paxil,39,1716,1729,"\n', '                        oselabeledaefromdruguse                          2%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,paxil,40,1729,1742,"\n', '                        oselabeledaefromdruguse                       1%           0%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,paxil,41,1742,1757,"\n', '   nonoseaegeneralterm        oselabeledaefromdruguse                       23%          9%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,paxil,42,1757,1770,"\n', '                        oselabeledaefromdruguse                        13%          6%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,paxil,43,1770,1783,"\n', '                        oselabeledaefromdruguse                         13%          6%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,paxil,44,1783,1796,"\n', '                        oselabeledaefromdruguse                           8%           2%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,paxil,45,1796,1809,"\n', '                        oselabeledaefromdruguse                      5%           3%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,paxil,46,1809,1822,"\n', '                        oselabeledaefromdruguse                          5%           3%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,paxil,47,1822,1835,"\n', '                        oselabeledaefromdruguse                      4%           2%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,paxil,48,1835,1848,"\n', '                        oselabeledaefromdruguse                 3%           0%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,paxil,49,1848,1861,"\n', '                        oselabeledaefromdruguse                  2%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,paxil,50,1861,1889,"\n', '                        oselabeledaefromdruguse                        1%           0%           \n', '   nonoseaegeneralterm           oselabeledaefromdruguse                             4%           0%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,paxil,51,1889,1905,"\n', '   nonoseaegeneralterm        oselabeledaefromdruguse                   4%           1%           \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,paxil,52,1905,1917,"', '                        oselabeledaefromdruguse                 2%           0%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,paxil,53,1917,1949,"\n', '   nonoseaegeneralterm     oselabeledaefromdruguse d       13%          0%           \n', '                       Other  oselabeledaefromdruguse e    10%          0%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
54,paxil,54,1949,1981,"\n', '                        oselabeledaefromdruguse                3%           1%           \n', '                        oselabeledaefromdruguse              3%           0%           \n', '                        oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,paxil,55,1981,1983,g      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,paxil,56,1983,1989,2%           0%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,paxil,57,1989,1994,"\n', '          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,paxil,58,1994,2025,"a. Events reported by at least 1% of patients treated with PAXIL are included, except the following events which had an incidence on placebo >= PAXIL:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,paxil,59,2025,2181,"nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo (includes mostly "" nonoseaeaeratelteqplacebo  or "" nonoseaeaeratelteqplacebo ),  nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo \n', ' \n', '\n', ' b. Includes mostly "" oselabeledaefromdruguse  and "" oselabeledaefromdruguse ""\n', '\n', ' c. Percentage corrected for gender.\n', '\n', ' d. Mostly "" oselabeledaefromdruguse ""\n', '\n', ' e. Includes "" oselabeledaefromdruguse "" "" oselabeledaefromdruguse "" "" oselabeledaefromdruguse  oselabeledaefromdruguse ejaculation/ oselabeledaefromdruguse "" and "" oselabeledaefromdruguse "" and "" oselabeledaefromdruguse ""\n', '\n', ' f. Includes mostly "" oselabeledaefromdruguse  and "" oselabeledaefromdruguse ""\n', '\n', ' g. Includes mostly "" oselabeledaefromdruguse  and "" oselabeledaefromdruguse  oselabeledaefromdruguse climax/ oselabeledaefromdruguse """,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
60,paxil,60,2181,2182,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,paxil,61,2182,2339,"', '\n', '     Obsessive Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder:  \n', '\n', '  Table 3 enumerates adverse events that occurred at a frequency of 2% or more among  notaecandidateindication patients on PAXIL who participated in placebo-controlled trials of 12-weeks duration in which patients were dosed in a range of 20 mg to 60 mg/day or among patients with  notaecandidateindication on PAXIL who participated in placebo-controlled trials of 10- to 12-weeks duration in which patients were dosed in a range of 10 mg to 60 mg/day or among patients with  notaecandidateindication on PAXIL who participated in placebo-controlled trials of 12-weeks duration in which patients were dosed in a range of 20 mg to 50 mg/day.\n', '\n', ' Table 3.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
62,paxil,62,2339,2363,"Treatment-Emergent Adverse Experience Incidence in Placebo-Controlled Clinical Trials for Obsessive Compulsive Disorder, Panic Disorder, and Social Anxiety Disordera",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,paxil,63,2363,2371,"\n', '  Body System        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,paxil,64,2371,2378,Preferred Term       Obsessive Compulsive Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,paxil,65,2378,2381,Panic Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,paxil,66,2381,2385,Social Anxiety Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,paxil,67,2385,2398,"\n', '  PAXIL  (n = 542)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,paxil,68,2398,2406,Placebo  (n = 265)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,paxil,69,2406,2414,PAXIL  (n = 469)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,paxil,70,2414,2422,Placebo  (n = 324)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,paxil,71,2422,2428,PAXIL  (n = 425,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,paxil,72,2428,2438,)    Placebo  (n = 339)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,paxil,73,2438,2491,"\n', '   nonoseaegeneralterm     oselabeledaefromdruguse             22%          14%          14%          5%           22%          14%          \n', '                      oselabeledaefromdruguse       -            -            4%           3%           -            -            \n', '                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,paxil,74,2491,2512,"oselabeledaefromdruguse           3%           2%           -            -            -            -            \n', '                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,paxil,75,2512,2600,"oselabeledaefromdruguse            -            -            3%           2%           -            -            \n', '                      oselabeledaefromdruguse               2%           1%           2%           1%           -            -            \n', '                      oselabeledaefromdruguse               -            -            -            -            3%           1%           \n', '   nonoseaegeneralterm      oselabeledaefromdruguse         4%           1%           -            -            -            -            \n', '                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,paxil,76,2600,2643,"oselabeledaefromdruguse          2%           0%           -            -            -            -            \n', '   nonoseaegeneralterm        oselabeledaefromdruguse             9%           3%           14%          6%           9%           2%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,paxil,77,2643,2691,"\n', '                      oselabeledaefromdruguse                 3%           2%           -            -            -            -            \n', '   nonoseaegeneralterm     oselabeledaefromdruguse               23%          10%          23%          17%          25%          7%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
78,paxil,78,2691,2741,"\n', '                      oselabeledaefromdruguse            18%          9%           18%          11%          9%           3%           \n', '                      oselabeledaefromdruguse         16%          6%           8%           5%           5%           2%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,paxil,79,2741,2766,"\n', '                      oselabeledaefromdruguse             10%          10%          12%          7%           9%           6%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,paxil,80,2766,2773,"\n', '                      oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,paxil,81,2773,2791,9%           3%           7%           3%           8%           2%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,paxil,82,2791,2812,"\n', '                      oselabeledaefromdruguse            -            -            -            -            4%           2%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,paxil,83,2812,2877,"\n', '                      oselabeledaefromdruguse           -            -            -            -            4%           2%           \n', '                      oselabeledaefromdruguse    4%           3%           2%           1%           -            -            \n', '                      oselabeledaefromdruguse             -            -            -            -            2%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,paxil,84,2877,2900,"\n', '   nonoseaegeneralterm     oselabeledaefromdruguse              -            -            -            -            4%           3%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,paxil,85,2900,2927,"\n', '   nonoseaegeneralterm      oselabeledaefromdruguse             24%          13%          18%          10%          21%          16%          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
86,paxil,86,2927,2952,"\n', '                      oselabeledaefromdruguse           24%          7%           19%          11%          22%          5%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,paxil,87,2952,3025,"\n', '                      oselabeledaefromdruguse            12%          6%           14%          10%          11%          7%           \n', '                      oselabeledaefromdruguse               11%          1%           9%           1%           9%           1%           \n', '                      oselabeledaefromdruguse          9%           8%           -            -            8%           7%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,paxil,88,3025,3050,"\n', '                      oselabeledaefromdruguse     7%           4%           9%           1%           12%          1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,paxil,89,3050,3106,"\n', '                      oselabeledaefromdruguse            -            -            5%           4%           3%           1%           \n', '                      oselabeledaefromdruguse              -            -            5%           4%           5%           4%           \n', '                      oselabeledaefromdruguse      4%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,paxil,90,3106,3122,"1%           -            -            -            -            \n', '                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,paxil,91,3122,3124,oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,paxil,92,3124,3140,3%           2%           -            -            4%           1%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,paxil,93,3140,3223,"\n', '                      oselabeledaefromdruguse    3%           0%           -            -            -            -            \n', '                      oselabeledaefromdruguse            3%           0%           3%           2%           2%           1%           \n', '                      oselabeledaefromdruguse              2%           1%           -            -            -            -            \n', '   nonoseaegeneralterm     oselabeledaefromdruguse             -            -            3%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
94,paxil,94,3223,3235,"0%           -            -            \n', '                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,paxil,95,3235,3251,oselabeledaefromdruguse          -            -            -            -            4%           2%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,paxil,96,3251,3272,"\n', '                      oselabeledaefromdruguse                 -            -            -            -            5%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,paxil,97,3272,3297,"\n', '   nonoseaegeneralterm      oselabeledaefromdruguse      4%           2%           -            -            4%           1%           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
98,paxil,98,3297,3327,"\n', '                      oselabeledaefromdruguse     2%           0%           -            -            -            -            \n', '   nonoseaegeneralterm     oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
99,paxil,99,3327,3345,23%          1%           21%          1%           28%          1%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,paxil,100,3345,3373,"\n', '                      oselabeledaefromdruguse         -            -            -            -            5%           4%           \n', '                      oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,paxil,101,3373,3391,3%           0%           9%           1%           9%           1%           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,paxil,102,3391,3416,"\n', '                      oselabeledaefromdruguse           8%           1%           5%           0%           5%           1%           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,paxil,103,3416,3444,"\n', '                      oselabeledaefromdruguse    3%           1%           2%           0%           -            -            \n', '                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,paxil,104,3444,3767,"oselabeledaefromdruguse    3%           0%           -            -            -            -            \n', '                      oselabeledaefromdruguse    2%           1%           2%           1%           -            -            \n', '              a. Events reported by at least 2% of  notaecandidateindication   notaecandidateindication  and  notaecandidateindication in patients treated with PAXIL are included, except the following events which had an incidence on placebo >= PAXIL: [ notaecandidateindication :  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo  [ notaecandidateindication :  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo  [ notaecandidateindication :  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo \n', ' \n', '\n', ' b. Percentage corrected for gender.\n', '\n', '     Generalized Anxiety Disorder and Posttraumatic Stress Disorder:  \n', '\n', '  Table 4 enumerates adverse events that occurred at a frequency of 2% or more among  notaecandidateindication patients on PAXIL who participated in placebo-controlled trials of 8-weeks duration in which patients were dosed in a range of 10 mg/day to 50 mg/day or among  notaecandidateindication patients on PAXIL who participated in placebo-controlled trials of 12-weeks duration in which patients were dosed in a range of 20 mg/day to 50 mg/day.\n', '\n', ' Table 4.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
105,paxil,105,3767,3787,Treatment-Emergent Adverse Experience Incidence in Placebo-Controlled Clinical Trials for Generalized Anxiety Disorder and Posttraumatic Stress Disordera,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,paxil,106,3787,3795,"\n', '  Body System          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,paxil,107,3795,3798,Preferred Term           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,paxil,108,3798,3802,Generalized Anxiety Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,paxil,109,3802,3806,Posttraumatic Stress Disorder    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,paxil,110,3806,3819,"\n', '  PAXIL  (n = 735)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,paxil,111,3819,3827,Placebo  (n = 529)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,paxil,112,3827,3835,PAXIL  (n = 676)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,paxil,113,3835,3843,Placebo  (n = 504)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,paxil,114,3843,3864,"\n', '   nonoseaegeneralterm       oselabeledaefromdruguse                 14%              6%               12%              4%               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
115,paxil,115,3864,3871,"\n', '   oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,paxil,116,3871,3900,"17%                      14%              -                -                \n', '   oselabeledaefromdruguse            6%                       3%               5%               4%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,paxil,117,3900,3926,"\n', '   oselabeledaefromdruguse                                                 4%               3%               \n', '   oselabeledaefromdruguse                                                         6%               5%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,paxil,118,3926,4008,"\n', '   nonoseaegeneralterm        oselabeledaefromdruguse             3%               1%               2%               1%               \n', '   nonoseaegeneralterm          oselabeledaefromdruguse                 6%               2%               5%               1%               \n', '   nonoseaegeneralterm      oselabeledaefromdruguse                   20%              5%               19%              8%               \n', '   oselabeledaefromdruguse            11%                      5%               10%              5%               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
119,paxil,119,4008,4065,"\n', '   oselabeledaefromdruguse         10%                      2%               5%               3%               \n', '   oselabeledaefromdruguse             9%                       7%               11%              5%               \n', '   oselabeledaefromdruguse    5%                       1%               6%               3%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,paxil,120,4065,4122,"\n', '   oselabeledaefromdruguse             3%                       2%               3%               2%               \n', '   oselabeledaefromdruguse            -                        -                5%               3%               \n', '   nonoseaegeneralterm        oselabeledaefromdruguse                 11%              8%               12%              11%              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,paxil,121,4122,4160,"\n', '   oselabeledaefromdruguse           15%                      5%               16%              5%               \n', '   oselabeledaefromdruguse            6%                       5%               6%               5%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,paxil,122,4160,4215,"\n', '   oselabeledaefromdruguse               5%                       1%               4%               1%               \n', '   oselabeledaefromdruguse          4%                       3%               -                -                \n', '   oselabeledaefromdruguse     9%                       2%               5%               2%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,paxil,123,4215,4325,"\n', '   oselabeledaefromdruguse                                                3%               2%               \n', '   nonoseaegeneralterm     oselabeledaefromdruguse     7%               5%               -                -                \n', '   oselabeledaefromdruguse            4%                       3%               -                -                \n', '   oselabeledaefromdruguse                 4%                       -                2%               <1%              \n', '   nonoseaegeneralterm        oselabeledaefromdruguse          2%               1%               3%               1%               \n', '   nonoseaegeneralterm     oselabeledaefromdruguse    25%              2%               13%              2%               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,paxil,124,4325,4344,"\n', '   oselabeledaefromdruguse    4%                       1%               5%               1%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,paxil,125,4344,4454,"\n', '   oselabeledaefromdruguse           4%                       3%               9%               1%               \n', '            a. Events reported by at least 2% of  notaecandidateindication and  notaecandidateindication in patients treated with PAXIL are included, except the following events which had an incidence on placebo >= PAXIL [ notaecandidateindication :  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo  [ notaecandidateindication :  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  and  nonoseaeaeratelteqplacebo \n', ' \n', '\n', '",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
126,paxil,126,4454,4552,"b. Percentage corrected for gender.\n', '\n', '     Dose Dependency of Adverse Events:  \n', '\n', '  A comparison of adverse event rates in a fixed-dose study comparing 10, 20, 30, and 40 mg/day of PAXIL with placebo in the treatment of major depressive disorder revealed a clear dose dependency for some of the more common adverse events associated with use of PAXIL, as shown in Table 5:\n', '\n', ' Table 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,paxil,127,4552,4571,Treatment-Emergent Adverse Experience Incidence in a Dose-Comparison Trial in the Treatment of Major Depressive Disordera,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,paxil,128,4571,4582,"\n', '   Body System/Preferred Term       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,paxil,129,4582,4586,Placebo      PAXIL     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,paxil,130,4586,4605,"\n', '   n = 51                           10 mg    n = 102      20 mg    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,paxil,131,4605,4612,n = 104      30 mg    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,paxil,132,4612,4619,n = 101      40 mg    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,paxil,133,4619,4623,n = 102     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,paxil,134,4623,4635,"\n', '  \n', '   nonoseaegeneralterm                                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
135,paxil,135,4635,4657,"\n', '   oselabeledaefromdruguse                         0.0%        2.9%       10.6%      13.9%      12.7%      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,paxil,136,4657,4664,"\n', '   nonoseaegeneralterm                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
137,paxil,137,4664,4686,"\n', '   oselabeledaefromdruguse                         2.0%        1.0%       6.7%       8.9%       11.8%      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,paxil,138,4686,4693,"\n', '   nonoseaegeneralterm                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,paxil,139,4693,4781,"\n', '   oselabeledaefromdruguse                     5.9%        4.9%       7.7%       9.9%       12.7%      \n', '   oselabeledaefromdruguse               2.0%        2.0%       5.8%       4.0%       4.9%       \n', '   oselabeledaefromdruguse                         7.8%        9.8%       19.2%      7.9%       14.7%      \n', '   oselabeledaefromdruguse                        2.0%        10.8%      18.3%      15.8%      20.6%      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,paxil,140,4781,4803,"\n', '   oselabeledaefromdruguse                           13.7%       14.7%      26.9%      34.7%      36.3%      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,paxil,141,4803,4854,"\n', '   nonoseaegeneralterm                                                                           \n', '   oselabeledaefromdruguse                          0.0%        2.0%       5.8%       5.9%       5.9%       \n', '   oselabeledaefromdruguse                        3.9%        6.9%       6.7%       8.9%       12.7%      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
142,paxil,142,4854,4972,"\n', '   oselabeledaefromdruguse                      0.0%        5.9%       5.8%       4.0%       2.9%       \n', '   oselabeledaefromdruguse                      0.0%        2.9%       1.0%       5.0%       5.9%       \n', '   oselabeledaefromdruguse                       7.8%        12.7%      18.3%      20.8%      21.6%      \n', '   oselabeledaefromdruguse                           0.0%        0.0%       7.7%       7.9%       14.7%      \n', '   nonoseaegeneralterm                                                                           \n', '   oselabeledaefromdruguse                   2.0%        2.9%       2.9%       2.0%       7.8%       \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,paxil,143,4972,4978,"', '   nonoseaegeneralterm                                                                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
144,paxil,144,4978,5000,"\n', '   oselabeledaefromdruguse             0.0%        5.8%       6.5%       10.6%      13.0%      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,paxil,145,5000,5022,"\n', '   oselabeledaefromdruguse                        0.0%        1.9%       4.3%       6.4%       1.9%       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,paxil,146,5022,5136,"\n', '   oselabeledaefromdruguse           0.0%        3.8%       8.7%       6.4%       3.7%       \n', '            a. Rule for including adverse events in table: Incidence at least 5% for 1 of paroxetine groups and >= twice the placebo incidence for at least 1 paroxetine group.\n', ' \n', '\n', ' In a fixed-dose study comparing placebo and 20, 40, and 60 mg of PAXIL in the treatment of  notaecandidateindication  there was no clear relationship between adverse events and the dose of PAXIL to which patients were assigned.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
147,paxil,147,5136,5227,"No new adverse events were observed in the group treated with 60 mg of PAXIL compared to any of the other treatment groups.\n', '\n', ' In a fixed-dose study comparing placebo and 10, 20, and 40 mg of PAXIL in the treatment of  notaecandidateindication  there was no clear relationship between adverse events and the dose of PAXIL to which patients were assigned, except for  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
148,paxil,148,5227,5376,"In flexible-dose studies, no new adverse events were observed in patients receiving 60 mg of PAXIL compared to any of the other treatment groups.\n', '\n', ' In a fixed-dose study comparing placebo and 20, 40, and 60 mg of PAXIL in the treatment of social  notaecandidateindication  for most of the adverse events, there was no clear relationship between adverse events and the dose of PAXIL to which patients were assigned.\n', '\n', ' In a fixed-dose study comparing placebo and 20 and 40 mg of PAXIL in the treatment of generalized  notaecandidateindication  for most of the adverse events, there was no clear relationship between adverse events and the dose of PAXIL to which patients were assigned, except for the following adverse events:  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
149,paxil,149,5376,5383,oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,paxil,150,5383,5582,"\n', '\n', ' In a fixed-dose study comparing placebo and 20 and 40 mg of PAXIL in the treatment of  notaecandidateindication  for most of the adverse events, there was no clear relationship between adverse events and the dose of PAXIL to which patients were assigned, except for  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '     Adaptation to Certain Adverse Events:  \n', '\n', '  Over a 4- to 6-week period, there was evidence of adaptation to some adverse events with continued therapy (e.g.,  oselabeledaefromdruguse and  oselabeledaefromdruguse , but less to other effects (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse .\n', '\n', '     Male and Female Sexual Dysfunction With SSRIs:  \n', '\n', '  Although  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction desire, sexual  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction desire, sexual performance, and sexual  nonoseaeaeonlyasinstruction often occur as manifestations of a  notaecandidatepreexistingconditionorriskfactor  they may also be a consequence of pharmacologic treatment.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
151,paxil,151,5582,5654,"In particular, some evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can cause such  oselabeledaeclasseffect \n', '\n', ' Reliable estimates of the incidence and severity of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction desire,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction desire, performance, and  nonoseaeaeonlyasinstruction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,paxil,152,5654,5743,"Accordingly, estimates of the incidence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction experience and  nonoseaeaeonlyasinstruction cited in product labeling, are likely to underestimate their actual incidence.\n', '\n', ' In placebo-controlled clinical trials involving more than 3,200 patients, the ranges for the reported incidence of  nonoseaeaeonlyasinstruction in males and females with  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication are displayed in Table 6.\n', '\n', ' Table 6.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
153,paxil,153,5743,5771,"Incidence of Sexual Adverse Events in Controlled Clinical Trials \n', '                             PAXIL       Placebo     \n', '  n (males)                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,paxil,154,5771,5773,1446        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,paxil,155,5773,5775,1042        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,paxil,156,5775,5809,"\n', '   oselabeledaefromdruguse           6-15%       0-5%        \n', '   oselabeledaefromdruguse    13-28%      0-2%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,paxil,157,5809,5826,"\n', '   oselabeledaefromdruguse                  2-9%        0-3%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,paxil,158,5826,5838,"\n', '  n (females)                1822        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,paxil,159,5838,5840,1340        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,paxil,160,5840,5857,"\n', '   oselabeledaefromdruguse           0-9%        0-2%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,paxil,161,5857,5874,"\n', '   oselabeledaefromdruguse       2-9%        0-1%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,paxil,162,5874,5917,"\n', '         There are no adequate and well-controlled studies examining  nonoseaeaeonlyasinstruction with paroxetine treatment.\n', ' \n', '\n', ' Paroxetine treatment has been associated with several cases of  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,paxil,163,5917,6030,"In those cases with a known outcome, patients recovered without sequelae.\n', '\n', ' While it is difficult to know the precise risk of  nonoseaeaeonlyasinstruction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.\n', '\n', '     Weight and Vital Sign Changes:  \n', '\n', '  Significant  oselabeledaefromdruguse may be an undesirable result of treatment with PAXIL for some patients but, on average, patients in controlled trials had minimal (about 1 pound)  oselabeledaefromdruguse versus smaller changes on placebo and active control.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,paxil,164,6030,6094,"No significant  nonoseaenegation  nonoseaenegation vital signs (systolic and  nonoseaenegation  nonoseaenegation vital signs ( nonoseaenegation and diastolic  nonoseaenegation  nonoseaeaeonlyasinstruction vital signs (systolic and diastolic blood pressure,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction vital signs (systolic and diastolic blood pressure, pulse and  nonoseaeaeonlyasinstruction  were observed in patients treated with PAXIL in controlled clinical trials.\n'",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
165,paxil,165,6094,6114,", '\n', '     ECG Changes:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,paxil,166,6114,6194,"In an analysis of ECGs obtained in 682 patients treated with PAXIL and 415 patients treated with placebo in controlled clinical trials, no clinically significant  nonoseaeaeratelteqplacebo of either group.\n', '\n', '     Liver Function Tests:  \n', '\n', '  In placebo-controlled clinical trials, patients treated with PAXIL exhibited  nonoseaeaeratelteqplacebo at no greater rate than that seen in placebo-treated patients.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
167,paxil,167,6194,6375,"In particular, the PAXIL-versus-placebo comparisons for  nonoseaeaeratelteqplacebo  SGOT, SGPT, and bilirubin revealed no differences in the percentage of patients with marked  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo  SGPT, and bilirubin revealed no differences in the percentage of patients with marked  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo  and bilirubin revealed no differences in the percentage of patients with marked  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo revealed no differences in the percentage of patients with marked  nonoseaeaeratelteqplacebo \n', '\n', '     Hallucinations:  \n', '\n', '  In pooled clinical trials of immediate-release paroxetine hydrochloride,  oselabeledaefromdruguse were observed in 22 of 9089 patients receiving drug and 4 of 3187 patients receiving placebo.\n', '\n', '   Other Events Observed During the Premarketing Evaluation of PAXIL:\n', '\n', '  During its premarketing assessment in  notaecandidateindication  multiple doses of PAXIL were administered to 6,145 patients in phase 2 and 3 studies.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
168,paxil,168,6375,6418,"The conditions and duration of exposure to PAXIL varied greatly and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, and fixed-dose, and titration studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,paxil,169,6418,6456,"During premarketing clinical trials in  notaecandidateindication   notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication  542, 469, 522, 735, and 676 patients, respectively, received multiple doses of PAXIL.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
170,paxil,170,6456,6474,Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,paxil,171,6474,6536,"Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.\n', '\n', ' In the tabulations that follow, reported adverse events were classified using a standard COSTART-based Dictionary terminology.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,paxil,172,6536,6572,"The frequencies presented, therefore, represent the proportion of the 9,089 patients exposed to multiple doses of PAXIL who experienced an event of the type cited on at least 1 occasion while receiving PAXIL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,paxil,173,6572,6607,"All reported events are included except those already listed in Tables 2 to 5, those reported in terms so general as to be uninformative and those events where a drug cause was remote.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,paxil,174,6607,6656,"It is important to emphasize that although the events reported occurred during treatment with paroxetine, they were not necessarily caused by it.\n', '\n', ' Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,paxil,175,6656,6717,": Frequent adverse events are those occurring on 1 or more occasions in at least 1/100 patients (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in fewer than 1/1,000 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,paxil,176,6717,6765,"Events of major clinical importance are also described in the PRECAUTIONS section.\n', '\n', '     Body as a Whole:  \n', '\n', '    Infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,paxil,177,6765,6768,rare:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,paxil,178,6768,6782,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,paxil,179,6782,6783,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,paxil,180,6783,6801,"\n', '\n', '     Cardiovascular System:  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,paxil,181,6801,6827,"', '    Frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,paxil,182,6827,6830,rare:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,paxil,183,6830,6868,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,paxil,184,6868,6869,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,paxil,185,6869,6973,"\n', '\n', '     Digestive System:  \n', '\n', '    Infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,paxil,186,6973,6974,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,paxil,187,6974,7008,"\n', '\n', '     Endocrine System:  \n', '\n', '    Rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,paxil,188,7008,7043,"\n', '\n', '     Hemic and Lymphatic Systems:  \n', '\n', '    Infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,paxil,189,7043,7075,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,paxil,190,7075,7091,"\n', '\n', '     Metabolic and Nutritional:  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,paxil,191,7091,7108,", '\n', '    Frequent:   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,paxil,192,7108,7118,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,paxil,193,7118,7158,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,paxil,194,7158,7176,"\n', '\n', '     Musculoskeletal System:  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,paxil,195,7176,7206,"', '    Frequent:   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,paxil,196,7206,7224,"\n', '\n', '     Nervous System:  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,paxil,197,7224,7274,"', '    Frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,paxil,198,7274,7277,rare:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,paxil,199,7277,7339,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,paxil,200,7339,7340,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,paxil,201,7340,7397,"\n', '\n', '     Respiratory System:  \n', '\n', '    Infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,paxil,202,7397,7398,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,paxil,203,7398,7446,"', '\n', '     Skin and Appendages:  \n', '\n', '    Frequent:   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,paxil,204,7446,7478,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,paxil,205,7478,7523,"\n', '\n', '     Special Senses:  \n', '\n', '    Frequent    :   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,paxil,206,7523,7563,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,paxil,207,7563,7585,"\n', '\n', '     Urogenital System:  \n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,paxil,208,7585,7614,Infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,paxil,209,7614,7658,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,paxil,210,7658,7745,"\n', '\n', '   Postmarketing Reports:\n', '\n', '  Voluntary reports of adverse events in patients taking PAXIL that have been received since market introduction and not listed above that may have no causal relationship with the drug include  oselabeledaefromdruguse   oselabeledaefromdruguse (the most severe cases were  nonoseaegeneralterm due to  oselabeledaefromdruguse  and grossly  oselabeledaefromdruguse associated with severe  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
211,paxil,211,7745,7854,"symptoms suggestive of  oselabeledaefromdruguse and  oselabeledaefromdruguse   nonoseaeaefromdruginteraction which have included  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction which has been associated with concomitant use of pimozide;  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse  events related to  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ,  oselabeledaefromdruguse (such as  oselabeledaefromdruguse , and  oselabeledaefromdruguse in  notaecandidatepreexistingconditionorriskfactor women.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
212,paxil,212,7854,7874,There has been a case report of an elevated phenytoin level after 4 weeks of PAXIL and phenytoin coadministration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,paxil,213,7874,7989,"There has been a case report of severe  nonoseaeaefromdruginteraction \n', '\n', '    BOXED WARNING: Suicidality and Antidepressant Drugs\n', '\n', '  Suicidality and Antidepressant Drugs\n', '\n', '     Antidepressants increased the risk compared to placebo of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect ( oselabeledaeclasseffect  in children, adolescents, and young adults in short-term studies of  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  Anyone considering the use of PAXIL or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.",0,0,1,1,0,1,0,0,0,0,0,0,0,0,0
214,paxil,214,7989,8034,Short-term studies did not show an increase in the risk of  nonoseaeaeratelteqplacebo with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.  ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
215,paxil,215,8034,8098,"notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor are themselves associated with increases in the risk of  nonoseaeaeonlyasinstruction  Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  Families and caregivers should be advised of the need for close observation and communication with the prescriber.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
216,paxil,216,8098,8108,PAXIL is not approved for use in pediatric patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,paxil,217,8108,8195,"(See   WARNINGS  :   Clinical Worsening and  nonoseaeaeonlyasinstruction    PRECAUTIONS\n', '\n', '   General:\n', '\n', '    Activation of Mania/Hypomania:  \n', '\n', '  During premarketing testing,  oselabeledaefromdruguse or  oselabeledaefromdruguse occurred in approximately 1.0% of  notaecandidatepreexistingconditionorriskfactor patients treated with PAXIL compared to 1.1% of active-control and 0.3% of placebo-treated  notaecandidatepreexistingconditionorriskfactor patients.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
218,paxil,218,8195,8227,In a subset of patients classified as  notaecandidatepreexistingconditionorriskfactor  the rate of  oselabeledaefromdruguse episodes was 2.2% for PAXIL and 11.6% for the combined active-control groups.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
219,paxil,219,8227,8381,"As with all drugs effective in the treatment of  notaecandidateindication  PAXIL should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '     Seizures:  \n', '\n', '  During premarketing testing,  oselabeledaefromdruguse occurred in 0.1% of patients treated with PAXIL, a rate similar to that associated with other drugs effective in the treatment of  notaecandidateindication  PAXIL should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor  It should be discontinued in any patient who develops  nonoseaeaeonlyasinstruction \n', '\n', '     Discontinuation of Treatment With PAXIL:  \n', '\n', '  Recent clinical trials supporting the various approved indications for PAXIL employed a taper-phase regimen, rather than an abrupt discontinuation of treatment.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
220,paxil,220,8381,8412,The taper-phase regimen used in  notaecandidateindication and  notaecandidateindication clinical trials involved an incremental decrease in the daily dose by 10 mg/day at weekly intervals.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
221,paxil,221,8412,8623,"When a daily dose of 20 mg/day was reached, patients were continued on this dose for 1 week before treatment was stopped.\n', '\n', ' With this regimen in those studies, the following adverse events were reported at an incidence of 2% or greater for PAXIL and were at least twice that reported for placebo:  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  In the majority of patients, these events were mild to moderate and were self-limiting and did not require medical intervention.\n', '\n', ' During marketing of PAXIL and other SSRIs and SNRIs, there have been spontaneous reports of  oselabeledaefromdruguse of these drugs (particularly when abrupt), including the following:  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal (e.g.,  nonoseaeodorwithdrawal such as  nonoseaeodorwithdrawal and  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  While these events are generally self-limiting, there have been reports of serious  oselabeledaefromdruguse \n', '\n', ' Patients should be monitored for these  nonoseaeaeonlyasinstruction with PAXIL.",1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
222,paxil,222,8623,8638,A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,paxil,223,8638,8664,"If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,paxil,224,8664,8785,"Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see  DOSAGE AND ADMINISTRATION  ).\n', '\n', ' See also  PRECAUTIONS  :  Pediatric Use  , for adverse events reported upon discontinuation of treatment with PAXIL in pediatric patients.\n', '\n', '     Tamoxifen:  \n', '\n', ""  Some studies have shown that the efficacy of tamoxifen, as measured by the risk of  nonoseaeaeonlyasinstruction relapse/ nonoseaegeneralterm  may be reduced when co-prescribed with paroxetine as a result of paroxetine's irreversible inhibition of CYP2D6 (see Drug Interactions).",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
225,paxil,225,8785,8797,"However, other studies have failed to demonstrate such a risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,paxil,226,8797,8818,It is uncertain whether the coadministration of paroxetine and tamoxifen has a significant adverse effect on the efficacy of tamoxifen.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,paxil,227,8818,8832,One study suggests that the risk may increase with longer duration of coadministration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,paxil,228,8832,8920,"When tamoxifen is used for the treatment or prevention of  notaecandidatepreexistingconditionorriskfactor  prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition.\n"", '\n', '     Akathisia:  \n', '\n', '  The use of paroxetine or other SSRIs has been associated with the development of  oselabeledaefromdruguse  which is characterized by an inner sense of  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication such as an  nonoseaemanifestationorcomplication usually associated with subjective  nonoseaemanifestationorcomplication  ",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
229,paxil,229,8920,8969,"This is most likely to occur within the first few weeks of treatment.\n', '\n', '     Hyponatremia:  \n', '\n', '   oselabeledaefromdruguse may occur as a result of treatment with SSRIs and SNRIs, including PAXIL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,paxil,230,8969,8986,"In many cases, this  oselabeledaefromdruguse appears to be the result of the  oselabeledaefromdruguse .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,paxil,231,8986,8994,Cases with  oselabeledaefromdruguse have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,paxil,232,8994,9010,Elderly patients may be at greater risk of developing  oselabeledaeclasseffect with SSRIs and SNRIs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,paxil,233,9010,9029,"Also, patients taking diuretics or who are otherwise  notaecandidatepreexistingconditionorriskfactor may be at greater risk (see  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
234,paxil,234,9029,9038,PRECAUTIONS  :  Geriatric Use  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,paxil,235,9038,9157,"Discontinuation of PAXIL should be considered in patients with symptomatic  nonoseaeaeonlyasinstruction and appropriate medical intervention should be instituted.\n', '\n', ' Signs and symptoms of  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  which may lead to  nonoseaemanifestationorcomplication  Signs and symptoms associated with more severe and/or acute cases have included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm \n', '\n', '     Abnormal Bleeding:  \n', '\n', '  SSRIs and SNRIs, including paroxetine, may increase the risk of  oselabeledaefromdruguse events.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
236,paxil,236,9157,9179,"Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,paxil,237,9179,9340,"Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of  oselabeledaeclasseffect   oselabeledaeclasseffect events related to SSRIs and SNRIs use have ranged from  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect to life-threatening  oselabeledaeclasseffect  Patients should be cautioned about the risk of  nonoseaeaefromdruginteraction associated with the concomitant use of paroxetine and NSAIDs, aspirin, or other drugs that affect coagulation.\n', '\n', '     Bone Fracture:  \n', '\n', '  Epidemiological studies on  oselabeledaeclasseffect risk following exposure to some antidepressants, including SSRIs, have reported an association between antidepressant treatment and  oselabeledaeclasseffect  There are multiple possible causes for this observation and it is unknown to what extent  nonoseaeaeonlyasinstruction risk is directly attributable to SSRI treatment.",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
238,paxil,238,9340,9422,"The possibility of a  nonoseaeaeonlyasinstruction  that is, a  nonoseaeaeonlyasinstruction in a patient with  notaecandidatepreexistingconditionorriskfactor  should be considered in patients treated with paroxetine who present with unexplained  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication \n', '\n', '     Use in Patients With Concomitant Illness:  \n', '\n', '  Clinical experience with PAXIL in patients with certain concomitant systemic illness is limited.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
239,paxil,239,9422,9465,"Caution is advisable in using PAXIL in patients with diseases or conditions that could affect metabolism or hemodynamic responses.\n', '\n', ' As with other SSRIs,  oselabeledaefromdruguse has been infrequently reported in premarketing studies with PAXIL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,paxil,240,9465,9482,A few cases of  oselabeledaefromdruguse associated with paroxetine therapy have been reported in the literature.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,paxil,241,9482,9556,"As  nonoseaeaeonlyasinstruction can cause  nonoseaeaeonlyasinstruction in patients with  notaecandidatepreexistingconditionorriskfactor  caution should be used when PAXIL is prescribed for patients with  notaecandidatepreexistingconditionorriskfactor \n', '\n', "" PAXIL has not been evaluated or used to any appreciable extent in patients with a recent history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  Patients with these diagnoses were excluded from clinical studies during the product's premarket testing.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
242,paxil,242,9556,9780,"Evaluation of electrocardiograms of 682 patients who received PAXIL in double-blind, placebo-controlled trials, however, did not indicate that PAXIL is associated with the development of significant  nonoseaeaeonlyasinstruction  Similarly, PAXIL does not cause any clinically important  nonoseaenegation  nonoseaenegation heart rate or  nonoseaenegation \n"", '\n', ' Increased plasma concentrations of paroxetine occur in patients with severe  notaecandidatepreexistingconditionorriskfactor ( notaecandidatepreexistingconditionorriskfactor ) or severe  notaecandidatepreexistingconditionorriskfactor  A lower starting dose should be used in such patients (see  DOSAGE AND ADMINISTRATION  ).\n', '\n', '    Information for Patients:\n', '\n', '  PAXIL should not be chewed or crushed, and should be swallowed whole.\n', '\n', ' Patients should be cautioned about the risk of  nonoseaeaeonlyasinstruction with the concomitant use of PAXIL and triptans, tramadol, or other serotonergic agents.\n', '\n', ' Patients should be advised that taking Paxil can cause mild  nonoseaeaeonlyasinstruction  which in susceptible individuals, can lead to an episode of  nonoseaeaeonlyasinstruction  Pre-existing  notaecandidatepreexistingconditionorriskfactor is almost always  notaecandidatepreexistingconditionorriskfactor because  notaecandidatepreexistingconditionorriskfactor  when diagnosed, can be treated definitively with iridectomy.  ",1,0,1,0,0,0,0,1,0,0,0,0,0,0,0
243,paxil,243,9780,9862,"nonoseaeaeonlyasinstruction is not a risk factor for  nonoseaeaeonlyasinstruction  Patients may wish to be examined to determine whether they are susceptible to  nonoseaeaeonlyasinstruction  and have a prophylactic procedure (e.g., iridectomy), if they are susceptible.\n', '\n', ' Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with PAXIL and should counsel them in its appropriate use.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,paxil,244,9862,9871,A patient Medication Guide is available for PAXIL.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,paxil,245,9871,9900,"The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,paxil,246,9900,9925,Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,paxil,247,9925,10060,"The complete text of the Medication Guide is reprinted at the end of this document.\n', '\n', ' Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking PAXIL.\n', '\n', '     Clinical Worsening and Suicide Risk:  \n', '\n', ""  Patients, their families, and their caregivers should be encouraged to be alert to the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  other  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially early during antidepressant treatment and when the dose is adjusted up or down.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,paxil,248,10060,10091,"Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,paxil,249,10091,10126,"Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,paxil,250,10126,10169,"Symptoms such as these may be associated with an increased risk for  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thinking and  nonoseaeaeonlyasinstruction and indicate a need for very close monitoring and possibly changes in the medication.\n"", '\n', '     Drugs",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,paxil,251,10169,10251,"That Interfere With Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin):  \n', '\n', '  Patients should be cautioned about the concomitant use of paroxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of  nonoseaeaefromdruginteraction \n', '\n', '     Interference",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
252,paxil,252,10251,10289,"With Cognitive and Motor Performance:  \n', '\n', '  Any psychoactive drug may  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction judgment,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction judgment, thinking, or  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,paxil,253,10289,10335,"Although in controlled studies PAXIL has not been shown to  nonoseaenegation  patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that therapy with PAXIL does not affect their ability to engage in such activities.\n',",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
254,paxil,254,10335,10428,"'\n', '     Completing Course of Therapy:  \n', '\n', '  While patients may notice improvement with treatment with PAXIL in 1 to 4 weeks, they should be advised to continue therapy as directed.\n', '\n', '      Concomitant Medication:    Patients should be advised to inform their physician if they are taking, or plan to take, any prescription or over-the-counter drugs, since there is a potential for interactions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,paxil,255,10428,10481,"Alcohol:  \n', ' \n', '\n', '  Although PAXIL has not been shown to increase the  nonoseaeaeonlyasinstruction and motor  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction mental and  nonoseaeaeonlyasinstruction caused by alcohol, patients should be advised to avoid alcohol while taking PAXIL.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,paxil,256,10481,10526,"'\n', '     Pregnancy:  \n', '\n', '  Patients should be advised to notify their physician if they become  nonoseaeaeonlyasinstruction or intend to become  nonoseaeaeonlyasinstruction during therapy (see  WARNINGS  :",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,paxil,257,10526,10539,Usage in  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  ).\n,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,paxil,258,10539,10624,"', '\n', '     Nursing:  \n', '\n', '  Patients should be advised to notify their physician if they are breastfeeding an infant (see  PRECAUTIONS  :  Nursing Mothers  ).\n', '\n', '    Laboratory Tests:\n', '\n', '  There are no specific laboratory tests recommended.\n', '\n', '    Drug Interactions:\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,paxil,259,10624,10640,"', '    Tryptophan:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,paxil,260,10640,10660,"As with other serotonin reuptake inhibitors, an interaction between paroxetine and tryptophan may occur when they are coadministered.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,paxil,261,10660,10689,"Adverse experiences, consisting primarily of  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  and  nonoseaeaefromdruginteraction  have been reported when tryptophan was administered to patients taking PAXIL.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
262,paxil,262,10689,10813,"Consequently, concomitant use of PAXIL with tryptophan is not recommended (see  WARNINGS  :  Serotonin Syndrome  ).\n', '\n', '     Monoamine Oxidase Inhibitors:  \n', '\n', '  See  CONTRAINDICATIONS  and  WARNINGS  .\n', '\n', '     Pimozide:  \n', '\n', '  In a controlled study of healthy volunteers, after PAXIL was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmaxof 62%, compared to pimozide administered alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,paxil,263,10813,10829,The increase in pimozide AUC and Cmaxis due to the CYP2D6 inhibitory properties of paroxetine.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,paxil,264,10829,10980,"Due to the narrow therapeutic index of pimozide and its known ability to  nonoseaeaefromdruginteraction  concomitant use of pimozide and PAXIL is contraindicated (see  CONTRAINDICATIONS  ).\n', '\n', '     Serotonergic Drugs:  \n', '\n', ""  Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for  nonoseaeaefromdruginteraction  caution is advised when PAXIL is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St. John's Wort (see  WARNINGS  :   nonoseaeaeonlyasinstruction  ).\n"", '\n', ' The concomitant use of PAXIL with MAOIs (including linezolid and intravenous methylene blue) is contraindicated (see  CONTRAINDICATIONS  ).",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
265,paxil,265,10980,10998,"The concomitant use of PAXIL with other SSRIs, SNRIs or tryptophan is not recommended (see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,paxil,266,10998,11002,PRECAUTIONS  :  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,paxil,267,11002,11006,Drug Interactions  :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,paxil,268,11006,11089,"Tryptophan  ).\n', '\n', '     Thioridazine:  \n', '\n', '  See  CONTRAINDICATIONS  and  WARNINGS  .\n', '\n', '     Warfarin:  \n', '\n', '  Preliminary data suggest that there may be a pharmacodynamic interaction (that causes an  nonoseaeaefromdruginteraction diathesis in the face of unaltered prothrombin time) between paroxetine and warfarin.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
269,paxil,269,11089,11111,"Since there is little clinical experience, the concomitant administration of PAXIL and warfarin should be undertaken with caution (see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,paxil,270,11111,11114,PRECAUTIONS  :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,paxil,271,11114,11121,Drugs That Interfere With Hemostasis  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,paxil,272,11121,11161,".\n', '\n', '     Triptans:  \n', '\n', '  There have been rare postmarketing reports of  nonoseaeaefromdruginteraction with the use of an SSRI and a triptan.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
273,paxil,273,11161,11191,"If concomitant use of PAXIL with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,paxil,274,11191,11195,WARNINGS  :  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,paxil,275,11195,11223,"Serotonin Syndrome  ).\n', '\n', '     Drugs Affecting Hepatic Metabolism:  \n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,paxil,276,11223,11244,"The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug-metabolizing enzymes.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,paxil,277,11244,11257,"'\n', '     Cimetidine:  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,paxil,278,11257,11270,"\n', ""  Cimetidine inhibits many cytochrome P450(oxidative) enzymes.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,paxil,279,11270,11318,"In a study where PAXIL (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,paxil,280,11318,11343,"Therefore, when these drugs are administered concurrently, dosage adjustment of PAXIL after the 20-mg starting dose should be guided by clinical effect.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,paxil,281,11343,11382,"The effect of paroxetine on cimetidine's pharmacokinetics was not studied.\n"", '\n', '     Phenobarbital:  \n', '\n', '  Phenobarbital induces many cytochrome P450(oxidative) enzymes.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,paxil,282,11382,11430,"When a single oral 30-mg dose of PAXIL was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T1/2were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,paxil,283,11430,11441,The effect of paroxetine on phenobarbital pharmacokinetics was not studied.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,paxil,284,11441,11467,"Since PAXIL exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,paxil,285,11467,11559,"No initial dosage adjustment of PAXIL is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.\n', '\n', '     Phenytoin:  \n', '\n', '  When a single oral 30-mg dose of PAXIL was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T1/2 were reduced (by an average of 50% and 35%, respectively) compared to PAXIL administered alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,paxil,286,11559,11605,"In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,paxil,287,11605,11630,"Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,paxil,288,11630,11719,"No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see  ADVERSE REACTIONS  :  Postmarketing Reports  ).\n', '\n', '     Drugs Metabolized by CYP2D6:  \n', '\n', '  Many drugs, including most drugs effective in the treatment of  notaecandidateindication (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450isozyme CYP2D6.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
289,paxil,289,11719,11738,"Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,paxil,290,11738,11758,"In most patients (>90%), this CYP2D6 isozyme is saturated early during dosing with PAXIL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,paxil,291,11758,11785,"In 1 study, daily dosing of PAXIL (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,paxil,292,11785,11805,"Cmax, AUC, and T1/2 by an average of approximately 2-, 5-, and 3-fold, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,paxil,293,11805,11820,"Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,paxil,294,11820,11877,"In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,paxil,295,11877,11897,The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,paxil,296,11897,11923,"In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,paxil,297,11923,11956,This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmaxvalues that were 3- to 4-fold greater than when atomoxetine was given alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,paxil,298,11956,12155,"Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.\n', '\n', ' Concomitant use of PAXIL with other drugs metabolized by cytochrome CYP2D6 has not been formally studied but may require lower doses than usually prescribed for either PAXIL or the other drug.\n', '\n', ' Therefore, coadministration of PAXIL with other drugs that are metabolized by this isozyme, including certain drugs effective in the treatment of  notaecandidateindication (e.g., nortriptyline, amitriptyline, imipramine, desipramine, and fluoxetine), phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\n', '\n', ' However, due to the risk of serious  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction potentially associated with elevated plasma levels of thioridazine, paroxetine and thioridazine should not be coadministered (see  CONTRAINDICATIONS  and  WARNINGS  ).\n', '\n', '",0,0,0,1,0,1,0,0,0,0,0,0,0,0,0
299,paxil,299,12155,12167,Tamoxifen is a pro-drug requiring metabolic activation by CYP2D6.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,paxil,300,12167,12306,"Inhibition of CYP2D6 by paroxetine may lead to reduced plasma concentrations of an active metabolite (endoxifen) and hence reduced efficacy of tamoxifen (see  PRECAUTIONS  ).\n', '\n', ' At steady state, when the CYP2D6 pathway is essentially saturated, paroxetine clearance is governed by alternative P450isozymes that, unlike CYP2D6, show no evidence of saturation (see  PRECAUTIONS  : Tricyclic Antidepressants [TCAs]  ).\n', '\n', '     Drugs Metabolized by Cytochrome CYP3A4:  \n', '\n', ""  An in vivo  interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,paxil,301,12306,12359,"In addition, in vitro  studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,paxil,302,12359,12454,"Based on the assumption that the relationship between paroxetine's in vitro  Kiand its lack of effect on terfenadine's in vivo  clearance predicts its effect on other CYP3A4 substrates, paroxetine's extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.\n"", '\n', '     Tricyclic Antidepressants (TCAs):  \n', '\n', '  Caution is indicated in the coadministration of tricyclic antidepressants (TCAs) with PAXIL, because paroxetine may inhibit TCA metabolism.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,paxil,303,12454,12559,"Plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced, if a TCA is coadministered with PAXIL (see  PRECAUTIONS  : Drugs Metabolized by Cytochrome CYP2D6  ).\n', '\n', '     Drugs Highly Bound to Plasma Protein:  \n', '\n', '  Because paroxetine is highly bound to plasma protein, administration of PAXIL to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,paxil,304,12559,12583,"Conversely, adverse effects could result from displacement of paroxetine by other highly bound drugs.\n', '\n', '     Drugs",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,paxil,305,12583,12619,"That Interfere With Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin):  \n', '\n', '  Serotonin release by platelets plays an important role in hemostasis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,paxil,306,12619,12690,"Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper  nonoseaeaefromdruginteraction have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of  nonoseaeaefromdruginteraction  Altered anticoagulant effects, including  nonoseaeaefromdruginteraction  have been reported when SSRIs or SNRIs are coadministered with warfarin.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
307,paxil,307,12690,12795,"Patients receiving warfarin therapy should be carefully monitored when paroxetine is initiated or discontinued.\n', '\n', '     Alcohol:  \n', '\n', '  Although PAXIL does not increase the  nonoseaenegation and motor  nonoseaenegation  nonoseaenegation mental and  nonoseaenegation caused by alcohol, patients should be advised to avoid alcohol while taking PAXIL.\n', '\n', '     Lithium:  \n', '\n', '  A multiple-dose study has shown that there is no pharmacokinetic interaction between PAXIL and lithium carbonate.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
308,paxil,308,12795,12852,"However, due to the potential for  nonoseaeaefromdruginteraction  caution is advised when PAXIL is coadministered with lithium.\n', '\n', '     Digoxin:  \n', '\n', '  The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
309,paxil,309,12852,12868,Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,paxil,310,12868,12898,"Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.\n', '\n', '     Diazepam:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,paxil,311,12898,12922,"\n', '\n', '  Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,paxil,312,12922,13004,"The effects of paroxetine on diazepam were not evaluated.\n', '\n', '     Procyclidine:  \n', '\n', '  Daily oral dosing of PAXIL (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cminvalues of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,paxil,313,13004,13084,"If anticholinergic effects are seen, the dose of procyclidine should be reduced.\n', '\n', '     Beta-Blockers:  \n', '\n', '  In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with PAXIL (30 mg once daily) for the final 10 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,paxil,314,13084,13100,The effects of propranolol on paroxetine have not been evaluated (see  ADVERSE REACTIONS:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,paxil,315,13100,13139,"Postmarketing Reports  ).\n', '\n', '     Theophylline:  \n', '\n', '  Reports of elevated theophylline levels associated with treatment with PAXIL have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,paxil,316,13139,13200,"While this interaction has not been formally studied, it is recommended that theophylline levels be monitored when these drugs are concurrently administered.\n', '\n', '     Fosamprenavir/Ritonavir:  \n', '\n', '  Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,paxil,317,13200,13266,"Any dose adjustment should be guided by clinical effect (tolerability and efficacy).\n', '\n', '     Electroconvulsive Therapy (ECT):  \n', '\n', '  There are no clinical studies of the combined use of ECT and PAXIL.\n', '\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility:\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,paxil,318,13266,13330,", '\n', '    Carcinogenesis:  \n', '\n', '  Two-year carcinogenicity studies were conducted in rodents given paroxetine in the diet at 1, 5, and 25 mg/kg/day (mice) and 1, 5, and 20 mg/kg/day (rats).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,paxil,319,13330,13368,These doses are up to 2.4 (mouse) and 3.9 (rat) times the MRHD for  notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication on a mg/m  2  basis.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
320,paxil,320,13368,13415,"Because the MRHD for  notaecandidateindication is slightly less than that for  notaecandidateindication (50 mg versus 60 mg), the doses used in these carcinogenicity studies were only 2.0 (mouse) and 3.2 (rat) times the MRHD for  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
321,paxil,321,13415,13476,"There was a significantly greater number of male rats in the high-dose group with  nonoseaeaeanimal (1/100, 0/50, 0/50, and 4/50 for control, low-, middle-, and high-dose groups, respectively) and a significantly increased linear trend across dose groups for the occurrence of  nonoseaeaeanimal in male rats.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
322,paxil,322,13476,13482,Female rats were not affected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,paxil,323,13482,13513,"Although there was a dose-related increase in the number of  nonoseaeaeanimal in mice, there was no drug-related increase in the number of mice with  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
324,paxil,324,13513,13515,nonoseaeaeanimal  ,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
325,paxil,325,13515,13559,"The relevance of these findings to humans is unknown.\n', '\n', '     Mutagenesis:  \n', '\n', '  Paroxetine produced no  nonoseaeaeanimal in a battery of 5 in vitro  and 2",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
326,paxil,326,13559,13568,in vivo  assays that included the following:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,paxil,327,13568,13655,"Bacterial mutation assay, mouse  nonoseaeaeanimal mutation assay, unscheduled DNA synthesis assay, and tests for  nonoseaeaeanimal in vivo  in mouse bone marrow and in vitro  in human lymphocytes and in a dominant lethal test in rats.\n', '\n', '     Impairment of Fertility:  \n', '\n', '  Some clinical studies have shown that SSRIs (including paroxetine) may  oselabeledaefromdruguse during SSRI treatment, which may  nonoseaemanifestationorcomplication \n",0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
328,paxil,328,13655,13723,"', '\n', ' A reduced  nonoseaeaeanimal rate was found in reproduction studies in rats at a dose of paroxetine of 15 mg/kg/day, which is 2.9 times the MRHD for  notaecandidateindication   notaecandidateindication   notaecandidateindication  and  notaecandidateindication or 2.4 times the MRHD for  notaecandidateindication on a mg/m  2  basis.  ",0,0,0,1,0,0,0,0,1,0,0,0,0,0,0
329,paxil,329,13723,13738,nonoseaeaeanimal of male rats after dosing in toxicity studies for 2 to 52 weeks.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
330,paxil,330,13738,13963,"These lesions consisted of  nonoseaeaeanimal at 50 mg/kg/day and  nonoseaeaeanimal with  nonoseaeaeanimal at 25 mg/kg/day (9.8 and 4.9 times the MRHD for  notaecandidateindication   notaecandidateindication  and  notaecandidateindication  8.2 and 4.1 times the MRHD for  notaecandidateindication and PD on a mg/m  2  basis).\n', '\n', '     Pregnancy:  \n', '\n', '   nonoseaeaeonlyasinstruction Category D. See  WARNINGS: Usage in  nonoseaeaeonlyasinstruction  :  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  .\n', '\n', '    Labor and Delivery:\n', '\n', '  The effect of paroxetine on labor and delivery in humans is unknown.\n', '\n', '    Nursing Mothers:\n', '\n', '  Like many other drugs, paroxetine is secreted in human milk, and caution should be exercised when PAXIL is administered to a nursing woman.\n', '\n', '    Pediatric Use:\n', '\n', '  Safety and effectiveness in the pediatric population have not been established (see  BOX WARNING  and  WARNINGS  : Clinical Worsening and Suicide Risk).",1,0,0,1,0,0,0,0,1,0,0,0,0,0,0
331,paxil,331,13963,13997,"Three placebo-controlled trials in 752 pediatric patients with  notaecandidateindication have been conducted with PAXIL, and the data were not sufficient to support a claim for use in pediatric patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
332,paxil,332,13997,14019,Anyone considering the use of PAXIL in a child or adolescent must balance the potential risks with the clinical need.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
333,paxil,333,14019,14034,oselabeledaeclasseffect and  oselabeledaeclasseffect have been observed in association with the use of SSRIs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,paxil,334,14034,14137,"Consequently, regular monitoring of weight and growth should be performed in children and adolescents treated with an SSRI such as PAXIL.\n', '\n', ' In placebo-controlled clinical trials conducted with pediatric patients, the following adverse events were reported in at least 2% of pediatric patients treated with PAXIL and occurred at a rate at least twice that for pediatric patients receiving placebo:  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,paxil,335,14137,14280,"\n', '\n', '  oselabeledaefromdruguse with PAXIL in the pediatric clinical trials that included a taper phase regimen, which occurred in at least 2% of patients who received PAXIL and which occurred at a rate at least twice that of placebo, were:  nonoseaeodorwithdrawal (including  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal (see  DOSAGE AND ADMINISTRATION: Discontinuation of Treatment With PAXIL  ).\n', '\n', '    Geriatric Use:\n', '\n', '  SSRIs and SNRIs, including PAXIL, have been associated with cases of clinically significant  oselabeledaefromdruguse in elderly patients, who may be at greater risk for this adverse event (see  ",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
336,paxil,336,14280,14283,PRECAUTIONS:  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,paxil,337,14283,14363,"nonoseaeaeonlyasinstruction    WARNINGS\n', '\n', '   Clinical Worsening and Suicide Risk:\n', '\n', '  Patients with  notaecandidateindication , both adult and pediatric, may experience worsening of their  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
338,paxil,338,14363,14389,nonoseaeaeonlyasinstruction is a known risk of  notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
339,paxil,339,14389,14426,"There has been a long-standing concern, however, that antidepressants may have a role in inducing  oselabeledaeclasseffect and the emergence of  oselabeledaeclasseffect in certain patients during the early phases of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,paxil,340,14426,14574,"Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect ( oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an increase in the risk of  nonoseaeaeratelteqplacebo with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.\n', '\n', ' The pooled analyses of placebo-controlled trials in children and adolescents with  notaecandidateindication   notaecandidateindication , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients.",0,0,1,1,0,0,1,0,0,0,0,0,0,0,0
341,paxil,341,14574,14616,"The pooled analyses of placebo-controlled trials in adults with  notaecandidateindication or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
342,paxil,342,14616,14644,"There was considerable variation in risk of  oselabeledaeclasseffect among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,paxil,343,14644,14666,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across the different indications, with the highest incidence in  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
344,paxil,344,14666,14687,"The risk differences (drug vs placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,paxil,345,14687,14833,"These risk differences (drug-placebo difference in the number of cases of  nonoseaeaeonlyasinstruction per 1,000 patients treated) are provided in Table 1.\n', '\n', ' Table 1 \n', '  Age Range      Drug-Placebo Difference in Number of Cases of  oselabeledaeclasseffect per 1,000 Patients Treated    \n', '  Increases Compared to Placebo    \n', '  <18            14 additional cases                                                                 \n', '  18-24          5 additional cases                                                                  \n', '  Decreases Compared to Placebo    \n', '  25-64          1 fewer case                                                                        \n', '  >=65           6 fewer cases                                                                       \n', '        No  nonoseaenegation occurred in any of the pediatric trials.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
346,paxil,346,14833,14891,"There were  nonoseaeaeonlyasinstruction in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction risk extends to longer-term use, i.e., beyond several months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,paxil,347,14891,14982,"However, there is substantial evidence from placebo-controlled maintenance trials in adults with  notaecandidatepreexistingconditionorriskfactor that the use of antidepressants can delay the recurrence of  nonoseaeaeonlyasinstruction \n', '\n', '  All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
348,paxil,348,14982,15049,"\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with antidepressants for  notaecandidateindication as well as for other indications, both psychiatric and nonpsychiatric.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
349,paxil,349,15049,15306,"Although a causal link between the emergence of such symptoms and either the  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose  notaecandidateindication is persistently worse, or who are experiencing emergent  nonoseaeaeonlyasinstruction or symptoms that might be precursors to worsening  nonoseaemanifestationorcomplication or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', ' If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see  PRECAUTIONS  and  DOSAGE AND ADMINISTRATION  : Discontinuation of Treatment With PAXIL, for a description of the risks of discontinuation of PAXIL).\n', '\n', '  Families and caregivers of patients being treated with antidepressants for  notaecandidateindication or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to healthcare providers.",1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
350,paxil,350,15306,15318,Such monitoring should include daily observation by families and caregivers.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,paxil,351,15318,15429,"Prescriptions for PAXIL should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of  nonoseaeaeonlyasinstruction \n', '\n', '    Screening Patients for Bipolar Disorder:\n', '\n', '  A  nonoseaeaeonlyasinstruction may be the initial presentation of  notaecandidatepreexistingconditionorriskfactor  It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of  nonoseaeaeonlyasinstruction in patients at risk for  notaecandidatepreexistingconditionorriskfactor  Whether any of the symptoms described above represent such a conversion is unknown.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
352,paxil,352,15429,15479,"However, prior to initiating treatment with an antidepressant, patients with  notaecandidatepreexistingconditionorriskfactor should be adequately screened to determine if they are at risk for  notaecandidatepreexistingconditionorriskfactor  such screening should include a detailed  notaecandidatepreexistingconditionorriskfactor history, including a  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
353,paxil,353,15479,15679,"It should be noted that PAXIL is not approved for use in treating  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    Serotonin Syndrome:\n', '\n', ""  The development of a potentially life-threatening  oselabeledaefromdruguse has been reported with SNRIs and SSRIs, including PAXIL, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat  notaecandidatepreexistingconditionorriskfactor and also others, such as linezolid and intravenous methylene blue).\n"", '\n', '  nonoseaeaeonlyasinstruction symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
354,paxil,354,15679,15712,"Patients should be monitored for the emergence of  nonoseaeaeonlyasinstruction \n', '\n', ' The concomitant use of PAXIL with MAOIs intended to treat  notaecandidatepreexistingconditionorriskfactor is contraindicated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
355,paxil,355,15712,15735,PAXIL should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,paxil,356,15735,15766,All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,paxil,357,15766,15792,No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,paxil,358,15792,15819,There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking PAXIL.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,paxil,359,15819,16037,"PAXIL should be discontinued before initiating treatment with the MAOI (see  CONTRAINDICATIONS  and  DOSAGE AND ADMINISTRATION  ).\n', '\n', "" If concomitant use of PAXIL with certain other serotonergic drugs, i.e., triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, amphetamines, and St. John's Wort is clinically warranted, be aware of a potential increased risk for  nonoseaeaefromdruginteraction  particularly during treatment initiation and dose increases.\n"", '\n', ' Treatment with PAXIL and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.\n', '\n', '    Angle-Closure Glaucoma:\n', '\n', '  The  oselabeledaefromdruguse that occurs following use of many antidepressant drugs including Paxil may trigger an  oselabeledaefromdruguse in a patient with  notaecandidatepreexistingconditionorriskfactor who does not have a patent iridectomy.\n', '\n', '    Potential Interaction With Thioridazine:\n', '\n', '   Thioridazine administration alone produces  nonoseaeaefromdruginteraction  which is associated with serious  nonoseaeaefromdruginteraction  such as  nonoseaeaefromdruginteraction  - type  nonoseaeaefromdruginteraction  and  nonoseaeaefromdruginteraction  ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
360,paxil,360,16037,16046,This effect appears to be dose related.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,paxil,361,16046,16079,"\n', '\n', '  An   in vivo   study suggests that drugs which inhibit CYP2D6, such as paroxetine, will elevate plasma levels of thioridazine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,paxil,362,16079,16105,"Therefore, it is recommended that paroxetine not be used in combination with thioridazine (see  CONTRAINDICATIONS  and  PRECAUTIONS  ).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,paxil,363,16105,16125,"\n', '\n', '    Usage in Pregnancy:\n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,paxil,364,16125,16127,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,paxil,365,16127,16158,"\n', '\n', '  Epidemiological studies have shown that  oselabeledaefromdruguse have an increased risk of  oselabeledaefromdruguse  oselabeledaefromdruguse malformations, particularly  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,paxil,366,16158,16228,"The findings from these studies are summarized below:\n', '\n', ' *    A study based on Swedish national registry data demonstrated that  oselabeledaefromdruguse (2% risk in paroxetine-exposed infants) compared to the entire registry population (1% risk), for an odds ratio (OR) of 1.8 (95% confidence interval 1.1 to 2.8).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,paxil,367,16228,16245,No increase in the risk of  nonoseaeaeonlyasinstruction was seen in the paroxetine-exposed infants.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
368,paxil,368,16245,16258,The  oselabeledaefromdruguse were primarily  oselabeledaefromdruguse  and  oselabeledaefromdruguse .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,paxil,369,16258,16273,nonoseaeaeonlyasinstruction range in severity from those that resolve spontaneously to those which require surgery.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,paxil,370,16273,16312,"\n', ' *    A separate retrospective cohort study from the United States (United Healthcare data) evaluated 5,956 infants of mothers dispensed antidepressants during the first trimester (n = 815 for paroxetine).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
371,paxil,371,16312,16358,"This study showed a trend towards an increased risk for  oselabeledaefromdruguse for paroxetine (risk of 1.5%) compared to other antidepressants (risk of 1%), for an OR of 1.5 (95% confidence interval 0.8 to 2.9).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,paxil,372,16358,16369,Of the 12  oselabeledaefromdruguse  9 had  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
373,paxil,373,16369,16416,This study also suggested an increased risk of overall major  oselabeledaefromdruguse  oselabeledaefromdruguse malformations including  oselabeledaefromdruguse for paroxetine (4% risk) compared to other (2% risk) antidepressants (OR 1.8; 95% confidence interval 1.2 to 2.8).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,paxil,374,16416,16469,"\n', ' *    Two large case-control studies using separate databases, each with >9,000  nonoseaeaeonlyasinstruction cases and >4,000 controls, found that maternal use of paroxetine during the first trimester of pregnancy was associated with a 2- to 3-fold increased risk of  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,paxil,375,16469,16516,"In one study the odds ratio was 2.5 (95% confidence interval, 1.0 to 6.0, 7 exposed infants) and in the other study the odds ratio was 3.3 (95% confidence interval, 1.3 to 8.8, 6 exposed infants).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,paxil,376,16516,16548,"\n', '    Other studies have found varying results as to whether there was an increased risk of overall,  nonoseaeaeonlyasinstruction  or specific  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,paxil,377,16548,16612,A meta-analysis of epidemiological data over a 16-year period (1992 to 2008) on first trimester paroxetine use in  notaecandidatepreexistingconditionorriskfactor and  nonoseaeaeonlyasinstruction included the above-noted studies in addition to others (n = 17 studies that included overall  nonoseaeaeonlyasinstruction and n = 14 studies that included  nonoseaeaeonlyasinstruction  n = 20 distinct studies).,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
378,paxil,378,16612,16669,"While subject to limitations, this meta-analysis suggested an increased occurrence of  oselabeledaefromdruguse (prevalence odds ratio [POR] 1.5; 95% confidence interval 1.2 to 1.9) and overall  oselabeledaefromdruguse (POR 1.2; 95% confidence interval 1.1 to 1.4) with paroxetine use during the first trimester.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,paxil,379,16669,16789,"It was not possible in this meta-analysis to determine the extent to which the observed prevalence of  nonoseaeaeonlyasinstruction might have contributed to that of overall  nonoseaeaeonlyasinstruction  nor was it possible to determine whether any specific types of  nonoseaeaeonlyasinstruction might have contributed to the observed prevalence of all  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' If a patient becomes  nonoseaeaeonlyasinstruction while taking paroxetine, she should be advised of the potential  oselabeledaefromdruguse  Unless the benefits of paroxetine to the mother justify continuing treatment, consideration should be given to either discontinuing paroxetine therapy or switching to another antidepressant (see  PRECAUTIONS  :  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,paxil,380,16789,16798,Discontinuation of Treatment With PAXIL   )  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
381,paxil,381,16798,16879,"For women who intend to become  nonoseaeaeonlyasinstruction or are in their first trimester of  notaecandidatepreexistingconditionorriskfactor  paroxetine should only be initiated after consideration of the other available treatment options.\n', '\n', '     Animal Findings:  \n', '\n', '  Reproduction studies were performed at doses up to 50 mg/kg/day in rats and 6 mg/kg/day in rabbits administered during organogenesis.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
382,paxil,382,16879,16911,These doses are approximately 8 (rat) and 2 (rabbit) times the maximum recommended human dose (MRHD) on an mg/m  2  basis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
383,paxil,383,16911,16954,"These studies have revealed no evidence of  nonoseaeaeanimal  However, in rats, there was an increase in pup deaths during the first 4 days of lactation when dosing occurred during the last trimester of gestation and continued throughout lactation.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
384,paxil,384,16954,16985,This effect occurred at a dose of 1 mg/kg/day or approximately one-sixth of the MRHD on an mg/m  2  basis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
385,paxil,385,16985,16998,The no-effect dose for rat pup mortality was not determined.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
386,paxil,386,16998,17065,"The cause of these  nonoseaegeneralterm is not known.\n', '\n', '     Nonteratogenic Effects:  \n', '\n', '   oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization,  oselabeledaefromdruguse support, and tube feeding.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
387,paxil,387,17065,17073,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,paxil,388,17073,17118,"Reported clinical findings have included respiratory  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,paxil,389,17118,17126,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,paxil,390,17126,17173,"Reported clinical findings have included respiratory distress,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,paxil,391,17173,17181,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
392,paxil,392,17181,17230,"Reported clinical findings have included respiratory distress, cyanosis,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
393,paxil,393,17230,17238,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,paxil,394,17238,17289,"Reported clinical findings have included respiratory distress, cyanosis, apnea,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,paxil,395,17289,17297,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
396,paxil,396,17297,17359,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube  oselabeledaefromdruguse  Such complications can arise immediately upon delivery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
397,paxil,397,17359,17416,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
398,paxil,398,17416,17424,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,paxil,399,17424,17483,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
400,paxil,400,17483,17491,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
401,paxil,401,17491,17552,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
402,paxil,402,17552,17560,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
403,paxil,403,17560,17625,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting,  oselabeledaefromdruguse lycemia, hypo oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
404,paxil,404,17625,17633,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
405,paxil,405,17633,17698,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
406,paxil,406,17698,17706,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
407,paxil,407,17706,17775,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia,  oselabeledaefromdruguse onia, hyper oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,paxil,408,17775,17783,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
409,paxil,409,17783,17852,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
410,paxil,410,17852,17860,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
411,paxil,411,17860,17931,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
412,paxil,412,17931,17939,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
413,paxil,413,17939,18012,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness,  oselabeledaefromdruguse  oselabeledaefromdruguse exposed to PAXIL and other SSRIs or serotonin and norepinephrine reuptake inhibitors (SNRIs), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,paxil,414,18012,18020,Such complications can arise immediately upon delivery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
415,paxil,415,18020,18060,"Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,paxil,416,18060,18082,"These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
417,paxil,417,18082,18135,"It should be noted that, in some cases, the clinical picture is consistent with  oselabeledaefromdruguse (see  WARNINGS  :   nonoseaeaeonlyasinstruction  ).\n', '\n', ' Infants exposed to SSRIs in pregnancy may have an increased risk for persistent  oselabeledaefromdruguse .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
418,paxil,418,18135,18183,"oselabeledaefromdruguse occurs in 1 - 2 per 1,000 live births in the general population and is associated with substantial neonatal morbidity and  nonoseaegeneralterm  Several recent epidemiologic studies suggest a positive statistical association between SSRI use (including PAXIL) in  notaecandidatepreexistingconditionorriskfactor and  oselabeledaeclasseffect  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
419,paxil,419,18183,18247,"Other studies do not show a significant statistical association.\n', '\n', ' Physicians should also note the results of a prospective longitudinal study of 201  notaecandidatepreexistingconditionorriskfactor women with a history of  notaecandidateindication  who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
420,paxil,420,18247,18320,"Women who discontinued antidepressant medication during  notaecandidatepreexistingconditionorriskfactor showed a significant increase in relapse of their major  notaecandidatepreexistingconditionorriskfactor compared to those women who remained on antidepressant medication throughout  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' When treating a  notaecandidatepreexistingconditionorriskfactor woman with PAXIL, the physician should carefully consider both the potential risks of taking an SSRI, along with the established benefits of treating  notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,simponi,0,0,43,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse reactions (incidence > 5%) are upper respiratory tract infection, nasopharyngitis, injection site reactions (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,simponi,1,43,87,"\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,simponi,2,87,116,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,simponi,3,116,236,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' The safety data described below are based on 5 pooled, randomized, double-blind, controlled Phase 3 trials in patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication (Trials RA-1, RA-2, RA-3,  notaecandidateindication  and  notaecandidateindication   [see  Clinical Studies (14.1  ,  14.2  , and  14.3)  ]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,simponi,4,236,268,These 5 trials included 639 control-treated patients and 1659 SIMPONI-treated patients including 1089 with  notaecandidateindication  292 with  notaecandidateindication  and 278 with  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
5,simponi,5,268,320,"The safety data in 1233 SIMPONI-treated patients with  notaecandidateindication from 3 pooled, randomized, double-blind, controlled Phase 2/3 trials are also described below (Trials UC-1, UC-2, and UC-3)  [see  Clinical Studies (14.4)  ].  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
6,simponi,6,320,365,The proportion of patients who discontinued treatment due to adverse reactions in the controlled Phase 3 trials through Week 16 in  notaecandidateindication   notaecandidateindication and  notaecandidateindication was 2% for SIMPONI-treated patients and 3% for placebo-treated patients.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,simponi,7,365,415,"The most common adverse reactions leading to discontinuation of SIMPONI in the controlled Phase 3 trials in  notaecandidateindication   notaecandidateindication and  notaecandidateindication through Week 16 were  oselabeledaefromdruguse (0.2%),  oselabeledaefromdruguse (0.2%), and  oselabeledaefromdruguse (0.2%).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,simponi,8,415,532,"The most common adverse drug reactions leading to discontinuation through Week 60 of the  notaecandidateindication trials in patients who received SIMPONI induction and 100 mg during maintenance compared with patients who received SIMPONI induction and placebo during maintenance were  oselabeledaefromdruguse (0.3% vs 0.6%) and  oselabeledaefromdruguse (0.3% vs 0%), respectively.\n', '\n', ' The most serious adverse reactions were:\n', '\n', ' *  Serious  oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
9,simponi,9,532,537,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,simponi,10,537,606,"oselabeledaefromdruguse and  oselabeledaefromdruguse were the most common adverse reactions reported in the combined Phase 3  notaecandidateindication   notaecandidateindication and  notaecandidateindication trials through Week 16, occurring in 7% and 6% of SIMPONI-treated patients as compared with 6% and 5% of control-treated patients, respectively.\n', ' \n', '\n', '     Infections  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
11,simponi,11,606,632,"\n', '\n', ' In controlled Phase 3 trials through Week 16 in  notaecandidateindication   notaecandidateindication  and  notaecandidateindication   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,simponi,12,632,653,oselabeledaefromdruguse were observed in 28% of SIMPONI-treated patients compared to 25% of control-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,simponi,13,653,678,For serious  oselabeledaefromdruguse  see the Warnings and Precautions section  [see  Warnings and Precautions (5.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,simponi,14,678,719,"In the controlled Phase 2/3 trial of SIMPONI induction through Week 6 in  notaecandidateindication  the rates of  oselabeledaefromdruguse were similar in SIMPONI 200/100 mg-treated patients and placebo-treated patients, or approximately 12%.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,simponi,15,719,813,"Through Week 60, the incidence per patient year of  oselabeledaefromdruguse was similar in patients who received SIMPONI induction and 100 mg during maintenance compared with patients who received SIMPONI induction and placebo during the maintenance portion of the  notaecandidateindication trial.\n', '\n', '      oselabeledaefromdruguse  \n', '\n', ' In the controlled Phase 2/3 trial of SIMPONI induction through Week 6, no cases of  nonoseaenegation were observed in SIMPONI 200/100 mg-treated patients or placebo-treated patients.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
16,simponi,16,813,832,"Through Week 60, there were no cases of  nonoseaenegation in the SIMPONI 100-mg group during maintenance.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
17,simponi,17,832,889,"One case of  oselabeledaefromdruguse was observed in the placebo maintenance group in a patient who received SIMPONI 400/200 mg during induction.\n', '\n', '      oselabeledaefromdruguse  \n', '\n', ' There have been reports of severe  oselabeledaeclasseffect including  oselabeledaeclasseffect in patients receiving TNF blockers.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,simponi,18,889,916,"In controlled Phase 3 trials of SIMPONI in patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication through Week 16,  oselabeledaefromdruguse >= 5",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
19,simponi,19,916,961,* ULN occurred in 0.2% of control-treated patients and 0.7% of SIMPONI-treated patients and  oselabeledaefromdruguse >= 3 * ULN occurred in 2% of control-treated patients and 2% of SIMPONI-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,simponi,20,961,1066,"Since many of the patients in the Phase 3 trials for  notaecandidateindication   notaecandidateindication  and  notaecandidateindication were also taking medications that cause  nonoseaeaefromdruginteraction (e.g., NSAIDs, MTX), the relationship between SIMPONI and  nonoseaeaeonlyasinstruction is not clear.\n', '\n', ' In Phase 2/3  notaecandidateindication trials, the incidence of  nonoseaeaeratelteqplacebo >= 5 * ULN was similar in SIMPONI-treated patients and placebo-treated patients, or approximately 1%, with an average duration of follow-up of 46 weeks and 18 weeks, respectively.  ",1,0,0,1,0,1,1,0,0,0,0,0,0,0,0
21,simponi,21,1066,1210,"oselabeledaefromdruguse >= 3 * ULN occurred in 2.0% of SIMPONI-treated patients compared with 1.5% of placebo-treated patients with an average duration of follow-up of 46 weeks and 18 weeks, respectively.\n', '\n', '     Autoimmune Disorders and Autoantibodies  \n', '\n', ' In the controlled Phase 3 trials in patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication through Week 14, there was no association of SIMPONI treatment and the development of newly  nonoseaenegation  In Phase 3 trials in  notaecandidateindication   notaecandidateindication  and  notaecandidateindication through 1 year of follow-up, 4.0% of SIMPONI-treated patients and 2.6% of control patients were newly  oselabeledaefromdruguse (at titers of 1:160 or greater).",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
22,simponi,22,1210,1233,The frequency of  nonoseaeaeonlyasinstruction at 1 year of follow-up was uncommon in patients who were  notaecandidatepreexistingconditionorriskfactor at baseline.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
23,simponi,23,1233,1289,"Through Week 60 of the  notaecandidateindication trials, 3.5% of patients who received SIMPONI induction and 100 mg during maintenance were newly  oselabeledaefromdruguse (at titers of 1:160 or greater) compared with 3.5% of patients who received SIMPONI induction and placebo during the maintenance portion of the  notaecandidateindication trial.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,simponi,24,1289,1340,The frequency of  oselabeledaefromdruguse at 1 year of follow-up in patients who were  notaecandidatepreexistingconditionorriskfactor at baseline was 0.5% in patients receiving SIMPONI induction and 100 mg during maintenance compared with 0% in patients who received SIMPONI induction and placebo during maintenance  [see  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
25,simponi,25,1340,1347,Warnings and Precautions (5.5)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,simponi,26,1347,1356,"]  .\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,simponi,27,1356,1362,'     Injection Site Reactions  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,simponi,28,1362,1407,"\n', '\n', ' In controlled Phase 3 trials through Week 16 in  notaecandidateindication   notaecandidateindication and  notaecandidateindication  6% of SIMPONI-treated patients had  oselabeledaefromdruguse compared with 2% of control-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,simponi,29,1407,1423,The majority of the  oselabeledaefromdruguse were mild and the most frequent manifestation was  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,simponi,30,1423,1464,"\n', '\n', ' In the controlled Phase 2/3 trial through Week 6 in  notaecandidateindication  3.4% of SIMPONI-treated patients had  oselabeledaefromdruguse compared with 1.5% in control-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
31,simponi,31,1464,1482,The majority of the  oselabeledaefromdruguse were mild and moderate and the most frequent manifestation was  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,simponi,32,1482,1571,"\n', '\n', ' In controlled Phase 2 and 3 trials in  notaecandidateindication   notaecandidateindication   notaecandidateindication  and Phase 2/3  notaecandidateindication trials, no patients treated with SIMPONI developed  nonoseaenegation \n', '\n', '     Immunogenicity  \n', '\n', '  oselabeledaefromdruguse were detected in 57 (4%) of SIMPONI-treated patients across the Phase 3  notaecandidateindication   notaecandidateindication  and  notaecandidateindication trials through Week 24.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
33,simponi,33,1571,1582,Similar rates were observed in each of the 3 indications.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,simponi,34,1582,1639,"Patients who received SIMPONI with concomitant MTX had a lower proportion of  oselabeledaefromdruguse than patients who received SIMPONI without MTX (approximately 2% vs. 7%, respectively).\n', '\n', ' The presence of serum concentrations of golimumab can interfere with the detection of  nonoseaeaeonlyasinstruction leading to inconclusive results.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,simponi,35,1639,1678,"In  notaecandidateindication trials, 34 (3%), 341 (28%) and 823 (69%) of SIMPONI-treated subjects were  oselabeledaefromdruguse  nonoseaeaeonlyasinstruction and inconclusive  nonoseaeaeonlyasinstruction  respectively.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
36,simponi,36,1678,1824,"Treatment with concomitant immunomodulators (AZA, 6-MP and MTX) resulted in a lower proportion of patients with  oselabeledaefromdruguse than patients receiving SIMPONI without immunomodulators (2% vs. 4%, respectively).\n', '\n', ' Of the patients with a  oselabeledaefromdruguse in the Phase 2 and 3 trials, most were determined to have  oselabeledaefromdruguse as measured by a cell-based functional assay.\n', '\n', ' The small number of patients  oselabeledaefromdruguse limits the ability to draw definitive conclusions regarding the relationship between  nonoseaeaeonlyasinstruction and clinical efficacy or safety measures.\n', '\n', ' The data above reflect the percentage of patients whose test results were considered  nonoseaeaeonlyasinstruction in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,simponi,37,1824,1857,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,simponi,38,1857,1927,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction to other products or results from different assays may be misleading.\n', '\n', '     Other Adverse Reactions  \n', '\n', ' Table 1 summarizes the adverse drug reactions that occurred at a rate of at least 1% in the SIMPONI +/-",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,simponi,39,1927,1940,DMARD group and with a higher incidence than in the placebo +/-,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,simponi,40,1940,1984,"DMARD group during the controlled period of the 5 pooled Phase 3 trials through Week 16 in patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication \n', '\n', ' Table 1: Adverse Drug Reactions Reported by >",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
41,simponi,41,1984,2043,"= 1% of SIMPONI-Treated Patients and With a Higher Incidence Than Placebo-Treated Patients in the Phase 3 Trials of RA, PsA, and AS through Week 16Patients may have taken concomitant MTX, sulfasalazine, hydroxychloroquine, low dose corticosteroids (<= 10 mg of prednisone/day or equivalent),",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,simponi,42,2043,2050,and/or NSAIDs during the trials).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,simponi,43,2050,2058,"\n', '                                                 SIMPONI +/-",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,simponi,44,2058,2063,DMARDs              Placebo +/-,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,simponi,45,2063,2065,DMARDs         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,simponi,46,2065,2079,"\n', '  \n', ' Patients treated                                       1659                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,simponi,47,2079,2081,639                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,simponi,48,2081,2101,"\n', ' Adverse Reaction                                                                                           \n', '    nonoseaegeneralterm                                                                              \n', '    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,simponi,49,2101,2118,( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse                16%                             13%                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,simponi,50,2118,2143,"\n', '    oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse influenza and  oselabeledaefromdruguse                 5%                              3%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,simponi,51,2143,2156,"\n', '    oselabeledaefromdruguse                                            2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,simponi,52,2156,2169,"\n', '    oselabeledaefromdruguse                         2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,simponi,53,2169,2182,"\n', '    oselabeledaefromdruguse                                             2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,simponi,54,2182,2189,"\n', '    nonoseaegeneralterm                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
55,simponi,55,2189,2231,"\n', '    oselabeledaefromdruguse  oselabeledaefromdruguse (injection site erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse (injection site erythema, urticaria,  oselabeledaefromdruguse  oselabeledaefromdruguse (injection site erythema, urticaria, induration,  oselabeledaefromdruguse  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,simponi,56,2231,2246,"injection site erythema, urticaria, induration, pain,  oselabeledaefromdruguse  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,simponi,57,2246,2263,"injection site erythema, urticaria, induration, pain, bruising,  oselabeledaefromdruguse  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,simponi,58,2263,2282,"injection site erythema, urticaria, induration, pain, bruising, pruritus,  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,simponi,59,2282,2306,"oselabeledaefromdruguse erythema, urticaria, induration, pain, bruising, pruritus, irritation,  oselabeledaefromdruguse                 6%                              2%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,simponi,60,2306,2313,"\n', '    nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,simponi,61,2313,2326,"\n', '    oselabeledaefromdruguse                    4%                              3%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,simponi,62,2326,2339,"\n', '    oselabeledaefromdruguse                  3%                              2%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,simponi,63,2339,2359,"\n', '    nonoseaegeneralterm                                                                                       \n', '    oselabeledaefromdruguse                                          3%                              2%                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,simponi,64,2359,2366,"\n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,simponi,65,2366,2379,"\n', '    oselabeledaefromdruguse                                             2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,simponi,66,2379,2392,"\n', '    oselabeledaefromdruguse                                           2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,simponi,67,2392,2426,"\n', '    nonoseaegeneralterm                                                                               \n', '    oselabeledaefromdruguse                                          1%                             <1%                 \n', '             Less Common Clinical Trial Adverse Drug Reactions  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,simponi,68,2426,2494,"\n', ' \n', '\n', ' Adverse drug reactions that occurred <1% in SIMPONI-treated patients during the SIMPONI clinical trials that do not appear in the Warnings and Precautions section included the following events listed by system organ class:\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,simponi,69,2494,2502,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,simponi,70,2502,2547,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse  oselabeledaefromdruguse (new onset or worsening, palmar/ oselabeledaefromdruguse  oselabeledaefromdruguse (new onset or worsening,  oselabeledaefromdruguse  oselabeledaefromdruguse (new onset or worsening, palmar/plantar and  oselabeledaefromdruguse ,  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,simponi,71,2547,2559,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
72,simponi,72,2559,2669,"\n', '\n', '     Other Clinical Trial Adverse Drug Reactions in Ulcerative Colitis Clinical Trials  \n', '\n', ' In the Phase 2/3 trials in  notaecandidateindication evaluating 1233 SIMPONI-treated patients, no new adverse drug reactions were identified and the frequency of adverse drug reactions was similar to the safety profile observed in patients with  notaecandidateindication   notaecandidateindication and  notaecandidateindication \n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of golimumab.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
73,simponi,73,2669,2721,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to SIMPONI exposure.\n', '\n', '    nonoseaegeneralterm   Serious  oselabeledaefromdruguse (including  oselabeledaefromdruguse   [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,simponi,74,2721,2733,"Warnings and Precautions (5.11)  ]  ,  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,simponi,75,2733,2738,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,simponi,76,2738,2747,nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse  [see  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,simponi,77,2747,2756,Warnings and Precautions (5.2)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,simponi,78,2756,2782,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
79,simponi,79,2782,2783,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,simponi,80,2783,2794,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,simponi,81,2794,2798,WARNING:  SERIOUS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,simponi,82,2798,2802,INFECTIONS AND MALIGNANCY\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,simponi,83,2802,2813,", '\n', '    WARNING:  SERIOUS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,simponi,84,2813,2817,INFECTIONS AND MALIGNANCY  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,simponi,85,2817,2829,"\n', '\n', '    EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,simponi,86,2829,2832,WARNING:  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,simponi,87,2832,2840,"SERIOUS INFECTIONS AND MALIGNANCY\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,simponi,88,2840,2854,"', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,simponi,89,2854,2921,"\n', '\n', ' *  Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI (5.1) \n', ' *  Discontinue SIMPONI if a patient develops a serious infection or sepsis (5.1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,simponi,90,2921,2933,"\n', ' *  Perform test for latent TB;",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,simponi,91,2933,2973,"if positive, start treatment for TB prior to starting SIMPONI (5.1) \n', ' *  Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,simponi,92,2973,3009,"\n', ' *  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI is a member (5.2)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,simponi,93,3009,3015,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,simponi,94,3015,3030,"', ' \n', '\n', '    SERIOUS INFECTIONS  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,simponi,95,3030,3079,"\n', '\n', '   Patients treated with SIMPONI  (r)   are at increased risk for developing serious  oselabeledaefromdruguse that may lead to hospitalization or  nonoseaegeneralterm   [see   Warnings and Precautions (5.1)  ]  .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,simponi,96,3079,3098,Most patients who developed these  nonoseaeaefromdruginteraction were taking concomitant  nonoseaeaeonlyasinstruction such as methotrexate or corticosteroids.   ,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
97,simponi,97,3098,3185,"\n', '\n', '   Discontinue SIMPONI if a patient develops a serious  nonoseaeaeonlyasinstruction   \n', '\n', '   Reported  oselabeledaeclasseffect with TNF blockers, of which SIMPONI is a member, include:    \n', '\n', ' *   oselabeledaeclasseffect  including  oselabeledaeclasseffect  Patients with  oselabeledaeclasseffect have frequently presented  oselabeledaeclasseffect disseminated or  oselabeledaeclasseffect  oselabeledaeclasseffect have frequently presented with  oselabeledaeclasseffect or extrapulmonary disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,simponi,98,3185,3197,Test patients for  nonoseaeaeonlyasinstruction before SIMPONI use and during therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,simponi,99,3197,3207,Initiate treatment for  notaecandidatepreexistingconditionorriskfactor prior to SIMPONI use.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
100,simponi,100,3207,3260,"\n', ' *   oselabeledaeclasseffect including  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  Patients with  oselabeledaeclasseffect  oselabeledaefromdruguse or other invasive fungal infections may present with  oselabeledaefromdruguse  oselabeledaeclasseffect may present with disseminated, rather than localized, disease.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,simponi,101,3260,3275,nonoseaeaeonlyasinstruction and antibody  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction in some patients with active  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,simponi,102,3275,3418,"Consider empiric antifungal therapy in patients at risk for  nonoseaeaeonlyasinstruction who develop severe  nonoseaegeneralterm  \n', ' *   oselabeledaeclasseffect  viral, and other  oselabeledaeclasseffect  oselabeledaeclasseffect  and other  oselabeledaeclasseffect  oselabeledaeclasseffect  including  oselabeledaeclasseffect and  oselabeledaeclasseffect  \n', '      Consider the risks and benefits of treatment with SIMPONI prior to initiating therapy in patients with chronic or recurrent  nonoseaeaeonlyasinstruction   \n', ' \n', '\n', '   Monitor patients closely for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with SIMPONI, including the possible development of  nonoseaeaeonlyasinstruction in patients who  notaecandidatepreexistingconditionorriskfactor for latent  notaecandidatepreexistingconditionorriskfactor prior to initiating therapy   [see   Warnings and Precautions (5.1)  ]  .  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
103,simponi,103,3418,3448,"\n', '\n', '     MALIGNANCY  \n', '\n', '    oselabeledaeclasseffect and other  oselabeledaeclasseffect  some  nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,simponi,104,3448,3453,5 WARNINGS AND PRECAUTIONS\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,simponi,105,3453,3477,", '\n', '   EXCERPT:    *  Serious Infections: Do not start SIMPONI during an active infection.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,simponi,106,3477,3497,"If an infection develops, monitor carefully, and stop SIMPONI if infection becomes serious (  5.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,simponi,107,3497,3501,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,simponi,108,3501,3507,*  Invasive Fungal Infections:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,simponi,109,3507,3559,"For patients who develop a systemic illness on SIMPONI, consider empiric antifungal therapy for those who reside in or travel to regions where mycoses are endemic (  5.1  ) \n', ' *  Hepatitis B Reactivation: Monitor HBV carriers during and several months after therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,simponi,110,3559,3582,"If reactivation occurs, stop SIMPONI and begin antiviral therapy (  5.1  ) \n', ' *  Malignancies:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,simponi,111,3582,3594,Incidence of lymphoma was greater than in the general U.S. population.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,simponi,112,3594,3630,"Cases of other malignancies have been observed among patients receiving TNF blockers (  5.2  ) \n', ' *  Congestive Heart Failure: Worsening, or new onset, may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,simponi,113,3630,3643,Stop SIMPONI if new or worsening symptoms occur (  5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,simponi,114,3643,3647,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,simponi,115,3647,3663,*  Demyelinating Disorders: Exacerbation or new onset may occur (  5.4  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,simponi,116,3663,3667,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,simponi,117,3667,3684,*  Lupus-like Syndrome: Discontinue SIMPONI if symptoms develop (  5.5  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,simponi,118,3684,3688,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,simponi,119,3688,3706,*  Hypersensitivity Reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur (  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,simponi,120,3706,3881,"\n', '    \n', ' \n', '\n', '   5.1 Serious Infections\n', '\n', '  Patients treated with SIMPONI are at increased risk for developing serious  oselabeledaefromdruguse involving various organ systems and sites that may lead to hospitalization or  nonoseaegeneralterm \n', '\n', '  oselabeledaeclasseffect  mycobacterial, invasive fungal, viral, or parasitic  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial,  oselabeledaeclasseffect  invasive fungal, viral, or parasitic  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial, mycobacterial,  oselabeledaeclasseffect  viral, or parasitic  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial, mycobacterial, invasive fungal,  oselabeledaeclasseffect  or parasitic  oselabeledaeclasseffect  oselabeledaeclasseffect bacterial, mycobacterial, invasive fungal, viral, or  oselabeledaeclasseffect  oselabeledaefromdruguse due to bacterial, mycobacterial, invasive fungal, viral, or parasitic organisms including  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,simponi,121,3881,3889,oselabeledaeclasseffect have been reported with TNF blockers.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,simponi,122,3889,3900,Patients have frequently presented with disseminated rather than localized disease.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,simponi,123,3900,4164,"The concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious  nonoseaeaefromdruginteraction  therefore, the concomitant use of SIMPONI and these biologic products is not recommended [see  Warnings and Precautions (5.6  ,  5.7)  and  Drug Interactions (7.2)  ]  .\n', '\n', ' Treatment with SIMPONI should not be initiated in patients with an  notaecandidatepreexistingconditionorriskfactor  including clinically important  notaecandidatepreexistingconditionorriskfactor  Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant  nonoseaegeneralterm such as corticosteroids or methotrexate may be at greater risk of  nonoseaeaefromdruginteraction  Consider the risks and benefits of treatment prior to initiating SIMPONI in patients:\n', '\n', ' *  with chronic or recurrent  notaecandidatepreexistingconditionorriskfactor  \n', ' *  who have been  notaecandidatepreexistingconditionorriskfactor  \n', ' *  with a history of an  notaecandidatepreexistingconditionorriskfactor  \n', ' *  who have resided or traveled in areas of endemic  nonoseaeaeonlyasinstruction or endemic  nonoseaeaeonlyasinstruction  such as  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  or \n', ' *  with underlying conditions that may  notaecandidatepreexistingconditionorriskfactor  \n', '       Monitoring  \n', ' \n', '\n', ' Closely monitor patients for the development of signs and symptoms of  nonoseaeaeonlyasinstruction during and after treatment with SIMPONI.",1,1,1,0,0,1,0,0,0,0,0,0,0,0,0
124,simponi,124,4164,4284,"Discontinue SIMPONI if a patient develops a serious  nonoseaeaeonlyasinstruction  an  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  For a patient who develops a new  nonoseaeaeonlyasinstruction during treatment with SIMPONI, perform a prompt and complete diagnostic workup appropriate for an  nonoseaeaeonlyasinstruction patient, initiate appropriate antimicrobial therapy, and closely monitor them.\n', '\n', '    Serious Infection in Clinical Trials  \n', '\n', ' In controlled Phase 3 trials through Week 16 in patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication  serious  oselabeledaefromdruguse were observed in 1.4% of SIMPONI-treated patients and 1.3% of control-treated patients.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
125,simponi,125,4284,4351,"In the controlled Phase 3 trials through Week 16 in patients with  notaecandidateindication   notaecandidateindication  and  notaecandidateindication  the incidence of serious  oselabeledaefromdruguse per 100 patient-years of follow-up was 5.7 (95% CI: 3.8, 8.2) for the SIMPONI group and 4.2 (95% CI: 1.8, 8.2) for the placebo group.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,simponi,126,4351,4376,In the controlled Phase 2/3 trial through Week 6 of SIMPONI induction in  notaecandidateindication  the incidence of serious  oselabeledaefromdruguse in SIMPONI 200/100,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
127,simponi,127,4376,4395,mg-treated patients was similar to the incidence of serious  oselabeledaefromdruguse in placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,simponi,128,4395,4437,"Through Week 60, the incidence of serious  oselabeledaefromdruguse was similar in patients who received SIMPONI induction and 100 mg during maintenance compared with patients who received SIMPONI induction and placebo during the maintenance portion of the  notaecandidateindication trial.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
129,simponi,129,4437,4566,"Serious  oselabeledaefromdruguse observed in SIMPONI-treated patients included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '    Tuberculosis  \n', '\n', ' Cases of  oselabeledaeclasseffect or new  oselabeledaefromdruguse have been observed in patients receiving TNF blockers, including patients who have previously received treatment for  notaecandidatepreexistingconditionorriskfactor or active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  Evaluate patients for  nonoseaeaeonlyasinstruction risk factors and test for  nonoseaeaeonlyasinstruction prior to initiating SIMPONI and periodically during therapy.\n', '\n', ' Treatment of  nonoseaeaeonlyasinstruction prior to therapy with TNF blockers has been shown to reduce the risk of  nonoseaeaeonlyasinstruction during therapy.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
130,simponi,130,4566,4876,"Prior to initiating SIMPONI, assess if treatment for  nonoseaeaeonlyasinstruction is needed; an induration of 5 mm or greater is a  nonoseaeaeonlyasinstruction  even for patients previously vaccinated with  nonoseaeaeonlyasinstruction .\n', '\n', ' Consider  nonoseaeaeonlyasinstruction therapy prior to initiation of SIMPONI in patients with a past history of  notaecandidatepreexistingconditionorriskfactor or active  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor in whom an adequate course of treatment cannot be confirmed, and for patients with a  notaecandidatepreexistingconditionorriskfactor but having risk factors for  notaecandidatepreexistingconditionorriskfactor  Consultation with a physician with expertise in the treatment of  nonoseaeaeonlyasinstruction is recommended to aid in the decision whether initiating  nonoseaeaeonlyasinstruction therapy is appropriate for an individual patient.\n', '\n', ' Cases of  oselabeledaefromdruguse have occurred in patients treated with SIMPONI during and after treatment for  notaecandidatepreexistingconditionorriskfactor  Monitor patients for the development of signs and symptoms of  nonoseaeaeonlyasinstruction including patients who tested  nonoseaeaeonlyasinstruction prior to initiating therapy, patients who are on treatment for  notaecandidatepreexistingconditionorriskfactor  or patients who were previously treated for  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Consider  nonoseaeaeonlyasinstruction in the differential diagnosis in patients who develop a new  nonoseaeaeonlyasinstruction during SIMPONI treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of  nonoseaeaeonlyasinstruction  or who have had close contact with a person with  nonoseaeaeonlyasinstruction \n', '\n', ' In the controlled and uncontrolled portions of the Phase 2  notaecandidateindication and Phase 3  notaecandidateindication   notaecandidateindication  and  notaecandidateindication trials, the incidence of  oselabeledaefromdruguse was 0.23 and 0 per 100 patient-years in 2347 SIMPONI-treated patients and 674 placebo-treated patients, respectively.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
131,simponi,131,4876,4890,Cases of  oselabeledaefromdruguse included  oselabeledaefromdruguse and extrapulmonary  oselabeledaefromdruguse  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,simponi,132,4890,4947,The overwhelming majority of the  nonoseaeaeonlyasinstruction cases occurred in countries with a high incidence rate of  nonoseaeaeonlyasinstruction  In the controlled Phase 2/3 trial of SIMPONI induction through Week 6 in  notaecandidateindication  no cases of  nonoseaenegation were observed in SIMPONI 200/100 mg-treated patients or in placebo-treated patients.,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0
133,simponi,133,4947,4991,"Through Week 60, the incidence per 100 patient-years of  oselabeledaefromdruguse in patients who received SIMPONI induction and 100 mg during the maintenance portion of the  notaecandidateindication trial was 0.52 (95% CI: 0.11, 1.53).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
134,simponi,134,4991,5060,"One case of  oselabeledaefromdruguse was observed in the placebo maintenance group in a patient who received SIMPONI intravenous (IV) induction.\n', '\n', '     oselabeledaefromdruguse  \n', '\n', ' If patients develop a serious  nonoseaeaeonlyasinstruction and they reside or travel in regions where  nonoseaeaeonlyasinstruction are endemic, consider  nonoseaeaeonlyasinstruction in the differential diagnosis.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,simponi,135,5060,5092,"Consider appropriate empiric antifungal therapy, and take into account both the risk for severe  nonoseaeaeonlyasinstruction and the risks of antifungal therapy while a diagnostic workup is being performed.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,simponi,136,5092,5106,nonoseaeaeonlyasinstruction and antibody  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction in some patients with  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,simponi,137,5106,5173,"To aid in the management of such patients, consider consultation with a physician with expertise in the diagnosis and treatment of  nonoseaeaeonlyasinstruction \n', '\n', '    Hepatitis B Virus Reactivation  \n', '\n', ' The use of TNF blockers including SIMPONI has been associated with  oselabeledaefromdruguse  in patients who are  notaecandidatepreexistingconditionorriskfactor .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
138,simponi,138,5173,5191,"In some instances,  nonoseaeaeonlyasinstruction occurring in conjunction with TNF blocker therapy has been  nonoseaegeneralterm  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,simponi,139,5191,5228,"The majority of these reports have occurred in patients who received concomitant  nonoseaeaeonlyasinstruction \n', '\n', ' All patients should be tested for  nonoseaeaeonlyasinstruction before initiating TNF-blocker therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,simponi,140,5228,5256,For patients who test  nonoseaeaeonlyasinstruction  consultation with a physician with expertise in the treatment of  nonoseaeaeonlyasinstruction is recommended before initiating TNF-blocker therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,simponi,141,5256,5281,"The risks and benefits of treatment should be considered prior to prescribing TNF blockers, including SIMPONI, to patients who are  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
142,simponi,142,5281,5307,Adequate data are not available on whether antiviral therapy can reduce the risk of  nonoseaeaeonlyasinstruction in  notaecandidatepreexistingconditionorriskfactor who are treated with TNF blockers.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
143,simponi,143,5307,5371,"Patients who are  notaecandidatepreexistingconditionorriskfactor and require treatment with TNF blockers should be closely monitored for clinical and laboratory signs of active  nonoseaeaeonlyasinstruction throughout therapy and for several months following termination of therapy.\n', '\n', ' In patients who develop  nonoseaeaeonlyasinstruction  TNF blockers should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
144,simponi,144,5371,5387,The safety of resuming TNF blockers after  nonoseaeaeonlyasinstruction has been controlled is not known.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,simponi,145,5387,5426,"Therefore, prescribers should exercise caution when considering resumption of TNF blockers in this situation and monitor patients closely.\n', '\n', '    5.2 Malignancies\n', '\n', ""   oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,simponi,146,5426,5468,"some  nonoseaegeneralterm  have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which SIMPONI is a member.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
147,simponi,147,5468,5489,Approximately half the cases were  oselabeledaeclasseffect  including  oselabeledaeclasseffect and non-Hodgkin's  oselabeledaeclasseffect  oselabeledaeclasseffect  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,simponi,148,5489,5524,The other cases represented a variety of  oselabeledaeclasseffect  including rare  oselabeledaeclasseffect that are usually associated with  nonoseaeaeonlyasinstruction  and  oselabeledaefromdruguse that are not usually observed in children and adolescents.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,simponi,149,5524,5551,The  oselabeledaeclasseffect occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF-blocker therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,simponi,150,5551,5561,Most of the patients were receiving concomitant  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,simponi,151,5561,5683,"These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.\n"", '\n', ' The risks and benefits of TNF-blocker treatment, including SIMPONI, should be considered prior to initiating therapy in patients with a known  notaecandidatepreexistingconditionorriskfactor other than a successfully treated  notaecandidatepreexistingconditionorriskfactor  or when considering continuing a TNF-blocker in patients who develop a  nonoseaeaeonlyasinstruction \n', '\n', ' In the controlled portions of clinical trials of TNF blockers, including SIMPONI, more cases of  oselabeledaefromdruguse have been observed among patients receiving anti-TNF treatment compared with patients in the control groups.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
152,simponi,152,5683,5760,"During the controlled portions of the Phase 2 trials in  notaecandidateindication  and the Phase 3 trials in  notaecandidateindication   notaecandidateindication and  notaecandidateindication  the incidence of  oselabeledaefromdruguse per 100 patient-years of follow-up was 0.21 (95% CI: 0.03, 0.77) in the combined SIMPONI group compared with an incidence of 0 (95% CI: 0, 0.96) in the placebo group.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
153,simponi,153,5760,5818,"In the controlled and uncontrolled portions of these clinical trials in 2347 SIMPONI-treated patients with a median follow-up of 1.4 years, the incidence of  oselabeledaefromdruguse was 3.8-fold higher than expected in the general U.S. population according to the SEER database (adjusted for age, gender, and race).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,simponi,154,5818,5820,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,simponi,155,5820,5839,"Through Week 60 of the  notaecandidateindication trials, there were no cases of  nonoseaenegation with SIMPONI.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
156,simponi,156,5839,5893,Patients with  notaecandidateindication and other  notaecandidatepreexistingconditionorriskfactor  particularly patients with highly active disease and/or chronic exposure to  nonoseaeaeonlyasinstruction  may be at higher risk (up to several fold) than the general population for the development of  nonoseaeaeonlyasinstruction  even in the absence of TNF-blocking therapy.,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
157,simponi,157,5893,5922,"Cases of  oselabeledaeclasseffect and chronic  oselabeledaeclasseffect  oselabeledaeclasseffect have been reported with TNF-blocker use, including SIMPONI, in  notaecandidateindication and other indications.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
158,simponi,158,5922,5983,"Even in the absence of TNF-blocker therapy, patients with  notaecandidateindication may be at a higher risk (approximately 2-fold) than the general population for the development of  nonoseaeaeonlyasinstruction \n', '\n', ' Rare postmarketing cases of  oselabeledaeclasseffect  have been reported in patients treated with TNF-blocking agents.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
159,simponi,159,5983,6001,This rare type of  nonoseaeaeonlyasinstruction has a very aggressive disease course and is usually  nonoseaegeneralterm  ,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
160,simponi,160,6001,6021,Nearly all of the reported TNF blocker associated cases have occurred in patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidateindication  ,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
161,simponi,161,6021,6031,The majority were in adolescent and young adult males.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,simponi,162,6031,6059,Almost all these patients had received treatment with azathioprine (AZA) or 6-mercaptopurine (6-MP) concomitantly with a TNF blocker at or prior to diagnosis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,simponi,163,6059,6076,The potential risk with the combination of AZA or 6-MP and SIMPONI should be carefully considered.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,simponi,164,6076,6160,"A risk for the development for  nonoseaeaeonlyasinstruction in patients treated with TNF blockers cannot be excluded.\n', '\n', ' During the controlled portions of the Phase 2 trial in  notaecandidateindication  and the Phase 3 trials in  notaecandidateindication   notaecandidateindication and  notaecandidateindication  the incidence of  nonoseaeaeratelteqplacebo other than  nonoseaeaeonlyasinstruction per 100 patient-years of follow-up was not elevated in the combined SIMPONI group compared with the placebo group.",1,0,0,1,0,0,1,0,0,0,0,0,0,0,0
165,simponi,165,6160,6213,"In the controlled and uncontrolled portions of these trials, the incidence of  nonoseaeaeratelteqplacebo  other than  nonoseaeaeonlyasinstruction  in SIMPONI-treated patients was similar to that expected in the general U.S. population according to the SEER database (adjusted for age, gender, and race).  ",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
166,simponi,166,6213,6215,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,simponi,167,6215,6253,In the 6-week placebo-controlled portions of the SIMPONI Phase 2/3 clinical trials in  notaecandidateindication  the incidence of  nonoseaeaeratelteqplacebo (excluding  nonoseaenegation  was similar between the SIMPONI and the placebo group.,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0
168,simponi,168,6253,6291,"Through Week 60, the incidence of  nonoseaeaeonlyasinstruction (excluding  nonoseaenegation  was similar to the general U.S. population according to the SEER database (adjusted for age, gender, and race).  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
169,simponi,169,6291,6293,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,simponi,170,6293,6324,"Short follow-up periods, such as those of one year or less in the studies above, may not adequately reflect the true incidence of  nonoseaeaeonlyasinstruction .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,simponi,171,6324,6410,"\n', '\n', ' It is not known if SIMPONI treatment influences the risk for developing  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  All patients with  notaecandidateindication who are at increased risk for  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (for example, patients with long-standing  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor , or who had a prior history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor should be screened for  nonoseaeaeonlyasinstruction at regular intervals before therapy and throughout their disease course.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
172,simponi,172,6410,6421,This evaluation should include colonoscopy and biopsies per local recommendations.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,simponi,173,6421,6482,"In patients with newly diagnosed  nonoseaeaeonlyasinstruction treated with SIMPONI, the risks and benefits to the individual patient must be carefully reviewed and consideration should be given to whether therapy should be continued.\n', '\n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in patients treated with TNF-blocking agents, including SIMPONI.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,simponi,174,6482,6559,"Periodic skin examination is recommended for all patients, particularly those with risk factors for  nonoseaeaeonlyasinstruction   \n', '\n', ' In controlled trials of other TNF blockers in patients at higher risk for  nonoseaeaeonlyasinstruction (e.g., patients with  notaecandidatepreexistingconditionorriskfactor , patients with  notaecandidatepreexistingconditionorriskfactor treated with concomitant cyclophosphamide) a greater portion of  nonoseaeaeforanotherdruginclass occurred in the TNF-blocker group compared to the controlled group.",1,0,1,0,0,0,0,0,0,0,0,0,1,0,0
175,simponi,175,6559,6610,"In an exploratory 1-year clinical trial evaluating the use of 50 mg, 100 mg, and 200 mg of SIMPONI in 309 patients with severe persistent  notaecandidatepreexistingconditionorriskfactor  6 patients developed  oselabeledaefromdruguse other than  nonoseaenegation in the SIMPONI groups compared to none in the control group.",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
176,simponi,176,6610,6661,"Three of the 6 patients were in the 200-mg SIMPONI group.\n', '\n', '    5.3 Congestive Heart Failure\n', '\n', '  Cases of  oselabeledaefromdruguse  and new onset  oselabeledaeclasseffect have been reported with TNF blockers, including SIMPONI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,simponi,177,6661,6669,Some cases had a  nonoseaegeneralterm outcome.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,simponi,178,6669,6732,In several exploratory trials of other TNF blockers in the treatment of  nonoseaeaeonlyasinstruction  there were greater proportions of TNF-blocker-treated patients who had  nonoseaeaeforanotherdruginclass requiring hospitalization or increased  nonoseaegeneralterm  SIMPONI has not been studied in patients with a history of  notaecandidatepreexistingconditionorriskfactor and SIMPONI should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor  ,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0
179,simponi,179,6732,6768,"If a decision is made to administer SIMPONI to patients with  notaecandidatepreexistingconditionorriskfactor  these patients should be closely monitored during therapy, and SIMPONI should be discontinued if new or worsening symptoms of  nonoseaeaeonlyasinstruction",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
180,simponi,180,6768,6848,"appear.\n', '\n', '    5.4 Demyelinating Disorders\n', '\n', '  Use of TNF blockers, of which SIMPONI is a member, has been associated with rare cases of new onset or exacerbation of  oselabeledaeclasseffect  including  oselabeledaeclasseffect  and  oselabeledaeclasseffect  including  oselabeledaeclasseffect  Cases of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have rarely been reported in patients treated with SIMPONI",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,simponi,181,6848,6860,[see  Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,simponi,182,6860,6953,"Prescribers should exercise caution in considering the use of TNF blockers, including SIMPONI, in patients with  notaecandidatepreexistingconditionorriskfactor or peripheral  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  Discontinuation of SIMPONI should be considered if these disorders develop.\n', '\n', '    5.5  oselabeledaefromdruguse \n', '  Treatment with TNF blockers, including SIMPONI, may result in the formation of  oselabeledaefromdruguse  and, rarely, in the development of a  oselabeledaefromdruguse [see  Adverse Reactions (6.1)  ]  .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
183,simponi,183,6953,7138,"If a patient develops symptoms suggestive of a  nonoseaeaeonlyasinstruction following treatment with SIMPONI, treatment should be discontinued.\n', '\n', '    5.6 Use with Abatacept\n', '\n', '  In controlled trials, the concurrent administration of another TNF blocker and abatacept was associated with a greater proportion of serious  nonoseaeaefromdruginteraction than the use of a TNF blocker alone; and the combination therapy, compared to the use of a TNF blocker alone, has not demonstrated improved clinical benefit in the treatment of  notaecandidateindication  Therefore, the combination of TNF blockers, including SIMPONI, and abatacept is not recommended [see  Drug Interactions (7.2)  ]  .\n', '\n', '    5.7 Use with Anakinra\n', '\n', '  Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF blocker was associated with a greater portion of serious  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction and no additional benefits compared with the TNF-blocker alone.",1,0,0,1,0,1,0,0,0,0,0,0,0,0,0
184,simponi,184,7138,7258,"Therefore, the combination of anakinra with TNF blockers, including SIMPONI, is not recommended [see  Drug Interactions (7.2)  ]  .\n', '\n', '    5.8 Switching Between Biological Disease-Modifying Antirheumatic Drugs\n', '\n', '  Care should be taken when switching from one biological product to another biological product since overlapping biological activity may further increase the risk of  nonoseaeaeonlyasinstruction \n', '\n', '    5.9  oselabeledaefromdruguse \n', '  There have been postmarketing reports of  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect in patients receiving TNF blockers.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,simponi,185,7258,7283,"In clinical trials, cases of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have also occurred in SIMPONI-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,simponi,186,7283,7352,"Caution should be exercised when using TNF blockers, including SIMPONI, in patients who have or have had significant  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.10 Vaccinations/Therapeutic Infectious Agents\n', '\n', '   Live Vaccines  \n', '\n', ' Patients treated with SIMPONI may receive vaccinations, except for live vaccines.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
187,simponi,187,7352,7383,"In patients receiving anti-TNF therapy, limited data are available on the response to live vaccination, or on the secondary transmission of  nonoseaeaefromdruginteraction by live vaccines.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
188,simponi,188,7383,7410,"Use of live vaccines could result in clinical  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction \n', '\n', '    Therapeutic Infectious Agents  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
189,simponi,189,7410,7452,"\n', '\n', ' Other uses of  nonoseaeaeonlyasinstruction such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of  nonoseaeaeonlyasinstruction  could result in clinical  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction  ",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
190,simponi,190,7452,7524,"It is recommended that therapeutic  nonoseaeaeonlyasinstruction agents not be given concurrently with SIMPONI.\n', '\n', '    Non-live Vaccines  \n', '\n', ' In the Phase 3  notaecandidateindication trial, after  nonoseaeaeonlyasinstruction  a similar proportion of SIMPONI-treated and placebo-treated patients were able to  nonoseaeaeonlyasinstruction of at least a 2-fold  nonoseaeaeonlyasinstruction  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
191,simponi,191,7524,7557,"In both SIMPONI-treated and placebo-treated patients, the proportions of patients with response to  nonoseaeaeonlyasinstruction were lower among patients receiving MTX compared with patients not receiving MTX.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,simponi,192,7557,7610,"The data suggest that SIMPONI does not  nonoseaenegation to the  nonoseaeaeonlyasinstruction \n', '\n', '    5.11 Hypersensitivity Reactions\n', '\n', '  In postmarketing experience, serious systemic  oselabeledaefromdruguse (including  oselabeledaefromdruguse  have been reported following SIMPONI administration.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
193,simponi,193,7610,7622,Some of these reactions occurred after the first administration of SIMPONI.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,simponi,194,7622,7636,If an  nonoseaeaeonlyasinstruction or other serious allergic  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,risperdal,0,0,142,"['  6 ADVERSE REACTIONS\n', '\n', '  The following are discussed in more detail in other sections of the labeling:\n', '\n', ' *  Increased mortality in elderly patients with  notaecandidatepreexistingconditionorriskfactor [see    Boxed Warning    and    Warnings and Precautions (5.1)  ]  \n', ' *   nonoseaeaefromofflabel  including  nonoseaeaefromofflabel  in elderly patients with  notaecandidatepreexistingconditionorriskfactor [see    Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see    Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaeclasseffect [see    Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaeclasseffect ( oselabeledaefromdruguse and  oselabeledaefromdruguse   ",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
1,risperdal,1,142,151,oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,risperdal,2,151,170,"Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,risperdal,3,170,183,"Warnings and Precautions (5.6)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,risperdal,4,183,186,*   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,risperdal,5,186,189,[see    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,risperdal,6,189,192,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,risperdal,7,192,208,"(5.7)  ]  \n', ' *   nonoseaemanifestationorcomplication [see  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
8,risperdal,8,208,242,"Warnings and Precautions (5.8)  ]  \n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [see  Warnings and Precautions (5.9)  ]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,risperdal,9,242,246,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,risperdal,10,246,318,"*  Potential for  oselabeledaefromdruguse and motor  oselabeledaefromdruguse  oselabeledaefromdruguse [see  Warnings and Precautions (5.10)  ]  \n', ' *   oselabeledaefromdruguse [see    Warnings and Precautions (5.11)  ]  \n', ' *   oselabeledaeclasseffect [see    Warnings and Precautions (5.12)  ]  \n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,risperdal,11,318,327,Warnings and Precautions (5.13)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,risperdal,12,327,337,"\n', ' *   oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,risperdal,13,337,369,"Warnings and Precautions (5.14)  ]  \n', ' *  Patients with  notaecandidatepreexistingconditionorriskfactor [see    Warnings and Precautions (5.15)  ].  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
14,risperdal,14,369,392,"\n', '    The most common adverse reactions in clinical trials (>5% and twice placebo) were  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,risperdal,15,392,443,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,risperdal,16,443,486,"\n', ' \n', '\n', ' The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in >1% of adults and/or >2% of pediatrics) were  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,risperdal,17,486,494,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,risperdal,18,494,500,oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,risperdal,19,500,506,"[see      Adverse Reactions,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,risperdal,20,506,515,Discontinuations Due to Adverse Reactions (6.1)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,risperdal,21,515,565,"]  .\n', '\n', ' The data described in this section are derived from a clinical trial database consisting of 9803 adult and pediatric patients exposed to one or more doses of RISPERDAL  (r)  for the treatment of  notaecandidateindication   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
22,risperdal,22,565,590,"notaecandidateindication   notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor in pediatrics and  notaecandidatepreexistingconditionorriskfactor patients with  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  Of these 9803 patients,",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
23,risperdal,23,590,613,"2687 were patients who received RISPERDAL  (r)  while participating in double-blind, placebo-controlled trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,risperdal,24,613,685,"The conditions and duration of treatment with RISPERDAL  (r)  varied greatly and included (in overlapping categories) double-blind, fixed- and flexible-dose, placebo- or active-controlled studies and open-label phases of studies, inpatients and outpatients, and short-term (up to 12 weeks) and longer-term (up to 3 years) exposures.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,risperdal,25,685,801,"Safety was assessed by collecting adverse events and performing physical examinations, vital signs, body weights, laboratory analyses, and ECGs.\n', '\n', '   EXCERPT:   The most common adverse reactions in clinical trials (>=5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,risperdal,26,801,850,"(  6  )\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc.    at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,risperdal,27,850,879,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,risperdal,28,879,1021,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '     Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials - Schizophrenia  \n', '\n', '     Adult Patients with Schizophrenia  \n', '\n', ' Table 8 lists the adverse reactions reported in 2% or more of RISPERDAL  (r)  -treated adult patients with  notaecandidateindication in three 4- to 8-week, double-blind, placebo-controlled trials.\n', '\n', ' Table 8.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,risperdal,29,1021,1060,"Adverse Reactions in >=2% of RISPERDAL(r)-Treated Adult Patients (and greater than placebo) with Schizophrenia in Double-Blind, Placebo-Controlled Trials \n', '                                           Percentage of Patients Reporting Reaction   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,risperdal,30,1060,1071,"\n', '                                             RISPERDAL  (r)                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,risperdal,31,1071,1103,"\n', ' System/Organ Class  Adverse Reaction      2-8 mg per day(N=366)  >8-16 mg per day(N=198)     Placebo(N=225)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,risperdal,32,1103,1113,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,risperdal,33,1113,1133,"nonoseaegeneralterm                                                                                          \n', '    oselabeledaefromdruguse                                      1                     3                     0             \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,risperdal,34,1133,1135,nonoseaegeneralterm                                                                                              ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,risperdal,35,1135,1142,"\n', '    oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,risperdal,36,1142,1173,"3                     1                     1             \n', '    nonoseaegeneralterm                                                                                 \n', '    oselabeledaefromdruguse                                           9                     4                     4             \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,risperdal,37,1173,1210,"oselabeledaefromdruguse                                     8                     9                     6             \n', '    oselabeledaefromdruguse                                        8                     6                     5             \n', '    oselabeledaefromdruguse                                        4                     0                     1             \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,risperdal,38,1210,1247,"'    oselabeledaefromdruguse                             3                     1                     1             \n', '    oselabeledaefromdruguse                          2                     1                     <1            \n', '    oselabeledaefromdruguse                                         2                     1                     1             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,risperdal,39,1247,1252,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,risperdal,40,1252,1287,"nonoseaegeneralterm                                                                                          \n', '    oselabeledaefromdruguse                                          3                     1                     0             \n', '    oselabeledaefromdruguse                                       2                     2                     1             \n', '    oselabeledaefromdruguse                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,risperdal,41,1287,1301,"2                     1                     <1            \n', '    nonoseaegeneralterm                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,risperdal,42,1301,1360,"\n', '    oselabeledaefromdruguse                                  3                     4                     3             \n', '    oselabeledaefromdruguse                2                     3                     1             \n', '    oselabeledaefromdruguse                                        1                     2                     1             \n', '    oselabeledaefromdruguse                          1                     3                     0             \n', '    nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,risperdal,43,1360,1381,"\n', '    oselabeledaefromdruguse           1                     2                     <1            \n', '    oselabeledaefromdruguse                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,risperdal,44,1381,1395,"<1                    2                     0             \n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,risperdal,45,1395,1429,"\n', '    oselabeledaefromdruguse                                        4                     1                     1             \n', '    oselabeledaefromdruguse                                       2                     3                     <1            \n', '    oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,risperdal,46,1429,1435,2                     1                     1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,risperdal,47,1435,1440,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,risperdal,48,1440,1442,nonoseaegeneralterm                                                                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,risperdal,49,1442,1511,"\n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse ]            14                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,risperdal,50,1511,1513,17                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,risperdal,51,1513,1515,8             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,risperdal,52,1515,1526,"\n', '    oselabeledaefromdruguse                                        10                    10                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,risperdal,53,1526,1528,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,risperdal,54,1528,1554,"\n', '    oselabeledaefromdruguse                                         10                    5                     2             \n', '    oselabeledaefromdruguse                                        7                     4                     2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,risperdal,55,1554,1561,"\n', '    oselabeledaefromdruguse                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,risperdal,56,1561,1574,"3                     4                     2             \n', '    oselabeledaefromdruguse                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,risperdal,57,1574,1593,"2                     3                     1             \n', '    oselabeledaefromdruguse                               2                     0                     0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,risperdal,58,1593,1600,"\n', '    nonoseaegeneralterm                                                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,risperdal,59,1600,1622,"\n', '    oselabeledaefromdruguse                                         32                    25                    27            \n', '    oselabeledaefromdruguse                                          16                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,risperdal,60,1622,1624,11                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,risperdal,61,1624,1626,11            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,risperdal,62,1626,1633,"\n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,risperdal,63,1633,1680,"\n', '    oselabeledaefromdruguse                                 4                     6                     2             \n', '    oselabeledaefromdruguse                                          1                     2                     0             \n', '    oselabeledaefromdruguse                                        <1                    2                     0             \n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,risperdal,64,1680,1706,"\n', '    oselabeledaefromdruguse                                             1                     4                     1             \n', '    oselabeledaefromdruguse                                         1                     3                     0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,risperdal,65,1706,1713,"\n', '    nonoseaegeneralterm                                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,risperdal,66,1713,1736,"\n', '    oselabeledaefromdruguse                          2                     1                     0             \n', '              Pediatric Patients with Schizophrenia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,risperdal,67,1736,1794,"\n', ' \n', '\n', ' Table 9 lists the adverse reactions reported in 5% or more of RISPERDAL  (r)  -treated pediatric patients with  notaecandidateindication in a 6-week double-blind, placebo-controlled trial.\n', '\n', ' Table 9.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
68,risperdal,68,1794,1819,Adverse Reactions in >=5% of RISPERDAL(r)-Treated Pediatric Patients (and greater than placebo) with Schizophrenia in a Double-Blind Trial,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,risperdal,69,1819,1837,"\n', '                                           Percentage of Patients Reporting Reaction   \n', '                                             RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,risperdal,70,1837,1841,(r)                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,risperdal,71,1841,1853,"\n', ' System/Organ Class  Adverse Reaction      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,risperdal,72,1853,1864,1-3 mg per day(N=55)  4-6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,risperdal,73,1864,1869,mg per day(N=51)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,risperdal,74,1869,1872,Placebo(N=54)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,risperdal,75,1872,1882,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,risperdal,76,1882,1884,nonoseaegeneralterm                                                                                 ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,risperdal,77,1884,1897,"\n', '    oselabeledaefromdruguse                          0                     10                    2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,risperdal,78,1897,1911,"\n', '    nonoseaegeneralterm                                                                                   \n', '    oselabeledaefromdruguse                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
79,risperdal,79,1911,1915,24                    12                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,risperdal,80,1915,1917,4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,risperdal,81,1917,1959,"\n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse ]            16                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,risperdal,82,1959,1963,28                    11            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,risperdal,83,1963,1974,"\n', '    oselabeledaefromdruguse                                           11                    10                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,risperdal,84,1974,1976,6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,risperdal,85,1976,1989,"\n', '    oselabeledaefromdruguse                                        9                     10                    4             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,risperdal,86,1989,1994,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,risperdal,87,1994,2009,"oselabeledaefromdruguse                                        7                     14                    2             \n', '    oselabeledaefromdruguse                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,risperdal,88,2009,2022,"2                     6                     0             \n', '    nonoseaegeneralterm                                                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,risperdal,89,2022,2134,"\n', '    oselabeledaefromdruguse                                          7                     6                     0             \n', '              Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials -  notaecandidateindication  \n', ' \n', '\n', '     Adult Patients with Bipolar Mania  \n', '\n', ' Table 10 lists the adverse reactions reported in 2% or more of RISPERDAL  (r)  -treated adult patients with  notaecandidateindication in four 3-week, double-blind, placebo-controlled monotherapy trials.\n', '\n', ' Table 10.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
90,risperdal,90,2134,2164,"Adverse Reactions in >=2% of RISPERDAL(r)-Treated Adult Patients (and greater than placebo) with Bipolar Mania in Double-Blind, Placebo-Controlled Monotherapy Trials",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,risperdal,91,2164,2175,"\n', '                                                     Percentage of Patients Reporting Reaction   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,risperdal,92,2175,2204,"\n', ' System/Organ Class  Adverse Reaction                RISPERDAL  (r)  1-6 mg per day(N=448)       Placebo(N=424)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,risperdal,93,2204,2225,"\n', '  \n', '    nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse                                                2                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
94,risperdal,94,2225,2227,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,risperdal,95,2227,2245,"\n', '    nonoseaegeneralterm                                                                               \n', '    oselabeledaefromdruguse                                                        5                          2               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,risperdal,96,2245,2252,"\n', '    oselabeledaefromdruguse                                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,risperdal,97,2252,2256,3                          2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,risperdal,98,2256,2265,"\n', '    oselabeledaefromdruguse                                       3                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,risperdal,99,2265,2267,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,risperdal,100,2267,2276,"\n', '    oselabeledaefromdruguse                                            2                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,risperdal,101,2276,2295,"<1               \n', '    nonoseaegeneralterm                                                                                        \n', '    oselabeledaefromdruguse                                                       2                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,risperdal,102,2295,2297,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,risperdal,103,2297,2304,"\n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,risperdal,104,2304,2361,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ]              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,risperdal,105,2361,2365,25                          9               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,risperdal,106,2365,2385,"\n', '    oselabeledaefromdruguse                                                     11                          4               \n', '    oselabeledaefromdruguse                                                     9                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,risperdal,107,2385,2387,3               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,risperdal,108,2387,2394,"\n', '    oselabeledaefromdruguse                                                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,risperdal,109,2394,2398,6                          3               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,risperdal,110,2398,2407,"\n', '    oselabeledaefromdruguse                                                     6                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,risperdal,111,2407,2409,5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,risperdal,112,2409,2418,"\n', '    oselabeledaefromdruguse                                                      5                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,risperdal,113,2418,2420,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,risperdal,114,2420,2429,"\n', '    oselabeledaefromdruguse                                                      2                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,risperdal,115,2429,2431,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,risperdal,116,2431,2489,"\n', '         Table 11 lists the adverse reactions reported in 2% or more of RISPERDAL  (r)  -treated adult patients with  notaecandidateindication in two 3-week, double-blind, placebo-controlled adjuvant therapy trials.\n', ' \n', '\n', ' Table 11.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
117,risperdal,117,2489,2520,"Adverse Reactions in >=2% of RISPERDAL(r)-Treated Adult Patients (and greater than placebo) with Bipolar Mania in Double-Blind, Placebo-Controlled Adjunctive Therapy Trials",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,risperdal,118,2520,2572,"\n', '                                           Percentage of Patients Reporting Reaction   \n', ' System/Organ Class                         RISPERDAL  (r)  + Mood Stabilizer   Placebo + Mood Stabilizer   \n', '   Adverse Reaction                                      (N=127)                         (N=126)            \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,risperdal,119,2572,2594,"', '  \n', '    nonoseaegeneralterm                                                                                        \n', '    oselabeledaefromdruguse                                             2                               0               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,risperdal,120,2594,2659,"\n', '    nonoseaegeneralterm                                                                               \n', '    oselabeledaefromdruguse                                                9                               8               \n', '    oselabeledaefromdruguse                                                   6                               4               \n', '    oselabeledaefromdruguse                                                 6                               4               \n', '    oselabeledaefromdruguse                                  2                               0               \n', '    nonoseaegeneralterm                                                                                        \n', '    oselabeledaefromdruguse                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,risperdal,121,2659,2663,2                               1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,risperdal,122,2663,2670,"\n', '    nonoseaegeneralterm                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,risperdal,123,2670,2681,"\n', '    oselabeledaefromdruguse                                  2                               1               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,risperdal,124,2681,2688,"\n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
125,risperdal,125,2688,2717,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse ]                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,risperdal,126,2717,2719,14                               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,risperdal,127,2719,2721,4               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,risperdal,128,2721,2737,"\n', '  oselabeledaefromdruguse                                                   9                               4               \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,risperdal,129,2737,2743,oselabeledaefromdruguse                                                8                               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,risperdal,130,2743,2759,"\n', '    oselabeledaefromdruguse                                                7                               2               \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,risperdal,131,2759,2765,oselabeledaefromdruguse                                                   6                               2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,risperdal,132,2765,2792,"\n', '    oselabeledaefromdruguse                                                 2                               1               \n', '    nonoseaegeneralterm                                                                                    \n', '    oselabeledaefromdruguse                                                  3                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
133,risperdal,133,2792,2794,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,risperdal,134,2794,2801,"\n', '    nonoseaegeneralterm                                                                     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
135,risperdal,135,2801,2810,"\n', '    oselabeledaefromdruguse                                   5                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,risperdal,136,2810,2812,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,risperdal,137,2812,2823,"\n', '    oselabeledaefromdruguse                                                    2                               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,risperdal,138,2823,2892,"\n', '             Pediatric Patients with  notaecandidateindication  \n', ' \n', '\n', ' Table 12 lists the adverse reactions reported in 5% or more of RISPERDAL  (r)  -treated pediatric patients with  notaecandidateindication in a 3-week double-blind, placebo-controlled trial.\n', '\n', ' Table 12.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
139,risperdal,139,2892,2921,"Adverse Reactions in >=5% of RISPERDAL(r)-Treated Pediatric Patients (and greater than placebo) with Bipolar Mania in Double-Blind, Placebo-Controlled Trials",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,risperdal,140,2921,2939,"\n', '                                           Percentage of Patients Reporting Reaction   \n', '                                             RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,risperdal,141,2939,2943,(r)                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,risperdal,142,2943,2966,"\n', ' System/Organ Class  Adverse Reaction      0.5-2.5 mg per day(N=50)  3-6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,risperdal,143,2966,2971,mg per day(N=61)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,risperdal,144,2971,2984,"Placebo(N=58)       \n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,risperdal,145,2984,2986,nonoseaegeneralterm                                                                                              ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
146,risperdal,146,2986,3006,"\n', '    oselabeledaefromdruguse                                   4                     7                     0             \n', '    nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
147,risperdal,147,3006,3017,"\n', '    oselabeledaefromdruguse                             16                    13                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,risperdal,148,3017,3019,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,risperdal,149,3019,3030,"\n', '    oselabeledaefromdruguse                                           16                    13                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,risperdal,150,3030,3032,7             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,risperdal,151,3032,3043,"\n', '    oselabeledaefromdruguse                                         10                    10                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,risperdal,152,3043,3045,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,risperdal,153,3045,3084,"\n', '    oselabeledaefromdruguse                                         8                     7                     2             \n', '    oselabeledaefromdruguse                                        10                    3                     2             \n', '    oselabeledaefromdruguse                               6                     0                     2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,risperdal,154,3084,3102,"\n', '    nonoseaegeneralterm                                                                                          \n', '    oselabeledaefromdruguse                                          18                    30                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
155,risperdal,155,3102,3104,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,risperdal,156,3104,3155,"\n', '    nonoseaegeneralterm                                                                         \n', '    oselabeledaefromdruguse                               4                     7                     2             \n', '    nonoseaegeneralterm                                                                                   \n', '    oselabeledaefromdruguse                                         42                    56                    19            \n', '    oselabeledaefromdruguse                                        16                    13                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
157,risperdal,157,3155,3157,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,risperdal,158,3157,3224,"\n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse   oselabeledaefromdruguse includes  oselabeledaefromdruguse and  oselabeledaefromdruguse ]            6                     12                    3             \n', '    oselabeledaefromdruguse                                         6                     5                     0             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,risperdal,159,3224,3259,"oselabeledaefromdruguse                                        0                     8                     2             \n', '    nonoseaegeneralterm                                                                                      \n', '    oselabeledaefromdruguse                                          0                     8                     3             \n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
160,risperdal,160,3259,3266,"\n', '    oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,risperdal,161,3266,3268,10                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,risperdal,162,3268,3279,"3                     5             \n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
163,risperdal,163,3279,3316,"\n', '    oselabeledaefromdruguse                                             0                     7                     2             \n', '              Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials - Autistic Disorder  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,risperdal,164,3316,3389,"\n', ' \n', '\n', ' Table 13 lists the adverse reactions reported in 5% or more of RISPERDAL  (r)  -treated pediatric patients treated for  notaecandidateindication  notaecandidatepreexistingconditionorriskfactor in two 8-week, double-blind, placebo-controlled trials and one 6-week double-blind, placebo-controlled study.\n', '\n', ' Table 13.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
165,risperdal,165,3389,3422,"Adverse Reactions in >=5% of RISPERDAL(r)-Treated Pediatric Patients (and greater than placebo) Treated for Irritability Associated with Autistic Disorder in Double-Blind, Placebo-Controlled Trials",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,risperdal,166,3422,3437,"\n', '                                                          Percentage of Patients Reporting Reaction   \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,risperdal,167,3437,3455,System/Organ Class                                       RISPERDAL  (r)  0.5-4.0 mg/day  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,risperdal,168,3455,3457,Placebo                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,risperdal,169,3457,3469,"\n', '   Adverse Reaction                                       (N=107)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,risperdal,170,3469,3473,(N=115)                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,risperdal,171,3473,3492,"\n', '  \n', '    nonoseaegeneralterm                                                                               \n', '    oselabeledaefromdruguse                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
172,risperdal,172,3492,3505,"20                         17                     \n', '    oselabeledaefromdruguse                                           17                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,risperdal,173,3505,3507,6                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,risperdal,174,3507,3516,"\n', '    oselabeledaefromdruguse                                              10                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,risperdal,175,3516,3518,4                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,risperdal,176,3518,3540,"\n', '    oselabeledaefromdruguse                                                 8                          5                      \n', '    oselabeledaefromdruguse                                7                          1                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,risperdal,177,3540,3547,"\n', '    nonoseaegeneralterm                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
178,risperdal,178,3547,3556,"\n', '    oselabeledaefromdruguse                                                31                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,risperdal,179,3556,3558,9                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,risperdal,180,3558,3567,"\n', '    oselabeledaefromdruguse                                                16                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,risperdal,181,3567,3587,"13                     \n', '    oselabeledaefromdruguse                                                 7                          4                      \n', '    nonoseaegeneralterm                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
182,risperdal,182,3587,3596,"\n', '    oselabeledaefromdruguse                                        19                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,risperdal,183,3596,3598,9                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,risperdal,184,3598,3605,"\n', '    oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,risperdal,185,3605,3614,"9                          7                      \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,risperdal,186,3614,3627,"oselabeledaefromdruguse                      8                          3                      \n', '    nonoseaegeneralterm                                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
187,risperdal,187,3627,3645,"\n', '    oselabeledaefromdruguse                                       8                          2                      \n', '    nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
188,risperdal,188,3645,3670,"\n', '    oselabeledaefromdruguse                                     44                         15                     \n', '    nonoseaegeneralterm                                                                                 \n', '    oselabeledaefromdruguse                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
189,risperdal,189,3670,3672,63                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,risperdal,190,3672,3683,"15                     \n', '    oselabeledaefromdruguse                                               12                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,risperdal,191,3683,3685,4                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,risperdal,192,3685,3692,"\n', '    oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,risperdal,193,3692,3708,"12                         10                     \n', '    oselabeledaefromdruguse                                                 8                          1                      \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,risperdal,194,3708,3718,"', '    oselabeledaefromdruguse                                              8                          2                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,risperdal,195,3718,3764,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ]   8                          1                      \n', '    nonoseaegeneralterm                                                                              \n', '    oselabeledaefromdruguse                                               16                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
196,risperdal,196,3764,3767,10                     \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,risperdal,197,3767,3773,"', '    nonoseaegeneralterm                                                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
198,risperdal,198,3773,3804,"\n', '    oselabeledaefromdruguse                                                  17                         12                     \n', '    oselabeledaefromdruguse                                             12                         10                     \n', '    oselabeledaefromdruguse                                       10                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,risperdal,199,3804,3806,4                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,risperdal,200,3806,3833,"\n', '    nonoseaegeneralterm                                                                   \n', '    oselabeledaefromdruguse                                                   8                          5                      \n', '             Other Adverse Reactions Observed",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
201,risperdal,201,3833,3919,"During the Clinical Trial Evaluation of Risperidone  \n', ' \n', '\n', ' The following additional adverse reactions occurred across all placebo-controlled, active-controlled, and open-label studies of RISPERDAL  (r)  in adults and pediatric patients.\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
202,risperdal,202,3919,3929,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
203,risperdal,203,3929,3967,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
204,risperdal,204,3967,3987,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
205,risperdal,205,3987,4025,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
206,risperdal,206,4025,4075,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
207,risperdal,207,4075,4105,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
208,risperdal,208,4105,4117,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
209,risperdal,209,4117,4139,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
210,risperdal,210,4139,4185,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
211,risperdal,211,4185,4211,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
212,risperdal,212,4211,4225,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
213,risperdal,213,4225,4253,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
214,risperdal,214,4253,4281,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
215,risperdal,215,4281,4311,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
216,risperdal,216,4311,4321,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
217,risperdal,217,4321,4322,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,risperdal,218,4322,4334,"', '     Additional Adverse Reactions Reported with RISPERDAL CONSTA  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,risperdal,219,4334,4341,"(r)    \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,risperdal,220,4341,4414,"'\n', ' The following is a list of additional adverse reactions that have been reported during the premarketing evaluation of RISPERDAL CONSTA  (r)  , regardless of frequency of occurrence:\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
221,risperdal,221,4414,4436,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
222,risperdal,222,4436,4456,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
223,risperdal,223,4456,4479,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
224,risperdal,224,4479,4482,nonoseaegeneralterm   oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
225,risperdal,225,4482,4498,"\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
226,risperdal,226,4498,4574,"\n', '     Discontinuations Due to Adverse Reactions  \n', '\n', '      notaecandidateindication - Adults  \n', '\n', ' Approximately 7% (39/564) of RISPERDAL  (r)  -treated patients in double-blind, placebo-controlled trials discontinued treatment due to an adverse reaction, compared with 4% (10/225) who were receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
227,risperdal,227,4574,4603,"The adverse reactions associated with discontinuation in 2 or more RISPERDAL  (r)  -treated patients were:\n', '\n', ' Table 14.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,risperdal,228,4603,4618,Adverse Reactions Associated With Discontinuation in 2 or More RISPERDAL(r)-Treated Adult Patients in Schizophrenia Trials,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,risperdal,229,4618,4625,"\n', '                                RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,risperdal,230,4625,4636,"(r)                                     \n', ' Adverse Reaction               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,risperdal,231,4636,4677,"2-8 mg/day(N=366)         >8-16 mg/day(N=198)          Placebo(N=225)         \n', '  \n', '  oselabeledaefromdruguse                            1.4%                       1.0%                        0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,risperdal,232,4677,4709,"\n', '  oselabeledaefromdruguse                               1.4%                        0%                         0%               \n', '  oselabeledaefromdruguse                             0.8%                        0%                         0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,risperdal,233,4709,4725,"\n', '  oselabeledaefromdruguse                         0.8%                        0%                         0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,risperdal,234,4725,4741,"\n', '  oselabeledaefromdruguse                           0.8%                        0%                         0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,risperdal,235,4741,4757,"\n', '  oselabeledaefromdruguse                             0.5%                        0%                         0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,risperdal,236,4757,4773,"\n', '  oselabeledaefromdruguse                            0.5%                        0%                         0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,risperdal,237,4773,4789,"\n', '  oselabeledaefromdruguse                       0.5%                        0%                         0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,risperdal,238,4789,4805,"\n', '  oselabeledaefromdruguse              0.3%                       0.5%                        0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,risperdal,239,4805,4821,"\n', '  oselabeledaefromdruguse                            0.3%                       2.0%                        0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,risperdal,240,4821,4943,"\n', '          Discontinuation for  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  was 1% in placebo-treated patients, and 3.4% in active control-treated patients in a double-blind, placebo- and active-controlled trial.\n', ' \n', '\n', '     Schizophrenia - Pediatrics  \n', '\n', ' Approximately 7% (7/106), of RISPERDAL  (r)  -treated patients discontinued treatment due to an adverse reaction in a double-blind, placebo-controlled trial, compared with 4% (2/54) placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,risperdal,241,4943,5093,"The adverse reactions associated with discontinuation for at least one RISPERDAL  (r)  -treated patient were  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%),  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (1%).\n', '\n', '     Bipolar Mania - Adults  \n', '\n', ' In double-blind, placebo-controlled trials with RISPERDAL  (r)  as monotherapy, approximately 6% (25/448) of RISPERDAL  (r)  -treated patients discontinued treatment due to an adverse event, compared with approximately 5% (19/424) of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,risperdal,242,5093,5119,"The adverse reactions associated with discontinuation in RISPERDAL  (r)  -treated patients were:\n', '\n', ' Table 15.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,risperdal,243,5119,5136,Adverse Reactions Associated With Discontinuation in 2 or More RISPERDAL(r)-Treated Adult Patients in Bipolar Mania Clinical Trials,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,risperdal,244,5136,5178,"\n', ' Adverse Reaction                                    RISPERDAL  (r)  1-6 mg/day(N=448)       Placebo(N=424)         \n', '  \n', '  oselabeledaefromdruguse                                                  0.4%                        0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,risperdal,245,5178,5191,"\n', '  oselabeledaefromdruguse                                                      0.2%                        0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,risperdal,246,5191,5204,"\n', '  oselabeledaefromdruguse                                                     0.2%                        0%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,risperdal,247,5204,5217,"\n', '  oselabeledaefromdruguse                            0.2%                       0.2%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,risperdal,248,5217,5230,"\n', '  oselabeledaefromdruguse                          0.2%                       0.2%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,risperdal,249,5230,5240,"\n', '             Bipolar Mania - Pediatrics  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,risperdal,250,5240,5245,"\n', ' \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,risperdal,251,5245,5296,"', '\n', ' In a double-blind, placebo-controlled trial 12% (13/111) of RISPERDAL  (r)  -treated patients discontinued due to an adverse reaction, compared with 7% (4/58) of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,risperdal,252,5296,5570,"The adverse reactions associated with discontinuation in more than one RISPERDAL  (r)  -treated pediatric patient were  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (2%), and  oselabeledaefromdruguse (2%).\n', '\n', '     Autistic Disorder - Pediatrics  \n', '\n', ' In the two 8-week, placebo-controlled trials in pediatric patients treated for  notaecandidateindication  notaecandidatepreexistingconditionorriskfactor (n=156), one RISPERDAL  (r)  -treated patient discontinued due to an adverse reaction ( oselabeledaefromdruguse , and one placebo-treated patient discontinued due to an adverse event.\n', '\n', '     Dose Dependency of Adverse Reactions in Clinical Trials  \n', '\n', '     Extrapyramidal Symptoms  \n', '\n', ' Data from two fixed-dose trials in adults with  notaecandidateindication provided evidence of dose-relatedness for  oselabeledaefromdruguse associated with RISPERDAL  (r)  treatment.\n', '\n', ' Two methods were used to measure  nonoseaeaeonlyasinstruction  in an 8-week trial comparing 4 fixed doses of RISPERDAL  (r)  (2, 6, 10, and 16 mg/day), including (1) a  nonoseaeaeonlyasinstruction score (mean change from baseline) from the  nonoseaeaeonlyasinstruction Rating Scale, and (2) incidence of spontaneous complaints of  nonoseaeaeonlyasinstruction \n', '\n', ' Table 16.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
253,risperdal,253,5570,5574,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,risperdal,254,5574,5608,Dose Groups             Placebo       RISPERDAL  (r)  2 mg  RISPERDAL  (r)  6 mg  RISPERDAL  (r)  10 mg  RISPERDAL  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,risperdal,255,5608,5615,(r)  16 mg   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,risperdal,256,5615,5635,"\n', '  \n', '  oselabeledaefromdruguse              1.2                0.9                1.8               2.4               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,risperdal,257,5635,5637,2.6          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,risperdal,258,5637,5642,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,risperdal,259,5642,5660,oselabeledaefromdruguse Incidence             13%                17%                21%               21%               35%          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,risperdal,260,5660,5719,"\n', '            Similar methods were used to measure  nonoseaeaeonlyasinstruction (EPS) in an 8-week trial comparing 5 fixed doses of RISPERDAL  (r)  (1, 4, 8, 12, and 16 mg/day):\n', ' \n', '\n', ' Table 17.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,risperdal,261,5719,5755,"\n', ' Dose Groups        RISPERDAL  (r)  1 mg  RISPERDAL  (r)  4 mg  RISPERDAL  (r)  8 mg  RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,risperdal,262,5755,5764,(r)  12 mg  RISPERDAL  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,risperdal,263,5764,5771,(r)  16 mg   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,risperdal,264,5771,5787,"\n', '  \n', '  oselabeledaefromdruguse              0.6                1.7                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,risperdal,265,5787,5791,2.4               2.9               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,risperdal,266,5791,5799,"4.1          \n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,risperdal,267,5799,5861,"Incidence             7%                 12%                17%               18%               20%          \n', '                Dystonia  \n', ' \n', '\n', '     Class Effect:  Symptoms of  oselabeledaeclasseffect   oselabeledaeclasseffect  may occur in susceptible individuals during the first few days of treatment.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,risperdal,268,5861,5911,"nonoseaeaeonlyasinstruction include:  nonoseaemanifestationorcomplication  sometimes progressing to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication  While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
269,risperdal,269,5911,5995,"An elevated risk of  nonoseaeaeonlyasinstruction is observed in males and younger age groups.\n', '\n', '     Other Adverse Reactions  \n', '\n', ' Adverse event data elicited by a checklist for side effects from a large study comparing 5 fixed doses of RISPERDAL  (r)  (1, 4, 8, 12, and 16 mg/day) were explored for dose-relatedness of adverse events.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,risperdal,270,5995,6082,"A Cochran-Armitage Test for trend in these data revealed a positive trend (p<0.05) for the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '      oselabeledaefromdruguse  \n', '\n', '  oselabeledaefromdruguse was observed in short-term, controlled trials and longer-term uncontrolled studies in adult and pediatric patients  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,risperdal,271,6082,6085,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,risperdal,272,6085,6114,"Warnings and Precautions (5.5)  ,  Adverse Reactions (6)  , and  Use in Specific Populations (8.4)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,risperdal,273,6114,6240,"\n', '\n', '     Changes in ECG Parameters  \n', '\n', ' Between-group comparisons for pooled placebo-controlled trials in adults revealed no statistically significant differences between risperidone and placebo in mean  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo from basel nonoseaeaeratelteqplacebo  in ECG parameters, including QT, QTc, and PR intervals, and  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo from basel nonoseaeaeratelteqplacebo  in ECG parameters, including QT, QTc, and  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo from basel nonoseaeaeratelteqplacebo  in ECG parameters, including QT,  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo from basel nonoseaeaeratelteqplacebo  in ECG parameters, including  nonoseaeaeratelteqplacebo  QTc, and PR intervals, and heart rate.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
274,risperdal,274,6240,6278,"When all RISPERDAL  (r)  doses were pooled from randomized controlled trials in several indications, there was a mean  oselabeledaefromdruguse of 1 beat per minute compared to no change for placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,risperdal,275,6278,6318,"In short-term  notaecandidateindication trials, higher doses of risperidone (8-16 mg/day) were associated with a higher mean  oselabeledaefromdruguse compared to placebo (4-6 beats per minute).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
276,risperdal,276,6318,6401,"In pooled placebo-controlled  notaecandidateindication trials in adults, there were small  nonoseaeaeratelteqplacebo  similar among all treatment groups.\n', '\n', ' In the two placebo-controlled trials in children and adolescents with  notaecandidateindication (aged 5 - 16 years) mean changes in  oselabeledaefromdruguse were an  oselabeledaefromdruguse of 8.4 beats per minute in the RISPERDAL  (r)  groups and 6.5 beats per minute in the placebo group.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
277,risperdal,277,6401,6466,"There were no other notable  nonoseaenegation \n', '\n', ' In a placebo-controlled  notaecandidateindication trial in children and adolescents (aged 10 - 17 years), there were no significant  nonoseaenegation  other than the effect of RISPERDAL  (r)  to transiently  oselabeledaefromdruguse (< 6 beats per minute).",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
278,risperdal,278,6466,6537,"In two controlled  notaecandidateindication trials in adolescents (aged 13 - 17 years), there were no clinically meaningful  nonoseaenegation  nonoseaenegation ECG parameters including  nonoseaenegation between treatment groups or within treatment groups over time.\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during postapproval use of risperidone.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
279,risperdal,279,6537,6569,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,risperdal,280,6569,6643,"These adverse reactions include:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse in patients with  notaecandidatepreexistingconditionorriskfactor   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
281,risperdal,281,6643,6658,"WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,risperdal,282,6658,6676,"\n', '    WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,risperdal,283,6676,6775,"\n', '\n', '    Elderly patients with  notaecandidatepreexistingconditionorriskfactor treated with antipsychotic drugs are at an increased risk of  nonoseaegeneralterm  RISPERDAL  (r)   (risperidone) is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Cerebrovascular events, including stroke, in elderly patients with dementia-related psychosis: RISPERDAL  (r)  is not approved for use in patients with dementia-related psychosis.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
284,risperdal,284,6775,6780,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,risperdal,285,6780,6784,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,risperdal,286,6784,6805,*  Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of RISPERDAL  (r)  and close monitoring.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,risperdal,287,6805,6831,"(  5.3  ) \n', ' *  Tardive dyskinesia: Consider discontinuing RISPERDAL  (r)  if clinically indicated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,risperdal,288,6831,6849,"(  5.4  ) \n', ' *  *   Hyperglycemia and Diabetes Mellitus:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,risperdal,289,6849,6865,"Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,risperdal,290,6865,6878,Monitor glucose regularly in patients with diabetes or at risk for diabetes.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,risperdal,291,6878,6903,"(  5.5  ) \n', ' *   Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,risperdal,292,6903,6917,"(  5.5  ) \n', ' *   Weight Gain:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,risperdal,293,6917,6924,Significant weight gain has been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,risperdal,294,6924,6928,Monitor weight gain.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,risperdal,295,6928,6941,"(  5.5  ) \n', '   Metabolic Changes:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,risperdal,296,6941,6957,Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,risperdal,297,6957,6969,"These metabolic changes include hyperglycemia, dyslipidemia, and weight gain.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,risperdal,298,6969,6991,"(  5.5  ) \n', ' *  Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,risperdal,299,6991,7019,"(  5.6  ) \n', ' *  Orthostatic hypotension: For patients at risk, consider a lower starting dose and slower titration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,risperdal,300,7019,7058,"(  5.7  ) \n', ' *  Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts in patients with a history of clinically significant low white blood cell count (WBC).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,risperdal,301,7058,7082,Consider discontinuing RISPERDAL  (r)  if a clinically significant decline in WBC occurs in the absence of other causative factors.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,risperdal,302,7082,7106,"(  5.9  ) \n', ' *  Potential for cognitive and motor impairment: Use caution when operating machinery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,risperdal,303,7106,7137,"(  5.10  ) \n', ' *  Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,risperdal,304,7137,7142,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,risperdal,305,7142,7248,"\n', '    \n', ' \n', '\n', '   5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis\n', '\n', '  Elderly patients with  notaecandidatepreexistingconditionorriskfactor treated with antipsychotic drugs are at an increased risk of  nonoseaegeneralterm  Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of  nonoseaegeneralterm in drug-treated patients of between 1.6 to 1.7 times the risk of  nonoseaegeneralterm in placebo-treated patients.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
306,risperdal,306,7248,7286,"Over the course of a typical 10-week controlled trial, the rate of  nonoseaegeneralterm in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
307,risperdal,307,7286,7333,"Although the causes of  nonoseaegeneralterm were varied, most of the  nonoseaeaefromofflabel appeared to be either  nonoseaeaefromofflabel  nonoseaegeneralterm appeared to be either cardiovascular (e.g.,  nonoseaeaefromofflabel   nonoseaeaefromofflabel  or  nonoseaeaefromofflabel (e.g.,  nonoseaeaefromofflabel  in nature.",0,1,0,0,0,0,0,0,0,0,1,0,0,0,0
308,risperdal,308,7333,7446,"Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase  nonoseaegeneralterm  The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.\n', '\n', ' In two of four placebo-controlled trials in  notaecandidatepreexistingconditionorriskfactor patients with  notaecandidatepreexistingconditionorriskfactor  a higher incidence of mortality was observed in patients treated with furosemide plus RISPERDAL  (r)  when compared to patients treated with RISPERDAL  (r)  alone or with placebo plus furosemide.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
309,risperdal,309,7446,7573,"No pathological mechanism has been identified to explain this finding, and no consistent pattern for cause of  nonoseaegeneralterm was observed.\n', '\n', ' RISPERDAL  (r)  (risperidone) is not approved for the treatment of  notaecandidatepreexistingconditionorriskfactor [see  Boxed Warning  ]  .\n', '\n', '    5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis\n', '\n', '   nonoseaeaefromofflabel (e.g.,  nonoseaeaefromofflabel   nonoseaeaefromofflabel , including  nonoseaegeneralterm  were reported in patients (mean age 85 years; range 73-97) in trials of risperidone in elderly patients with  notaecandidatepreexistingconditionorriskfactor  ",0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
310,risperdal,310,7573,7600,"In placebo-controlled trials, there was a significantly higher incidence of  nonoseaeaefromofflabel in patients treated with risperidone compared to patients treated with placebo.",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
311,risperdal,311,7600,7602,RISPERDAL  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,risperdal,312,7602,7679,"(r)  is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor  [see     Boxed Warning     and     Warnings and Precautions (5.1)  ]  \n', '\n', '    5.3 Neuroleptic Malignant Syndrome\n', '\n', '  Antipsychotic drugs including RISPERDAL  (r)  can cause a potentially  nonoseaegeneralterm symptom complex referred to as  oselabeledaefromdruguse .",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
313,risperdal,313,7679,7712,Clinical manifestations of  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication pulse or  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication .,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
314,risperdal,314,7712,7746,"Additional signs may include  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication \n', '\n', ' The diagnostic evaluation of patients with this syndrome is complicated.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
315,risperdal,315,7746,7787,"In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  etc.) and untreated or inadequately treated  nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,risperdal,316,7787,7866,"Other important considerations in the differential diagnosis include  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction \n', '\n', ' The management of  nonoseaeaeonlyasinstruction should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,risperdal,317,7866,7912,"There is no general agreement about specific pharmacological treatment regimens for uncomplicated  nonoseaeaeonlyasinstruction \n', '\n', ' If a patient requires antipsychotic drug treatment after recovery from  nonoseaeaeonlyasinstruction  the potential reintroduction of drug therapy should be carefully considered.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,risperdal,318,7912,7962,"The patient should be carefully monitored, since recurrences of  nonoseaeaeonlyasinstruction have been reported.\n', '\n', '    5.4  oselabeledaeclasseffect \n', '  A syndrome of potentially irreversible, involuntary,  oselabeledaeclasseffect may develop in patients treated with antipsychotic drugs.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,risperdal,319,7962,7999,The risk of developing  nonoseaeaeonlyasinstruction and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,risperdal,320,7999,8054,"However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.\n', '\n', ' There is no known treatment for established cases of  nonoseaeaeonlyasinstruction  although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,risperdal,321,8054,8084,"Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,risperdal,322,8084,8184,"The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.\n', '\n', ' Given these considerations, prescribe RISPERDAL  (r)  in a manner that is most likely to minimize the occurrence of  nonoseaeaeonlyasinstruction  Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that: (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
323,risperdal,323,8184,8210,"In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,risperdal,324,8210,8250,"The need for continued treatment should be reassessed periodically.\n', '\n', ' If signs and symptoms of  nonoseaeaeonlyasinstruction appear in a patient treated with RISPERDAL  (r)  , consider drug discontinuation.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,risperdal,325,8250,8306,"However, some patients may require treatment with RISPERDAL  (r)  despite the presence of the syndrome.\n', '\n', '    5.5 Metabolic Changes\n', '\n', '  Atypical antipsychotic drugs have been associated with  oselabeledaeclasseffect that may increase cardiovascular/cerebrovascular risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,risperdal,326,8306,8404,"These  nonoseaeaeonlyasinstruction include  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  While all of the drugs in the class have been shown to produce some  oselabeledaeclasseffect  each drug has its own specific risk profile.\n', '\n', '    Hyperglycemia and Diabetes Mellitus  \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse  in some cases extreme and associated with  oselabeledaefromdruguse or  oselabeledaefromdruguse or  nonoseaegeneralterm  have been reported in patients treated with atypical antipsychotics including RISPERDAL  (r)  .",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
327,risperdal,327,8404,8445,Assessment of the relationship between atypical antipsychotic use and  nonoseaeaeonlyasinstruction is complicated by the possibility of an increased background risk of  notaecandidatepreexistingconditionorriskfactor in patients with  notaecandidateindication and the increasing incidence of  notaecandidatepreexistingconditionorriskfactor in the general population.,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
328,risperdal,328,8445,8463,"Given these confounders, the relationship between atypical antipsychotic use and  nonoseaeaeonlyasinstruction is not completely understood.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,risperdal,329,8463,8485,"However, epidemiological studies suggest an increased risk of treatment-emergent  oselabeledaeclasseffect in patients treated with the atypical antipsychotics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,risperdal,330,8485,8585,"Precise risk estimates for  nonoseaeaeonlyasinstruction in patients treated with atypical antipsychotics are not available.\n', '\n', ' Patients with an established diagnosis of  notaecandidatepreexistingconditionorriskfactor who are started on atypical antipsychotics, including RISPERDAL  (r)  , should be monitored regularly for  nonoseaeaeonlyasinstruction  Patients with risk factors for  nonoseaeaeonlyasinstruction (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  who are starting treatment with atypical antipsychotics, including RISPERDAL  (r)  , should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
331,risperdal,331,8585,8648,"Any patient treated with atypical antipsychotics, including RISPERDAL  (r)  , should be monitored for symptoms of  nonoseaeaeonlyasinstruction including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Patients who develop symptoms of  nonoseaeaeonlyasinstruction during treatment with atypical antipsychotics, including RISPERDAL  (r)  , should undergo fasting blood glucose testing.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
332,risperdal,332,8648,8742,"In some cases,  nonoseaeaeonlyasinstruction has resolved when the atypical antipsychotic, including RISPERDAL  (r)  , was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of RISPERDAL  (r)  .\n', '\n', ' Pooled data from three double-blind, placebo-controlled  notaecandidateindication studies and four double-blind, placebo-controlled  notaecandidateindication monotherapy studies are presented in Table 2.\n', '\n', ' Table 2.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
333,risperdal,333,8742,8761,"Change in Random Glucose from Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,risperdal,334,8761,8777,"Studies in Adult Subjects with Schizophrenia or Bipolar Mania \n', '                                                                RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,risperdal,335,8777,8781,(r)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,risperdal,336,8781,8820,"\n', '                                          Placebo                  1-8 mg/day                >8-16 mg/day     \n', '  \n', '                                        oselabeledaefromdruguse (mg/dL)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,risperdal,337,8820,8836,"\n', '                                          n=555                      n=748                      n=164         \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
338,risperdal,338,8836,8855,"oselabeledaefromdruguse                             -1.4                        0.8                        0.6         \n', '                                       Proportion of patients with shifts     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
339,risperdal,339,8855,8871,"\n', '  nonoseaeaeratelteqplacebo     0.6%(3/525)                0.4%(3/702)                 0%(0/158)      ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
340,risperdal,340,8871,8995,"\n', '          In longer-term, controlled and uncontrolled studies, RISPERDAL  (r)  was associated with a  oselabeledaefromdruguse of +2.8 mg/dL at Week 24 (n=151) and +4.1 mg/dL at Week 48 (n=50).\n', ' \n', '\n', ' Data from the placebo-controlled 3- to 6-week study in children and adolescents with  notaecandidateindication (13-17 years of age),  notaecandidateindication (10-17 years of age), or  notaecandidateindication (5 to 17 years of age) are presented in Table 3.\n', '\n', ' Table 3.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
341,risperdal,341,8995,9050,"Change in Fasting Glucose from Three Placebo-Controlled, 3- to 6-Week, Fixed-Dose Studies in Children and Adolescents with Schizophrenia (13-17 years of age), Bipolar Mania (10-17 years of age), or Autistic Disorder (5 to 17 years of age)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
342,risperdal,342,9050,9057,"\n', '                                                                                RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,risperdal,343,9057,9063,(r)              \n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,risperdal,344,9063,9075,", '                                                 Placebo                          0.5-6 mg/day              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,risperdal,345,9075,9087,"\n', '  \n', '                                      oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,risperdal,346,9087,9092,mg/dL)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
347,risperdal,347,9092,9093,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,risperdal,348,9093,9101,"', '                                                  n=76                               n=135                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,risperdal,349,9101,9112,"\n', '  oselabeledaefromdruguse                                     -1.3                                2.6                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,risperdal,350,9112,9136,"\n', '                                     Proportion of patients with shifts     \n', '  oselabeledaefromdruguse                0%(0/64)                          0.8%(1/120)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,risperdal,351,9136,9193,"\n', '         In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL  (r)  was associated with a  oselabeledaefromdruguse of +5.2 mg/dL at Week 24 (n=119).\n', ' \n', '\n', '     oselabeledaeclasseffect  \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
352,risperdal,352,9193,9227,"', '\n', '  oselabeledaeclasseffect have been observed in patients treated with atypical antipsychotics.\n', '\n', ' Pooled data from 7 placebo-controlled, 3-",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
353,risperdal,353,9227,9261,"to 8- week, fixed- or flexible-dose studies in adult subjects with  notaecandidateindication or  notaecandidateindication are presented in Table 4.\n', '\n', ' Table 4.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
354,risperdal,354,9261,9296,"Change in Random Lipids from Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects with Schizophrenia or Bipolar Mania \n', '                                                                RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
355,risperdal,355,9296,9300,(r)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,risperdal,356,9300,9342,"\n', '                                          Placebo                  1-8 mg/day                >8-16 mg/day     \n', '  \n', '                                       Mean change from baseline (mg/dL)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,risperdal,357,9342,9349,"\n', '   oselabeledaefromdruguse                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,risperdal,358,9349,9355,n=559                      n=742                      n=156         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,risperdal,359,9355,9364,"\n', '  oselabeledaefromdruguse                       0.6                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
360,risperdal,360,9364,9366,6.9                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,risperdal,361,9366,9368,1.8         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
362,risperdal,362,9368,9380,"\n', '                                                                                                              \n', '   oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,risperdal,363,9380,9382,n=183                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,risperdal,364,9382,9386,n=307                      n=123         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,risperdal,365,9386,9395,"\n', '  oselabeledaefromdruguse                      -17.4                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,risperdal,366,9395,9397,-4.9                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,risperdal,367,9397,9399,-8.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
368,risperdal,368,9399,9415,"\n', '                                                                                                              \n', '                                       Proportion of patients With Shifts     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,risperdal,369,9415,9431,"\n', '   oselabeledaefromdruguse        2.7%                       4.3%                       6.3%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,risperdal,370,9431,9448,"\n', '                                         (10/368)                   (22/516)                    (6/96)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
371,risperdal,371,9448,9464,"\n', '   oselabeledaefromdruguse     1.1%(2/180)                2.7%(8/301)                2.5%(3/121)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,risperdal,372,9464,9624,"\n', '          In longer-term, controlled and uncontrolled studies, RISPERDAL  (r)  was associated with a  oselabeledaefromdruguse  oselabeledaefromdruguse (a)  oselabeledaefromdruguse cholesterol of +4.4 mg/dL at Week 24 (n=231) and +5.5 mg/dL at Week 48 (n=86); and (b) non-fasting  oselabeledaefromdruguse of +19.9 mg/dL at Week 24 (n=52).\n', ' \n', '\n', ' Pooled data from 3 placebo-controlled, 3- to 6-week, fixed-dose studies in children and adolescents with  notaecandidateindication (13-17 years of age),  notaecandidateindication (10-17 years of age), or  notaecandidateindication (5-17 years of age) are presented in Table 5.\n', '\n', ' Table 5.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
373,risperdal,373,9624,9679,"Change in Fasting Lipids from Three Placebo-Controlled, 3- to 6-Week, Fixed-Dose Studies in Children and Adolescents with Schizophrenia (13-17 Years of Age), Bipolar Mania (10-17 Years of Age), or Autistic Disorder (5 to 17 Years of Age)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,risperdal,374,9679,9686,"\n', '                                                                                RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,risperdal,375,9686,9692,(r)              \n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,risperdal,376,9692,9704,", '                                                 Placebo                          0.5-6 mg/day              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,risperdal,377,9704,9724,"\n', '  \n', '                                     Mean change from baseline (mg/dL)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,risperdal,378,9724,9735,"\n', '   oselabeledaefromdruguse                                     n=74                               n=133                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,risperdal,379,9735,9744,"\n', '  oselabeledaefromdruguse                              0.3                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,risperdal,380,9744,9746,-0.3                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
381,risperdal,381,9746,9800,"\n', '                                                                                                            \n', '   oselabeledaefromdruguse                                             n=22                                n=22                  \n', '  oselabeledaefromdruguse                              3.7                                 0.5                  \n', '                                                                                                            \n', '   oselabeledaefromdruguse                                             n=22                                n=22                  \n', '  oselabeledaefromdruguse                              1.6                                -1.9                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
382,risperdal,382,9800,9814,"\n', '                                                                                                            \n', '   oselabeledaefromdruguse                                   n=77                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
383,risperdal,383,9814,9816,n=138                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
384,risperdal,384,9816,9825,"\n', '  oselabeledaefromdruguse                              -9.0                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
385,risperdal,385,9825,9827,-2.6                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
386,risperdal,386,9827,9853,"\n', '                                                                                                            \n', '                                     Proportion of patients with shifts     \n', '   oselabeledaefromdruguse               2.4%(1/42)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
387,risperdal,387,9853,9856,3.8%(3/80)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,risperdal,388,9856,9866,"\n', '   oselabeledaefromdruguse                0%(0/16)                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,risperdal,389,9866,9869,0%(0/16)                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,risperdal,390,9869,9876,"\n', '   oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,risperdal,391,9876,9879,0%(0/19)                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
392,risperdal,392,9879,9882,10%(2/20)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
393,risperdal,393,9882,9895,"\n', '   oselabeledaefromdruguse               1.5%(1/65)                         7.1%(8/113)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,risperdal,394,9895,10018,"\n', '         In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL  (r)  was associated with a  oselabeledaefromdruguse  oselabeledaefromdruguse (a)  oselabeledaefromdruguse cholesterol of +2.1 mg/dL at Week 24 (n=114); (b) fasting  oselabeledaefromdruguse  oselabeledaefromdruguse (a)  oselabeledaefromdruguse cholesterol of +2.1 mg/dL at Week 24 (n=114); (b) fasting LDL of -0.2 mg/dL at Week 24 (n=103); (c) fasting  oselabeledaefromdruguse  oselabeledaefromdruguse (a)  oselabeledaefromdruguse cholesterol of +2.1 mg/dL at Week 24 (n=114);",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,risperdal,395,10018,10086,"(b) fasting LDL of -0.2 mg/dL at Week 24 (n=103); (c) fasting HDL of +0.4 mg/dL at Week 24 (n=103); and (d) fasting  oselabeledaefromdruguse of +6.8 mg/dL at Week 24 (n=120).\n', ' \n', '\n', '    Weight Gain  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
396,risperdal,396,10086,10104,"\n', '\n', '  oselabeledaeclasseffect has been observed with atypical antipsychotic use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
397,risperdal,397,10104,10170,"Clinical monitoring of weight is recommended.\n', '\n', ' Data on mean  nonoseaeaeonlyasinstruction and the proportion of subjects meeting a  nonoseaeaeonlyasinstruction criterion of 7% or greater of body weight from 7 placebo-controlled, 3- to 8- week, fixed- or flexible-dose studies in adult subjects with  notaecandidateindication or  notaecandidateindication are presented in Table",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
398,risperdal,398,10170,10181,"6.\n', '\n', ' Table 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
399,risperdal,399,10181,10218,"Mean Change in Body Weight (kg) and the Proportion of Subjects with >=7% Gain in Body Weight From Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
400,risperdal,400,10218,10227,Studies in Adult Subjects With Schizophrenia or Bipolar Mania,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
401,risperdal,401,10227,10234,"\n', '                                                           RISPERDAL  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
402,risperdal,402,10234,10239,(r)          \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
403,risperdal,403,10239,10281,"', '                                 Placebo(n=597)            1-8 mg/day(n=769)         >8-16 mg/day(n=158)      \n', '  \n', '   oselabeledaefromdruguse                 -0.3                        0.7                        2.2              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
404,risperdal,404,10281,10464,"\n', '   oselabeledaefromdruguse                                                                                                 \n', ' >=7% increase from baseline            2.9%                       8.7%                       20.9%             \n', '          In longer-term, controlled and uncontrolled studies, RISPERDAL  (r)  was associated with a  oselabeledaefromdruguse of +4.3 kg at Week 24 (n=395) and +5.3 kg at Week 48 (n=203).\n', ' \n', '\n', ' Data on  nonoseaeaeonlyasinstruction and the proportion of subjects meeting the criterion of >=7%  nonoseaeaeonlyasinstruction from nine placebo-controlled, 3- to 8-week, fixed-dose studies in children and adolescents with  notaecandidateindication (13-17 years of age),  notaecandidateindication (10-17 years of age),  notaecandidateindication (5-17 years of age), or other  notaecandidatepreexistingconditionorriskfactor (5-17 years of age) are presented in Table 7.\n', '\n', ' Table 7.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
405,risperdal,405,10464,10548,"Mean Change in Body Weight (kg) and the Proportion of Subjects With >=7% Gain in Body Weight From Nine Placebo-Controlled, 3- to 8-Week, Fixed-Dose Studies in Children and Adolescents With Schizophrenia (13-17 Years of Age), Bipolar Mania (10-17 Years of Age), Autistic Disorder (5 to 17 Years of Age) or Other Psychiatric Disorders (5-17 Years of Age)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
406,risperdal,406,10548,10584,"\n', '                                                   Placebo(n=375)          RISPERDAL  (r)  0.5-6 mg/day(n=448)   \n', '  \n', '   oselabeledaefromdruguse                                   0.6                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
407,risperdal,407,10584,10586,2.0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,risperdal,408,10586,10593,"\n', '   oselabeledaefromdruguse                                                                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
409,risperdal,409,10593,10706,"\n', ' >=7% increase from baseline                            6.9%                           32.6%                \n', '         In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL  (r)  was associated with a  oselabeledaefromdruguse of +5.5 kg at Week 24 (n=748) and +8.0 kg at Week 48 (n=242).\n', ' \n', '\n', ' In a long-term, open-label extension study in adolescent patients with  notaecandidateindication   oselabeledaefromdruguse was reported as a treatment-emergent adverse event in 14% of patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
410,risperdal,410,10706,10731,In 103 adolescent patients with  notaecandidateindication  a  oselabeledaefromdruguse was observed after 8 months of RISPERDAL  (r)  treatment.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
411,risperdal,411,10731,10744,The majority of that increase was observed within the first 6 months.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
412,risperdal,412,10744,10854,"The average percentiles at baseline and 8 months, respectively, were 56 and 72 for weight, 55 and 58 for height, and 51 and 71 for body mass index.\n', '\n', ' In long-term, open-label trials (studies in patients with  notaecandidateindication or other  notaecandidatepreexistingconditionorriskfactor , a  oselabeledaefromdruguse after 12 months of RISPERDAL  (r)  treatment was observed, which was higher than the expected normal  oselabeledaefromdruguse (approximately 3 to 3.5 kg per year adjusted for age, based on Centers for Disease Control and Prevention normative data).",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
413,risperdal,413,10854,10875,The majority of that increase occurred within the first 6 months of exposure to RISPERDAL  (r)  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,risperdal,414,10875,10931,"The average percentiles at baseline and 12 months, respectively, were 49 and 60 for weight, 48 and 53 for height, and 50 and 62 for body mass index.\n', '\n', ' In one 3-week, placebo-controlled trial in children and adolescent patients with  notaecandidateindication   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
415,risperdal,415,10931,10994,"oselabeledaefromdruguse were higher in the RISPERDAL  (r)  groups than the placebo group, but not dose related (1.90 kg in the RISPERDAL  (r)  0.5-2.5 mg group, 1.44 kg in the RISPERDAL  (r)  3-6 mg group, and 0.65 kg in the placebo group).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,risperdal,416,10994,11048,"A similar trend was observed in the  oselabeledaefromdruguse \n', '\n', ' When treating pediatric patients with RISPERDAL  (r)  for any indication,  nonoseaeaeonlyasinstruction should be assessed against that expected with normal growth.\n', '\n', '    5.6  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
417,risperdal,417,11048,11077,"\n', '  As with other drugs that antagonize dopamine D2receptors, RISPERDAL  (r)   oselabeledaefromdruguse and the elevation persists during chronic administration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
418,risperdal,418,11077,11113,"RISPERDAL  (r)  is associated with higher levels of  oselabeledaefromdruguse than other antipsychotic agents.\n', '\n', '  nonoseaeaeonlyasinstruction may  nonoseaemanifestationorcomplication  resulting in  nonoseaemanifestationorcomplication  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
419,risperdal,419,11113,11132,"This, in turn, may  nonoseaemanifestationorcomplication by  nonoseaemanifestationorcomplication in both female and male patients.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
420,risperdal,420,11132,11136,oselabeledaeclasseffect   oselabeledaeclasseffect   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
421,risperdal,421,11136,11152,oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported in patients receiving prolactin-elevating compounds.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
422,risperdal,422,11152,11174,Long-standing  nonoseaeaeonlyasinstruction when associated with  nonoseaeaeonlyasinstruction may lead to  nonoseaeaeonlyasinstruction in both female and male subjects.\n',1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
423,risperdal,423,11174,11283,", '\n', ' Tissue culture experiments indicate that approximately one-third of human  nonoseaeaeonlyasinstruction are prolactin dependent in vitro  , a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected  notaecandidatepreexistingconditionorriskfactor  An increase in  nonoseaeaeanimal  mammary gland, and pancreatic islet cell  nonoseaeaeanimal  nonoseaeaeanimal  and pancreatic islet cell  nonoseaeaeanimal  nonoseaeaeanimal ( nonoseaeaeanimal   nonoseaeaeanimal and pancreatic  nonoseaeaeanimal  nonoseaeaeanimal  was observed in the risperidone carcinogenicity studies conducted in mice and rats [see     Nonclinical Toxicology (13.1)  ]  .",1,0,1,0,0,0,0,0,1,0,0,0,0,0,0
424,risperdal,424,11283,11386,"Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and  nonoseaenegation in humans; the available evidence is considered too limited to be conclusive at this time.\n', '\n', '    5.7 Orthostatic Hypotension\n', '\n', '  RISPERDAL  (r)  may induce  oselabeledaefromdruguse associated with  oselabeledaefromdruguse   oselabeledaefromdruguse  and in some patients,  oselabeledaefromdruguse  especially during the initial dose-titration period, probably reflecting its alpha-adrenergic antagonistic properties.  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
425,risperdal,425,11386,11416,oselabeledaefromdruguse was reported in 0.2% (6/2607) of RISPERDAL  (r)  -treated patients in Phase 2 and 3 studies in adults with  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
426,risperdal,426,11416,11485,"The risk of  oselabeledaefromdruguse and  oselabeledaefromdruguse may be minimized by limiting the initial dose to 2 mg total (either once daily or 1 mg twice daily) in normal adults and 0.5 mg twice daily in the elderly and patients with  notaecandidatepreexistingconditionorriskfactor or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor [see     Dosage and Administration (2.1    ,   2.4)  ]  .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
427,risperdal,427,11485,11502,Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
428,risperdal,428,11502,11513,A dose reduction should be considered if  nonoseaeaeonlyasinstruction occurs.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
429,risperdal,429,11513,11532,RISPERDAL  (r)  should be used with particular caution in patients with known  notaecandidatepreexistingconditionorriskfactor (,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
430,risperdal,430,11532,11587,"history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor ,  notaecandidatepreexistingconditionorriskfactor  and conditions which would predispose patients to  nonoseaeaeonlyasinstruction  e.g.,  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor  Clinically significant  nonoseaeaefromdruginteraction has been observed with concomitant use of RISPERDAL  (r)  and  nonoseaeaeonlyasinstruction",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
431,risperdal,431,11587,11616,"\n', '\n', '    5.8 Falls\n', '\n', '    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and sensory  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
432,risperdal,432,11616,11693,"oselabeledaefromdruguse have been reported with the use of antipsychotics, including RISPERDAL  (r)  , which may lead to  nonoseaemanifestationorcomplication and, consequently,  nonoseaemanifestationorcomplication or other  nonoseaemanifestationorcomplication  For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of  nonoseaeaeonlyasinstruction when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
433,risperdal,433,11693,11752,"\n', '\n', '    5.9 Leukopenia, Neutropenia, and Agranulocytosis\n', '\n', '   Class Effect:  In clinical trial and/or postmarketing experience, events of  oselabeledaefromdruguse  oselabeledaefromdruguse have been reported temporally related to antipsychotic agents, including RISPERDAL  (r)  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
434,risperdal,434,11752,11790,"oselabeledaefromdruguse has also been reported.\n', '\n', ' Possible risk factors for  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction include pre-existing  notaecandidatepreexistingconditionorriskfactor  and history of  notaecandidatepreexistingconditionorriskfactor leukopenia/ notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor neutropenia.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
435,risperdal,435,11790,11893,"Patients with a history of a clinically significant  notaecandidatepreexistingconditionorriskfactor or a  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor leukopenia/ notaecandidatepreexistingconditionorriskfactor should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of RISPERDAL  (r)  should be considered at the first sign of a clinically significant  nonoseaeaeonlyasinstruction in the absence of other causative factors.\n', '\n', ' Patients with clinically significant  nonoseaeaeonlyasinstruction should be carefully monitored for  nonoseaemanifestationorcomplication or other symptoms or signs of  nonoseaemanifestationorcomplication and treated promptly if such symptoms or signs occur.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
436,risperdal,436,11893,11934,"Patients with severe  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  ) should discontinue RISPERDAL  (r)  and have their WBC followed until recovery.\n', '\n', '    5.10 Potential for  oselabeledaefromdruguse and Motor  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
437,risperdal,437,11934,11965,"\n', '   oselabeledaefromdruguse was a commonly reported adverse reaction associated with RISPERDAL  (r)  treatment, especially when ascertained by direct questioning of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
438,risperdal,438,11965,12016,"This adverse reaction is dose-related, and in a study utilizing a checklist to detect adverse events, 41% of the high-dose patients (RISPERDAL  (r)  16 mg/day) reported  oselabeledaefromdruguse compared to 16% of placebo patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
439,risperdal,439,12016,12059,"Direct questioning is more sensitive for detecting adverse events than spontaneous reporting, by which 8% of RISPERDAL  (r)  16 mg/day patients and 1% of placebo patients reported  oselabeledaefromdruguse as an adverse reaction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
440,risperdal,440,12059,12219,"Since RISPERDAL  (r)  has the potential to  oselabeledaefromdruguse  oselabeledaefromdruguse judgment,  oselabeledaefromdruguse  oselabeledaefromdruguse judgment, thinking, or  oselabeledaefromdruguse  patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL  (r)  therapy does not affect them adversely.\n', '\n', '    5.11 Seizures\n', '\n', '  During premarketing testing in adult patients with  notaecandidateindication   oselabeledaefromdruguse occurred in 0.3% (9/2607) of RISPERDAL  (r)  -treated patients, two in association with  nonoseaeaeonlyasinstruction  RISPERDAL  (r)  should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.12  oselabeledaefromdruguse \n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse have been associated with antipsychotic drug use.  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
441,risperdal,441,12219,12268,nonoseaeaeonlyasinstruction is a common cause of morbidity and mortality in patients with advanced  notaecandidatepreexistingconditionorriskfactor  RISPERDAL  (r)  and other antipsychotic drugs should be used cautiously in patients at risk for  nonoseaeaeonlyasinstruction  [see     Boxed Warning  and  Warnings and Precautions,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
442,risperdal,442,12268,12274,(5.1)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
443,risperdal,443,12274,12286,"\n', '\n', '    5.13 Priapism\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
444,risperdal,444,12286,12301,", '\n', '   oselabeledaefromdruguse has been reported during postmarketing surveillance.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
445,risperdal,445,12301,12336,"Severe  nonoseaeaeonlyasinstruction may require surgical intervention.\n', '\n', '    5.14 Body Temperature Regulation\n', '\n', '   oselabeledaeclasseffect has been attributed to antipsychotic agents.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
446,risperdal,446,12336,12344,Both  oselabeledaefromdruguse and  oselabeledaefromdruguse '],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,effient,0,0,172,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction (  6.1  ).\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-545-5979 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  The following serious adverse reactions are also discussed elsewhere in the labeling:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse [see  Boxed Warning  and Warnings and Precautions (  5.1  ,  5.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,effient,1,172,191,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (  5.4  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,effient,2,191,262,"\n', '    Safety in patients with  notaecandidateindication undergoing PCI was evaluated in a clopidogrel-controlled study, TRITON-TIMI 38, in which 6741 patients were treated with Effient (60-mg loading dose and 10-mg once daily) for a median of 14.5 months (5802 patients were treated for over 6 months; 4136 patients were treated for more than 1 year).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
3,effient,3,262,284,"The population treated with Effient was 27 to 96 years of age, 25% female, and 92% Caucasian.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,effient,4,284,298,All patients in the TRITON-TIMI 38 study were to receive aspirin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,effient,5,298,425,"The dose of clopidogrel in this study was a 300-mg loading dose and 75-mg once daily.\n', ' \n', '\n', ' Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials cannot be directly compared with the rates observed in other clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '     Drug Discontinuation  \n', '\n', '\n', '\n', ' The rate of study drug discontinuation because of adverse reactions was 7.2% for Effient and 6.3% for clopidogrel.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,effient,6,425,584,"oselabeledaefromdruguse was the most common adverse reaction leading to study drug discontinuation for both drugs (2.5% for Effient and 1.4% for clopidogrel).\n', '\n', '\n', '\n', '     Bleeding  \n', '\n', '\n', '\n', '      nonoseaegeneralterm Unrelated to CABG Surgery  - In TRITON-TIMI 38, overall rates of TIMI Major or Minor  oselabeledaefromdruguse adverse reactions unrelated to coronary artery bypass graft surgery (CABG) were significantly higher on Effient than on clopidogrel, as shown in  Table 1  .\n', '\n', '\n', '\n', ' Table 1: Non-CABG-Related Bleedinga (TRITON-TIMI 38) \n', '   a  Patients may be counted in more than one row.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
7,effient,7,584,586,b  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,effient,8,586,592,See 5.1 for definition.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,effient,9,592,605,"\n', '  \n', '                                               Effient(%)(N=6741)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,effient,10,605,608,Clopidogrel(%)(N=6716)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,effient,11,608,622,"\n', '  TIMI Major or Minor  oselabeledaefromdruguse                 4.5                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,effient,12,622,636,"3.4                          \n', '  TIMI Major  oselabeledaefromdruguse                          2.2                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,effient,13,636,638,1.7                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,effient,14,638,649,"\n', '      Life-threatening                         1.3                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,effient,15,649,652,0.8                          \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,effient,16,652,660,"', '             nonoseaegeneralterm                              0.3                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,effient,17,660,662,0.1                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,effient,18,662,673,"\n', '            Symptomatic  oselabeledaefromdruguse     0.3                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,effient,19,673,687,"0.3                          \n', '            Requiring inotropes                0.3                            0.1                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,effient,20,687,714,"\n', '            Requiring surgical intervention    0.3                            0.3                          \n', '            Requiring transfusion (>=4 units)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,effient,21,714,730,"0.7                            0.5                          \n', '  TIMI Minor  oselabeledaefromdruguse                          2.4                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,effient,22,730,732,1.9                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,effient,23,732,752,"\n', '           Figure 1  demonstrates non-CABG related TIMI Major or Minor  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,effient,24,752,776,"The  nonoseaeaeonlyasinstruction rate is highest initially, as shown in  Figure 1  (inset: Days 0 to 7)  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,effient,25,776,788,[see Warnings and Precautions (  5.1  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,effient,26,788,808,".\n', ' \n', '\n', '    nonoseaeaeonlyasinstruction by Weight and Age  -",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,effient,27,808,937,"In TRITON-TIMI 38, non-CABG-related TIMI Major or Minor  nonoseaeaeonlyasinstruction rates in patients with the risk factors of age >=75 years and weight <60 kg are shown in  Table 2  .\n', '\n', '\n', '\n', ' Table 2:  oselabeledaefromdruguse Rates for Non-CABG-Related Bleeding by Weight and Age (TRITON-TIMI 38) \n', '   a  10-mg Effient maintenance dose   \n', '   b  75-mg clopidogrel maintenance dose   \n', '  \n', '                                    Major/Minor                      Fatal          \n', '  Effienta(%)                       ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,effient,28,937,940,Clopidogrelb(%)                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,effient,29,940,946,Effienta(%)    Clopidogrelb(%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,effient,30,946,952,"\n', '  Weight",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,effient,31,952,963,"<60 kg (N=308 Effient, N=356 clopidogrel)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,effient,32,963,965,10.1                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,effient,33,965,989,"6.5            0.0          0.3            \n', '  Weight >=60 kg (N=6373 Effient, N=6299 clopidogrel)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,effient,34,989,1014,"4.2                              3.3            0.3          0.1            \n', '  Age <75 years (N=5850 Effient, N=5822 clopidogrel)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,effient,35,1014,1022,3.8                              2.9            0.2          0.1            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,effient,36,1022,1029,"\n', '  Age >",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,effient,37,1029,1040,"=75 years (N=891 Effient, N=894 clopidogrel)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,effient,38,1040,1044,9.0                              6.9            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,effient,39,1044,1059,"1.0          0.1            \n', '                nonoseaegeneralterm Related to CABG  -",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,effient,40,1059,1080,"In TRITON-TIMI 38, 437 patients who received a thienopyridine underwent CABG during the course of the study.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,effient,41,1080,1115,The rate of CABG-related TIMI Major or Minor  oselabeledaefromdruguse was 14.1% for the Effient group and 4.5% in the clopidogrel group (  see    Table 3  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,effient,42,1115,1183,"The higher risk for  oselabeledaefromdruguse adverse reactions in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.\n', ' \n', '\n', ' Table 3: CABG-Related Bleedinga (TRITON-TIMI 38) \n', '   a  Patients may be counted in more than one row.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,effient,43,1183,1205,"\n', '  \n', '                                            Effient (%)(N=213)             Clopidogrel (%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,effient,44,1205,1223,"(N=224)           \n', '  TIMI Major or Minor  oselabeledaefromdruguse              14.1                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,effient,45,1223,1225,4.5                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,effient,46,1225,1250,"\n', '  TIMI Major  oselabeledaefromdruguse                       11.3                           3.6                              \n', '             nonoseaegeneralterm                           0.9                            0                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
47,effient,47,1250,1288,"\n', '            Reoperation                     3.8                            0.5                              \n', '            Transfusion of >=5 units        6.6                            2.2                              \n', '             nonoseaeaeonlyasinstruction         0                              0                                ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,effient,48,1288,1298,"\n', '  TIMI Minor  oselabeledaefromdruguse                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,effient,49,1298,1303,2.8                            0.9                              \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,effient,50,1303,1398,"', '              nonoseaeaeonlyasinstruction Reported as Adverse Reactions  -  oselabeledaefromdruguse reported as adverse reactions in TRITON-TIMI 38 were, for Effient and clopidogrel, respectively:  oselabeledaefromdruguse (6.2%, 3.3%),  oselabeledaefromdruguse (1.5%, 1.0%),  oselabeledaefromdruguse (0.6%, 0.5%),  oselabeledaefromdruguse (0.5%, 0.2%),  oselabeledaefromdruguse (0.5%, 0.2%),  oselabeledaefromdruguse (0.3%, 0.2%),  oselabeledaefromdruguse  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,effient,51,1398,1404,effusion/ oselabeledaefromdruguse  oselabeledaefromdruguse effusion/,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,effient,52,1404,1439,"hemorrhage/ oselabeledaefromdruguse  oselabeledaefromdruguse tamponade (0.3%, 0.2%), and  oselabeledaefromdruguse (0.0%, 0.1%).\n', ' \n', '\n', '     Malignancies  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,effient,53,1439,1484,"\n', '\n', '\n', '\n', ' During TRITON-TIMI 38, newly-diagnosed  oselabeledaefromdruguse were reported in 1.6% and 1.2% of patients treated with prasugrel and clopidogrel, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,effient,54,1484,1514,"The sites contributing to the differences were primarily  oselabeledaefromdruguse  oselabeledaefromdruguse were reported in 1.6% and 1.2% of patients treated with prasugrel and clopidogrel, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,effient,55,1514,1574,"The sites contributing to the differences were primarily colon and  oselabeledaefromdruguse  In another Phase 3 clinical study of  notaecandidateindication patients not undergoing PCI, in which data for  nonoseaeaeonlyasinstruction were prospectively collected, newly-diagnosed  nonoseaegeneralterm were reported in 1.8% and 1.7% of patients treated with prasugrel and clopidogrel, respectively.",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
56,effient,56,1574,1589,The site of  nonoseaegeneralterm was balanced between treatment groups except for  nonoseaeaeonlyasinstruction  ,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,effient,57,1589,1661,"The rates of  oselabeledaefromdruguse were 0.3% prasugrel, 0.1% clopidogrel and most were detected during investigation of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  It is unclear if these observations are causally-related, are the result of increased detection because of  nonoseaeaeonlyasinstruction  or are random occurrences.\n', '\n', '\n', '\n', '     Other Adverse Events  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
58,effient,58,1661,1751,"\n', '\n', '\n', '\n', ' In TRITON-TIMI 38, common and other important  nonoseaegeneralterm were, for Effient and clopidogrel, respectively: severe  oselabeledaefromdruguse (0.06%, 0.04%),  oselabeledaefromdruguse (2.2%, 2.0%),  oselabeledaefromdruguse (0.22%, 0.27%),  oselabeledaefromdruguse (0.36%, 0.36%), and  oselabeledaefromdruguse (0.06%, 0.04%).  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,effient,59,1751,1802,"Table 4  summarizes the adverse events reported by at least 2.5% of patients.\n', '\n', '\n', '\n', ' Table 4: Non-Hemorrhagic Treatment Emergent Adverse Events Reported by at Least 2.5% of Patients in Either Group",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,effient,60,1802,1811,"\n', '                                                   Effient (%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,effient,61,1811,1819,(N=6741)          Clopidogrel (%),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,effient,62,1819,1832,"(N=6716)     \n', '   oselabeledaefromdruguse                                     7.5                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,effient,63,1832,1834,7.1                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,effient,64,1834,1843,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,effient,65,1843,1856,"7.0                          7.4                         \n', '   oselabeledaefromdruguse                                         5.5                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,effient,66,1856,1858,5.3                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,effient,67,1858,1869,"\n', '   oselabeledaefromdruguse                                        5.0                          4.5                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,effient,68,1869,1891,"\n', '   oselabeledaefromdruguse                                          4.9                          4.5                         \n', '   oselabeledaefromdruguse                                           4.6                          4.3                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,effient,69,1891,1902,"\n', '   oselabeledaefromdruguse                                        4.1                          4.6                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,effient,70,1902,1911,"\n', '   oselabeledaefromdruguse                                            3.9                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,effient,71,1911,1913,4.1                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,effient,72,1913,1922,"\n', '   oselabeledaefromdruguse                                      3.9                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,effient,73,1922,1924,3.8                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,effient,74,1924,1933,"\n', '   oselabeledaefromdruguse                                          3.7                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,effient,75,1933,1935,4.8                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,effient,76,1935,1946,"\n', '   oselabeledaefromdruguse                           3.1                          3.5                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,effient,77,1946,1955,"\n', '   oselabeledaefromdruguse                              2.9                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,effient,78,1955,1957,3.1                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,effient,79,1957,1968,"\n', '   oselabeledaefromdruguse                                      2.9                          2.4                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,effient,80,1968,1977,"\n', '   oselabeledaefromdruguse ( oselabeledaefromdruguse                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,effient,81,1977,1979,2.8                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,effient,82,1979,1981,3.5                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,effient,83,1981,1988,"\n', '   oselabeledaefromdruguse                                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,effient,84,1988,1992,2.8                          2.4                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,effient,85,1992,1999,"\n', '   oselabeledaefromdruguse                                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,effient,86,1999,2003,2.7                          2.2                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,effient,87,2003,2010,"\n', '   oselabeledaefromdruguse                                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,effient,88,2010,2012,2.7                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,effient,89,2012,2014,3.0                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,effient,90,2014,2021,"\n', '   oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,effient,91,2021,2025,2.6                          2.6                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,effient,92,2025,2036,"\n', '   oselabeledaefromdruguse                                         2.3                          2.6                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,effient,93,2036,2062,"\n', '           6.2 Postmarketing Experience\n', '   The following adverse reactions have been identified during post approval use of Effient.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,effient,94,2062,2140,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '      nonoseaegeneralterm -     oselabeledaefromdruguse   oselabeledaefromdruguse (TTP)  [see Warnings and Precautions (  5.4  ) and Patient Counseling Information (  17  )]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
95,effient,95,2140,2164,"\n', '\n', '\n', '\n', '      nonoseaegeneralterm -     oselabeledaefromdruguse including  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,effient,96,2164,2165,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,effient,97,2165,2176,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,effient,98,2176,2178,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,effient,99,2178,2180,BLEEDING RISK,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,effient,100,2180,2181,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,effient,101,2181,2191,"', '\n', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,effient,102,2191,2193,BLEEDING RISK,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,effient,103,2193,2202,"\n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,effient,104,2202,2232,"*  Effient can cause significant, sometimes  nonoseaegeneralterm   oselabeledaefromdruguse [see Warnings and Precautions (5.1, 5.2) and Adverse Reactions (6.1)].",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,effient,105,2232,2268,"\n', ' *  Do not use Effient in patients with active pathological  notaecandidatecontraindication or a history of  notaecandidatecontraindication or  notaecandidatecontraindication [see Contraindications (4.1, 4.2)].",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
106,effient,106,2268,2347,"\n', ' *  In patients >=75 years of age, Effient is generally not recommended, because of the increased risk of  nonoseaegeneralterm and  oselabeledaefromdruguse and uncertain benefit, except in high-risk situations (patients with  notaecandidatepreexistingconditionorriskfactor or a history of prior  notaecandidatepreexistingconditionorriskfactor  where its effect appears to be greater and its use may be considered [see Use in Specific Populations (8.5)].",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
107,effient,107,2347,2372,"\n', ' *  Do not start Effient in patients likely to undergo urgent coronary artery bypass graft surgery (CABG).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,effient,108,2372,2395,"When possible, discontinue Effient at least 7 days prior to any surgery [see Warnings and Precautions (5.2)].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,effient,109,2395,2461,"\n', ' *  Additional risk factors for  nonoseaeaeonlyasinstruction include: body weight <60 kg;  notaecandidatepreexistingconditionorriskfactor  concomitant use of medications that increase the  nonoseaeaeonlyasinstruction (e.g., warfarin, heparin, fibrinolytic therapy, chronic use of non-steroidal anti-inflammatory drugs [NSAIDs]) [see Warnings and Precautions (5.1)].",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
110,effient,110,2461,2502,"\n', ' *  Suspect  nonoseaeaeonlyasinstruction in any patient who is  nonoseaemanifestationorcomplication and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of Effient",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
111,effient,111,2502,2512,[see Warnings and Precautions (5.1)].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,effient,112,2512,2528,"\n', ' *  If possible, manage  nonoseaeaeonlyasinstruction without discontinuing Effient.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,effient,113,2528,2572,"Discontinuing Effient, particularly in the first few weeks after  notaecandidatepreexistingconditionorriskfactor  increases the risk of subsequent  nonoseaeodorwithdrawal     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
114,effient,114,2572,2579,*    CABG-related bleeding:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,effient,115,2579,2594,Risk increases in patients receiving Effient who undergo CABG (  5.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,effient,116,2594,2622,"\n', ' *    Discontinuation of Effient: Premature discontinuation increases risk of stent thrombosis, MI, and death (  5.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,effient,117,2622,2647,"\n', ' *    Thrombotic thrombocytopenic purpura (TTP): TTP has been reported with Effient (  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,effient,118,2647,2681,"\n', ' *    Hypersensitivity: Hypersensitivity including angioedema has been reported with Effient including in patients with a history of hypersensitivity reaction to other thienopyridines (  5.5  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,effient,119,2681,2686,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,effient,120,2686,2820,"\n', ' \n', '\n', '   5.1 General Risk of Bleeding\n', '\n', '\n', '\n', '  Thienopyridines, including Effient, increase the risk of  oselabeledaefromdruguse  With the dosing regimens used in TRITON-TIMI 38, TIMI (Thrombolysis in  nonoseaeaeonlyasinstruction  Major (clinically overt  nonoseaeaeonlyasinstruction associated with a  nonoseaeaeonlyasinstruction >=5 g/dL, or  nonoseaeaeonlyasinstruction  and TIMI Minor (overt  nonoseaeaeonlyasinstruction associated with a  nonoseaeaeonlyasinstruction of >=3 g/dL but <5 g/dL)  oselabeledaefromdruguse events were more common on Effient than on clopidogrel [see Adverse Reactions (  6.1  )]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,effient,121,2820,2878,"The  oselabeledaefromdruguse risk is highest initially, as shown in  Figure 1  (events through 450 days; inset shows events through 7 days).\n', '\n', '\n', '\n', ' Figure 1: Non-CABG-Related TIMI Major or Minor Bleeding Events.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,effient,122,2878,2880,Figure 1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,effient,123,2880,3032,": Non-CABG-Related TIMI Major or Minor Bleeding Events.\n', ' \n', '\n', ' Suspect  nonoseaeaeonlyasinstruction in any patient who is  nonoseaemanifestationorcomplication and has recently undergone coronary angiography, PCI, CABG, or other surgical procedures even if the patient does not have overt signs of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Do not use Effient in patients with  notaecandidatecontraindication  prior  notaecandidatecontraindication or  notaecandidatecontraindication [see Contraindications (  4.1  ,  4.2  )]  .\n', '\n', '\n', '\n', ' Other risk factors for  nonoseaeaeonlyasinstruction are:\n', '\n', '\n', '\n', ' *    Age >=75 years.",1,0,0,0,1,0,0,0,0,0,0,1,0,0,0
124,effient,124,3032,3135,"Because of the risk of  oselabeledaefromdruguse (including  nonoseaegeneralterm  oselabeledaefromdruguse  and uncertain effectiveness in patients >=75 years of age, use of Effient is generally not recommended in these patients, except in high-risk situations (patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  where its effect appears to be greater and its use may be considered [see Adverse Reactions (  6.1  ), Use in Specific Populations (  8.5  ), Clinical Pharmacology (  12.3  ), and Clinical Trials (  14  )] .",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
125,effient,125,3135,3158,"\n', ' *    CABG or other surgical procedure [see Warnings and Precautions (  5.2  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,effient,126,3158,3170,"\n', ' *    Body weight <60 kg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,effient,127,3170,3209,"Consider a lower (5-mg) maintenance dose [see Dosage and Administration (  2  ), Adverse Reactions (  6.1  ), and Use in Specific Populations (  8.6  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,effient,128,3209,3271,"\n', ' *     notaecandidatepreexistingconditionorriskfactor (e.g., recent trauma, recent surgery, recent or recurrent  notaecandidatepreexistingconditionorriskfactor  active  notaecandidatepreexistingconditionorriskfactor  severe  notaecandidatepreexistingconditionorriskfactor  or moderate to severe  notaecandidatepreexistingconditionorriskfactor  [see Adverse Reactions (  6.1  ) and Use in Specific Populations (  8.7  ,  8.8  )] .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
129,effient,129,3271,3310,"\n', ' *    Medications that increase the risk of  nonoseaeaeonlyasinstruction (e.g., oral anticoagulants, chronic use of non-steroidal anti-inflammatory drugs [NSAIDs], and fibrinolytic agents).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,effient,130,3310,3349,"Aspirin and heparin were commonly used in TRITON-TIMI 38 [see Drug Interactions (  7.1  ,  7.2  .  7.3  ), and Clinical Studies (  14  )] .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,effient,131,3349,3397,"\n', ""    Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7-10 days), so withholding a dose will not be useful in managing a  nonoseaeaeonlyasinstruction event or the risk of  nonoseaeaeonlyasinstruction associated with an invasive procedure.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,effient,132,3397,3506,"Because the half-life of prasugrel's active metabolite is short relative to the lifetime of the platelet, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 6 hours of the loading dose or 4 hours of the maintenance dose may be less effective.\n"", ' \n', '\n', '  Figure 1    5.2 Coronary Artery Bypass Graft Surgery-Related Bleeding\n', '\n', '\n', '\n', '  The risk of  oselabeledaefromdruguse is increased in patients receiving Effient who undergo CABG.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,effient,133,3506,3586,"If possible, Effient should be discontinued at least 7 days prior to CABG.\n', '\n', '\n', '\n', ' Of the 437 patients who underwent CABG during TRITON-TIMI 38, the rates of CABG-related TIMI Major or Minor  oselabeledaefromdruguse were 14.1% in the Effient group and 4.5% in the clopidogrel group [see Adverse Reactions (  6.1  )]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,effient,134,3586,3612,The higher risk for  oselabeledaefromdruguse events in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,effient,135,3612,3662,"For patients receiving a thienopyridine within 3 days prior to CABG, the frequencies of TIMI Major or Minor  oselabeledaefromdruguse were 26.7% (12 of 45 patients) in the Effient group, compared with 5.0% (3 of 60 patients) in the clopidogrel group.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,effient,136,3662,3724,"For patients who received their last dose of thienopyridine within 4 to 7 days prior to CABG, the frequencies decreased to 11.3% (9 of 80 patients) in the prasugrel group and 3.4% (3 of 89 patients) in the clopidogrel group.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,effient,137,3724,3737,Do not start Effient in patients likely to undergo urgent CABG.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,effient,138,3737,3831,"nonoseaeaeonlyasinstruction may be treated with transfusion of blood products, including packed red blood cells and platelets; however, platelet transfusions within 6 hours of the loading dose or 4 hours of the maintenance dose may be less effective.\n', '\n', '\n', '\n', '    5.3 Discontinuation of Effient\n', '\n', '\n', '\n', '  Discontinue thienopyridines, including Effient, for  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,effient,139,3831,3840,The optimal duration of thienopyridine therapy is unknown.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,effient,140,3840,3993,"In patients who are managed with PCI and stent placement, premature discontinuation of any antiplatelet medication, including thienopyridines, conveys an increased risk of  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaegeneralterm  Patients who require premature discontinuation of a thienopyridine will be at increased risk for  nonoseaeodorwithdrawal  Lapses in therapy should be avoided, and if thienopyridines must be temporarily discontinued because of an adverse event(s), they should be restarted as soon as possible [see Contraindications (  4.1  ,  4.2  ) and Warnings and Precautions (  5.1  )]  .\n', '\n', '\n', '\n', '    5.4 Thrombotic Thrombocytopenic Purpura\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  has been reported with the use of Effient.  ",0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
141,effient,141,3993,4007,oselabeledaefromdruguse can occur after a brief exposure (<2 weeks).  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,effient,142,4007,4030,"nonoseaeaeonlyasinstruction is a serious condition that can be  nonoseaegeneralterm and requires urgent treatment, including plasmapheresis (plasma exchange).  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,effient,143,4030,4068,"nonoseaeaeonlyasinstruction is characterized by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication [ nonoseaemanifestationorcomplication  seen on peripheral smear),  nonoseaegeneralterm   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication [see Adverse Reactions (  6.2  )]  ",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
144,effient,144,4068,4127,".\n', '\n', '\n', '\n', '    5.5 Hypersensitivity Including Angioedema\n', '\n', '\n', '\n', '   oselabeledaefromdruguse including  oselabeledaefromdruguse has been reported in patients receiving Effient, including patients with a history of  notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,erbitux,0,0,56,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', ' *     oselabeledaefromdruguse [See   Boxed Warning  ,  Warnings and Precautions (5.1)   .]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,erbitux,1,56,80,"\n', ' *     oselabeledaefromdruguse [See   Boxed Warning  ,  Warnings and Precautions (5.2)   .]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,erbitux,2,80,99,"\n', ' *     oselabeledaefromdruguse [See   Warnings and Precautions (5.3)   .]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,erbitux,3,99,118,"\n', ' *     oselabeledaefromdruguse [See   Warnings and Precautions (5.4)   .]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,erbitux,4,118,140,"\n', ' *     oselabeledaefromdruguse and  oselabeledaefromdruguse [See   Warnings and Precautions (5.6)   .]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,erbitux,5,140,183,"\n', '    The most common adverse reactions in Erbitux clinical trials (incidence >=25%) include  oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,erbitux,6,183,222,"\n', ' \n', '\n', ' The most serious adverse reactions with Erbitux are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,erbitux,7,222,257,"\n', '\n', ' Across Studies 1, 3, 5, and 6, Erbitux was discontinued in 3-10% of patients because of adverse reactions.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,erbitux,8,257,302,"'\n', '   EXCERPT:   The most common adverse reactions (incidence >=25%) are: cutaneous adverse reactions (including rash, pruritus, and nail changes), headache, diarrhea, and infection.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,erbitux,9,302,349,"(6)  \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,erbitux,10,349,378,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,erbitux,11,378,480,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' The data below reflect exposure to Erbitux in 1373 patients with  notaecandidateindication or  notaecandidateindication in randomized Phase 3 (Studies 1 and 5) or Phase 2 (Studies 3 and 6) trials treated at the recommended dose and schedule for medians of 7 to 14 weeks.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,erbitux,12,480,535,"[See    Clinical Studies (14)    .]\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse  which included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse occurred in 15-21% of patients across studies.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
13,erbitux,13,535,568,"Grades 3 and 4  oselabeledaefromdruguse occurred in 2-5% of patients;  oselabeledaefromdruguse were  nonoseaegeneralterm in 1 patient.\n', '\n', '    nonoseaegeneralterm   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
14,erbitux,14,568,586,"The incidence of  oselabeledaefromdruguse was variable across studies, ranging from 13-35%.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,erbitux,15,586,624,"oselabeledaefromdruguse occurred in 1-4% of patients.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse occurred in 1% of patients with  notaecandidateindication \n', '\n', '     ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
16,erbitux,16,624,642,"Squamous Cell Carcinoma of the Head and Neck  \n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,erbitux,17,642,649,Erbitux in Combination with Radiation Therapy  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,erbitux,18,649,687,"\n', '\n', '    Table 2  contains selected adverse reactions in 420 patients receiving radiation therapy either alone or with Erbitux for locally or regionally advanced  notaecandidateindication in Study 1.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
19,erbitux,19,687,719,"Erbitux was administered at the recommended dose and schedule (400 mg/m  2  initial dose, followed by 250 mg/m  2  weekly).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,erbitux,20,719,756,"Patients received a median of 8 infusions (range 1-11).\n', '\n', ' Table 2: Incidence of Selected Adverse Reactions (>=10%) in Patients with Locoregionally",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,erbitux,21,756,758,Advanced SCCHN,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,erbitux,22,758,773,"\n', '   Body System  Preferred Term            Erbitux plus Radiation    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,erbitux,23,773,779,(n=208)      Radiation Therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,erbitux,24,779,796,"Alone    (n=212)     \n', '   Grades    1-4                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,erbitux,25,796,798,Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,erbitux,26,798,802,3 and 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,erbitux,27,802,808,Grades    1-4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,erbitux,28,808,810,Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,erbitux,29,810,823,"3 and 4     \n', '   % of Patients                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,erbitux,30,823,899,"\n', '  \n', '   a    Includes cases also reported as  oselabeledaefromdruguse   b     oselabeledaefromdruguse is defined as any event described at any time during the clinical study as "" oselabeledaefromdruguse  or "" oselabeledaefromdruguse , or any event occurring on the first day of dosing described as "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , or "" oselabeledaefromdruguse .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,erbitux,31,899,901,c    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,erbitux,32,901,938,"Based on laboratory measurements, not on reported adverse reactions, the number of subjects with tested samples varied from 205-206 for Erbitux plus Radiation arm; 209-210 for Radiation alone.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,erbitux,33,938,968,"d     oselabeledaefromdruguse is defined as any event described as "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , or "" oselabeledaefromdruguse .   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,erbitux,34,968,980,"\n', '  \n', '   nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,erbitux,35,980,1042,"\n', '   oselabeledaefromdruguse                               56               4                49                 5                  \n', '   oselabeledaefromdruguse                                  29               1                13                 1                  \n', '   oselabeledaefromdruguse                               19               <1               8                  <1                 \n', '   oselabeledaefromdruguse                      15               3                2                  0                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,erbitux,36,1042,1057,"\n', '   oselabeledaefromdruguse                              13               1                9                  1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,erbitux,37,1057,1070,"\n', '   oselabeledaefromdruguse                                 16               0                5                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,erbitux,38,1070,1072,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,erbitux,39,1072,1090,"\n', '   nonoseaegeneralterm                                                                                                      \n', '   oselabeledaefromdruguse                                 49               2                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,erbitux,40,1090,1109,"37                 2                  \n', '   oselabeledaefromdruguse                                 29               2                23                 4                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,erbitux,41,1109,1124,"\n', '   oselabeledaefromdruguse                               19               2                13                 1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,erbitux,42,1124,1137,"\n', '   oselabeledaefromdruguse                              14               0                9                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,erbitux,43,1137,1139,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,erbitux,44,1139,1157,"\n', '   nonoseaegeneralterm                                                                                          \n', '   oselabeledaefromdruguse                            84               11               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,erbitux,45,1157,1161,72                 7                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,erbitux,46,1161,1168,"\n', '   oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,erbitux,47,1168,1176,25               6                19                 8                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,erbitux,48,1176,1191,"\n', '   oselabeledaefromdruguse             43               2                21                 1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,erbitux,49,1191,1215,"\n', '   oselabeledaefromdruguse           38               1                24                 1                  \n', '   oselabeledaefromdruguse             33               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,erbitux,50,1215,1240,"<1               24                 0                  \n', '   nonoseaegeneralterm                                                                                                    \n', '   oselabeledaefromdruguse                            26               3                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,erbitux,51,1240,1244,19                 4                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,erbitux,52,1244,1251,"\n', '   nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,erbitux,53,1251,1258,"\n', '   oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,erbitux,54,1258,1260,87               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,erbitux,55,1260,1264,17               10                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,erbitux,56,1264,1266,1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,erbitux,57,1266,1275,"\n', '   oselabeledaefromdruguse                   86               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,erbitux,58,1275,1277,23               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,erbitux,59,1277,1281,90                 18                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,erbitux,60,1281,1296,"\n', '   oselabeledaefromdruguse              18               0                12                 1                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,erbitux,61,1296,1309,"\n', '   oselabeledaefromdruguse                               16               0                4                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,erbitux,62,1309,1311,0                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,erbitux,63,1311,1316,"\n', '           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,erbitux,64,1316,1389,"The incidence and severity of  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were similar in both arms of the study.\n', ' \n', '\n', '     Late Radiation Toxicity  \n', '\n', '  The overall incidence of  oselabeledaefromdruguse  oselabeledaefromdruguse (any grade) was higher in Erbitux in combination with radiation therapy compared with radiation therapy alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,erbitux,65,1389,1418,The following sites were affected:  oselabeledaefromdruguse  oselabeledaefromdruguse (any grade) was higher in Erbitux in combination with radiation therapy compared with radiation therapy alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,erbitux,66,1418,1457,"The following sites were affected: salivary glands (65% versus 56%),  oselabeledaefromdruguse  oselabeledaefromdruguse (any grade) was higher in Erbitux in combination with radiation therapy compared with radiation therapy alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,erbitux,67,1457,1505,"The following sites were affected: salivary glands (65% versus 56%), larynx (52% versus 36%),  oselabeledaefromdruguse  oselabeledaefromdruguse (any grade) was higher in Erbitux in combination with radiation therapy compared with radiation therapy alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,erbitux,68,1505,1563,"The following sites were affected: salivary glands (65% versus 56%), larynx (52% versus 36%), subcutaneous tissue (49% versus 45%),  oselabeledaefromdruguse  oselabeledaefromdruguse (any grade) was higher in Erbitux in combination with radiation therapy compared with radiation therapy alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,erbitux,69,1563,1631,"The following sites were affected: salivary glands (65% versus 56%), larynx (52% versus 36%), subcutaneous tissue (49% versus 45%), mucous membrane (48% versus 39%),  oselabeledaefromdruguse  oselabeledaefromdruguse (any grade) was higher in Erbitux in combination with radiation therapy compared with radiation therapy alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,erbitux,70,1631,1695,"The following sites were affected: salivary glands (65% versus 56%), larynx (52% versus 36%), subcutaneous tissue (49% versus 45%), mucous membrane (48% versus 39%), esophagus (44% versus 35%),  oselabeledaefromdruguse (42% versus 33%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,erbitux,71,1695,1760,"The incidence of Grade 3 or 4  nonoseaeaeratelteqplacebo was similar between the radiation therapy alone and the Erbitux plus radiation treatment groups.\n', '\n', '     Study 2: EU-Approved Cetuximab in Combination with Platinum-based Therapy with 5-Fluorouracil  \n', '\n', '  Study 2 used EU-approved cetuximab.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
72,erbitux,72,1760,1799,"Since U.S.-licensed Erbitux provides approximately 22% higher exposure relative to the EU-approved cetuximab, the data provided below may underestimate the incidence and severity of adverse reactions anticipated with Erbitux for this indication.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,erbitux,73,1799,1880,"However, the tolerability of the recommended dose is supported by safety data from additional studies of Erbitux [see    Clinical Pharmacology (12.3)    ].\n', '\n', '   Table 3  contains selected adverse reactions in 434 patients with recurrent locoregional disease or metastatic  notaecandidateindication receiving EU-approved cetuximab in combination with platinum-based therapy with 5-FU or platinum-based therapy with 5-FU alone in Study 2.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
74,erbitux,74,1880,1907,"Cetuximab was administered at 400 mg/m  2  for the initial dose, followed by 250 mg/m  2  weekly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,erbitux,75,1907,1925,"Patients received a median of 17 infusions (range 1-89).\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,erbitux,76,1925,1949,' Table 3: Incidence of Selected Adverse Reactions (>=10%) in Patients with Recurrent Locoregional Disease or Metastatic SCCHN,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,erbitux,77,1949,1961,"\n', '   System Organ Class  Preferred Term                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,erbitux,78,1961,1989,EU-Approved Cetuximab    plus Platinum-based Therapy    with 5-FU    (n=219)      Platinum-based Therapy    with 5-FU Alone(n=215)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,erbitux,79,1989,2000,"\n', '   Grades    1-4                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,erbitux,80,2000,2002,Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,erbitux,81,2002,2006,3 and 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,erbitux,82,2006,2012,Grades    1-4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,erbitux,83,2012,2014,Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,erbitux,84,2014,2027,"3 and 4     \n', '   % of Patients                                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,erbitux,85,2027,2049,"\n', '  \n', '   a     oselabeledaefromdruguse defined as any event of "" oselabeledaefromdruguse , """,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,erbitux,86,2049,2072,"oselabeledaefromdruguse , "" oselabeledaefromdruguse and/or  oselabeledaefromdruguse , "" oselabeledaefromdruguse , or "" oselabeledaefromdruguse  on the first day of dosing.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,erbitux,87,2072,2074,b     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,erbitux,88,2074,2088,oselabeledaefromdruguse - this term excludes  nonoseaenegation events which are presented separately.  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
89,erbitux,89,2088,2146,"c     oselabeledaefromdruguse defined as any event described as "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , or "" oselabeledaefromdruguse .Chemotherapy = cisplatin + 5-fluorouracil or carboplatin + 5-fluorouracil   \n', '  \n', '   nonoseaegeneralterm                                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,erbitux,90,2146,2159,"\n', '   oselabeledaefromdruguse                                     10              0               0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,erbitux,91,2159,2161,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,erbitux,92,2161,2192,"\n', '   nonoseaegeneralterm                                                                                     \n', '   oselabeledaefromdruguse                                             54              4               47            4             \n', '   oselabeledaefromdruguse                                           26              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
93,erbitux,93,2192,2196,5               16            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,erbitux,94,2196,2198,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,erbitux,95,2198,2218,"\n', '   nonoseaegeneralterm                                                                \n', '   oselabeledaefromdruguse                                            22              0               13            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,erbitux,96,2218,2220,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,erbitux,97,2220,2229,"\n', '   oselabeledaefromdruguse                                 10              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,erbitux,98,2229,2236,2               <1            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,erbitux,99,2236,2258,"\n', '   nonoseaegeneralterm                                                                                    \n', '   oselabeledaefromdruguse                                          44              11              27            8             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,erbitux,100,2258,2265,"\n', '   nonoseaegeneralterm                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
101,erbitux,101,2265,2272,"\n', '   oselabeledaefromdruguse                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,erbitux,102,2272,2274,25              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,erbitux,103,2274,2278,5               14            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,erbitux,104,2278,2280,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,erbitux,105,2280,2291,"\n', '   oselabeledaefromdruguse                                       12              4               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,erbitux,106,2291,2293,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,erbitux,107,2293,2295,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,erbitux,108,2295,2332,"\n', '   oselabeledaefromdruguse                                        12              7               7             5             \n', '   oselabeledaefromdruguse                                     11              5               5             1             \n', '   nonoseaegeneralterm                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,erbitux,109,2332,2347,"\n', '   oselabeledaefromdruguse                                     70              9               2             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,erbitux,110,2347,2356,"\n', '   oselabeledaefromdruguse                                               28              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,erbitux,111,2356,2360,5               2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,erbitux,112,2360,2362,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,erbitux,113,2362,2371,"\n', '   oselabeledaefromdruguse                                               22              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,erbitux,114,2371,2375,2               0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,erbitux,115,2375,2377,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,erbitux,116,2377,2392,"\n', '   oselabeledaefromdruguse                               15              2               0             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,erbitux,117,2392,2403,"\n', '   oselabeledaefromdruguse                                           14              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,erbitux,118,2403,2423,"<1            0             \n', '   oselabeledaefromdruguse                                           12              0               7             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,erbitux,119,2423,2460,"\n', '           For  nonoseaeaeonlyasinstruction  approximately 9% of subjects in both the EU-approved cetuximab plus chemotherapy and chemotherapy-only treatment arms in Study 2 experienced a  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,erbitux,120,2460,2514,"The majority of these events occurred in patients who received cisplatin/5-FU, with or without cetuximab as follows: 11% and 12% in patients who received cisplatin/5-FU with or without cetuximab, respectively, and 6% or 4% in patients who received carboplatin/5-FU with or without cetuximab, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,erbitux,121,2514,2534,"In both arms, the incidence of  oselabeledaefromdruguse was higher in the cisplatin with 5-FU containing subgroup.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,erbitux,122,2534,2627,"nonoseaegeneralterm attributed to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction was reported in 3% of the patients in the cetuximab plus platinum-based therapy with 5-FU arm and 2% in the platinum-based chemotherapy with 5-FU alone arm.\n', ' \n', '\n', '     Colorectal Cancer  \n', '\n', '    Study 4: EU-Approved Cetuximab in Combination with FOLFIRI  \n', '\n', '  Study 4 used EU-approved cetuximab.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,erbitux,123,2627,2647,U.S.-licensed Erbitux provides approximately 22% higher exposure to cetuximab relative to the EU-approved cetuximab.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,erbitux,124,2647,2672,The data provided below for Study 4 is consistent in incidence and severity of adverse reactions with those seen for Erbitux in this indication.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,erbitux,125,2672,2749,"The tolerability of the recommended dose is supported by safety data from additional studies of Erbitux [see    Clinical Pharmacology (12.3)    ].\n', '\n', '   Table 4  contains selected adverse reactions in 667 patients with  K-Ras  wild-type, EGFR-expressing,  notaecandidateindication receiving EU-approved cetuximab plus FOLFIRI or FOLFIRI alone in Study 4 [see    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,erbitux,126,2749,2758,Warnings and Precautions (5.8)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,erbitux,127,2758,2790,"Cetuximab was administered at the recommended dose and schedule (400 mg/m  2  initial dose, followed by 250 mg/m  2  weekly).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,erbitux,128,2790,2848,"Patients received a median of 26 infusions (range 1-224).\n', '\n', ' Table 4: Incidence of Selected Adverse Reactions Occurring in >=10% of Patients with K-Ras Wild-type and EGFR-expressing, Metastatic Colorectal Cancera \n', '   Body System  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,erbitux,129,2848,2851,Preferred Term                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,erbitux,130,2851,2857,EU-Approved Cetuximab    plus,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,erbitux,131,2857,2867,FOLFIRI    (n=317)      FOLFIRI Alone(n=350)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,erbitux,132,2867,2874,"\n', '   Grades    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,erbitux,133,2874,2878,1-4  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,erbitux,134,2878,2882,b                                    Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,erbitux,135,2882,2886,3 and 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,erbitux,136,2886,2892,Grades    1-4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,erbitux,137,2892,2894,Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,erbitux,138,2894,2907,"3 and 4     \n', '   % of Patients                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,erbitux,139,2907,2948,"\n', '  \n', '   a    Adverse reactions occurring in at least 10% of Erbitux combination arm with a frequency at least 5% greater than that seen in the FOLFIRI arm.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,erbitux,140,2948,2963,"b    Adverse reactions were graded using the NCI CTC, V 2.0.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,erbitux,141,2963,3102,"c     oselabeledaefromdruguse is defined as any event meeting the medical concepts of  oselabeledaefromdruguse  oselabeledaefromdruguse at any time during the clinical study or any event occurring on the first day of dosing and meeting the medical concepts of  oselabeledaefromdruguse and  oselabeledaefromdruguse or by the following events using MedDRA preferred terms: "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , ""epilepsy"", "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse ,  oselabeledaefromdruguse  "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , or "" oselabeledaefromdruguse .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,erbitux,142,3102,3104,d     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,erbitux,143,3104,3214,"oselabeledaefromdruguse is defined by the events using MedDRA preferred terms and included "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , "" oselabeledaefromdruguse , or "" oselabeledaefromdruguse .   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,erbitux,144,3214,3235,"\n', '  \n', '   nonoseaegeneralterm                                                                            \n', '   oselabeledaefromdruguse                                         49             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
145,erbitux,145,3235,3237,31             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,erbitux,146,3237,3239,42             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,erbitux,147,3239,3241,24             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,erbitux,148,3241,3248,"\n', '   nonoseaegeneralterm                                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
149,erbitux,149,3248,3257,"\n', '   oselabeledaefromdruguse                                      18             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,erbitux,150,3257,3264,<1             3              0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,erbitux,151,3264,3278,"\n', '   nonoseaegeneralterm                                                                                      \n', '   oselabeledaefromdruguse                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
152,erbitux,152,3278,3280,66             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,erbitux,153,3280,3282,16             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,erbitux,154,3282,3284,60             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,erbitux,155,3284,3286,10             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,erbitux,156,3286,3291,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,erbitux,157,3291,3312,"oselabeledaefromdruguse                                          31             3              19             1              \n', '   oselabeledaefromdruguse                                           16             0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,erbitux,158,3312,3316,9              0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,erbitux,159,3316,3334,"\n', '   nonoseaegeneralterm                                                                \n', '   oselabeledaefromdruguse                           14             2              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
160,erbitux,160,3334,3348,"<1             0              \n', '   oselabeledaefromdruguse                                             26             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,erbitux,161,3348,3350,1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,erbitux,162,3350,3354,14             1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,erbitux,163,3354,3437,"\n', '   nonoseaegeneralterm                                                                                     \n', '   oselabeledaefromdruguse                                          20             4              <1             0              \n', '   nonoseaegeneralterm                                                                                                  \n', '   oselabeledaefromdruguse                                    15             1              9              1              \n', '   nonoseaegeneralterm                                                                              \n', '   oselabeledaefromdruguse                                            30             3              23             2              \n', '   nonoseaegeneralterm                                                                          \n', '   oselabeledaefromdruguse                                      86             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
164,erbitux,164,3437,3439,18             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,erbitux,165,3439,3441,13             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,erbitux,166,3441,3468,"<1             \n', '      oselabeledaefromdruguse                                             44             9              4              0              \n', '      oselabeledaefromdruguse                             26             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,erbitux,167,3468,3470,5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,erbitux,168,3470,3475,<1             0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,erbitux,169,3475,3482,"\n', '      oselabeledaefromdruguse                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,erbitux,170,3482,3486,22             0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,erbitux,171,3486,3490,4              0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,erbitux,172,3490,3505,"\n', '      oselabeledaefromdruguse                                             14             2              0              0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,erbitux,173,3505,3520,"\n', '      oselabeledaefromdruguse                                         14             0              3              0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,erbitux,174,3520,3541,"\n', '   oselabeledaefromdruguse          19             4              4              <1             \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,erbitux,175,3541,3551,oselabeledaefromdruguse                                       19             2              1              0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,erbitux,176,3551,3559,"\n', '               Erbitux Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,erbitux,177,3559,3605,"\n', '     Table 5  contains selected adverse reactions in 242 patients with  K-Ras  wild-type, EGFR-expressing,  notaecandidateindication who received best supportive care (BSC) alone or with Erbitux in Study 5",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
178,erbitux,178,3605,3608,[see    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,erbitux,179,3608,3617,Warnings and Precautions (5.8)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,erbitux,180,3617,3649,"Erbitux was administered at the recommended dose and schedule (400 mg/m  2  initial dose, followed by 250 mg/m  2  weekly).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,erbitux,181,3649,3711,"Patients received a median of 17 infusions (range 1-51).\n', '\n', ' Table 5: Incidence of Selected Adverse Reactions Occurring in >=10% of Patients with K-Ras Wild-type, EGFR-expressing, Metastatic Colorectal Cancer Treated with Erbitux Monotherapya \n', '   Body System    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,erbitux,182,3711,3714,Preferred Term                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,erbitux,183,3714,3729,Erbitux plus BSC    (n=118)      BSC alone    (n=124)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,erbitux,184,3729,3740,"\n', '   Grades    1-4  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,erbitux,185,3740,3744,b                             Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,erbitux,186,3744,3748,3 and 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,erbitux,187,3748,3754,Grades    1-4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,erbitux,188,3754,3756,Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,erbitux,189,3756,3769,"3 and 4     \n', '   % of Patients                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,erbitux,190,3769,3812,"\n', '  \n', '   a    Adverse reactions occurring in at least 10% of Erbitux plus BSC arm with a frequency at least 5% greater than that seen in the BSC alone arm.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,erbitux,191,3812,3827,"b    Adverse reactions were graded using the NCI CTC, V 2.0.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,erbitux,192,3827,3889,c     oselabeledaefromdruguse is defined as any event ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  or other  oselabeledaefromdruguse  recorded by the investigator as infusion-related.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,erbitux,193,3889,3901,"\n', '  \n', '   nonoseaegeneralterm                                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
194,erbitux,194,3901,3916,"\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse                            95              16              21              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,erbitux,195,3916,3918,1               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,erbitux,196,3918,3933,"\n', '   oselabeledaefromdruguse                                     57              0               15              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,erbitux,197,3933,3955,"\n', '   oselabeledaefromdruguse                                     47              2               11              0               \n', '   oselabeledaefromdruguse                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,erbitux,198,3955,3959,35              0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,erbitux,199,3959,3978,"7               2               \n', '   oselabeledaefromdruguse                                 31              0               4               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,erbitux,200,3978,3985,"\n', '   nonoseaegeneralterm                                                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
201,erbitux,201,3985,4028,"\n', '   oselabeledaefromdruguse                                      91              31              79              29              \n', '   oselabeledaefromdruguse                                        25              3               16              0               \n', '   oselabeledaefromdruguse                           18              3               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,erbitux,202,4028,4030,0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,erbitux,203,4030,4041,"\n', '   oselabeledaefromdruguse   oselabeledaefromdruguse                               16              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,erbitux,204,4041,4047,1               3               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,erbitux,205,4047,4097,"\n', '   oselabeledaefromdruguse                                                                                                         \n', '   oselabeledaefromdruguse                                   59              18              37              10              \n', '   oselabeledaefromdruguse                                     38              2               11              0               \n', '   oselabeledaefromdruguse                                    15              4               8               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,erbitux,206,4097,4099,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,erbitux,207,4099,4106,"\n', '   nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
208,erbitux,208,4106,4121,"\n', '   oselabeledaefromdruguse                                      49              16              44              13              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,erbitux,209,4121,4152,"\n', '   oselabeledaefromdruguse                                        30              2               19              2               \n', '   nonoseaegeneralterm                                                                                             \n', '   oselabeledaefromdruguse                                       64              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
210,erbitux,210,4152,4156,6               50              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,erbitux,211,4156,4158,6               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,erbitux,212,4158,4167,"\n', '   oselabeledaefromdruguse                                 53              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,erbitux,213,4167,4212,"3               38              3               \n', '   oselabeledaefromdruguse                                     42              2               23              2               \n', '   oselabeledaefromdruguse                                     40              5               26              5               \n', '   oselabeledaefromdruguse                                   32              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,erbitux,214,4212,4218,1               10              0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,erbitux,215,4218,4233,"\n', '   oselabeledaefromdruguse                       22              12              16              5               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,erbitux,216,4233,4259,"\n', '   oselabeledaefromdruguse                                  13              5               3               0               \n', '   oselabeledaefromdruguse                                12              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,erbitux,217,4259,4263,6               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,erbitux,218,4263,4274,"\n', '   oselabeledaefromdruguse                            10              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,erbitux,219,4274,4278,5               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,erbitux,220,4278,4285,"\n', '   nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
221,erbitux,221,4285,4292,"\n', '   oselabeledaefromdruguse                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,erbitux,222,4292,4300,38              11              19              5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,erbitux,223,4300,4316,"\n', '   nonoseaegeneralterm                                                                                              \n', '   oselabeledaefromdruguse                                   14              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
224,erbitux,224,4316,4322,3               6               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,erbitux,225,4322,4329,"\n', '   nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
226,erbitux,226,4329,4336,"\n', '   oselabeledaefromdruguse                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,erbitux,227,4336,4338,45              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,erbitux,228,4338,4342,1               38              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,erbitux,229,4342,4344,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,erbitux,230,4344,4359,"\n', '   oselabeledaefromdruguse                                     27              0               13              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,erbitux,231,4359,4368,"\n', '   oselabeledaefromdruguse                                    18              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,erbitux,232,4368,4372,6               10              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,erbitux,233,4372,4374,2               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,erbitux,234,4374,4383,"\n', '   oselabeledaefromdruguse                                      14              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,erbitux,235,4383,4394,"1               5               1               \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,erbitux,236,4394,4398,oselabeledaefromdruguse                                   14              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,erbitux,237,4398,4400,0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,erbitux,238,4400,4404,5               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,erbitux,239,4404,4420,"\n', '               Erbitux in Combination with Irinotecan  \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,erbitux,240,4420,4446,"The most frequently reported adverse reactions in 354 patients treated with Erbitux plus irinotecan in clinical trials were  oselabeledaefromdruguse (88%),  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,erbitux,241,4446,4469,"oselabeledaefromdruguse  oselabeledaefromdruguse (73%),  oselabeledaefromdruguse (72%), and  oselabeledaefromdruguse (55%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,erbitux,242,4469,4538,"The most common Grades 3-4 adverse reactions included  oselabeledaefromdruguse (22%),  oselabeledaefromdruguse (17%),  oselabeledaefromdruguse  oselabeledaefromdruguse (16%), and  oselabeledaefromdruguse (14%).\n', '\n', '   6.2 Immunogenicity\n', '\n', '  As with all therapeutic proteins, there is potential for  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,erbitux,243,4538,4551,An ELISA methodology was used to characterize the incidence of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,erbitux,244,4551,4621,"In total, 105 Erbitux-treated patients with at least one post-baseline blood sample (>=4 weeks post first administration) were assessed for the development of  nonoseaeaeonlyasinstruction and the incidence of treatment-emergent  oselabeledaefromdruguse was <5%.\n', '\n', ' The incidence of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,erbitux,245,4621,4668,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,erbitux,246,4668,4720,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the  nonoseaeaeonlyasinstruction may be misleading.\n', '\n', '   6.3 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of Erbitux.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,erbitux,247,4720,4767,"Because these reactions are reported from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' *     oselabeledaefromdruguse \n', ' *     oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,erbitux,248,4767,4788,"\n', ' *     nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse  life-threatening and  nonoseaegeneralterm  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
249,erbitux,249,4788,4799,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,erbitux,250,4799,4801,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,erbitux,251,4801,4811,"SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,erbitux,252,4811,4817,"', '  WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,erbitux,253,4817,4835,"SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST\n', '\n', '       nonoseaegeneralterm    :   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
254,erbitux,254,4835,4866,"Serious  oselabeledaefromdruguse occurred with the administration of Erbitux in approximately 3% of patients in clinical trials, with  nonoseaegeneralterm outcome reported in less than 1 in 1000.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
255,erbitux,255,4866,4886,"[See     Warnings and Precautions (5.1)  ,   Adverse Reactions (6)    .]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,erbitux,256,4886,4920,"Immediately interrupt and permanently discontinue Erbitux infusion for serious  nonoseaeaeonlyasinstruction  [See     Dosage and Administration (2.4)  ,   Warnings and Precautions (5.1)    .]  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,erbitux,257,4920,4934,"\n', '\n', '      nonoseaegeneralterm    :    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
258,erbitux,258,4934,4980,"and/or  oselabeledaefromdruguse occurred in 2% of patients with  notaecandidateindication treated with Erbitux and radiation therapy in Study 1 and in 3% of patients with  notaecandidateindication    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
259,erbitux,259,4980,4996,*     Infusion Reactions: Immediately stop and permanently discontinue Erbitux for serious infusion reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,erbitux,260,4996,5002,Monitor patients following infusion.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,erbitux,261,5002,5006,(5.1)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,erbitux,262,5006,5007,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,erbitux,263,5007,5015,"', ' *     Cardiopulmonary Arrest:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,erbitux,264,5015,5025,Closely monitor serum electrolytes during and after Erbitux.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,erbitux,265,5025,5033,"(5.2  ,  5.6)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,erbitux,266,5033,5054,"\n', ' *     Pulmonary Toxicity: Interrupt therapy for acute onset or worsening of pulmonary symptoms.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,erbitux,267,5054,5058,(5.3)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,erbitux,268,5058,5067,"\n', ' *     Dermatologic Toxicity:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,erbitux,269,5067,5071,Mucocutaneous adverse reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,erbitux,270,5071,5075,Limit sun exposure.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,erbitux,271,5075,5083,Monitor for inflammatory or infectious sequelae.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,erbitux,272,5083,5091,"(2.4  ,  5.4)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,erbitux,273,5091,5092,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,erbitux,274,5092,5099,"', ' *     Hypomagnesemia:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,erbitux,275,5099,5114,Periodically monitor during and for at least 8 weeks following the completion of Erbitux.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,erbitux,276,5114,5120,Replete electrolytes as necessary.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,erbitux,277,5120,5124,(5.6)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,erbitux,278,5124,5149,"\n', ' *    Increased tumor progression, increased mortality, or lack of benefit in patients with Ras -mutant mCRC.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,erbitux,279,5149,5153,(5.7)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,erbitux,280,5153,5159,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,erbitux,281,5159,5222,"', ' \n', '\n', '   5.1 Infusion Reactions\n', '\n', '  Serious  oselabeledaefromdruguse  requiring medical intervention and immediate, permanent discontinuation of Erbitux included rapid onset of  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and/or  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,erbitux,282,5222,5263,"Severe (NCI CTC Grades 3 and 4)  oselabeledaefromdruguse occurred in 2-5% of 1373 patients in Studies 1, 3, 5, and 6 receiving Erbitux, with  nonoseaegeneralterm outcome in 1 patient.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
283,erbitux,283,5263,5345,"[See   Clinical Studies (14.1  ,  14.2)    .]\n', '\n', ' Approximately 90% of severe  oselabeledaefromdruguse occurred with the first infusion despite premedication with antihistamines.\n', '\n', ' Monitor patients for 1 hour following Erbitux infusions in a setting with resuscitation equipment and other agents necessary to treat  nonoseaeaeonlyasinstruction (eg, epinephrine, corticosteroids, intravenous antihistamines, bronchodilators, and oxygen).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,erbitux,284,5345,5451,"Monitor longer to confirm resolution of the event in patients requiring treatment for  nonoseaeaeonlyasinstruction \n', '\n', ' Immediately and permanently discontinue Erbitux in patients with serious  nonoseaeaeonlyasinstruction  [See   Boxed Warning  ,  Dosage and Administration (2.4)    .]\n', '\n', '    5.2 Cardiopulmonary Arrest\n', '\n', '   oselabeledaefromdruguse and/or  oselabeledaefromdruguse occurred in 4 (2%) of 208 patients treated with radiation therapy and Erbitux as compared to none of 212 patients treated with radiation therapy alone in Study 1.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,erbitux,285,5451,5475,"Three patients with prior history of  notaecandidatepreexistingconditionorriskfactor  nonoseaegeneralterm at home, with  nonoseaeaeonlyasinstruction as the presumed cause of  nonoseaegeneralterm  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
286,erbitux,286,5475,5504,"One of these patients had  notaecandidatepreexistingconditionorriskfactor and one had  notaecandidatepreexistingconditionorriskfactor   nonoseaegeneralterm occurred 27, 32, and 43 days after the last dose of Erbitux.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
287,erbitux,287,5504,5524,One patient with no prior history of  nonoseaenegation  nonoseaegeneralterm one day after the last dose of Erbitux.,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
288,erbitux,288,5524,5574,"In Study 2,  nonoseaegeneralterm  oselabeledaefromdruguse and/or  oselabeledaefromdruguse occurred in 7 (3%) of 219 patients treated with EU-approved cetuximab and platinum-based therapy with 5-FU as compared to 4 (2%) of 215 patients treated with chemotherapy alone.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
289,erbitux,289,5574,5595,Five of these 7 patients in the chemotherapy plus cetuximab arm received concomitant cisplatin and 2 patients received concomitant carboplatin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,erbitux,290,5595,5607,All 4 patients in the chemotherapy-alone arm received cisplatin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,erbitux,291,5607,5646,Carefully consider use of Erbitux in combination with radiation therapy or platinum-based therapy with 5-FU in  notaecandidateindication patients with a history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor in light of these risks.,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
292,erbitux,292,5646,5665,"Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,erbitux,293,5665,5676,"[See   Boxed Warning  ,  Warnings and Precautions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,erbitux,294,5676,5683,"(5.6)    .]\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,erbitux,295,5683,5692,"'\n', '    5.3  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,erbitux,296,5692,5827,"\n', '   oselabeledaefromdruguse , including 1  nonoseaegeneralterm  occurred in 4 of 1570 (<0.5%) patients receiving Erbitux in Studies 1, 3, and 6, as well as other studies, in  notaecandidateindication and  notaecandidateindication  Interrupt Erbitux for acute onset or  nonoseaemanifestationorcomplication  Permanently discontinue Erbitux for confirmed  nonoseaeaeonlyasinstruction \n', '\n', '    5.4 Dermatologic Toxicity\n', '\n', '   oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse drying and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (for example,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse with  oselabeledaefromdruguse   oselabeledaefromdruguse , and  oselabeledaefromdruguse occurred in patients receiving Erbitux therapy.  ",1,1,0,1,1,0,0,0,0,0,0,0,0,0,0
297,erbitux,297,5827,5850,"oselabeledaefromdruguse occurred in 76-88% of 1373 patients receiving Erbitux in Studies 1, 3, 5, and 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,erbitux,298,5850,5904,"Severe  oselabeledaefromdruguse occurred in 1-17% of patients.\n', '\n', '  oselabeledaefromdruguse usually developed within the first two weeks of therapy and resolved in a majority of the patients after cessation of treatment, although in nearly half, the event continued beyond 28 days.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,erbitux,299,5904,5939,"Life-threatening and  nonoseaegeneralterm  oselabeledaefromdruguse  oselabeledaefromdruguse blisters,  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse blisters, erosions, and  oselabeledaefromdruguse has also been observed in patients treated with Erbitux.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
300,erbitux,300,5939,5968,"It could not be determined whether these  nonoseaeaeonlyasinstruction were directly related to  nonoseaeaeonlyasinstruction or to idiosyncratic  nonoseaeaeonlyasinstruction (eg,  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,erbitux,301,5968,5989,Monitor patients receiving Erbitux for  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  Instruct patients to limit sun exposure during Erbitux therapy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,erbitux,302,5989,6059,"[See   Dosage and Administration (2.4)    .]\n', '\n', '    5.5 Use of Erbitux in Combination With Radiation and Cisplatin\n', '\n', '  In a controlled study, 940 patients with locally advanced  notaecandidateindication were randomized 1:1 to receive either Erbitux in combination with radiation therapy and cisplatin or radiation therapy and cisplatin alone.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
303,erbitux,303,6059,6094,The addition of Erbitux resulted in an increase in the incidence of Grade 3-4  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse compared to radiation and cisplatin alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,erbitux,304,6094,6126,Adverse reactions with  nonoseaegeneralterm outcome were reported in 20 patients (4.4%) in the Erbitux combination arm and 14 patients (3.0%) in the control arm.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
305,erbitux,305,6126,6152,Nine patients in the Erbitux arm (2.0%) experienced  oselabeledaefromdruguse compared to 4 patients (0.9%) in the control arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,erbitux,306,6152,6168,The main efficacy outcome of the study was progression-free survival (PFS).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,erbitux,307,6168,6322,"The addition of Erbitux to radiation and cisplatin did not improve PFS.\n', '\n', '    5.6 Hypomagnesemia and Electrolyte Abnormalities\n', '\n', '  In patients evaluated during clinical trials,  oselabeledaefromdruguse occurred in 55% of 365 patients receiving Erbitux in Study 5 and two other clinical trials in  notaecandidateindication and  notaecandidateindication  respectively, and was severe (NCI CTC Grades 3 and 4) in 6-17%.\n', '\n', ' In Study 2, where EU-approved cetuximab was administered in combination with platinum-based therapy, the addition of cetuximab to cisplatin and 5-FU resulted in an increased incidence of  oselabeledaefromdruguse (14% vs. 6%) and of Grade 3-4  oselabeledaefromdruguse (7% vs. 2%) compared to cisplatin and 5-FU alone.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
308,erbitux,308,6322,6355,"In contrast, the incidences of  nonoseaeaeratelteqplacebo were similar for those who received cetuximab, carboplatin, and 5-FU compared to carboplatin and 5-FU (4% vs. 4%).",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
309,erbitux,309,6355,6396,"No patient experienced Grade 3-4  nonoseaenegation in either arm in the carboplatin subgroup.\n', '\n', ' The onset of  oselabeledaefromdruguse and accompanying  oselabeledaefromdruguse occurred days to months after initiation of Erbitux.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
310,erbitux,310,6396,6422,Periodically monitor patients for  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  during and for at least 8 weeks following the completion of Erbitux.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,erbitux,311,6422,6451,"Replete electrolytes as necessary.\n', '\n', '    5.7 Increased Tumor Progression, Increased Mortality, or Lack of Benefit in Patients with Ras  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,erbitux,312,6451,6576,"-Mutant mCRC\n', '\n', '  Erbitux is not indicated for the treatment of patients with  notaecandidateindication that harbor somatic mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of either K-Ras  or N-Ras  and hereafter is referred to as "" Ras  .""\n', '\n', ' Retrospective subset analyses of Ras  -mutant and wild-type populations across several randomized clinical trials including Study 4 were conducted to investigate the role of Ras  mutations on the clinical effects of anti-EGFR-directed monoclonal antibodies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
313,erbitux,313,6576,6595,Use of cetuximab in patients with Ras  mutations resulted in no clinical benefit with treatment related toxicity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,erbitux,314,6595,6716,"[See   Indications and Usage (1.2)  ,  Clinical Pharmacology (12.1)  ,  Clinical Studies (14.2)    .]\n', '\n', '    5.8 Epidermal Growth Factor Receptor (EGFR) Expression and Response\n', '\n', '  Because expression of EGFR has been detected in nearly all  nonoseaeaeonlyasinstruction specimens, patients enrolled in the  notaecandidateindication clinical studies were not required to have immunohistochemical evidence of  nonoseaeaeonlyasinstruction prior to study entry.\n', '\n', ' Patients enrolled in the  notaecandidateindication clinical studies were required to have immunohistochemical evidence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction ']",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
0,votrient,0,0,54,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions in patients with advanced renal cell carcinoma (>=20%) are diarrhea, hypertension, hair color changes (depigmentation), nausea, anorexia, and vomiting.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,votrient,1,54,132,"(  6.1  )\n', '\n', '\n', '\n', ' The most common adverse reactions in patients with advanced soft tissue sarcoma (>=20%) are fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, hair color changes, vomiting, tumor pain, dysgeusia, headache, musculoskeletal pain, myalgia, gastrointestinal pain, and dyspnea.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,votrient,2,132,137,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,votrient,3,137,180,"\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,votrient,4,180,217,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,votrient,5,217,321,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' Potentially serious adverse reactions with VOTRIENT included:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.1)]  \n', ' *     oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,votrient,6,321,331,[see Warnings and Precautions (5.2)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,votrient,7,331,348,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.3)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,votrient,8,348,365,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.4)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,votrient,9,365,390,"\n', ' *     oselabeledaefromdruguse and venous  oselabeledaefromdruguse  oselabeledaefromdruguse [see Warnings and Precautions (5.5 and 5.6)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,votrient,10,390,407,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.7)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,votrient,11,407,430,"\n', ' *     oselabeledaefromdruguse  oselabeledaefromdruguse perforation and  oselabeledaefromdruguse [see Warnings and Precautions (5.8)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,votrient,12,430,450,"\n', ' *     oselabeledaefromdruguse (ILD)/ oselabeledaefromdruguse [see Warnings and Precautions (5.9)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,votrient,13,450,451,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,votrient,14,451,460,"', ' *     oselabeledaefromdruguse (RPLS)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,votrient,15,460,470,[see Warnings and Precautions (5.10)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,votrient,16,470,487,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.11)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,votrient,17,487,504,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.15)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,votrient,18,504,525,"\n', ' *     nonoseaeaefromdruginteraction with other cancer therapies [see Warnings and Precautions (5.16)]  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
19,votrient,19,525,560,"\n', '       notaecandidateindication   The safety of VOTRIENT has been evaluated in 977 patients in the monotherapy trials which included 586 patients with  notaecandidateindication at the time of NDA submission.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
20,votrient,20,560,599,"With a median duration of treatment of 7.4 months (range: 0.1 to 27.6), the most commonly observed adverse reactions (>=20%) in the 586 patients were  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,votrient,21,599,605,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,votrient,22,605,610,oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,votrient,23,610,662,"\n', ' \n', '\n', ' The data described below reflect the safety profile of VOTRIENT in 290  notaecandidateindication patients who participated in a randomized, double-blind, placebo-controlled trial  [see Clinical Studies (14.1)]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,votrient,24,662,697,The median duration of treatment was 7.4 months (range: 0 to 23) for patients who received VOTRIENT and 3.8 months (range: 0 to 22) for the placebo arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,votrient,25,697,710,Forty-two percent of patients on VOTRIENT required a dose interruption.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,votrient,26,710,722,Thirty-six percent of patients on VOTRIENT were dose reduced.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,votrient,27,722,759,"Table 1 presents the most common adverse reactions occurring in >=10% of patients who received VOTRIENT.\n', '\n', '\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,votrient,28,759,771,Adverse Reactions Occurring in >=10% of Patients with RCC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,votrient,29,771,852,"Who Received VOTRIENT \n', '                           VOTRIENT         Placebo       \n', '                           (N = 290)        (N = 145)     \n', '                           All Gradesa      Grade 3       Grade 4       All Gradesa      Grade 3       Grade 4       \n', '  Adverse Reactions        %                %             %             %                %             %             \n', '   oselabeledaefromdruguse                 52               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,votrient,30,852,864,3             <1            9                <1            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,votrient,31,864,871,"\n', '   oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,votrient,32,871,875,40               4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,votrient,33,875,877,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,votrient,34,877,879,10               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,votrient,35,879,904,"<1            0             \n', '   oselabeledaefromdruguse       38               <1            0             3                0             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,votrient,36,904,913,"\n', '   oselabeledaefromdruguse                   26               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,votrient,37,913,922,<1            0             9                0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,votrient,38,922,924,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,votrient,39,924,933,"\n', '   oselabeledaefromdruguse                 22               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,votrient,40,933,935,2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,votrient,41,935,937,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,votrient,42,937,939,10               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,votrient,43,939,964,"<1            0             \n', '   oselabeledaefromdruguse                 21               2             <1            8                2             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,votrient,44,964,973,"\n', '   oselabeledaefromdruguse                  19               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,votrient,45,973,977,2             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,votrient,46,977,981,8                1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,votrient,47,981,983,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,votrient,48,983,992,"\n', '   oselabeledaefromdruguse                 14               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,votrient,49,992,996,3             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,votrient,50,996,1000,8                0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,votrient,51,1000,1002,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,votrient,52,1002,1007,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,votrient,53,1007,1011,oselabeledaefromdruguse           11               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,votrient,54,1011,1015,2             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,votrient,55,1015,1019,1                0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,votrient,56,1019,1021,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,votrient,57,1021,1028,"\n', '   oselabeledaefromdruguse                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,votrient,58,1028,1032,10               0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,votrient,59,1032,1034,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,votrient,60,1034,1038,5                0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,votrient,61,1038,1040,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,votrient,62,1040,1045,"\n', '               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,votrient,63,1045,1119,"a  National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.\n', ' \n', '\n', ' Other adverse reactions observed more commonly in patients treated with VOTRIENT than placebo and that occurred in <10% (any grade) were  oselabeledaefromdruguse (8% versus <1%),  oselabeledaefromdruguse (5% versus 1%),  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,votrient,64,1119,1165,"oselabeledaefromdruguse  (8% versus <1%),  oselabeledaefromdruguse (5% versus <1%),  oselabeledaefromdruguse (4% versus <1%),  oselabeledaefromdruguse (1% versus 0%),  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,votrient,65,1165,1270,"oselabeledaefromdruguse  (6% versus <1%),  oselabeledaefromdruguse (9% versus 0%),  oselabeledaefromdruguse (8% versus 3%),  oselabeledaefromdruguse (3% versus 0%), and  oselabeledaefromdruguse (9% versus 3%).\n', '\n', '\n', '\n', ' Additional adverse reactions from other clinical trials in  notaecandidateindication patients treated with VOTRIENT are listed below:\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n',",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
66,votrient,66,1270,1335,"'\n', '\n', '\n', ' Table 2 presents the most common  nonoseaegeneralterm occurring in >10% of patients who received VOTRIENT and more commonly (>=5%) in patients who received VOTRIENT versus placebo.\n', '\n', '\n', '\n', ' Table 2.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,votrient,67,1335,1373,"Selected Laboratory Abnormalities Occurring in >10% of Patients with RCC Who Received VOTRIENT and More Commonly (>=5%) in Patients Who Received VOTRIENT versus Placebo \n', '                                VOTRIENT        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,votrient,68,1373,1392,"Placebo      \n', '                                (N = 290)       (N = 145)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,votrient,69,1392,1406,"\n', '                                All Gradesa     Grade 3      Grade 4      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,votrient,70,1406,1415,All Gradesa     Grade 3      Grade 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,votrient,71,1415,1434,"\n', '  Parameters                    %               %            %            %               %            %            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,votrient,72,1434,1469,"\n', '   nonoseaegeneralterm                                                                                                       \n', '      oselabeledaefromdruguse                 37              0            0            6               0            0            \n', '      oselabeledaefromdruguse                34              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
73,votrient,73,1469,1485,"1            <1           6               0            0            \n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,votrient,74,1485,1489,oselabeledaefromdruguse           32              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,votrient,75,1489,1499,<1           <1           5               0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,votrient,76,1499,1596,"<1           \n', '      oselabeledaefromdruguse            31              4            <1           24              1            0            \n', '   nonoseaegeneralterm                                                                                                         \n', '      oselabeledaefromdruguse              53              10           2            22              1            0            \n', '      oselabeledaefromdruguse              53              7            <1           19              <1           0            \n', '      oselabeledaefromdruguse          41              <1           0            33              1            0            \n', '      oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,votrient,77,1596,1605,36              3            <1           10              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,votrient,78,1605,1610,1            <1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,votrient,79,1610,1629,"\n', '      oselabeledaefromdruguse       34              4            0            11              0            0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,votrient,80,1629,1648,"\n', '      oselabeledaefromdruguse           31              4            1            24              4            0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,votrient,81,1648,1753,"\n', '      oselabeledaefromdruguse        26              <1           1            14              0            0            \n', '      oselabeledaefromdruguse          17              0            <1           3               0            0            \n', '               a  National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.\n', ' \n', '\n', '    notaecandidateindication   The safety of VOTRIENT has been evaluated in 382 patients with advanced  notaecandidateindication  with a median duration of treatment of 3.6 months (range: 0 to 53).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
82,votrient,82,1753,1844,"The most commonly observed adverse reactions (>=20%) in the 382 patients were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' The data described below reflect the safety profile of VOTRIENT in 240 patients who participated in a randomized, double-blind, placebo-controlled trial  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,votrient,83,1844,1854,[see Clinical Studies (14.2)]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,votrient,84,1854,1877,The median duration of treatment was 4.5 months (range: 0 to 24) for patients who received VOTRIENT and 1.9 months,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,votrient,85,1877,1889,(range: 0 to 24) for the placebo arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,votrient,86,1889,1902,Fifty-eight percent of patients on VOTRIENT required a dose interruption.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,votrient,87,1902,1915,Thirty-eight percent of patients on VOTRIENT had their dose reduced.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,votrient,88,1915,1929,Seventeen percent of patients who received VOTRIENT discontinued therapy due to adverse reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,votrient,89,1929,1966,"Table 3 presents the most common adverse reactions occurring in >=10% of patients who received VOTRIENT.\n', '\n', '\n', '\n', ' Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,votrient,90,1966,1978,Adverse Reactions Occurring in >=10% of Patients with STS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,votrient,91,1978,1990,"Who Received VOTRIENT \n', '                              VOTRIENT         Placebo      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,votrient,92,1990,2007,"\n', '                              (N = 240)        (N = 123)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,votrient,93,2007,2154,"\n', '                              All Gradesa      Grade 3      Grade 4      All Gradesa      Grade 3      Grade 4      \n', '  Adverse Reactions           %                %            %            %                %            %            \n', '   oselabeledaefromdruguse                     65               13           1            48               4            1            \n', '   oselabeledaefromdruguse                    59               5            0            15               1            0            \n', '   oselabeledaefromdruguse                      56               3            0            22               2            0            \n', '   oselabeledaefromdruguse            48               4            0            15               0            0            \n', '   oselabeledaefromdruguse                42               7            0            6                0            0            \n', '   oselabeledaefromdruguse          40               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,votrient,94,2154,2164,6            0            19               0            0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,votrient,95,2164,2183,"\n', '   oselabeledaefromdruguse          39               0            0            2                0            0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,votrient,96,2183,2217,"\n', '   oselabeledaefromdruguse                    33               3            0            11               1            0            \n', '   oselabeledaefromdruguse                  29               8            0            21               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,votrient,97,2217,2221,7            2            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,votrient,98,2221,2272,"\n', '   oselabeledaefromdruguse                   28               0            0            3                0            0            \n', '   oselabeledaefromdruguse                    23               1            0            8                0            0            \n', '   oselabeledaefromdruguse        23               2            0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,votrient,99,2272,2278,20               2            0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,votrient,100,2278,2316,"\n', '   oselabeledaefromdruguse                     23               2            0            9                0            0            \n', '   oselabeledaefromdruguse       23               3            0            9                4            0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,votrient,101,2316,2363,"\n', '   oselabeledaefromdruguse                     20               5            <1           17               5            1            \n', '   oselabeledaefromdruguse            18               <1           0            9                0            0            \n', '   oselabeledaefromdruguse                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,votrient,102,2363,2365,17               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,votrient,103,2365,2500,"<1           0            12               <1           0            \n', '   oselabeledaefromdruguse            14               2            0            9                2            0            \n', '   oselabeledaefromdruguse                   12               2            0            2                0            0            \n', '   oselabeledaefromdruguse                    12               0            0            1                0            0            \n', '   oselabeledaefromdruguse                   11               1            0            4                0            0            \n', '   oselabeledaefromdruguse               11               2            0            1                0            0            \n', '   oselabeledaefromdruguse       11               0            0            0                0            0            \n', '   oselabeledaefromdruguse                  11               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,votrient,104,2500,2574,"<1           0            3                0            0            \n', '   oselabeledaefromdruguse                  10               2            0            6                0            0            \n', '               a  National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.\n', ' \n', '\n', '   b  27 of the 28 cases of  oselabeledaefromdruguse were  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,votrient,105,2574,2789,"\n', '\n', '\n', '\n', ' Other adverse reactions observed more commonly in patients treated with VOTRIENT that occurred in >=5% of patients and at an incidence of more than 2% difference from placebo included  oselabeledaefromdruguse (9% versus 6%),  oselabeledaefromdruguse (8% versus 0%),  oselabeledaefromdruguse (8% versus 2%),  oselabeledaefromdruguse (8% versus 2%),  oselabeledaefromdruguse (8% versus 4%),  oselabeledaefromdruguse (7% versus 2%),  oselabeledaefromdruguse (6% versus <1%),  oselabeledaefromdruguse (5% versus 1%),  oselabeledaefromdruguse (5% versus 2%), and  oselabeledaefromdruguse (5% versus 0%).\n', '\n', '\n', '\n', ' Table 4 presents the most common  nonoseaegeneralterm occurring in >10% of patients who received VOTRIENT and more commonly (>=5%) in patients who received VOTRIENT versus placebo.\n', '\n', '\n', '\n', ' Table 4.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
106,votrient,106,2789,2821,Selected Laboratory Abnormalities Occurring in >10% of Patients with STS Who Received VOTRIENT and More Commonly (>=5%) in Patients Who Received VOTRIENT versus Placebo \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,votrient,107,2821,2829,"', '                                     VOTRIENT       Placebo     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,votrient,108,2829,2840,"\n', '                                     (N = 240)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,votrient,109,2840,2888,"(N = 123)    \n', '                                     All Gradesa    Grade 3     Grade 4     All Gradesa    Grade 3     Grade 4     \n', '  Parameters                         %              %           %           %              %           %           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,votrient,110,2888,2908,"\n', '   nonoseaegeneralterm                                                                                                      \n', '      oselabeledaefromdruguse                      44             1           0           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,votrient,111,2908,2912,15             0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,votrient,112,2912,2914,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,votrient,113,2914,2942,"\n', '      oselabeledaefromdruguse                 43             10          0           36             9           2           \n', '      oselabeledaefromdruguse                36             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,votrient,114,2942,2944,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,votrient,115,2944,2952,1           6              0           0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,votrient,116,2952,2971,"\n', '      oselabeledaefromdruguse                     33             4           0           7              0           0           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,votrient,117,2971,2987,"\n', '   nonoseaegeneralterm                                                                                                        \n', '      oselabeledaefromdruguse                   51             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
118,votrient,118,2987,2989,5           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,votrient,119,2989,2991,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,votrient,120,2991,2995,22             2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,votrient,121,2995,2997,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,votrient,122,2997,3002,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,votrient,123,3002,3006,oselabeledaefromdruguse                   46             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,votrient,124,3006,3008,8           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,votrient,125,3008,3010,2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,votrient,126,3010,3030,"18             2           1           \n', '      oselabeledaefromdruguse               45             <1          0           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,votrient,127,3030,3034,35             2           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,votrient,128,3034,3036,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,votrient,129,3036,3045,"\n', '      oselabeledaefromdruguse               34             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,votrient,130,3045,3047,1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,votrient,131,3047,3049,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,votrient,132,3049,3053,21             0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,votrient,133,3053,3055,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,votrient,134,3055,3062,"\n', '      oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,votrient,135,3062,3066,32             3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,votrient,136,3066,3068,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,votrient,137,3068,3072,23             1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,votrient,138,3072,3074,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,votrient,139,3074,3079,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,votrient,140,3079,3085,oselabeledaefromdruguse                31             4           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,votrient,141,3085,3087,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,votrient,142,3087,3093,20             3           0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,votrient,143,3093,3098,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,votrient,144,3098,3102,oselabeledaefromdruguse       29             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,votrient,145,3102,3106,1           0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,votrient,146,3106,3112,7              2           0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,votrient,147,3112,3121,"\n', '      oselabeledaefromdruguse             16             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,votrient,148,3121,3123,1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,votrient,149,3123,3125,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,votrient,150,3125,3129,11             0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,votrient,151,3129,3131,0           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,votrient,152,3131,3136,"\n', '               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,votrient,153,3136,3186,"a  National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.\n', ' \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse occurred frequently and was predominantly mild to moderate in severity in both the  notaecandidateindication and  notaecandidateindication clinical trials.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
154,votrient,154,3186,3237,"Patients should be advised how to manage mild  nonoseaeaeonlyasinstruction and to notify their healthcare provider if moderate to severe  nonoseaeaeonlyasinstruction occurs so appropriate management can be implemented to minimize its impact.\n', '\n', '\n', '\n', '    nonoseaegeneralterm   ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
155,votrient,155,3237,3264,"In a single-arm  notaecandidateindication trial,  oselabeledaefromdruguse in  oselabeledaefromdruguse values were observed for 27% (48/181) of patients.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
156,votrient,156,3264,3296,oselabeledaefromdruguse in  oselabeledaefromdruguse as an adverse reaction were reported for 4% (10/225) of patients and were Grade 3 for 6 patients and Grade 4 for 1 patient.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,votrient,157,3296,3361,"In the  notaecandidateindication trials of VOTRIENT, clinical  oselabeledaefromdruguse was observed in <1% (4/586) of patients.\n', '\n', '\n', '\n', '    nonoseaegeneralterm   Two of 290 patients treated with VOTRIENT and no patient on the placebo arm in the randomized  notaecandidateindication trial developed a  oselabeledaefromdruguse  ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
158,votrient,158,3361,3413,"In the randomized trial of VOTRIENT for the treatment of  notaecandidateindication   oselabeledaefromdruguse occurred in 3% (8/240) of patients treated with VOTRIENT and in no patients on the placebo arm.\n', '\n', '\n', '\n', '    nonoseaegeneralterm   ",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
159,votrient,159,3413,3466,In the randomized trial of VOTRIENT for the treatment of  notaecandidateindication   oselabeledaefromdruguse based on vital signs (<60 beats per minute) was observed in 19% (52/280) of patients treated with VOTRIENT and in 11% (16/144) of patients on the placebo arm.  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
160,votrient,160,3466,3498,oselabeledaefromdruguse was reported as an adverse reaction in 2% (7/290) of patients treated with VOTRIENT compared with <1% (1/145) of patients treated with placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,votrient,161,3498,3551,In the randomized trial of VOTRIENT for the treatment of  notaecandidateindication   oselabeledaefromdruguse based on vital signs (<60 beats per minute) was observed in 19% (45/238) of patients treated with VOTRIENT and in 4% (5/121) of patients on the placebo arm.  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
162,votrient,162,3551,3624,"oselabeledaefromdruguse was reported as an adverse reaction in 2% (4/240) of patients treated with VOTRIENT compared with <1% (1/123) of patients treated with placebo.\n', '\n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of VOTRIENT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,votrient,163,3624,3710,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse detachment/ oselabeledaefromdruguse  oselabeledaefromdruguse tear.\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
164,votrient,164,3710,3712,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,votrient,165,3712,3719,"HEPATOTOXICITY\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,votrient,166,3719,3723,'  WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,votrient,167,3723,3762,"HEPATOTOXICITY\n', '\n', '    Severe and  nonoseaegeneralterm  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,votrient,168,3762,3774,*    Increases in serum transaminase levels and bilirubin were observed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,votrient,169,3774,3781,Severe and fatal hepatotoxicity has occurred.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,votrient,170,3781,3794,Measure liver chemistries before the initiation of treatment and regularly during treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,votrient,171,3794,3816,"(  5.1  ) \n', ' *    Prolonged QT intervals and torsades de pointes have been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,votrient,172,3816,3830,Use with caution in patients at higher risk of developing QT interval prolongation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,votrient,173,3830,3838,Monitoring electrocardiograms and electrolytes should be considered.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,votrient,174,3838,3843,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,votrient,175,3843,3868,"\n', ' *    Cardiac dysfunction such as congestive heart failure and decreased left ventricular ejection fraction (LVEF) have occurred.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,votrient,176,3868,3876,Monitor blood pressure and manage hypertension promptly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,votrient,177,3876,3892,Baseline and periodic evaluation of LVEF is recommended in patients at risk of cardiac dysfunction.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,votrient,178,3892,3910,"(  5.3  ) \n', ' *    Fatal hemorrhagic events have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,votrient,179,3910,3945,"VOTRIENT has not been studied in patients who have a history of hemoptysis, cerebral, or clinically significant gastrointestinal hemorrhage in the past 6 months and should not be used in those patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,votrient,180,3945,3967,"(  5.4  ) \n', ' *    Arterial thromboembolic events have been observed and can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,votrient,181,3967,3981,Use with caution in patients who are at increased risk for these events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,votrient,182,3981,4010,"(  5.5  ) \n', ' *    Venous thromboembolic events (VTE) have been observed, including fatal pulmonary emboli (PE).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,votrient,183,4010,4020,Monitor for signs and symptoms of VTE and PE.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,votrient,184,4020,4055,"(  5.6  ) \n', ' *    Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) has been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,votrient,185,4055,4062,Permanently discontinue VOTRIENT if TMA occurs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,votrient,186,4062,4080,"(  5.7  ) \n', ' *    Gastrointestinal perforation or fistula has occurred.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,votrient,187,4080,4086,Fatal perforation events have occurred.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,votrient,188,4086,4099,Use with caution in patients at risk for gastrointestinal perforation or fistula.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,votrient,189,4099,4123,"(  5.8  ) \n', ' *    Interstitial lung disease (ILD)/pneumonitis have been observed and can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,votrient,190,4123,4132,Discontinue VOTRIENT in patients developing ILD or pneumonitis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,votrient,191,4132,4158,"(  5.9  ) \n', ' *    Reversible Posterior Leukoencephalopathy Syndrome (RPLS) has been observed and can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,votrient,192,4158,4166,Permanently discontinue VOTRIENT in patients developing RPLS.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,votrient,193,4166,4185,"(  5.10  ) \n', ' *    Hypertension including hypertensive crisis has been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,votrient,194,4185,4196,Blood pressure should be well controlled prior to initiating VOTRIENT.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,votrient,195,4196,4209,Monitor blood pressure within one week after starting VOTRIENT and frequently thereafter.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,votrient,196,4209,4214,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,votrient,197,4214,4233,"\n', ' *    Interruption of therapy with VOTRIENT is recommended in patients undergoing surgical procedures.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,votrient,198,4233,4248,"(  5.12  ) \n', ' *    Hypothyroidism may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,votrient,199,4248,4256,Monitoring of thyroid function tests is recommended.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,votrient,200,4256,4273,"(  5.13  ) \n', ' *    Proteinuria: Monitor urine protein.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,votrient,201,4273,4291,Interrupt treatment for 24-hour urine protein >=3 grams and discontinue for repeat episodes despite dose reductions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,votrient,202,4291,4304,"(  5.14  ) \n', ' *    Infection:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,votrient,203,4304,4322,"Serious infections (with or without neutropenia), some with fatal outcome, have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,votrient,204,4322,4333,Monitor for signs and symptoms and treat active infection promptly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,votrient,205,4333,4338,Interrupt or discontinue VOTRIENT.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,votrient,206,4338,4368,"(  5.15  ) \n', ' *    Animal studies have demonstrated VOTRIENT can severely affect organ growth and maturation during early post-natal development.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,votrient,207,4368,4380,The safety and effectiveness in pediatric patients have not been established.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,votrient,208,4380,4385,(  5.17  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,votrient,209,4385,4403,"\n', ' *    VOTRIENT can cause fetal harm when administered to a pregnant woman.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,votrient,210,4403,4426,Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant while taking VOTRIENT.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,votrient,211,4426,4529,"(  5.18  ,  8.1  ) \n', '    \n', ' \n', '\n', '   5.1 Hepatic Toxicity and Hepatic Impairment\n', '\n', '\n', '\n', '  In clinical trials with VOTRIENT,  oselabeledaefromdruguse  manifested as  oselabeledaefromdruguse in serum transaminases (ALT,  oselabeledaefromdruguse  oselabeledaefromdruguse in serum transaminases (ALT, AST) and  oselabeledaefromdruguse  oselabeledaefromdruguse in serum transaminases ( oselabeledaefromdruguse  oselabeledaefromdruguse (ALT, AST) and bilirubin, was observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,votrient,212,4529,4564,This  oselabeledaefromdruguse can be severe and  nonoseaegeneralterm  Patients older than 65 years are at greater risk for  nonoseaeaeonlyasinstruction [see Use in Specific Populations (8.5)]  .   ,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
213,votrient,213,4564,4589,oselabeledaefromdruguse occur early in the course of treatment (92.5% of all  oselabeledaefromdruguse of any grade occurred in the first 18 weeks),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,votrient,214,4589,4599,[see Dosage and Administration (2.2)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,votrient,215,4599,4643,".\n', '\n', '\n', '\n', ' In the randomized  notaecandidateindication trial,  oselabeledaefromdruguse was reported in 18% and 3% of the groups receiving VOTRIENT and placebo, respectively.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
216,votrient,216,4643,4665,oselabeledaefromdruguse was reported in 4% of patients who received VOTRIENT and in <1% of patients who received placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,votrient,217,4665,4671,Concurrent  oselabeledaefromdruguse in  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,votrient,218,4671,4747,">3 X ULN and  oselabeledaefromdruguse in the absence of significant  nonoseaenegation occurred in 2% (5/290) of patients on VOTRIENT and 1% (2/145) on placebo.\n', '\n', '\n', '\n', ' In the randomized  notaecandidateindication trial,  oselabeledaefromdruguse was reported in 18% and 5% of the groups receiving VOTRIENT and placebo, respectively.  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
219,votrient,219,4747,4766,"oselabeledaefromdruguse was reported in 5% and 2% of the groups receiving VOTRIENT and placebo, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,votrient,220,4766,4782,Concurrent  oselabeledaefromdruguse in  oselabeledaefromdruguse  oselabeledaefromdruguse ALT >3 X ULN and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,votrient,221,4782,4872,">2 X ULN in the absence of significant  nonoseaenegation occurred in 2% (4/240) of patients on VOTRIENT and <1% (1/123) on placebo.\n', '\n', '\n', '\n', ' Two-tenths percent of the patients (2/977) from trials that supported the  notaecandidateindication indication  nonoseaegeneralterm with  nonoseaegeneralterm and  oselabeledaefromdruguse and 0.4% of patients (1/240) in the randomized STS trial  nonoseaegeneralterm of  oselabeledaefromdruguse",0,1,0,1,0,0,0,1,0,0,0,0,0,0,0
222,votrient,222,4872,4912,"\n', '\n', '\n', '\n', ' *    Monitor serum liver tests before initiation of treatment with VOTRIENT and at Weeks 3, 5, 7, and 9.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,votrient,223,4912,4928,"Thereafter, monitor at Month 3 and at Month 4, and as clinically indicated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,votrient,224,4928,4937,Periodic monitoring should then continue after Month 4.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,votrient,225,4937,4972,"\n', ' *    Patients with isolated  nonoseaeaeonlyasinstruction and 8 X ULN may be continued on VOTRIENT with weekly monitoring of liver function until ALT returns to Grade 1 or baseline.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,votrient,226,4972,5001,"\n', ' *    Patients with isolated  nonoseaeaeonlyasinstruction of >8 X ULN should have VOTRIENT interrupted until they return to Grade 1 or baseline.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,votrient,227,5001,5054,If the potential benefit for reinitiating treatment with VOTRIENT is considered to outweigh the risk for  nonoseaeaeonlyasinstruction  then reintroduce VOTRIENT at a reduced dose of no more than 400 mg once daily and measure serum liver tests weekly for 8 weeks [see Dosage and Administration (2.2)] .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,votrient,228,5054,5075,"Following reintroduction of VOTRIENT, if  nonoseaeaeonlyasinstruction >3 X ULN recur, then VOTRIENT should be permanently discontinued.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,votrient,229,5075,5081,"\n', ' *    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,votrient,230,5081,5104,"If  nonoseaeaeonlyasinstruction >3 X ULN occur concurrently with  nonoseaeaeonlyasinstruction >2 X ULN, VOTRIENT should be permanently discontinued.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,votrient,231,5104,5111,Patients should be monitored until resolution.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,votrient,232,5111,5125,VOTRIENT is a uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) inhibitor.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,votrient,233,5125,5146,"Mild, indirect ( oselabeledaefromdruguse may occur in patients with  notaecandidatepreexistingconditionorriskfactor [see Clinical Pharmacology (12.5)] .",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
234,votrient,234,5146,5162,Patients with only a mild  nonoseaeaeonlyasinstruction  known  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction >,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,votrient,235,5162,5214,"3 X ULN should be managed as per the recommendations outlined for isolated  nonoseaeaeonlyasinstruction  \n', '    Concomitant use of VOTRIENT and simvastatin increases the risk of  nonoseaeaefromdruginteraction and should be undertaken with caution and close monitoring [see Drug Interactions (7.4)]  .",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
236,votrient,236,5214,5267,"Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT.\n', ' \n', '\n', ' In patients with pre-existing moderate  notaecandidatepreexistingconditionorriskfactor  the starting dose of VOTRIENT should be reduced or alternatives to VOTRIENT should be considered.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
237,votrient,237,5267,5302,"Treatment with VOTRIENT is not recommended in patients with pre-existing severe  notaecandidatepreexistingconditionorriskfactor  defined as total  notaecandidatepreexistingconditionorriskfactor with any level of ALT [see Dosage and Administration (2.2),",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
238,votrient,238,5302,5317,"Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,votrient,239,5317,5389,".\n', '\n', '\n', '\n', '    5.2 QT Prolongation and Torsades de Pointes\n', '\n', '\n', '\n', '  In the  notaecandidateindication trials of VOTRIENT,  oselabeledaefromdruguse (>=500 msec) was identified on routine electrocardiogram monitoring in 2% (11/558) of patients.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
240,votrient,240,5389,5464,"oselabeledaefromdruguse occurred in <1% (2/977) of patients who received VOTRIENT in the monotherapy trials.\n', '\n', '\n', '\n', ' In the randomized  notaecandidateindication and  notaecandidateindication trials, 1% (3/290) of patients and 0.4% (1/240) of patients, respectively, who received VOTRIENT had post-baseline values between 500 to 549 msec.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
241,votrient,241,5464,5487,Post-baseline QT data were only collected in the  notaecandidateindication trial if  nonoseaegeneralterm were reported as an adverse reaction.,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
242,votrient,242,5487,5646,"None of the 268 patients who received placebo on the two trials had post-baseline  nonoseaenegation \n', '\n', '\n', '\n', ' VOTRIENT should be used with caution in patients with a history of  notaecandidatepreexistingconditionorriskfactor  in patients taking antiarrhythmics or other medications that may  nonoseaeaeonlyasinstruction  and those with relevant  notaecandidatepreexistingconditionorriskfactor cardiac  notaecandidatepreexistingconditionorriskfactor  When using VOTRIENT, baseline and periodic monitoring of electrocardiograms and maintenance of electrolytes (e.g., calcium, magnesium, potassium) within the normal range should be performed.\n', '\n', '\n', '\n', '    5.3 Cardiac Dysfunction\n', '\n', '\n', '\n', '  In clinical trials with VOTRIENT, events of  oselabeledaefromdruguse such as  oselabeledaefromdruguse (LVEF) and  oselabeledaefromdruguse have occurred.",1,0,1,0,0,0,0,1,0,0,0,0,0,0,0
243,votrient,243,5646,5680,"In the overall safety population for  notaecandidateindication (N = 586),  oselabeledaefromdruguse was observed in 0.6% (4/586) of patients without routine on-study LVEF monitoring.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
244,votrient,244,5680,5729,"In a randomized  notaecandidateindication trial of VOTRIENT compared with sunitinib,  nonoseaeaeonlyasinstruction was defined as symptoms of  nonoseaeaeonlyasinstruction or >=15% absolute  nonoseaeaeonlyasinstruction compared with baseline or a  nonoseaeaeonlyasinstruction compared with baseline that is also below the lower limit of normal.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
245,votrient,245,5729,5766,"In patients who had baseline and follow up LVEF measurements,  oselabeledaefromdruguse occurred in 13% (47/362) of patients on VOTRIENT compared with 11% (42/369) of patients on sunitinib.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,votrient,246,5766,5778,oselabeledaefromdruguse occurred in 0.5% of patients on each arm.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,votrient,247,5778,5810,"In the randomized  notaecandidateindication trial,  oselabeledaefromdruguse occurred in 11% (16/142) of patients on VOTRIENT compared with 5% (2/40) of patients on placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
248,votrient,248,5810,5927,"One percent (3/240) of patients on VOTRIENT in the  notaecandidateindication trial had  oselabeledaefromdruguse which did not resolve in one patient.\n', '\n', '\n', '\n', ' Fourteen of the 16 patients with  oselabeledaefromdruguse treated with VOTRIENT in the  notaecandidateindication trial had concurrent  notaecandidatepreexistingconditionorriskfactor which may have exacerbated  nonoseaegeneralterm in patients at risk (e.g., those with prior anthracycline therapy) possibly by  nonoseaeaeonlyasinstruction  Blood pressure should be monitored and managed promptly using a combination of  nonoseaeaeonlyasinstruction and dose modification of VOTRIENT (interruption and re-initiation at a reduced dose based on clinical judgment)",1,1,1,1,0,0,0,0,0,0,0,0,0,0,0
249,votrient,249,5927,5938,[see Warnings and Precautions (5.11)]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,votrient,250,5938,6037,"Patients should be carefully monitored for clinical signs or symptoms of  nonoseaeaeonlyasinstruction  Baseline and periodic evaluation of LVEF is recommended in patients at risk of  nonoseaeaeonlyasinstruction including previous anthracycline exposure.\n', '\n', '\n', '\n', '    5.4 Hemorrhagic Events\n', '\n', '\n', '\n', '  Fatal  oselabeledaefromdruguse occurred in 0.9% (5/586) in the  notaecandidateindication trials; there were no reports of  nonoseaegeneralterm  nonoseaenegation in the  notaecandidateindication trials.",1,1,0,1,0,0,0,1,0,0,0,0,0,0,0
251,votrient,251,6037,6071,"In the randomized  notaecandidateindication trial, 13% (37/290) of patients treated with VOTRIENT and 5% (7/145) of patients on placebo experienced at least 1  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
252,votrient,252,6071,6112,"The most common  oselabeledaefromdruguse in the patients treated with VOTRIENT were  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (2%), and  oselabeledaefromdruguse (1%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,votrient,253,6112,6146,"Nine of 37 patients treated with VOTRIENT who had  oselabeledaefromdruguse experienced serious events including  oselabeledaefromdruguse  gastrointestinal, and genitourinary  oselabeledaefromdruguse  oselabeledaefromdruguse  and genitourinary  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,votrient,254,6146,6171,One percent (4/290) of patients treated with VOTRIENT  nonoseaegeneralterm from  oselabeledaefromdruguse compared with no (0/145) patients on placebo.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
255,votrient,255,6171,6255,"In the overall safety population in  notaecandidateindication (N = 586),  oselabeledaefromdruguse intracranial  oselabeledaefromdruguse  oselabeledaefromdruguse was observed in <1% (2/586) of patients treated with VOTRIENT.\n', '\n', '\n', '\n', ' In the randomized  notaecandidateindication trial, 22% (53/240) of patients treated with VOTRIENT compared with 8% (10/123) treated with placebo experienced at least 1  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
256,votrient,256,6255,6283,"The most common  oselabeledaefromdruguse were  oselabeledaefromdruguse (8%),  oselabeledaefromdruguse (3%), and  oselabeledaefromdruguse (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,votrient,257,6283,6426,"Grade 4  oselabeledaefromdruguse in the  notaecandidateindication population occurred in 1% (3/240) of patients and included  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' VOTRIENT has not been studied in patients who have a history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or clinically significant  notaecandidatepreexistingconditionorriskfactor in the past 6 months and should not be used in those patients.\n', '\n', '\n', '\n', '    5.5 Arterial Thromboembolic Events\n', '\n', '\n', '\n', '  Fatal  oselabeledaefromdruguse were observed in 0.3% (2/586) of patients in the  notaecandidateindication trials and in no patients in the  notaecandidateindication trials.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
258,votrient,258,6426,6475,"In the randomized  notaecandidateindication trial, 2% (5/290) of patients receiving VOTRIENT experienced  oselabeledaefromdruguse  oselabeledaefromdruguse infarction or  oselabeledaefromdruguse  0.3% (1/290) had a  oselabeledaefromdruguse  and 1% (4/290) had an event of  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
259,votrient,259,6475,6517,"In the randomized  notaecandidateindication trial, 2% (4/240) of patients receiving VOTRIENT experienced a  oselabeledaefromdruguse or  oselabeledaefromdruguse  0.4% (1/240) had a  oselabeledaefromdruguse and there were no incidents of  nonoseaenegation  ",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
260,votrient,260,6517,6531,No  nonoseaenegation were reported in patients who received placebo in either trial.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
261,votrient,261,6531,6557,VOTRIENT should be used with caution in patients who are at increased risk for these events or who have had a history of these events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,votrient,262,6557,6647,"VOTRIENT has not been studied in patients who have had an  notaecandidatepreexistingconditionorriskfactor within the previous 6 months and should not be used in those patients.\n', '\n', '\n', '\n', '    5.6 Venous Thromboembolic Events\n', '\n', '\n', '\n', '  In  notaecandidatepreexistingconditionorriskfactor and  notaecandidateindication trials of VOTRIENT,  oselabeledaefromdruguse (VTE) including  oselabeledaefromdruguse and fatal  oselabeledaefromdruguse (PE) have occurred.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
263,votrient,263,6647,6673,"In the randomized  notaecandidateindication trial,  oselabeledaefromdruguse were reported in 5% of patients treated with VOTRIENT compared with 2% with placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
264,votrient,264,6673,6690,"In the randomized  notaecandidateindication trial, the rate was 1% in both arms.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
265,votrient,265,6690,6713,nonoseaegeneralterm  oselabeledaefromdruguse occurred in 1% (2/240) of  notaecandidateindication patients receiving VOTRIENT and in no patients receiving placebo.,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
266,votrient,266,6713,6725,There were no fatal  nonoseaenegation in the  notaecandidateindication trial.,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
267,votrient,267,6725,6812,"Monitor for signs and symptoms of  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.7 Thrombotic Microangiopathy\n', '\n', '\n', '\n', '   oselabeledaefromdruguse (TMA), including  oselabeledaefromdruguse (TTP) and  oselabeledaefromdruguse (HUS), has been reported in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,votrient,268,6812,6824,VOTRIENT is not indicated for use in combination with other agents.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,votrient,269,6824,6841,Six of the 7  oselabeledaefromdruguse cases occurred within 90 days of the initiation of VOTRIENT.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,votrient,270,6841,6852,Improvement of  nonoseaeaeonlyasinstruction was observed after treatment was discontinued.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,votrient,271,6852,6947,"Monitor for signs and symptoms of  nonoseaeaeonlyasinstruction  Permanently discontinue VOTRIENT in patients developing  nonoseaeaeonlyasinstruction  Manage as clinically indicated.\n', '\n', '\n', '\n', '    5.8 Gastrointestinal Perforation and Fistula\n', '\n', '\n', '\n', '  In the  notaecandidateindication and  notaecandidateindication trials,  nonoseaeaeonlyasinstruction perforation or fistula occurred in 0.9% (5/586) of patients and 1% (4/382) of patients receiving VOTRIENT, respectively.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
272,votrient,272,6947,6983,"Fatal  nonoseaeaeonlyasinstruction  oselabeledaefromdruguse perforation or  oselabeledaefromdruguse  oselabeledaefromdruguse or fistula occurred in 0.9% (5/586) of patients and 1% (4/382) of patients receiving VOTRIENT, respectively.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,votrient,273,6983,7016,nonoseaegeneralterm perforations occurred in 0.3% (2/586) of these patients in the  notaecandidateindication trials and in 0.3% (1/382) of these patients in the  notaecandidateindication trials.,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
274,votrient,274,7016,7030,Monitor for signs and symptoms of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction perforation or  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,votrient,275,7030,7085,"\n', '\n', '\n', '\n', '    5.9  oselabeledaefromdruguse /Pneumonitis\n', '\n', '\n', '\n', '    oselabeledaefromdruguse  oselabeledaefromdruguse  which can be  nonoseaegeneralterm  has been reported in association with VOTRIENT.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
276,votrient,276,7085,7104,"In clinical trials,  oselabeledaefromdruguse  oselabeledaefromdruguse occurred in 0.1% of patients treated with VOTRIENT.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,votrient,277,7104,7106,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,votrient,278,7106,7144,", '\n', '\n', '\n', '  Monitor patients for pulmonary symptoms indicative of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and discontinue VOTRIENT in patients developing  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,votrient,279,7144,7183,"\n', '\n', '\n', '\n', '    5.10 Reversible Posterior Leukoencephalopathy Syndrome\n', '\n', '\n', '\n', '   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,votrient,280,7183,7198,(RPLS) has been reported in patients receiving VOTRIENT and may be  nonoseaegeneralterm,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
281,votrient,281,7198,7229,"\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction is a  nonoseaegeneralterm which can present with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   ",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
282,votrient,282,7229,7255,nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and other  nonoseaegeneralterm and neurologic  nonoseaegeneralterm  nonoseaegeneralterm  Mild to severe  nonoseaemanifestationorcomplication may be present.,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
283,votrient,283,7255,7268,The diagnosis of  nonoseaeaeonlyasinstruction is optimally confirmed by magnetic resonance imaging.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,votrient,284,7268,7334,"Permanently discontinue VOTRIENT in patients developing  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.11 Hypertension\n', '\n', '\n', '\n', '  In clinical trials,  oselabeledaefromdruguse ( oselabeledaefromdruguse or  oselabeledaefromdruguse  and  oselabeledaefromdruguse were observed in patients treated with VOTRIENT.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,votrient,285,7334,7346,Blood pressure should be well controlled prior to initiating VOTRIENT.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,votrient,286,7346,7376,oselabeledaefromdruguse occurs early in the course of treatment (40% of cases occurred by Day 9 and 90% of cases occurred in the first 18 weeks).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,votrient,287,7376,7401,Blood pressure should be monitored early after starting treatment (no longer than one week) and frequently thereafter to ensure blood pressure control.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,votrient,288,7401,7438,Approximately 40% of patients who received VOTRIENT experienced  oselabeledaefromdruguse  Grade 3  oselabeledaefromdruguse was reported in 4% to 7% of patients receiving VOTRIENT [see Adverse Reactions (6.1)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,votrient,289,7438,7475,".\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction should be treated promptly with standard  nonoseaeaeonlyasinstruction and dose reduction or interruption of VOTRIENT as clinically warranted.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,votrient,290,7475,7501,VOTRIENT should be discontinued if there is evidence of  nonoseaeaeonlyasinstruction or if  nonoseaeaeonlyasinstruction is severe and persistent despite  nonoseaeaeonlyasinstruction and dose reduction.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,votrient,291,7501,7525,Approximately 1% of patients required permanent discontinuation of VOTRIENT because of  oselabeledaefromdruguse [see Dosage and Administration (2.2)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,votrient,292,7525,7576,".\n', '\n', '\n', '\n', '    5.12 Wound Healing\n', '\n', '\n', '\n', '  No formal trials on the effect of VOTRIENT on  nonoseaeaeonlyasinstruction have been conducted.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,votrient,293,7576,7608,Since vascular endothelial growth factor receptor (VEGFR) inhibitors such as pazopanib may  oselabeledaeclasseffect  treatment with VOTRIENT should be stopped at least 7 days prior to scheduled surgery.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,votrient,294,7608,7626,The decision to resume VOTRIENT after surgery should be based on clinical judgment of adequate wound healing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,votrient,295,7626,7721,"VOTRIENT should be discontinued in patients with  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.13 Hypothyroidism\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  confirmed based on a simultaneous  oselabeledaefromdruguse and  oselabeledaefromdruguse  was reported in 7% (19/290) of patients treated with VOTRIENT in the randomized  notaecandidateindication trial and in 5% (11/240) of patients treated with VOTRIENT in the randomized  notaecandidateindication trial.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
296,votrient,296,7721,7734,No patients on the placebo arm of either trial had  nonoseaenegation  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
297,votrient,297,7734,7769,"In  notaecandidateindication and  notaecandidateindication trials of VOTRIENT,  oselabeledaefromdruguse was reported as an adverse reaction in 4% (26/586) and 5% (20/382) of patients, respectively.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
298,votrient,298,7769,7843,"Proactive monitoring of thyroid function tests is recommended.\n', '\n', '\n', '\n', '    5.14 Proteinuria\n', '\n', '\n', '\n', '  In the randomized  notaecandidateindication trial,  oselabeledaefromdruguse was reported as an adverse reaction in 9% (27/290) of patients receiving VOTRIENT and in no patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
299,votrient,299,7843,7857,"In 2 patients,  oselabeledaefromdruguse led to discontinuation of treatment with VOTRIENT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,votrient,300,7857,7900,"In the randomized  notaecandidateindication trial,  oselabeledaefromdruguse was reported as an adverse reaction in 1% (2/240) of patients, and  oselabeledaefromdruguse was reported in 1 patient treated with VOTRIENT compared with none in patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
301,votrient,301,7900,7909,Treatment was withdrawn in the patient with  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,votrient,302,7909,7945,"\n', '\n', '\n', '\n', ' Baseline and periodic urinalysis during treatment is recommended with follow up measurement of 24-hour urine protein as clinically indicated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,votrient,303,7945,7954,Interrupt VOTRIENT and dose reduce for 24-hour urine protein,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,votrient,304,7954,7976,>=3 grams; discontinue VOTRIENT for repeat episodes despite dose reductions [see Dosage and Administration (2.2)]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,votrient,305,7976,8033,".\n', '\n', '\n', '\n', '    5.15 Infection\n', '\n', '\n', '\n', '  Serious  oselabeledaefromdruguse  oselabeledaefromdruguse ( oselabeledaefromdruguse or without  oselabeledaefromdruguse , including some with fatal outcome, have been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,votrient,306,8033,8113,"Monitor patients for signs and symptoms of  nonoseaeaeonlyasinstruction  Institute appropriate anti-infective therapy promptly and consider interruption or discontinuation of VOTRIENT for serious  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.16 Increased Toxicity with Other Cancer Therapy\n', '\n', '\n', '\n', '  VOTRIENT is not indicated for use in combination with other agents.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,votrient,307,8113,8136,Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to concerns over increased toxicity and  nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
308,votrient,308,8136,8151,The  nonoseaegeneralterm toxicities observed included  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  and  nonoseaeaefromdruginteraction  ,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
309,votrient,309,8151,8216,"A safe and effective combination dose has not been established with these regimens.\n', '\n', '\n', '\n', '    5.17 Increased Toxicity in Developing Organs\n', '\n', '\n', '\n', '  The safety and effectiveness of VOTRIENT in pediatric patients have not been established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,votrient,310,8216,8226,VOTRIENT is not indicated for use in pediatric patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,votrient,311,8226,8248,"Based on its mechanism of action, pazopanib may have severe  oselabeledaefromdruguse  nonoseaeaeanimal during early post-natal development.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
312,votrient,312,8248,8310,"Administration of pazopanib to juvenile rats less than 21 days old resulted in  nonoseaeaeanimal  nonoseaeaeanimal lungs,  nonoseaeaeanimal  nonoseaeaeanimal lungs, liver,  nonoseaeaeanimal  nonoseaeaeanimal to the lungs, liver, heart, and  nonoseaeaeanimal and in  nonoseaegeneralterm at doses significantly lower than the clinically recommended dose or doses tolerated in older animals.",0,1,0,0,0,0,0,0,1,0,0,0,0,0,0
313,votrient,313,8310,8341,"VOTRIENT may potentially cause serious  oselabeledaefromdruguse in pediatric patients, particularly in patients younger than 2 years of age [see Use in Specific Populations (8.4)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,votrient,314,8341,8389,".\n', '\n', '\n', '\n', '    5.18 Pregnancy\n', '\n', '\n', '\n', '  VOTRIENT can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
315,votrient,315,8389,8405,"Based on its mechanism of action, VOTRIENT is expected to result in  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,votrient,316,8405,8418,"In pre-clinical studies in rats and rabbits, pazopanib was  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,votrient,317,8418,8428,nonoseaeaeanimal   nonoseaeaeanimal   nonoseaeaeanimal  and  nonoseaeaeanimal \n,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
318,votrient,318,8428,8459,"', '\n', '\n', '\n', ' There are no adequate and well-controlled studies of VOTRIENT in  notaecandidatepreexistingconditionorriskfactor women.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
319,votrient,319,8459,8505,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while taking this drug, the patient should be apprised of the potential  oselabeledaefromdruguse  Women of childbearing potential should be advised to avoid becoming  nonoseaeaeonlyasinstruction ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,vimpat,0,0,62,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are described below and elsewhere in the labeling:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse Behavior and  oselabeledaefromdruguse [ see  Warnings and Precautions (5.1)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,vimpat,1,62,83,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [ see  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,vimpat,2,83,89,"\n', ' *   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,vimpat,3,89,96,oselabeledaefromdruguse and Conduction  oselabeledaefromdruguse  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,vimpat,4,96,111,Rhythm and  oselabeledaefromdruguse [ see  Warnings and Precautions (5.3)   ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,vimpat,5,111,129,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.4)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,vimpat,6,129,147,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.5)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,vimpat,7,147,156,"\n', '   *  Monotherapy:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,vimpat,8,156,211,"Most common adverse reactions are similar to those seen in adjunctive therapy studies (  6.1  ) \n', ' *  Adjunctive therapy: Most common adverse reactions (>=10% and greater than placebo) are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,vimpat,9,211,219,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,vimpat,10,219,338,"To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,vimpat,11,338,352,In the premarketing development of adjunctive therapy for  notaecandidateindication onset  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,vimpat,12,352,381,"1327 patients received VIMPAT in controlled and uncontrolled trials, of whom 1000 were treated for longer than 6 months, and 852 for longer than 12 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,vimpat,13,381,456,"The monotherapy development program included 425 patients, 310 of whom were treated for longer than 6 months, and 254 for longer than 12 months.\n', '\n', '\n', '\n', '     VIMPAT Tablet and Oral Solution  \n', '\n', '\n', '\n', '     Monotherapy Historical-Control Trial (Study 1)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,vimpat,14,456,474,"\n', '\n', '\n', '\n', ' *     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,vimpat,15,474,510,"In the monotherapy trial, 16% of patients randomized to receive VIMPAT at the recommended doses of 300 and 400 mg/day discontinued from the trial as a result of an adverse reaction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,vimpat,16,510,558,"The adverse reaction most commonly (>=1% on VIMPAT) leading to discontinuation was  oselabeledaefromdruguse  \n', '   *     Adverse reactions that occurred in this study were generally similar to those that occurred in adjunctive placebo-controlled studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,vimpat,17,558,586,"One adverse reaction,  oselabeledaefromdruguse  occurred at a rate of >=2% and was not reported at a similar rate in previous studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,vimpat,18,586,607,This adverse reaction has also been observed in postmarketing experience [ see  Adverse Reactions (6.2)   ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,vimpat,19,607,624,"Because this study did not include a placebo control group, causality could not be established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,vimpat,20,624,672,"\n', '   *      oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse all occurred at lower incidences during the AED Withdrawal Phase and Monotherapy Phase, compared with the Titration Phase [ see  Clinical Studies (14.1)   ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,vimpat,21,672,705,"\n', '        Adjunctive Therapy Controlled Trials (Studies 2, 3, and 4)  \n', ' \n', '\n', ' *     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,vimpat,22,705,767,"In adjunctive therapy controlled clinical trials, the rate of discontinuation as a result of an adverse reaction was 8% and 17% in patients randomized to receive VIMPAT at the recommended doses of 200 and 400 mg/day, respectively, 29% at 600 mg/day, and 5% in patients randomized to receive placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,vimpat,23,767,850,"The adverse reactions most commonly (>1% on VIMPAT and greater than placebo) leading to discontinuation were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  \n', '   *     Table 2 gives the incidence of adverse reactions that occurred in >=2% of adult patients with  notaecandidateindication onset  notaecandidateindication in the VIMPAT total group and for which the incidence was greater than placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,vimpat,24,850,858,"\n', '   Table 2:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,vimpat,25,858,886,"Adverse Reactions Incidence in Adjunctive Therapy Pooled, Placebo-Controlled Trials in Patients with Partial-Onset Seizures (Studies 2, 3, and 4)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,vimpat,26,886,918,"\n', ' System Organ Class/Preferred Term   PlaceboN=364%    VIMPAT200 mg/dayN=270%  VIMPAT400 mg/dayN=471%  VIMPAT600 mg/dayN=203%  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,vimpat,27,918,931,"VIMPATTotalN=944%   \n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,vimpat,28,931,933,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,vimpat,29,933,957,"\n', '    oselabeledaefromdruguse                    1                 5                 3                 4                 4           \n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,vimpat,30,957,996,"\n', '    oselabeledaefromdruguse                   2                 6                 10                16                11          \n', '    oselabeledaefromdruguse             3                 2                 9                 16                8           \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,vimpat,31,996,998,nonoseaegeneralterm     ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,vimpat,32,998,1015,"\n', '    oselabeledaefromdruguse                     4                 7                 11                17                11          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,vimpat,33,1015,1080,"\n', '    oselabeledaefromdruguse                   3                 6                 9                 16                9           \n', '    oselabeledaefromdruguse                   3                 3                 5                 4                 4           \n', '    nonoseaegeneralterm     \n', '    oselabeledaefromdruguse                    6                 7                 7                 15                9           \n', '    oselabeledaefromdruguse           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,vimpat,34,1080,1109,"<1                <1                2                 4                 2           \n', '    oselabeledaefromdruguse                   1                 2                 2                 4                 2           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,vimpat,35,1109,1116,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,vimpat,36,1116,1123,"\n', '    oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,vimpat,37,1123,1125,3                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,vimpat,38,1125,1131,3                 4                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,vimpat,39,1131,1133,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,vimpat,40,1133,1138,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,vimpat,41,1138,1144,oselabeledaefromdruguse            2                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,vimpat,42,1144,1146,3                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,vimpat,43,1146,1148,3                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,vimpat,44,1148,1150,3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,vimpat,45,1150,1174,"\n', '    nonoseaegeneralterm     \n', '    oselabeledaefromdruguse                  8                 16                30                53                31          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
46,vimpat,46,1174,1191,"\n', '    oselabeledaefromdruguse                   9                 11                14                12                13          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,vimpat,47,1191,1217,"\n', '    oselabeledaefromdruguse                     2                 4                 7                 15                8           \n', '    oselabeledaefromdruguse                 5                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,vimpat,48,1217,1225,5                 8                 8                 7           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,vimpat,49,1225,1249,"\n', '    oselabeledaefromdruguse                     4                 4                 6                 12                7           \n', '    oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,vimpat,50,1249,1253,4                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,vimpat,51,1253,1257,5                 10                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,vimpat,52,1257,1259,5           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,vimpat,53,1259,1264,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,vimpat,54,1264,1268,oselabeledaefromdruguse           0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,vimpat,55,1268,1270,1                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,vimpat,56,1270,1274,5                 6                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,vimpat,57,1274,1276,4           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,vimpat,58,1276,1281,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,vimpat,59,1281,1300,"oselabeledaefromdruguse          2                 1                 2                 6                 2           \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,vimpat,60,1300,1317,"\n', '    oselabeledaefromdruguse                 1                 2                 2                 2                 2           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,vimpat,61,1317,1324,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,vimpat,62,1324,1341,"\n', '    oselabeledaefromdruguse                   1                 3                 2                 3                 2           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,vimpat,63,1341,1359,"\n', '            The overall adverse reaction rate was similar in male and female patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,vimpat,64,1359,1448,"Although there were few non-Caucasian patients, no differences in the incidences of adverse events compared to Caucasian patients were observed.\n', ' \n', '\n', '     Laboratory Abnormalities  \n', '\n', '\n', '\n', ' *      oselabeledaefromdruguse in  oselabeledaefromdruguse have occurred in controlled trials with VIMPAT in adult patients with  notaecandidateindication onset  notaecandidateindication who were taking 1 to 3 concomitant anti-epileptic drugs.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
65,vimpat,65,1448,1454,oselabeledaefromdruguse of  oselabeledaefromdruguse to >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,vimpat,66,1454,1477,=3* ULN occurred in 0.7% (7/935) of VIMPAT patients and 0% (0/356) of placebo patients .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,vimpat,67,1477,1507,"One case of  oselabeledaefromdruguse with  nonoseaemanifestationorcomplication occurred in one healthy subject 10 days after VIMPAT treatment completion, along with  oselabeledaefromdruguse ( nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication .",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
68,vimpat,68,1507,1526,Serologic studies were negative for  nonoseaenegation  Transaminases returned to normal within one month without specific treatment.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
69,vimpat,69,1526,1537,"At the time of this event, bilirubin was normal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,vimpat,70,1537,1551,The  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication was interpreted as a  oselabeledaefromdruguse to VIMPAT.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
71,vimpat,71,1551,1560,"\n', '        Other Adverse Reactions  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,vimpat,72,1560,1574,"\n', ' \n', '\n', ' *     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,vimpat,73,1574,1614,The following is a list of adverse reactions reported by patients treated with VIMPAT in all clinical trials in patients with  notaecandidateindication onset  notaecandidateindication  including controlled trials and long-term open-label extension trials.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
74,vimpat,74,1614,1627,Adverse reactions addressed in other tables or sections are not listed here.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,vimpat,75,1627,1639,"\n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,vimpat,76,1639,1675,"\n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse \n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse \n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,vimpat,77,1675,1689,"\n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
78,vimpat,78,1689,1729,"\n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse \n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse \n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
79,vimpat,79,1729,1743,"\n', '   *      nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
80,vimpat,80,1743,1835,"\n', '        VIMPAT Injection  \n', ' \n', '\n', ' Adverse reactions with intravenous administration generally were similar to those that occurred with the oral formulation, although intravenous administration was associated with local adverse reactions such as  oselabeledaefromdruguse  oselabeledaefromdruguse pain or  oselabeledaefromdruguse  oselabeledaefromdruguse pain or discomfort (2.5%),  oselabeledaefromdruguse  oselabeledaefromdruguse pain or discomfort (2.5%), irritation (1%), and  oselabeledaefromdruguse (0.5%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,vimpat,81,1835,1862,One case of profound  nonoseaeaefromdruginteraction (26 bpm: BP 100/60 mmHg) occurred in a patient during a 15-minute infusion of 150 mg VIMPAT.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
82,vimpat,82,1862,1871,This patient was on a beta-blocker.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,vimpat,83,1871,1976,"Infusion was discontinued and the patient experienced a rapid recovery.\n', '\n', '\n', '\n', ' The safety of a 15-minute loading dose administration of VIMPAT Injection 200 mg to 400 mg followed by oral administration of VIMPAT given twice daily at the same total daily dose as the initial intravenous infusion was assessed in an open-label study in patients with  notaecandidateindication onset  notaecandidateindication  Patients had to have been maintained on a stable dose regimen of 1 to 2 marketed antiepileptics for at least 28 days prior to treatment assignment.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
84,vimpat,84,1976,2050,"Treatment groups were as follows:\n', '\n', '\n', '\n', ' *  Single dose of intravenous VIMPAT Injection 200 mg followed by oral VIMPAT 200 mg/day (100 mg every 12 hours) \n', ' *  Single dose of intravenous VIMPAT Injection 300 mg followed by oral VIMPAT 300 mg/day (150 mg every 12 hours)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,vimpat,85,2050,2054,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,vimpat,86,2054,2080,*  Single dose of intravenous VIMPAT Injection 400 mg followed by oral VIMPAT 400 mg/day (200 mg every 12 hours).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,vimpat,87,2080,2178,"\n', '    Table 3 gives the incidence of adverse reactions that occurred in >=5% of adult patients in any VIMPAT dosing group.\n', ' \n', '\n', ' Table 3: Adverse Reactions in a 15-minute Infusion Study in Patients with Partial-Onset Seizures \n', ' System Organ Class/Preferred Term                 VIMPAT 200 mgN=25%  VIMPAT 300 mgN=50%  VIMPAT 400 mgN=25%  VIMPAT TotalN=100%   \n', '  \n', '    nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
88,vimpat,88,2178,2187,"\n', '    oselabeledaefromdruguse                                              4              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,vimpat,89,2187,2202,"6             20              9         \n', '    oselabeledaefromdruguse                                        0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,vimpat,90,2202,2208,4             12              5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,vimpat,91,2208,2215,"\n', '    nonoseaegeneralterm                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
92,vimpat,92,2215,2224,"\n', '    oselabeledaefromdruguse                                                0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,vimpat,93,2224,2226,16             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,vimpat,94,2226,2230,24             14         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,vimpat,95,2230,2239,"\n', '    oselabeledaefromdruguse                                             0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,vimpat,96,2239,2243,6             12              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,vimpat,97,2243,2245,6         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,vimpat,98,2245,2254,"\n', '    oselabeledaefromdruguse                                              0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,vimpat,99,2254,2275,"4             12              5         \n', '    oselabeledaefromdruguse                                      4              4              8              5         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,vimpat,100,2275,2305,"\n', '    oselabeledaefromdruguse                                     0              6              8              5         \n', '    oselabeledaefromdruguse                                              0              8              0              4         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,vimpat,101,2305,2312,"\n', '    nonoseaegeneralterm                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,vimpat,102,2312,2319,"\n', '    oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,vimpat,103,2319,2321,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,vimpat,104,2321,2323,18             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,vimpat,105,2323,2327,12             12         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,vimpat,106,2327,2355,"\n', '    oselabeledaefromdruguse                                      8              2              0              3         \n', '    oselabeledaefromdruguse                                            0              0             12              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,vimpat,107,2355,2357,3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,vimpat,108,2357,2371,"\n', '    nonoseaegeneralterm                                                                                     \n', '    oselabeledaefromdruguse                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,vimpat,109,2371,2375,20             46             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,vimpat,110,2375,2377,60             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,vimpat,111,2377,2379,43         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,vimpat,112,2379,2388,"\n', '    oselabeledaefromdruguse                                            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,vimpat,113,2388,2390,34             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,vimpat,114,2390,2394,36             26         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,vimpat,115,2394,2401,"\n', '    oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,vimpat,116,2401,2407,8              4             16              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,vimpat,117,2407,2409,8         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,vimpat,118,2409,2424,"\n', '    oselabeledaefromdruguse                                           8              6              4              6         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,vimpat,119,2424,2433,"\n', '    oselabeledaefromdruguse                                                0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,vimpat,120,2433,2448,"6              4              4         \n', '    oselabeledaefromdruguse                                 0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,vimpat,121,2448,2452,6              0              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,vimpat,122,2452,2454,3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,vimpat,123,2454,2533,"\n', '    nonoseaegeneralterm                                                                         \n', '    oselabeledaefromdruguse                                              0              6              4              4         \n', '    oselabeledaefromdruguse                                         0              0              8              2         \n', '           Adverse reactions that occurred with infusion of VIMPAT 200 mg over 15-minutes followed by VIMPAT 100 mg administered orally twice per day were similar in frequency to those that occurred in 3-month adjunctive therapy controlled trials.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,vimpat,124,2533,2620,"Considering the difference in period of observations (1 week vs. 3 months), the incidence of CNS adverse reactions, such as  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse may be higher with 15-minute administration of VIMPAT Injection than with administration over a 30-to 60-minute period.\n', ' \n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of VIMPAT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,vimpat,125,2620,2694,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
126,vimpat,126,2694,2760,"\n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Monitor patients for suicidal behavior and ideation (  5.1  ) \n', '",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,vimpat,127,2760,2773,*  VIMPAT may cause dizziness and ataxia (  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,vimpat,128,2773,2777,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,vimpat,129,2777,2830,"*  Cardiac Rhythm and Conduction Abnormalities: ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state maintenance dose is recommended in patients with known cardiac conduction problems, taking drugs known to induce PR interval prolongation, or with severe cardiac disease (  5.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,vimpat,130,2830,2845,"\n', ' *  VIMPAT may cause syncope (  5.4  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,vimpat,131,2845,2849,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,vimpat,132,2849,2952,"*  VIMPAT should be gradually withdrawn to minimize the potential of increased seizure frequency (  5.5  ) \n', ' *  Multiorgan Hypersensitivity Reactions (  5.6  ) \n', '    \n', ' \n', '\n', '   5.1 Suicidal Behavior and Ideation\n', '\n', '\n', '\n', '  Antiepileptic drugs (AEDs), including VIMPAT, increase the risk of  oselabeledaefromdruguse  oselabeledaefromdruguse thoughts or  oselabeledaefromdruguse in patients taking these drugs for any indication.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,vimpat,133,2952,3063,"Patients treated with any AED for any indication should be monitored for the emergence or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction  and/or any unusual  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or behavior.\n', '\n', '\n', '\n', ' Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking or  oselabeledaeclasseffect compared to patients randomized to placebo.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,vimpat,134,3063,3132,"In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of  oselabeledaeclasseffect  oselabeledaeclasseffect behavior or  oselabeledaeclasseffect among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking or  oselabeledaeclasseffect for every 530 patients treated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,vimpat,135,3132,3222,"There were four  oselabeledaeclasseffect in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' The increased risk of  oselabeledaeclasseffect  oselabeledaeclasseffect thoughts or  oselabeledaeclasseffect with AEDs was observed as early as one week after starting treatment with AEDs and persisted for the duration of treatment assessed.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,vimpat,136,3222,3269,"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction beyond 24 weeks could not be assessed.\n', '\n', '\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,vimpat,137,3269,3290,The risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts or  nonoseaeaeonlyasinstruction was generally consistent among drugs in the data analyzed.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,vimpat,138,3290,3321,The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,vimpat,139,3321,3417,"The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.\n', '\n', '\n', '\n', ' Table 1 shows absolute and relative risk by indication for all evaluated AEDs.\n', '\n', '\n', '\n', ' Table 1 Risk by Indication for Antiepileptic Drugs in the Pooled Analysis \n', ' Indication            Placebo Patients with Events Per 1000 Patients  Drug Patients with Events Per 1000 Patients  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,vimpat,140,3417,3420,Relative Risk:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,vimpat,141,3420,3435,Incidence of Events in Drug Patients/Incidence in Placebo Patients  Risk Difference:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,vimpat,142,3435,3444,Additional Drug Patients with Events Per 1000 Patients   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,vimpat,143,3444,3454,"\n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,vimpat,144,3454,3471,"notaecandidatepreexistingconditionorriskfactor                      1.0                   3.4                   3.5                   2.4            \n', '  notaecandidatepreexistingconditionorriskfactor                   ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
145,vimpat,145,3471,3475,5.7                   8.5                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,vimpat,146,3475,3479,1.5                   2.9            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,vimpat,147,3479,3480,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,vimpat,148,3480,3487,"', ' Other                         1.0                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,vimpat,149,3487,3512,"1.8                   1.9                   0.9            \n', ' Total                         2.4                   4.3                   1.8                   1.9            \n', '           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,vimpat,150,3512,3583,"The relative risk for  oselabeledaeclasseffect thoughts or  oselabeledaeclasseffect  oselabeledaeclasseffect or behavior was higher in clinical trials for  notaecandidatepreexistingconditionorriskfactor than in clinical trials for  notaecandidatepreexistingconditionorriskfactor or other conditions, but the absolute risk differences were similar.\n', ' \n', '\n', ' Anyone considering prescribing VIMPAT or any other AED must balance this risk with the risk of untreated illness.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
151,vimpat,151,3583,3879,"notaecandidatepreexistingconditionorriskfactor and many other illnesses for which antiepileptics are prescribed are themselves associated with morbidity and mortality and an increased risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  Should  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.\n', '\n', '\n', '\n', ' Patients, their caregivers, and families should be informed that AEDs increase the risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of  nonoseaeaeonlyasinstruction  any unusual  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction mood or  nonoseaeaeonlyasinstruction  or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts,  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction should be reported immediately to healthcare providers.\n', '\n', '\n', '\n', '    5.2 Dizziness and Ataxia\n', '\n', '\n', '\n', '  VIMPAT may cause  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' In patients with  notaecandidateindication onset  notaecandidateindication taking 1 to 3 concomitant AEDs,  oselabeledaefromdruguse was experienced by 25% of patients randomized to the recommended doses (200 to 400 mg/day) of VIMPAT (compared with 8% of placebo patients) and was the adverse event most frequently leading to discontinuation (3%).  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
152,vimpat,152,3879,3912,oselabeledaefromdruguse was experienced by 6% of patients randomized to the recommended doses (200 to 400 mg/day) of VIMPAT (compared to 2% of placebo patients).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,vimpat,153,3912,3927,The onset of  oselabeledaefromdruguse and  oselabeledaefromdruguse was most commonly observed during titration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,vimpat,154,3927,3950,There was a substantial increase in these adverse events at doses higher than 400 mg/day [ see  Adverse Reactions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,vimpat,155,3950,3954,6.1)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,vimpat,156,3954,4043,".\n', '\n', '\n', '\n', '    5.3 Cardiac Rhythm and Conduction Abnormalities\n', '\n', '\n', '\n', '   PR interval prolongation  \n', '\n', '\n', '\n', ' Dose-dependent  oselabeledaefromdruguse with VIMPAT have been observed in clinical studies in patients and in healthy volunteers [ see  Clinical Pharmacology (12.2)    ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,vimpat,157,4043,4095,In adjunctive clinical trials in patients with  notaecandidateindication onset  notaecandidateindication  asymptomatic  oselabeledaefromdruguse (AV)  oselabeledaefromdruguse was observed as an adverse reaction in 0.4% (4/944) of patients randomized to receive VIMPAT and 0% (0/364) of patients randomized to receive placebo.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
158,vimpat,158,4095,4135,In clinical trials in patients with  notaecandidatepreexistingconditionorriskfactor  asymptomatic  oselabeledaefromdruguse was observed as an adverse reaction in 0.5% (5/1023) of patients receiving VIMPAT and 0% (0/291) of patients receiving placebo.  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
159,vimpat,159,4135,4169,oselabeledaefromdruguse and complete  oselabeledaefromdruguse  oselabeledaefromdruguse have been reported in patients in  notaecandidatepreexistingconditionorriskfactor studies and in patients with  notaecandidatepreexistingconditionorriskfactor  When VIMPAT is given with other drugs that  nonoseaeaeonlyasinstruction   ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
160,vimpat,160,4169,4273,"nonoseaeaefromdruginteraction is possible.\n', '\n', '\n', '\n', '  VIMPAT should be used with caution in patients with known conduction problems (e.g., marked  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor without pacemaker),  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor , on concomitant medications that  nonoseaeaeonlyasinstruction  or with severe  notaecandidatepreexistingconditionorriskfactor such as  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor  In such patients, obtaining an ECG before beginning VIMPAT, and after VIMPAT is titrated to steady-state maintenance dose, is recommended.",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
161,vimpat,161,4273,4292,"In addition, these patients should be closely monitored if they are administered VIMPAT through the intravenous route.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,vimpat,162,4292,4312,One case of profound  oselabeledaefromdruguse was observed in a patient during a 15-minute infusion of 150 mg VIMPAT.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,vimpat,163,4312,4362,"There were two postmarketing reports of  nonoseaeaefromdruginteraction in patients with significant  notaecandidatepreexistingconditionorriskfactor and also receiving metoprolol and amlodipine during infusion of VIMPAT injection at doses higher than recommended [ see  Adverse Reactions (6.1)  ,  Drug Interactions (7.2)  ].    ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
164,vimpat,164,4362,4401,"\n', '\n', '\n', '\n', '    Atrial fibrillation and Atrial flutter  \n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,vimpat,165,4401,4429,"In the short-term investigational trials of VIMPAT in  notaecandidatepreexistingconditionorriskfactor patients, there were no cases of  nonoseaenegation  nonoseaenegation fibrillation or  nonoseaenegation  ",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
166,vimpat,166,4429,4449,Both  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in open label  notaecandidatepreexistingconditionorriskfactor trials and in postmarketing experience.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
167,vimpat,167,4449,4483,In patients with  notaecandidatepreexistingconditionorriskfactor  0.5% of patients treated with VIMPAT experienced an adverse reaction of  oselabeledaefromdruguse or  oselabeledaefromdruguse  compared to 0% of placebo-treated patients.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
168,vimpat,168,4483,4505,"VIMPAT administration may predispose to  oselabeledaefromdruguse ( oselabeledaefromdruguse  oselabeledaefromdruguse fibrillation or  oselabeledaefromdruguse , especially in patients with  notaecandidatepreexistingconditionorriskfactor",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
169,vimpat,169,4505,4508,and/or  notaecandidatepreexistingconditionorriskfactor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
170,vimpat,170,4508,4531,"\n', '\n', '\n', '\n', '    5.4 Syncope\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,vimpat,171,4531,4572,"', '\n', '\n', '   In the short-term controlled trials of VIMPAT in epilepsy patients with no significant system illnesses, there was no increase in  nonoseaeaeratelteqplacebo compared to placebo.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
172,vimpat,172,4572,4639,In the short-term controlled trials of VIMPAT in patients with  notaecandidatepreexistingconditionorriskfactor  1.2% of patients who were treated with VIMPAT reported an adverse reaction of  oselabeledaefromdruguse or  oselabeledaefromdruguse  compared to 0% of placebo-treated patients with  notaecandidatepreexistingconditionorriskfactor  Most of the cases of  oselabeledaefromdruguse were observed in patients receiving doses above 400 mg/day.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
173,vimpat,173,4639,4651,The cause of  nonoseaeaeonlyasinstruction was not determined in most cases.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,vimpat,174,4651,4697,"However, several were associated with either  nonoseaeaeonlyasinstruction orthostatic  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction flutter/ nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction fibrillation (and associated  nonoseaeaeonlyasinstruction , or  oselabeledaefromdruguse  Cases of  oselabeledaefromdruguse have also been observed in open-label clinical  notaecandidatepreexistingconditionorriskfactor studies.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
175,vimpat,175,4697,4845,"These cases were associated with a history of risk factors for  notaecandidatepreexistingconditionorriskfactor and the use of  notaecandidatepreexistingconditionorriskfactor   \n', '\n', '\n', '\n', '    5.5 Withdrawal of Antiepileptic Drugs (AEDs)\n', '\n', '\n', '\n', '  As with all AEDs, VIMPAT should be withdrawn gradually (over a minimum of 1 week) to minimize the potential of  nonoseaeodorwithdrawal in patients with  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.6 Multiorgan Hypersensitivity Reactions\n', '\n', '\n', '\n', '  One case of symptomatic  oselabeledaefromdruguse and  oselabeledaefromdruguse was observed among 4011 subjects exposed to VIMPAT during clinical development.",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
176,vimpat,176,4845,4860,"The event occurred in a healthy volunteer, 10 days after stopping VIMPAT treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,vimpat,177,4860,4877,The subject was not taking any concomitant medication and potential known  nonoseaenegation were  nonoseaenegation  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
178,vimpat,178,4877,4889,"The subject fully recovered within a month, without specific treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,vimpat,179,4889,4986,"The case is consistent with a delayed  oselabeledaefromdruguse  Additional potential cases included 2 with  oselabeledaefromdruguse and  oselabeledaefromdruguse and 1 with  oselabeledaefromdruguse and  oselabeledaefromdruguse of uncertain etiology.\n', '\n', '\n', '\n', '  oselabeledaeclasseffect  have been reported with other antiepileptics and typically, although not exclusively, present with  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication associated with other organ system involvement, that may or may not include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication ']",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,xalkori,0,0,115,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse (Pneumonitis) [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,xalkori,1,115,126,*  Severe  oselabeledaefromdruguse [see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,xalkori,2,126,140,"(5.5)  ]  \n', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,xalkori,3,140,182,"The most common adverse reactions (>=25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,xalkori,4,182,227,"(  6  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,xalkori,5,227,256,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,xalkori,6,256,445,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' The data in the Warnings and Precautions section reflect exposure to XALKORI in 1719 patients who received XALKORI 250 mg twice daily enrolled on Studies 1 (including an additional 109 patients who crossed over from the control arm), 2, 3, a single arm trial (n=1063) of  notaecandidateindication  notaecandidateindication  and an additional  notaecandidateindication  notaecandidateindication expansion cohort of a dose finding study (n=154)  [see  Warnings and Precautions (5)  ]  .\n', '\n', ' The data described below is based primarily on 343 patients with  notaecandidateindication  notaecandidateindication who received XALKORI 250 mg twice daily from 2 open-label, randomized, active-controlled trials (Studies 1 and 2).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,xalkori,7,445,591,"The safety of XALKORI was also evaluated in 50 patients with ROS1-positive  notaecandidateindication from a single-arm study (Study 3).\n', '\n', ' The most common adverse reactions (>=25%) of XALKORI are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '     Previously Untreated ALK-Positive Metastatic NSCLC - Study 1  \n', '\n', ' The data in Table 3 are derived from 340 patients with  notaecandidateindication metastatic  notaecandidateindication who had not received previous systemic treatment for advanced disease who received treatment in a randomized, multicenter, open-label, active-controlled trial (Study 1).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,xalkori,8,591,629,"Patients in the XALKORI arm (n=171) received XALKORI 250 mg orally twice daily until documented disease progression, intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,xalkori,9,629,692,A total of 169 patients in the chemotherapy arm received pemetrexed 500 mg/m  2  in combination with cisplatin 75 mg/m  2  (n=91) or carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 5 or 6 mg min/mL (n=78).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,xalkori,10,692,719,"Chemotherapy was given by intravenous infusion every 3 weeks for up to 6 cycles, in the absence of dose-limiting chemotherapy-related toxicities.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,xalkori,11,719,773,"After 6 cycles, patients remained on study with no additional anticancer treatment, and tumor assessments continued until documented disease progression.\n', '\n', ' The median duration of study treatment was 10.9 months for patients in the XALKORI arm and 4.1 months for patients in the chemotherapy arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,xalkori,12,773,791,Median duration of treatment was 5.2 months for patients who received XALKORI after cross over from chemotherapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,xalkori,13,791,819,"Across the 340 patients who were treated in Study 1, the median age was 53 years; 16% of patients were older than 65 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,xalkori,14,819,856,"A total of 62% of patients were female and 46% were Asian.\n', '\n', ' Serious adverse events were reported in 58 patients (34%) treated with XALKORI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,xalkori,15,856,883,The most frequent serious adverse events reported in patients treated with XALKORI were  oselabeledaefromdruguse (4.1%) and  oselabeledaefromdruguse (2.9%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,xalkori,16,883,932,"Fatal adverse events in XALKORI-treated patients occurred in 2.3% patients, consisting of  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', ' Dose reductions due to adverse reactions were required in 6.4% of XALKORI-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,xalkori,17,932,976,"The most frequent adverse reactions that led to dose reduction in these patients were  oselabeledaefromdruguse (1.8%) and  oselabeledaefromdruguse (1.8%).\n', '\n', ' Permanent discontinuation of XALKORI treatment for adverse reactions was 8.2%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,xalkori,18,976,1044,"The most frequent adverse reactions that led to permanent discontinuation in XALKORI-treated patients were  oselabeledaefromdruguse (1.2%),  oselabeledaefromdruguse (1.2%), and  oselabeledaefromdruguse (1.2%).\n', '\n', ' Tables 3 and 4 summarize common adverse reactions and  nonoseaegeneralterm in XALKORI-treated patients.\n', '\n', ' Table 3.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,xalkori,19,1044,1051,Adverse Reactions Reported at a Higher Incidence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,xalkori,20,1051,1129,"(>=5% Higher for All Grades or >=2% Higher for Grades 3-4) with XALKORI than Chemotherapy in Study 1Adverse reactions were graded using NCI CTCAE version 4.0.Includes cases reported within the clustered terms: \n', ' Adverse Reaction                     XALKORI(N=171)   Chemotherapy (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin)(N=169)   \n', ' All Grades(%)                         Grade 3-4(%)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,xalkori,21,1129,1133,All Grades(%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,xalkori,22,1133,1139,Grade 3-4(%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,xalkori,23,1139,1160,"\n', '  \n', '    nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse            6                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,xalkori,24,1160,1184,"2                 2                  0            \n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,xalkori,25,1184,1188,14                1                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,xalkori,26,1188,1192,1                  0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,xalkori,27,1192,1199,"\n', '    nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,xalkori,28,1199,1227,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,xalkori,29,1227,1235,71                1                10                  0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,xalkori,30,1235,1242,"\n', '    nonoseaegeneralterm                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,xalkori,31,1242,1323,"\n', '    oselabeledaefromdruguse                                 46                2                36                  3            \n', '    oselabeledaefromdruguse                                 61                2                13                  1            \n', '    oselabeledaefromdruguse                             43                2                30                  0            \n', '    oselabeledaefromdruguse                                14                0                 2                  0            \n', '    oselabeledaefromdruguse                                10                1                 2                  1            \n', '    oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,xalkori,32,1323,1341,[note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,xalkori,33,1341,1349,26                0                12                  0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,xalkori,34,1349,1367,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse .]          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,xalkori,35,1367,1369,6                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,xalkori,36,1369,1375,2                 1                  0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,xalkori,37,1375,1382,"\n', '    nonoseaegeneralterm                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,xalkori,38,1382,1408,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,xalkori,39,1408,1438,"49                1                12                  1            \n', '    oselabeledaefromdruguse                                  19                0                11                  1            \n', '    nonoseaegeneralterm                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,xalkori,40,1438,1460,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,xalkori,41,1460,1464,32                0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,xalkori,42,1464,1468,12                  1            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,xalkori,43,1468,1475,"\n', '    nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,xalkori,44,1475,1491,"\n', '    oselabeledaefromdruguse                          8                1                 2                  0            \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,xalkori,45,1491,1497,"', '    nonoseaegeneralterm                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
46,xalkori,46,1497,1504,"\n', '    oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,xalkori,47,1504,1512,16                0                 7                  0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,xalkori,48,1512,1523,"\n', '    oselabeledaefromdruguse                              8                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,xalkori,49,1523,1527,2                  1            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,xalkori,50,1527,1556,"\n', '    nonoseaegeneralterm                                                                                     \n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,xalkori,51,1556,1560,18                0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,xalkori,52,1560,1575,"10                  1            \n', '    oselabeledaefromdruguse                                26                0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,xalkori,53,1575,1579,5                  0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,xalkori,54,1579,1595,"\n', '    oselabeledaefromdruguse                                 22                1                15                  0            \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,xalkori,55,1595,1721,"', '           Additional adverse reactions occurring at an overall incidence between 1% and 60% in patients treated with XALKORI included  oselabeledaefromdruguse (56%),  oselabeledaefromdruguse (30%),  oselabeledaefromdruguse (29%),  oselabeledaefromdruguse (21%;  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (5%),  oselabeledaefromdruguse (1%;  oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (1%;  oselabeledaefromdruguse .\n', ' \n', '\n', ' Table 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,xalkori,56,1721,1742,Laboratory Abnormalities with Grade 3 or 4 Incidence of >=4% in XALKORI-Treated Patients in Study 1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,xalkori,57,1742,1753,"\n', ' Laboratory Abnormality         XALKORI           Chemotherapy      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,xalkori,58,1753,1768,"\n', '                              Any Grade(%)        Grade 3-4(%)         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,xalkori,59,1768,1778,Any Grade(%)          Grade 3-4(%)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,xalkori,60,1778,1787,"\n', '  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,xalkori,61,1787,1836,Additional  nonoseaegeneralterm in patients treated with XALKORI was an  oselabeledaefromdruguse (Any Grade: 99%; Grade 3: 2%; Grade 4: 0%) compared to the chemotherapy arm (Any Grade: 92%; Grade 3: 0%;,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,xalkori,62,1836,1844,Grade 4: 1%).   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,xalkori,63,1844,1854,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,xalkori,64,1854,1856,nonoseaegeneralterm                                                                                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,xalkori,65,1856,1865,"\n', '    oselabeledaefromdruguse                     52                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,xalkori,66,1865,1869,11                   59                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,xalkori,67,1869,1871,16            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,xalkori,68,1871,1893,"\n', '    oselabeledaefromdruguse                     48                  7                    53                    13            \n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,xalkori,69,1893,1894,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,xalkori,70,1894,1902,"', '    oselabeledaefromdruguse                   79                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,xalkori,71,1902,1906,15                   33                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,xalkori,72,1906,1908,2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,xalkori,73,1908,1917,"\n', '    oselabeledaefromdruguse                   66                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,xalkori,74,1917,1919,8                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,xalkori,75,1919,1921,28                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,xalkori,76,1921,1923,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,xalkori,77,1923,1932,"\n', '    oselabeledaefromdruguse                32                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,xalkori,78,1932,1936,10                   21                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,xalkori,79,1936,2001,"6             \n', '               Previously Treated ALK-Positive Metastatic NSCLC - Study 2  \n', ' \n', '\n', ' The data in Table 5 are derived from 343 patients with  notaecandidateindication  notaecandidateindication enrolled in a randomized, multicenter, active-controlled, open-label trial (Study 2).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
80,xalkori,80,2001,2039,"Patients in the XALKORI arm (n=172) received XALKORI 250 mg orally twice daily until documented disease progression, intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,xalkori,81,2039,2101,"A total of 171 patients in the chemotherapy arm received pemetrexed 500 mg/m  2  (n=99) or docetaxel 75 mg/m  2  (n=72) by intravenous infusion every 3 weeks until documented disease progression, intolerance to therapy, or the investigator determined that the patient was no longer experiencing clinical benefit.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,xalkori,82,2101,2152,"Patients in the chemotherapy arm received pemetrexed unless they had received pemetrexed as part of first-line or maintenance treatment.\n', '\n', ' The median duration of study treatment was 7.1 months for patients who received XALKORI and 2.8 months for patients who received chemotherapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,xalkori,83,2152,2191,"Across the 347 patients who were randomized to study treatment (343 received at least 1 dose of study treatment), the median age was 50 years; 14% of patients were older than 65 years.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,xalkori,84,2191,2241,"A total of 56% of patients were female and 45% of patients were Asian.\n', '\n', ' Serious adverse reactions were reported in 64 patients (37.2%) treated with XALKORI and 40 patients (23.4%) in the chemotherapy arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,xalkori,85,2241,2284,"The most frequent serious adverse reactions reported in patients treated with XALKORI were  oselabeledaefromdruguse (4.1%),  oselabeledaefromdruguse (3.5%),  oselabeledaefromdruguse (2.3%), and  oselabeledaefromdruguse (2.9%).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,xalkori,86,2284,2327,"nonoseaegeneralterm adverse reactions in XALKORI-treated patients in Study 2 occurred in 9 (5%) patients, consisting of:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
87,xalkori,87,2327,2352,"\n', '\n', ' Dose reductions due to adverse reactions were required in 16% of XALKORI-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,xalkori,88,2352,2413,"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were  oselabeledaefromdruguse (7.6%) including some patients with concurrent  oselabeledaefromdruguse   oselabeledaefromdruguse (2.9%), and  oselabeledaefromdruguse (2.3%).\n', '\n', ' XALKORI was discontinued for adverse reactions in 15% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,xalkori,89,2413,2490,"The most frequent adverse reactions that led to discontinuation of XALKORI were  oselabeledaefromdruguse (1.7%),  oselabeledaefromdruguse and AST  oselabeledaefromdruguse  oselabeledaefromdruguse (1.2%),  oselabeledaefromdruguse (1.2%), and  oselabeledaefromdruguse (1.2%).\n', '\n', ' Tables 5 and 6 summarize common adverse reactions and  nonoseaegeneralterm in XALKORI-treated patients.\n', '\n', ' Table 5.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,xalkori,90,2490,2497,Adverse Reactions Reported at a Higher Incidence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,xalkori,91,2497,2554,"(>=5% Higher for All Grades or >=2% Higher for Grades 3/4) with XALKORI than Chemotherapy in Study 2Adverse reactions were graded using NCI CTCAE version 4.0.Includes cases reported within the clustered terms: \n', ' Adverse Reaction                          XALKORI(N=172)   Chemotherapy(Pemetrexed or Docetaxel)(N=171)   \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,xalkori,92,2554,2562,"', '                                            All Grades(%)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,xalkori,93,2562,2568,Grade 3-4(%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,xalkori,94,2568,2572,All Grades(%)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,xalkori,95,2572,2578,Grade 3-4(%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,xalkori,96,2578,2610,"\n', '  \n', '    nonoseaegeneralterm                                                                                     \n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
97,xalkori,97,2610,2633,"22                1                8                0          \n', '    oselabeledaefromdruguse                                     26                0                9                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,xalkori,98,2633,2648,"\n', '    oselabeledaefromdruguse                                        3                3                0                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,xalkori,99,2648,2655,"\n', '    nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,xalkori,100,2655,2683,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,xalkori,101,2683,2718,"60                0                9                0          \n', '    nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse                 5                3                0                0          \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,xalkori,102,2718,2731,oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse .]          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,xalkori,103,2731,2746,"5                0                0                0          \n', '    nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,xalkori,104,2746,2766,"\n', '    oselabeledaefromdruguse                              10                1                4                0          \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,xalkori,105,2766,2768,nonoseaegeneralterm                                                                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
106,xalkori,106,2768,2783,"\n', '    oselabeledaefromdruguse                                      47                1               18                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,xalkori,107,2783,2788,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,xalkori,108,2788,2809,"oselabeledaefromdruguse                                        55                1               37                1          \n', '    oselabeledaefromdruguse                                      60                0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,xalkori,109,2809,2813,19                1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,xalkori,110,2813,2818,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,xalkori,111,2818,2843,"oselabeledaefromdruguse                                  42                2               23                0          \n', '    oselabeledaefromdruguse                                      8                0                3                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,xalkori,112,2843,2850,"\n', '    nonoseaegeneralterm                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,xalkori,113,2850,2874,"\n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,xalkori,114,2874,2880,26                0               13                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,xalkori,115,2880,2882,1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,xalkori,116,2882,2907,"\n', '    nonoseaegeneralterm                                                                         \n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse .]          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
117,xalkori,117,2907,2950,"6                5                2                2          \n', '    nonoseaegeneralterm                                                                         \n', '    oselabeledaefromdruguse [note:  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse .]         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
118,xalkori,118,2950,2954,31                0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,xalkori,119,2954,2958,16                0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,xalkori,120,2958,3089,"\n', '           Additional adverse reactions occurring at an overall incidence between 1% and 30% in patients treated with XALKORI included  oselabeledaefromdruguse (27%),  oselabeledaefromdruguse (27%),  oselabeledaefromdruguse (19%;  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse (9%),  oselabeledaefromdruguse (4%;  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse (4%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (1%;  oselabeledaefromdruguse .\n', ' \n', '\n', ' Table 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,xalkori,121,3089,3110,Laboratory Abnormalities with Grade 3 or 4 Incidence of >=4% in XALKORI-Treated Patients in Study 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,xalkori,122,3110,3136,"\n', ' Laboratory Abnormality                        XALKORI       Chemotherapy     \n', '                                            Any Grade(%)     Grade 3-4(%)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,xalkori,123,3136,3146,Any Grade(%)     Grade 3-4(%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,xalkori,124,3146,3155,"\n', '  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,xalkori,125,3155,3212,Additional  nonoseaegeneralterm in patients treated with XALKORI was an  oselabeledaefromdruguse (Any Grade: 96%; Grade 3: 1%; Grade 4: 0%) compared to the chemotherapy arm (Any Grade: 72%; Grade 3: 0%; Grade 4: 0%).   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
126,xalkori,126,3212,3222,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,xalkori,127,3222,3224,nonoseaegeneralterm                                                                                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
128,xalkori,128,3224,3231,"\n', '    oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,xalkori,129,3231,3252,"49               12               28               12          \n', '    oselabeledaefromdruguse                                   51                9               60               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,xalkori,130,3252,3254,25          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,xalkori,131,3254,3261,"\n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
132,xalkori,132,3261,3266,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,xalkori,133,3266,3274,oselabeledaefromdruguse                                 76               17               38                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,xalkori,134,3274,3276,4          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,xalkori,135,3276,3311,"\n', '    oselabeledaefromdruguse                                 61                9               33                0          \n', '    oselabeledaefromdruguse                                   18                4               10                1          \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,xalkori,136,3311,3321,oselabeledaefromdruguse                              28                5               25                6          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,xalkori,137,3321,3333,"\n', '               ROS1-Positive Metastatic NSCLC - Study 3  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,xalkori,138,3333,3387,"\n', ' \n', '\n', ' The safety profile of XALKORI from Study 3, which was evaluated in 50 patients with ROS1-positive  notaecandidateindication  was generally consistent with the safety profile of XALKORI evaluated in patients with  notaecandidateindication  notaecandidateindication (n=1669).  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
139,xalkori,139,3387,3410,oselabeledaefromdruguse occurred in 92% of patients in Study 3; 90% were Grade 1 and 2% were Grade 2.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,xalkori,140,3410,3482,"The median duration of exposure to XALKORI was 34.4 months.\n', '\n', '     Description of Selected Adverse Drug Reactions  \n', '\n', '     Vision disorders  \n', '\n', '  oselabeledaefromdruguse  most commonly  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse  occurred in 1084 (63.1%) of 1719 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,xalkori,141,3482,3497,The majority (95%) of these patients had Grade 1  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,xalkori,142,3497,3520,There were 13 (0.8%) patients with Grade 3 and 4 (0.2%) patients with Grade 4  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,xalkori,143,3520,3564,"\n', '\n', ' Based on the Visual Symptom Assessment Questionnaire (VSAQ-ALK), patients treated with XALKORI in Studies 1 and 2 reported a higher incidence of  oselabeledaefromdruguse compared to patients treated with chemotherapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,xalkori,144,3564,3579,The onset of  oselabeledaefromdruguse generally was within the first week of drug administration.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,xalkori,145,3579,3690,"The majority of patients on the XALKORI arms in Studies 1 and 2 (>50%) reported  oselabeledaefromdruguse which occurred at a frequency of 4-7 days each week, lasted up to 1 minute, and had mild or no impact (scores 0 to 3 out of a maximum score of 10) on daily activities as captured in the VSAQ-ALK questionnaire.\n', '\n', '     Neuropathy  \n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse  most commonly  oselabeledaefromdruguse in nature, occurred in 435 (25%) of 1719 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,xalkori,146,3690,3757,"Most events (95%) were Grade 1 or Grade 2 in severity.\n', '\n', '     Renal cysts  \n', '\n', '  oselabeledaefromdruguse were experienced by 52 (3%) of 1719 patients.\n', '\n', ' The majority of  oselabeledaefromdruguse in XALKORI-treated patients were complex.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,xalkori,147,3757,3772,"oselabeledaefromdruguse occurred, in some cases with imaging characteristics suggestive of  nonoseaeaeonlyasinstruction formation.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,xalkori,148,3772,3856,"However, across clinical trials no  nonoseaenegation were confirmed by microbiology tests.\n', '\n', '      oselabeledaefromdruguse  \n', '\n', ' The estimated  oselabeledaefromdruguse from a baseline median of 96.42 mL/min/1.73 m  2  (n=1681) to a median of 80.23 mL/min/1.73 m  2  at 2 weeks (n=1499) in patients with  notaecandidateindication advanced  notaecandidateindication who received XALKORI in clinical trials.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
149,xalkori,149,3856,3872,No clinically relevant changes occurred in median eGFR from 12 to 104 weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,xalkori,150,3872,3894,Median  nonoseaeaeonlyasinstruction (83.02 mL/min/1.73 m  2  ) 4 weeks after the last dose of XALKORI.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,xalkori,151,3894,3946,"Overall, 76% of patients had a  oselabeledaefromdruguse to <90 mL/min/1.73 m  2  , 38% had a  oselabeledaefromdruguse to  oselabeledaefromdruguse to <60 mL/min/1.73 m  2  , and 3.6% had a  oselabeledaefromdruguse to  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,xalkori,152,3946,3951,5 WARNINGS AND PRECAUTIONS\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,xalkori,153,3951,3974,", '\n', '   EXCERPT:    *  Hepatotoxicity: Fatal hepatotoxicity occurred in 0.1% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,xalkori,154,3974,3980,Monitor with periodic liver testing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,xalkori,155,3980,3991,"Temporarily suspend, dose reduce, or permanently discontinue XALKORI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,xalkori,156,3991,4015,"(  5.1  ) \n', ' *  Interstitial Lung Disease (ILD)/Pneumonitis: Occurred in 2.9% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,xalkori,157,4015,4024,Permanently discontinue in patients with ILD/pneumonitis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,xalkori,158,4024,4029,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,xalkori,159,4029,4033,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,xalkori,160,4033,4039,*  QT Interval Prolongation:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,xalkori,161,4039,4046,Occurred in 2.1% of patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,xalkori,162,4046,4072,"Monitor electrocardiograms and electrolytes in patients who have a history of or predisposition for QTc prolongation, or who are taking medications that prolong QT.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,xalkori,163,4072,4083,"Temporarily suspend, dose reduce, or permanently discontinue XALKORI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,xalkori,164,4083,4101,"(  5.3  ) \n', ' *  Bradycardia: XALKORI can cause bradycardia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,xalkori,165,4101,4109,Monitor heart rate and blood pressure regularly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,xalkori,166,4109,4120,"Temporarily suspend, dose reduce, or permanently discontinue XALKORI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,xalkori,167,4120,4135,"(  5.4  ) \n', ' *  Severe Visual Loss:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,xalkori,168,4135,4142,Reported in 0.2% of patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,xalkori,169,4142,4151,Discontinue XALKORI in patients with severe visual loss.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,xalkori,170,4151,4156,Perform an ophthalmological evaluation.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,xalkori,171,4156,4177,"(  5.5  ) \n', ' *  Embryo-Fetal Toxicity: Can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,xalkori,172,4177,4195,Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,xalkori,173,4195,4208,"(  5.6  ,  8.1  ,  8.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,xalkori,174,4208,4257,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdruguse \n', '   oselabeledaefromdruguse with  nonoseaegeneralterm outcome occurred in 2 (0.1%) of the 1719 patients treated with XALKORI across clinical trials.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
175,xalkori,175,4257,4310,"Concurrent  oselabeledaefromdruguse  oselabeledaefromdruguse in alanine aminotransferase (ALT) or  oselabeledaefromdruguse  greater than or equal to 3 times the upper limit of normal (ULN) and  oselabeledaefromdruguse  with normal alkaline phosphatase, occurred in 10 patients (<1%) treated with XALKORI.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,xalkori,176,4310,4323,oselabeledaefromdruguse ALT or  oselabeledaefromdruguse  oselabeledaefromdruguse or AST greater than 5 times,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,xalkori,177,4323,4342,"the ULN occurred in 187 (11.2%) and 95 (5.7%) patients, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,xalkori,178,4342,4519,"Seventeen patients (1.0%) required permanent discontinuation due to  oselabeledaefromdruguse   oselabeledaefromdruguse generally occurred within the first 2 months of treatment.\n', '\n', ' Monitor liver function tests, including ALT, AST, and total bilirubin, every 2 weeks during the first 2 months of treatment, then once a month, and as clinically indicated, with more frequent repeat testing for  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction liver transaminases,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction liver transaminases, alkaline phosphatase, or  nonoseaeaeonlyasinstruction in patients who develop  nonoseaeaeonlyasinstruction  Temporarily suspend, dose reduce, or permanently discontinue XALKORI as described in Table 2 [see  Dosage and Administration (2.3)  and  Adverse Reactions (6)  ]  .\n', '\n', '    5.2 Interstitial Lung Disease (Pneumonitis)\n', '\n', '  Severe, life-threatening, or fatal  oselabeledaefromdruguse / oselabeledaefromdruguse can occur in patients treated with XALKORI.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,xalkori,179,4519,4565,"Across clinical trials (n=1719), 50 XALKORI-treated patients (2.9%) had  oselabeledaefromdruguse of any grade, 18 patients (1.0%) had Grade 3 or 4  oselabeledaefromdruguse  and 8 patients (0.5%) had  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,xalkori,180,4565,4599,"nonoseaegeneralterm  oselabeledaefromdruguse   oselabeledaefromdruguse generally occurred within 3 months after the initiation of XALKORI.\n', '\n', ' Monitor patients for  nonoseaeaeonlyasinstruction indicative of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
181,xalkori,181,4599,4621,Exclude other potential causes of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  and permanently discontinue XALKORI in patients diagnosed with  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,xalkori,182,4621,4671,"[see  Dosage and Administration (2.3)  and  Adverse Reactions (6)  ]  .\n', '\n', '    5.3 QT Interval Prolongation\n', '\n', '   oselabeledaefromdruguse can occur in patients treated with XALKORI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,xalkori,183,4671,4892,"Across clinical trials, 34 of 1616 patients (2.1%) had  oselabeledaefromdruguse (corrected QT for heart rate by the Fridericia method)  oselabeledaefromdruguse and 79 of 1582 patients (5.0%) had an  oselabeledaefromdruguse greater than or equal to 60 ms by automated machine-read evaluation of ECGs.\n', '\n', ' Avoid use of XALKORI in patients with  notaecandidatepreexistingconditionorriskfactor  Monitor ECGs and electrolytes in patients with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or who are taking medications that are known to  nonoseaeaeonlyasinstruction  Permanently discontinue XALKORI in patients who develop  nonoseaeaeonlyasinstruction or greater than or equal to 60 ms change from baseline with  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction or signs/symptoms of  nonoseaeaeonlyasinstruction  Withhold XALKORI in patients who develop  nonoseaeaeonlyasinstruction on at least 2 separate ECGs until recovery to a QTc less than or equal to 480 ms, then resume XALKORI at a reduced dose as described in Table 2 [see  Dosage and Administration (2.3)  and  Clinical Pharmacology (12.2)  ]  .\n', '\n', '    5.4 Bradycardia\n', '\n', '  Symptomatic  oselabeledaefromdruguse can occur in patients receiving XALKORI.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
184,xalkori,184,4892,4912,"Across clinical trials,  oselabeledaefromdruguse occurred in 219 (12.7%) of 1719 patients treated with XALKORI.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,xalkori,185,4912,4979,"Grade 3  oselabeledaefromdruguse occurred in 2.4% of XALKORI-treated patients and in 0.6% of the chemotherapy-treated patients.\n', '\n', ' Avoid using XALKORI in combination with other agents known to cause  nonoseaeaeonlyasinstruction (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin) to the extent possible.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,xalkori,186,4979,4987,Monitor heart rate and blood pressure regularly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,xalkori,187,4987,5034,"In cases of  nonoseaeaeonlyasinstruction that is not life-threatening, hold XALKORI until recovery to asymptomatic  nonoseaeaeonlyasinstruction or to a heart rate of 60 bpm or above, re-evaluate the use of concomitant medications, and adjust the dose of XALKORI.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,xalkori,188,5034,5165,"Permanently discontinue for life-threatening  nonoseaeaeonlyasinstruction due to XALKORI; however, if associated with concomitant medications known to cause  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  hold XALKORI until recovery to asymptomatic  nonoseaeaeonlyasinstruction or to a heart rate of 60 bpm or above, and if concomitant medications can be adjusted or discontinued, restart XALKORI at 250 mg once daily with frequent monitoring [see  Dosage and Administration (2.3)  and  Adverse Reactions (6)  ]  .\n', '\n', '    5.5 Severe Visual Loss\n', '\n', '  Across all clinical trials, the incidence of Grade 4  oselabeledaefromdruguse with  oselabeledaefromdruguse was 0.2% (4/1719).  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,xalkori,189,5165,5211,"oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported as potential causes of  oselabeledaefromdruguse \n', '\n', ' Discontinue XALKORI in patients with new onset of severe  nonoseaeaeonlyasinstruction (best corrected vision less than 20/200 in one or both eyes).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,xalkori,190,5211,5247,"Perform an ophthalmological evaluation consisting of best corrected visual acuity, retinal photographs, visual fields, optical coherence tomography (OCT) and other evaluations as appropriate for new onset of severe  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,xalkori,191,5247,5291,"There is insufficient information to characterize the risks of resumption of XALKORI in patients with a severe  nonoseaeaeonlyasinstruction  a decision to resume XALKORI should consider the potential benefits to the patient.\n', '\n', '    5.6  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,xalkori,192,5291,5316,"\n', '  Based on its mechanism of action, XALKORI can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
193,xalkori,193,5316,5362,"In animal reproduction studies, oral administration of crizotinib in  nonoseaeaeanimal rats during organogenesis at exposures similar to those observed with the maximum recommended human dose resulted in  nonoseaeaeanimal and  nonoseaeaeanimal  Advise  notaecandidatepreexistingconditionorriskfactor women of the potential  oselabeledaefromdruguse ']",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
0,natroba,0,0,34,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse events (>1% ) were application site erythema and ocular erythema.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,natroba,1,34,39,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,natroba,2,39,100,"\n', '\n', '\n', '\n', ' \n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact ParaPRO, LLC at 1-855-628-7622 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,natroba,3,100,137,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Studies Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,natroba,4,137,286,"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' NATROBA Topical Suspension was studied in two randomized, active-controlled trials (N=552) in subjects with head lice; the results are presented in Table 1.\n', '\n', '\n', '\n', ' Table 1: Selected Adverse Events Occurring in at least 1% of Subjects \n', ' Signs                                            Spinosad(N=552)               Permethrin 1%(N=457)        \n', '  \n', '  oselabeledaefromdruguse                            17 (3%)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,natroba,5,286,292,31 (7%)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,natroba,6,292,305,"\n', '  oselabeledaefromdruguse                                      12 (2%)                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,natroba,7,305,311,15 (3%)               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,natroba,8,311,330,"\n', '  oselabeledaefromdruguse                           5 (1%)                          7 (2%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,natroba,9,330,362,"\n', '      Other less common reactions (less than 1% but more than 0.1%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,natroba,10,362,385,"5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,natroba,11,385,408,*  Benzyl alcohol toxicity: Not recommended in infants below the age of 6 months; potential for increased systemic absorption.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,natroba,12,408,413,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,natroba,13,413,470,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdrugcomponent \n', '\n', '\n', '  NATROBA Topical Suspension contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,natroba,14,470,490,Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and  oselabeledaefromdrugcomponent and  oselabeledaefromdrugcomponent '],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,belsomra,0,0,119,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse hypnopompic  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,belsomra,1,119,122,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,belsomra,2,122,131,Warnings and Precautions (5.6)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,belsomra,3,131,132,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,belsomra,4,132,139,"', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,belsomra,5,139,226,"The most common adverse reaction (reported in 5% or more of patients treated with BELSOMRA and at least twice the placebo rate) with BELSOMRA was somnolence (  6.1  ).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,belsomra,6,226,263,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,belsomra,7,263,453,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' In 3-month controlled efficacy trials (Study 1 and Study 2), 1263 patients were exposed to BELSOMRA including 493 patients who received BELSOMRA 15 mg or 20 mg (see  Table 1  ).\n', '\n', '\n', '\n', ' In a long-term study, additional patients (n=521) were treated with BELSOMRA at higher than recommended doses, including a total of 160 patients who received BELSOMRA for at least one year.\n', '\n', '\n', '\n', ' Table 1: Patient Exposure to BELSOMRA 15 mg or 20 mg in Study 1 and Study 2 \n', ' Patients Treated                              BELSOMRA15",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,belsomra,8,453,456,mg                      BELSOMRA20,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,belsomra,9,456,458,mg             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,belsomra,10,458,466,"\n', '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,belsomra,11,466,508,"' For >= 1 Day (n)                                   202                                291                  \n', '   Men (n)                                          69                                 105                  \n', '   Women (n)                                        133                                186                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,belsomra,12,508,527,"\n', '   Mean Age (years)                                 70                                 45                   \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,belsomra,13,527,635,"For >= 3 Months (n)                                118                                172                  \n', '         The pooled safety data described below (see  Table 2  ) reflect the adverse reaction profile during the first 3 months of treatment.\n', ' \n', '\n', '     Adverse Reactions Resulting in Discontinuation of Treatment  \n', '\n', '\n', '\n', ' The incidence of discontinuation due to adverse reactions for patients treated with 15 mg or 20 mg of BELSOMRA was 3% compared to 5% for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,belsomra,14,635,830,"No individual adverse reaction led to discontinuation at an incidence >=1%.\n', '\n', '\n', '\n', '     Most Common Adverse Reactions  \n', '\n', '\n', '\n', ' In clinical trials of patients with  notaecandidateindication treated with BELSOMRA 15 mg or 20 mg, the most common adverse reaction (reported in 5% or more of patients treated with BELSOMRA and at least twice the placebo rate) was  oselabeledaefromdruguse (BELSOMRA 7%; placebo 3%).\n', '\n', '\n', '\n', ' Table 2 shows the percentage of patients with adverse reactions during the first three months of treatment, based on the pooled data from 3-month controlled efficacy trials (Study 1 and Study 2).\n', '\n', '\n', '\n', ' At doses of 15 or 20 mg, the incidence of  oselabeledaefromdruguse was higher in females (8%) than in males (3%).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,belsomra,15,830,899,"Of the adverse reactions reported in Table 2, the following occurred in women at an incidence of at least twice that in men:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' The adverse reaction profile in elderly patients was generally consistent with non-elderly patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,belsomra,16,899,1000,"The adverse reactions reported during long-term treatment up to 1 year were generally consistent with those observed during the first 3 months of treatment.\n', '\n', '\n', '\n', ' Table 2: Percentage of Patients with Adverse Reactions Incidence >=2% and Greater than Placebo in 3-Month Controlled Efficacy Trials (Study 1 and Study 2) \n', '                                                  Placebo               BELSOMRA(20 mg in non-elderly or 15 mg in elderly patients)   \n', '                                                   n=767                              n=493                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,belsomra,17,1000,1012,"\n', '  \n', '  nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,belsomra,18,1012,1021,"\n', '    oselabeledaefromdruguse                                          1                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,belsomra,19,1021,1023,2                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,belsomra,20,1023,1032,"\n', '    oselabeledaefromdruguse                                         1                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,belsomra,21,1032,1041,"2                   \n', '  nonoseaegeneralterm                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,belsomra,22,1041,1050,"\n', '    oselabeledaefromdruguse                  1                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,belsomra,23,1050,1059,"2                   \n', '  nonoseaegeneralterm                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,belsomra,24,1059,1068,"\n', '    oselabeledaefromdruguse                                          6                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,belsomra,25,1068,1079,"7                   \n', '    oselabeledaefromdruguse                                        3                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,belsomra,26,1079,1090,"7                   \n', '    oselabeledaefromdruguse                                         2                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,belsomra,27,1090,1092,3                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,belsomra,28,1092,1108,"\n', '  nonoseaegeneralterm                                                                                      \n', '    oselabeledaefromdruguse                                   1                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,belsomra,29,1108,1110,2                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,belsomra,30,1110,1126,"\n', '  nonoseaegeneralterm                                                                         \n', '    oselabeledaefromdruguse                                             1                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,belsomra,31,1126,1247,"2                   \n', '             Dose Relationship for Adverse Reactions  \n', ' \n', '\n', ' There is evidence of a dose relationship for many of the adverse reactions associated with BELSOMRA use, particularly for certain  nonoseaegeneralterm \n', '\n', '\n', '\n', ' In a placebo-controlled crossover study (Study 3), non-elderly adult patients were treated for up to one month with BELSOMRA at doses of 10 mg, 20 mg, 40 mg (2 times the maximum recommended dose) or 80 mg (4 times the maximum recommended dose).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,belsomra,32,1247,1292,"In patients treated with BELSOMRA 10 mg (n=62), although no adverse reactions were reported at an incidence of >=2%, the types of adverse reactions observed were similar to those observed in patients treated with BELSOMRA 20 mg.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,belsomra,33,1292,1346,"BELSOMRA was associated with a dose-related increase in  oselabeledaefromdruguse  2% at the 10 mg dose, 5% at the 20 mg dose, 12% at the 40 mg dose, and 11% at the 80 mg dose, compared to <1% for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,belsomra,34,1346,1426,"BELSOMRA was also associated with a dose-related  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Daytime somnolence: Risk of impaired alertness and motor coordination, including impaired driving; risk increases with dose; caution patients taking 20 mg against next-day driving and other activities requiring complete mental alertness (  5.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,belsomra,35,1426,1458,"\n', ' *  Need to evaluate for co-morbid diagnoses: Reevaluate if insomnia persists after 7 to 10 days of treatment (  5.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,belsomra,36,1458,1483,"\n', ' *  Nighttime ""sleep-driving"" and other complex behaviors while out of bed and not fully awake.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,belsomra,37,1483,1503,"Risk increases with dose, with use of CNS depressants, and with alcohol (  5.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,belsomra,38,1503,1520,"\n', ' *  Depression: Worsening of depression or suicidal thinking may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,belsomra,39,1520,1525,Risk increases with dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,belsomra,40,1525,1537,Immediately evaluate any new behavioral changes (  5.4  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,belsomra,41,1537,1564,"\n', ' *  Compromised respiratory function: Effect on respiratory function should be considered (  5.5  ,  8.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,belsomra,42,1564,1594,"\n', ' *  Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms: Risk increases with dose (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,belsomra,43,1594,1655,"\n', '    \n', ' \n', '\n', '   5.1 CNS Depressant Effects and Daytime Impairment\n', '\n', '\n', '\n', '  BELSOMRA is a central nervous system (CNS) depressant that can  oselabeledaefromdruguse even when used as prescribed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,belsomra,44,1655,1701,"Prescribers should monitor for  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  but impairment can occur in the absence of symptoms, and may not be reliably detected by ordinary clinical exam (i.e., less than formal testing of daytime wakefulness and/or psychomotor performance).  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,belsomra,45,1701,1753,"oselabeledaefromdruguse may persist in some patients for up to several days after discontinuing BELSOMRA.\n', '\n', '\n', '\n', ' BELSOMRA can  oselabeledaefromdruguse and may  oselabeledaefromdruguse  Discontinue or decrease the dose in patients who drive if  nonoseaeaeonlyasinstruction develops.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,belsomra,46,1753,1781,"In a study of healthy adults,  oselabeledaefromdruguse in some individuals taking 20 mg BELSOMRA [see  Clinical Studies (14.2)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,belsomra,47,1781,1823,"Although pharmacodynamic tolerance or adaptation to some adverse depressant effects of BELSOMRA may develop with daily use, patients using the 20 mg dose of BELSOMRA should be cautioned against next-day driving and other activities requiring full mental alertness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,belsomra,48,1823,1913,"Patients taking lower doses of BELSOMRA should also be cautioned about the potential for  nonoseaeaeonlyasinstruction because there is individual variation in sensitivity to BELSOMRA.\n', '\n', '\n', '\n', ' Co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol)  nonoseaeaefromdruginteraction  Patients should be advised not to consume alcohol in combination with BELSOMRA because of additive effects [see  Drug Interactions (7.1)  ]  .",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
49,belsomra,49,1913,1934,Dosage adjustments of BELSOMRA and of concomitant CNS depressants may be necessary when administered together because of potentially additive effects.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,belsomra,50,1934,1961,The use of BELSOMRA with other drugs to treat  notaecandidateindication is not recommended [see  Dosage and Administration (2.3)  ].  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
51,belsomra,51,1961,2037,"\n', '\n', '\n', '\n', ' The risk of  nonoseaegeneralterm  including  nonoseaeaeonlyasinstruction  is increased if BELSOMRA is taken with less than a full night of sleep remaining, if a higher than the recommended dose is taken, if co-administered with other CNS depressants, or if co-administered with other drugs that increase blood levels of BELSOMRA.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,belsomra,52,2037,2132,"Patients should be cautioned against driving and other activities requiring complete mental alertness if BELSOMRA is taken in these circumstances.\n', '\n', '\n', '\n', '    5.2 Need to Evaluate for Co-morbid Diagnoses\n', '\n', '\n', '\n', '  Because  notaecandidatepreexistingconditionorriskfactor may be the presenting manifestation of a  notaecandidatepreexistingconditionorriskfactor and/or psychiatric  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  treatment of  notaecandidateindication should be initiated only after careful evaluation of the patient.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
53,belsomra,53,2132,2167,The failure of  notaecandidateindication to remit after 7 to 10 days of treatment may indicate the presence of a primary  notaecandidatepreexistingconditionorriskfactor and/or medical  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor that should be evaluated.  ,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
54,belsomra,54,2167,2214,"notaecandidatepreexistingconditionorriskfactor or the emergence of new  notaecandidatepreexistingconditionorriskfactor or behavioral  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor may be the result of an unrecognized underlying  notaecandidatepreexistingconditionorriskfactor or physical  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  and can emerge during the course of treatment with hypnotic drugs such as BELSOMRA.\n',",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
55,belsomra,55,2214,2238,"'\n', '\n', '\n', '    5.3 Abnormal Thinking and Behavioral Changes\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,belsomra,56,2238,2292,"', '\n', '\n', '  A variety of  oselabeledaefromdruguse and behavioral  oselabeledaefromdruguse  oselabeledaefromdruguse (e.g.,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect and other  oselabeledaefromdruguse  have been reported to occur in association with the use of hypnotics such as BELSOMRA.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,belsomra,57,2292,2355,"oselabeledaeclasseffect such as  oselabeledaeclasseffect (i.e.,  oselabeledaeclasseffect after taking a hypnotic) and other  oselabeledaeclasseffect (e.g.,  oselabeledaefromdruguse  making phone calls, or having sex),  oselabeledaefromdruguse  oselabeledaefromdruguse  or having sex),  oselabeledaefromdruguse  oselabeledaefromdruguse ,  oselabeledaefromdruguse  have been reported in association with the use of hypnotics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,belsomra,58,2355,2372,These events can occur in hypnotic-naive as well as in hypnotic-experienced persons.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,belsomra,59,2372,2388,The use of alcohol and other CNS depressants may increase the risk of such behaviors.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,belsomra,60,2388,2463,"Discontinuation of BELSOMRA should be strongly considered for patients who report any  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.4 Worsening of Depression/Suicidal Ideation\n', '\n', '\n', '\n', '  In clinical studies, a dose-dependent  oselabeledaefromdruguse was observed in patients taking BELSOMRA as assessed by questionnaire.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,belsomra,61,2463,2524,"Immediately evaluate patients with  nonoseaeaeonlyasinstruction or any new behavioral sign or symptom.\n', '\n', '\n', '\n', ' In primarily  notaecandidatepreexistingconditionorriskfactor patients treated with sedative-hypnotics,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect (including  oselabeledaeclasseffect  have been reported.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
62,belsomra,62,2524,2539,nonoseaeaeonlyasinstruction may be present in such patients and protective measures may be required.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,belsomra,63,2539,2688,"nonoseaeaeonlyasinstruction is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed for the patient at any one time.\n', '\n', '\n', '\n', ' The emergence of any new  nonoseaeaeonlyasinstruction of concern requires careful and immediate evaluation.\n', '\n', '\n', '\n', '    5.5 Patients with Compromised Respiratory Function\n', '\n', '\n', '\n', '  Effect of BELSOMRA on respiratory function should be considered if prescribed to patients with  notaecandidatepreexistingconditionorriskfactor  BELSOMRA has not been studied in patients with severe  notaecandidatepreexistingconditionorriskfactor (OSA) or severe  notaecandidatepreexistingconditionorriskfactor (COPD) [see  Use in Specific Populations (8.6)  ].  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
64,belsomra,64,2688,2722,"\n', '\n', '\n', '\n', '    5.6 Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, Cataplexy-like Symptoms\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,belsomra,65,2722,2768,"', '\n', '\n', '   oselabeledaefromdruguse  an  nonoseaemanifestationorcomplication  and  oselabeledaefromdruguse hypnopompic  oselabeledaefromdruguse  oselabeledaefromdruguse  including  nonoseaemanifestationorcomplication and disturbing  nonoseaemanifestationorcomplication by the patient, can occur with the use of BELSOMRA.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
66,belsomra,66,2768,2810,"Prescribers should explain the nature of these events to patients when prescribing BELSOMRA.\n', '\n', '\n', '\n', '  oselabeledaefromdruguse can occur, with risk increasing with the dose of BELSOMRA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,belsomra,67,2810,2820,Such symptoms can include periods of  oselabeledaefromdruguse '],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,aranesp,0,0,8,['    6         ADVERSE REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,aranesp,1,8,60,"\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', ' *  Increased  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse [see Warnings and Precautions (    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
2,aranesp,2,60,65,5.1    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,aranesp,3,65,104,"\n', ' *  Increased  nonoseaegeneralterm and/or Increased Risk of  oselabeledaefromdruguse  oselabeledaefromdruguse Progression or  oselabeledaefromdruguse in Patients with  notaecandidatepreexistingconditionorriskfactor  [see Warnings and Precautions (    5.2    )]  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
4,aranesp,4,104,119,"\n', ' *   oselabeledaefromdruguse  [see Warnings and Precautions (    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,aranesp,5,119,124,5.3    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,aranesp,6,124,131,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,aranesp,7,131,143,[see Warnings and Precautions (    5.4    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,aranesp,8,143,150,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,aranesp,9,150,155,[see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,aranesp,10,155,162,(    5.6    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,aranesp,11,162,166,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,aranesp,12,166,184,*  Serious  oselabeledaefromdruguse  [see Warnings and Precautions (    5.7    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,aranesp,13,184,194,"\n', ' *  Severe  oselabeledaefromdruguse [",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,aranesp,14,194,198,see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,aranesp,15,198,205,(    5.8    )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,aranesp,16,205,215,"\n', '   *  Patients with  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,aranesp,17,215,251,notaecandidatepreexistingconditionorriskfactor  Adverse reactions in >= 10% of Aranesp-treated patients in clinical studies were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (  6.1  ).,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
18,aranesp,18,251,252,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,aranesp,19,252,264,"', ' *  Patients with  notaecandidatepreexistingconditionorriskfactor Receiving Chemotherapy:",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
20,aranesp,20,264,294,Adverse reactions in >= 1% of Aranesp-treated patients in clinical studies were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (  6.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,aranesp,21,294,302,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,aranesp,22,302,337,"To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,aranesp,23,337,371,"\n', ' \n', '\n', ' \n', '\n', '  6.1       Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,aranesp,24,371,483,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.\n', '\n', '   Patients    with Chronic Kidney Disease  \n', '\n', '   Adult Patients  \n', '\n', ' Adverse reactions were determined based on pooled data from 5 randomized, active-controlled studies of Aranesp with a total of 1357 patients (Aranesp 766, epoetin alfa 591).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,aranesp,25,483,515,"The median duration of exposure for patients receiving Aranesp was 340 days, with 580 patients exposed for greater than 6 months and 360 patients exposed for greater than 1 year.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,aranesp,26,515,540,"The median (25th, 75th percentiles) weight-adjusted dose of Aranesp was 0.50 mcg/kg (0.32, 0.81).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,aranesp,27,540,559,The median (range) age for patients administered Aranesp was 62 years (18 to 88).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,aranesp,28,559,620,"In the Aranesp group, 55% were male, 72% were white, 83% were receiving dialysis, and 17% were not receiving dialysis.\n', '\n', ' Table 5 lists adverse reactions occurring in >= 5% of patients treated with Aranesp.\n', '\n', ' Table 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,aranesp,29,620,643,"Adverse Reactions Occurring in >= 5% of Patients with CKD \n', '   Adverse Reaction      Patients Treated    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,aranesp,30,643,647,w    ith    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,aranesp,31,647,665,"Aranesp    (n = 766)     \n', '  oselabeledaefromdruguse     31%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,aranesp,32,665,685,"\n', '  oselabeledaefromdruguse          17%               \n', '  oselabeledaefromdruguse  17%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,aranesp,33,685,705,"\n', '  oselabeledaefromdruguse            12%               \n', '  oselabeledaefromdruguse  10%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,aranesp,34,705,725,"\n', '  oselabeledaefromdruguse  8%                \n', '  oselabeledaefromdruguse  8%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,aranesp,35,725,735,"\n', '  oselabeledaefromdruguse   7%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,aranesp,36,735,747,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse    5%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,aranesp,37,747,757,"\n', '  oselabeledaefromdruguse  5%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,aranesp,38,757,831,"\n', '        Rates of adverse reactions with Aranesp therapy were similar to those observed with other recombinant erythropoietins in these studies.\n', ' \n', '\n', '   Pediatric Patients  \n', '\n', ' Adverse reactions were determined based on pooled data from 2 randomized, controlled trials   [see Clinical Studies (      14.1      )]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,aranesp,39,831,856,"In one study, Aranesp was administered to 81 pediatric patients with  notaecandidatepreexistingconditionorriskfactor who had stable hemoglobin concentrations while previously receiving epoetin alfa.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
40,aranesp,40,856,904,"In a second study, Aranesp was administered to 114 anemic pediatric patients with  notaecandidatepreexistingconditionorriskfactor receiving or not receiving dialysis for initial treatment of  notaecandidateindication  In these studies, the most frequently reported serious adverse reactions with Aranesp were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
41,aranesp,41,904,922,The most commonly reported adverse reactions were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,aranesp,42,922,953,"Aranesp administration was discontinued because of  oselabeledaefromdruguse in 2 patients and  oselabeledaefromdruguse in 3 patients.\n', '\n', '   Patients    with    Cancer    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,aranesp,43,953,1006,"Receiving Chemotherapy  \n', '\n', ' Adverse reactions were based on data from a randomized, double-blind, placebo-controlled study of Aranesp in 597 patients (Aranesp 301, placebo 296) with extensive stage  notaecandidatepreexistingconditionorriskfactor  receiving platinum-based chemotherapy.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
44,aranesp,44,1006,1049,"All patients were white, 64% were male, and the median age was 61 years (range: 28 to 82 years); 25% of the study population were from North America, Western Europe, and Australia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,aranesp,45,1049,1142,"Patients received Aranesp at a dose of 300 mcg or placebo weekly for 4 weeks then every 3 weeks for a total of 24 weeks, and the median duration of exposure was 19 weeks (range: 1 to 26 weeks).\n', '\n', ' Adverse reactions     were also based on     data from 7 randomized, double-blind, placebo-controlled studies, including the SCLC study described above, that enrolled 2112 patients (Aranesp 1203, placebo 909) with  notaecandidatepreexistingconditionorriskfactor   ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
46,aranesp,46,1142,1191,"Most patients were white (95%), male (52%), and the median age was 63 years (range: 18 to 91 years); 73% of the study population were from North America, Western Europe, and Australia.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,aranesp,47,1191,1215,"Dosing and schedules varied by study from once weekly to once every 4 weeks, and the median duration of exposure was 12 weeks",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,aranesp,48,1215,1218,(range:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,aranesp,49,1218,1232,"1 to 27 weeks).\n', '\n', ' Table 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,aranesp,50,1232,1247,"Thrombovascular Adverse Reactions in Patients Receiving Chemotherapy \n', '                    SCLC Study       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,aranesp,51,1247,1255,All Placebo  -  controlled Studies     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,aranesp,52,1255,1263,"\n', '   Adverse Reaction      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,aranesp,53,1263,1279,Aranesp    (n = 301)      Placebo    (n = 296)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,aranesp,54,1279,1287,Aranesp    (n = 1203)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,aranesp,55,1287,1289,Placebo    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,aranesp,56,1289,1295,(n = 909)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,aranesp,57,1295,1309,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse  n (%)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,aranesp,58,1309,1333,24 (8.0%)        13 (4.4%)        73 (6.1%)        37 (4.1%)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,aranesp,59,1333,1347,"\n', '      oselabeledaefromdruguse  oselabeledaefromdruguse  n (%)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,aranesp,60,1347,1371,24 (8.0%)        13 (4.4%)        73 (6.1%)        37 (4.1%)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,aranesp,61,1371,1372,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,aranesp,62,1372,1430,"', '     Arterial     10 (3.3%)        3 (1.0%)         15 (1.2%)        5 (0.6%)          \n', '        Myocardial infarction  5 (1.7%)         0                7 (0.6%)         2 (0.2%)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,aranesp,63,1430,1459,"\n', '      oselabeledaefromdruguse  oselabeledaefromdruguse  5 (1.7%)         0                7 (0.6%)         2 (0.2%)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,aranesp,64,1459,1464,"\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,aranesp,65,1464,1490,Venous       14 (4.7%)        10 (3.4%)        60 (5.0%)        32 (3.5%)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,aranesp,66,1490,1498,"\n', '         oselabeledaefromdruguse  5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,aranesp,67,1498,1521,(1.7%)         3 (1.0%)         16 (1.3%)        6 (0.7%)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,aranesp,68,1521,1534,"\n', '      oselabeledaefromdruguse  14 (4.7%)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,aranesp,69,1534,1544,9(3.0%)          20 (1.7%)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,aranesp,70,1544,1550,17 (1.9%)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,aranesp,71,1550,1574,"\n', '           *  oselabeledaefromdruguse encompasses  oselabeledaefromdruguse and  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse (ischemic and  oselabeledaefromdruguse .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,aranesp,72,1574,1625,"Events in this category may also be included under  oselabeledaefromdruguse ""\n', ' \n', '\n', ' In addition to the  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse occurred at a higher incidence in patients taking Aranesp compared to patients on placebo.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,aranesp,73,1625,1666,"Among all placebo-controlled studies,  oselabeledaefromdruguse (13.2% vs. 9.4%) and  oselabeledaefromdruguse (12.8% vs. 9.7%) were reported more frequently in patients receiving Aranesp compared to the placebo group.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,aranesp,74,1666,1814,"In the  notaecandidatepreexistingconditionorriskfactor study the incidence of  oselabeledaefromdruguse (10.3% vs. 3.4%) and  oselabeledaefromdruguse (5.6% vs. 5.1%) in the Aranesp-treated patients compared to those receiving placebo.\n', '\n', '   6.2       Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during postmarketing use of Aranesp.\n', '\n', ' Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' *   oselabeledaefromdruguse [  see Warnings and Precautions (    5.4    )  ]  \n', ' *   oselabeledaefromdruguse [  see Warnings and Precautions",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
75,aranesp,75,1814,1867,"(    5.6    )  ]  \n', ' *  Serious  oselabeledaefromdruguse  [  see Warnings and Precautions (    5.7    )  ]  \n', ' *  Severe  oselabeledaefromdruguse [see Warnings and Precautions (    5.8    )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,aranesp,76,1867,1879,"\n', '      6.3       Immunogenicity\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,aranesp,77,1879,1923,"As with all therapeutic proteins, there is a potential for  oselabeledaefromdruguse \n', '\n', ' In clinical studies, the percentage of patients with  oselabeledaefromdruguse was examined using the Biacore  (r)  assay.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,aranesp,78,1923,1939,Sera from 1501 patients with  notaecandidatepreexistingconditionorriskfactor and 1159 patients with  notaecandidatepreexistingconditionorriskfactor were tested.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
79,aranesp,79,1939,1970,"At baseline, prior to Aranesp treatment,  notaecandidatepreexistingconditionorriskfactor in 59 patients (4%) with  notaecandidatepreexistingconditionorriskfactor and 36 patients with  notaecandidatepreexistingconditionorriskfactor (3%).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
80,aranesp,80,1970,1990,"During Aranesp therapy (range: 22 to 177 weeks), a follow-up sample was taken.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,aranesp,81,1990,2005,One additional patient with  notaecandidatepreexistingconditionorriskfactor and 8 additional patients with  notaecandidatepreexistingconditionorriskfactor developed  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
82,aranesp,82,2005,2007,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,aranesp,83,2007,2052,"In two studies of pediatric patients with  notaecandidatepreexistingconditionorriskfactor aged 2-16, 20 of 111 patients with  notaecandidatepreexistingconditionorriskfactor (18%) receiving dialysis and 6 of 69 patients (9%) not receiving dialysis had  oselabeledaefromdruguse at baseline.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
84,aranesp,84,2052,2096,"During therapy, 4 additional patients receiving dialysis and 4 additional patients not receiving dialysis developed  oselabeledaefromdruguse \n', '\n', ' None of the patients had  nonoseaenegation or endogenous erythropoietin at baseline or at end of study.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
85,aranesp,85,2096,2112,No clinical sequelae consistent with  nonoseaeaeonlyasinstruction were associated with the  nonoseaeaeonlyasinstruction these  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,aranesp,86,2112,2137,"\n', '\n', ' The incidence of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,aranesp,87,2137,2185,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,aranesp,88,2185,2245,"For these reasons, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction may be misleading.\n', '\n', '  nonoseaeaeonlyasinstruction and other ESAs can result in  nonoseaeaeonlyasinstruction or severe  nonoseaeaeonlyasinstruction (with or without other  nonoseaeaeonlyasinstruction \n', '\n', '    BOXED WARNING:",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,aranesp,89,2245,2249,WARNING: ESAs INCREASE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,aranesp,90,2249,2268,"THE RISK OF DEATH,  oselabeledaeclasseffect  STROKE,  oselabeledaeclasseffect   oselabeledaeclasseffect ANDTUMOR PROGRESSION OR RECURRENCE\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,aranesp,91,2268,2277,", '\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,aranesp,92,2277,2279,ESAs INCREASE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,aranesp,93,2279,2325,"THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS     AND    TUMOR PROGRESSION OR RECURRENCE  \n', '\n', '     notaecandidatepreexistingconditionorriskfactor   \n', '\n', ' *  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
94,aranesp,94,2325,2365,"In controlled trials, patients experienced greater risks for  nonoseaegeneralterm  serious  oselabeledaeclasseffect  and  oselabeledaeclasseffect when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
95,aranesp,95,2365,2375,[see Warnings and Precautions (5.1)].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,aranesp,96,2375,2412,"\n', ' *  No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks [see Dosage and Administration (2.2)].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,aranesp,97,2412,2446,"\n', ' *  Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions (5.1)].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,aranesp,98,2446,2550,"\n', '       notaecandidatepreexistingconditionorriskfactor   \n', ' \n', '\n', ' *  ESAs shortened overall survival and/or increased the risk of  oselabeledaeclasseffect  oselabeledaeclasseffect progression or  oselabeledaeclasseffect in clinical studies of patients with  notaecandidatepreexistingconditionorriskfactor  non-small cell lung, head and neck, lymphoid, and cervical  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  head and neck, lymphoid, and cervical  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  lymphoid, and cervical  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  and cervical  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor [see Warnings and Precautions (5.2)].",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
99,aranesp,99,2550,2596,"\n', ' *  To decrease these risks, as well as the risk of serious  nonoseaeaeonlyasinstruction and thromboembolic  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.3)].",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,aranesp,100,2596,2618,"\n', ' *  Use ESAs only for  notaecandidateindication [see Indications and Usage (1.2)].",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
101,aranesp,101,2618,2652,"\n', ' *  ESAs are not indicated for patients receiving  notaecandidatepreexistingconditionorriskfactor     5        WARNINGS AND PRECAUTIONS  \n', '\n', '   EXCERPT:    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
102,aranesp,102,2652,2707,"*  Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using Aranesp to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit (  5.1  and  14.1  ).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,aranesp,103,2707,2723,Use caution in patients with coexistent cardiovascular disease and stroke (  5.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,aranesp,104,2723,2749,"\n', ' *  Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer (  5.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,aranesp,105,2749,2773,"\n', ' *  Hypertension: Control hypertension prior to initiating and during treatment with Aranesp (  5.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,aranesp,106,2773,2797,"\n', ' *  Seizures: Aranesp increases the risk for seizures in patients with CKD (  5.4  ).Increase",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,aranesp,107,2797,2815,monitoring of these patients for changes in seizure frequency or premonitory symptoms (  5.4  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,aranesp,108,2815,2823,"\n', ' *  PRCA:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,aranesp,109,2823,2847,"If severe anemia and low reticulocyte count develop during Aranesp treatment, withhold Aranesp and evaluate for PRCA (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,aranesp,110,2847,2868,"\n', ' *  Serious Allergic Reactions: Discontinue Aranesp and manage reactions (  5.7  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,aranesp,111,2868,2886,"\n', ' *  Severe Cutaneous Reactions: Discontinue Aranesp (  5.8  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,aranesp,112,2886,2988,"\n', '    \n', ' \n', '\n', '   5.1       Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism\n', '\n', '    *  In controlled clinical trials of patients with  notaecandidatepreexistingconditionorriskfactor comparing higher hemoglobin targets (13 - 14 g/dL) to lower targets (9 - 11.3 g/dL), Aranesp and other ESAs increased the risk of  nonoseaegeneralterm   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and other  oselabeledaeclasseffect in the higher target groups.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
113,aranesp,113,2988,3029,"\n', ' *  Using Aranesp to target a  nonoseaeaeonlyasinstruction increases the risk of serious  nonoseaeaefromofflabel and has not been shown to provide additional benefit [see Clinical Studies (    14.1    )] .  ",1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
114,aranesp,114,3029,3054,Use caution in patients with coexistent  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor  [see Dosage and Administration (    2.2    )] .  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
115,aranesp,115,3054,3082,Patients with  notaecandidatepreexistingconditionorriskfactor and an insufficient hemoglobin response to ESA therapy may be at even greater risk for  oselabeledaeclasseffect and  nonoseaegeneralterm than other patients.,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
116,aranesp,116,3082,3093,A rate of  nonoseaeaeonlyasinstruction may contribute to these risks.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,aranesp,117,3093,3124,"\n', ' *  In controlled clinical trials of patients with  notaecandidatepreexistingconditionorriskfactor  Aranesp and other ESAs increased the risks for  nonoseaegeneralterm and serious  oselabeledaeclasseffect  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
118,aranesp,118,3124,3140,"These adverse reactions included  oselabeledaefromdruguse and  oselabeledaefromdruguse  \n', ' *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,aranesp,119,3140,3178,"In controlled clinical trials, ESAs increased the risk of  nonoseaegeneralterm in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of  oselabeledaefromdruguse  oselabeledaefromdruguse  in patients undergoing orthopedic procedures.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,aranesp,120,3178,3238,"\n', '    The design and overall results of the 3 large trials comparing  nonoseaeaeonlyasinstruction are shown in Table 3.\n', ' \n', '\n', ' Table 3: Randomized Controlled Trials Showing Adverse Cardiovascular Outcomes in Patients with CKD \n', '                   Normal Hematocrit Study (NHS)   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,aranesp,121,3238,3257,(N = 12   65   )     CHOIR   (N = 1432)     TREAT   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,aranesp,122,3257,3263,(N = 4038)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,aranesp,123,3263,3273,"\n', '  Time Period of Trial    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,aranesp,124,3273,3285,1993 to 1996     2003 to 2006     2004 to 2009      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,aranesp,125,3285,3308,"\n', '  Population      Adult patients with CKD on hemodialysis with coexisting CHF or CAD, hematocrit 30 +/-",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,aranesp,126,3308,3369,"3% on epoetin alfa  Adult patients with CKD not on dialysis with hemoglobin< 11 g/dL not previously administered epoetin alfa  Adult patients with CKD not on dialysis with type II diabetes, hemoglobin<= 11 g/dL   \n', '  Hemoglobin Target; Higher vs. Lower (g/dL)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,aranesp,127,3369,3373,14.0 vs. 10.0    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,aranesp,128,3373,3377,13.5 vs. 11.3    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,aranesp,129,3377,3380,13.0 vs. >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,aranesp,130,3380,3396,"= 9.0   \n', '  Median   (Q1, Q3)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,aranesp,131,3396,3448,"Achieved Hemoglobin level   (g/dL)    12.6 (11.6, 13.3) vs. 10.3 (10.0, 10.7)  13.0 (12.2, 13.4) vs. 11.4 (11.1, 11.6)  12.5 (12.0, 12.8) vs. 10.6 (9.9, 11.3)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,aranesp,132,3448,3545,"\n', '  Primary Endpoint    All-cause mortality or non-fatal MI  All-cause mortality, MI, hospitalization for CHF, or stroke  All-cause mortality, MI, myocardial ischemia, heart failure, and stroke   \n', '  Hazard Ratio or Relative Risk (95% CI)    1.28 (1.06 - 1.56)   1.34 (1.03 - 1.74)  1.05 (0.94 - 1.17)   \n', '  Adverse Outcome for Higher Target Group    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,aranesp,133,3545,3607,"All-cause mortality  All-cause mortality  Stroke            \n', '  Hazard Ratio or Relative Risk (95% CI)    1.27 (1.04 - 1.54)  1.48 (0.97 - 2.27)  1.92 (1.38 - 2.68)   \n', '           Patients with   Chronic   Kidney Disease  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,aranesp,134,3607,3626,"\n', ' \n', '\n', ' Normal Hematocrit Study (NHS):",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,aranesp,135,3626,3678,"A prospective, randomized, open-label study of 1265 patients with  notaecandidateindication on dialysis with documented evidence of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor was designed to test the hypothesis that a higher target hematocrit (Hct) would result in improved outcomes compared with a lower target Hct.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
136,aranesp,136,3678,3699,"In this study, patients were randomized to epoetin alfa treatment targeted to a maintenance hemoglobin of either 14 +/-",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,aranesp,137,3699,3707,1 g/dL or 10 +/-,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,aranesp,138,3707,3708,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,aranesp,139,3708,3712,g/dL.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,aranesp,140,3712,3732,The trial was terminated early with adverse safety findings of higher  nonoseaegeneralterm in the high hematocrit target group.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
141,aranesp,141,3732,3796,"Higher  nonoseaegeneralterm (35% vs. 29%) was observed for the patients randomized to a target hemoglobin of 14 g/dL than for the patients randomized to a target hemoglobin of 10 g/dL.  For all-cause  nonoseaegeneralterm  the HR = 1.27; 95% CI (1.04, 1.54); p=0.018.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
142,aranesp,142,3796,3835,"The incidence of  nonoseaenegation  nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass  and other  nonoseaeaeforanotherdruginclass was also higher in the group randomized to a target hemoglobin of 14 g/dL.\n', '\n', ' CHOIR:",0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
143,aranesp,143,3835,3883,"A randomized, prospective trial, 1432 patients with  notaecandidateindication who were not undergoing dialysis and who had not previously received epoetin alfa therapy were randomized to epoetin alfa treatment targeting a maintenance hemoglobin concentration of either 13.5 g/dL or 11.3 g/dL.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
144,aranesp,144,3883,3893,The trial was terminated early with adverse safety findings.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,aranesp,145,3893,3969,"A  nonoseaeaeforanotherdruginclass ( nonoseaegeneralterm   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass  or hospitalization for  nonoseaeaeforanotherdruginclass  occurred in 125 of the 715 patients (18%) in the higher hemoglobin group compared to 97 of the 717 patients (14%) in the lower hemoglobin group [hazard ratio (HR) 1.34, 95% CI: 1.03, 1.74; p = 0.03].\n', '\n', ' TREAT:",0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
146,aranesp,146,3969,4025,"A randomized, double-blind, placebo-controlled, prospective trial of 4038 patients with  notaecandidatepreexistingconditionorriskfactor not on dialysis (eGFR of 20 - 60 mL/min),  notaecandidateindication ( nonoseaeaeonlyasinstruction , and  notaecandidatepreexistingconditionorriskfactor  patients were randomized to receive either Aranesp treatment or a matching placebo.  ",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
147,aranesp,147,4025,4042,Placebo group patients also received Aranesp when their hemoglobin levels were below 9 g/dL.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,aranesp,148,4042,4217,"The trial objectives were to demonstrate the benefit of Aranesp treatment of the  notaecandidateindication to a target hemoglobin level of 13 g/dL, when compared to a ""placebo"" group, by reducing the occurrence of either of two primary endpoints: (1) a composite cardiovascular endpoint of all-cause  nonoseaegeneralterm or a specified  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  or (2) a composite renal endpoint of all-cause  nonoseaegeneralterm or progression to  nonoseaeaeonlyasinstruction   The overall risks for each of the two primary endpoints (the cardiovascular composite and the renal composite) were not reduced with Aranesp treatment (see Table3), but the risk of  nonoseaeaefromofflabel was increased nearly two-fold in the Aranesp-treated group versus the placebo group: annualized  nonoseaeaefromofflabel rate 2.1% vs. 1.1%, respectively, HR 1.92; 95% CI: 1.38, 2.68; p < 0.001.",1,1,0,1,0,0,0,0,0,0,1,0,0,0,0
149,aranesp,149,4217,4265,"The relative risk of  nonoseaeaefromofflabel was particularly high in patients with a prior  notaecandidatepreexistingconditionorriskfactor  annualized  nonoseaeaefromofflabel rate 5.2% in the Aranesp treated group and 1.9% in the placebo group, HR 3.07; 95% CI: 1.44, 6.54.  ",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
150,aranesp,150,4265,4308,"Also, among Aranesp-treated subjects with a past history of  notaecandidatepreexistingconditionorriskfactor  there were more  nonoseaegeneralterm due to all causes and more  nonoseaegeneralterm adjudicated as due to  nonoseaeaeonlyasinstruction  in comparison with the control group.\n',",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
151,aranesp,151,4308,4409,"'\n', '  Patients with Cancer  \n', '\n', ' An increased incidence of  oselabeledaeclasseffect  some serious and life-threatening, occurred in patients with  notaecandidatepreexistingconditionorriskfactor treated with ESAs.\n', '\n', ' In a randomized, placebo-controlled study (Study 2 in Table 4  [   see Warnings and Precautions (     5.2     )   ]  ) of 939 women with  notaecandidatepreexistingconditionorriskfactor receiving chemotherapy, patients received either weekly epoetin alfa or placebo for up to a year.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
152,aranesp,152,4409,4449,This study was designed to show that survival was superior when epoetin alfa was administered to prevent  nonoseaeaeonlyasinstruction (maintain hemoglobin levels between 12 and 14 g/dL or hematocrit between 36% and 42%).,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,aranesp,153,4449,4503,This study was terminated prematurely when interim results demonstrated a higher  nonoseaegeneralterm at 4 months (8.7% vs. 3.4%) and a higher rate of  nonoseaegeneralterm  nonoseaeaeforanotherdruginclass (1.1% vs. 0.2%) in the first 4 months of the study among patients treated with epoetin alfa.,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
154,aranesp,154,4503,4565,"Based on Kaplan-Meier estimates, at the time of study termination, the 12-month survival was lower in the epoetin alfa group than in the placebo group (70% vs. 76%; HR 1.37, 95% CI: 1.07, 1.75; p = 0.012).\n', '\n', '  Patients Having Surgery  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,aranesp,155,4565,4614,"\n', '\n', ' Aranesp     is not approved for reduction of RBC transfusions in patients scheduled for surgical procedures.\n', '\n', ' An increased incidence of  oselabeledaefromdruguse in patients receiving epoetin alfa undergoing surgical orthopedic procedures was demonstrated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,aranesp,156,4614,4661,"In a randomized, controlled study, 680 adult patients, not receiving prophylactic anticoagulation and undergoing spinal surgery, received epoetin alfa and standard of care (SOC) treatment (n = 340) or SOC treatment alone (n = 340).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,aranesp,157,4661,4709,"A higher incidence of  oselabeledaefromdruguse  determined by either color flow duplex imaging or by clinical symptoms, was observed in the epoetin alfa group (16 [4.7%] patients) compared with the SOC group (7 [2.1%] patients).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,aranesp,158,4709,4811,"In addition to the 23 patients with  oselabeledaefromdruguse included in the primary analysis, 19 [2.8%] patients experienced 1 other  oselabeledaefromdruguse  each (12 [3.5%] in the epoetin alfa group and 7 [2.1%] in the SOC group).\n', '\n', ' Increased  nonoseaegeneralterm was observed in a randomized, placebo-controlled study of epoetin alfa in adult patients who were undergoing CABG surgery (7  nonoseaegeneralterm in 126 patients randomized to epoetin alfa versus no  nonoseaenegation among 56 patients receiving placebo).",0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
159,aranesp,159,4811,4843,"Four of these  nonoseaegeneralterm occurred during the period of study drug administration and all 4  nonoseaegeneralterm were associated with  nonoseaeaeonlyasinstruction \n', '\n', '    ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
160,aranesp,160,4843,4898,"5.2       Increased Mortality and/or Increased Risk of  oselabeledaeclasseffect  oselabeledaeclasseffect Progression or  oselabeledaeclasseffect in Patients with Cancer\n', '\n', '  ESAs resulted in decreased locoregional control/progression-free survival (PFS) and/or overall survival (OS) (see Table 4).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,aranesp,161,4898,4989,"\n', '\n', '  Adverse effects on PFS and/or OS were observed in studies of patients receiving chemotherapy for  notaecandidatepreexistingconditionorriskfactor (Studies 1, 2, and 4),  notaecandidatepreexistingconditionorriskfactor (Study 3), and  notaecandidatepreexistingconditionorriskfactor (Study 5); in patients with advanced  notaecandidatepreexistingconditionorriskfactor receiving radiation therapy (Studies 6 and 7), and in patients with  notaecandidatepreexistingconditionorriskfactor or various malignancies who were not receiving chemotherapy or radiotherapy (Studies 8 and 9).  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
162,aranesp,162,4989,5000,"\n', '\n', ' Table 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,aranesp,163,5000,5021,"Randomized, Controlled Studies with Decreased Survival and/or Decreased Locoregional Control \n', '  Study/Tumor/(n)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,aranesp,164,5021,5027,Hemoglobin   Target     Hemoglobin   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,aranesp,165,5027,5034,"(Median;   Q1, Q3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,aranesp,166,5034,5040,*)     Primary Efficacy   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,aranesp,167,5040,5042,Outcome     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,aranesp,168,5042,5046,Adverse Outcome for   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,aranesp,169,5046,5059,"ESA  - containing Arm     \n', '  Chemotherapy     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,aranesp,170,5059,5073,"\n', '  Study 1   notaecandidatepreexistingconditionorriskfactor n = 2098)  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
171,aranesp,171,5073,5086,"<=12 g/dL        11.6 g/dL;10.7, 12.1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,aranesp,172,5086,5090,g/dL  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,aranesp,173,5090,5105,Progression-freesurvival (PFS)  Decreased progression-free and overall survival   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,aranesp,174,5105,5161,"\n', '  Study   2   notaecandidatepreexistingconditionorriskfactor (n = 939)  12-14 g/dL       12.9 g/dL;12.2, 13.3 g/dL  12-month overall survival  Decreased 12-month survival   \n', '  Study   3   notaecandidatepreexistingconditionorriskfactor n = 344)  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
175,aranesp,175,5161,5217,"13-15 g/dL (M)13-14 g/dL (F)  11 g/dL;9.8, 12.1 g/dL  Proportion of patients achieving a hemoglobin response  Decreased overall survival   \n', '  Study   4  Early  notaecandidatepreexistingconditionorriskfactor n = 733)  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
176,aranesp,176,5217,5250,"12.5-13 g/dL     13.1 g/dL;12.5, 13.7 g/dL  Relapse-free and overall survival  Decreased 3-year relapse-free and overall survival   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,aranesp,177,5250,5328,"\n', '  Study   5   notaecandidatepreexistingconditionorriskfactor n = 114)  12-14 g/dL       12.7 g/dL;12.1, 13.3 g/dL  Progression-free and overall survival and locoregional control  Decreased 3-year progression-free and overall survival and locoregional control   \n', '  Radiotherapy Alone     \n', '  Study   6   notaecandidatepreexistingconditionorriskfactor n = 351)  >",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
178,aranesp,178,5328,5339,= 15 g/dL (M)>= 14 g/dL,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,aranesp,179,5339,5377,"(F)  Not available    Locoregional progression-free survival  Decreased 5-year locoregional progression-free and overall survival   \n', '  Study   7   notaecandidatepreexistingconditionorriskfactor n = 522)  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
180,aranesp,180,5377,5387,14-15.5 g/dL     Not available    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,aranesp,181,5387,5391,Locoregional disease control  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,aranesp,182,5391,5396,Decreased locoregional disease control   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,aranesp,183,5396,5401,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,aranesp,184,5401,5424,"No Chemotherapy or Radiotherapy     \n', '  Study   8   notaecandidatepreexistingconditionorriskfactor n = 70)  12-14",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
185,aranesp,185,5424,5428,g/dL       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,aranesp,186,5428,5471,"Not available    Quality of life  Decreased overall survival   \n', '  Study   9   notaecandidatepreexistingconditionorriskfactor n = 989)  12-13 g/dL       10.6 g/dL;9.4, 11.8 g/dL  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
187,aranesp,187,5471,5520,"RBC transfusions  Decreased overall survival   \n', '           *Q1 = 25th percentile\n', ' \n', '\n', ' Q3 = 75th percentile\n', '\n', ' This study did not include a defined hemoglobin target.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,aranesp,188,5520,5588,"Doses were titrated to achieve and maintain the lowest hemoglobin level sufficient to avoid transfusion and not to exceed 12 g/dL.\n', '\n', '  Decreased Overall Survival  \n', '\n', ' Study 2 was described in the previous section     [   see Warnings and Precautions (     5.1     )   ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,aranesp,189,5588,5608,nonoseaegeneralterm at 4 months (8.7% vs. 3.4%) was significantly higher in the epoetin alfa arm.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
190,aranesp,190,5608,5653,The most common investigator-attributed cause of  nonoseaegeneralterm within the first 4 months was disease progression; 28 of 41  nonoseaegeneralterm in the epoetin alfa arm and 13 of 16  nonoseaegeneralterm in the placebo arm were attributed to disease progression.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
191,aranesp,191,5653,5668,Investigator-assessed time to  nonoseaeaeratelteqplacebo was not different between the 2 groups.,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
192,aranesp,192,5668,5738,"Survival at 12 months was significantly lower in the epoetin alfa arm (70% vs. 76%; HR 1.37, 95% CI: 1.07, 1.75; p = 0.012).\n', '\n', ' Study 3 was a randomized, double-blind study (darbepoetin alfa vs. placebo)     conducted in 344  notaecandidateindication patients with  notaecandidatepreexistingconditionorriskfactor receiving chemotherapy.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
193,aranesp,193,5738,5923,"With a median follow-up of 29 months, overall  nonoseaegeneralterm rates were significantly higher among patients randomized to darbepoetin alfa as compared to placebo (HR 1.36, 95% CI: 1.02, 1.82).\n', '\n', ' Study 8 was a multicenter, randomized, double-blind study (epoetin alfa vs. placebo) in which patients with  notaecandidatepreexistingconditionorriskfactor receiving only palliative radiotherapy or no active therapy were treated with epoetin alfa to achieve and maintain hemoglobin levels between 12 and 14 g/dL. Following an interim analysis of 70 patients (planned accrual 300 patients), a significant difference in survival in favor of the patients in the placebo arm of the study was observed (median survival 63 vs. 129 days; HR 1.84; p = 0.04).\n', '\n', ' Study 9 was a randomized, double-blind study (darbepoetin alfa vs. placebo) in 989  notaecandidateindication patients with  notaecandidatepreexistingconditionorriskfactor  neither receiving nor planning to receive chemotherapy or radiation therapy.",0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
194,aranesp,194,5923,5940,There was no evidence of a statistically significant reduction in proportion of patients receiving RBC transfusions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,aranesp,195,5940,6031,"The median survival was shorter in the darbepoetin alfa treatment group than in the placebo group (8 months vs. 10.8 months; HR 1.30, 95% CI: 1.07, 1.57).\n', '\n', '  Decreased Progression  - free Survival and   Overall Survival  \n', '\n', '  Study 1 was a randomized, open-label, multicenter study in 2,098  notaecandidateindication women with  notaecandidatepreexistingconditionorriskfactor  who received first line or second line chemotherapy.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
196,aranesp,196,6031,6068,This was a non inferiority study designed to rule out a 15% risk increase in  nonoseaeaeonlyasinstruction or  nonoseaegeneralterm of epoetin alfa plus standard of care (SOC) as compared with SOC alone.,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
197,aranesp,197,6068,6109,"The median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,aranesp,198,6109,6123,"At the time of clinical data cutoff, 1337  nonoseaegeneralterm were reported.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
199,aranesp,199,6123,6158,"Median overall survival in the epoetin alfa plus SOC group was 17.2 months compared with 17.4 months in the SOC alone group (HR 1.06, 95% CI: 0.95, 1.18).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,aranesp,200,6158,6200,There were more  nonoseaegeneralterm from disease progression in the epoetin alfa plus SOC arm (59% vs. 56%) and more  oselabeledaefromdruguse in the epoetin alfa plus SOC arm (3% vs. 1%).  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
201,aranesp,201,6200,6244,"\n', '\n', ' Study 4 was a randomized, open-label, controlled, factorial design study in which darbepoetin alfa was administered to prevent  notaecandidateindication in 733 women receiving neo-adjuvant  notaecandidatepreexistingconditionorriskfactor treatment.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
202,aranesp,202,6244,6260,A final analysis was performed after a median follow-up of approximately 3 years.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,aranesp,203,6260,6359,"The 3-year survival rate was lower (86% vs. 90%; HR 1.42, 95% CI: 0.93, 2.18) and the 3-year relapse-free survival rate was lower (72% vs. 78%; HR 1.33, 95% CI: 0.99, 1.79) in the darbepoetin alfa-treated arm compared to the control arm.\n', '\n', ' Study 5 was a randomized, open-label, controlled study that enrolled 114 of a planned 460 patients with  notaecandidatepreexistingconditionorriskfactor receiving chemotherapy and radiotherapy.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
204,aranesp,204,6359,6384,Patients were randomized to receive epoetin alfa to maintain hemoglobin between 12 and 14 g/dL or to RBC transfusion support as needed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,aranesp,205,6384,6413,The study was terminated prematurely due to an increase in  nonoseaeaefromofflabel in epoetin alfa-treated patients compared to control (19% vs. 9%).,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
206,aranesp,206,6413,6446,Both local recurrence (21% vs. 20%) and distant recurrence (12% vs. 7%) were more frequent in epoetin alfa-treated patients compared to control.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,aranesp,207,6446,6485,"Progression-free survival at 3 years was lower in the epoetin alfa-treated group compared to control (59% vs. 62%; HR 1.06, 95% CI: 0.58, 1.91).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,aranesp,208,6485,6570,"Overall survival at 3 years was lower in the epoetin alfa-treated group compared to control (61% vs. 71%; HR 1.28, 95% CI: 0.68, 2.42).\n', '\n', ' Study 6 was a randomized, placebo-controlled study in 351 patients with  notaecandidatepreexistingconditionorriskfactor where epoetin beta or placebo was administered to achieve target hemoglobins >= 14 and >= 15 g/dL for women and men, respectively.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
209,aranesp,209,6570,6616,"Locoregional progression-free survival was significantly shorter in patients receiving epoetin beta (HR 1.62, 95% CI: 1.22, 2.14; p = 0.0008) with medians of 406 days and 745 days in the epoetin beta and placebo arms respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,aranesp,210,6616,6710,"Overall survival was significantly shorter in patients receiving epoetin beta (HR 1.39, 95% CI: 1.05, 1.84; p = 0.02).\n', '\n', '  Decreased Locoregional C   ontrol  \n', '\n', ' Study 7 was a randomized, open-label, controlled study conducted in 522 patients with  notaecandidatepreexistingconditionorriskfactor of the head and neck receiving radiation therapy alone (no chemotherapy) who were randomized to receive darbepoetin alfa to maintain hemoglobin levels of 14 to15.5 g",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
211,aranesp,211,6710,6717,/dL or no darbepoetin alfa.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,aranesp,212,6717,6756,"An interim analysis performed on 484 patients demonstrated that locoregional control at 5 years was significantly shorter in patients receiving darbepoetin alfa (RR 1.44, 95% CI: 1.06, 1.96; p = 0.02).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,aranesp,213,6756,6806,"Overall survival was shorter in patients receiving darbepoetin alfa     (RR 1.28, 95% CI: 0.98, 1.68; p = 0.08).\n', '\n', '    5.3        oselabeledaefromdruguse \n', '  Aranesp is contraindicated in patients with  notaecandidatecontraindication  ",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
214,aranesp,214,6806,6834,"In Aranesp clinical studies, approximately 40% of patients with  notaecandidatepreexistingconditionorriskfactor required initiation or intensification of antihypertensive therapy during the early phase of treatment.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
215,aranesp,215,6834,6869,"oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported in patients with  notaecandidatepreexistingconditionorriskfactor receiving Aranesp.\n', '\n', ' Appropriately control  notaecandidatepreexistingconditionorriskfactor prior to initiation of and during treatment with Aranesp.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
216,aranesp,216,6869,6882,Reduce or withhold Aranesp if blood pressure becomes     difficult to control.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,aranesp,217,6882,6959,"Advise patients of the importance of compliance with antihypertensive therapy and dietary restrictions [   see Patient Counseling Information (     17     )   ]  .\n', '\n', '    5.4       Seizures\n', '\n', '  Aranesp increases the risk of  oselabeledaefromdruguse in patients with  notaecandidatepreexistingconditionorriskfactor  During the first several months following initiation of Aranesp, monitor patients closely for  nonoseaeaeonlyasinstruction  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
218,aranesp,218,6959,7035,"Advise patients to contact their healthcare practitioner for new-onset  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or change in  nonoseaeaeonlyasinstruction frequency.\n', '\n', '    5.5       Lack or Loss of Hemoglobin Response to Aranesp\n', '\n', '  For lack or loss of hemoglobin response to Aranesp, initiate a search for causative factors (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,aranesp,219,7035,7067,"If typical causes of lack or loss of hemoglobin response are excluded, evaluate for  nonoseaeaeonlyasinstruction [   see Warnings and Precautions (     5.6     )   ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,aranesp,220,7067,7103,In the absence of  nonoseaeaeonlyasinstruction  follow dosing recommendations for management of patients with an insufficient hemoglobin response to Aranesp therapy [see Dosage and   Administration   (     2.2     )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,aranesp,221,7103,7115,".\n', '\n', '    5.6        oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,aranesp,222,7115,7153,"\n', '  Cases of  oselabeledaefromdruguse and of severe  oselabeledaefromdruguse  with or without other  oselabeledaefromdruguse that arise following the development of  oselabeledaefromdruguse have been reported in patients treated with Aranesp.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,aranesp,223,7153,7170,This has been reported predominantly in patients with  notaecandidatepreexistingconditionorriskfactor receiving ESAs by subcutaneous administration.  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
224,aranesp,224,7170,7262,"nonoseaeaefromofflabel has also been reported in patients receiving ESAs for  notaecandidatepreexistingconditionorriskfactor related to  notaecandidatepreexistingconditionorriskfactor treatment (an indication for which Aranesp is not approved).\n', '\n', ' If severe  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction develop during treatment with Aranesp, withhold Aranesp and evaluate patients for  nonoseaeaeonlyasinstruction  Contact Amgen (1-800-77-AMGEN) to perform assays for binding and  nonoseaeaeonlyasinstruction   Permanently discontinue Aranesp in patients who develop  nonoseaeaeonlyasinstruction following treatment with Aranesp or other erythropoietin protein drugs.",1,0,1,0,0,0,0,0,0,0,1,0,0,0,0
225,aranesp,225,7262,7313,"Do not switch patients to other ESAs.\n', '\n', '    5.7       Serious Allergic Reactions\n', '\n', '  Serious  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse may occur with Aranesp.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,aranesp,226,7313,7333,"Immediately and permanently discontinue Aranesp and administer appropriate therapy if a serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction occurs.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,aranesp,227,7333,7343,"'\n', '    5.8 Severe  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,aranesp,228,7343,7380,"\n', '    oselabeledaefromdruguse and  oselabeledaefromdruguse including  oselabeledaefromdruguse and  oselabeledaefromdruguse / oselabeledaefromdruguse , have been reported in patients treated with ESAs (including Aranesp) in the post-marketing setting.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,aranesp,229,7380,7401,Discontinue Aranesp therapy immediately if a severe  nonoseaeaeonlyasinstruction  such as  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  is suspected.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,aranesp,230,7401,7435,"\n', '\n', '    5.9       Dialysis Management\n', '\n', '  Patients may require adjustments in their dialysis prescriptions after initiation of Aranesp.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,aranesp,231,7435,7450,Patients receiving Aranesp may require increased anticoagulation with heparin to prevent  oselabeledaefromdruguse '],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,relistor,0,0,77,"['    6 ADVERSE REACTIONS\n', '\n', '  Serious and important adverse reactions described elsewhere in labeling include:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.1  )]  \n', ' *  Severe or persistent  oselabeledaefromdruguse [see Warnings and Precautions (  5.2  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,relistor,1,77,84,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,relistor,2,84,96,[see Warnings and Precautions (  5.3  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,relistor,3,96,189,"\n', '   *  The most common adverse reactions (>= 1%) in adult patients with  notaecandidateindication and  notaecandidateindication are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (  6.1  ) \n', ' *  The most common adverse reactions (>= 5%) in adult patients with  notaecandidateindication and advanced illness are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (  6.1  )",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,relistor,4,189,197,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,relistor,5,197,227,"To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals Inc. at 1-800-508-0024 or FDA at 1-800-FDA-1088 or      www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,relistor,6,227,260,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,relistor,7,260,380,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', '   Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain  \n', '\n', '\n', '\n', ' The safety of RELISTOR was evaluated in a double-blind, placebo-controlled trial in adult patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor receiving opioid analgesia.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
8,relistor,8,380,435,"This study (Study 1) included a 4-week, double-blind, placebo-controlled period in which adult patients were randomized to receive RELISTOR 12 mg once daily (150 patients) or placebo (162 patients) [  see    Clinical Studies (    14.1        )  ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,relistor,9,435,506,"After 4 weeks of double-blind treatment, patients began an 8-week open-label treatment period during which RELISTOR 12 mg was administered less frequently than the recommended dosage regimen of 12 mg once daily.\n', '\n', '\n', '\n', ' Adverse reactions in adult patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor receiving RELISTOR are shown in Table 2.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
10,relistor,10,506,576,"The adverse reactions in the table below may reflect symptoms of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '\n', '  Table 2:  Adverse Reactions* in 4-Week Double-Blind, Placebo-Controlled Period of Clinical Study of RELISTOR in Adult Patients with Opioid-InducedConstipation and Chronic Non-Cancer Pain    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,relistor,11,576,584,"\n', '  Adverse Reaction    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,relistor,12,584,585,RELISTOR,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,relistor,13,585,590,12 mg once dailyn =,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,relistor,14,590,592,150      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,relistor,15,592,611,"Placebo  n = 162   \n', '   oselabeledaefromdruguse    21%             6%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,relistor,16,611,637,"\n', '   oselabeledaefromdruguse           9%              6%                \n', '   oselabeledaefromdruguse         6%               4%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,relistor,17,637,650,"\n', '   oselabeledaefromdruguse    6%              1%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,relistor,18,650,690,"\n', '   oselabeledaefromdruguse        3%              2%                \n', '  oselabeledaefromdruguse           1%               < 1%              \n', '  oselabeledaefromdruguse           1%               0%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,relistor,19,690,721,"\n', '  *Adverse reactions occuring in >= 1% of patients receiving RELISTOR 12 mg once daily and at an incidence greater than placebo.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,relistor,20,721,830,"\n', '         .\n', ' \n', '\n', ' During the 4-week double-blind period, in patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor that received RELISTOR 12 mg every other day, there was a higher incidence of adverse reactions, including  oselabeledaefromdruguse (12%),  oselabeledaefromdruguse (12%),  oselabeledaefromdruguse (7%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%), and  oselabeledaefromdruguse (2%) as compared to daily Relistor dosing.  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
21,relistor,21,830,833,Use of RELISTOR,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,relistor,22,833,861,12 mg every other day is not recommended in patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor  [see Dosage and Administration (2.2)]  .,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
23,relistor,23,861,900,The rates of discontinuation due to adverse reactions during the double-blind period (Study 1) were higher in the RELISTOR once daily (7%) than the placebo group (3%).   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,relistor,24,900,971,"oselabeledaefromdruguse was the most common adverse reaction resulting in discontinuation from the double-blind period in the RELISTOR once daily group (2%).\n', '\n', '\n', '\n', ' The safety of RELISTOR was also evaluated in a 48-week, open-label, uncontrolled trial in 1034 adult patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor (Study 2).",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
25,relistor,25,971,1002,"Patients were allowed to administer RELISTOR 12 mg less frequently than the recommended dosage regimen of 12 mg once daily, and took a median of 6 doses per week.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,relistor,26,1002,1029,A total of 624 patients (60%) completed at least 24 weeks of treatment and 477 (46%) completed the 48-week study.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,relistor,27,1029,1052,The adverse reactions seen in this study were similar to those observed during the 4-week double-blind period of Study 1.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,relistor,28,1052,1084,"Additionally, in Study 2, investigators reported 4  nonoseaeaeonlyasinstruction (1  nonoseaegeneralterm , 1  nonoseaeaeonlyasinstruction ( nonoseaegeneralterm , 1  nonoseaegeneralterm  nonoseaeaeonlyasinstruction and 1  nonoseaeaeonlyasinstruction  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,relistor,29,1084,1170,"It is not possible to establish a relationship between these events and RELISTOR.\n', '\n', '\n', '\n', '   Opioid-Induced Constipation in Adult Patients with Advanced Illness  \n', '\n', '\n', '\n', ' The safety of RELISTOR was evaluated in two, double-blind, placebo-controlled trials in adult patients with  notaecandidateindication and advanced illness receiving palliative care:",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
30,relistor,30,1170,1213,"Study 3 included a single-dose, double-blind, placebo-controlled period, whereas Study 4 included a 14-day multiple dose, double-blind, placebo-controlled period [see  Clinical Studies (    14        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,relistor,31,1213,1219,.2        )  ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,relistor,32,1219,1314,"\n', '\n', '\n', '\n', ' The most common (>= 5%) adverse reactions in adult patients with  notaecandidateindication and advanced illness receiving RELISTOR are shown in Table 3 below.\n', '\n', '\n', '\n', '\n', '  Table 3: Adverse Reactions from all Doses in Double-Blind, Placebo-Controlled Clinical Studies of RELISTOR in Adult Patients with Opioid-Induced Constipation and Advanced Illness",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
33,relistor,33,1314,1316,*    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,relistor,34,1316,1329,"\n', '  Adverse Reaction    RELISTORn = 165    Placebon",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,relistor,35,1329,1345,"= 123    \n', '   oselabeledaefromdruguse    29%              10%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,relistor,36,1345,1397,"\n', '   oselabeledaefromdruguse       13%              6%               \n', '   oselabeledaefromdruguse           12%              5%               \n', '   oselabeledaefromdruguse        7%               2%               \n', '   oselabeledaefromdruguse         6%               2%               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,relistor,37,1397,1440,"\n', '  * Adverse reactions occuring in >= 5% of patients receiving all doses of RELISTOR (0.075, 0.15, and 0.30 mg/kg/dose) and at an incidence greater than placebo.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,relistor,38,1440,1519,"\n', '         The rates of discontinuation due to adverse events during the double-blind placebo controlled clinical trials (Study 3 and Study 4) were comparable between RELISTOR (1%) and placebo (2%).\n', ' \n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of RELISTOR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,relistor,39,1519,1571,"Because they are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '    nonoseaegeneralterm  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,relistor,40,1571,1606,"\n', '\n', '\n', '\n', ' Perforation,  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,relistor,41,1606,1608,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,relistor,42,1608,1638,"\n', '\n', '\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   Cases of  oselabeledaefromdruguse     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,relistor,43,1638,1683,"5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *   Gastrointestinal perforation : Consider the overall risk benefit in patients with known or suspected lesions of the GI tract.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,relistor,44,1683,1703,"Monitor for severe, persistent or worsening abdominal pain; discontinue if development of symptoms (  5.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,relistor,45,1703,1753,"\n', ' *   Severe or persistent diarrhea : Discontinue if severe or persistent diarrhea occurs during treatment (  5.2  ) \n', ' *   Opioid withdrawal : Consider the overall risk benefit in patients with disruptions to the blood-brain barrier.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,relistor,46,1753,1762,Monitor closely for symptoms of opioid withdrawal (  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,relistor,47,1762,1765,5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,relistor,48,1765,1845,"\n', '    \n', ' \n', '\n', '   5.1 Gastrointestinal Perforation\n', '\n', '\n', '\n', '   Cases of  oselabeledaefromdruguse have been reported in adult patients with  notaecandidateindication and advanced illness with conditions that may be associated with localized or diffuse  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor .",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
49,relistor,49,1845,1877,"Take into account the overall risk-benefit profile when using RELISTOR in patients with these conditions or other conditions which might result in  nonoseaeaeonlyasinstruction (e.g.,  notaecandidatepreexistingconditionorriskfactor .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
50,relistor,50,1877,1889,"Monitor for the development of severe, persistent, or worsening  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,relistor,51,1889,1911,nonoseaeaeonlyasinstruction  discontinue RELISTOR in patients who develop this symptom [see Contraindications (  4  )]  .  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,relistor,52,1911,2044,"\n', '\n', '\n', '\n', '    5.2 Severe or Persistent  oselabeledaefromdruguse \n', '\n', '\n', '  If severe or persistent  nonoseaeaeonlyasinstruction occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their healthcare provider.\n', '\n', '\n', '\n', '    5.3 Opioid Withdrawal\n', '\n', '\n', '\n', '   Symptoms consistent with  oselabeledaefromdruguse  including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication have occurred in patients treated with RELISTOR [see Adverse Reactions (  6.1  )]  .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
53,relistor,53,2044,2076,Patients having  notaecandidatepreexistingconditionorriskfactor may be at increased risk for  nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction  Take into account the overall risk-benefit profile when using RELISTOR in such patients.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
54,relistor,54,2076,2088,Monitor for adequacy of analgesia and symptoms of  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,movantik,0,0,45,"['    6 ADVERSE REACTIONS\n', '\n', '  Serious and important adverse reactions described elsewhere in labeling include:\n', '\n', '\n', '\n', ' *     nonoseaeaeforanotherdruginclass [ see  ",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
1,movantik,1,45,53,Warnings and Precautions (5.1)   ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,movantik,2,53,71,"\n', ' *     oselabeledaefromdruguse [ see    Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,movantik,3,71,79,"\n', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,movantik,4,79,152,"The most common adverse reactions in clinical trials (>= 3%) are: abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache  (6.1)  \n', ' \n', '\n', ' To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,movantik,5,152,189,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,movantik,6,189,383,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The data described below reflect exposure to MOVANTIK in 1497 patients in clinical trials, including 537 patients exposed for greater than six months, and 320 patients exposed for 12 months.\n', '\n', '\n', '\n', ' The safety data described in Table 1 are derived from two double-blind, placebo-controlled trials (Studies 1 and 2) in patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor [  see      Clinical Studies (14)    ].\n', '\n', '\n', '\n', ' Study 3 (n=302) was a safety extension study that allowed patients from Study 1 to continue the same blinded treatment for an additional 12 weeks.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
7,movantik,7,383,468,"Safety data for patients in Study 3 are similar to those listed in Table 1.\n', '\n', '\n', '\n', ' Study 4 (n=844) was a Phase 3, 52-week, multi-center, open-label, randomized, parallel group, safety and tolerability study of naloxegol versus usual care treatment for OIC (as determined by the investigator and excluding peripheral opioid antagonists) in patients with  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
8,movantik,8,468,483,The population enrolled in Study 4 was similar to that of the other studies.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,movantik,9,483,507,Eligible patients were randomized in a 2:1 ratio to receive either naloxegol 25 mg once daily or usual care treatment for  notaecandidateindication  ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
10,movantik,10,507,545,"The most commonly used laxatives in the usual care group were rectal stimulants (e.g., bisacodyl), oral stimulants (e.g., senna), and oral osmotics (e.g., macrogol, magnesium).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,movantik,11,545,626,"Safety data for patients in Study 4 are similar to those listed in Table 1.\n', '\n', '\n', '\n', ' Table 1 lists adverse reactions in pooled Studies 1 and 2 occurring in >= 3% of patients receiving MOVANTIK 12.5 mg or 25 mg and at an incidence greater than placebo.\n', '\n', '\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,movantik,12,626,651,Adverse ReactionsAdverse reactions occurring in >=3% of patients receiving MOVANTIK 12.5 mg or 25 mg and at an incidence greater than placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,movantik,13,651,673,"in Patients with  notaecandidateindication and  notaecandidatepreexistingconditionorriskfactor (Studies 1 and 2) \n', '                                Adverse Reaction            ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
14,movantik,14,673,694,"\n', '                                                              MOVANTIK 25 mg  (n=446)    MOVANTIK 12.5 mg  (n=441)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,movantik,15,694,700,Placebo  (n=444)         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,movantik,16,700,728,"\n', '                                oselabeledaefromdruguse               \n', '                                                              21%                      12%                      7%                       \n', '                                oselabeledaefromdruguse                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,movantik,17,728,749,"\n', '                                                              9%                       6%                       5%                       \n', '                                oselabeledaefromdruguse                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,movantik,18,749,751,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,movantik,19,751,770,", '                                                              8%                       7%                       5%                       \n', '                                oselabeledaefromdruguse                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,movantik,20,770,791,"\n', '                                                              6%                       3%                       3%                       \n', '                                oselabeledaefromdruguse                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,movantik,21,791,826,"\n', '                                                              5%                       3%                       4%                       \n', '                                oselabeledaefromdruguse                     \n', '                                                              4%                       4%                       3%                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,movantik,22,826,833,"\n', '                                oselabeledaefromdruguse                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,movantik,23,833,856,"\n', '                                                              3%                       <1%                      <1%                      \n', '             oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,movantik,24,856,944,"\n', ' \n', '\n', ' Possible  oselabeledaefromdruguse  defined as at least three adverse reactions potentially related to  oselabeledaefromdruguse that occurred on the same day and were not all related to the gastrointestinal system, occurred in less than 1% (1/444) of placebo subjects, 1% (5/441) receiving MOVANTIK 12.5 mg, and 3% (14/446) receiving MOVANTIK 25 mg in Studies 1 and 2 regardless of maintenance opioid treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,movantik,25,944,1038,"Symptoms included but were not limited to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Patients receiving methadone as therapy for their pain condition were observed in Studies 1 and 2 to have a higher frequency of  nonoseaegeneralterm     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *     Gastrointestinal perforation : Consider the overall risk benefit in patients with known or suspected lesions of the GI tract.",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
26,movantik,26,1038,1083,"Monitor for severe, persistent or worsening abdominal pain; discontinue if development of symptoms  (5.1)   \n', ' *     Opioid withdrawal : Consider the overall risk benefit in patients with disruptions to the blood-brain barrier.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,movantik,27,1083,1094,Monitor for symptoms of opioid withdrawal  (5.2)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,movantik,28,1094,1116,"\n', '    \n', ' \n', '\n', '   5.1 Gastrointestinal Perforation\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,movantik,29,1116,1175,", '\n', '\n', '\n', '  Cases of  nonoseaeaeforanotherdruginclass have been reported with use of another peripherally acting opioid antagonist in patients with conditions that may be associated with localized or diffuse  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor .",0,0,1,0,0,0,0,0,0,0,0,0,1,0,0
30,movantik,30,1175,1207,"Take into account the overall risk-benefit profile when using MOVANTIK in patients with these conditions or other conditions which might result in  nonoseaegeneralterm (e.g.,  notaecandidatepreexistingconditionorriskfactor .",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
31,movantik,31,1207,1237,"Monitor for the development of severe, persistent or worsening  nonoseaeaeonlyasinstruction  discontinue MOVANTIK in patients who develop this symptom [ see     Contraindications (4)    ]",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,movantik,32,1237,1316,".\n', '\n', '\n', '\n', '    5.2 Opioid Withdrawal\n', '\n', '\n', '\n', '  Clusters of symptoms consistent with  oselabeledaefromdruguse  including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication have occurred in patients treated with MOVANTIK [ see     Adverse Reactions (6.1)    ].",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
33,movantik,33,1316,1361,"In addition, patients receiving methadone as therapy for their  notaecandidatepreexistingconditionorriskfactor condition were observed in clinical trials to have a higher frequency of  nonoseaegeneralterm that may have been related to  nonoseaeaeonlyasinstruction than patients receiving other opioids [ see     Adverse Reactions (",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
34,movantik,34,1361,1366,6.1)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,movantik,35,1366,1398,Patients having  notaecandidatepreexistingconditionorriskfactor may be at increased risk for  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  Take into account the overall risk-benefit profile when using MOVANTIK in such patients.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
36,movantik,36,1398,1406,Monitor for symptoms of  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,lexapro,0,0,241,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most commonly observed adverse reactions (incidence >= 5% and at least twice the incidence of placebo patients) are: insomnia, ejaculation disorder (primarily ejaculatory delay), nausea, sweating increased, fatigue and somnolence, decreased libido, and anorgasmia (  6.1  ).\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800- 433-8871, or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch  .\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n', '\n', '     Clinical Trial Data Sources  \n', '\n', '     Pediatrics (6 -17 years)  \n', '\n', ' Adverse events were collected in 576 pediatric patients (286 Lexapro, 290 placebo) with  notaecandidateindication in double-blind placebo-controlled studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
1,lexapro,1,241,314,"Safety and effectiveness of Lexapro in pediatric patients less than 12 years of age has not been established.\n', '\n', '     Adults  \n', '\n', ' Adverse events information for Lexapro was collected from 715 patients with  notaecandidateindication who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebo-controlled trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
2,lexapro,2,314,332,An additional 284 patients with  notaecandidateindication were newly exposed to escitalopram in open-label trials.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
3,lexapro,3,332,396,"The adverse event information for Lexapro in patients with  notaecandidateindication was collected from 429 patients exposed to escitalopram and from 427 patients exposed to placebo in double-blind, placebo-controlled trials.\n', '\n', ' Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,lexapro,4,396,431,"Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,lexapro,5,431,491,"In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events.\n', '\n', ' The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,lexapro,6,491,587,"An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.\n', '\n', '     Adverse Events Associated with Discontinuation of Treatment  \n', '\n', '      notaecandidateindication  \n', '\n', '     Pediatrics (6 -17 years)  \n', '\n', ' Adverse events were associated with discontinuation of 3.5% of 286 patients receiving Lexapro and 1% of 290 patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,lexapro,7,587,629,"The most common adverse event (incidence at least 1% for Lexapro and greater than placebo) associated with discontinuation was  oselabeledaefromdruguse (1% Lexapro, 0% placebo).\n', '\n', '     Adults  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,lexapro,8,629,673,"\n', '\n', ' Among the 715  notaecandidateindication patients who received Lexapro in placebo-controlled trials, 6% discontinued treatment due to an adverse event, as compared to 2% of 592 patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
9,lexapro,9,673,712,"In two fixed-dose studies, the rate of discontinuation for adverse events in patients receiving 10 mg/day Lexapro was not significantly different from the rate of discontinuation for adverse events in patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,lexapro,10,712,767,"The rate of discontinuation for adverse events in patients assigned to a fixed dose of 20 mg/day Lexapro was 10%, which was significantly different from the rate of discontinuation for adverse events in patients receiving 10 mg/day Lexapro (4%) and placebo (3%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,lexapro,11,767,836,"Adverse events that were associated with the discontinuation of at least 1% of patients treated with Lexapro, and for which the rate was at least twice that of placebo, were  oselabeledaefromdruguse (2%) and  oselabeledaefromdruguse (2% of male patients).\n', '\n', '      notaecandidateindication  \n', '\n', '     Adults  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,lexapro,12,836,886,"\n', '\n', ' Among the 429  notaecandidateindication patients who received Lexapro 10-20 mg/day in placebo-controlled trials, 8% discontinued treatment due to an adverse event, as compared to 4% of 427 patients receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,lexapro,13,886,1019,"Adverse events that were associated with the discontinuation of at least 1% of patients treated with Lexapro, and for which the rate was at least twice the placebo rate, were  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse (1%), and  oselabeledaefromdruguse (1%).\n', '\n', '     Incidence of Adverse Reactions in Placebo-Controlled Clinical Trials  \n', '\n', '      notaecandidateindication  \n', '\n', '     Pediatrics (6 -17 years)  \n', '\n', ' The overall profile of adverse reactions in pediatric patients was generally similar to that seen in adult studies, as shown in  Table 2  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
14,lexapro,14,1019,1139,"However, the following adverse reactions (excluding those which appear in  Table 2  and those for which the coded terms were uninformative or misleading) were reported at an incidence of at least 2% for Lexapro and greater than placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '     Adults  \n', '\n', ' The most commonly observed adverse reactions in Lexapro patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were  oselabeledaefromdruguse   oselabeledaefromdruguse (primarily  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,lexapro,15,1139,1193,"\n', '\n', '   Table 2  enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred among 715  notaecandidateindication patients who received Lexapro at doses ranging from 10 to 20 mg/day in placebo-controlled trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
16,lexapro,16,1193,1232,"Events included are those occurring in 2% or more of patients treated with Lexapro and for which the incidence in patients treated with Lexapro was greater than the incidence in placebo-treated patients.\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,lexapro,17,1232,1268,"', ' TABLE 2 Treatment-Emergent Adverse Reactions observed with a frequency of >= 2% and greater than placebo for Major Depressive Disorder \n', '  1Primarily  oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,lexapro,18,1268,1288,"\n', '  2Denominator used was for males only (N=225 Lexapro; N=188 placebo).    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,lexapro,19,1288,1308,"\n', '  3Denominator used was for females only (N=490 Lexapro; N=404 placebo).    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,lexapro,20,1308,1318,"\n', '  \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,lexapro,21,1318,1336,"Adverse Reaction                              Lexapro                       Placebo                     \n', '                                                 (N=715)%                      (N=592)%                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,lexapro,22,1336,1369,"\n', '    nonoseaegeneralterm                                                                      \n', '  oselabeledaefromdruguse                                     6%                            5%                            \n', '  oselabeledaefromdruguse                            5%                            2%                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,lexapro,23,1369,1389,"\n', '    nonoseaegeneralterm                                                                \n', '  oselabeledaefromdruguse                                     5%                            3%                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,lexapro,24,1389,1409,"\n', '    nonoseaegeneralterm                                                                              \n', '  oselabeledaefromdruguse                                        15%                           7%                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,lexapro,25,1409,1422,"\n', '  oselabeledaefromdruguse                                      8%                            5%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,lexapro,26,1422,1435,"\n', '  oselabeledaefromdruguse                                  3%                            1%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,lexapro,27,1435,1448,"\n', '  oselabeledaefromdruguse                                   3%                            1%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,lexapro,28,1448,1461,"\n', '  oselabeledaefromdruguse                                2%                            1%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,lexapro,29,1461,1481,"\n', '    nonoseaegeneralterm                                                                                                 \n', '  oselabeledaefromdruguse                       5%                            4%                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,lexapro,30,1481,1494,"\n', '  oselabeledaefromdruguse                                       5%                            2%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,lexapro,31,1494,1508,"\n', '    nonoseaegeneralterm                                                                                   \n', '  oselabeledaefromdruguse                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,lexapro,32,1508,1514,9%                            4%                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,lexapro,33,1514,1527,"\n', '  oselabeledaefromdruguse                                    6%                            2%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,lexapro,34,1527,1540,"\n', '  oselabeledaefromdruguse                            3%                            1%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,lexapro,35,1540,1553,"\n', '  oselabeledaefromdruguse                              3%                            1%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,lexapro,36,1553,1567,"\n', '    nonoseaegeneralterm                                                                            \n', '  oselabeledaefromdruguse                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,lexapro,37,1567,1573,5%                            4%                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,lexapro,38,1573,1586,"\n', '  oselabeledaefromdruguse                                     3%                            2%                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,lexapro,39,1586,1609,"\n', '    nonoseaegeneralterm                                                                                              \n', '  oselabeledaefromdruguse  1,2                     9%                            <1%                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,lexapro,40,1609,1616,"\n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,lexapro,41,1616,1625,2                                  3%                            <1%                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,lexapro,42,1625,1632,"\n', '  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,lexapro,43,1632,1637,3                                 2%                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,lexapro,44,1637,1641,<1%                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,lexapro,45,1641,1642,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,lexapro,46,1642,1650,"', '             Generalized Anxiety Disorder  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,lexapro,47,1650,1665,"\n', ' \n', '\n', '     Adults  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,lexapro,48,1665,1701,"\n', '\n', ' The most commonly observed adverse reactions in Lexapro patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,lexapro,49,1701,1719,"oselabeledaefromdruguse   oselabeledaefromdruguse (primarily  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,lexapro,50,1719,1768,"\n', '\n', '     Table 3    enumerates the incidence, rounded to the nearest percent of treatment-emergent adverse events that occurred among 429  notaecandidateindication patients who received Lexapro 10 to 20 mg/day in placebo-controlled trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
51,lexapro,51,1768,1863,"Events included are those occurring in 2% or more of patients treated with Lexapro and for which the incidence in patients treated with Lexapro was greater than the incidence in placebo-treated patients.\n', '\n', ' TABLE 3 Treatment-Emergent Adverse Reactions observed with a frequency of >= 2% and greater than placebo for Generalized Anxiety Disorder \n', '  1Primarily  oselabeledaefromdruguse                     \n', '  2Denominator used was for males only (N=182 Lexapro; N=195 placebo).    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,lexapro,52,1863,1883,"\n', '  3Denominator used was for females only (N=247 Lexapro; N=232 placebo).    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,lexapro,53,1883,1896,"\n', '  \n', '   Adverse Reactions                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,lexapro,54,1896,1911,"Lexapro                     Placebo                    \n', '                                                    (N=429)%                    (N=427)%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,lexapro,55,1911,1944,"\n', '    nonoseaegeneralterm                                                                      \n', '     oselabeledaefromdruguse                                     9%                          5%                           \n', '     oselabeledaefromdruguse                            4%                          1%                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,lexapro,56,1944,1961,"\n', '    nonoseaegeneralterm                                                             \n', '     oselabeledaefromdruguse                                      24%                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,lexapro,57,1961,1964,17%                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,lexapro,58,1964,1977,"\n', '     oselabeledaefromdruguse                                   2%                          1%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,lexapro,59,1977,1984,"\n', '    nonoseaegeneralterm                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,lexapro,60,1984,1997,"\n', '     oselabeledaefromdruguse                                        18%                         8%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,lexapro,61,1997,2010,"\n', '     oselabeledaefromdruguse                                      8%                          6%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,lexapro,62,2010,2023,"\n', '     oselabeledaefromdruguse                                  5%                          4%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,lexapro,63,2023,2036,"\n', '     oselabeledaefromdruguse                                   3%                          2%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,lexapro,64,2036,2049,"\n', '     oselabeledaefromdruguse                                      3%                          1%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,lexapro,65,2049,2056,"\n', '     oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,lexapro,66,2056,2062,2%                          1%                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,lexapro,67,2062,2075,"\n', '     oselabeledaefromdruguse                                    2%                          1%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,lexapro,68,2075,2088,"\n', '     oselabeledaefromdruguse                                     2%                          0%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,lexapro,69,2088,2095,"\n', '    nonoseaegeneralterm                                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,lexapro,70,2095,2108,"\n', '     oselabeledaefromdruguse                                       8%                          2%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,lexapro,71,2108,2121,"\n', '     oselabeledaefromdruguse                       5%                          4%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,lexapro,72,2121,2146,"\n', '    nonoseaegeneralterm                                                                         \n', '     oselabeledaefromdruguse Shoulder  oselabeledaefromdruguse  oselabeledaefromdruguse                            3%                          1%                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
73,lexapro,73,2146,2153,"\n', '    nonoseaegeneralterm                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,lexapro,74,2153,2166,"\n', '     oselabeledaefromdruguse                                    13%                         7%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,lexapro,75,2166,2179,"\n', '     oselabeledaefromdruguse                                      12%                         6%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,lexapro,76,2179,2192,"\n', '     oselabeledaefromdruguse                              7%                          2%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,lexapro,77,2192,2205,"\n', '     oselabeledaefromdruguse                             3%                          2%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,lexapro,78,2205,2218,"\n', '     oselabeledaefromdruguse                            3%                          1%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,lexapro,79,2218,2231,"\n', '     oselabeledaefromdruguse                                      3%                          1%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,lexapro,80,2231,2251,"\n', '    nonoseaegeneralterm                                                                            \n', '     oselabeledaefromdruguse                                       2%                          1%                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,lexapro,81,2251,2258,"\n', '    nonoseaegeneralterm                                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
82,lexapro,82,2258,2273,"\n', '     oselabeledaefromdruguse  1,2                     14%                         2%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,lexapro,83,2273,2280,"\n', '     oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,lexapro,84,2280,2302,"3                                 6%                          <1%                          \n', '     oselabeledaefromdruguse                            2%                          1%                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,lexapro,85,2302,2374,"\n', '             Dose Dependency of Adverse Reactions  \n', ' \n', '\n', ' The potential dose dependency of common adverse reactions (defined as an incidence rate of >=5% in either the 10 mg or 20 mg Lexapro groups) was examined on the basis of the combined incidence of adverse reactions in two fixed-dose trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,lexapro,86,2374,2428,"The overall incidence rates of adverse events in 10 mg Lexapro-treated patients (66%) was similar to that of the placebo-treated patients (61%), while the incidence rate in 20 mg/day Lexapro-treated patients was greater (86%).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,lexapro,87,2428,2522,"Table 4  shows common adverse reactions that occurred in the 20 mg/day Lexapro group with an incidence that was approximately twice that of the 10 mg/day Lexapro group and approximately twice that of the placebo group.\n', '\n', ' TABLE 4 Incidence of Common Adverse Reactions in Patients with Major Depressive Disorder \n', '   Adverse Reaction                  Placebo               10 mg/day                  20 mg/day             \n', '                                     (N=311)               Lexapro                    Lexapro               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,lexapro,88,2522,2523,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,lexapro,89,2523,2535,"', '                                                           (N=310)                    (N=125)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,lexapro,90,2535,2622,"\n', '    oselabeledaefromdruguse                        4%                    7%                         14%                     \n', '    oselabeledaefromdruguse                        5%                    6%                         14%                     \n', '    oselabeledaefromdruguse                       3%                    4%                         9%                      \n', '    oselabeledaefromdruguse                      1%                    4%                         9%                      \n', '    oselabeledaefromdruguse                       2%                    4%                         7%                      \n', '    oselabeledaefromdruguse              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,lexapro,91,2622,2705,"<1%                   3%                         8%                      \n', '    oselabeledaefromdruguse                    1%                    3%                         6%                      \n', '    oselabeledaefromdruguse                         2%                    2%                         6%                      \n', '    oselabeledaefromdruguse                     1%                    2%                         6%                      \n', '              Male and Female Sexual Dysfunction with SSRIs  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,lexapro,92,2705,2733,Although  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction often occur as manifestations of a  notaecandidatepreexistingconditionorriskfactor  they may also be a consequence of pharmacologic treatment.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
93,lexapro,93,2733,2802,"In particular, some evidence suggests that SSRIs can cause such  oselabeledaeclasseffect \n', '\n', ' Reliable estimates of the incidence and severity of  nonoseaeaeonlyasinstruction desire, performance, and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction desire,  nonoseaeaeonlyasinstruction  and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,lexapro,94,2802,2858,"Accordingly, estimates of the incidence of  nonoseaeaeonlyasinstruction experience and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and performance cited in product labeling are likely to underestimate their actual incidence.\n', '\n', ' TABLE 5 Incidence of Sexual Side Effects in Placebo-Controlled Clinical Trials \n', '   Adverse Event                        ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,lexapro,95,2858,2862,Lexapro                           Placebo                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,lexapro,96,2862,2884,"\n', '                                      In Males Only                      \n', '                                      (N=407)                           (N=383)                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,lexapro,97,2884,2890,"\n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,lexapro,98,2890,2900,primarily  oselabeledaefromdruguse   12%                               1%                                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,lexapro,99,2900,2913,"\n', '  oselabeledaefromdruguse                     6%                                2%                                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,lexapro,100,2913,2923,"\n', '     oselabeledaefromdruguse                         2%                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,lexapro,101,2923,2927,<1%                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,lexapro,102,2927,2932,"\n', '                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,lexapro,103,2932,2972,"In Females Only                    \n', '                                      (N=737)                           (N=636)                            \n', '  oselabeledaefromdruguse                     3%                                1%                                 \n', '  oselabeledaefromdruguse                           3%                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,lexapro,104,2972,2976,<1%                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,lexapro,105,2976,3059,"\n', '         There are no adequately designed studies examining  nonoseaeaeonlyasinstruction with escitalopram treatment.\n', ' \n', '\n', '  oselabeledaeclasseffect has been reported with all SSRIs.\n', '\n', ' While it is difficult to know the precise risk of  nonoseaeaeonlyasinstruction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.\n', '\n', '     Vital Sign Changes  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,lexapro,106,3059,3119,"\n', '\n', ' Lexapro and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,lexapro,107,3119,3136,These analyses did not reveal any clinically important changes in vital signs associated with Lexapro treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,lexapro,108,3136,3272,"In addition, a comparison of supine and standing vital sign measures in subjects receiving Lexapro indicated that Lexapro treatment is not associated with  nonoseaenegation \n', '\n', '     Weight Changes  \n', '\n', ' Patients treated with Lexapro in controlled trials did not differ from placebo-treated patients with regard to clinically important  nonoseaenegation \n', '\n', '     Laboratory Changes  \n', '\n', ' Lexapro and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables, and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
109,lexapro,109,3272,3378,"These analyses revealed no clinically important  nonoseaegeneralterm parameters associated with Lexapro treatment.\n', '\n', '      oselabeledaefromdruguse  \n', '\n', ' Electrocardiograms from Lexapro (N=625) and placebo (N=527) groups were compared with respect to outliers defined as subjects with  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction over 60 msec from baseline or  nonoseaeaeonlyasinstruction post-dose, and subjects with  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction increases to over 100 bpm or  nonoseaeaeonlyasinstruction to less than 50 bpm with a 25% change from baseline ( nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction outliers, respectively).",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,lexapro,110,3378,3403,None of the patients in the Lexapro group had a  nonoseaenegation  nonoseaeaeratelteqplacebo compared to 0.2% of patients in the placebo group.,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
111,lexapro,111,3403,3420,The incidence of  nonoseaeaeratelteqplacebo outliers was 0.2% in the Lexapro and the placebo group.,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
112,lexapro,112,3420,3478,"The incidence of  oselabeledaefromdruguse outliers was 0.5% in the Lexapro group and 0.2% in the placebo group.\n', '\n', ' QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg) controlled cross-over, escalating multiple-dose study in 113 healthy subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,lexapro,113,3478,3519,"The maximum mean  (95% upper confidence bound)  difference from placebo arm were 4.5 (6.4) and 10.7 (12.7) msec for 10 mg and supratherapeutic 30 mg escitalopram given once daily, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,lexapro,114,3519,3561,"Based on the established exposure-response relationship, the  oselabeledaefromdruguse  Escitalopram 30 mg given once daily resulted in mean Cmaxof 1.7-fold higher than the mean Cmaxfor the maximum recommended therapeutic dose at steady state (20 mg).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,lexapro,115,3561,3667,"The exposure under supratherapeutic 30 mg dose is similar to the steady state concentrations expected in CYP2C19 poor metabolizers following a therapeutic dose of 20 mg.\n', '\n', '     Other Reactions Observed During the Premarketing Evaluation of Lexapro  \n', '\n', ' Following is a list of treatment-emergent adverse events, as defined in the introduction to the    ADVERSE REACTIONS    section, reported by the 1428 patients treated with Lexapro for periods of up to one year in double-blind or open-label clinical trials during its premarketing evaluation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,lexapro,116,3667,3738,"The listing does not include those events already listed in    Tables 2  &  3    , those events for which a drug cause was remote and at a rate less than 1% or lower than placebo, those events which were so general as to be uninformative, and those events reported only once which did not have a substantial probability of being acutely life threatening.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,lexapro,117,3738,3745,Events are categorized by body system.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,lexapro,118,3745,3831,"Events of major clinical importance are described in the Warnings and Precautions section (  5  ).\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
119,lexapro,119,3831,3861,"\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,lexapro,120,3861,3915,"\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,lexapro,121,3915,3928,"', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
122,lexapro,122,3928,3942,"', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,lexapro,123,3942,3958,"\n', '\n', '  nonoseaegeneralterm -  oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,lexapro,124,3958,3990,"', '\n', '   6.2 Post-Marketing Experience\n', '\n', '    Adverse Reactions Reported Subsequent to the Marketing of Escitalopram  \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,lexapro,125,3990,4013,"', '\n', ' The following additional adverse reactions have been identified from spontaneous reports of escitalopram received worldwide.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,lexapro,126,4013,4047,"These adverse reactions have been chosen for inclusion because of a combination of seriousness, frequency of reporting, or potential causal connection to escitalopram and have not been listed elsewhere in labeling.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,lexapro,127,4047,4082,"However, because these adverse reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,lexapro,128,4082,4108,"These events include:\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
129,lexapro,129,4108,4134,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,lexapro,130,4134,4158,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
131,lexapro,131,4158,4176,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
132,lexapro,132,4176,4196,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
133,lexapro,133,4196,4218,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
134,lexapro,134,4218,4236,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
135,lexapro,135,4236,4274,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,lexapro,136,4274,4292,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
137,lexapro,137,4292,4310,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,lexapro,138,4310,4363,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (or  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
139,lexapro,139,4363,4448,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse isual and  oselabeledaefromdruguse  oselabeledaefromdruguse and auditory),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
140,lexapro,140,4448,4465,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
141,lexapro,141,4465,4478,"', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
142,lexapro,142,4478,4496,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,lexapro,143,4496,4524,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
144,lexapro,144,4524,4548,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
145,lexapro,145,4548,4560,"\n', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,lexapro,146,4560,4565,WARNINGS: SUICIDALITY AND ANTIDEPRESSANT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,lexapro,147,4565,4568,"DRUGS\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,lexapro,148,4568,4579,"'\n', '  WARNINGS: SUICIDALITY AND ANTIDEPRESSANT",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,lexapro,149,4579,4581,DRUGS\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,lexapro,150,4581,4639,", '\n', '\n', '\n', '    Antidepressants increased the risk compared to placebo of  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior ( oselabeledaeclasseffect  in children, adolescents, and young adults in short-term studies of  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
151,lexapro,151,4639,4667,"Anyone considering the use of Lexapro or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,lexapro,152,4667,4712,Short-term studies did not show an increase in the risk of  nonoseaenegation with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
153,lexapro,153,4712,4778,"notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor are themselves associated with increases in the risk of  nonoseaeaeonlyasinstruction  Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  or unusual  nonoseaeaeonlyasinstruction  Families and caregivers should be advised of the need for close observation and communication with the prescriber.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
154,lexapro,154,4778,4795,Lexapro is not approved for use in pediatric patients less than 12 years of age.     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,lexapro,155,4795,4801,[See Warnings and Precautions:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,lexapro,156,4801,4863,"Clinical Worsening and  nonoseaeaeonlyasinstruction    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Clinical Worsening/Suicide Risk: Monitor for clinical worsening, suicidality and unusual change in behavior, especially, during the initial few months of therapy or at times of dose changes (  5.1  ).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,lexapro,157,4863,4872,"\n', "" *  Serotonin Syndrome:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,lexapro,158,4872,4926,"Serotonin syndrome has been reported with SSRIs and SNRIs, including Lexapro, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,lexapro,159,4926,4938,"If such symptoms occur, discontinue Lexapro and initiate supportive treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,lexapro,160,4938,4978,"If concomitant use of Lexapro with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases (  5.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,lexapro,161,4978,5009,"\n"", ' *  Discontinuation of Treatment with Lexapro: A gradual reduction in dose rather than abrupt cessation is recommended whenever possible (  5.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,lexapro,162,5009,5033,"\n', ' *  Seizures: Prescribe with care in patients with a history of seizure (  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,lexapro,163,5033,5044,"\n', ' *  Activation of Mania/Hypomania",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,lexapro,164,5044,5060,: Use cautiously in patients with a history of mania (  5.5  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,lexapro,165,5060,5080,"\n', ' *  Hyponatremia: Can occur in association with SIADH (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,lexapro,166,5080,5112,"\n', ' *  Abnormal Bleeding: Use caution in concomitant use with NSAIDs, aspirin, warfarin or other drugs that affect coagulation (  5.7  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,lexapro,167,5112,5136,"\n', ' *  Interference with Cognitive and Motor Performance: Use caution when operating machinery (  5.8  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,lexapro,168,5136,5146,"\n', ' *  Angle Closure Glaucoma:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,lexapro,169,5146,5162,Angle closure glaucoma has occurred in patients with untreated anatomically narrow angles treated with antidepressants.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,lexapro,170,5162,5201,"(  5.9  ) \n', ' *  Use in Patients with Concomitant Illness: Use caution in patients with diseases or conditions that produce altered metabolism or hemodynamic responses (  5.10  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,lexapro,171,5201,5247,"\n', '    \n', ' \n', '\n', '   5.1 Clinical Worsening and Suicide Risk\n', '\n', '  Patients with  notaecandidateindication , both adult and pediatric, may experience  nonoseaeaeonlyasinstruction",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
172,lexapro,172,5247,5286,"and/or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,lexapro,173,5286,5312,nonoseaeaeonlyasinstruction is a known risk of  notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
174,lexapro,174,5312,5349,"There has been a long-standing concern, however, that antidepressants may have a role in inducing  oselabeledaeclasseffect and the emergence of  oselabeledaeclasseffect in certain patients during the early phases of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,lexapro,175,5349,5499,"Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior ( oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an increase in the risk of  nonoseaenegation with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.\n', '\n', ' The pooled analyses of placebo-controlled trials in children and adolescents with  notaecandidateindication   notaecandidatepreexistingconditionorriskfactor , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients.",0,0,1,1,0,0,0,1,0,0,0,0,0,0,0
176,lexapro,176,5499,5541,"The pooled analyses of placebo-controlled trials in adults with  notaecandidateindication or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
177,lexapro,177,5541,5569,"There was considerable variation in risk of  oselabeledaeclasseffect among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,lexapro,178,5569,5591,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across the different indications, with the highest incidence in  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
179,lexapro,179,5591,5612,"The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,lexapro,180,5612,5642,These risk differences (drug-placebo difference in the number of cases of  nonoseaeaeonlyasinstruction per 1000 patients treated) are provided in   Table 1  .  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,lexapro,181,5642,5674,"\n', '\n', ' TABLE 1 \n', '  Age Range                           Drug-Placebo Difference in Number of Cases of  oselabeledaeclasseffect per 1000 Patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,lexapro,182,5674,5697,"Treated     \n', '                                     Increases Compared to Placebo                                       \n', ' <18                                 14 additional cases                                                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,lexapro,183,5697,5709,"\n', ' 18-24                               5 additional cases                                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,lexapro,184,5709,5710,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,lexapro,185,5710,5739,"', '                                     Decreases Compared to Placebo                                       \n', ' 25-64                               1 fewer case                                                        \n', ' >=65                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,lexapro,186,5739,5743,6 fewer cases                                                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,lexapro,187,5743,5759,"\n', '        No  nonoseaenegation occurred in any of the pediatric trials.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
188,lexapro,188,5759,5817,"There were  nonoseaeaeonlyasinstruction in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction risk extends to longer-term use, i.e., beyond several months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,lexapro,189,5817,5972,"However, there is substantial evidence from placebo-controlled maintenance trials in adults with  notaecandidatepreexistingconditionorriskfactor that the use of antidepressants can delay the recurrence of  nonoseaeaeonlyasinstruction \n', '\n', ' All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with antidepressants for  notaecandidateindication as well as for other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
190,lexapro,190,5972,6209,"Although a causal link between the emergence of such symptoms and either the  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose  notaecandidateindication is persistently worse, or who are experiencing emergent  nonoseaeaeonlyasinstruction or symptoms that might be precursors to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', ' If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt  nonoseaeaeonlyasinstruction [ see Dosage and Administration (  2.4  )  ].\n', '\n', ' Families and caregivers of patients being treated with antidepressants for  notaecandidateindication or other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to health care providers.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
191,lexapro,191,6209,6233,Such monitoring should include daily observation by families and caregivers [ see also Patient Counseling Information (  17.1  )  ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,lexapro,192,6233,6345,"Prescriptions for Lexapro should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of  nonoseaeaeonlyasinstruction \n', '\n', '    Screening Patients for Bipolar Disorder  \n', '\n', ' A  nonoseaeaeonlyasinstruction may be the initial presentation of  notaecandidatepreexistingconditionorriskfactor  It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of  nonoseaeaeonlyasinstruction in patients at risk for  notaecandidatepreexistingconditionorriskfactor  Whether any of the symptoms described above represent such a conversion is unknown.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
193,lexapro,193,6345,6395,"However, prior to initiating treatment with an antidepressant, patients with  notaecandidatepreexistingconditionorriskfactor should be adequately screened to determine if they are at risk for  notaecandidatepreexistingconditionorriskfactor  such screening should include a detailed  notaecandidatepreexistingconditionorriskfactor history, including a  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
194,lexapro,194,6395,6595,"It should be noted that Lexapro is not approved for use in treating  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.2 Serotonin Syndrome\n', '\n', ""  The development of a potentially life-threatening  oselabeledaefromdruguse has been reported with SNRIs and SSRIs, including Lexapro, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat  notaecandidatepreexistingconditionorriskfactor and also others, such as linezolid and intravenous methylene blue).\n"", '\n', '  nonoseaeaeonlyasinstruction symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
195,lexapro,195,6595,6628,"Patients should be monitored for the emergence of  nonoseaeaeonlyasinstruction \n', '\n', ' The concomitant use of Lexapro with MAOIs intended to treat  notaecandidatepreexistingconditionorriskfactor is contraindicated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
196,lexapro,196,6628,6651,Lexapro should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,lexapro,197,6651,6682,All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,lexapro,198,6682,6708,No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,lexapro,199,6708,6735,There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Lexapro.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,lexapro,200,6735,6999,"Lexapro should be discontinued before initiating treatment with the MAOI [ see Contraindications (  4.1  ) and Dosage and Administration (  2.5  and  2.6  )  ].\n', '\n', "" If concomitant use of Lexapro with other serotonergic drugs including, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, amphetamine and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for  nonoseaeaefromdruginteraction  particularly during treatment initiation and dose increases.\n"", '\n', ' Treatment with Lexapro and any concomitant serotonergic agents, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.\n', '\n', '    5.3 Discontinuation of Treatment with Lexapro\n', '\n', '  During marketing of Lexapro and other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of  oselabeledaefromdruguse of these drugs, particularly when abrupt, including the following:  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal (e.g.,  nonoseaeodorwithdrawal such as  nonoseaeodorwithdrawal ,  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  While these events are generally self-limiting, there have been reports of serious  oselabeledaefromdruguse \n', '\n', ' Patients should be monitored for these symptoms when discontinuing treatment with Lexapro.",0,0,0,0,0,1,0,0,0,1,0,0,0,0,0
201,lexapro,201,6999,7014,A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,lexapro,202,7014,7040,"If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,lexapro,203,7040,7126,"Subsequently, the physician may continue decreasing the dose but at a more gradual rate [ see Dosage and Administration (  2.4  )  ].\n', '\n', '    5.4 Seizures\n', '\n', ""  Although anticonvulsant effects of racemic citalopram have been observed in animal studies, Lexapro has not been systematically evaluated in patients with a  notaecandidatepreexistingconditionorriskfactor  These patients were excluded from clinical studies during the product's premarketing testing.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
204,lexapro,204,7126,7145,"In clinical trials of Lexapro, cases of  oselabeledaefromdruguse have been reported in association with Lexapro treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,lexapro,205,7145,7235,"Like other drugs effective in the treatment of  notaecandidateindication  Lexapro should be introduced with care in patients with a history of  notaecandidatepreexistingconditionorriskfactor \n"", '\n', '    5.5 Activation of Mania/Hypomania\n', '\n', '  In placebo-controlled trials of Lexapro in  notaecandidateindication  activation of  oselabeledaefromdruguse  oselabeledaefromdruguse was reported in one (0.1%) of 715 patients treated with Lexapro and in none of the 592 patients treated with placebo.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
206,lexapro,206,7235,7250,One additional case of  oselabeledaefromdruguse has been reported in association with Lexapro treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,lexapro,207,7250,7345,"Activation of  oselabeledaefromdruguse  oselabeledaefromdruguse has also been reported in a small proportion of patients with  notaecandidateindication treated with racemic citalopram and other marketed drugs effective in the treatment of  notaecandidateindication  As with all drugs effective in the treatment of  notaecandidateindication  Lexapro should be used cautiously in patients with a history of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.6 Hyponatremia\n', '\n', '   oselabeledaefromdruguse may occur as a result of treatment with SSRIs and SNRIs, including Lexapro.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
208,lexapro,208,7345,7370,"In many cases, this  oselabeledaefromdruguse appears to be the result of the  oselabeledaefromdruguse , and was reversible when Lexapro was discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,lexapro,209,7370,7378,Cases with  oselabeledaefromdruguse have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,lexapro,210,7378,7394,Elderly patients may be at greater risk of developing  oselabeledaeclasseffect with SSRIs and SNRIs.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,lexapro,211,7394,7412,"Also, patients taking diuretics or who are otherwise  notaecandidatepreexistingconditionorriskfactor may be at greater risk [ see",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
212,lexapro,212,7412,7421,Geriatric Use (  8.5    )].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,lexapro,213,7421,7538,"Discontinuation of Lexapro should be considered in patients with symptomatic  nonoseaeaeonlyasinstruction and appropriate medical intervention should be instituted.\n', '\n', ' Signs and symptoms of  nonoseaeaeonlyasinstruction include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  which may lead to  nonoseaemanifestationorcomplication  Signs and symptoms associated with more severe and/or acute cases have included  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaegeneralterm \n', '\n', '    5.7 Abnormal Bleeding\n', '\n', '  SSRIs and SNRIs, including Lexapro, may increase the risk of  oselabeledaefromdruguse events.",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
214,lexapro,214,7538,7560,"Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to the risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,lexapro,215,7560,7789,"Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of  oselabeledaeclasseffect   oselabeledaeclasseffect events related to SSRIs and SNRIs use have ranged from  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect to life-threatening  oselabeledaeclasseffect \n', '\n', ' Patients should be cautioned about the risk of  nonoseaeaefromdruginteraction associated with the concomitant use of Lexapro and NSAIDs, aspirin, or other drugs that affect coagulation.\n', '\n', '    5.8 Interference with Cognitive and Motor Performance\n', '\n', '  In a study in normal volunteers, Lexapro 10 mg/day did not produce  nonoseaenegation  nonoseaenegation intellectual function or  nonoseaenegation  Because any psychoactive drug may  oselabeledaeclasseffect judgment, thinking, or  oselabeledaeclasseffect  oselabeledaeclasseffect judgment,  oselabeledaeclasseffect  oselabeledaeclasseffect  thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Lexapro therapy does not affect their ability to engage in such activities.\n', '\n', '       5.9 Angle Closure Glaucoma\n', '\n', '     Angle Closure Glaucoma:",0,0,0,0,0,1,0,1,0,0,0,0,0,0,0
216,lexapro,216,7789,7813,The  oselabeledaefromdruguse that occurs following use of many antidepressant drugs including Lexapro may trigger an  oselabeledaefromdruguse in a patient with  notaecandidatepreexistingconditionorriskfactor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
217,lexapro,217,7813,7851,"\n', '\n', '    5.10 Use in Patients with Concomitant Illness\n', '\n', '  Clinical experience with Lexapro in patients with certain concomitant systemic illnesses is limited.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,lexapro,218,7851,7938,"Caution is advisable in using Lexapro in patients with diseases or conditions that produce  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction \n', '\n', "" Lexapro has not been systematically evaluated in patients with a recent history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing.\n"", '\n', ' In subjects with  notaecandidatepreexistingconditionorriskfactor  clearance of racemic citalopram was decreased and plasma concentrations were increased.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
219,lexapro,219,7938,7991,"The recommended dose of Lexapro in  notaecandidatepreexistingconditionorriskfactor patients is 10 mg/day [ see Dosage and Administration (  2.3  )  ].\n', '\n', ' Because escitalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
220,lexapro,220,7991,8002,Until adequate numbers of patients with severe  notaecandidatepreexistingconditionorriskfactor '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,rapivab,0,0,82,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in other sections of the labeling:\n', '\n', '\n', '\n', ' *  Serious  oselabeledaefromdruguse and hypersensitivity  oselabeledaefromdruguse  oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,rapivab,1,82,107,"\n', '      EXCERPT:   Most common adverse reaction (incidence >2%) is diarrhea (  6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,rapivab,2,107,281,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-844-273-2327 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In five randomized, double-blind, controlled trials, 1,399 subjects with acute uncomplicated  notaecandidateindication received a single dose of RAPIVAB, administered intravenously or intramuscularly, at doses up to 600 mg.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
3,rapivab,3,281,320,"Among the 664 subjects receiving RAPIVAB 600 mg (intravenous or intramuscular), the most commonly observed adverse reaction was  oselabeledaefromdruguse  occurring at a rate of 8% versus 7% in subjects receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,rapivab,4,320,391,"No subject receiving RAPIVAB 600 mg experienced a serious adverse event and less than 1% discontinued study because of an adverse reaction.\n', '\n', '\n', '\n', ' Clinically significant  nonoseaegeneralterm (DAIDS Grade 2-4) listed in Table 2 occurred more frequently in subjects treated with RAPIVAB 600 mg (intravenous or intramuscular) than placebo.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
5,rapivab,5,391,442,"Only events occurring at >=2% are included.\n', '\n', '\n', '\n', ' Table 2: Laboratory Abnormalities Occurring in >=2% of Subjects Treated with RAPIVAB 600 mg \n', ' Laboratory Parameter Abnormality                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,rapivab,6,442,446,RAPIVAB 600 mg                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,rapivab,7,446,464,"Placebo          \n', '  \n', '    oselabeledaefromdruguse                       (N=654)3%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,rapivab,8,464,475,"(N=430)2%         \n', '    oselabeledaefromdruguse                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,rapivab,9,475,479,(N=660)5%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,rapivab,10,479,498,"(N=433)3%         \n', '    oselabeledaefromdruguse                        (N=654)4%                  (N=431)2%         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,rapivab,11,498,509,"\n', '    oselabeledaefromdruguse                             (N=654)8%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,rapivab,12,509,518,"(N=430)6%         \n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,rapivab,13,518,632,"In a subset of subjects with serious  notaecandidateindication requiring hospitalization treated with RAPIVAB 600 mg as monotherapy (N=101) the following adverse reactions were also reported more frequently with RAPIVAB as compared to placebo:  oselabeledaefromdruguse (4% versus 2%),  oselabeledaefromdruguse (3% versus 0%),  oselabeledaefromdruguse (3% versus 2%), and  oselabeledaefromdruguse (2% versus 0%).\n', ' \n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following additional adverse reactions have been identified during postapproval use of RAPIVAB in Japan.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
14,rapivab,14,632,685,"Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
15,rapivab,15,685,687,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,rapivab,16,687,690,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,rapivab,17,690,699,Warnings and Precautions (5.1)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,rapivab,18,699,766,"\n', '\n', '\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Serious skin/hypersensitivity reactions such as Stevens-Johnson syndrome and erythema multiforme have occurred with RAPIVAB.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,rapivab,19,766,801,"(  5.1  ) \n', ' *  Neuropsychiatric events: Patients with influenza may be at an increased risk of hallucinations, delirium and abnormal behavior early in their illness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,rapivab,20,801,808,Monitor for signs of abnormal behavior.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,rapivab,21,808,813,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,rapivab,22,813,819,"\n', '    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,rapivab,23,819,883,"', ' \n', '\n', '   5.1 Serious Skin/ oselabeledaefromdruguse \n', '\n', '\n', '  Rare cases of serious  oselabeledaefromdruguse  including  oselabeledaefromdruguse  have been reported with RAPIVAB in clinical studies and in postmarketing experience;  oselabeledaefromdruguse has been reported with RAPIVAB in postmarketing experience.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,rapivab,24,883,916,"Appropriate treatment should be instituted if a serious  nonoseaegeneralterm occurs or is suspected.\n', '\n', '\n', '\n', '    5.2  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,rapivab,25,916,969,"\n', '\n', '\n', '   notaecandidateindication can be associated with a variety of  nonoseaeaeonlyasinstruction and behavioral  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction that can include events such as  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  in some cases resulting in  nonoseaegeneralterm outcomes.",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
26,rapivab,26,969,1039,"These events may occur in the setting of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor but can occur in uncomplicated  notaecandidateindication as well.\n', '\n', '\n', '\n', ' There have been postmarketing reports (from Japan) of  oselabeledaefromdruguse and  oselabeledaefromdruguse leading to  nonoseaemanifestationorcomplication in patients with  notaecandidateindication who were receiving neuraminidase inhibitors, including RAPIVAB.",0,0,1,1,1,0,0,0,0,0,0,0,0,0,0
27,rapivab,27,1039,1064,"Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made, but they appear to be uncommon.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,rapivab,28,1064,1082,These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,rapivab,29,1082,1094,The contribution of RAPIVAB to these events has not been established.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,rapivab,30,1094,1165,"Patients with  notaecandidateindication should be closely monitored for signs of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.3 Risk of Bacterial Infections\n', '\n', '\n', '\n', '  There is no evidence for efficacy of RAPIVAB in any illness caused by agents other than  notaecandidateindication viruses.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
31,rapivab,31,1165,1227,"Serious  nonoseaeaeonlyasinstruction may begin with  nonoseaeaeonlyasinstruction or may coexist with or occur as complications during the course of  notaecandidateindication  RAPIVAB has not been shown to prevent such complications.\n', '\n', '\n', '\n', ' Prescribers should be alert to the potential for  nonoseaeaeonlyasinstruction bacterial  nonoseaeaeonlyasinstruction ']",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
0,lastacaft,0,0,119,"['    6 ADVERSE REACTIONS\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', '   EXCERPT:   The most common ocular adverse reactions, occurring in less than 4% of eyes treated with LASTACAFT  (r)  , were eye irritation, burning and/or stinging on instillation, eye redness, and eye pruritus.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,lastacaft,1,119,168,"(  6.1  )\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,lastacaft,2,168,253,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Studies Experience\n', '\n', '  The most frequent  oselabeledaefromdruguse  occurring in less than 4% of eyes treated with LASTACAFT  (r)  , were  oselabeledaefromdruguse  oselabeledaefromdruguse irritation,  oselabeledaefromdruguse  oselabeledaefromdruguse irritation, burning and/or  oselabeledaefromdruguse upon instillation,  oselabeledaefromdruguse and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,lastacaft,3,253,319,"\n', '\n', '\n', '\n', '   6.2 Non-ocular Adverse Reactions\n', '\n', '  The most frequent non-ocular adverse reactions, occurring in less than 3% of subjects with eyes treated with LASTACAFT  (r)  , were  oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,lastacaft,4,319,379,"Some of these events were similar to the underlying disease being studied.\n', '\n', '\n', '\n', '   6.3 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during postmarketing use of LASTACAFT  (r)  in clinical practice.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,lastacaft,5,379,399,"Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,lastacaft,6,399,418,These reactions include:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,lastacaft,7,418,443,"5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,lastacaft,8,443,469,"To minimize the risk of eye injury and contamination, do not touch dropper tip to eyelids and surrounding areas, or any other surface.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,lastacaft,9,469,478,Keep bottle tightly closed when not in use.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,lastacaft,10,478,507,"(  5.1  ) \n', ' *  LASTACAFT  (r)  should not be used to treat contact lens-related irritation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,lastacaft,11,507,512,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,lastacaft,12,512,537,"\n', ' *  Remove contact lenses prior to instillation of LASTACAFT  (r)  . (  5.2  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,lastacaft,13,537,611,"\n', '    \n', ' \n', '\n', '   5.1 Potential for Eye Injury and Contamination\n', '\n', '\n', '\n', '  To minimize  nonoseaeaeonlyasinstruction and contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,lastacaft,14,611,701,"Keep bottle tightly closed when not in use.\n', '\n', '\n', '\n', '    5.2 Contact Lens Use\n', '\n', '\n', '\n', '  Patients should be advised not to wear a contact lens if their eye is red.\n', '\n', '\n', '\n', ' LASTACAFT  (r)  should not be used to treat  notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,pennsaid,0,0,50,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.1)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,pennsaid,1,50,84,"\n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse Bleeding, Ulceration and  oselabeledaefromdruguse  oselabeledaefromdruguse Bleeding,  oselabeledaefromdruguse and Perforation [ see  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,pennsaid,2,84,102,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.3)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,pennsaid,3,102,120,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.4)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,pennsaid,4,120,141,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [ see  Warnings and Precautions (5.5)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,pennsaid,5,141,161,"\n', ' *   oselabeledaeclasseffect and  oselabeledaeclasseffect [ see  Warnings and Precautions (5.6)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,pennsaid,6,161,180,"] \n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.7)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,pennsaid,7,180,200,"\n', ' *  Serious  oselabeledaefromdruguse [ see  Warnings and Precautions (5.9)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,pennsaid,8,200,218,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.11)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,pennsaid,9,218,226,"\n', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,pennsaid,10,226,238,The most common adverse reactions with PENNSAID are application site reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,pennsaid,11,238,285,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma USA Inc. at 1-866-479-6742 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,pennsaid,12,285,314,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,pennsaid,13,314,394,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', "" The data described below reflect exposure to PENNSAID of 130 patients treated for 4 weeks (mean duration of 28 days) in one Phase 2 controlled trial.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,pennsaid,14,394,435,"This population's mean age was approximately 60 years, 85% of patients were Caucasian, 65% were females, and all patients had primary  notaecandidateindication  The most common adverse events with PENNSAID were  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,pennsaid,15,435,769,"These events were the most common reason for withdrawing from the study.\n"", '\n', '     Application Site Reactions:  \n', '\n', ' In this controlled trial,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following:  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%),  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%),  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%),  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%),  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%), pain (2%),  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%), pain (2%), induration (2%),  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness (22%), exfoliation (7%), erythema (4%), pruritus (2%), pain (2%), induration (2%), rash (2%), and  oselabeledaefromdruguse (<1%).\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,pennsaid,16,769,836,"'\n', '     Other Common Adverse Reactions:  \n', '\n', ' Table 1 lists all adverse reactions occurring in >1% of patients receiving PENNSAID, where the rate in the PENNSAID group exceeded vehicle, from a controlled study conducted in patients with  notaecandidateindication \n', '\n', ' Table 1:",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
17,pennsaid,17,836,883,"Incidence of Adverse Reactions Occurring in >1% of Subjects with Osteoarthritis Using PENNSAID and More Often than in Subjects with OA Using Vehicle Control (Pooled) \n', ' Adverse Reaction                                       PENNSAIDN=130n (%)      Vehicle ControlN=129n (%)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,pennsaid,18,883,948,"\n', '  \n', '    oselabeledaefromdruguse                                    4 (3%)                     1 (<1%)            \n', '    oselabeledaefromdruguse                                2 (2%)                     1 (<1%)            \n', '    oselabeledaefromdruguse                                                  2 (2%)                     1 (<1%)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,pennsaid,19,948,968,"\n', '    oselabeledaefromdruguse                                           2 (2%)                     1 (<1%)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,pennsaid,20,968,983,"\n', '    oselabeledaefromdruguse                                                     2 (2%)                        0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,pennsaid,21,983,1023,"\n', '             PENNSAID 1.5%  \n', ' \n', '\n', ' The safety of PENNSAID 2% is based in part, on prior experience with PENNSAID 1.5%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,pennsaid,22,1023,1091,"The data described below reflect exposure to PENNSAID 1.5% of 911 patients treated between 4 and 12 weeks (mean duration of 49 days) in seven Phase 3 controlled trials, as well as exposure of 793 patients treated in an open-label study, including 463 patients treated for at least 6 months, and 144 patients treated for at least 12 months.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,pennsaid,23,1091,1133,"The population mean age was approximately 60 years, 89% of patients were Caucasian, 64% were females, and all patients had primary  notaecandidateindication  The most common adverse events with PENNSAID 1.5% were  oselabeledaefromdruguse  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,pennsaid,24,1133,1396,"These events were the most common reason for withdrawing from the studies.\n', '\n', '     Application Site Reactions:  \n', '\n', ' In controlled trials,  nonoseaegeneralterm  oselabeledaefromdruguse reactions were characterized by one or more of the following:  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema, induration,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema, induration, vesicles,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema, induration, vesicles, paresthesia,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema, induration, vesicles, paresthesia, pruritus,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema, induration, vesicles, paresthesia, pruritus, vasodilation,  oselabeledaefromdruguse  oselabeledaefromdruguse reactions were characterized by one or more of the following: dryness, erythema, induration, vesicles, paresthesia, pruritus, vasodilation, acne, and  oselabeledaefromdruguse  The most frequent of these reactions were  oselabeledaefromdruguse (32%),  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
25,pennsaid,25,1396,1426,"oselabeledaefromdruguse characterized by  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication (9%),  oselabeledaefromdruguse  oselabeledaefromdruguse vesicles (2%) and  oselabeledaefromdruguse (4%).",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
26,pennsaid,26,1426,1459,"In one controlled trial, a higher rate of  oselabeledaefromdruguse (4%) was observed after treatment of 152 subjects with the combination of PENNSAID 1.5% and oral diclofenac.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,pennsaid,27,1459,1576,"In the open-label uncontrolled long-term safety study,  oselabeledaefromdruguse occurred in 13% and  oselabeledaefromdruguse in 10% of patients, generally within the first 6 months of exposure, leading to a withdrawal rate for an application site event of 14%.\n', '\n', '     Other Common Adverse Reactions:  \n', '\n', ' In controlled trials, subjects treated with PENNSAID 1.5% experienced some adverse events associated with the NSAID class more frequently than subjects using placebo ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  see  Table 2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,pennsaid,28,1576,1778,"The combination of PENNSAID 1.5% and oral diclofenac, compared to oral diclofenac alone, resulted in a higher rate of  nonoseaeaefromdruginteraction (3% vs. less than 1%), and more frequent  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction creatinine (12% vs. 7%),  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction creatinine (12% vs. 7%), urea (20% vs. 12%), and  nonoseaeaefromdruginteraction (13% vs. 9%), but no difference in  nonoseaeaeonlyasinstruction \n', '\n', ' Table 2 lists all adverse reactions occurring in >=1% of patients receiving PENNSAID 1.5%, where the rate in the PENNSAID 1.5% group exceeded placebo, from seven controlled studies conducted in patients with  notaecandidateindication  Since these trials were of different durations, these percentages do not capture cumulative rates of occurrence.\n', '\n', ' Table 2: Adverse Reactions Occurring in >=1% of Patients Treated with PENNSAID 1.5% Topical Solution in Placebo and Oral Diclofenac-Controlled Trials \n', ' Treatment Group:                                       PENNSAID 1.5%N=911        ",1,0,0,1,0,1,0,0,0,0,0,0,0,0,0
29,pennsaid,29,1778,1781,Topical PlaceboN=332      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,pennsaid,30,1781,1853,"\n', ' Adverse Reaction                                              N (%)                      N (%)             \n', '  \n', '  oselabeledaefromdruguse                                  292 (32)                    17 (5)             \n', '  oselabeledaefromdruguse                         83 (9)                      6 (2)             \n', '  oselabeledaefromdruguse                                                    72 (8)                     13 (4)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,pennsaid,31,1853,1860,"\n', '  oselabeledaefromdruguse                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,pennsaid,32,1860,1870,54 (6)                     10 (3)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,pennsaid,33,1870,1884,"\n', '  oselabeledaefromdruguse                                                   35 (4)                     1 (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,pennsaid,34,1884,1900,"<1)             \n', '  oselabeledaefromdruguse                                   34 (4)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,pennsaid,35,1900,1901,7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,pennsaid,36,1901,1934,"(2)             \n', '  oselabeledaefromdruguse                                                     33 (4)                      7 (2)             \n', '  oselabeledaefromdruguse                                                       33 (4)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,pennsaid,37,1934,1935,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,pennsaid,38,1935,1956,"(1)             \n', '  oselabeledaefromdruguse                                                  40 (4)                     13 (4)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,pennsaid,39,1956,1982,"\n', '  oselabeledaefromdruguse                                                 29 (3)                     1 (<1)             \n', '  oselabeledaefromdruguse                                                        26",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,pennsaid,40,1982,2001,"(3)                        0               \n', '  oselabeledaefromdruguse (Non-Application Site)                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,pennsaid,41,2001,2011,25 (3)                      5 (2)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,pennsaid,42,2011,2019,"\n', '  oselabeledaefromdruguse                                                    25",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,pennsaid,43,2019,2059,"(3)                      8 (2)             \n', '  oselabeledaefromdruguse                                                   19 (2)                     1 (<1)             \n', '  oselabeledaefromdruguse (Non-Application Site)                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,pennsaid,44,2059,2070,19 (2)                     1 (<1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,pennsaid,45,2070,2081,"\n', '  oselabeledaefromdruguse  vesicles  oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,pennsaid,46,2081,2082,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,pennsaid,47,2082,2088,(2)                        0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,pennsaid,48,2088,2094,"\n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,pennsaid,49,2094,2101,(Non-Application Site)                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,pennsaid,50,2101,2108,14 (2)                     3 (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,pennsaid,51,2108,2117,"<1)             \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,pennsaid,52,2117,2129,nonoseaeaeratelteqplacebo                                            22 (2)                      7 (2)             ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
53,pennsaid,53,2129,2135,"\n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,pennsaid,54,2135,2143,(Non-Application Site)                              15,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,pennsaid,55,2143,2212,"(2)                     2 (<1)             \n', '  oselabeledaefromdruguse                                                    10 (1)                     2 (<1)             \n', '  oselabeledaefromdruguse                                                    11 (1)                     1 (<1)             \n', '  oselabeledaefromdruguse (not otherwise specified)           11 (1)                     3 (<1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,pennsaid,56,2212,2244,"\n', '           6.2 Postmarketing Experience\n', '   In postmarketing surveillance, the following adverse reactions have been reported during post- approval use of PENNSAID 1.5%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,pennsaid,57,2244,2310,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,pennsaid,58,2310,2320,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,pennsaid,59,2320,2348,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,pennsaid,60,2348,2356,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,pennsaid,61,2356,2366,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,pennsaid,62,2366,2382,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,pennsaid,63,2382,2400,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,pennsaid,64,2400,2420,"\n', '    nonoseaegeneralterm  At the  oselabeledaefromdruguse    oselabeledaefromdruguse  oselabeledaefromdruguse   rash,  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,pennsaid,65,2420,2447,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,pennsaid,66,2447,2453,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,pennsaid,67,2453,2455,oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,pennsaid,68,2455,2456,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,pennsaid,69,2456,2466,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,pennsaid,70,2466,2467,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,pennsaid,71,2467,2478,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,pennsaid,72,2478,2480,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,pennsaid,73,2480,2489,"RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,pennsaid,74,2489,2497,"'\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,pennsaid,75,2497,2508,"RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,pennsaid,76,2508,2517,"'\n', '  EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,pennsaid,77,2517,2519,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,pennsaid,78,2519,2546,"RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS  \n', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,pennsaid,79,2546,2554,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,pennsaid,80,2554,2628,"*  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal This risk may occur early in treatment and may increase with duration of use (5.1) \n', ' *  PENNSAID is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,pennsaid,81,2628,2632,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,pennsaid,82,2632,2665,"*  NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,pennsaid,83,2665,2679,These events can occur at any time during use and without warning symptoms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,pennsaid,84,2679,2768,"Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2) \n', '    \n', ' \n', '\n', '    Cardiovascular Thrombotic Events  \n', '\n', ' *  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious  oselabeledaeclasseffect  including  oselabeledaeclasseffect  and  oselabeledaeclasseffect  which can be  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,pennsaid,85,2768,2783,This risk may occur early in treatment and may increase with duration of use.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,pennsaid,86,2783,2793,[see Warnings and Precautions (5.1)].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,pennsaid,87,2793,2829,"\n', ' *  PENNSAID is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,pennsaid,88,2829,2923,"\n', '        Gastrointestinal Bleeding, Ulceration, and Perforation  \n', ' \n', '\n', ' *  NSAIDs cause an increased risk of serious  oselabeledaeclasseffect adverse events including  oselabeledaeclasseffect  oselabeledaeclasseffect adverse events including bleeding,  oselabeledaeclasseffect  oselabeledaeclasseffect (GI)  oselabeledaeclasseffect including bleeding, ulceration, and  oselabeledaeclasseffect stomach or  oselabeledaeclasseffect  oselabeledaeclasseffect or intestines, which can be  nonoseaegeneralterm  These events can occur at any time during use and without warning symptoms.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,pennsaid,89,2923,2975,"Elderly patients and patients with a prior history of  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor are at greater risk for serious  nonoseaeaeonlyasinstruction    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
90,pennsaid,90,2975,2998,Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (  5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,pennsaid,91,2998,3022,"\n', ' *   Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,pennsaid,92,3022,3034,"Monitor blood pressure (  5.4  ,  7  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,pennsaid,93,3034,3044,"\n', ' *   Heart Failure and Edema",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,pennsaid,94,3044,3071,: Avoid use of PENNSAID in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (  5.5  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,pennsaid,95,3071,3080,"\n', ' *   Renal Toxicity :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,pennsaid,96,3080,3099,"Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,pennsaid,97,3099,3125,Avoid use of PENNSAID in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (  5.6  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,pennsaid,98,3125,3129,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,pennsaid,99,3129,3147,*   Anaphylactic Reactions : Seek emergency help if an anaphylactic reaction occurs (  5.7  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,pennsaid,100,3147,3172,"\n', ' *   Exacerbation of Asthma Related to Aspirin Sensitivity : PENNSAID is contraindicated in patients with aspirin-sensitive asthma.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,pennsaid,101,3172,3211,"Monitor patients with preexisting asthma (without aspirin sensitivity) (  5.8  ) \n', ' *   Serious Skin Reactions : Discontinue PENNSAID at first appearance of skin rash or other signs of hypersensitivity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,pennsaid,102,3211,3231,"(  5.9  ,  5.14  ) \n', ' *   Premature Closure of Fetal Ductus",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,pennsaid,103,3231,3233,Arteriosus :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,pennsaid,104,3233,3252,"Avoid use in pregnant women starting at 30 weeks gestation (  5.10  ,  8.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,pennsaid,105,3252,3284,"\n', ' *   Hematologic Toxicity : Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (  5.11  ,  7  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,pennsaid,106,3284,3306,"\n', ' *   Exposure to light: Avoid exposure of treated knee(s) to natural or artificial sunlight.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,pennsaid,107,3306,3311,(  5.11  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,pennsaid,108,3311,3329,"\n', ' *   Eye Contact : Avoid contact of PENNSAID with eyes and mucosa.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,pennsaid,109,3329,3354,"(  5.15  ) \n', ' *   Oral Nonsteroidal Anti-inflammatory Drugs : Avoid concurrent use with oral NSAIDs.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,pennsaid,110,3354,3448,"(  5.16  ) \n', '    \n', ' \n', '\n', '   5.1 Cardiovascular Thrombotic Events\n', '\n', '   Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious  oselabeledaeclasseffect  including  oselabeledaeclasseffect , and  oselabeledaeclasseffect  which can be  nonoseaegeneralterm  Based on available data, it is unclear that the risk for  nonoseaeaeonlyasinstruction is similar for all NSAIDs.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,pennsaid,111,3448,3480,The relative increase in serious  nonoseaeaeonlyasinstruction over baseline conferred by NSAID use appears to be similar in those with and without known  notaecandidatepreexistingconditionorriskfactor or risk factors for  notaecandidatepreexistingconditionorriskfactor  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
112,pennsaid,112,3480,3508,"However, patients with known  notaecandidatepreexistingconditionorriskfactor or risk factors had a higher absolute incidence of excess serious  nonoseaeaeonlyasinstruction  due to their increased baseline rate.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
113,pennsaid,113,3508,3530,Some observational studies found that this increased risk of serious  oselabeledaeclasseffect began as early as the first weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,pennsaid,114,3530,3545,The increase in  nonoseaeaeonlyasinstruction has been observed most consistently at higher doses.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,pennsaid,115,3545,3550,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,pennsaid,116,3550,3580,"', ' To minimize the potential risk for an adverse  nonoseaeaeonlyasinstruction in NSAID-treated patients, use the lowest effective dose for the shortest duration possible.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,pennsaid,117,3580,3657,"Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous  nonoseaenegation  Patients should be informed about the symptoms of serious  nonoseaeaeonlyasinstruction and the steps to take if they occur.\n', '\n', ' There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious  nonoseaeaeonlyasinstruction associated with NSAID use.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
118,pennsaid,118,3657,3680,"The concurrent use of aspirin and an NSAID, such as diclofenac, increases the risk of serious  nonoseaeaefromdruginteraction [ see  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
119,pennsaid,119,3680,3688,Warnings and Precautions (5.2)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,pennsaid,120,3688,3706,".\n', '\n', '    Status Post Coronary Artery Bypass Graft (CABG)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,pennsaid,121,3706,3710,Surgery  \n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,pennsaid,122,3710,3838,", '\n', ' Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of  notaecandidateindication in the first 10-14 days following CABG surgery found an increased incidence of  nonoseaeaefromofflabel and  nonoseaeaefromofflabel  NSAIDs are contraindicated in the setting of CABG [ see  Contraindications (4)    ].\n', '\n', '    Post-MI Patients  \n', '\n', ' Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the  notaecandidatepreexistingconditionorriskfactor period were at increased risk of  oselabeledaeclasseffect   oselabeledaeclasseffect  and all-cause  nonoseaegeneralterm beginning in the first week of treatment.",0,1,1,1,0,0,0,0,0,0,1,0,0,0,0
123,pennsaid,123,3838,3880,"In this same cohort, the incidence of  nonoseaegeneralterm in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,pennsaid,124,3880,4011,"Although the absolute rate of  nonoseaegeneralterm declined somewhat after the first year  notaecandidatepreexistingconditionorriskfactor  the increased relative risk of  nonoseaegeneralterm in NSAID users persisted over at least the next four years of follow-up.\n', '\n', ' Avoid the use of PENNSAID in patients with a recent  notaecandidatepreexistingconditionorriskfactor unless the benefits are expected to outweigh the risk of recurrent  nonoseaeaeonlyasinstruction  If PENNSAID is used in patients with a recent  notaecandidatepreexistingconditionorriskfactor  monitor patients for signs of  nonoseaeaeonlyasinstruction \n', '\n', '    5.2 Gastrointestinal Bleeding, Ulceration, and Perforation\n', '\n', '  NSAIDs, including diclofenac, cause serious  oselabeledaefromdruguse adverse events including  oselabeledaefromdruguse  oselabeledaefromdruguse",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
125,pennsaid,125,4011,4019,"adverse events including inflammation,  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,pennsaid,126,4019,4083,"oselabeledaefromdruguse adverse events including inflammation, bleeding,  oselabeledaefromdruguse  oselabeledaefromdruguse including inflammation, bleeding, ulceration, and  oselabeledaefromdruguse esophagus, stomach,  oselabeledaefromdruguse  oselabeledaefromdruguse esophagus, stomach, small intestine, or  oselabeledaefromdruguse  oselabeledaefromdruguse esophagus,  oselabeledaefromdruguse  oselabeledaefromdruguse  stomach, small intestine, or large intestine, which can be  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,pennsaid,127,4083,4105,"These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,pennsaid,128,4105,4123,Only one in five patients who develop a serious  nonoseaegeneralterm on NSAID therapy is symptomatic.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
129,pennsaid,129,4123,4172,"oselabeledaeclasseffect  oselabeledaeclasseffect ulcers, gross bleeding, or  oselabeledaeclasseffect  oselabeledaeclasseffect ulcers,  oselabeledaeclasseffect  or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,pennsaid,130,4172,4245,"However, even short-term NSAID therapy is not without risk.\n', '\n', '    Risk Factors for GI Bleeding, Ulceration, and Perforation  \n', '\n', ' Patients with a prior history of  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor who used NSAIDs had a greater than 10-fold increased risk for developing a  oselabeledaeclasseffect compared to patients without these risk factors.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
131,pennsaid,131,4245,4300,"Other factors that increase the risk of  nonoseaeaeonlyasinstruction in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,pennsaid,132,4300,4315,Most postmarketing reports of  nonoseaegeneralterm  oselabeledaefromdruguse occurred in elderly or debilitated patients.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
133,pennsaid,133,4315,4375,"Additionally, patients with advanced  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor are at increased risk for  nonoseaeaeonlyasinstruction \n', '\n', '    Strategies to Minimize the GI Risks in NSAID-treated patients:  \n', '\n', ' *  Use the lowest effective dosage for the shortest possible duration.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
134,pennsaid,134,4375,4392,"\n', ' *  Avoid administration of more than one NSAID at a time.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,pennsaid,135,4392,4438,"\n', ' *  Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of  nonoseaeaeonlyasinstruction  For such patients, as well as those with active  notaecandidatepreexistingconditionorriskfactor  consider alternate therapies other than NSAIDs.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
136,pennsaid,136,4438,4463,"\n', ' *  Remain alert for signs and symptoms of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ulceration and  nonoseaeaeonlyasinstruction during NSAID therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,pennsaid,137,4463,4495,"\n', ' *  If a serious  nonoseaegeneralterm is suspected, promptly initiate evaluation and treatment, and discontinue PENNSAID until a serious  nonoseaegeneralterm is ruled out.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,pennsaid,138,4495,4536,"\n', ' *  In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of  nonoseaeaeonlyasinstruction [ see  Drug Interactions (7)   ].",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,pennsaid,139,4536,4650,"\n', '       5.3 Hepatotoxicity\n', ' \n', '\n', '  In clinical trials of oral diclofenac containing products, meaningful  oselabeledaeclasseffect (i.e., more than 3 times the ULN)  oselabeledaeclasseffect  occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment (ALT was not measured in all studies).\n', '\n', ' In a large, open-label, controlled trial of 3,700 patients treated with oral diclofenac for 2 - 6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,pennsaid,140,4650,4659,Meaningful  oselabeledaeclasseffect ALT and/or  oselabeledaeclasseffect  oselabeledaeclasseffect,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,pennsaid,141,4659,4690,"and/or AST occurred in about 4% of 3,700 patients and included marked elevations (greater than 8 times the ULN) in about 1% of the 3,700 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,pennsaid,142,4690,4754,"In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3 to 8 times the ULN), and marked (greater than 8 times the ULN)  oselabeledaefromdruguse ALT or  oselabeledaefromdruguse  oselabeledaefromdruguse or AST was observed in patients receiving diclofenac when compared to other NSAIDs.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,pennsaid,143,4754,4790,"oselabeledaefromdruguse were seen more frequently in patients with  notaecandidateindication than in those with  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Almost all meaningful  nonoseaeaeonlyasinstruction were detected before patients became symptomatic.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
144,pennsaid,144,4790,4898,"Abnormal tests occurred during the first 2 months of therapy with oral diclofenac in 42 of the 51 patients in all trials who developed marked  oselabeledaefromdruguse \n', '\n', ' In postmarketing reports, cases of  oselabeledaefromdruguse have been reported in the first month, and in some cases, the first 2 months of NSAID therapy, but can occur at any time during treatment with diclofenac.\n', '\n', ' Postmarketing surveillance has reported cases of severe  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse with and without  nonoseaemanifestationorcomplication  and  oselabeledaefromdruguse  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
145,pennsaid,145,4898,4962,"Some of these reported cases resulted in  nonoseaegeneralterm or liver transplantation.\n', '\n', ' In a European retrospective population-based, case-controlled study, 10 cases of oral diclofenac associated  oselabeledaefromdruguse with current use compared with non-use of diclofenac were associated with a statistically significant 4-fold adjusted odds ratio of  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
146,pennsaid,146,4962,5046,"In this particular study, based on an overall number of 10 cases of  oselabeledaefromdruguse associated with diclofenac, the adjusted odds ratio increased further with female gender, doses of 150 mg or more, and duration of use for more than 90 days.\n', '\n', ' Physicians should measure transaminases at baseline and periodically in patients receiving long-term therapy with diclofenac, because severe  nonoseaeaeonlyasinstruction may develop without a prodrome of distinguishing symptoms.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,pennsaid,147,5046,5061,The optimum times for making the first and subsequent transaminase measurements are not known.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,pennsaid,148,5061,5085,"Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,pennsaid,149,5085,5146,"However, severe  nonoseaegeneralterm can occur at any time during treatment with diclofenac.\n', '\n', ' If  nonoseaeaeonlyasinstruction persist or worsen, if clinical signs and/or symptoms consistent with  nonoseaeaeonlyasinstruction develop, or if systemic manifestations occur (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  etc.)",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
150,pennsaid,150,5146,5192,", PENNSAID should be discontinued immediately.\n', '\n', ' Inform patients of the warning signs and symptoms of  nonoseaeaeonlyasinstruction (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
151,pennsaid,151,5192,5266,"If clinical signs and symptoms consistent with  nonoseaeaeonlyasinstruction develop, or if systemic manifestations occur (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  etc.), discontinue PENNSAID immediately, and perform a clinical evaluation of the patient.\n', '\n', ' To minimize the potential risk for an adverse  nonoseaeaeonlyasinstruction in patients treated with PENNSAID, use the lowest effective dose for the shortest duration possible.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
152,pennsaid,152,5266,5369,"Exercise caution when prescribing PENNSAID with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics).\n', '\n', '    5.4 Hypertension\n', '\n', '  NSAIDs, including PENNSAID, can lead to new onset of  oselabeledaefromdruguse or  oselabeledaefromdruguse  either of which may contribute to the increased incidence of  nonoseaemanifestationorcomplication  Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs [ see  Drug Interactions (",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
153,pennsaid,153,5369,5373,7)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,pennsaid,154,5373,5465,".\n', '\n', ' Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.\n', '\n', '    5.5 Heart Failure and Edema\n', '\n', ""   The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for  oselabeledaeclasseffect in COX-2 selective treated patients and nonselective NSAID-treated patients compared to placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,pennsaid,155,5465,5520,"In a Danish National Registry study of patients with  notaecandidatepreexistingconditionorriskfactor  NSAID use increased the risk of  oselabeledaeclasseffect  hospitalization for  oselabeledaeclasseffect  and  nonoseaegeneralterm   \n"", '\n', ' Additionally,  oselabeledaeclasseffect and  oselabeledaeclasseffect have been observed in some patients treated with NSAIDs.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
156,pennsaid,156,5520,5554,"Use of diclofenac may blunt the  nonoseaeaeonlyasinstruction of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs])",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,pennsaid,157,5554,5560,[ see  Drug Interactions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,pennsaid,158,5560,5564,7)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,pennsaid,159,5564,5693,".\n', '\n', ' Avoid the use of PENNSAID in patients with severe  notaecandidatepreexistingconditionorriskfactor unless the benefits are expected to outweigh the risk of  nonoseaeaeonlyasinstruction  If PENNSAID is used in patients with severe  notaecandidatepreexistingconditionorriskfactor  monitor patients for signs of  nonoseaeaeonlyasinstruction \n', '\n', '    5.6 Renal Toxicity and Hyperkalemia\n', '\n', '   Renal Toxicity  \n', '\n', ' Long-term administration of NSAIDs has resulted in  oselabeledaeclasseffect and other  oselabeledaeclasseffect \n', '\n', '  oselabeledaeclasseffect has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
160,pennsaid,160,5693,5771,"In these patients, administration of an NSAID may cause a dose-dependent  nonoseaemanifestationorcomplication prostaglandin formation and, secondarily, in  nonoseaemanifestationorcomplication  oselabeledaeclasseffect and, secondarily, in renal blood flow, which may precipitate overt  nonoseaemanifestationorcomplication  Patients at greatest risk of this reaction are those with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  those taking diuretics and ACE-inhibitors or ARBs, and the elderly.",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
161,pennsaid,161,5771,5850,"Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.\n', '\n', ' No information is available from controlled clinical studies regarding the use of PENNSAID in patients with advanced  notaecandidatepreexistingconditionorriskfactor  The  oselabeledaefromdruguse of PENNSAID may hasten the  oselabeledaefromdruguse in patients with preexisting  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Correct volume status in  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor patients prior to initiating PENNSAID.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
162,pennsaid,162,5850,5865,Monitor renal function in patients with  notaecandidatepreexistingconditionorriskfactor or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor   ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
163,pennsaid,163,5865,5882,notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor during use of PENNSAID [ see  Drug Interactions (,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
164,pennsaid,164,5882,5887,7)    ].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,pennsaid,165,5887,5971,"Avoid the use of PENNSAID in patients with advanced  notaecandidatepreexistingconditionorriskfactor unless the benefits are expected to outweigh the risk of  nonoseaeaeonlyasinstruction  If PENNSAID is used in patients with advanced  notaecandidatepreexistingconditionorriskfactor  monitor patients for signs of  nonoseaeaeonlyasinstruction \n', '\n', '    Hyperkalemia  \n', '\n', '  oselabeledaeclasseffect  including  oselabeledaeclasseffect  have been reported with use of NSAIDs, even in some patients without  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
166,pennsaid,166,5971,6115,"In patients with normal renal function, these effects have been attributed to a  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.7 Anaphylactic Reactions\n', '\n', '  Diclofenac has been associated with  oselabeledaefromdruguse in patients with and without known  notaecandidatecontraindication and in patients with  notaecandidatecontraindication [ see  Contraindications (4)  and  Warnings and Precautions (5.8)    ].\n', '\n', ' Seek emergency help if an  nonoseaeaeonlyasinstruction occurs.\n', '\n', '    5.8  oselabeledaeclasseffect \n', '  A subpopulation of patients with  notaecandidatepreexistingconditionorriskfactor may have  notaecandidatepreexistingconditionorriskfactor which may include chronic  notaecandidatepreexistingconditionorriskfactor complicated by  notaecandidatepreexistingconditionorriskfactor  severe, potentially  nonoseaegeneralterm  notaecandidatepreexistingconditionorriskfactor  and/or  notaecandidatepreexistingconditionorriskfactor and other NSAIDs.",1,1,1,0,0,0,0,0,0,0,0,1,0,0,0
167,pennsaid,167,6115,6149,"Because  oselabeledaeclasseffect has been reported in such aspirin-sensitive patients, PENNSAID is contraindicated in patients with this form of aspirin sensitivity [ see  Contraindications (4)    ].",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,pennsaid,168,6149,6232,"When PENNSAID is used in patients with preexisting  notaecandidatepreexistingconditionorriskfactor (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of  nonoseaeaeonlyasinstruction \n', '\n', '    5.9 Serious Skin Reactions\n', '\n', '  NSAIDs, including diclofenac, can cause serious  oselabeledaefromdruguse such as  oselabeledaefromdruguse   oselabeledaefromdruguse (SJS), and  oselabeledaefromdruguse (TEN), which can be  nonoseaegeneralterm  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
169,pennsaid,169,6232,6240,These serious events may occur without warning.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,pennsaid,170,6240,6382,"Inform patients about the signs and symptoms of serious  nonoseaeaeonlyasinstruction  and to discontinue the use of PENNSAID at the first appearance of  nonoseaemanifestationorcomplication or any other sign of  nonoseaeaeonlyasinstruction  PENNSAID is contraindicated in patients with previous serious  notaecandidatecontraindication [ see  Contraindications (4)    ].\n', '\n', ' Do not apply PENNSAID to open  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  as it may affect absorption and tolerability of the drug.\n', '\n', '    5.10 Premature Closure of Fetal Ductus Arteriosus\n', '\n', '  Diclofenac may cause  oselabeledaefromdruguse  Avoid use of NSAIDs, including PENNSAID, in  notaecandidatepreexistingconditionorriskfactor women starting at 30 weeks of gestation (third trimester) [ see  ",1,0,1,0,1,0,0,0,0,0,0,1,0,0,0
171,pennsaid,171,6382,6391,Use in Specific Populations (8.1)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,pennsaid,172,6391,6417,".\n', '\n', '    5.11  oselabeledaefromdruguse \n', '   oselabeledaeclasseffect has occurred in NSAID-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,pennsaid,173,6417,6437,This may be due to occult or gross  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or an incompletely described  notaecandidateindication  ,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
174,pennsaid,174,6437,6454,If a patient treated with PENNSAID has any signs or symptoms of  nonoseaeaeonlyasinstruction  monitor hemoglobin,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,pennsaid,175,6454,6458,"or hematocrit.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,pennsaid,176,6458,6477,"'\n', ' NSAIDs, including PENNSAID, may increase the risk of  oselabeledaefromdruguse events.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,pennsaid,177,6477,6521,"Co-morbid conditions such as  notaecandidatepreexistingconditionorriskfactor or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
178,pennsaid,178,6521,6529,Monitor these patients for signs of  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,pennsaid,179,6529,6535,[ see  Drug Interactions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,pennsaid,180,6535,6539,7)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,pennsaid,181,6539,6557,".\n', '\n', '    5.12  oselabeledaefromdruguse  oselabeledaefromdruguse Inflammation and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,pennsaid,182,6557,6664,"\n', '  The pharmacological activity of PENNSAID in  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction inflammation, and possibly  nonoseaeaeonlyasinstruction  may diminish the utility of diagnostic signs in detecting  nonoseaeaeonlyasinstruction \n', '\n', '    5.13 Laboratory Monitoring\n', '\n', '  Because serious  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [ see  Warnings and Precautions (5.2  ,  5.3  ,  5.6)    ]",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,pennsaid,183,6664,6666,.\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,pennsaid,184,6666,6715,", '\n', '    5.14 Sun Exposure\n', '\n', '  Instruct patients to avoid exposure to natural or artificial sunlight on treated knee(s) because studies in animals indicated topical diclofenac treatment resulted in an earlier onset of  nonoseaeaeanimal  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
185,pennsaid,185,6715,6756,"The potential effects of PENNSAID on  nonoseaeaeonlyasinstruction in humans are not known.\n', '\n', '    5.15 Eye Exposure\n', '\n', '  Avoid contact of PENNSAID with eyes and mucosa.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,pennsaid,186,6756,6848,"Advise patients that if eye contact occurs, immediately wash out the  nonoseaeaeonlyasinstruction with water or saline and consult a physician if  nonoseaeaeonlyasinstruction persists for more than an hour.\n', '\n', '    5.16 Oral Nonsteroidal Anti-Inflammatory Drugs\n', '\n', '  Concomitant use of oral NSAIDs with PENNSAID 1.5% resulted in a higher rate of  nonoseaeaefromdruginteraction  more frequent  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction creatinine,  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction creatinine, urea and  nonoseaeaefromdruginteraction ']",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
0,asclera,0,0,42,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common adverse reactions occurring at least 3% more frequently than on placebo are mild local reactions at the site of injection.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,asclera,1,42,94,"(  6  )\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Merz North America, Inc. at 1-866-862-1211 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,asclera,2,94,131,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Study Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,asclera,3,131,230,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In 5 controlled randomized clinical trials, Asclera has been administered to 401 patients with small or very small  notaecandidateindication ( notaecandidateindication and spider  notaecandidateindication  notaecandidateindication  and compared with another sclerosing agent and with placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
4,asclera,4,230,238,Patients were 18 to 70 years old.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,asclera,5,238,311,"The patient population was predominately female and consisted of Caucasian and Asian patients.\n', '\n', '\n', '\n', ' Table 1 shows adverse events more common with Asclera or sodium tetradecyl sulfate (STS) 1% than with placebo by at least 3% in the placebo- controlled EASI study  (see  Clinical Studies [14]  )  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,asclera,6,311,356,"All of these were  oselabeledaefromdruguse and most were mild.\n', '\n', '\n', '\n', ' Table 1: Adverse Reactions in EASI-study \n', '                                  ASCLERA (180 patients)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,asclera,7,356,364,STS 1% (105 patients)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,asclera,8,364,370,Placebo (53 patients)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,asclera,9,370,391,"\n', '  \n', '  oselabeledaefromdruguse                  42%                       65%                      19%             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,asclera,10,391,412,"\n', '  oselabeledaefromdruguse                 41%                       73%                      30%             \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,asclera,11,412,423,oselabeledaefromdruguse              38%                       74%                      4%              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,asclera,12,423,471,"\n', '  oselabeledaefromdruguse                       24%                       31%                      9%              \n', '  oselabeledaefromdruguse                   19%                       27%                      4%              \n', '  oselabeledaefromdruguse                     16%                       21%                      6%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,asclera,13,471,487,"\n', '  oselabeledaefromdruguse                         8%                       20%                      4%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,asclera,14,487,503,"\n', '  oselabeledaefromdruguse                  6%                       1%                       0%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,asclera,15,503,594,"\n', '          Ultrasound examinations at one week (+/-3 days) and 12 weeks (+/-2 weeks) after treatment did not reveal  nonoseaenegation in any treatment group.\n', ' \n', '\n', '   6.2 Post-marketing Safety Experience\n', '\n', '  The following adverse reactions have been reported during use of polidocanol in world-wide experience; in some of these cases these adverse events have been serious or troublesome.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
16,asclera,16,594,657,"Because these reactions are reported voluntarily from a population of uncertain size and without a control group, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse generalized,  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,asclera,17,657,688,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (local),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,asclera,18,688,705,"', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,asclera,19,705,729,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
20,asclera,20,729,745,"\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,asclera,21,745,840,"\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (in the area of sclerotherapy)\n', '\n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,asclera,22,840,848,*  Be prepared to treat anaphylaxis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,asclera,23,848,871,"(  5.1  ) \n', ' *  Do not inject intra-arterially. (  5.2  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,asclera,24,871,884,"\n', ' *  Do not inject intra-perivascularily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,asclera,25,884,910,"(  5.3  ) \n', '    \n', ' \n', '\n', '   5.1 Anaphylaxis\n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,asclera,26,910,943,", '\n', '\n', '\n', '   Severe  oselabeledaefromdruguse have been reported following polidocanol use, including  oselabeledaefromdruguse  some of them  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,asclera,27,943,961,nonoseaegeneralterm  Severe reactions are more frequent with use of larger volumes (> 3 mL).,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,asclera,28,961,970,The dose of polidocanol should therefore be minimized.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,asclera,29,970,979,Be prepared to treat  nonoseaeaeonlyasinstruction appropriately.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,asclera,30,979,1072,"\n', '\n', '\n', '\n', ' Severe  nonoseaeaeonlyasinstruction  including  nonoseaemanifestationorcomplication  may occur following  nonoseaeaeonlyasinstruction  therefore, care should be taken in intravenous needle placement and the smallest effective volume at each injection site should be used.\n', '\n', '\n', '\n', ' After the injection session is completed, apply compression with a stocking or bandage, and have the patient walk for 15-20 minutes.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
31,asclera,31,1072,1094,Keep the patient under supervision during this period to treat any  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (see  Dosage and Administration,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,asclera,32,1094,1103,"[2]  )  .\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,asclera,33,1103,1151,"'\n', '\n', '\n', '    5.2 Accidental Intra-arterial Injection\n', '\n', '\n', '\n', '   oselabeledaemedicationerror can cause severe  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
34,asclera,34,1151,1208,"If this occurs consult a vascular surgeon immediately.\n', '\n', '\n', '\n', '    5.3 Inadvertent Perivascular Injection\n', '\n', '\n', '\n', '   oselabeledaemedicationerror of Asclera can cause  nonoseaemanifestationorcomplication  If  nonoseaeaeonlyasinstruction ']",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,viekira,0,0,102,"['    6 ADVERSE REACTIONS\n', '\n', '  If VIEKIRA PAK is administered with ribavirin (RBV), refer to the prescribing information for ribavirin for a list of ribavirin-associated adverse reactions.\n', '\n', '\n', '\n', ' The following adverse reaction is described below and elsewhere in the labeling:\n', '\n', '\n', '\n', ' *  Increased Risk of  oselabeledaefromdruguse [see Warnings and Precautions (  5.1  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,viekira,1,102,110,"\n', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,viekira,2,110,147,"In subjects receiving VIEKIRA PAK with ribavirin, the most commonly reported adverse reactions (greater than 10% of subjects) were fatigue, nausea, pruritus, other skin reactions, insomnia and asthenia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,viekira,3,147,179,"In subjects receiving VIEKIRA PAK without ribavirin, the most commonly reported adverse reactions (greater than or equal to 5% of subjects) were nausea, pruritus and insomnia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,viekira,4,179,224,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,viekira,5,224,261,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,viekira,6,261,440,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of VIEKIRA PAK cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The safety assessment was based on data from six Phase 3 clinical trials in more than 2,000 subjects who received VIEKIRA PAK with or without ribavirin for 12 or 24 weeks.\n', '\n', '\n', '\n', '   VIEKIRA PAK with Ribavirin in Placebo-Controlled Trials  \n', '\n', '\n', '\n', ' The safety of VIEKIRA PAK in combination with ribavirin was assessed in 770 subjects with chronic  notaecandidateindication in two placebo-controlled trials (SAPPHIRE-I and -II)  [see Clinical Studies (  14.1  ,  14.2  )]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,viekira,7,440,484,Adverse reactions that occurred more often in subjects treated with VIEKIRA PAK in combination with ribavirin compared to placebo were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  other  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (see  Table 3  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,viekira,8,484,495,The majority of the adverse reactions were mild in severity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,viekira,9,495,508,Two percent of subjects experienced a serious adverse event (SAE).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,viekira,10,508,542,"The proportion of subjects who permanently discontinued treatment due to adverse reactions was less than 1%.\n', '\n', '\n', '\n', ' Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,viekira,11,542,559,Adverse Reactions with >=5% Greater Frequency Reported in Subjects with Chronic HCV GT1 Infection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,viekira,12,559,573,Treated with VIEKIRA PAK in Combination with Ribavirin Compared to Placebo for 12 Weeks,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,viekira,13,573,602,"\n', '                    SAPPHIRE-I and -II     \n', '  \n', '                    VIEKIRA PAK + RBV    12 Weeks    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,viekira,14,602,608,N = 770    %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,viekira,15,608,613,Placebo    12 Weeks    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,viekira,16,613,619,N = 255    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,viekira,17,619,639,"\n', '  oselabeledaefromdruguse          34               26                \n', '  oselabeledaefromdruguse           22               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,viekira,18,639,641,15                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,viekira,19,641,652,"\n', '  oselabeledaefromdruguse         18               7                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,viekira,20,652,661,"\n', '  oselabeledaefromdruguse  $    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,viekira,21,661,665,16               9                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,viekira,22,665,681,"\n', '  oselabeledaefromdruguse         14               8                 \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,viekira,23,681,685,oselabeledaefromdruguse         14               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,viekira,24,685,687,7                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,viekira,25,687,709,"\n', "" *Grouped term ' oselabeledaefromdruguse  included the preferred terms  oselabeledaefromdruguse and  oselabeledaefromdruguse   $  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,viekira,26,709,751,Grouped terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,viekira,27,751,769,"\n"", '        VIEKIRA PAK with and without Ribavirin in Regimen-Controlled Trials  \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,viekira,28,769,834,"', ' \n', '\n', ' VIEKIRA PAK with and without ribavirin was assessed in 401 and 509 subjects with  notaecandidateindication  respectively, in three clinical trials (PEARL-II, PEARL-III and PEARL-IV)  [see Clinical Studies (  14.1  ,  14.2  )]  .  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,viekira,29,834,864,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were identified as adverse events occurring more often in subjects treated with VIEKIRA PAK in combination with ribavirin (see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,viekira,30,864,869,Table 4  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,viekira,31,869,881,The majority of adverse events were mild to moderate in severity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,viekira,32,881,928,"The proportion of subjects who permanently discontinued treatment due to adverse events was less than 1% for both VIEKIRA PAK in combination with ribavirin and VIEKIRA PAK alone.\n', '\n', '\n', '\n', ' Table 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,viekira,33,928,932,Adverse Events with >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,viekira,34,932,960,=5% Greater Frequency Reported in Subjects with Chronic HCV GT1 Infection Treated with VIEKIRA PAK in Combination with Ribavirin Compared to VIEKIRA PAK for 12 Weeks,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,viekira,35,960,991,"\n', '                    PEARL-II, -III and -IV     \n', '  \n', '                    VIEKIRA PAK + RBV    12 Weeks    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,viekira,36,991,1003,N = 401    %      VIEKIRA PAK    12 Weeks    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,viekira,37,1003,1009,N = 509    %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,viekira,38,1009,1016,"\n', '  oselabeledaefromdruguse           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,viekira,39,1016,1020,16               8                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,viekira,40,1020,1040,"\n', '  oselabeledaefromdruguse         13               7                 \n', '  oselabeledaefromdruguse         12               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,viekira,41,1040,1042,5                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,viekira,42,1042,1053,"\n', '  oselabeledaefromdruguse         9                4                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,viekira,43,1053,1149,"\n', "" *Grouped term ' oselabeledaefromdruguse  included the preferred terms  oselabeledaefromdruguse and  oselabeledaefromdruguse    \n"", '        VIEKIRA PAK with Ribavirin in Subjects with Compensated Cirrhosis  \n', ' \n', '\n', ' VIEKIRA PAK with ribavirin was assessed in 380 subjects with  notaecandidateindication who were treated for 12 (n=208) or 24 (n=172) weeks duration (TURQUOISE-II)  [see Clinical Studies (  14.1  ,  14.3  )]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
44,viekira,44,1149,1174,The type and severity of adverse events in subjects with  notaecandidateindication was comparable to  notaecandidatepreexistingconditionorriskfactor subjects in other phase 3 trials.  ,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
45,viekira,45,1174,1194,oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse occurred at least 5% more often in subjects treated for 24 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,viekira,46,1194,1212,The majority of adverse events occurred during the first 12 weeks of dosing in both treatment arms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,viekira,47,1212,1224,Most of the adverse events were mild to moderate in severity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,viekira,48,1224,1355,"The proportion of subjects treated with VIEKIRA PAK for 12 and 24 weeks with SAEs was 6% and 5%, respectively and 2% of subjects permanently discontinued treatment due to adverse events in each treatment arm.\n', '\n', '\n', '\n', '   Skin Reactions  \n', '\n', '\n', '\n', ' In PEARL-II, -III and -IV, 7% of subjects receiving VIEKIRA PAK alone and 10% of subjects receiving VIEKIRA PAK with ribavirin reported  oselabeledaefromdruguse  In SAPPHIRE-I and -II 16% of subjects receiving VIEKIRA PAK with ribavirin and 9% of subjects receiving placebo reported  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,viekira,49,1355,1381,"In TURQUOISE-II, 18% and 24% of subjects receiving VIEKIRA PAK with ribavirin for 12 or 24 weeks reported  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,viekira,50,1381,1392,The majority of events were graded as mild in severity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,viekira,51,1392,1456,"There were no serious events or  nonoseaenegation  such as  nonoseaenegation ,  nonoseaenegation ,  nonoseaenegation  or  nonoseaenegation .\n', '\n', '\n', '\n', '   Laboratory Abnormalities  \n', '\n', '\n', '\n', '   Serum ALT Elevations  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
52,viekira,52,1456,1495,"\n', '\n', '\n', '\n', ' Approximately 1% of subjects treated with VIEKIRA PAK experienced post-baseline serum  oselabeledaefromdruguse (ULN) after starting treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,viekira,53,1495,1534,The incidence increased to 25% (4/16) among women taking a concomitant ethinyl estradiol containing medication  [see Contraindications (  4  ) and Warnings and Precautions (  5.1  )]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,viekira,54,1534,1615,"The incidence of clinically relevant  nonoseaeaefromdruginteraction among women using estrogens other than ethinyl estradiol, such as estradiol and conjugated estrogens used in hormone replacement therapy was 3% (2/59).\n', '\n', '\n', '\n', '  oselabeledaefromdruguse were typically asymptomatic, generally occurred during the first 4 weeks of treatment (mean time 20 days, range 8-57 days) and most resolved with ongoing therapy.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
55,viekira,55,1615,1661,The majority of these  oselabeledaefromdruguse were assessed as  oselabeledaefromdruguse   nonoseaeaeonlyasinstruction in  nonoseaeaeonlyasinstruction were generally not associated with  nonoseaenegation   nonoseaenegation was not a risk factor for  nonoseaeaeonlyasinstruction  [see Warnings and Precautions (  5.1  )]  ,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
56,viekira,56,1661,1682,".\n', '\n', '\n', '\n', '   Serum Bilirubin Elevations  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,viekira,57,1682,1703,"\n', '\n', '\n', '\n', ' Post-baseline  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,viekira,58,1703,1731,at least 2 x ULN were observed in 15% of subjects receiving VIEKIRA PAK with ribavirin compared to 2% in those receiving VIEKIRA PAK alone.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,viekira,59,1731,1769,"These  oselabeledaefromdruguse and related to the inhibition of the bilirubin transporters OATP1B1/1B3 by  oselabeledaefromdruguse   oselabeledaefromdruguse occurred after initiation of treatment, peaked by study Week 1, and generally resolved with ongoing therapy.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,viekira,60,1769,1841,"nonoseaenegation were not associated with serum  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '   Anemia/Decreased Hemoglobin  \n', '\n', '\n', '\n', ' Across all Phase 3 studies, the mean change from baseline in hemoglobin levels in subjects treated with VIEKIRA PAK in combination with ribavirin was -2.4",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
61,viekira,61,1841,1857,g/dL and the mean change in subjects treated with VIEKIRA PAK alone was -0.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,viekira,62,1857,1881,g/dL.  oselabeledaefromdruguse levels occurred early in treatment (Week 1-2) with further reductions through Week 3.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,viekira,63,1881,1899,oselabeledaefromdruguse during the remainder of treatment and returned towards baseline levels by post-treatment Week 4.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,viekira,64,1899,1924,Less than 1% of subjects treated with VIEKIRA PAK with ribavirin had  oselabeledaefromdruguse to less than 8.0 g/dL during treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,viekira,65,1924,1958,Seven percent of subjects treated with VIEKIRA PAK in combination with ribavirin underwent a ribavirin dose reduction due to a  oselabeledaefromdruguse  three subjects received a blood transfusion and five required erythropoietin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,viekira,66,1958,1967,One patient discontinued therapy due to  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,viekira,67,1967,2046,"No subjects treated with VIEKIRA PAK alone had a  nonoseaenegation \n', '\n', '\n', '\n', '   VIEKIRA PAK in HCV/HIV-1 Co-infected Subjects  \n', '\n', '\n', '\n', ' VIEKIRA PAK with ribavirin was assessed in 63 subjects with  notaecandidateindication  notaecandidatepreexistingconditionorriskfactor co-infection who were on stable antiretroviral therapy.",0,0,1,1,0,0,0,1,0,0,0,0,0,0,0
68,viekira,68,2046,2149,"The most common adverse events occurring in at least 10% of subjects were  oselabeledaefromdruguse (48%),  oselabeledaefromdruguse (19%),  oselabeledaefromdruguse (17%),  oselabeledaefromdruguse (16%),  oselabeledaefromdruguse (13%),  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse (10%), and  oselabeledaefromdruguse (10%).\n', '\n', '\n', '\n', '  oselabeledaefromdruguse greater than 2 x ULN (mostly indirect) occurred in 34 (54%) subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,viekira,69,2149,2178,Fifteen of these subjects were also receiving atazanavir at the time of  oselabeledaefromdruguse and nine also had adverse events of  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,viekira,70,2178,2219,"None of the subjects with  nonoseaeaeonlyasinstruction had concomitant  nonoseaenegation  [see Warnings and Precautions (  5.4  ), Adverse Reactions (  6.1  ) and Clinical Studies (  14.6  )]  .",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
71,viekira,71,2219,2341,"No subject experienced a grade 3  nonoseaenegation \n', '\n', '\n', '\n', ' Seven subjects (11%) had at least one post-baseline  oselabeledaefromdruguse  and six of these subjects had a ribavirin dose modification; no subject in this small cohort required a blood transfusion or erythropoietin.\n', '\n', '\n', '\n', ' Median  oselabeledaefromdruguse of 47 cells/mm  3  and 62 cells/mm  3  were observed at the end of 12 and 24 weeks of treatment, respectively, and most returned to baseline levels post-treatment.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
72,viekira,72,2341,2363,Two subjects had  oselabeledaefromdruguse to less than 200 cells/mm  3  during treatment without a  nonoseaenegation  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
73,viekira,73,2363,2484,"No subject experienced an  nonoseaenegation \n', '\n', '\n', '\n', '   VIEKIRA PAK in Selected Liver Transplant Recipients  \n', '\n', '\n', '\n', ' VIEKIRA PAK with ribavirin was assessed in 34  notaecandidatepreexistingconditionorriskfactor subjects with  notaecandidateindication HCV  notaecandidateindication  Adverse events occurring in more than 20% of subjects included  oselabeledaefromdruguse 50%,  oselabeledaefromdruguse 44%,  oselabeledaefromdruguse 32%,  oselabeledaefromdruguse 26%,  oselabeledaefromdruguse 26%,  oselabeledaefromdruguse 24%,  oselabeledaefromdruguse 24%,  oselabeledaefromdruguse 21% and  oselabeledaefromdruguse 21%.",0,0,1,1,0,0,0,1,0,0,0,0,0,0,0
74,viekira,74,2484,2524,Ten subjects (29%) had at least one post-baseline  oselabeledaefromdruguse  Ten subjects underwent a ribavirin dose modification due to decrease in hemoglobin and 3% (1/34) had an interruption of ribavirin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,viekira,75,2524,2545,"Five subjects received erythropoietin, all of whom initiated ribavirin at the starting dose of 1000 to 1200 mg daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,viekira,76,2545,2647,"No subject received a blood transfusion  [see Clinical Studies (  14.5  )]  .\n', '\n', '\n', '\n', '   6.2 Post-Marketing Adverse Reactions\n', '\n', '   oselabeledaefromdruguse (including  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *   ALT Elevations : Discontinue ethinyl estradiol-containing medications prior to starting VIEKIRA PAK (alternative contraceptive methods are recommended).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,viekira,77,2647,2662,Perform hepatic laboratory testing on all patients during the first 4 weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,viekira,78,2662,2679,"For ALT elevations on VIEKIRA PAK, monitor closely and follow recommendations in full prescribing information.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,viekira,79,2679,2685,(  5.1  ) \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,viekira,80,2685,2697,"', ' *   Risks Associated With Ribavirin Combination Treatment :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,viekira,81,2697,2718,"If VIEKIRA PAK is administered with ribavirin, the warnings and precautions for ribavirin also apply to this combination regimen.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,viekira,82,2718,2723,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,viekira,83,2723,2732,"\n', ' *   Drug Interactions :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,viekira,84,2732,2766,"The concomitant use of VIEKIRA PAK and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeutic effect of VIEKIRA PAK.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,viekira,85,2766,2811,"(  5.3  ) \n', '    \n', ' \n', '\n', '   5.1 Increased Risk of ALT Elevations\n', '\n', '\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,viekira,86,2811,2858,"During clinical trials with VIEKIRA PAK with or without ribavirin,  oselabeledaefromdruguse to greater than 5 times the upper limit of normal (ULN) occurred in approximately 1% of all subjects [see Adverse Reactions (  6.1  )]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,viekira,87,2858,2937,"oselabeledaefromdruguse were typically asymptomatic, occurred during the first 4 weeks of treatment, and declined within two to eight weeks of onset with continued dosing of VIEKIRA PAK with or without ribavirin.\n', '\n', '\n', '\n', ' These  nonoseaeaefromdruginteraction were significantly more frequent in female subjects who were using ethinyl estradiol-containing medications such as combined oral contraceptives, contraceptive patches or contraceptive vaginal rings.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
88,viekira,88,2937,2963,Ethinyl estradiol-containing medications must be discontinued prior to starting therapy with VIEKIRA PAK [see Contraindications (  4  )]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,viekira,89,2963,2986,"Alternative methods of contraception (e.g, progestin only contraception or non-hormonal methods) are recommended during VIEKIRA PAK therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,viekira,90,2986,3123,"Ethinyl estradiol-containing medications can be restarted approximately 2 weeks following completion of treatment with VIEKIRA PAK.\n', '\n', '\n', '\n', ' Women using estrogens other than ethinyl estradiol, such as estradiol and conjugated estrogens used in hormone replacement therapy had a rate of  nonoseaeaeonlyasinstruction similar to those not receiving any estrogens; however, due to the limited number of subjects taking these other estrogens, caution is warranted for co-administration with VIEKIRA PAK [see Adverse Reactions (  6.1  )]  .\n', '\n', '\n', '\n', ' Hepatic laboratory testing should be performed during the first 4 weeks of starting treatment and as clinically indicated thereafter.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,viekira,91,3123,3192,"If  nonoseaeaeonlyasinstruction above baseline levels, it should be repeated and monitored closely:\n', '\n', '\n', '\n', ' *  Patients should be instructed to consult their health care professional without delay if they have onset of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  \n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,viekira,92,3192,3298,"*  Consider discontinuing VIEKIRA PAK if  nonoseaeaeonlyasinstruction  \n', ' *  Discontinue VIEKIRA PAK if  nonoseaeaeonlyasinstruction is accompanied by signs or symptoms of  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication conjugated bilirubin,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication conjugated bilirubin, alkaline phosphatase, or  nonoseaemanifestationorcomplication  \n', '       5.2 Risks Associated With Ribavirin Combination Treatment\n', ' \n', '\n', '  If VIEKIRA PAK is administered with ribavirin, the warnings and precautions for ribavirin, in particular the  nonoseaeaeonlyasinstruction avoidance warning, apply to this combination regimen.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
93,viekira,93,3298,3437,"Refer to the ribavirin prescribing information for a full list of the warnings and precautions for ribavirin.\n', '\n', '\n', '\n', '    5.3 Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions\n', '\n', '\n', '\n', '  The concomitant use of VIEKIRA PAK and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to:\n', '\n', '\n', '\n', ' *  Loss of therapeutic effect of VIEKIRA PAK and possible  nonoseaeaefromdruginteraction \n', ' *  Possible clinically significant adverse reactions from greater exposures of concomitant drugs or components of VIEKIRA PAK.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
94,viekira,94,3437,3462,"\n', '    See Table 5 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,viekira,95,3462,3474,[see Drug Interactions (  7  )]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,viekira,96,3474,3525,Consider the potential for drug interactions prior to and during VIEKIRA PAK therapy; review concomitant medications during VIEKIRA PAK therapy; and monitor for the adverse reactions associated with the concomitant drugs [see Contraindications (  4  ) and Drug Interactions (  7  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,viekira,97,3525,3587,".\n', ' \n', '\n', '    5.4 Risk of HIV-1 Protease Inhibitor Drug Resistance in HCV/HIV-1 Co-infected Patients\n', '\n', '\n', '\n', '  The ritonavir component of VIEKIRA PAK is also an HIV-1 protease inhibitor and can  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,viekira,98,3587,3618,Any  notaecandidateindication  notaecandidatepreexistingconditionorriskfactor co-infected patients treated with VIEKIRA PAK should also be on a suppressive antiretroviral drug regimen to reduce the risk of  nonoseaeaeonlyasinstruction '],1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
0,kadcyla,0,0,85,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [See  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [See  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,kadcyla,1,85,104,"[See  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,kadcyla,2,104,125,"[See  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,kadcyla,3,125,144,"[See  Warnings and Precautions (5.5)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,kadcyla,4,144,163,"[See  Warnings and Precautions (5.6)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,kadcyla,5,163,182,"[See  Warnings and Precautions (5.7)  ]  \n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,kadcyla,6,182,196,[See  Warnings and Precautions (5.8)  ]  \n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,kadcyla,7,196,202,", '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,kadcyla,8,202,242,"The most common adverse drug reactions (frequency > 25%) with KADCYLA (n=884 treated patients) were fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation and epistaxis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,kadcyla,9,242,247,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,kadcyla,10,247,286,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,kadcyla,11,286,323,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,kadcyla,12,323,404,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In clinical trials, KADCYLA has been evaluated as single-agent in 884 patients with  notaecandidateindication metastatic  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,kadcyla,13,404,447,The most common (frequency >= 25%) adverse drug reactions (ADRs) seen in 884 patients treated with KADCYLA were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,kadcyla,14,447,503,"\n', '\n', '\n', '\n', ' The ADRs described in  Table 6  were identified in patients with  notaecandidateindication metastatic  notaecandidateindication treated in a randomized trial (Study 1)  [see  Clinical Studies (14.1)  ]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,kadcyla,15,503,514,Patients were randomized to receive KADCYLA or lapatinib plus capecitabine.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,kadcyla,16,514,547,"The median duration of study treatment was 7.6 months for patients in the KADCYLA-treated group and 5.5 months and 5.3 months for patients treated with lapatinib and capecitabine, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,kadcyla,17,547,558,Two hundred and eleven (43.1%) patients experienced >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,kadcyla,18,558,586,= Grade 3 adverse events in the KADCYLA-treated group compared with 289 (59.2%) patients in the lapatinib plus capecitabine-treated group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,kadcyla,19,586,606,Dose adjustments for KADCYLA were permitted  [see  Dosage and Administration (2.2)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,kadcyla,20,606,650,"Thirty-two patients (6.5%) discontinued KADCYLA due to an adverse event, compared with 41 patients (8.4%) who discontinued lapatinib, and 51 patients (10.5%) who discontinued capecitabine due to an adverse event.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,kadcyla,21,650,683,The most common adverse events leading to KADCYLA withdrawal were  oselabeledaefromdruguse and  oselabeledaefromdruguse  Eighty patients (16.3%) treated with KADCYLA had adverse events leading to dose reductions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,kadcyla,22,683,713,The most frequent adverse events leading to dose reduction of KADCYLA (in >= 1% of patients) included  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,kadcyla,23,713,732,Adverse events that led to dose delays occurred in 116 (23.7%) of KADCYLA treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,kadcyla,24,732,767,The most frequent adverse events leading to a dose delay of KADCYLA (in >= 1% of patients) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,kadcyla,25,767,812,"\n', '\n', '\n', '\n', '   Table 6  reports the ADRs that occurred in patients in the KADCYLA-treated group (n=490) of the randomized trial (Study 1).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,kadcyla,26,812,823,Selected  nonoseaegeneralterm are shown in  Table 7  .,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
27,kadcyla,27,823,846,The most common ADRs seen with KADCYLA in the randomized trial (frequency > 25%) were  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,kadcyla,28,846,860,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,kadcyla,29,860,866,The most common NCI-CTCAE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,kadcyla,30,866,871,(version 3) >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,kadcyla,31,871,895,= Grade 3 ADRs (frequency >2%) were  oselabeledaefromdrugcomponent   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,kadcyla,32,895,1056,"\n', '\n', '\n', '\n', ' Table 6 Summary of Adverse Drug Reactions Occurring in Patients on the KADCYLA Treatment Arm in the Randomized Trial (Study 1) \n', ' Adverse Drug Reactions (MedDRA)System Organ Class  KADCYLA(3.6 mg/kg)n=490Frequency rate %  Lapatinib (1250 mg) + Capecitabine (2000 mg/m  2  )n=488Frequency rate %   \n', '                                           All grades (%)   Grade 3 - 4 (%)  All grades (%)   Grade 3 - 4 (%)   \n', '  \n', ' ND = Not determined                        \n', '  \n', '    nonoseaegeneralterm     \n', '  oselabeledaefromdruguse                                     6.7              2.0              9.0              4.3         \n', '  oselabeledaefromdruguse                                         14.3              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,kadcyla,33,1056,1067,"4.1             10.5              2.5         \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,kadcyla,34,1067,1084,"oselabeledaefromdruguse                               31.2             14.5              3.3              0.4         \n', '    nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,kadcyla,35,1084,1106,"\n', '  oselabeledaefromdruguse                    1.8              0.2              3.3              0.4         \n', '    nonoseaegeneralterm                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,kadcyla,36,1106,1117,"\n', '  oselabeledaefromdruguse                           3.3               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,kadcyla,37,1117,1121,2.5               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,kadcyla,38,1121,1132,"\n', '  oselabeledaefromdruguse                                         3.9               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,kadcyla,39,1132,1136,3.1               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,kadcyla,40,1136,1147,"\n', '  oselabeledaefromdruguse                                  4.5               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,kadcyla,41,1147,1151,0.8               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,kadcyla,42,1151,1162,"\n', '  oselabeledaefromdruguse                                  3.9               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,kadcyla,43,1162,1166,2.3               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,kadcyla,44,1166,1188,"\n', '    nonoseaegeneralterm               \n', '  oselabeledaefromdruguse                                       9.2               0              11.5              0.4         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,kadcyla,45,1188,1214,"\n', '  oselabeledaefromdruguse                                     14.1              0.2             32.6              2.5         \n', '  oselabeledaefromdruguse                                      16.7               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,kadcyla,46,1214,1231,"4.9              0.2         \n', '  oselabeledaefromdruguse                                 18.6              0.8             17.6              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,kadcyla,47,1231,1242,"1.6         \n', '  oselabeledaefromdruguse                                       19.2              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,kadcyla,48,1242,1246,0.8             29.9              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,kadcyla,49,1246,1248,4.5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,kadcyla,50,1248,1253,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,kadcyla,51,1253,1257,oselabeledaefromdruguse                                       24.1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,kadcyla,52,1257,1261,1.6             79.7             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,kadcyla,53,1261,1263,20.7         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,kadcyla,54,1263,1272,"\n', '  oselabeledaefromdruguse                                   26.5              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,kadcyla,55,1272,1274,0.4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,kadcyla,56,1274,1278,11.1               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,kadcyla,57,1278,1289,"\n', '  oselabeledaefromdruguse                                         39.8              0.8             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,kadcyla,58,1289,1300,"45.1              2.5         \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,kadcyla,59,1300,1307,"\n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,kadcyla,60,1307,1311,7.1               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,kadcyla,61,1311,1326,"8.2              0.2         \n', '  oselabeledaefromdruguse                                          7.6               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,kadcyla,62,1326,1330,3.1               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,kadcyla,63,1330,1360,"\n', '  oselabeledaefromdruguse                                        18.6              0.2              8.4              0.4         \n', '  oselabeledaefromdruguse                                       17.8              0.4             17.6              1.6         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,kadcyla,64,1360,1369,"\n', '  oselabeledaefromdruguse                                        36.3              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,kadcyla,65,1369,1375,2.5             28.3              3.5         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,kadcyla,66,1375,1382,"\n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,kadcyla,67,1382,1419,"\n', '  oselabeledaefromdruguse                0.4              ND                0                0          \n', '  oselabeledaefromdruguse                             0.4              0.2               0                0          \n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,kadcyla,68,1419,1430,"\n', '  oselabeledaefromdruguse                           2.2               0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,kadcyla,69,1430,1434,0.8               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,kadcyla,70,1434,1441,"\n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,kadcyla,71,1441,1448,"\n', '  oselabeledaefromdruguse                       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,kadcyla,72,1448,1450,1.4               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,kadcyla,73,1450,1456,0               0.2               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,kadcyla,74,1456,1463,"\n', '    nonoseaegeneralterm              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
75,kadcyla,75,1463,1474,"\n', '  oselabeledaefromdruguse                         9.4              0.6              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,kadcyla,76,1474,1478,3.9               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,kadcyla,77,1478,1485,"\n', '    nonoseaegeneralterm                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
78,kadcyla,78,1485,1500,"\n', '  oselabeledaefromdruguse            4.7              0.4              3.7              0.4         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,kadcyla,79,1500,1507,"\n', '  oselabeledaefromdruguse                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,kadcyla,80,1507,1537,"28.8              8.0             14.3              2.5         \n', '    nonoseaegeneralterm       \n', '  oselabeledaefromdruguse                                    10.2              2.7              9.4              4.7         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,kadcyla,81,1537,1544,"\n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
82,kadcyla,82,1544,1789,"\n', '  oselabeledaefromdruguse                                        14.1              0.6              3.7               0          \n', '  oselabeledaefromdruguse                                     19.2              0.6              8.4               0          \n', '  oselabeledaefromdruguse                           36.1              1.8             30.5              1.4         \n', '    nonoseaegeneralterm                 \n', '  oselabeledaefromdruguse                                       8.0               0               4.1              0.2         \n', '  oselabeledaefromdruguse                                      10.2              0.4             10.7              0.2         \n', '  oselabeledaefromdruguse                          21.2              2.2             13.5              0.2         \n', '  oselabeledaefromdruguse                                       28.2              0.8             14.5              0.8         \n', '    nonoseaegeneralterm                    \n', '  oselabeledaefromdruguse                                       12.0              0.4              8.6              0.2         \n', '    nonoseaegeneralterm     \n', '  oselabeledaefromdruguse                                     1.2               0                0                0          \n', '  oselabeledaefromdruguse                                        12.0              0.8              8.0              0.4         \n', '  oselabeledaefromdruguse                                          18.2              0.2             13.1              0.2         \n', '  oselabeledaefromdruguse                                      22.5              0.2              8.4               0          \n', '    nonoseaegeneralterm     \n', '  oselabeledaefromdruguse                                        5.5              0.2              9.2               0          \n', '  oselabeledaefromdruguse                                           11.6               0              27.5              1.8         \n', '    nonoseaegeneralterm                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
83,kadcyla,83,1789,1829,"\n', '  oselabeledaefromdruguse                                     32.2              1.8             16.4              0.8         \n', '  oselabeledaefromdruguse                                    5.1              1.2              2.3              0.4         \n', '          Table 7 Selected Laboratory Abnormalities",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,kadcyla,84,1829,1874,"\n', ' Parameter                     KADCYLA(3.6 mg/kg)  Lapatinib (1250 mg) + Capecitabine (2000 mg/m  2  )   \n', ' All Grade %                    Grade 3 %     Grade 4 %    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,kadcyla,85,1874,1878,All Grade %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,kadcyla,86,1878,1911,"Grade 3 %     Grade 4 %     \n', '  \n', '  oselabeledaefromdruguse                17            <1            0             57            2             0         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,kadcyla,87,1911,1916,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,kadcyla,88,1916,1920,oselabeledaefromdruguse                      98            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,kadcyla,89,1920,1931,7             <1            65            3             0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,kadcyla,90,1931,1936,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,kadcyla,91,1936,1940,oselabeledaefromdruguse                      82            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,kadcyla,92,1940,1951,5             <1            54            3             0         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,kadcyla,93,1951,1956,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,kadcyla,94,1956,1979,"oselabeledaefromdruguse           83            14            3             21            <1            <1        \n', '  oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,kadcyla,95,1979,1987,60            4             1             64            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,kadcyla,96,1987,1989,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,kadcyla,97,1989,1992,<1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,kadcyla,98,1992,2001,"\n', '  oselabeledaefromdruguse              39            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,kadcyla,99,2001,2017,"3             <1            38            6             2         \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,kadcyla,100,2017,2025,oselabeledaefromdruguse                33            3             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,kadcyla,101,2025,2027,31            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,kadcyla,102,2027,2029,6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,kadcyla,103,2029,2032,<1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,kadcyla,104,2032,2141,"\n', '              oselabeledaefromdruguse has been observed in two patients (0.2%) with  notaecandidateindication metastatic  notaecandidateindication in clinical trials (n=884) with KADCYLA as single-agent.\n', ' \n', '\n', '   6.2 Immunogenicity\n', '\n', '  As with all therapeutic proteins, there is the potential for an  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' A total of 836 patients from six clinical studies were tested at multiple time points for  nonoseaeaeonlyasinstruction  responses to KADCYLA.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
105,kadcyla,105,2141,2165,"Following KADCYLA dosing, 5.3% (44/836) of patients tested  oselabeledaefromdruguse at one or more post-dose time points.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,kadcyla,106,2165,2209,"The presence of KADCYLA in patient serum at the time of  nonoseaeaeonlyasinstruction sampling may interfere with the ability of this assay to detect  nonoseaeaeonlyasinstruction  As a result, data may not accurately reflect the true incidence of  nonoseaeaeonlyasinstruction development.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,kadcyla,107,2209,2250,"In addition,  nonoseaeaeonlyasinstruction has not been assessed.\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction data are highly dependent on the sensitivity and specificity of the test methods used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,kadcyla,108,2250,2289,"Additionally, the observed incidence of a positive result in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication and the underlying disease.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,kadcyla,109,2289,2308,"Therefore, comparison of the incidence of  nonoseaeaeonlyasinstruction with the incidence of  nonoseaeaeonlyasinstruction may be misleading.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,kadcyla,110,2308,2325,"Clinical significance of  nonoseaeaeonlyasinstruction \n', '\n', '    BOXED WARNING:",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,kadcyla,111,2325,2326,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,kadcyla,112,2326,2343,"', '\n', '    Do Not Substitute KADCYLA for or with Trastuzumab  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,kadcyla,113,2343,2362,"\n', '\n', '\n', '\n', '   WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,kadcyla,114,2362,2372,"HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,kadcyla,115,2372,2411,"\n', '\n', '\n', '\n', ' *   nonoseaegeneralterm  Serious  oselabeledaefromdruguse has been reported, including  oselabeledaefromdruguse and  nonoseaegeneralterm in patients treated with KADCYLA.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,kadcyla,116,2411,2429,Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,kadcyla,117,2429,2454,"Reduce dose or discontinue KADCYLA as appropriate in cases of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction serum transaminases or  nonoseaeaeonlyasinstruction  (2.2, 5.1)",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,kadcyla,118,2454,2470,"\n', ' *   oselabeledaefromdruguse  KADCYLA administration may lead to  oselabeledaefromdruguse .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,kadcyla,119,2470,2485,Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,kadcyla,120,2485,2541,"Withhold treatment for clinically significant  nonoseaeaeonlyasinstruction  (2.2, 5.2) \n', ' *   oselabeledaefromdruguse  Exposure to KADCYLA can result in  oselabeledaefromdruguse or  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,kadcyla,121,2541,2559,*  Pulmonary Toxicity: Permanently discontinue KADCYLA in patients diagnosed with interstitial lung disease or pneumonitis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,kadcyla,122,2559,2568,"(  2.2  ,  5.4  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,kadcyla,123,2568,2592,"\n', ' *  Infusion-Related Reactions, Hypersensitivity Reactions: Monitor for signs and symptoms during and after infusion.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,kadcyla,124,2592,2614,"If significant infusion-related reactions or hypersensitivity reactions occur, slow or interrupt the infusion and administer appropriate medical therapies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,kadcyla,125,2614,2625,Permanently discontinue KADCYLA for life threatening infusion-related reaction.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,kadcyla,126,2625,2639,"(  2.1  ,  2.2  ,  5.5  ) \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,kadcyla,127,2639,2646,"', ' *  Hemorrhage:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,kadcyla,128,2646,2680,"Fatal cases of hemorrhage occurred in clinical trials among patients with no known identified risk factors, as well as among patients with thrombocytopenia and those receiving anti-coagulation and antiplatelet therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,kadcyla,129,2680,2696,Use caution with these agents and consider additional monitoring when concomitant use is medically necessary .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,kadcyla,130,2696,2718,"(  5.6  ) \n', ' *  Thrombocytopenia: Monitor platelet counts prior to each KADCYLA dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,kadcyla,131,2718,2724,Institute dose modifications as appropriate.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,kadcyla,132,2724,2747,"(  2.2  ,  5.7  ) \n', ' *  Neurotoxicity: Monitor for signs or symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,kadcyla,133,2747,2760,Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,kadcyla,134,2760,2781,"(  2.2  ,  5.8  ,  13.2  ) \n', ' *  HER2 Testing",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,kadcyla,135,2781,2794,: Perform using FDA-approved tests by laboratories with demonstrated proficiency.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,kadcyla,136,2794,2875,"(  5.9  ) \n', '    \n', ' \n', '\n', '   5.1 Hepatotoxicity\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  predominantly in the form of asymptomatic, transient  oselabeledaefromdruguse in the concentrations of serum  oselabeledaefromdruguse  has been observed in clinical trials with KADCYLA [see  Adverse Reactions (6.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,kadcyla,137,2875,2904,Serious  oselabeledaefromdruguse  including at least two  nonoseaegeneralterm cases of severe  oselabeledaefromdruguse and associated  oselabeledaefromdruguse  have been reported in clinical trials with KADCYLA.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
138,kadcyla,138,2904,2925,"Some of the observed cases may have been confounded by comorbidities and/or concomitant medications with known  nonoseaeaeonlyasinstruction potential.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,kadcyla,139,2925,2956,"'\n', '\n', '\n', ' Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,kadcyla,140,2956,2982,Patients with known active  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor were excluded from Study 1 [see  Clinical Studies (14.1)  ]  .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
141,kadcyla,141,2982,2999,Reduce the dose or discontinue KADCYLA as appropriate in cases of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction serum transaminases,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,kadcyla,142,2999,3015,and/or  nonoseaeaeonlyasinstruction [see  Dosage and Administration (2.2)  ]  .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,kadcyla,143,3015,3101,"Permanently discontinue KADCYLA treatment in patients with  nonoseaeaeonlyasinstruction and concomitant  nonoseaeaeonlyasinstruction  KADCYLA has not been studied in patients with serum  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction prior to the initiation of treatment.\n', '\n', '\n', '\n', '  In clinical trials of KADCYLA, cases of  oselabeledaefromdruguse  of the liver have been identified from liver biopsies (3 cases out of 884 treated patients, one of which was  nonoseaegeneralterm .",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
144,kadcyla,144,3101,3132,Two of these three cases of  oselabeledaefromdruguse were observed in the randomized trial (Study 1) [see  Adverse Reactions (6.1)  ]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,kadcyla,145,3132,3146,nonoseaeaeonlyasinstruction is a rare  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction may lead to  nonoseaemanifestationorcomplication  ,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
146,kadcyla,146,3146,3159,The diagnosis of  nonoseaeaeonlyasinstruction can be confirmed only by histopathology.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,kadcyla,147,3159,3213,nonoseaeaeonlyasinstruction should be considered in all patients with clinical symptoms of  nonoseaeaeonlyasinstruction and/or  nonoseaeaeonlyasinstruction seen on the computed tomography (CT) scan of the liver but with normal transaminases and no other manifestations of  nonoseaenegation  Upon diagnosis of  nonoseaeaeonlyasinstruction  KADCYLA treatment must be permanently discontinued.  ,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
148,kadcyla,148,3213,3263,"\n', '\n', '\n', '\n', '    5.2 Left Ventricular Dysfunction\n', '\n', '\n', '\n', '  Patients treated with KADCYLA are at increased risk of developing  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,kadcyla,149,3263,3275,A  oselabeledaefromdruguse has been observed in patients treated with KADCYLA.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,kadcyla,150,3275,3369,"In the randomized trial (Study 1),  oselabeledaefromdruguse occurred in 1.8% of patients in the KADCYLA-treated group and 3.3% of patients in the lapatinib plus capecitabine-treated group [see  Adverse Reactions (6.1)  ]  .\n', '\n', '\n', '\n', "" Assess LVEF prior to initiation of KADCYLA and at regular intervals (e.g. every three months) during treatment to ensure the LVEF is within the institution's normal limits.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,kadcyla,151,3369,3387,Treatment with KADCYLA has not been studied in patients with  notaecandidatepreexistingconditionorriskfactor prior to initiation of treatment.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
152,kadcyla,152,3387,3432,"If, at routine monitoring,  nonoseaeaeonlyasinstruction is < 40%, or is 40% to 45% with a 10% or greater absolute  nonoseaeaeonlyasinstruction below the pretreatment value, withhold KADCYLA and repeat LVEF assessment within approximately 3 weeks.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,kadcyla,153,3432,3458,Permanently discontinue KADCYLA if the LVEF has not improved or has declined further [see  Dosage and Administration (2.2)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,kadcyla,154,3458,3546,"Patients with a history of  notaecandidatepreexistingconditionorriskfactor , serious  notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor within 6 months were excluded from Study 1 [see  Clinical Studies (14.1)  ]  .\n"", '\n', '\n', '\n', '    5.3 Embryo-Fetal Toxicity\n', '\n', '\n', '\n', '  KADCYLA can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
155,kadcyla,155,3546,3577,There are no adequate and well-controlled studies of KADCYLA in  notaecandidatepreexistingconditionorriskfactor women and no reproductive and developmental toxicology studies have been conducted with ado-trastuzumab emtansine.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
156,kadcyla,156,3577,3705,"Nevertheless, treatment with trastuzumab, the antibody component of KADCYLA, during  notaecandidatepreexistingconditionorriskfactor in the postmarketing setting has resulted in  oselabeledaefromdruguse  some associated with  nonoseaegeneralterm  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  DM1, the  nonoseaeaeonlyasinstruction component of KADCYLA, can be expected to cause  oselabeledaefromdruguse based on its mechanism of action.\n', '\n', '\n', '\n', '  If KADCYLA is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while receiving KADCYLA or within 7 months following the last dose of KADCYLA, apprise the patient of the potential  oselabeledaefromdruguse [see  Use in Specific Populations (8.1)  ]  .  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
157,kadcyla,157,3705,3733,"\n', '\n', '\n', '\n', '  Verify  nonoseaeaeonlyasinstruction status prior to the initiation of KADCYLA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,kadcyla,158,3733,3754,Advise patients of the risks of  oselabeledaefromdruguse and  oselabeledaefromdruguse and the need for contraception during and after treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,kadcyla,159,3754,3817,"Advise patients to contact their healthcare provider immediately if they suspect they may be  nonoseaeaeonlyasinstruction  If KADCYLA is administered during  notaecandidatepreexistingconditionorriskfactor or if a patient becomes  nonoseaeaeonlyasinstruction while receiving KADCYLA or within 7 months following the last dose of KADCYLA, immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
160,kadcyla,160,3817,3865,"Encourage women who may be exposed during  nonoseaeaeonlyasinstruction or within 7 months prior to conception, to enroll in the MotHER  nonoseaeaeonlyasinstruction Registry by contacting 1-800-690-6720 [see  Patient Counseling Information (17)  ]  .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,kadcyla,161,3865,3907,"\n', '\n', '\n', '\n', '    5.4  oselabeledaefromdruguse \n', '\n', '\n', '  Cases of  oselabeledaefromdruguse , including  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,kadcyla,162,3907,3926,some leading to  oselabeledaefromdruguse or  nonoseaegeneralterm outcome have been reported in clinical trials with KADCYLA.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
163,kadcyla,163,3926,3982,"oselabeledaefromdruguse at an incidence of 0.8% (7 out of 884 treated patients) has been reported, with one case of grade 3  oselabeledaefromdruguse  Signs and symptoms include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  These events may or may not occur as sequelae of  nonoseaeaeonlyasinstruction  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
164,kadcyla,164,3982,4207,"In the randomized trial (Study 1), the overall frequency of  oselabeledaefromdruguse was 1.2% [see  Adverse Reactions (6.1)  ]  .\n', '\n', '\n', '\n', ' Permanently discontinue treatment with KADCYLA in patients diagnosed with  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Patients with  notaecandidatepreexistingconditionorriskfactor due to complications of  notaecandidatepreexistingconditionorriskfactor and co-morbidities may be at increased risk of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.5 Infusion-Related Reactions, Hypersensitivity Reactions\n', '\n', '\n', '\n', '  Treatment with KADCYLA has not been studied in patients who had trastuzumab permanently discontinued due to  nonoseaeaeonlyasinstruction  and/or  nonoseaeaeonlyasinstruction  treatment with KADCYLA is not recommended for these patients.\n', '\n', '\n', '\n', '  oselabeledaefromdruguse  characterized by one or more of the following symptoms -  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported in clinical trials of KADCYLA.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
165,kadcyla,165,4207,4242,"In the randomized trial (Study 1), the overall frequency of  oselabeledaefromdruguse in patients treated with KADCYLA was 1.4% [see  Adverse Reactions (6.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,kadcyla,166,4242,4264,"In most patients, these reactions resolved over the course of several hours to a day after the infusion was terminated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,kadcyla,167,4264,4305,KADCYLA treatment should be interrupted in patients with severe  nonoseaeaeonlyasinstruction  KADCYLA treatment should be permanently discontinued in the event of a life-threatening  nonoseaeaeonlyasinstruction [see  Dosage and Administration (2.2)  ]  .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,kadcyla,168,4305,4362,"Patients should be observed closely for  nonoseaeaeonlyasinstruction reactions, especially during the first infusion.\n', '\n', '\n', '\n', ' One case of a serious,  oselabeledaefromdruguse anaphylactic-like  oselabeledaefromdruguse  oselabeledaefromdruguse has been observed in clinical trials of single-agent KADCYLA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,kadcyla,169,4362,4448,"Medications to treat such reactions, as well as emergency equipment, should be available for immediate use.\n', '\n', '\n', '\n', '    5.6 Hemorrhage\n', '\n', '\n', '\n', '   Cases of  oselabeledaefromdruguse  including  oselabeledaefromdruguse  respiratory, and gastrointestinal  oselabeledaefromdruguse  oselabeledaefromdruguse  and gastrointestinal  oselabeledaefromdruguse  oselabeledaefromdruguse  have been reported in clinical trials with Kadcyla.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,kadcyla,170,4448,4460,Some of these  oselabeledaefromdruguse events resulted in  nonoseaegeneralterm outcomes.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
171,kadcyla,171,4460,4496,"In the randomized trial (Study 1), the overall frequency of  oselabeledaefromdruguse was 32.2% in the KADCYLA-treated group and 16.4% in the lapatinib plus capecitabine-treated group.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,kadcyla,172,4496,4537,The incidence of >= Grade 3  oselabeledaefromdruguse was 1.8% in the KADCYLA-treated group and 0.8% in the lapatinib plus capecitabine-treated group [see  Adverse Reactions (6.1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,kadcyla,173,4537,4573,"Although, in some of the observed cases the patients were also receiving anti-coagulation therapy, antiplatelet therapy, or had  notaecandidatepreexistingconditionorriskfactor  in others there were no known additional risk factors.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
174,kadcyla,174,4573,4590,Use caution with these agents and consider additional monitoring when concomitant use is medically necessary.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,kadcyla,175,4590,4613,"\n', '\n', '\n', '\n', '    5.7 Thrombocytopenia\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,kadcyla,176,4613,4647,"', '\n', '\n', '   oselabeledaefromdruguse  or  oselabeledaefromdruguse  was reported in clinical trials of KADCYLA (103 of 884 treated patients with >=",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,kadcyla,177,4647,4660,Grade 3; 283 of 884 treated patients with any Grade).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,kadcyla,178,4660,4701,"The majority of these patients had Grade 1 or 2 events (< LLN to >= 50,000/mm  3  ) with the nadir occurring by day 8 and generally improving to Grade 0 or 1 (>= 75,000",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,kadcyla,179,4701,4703,/mm  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,kadcyla,180,4703,4706,3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,kadcyla,181,4706,4712,by the next scheduled dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,kadcyla,182,4712,4792,"In clinical trials of KADCYLA, the incidence and severity of  nonoseaeaeonlyasinstruction were higher in Asian patients.\n', '\n', '\n', '\n', ' In the randomized trial (Study 1), the overall frequency of  oselabeledaefromdruguse was 31.2% in the KADCYLA-treated group and 3.3% in the lapatinib plus capecitabine-treated group [see  Adverse Reactions (6.1)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,kadcyla,183,4792,4822,The incidence of >= Grade 3  oselabeledaefromdruguse was 14.5% in the KADCYLA-treated group and 0.4% in the lapatinib plus capecitabine-treated group.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,kadcyla,184,4822,4897,"In Asian patients, the incidence of >= Grade 3  oselabeledaefromdruguse was 45.1% in the KADCYLA-treated group and 1.3% in the lapatinib plus capecitabine-treated group.\n', '\n', '\n', '\n', ' Monitor platelet counts prior to initiation of KADCYLA and prior to each KADCYLA dose [see  Dosage and Administration (2.2)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,kadcyla,185,4897,4917,KADCYLA has not been studied in patients with  notaecandidatepreexistingconditionorriskfactor mm  3  prior to initiation of treatment.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
186,kadcyla,186,4917,4967,"In the event of  nonoseaeaeonlyasinstruction to Grade 3 or greater (< 50,000/mm  3  ) do not administer KADCYLA until platelet counts recover to Grade 1 (>= 75,000/mm  3  ) [see  Dosage and Administration (2.2)  ]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,kadcyla,187,4967,4972,Patients with  notaecandidatepreexistingconditionorriskfactor (,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
188,kadcyla,188,4972,5012,"< 100,000/mm  3  ) and patients on anti-coagulant treatment should be closely monitored during treatment with KADCYLA.\n', '\n', '\n', '\n', '    5.8  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,kadcyla,189,5012,5042,"\n', '\n', '\n', '   oselabeledaefromdruguse  mainly as Grade 1 and predominantly sensory, was reported in clinical trials of KADCYLA",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,kadcyla,190,5042,5064,(14 of 884 treated patients with >= Grade 3; 196 of 884 treated patients with any Grade).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,kadcyla,191,5064,5111,"In the randomized trial (Study 1), the overall frequency of  oselabeledaefromdruguse was 21.2% in the KADCYLA-treated group and 13.5% in the lapatinib plus capecitabine-treated group [see  Adverse Reactions (6.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,kadcyla,192,5111,5177,"The incidence of >= Grade 3  oselabeledaefromdruguse was 2.2% in the KADCYLA-treated group and 0.2% in the lapatinib plus capecitabine-treated group.\n', '\n', '\n', '\n', ' KADCYLA should be temporarily discontinued in patients experiencing Grade 3 or 4  nonoseaeaeonlyasinstruction until resolution to <= Grade 2.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,kadcyla,193,5177,5273,"Patients should be clinically monitored on an ongoing basis for signs or symptoms of  nonoseaeaeonlyasinstruction [see  Nonclinical Toxicology (13.2)  ]  .\n', '\n', '\n', '\n', '    5.9 HER2 Testing\n', '\n', '\n', '\n', '  Detection of  notaecandidateindication is necessary for selection of patients appropriate for KADCYLA therapy because these are the only patients studied for whom benefit has been shown [see  Indications and Usage",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
194,kadcyla,194,5273,5288,"(1)  ,  Clinical Studies (14.1)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,kadcyla,195,5288,5338,"In the randomized study (Study 1), patients with  notaecandidateindication were required to have evidence of  notaecandidateindication defined as 3+ IHC by Dako HerceptestTM or evidence of overexpression defined as FISH amplification ratio >= 2.0 by Dako HER2  FISH PharmDxTM test kit.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
196,kadcyla,196,5338,5393,"Only limited data were available for patients whose  notaecandidateindication was positive by FISH and 0 or 1+ by IHC.\n', '\n', '\n', '\n', ' Assessment of HER2 status should be performed by laboratories with demonstrated proficiency in the specific technology being utilized.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
197,kadcyla,197,5393,5480,"Improper assay performance, including use of sub- optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.\n', '\n', '\n', '\n', '    5.10 Extravasation\n', '\n', '\n', '\n', '  In KADCYLA clinical studies, reactions secondary to  oselabeledaefromdruguse have been observed.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,kadcyla,198,5480,5557,"These reactions, observed more frequently within 24 hours of infusion, were usually mild and comprised  oselabeledaefromdruguse  tenderness, skin irrit oselabeledaefromdruguse on, pain, or swelling at  oselabeledaefromdruguse  oselabeledaefromdruguse  skin irrit oselabeledaefromdruguse on, pain, or swelling at  oselabeledaefromdruguse  oselabeledaefromdruguse  pain, or swelling  oselabeledaefromdruguse  oselabeledaefromdruguse  or swelling  oselabeledaefromdruguse  oselabeledaefromdruguse  Specific treatment for KADCYLA  nonoseaeaeonlyasinstruction is unknown.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,kadcyla,199,5557,5562,The  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,striverdi,0,0,65,"['    6  ADVERSE REACTIONS\n', '\n', '    Long-acting beta2-adrenergic agonists, such as STRIVERDI RESPIMAT, increase the risk of  nonoseaeaefromofflabel related  nonoseaegeneralterm  STRIVERDI RESPIMAT is not indicated for the treatment of  notaecandidatecontraindication [  see Boxed Warning and Warning and Precautions (  5.1  )  ].  ",0,1,0,0,0,0,0,0,0,0,1,1,0,0,0
1,striverdi,1,65,128,"\n', '\n', '\n', '\n', '   EXCERPT:   Most common adverse reactions (incidence >=2% and more than placebo) are nasopharyngitis, upper respiratory tract infection, bronchitis, urinary tract infection, cough, dizziness, rash, diarrhea, back pain and arthralgia (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,striverdi,2,128,131,6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,striverdi,3,131,188,"\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY, or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,striverdi,4,188,230,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,striverdi,5,230,306,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The STRIVERDI RESPIMAT clinical development program included seven dose-ranging trials and eight confirmatory trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,striverdi,6,306,325,Four of the confirmatory trials were 6-week cross-over trials and four were 48-week parallel group trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,striverdi,7,325,402,"Adverse reactions observed in the dose-ranging trials and four 6-week cross-over trials were consistent with those observed in the 48-week parallel group trials, which formed the primary safety database.\n', '\n', '\n', '\n', ' The primary safety database consisted of pooled data from the four 48-week double-blind, active and placebo-controlled, parallel group confirmatory clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,striverdi,8,402,426,These trials included 3104 adult  notaecandidateindication patients (77% males and 23% females) 40 years of age and older.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
9,striverdi,9,426,450,"Of these patients, 876 and 883 patients were treated with STRIVERDI RESPIMAT 5 mcg and 10 mcg once-daily, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,striverdi,10,450,491,The STRIVERDI RESPIMAT groups were composed of mostly Caucasians (66%) with a mean age of 64 years and a mean percent predicted FEV1at baseline of 44% for both the 5 mcg and 10 mcg treatment groups.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,striverdi,11,491,559,"Control arms for comparison included placebo in all four trials plus formoterol 12 mcg in two trials.\n', '\n', '\n', '\n', ' In these four clinical trials, seventy-two percent (72%) of patients exposed to any dose of STRIVERDI RESPIMAT reported an adverse reaction compared to 71% in the placebo group.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,striverdi,12,559,587,The proportion of patients who discontinued due to an adverse reaction was 7.2% for STRIVERDI RESPIMAT treated patients compared to 8.8% for placebo treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,striverdi,13,587,766,"The adverse reaction most commonly leading to discontinuation was  oselabeledaefromdruguse  The most common serious adverse reactions were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' Table 1 shows all adverse drug reactions reported by at least 2% of patients (and higher than placebo) who received STRIVERDI RESPIMAT 5 mcg during the 48-week trials.\n', '\n', '\n', '\n', '   Table 1: Number and frequency of adverse drug reactions greater than 2% (and higher than placebo) in COPD patients exposed to STRIVERDI RESPIMAT 5 mcg: Pooled data from the four 48-week, double-blind, active- and placebo-controlled clinical trials in COPD patients 40 years of age and older  \n', '\n', '\n', '\n', '\n', ' *  oselabeledaefromdruguse includes a grouping of similar terms.                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,striverdi,14,766,798,"\n', '  \n', '   Treatment                                                          STRIVERDI5 mcg once-daily        Placebo       \n', '    nonoseaegeneralterm (adverse drug reaction)                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
15,striverdi,15,798,808,n=876n (%)         n=885n (%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,striverdi,16,808,840,"\n', '   nonoseaegeneralterm                                                                               \n', '       oselabeledaefromdruguse                                                    99 (11.3)           68 (7.7)       \n', '       oselabeledaefromdruguse                                   72",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,striverdi,17,840,849,(8.2)           66 (7.5)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,striverdi,18,849,895,"\n', '       oselabeledaefromdruguse                                                          41 (4.7)           32 (3.6)       \n', '       oselabeledaefromdruguse                                             22 (2.5)            9 (1.0)       \n', '   nonoseaegeneralterm                                                          \n', '       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,striverdi,19,895,914,"oselabeledaefromdruguse                                                               37 (4.2)           35 (4.0)       \n', '   nonoseaegeneralterm                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
20,striverdi,20,914,931,"\n', '       oselabeledaefromdruguse                                                           20 (2.3)           19 (2.1)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,striverdi,21,931,938,"\n', '   nonoseaegeneralterm                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,striverdi,22,938,962,"\n', '       oselabeledaefromdruguse                                                                19 (2.2)           10 (1.1)       \n', '   nonoseaegeneralterm                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,striverdi,23,962,986,"\n', '       oselabeledaefromdruguse                                                            25 (2.9)           22 (2.5)       \n', '   nonoseaegeneralterm                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,striverdi,24,986,1003,"\n', '       oselabeledaefromdruguse                                                           31 (3.5)           24 (2.7)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,striverdi,25,1003,1053,"\n', '       oselabeledaefromdruguse                                                          18 (2.1)            7 (0.8)       \n', '      Additional adverse reactions that occurred in greater than 2% (and higher than placebo) of patients exposed to STRIVERDI RESPIMAT 10 mcg were  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,striverdi,26,1053,1058,oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,striverdi,27,1058,1072,"\n', ' \n', '\n', '  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,striverdi,28,1072,1073,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,striverdi,29,1073,1084,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,striverdi,30,1084,1098,"WARNING: ASTHMA-RELATED DEATH\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,striverdi,31,1098,1100,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,striverdi,32,1100,1204,"ASTHMA-RELATED DEATH\n', '\n', '    Long-acting beta2-adrenergic agonists (LABA) increase the risk of  nonoseaeaefromofflabel related  nonoseaegeneralterm \n', '\n', 'Data from a large, placebo-controlled US study that compared the safety\n', '\n', 'of another long-acting beta2-adrenergic agonist\n', '\n', '(salmeterol) or placebo added to usual  notaecandidatecontraindication therapy showed an increase\n', '\n', 'in  nonoseaeaefromofflabel related  nonoseaegeneralterm in patients receiving salmeterol.",0,1,0,0,0,0,0,0,0,0,1,1,0,0,0
33,striverdi,33,1204,1240,"This finding\n', '\n', 'with salmeterol is considered a class effect of LABA, including olodaterol,\n', '\n', 'the active ingredient in STRIVERDI RESPIMAT.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,striverdi,34,1240,1306,"The safety and efficacy\n', '\n', 'of STRIVERDI RESPIMAT in patients with  notaecandidatecontraindication have not been established.\n', '\n', ' STRIVERDI RESPIMAT is not indicated for the treatment of  notaecandidatecontraindication     5  WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
35,striverdi,35,1306,1323,*  Do not initiate STRIVERDI RESPIMAT in acutely deteriorating COPD patients (  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,striverdi,36,1323,1338,"\n', ' *  Do not use for relief of acute symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,striverdi,37,1338,1352,Concomitant short-acting beta2-agonists can be used as needed for acute relief.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,striverdi,38,1352,1357,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,striverdi,39,1357,1370,"\n', ' *  Do not exceed the recommended dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,striverdi,40,1370,1397,"Excessive use of STRIVERDI RESPIMAT, or use in conjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,striverdi,41,1397,1416,"(  5.3  ) \n', ' *  Life-threatening paradoxical bronchospasm can occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,striverdi,42,1416,1421,Discontinue STRIVERDI RESPIMAT immediately.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,striverdi,43,1421,1458,"(  5.4  ) \n', ' *  Use with caution in patients with cardiovascular or convulsive disorders, thyrotoxicosis or sensitivity to sympathomimetic drugs (  5.5  ,  5.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,striverdi,44,1458,1487,"\n', '    \n', ' \n', '\n', '   5.1 Asthma-Related Death [ see Boxed Warning  ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,striverdi,45,1487,1563,"\n', '\n', '\n', '\n', '    *   Data from a large placebo-controlled study in  notaecandidatecontraindication patients showed that long-acting beta2-adrenergic agonists may increase the risk of  nonoseaeaefromofflabel related  nonoseaegeneralterm  Data are not available to determine whether the rate of  nonoseaegeneralterm in patients with  notaecandidateindication is increased by long-acting beta2-adrenergic agonists.  ",0,1,0,1,0,0,0,0,0,0,1,1,0,0,0
46,striverdi,46,1563,1640,"\n', ' *   A 28-week, placebo-controlled US study comparing the safety of another long-acting beta2-adrenergic agonist (salmeterol) with placebo, each added to usual  notaecandidatecontraindication therapy, showed an increase in  nonoseaeaefromofflabel related  nonoseaegeneralterm in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34).",0,1,0,0,0,0,0,0,0,0,1,1,0,0,0
47,striverdi,47,1640,1665,"The increased risk of  nonoseaeaefromofflabel related  nonoseaegeneralterm is considered a class effect of long-acting beta2-adrenergic agonists, including STRIVERDI RESPIMAT.",0,1,0,0,0,0,0,0,0,0,1,0,0,0,0
48,striverdi,48,1665,1691,No study adequate to determine whether the rate of  nonoseaeaeonlyasinstruction related  nonoseaegeneralterm is increased in patients treated with STRIVERDI RESPIMAT has been conducted.,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,striverdi,49,1691,1708,The safety and efficacy of STRIVERDI RESPIMAT in patients with  notaecandidatepreexistingconditionorriskfactor have not been established.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
50,striverdi,50,1708,1730,STRIVERDI RESPIMAT is not indicated for the treatment of  notaecandidatecontraindication [ see Contraindications (  4  ) ].  ,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
51,striverdi,51,1730,1775,"\n', '       5.2 Deterioration of Disease and Acute Episodes\n', ' \n', '\n', '  STRIVERDI RESPIMAT should not be initiated in patients with  notaecandidatepreexistingconditionorriskfactor  which may be a life-threatening condition.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
52,striverdi,52,1775,1787,STRIVERDI RESPIMAT has not been studied in patients with  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
53,striverdi,53,1787,1863,"The use of STRIVERDI RESPIMAT in this setting is inappropriate.\n', '\n', '\n', '\n', ' STRIVERDI RESPIMAT should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of  nonoseaeaeonlyasinstruction  STRIVERDI RESPIMAT has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,striverdi,54,1863,1970,"Acute symptoms should be treated with an inhaled short-acting beta2-agonist.\n', '\n', '\n', '\n', ' When beginning STRIVERDI RESPIMAT, patients who have been taking inhaled, short-acting beta2-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute  nonoseaeaeonlyasinstruction  When prescribing STRIVERDI RESPIMAT, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient on how it should be used.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,striverdi,55,1970,2020,"Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated.\n', '\n', '\n', '\n', ""  notaecandidateindication may deteriorate acutely over a period of hours or chronically over several days or longer.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
56,striverdi,56,2020,2067,"If STRIVERDI RESPIMAT no longer controls symptoms of  nonoseaeaeonlyasinstruction  or the patient's inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,striverdi,57,2067,2090,"In this setting, a re-evaluation of the patient and the  notaecandidateindication treatment regimen should be undertaken at once.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
58,striverdi,58,2090,2197,"Increasing the daily dosage of STRIVERDI RESPIMAT beyond the recommended dose is not appropriate in this situation.\n"", '\n', '\n', '\n', '    5.3 Excessive Use of STRIVERDI RESPIMAT and Use with Long-Acting Beta2-Agonists\n', '\n', '\n', '\n', '  As with other inhaled drugs containing beta2-adrenergic agents, STRIVERDI RESPIMAT should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists, as an  nonoseaeodorwithdrawal may result.",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
59,striverdi,59,2197,2270,"Clinically significant  nonoseaegeneralterm and  nonoseaegeneralterm have been reported in association with excessive use of inhaled sympathomimetic drugs.\n', '\n', '\n', '\n', '    5.4 Paradoxical Bronchospasm\n', '\n', '\n', '\n', '  As with other inhaled beta2-agonists, STRIVERDI RESPIMAT may produce  oselabeledaefromdruguse that may be life-threatening.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,striverdi,60,2270,2368,"If  nonoseaeaeonlyasinstruction occurs, STRIVERDI RESPIMAT should be discontinued immediately and alternative therapy instituted.\n', '\n', '\n', '\n', '    5.5 Cardiovascular Effects\n', '\n', '\n', '\n', '  STRIVERDI RESPIMAT, like other beta2-agonists, can produce a clinically significant  oselabeledaeclasseffect in some patients as measured by  oselabeledaefromdruguse in pulse rate,  oselabeledaefromdruguse or diastolic  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse in pulse rate, systolic or  oselabeledaefromdruguse  and/or symptoms.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,striverdi,61,2368,2381,"If such effects occur, STRIVERDI RESPIMAT may need to be discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,striverdi,62,2381,2410,"In addition, beta-agonists have been reported to produce  oselabeledaeclasseffect  such as  oselabeledaeclasseffect e T  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,striverdi,63,2410,2419,The clinical significance of these findings is unknown.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,striverdi,64,2419,2529,"Long acting beta2-adrenergic agonists should be administered with caution in patients with  notaecandidatepreexistingconditionorriskfactor  especially  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.6 Co-existing Conditions\n', '\n', '\n', '\n', '  STRIVERDI RESPIMAT, like other sympathomimetic amines, should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  in patients with known or suspected  notaecandidatepreexistingconditionorriskfactor of the  notaecandidatepreexistingconditionorriskfactor  and in patients who are unusually responsive to sympathomimetic amines.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
65,striverdi,65,2529,2620,"Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to  nonoseaeaeforanotherdruginclass and  nonoseaeaeforanotherdruginclass \n', '\n', '\n', '\n', '    5.7 Hypokalemia and Hyperglycemia\n', '\n', '\n', '\n', '  Beta-adrenergic agonists may produce significant  oselabeledaeclasseffect in some patients, which has the potential to produce adverse  nonoseaemanifestationorcomplication [ see Clinical Pharmacology (  12.2  )  ].",0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
66,striverdi,66,2620,2631,"The  oselabeledaeclasseffect is usually transient, not requiring supplementation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,striverdi,67,2631,2741,"Inhalation of high doses of beta2-adrenergic agonists may produce  oselabeledaeclasseffect \n', '\n', '\n', '\n', ' In patients with severe  notaecandidateindication   nonoseaeaeonlyasinstruction may be potentiated by  notaecandidatepreexistingconditionorriskfactor and concomitant treatment [ see Drug Interactions (  7.2  )  ], which may increase the susceptibility for  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Clinically notable  nonoseaeaeratelteqplacebo or  nonoseaeaeratelteqplacebo were infrequent during clinical studies with long-term administration of STRIVERDI RESPIMAT with the rates similar to those for placebo controls.",1,0,1,1,0,0,1,0,0,0,0,0,0,0,0
68,striverdi,68,2741,2800,"STRIVERDI RESPIMAT has not been investigated in patients whose  notaecandidatepreexistingconditionorriskfactor is not well controlled.\n', '\n', '\n', '\n', '    5.8 Hypersensitivity Reactions\n', '\n', '\n', '\n', '  Immediate  oselabeledaefromdruguse  including  oselabeledaefromdruguse ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,doxil,0,0,113,"['  6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in more detail in other sections of the labeling.\n', '\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,doxil,1,113,157,The most common adverse reactions (>20%) observed with DOXIL are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,doxil,2,157,263,"\n', ' \n', '\n', '   EXCERPT:   Most common adverse reactions (>20%) are asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-foot syndrome, rash, neutropenia, thrombocytopenia, and anemia (  6  ).\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS contact Janssen Products, LP at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,doxil,3,263,294,"\n', '\n', ' \n', '\n', '  6.1 Adverse Reactions in Clinical Trials\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,doxil,4,294,463,"Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates on other clinical trials and may not reflect the rates observed in clinical practice.\n', '\n', ' The safety data reflect exposure to DOXIL in 1310 patients including: 239 patients with  notaecandidateindication  753 patients with  notaecandidateindication  and 318 patients with  notaecandidateindication \n', '\n', ' The following tables present adverse reactions from clinical trials of single-agent DOXIL in  notaecandidateindication and  notaecandidateindication \n', '\n', '   Patients With Ovarian Cancer\n', '\n', ' The safety data described below are from Trial 4, which included 239 patients with  notaecandidateindication treated with DOXIL 50 mg/m  2  once every 4 weeks for a minimum of four courses in a randomized, multicenter, open-label study.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
5,doxil,5,463,486,"In this trial, patients received DOXIL for a median number of 3.2 months (range 1 day to 25.8 months).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,doxil,6,486,574,"The median age of the patients is 60 years (range 27 to 87), with 91% Caucasian, 6% Black, and 3% Hispanic or Other.\n', '\n', ' Table 3 presents the  nonoseaeaeonlyasinstruction from Trial 4.\n', '\n', ' Table 3: Hematologic Adverse Reactions in Trial 4 \n', '                                               DOXIL Patients(n=239)         Topotecan Patients(n=235)      \n', '  \n', '  oselabeledaefromdruguse                                                                                                ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,doxil,7,574,592,"\n', '   500 - <1000/mm  3                                     8%                             14%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,doxil,8,592,600,"\n', '   <500/mm  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,doxil,9,600,608,3                                           4.2%                            62%                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,doxil,10,608,616,"\n', '  oselabeledaefromdruguse                                                                                                     \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,doxil,11,616,634,"', '   6.5 - <8 g/dL                                         5%                             25%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,doxil,12,634,651,"\n', '   < 6.5 g/dL                                           0.4%                            4.3%                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,doxil,13,651,658,"\n', '  oselabeledaefromdruguse                                                                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,doxil,14,658,682,"\n', '   10,000 - <50,000/mm  3                               1.3%                            17%                 \n', '   <",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,doxil,15,682,684,"10,000/mm  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,doxil,16,684,689,3                                        0.0%                            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,doxil,17,689,692,17%                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,doxil,18,692,708,"\n', '         Table 4 presents the  nonoseaeaeonlyasinstruction from Trial 4.\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,doxil,19,708,729,"' \n', '\n', ' Table 4: Non-Hematologic Adverse Reactions in Trial 4 \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,doxil,20,729,789,"', ' Non-Hematologic Adverse Reaction 10% or Greater  DOXIL (%) treated(n=239)  Topotecan (%) treated(n=235)   \n', '                                             All grades       Grades 3-4       All grades       Grades 3-4      \n', '  \n', '      nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
21,doxil,21,789,804,"\n', '      oselabeledaefromdruguse                                    40                7               52                8          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,doxil,22,804,819,"\n', '      oselabeledaefromdruguse                                       21               0.8              31                6          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,doxil,23,819,830,"\n', '      oselabeledaefromdruguse                    14               3.8              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,doxil,24,830,834,3.4               0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,doxil,25,834,841,"\n', '      oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,doxil,26,841,845,12               1.7              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,doxil,27,845,856,"10               0.9         \n', '      oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,doxil,28,856,858,12               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,doxil,29,858,864,2.1               6               0.9         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,doxil,30,864,879,"\n', '      oselabeledaefromdruguse                                    11               0.8              15                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,doxil,31,879,886,"\n', '      nonoseaegeneralterm                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,doxil,32,886,893,"\n', '      oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,doxil,33,893,897,46                5               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,doxil,34,897,899,63                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,doxil,35,899,901,8          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,doxil,36,901,906,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,doxil,37,906,910,oselabeledaefromdruguse                                  41                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,doxil,38,910,916,8               15               0.4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,doxil,39,916,927,"\n', '      oselabeledaefromdruguse                                    33                8               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,doxil,40,927,931,44               10          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,doxil,41,931,940,"\n', '      oselabeledaefromdruguse                                    21               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,doxil,42,940,944,2.5              35               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,doxil,43,944,946,4.2         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,doxil,44,946,955,"\n', '      oselabeledaefromdruguse                                    20               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,doxil,45,955,959,2.5              22               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,doxil,46,959,961,1.3         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,doxil,47,961,983,"\n', '      oselabeledaefromdruguse                                   12               0.8              14                0          \n', '      nonoseaegeneralterm                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,doxil,48,983,990,"\n', '      oselabeledaefromdruguse                                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,doxil,49,990,994,4.2               0               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,doxil,50,994,998,10                0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,doxil,51,998,1005,"\n', '      nonoseaegeneralterm                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,doxil,52,1005,1016,"\n', '      oselabeledaefromdruguse                                 16                0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,doxil,53,1016,1020,18               0.4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,doxil,54,1020,1029,"\n', '      oselabeledaefromdruguse                                     15               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,doxil,55,1029,1033,4.1              23               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,doxil,56,1033,1050,"4.3         \n', '      oselabeledaefromdruguse                             10                0               12                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,doxil,57,1050,1081,"\n', '      nonoseaegeneralterm                    \n', '      oselabeledaefromdruguse                          51               24               0.9               0          \n', '      oselabeledaefromdruguse                                        29               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
58,doxil,58,1081,1083,4.2              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,doxil,59,1083,1087,12               0.4         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,doxil,60,1087,1100,"\n', '      oselabeledaefromdruguse                                    19               N/A              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,doxil,61,1100,1103,52               N,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,doxil,62,1103,1106,/A         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,doxil,63,1106,1168,"\n', '           The following additional adverse reactions were observed in patients with  notaecandidateindication with doses administered every four weeks (Trial 4).\n', ' \n', '\n', '   Incidence 1% to 10%\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
64,doxil,64,1168,1190,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,doxil,65,1190,1202,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,doxil,66,1202,1224,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,doxil,67,1224,1258,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,doxil,68,1258,1290,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,doxil,69,1290,1394,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', ""   Patients With AIDS-Related Kaposi's Sarcoma\n"", '\n', ' The safety data described is based on the experience reported in 753 patients with  notaecandidateindication  enrolled in four open-label, uncontrolled trials of DOXIL administered at doses ranging from 10 to 40 mg/m  2  every 2 to 3 weeks.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
70,doxil,70,1394,1436,"Demographics of the population were: median age 38.7 years (range 24-70); 99% male; 88% Caucasian, 6% Hispanic, 4% Black, and 2% Asian/other/unknown.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,doxil,71,1436,1473,The majority of patients were treated with 20 mg/m  2  of DOXIL every 2 to 3 weeks with a median exposure of 4.2 months (range 1 day to 26.6 months).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,doxil,72,1473,1584,"The median cumulative dose was 120 mg/m  2  (range 3.3 to 798.6 mg/m  2  ); 3% received cumulative doses of greater than 450 mg/m  2  .\n', '\n', ' Disease characteristics were: 61% poor risk for  notaecandidatepreexistingconditionorriskfactor  91% poor risk for immune system, and 47% poor risk for  notaecandidatepreexistingconditionorriskfactor  36% were poor risk for all three categories; median CD4 count 21 cells/mm  3  (51% less than 50 cells/mm  3  );",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
73,doxil,73,1584,1771,"mean absolute neutrophil count at study entry approximately 3,000 cells/mm  3  .\n', '\n', ' Of the 693 patients with concomitant medication information, 59% were on one or more antiretroviral medications [35% zidovudine (AZT), 21% didanosine (ddI), 16% zalcitabine (ddC), and 10% stavudine (D4T)]; 85% received  nonoseaeaeonlyasinstruction (54% sulfamethoxazole/trimethoprim); 85% received antifungal medications (76% fluconazole); 72% received antivirals (56% acyclovir, 29% ganciclovir, and 16% foscarnet) and 48% patients received colony-stimulating factors (sargramostim/filgrastim) during their course of treatment.\n', '\n', "" Adverse reactions led to discontinuation of treatment in 5% of patients with  notaecandidateindication and included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   notaecandidatepreexistingconditionorriskfactor  and unspecified reasons.",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
74,doxil,74,1771,1833,"Tables 5 and 6 summarize adverse reactions reported in patients treated with DOXIL for AIDS-related Kaposi's sarcoma in a pooled analysis of the four trials.\n"", '\n', "" Table 5: Hematologic Adverse Reactions Reported in Patients With AIDS-Related Kaposi's Sarcoma \n"", ""                                     Patients With Refractory or Intolerant AIDS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,doxil,75,1833,1896,"-Related Kaposi's Sarcoma(n=74 [note: This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.] )  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,doxil,76,1896,1901,Total Patients With  notaecandidateindication,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
77,doxil,77,1901,1925,n=720 [note: This includes only subjects with  notaecandidateindication who had available data from the 4 pooled trials.] )   ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
78,doxil,78,1925,1937,"\n"", '  \n', '  oselabeledaefromdruguse                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,doxil,79,1937,1953,"\n', '   < 1000/mm  3                                     46%                                49%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,doxil,80,1953,1961,"\n', '   < 500/mm  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,doxil,81,1961,1969,3                                      11%                                13%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,doxil,82,1969,1976,"\n', '  oselabeledaefromdruguse                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,doxil,83,1976,1993,"\n', '   < 10 g/dL                                        58%                                55%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,doxil,84,1993,2004,"\n', '   < 8 g/dL                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,doxil,85,2004,2010,16%                                18%                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,doxil,86,2010,2017,"\n', '  oselabeledaefromdruguse                     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,doxil,87,2017,2038,"\n', '   < 150,000/mm  3                                  61%                                61%                  \n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,doxil,88,2038,2049,"< 25,000/mm  3                                  1.4%                               4.2%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,doxil,89,2049,2050,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,doxil,90,2050,2077,"', ""        Table 6: Non-Hematologic Adverse Reactions Reported in >= 5% of Patients With AIDS-Related Kaposi's Sarcoma",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,doxil,91,2077,2089,"\n"", "" Adverse Reactions                   Patients With Refractory or Intolerant",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,doxil,92,2089,2098,AIDS-Related Kaposi's Sarcoma(n=77 [note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,doxil,93,2098,2153,"This includes a subset of subjects who were retrospectively identified as having disease progression on prior systemic combination chemotherapy (at least 2 cycles of a regimen containing at least 2 of 3 treatments: bleomycin, vincristine or vinblastine, or doxorubicin) or as being intolerant to such therapy.] )  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,doxil,94,2153,2165,Total Patients With AIDS-Related Kaposi's Sarcoma(n=705 [note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,doxil,95,2165,2187,This includes only subjects with  notaecandidateindication who had available adverse event data from the 4 pooled trials.] )   ,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
96,doxil,96,2187,2205,"\n"", '  \n', '  oselabeledaefromdruguse                                             18%                                17%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,doxil,97,2205,2218,"\n', '  oselabeledaefromdruguse                                           7%                                 10%                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,doxil,98,2218,2231,"\n', '  oselabeledaefromdruguse                                              8%                                 9%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,doxil,99,2231,2257,"\n', '  oselabeledaefromdruguse                                           9%                                 9%                   \n', '  oselabeledaefromdruguse                     1.3%                                8%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,doxil,100,2257,2277,"\n', '  oselabeledaefromdruguse                                           8%                                 8%                   \n', '  oselabeledaefromdruguse                                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,doxil,101,2277,2283,5%                                 8%                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,doxil,102,2283,2309,"\n', '  oselabeledaefromdruguse                                         5%                                 7%                   \n', '  oselabeledaefromdruguse                                   1.3%                                6%                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,doxil,103,2309,2364,"\n', '         The following additional adverse reactions were observed in 705 patients with  notaecandidateindication \n', ' \n', '\n', '   Incidence 1% to 5%\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
104,doxil,104,2364,2413,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
105,doxil,105,2413,2456,"', '\n', '    nonoseaeaeonlyasinstruction    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '   Other:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '   ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,doxil,106,2456,2501,"Incidence Less Than 1%\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,doxil,107,2501,2513,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
108,doxil,108,2513,2525,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,doxil,109,2525,2540,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,doxil,110,2540,2553,"', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,doxil,111,2553,2576,"\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
112,doxil,112,2576,2623,"Patients With Multiple Myeloma\n', '\n', ' The safety data described are from 318 patients treated with DOXIL (30 mg/m  2  ) administered on day 4 following bortezomib (1.3 mg/m  2  i.v.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,doxil,113,2623,2653,"bolus on days 1, 4, 8 and 11) every 3 weeks, in a randomized, open-label, multicenter study (Trial 6).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,doxil,114,2653,2683,"In this trial, patients in the DOXIL + bortezomib combination group were treated for a median number of 4.5 months (range 21 days to 13.5 months).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,doxil,115,2683,2717,"The population was 28 to 85 years of age (median age 61), 58% male, 90% Caucasian, 6% Black, and 4% Asian and Other.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,doxil,116,2717,2769,"Table 7 lists adverse reactions reported in 10% or more of patients treated with DOXIL in combination with bortezomib for  notaecandidateindication \n', '\n', ' Table 7: Frequency of Treatment-Emergent Adverse Reactions Reported in >=10% Patients Treated for Multiple Myeloma",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
117,doxil,117,2769,2805,"With DOXIL in Combination With Bortezomib \n', ' Adverse Reaction                          DOXIL + bortezomib(n=318)  Bortezomib(n=318)   \n', '                                               Any (%)         Grade 3-4         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,doxil,118,2805,2836,"Any (%)         Grade 3-4      \n', '  \n', '    nonoseaegeneralterm                                                                         \n', '  oselabeledaefromdruguse                                     36               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
119,doxil,119,2836,2838,32               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,doxil,120,2838,2840,22               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,doxil,121,2840,2842,16          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,doxil,122,2842,2849,"\n', '  oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,doxil,123,2849,2851,33               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,doxil,124,2851,2864,"24               28               17          \n', '  oselabeledaefromdruguse                                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,doxil,125,2864,2866,25                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,doxil,126,2866,2903,"9               21                9          \n', '    nonoseaegeneralterm                                                                         \n', '  oselabeledaefromdruguse                                         36                7               28                3          \n', '  oselabeledaefromdruguse                                         31                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,doxil,127,2903,2929,"1               22                1          \n', '  oselabeledaefromdruguse                                        22                6               18                4          \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,doxil,128,2929,2931,nonoseaegeneralterm                                                                                   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
129,doxil,129,2931,2970,"\n', '  oselabeledaefromdruguse                                          48                3               40                1          \n', '  oselabeledaefromdruguse                                        46                7               39                5          \n', '  oselabeledaefromdruguse                                        32                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,doxil,130,2970,3024,"4               22                1          \n', '  oselabeledaefromdruguse                                    31                1               31                1          \n', '  oselabeledaefromdruguse  oselabeledaefromdruguse                            20                2                5               <1          \n', '  oselabeledaefromdruguse                                  11                1                8                1          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,doxil,131,3024,3031,"\n', '    nonoseaegeneralterm                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
132,doxil,132,3031,3046,"\n', '  oselabeledaefromdruguse                                   11                2                9                2          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,doxil,133,3046,3068,"\n', '  oselabeledaefromdruguse                                  10                0                6                1          \n', '    nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
134,doxil,134,3068,3083,"\n', '  oselabeledaefromdruguse                                12                0                4                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,doxil,135,3083,3103,"\n', '    nonoseaegeneralterm                                                                         \n', '  oselabeledaefromdruguse                                        19                2               14               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,doxil,136,3103,3146,"<1          \n', '    nonoseaegeneralterm                                                                                     \n', '  oselabeledaefromdruguse [note:  oselabeledaefromdruguse includes the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse NOS.]         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
137,doxil,137,3146,3159,"42                7               45               11          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,doxil,138,3159,3180,"oselabeledaefromdruguse                                       17                3               20                4          \n', '  oselabeledaefromdruguse  oselabeledaefromdruguse                         13               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,doxil,139,3180,3187,<1               10                0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,doxil,140,3187,3222,"\n', '    nonoseaegeneralterm                                                                         \n', '  oselabeledaefromdruguse                                           18                0               12                0          \n', '    nonoseaegeneralterm                                                                         \n', '  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
141,doxil,141,3222,3253,[note:  oselabeledaefromdruguse includes the following adverse reactions:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse generalized.]         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,doxil,142,3253,3255,22                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,doxil,143,3255,3266,"1               18                1          \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,doxil,144,3266,3272,oselabeledaefromdruguse                              19                6               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,doxil,145,3272,3304,"<1                0          \n', '             6.2 Postmarketing Experience\n', '   The following additional adverse reactions have been identified during post approval use of DOXIL.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,doxil,146,3304,3386,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse (in some cases  nonoseaegeneralterm \n', '\n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
147,doxil,147,3386,3392,"\n', '    oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,doxil,148,3392,3393,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,doxil,149,3393,3404,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,doxil,150,3404,3422,"WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS\n', '\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,doxil,151,3422,3429,CARDIOMYOPATHY and INFUSION-RELATED REACTIONS  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,doxil,152,3429,3438,"\n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,doxil,153,3438,3470,*  DOXIL (doxorubicin HCl liposome injection) can cause  oselabeledaefromdruguse  including  oselabeledaefromdruguse  as the total cumulative dose of doxorubicin HCl approaches 550 mg/m2.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,doxil,154,3470,3509,"In a clinical study of 250 patients with advanced  notaecandidateindication who were treated with DOXIL, the risk of  oselabeledaefromdruguse was 11% when the cumulative anthracycline dose was between 450-550 mg/m2.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
155,doxil,155,3509,3526,Prior use of other anthracyclines or anthracenediones should be included in calculations of total cumulative dosage.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,doxil,156,3526,3554,The risk of  oselabeledaefromdruguse may be increased at lower cumulative doses in patients with prior mediastinal irradiation [see Warnings and Precautions (5.1)].,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,doxil,157,3554,3608,"\n', ' *   oselabeledaefromdruguse consisting of, but not limited to,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse chest or  oselabeledaefromdruguse  oselabeledaefromdruguse or throat, and/or  oselabeledaefromdruguse occurred in 11% of patients with  notaecandidateindication treated with DOXIL.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
158,doxil,158,3608,3619,"Serious, life-threatening and  nonoseaegeneralterm  oselabeledaefromdruguse    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
159,doxil,159,3619,3643,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *  Hand-Foot Syndrome may occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,doxil,160,3643,3652,Dose modification or discontinuation may be required (  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,doxil,161,3652,3655,5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,doxil,162,3655,3659,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,doxil,163,3659,3669,*  Embryofetal Toxicity: Can cause fetal harm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,doxil,164,3669,3677,Advise of potential risk to a fetus.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,doxil,165,3677,3693,"Use effective contraception (  5.5  ,  8.1  ,  8.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,doxil,166,3693,3733,"\n', '    \n', ' \n', '\n', '   5.1 Cardiomyopathy\n', '\n', '  Doxorubicin HCl can result in  oselabeledaefromdruguse  including  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,doxil,167,3733,3749,The risk of  oselabeledaefromdruguse with doxorubicin HCl is generally proportional to the cumulative exposure.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,doxil,168,3749,3815,"The relationship between cumulative DOXIL dose and the risk of  nonoseaeaeonlyasinstruction has not been determined.\n', '\n', ' In a clinical study in 250 patients with advanced  notaecandidateindication who were treated with DOXIL, the risk of  oselabeledaefromdruguse was 11% when the cumulative anthracycline dose was between 450-550 mg/m  2  .  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
169,doxil,169,3815,3852,nonoseaeaeonlyasinstruction was defined as  nonoseaemanifestationorcomplication  from baseline where LVEF remained in the normal range or a >10%  nonoseaemanifestationorcomplication from baseline where LVEF was less than the institutional lower limit of normal.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
170,doxil,170,3852,3910,"Two percent of patients developed signs and symptoms of  oselabeledaefromdruguse without documented evidence of  nonoseaenegation \n', '\n', ' Assess left ventricular cardiac function (e.g. MUGA or echocardiogram) prior to initiation of DOXIL, during treatment to detect acute changes, and after treatment to detect delayed  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
171,doxil,171,3910,4021,"Administer DOXIL to patients with a history of  notaecandidatepreexistingconditionorriskfactor only when the potential benefit of treatment outweighs the risk.\n', '\n', '    5.2 Infusion-Related Reactions\n', '\n', '  Serious and sometimes life-threatening  oselabeledaefromdruguse characterized by one or more of the following symptoms can occur with DOXIL:  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication chest and  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and throat,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  ",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
172,doxil,172,4021,4032,The majority of  oselabeledaefromdruguse occurred during the first infusion.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,doxil,173,4032,4058,"Of 239 patients with  notaecandidateindication treated with DOXIL in Trial 4, 7% of patients experienced acute  oselabeledaefromdruguse resulting in dose interruption.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
174,doxil,174,4058,4069,All occurred during cycle 1 and none during subsequent cycles.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,doxil,175,4069,4095,Across multiple studies of DOXIL monotherapy including this and other studies enrolling 760 patients with various  notaecandidateindication  11% of patients had  oselabeledaefromdruguse,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
176,doxil,176,4095,4125,"\n', '\n', ' Ensure that medications to treat  nonoseaeaeonlyasinstruction and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation of DOXIL.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,doxil,177,4125,4154,Initiate DOXIL infusions at a rate of 1 mg/min and increase rate as tolerated [see  Dosage and Administration (2.6)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,doxil,178,4154,4176,In the event of an  nonoseaeaeonlyasinstruction  temporarily stop the drug until resolution then resume at a reduced infusion rate.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,doxil,179,4176,4199,"Discontinue DOXIL infusion for serious or life-threatening  nonoseaeaeonlyasinstruction \n', '\n', '    5.3  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,doxil,180,4199,4266,"\n', '\n', '  In Trial 4, the incidence of  oselabeledaefromdruguse was 51% of patients in the DOXIL arm and 0.9% of patients in the topotecan arm, including 24% Grade 3 or 4 cases of  oselabeledaefromdruguse in DOXIL-treated patients and no Grade 3 or 4 cases in topotecan-treated patients.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,doxil,181,4266,4304,"oselabeledaefromdruguse or other  oselabeledaefromdruguse required discontinuation of DOXIL in 4.2% of patients.\n', '\n', '  oselabeledaefromdruguse was generally observed after 2 or 3 cycles of treatment but may occur earlier.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,doxil,182,4304,4317,Delay DOXIL for the first episode of Grade 2 or greater  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,doxil,183,4317,4330,[see  Dosage and Administration (2.5)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,doxil,184,4330,4389,"Discontinue DOXIL if  nonoseaeaeonlyasinstruction is severe and debilitating.\n', '\n', '    5.4 Secondary Oral Neoplasms\n', '\n', '   oselabeledaefromdruguse  primarily  oselabeledaefromdruguse  have been reported from post-marketing experience in patients with long-term (more than one year) exposure to DOXIL.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,doxil,185,4389,4409,These  oselabeledaefromdruguse were diagnosed both during treatment with DOXIL and up to 6 years after the last dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,doxil,186,4409,4490,"Examine patients at regular intervals for the presence of  nonoseaemanifestationorcomplication or with any  nonoseaemanifestationorcomplication that may be indicative of secondary  nonoseaeaeonlyasinstruction \n', '\n', ' The altered pharmacokinetics and preferential tissue distribution of liposomal doxorubicin that contributes to enhanced  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction compared to free doxorubicin may play a role in the development of  nonoseaeaeonlyasinstruction with long-term use.\n', '\n', '    5.5  oselabeledaefromdruguse",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
187,doxil,187,4490,4513,"\n', '  Based on animal data, DOXIL can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
188,doxil,188,4513,4533,"At doses approximately 0.12 times the recommended clinical dose, DOXIL was  nonoseaeaeanimal and  nonoseaeaeanimal in rabbits.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
189,doxil,189,4533,4544,Advise  notaecandidatepreexistingconditionorriskfactor women of the potential  oselabeledaefromdruguse '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,istodax,0,0,70,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are described in more detail in other sections of the prescribing information.\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,istodax,1,70,83,"Warnings and Precautions (5.2)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,istodax,2,83,122,"*   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,istodax,3,122,125,EXCERPT:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,istodax,4,125,201,"The most common adverse reactions were neutropenia, lymphopenia, thrombocytopenia, infections, nausea, fatigue, vomiting, anorexia, anemia, and ECG T-wave changes (  6  ).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,istodax,5,201,238,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,istodax,6,238,300,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', '   notaecandidateindication   ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
7,istodax,7,300,334,The safety of ISTODAX was evaluated in 185 patients with  notaecandidateindication in 2 single arm clinical studies in which patients received a starting dose of 14 mg/m  2  .,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
8,istodax,8,334,424,"The mean duration of treatment in these studies was 5.6 months (range: <1 to 83.4 months).\n', '\n', '\n', '\n', '   \n', '\n', '  Common Adverse Reactions\n', '\n', '\n', '\n', ' Table 1 summarizes the most frequent adverse reactions (> 20%) regardless of causality using the National Cancer Institute-Common Terminology Criteria for Adverse Events",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,istodax,9,424,433,"(NCI-CTCAE, Version 3.0).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,istodax,10,433,454,"Due to methodological differences between the studies, the AE data are presented separately for Study 1 and Study 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,istodax,11,454,466,Adverse reactions are ranked by their incidence in Study 1.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,istodax,12,466,486,"nonoseaegeneralterm commonly reported (> 20%) as adverse reactions are included in Table 1.\n', '\n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
13,istodax,13,486,500,"', '\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,istodax,14,500,514,Adverse Reactions Occurring in >20% of Patients in Either CTCL Study (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,istodax,15,514,516,N=185),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,istodax,16,516,536,"\n', '   Adverse Reactions n (%)                   Study 1(n=102)      Study 2(n=83)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,istodax,17,536,544,"\n', '   All grades                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,istodax,18,544,549,Grade 3 or 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,istodax,19,549,613,"All grades       Grade 3 or 4     \n', '   Any adverse reaction                        99 (97)          36 (35)         83 (100)          68 (82)       \n', '  oselabeledaefromdruguse                                        57 (56)           3 (3)           71 (86)           5 (6)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,istodax,20,613,623,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse                              54",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,istodax,21,623,628,(53)           8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,istodax,22,628,636,(8)           64 (77)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,istodax,23,636,641,12 (14)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,istodax,24,641,649,"\n', '  oselabeledaefromdruguse                                    47",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,istodax,25,649,658,(46)          11 (11)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,istodax,26,658,668,45 (54)          27 (33)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,istodax,27,668,675,"\n', '  oselabeledaefromdruguse                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,istodax,28,675,696,35 (34)          1 (<1)           43 (52)          8 (10)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,istodax,29,696,732,"\n', '  oselabeledaefromdruguse                                      23 (23)          1 (<1)           45 (54)           3 (4)        \n', '  oselabeledaefromdruguse                                22",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,istodax,30,732,738,(22)          1 (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,istodax,31,738,761,"<1)           23 (28)             0          \n', '  oselabeledaefromdruguse                                      20 (20)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,istodax,32,761,777,1 (<1)           22 (27)           1 (1)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,istodax,33,777,831,"\n', '  oselabeledaefromdruguse                                       20 (20)           4 (4)           19 (23)           1 (1)        \n', '  oselabeledaefromdruguse                                        19 (19)           3 (3)           60 (72)          13 (16)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,istodax,34,831,839,"\n', '  oselabeledaefromdruguse                              17",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,istodax,35,839,845,(17)             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,istodax,36,845,846,54,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,istodax,37,846,855,(65)          12 (14)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,istodax,38,855,869,"\n', '  oselabeledaefromdruguse                                     15 (15)             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,istodax,39,869,870,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,istodax,40,870,876,(40)             0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,istodax,41,876,884,"\n', '  oselabeledaefromdruguse                                  12",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,istodax,42,884,930,"(12)           2 (2)           32 (39)           1 (1)        \n', '  oselabeledaefromdruguse                                   11 (11)           4 (4)           47 (57)          22 (27)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,istodax,43,930,957,"\n', '  oselabeledaefromdruguse                                    7 (7)            3 (3)           19 (23)           3 (4)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,istodax,44,957,971,"\n', '  oselabeledaefromdruguse                                       7 (7)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,istodax,45,971,981,26 (31)           5 (6)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,istodax,46,981,995,"\n', '  oselabeledaefromdruguse                                    6 (6)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,istodax,47,995,1005,17 (20)           2 (2)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,istodax,48,1005,1034,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse              4 (4)           1 (<1)           22 (27)           7 (8)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,istodax,49,1034,1048,"\n', '  oselabeledaefromdruguse                                   4 (4)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,istodax,50,1048,1053,43 (52)           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,istodax,51,1053,1054,5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,istodax,52,1054,1072,"(6)        \n', '  oselabeledaefromdruguse                                     4 (4)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,istodax,53,1072,1082,38 (46)          18 (22)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,istodax,54,1082,1090,"\n', '  oselabeledaefromdruguse                                    4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,istodax,55,1090,1096,(4)              0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,istodax,56,1096,1106,47 (57)          31 (37)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,istodax,57,1106,1120,"\n', '  oselabeledaefromdruguse             3 (3)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,istodax,58,1120,1121,18,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,istodax,59,1121,1144,"(22)           2 (2)        \n', '  oselabeledaefromdruguse           3 (3)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,istodax,60,1144,1145,23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,istodax,61,1145,1154,(28)           3 (4)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,istodax,62,1154,1162,"\n', '  oselabeledaefromdruguse                                3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,istodax,63,1162,1182,(3)           1 (<1)           40 (48)           3 (4)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,istodax,64,1182,1196,"\n', '  oselabeledaefromdruguse            2 (2)              0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,istodax,65,1196,1203,52 (63)             0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,istodax,66,1203,1230,"\n', '  oselabeledaefromdruguse                                  2 (2)            2 (2)           42 (51)           1 (1)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,istodax,67,1230,1296,"\n', '  oselabeledaefromdruguse                                  1 (<1)           1 (<1)           17 (20)           2 (2)        \n', '  oselabeledaefromdruguse                                  0                0             22 (27)           7 (8)        \n', '  oselabeledaefromdruguse                                 0                0             22 (27)          8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,istodax,68,1296,1311,"(10)        \n', '  oselabeledaefromdruguse                                    0                0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,istodax,69,1311,1317,27 (33)           7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,istodax,70,1317,1320,(8)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,istodax,71,1320,1411,"\n', '             \n', '   Serious Adverse Reactions\n', '\n', '\n', '\n', '  oselabeledaefromdruguse were the most common type of SAE reported in both studies with 8 patients (8%) in Study 1 and 26 patients (31%) in Study 2 experiencing a serious  oselabeledaefromdruguse  Serious adverse reactions reported in > 2% of patients in Study 1 were  oselabeledaefromdruguse and  oselabeledaefromdruguse (3%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,istodax,72,1411,1433,"In Study 2, serious adverse reactions in > 2% of patients were  oselabeledaefromdruguse (7%),  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,istodax,73,1433,1503,"oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (6%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (5%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse (4%).\n', '\n', '\n', '\n', ' Most  nonoseaegeneralterm were due to disease progression.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,istodax,74,1503,1543,"In Study 1, there were two  nonoseaegeneralterm due to  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction  In Study 2, there were six  nonoseaegeneralterm due to  nonoseaeaeonlyasinstruction (4),  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
75,istodax,75,1543,1607,"\n', '\n', '\n', '\n', '   \n', '\n', '  Discontinuations\n', '\n', '\n', '\n', ' Discontinuation due to an adverse event occurred in 21% of patients in Study 1 and 11% in Study 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,istodax,76,1607,1655,"Discontinuations occurring in at least 2% of patients in either study included  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '   Peripheral T-Cell Lymphoma  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,istodax,77,1655,1721,"\n', '\n', '\n', '\n', ' The safety of ISTODAX was evaluated in 178 patients with  notaecandidateindication in a sponsor-conducted pivotal study (Study 3) and a secondary NCI-sponsored study (Study 4) in which patients received a starting dose of 14 mg/m  2  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
78,istodax,78,1721,1808,"The mean duration of treatment and number of cycles were 5.6 months and 6 cycles in Study 3 and 9.6 months and 8 cycles in Study 4.\n', '\n', '\n', '\n', ' Common Adverse Reactions\n', '\n', '\n', '\n', ' Table 2 summarizes the most frequent adverse reactions (>= 10%) regardless of causality, using the NCI-CTCAE, Version 3.0.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,istodax,79,1808,1822,The AE data are presented separately for Study 3 and Study 4.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,istodax,80,1822,1857,"nonoseaegeneralterm commonly reported (>= 10%) as adverse reactions are included in Table 2.\n', '\n', '\n', '\n', ' Table 2.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,istodax,81,1857,1881,Adverse Reactions Occurring in >=10% of Patients with PTCL in Study 3 and Corresponding Incidence in Study 4 (N=178),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,istodax,82,1881,1893,"\n', '   Adverse Reactions n (%)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,istodax,83,1893,1897,Study 3(N=131)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,istodax,84,1897,1901,Study 4(N=47)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,istodax,85,1901,1965,"\n', ' All grades                                  Grade 3 or 4      All grades       Grade 3 or 4     \n', '   Any adverse reactions                      128 (97)          88 (67)         47 (100)          40 (85)       \n', '  nonoseaegeneralterm                                                                                     \n', '      oselabeledaefromdruguse                                    77",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
86,istodax,86,1965,1984,(59)           3 (2)           35 (75)           3 (6)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,istodax,87,1984,2038,"\n', '      oselabeledaefromdruguse                                  51 (39)           6 (5)           19 (40)           4 (9)        \n', '      oselabeledaefromdruguse                                  47 (36)           3 (2)           17 (36)           1 (2)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,istodax,88,2038,2046,"\n', '      oselabeledaefromdruguse                              39",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,istodax,89,2046,2052,(30)          1 (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,istodax,90,2052,2093,"<1)           19 (40)           1 (2)        \n', '      oselabeledaefromdruguse                            18 (14)           3 (2)           6 (13)            1 (2)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,istodax,91,2093,2096,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,istodax,92,2096,2121,"'      oselabeledaefromdruguse                                14 (11)             0              3 (6)              0          \n', '  nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
93,istodax,93,2121,2176,"\n', '      oselabeledaefromdruguse  oselabeledaefromdruguse                          72 (55)          11 (8)           36 (77)          9 (19)        \n', '      oselabeledaefromdruguse                                   46 (35)           8 (6)           22 (47)          8 (17)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,istodax,94,2176,2184,"\n', '      oselabeledaefromdruguse                                    14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,istodax,95,2184,2190,(11)          1 (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,istodax,96,2190,2201,<1)           8 (17)              0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,istodax,97,2201,2233,"\n', '      oselabeledaefromdruguse                          13 (10)          1 (<1)            3 (6)              0          \n', '  nonoseaegeneralterm                                                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
98,istodax,98,2233,2245,"\n', '      oselabeledaefromdruguse                          53 (41)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,istodax,99,2245,2260,32 (24)          34 (72)          17 (36)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,istodax,100,2260,2273,"\n', '      oselabeledaefromdruguse                               39 (30)          26",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,istodax,101,2273,2282,(20)          31 (66)          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,istodax,102,2282,2283,22,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,istodax,103,2283,2287,(47)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,istodax,104,2287,2295,"\n', '      oselabeledaefromdruguse                                    33",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,istodax,105,2295,2314,(25)          14 (11)          29 (62)          13 (28)       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,istodax,106,2314,2341,"\n', '      oselabeledaefromdruguse                                16 (12)           8 (6)           26 (55)          21 (45)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,istodax,107,2341,2348,"\n', '  nonoseaegeneralterm                                                                             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
108,istodax,108,2348,2383,"\n', '      oselabeledaefromdruguse                                  37 (28)           2 (2)           21 (45)           1 (2)        \n', '      oselabeledaefromdruguse                               14",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,istodax,109,2383,2402,(11)           3 (2)           8 (17)            1 (2)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,istodax,110,2402,2423,"\n', '  nonoseaegeneralterm                                                                                       \n', '      oselabeledaefromdruguse                                 27 (21)             0             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,istodax,111,2423,2426,13 (28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,istodax,112,2426,2430,)             0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,istodax,113,2430,2444,"\n', '      oselabeledaefromdruguse                                  19 (15)             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,istodax,114,2444,2445,16,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,istodax,115,2445,2461,"(34)           1 (2)        \n', '  nonoseaegeneralterm                                                                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,istodax,116,2461,2475,"\n', '      oselabeledaefromdruguse                                     23 (18)             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,istodax,117,2475,2478,10 (21,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,istodax,118,2478,2482,)             0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,istodax,119,2482,2516,"\n', '      oselabeledaefromdruguse                                   17 (13)           3 (2)           10 (21)           2 (4)        \n', '  nonoseaegeneralterm                                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,istodax,120,2516,2530,"\n', '      oselabeledaefromdruguse                          14 (11)             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,istodax,121,2530,2537,7 (15)              0          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,istodax,122,2537,2544,"\n', '  nonoseaegeneralterm                                                                                              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,istodax,123,2544,2562,"\n', '      oselabeledaefromdruguse                               13 (10)             0                0                0          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,istodax,124,2562,2592,"\n', '           Serious Adverse Reactions\n', ' \n', '\n', '  oselabeledaefromdruguse were the most common type of SAE reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,istodax,125,2592,2623,"In Study 3, 26 patients (20%) experienced a serious  oselabeledaefromdruguse  including 6 patients (5%) with serious treatment-related  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,istodax,126,2623,2677,"In Study 4, 11 patients (23%) experienced a serious  oselabeledaefromdruguse  including 8 patients (17%) with serious treatment-related  oselabeledaefromdruguse  Serious adverse reactions reported in >= 2% of patients in Study 3 were  oselabeledaefromdruguse (8%),  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,istodax,127,2677,2723,"oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (5%),  oselabeledaefromdruguse   oselabeledaefromdruguse  (4%),  oselabeledaefromdruguse   oselabeledaefromdruguse (3%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,istodax,128,2723,2876,"In Study 4, serious adverse reactions in >= 2 patients were  oselabeledaefromdruguse (17%),  oselabeledaefromdruguse   oselabeledaefromdruguse (13%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (11%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (9%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (6%),  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  packed red blood cell transfusion, and platelet transfusion (4%).\n', '\n', '\n', '\n', '  oselabeledaefromdruguse has occurred in 1% of patients with  notaecandidateindication patients in clinical trials in Western population enrolled in Study 3 and Study 4  [see  Warnings and Precautions (5.2)  ].  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
129,istodax,129,2876,2925,"\n', '\n', '\n', '\n', '  nonoseaegeneralterm due to all causes within 30 days of the last dose of ISTODAX occurred in 7% of patients in Study 3 and 17% of patients in Study 4.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
130,istodax,130,2925,2963,"In Study 3, there were 5  nonoseaegeneralterm unrelated to disease progression that were due to  nonoseaeaeonlyasinstruction  including  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  oselabeledaefromdruguse  nonoseaeaeonlyasinstruction  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
131,istodax,131,2963,3015,"In Study 4, there were 3  nonoseaegeneralterm unrelated to disease progression that were due to  oselabeledaefromdruguse   nonoseaeaeonlyasinstruction in the setting of  nonoseaeaeonlyasinstruction  and  nonoseaegeneralterm of unknown cause.\n', '\n', '\n', '\n', '   Discontinuations  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
132,istodax,132,3015,3056,"\n', '\n', '\n', '\n', ' Discontinuation due to an adverse event occurred in 19% of patients in Study 3 and in 28% of patients in Study 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,istodax,133,3056,3081,"In Study 3,  oselabeledaefromdruguse and  oselabeledaefromdruguse were the only events leading to treatment discontinuation in at least 2% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,istodax,134,3081,3113,"In Study 4, events leading to treatment discontinuation in >= 2 patients were  oselabeledaefromdruguse (11%),  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse     5",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,istodax,135,3113,3175,"WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Myelosuppression: ISTODAX can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia; monitor blood counts during treatment with ISTODAX; interrupt and/or modify the dose as necessary (  2.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,istodax,136,3175,3183,"\n', ' *  Infections:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,istodax,137,3183,3188,Fatal and serious infections.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,istodax,138,3188,3200,Reactivation of DNA viruses (Epstein Barr and hepatitis B).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,istodax,139,3200,3218,Consider monitoring and prophylaxis in patients with evidence of prior hepatitis B (  5.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,istodax,140,3218,3260,"\n', ' *  Electrocardiographic (ECG) changes: Consider cardiovascular monitoring in patients with congenital long QT syndrome, a history of significant cardiovascular disease, and patients taking medicinal products that lead to significant QT prolongation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,istodax,141,3260,3280,Ensure that potassium and magnesium are within the normal range before administration of ISTODAX (  5.3  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,istodax,142,3280,3318,"\n', ' *  Tumor lysis syndrome: Patients with advanced stage disease and/or high tumor burden are at greater risk and should be closely monitored and appropriate precautions taken (  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,istodax,143,3318,3341,"\n', ' *  Embryo-fetal toxicity: ISTODAX may cause fetal harm when administered to a pregnant woman.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,istodax,144,3341,3366,"Advise women of potential hazard to the fetus and to avoid pregnancy while receiving ISTODAX (  5.5  ,  8.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,istodax,145,3366,3387,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,istodax,146,3387,3455,"\n', '\n', '\n', '  Treatment with ISTODAX can cause  oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse and  oselabeledaefromdruguse , and  oselabeledaefromdruguse  Monitor blood counts regularly during treatment with ISTODAX, and modify the dose as necessary [see  Dosage and Administration (2.2)  and  Adverse Reactions (6)  ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,istodax,147,3455,3531,"\n', '\n', '\n', '\n', '    5.2 Infections\n', '\n', '\n', '\n', '    nonoseaegeneralterm and serious  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse  oselabeledaefromdruguse  including Epstein Barr and  oselabeledaefromdruguse viruses, have been reported in clinical trials with ISTODAX.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
148,istodax,148,3531,3543,These can occur during treatment and within 30 days after treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,istodax,149,3543,3585,The risk of life threatening infections may be greater in patients with a history of prior treatment with monoclonal antibodies directed against lymphocyte antigens and in patients with  notaecandidatepreexistingconditionorriskfactor [see  Adverse Reactions (6)  ].    ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
150,istodax,150,3585,3630,"\n', '\n', '\n', '\n', '   oselabeledaefromdruguse has occurred in 1% of  notaecandidateindication patients in clinical trials in Western populations [see  Adverse Reactions (6)  ]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
151,istodax,151,3630,3650,"In patients with evidence of prior  notaecandidatepreexistingconditionorriskfactor  consider monitoring for reactivation, and consider antiviral prophylaxis.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
152,istodax,152,3650,3765,"\n', '\n', '\n', '\n', '   oselabeledaefromdruguse of  oselabeledaefromdruguse leading to  nonoseaemanifestationorcomplication has occurred in a trial of patients with relapsed or refractory extranodal NK/ notaecandidateindication  In one case, ganciclovir prophylaxis failed to prevent  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '    5.3 Electrocardiographic Changes\n', '\n', '\n', '\n', '  Several treatment-emergent morphological  oselabeledaefromdruguse (including  oselabeledaefromdruguse and ST-segment  oselabeledaefromdruguse  oselabeledaefromdruguse  have been reported in clinical studies.",1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
153,istodax,153,3765,3785,The clinical significance of these changes is unknown [see  Adverse Reactions (6)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,istodax,154,3785,3873,"\n', '\n', '\n', '\n', ' In patients with  notaecandidatepreexistingconditionorriskfactor  patients with a history of significant  notaecandidatepreexistingconditionorriskfactor  and patients taking anti-arrhythmic medicines or medicinal products that lead to significant  nonoseaeaeonlyasinstruction  consider cardiovascular monitoring of ECGs at baseline and periodically during treatment.\n', '\n', '\n', '\n', ' Confirm that potassium and magnesium levels are within normal range before administration of ISTODAX",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
155,istodax,155,3873,3885,[see  Adverse Reactions (6)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,istodax,156,3885,4030,"\n', '\n', '\n', '\n', '    5.4 Tumor Lysis Syndrome\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  has been reported to occur in 1% of patients with  notaecandidatepreexistingconditionorriskfactor stage  notaecandidateindication and 2% of patients with Stage III/IV  notaecandidateindication  Patients with advanced stage disease and/or high  notaecandidatepreexistingconditionorriskfactor burden may be at greater risk, should be closely monitored, and managed as appropriate.\n', '\n', '\n', '\n', '    5.5 Use in Pregnancy\n', '\n', '\n', '\n', '  There are no adequate and well-controlled studies of ISTODAX in  notaecandidatepreexistingconditionorriskfactor women.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
157,istodax,157,4030,4056,"However, based on its mechanism of action and findings in animals, ISTODAX may cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
158,istodax,158,4056,4092,"In an animal reproductive study, romidepsin was  nonoseaeaeanimal and resulted in adverse  nonoseaeaeanimal at exposures below those in patients at the recommended dose of 14 mg/m  2  /week.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
159,istodax,159,4092,4124,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while taking ISTODAX, the patient should be apprised of the potential  oselabeledaefromdruguse ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,singulair,0,0,120,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse reactions (incidence >=5% and greater than placebo listed in descending order of frequency): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis (  6.1  ).\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,singulair,1,120,149,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,singulair,2,149,195,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,singulair,3,195,272,"In the following description of clinical trials experience, adverse reactions are listed regardless of causality assessment.\n', '\n', ' The most common adverse reactions (incidence >=5% and greater than placebo; listed in descending order of frequency) in controlled clinical trials were:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,singulair,4,272,324,"\n', '\n', '   Adults and Adolescents 15 Years of Age and Older with Asthma  \n', '\n', ' SINGULAIR has been evaluated for safety in approximately 2950 adult and adolescent patients 15 years of age and older in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,singulair,5,324,429,"In placebo-controlled clinical trials, the following adverse experiences reported with SINGULAIR occurred in greater than or equal to 1% of patients and at an incidence greater than that in patients treated with placebo:\n', '\n', ' Table 1: Adverse Experiences Occurring in >=1% of Patients with an Incidence Greater than that in Patients Treated with Placebo \n', '                                          SINGULAIR 10 mg/day(%)(n=1955)        Placebo(%)(n=1180)         \n', '  \n', '    nonoseaegeneralterm       oselabeledaefromdruguse   oselabeledaefromdruguse     oselabeledaefromdruguse  oselabeledaefromdruguse     oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
6,singulair,6,429,433,oselabeledaefromdruguse           2.91.81.51.0                    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,singulair,7,433,435,2.51.20.90.8            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,singulair,8,435,454,"\n', '    nonoseaegeneralterm       oselabeledaefromdruguse     oselabeledaefromdruguse   oselabeledaefromdruguse     oselabeledaefromdruguse   oselabeledaefromdruguse            2.11.71.5                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
9,singulair,9,454,456,1.11.00.5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,singulair,10,456,467,"\n', '    nonoseaegeneralterm       oselabeledaefromdruguse     oselabeledaefromdruguse             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
11,singulair,11,467,469,18.41.9                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,singulair,12,469,471,18.11.4               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,singulair,13,471,486,"\n', '    nonoseaegeneralterm       oselabeledaefromdruguse     oselabeledaefromdruguse     oselabeledaefromdruguse   oselabeledaefromdruguse            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
14,singulair,14,486,488,4.22.71.6                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,singulair,15,488,490,3.92.41.3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,singulair,16,490,499,"\n', '    nonoseaegeneralterm       oselabeledaefromdruguse               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,singulair,17,499,542,"1.6                             1.2                 \n', '    nonoseaegeneralterm   [note: Number of patients tested (SINGULAIR and placebo, respectively): ALT and AST, 1935, 1170;  oselabeledaefromdruguse  1924, 1159.]      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,singulair,18,542,550,oselabeledaefromdruguse     oselabeledaefromdruguse     oselabeledaefromdruguse            2.11.61.0                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,singulair,19,550,552,2.01.20.9              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,singulair,20,552,655,"\n', '         The frequency of less common adverse events was comparable between SINGULAIR and placebo.\n', ' \n', '\n', ' The safety profile of SINGULAIR, when administered as a single dose for prevention of  notaecandidateindication in adult and adolescent patients 15 years of age and older, was consistent with the safety profile previously described for SINGULAIR.\n', '\n', ' Cumulatively, 569 patients were treated with SINGULAIR for at least 6 months, 480 for one year, and 49 for two years in clinical trials.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
21,singulair,21,655,711,"With prolonged treatment, the adverse experience profile did not significantly change.\n', '\n', '   Pediatric Patients 6 to 14 Years of Age with Asthma  \n', '\n', ' SINGULAIR has been evaluated for safety in 476 pediatric patients 6 to 14 years of age.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,singulair,22,711,737,"Cumulatively, 289 pediatric patients were treated with SINGULAIR for at least 6 months, and 241 for one year or longer in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,singulair,23,737,762,"The safety profile of SINGULAIR in the 8-week, double-blind, pediatric efficacy trial was generally similar to the adult safety profile.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,singulair,24,762,819,"In pediatric patients 6 to 14 years of age receiving SINGULAIR, the following events occurred with a frequency >=2% and more frequently than in pediatric patients who received placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,singulair,25,819,833,The frequency of less common adverse events was comparable between SINGULAIR and placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,singulair,26,833,920,"With prolonged treatment, the adverse experience profile did not significantly change.\n', '\n', ' The safety profile of SINGULAIR, when administered as a single dose for prevention of  notaecandidateindication in pediatric patients 6 years of age and older, was consistent with the safety profile previously described for SINGULAIR.\n', '\n', ' In studies evaluating growth rate, the safety profile in these pediatric patients was consistent with the safety profile previously described for SINGULAIR.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
27,singulair,27,920,1050,"In a 56-week, double-blind study evaluating growth rate in pediatric patients 6 to 8 years of age receiving SINGULAIR, the following events not previously observed with the use of SINGULAIR in this age group occurred with a frequency >=2% and more frequently than in pediatric patients who received placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '   Pediatric Patients 2 to 5 Years of Age with Asthma  \n', '\n', ' SINGULAIR has been evaluated for safety in 573 pediatric patients 2 to 5 years of age in single- and multiple-dose studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,singulair,28,1050,1090,"Cumulatively, 426 pediatric patients 2 to 5 years of age were treated with SINGULAIR for at least 3 months, 230 for 6 months or longer, and 63 patients for one year or longer in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,singulair,29,1090,1162,"In pediatric patients 2 to 5 years of age receiving SINGULAIR, the following events occurred with a frequency >=2% and more frequently than in pediatric patients who received placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,singulair,30,1162,1187,"\n', '\n', '   Pediatric Patients 6 to 23 Months of Age with Asthma  \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,singulair,31,1187,1233,"', ' Safety and effectiveness in pediatric patients younger than 12 months of age with  notaecandidatepreexistingconditionorriskfactor have not been established.\n', '\n', ' SINGULAIR has been evaluated for safety in 175 pediatric patients 6 to 23 months of age.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
32,singulair,32,1233,1270,"The safety profile of SINGULAIR in a 6-week, double-blind, placebo-controlled clinical study was generally similar to the safety profile in adults and pediatric patients 2 to 14 years of age.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,singulair,33,1270,1321,"In pediatric patients 6 to 23 months of age receiving SINGULAIR, the following events occurred with a frequency >=2% and more frequently than in pediatric patients who received placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,singulair,34,1321,1356,"The frequency of less common adverse events was comparable between SINGULAIR and placebo.\n', '\n', '   Adults and Adolescents 15 Years of Age and Older with Seasonal Allergic Rhinitis  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,singulair,35,1356,1386,"\n', '\n', ' SINGULAIR has been evaluated for safety in 2199 adult and adolescent patients 15 years of age and older in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,singulair,36,1386,1407,SINGULAIR administered once daily in the morning or in the evening had a safety profile similar to that of placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,singulair,37,1407,1453,"In placebo-controlled clinical trials, the following event was reported with SINGULAIR with a frequency >=1% and at an incidence greater than placebo:  oselabeledaefromdruguse  1.9% of patients receiving SINGULAIR vs. 1.5% of patients receiving placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,singulair,38,1453,1475,"In a 4-week, placebo-controlled clinical study, the safety profile was consistent with that observed in 2-week studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,singulair,39,1475,1510,"The incidence of  nonoseaeaeratelteqplacebo was similar to that of placebo in all studies.\n', '\n', '   Pediatric Patients 2 to 14 Years of Age with Seasonal Allergic Rhinitis  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
40,singulair,40,1510,1552,"\n', '\n', ' SINGULAIR has been evaluated in 280 pediatric patients 2 to 14 years of age in a 2-week, multicenter, double-blind, placebo-controlled, parallel-group safety study.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,singulair,41,1552,1569,SINGULAIR administered once daily in the evening had a safety profile similar to that of placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,singulair,42,1569,1625,"In this study, the following events occurred with a frequency >=2% and at an incidence greater than placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '   Adults and Adolescents 15 Years of Age and Older with Perennial Allergic Rhinitis  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,singulair,43,1625,1667,"\n', '\n', ' SINGULAIR has been evaluated for safety in 3357 adult and adolescent patients 15 years of age and older with  notaecandidateindication of whom 1632 received SINGULAIR in two, 6-week, clinical studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
44,singulair,44,1667,1691,SINGULAIR administered once daily had a safety profile consistent with that observed in patients with  notaecandidateindication and similar to that of placebo.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
45,singulair,45,1691,1733,"In these two studies, the following events were reported with SINGULAIR with a frequency >=1% and at an incidence greater than placebo:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,singulair,46,1733,1766,"The incidence of  nonoseaeaeratelteqplacebo was similar to that of placebo.\n', '\n', '   Pediatric Patients 6 Months to 14 Years of Age with Perennial Allergic Rhinitis  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
47,singulair,47,1766,1804,"\n', '\n', ' The safety in patients 2 to 14 years of age with  notaecandidateindication is supported by the safety in patients 2 to 14 years of age with  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
48,singulair,48,1804,1873,"The safety in patients 6 to 23 months of age is supported by data from pharmacokinetic and safety and efficacy studies in  notaecandidateindication in this pediatric population and from adult pharmacokinetic studies.\n', '\n', '   6.2 Post-Marketing Experience\n', '\n', '  The following adverse reactions have been identified during post-approval use of SINGULAIR.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
49,singulair,49,1873,1934,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,singulair,50,1934,1999,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse including  oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse thinking and  oselabeledaefromdruguse  oselabeledaefromdruguse and behavior (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,singulair,51,1999,2072,"Warnings and Precautions (5.4)  ]  .\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,singulair,52,2072,2092,"\n', '\n', '  nonoseaegeneralterm  Cases of  oselabeledaefromdruguse   oselabeledaefromdruguse  and  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,singulair,53,2092,2102,oselabeledaefromdruguse have been reported in patients treated with SINGULAIR.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,singulair,54,2102,2170,"Most of these occurred in combination with other confounding factors, such as use of other medications, or when SINGULAIR was administered to patients who had underlying potential for  notaecandidatepreexistingconditionorriskfactor such as alcohol use or other forms of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
55,singulair,55,2170,2187,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse including  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
56,singulair,56,2187,2258,"\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse in children.\n', '\n', '  nonoseaegeneralterm   oselabeledaefromdruguse \n', '\n', ' Patients with  notaecandidateindication on therapy with SINGULAIR may present with  oselabeledaefromdruguse  sometimes presenting with clinical features of  oselabeledaefromdruguse consistent with  oselabeledaefromdruguse  a condition which is often treated with systemic corticosteroid therapy.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
57,singulair,57,2258,2272,These events have been sometimes associated with the reduction of oral corticosteroid therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,singulair,58,2272,2280,Physicians should be alert to  nonoseaemanifestationorcomplication   ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
59,singulair,59,2280,2286,nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
60,singulair,60,2286,2305,"and/or  nonoseaemanifestationorcomplication    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
61,singulair,61,2305,2323,*  Do not prescribe SINGULAIR to treat an acute asthma attack (  5.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,singulair,62,2323,2343,"\n', ' *  Advise patients to have appropriate rescue medication available (  5.1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,singulair,63,2343,2356,"\n', ' *  Inhaled corticosteroid may be reduced gradually.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,singulair,64,2356,2372,Do not abruptly substitute SINGULAIR for inhaled or oral corticosteroids (  5.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,singulair,65,2372,2405,"\n', ' *  Patients with known aspirin sensitivity should continue to avoid aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR (  5.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,singulair,66,2405,2419,"\n', ' *  Neuropsychiatric events have been reported with SINGULAIR.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,singulair,67,2419,2428,Instruct patients to be alert for neuropsychiatric events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,singulair,68,2428,2452,Evaluate the risks and benefits of continuing treatment with SINGULAIR if such events occur (  5.4  and  6.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,singulair,69,2452,2479,"\n', ' *  Systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,singulair,70,2479,2502,These events have been sometimes associated with the reduction of oral corticosteroid therapy (  5.5  and  6.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,singulair,71,2502,2527,"\n', ' *  Inform patients with phenylketonuria that the 4-mg and 5-mg chewable tablets contain phenylalanine (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,singulair,72,2527,2587,"\n', '    \n', ' \n', '\n', '   5.1 Acute Asthma\n', '\n', '  SINGULAIR is not indicated for use in the reversal of  notaecandidatepreexistingconditionorriskfactor in  notaecandidatepreexistingconditionorriskfactor  including  notaecandidatepreexistingconditionorriskfactor  Patients should be advised to have appropriate rescue medication available.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
73,singulair,73,2587,2617,"Therapy with SINGULAIR can be continued during  notaecandidatepreexistingconditionorriskfactor  Patients who have  notaecandidatepreexistingconditionorriskfactor should have available for rescue a short-acting inhaled beta-agonist.\n',",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
74,singulair,74,2617,2701,"'\n', '    5.2 Concomitant Corticosteroid Use\n', '\n', '  While the dose of inhaled corticosteroid may be reduced gradually under medical supervision, SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids.\n', '\n', '    5.3 Aspirin Sensitivity\n', '\n', '  Patients with known  notaecandidatepreexistingconditionorriskfactor should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking SINGULAIR.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
75,singulair,75,2701,2787,"Although SINGULAIR is effective in improving airway function in  notaecandidatepreexistingconditionorriskfactor with documented  notaecandidatepreexistingconditionorriskfactor  it has not been shown to truncate  notaecandidatepreexistingconditionorriskfactor and other non-steroidal anti-inflammatory drugs in  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor patients [see  Clinical Studies (14.1)  ]  .\n', '\n', '    5.4 Neuropsychiatric Events\n', '\n', '    oselabeledaefromdruguse have been reported in adult, adolescent, and pediatric patients taking SINGULAIR.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
76,singulair,76,2787,2845,"Post-marketing reports with SINGULAIR use include  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  oselabeledaefromdruguse and behavior (including  oselabeledaefromdruguse ,  oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,singulair,77,2845,2866,The clinical details of some post-marketing reports involving SINGULAIR appear consistent with a drug-induced effect.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,singulair,78,2866,2897,"\n', '\n', ' Patients and prescribers should be alert for  nonoseaeaeonlyasinstruction  Patients should be instructed to notify their prescriber if these changes occur.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,singulair,79,2897,2926,Prescribers should carefully evaluate the risks and benefits of continuing treatment with SINGULAIR if such events occur [see  Adverse Reactions (6.2)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,singulair,80,2926,2984,"\n', '\n', '    5.5 Eosinophilic Conditions\n', '\n', '  Patients with  notaecandidateindication on therapy with SINGULAIR may present with  oselabeledaefromdruguse  sometimes presenting with clinical features of  oselabeledaefromdruguse consistent with  oselabeledaefromdruguse  a condition which is often treated with systemic corticosteroid therapy.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
81,singulair,81,2984,2998,These events have been sometimes associated with the reduction of oral corticosteroid therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,singulair,82,2998,3006,Physicians should be alert to  nonoseaemanifestationorcomplication   ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
83,singulair,83,3006,3020,nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication presenting in their patients.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
84,singulair,84,3020,3045,A causal association between SINGULAIR and these underlying conditions has not been established [see  Adverse Reactions (6.2)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,singulair,85,3045,3067,"\n', '\n', '    5.6 Phenylketonuria\n', '\n', '   notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,lynparza,0,0,50,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed elsewhere in the labeling:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse  oselabeledaefromdruguse [see    Warnings and Precautions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,lynparza,1,50,66,"(5.1)    ]  \n', ' *     oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,lynparza,2,66,69,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,lynparza,3,69,108,"(5.2)    ]  \n', '   *    Most common adverse reactions (>=20%) in clinical trials were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse ,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,lynparza,4,108,112,oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,lynparza,5,112,128,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,lynparza,6,128,132,oselabeledaefromdruguse  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,lynparza,7,132,149,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse and  oselabeledaefromdruguse  oselabeledaefromdruguse pain/ oselabeledaefromdruguse  (  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,lynparza,8,149,152,6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,lynparza,9,152,192,"\n', ' *    Most common laboratory abnormalities (>=25%) were  oselabeledaefromdruguse in  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  (  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,lynparza,10,192,227,"\n', '      EXCERPT:   To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,lynparza,11,227,260,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trial Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,lynparza,12,260,431,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' Lynparza 400 mg twice daily as monotherapy, has been studied in 300 patients with g   notaecandidateindication  and 223 of these patients had received 3 or more prior lines of chemotherapy.\n', '\n', '\n', '\n', ' In the 223 patients with  notaecandidateindication who received 3 or more prior lines of chemotherapy (including 137 patients in Study 1 with measureable disease)  [see      Clinical Studies (14)      ]  , adverse reactions led to dose interruption in 40% of patients, dose reduction in 4%, and discontinuation in 7%.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,lynparza,13,431,475,There were 8 (4%) patients with adverse reactions leading to  nonoseaegeneralterm  two were attributed to  oselabeledaefromdruguse  and one each was attributed to  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and suture rupture.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
14,lynparza,14,475,520,Table 1 presents the frequency of adverse reactions reported in >=20% of 223 patients (in 6 studies) with  notaecandidateindication who had received 3 or more prior lines of chemotherapy who were treated with Lynparza 400 mg twice daily.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
15,lynparza,15,520,580,"The median exposure to Lynparza in these patients was 158 days.\n', '\n', '\n', '\n', ' Table 1 Adverse Reactions Reported in >=20% of Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza \n', '                                                       3 or more lines of prior chemotherapy    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,lynparza,16,580,613,"\n', '  Adverse Reaction                                     Grades 1-4  N=223  %    Grades 3-4  N=223  %    \n', '   nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,lynparza,17,613,620,"\n', '                                                       oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,lynparza,18,620,636,"\n', '                                                                                                            34                      18                     \n', '   nonoseaegeneralterm                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
19,lynparza,19,636,663,"\n', '                                                       oselabeledaefromdruguse  oselabeledaefromdruguse pain/ oselabeledaefromdruguse                           \n', '                                                                                                            43                      8                      \n', '                                                       oselabeledaefromdruguse                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,lynparza,20,663,679,"\n', '                                                                                                            22                      1                      \n', '                                                       oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,lynparza,21,679,695,"\n', '                                                                                                            64                      3                      \n', '                                                       oselabeledaefromdruguse                                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,lynparza,22,695,711,"\n', '                                                                                                            43                      4                      \n', '                                                       oselabeledaefromdruguse                                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,lynparza,23,711,925,"\n', '                                                                                                            31                      1                      \n', '                                                       oselabeledaefromdruguse                                           \n', '                                                                                                            25                      0                      \n', '   nonoseaegeneralterm                                    \n', '                                                       oselabeledaefromdruguse  oselabeledaefromdruguse                                    \n', '                                                                                                            66                      8                      \n', '   nonoseaegeneralterm                                                                         \n', '                                                       oselabeledaefromdruguse  oselabeledaefromdruguse                                 \n', '                                                                                                            26                      0                      \n', '   nonoseaegeneralterm                                                     \n', '                                                       oselabeledaefromdruguse  oselabeledaefromdruguse                     \n', '                                                                                                            21                      0                      \n', '                                                       oselabeledaefromdruguse                                             \n', '                                                                                                            22                      0                      \n', '         Table 2 presents the frequency of  nonoseaeaeonlyasinstruction in the 223 patients with  notaecandidateindication who had received three or more prior lines of chemotherapy receiving Lynparza 400 mg twice daily.\n', ' \n', '\n', ' Table 2 Laboratory Abnormalities Reported in Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza \n', '  Laboratory Parameter1                                3 or more lines of prior chemotherapy    \n', '  Grades 1-4  N=223  %                                 Grades 3-4  ",1,1,0,1,0,0,0,0,0,0,0,0,0,0,0
24,lynparza,24,925,929,N=223  %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,lynparza,25,929,961,"\n', '   oselabeledaefromdruguse ( oselabeledaefromdruguse                       90                      15                     \n', '   oselabeledaefromdruguse ( oselabeledaefromdruguse     25                      7                      \n', '   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,lynparza,26,961,1062,"( oselabeledaefromdruguse              30                      3                      \n', '   oselabeledaefromdruguse ( oselabeledaefromdruguse                 56                      17                     \n', '   oselabeledaefromdruguse                    57                      -                      \n', '   oselabeledaefromdruguse                               30                      2                      \n', '         The following adverse reactions and  nonoseaeaeonlyasinstruction have been identified in >=10 to <20% of the 223 patients receiving Lynparza and not included in the table:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,lynparza,27,1062,1135,"The following adverse reactions and  nonoseaeaeonlyasinstruction have been identified in >=1 to <10% of the 223 patients receiving Lynparza and not included in the table:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse , and  oselabeledaefromdruguse",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,lynparza,28,1135,1201,"\n', ' \n', '\n', ' Table 3 presents adverse reactions reported in >=20% of patients from a randomized trial of Lynparza 400 mg twice daily as maintenance monotherapy compared to placebo in patients with platinum sensitive, relapsed, high-grade serous  notaecandidateindication following treatment with 2 or more platinum-containing regimens.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
29,lynparza,29,1201,1214,Table 4 presents the  nonoseaeaeonlyasinstruction in patients from this randomized trial.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,lynparza,30,1214,1231,"Of the 96 patients with  notaecandidateindication  53 received Lynparza, and 43 received placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
31,lynparza,31,1231,1322,"The median duration on treatment with Lynparza was 11.1 months for patients with a  notaecandidateindication compared to 4.4 months for patients with  notaecandidateindication on placebo.\n', '\n', '\n', '\n', ' Adverse reactions led to dose interruptions in 26% of those receiving Lynparza and 7% of those receiving placebo; dose reductions in 15% of Lynparza and 5% of placebo patients; and discontinuation in 9% of Lynparza and 0% in placebo patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
32,lynparza,32,1322,1386,"One (2%) patient on Lynparza  nonoseaegeneralterm as a result of an adverse reaction.\n', '\n', '\n', '\n', ' Table 3 Adverse Reactions Reported in >=20% of Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial \n', '  Adverse Reactions                        Lynparza  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,lynparza,33,1386,1388,N=53    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,lynparza,34,1388,1392,Placebo  N=43    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,lynparza,35,1392,1404,"\n', '                                           Grades 1-4  %    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,lynparza,36,1404,1411,Grades 3-4  %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,lynparza,37,1411,1418,Grades 1-4  %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,lynparza,38,1418,1425,Grades 3-4  %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,lynparza,39,1425,1432,"\n', '   nonoseaegeneralterm                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,lynparza,40,1432,1452,"\n', '                                           oselabeledaefromdruguse                                  \n', '                                                                                    25              4               7                  2                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,lynparza,41,1452,1459,"\n', '   nonoseaegeneralterm               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,lynparza,42,1459,1470,"\n', '                                           oselabeledaefromdruguse  oselabeledaefromdruguse pain/ oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,lynparza,43,1470,1479,"\n', '                                                                                    47              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,lynparza,44,1479,1483,58                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,lynparza,45,1483,1499,"\n', '                                           oselabeledaefromdruguse                      \n', '                                                                                    25              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,lynparza,46,1499,1503,14                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,lynparza,47,1503,1519,"\n', '                                           oselabeledaefromdruguse                                  \n', '                                                                                    75              2               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,lynparza,48,1519,1523,37                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,lynparza,49,1523,1530,"\n', '                                           oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,lynparza,50,1530,1543,"\n', '                                                                                    32              4               9                  0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,lynparza,51,1543,1550,"\n', '                                           oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,lynparza,52,1550,1563,"\n', '                                                                                    28              4               21                 2                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,lynparza,53,1563,1570,"\n', '                                           oselabeledaefromdruguse                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,lynparza,54,1570,1579,"\n', '                                                                                    25              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,lynparza,55,1579,1583,14                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,lynparza,56,1583,1590,"\n', '                                           oselabeledaefromdruguse                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,lynparza,57,1590,1599,"\n', '                                                                                    21              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,lynparza,58,1599,1603,9                  0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,lynparza,59,1603,1610,"\n', '   nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,lynparza,60,1610,1643,"\n', '                                           oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse   \n', '                                                                                    68              6               53                 2                 \n', '   nonoseaegeneralterm                                                                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,lynparza,61,1643,1654,"\n', '                                           oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,lynparza,62,1654,1663,"\n', '                                                                                    43              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,lynparza,63,1663,1667,16                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,lynparza,64,1667,1674,"\n', '   nonoseaegeneralterm                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,lynparza,65,1674,1711,"\n', '                                           oselabeledaefromdruguse  oselabeledaefromdruguse         \n', '                                                                                                   32             \n', '                                                 4              \n', '                                                    21                \n', '                                                         0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,lynparza,66,1711,1751,"\n', '                                      \n', '                                           oselabeledaefromdruguse                                 \n', '                                                                                                   25             \n', '                                                 2              \n', '                                                    12                \n', '                                                         0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,lynparza,67,1751,1791,"\n', '                                      \n', '                                           oselabeledaefromdruguse                               \n', '                                                                                                   25             \n', '                                                 6              \n', '                                                    21                \n', '                                                         0                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,lynparza,68,1791,1803,"\n', '                                      \n', '   nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,lynparza,69,1803,1810,"\n', '                                           oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,lynparza,70,1810,1819,"\n', '                                                                                    25              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,lynparza,71,1819,1823,19                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,lynparza,72,1823,1837,"\n', '   nonoseaegeneralterm                                                                         \n', '                                           oselabeledaefromdruguse                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
73,lynparza,73,1837,1846,"\n', '                                                                                    21              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,lynparza,74,1846,1850,14                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,lynparza,75,1850,1857,"\n', '   nonoseaegeneralterm                                                                                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,lynparza,76,1857,1866,"\n', '                                           oselabeledaefromdruguse  oselabeledaefromdruguse                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,lynparza,77,1866,1875,"\n', '                                                                                    25              0               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,lynparza,78,1875,1879,14                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,lynparza,79,1879,1912,"\n', '          Table 4 Laboratory Abnormalities in Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial \n', '  Laboratory parameter1                    Lynparza  N=53    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,lynparza,80,1912,1916,Placebo  N=43    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,lynparza,81,1916,1928,"\n', '                                           Grades 1-4  %    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,lynparza,82,1928,1935,Grades 3-4  %    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,lynparza,83,1935,1942,Grades 1-4  %      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,lynparza,84,1942,1949,Grades 3-4  %     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,lynparza,85,1949,1958,"\n', '   oselabeledaefromdruguse                   85              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,lynparza,86,1958,1960,8               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,lynparza,87,1960,1964,58                 2                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,lynparza,88,1964,1971,"\n', '   oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,lynparza,89,1971,1973,32              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,lynparza,90,1973,1979,8               23                 0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,lynparza,91,1979,1988,"\n', '   oselabeledaefromdruguse                    26              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,lynparza,92,1988,2039,"6               19                 0                 \n', '   oselabeledaefromdruguse        85              -               44                 -                 \n', '   oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,lynparza,93,2039,2066,"*    Myelodysplastic syndrome/Acute Myeloid Leukemia: (MDS/AML) occurred in patients exposed to Lynparza, and some cases were fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,lynparza,94,2066,2077,Monitor patients for hematological toxicity at baseline and monthly thereafter.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,lynparza,95,2077,2085,Discontinue if MDS/AML is confirmed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,lynparza,96,2085,2111,"(  5.1  ) \n', ' *    Pneumonitis: occurred in patients exposed to Lynparza, and some cases were fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,lynparza,97,2111,2118,Interrupt treatment if pneumonitis is suspected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,lynparza,98,2118,2124,Discontinue if pneumonitis is confirmed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,lynparza,99,2124,2129,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,lynparza,100,2129,2146,"\n', ' *    Embryo-Fetal toxicity: Lynparza can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,lynparza,101,2146,2163,Advise females of reproductive potential of the potential risk to a fetus and to avoid pregnancy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,lynparza,102,2163,2172,"(  5.3  ,  8.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,lynparza,103,2172,2233,"\n', '    \n', ' \n', '\n', '   5.1 Myelodysplastic syndrome/Acute Myeloid Leukemia\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse (MDS/AML) have been confirmed in 6 out of 298 (2%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,lynparza,104,2233,2285,"patients enrolled in a single arm trial of Lynparza monotherapy, in patients with deleterious or suspected deleterious germline  notaecandidateindication  In a randomized placebo controlled trial,  oselabeledaefromdruguse  oselabeledaefromdruguse occurred in 3 out of 136 (2%) patients with advanced  notaecandidateindication treated with Lynparza.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
105,lynparza,105,2285,2307,"Overall,  oselabeledaefromdruguse  oselabeledaefromdruguse were reported in 22 of 2,618 (<1%) patients treated with Lynparza.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,lynparza,106,2307,2355,The majority of  oselabeledaefromdruguse  oselabeledaefromdruguse cases (17 of 22 cases) were  nonoseaegeneralterm  and the duration of therapy with Lynparza in patients who developed secondary  oselabeledaefromdruguse cancer-therapy related  oselabeledaefromdruguse varied from <6 months to >2 years.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,lynparza,107,2355,2394,"All patients had previous chemotherapy with platinum agents and/or other DNA damaging agents.\n', '\n', '\n', '\n', ' Monitor complete blood count testing at baseline and monthly thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,lynparza,108,2394,2417,Do not start Lynparza until patients have recovered from  nonoseaeaeonlyasinstruction caused by previous chemotherapy (<=CTCAE Grade 1).,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,lynparza,109,2417,2432,For prolonged  nonoseaeaeonlyasinstruction  interrupt Lynparza and monitor blood counts weekly until recovery.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,lynparza,110,2432,2468,"If the levels have not recovered to CTCAE Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,lynparza,111,2468,2482,"If  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction is confirmed, discontinue Lynparza.\n', '\n",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,lynparza,112,2482,2530,"', '\n', '\n', '    5.2 Pneumonitis\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  including  nonoseaegeneralterm cases, occurred in <1% of patients treated with Lynparza.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,lynparza,113,2530,2564,"If patients present with new or  nonoseaegeneralterm such as  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or a radiological abnormality occurs, interrupt treatment with Lynparza and initiate prompt investigation.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,lynparza,114,2564,2627,"If  nonoseaeaeonlyasinstruction is confirmed, discontinue Lynparza.\n', '\n', '\n', '\n', '    5.3  oselabeledaefromdruguse \n', '\n', '\n', '  Lynparza can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman based on its mechanism of action and findings in animals.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
115,lynparza,115,2627,2654,Olaparib was  nonoseaeaeanimal and caused  nonoseaeaeanimal in rats at exposures below those in patients receiving the recommended human dose of 400 mg twice daily.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
116,lynparza,116,2654,2714,"If the patient becomes  nonoseaeaeonlyasinstruction while taking this drug, apprise the patient of the potential  oselabeledaefromdruguse [see     Use in Specific Populations (8.1)     ]  .\n', '\n', '\n', '\n', ' Advise females of reproductive potential to avoid becoming  nonoseaeaeonlyasinstruction ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,livalo,0,0,75,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed in greater detail in other sections of the label:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse with  oselabeledaefromdruguse and  nonoseaemanifestationorcomplication and  oselabeledaefromdruguse (including  oselabeledaefromdruguse  [see Warnings and Precautions (  5.1  )].  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
1,livalo,1,75,95,"\n', ' *   oselabeledaefromdruguse [see Warning and Precautions (  5.2  )].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,livalo,2,95,130,"\n', '    Of 4,798 patients enrolled in 10 controlled clinical studies and 4 subsequent open-label extension studies, 3,291 patients were administered pitavastatin 1 mg to 4 mg daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,livalo,3,130,152,The mean continuous exposure of pitavastatin (1 mg to 4 mg) was 36.7 weeks (median 51.1 weeks).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,livalo,4,152,183,The mean age of the patients was 60.9 years (range; 18 years - 89 years) and the gender distribution was 48% males and 52% females.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,livalo,5,183,258,"Approximately 93% of the patients were Caucasian, 7% were Asian/Indian, 0.2% were African American and 0.3% were Hispanic and other.\n', ' \n', '\n', '   EXCERPT:   The most frequent adverse reactions (rate >=2.0% in at least one marketed dose) were myalgia, back pain, diarrhea, constipation and pain in extremity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,livalo,6,258,311,"(  6  )\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Kowa Pharmaceuticals America, Inc. at 1-877-334-3464 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,livalo,7,311,348,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Studies Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,livalo,8,348,453,"Because clinical studies on LIVALO are conducted in varying study populations and study designs, the frequency of adverse reactions observed in the clinical studies of LIVALO cannot be directly compared with that in the clinical studies of other HMG-CoA reductase inhibitors and may not reflect the frequency of adverse reactions observed in clinical practice.\n', '\n', '\n', '\n', ' Adverse reactions reported in >= 2% of patients in controlled clinical studies and at a rate greater than or equal to placebo are shown in  Table 1  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,livalo,9,453,481,"These studies had treatment duration of up to 12 weeks.\n', '\n', '\n', '\n', ' Table 1.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,livalo,10,481,484,Adverse Reactions*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,livalo,11,484,518,"Reported by >=2.0% of Patients Treated with LIVALO and > Placebo in Short-Term Controlled Studies \n', '  * Adverse reactions by MedDRA preferred term.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,livalo,12,518,531,"\n', '  \n', ' AdverseReactions*  PlaceboN=",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,livalo,13,531,542,208        LIVALO1 mgN=309     LIVALO2 mgN=951          LIVALO4 mgN=1540        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,livalo,14,542,561,"\n', '  oselabeledaefromdruguse         2.9%                 3.9%                1.8%                     1.4%                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,livalo,15,561,580,"\n', '  oselabeledaefromdruguse      1.9%                 3.6%                1.5%                     2.2%                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,livalo,16,580,599,"\n', '  oselabeledaefromdruguse          1.9%                 2.6%                1.5%                     1.9%                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,livalo,17,599,638,"\n', '  oselabeledaefromdruguse           1.4%                 1.9%                2.8%                     3.1%                    \n', '  oselabeledaefromdruguse  1.9%                 2.3%                0.6%                     0.9%                    \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,livalo,18,638,660,"', '           Other adverse reactions reported from clinical studies were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,livalo,19,660,682,"\n', ' \n', '\n', ' The following laboratory abnormalities have also been reported:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,livalo,20,682,692,"oselabeledaefromdruguse  oselabeledaefromdruguse creatine phosphokinase,  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,livalo,21,692,701,"creatine phosphokinase, transaminases,  oselabeledaefromdruguse  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,livalo,22,701,726,"creatine phosphokinase, transaminases, alkaline phosphatase,  oselabeledaefromdruguse  oselabeledaefromdruguse creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin, and  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,livalo,23,726,786,"\n', '\n', '\n', '\n', ' In controlled clinical studies and their open-label extensions, 3.9% (1 mg), 3.3% (2 mg), and 3.7% (4 mg) of pitavastatin-treated patients were discontinued due to adverse reactions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,livalo,24,786,887,"The most common adverse reactions that led to treatment discontinuation were:  oselabeledaefromdruguse (0.6% on 4 mg) and  oselabeledaefromdruguse (0.5% on 4 mg).\n', '\n', '\n', '\n', '  oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported with LIVALO.\n', '\n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during postapproval use of LIVALO.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,livalo,25,887,994,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', ' Adverse reactions associated with LIVALO therapy reported since market introduction, regardless of causality assessment, include the following:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm and non-fatal  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,livalo,26,994,1038,"\n', '\n', '\n', '\n', ' There have been rare postmarketing reports of  oselabeledaeclasseffect (e.g.,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  associated with statin use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,livalo,27,1038,1048,These  oselabeledaefromdruguse have been reported for all statins.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,livalo,28,1048,1166,"The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).\n', '\n', '\n', '\n', ' There have been rare reports of  oselabeledaeclasseffect     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *   Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase in a dose-dependent manner, with advanced age (>=65), renal impairment, and inadequately treated hypothyroidism.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,livalo,29,1166,1190,"Advise patients to promptly report unexplained and/or persistent muscle pain, tenderness, or weakness, and discontinue LIVALO (  5.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,livalo,30,1190,1191,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,livalo,31,1191,1208,"', ' *   Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,livalo,32,1208,1225,Check liver enzyme tests before initiating therapy and as clinically indicated thereafter (  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,livalo,33,1225,1291,"\n', '    \n', ' \n', '\n', '   5.1 Skeletal Muscle Effects\n', '\n', '\n', '\n', '   Cases of  oselabeledaefromdruguse and  oselabeledaefromdruguse with  nonoseaemanifestationorcomplication secondary to  oselabeledaefromdruguse have been reported with HMG-CoA reductase inhibitors, including LIVALO.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
34,livalo,34,1291,1359,"These risks can occur at any dose level, but increase in a dose-dependent manner.\n', '\n', '\n', '\n', ' LIVALO should be prescribed with caution in patients with predisposing factors for  nonoseaeaeonlyasinstruction  These factors include advanced age (>=65 years),  notaecandidatepreexistingconditionorriskfactor  and inadequately treated  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
35,livalo,35,1359,1381,The risk of  nonoseaeaefromdruginteraction may also be increased with concurrent administration of fibrates or lipid-modifying doses of niacin.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
36,livalo,36,1381,1444,"LIVALO should be administered with caution in patients with  notaecandidatepreexistingconditionorriskfactor  in elderly patients, or when used concomitantly with fibrates or lipid-modifying doses of niacin [see Drug Interactions (  7.6  ), Use in Specific Populations (  8.5  ,  8.6  ) and Clinical Pharmacology (  12.3  )].  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
37,livalo,37,1444,1516,"\n', '\n', '\n', '\n', ' Cases of  nonoseaeaefromdruginteraction  including  nonoseaeaefromdruginteraction  have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing LIVALO with colchicine [see Drug Interactions  (  7.7  )].\n', '\n', '\n', '\n",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
38,livalo,38,1516,1538,"', ' There have been rare reports of  oselabeledaeclasseffect , an  oselabeledaeclasseffect  associated with statin use.   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,livalo,39,1538,1607,"nonoseaeaeonlyasinstruction is characterized by:  nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication  which persist despite discontinuation of statin treatment; muscle biopsy showing  nonoseaemanifestationorcomplication without significant  nonoseaenegation  improvement with  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' LIVALO therapy should be discontinued if markedly  nonoseaemanifestationorcomplication  levels occur or  nonoseaeaeonlyasinstruction is diagnosed or suspected.",1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
40,livalo,40,1607,1678,"LIVALO therapy should also be temporarily withheld in any patient with an acute, serious condition suggestive of  nonoseaeaeonlyasinstruction or predisposing to the development of  nonoseaeaeonlyasinstruction secondary to  nonoseaeaeonlyasinstruction (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  major surgery, trauma,  notaecandidatepreexistingconditionorriskfactor  endocrine, and electrolyte  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  and electrolyte  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  or uncontrolled  notaecandidatepreexistingconditionorriskfactor .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
41,livalo,41,1678,1770,"All patients should be advised to promptly report unexplained  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication  particularly if accompanied by  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication or if  nonoseaeaeonlyasinstruction persist after discontinuing LIVALO.\n', '\n', '\n', '\n', '    5.2 Liver Enzyme Abnormalities\n', '\n', '\n', '\n', '   oselabeledaefromdruguse in  oselabeledaefromdruguse  oselabeledaefromdruguse in serum transaminases ( oselabeledaefromdruguse  oselabeledaefromdruguse in  oselabeledaefromdruguse transaminases (aspartate aminotransferase [",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
42,livalo,42,1770,1782,AST]/serum  oselabeledaefromdruguse  oselabeledaefromdruguse in serum transaminases (aspartate aminotransferase [,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,livalo,43,1782,1797,"AST]/serum glutamic-oxaloacetic transaminase, or  oselabeledaefromdruguse  oselabeledaefromdruguse in  oselabeledaefromdruguse transaminases",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,livalo,44,1797,1801,(aspartate aminotransferase [,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,livalo,45,1801,1811,"AST]/serum  oselabeledaefromdruguse xaloacetic transaminase, or alanine aminotransferase [",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,livalo,46,1811,1828,"ALT]/serum glutamic- oselabeledaefromdruguse  have been reported with HMG-CoA reductase inhibitors, including LIVALO.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,livalo,47,1828,1892,"In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy.\n', '\n', '\n', '\n', ' In placebo-controlled Phase 2 studies,  nonoseaenegation was not observed in the placebo, LIVALO 1 mg, or LIVALO 2 mg groups.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
48,livalo,48,1892,1908,One out of 202 patients (0.5%) administered LIVALO 4 mg had  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,livalo,49,1908,1985,"\n', '\n', '\n', '\n', ' It is recommended that liver enzyme tests be performed before the initiation of LIVALO and if signs or symptoms of  nonoseaeaeonlyasinstruction occur.\n', '\n', '\n', '\n', ' There have been rare postmarketing reports of  nonoseaegeneralterm and non-fatal  oselabeledaefromdruguse in patients taking statins, including pitavastatin.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,livalo,50,1985,2008,"If serious  nonoseaeaeonlyasinstruction with clinical symptoms and/or  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication occurs during treatment with LIVALO, promptly interrupt therapy.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
51,livalo,51,2008,2058,"If an alternate etiology is not found do not restart LIVALO.\n', '\n', '\n', '\n', ' As with other HMG-CoA reductase inhibitors, LIVALO should be used with caution in patients who consume substantial quantities of alcohol.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,livalo,52,2058,2089,Active  notaecandidatecontraindication  which may include unexplained persistent  notaecandidatecontraindication  is a contraindication to the use of LIVALO [see Contraindications (  4  )].  ,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
53,livalo,53,2089,2136,"\n', '\n', '\n', '\n', '    5.3 Endocrine Function\n', '\n', '\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse HbA1c and  oselabeledaefromdruguse ']",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,remeron,0,0,69,"['  ADVERSE REACTIONS\n', '\n', '  Associated with Discontinuation of Treatment\n', '\n', '  Approximately 16% of the 453 patients who received REMERON (mirtazapine) Tablets in US 6-week controlled clinical trials discontinued treatment due to an adverse experience, compared to 7% of the 361 placebo-treated patients in those studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,remeron,1,69,149,"The most common events (>=1%) associated with discontinuation and considered to be drug related (i.e., those events associated with dropout at a rate at least twice that of placebo) are included in Table 2.\n', '\n', ' Table 2: Common Adverse Events Associated With Discontinuation of Treatment in 6-Week US REMERON Trials \n', ' Adverse Event         Percentage of Patients Discontinuing With Adverse Event   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,remeron,2,149,163,"\n', ' REMERON (n=453)                   Placebo (n=361)                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,remeron,3,163,461,"\n', '  \n', '  oselabeledaefromdruguse                             10.4%                                      2.2%                     \n', '  oselabeledaefromdruguse                                  1.5%                                       0%                      \n', '           Commonly Observed Adverse Events in US Controlled Clinical Trials\n', '   The most commonly observed adverse events associated with the use of REMERON (mirtazapine) Tablets (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (REMERON incidence at least twice that for placebo) are listed in Table 3.\n', '\n', ' Table 3: Common Treatment-Emergent Adverse Events Associated With the Use of REMERON in 6-Week US Trials \n', ' Adverse Event                   Percentage of Patients Reporting Adverse Event   \n', ' REMERON (n=453)                           Placebo (n=361)             \n', '  \n', '  oselabeledaefromdruguse                                      54%                                  18%                   \n', '  oselabeledaefromdruguse                              17%                                  2%                    \n', '  oselabeledaefromdruguse                                     12%                                  2%                    \n', '  oselabeledaefromdruguse                                       7%                                   3%                    \n', '           Adverse Events Occurring at an Incidence of 1% or More Among REMERON-Treated Patients\n', '   Table 4 enumerates adverse events that occurred at an incidence of 1% or more, and were more frequent than in the placebo group, among REMERON (mirtazapine) Tablets-treated patients who participated in short-term US placebo-controlled trials in which patients were dosed in a range of 5 to 60 mg/day.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,remeron,4,461,487,This table shows the percentage of patients in each group who had at least 1 episode of an event at some time during their treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,remeron,5,487,549,"Reported adverse events were classified using a standard COSTART-based dictionary terminology.\n', '\n', ' The prescriber should be aware that these figures cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,remeron,6,549,573,"Similarly, the cited frequencies cannot be compared with figures obtained from other investigations involving different treatments, uses, and investigators.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,remeron,7,573,741,"The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side-effect incidence rate in the population studied.\n', '\n', ' Table 4: Incidence of Adverse Clinical ExperiencesEvents reported by at least 1% of patients treated with REMERON are included, except the following events, which had an incidence on placebo greater than or equal to REMERON:  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  (>=1%) in Short-Term US Controlled Studies \n', ' Body System  Adverse Clinical  Experience          REMERON(n=453)                  Placebo(n=361)           \n', '  \n', '    nonoseaegeneralterm                          ",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
8,remeron,8,741,754,"\n', '    oselabeledaefromdruguse                                              8%                              5%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,remeron,9,754,767,"\n', '    oselabeledaefromdruguse                                          5%                              3%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,remeron,10,767,780,"\n', '    oselabeledaefromdruguse                                             2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,remeron,11,780,781,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,remeron,12,781,787,"', '    nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
13,remeron,13,787,800,"\n', '    oselabeledaefromdruguse                                            25%                             15%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,remeron,14,800,813,"\n', '    oselabeledaefromdruguse                                   17%                              2%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,remeron,15,813,826,"\n', '    oselabeledaefromdruguse                                         13%                              7%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,remeron,16,826,833,"\n', '    nonoseaegeneralterm      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,remeron,17,833,846,"\n', '    oselabeledaefromdruguse                                          12%                              2%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,remeron,18,846,859,"\n', '    oselabeledaefromdruguse                                      2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,remeron,19,859,872,"\n', '    oselabeledaefromdruguse                                                 1%                              0%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,remeron,20,872,874,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,remeron,21,874,892,", '    nonoseaegeneralterm                   \n', '    oselabeledaefromdruguse                                               2%                              1%                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,remeron,22,892,899,"\n', '    nonoseaegeneralterm                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,remeron,23,899,912,"\n', '    oselabeledaefromdruguse                                           54%                             18%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,remeron,24,912,925,"\n', '    oselabeledaefromdruguse                                             7%                              3%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,remeron,25,925,938,"\n', '    oselabeledaefromdruguse                                       4%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,remeron,26,938,951,"\n', '    oselabeledaefromdruguse                                     3%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,remeron,27,951,964,"\n', '    oselabeledaefromdruguse                                                2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,remeron,28,964,977,"\n', '    oselabeledaefromdruguse                                             2%                              0%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,remeron,29,977,984,"\n', '    nonoseaegeneralterm                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,remeron,30,984,985,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,remeron,31,985,997,"', '    oselabeledaefromdruguse                                               1%                              0%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,remeron,32,997,1004,"\n', '    nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,remeron,33,1004,1017,"\n', '    oselabeledaefromdruguse                                     2%                              1%                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,remeron,34,1017,1024,"\n', '            oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,remeron,35,1024,1053,"The electrocardiograms for 338 patients who received REMERON (mirtazapine) Tablets and 261 patients who received placebo in 6-week, placebo-controlled trials were analyzed.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,remeron,36,1053,1077,nonoseaenegation was not observed among mirtazapine-treated patients;  oselabeledaefromdruguse was +1.6 msec for mirtazapine and -3.1 msec for placebo.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
37,remeron,37,1077,1096,"Mirtazapine was associated with a mean  oselabeledaefromdruguse of 3.4 bpm, compared to 0.8 bpm for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,remeron,38,1096,1145,"The clinical significance of these changes is unknown.\n', '\n', ' The effect of REMERON (mirtazapine) on QTc interval was assessed in a clinical randomized trial with placebo and positive (moxifloxacin) controls involving 54 healthy volunteers using exposure response analysis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,remeron,39,1145,1158,This trial showed a positive relationship between mirtazapine concentrations and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,remeron,40,1158,1197,"However, the degree of  nonoseaeaeonlyasinstruction observed with both 45 mg (therapeutic) and 75 mg (supratherapeutic) doses of mirtazapine was not at a level generally considered to be clinically meaningful.\n', '\n",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,remeron,41,1197,1205,"', '   Other Adverse Events Observed",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,remeron,42,1205,1241,"During the Premarketing Evaluation of REMERON\n', '\n', '  During its premarketing assessment, multiple doses of REMERON (mirtazapine) Tablets were administered to 2796 patients in clinical studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,remeron,43,1241,1283,"The conditions and duration of exposure to mirtazapine varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,remeron,44,1283,1301,Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,remeron,45,1301,1363,"Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.\n', '\n', ' In the tabulations that follow, reported adverse events were classified using a standard COSTART-based dictionary terminology.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,remeron,46,1363,1399,"The frequencies presented, therefore, represent the proportion of the 2796 patients exposed to multiple doses of REMERON who experienced an event of the type cited on at least 1 occasion while receiving REMERON.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,remeron,47,1399,1542,"All reported events are included except those already listed in Table 4, those adverse experiences subsumed under COSTART terms that are either overly general or excessively specific so as to be uninformative, and those events for which a drug cause was very remote.\n', '\n', ' It is important to emphasize that, although the events reported occurred during treatment with REMERON, they were not necessarily caused by it.\n', '\n', ' Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on 1 or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,remeron,48,1542,1556,Only those events not already listed in Table 4 appear in this listing.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,remeron,49,1556,1671,"Events of major clinical importance are also described in the WARNINGS and PRECAUTIONS sections.\n', '\n', '    nonoseaegeneralterm  :  frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   rare:   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm  :  frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,remeron,50,1671,1684,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
51,remeron,51,1684,1713,frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,remeron,52,1713,1716,rare:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,remeron,53,1716,1741,"oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse of liver,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,remeron,54,1741,1742,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,remeron,55,1742,1743,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,remeron,56,1743,1774,"', '\n', '    nonoseaegeneralterm  :  rare:   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,remeron,57,1774,1790,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,remeron,58,1790,1803,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,remeron,59,1803,1815,frequent:   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,remeron,60,1815,1831,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,remeron,61,1831,1844,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,remeron,62,1844,1858,frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,remeron,63,1858,1874,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,remeron,64,1874,1887,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
65,remeron,65,1887,1951,frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,remeron,66,1951,1984,"rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,remeron,67,1984,1997,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,remeron,68,1997,2015,frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,remeron,69,2015,2018,rare:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,remeron,70,2018,2024,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,remeron,71,2024,2025,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,remeron,72,2025,2038,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
73,remeron,73,2038,2058,frequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,remeron,74,2058,2070,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,remeron,75,2070,2104,"\n', '\n', '    nonoseaegeneralterm  :  infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,remeron,76,2104,2116,rare:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,remeron,77,2116,2129,"\n', '\n', '    nonoseaegeneralterm  :  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
78,remeron,78,2129,2161,frequent:   oselabeledaefromdruguse   infrequent:   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,remeron,79,2161,2164,rare:   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,remeron,80,2164,2178,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,remeron,81,2178,2179,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,remeron,82,2179,2192,"\n', '\n', '   Other Adverse Events Observed",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,remeron,83,2192,2235,"During Postmarketing Evaluation of REMERON\n', '\n', '  Adverse events reported since market introduction, which were temporally (but not necessarily causally) related to mirtazapine therapy, include cases of the  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,remeron,84,2235,2299,"In the majority of these cases, however, concomitant drugs were implicated.\n', '\n', ' Cases of severe  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse have also been reported.\n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,remeron,85,2299,2402,"\n', '\n', '    Suicidality and Antidepressant Drugs  \n', '\n', '   Antidepressants increased the risk compared to placebo of  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior ( oselabeledaeclasseffect  in children, adolescents, and young adults in short-term studies of  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  Anyone considering the use of REMERON  (r)   (mirtazapine) Tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
86,remeron,86,2402,2447,Short-term studies did not show an increase in the risk of  nonoseaeaeratelteqplacebo with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.  ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
87,remeron,87,2447,2512,"notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor are themselves associated with increases in the risk of  nonoseaeaeonlyasinstruction  Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  or unusual  nonoseaeaeonlyasinstruction  Families and caregivers should be advised of the need for close observation and communication with the prescriber.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
88,remeron,88,2512,2522,REMERON is not approved for use in pediatric patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,remeron,89,2522,2527,(See   WARNINGS:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,remeron,90,2527,2561,"Clinical Worsening and  nonoseaeaeonlyasinstruction    PRECAUTIONS\n', '\n', '   General\n', '\n', '   Discontinuation Symptoms\n', '\n', '  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,remeron,91,2561,2587,"There have been reports of  oselabeledaefromdruguse (mirtazapine) Tablets (particularly when abrupt), including but not limited to the following:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,remeron,92,2587,2601,"nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal (including  nonoseaeodorwithdrawal and  nonoseaeodorwithdrawal ,  ",0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
93,remeron,93,2601,2631,nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaeodorwithdrawal  or other symptoms which may be of clinical significance.,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
94,remeron,94,2631,2644,The majority of the reported cases are mild and self-limiting.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,remeron,95,2644,2768,"Even though these have been reported as adverse reactions, it should be realized that these symptoms may be related to underlying disease.\n', '\n', ' Patients currently taking REMERON should NOT discontinue treatment abruptly, due to risk of  oselabeledaefromdruguse  At the time that a medical decision is made to discontinue treatment with REMERON, a gradual reduction in the dose, rather than an abrupt cessation, is recommended.\n', '\n', '    Akathisia/Psychomotor Restlessness\n', '\n', '  The use of antidepressants has been associated with the development of  oselabeledaeclasseffect  characterized by a  oselabeledaefromdruguse  often accompanied by an  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,remeron,96,2768,2782,This is most likely to occur within the first few weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,remeron,97,2782,2824,"In patients who develop these symptoms, increasing the dose may be detrimental.\n', '\n', '    Hyponatremia\n', '\n', '   oselabeledaefromdruguse has been reported very rarely with the use of mirtazapine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,remeron,98,2824,2866,"Caution should be exercised in patients at risk, such as elderly patients or patients concomitantly treated with medications known to cause  nonoseaeaeonlyasinstruction \n', '\n', '    Somnolence\n', '\n', ""  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,remeron,99,2866,2900,"In US controlled studies,  oselabeledaefromdruguse was reported in 54% of patients treated with REMERON (mirtazapine) Tablets, compared to 18% for placebo and 60% for amitriptyline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,remeron,100,2900,2925,"In these studies,  oselabeledaefromdruguse resulted in discontinuation for 10.4% of REMERON-treated patients, compared to 2.2% for placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,remeron,101,2925,2940,It is unclear whether or not tolerance develops to the somnolent effects of REMERON.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,remeron,102,2940,2983,Because of the potentially significant effects of REMERON on  nonoseaeaeonlyasinstruction  patients should be cautioned about engaging in activities requiring alertness until they have been able to assess the drug's effect on their own psychomotor performance (see  PRECAUTIONS:,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,remeron,103,2983,2989,Information for Patients  ).\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,remeron,104,2989,3036,""", '\n', '    Dizziness\n', '\n', '  In US controlled studies,  oselabeledaefromdruguse was reported in 7% of patients treated with REMERON, compared to 3% for placebo and 14% for amitriptyline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,remeron,105,3036,3107,"It is unclear whether or not tolerance develops to the  nonoseaeaeonlyasinstruction observed in association with the use of REMERON.\n', '\n', '    Increased Appetite/Weight Gain\n', '\n', '  In US controlled studies,  oselabeledaefromdruguse was reported in 17% of patients treated with REMERON, compared to 2% for placebo and 6% for amitriptyline.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,remeron,106,3107,3137,"In these same trials,  oselabeledaefromdruguse was reported in 7.5% of patients treated with mirtazapine, compared to 0% for placebo and 5.9% for amitriptyline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,remeron,107,3137,3218,"In a pool of premarketing US studies, including many patients for long-term, open-label treatment, 8% of patients receiving REMERON discontinued for  oselabeledaefromdruguse  In an 8-week-long pediatric clinical trial of doses between 15 to 45 mg/day, 49% of REMERON-treated patients had a  oselabeledaefromdruguse of at least 7%, compared to 5.7% of placebo-treated patients (see  PRECAUTIONS:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,remeron,108,3218,3223,Pediatric Use  ).\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,remeron,109,3223,3261,"', '\n', '    Cholesterol/Triglycerides\n', '\n', '  In US controlled studies, nonfasting  oselabeledaefromdruguse to >=20% above the upper limits of normal",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,remeron,110,3261,3284,"were observed in 15% of patients treated with REMERON, compared to 7% for placebo and 8% for amitriptyline.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,remeron,111,3284,3294,"In these same studies, nonfasting  oselabeledaefromdruguse to >",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,remeron,112,3294,3395,"=500 mg/dL were observed in 6% of patients treated with mirtazapine, compared to 3% for placebo and 3% for amitriptyline.\n', '\n', '     oselabeledaefromdruguse \n', '  Clinically significant  oselabeledaefromdruguse (>=3 times the upper limit of the normal range) were observed in 2.0% (8/424) of patients exposed to REMERON in a pool of short-term US controlled trials, compared to 0.3% (1/328) of placebo patients and 2.0% (3/181) of amitriptyline patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,remeron,113,3395,3438,"Most of these patients with  nonoseaeaeonlyasinstruction did not develop signs or symptoms associated with  nonoseaenegation  While some patients were discontinued for the  oselabeledaefromdruguse  in other cases, the enzyme levels returned to normal despite continued REMERON treatment.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
114,remeron,114,3438,3505,"REMERON should be used with caution in patients with  notaecandidatepreexistingconditionorriskfactor (see  CLINICAL PHARMACOLOGY  and  DOSAGE AND ADMINISTRATION  ).\n', '\n', '    Activation of Mania/Hypomania\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse occurred in approximately 0.2% (3/1299 patients) of REMERON-treated patients in US studies.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
115,remeron,115,3505,3535,"Although the incidence of  oselabeledaefromdruguse  oselabeledaefromdruguse was very low during treatment with mirtazapine, it should be used carefully in patients with a history of  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
116,remeron,116,3535,3536,notaecandidatepreexistingconditionorriskfactor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
117,remeron,117,3536,3578,"\n', '\n', '    Seizure\n', '\n', '  In premarketing clinical trials, only 1  oselabeledaefromdruguse was reported among the 2796 US and non-US patients treated with REMERON.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,remeron,118,3578,3596,"However, no controlled studies have been carried out in patients with a history of  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
119,remeron,119,3596,3644,"Therefore, care should be exercised when mirtazapine is used in these patients.\n', '\n', '    Use in Patients with Concomitant Illness\n', '\n', '  Clinical experience with REMERON in patients with concomitant systemic illness is limited.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,remeron,120,3644,3715,"Accordingly, care is advisable in prescribing mirtazapine for patients with diseases or conditions that affect metabolism or hemodynamic responses.\n', '\n', ' REMERON has not been systematically evaluated or used to any appreciable extent in patients with a recent history of  notaecandidatepreexistingconditionorriskfactor or other significant  notaecandidatepreexistingconditionorriskfactor  REMERON was associated with significant  oselabeledaefromdruguse in early clinical pharmacology trials with normal volunteers.  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
121,remeron,121,3715,3727,oselabeledaefromdruguse was infrequently observed in clinical trials with  notaecandidatepreexistingconditionorriskfactor patients.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
122,remeron,122,3727,3899,"REMERON should be used with caution in patients with known  notaecandidatepreexistingconditionorriskfactor or cerebrovascular  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor that could be exacerbated by  nonoseaeaeonlyasinstruction (history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor  and conditions that would predispose patients to  nonoseaeaeonlyasinstruction ( notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and treatment with antihypertensive medication).\n', '\n', ' Mirtazapine clearance is decreased in patients with moderate [ notaecandidatepreexistingconditionorriskfactor  ] and severe [ notaecandidatepreexistingconditionorriskfactor  ]  notaecandidatepreexistingconditionorriskfactor  and also in patients with  notaecandidatepreexistingconditionorriskfactor  Caution is indicated in administering REMERON to such patients (see  CLINICAL PHARMACOLOGY  and  DOSAGE AND ADMINISTRATION  ).\n', '\n', '    Information for Patients\n', '\n', '  Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with REMERON (mirtazapine) Tablets and should counsel them in its appropriate use.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
123,remeron,123,3899,3933,"A patient Medication Guide about ""Antidepressant Medicines,  nonoseaeaeonlyasinstruction and other Serious  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction Thoughts or  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or Actions"" is available for REMERON.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,remeron,124,3933,3962,"The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,remeron,125,3962,3987,Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,remeron,126,3987,4119,"The complete text of the Medication Guide is reprinted at the end of this document.\n', '\n', ' Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking REMERON.\n', '\n', '    Clinical Worsening and Suicide Risk\n', '\n', ""  Patients, their families, and their caregivers should be encouraged to be alert to the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction ,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  other  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially early during antidepressant treatment and when the dose is adjusted up or down.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,remeron,127,4119,4150,"Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,remeron,128,4150,4185,"Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patient's presenting symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,remeron,129,4185,4367,"Symptoms such as these may be associated with an increased risk for  nonoseaeaeonlyasinstruction thinking and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behavior and indicate a need for very close monitoring and possibly changes in the medication.\n"", '\n', '    Agranulocytosis\n', '\n', '  Patients who are to receive REMERON should be warned about the risk of developing  nonoseaeaeonlyasinstruction  Patients should be advised to contact their physician if they experience any indication of  nonoseaeaeonlyasinstruction such as  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or other possible signs of  nonoseaeaeonlyasinstruction  Particular attention should be paid to any flu-like complaints or other symptoms that might suggest  nonoseaeaeonlyasinstruction \n', '\n', '    Interference with Cognitive and Motor Performance\n', '\n', '  REMERON may  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction judgment, thinking, and particularly,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction judgment,  nonoseaeaeonlyasinstruction  and particularly, motor skills, because of its prominent  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,remeron,130,4367,4374,The  nonoseaeaeonlyasinstruction associated with mirtazapine use,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,remeron,131,4374,4394,"may  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction drive,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction drive, use machines, or  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,remeron,132,4394,4627,"Thus, patients should be cautioned about engaging in hazardous activities until they are reasonably certain that REMERON therapy does not  nonoseaenegation \n', '\n', '    Completing Course of Therapy\n', '\n', '  While patients may notice improvement with REMERON therapy in 1 to 4 weeks, they should be advised to continue therapy as directed.\n', '\n', '    Concomitant Medication\n', '\n', '  Patients should be advised to inform their physician if they are taking, or intend to take, any prescription or over-the-counter drugs, since there is a potential for REMERON to interact with other drugs.\n', '\n', "" Patients should be made aware of a potential increased risk for  nonoseaeaeonlyasinstruction if concomitant use of REMERON with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's wort, is clinically warranted, particularly during treatment initiation and dose increases.\n"", '\n', '    Alcohol\n', '\n', '  The  nonoseaeaeonlyasinstruction cognitive and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and motor  nonoseaeaeonlyasinstruction produced by REMERON has been shown to be additive with those produced by alcohol.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
133,remeron,133,4627,4998,"Accordingly, patients should be advised to avoid alcohol while taking mirtazapine.\n', '\n', '    Pregnancy\n', '\n', '  Patients should be advised to notify their physician if they become  nonoseaeaeonlyasinstruction or intend to become  nonoseaeaeonlyasinstruction during REMERON therapy.\n', '\n', '    Nursing\n', '\n', '  Patients should be advised to notify their physician if they are breastfeeding an infant.\n', '\n', '    Laboratory Tests\n', '\n', '  There are no routine laboratory tests recommended.\n', '\n', '    Drug Interactions\n', '\n', '  As with other drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.) is a possibility (see  CLINICAL PHARMACOLOGY  ).\n', '\n', '    Monoamine Oxidase Inhibitors\n', '\n', '  (See  CONTRAINDICATIONS  ,  WARNINGS  , and  DOSAGE AND ADMINISTRATION  .)\n', '\n', '    Serotonergic Drugs\n', '\n', '  (See  CONTRAINDICATIONS  and  WARNINGS  .)\n', '\n', '    Drugs Affecting Hepatic Metabolism\n', '\n', '  The metabolism and pharmacokinetics of REMERON (mirtazapine) Tablets may be affected by the induction or inhibition of drug-metabolizing enzymes.\n', '\n', '    Drugs that are Metabolized by and/or Inhibit Cytochrome P450 Enzymes\n', '\n', '   CYP Enzyme Inducers\n', '\n', '  (these studies used both drugs at steady state)\n', '\n', '    Phenytoin\n', '\n', '  In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,remeron,134,4998,5039,"Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.\n', '\n', '    Carbamazepine\n', '\n', '  In healthy male patients (n=24), carbamazepine (400 mg b.i.d.)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,remeron,135,5039,5047,increased mirtazapine (15 mg b.i.d.),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,remeron,136,5047,5100,"clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 60%.\n', '\n', ' When phenytoin, carbamazepine, or another inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,remeron,137,5100,5147,"If treatment with such a medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.\n', '\n', '    CYP Enzyme Inhibitors\n', '\n', '   Cimetidine\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,remeron,138,5147,5193,"In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,remeron,139,5193,5207,Under the Curve (AUC) of mirtazapine increased more than 50%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,remeron,140,5207,5219,Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,remeron,141,5219,5545,"The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.\n', '\n', '    Ketoconazole\n', '\n', '  In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.\n', '\n', ' Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.\n', '\n', '    Paroxetine\n', '\n', '  In an in vivo  interaction study in healthy, CYP2D6 extensive metabolizer patients (n=24), mirtazapine (30 mg/day), at steady state, did not cause relevant changes in the pharmacokinetics of steady state paroxetine (40 mg/day), a CYP2D6 inhibitor.\n', '\n', '    Other Drug-Drug Interactions\n', '\n', '   Amitriptyline\n', '\n', '  In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.\n', '\n', '    Warfarin\n', '\n', '  In healthy male subjects (n=16), mirtazapine (30 mg daily), at steady state, caused a small (0.2) but statistically significant  nonoseaeaefromdruginteraction  in subjects treated with warfarin.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
142,remeron,142,5545,5639,"As at a higher dose of mirtazapine, a more pronounced effect can not be excluded, it is advisable to monitor the INR in case of concomitant treatment of warfarin with mirtazapine.\n', '\n', '    Lithium\n', '\n', '  No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of lithium (600 mg/day for 10 days) at steady state and a single 30-mg dose of mirtazapine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,remeron,143,5639,5766,"The effects of higher doses of lithium on the pharmacokinetics of mirtazapine are unknown.\n', '\n', '    Risperidone\n', '\n', '  In an in vivo  , nonrandomized, interaction study, subjects (n=6) in need of treatment with an antipsychotic and antidepressant drug, showed that mirtazapine (30 mg daily) at steady state did not influence the pharmacokinetics of risperidone (up to 3 mg b.i.d.).\n', '\n', '    Alcohol\n', '\n', '  Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,remeron,144,5766,5795,"However, the  nonoseaeaefromdruginteraction and motor  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction cognitive and  nonoseaeaefromdruginteraction produced by REMERON were shown to be additive with those produced by alcohol.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
145,remeron,145,5795,5850,"Accordingly, patients should be advised to avoid alcohol while taking REMERON.\n', '\n', '    Diazepam\n', '\n', '  Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,remeron,146,5850,5870,"However, the  nonoseaeaefromdruginteraction produced by REMERON has been shown to be additive with those caused by diazepam.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
147,remeron,147,5870,6029,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON.\n', '\n', '    QTc-Prolonging Drugs\n', '\n', '  The risk of  nonoseaeaefromdruginteraction and/or  nonoseaeaefromdruginteraction (e.g.,  nonoseaeaefromdruginteraction  may be increased with concomitant use of medicines which  nonoseaeaeonlyasinstruction (e.g., some antipsychotics and antibiotics) and in case of mirtazapine overdose (see  ADVERSE REACTIONS  and  OVERDOSE  sections).\n', '\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility\n', '\n', '   Carcinogenesis\n', '\n', '   nonoseaeaeanimal studies were conducted with mirtazapine given in the diet at doses of 2, 20, and 200 mg/kg/day to mice and 2, 20, and 60 mg/kg/day to rats.",1,0,0,0,0,1,0,0,1,0,0,0,0,0,0
148,remeron,148,6029,6068,"The highest doses used are approximately 20 and 12 times the maximum recommended human dose (MRHD) of 45 mg/day on an mg/m  2  basis in mice and rats, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,remeron,149,6068,6092,There was an increased incidence of  nonoseaeaeanimal adenoma and  nonoseaeaeanimal  nonoseaeaeanimal and carcinoma in male mice at the high dose.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
150,remeron,150,6092,6138,"In rats, there was an increase in  nonoseaeaeanimal in females at the mid and high doses and in  nonoseaeaeanimal and  nonoseaeaeanimal adenoma/cystadenoma and  nonoseaeaeanimal  nonoseaeaeanimal  nonoseaeaeanimal adenoma/ nonoseaeaeanimal and carcinoma in males at the high dose.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
151,remeron,151,6138,6337,"The data suggest that the above effects could possibly be mediated by non-genotoxic mechanisms, the relevance of which to humans is not known.\n', '\n', ' The doses used in the mouse study may not have been high enough to fully characterize the  nonoseaeaeonlyasinstruction potential of REMERON (mirtazapine) Tablets.\n', '\n', '    Mutagenesis\n', '\n', '  Mirtazapine was not  nonoseaeaeanimal or  nonoseaeaeanimal and did not induce general DNA damage as determined in several  nonoseaeaeanimal tests: Ames test, in vitro  gene mutation assay in Chinese hamster V 79 cells, in vitro  sister chromatid exchange assay in cultured rabbit lymphocytes, in vivo  bone marrow micronucleus test in rats, and unscheduled DNA synthesis assay in HeLa cells.\n', '\n', '     nonoseaeaeanimal \n', '  In a fertility study in rats, mirtazapine was given at doses up to 100 mg/kg [20 times the maximum recommended human dose (MRHD) on an mg/m  2  basis].",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
152,remeron,152,6337,6395,"Mating and conception were not affected by the drug, but estrous cycling was disrupted at doses that were 3 or more times the MRHD, and  nonoseaeaeanimal occurred at 20 times the MRHD.\n', '\n', '    Pregnancy\n', '\n', '   Teratogenic Effects\n', '\n",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
153,remeron,153,6395,6485,"', '   Pregnancy Category C\n', '\n', '  Reproduction studies in  nonoseaeaeanimal rats and rabbits at doses up to 100 mg/kg and 40 mg/kg, respectively [20 and 17 times the maximum recommended human dose (MRHD) on an mg/m  2  basis, respectively], have revealed no evidence of  nonoseaeaeanimal  However, in rats, there was an increase in  nonoseaeaeanimal in dams treated with mirtazapine.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
154,remeron,154,6485,6514,There was an increase in  nonoseaeaeanimal during the first 3 days of lactation and a  nonoseaeaeanimal  The cause of these  nonoseaegeneralterm is not known.,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0
155,remeron,155,6514,6544,"The effects occurred at doses that were 20 times the MRHD, but not at 3 times the MRHD, on an mg/m  2  basis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,remeron,156,6544,6558,There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
157,remeron,157,6558,6664,"Because animal reproduction studies are not always predictive of human response, this drug should be used during  notaecandidatepreexistingconditionorriskfactor only if clearly needed.\n', '\n', '    Nursing Mothers\n', '\n', '  Because some REMERON may be excreted into breast milk, caution should be exercised when REMERON (mirtazapine) Tablets are administered to nursing women.\n', '\n', '    Pediatric Use\n', '\n', '  Safety and effectiveness in the pediatric population have not been established (see  BOXED WARNING  and  WARNINGS:",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
158,remeron,158,6664,6672,Clinical Worsening and Suicide Risk  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,remeron,159,6672,6710,"Two placebo-controlled trials in 258 pediatric patients with  notaecandidateindication have been conducted with REMERON (mirtazapine) Tablets, and the data were not sufficient to support a claim for use in pediatric patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
160,remeron,160,6710,6782,"Anyone considering the use of REMERON in a child or adolescent must balance the potential risks with the clinical need.\n', '\n', ' In an 8-week-long pediatric clinical trial of doses between 15 to 45 mg/day, 49% of REMERON-treated patients had a  oselabeledaefromdruguse of at least 7%, compared to 5.7% of placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,remeron,161,6782,6815,The mean  oselabeledaefromdruguse was 4 kg (2 kg SD) for REMERON-treated patients versus 1 kg (2 kg SD) for placebo-treated patients (see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,remeron,162,6815,6828,"PRECAUTIONS:  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  ).\n', '\n",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,remeron,163,6828,6834,"', '    Geriatric Use\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,remeron,164,6834,6865,"', '\n', '  Approximately 190 elderly individuals (>=65 years of age) participated in clinical studies with REMERON (mirtazapine) Tablets.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,remeron,165,6865,6917,"This drug is known to be substantially excreted by the kidney (75%), and the risk of decreased clearance of this drug is greater in patients with  notaecandidatepreexistingconditionorriskfactor  Because elderly patients are more likely to have  notaecandidatepreexistingconditionorriskfactor  care should be taken in dose selection.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
166,remeron,166,6917,6927,Sedating drugs may cause  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,remeron,167,6927,6963,"WARNINGS\n', '\n', '   Clinical Worsening and Suicide Risk\n', '\n', '  Patients with  notaecandidateindication , both adult and pediatric, may experience  nonoseaeaeonlyasinstruction",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
168,remeron,168,6963,7004,"and/or the emergence of  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction and behavior ( nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,remeron,169,7004,7005,nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,remeron,170,7005,7029,a known risk of  notaecandidatepreexistingconditionorriskfactor and certain other  notaecandidatepreexistingconditionorriskfactor  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
171,remeron,171,7029,7066,"There has been a long-standing concern, however, that antidepressants may have a role in inducing  oselabeledaeclasseffect and the emergence of  oselabeledaeclasseffect in certain patients during the early phases of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,remeron,172,7066,7218,"Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  oselabeledaeclasseffect and behavior ( oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidateindication  and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an increase in the risk of  nonoseaeaeratelteqplacebo with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.\n', '\n', ' The pooled analyses of placebo-controlled trials in children and adolescents with  notaecandidateindication   notaecandidatepreexistingconditionorriskfactor , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients.",0,0,1,1,0,0,1,0,0,0,0,0,0,0,0
173,remeron,173,7218,7260,"The pooled analyses of placebo-controlled trials in adults with  notaecandidateindication or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
174,remeron,174,7260,7289,"There was considerable variation in risk of  oselabeledaeclasseffect among drugs, but a tendency toward an  oselabeledaeclasseffect in the younger patients for almost all drugs studied.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,remeron,175,7289,7310,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across different indications, with the highest incidence in  notaecandidateindication  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
176,remeron,176,7310,7331,"The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,remeron,177,7331,7414,"These risk differences (drug-placebo difference in the number of cases of  nonoseaeaeonlyasinstruction per 1000 patients treated) are provided in Table 1.\n', '\n', ' Table 1 \n', ' Age Range                  Drug-Placebo Difference in Number of Cases of  oselabeledaeclasseffect per 1000 Patients Treated   \n', '  \n', ' Increases Compared to Placebo   \n', ' <18                        14 additional cases                                                           ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,remeron,178,7414,7426,"\n', ' 18-24                      5 additional cases                                                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,remeron,179,7426,7435,"\n', ' Decreases Compared to Placebo   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,remeron,180,7435,7475,"\n', ' 25-64                      1 fewer case                                                                  \n', ' >=65                       6 fewer cases                                                                 \n', '        No  nonoseaenegation occurred in any of the pediatric trials.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
181,remeron,181,7475,7533,"There were  nonoseaeaeonlyasinstruction in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction risk extends to longer-term use, i.e., beyond several months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,remeron,182,7533,7624,"However, there is substantial evidence from placebo-controlled maintenance trials in adults with  notaecandidateindication that the use of antidepressants can delay the recurrence of  nonoseaeaeonlyasinstruction \n', '\n', '  All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.  ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
183,remeron,183,7624,7692,"\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with antidepressants for  notaecandidateindication as well as for other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
184,remeron,184,7692,7881,"Although a causal link between the emergence of such symptoms and either the  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose  notaecandidateindication is persistently worse, or who are experiencing emergent  nonoseaeaeonlyasinstruction or symptoms that might be precursors to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', '  Families and caregivers of patients being treated with antidepressants for  notaecandidateindication or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to health care providers.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
185,remeron,185,7881,7893,Such monitoring should include daily observation by families and caregivers.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,remeron,186,7893,8008,"Prescriptions for REMERON (mirtazapine) Tablets should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of  nonoseaeaeonlyasinstruction \n', '\n', '    Screening Patients for Bipolar Disorder\n', '\n', '  A  nonoseaeaeonlyasinstruction may be the initial presentation of  notaecandidatepreexistingconditionorriskfactor  It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of  nonoseaeaeonlyasinstruction in patients at risk for  notaecandidatepreexistingconditionorriskfactor  Whether any of the symptoms described above represent such a conversion is unknown.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
187,remeron,187,8008,8058,"However, prior to initiating treatment with an antidepressant, patients with  notaecandidatepreexistingconditionorriskfactor should be adequately screened to determine if they are at risk for  notaecandidatepreexistingconditionorriskfactor  such screening should include a detailed  notaecandidatepreexistingconditionorriskfactor history, including a  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
188,remeron,188,8058,8140,"It should be noted that REMERON (mirtazapine) Tablets are not approved for use in treating  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    Agranulocytosis\n', '\n', '   In premarketing clinical trials, 2 (1 with  notaecandidatepreexistingconditionorriskfactor  out of 2796 patients treated with REMERON (mirtazapine) Tablets developed  oselabeledaefromdruguse [ oselabeledaefromdruguse  with associated signs and symptoms, e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  etc.]",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
189,remeron,189,8140,8157,and a third patient developed severe  oselabeledaefromdruguse ( oselabeledaefromdruguse  without any associated symptoms).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,remeron,190,8157,8182,"For these 3 patients, onset of severe  oselabeledaefromdruguse was detected on days 61, 9, and 14 of treatment, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,remeron,191,8182,8191,All 3 patients recovered after REMERON was stopped.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,remeron,192,8191,8240,"These 3 cases yield a crude incidence of severe  oselabeledaefromdruguse  oselabeledaefromdruguse (with or without  oselabeledaefromdruguse  of approximately 1.1 per thousand patients exposed, with a very wide 95% confidence interval, i.e., 2.2 cases per 10,000 to 3.1 cases per 1000.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,remeron,193,8240,8280,If a patient develops a  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or other signs of  nonoseaemanifestationorcomplication  along with a  nonoseaemanifestationorcomplication  treatment with REMERON should be discontinued and the patient should be closely monitored.  ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
194,remeron,194,8280,8464,"\n', '\n', '    Serotonin Syndrome\n', '\n', ""  The development of a potentially life-threatening  oselabeledaefromdruguse has been reported with SNRIs and SSRIs, including REMERON, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).\n"", '\n', '  nonoseaeaeonlyasinstruction symptoms may include  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaegeneralterm (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication  and/or  nonoseaegeneralterm (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
195,remeron,195,8464,8497,"Patients should be monitored for the emergence of  nonoseaeaeonlyasinstruction \n', '\n', ' The concomitant use of REMERON with MAOIs intended to treat  notaecandidatepreexistingconditionorriskfactor is contraindicated.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
196,remeron,196,8497,8520,REMERON should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,remeron,197,8520,8551,All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,remeron,198,8551,8577,No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,remeron,199,8577,8604,There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking REMERON.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,remeron,200,8604,8828,"REMERON should be discontinued before initiating treatment with the MAOI (see  CONTRAINDICATIONS  and  DOSAGE AND ADMINISTRATION  ).\n', '\n', "" If concomitant use of REMERON with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's wort, is clinically warranted, be aware of a potential increased risk for  nonoseaeaefromdruginteraction  particularly during treatment initiation and dose increases.\n"", '\n', ' Treatment with REMERON and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.\n', '\n', '    Angle-Closure Glaucoma\n', '\n', '  The  oselabeledaefromdruguse that occurs following use of many antidepressant drugs including REMERON may trigger an  oselabeledaefromdruguse in a patient with  notaecandidatepreexistingconditionorriskfactor who does not have a patent iridectomy.\n', '\n', '    QT Prolongation and Torsades de Pointes\n', '\n', '  The  nonoseaeaeonlyasinstruction of REMER nonoseaeaeonlyasinstruction (mirtazapine) on  nonoseaeaeonlyasinstruction was assessed in a clinical randomized trial with placebo and positive (moxifloxacin) controls involving 54 healthy volunteers using exposure response analysis.",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
201,remeron,201,8828,8841,This trial showed a positive relationship between mirtazapine concentrations and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,remeron,202,8841,8877,"However, the degree of  nonoseaeaeonlyasinstruction observed with both 45 mg (therapeutic) and 75 mg (supratherapeutic) doses of mirtazapine was not at a level generally considered to be clinically meaningful.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,remeron,203,8877,8908,"During the postmarketing use of mirtazapine, cases of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  have been reported (see  ADVERSE REACTIONS  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,remeron,204,8908,8951,"The majority of reports occurred in association with  nonoseaeaeonlyasinstruction or in patients with other risk factors for  nonoseaeaeonlyasinstruction  including concomitant use of  nonoseaeaeonlyasinstruction medicines (see  PRECAUTIONS, Drug Interactions  and  OVERDOSE  sections).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,remeron,205,8951,8986,Caution should be exercised when REMERON is prescribed in patients with known  notaecandidatepreexistingconditionorriskfactor or family history of  notaecandidatepreexistingconditionorriskfactor  and in concomitant use with other medicinal products thought to  nonoseaeaeonlyasinstruction '],1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,brilinta,0,0,53,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are also discussed elsewhere in the labeling:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse [ see  Warnings and Precautions (5.1)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,brilinta,1,53,72,"] \n', ' *     oselabeledaefromdruguse [ see  Warnings and Precautions (5.3)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,brilinta,2,72,80,"\n', '      EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,brilinta,3,80,93,Most common adverse reactions are bleeding 12% and dyspnea 14%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,brilinta,4,93,106,"(  5.1  ,  5.3  ,  6.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,brilinta,5,106,397,"\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch  \n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' BRILINTA has been evaluated for safety in more than 27000 patients, including more than 13000 patients treated for at least 1 year.\n', '\n', '\n', '\n', '   Bleeding in PLATO (Reduction in risk of thrombotic events in ACS)  \n', '\n', '\n', '\n', ' Figure 1 is a plot of time to the first non-CABG major  nonoseaeaeonlyasinstruction event.\n', '\n', '\n', '\n', '   Figure 1 - Kaplan-Meier estimate of time to first non-CABG PLATO-defined major bleeding event (PLATO)  \n', '\n', '\n', '\n', ' Frequency of  nonoseaeaeonlyasinstruction in PLATO is summarized in Tables 1 and 2.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,brilinta,6,397,452,"About half of the Non-CABG major  oselabeledaefromdruguse events were in the first 30 days.\n', '\n', '\n', '\n', ' Table 1 - Non-CABG related  oselabeledaefromdruguse (PLATO) \n', '                                                           BRILINTA        N=9235      Clopidogrel    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,brilinta,7,452,454,N=9186     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,brilinta,8,454,482,"\n', '  \n', '                                                          n (%) patients  with event    n (%) patients  with event    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,brilinta,9,482,539,"\n', '  PLATO Major + Minor                                     713 (7.7)                567 (6.2)                \n', '  Major                                                   362 (3.9)                306 (3.3)                \n', '   nonoseaegeneralterm Life-threatening                                  171 (1.9)                151 (1.6)                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
10,brilinta,10,539,725,"\n', '   nonoseaegeneralterm                                                   15 (0.2)                 16 (0.2)                 \n', '   oselabeledaefromdruguse ( nonoseaegeneralterm Life-threatening)        26 (0.3)                 15 (0.2)                 \n', '  PLATO Minor  oselabeledaefromdruguse  requires medical intervention to stop or treat  nonoseaeaeonlyasinstruction   PLATO Major  oselabeledaefromdruguse  any one of the following: fatal;  oselabeledaefromdruguse  oselabeledaefromdruguse  any one of the following: fatal; intracranial;  oselabeledaefromdruguse  oselabeledaefromdruguse  any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g.,  oselabeledaefromdruguse  nonoseaegeneralterm  intracranial; intrapericardial with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication requiring intervention; significantly disabling (e.g., intraocular with permanent  nonoseaemanifestationorcomplication ; associated with a  nonoseaemanifestationorcomplication of at least 3 g/dL (or a  nonoseaemanifestationorcomplication (Hct) of at least 9%); transfusion of 2 or more units.  ",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
11,brilinta,11,725,730,PLATO Major  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,brilinta,12,730,778,nonoseaegeneralterm life-threatening: any major  oselabeledaefromdruguse as described above and associated with a  nonoseaemanifestationorcomplication of more than 5 g/dL (or a  nonoseaemanifestationorcomplication (Hct) of at least 15%); transfusion of 4 or more units.   ,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
13,brilinta,13,778,780,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
14,brilinta,14,780,795,A  oselabeledaefromdruguse event that directly led to  nonoseaegeneralterm within 7 days.    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
15,brilinta,15,795,836,"\n', '         No baseline demographic factor altered the relative risk of  nonoseaeaeonlyasinstruction with BRILINTA compared to clopidogrel.\n', ' \n', '\n', ' In PLATO, 1584 patients underwent CABG surgery.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,brilinta,16,836,963,"The percentages of those patients who  nonoseaeaeonlyasinstruction are shown in Figure 2 and Table 2.\n', '\n', '\n', '\n', ""   Figure 2 - 'Major fatal/life-threatening' CABG-related bleeding by days from last dose of study drug to CABG procedure (PLATO)  \n"", '\n', '\n', '\n', ' X-axis is days from last dose of study drug prior to CABG.\n', '\n', '\n', '\n', ' The PLATO protocol recommended a procedure for withholding study drug prior to CABG or other major surgery without unblinding.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,brilinta,17,963,981,"If surgery was elective or non-urgent, study drug was interrupted temporarily, as follows:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,brilinta,18,981,1028,"If local practice was to allow antiplatelet effects to dissipate before surgery, capsules (blinded clopidogrel) were withheld 5 days before surgery and tablets (blinded ticagrelor) were withheld for a minimum of 24 hours and a maximum of 72 hours before surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,brilinta,19,1028,1063,If local practice was to perform surgery without waiting for dissipation of antiplatelet effects capsules and tablets were withheld 24 hours prior to surgery and use of aprotinin or other haemostatic agents was allowed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,brilinta,20,1063,1152,"If local practice was to use IPA monitoring to determine when surgery could be performed both the capsules and tablets were withheld at the same time and the usual monitoring procedures followed.\n', '\n', '\n', '\n', ' T Ticagrelor; C Clopidogrel\n', '\n', '\n', '\n', ' Table 2 - CABG-related  oselabeledaefromdruguse (PLATO) \n', '                                              BRILINTA90 mg BID  N=770       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,brilinta,21,1152,1165,"Clopidogrel  N=814            \n', '  PLATO Total Major                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,brilinta,22,1165,1212,"626 (81.3)                     666 (81.8)                    \n', '   nonoseaegeneralterm Life-threatening                      337 (43.8)                     350 (43.0)                    \n', '   nonoseaegeneralterm                                       6 (0.8)                        7 (0.9)                       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
23,brilinta,23,1212,1222,"\n', '  PLATO Major  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,brilinta,24,1222,1343,"any one of the following: fatal;  oselabeledaefromdruguse  oselabeledaefromdruguse  any one of the following: fatal; intracranial;  oselabeledaefromdruguse  oselabeledaefromdruguse  any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g.,  oselabeledaefromdruguse  nonoseaegeneralterm  intracranial; intrapericardial with  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication requiring intervention; significantly disabling (e.g., intraocular with permanent  nonoseaemanifestationorcomplication ; associated with a  nonoseaemanifestationorcomplication of at least 3 g/dL (or a  nonoseaemanifestationorcomplication (Hct) of at least 9%); transfusion of 2 or more units.  ",0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
25,brilinta,25,1343,1348,PLATO Major  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,brilinta,26,1348,1396,nonoseaegeneralterm life-threatening: any major  oselabeledaefromdruguse as described above and associated with a  nonoseaemanifestationorcomplication of more than 5 g/dL (or a  nonoseaemanifestationorcomplication (Hct) of at least 15%); transfusion of 4 or more units.    ,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
27,brilinta,27,1396,1401,"\n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,brilinta,28,1401,1656,"When antiplatelet therapy was stopped 5 days before CABG, major  oselabeledaefromdruguse occurred in 75% of BRILINTA treated patients and 79% on clopidogrel.\n', ' \n', '\n', '   Other Adverse Reactions in PLATO  \n', '\n', '\n', '\n', ' Adverse reactions that occurred at a rate of 4% or more in PLATO are shown in Table 3.\n', '\n', '\n', '\n', ' Table 3 - Percentage of patients reporting non-hemorrhagic adverse reactions at least 4% or more in either group and more frequently on BRILINTA (PLATO) \n', '                     BRILINTAN=9235      ClopidogrelN=9186     \n', '  \n', '   oselabeledaefromdruguse           13.8             7.8               \n', '   oselabeledaefromdruguse         4.5              3.9               \n', '   oselabeledaefromdruguse            4.3              3.8               \n', '           Bleeding in PEGASUS (Secondary Prevention in Patients with a History of Myocardial Infarction)  \n', ' \n', '\n', ' Overall outcome of  nonoseaeaeonlyasinstruction events in the PEGASUS study are shown in Table 4.\n', '\n', '\n', '\n', ' Table 4 -  oselabeledaefromdruguse events (PEGASUS) \n', '                                BRILINTA60 mg BID + Aspirin  N=6958    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,brilinta,29,1656,1659,Aspirin Alone  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,brilinta,30,1659,1661,N=6996    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,brilinta,31,1661,1676,"\n', '                                n (%)  patients  with event    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,brilinta,32,1676,1678,Events  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,brilinta,33,1678,1679,/100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,brilinta,34,1679,1688,pt yrs    n patients  with event    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,brilinta,35,1688,1690,Events  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,brilinta,36,1690,1691,/100,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,brilinta,37,1691,1694,pt yrs    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,brilinta,38,1694,1737,"\n', '  TIMI Major                    115 (1.7)           0.78              54 (0.8)               0.34             \n', '        nonoseaegeneralterm                    11 (0.2)            0.08              12 (0.2)               0.08             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,brilinta,39,1737,1801,"\n', '        oselabeledaefromdruguse    28 (0.4)            0.19              23 (0.3)               0.14             \n', '  TIMI Major or Minor           168 (2.4)           1.15              72 (1.0)               0.45             \n', '  TIMI Major:  nonoseaegeneralterm  oselabeledaefromdruguse  OR any  oselabeledaefromdruguse  OR",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,brilinta,40,1801,1833,"clinically overt signs of  oselabeledaefromdruguse associated with a  nonoseaemanifestationorcomplication  of >=5 g/dL, or a  nonoseaemanifestationorcomplication (Hct) of 15%.   ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
41,brilinta,41,1833,1835,nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,brilinta,42,1835,1850,A  oselabeledaefromdruguse event that directly led to  nonoseaegeneralterm within 7 days.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,brilinta,43,1850,1865,TIMI Minor: Clinically apparent with 3-5 g/dL  nonoseaemanifestationorcomplication     ,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
44,brilinta,44,1865,1870,"\n', '           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,brilinta,45,1870,1979,"The  nonoseaeaeonlyasinstruction profile of BRILINTA 60 mg compared to aspirin alone was consistent across multiple pre-defined subgroups (e.g., by age, gender, weight, race, geographic region, concurrent conditions, concomitant therapy, stent, and medical history) for TIMI Major and TIMI Major or Minor  nonoseaeaeonlyasinstruction events.\n', ' \n', '\n', '   Other Adverse Reactions in PEGASUS  \n', '\n', '\n', '\n', ' Adverse reactions that occurred in PEGASUS at rates of 3% or more are shown in Table",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,brilinta,46,1979,1994,"5.\n', '\n', '\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,brilinta,47,1994,2056,"' Table 5 - Non-hemorrhagic adverse reactions reported in >3.0% of patients in the ticagrelor 60 mg treatment group (PEGASUS) \n', '                BRILINTA    N=6958      ClopidogrelN=6996     \n', '  \n', '   oselabeledaefromdruguse      14.2            5.5             \n', '   oselabeledaefromdruguse    4.5             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,brilinta,48,2056,2067,"4.1             \n', '   oselabeledaefromdruguse     3.3             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,brilinta,49,2067,2070,2.5             \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,brilinta,50,2070,2088,"', '           Bradycardia  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,brilinta,51,2088,2134,"In a Holter substudy of about 3000 patients in PLATO, more patients had  oselabeledaefromdruguse with BRILINTA (6.0%) than with clopidogrel (3.5%) in the acute phase; rates were 2.2% and 1.6% respectively after 1 month.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,brilinta,52,2134,2159,"PLATO and PEGASUS excluded patients at increased risk of  notaecandidatepreexistingconditionorriskfactor events (e.g., patients who have  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  2  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
53,brilinta,53,2159,2181,nd  or 3  rd  degree  notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor and not protected with a pacemaker).,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
54,brilinta,54,2181,2209,"In PLATO,  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse were reported by 1.7% and 1.5% of BRILINTA 90 mg and clopidogrel patients, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,brilinta,55,2209,2252,"In PEGASUS,  oselabeledaefromdruguse was reported by 1.2% and 0.9% of patients on BRILINTA 60 mg and aspirin alone, respectively.\n', '\n', '\n', '\n', '     Lab abnormalities    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,brilinta,56,2252,2253,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,brilinta,57,2253,2311,"', '\n', '\n', '\n', ' Serum Uric Acid:\n', '\n', '\n', '\n', ' In PLATO,  oselabeledaefromdruguse approximately 0.6 mg/dL from baseline on BRILINTA 90 mg and approximately 0.2 mg/dL on clopidogrel.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,brilinta,58,2311,2321,The difference disappeared within 30 days of discontinuing treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,brilinta,59,2321,2380,"Reports of  oselabeledaefromdruguse did not differ between treatment groups in PLATO (0.6% in each group).\n', '\n', '\n', '\n', ' In PEGASUS,  oselabeledaefromdruguse approximately 0.2 mg/dL from baseline on BRILINTA 60 mg and no elevation was observed on aspirin alone.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,brilinta,60,2380,2399,"oselabeledaefromdruguse occurred more commonly in patients on BRILINTA than in patients on aspirin alone (1.5%,1.1%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,brilinta,61,2399,2471,"Mean  nonoseaeaeonlyasinstruction concentrations  nonoseaeaeonlyasinstruction  after treatment was stopped.\n', '\n', '\n', '\n', ' Serum Creatinine:\n', '\n', '\n', '\n', ' In PLATO, a >50%  oselabeledaefromdruguse was observed in 7.4% of patients receiving BRILINTA 90 mg compared to 5.9% of patients receiving clopidogrel.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,brilinta,62,2471,2487,The increases typically did not progress with ongoing treatment and often decreased with continued therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,brilinta,63,2487,2504,Evidence of reversibility upon discontinuation was observed even in those with the greatest on treatment increases.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,brilinta,64,2504,2569,"Treatment groups in PLATO did not differ for  oselabeledaefromdruguse such as  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' In PEGASUS,  oselabeledaefromdruguse concentration increased by >50% in approximately 4% of patients receiving BRILINTA 60 mg, similar to aspirin alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,brilinta,65,2569,2586,"The frequency of  oselabeledaefromdruguse \n', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,brilinta,66,2586,2592,WARNING:  (A),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,brilinta,67,2592,2598,"BLEEDING RISK, (B)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,brilinta,68,2598,2607,"ASPIRIN DOSE AND BRILINTA EFFECTIVENESS\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,brilinta,69,2607,2614,"', '  WARNING:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,brilinta,70,2614,2623,"(A) BLEEDING RISK, (B)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,brilinta,71,2623,2641,"ASPIRIN DOSE AND BRILINTA EFFECTIVENESS\n', '\n', '    A.  BLEEDING RISK  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,brilinta,72,2641,2646,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,brilinta,73,2646,2681,"', '\n', '\n', ' *  BRILINTA, like other antiplatelet agents, can cause significant, sometimes  nonoseaegeneralterm  oselabeledaefromdruguse (5.1, 6.1).",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
74,brilinta,74,2681,2710,"\n', ' *  Do not use BRILINTA in patients with active pathological  notaecandidatepreexistingconditionorriskfactor or a history of  notaecandidatepreexistingconditionorriskfactor (4.1, 4.2).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
75,brilinta,75,2710,2738,"\n', ' *  Do not start BRILINTA in patients undergoing urgent coronary artery bypass graft surgery (CABG) (5.1, 6.1).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,brilinta,76,2738,2754,"\n', ' *  If possible, manage  nonoseaeaeonlyasinstruction without discontinuing BRILINTA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,brilinta,77,2754,2787,"Stopping BRILINTA increases the risk of subsequent  nonoseaeaeonlyasinstruction     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,brilinta,78,2787,2804,*    Dyspnea was reported more frequently with BRILINTA than with control agents in clinical trials.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,brilinta,79,2804,2814,Dyspnea resulting from BRILINTA is self-limiting.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,brilinta,80,2814,2818,(5.3)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,brilinta,81,2818,2819,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,brilinta,82,2819,2828,"', ' *    Severe Hepatic Impairment:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,brilinta,83,2828,2836,Likely increase in exposure to ticagrelor.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,brilinta,84,2836,2840,(5.5)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,brilinta,85,2840,2841,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,brilinta,86,2841,2854,"', '    \n', ' \n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,brilinta,87,2854,2881,"', '    5.1 General Risk of Bleeding  \n', '\n', '\n', '\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,brilinta,88,2881,2906,Drugs that inhibit platelet function including BRILINTA increase the risk of  oselabeledaefromdruguse [see   Adverse Reactions (6.1)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,brilinta,89,2906,2933,"\n', '\n', '\n', '\n', '  If possible, manage  nonoseaeaeonlyasinstruction without discontinuing BRILINTA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,brilinta,90,2933,2945,Stopping BRILINTA increases the risk of subsequent  nonoseaeodorwithdrawal [ see        ,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
91,brilinta,91,2945,2963,Warnings and Precautions (5.4)        and  Adverse Reactions (6.1)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,brilinta,92,2963,2989,"\n', '\n', '\n', '\n', '    5.2 Concomitant Aspirin Maintenance Dose\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,brilinta,93,2989,3021,"', '\n', '\n', '  In PLATO the use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,brilinta,94,3021,3065,"Therefore, after the initial loading dose of aspirin, use BRILINTA with a maintenance dose of aspirin of 75-100 mg [ see     Dosage and Administration (2.1)     and     Clinical Studies (14.1)    ] .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,brilinta,95,3065,3170,"\n', '\n', '\n', '\n', '     5.3 Dyspnea  \n', '\n', '\n', '\n', '   In clinical trials, about 14% of patients treated with BRILINTA developed  oselabeledaefromdruguse   oselabeledaefromdruguse was usually mild to moderate in intensity and often resolved during continued treatment, but led to study drug discontinuation in 0.9% of BRILINTA and 0.1% of clopidogrel patients in PLATO and 4.3% of BRILINTA 60 mg and 0.7% on aspirin alone patients in PEGASUS.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,brilinta,96,3170,3207,"\n', '\n', '\n', '\n', '  In a substudy of PLATO, 199 subjects underwent pulmonary function testing irrespective of whether they reported  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,brilinta,97,3207,3231,There was no indication of an  nonoseaenegation function assessed after one month or after at least 6 months of chronic treatment.  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
98,brilinta,98,3231,3282,"\n', '\n', '\n', '\n', '  If a patient develops new, prolonged, or worsened  nonoseaeaeonlyasinstruction that is determined to be related to BRILINTA, no specific treatment is required; continue BRILINTA without interruption if possible.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,brilinta,99,3282,3301,"In the case of intolerable  nonoseaeaeonlyasinstruction requiring discontinuation of BRILINTA, consider prescribing another antiplatelet agent.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,brilinta,100,3301,3383,"\n', '\n', '\n', '\n', '     5.4 Discontinuation of BRILINTA  \n', '\n', '\n', '\n', '   Discontinuation of BRILINTA will increase the risk of  nonoseaeodorwithdrawal   nonoseaeodorwithdrawal  and  nonoseaegeneralterm  If BRILINTA must be temporarily discontinued (e.g., to treat  nonoseaeaeonlyasinstruction or for significant surgery), restart it as soon as possible.",1,1,0,0,0,0,0,0,0,1,0,0,0,0,0
101,brilinta,101,3383,3415,"When possible, interrupt therapy with BRILINTA for five days prior to surgery that has a major risk of  nonoseaeaeonlyasinstruction  Resume BRILINTA as soon as hemostasis is achieved.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,brilinta,102,3415,3439,"\n', '\n', '\n', '\n', '     5.5 Severe Hepatic Impairment  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,brilinta,103,3439,3477,", '\n', '\n', '\n', '   Avoid use of BRILINTA in patients with severe  notaecandidatepreexistingconditionorriskfactor  Severe  notaecandidatepreexistingconditionorriskfactor is likely to increase serum concentration of ticagrelor.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,brilinta,104,3477,3490,There are no studies of BRILINTA patients with severe  notaecandidatepreexistingconditionorriskfactor '],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,biaxin,0,0,30,"['  ADVERSE REACTIONS\n', '\n', '  The majority of side effects observed in clinical trials were of a mild and transient nature.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,biaxin,1,30,61,Fewer than 3% of adult patients without  notaecandidateindication and fewer than 2% of pediatric patients without  notaecandidateindication discontinued therapy because of drug-related side effects.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
2,biaxin,2,61,152,"Fewer than 2% of adult patients taking BIAXIN XL tablets discontinued therapy because of drug-related side effects.\n', '\n', ' The most frequently reported events in adults taking BIAXIN tablets (clarithromycin tablets, USP) were  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (2%),  oselabeledaefromdruguse  oselabeledaefromdruguse pain/ oselabeledaefromdruguse (2%), and  oselabeledaefromdruguse (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,biaxin,3,152,198,"In pediatric patients, the most frequently reported events were  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (3%),  oselabeledaefromdruguse (3%), and  oselabeledaefromdruguse (2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,biaxin,4,198,211,Most of these events were described as mild or moderate in severity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,biaxin,5,211,271,"Of the reported adverse events, only 1% was described as severe.\n', '\n', ' The most frequently reported events in adults taking BIAXIN XL (Clarithromycin extended-release tablets) were  oselabeledaefromdruguse (6%),  oselabeledaefromdruguse (7%), and  oselabeledaefromdruguse (3%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,biaxin,6,271,284,Most of these events were described as mild or moderate in severity.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,biaxin,7,284,353,"Of the reported adverse events, less than 1% were described as severe.\n', '\n', ' In the  notaecandidateindication and  notaecandidateindication studies overall  nonoseaegeneralterm were reported by a similar proportion of patients taking either BIAXIN tablets or BIAXIN XL tablets; however, patients taking BIAXIN XL tablets reported significantly less severe  nonoseaegeneralterm compared to patients taking BIAXIN tablets.",0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
8,biaxin,8,353,379,"In addition, patients taking BIAXIN XL tablets had significantly fewer premature discontinuations for drug-related  nonoseaegeneralterm or abnormal taste  nonoseaegeneralterm  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
9,biaxin,9,379,440,"adverse events compared to BIAXIN tablets.\n', '\n', ' In  notaecandidateindication studies conducted in adults comparing clarithromycin to erythromycin base or erythromycin stearate, there were fewer adverse events involving the digestive system in clarithromycin-treated patients compared to erythromycin-treated patients (13% vs 32%; p < 0.01).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
10,biaxin,10,440,522,"Twenty percent of erythromycin-treated patients discontinued therapy due to adverse events compared to 4% of clarithromycin-treated patients.\n', '\n', ' In two U.S. studies of  notaecandidateindication comparing clarithromycin to amoxicillin/potassium clavulanate in pediatric patients, there were fewer adverse events involving the digestive system in clarithromycin-treated patients compared to amoxicillin/potassium clavulanate-treated patients (21% vs. 40%, p < 0.001).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
11,biaxin,11,522,593,"One-third as many clarithromycin-treated patients reported  oselabeledaefromdruguse as did amoxicillin/potassium clavulanate-treated patients.\n', '\n', '   Post-Marketing Experience\n', '\n', '   oselabeledaefromdruguse ranging from  oselabeledaefromdruguse and mild  oselabeledaefromdruguse to rare cases of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse ,  oselabeledaefromdruguse and  oselabeledaefromdruguse have occurred.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,biaxin,12,593,627,Other spontaneously reported adverse events include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,biaxin,13,627,641,There have been reports of  oselabeledaefromdruguse in patients treated with BIAXIN.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,biaxin,14,641,650,nonoseaeaeonlyasinstruction is usually reversible with professional dental cleaning.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,biaxin,15,650,670,"There have been isolated reports of  oselabeledaefromdruguse  which is usually reversible, occurring chiefly in elderly women.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,biaxin,16,670,743,"Reports of  oselabeledaefromdruguse including  oselabeledaefromdruguse  usually in conjunction with  oselabeledaefromdruguse or  oselabeledaefromdruguse  have also been reported.\n', '\n', '  nonoseaegeneralterm including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported during post-marketing surveillance.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
17,biaxin,17,743,773,"Events usually resolve with discontinuation of the drug.\n', '\n', ' Adverse reactions related to  oselabeledaefromdruguse have been reported in postmarketing experience with clarithromycin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,biaxin,18,773,951,"(See  WARNINGS -  oselabeledaefromdruguse  ).\n', '\n', ' There have been rare reports of  oselabeledaefromdruguse  some of which have occurred in patients taking oral hypoglycemic agents or insulin.\n', '\n', ' There have been post-marketing reports of BIAXIN XL  oselabeledaefromdruguse  many of which have occurred in patients with anatomic (including  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  or functional  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' As with other macrolides, clarithromycin has been associated with  oselabeledaefromdruguse and  oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', ' There have been reports of  oselabeledaefromdruguse coincident with clarithromycin use.\n', '\n', ' There have been post-marketing reports of  nonoseaeaefromdruginteraction with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with  notaecandidatepreexistingconditionorriskfactor   nonoseaegeneralterm have been reported in some such patients.",0,1,1,0,0,1,0,0,0,0,0,0,0,0,0
19,biaxin,19,951,980,"(See  WARNINGS  and  PRECAUTIONS  .)\n', '\n', ' There have been reports of  oselabeledaefromdruguse coincident with clarithromycin use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,biaxin,20,980,1063,"In some reports, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol.\n', '\n', '   Changes in Laboratory Values\n', '\n', '  Changes in laboratory values with possible clinical significance were as follows:\n', '\n', '   Hepatic\n', '\n', '   oselabeledaefromdruguse  oselabeledaefromdruguse SGPT (ALT) < 1%;  oselabeledaefromdruguse  oselabeledaefromdruguse SGPT (ALT)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,biaxin,21,1063,1083,< 1%; SGOT (AST) < 1%;  oselabeledaefromdruguse  oselabeledaefromdruguse SGPT (ALT),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,biaxin,22,1083,1104,< 1%; SGOT (AST) < 1%; GGT < 1%;  oselabeledaefromdruguse  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,biaxin,23,1104,1108,SGPT (ALT),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,biaxin,24,1108,1139,< 1%; SGOT (AST) < 1%; GGT < 1%; alkaline phosphatase < 1%;  oselabeledaefromdruguse  oselabeledaefromdruguse SGPT (ALT),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,biaxin,25,1139,1292,"< 1%; SGOT (AST) < 1%; GGT < 1%; alkaline phosphatase < 1%; LDH < 1%;  oselabeledaefromdruguse < 1%\n', '\n', '   Hematologic\n', '\n', '   oselabeledaefromdruguse < 1%;  oselabeledaefromdruguse 1%\n', '\n', '   Renal\n', '\n', '   oselabeledaefromdruguse 4%;  oselabeledaefromdruguse    PRECAUTIONS\n', '\n', '   General\n', '\n', '  Prescribing BIAXIN in the absence of a proven or strongly suspected  notaecandidateindication or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.\n', '\n', ' Clarithromycin is principally excreted via the liver and kidney.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
26,biaxin,26,1292,1309,Clarithromycin may be administered without dosage adjustment to patients with  notaecandidatepreexistingconditionorriskfactor and normal renal function.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
27,biaxin,27,1309,1391,"However, in the presence of severe  notaecandidatepreexistingconditionorriskfactor with or without coexisting  notaecandidatepreexistingconditionorriskfactor  decreased dosage or prolonged dosing intervals may be appropriate.\n', '\n', ' Clarithromycin in combination with ranitidine bismuth citrate therapy is not recommended in patients with  notaecandidatepreexistingconditionorriskfactor  (See DOSAGE AND ADMINISTRATION  .)\n', '\n', ' Clarithromycin in combination with ranitidine bismuth citrate should not be used in patients with a history of  notaecandidatepreexistingconditionorriskfactor",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
28,biaxin,28,1391,1424,"\n', '\n', '  oselabeledaefromdruguse and new onset of symptoms of  oselabeledaefromdruguse has been reported in patients receiving clarithromycin therapy.\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,biaxin,29,1424,1484,"For information about precautions of other drugs indicated in combination with BIAXIN, refer to the PRECAUTIONS  section of their package inserts.\n', '\n', '    Information to Patients\n', '\n', '  Patients should be counseled that antibacterial drugs including BIAXIN should only be used to treat  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
30,biaxin,30,1484,1497,"They do not treat  notaecandidatecontraindication (e.g., the  notaecandidatecontraindication .",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
31,biaxin,31,1497,1535,"When BIAXIN is prescribed to treat a  notaecandidateindication  patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
32,biaxin,32,1535,1607,"Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by BIAXIN or other antibacterial drugs in the future.\n', '\n', '  oselabeledaeclasseffect is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,biaxin,33,1607,1646,"Sometimes after starting treatment with antibiotics, patients can  oselabeledaeclasseffect (with or without  oselabeledaeclasseffect and  oselabeledaeclasseffect  even as late as two or more months after having taken the last dose of the antibiotic.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,biaxin,34,1646,1726,"If this occurs, patients should contact their physician as soon as possible.\n', '\n', ' BIAXIN may interact with some drugs; therefore patients should be advised to report to their doctor the use of any other medications.\n', '\n', ' BIAXIN tablets and oral suspension can be taken with or without food and can be taken with milk; however, BIAXIN XL tablets should be taken with food.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,biaxin,35,1726,1769,"Do NOT  refrigerate the suspension.\n', '\n', '    Drug Interactions\n', '\n', '  Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,biaxin,36,1769,1794,Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,biaxin,37,1794,1921,"In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg q12h clarithromycin), the steady-state levels of Cmax, Cmin, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.\n', '\n', '  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction  and  nonoseaeaefromdruginteraction have been observed in patients receiving concurrent verapamil, belonging to the calcium channel blockers drug class.\n', '\n', ' Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
38,biaxin,38,1921,1969,"Blood level monitoring of carbamazepine may be considered.\n', '\n', ' When clarithromycin and terfenadine were coadministered, plasma concentrations of the active acid metabolite of terfenadine were threefold higher, on average, than the values observed when terfenadine was administered alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,biaxin,39,1969,1994,The pharmacokinetics of clarithromycin and the 14-OH-clarithromycin were not significantly affected by coadministration of terfenadine once clarithromycin reached steady-state conditions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,biaxin,40,1994,2003,Concomitant administration of clarithromycin with terfenadine is contraindicated.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,biaxin,41,2003,2036,"(See  CONTRAINDICATIONS  .)\n', '\n', ' Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,biaxin,42,2036,2076,"The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and t1/2increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,biaxin,43,2076,2142,"The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin.\n', '\n', ' Coadministration of clarithromycin with ranitidine bismuth citrate resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-hydroxy-clarithromycin plasma concentrations (31%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,biaxin,44,2142,2178,"These effects are clinically insignificant.\n', '\n', ' Simultaneous oral administration of BIAXIN tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,biaxin,45,2178,2214,"Following administration of clarithromycin 500 mg tablets twice daily with zidovudine 100 mg every 4 hours, the steady-state zidovudine AUC decreased 12% compared to administration of zidovudine alone (n=4).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,biaxin,46,2214,2230,Individual values ranged from a decrease of 34% to an increase of 14%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,biaxin,47,2230,2260,"When clarithromycin tablets were administered two to four hours prior to zidovudine, the steady-state zidovudine Cmaxincreased 100% whereas the AUC was unaffected (n=24).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,biaxin,48,2260,2274,Administration of clarithromycin and zidovudine should be separated by at least two hours.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,biaxin,49,2274,2363,"The impact of co-administration of clarithromycin extended-release tablets and zidovudine has not been evaluated.\n', '\n', ' Simultaneous administration of BIAXIN tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.\n', '\n', ' Following administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers, the steady-state clarithromycin Cminand AUC increased 33% and 18%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,biaxin,50,2363,2380,Steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,biaxin,51,2380,2442,"No dosage adjustment of clarithromycin is necessary when co-administered with fluconazole.\n', '\n', '    Ritonavir\n', '\n', '  Concomitant administration of clarithromycin and ritonavir (n = 22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,biaxin,52,2442,2458,Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,biaxin,53,2458,2500,"Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to  notaecandidateindication (see PRECAUTIONS - Drug   Interactions  ).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
54,biaxin,54,2500,2551,"Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.\n', '\n', ' Spontaneous reports in the post-marketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,biaxin,55,2551,2592,"Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously.\n', '\n', ' Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,biaxin,56,2592,2614,"When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,biaxin,57,2614,2634,Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in post-marketing surveillance.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,biaxin,58,2634,2652,Some patients have shown clinical signs consistent with  nonoseaeaefromdruginteraction  including potentially  nonoseaegeneralterm  nonoseaeaefromdruginteraction  ,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
59,biaxin,59,2652,2771,"Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.\n', '\n', ' Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.\n', '\n', ' Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,biaxin,60,2771,2818,"Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.\n', '\n', ' The following are examples of some clinically significant CYP3A based drug interactions.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,biaxin,61,2818,2904,"Interactions with other drugs metabolized by the CYP3A isoform are also possible.\n', '\n', '    Carbamazepine and Terfenadine\n', '\n', '  Increased serum concentrations of carbamazepine and the active acid metabolite of terfenadine were observed in clinical trials with clarithromycin.\n', '\n', '    Colchicine\n', '\n', '  Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,biaxin,62,2904,2916,Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,biaxin,63,2916,2952,"When a single dose of colchicine 0.6 mg was administered with clarithromycin 250 mg BID for 7 days, the colchicine Cmaxincreased 197% and the AUC0-increased 239% compared to administration of colchicine alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,biaxin,64,2952,2974,The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,biaxin,65,2974,3065,"Concomitant use of clarithromycin and colchicine is contraindicated in patients with  notaecandidatepreexistingconditionorriskfactor or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  (See WARNINGS  ).\n', '\n', '    Efavirenz, Nevirapine, Rifampicin, Rifabutin, and Rifapentine\n', '\n', '  Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
66,biaxin,66,3065,3097,"Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,biaxin,67,3097,3154,"Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A.\n', '\n', '    Sildenafil, Tadalafil, and Vardenafil\n', '\n', '  Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,biaxin,68,3154,3176,"Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,biaxin,69,3176,3178,Co-,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,biaxin,70,3178,3216,"administration of these phosphodiesterase inhibitors with clarithromycin is not recommended.\n', '\n', '    Tolterodine\n', '\n', '  The primary route of metabolism for tolterodine is via CYP2D6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,biaxin,71,3216,3236,"However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,biaxin,72,3236,3253,"In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,biaxin,73,3253,3341,"Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin.\n', '\n', '    Triazolobenzodiazepines (e.g., alprazolam, midazolam, triazolam)\n', '\n', '  When a single dose of midazolam was co-administered with clarithromycin tablets (500 mg twice daily for 7 days), midazolam AUC increased 174% after intravenous administration of midazolam and 600% after oral administration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,biaxin,74,3341,3367,"When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,biaxin,75,3367,3386,Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,biaxin,76,3386,3450,"For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.\n', '\n', ' There have been post-marketing reports of drug interactions and  nonoseaeaefromdruginteraction (e.g.,  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  with the concomitant use of clarithromycin and triazolam.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
77,biaxin,77,3450,3500,"Monitoring the patient for increased CNS pharmacological effects is suggested.\n', '\n', '    Atazanavir\n', '\n', '  Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,biaxin,78,3500,3541,"Following administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily), the clarithromycin AUC increased 94%, the 14-OH clarithromycin AUC decreased 70% and the atazanavir AUC increased 28%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,biaxin,79,3541,3561,"When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50%.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,biaxin,80,3561,3602,"Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to  notaecandidateindication (see PRECAUTIONS - Drug Interactions  ).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
81,biaxin,81,3602,3637,"Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.\n', '\n', '    Itraconazole\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,biaxin,82,3637,3661,"Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,biaxin,83,3661,3680,"Clarithromycin may increase the plasma concentrations of itraconazole, while itraconazole may increase the plasma concentrations of clarithromycin.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,biaxin,84,3680,3739,"Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.\n', '\n', '    Saquinavir\n', '\n', '  Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,biaxin,85,3739,3785,"Following administration of clarithromycin (500 mg bid) and saquinavir (soft gelatin capsules, 1200 mg tid) to 12 healthy volunteers, the steady-state saquinavir AUC and Cmaxincreased 177% and 187% respectively compared to administration of saquinavir alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,biaxin,86,3785,3817,"Clarithromycin AUC and Cmaxincreased 45% and 39% respectively, whereas the 14-OH clarithromycin AUC and Cmaxdecreased 24% and 34% respectively, compared to administration with clarithromycin alone.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,biaxin,87,3817,3839,No dose adjustment of clarithromycin is necessary when clarithromycin is co-administered with saquinavir in patients with normal renal function.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,biaxin,88,3839,3943,"When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to interaction between clarithromycin and ritonavir) (see PRECAUTIONS - Drug Interactions  ).\n', '\n', ' The following CYP3A based drug interactions have been observed with erythromycin products and/or with clarithromycin in post-marketing experience:\n', '\n', '    Antiarrhythmics\n', '\n', '  There have been post-marketing reports of  nonoseaeaefromdruginteraction occurring with concurrent use of clarithromycin and quinidine or disopyramide.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
89,biaxin,89,3943,3958,Electrocardiograms should be monitored for  nonoseaeaefromdruginteraction during coadministration of clarithromycin with these drugs.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
90,biaxin,90,3958,4014,"Serum concentrations of these medications should also be monitored.\n', '\n', '    Ergotamine/Dihydroergotamine\n', '\n', '  Post-marketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with  nonoseaeaefromdruginteraction characterized by  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
91,biaxin,91,4014,4103,"the extremities and other  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction extremities and other tissues including the  nonoseaeaefromdruginteraction  Concomitant administration of clarithromycin with ergotamine or dihydroergotamine is contraindicated (see CONTRAINDICATIONS  ).\n', '\n', '    Triazolobenziodidiazepines (Such as Triazolam and Alprazolam) and Related Benzodiazepines (Such as Midazolam)\n', '\n', '  Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
92,biaxin,92,4103,4167,"There have been post-marketing reports of drug interactions and  nonoseaeaefromdruginteraction (e.g.,  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  with the concomitant use of clarithromycin and triazolam.\n', '\n', '    Sildenafil (Viagra)\n', '\n', '  Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
93,biaxin,93,4167,4183,A similar interaction may occur with clarithromycin; reduction of sildenafil dosage should be considered.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,biaxin,94,4183,4342,"(See Viagra package insert.)\n', '\n', ' There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, bromocriptine and vinblastine.\n', '\n', ' Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS  .)\n', '\n', ' In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.\n', '\n', '    Carcinogenesis, Mutagenesis, Impairment of Fertility\n', '\n', '  The following in vitro  mutagenicity tests have been conducted with clarithromycin:\n', '\n', '  Salmonella  /Mammalian",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,biaxin,95,4342,4346,"Microsomes Test\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,biaxin,96,4346,4364,"'\n', ' Bacterial Induced Mutation Frequency Test\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,biaxin,97,4364,4540,"In Vitro  Chromosome Aberration Test\n', '\n', ' Rat Hepatocyte DNA Synthesis Assay\n', '\n', ' Mouse Lymphoma Assay\n', '\n', ' Mouse Dominant Lethal Study\n', '\n', ' Mouse Micronucleus Test\n', '\n', ' All tests had negative results except the In Vitro  Chromosome Aberration Test which was weakly positive in one test and negative in another.\n', '\n', ' In addition, a Bacterial Reverse-Mutation Test (Ames Test) has been performed on clarithromycin metabolites with negative results.\n', '\n', ' Fertility and reproduction studies have shown that daily doses of up to 160 mg/kg/day (1.3 times the recommended maximum human dose based on mg/m  2  ) to male and female rats caused no adverse effects on the estrous cycle, fertility, parturition, or number and viability of offspring.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,biaxin,98,4540,4586,"Plasma levels in rats after 150 mg/kg/day were 2 times the human serum levels.\n', '\n', ' In the 150 mg/kg/day monkey studies, plasma levels were 3 times the human serum levels.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,biaxin,99,4586,4624,"When given orally at 150 mg/kg/day (2.4 times the recommended maximum human dose based on mg/m  2  ), clarithromycin was shown to produce  nonoseaeaeanimal in monkeys.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
100,biaxin,100,4624,4737,"This effect has been attributed to marked  nonoseaeaeanimal of the drug at this high dose.\n', '\n', ' In rabbits, in utero   nonoseaeaeanimal occurred at an intravenous dose of 33 mg/m  2  , which is 17 times less than the maximum proposed human oral daily dose of 618 mg/m  2  .\n', '\n', ' Long-term studies in animals have not been performed to evaluate the carcinogenic potential of clarithromycin.\n', '\n', '    Pregnancy\n', '\n', '   Teratogenic Effects\n', '\n",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
101,biaxin,101,4737,4843,"', '   Pregnancy Category C\n', '\n', '  Four  nonoseaeaeonlyasinstruction studies in rats (three with oral doses and one with intravenous doses up to 160 mg/kg/day administered during the period of major organogenesis) and two in rabbits at oral doses up to 125 mg/kg/day (approximately 2 times the recommended maximum human dose based on mg/m  2  ) or intravenous doses of 30 mg/kg/day administered during gestation days 6 to 18 failed to demonstrate any  nonoseaenegation from clarithromycin.",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
102,biaxin,102,4843,4882,Two additional oral studies in a different rat strain at similar doses and similar conditions demonstrated a low incidence of  nonoseaeaeanimal at doses of 150 mg/kg/day administered during gestation days 6 to 15.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
103,biaxin,103,4882,4899,Plasma levels after 150 mg/kg/day were 2 times the human serum levels.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,biaxin,104,4899,4949,"Four studies in mice revealed a variable incidence of  nonoseaeaeanimal following oral doses of 1000 mg/kg/day (2 and 4 times the recommended maximum human dose based on mg/m  2  , respectively) during gestation days 6 to 15.  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
105,biaxin,105,4949,4961,nonoseaeaeanimal was also seen at 500 mg/kg/day.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
106,biaxin,106,4961,4980,The 1000 mg/kg/day exposure resulted in plasma levels 17 times the human serum levels.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,biaxin,107,4980,5047,"In monkeys, an oral dose of 70 mg/kg/day (an approximate equidose of the recommended maximum human dose based on mg/m  2  ) produced  nonoseaeaeanimal at plasma levels that were 2 times the human serum levels.\n', '\n', ' There are no adequate and well-controlled studies in  notaecandidatepreexistingconditionorriskfactor women.",0,0,1,0,0,0,0,0,1,0,0,0,0,0,0
108,biaxin,108,5047,5100,"Clarithromycin should be used during  nonoseaeaeonlyasinstruction only if the potential benefit justifies the potential  nonoseaeaeonlyasinstruction  (See WARNINGS  .)\n', '\n', '    Nursing Mothers\n', '\n', '  It is not known whether clarithromycin is excreted in human milk.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,biaxin,109,5100,5122,"Because many drugs are excreted in human milk, caution should be exercised when clarithromycin is administered to a nursing woman.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,biaxin,110,5122,5148,It is known that clarithromycin is excreted in the milk of lactating animals and that other drugs of this class are excreted in human milk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,biaxin,111,5148,5223,"Preweaned rats, exposed indirectly via consumption of milk from dams treated with 150 mg/kg/day for 3 weeks, were not adversely affected, despite data indicating higher drug levels in milk than in plasma.\n', '\n', '    Pediatric Use\n', '\n', '  Safety and effectiveness of clarithromycin in pediatric patients under 6 months of age have not been established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,biaxin,112,5223,5242,The safety of clarithromycin has not been studied in  notaecandidateindication patients under the age of 20 months.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
113,biaxin,113,5242,5256,Neonatal and juvenile animals tolerated clarithromycin in a manner similar to adult animals.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,biaxin,114,5256,5371,"Young animals were slightly more intolerant to acute overdosage and to subtle  nonoseaeaeanimal  nonoseaeaeanimal erythrocytes,  nonoseaeaeanimal  nonoseaeaeanimal in erythrocytes, platelets and  nonoseaeaeanimal but were less sensitive to toxicity in the liver, kidney, thymus, and genitalia.\n', '\n', '    Geriatric Use\n', '\n', '  In a steady-state study in which healthy elderly subjects (age 65 to 81 years old) were given 500 mg every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH clarithromycin were increased compared to those achieved in healthy young adults.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
115,biaxin,115,5371,5383,These changes in pharmacokinetics parallel known age-related  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,biaxin,116,5383,5404,"In clinical trials, elderly patients did not have an increased incidence of adverse events when compared to younger patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,biaxin,117,5404,5451,"Dosage adjustment should be considered in elderly patients with  notaecandidatepreexistingconditionorriskfactor    WARNINGS\n', '\n', '    oselabeledaefromdruguse \n', '   CLARITHROMYCIN SHOULD NOT BE USED IN  notaecandidatepreexistingconditionorriskfactor WOMEN EXCEPT IN CLINICAL CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
118,biaxin,118,5451,5492,"IF  nonoseaeaeonlyasinstruction OCCURS WHILE TAKING THIS DRUG, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL  oselabeledaefromdruguse  CLARITHROMYCIN HAS DEMONSTRATED  nonoseaeaeanimal AND/OR  nonoseaeaeanimal IN MONKEYS, RATS, MICE, AND RABBITS AT DOSES",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
119,biaxin,119,5492,5495,THAT PRODUCED PLASMA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,biaxin,120,5495,5500,LEVELS 2 TO 17 TIMES,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,biaxin,121,5500,5507,THE SERUM LEVELS ACHIEVED IN HUMANS TREATED,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,biaxin,122,5507,5514,AT THE MAXIMUM RECOMMENDED HUMAN DOSES.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,biaxin,123,5514,5524,(See PRECAUTIONS -    Pregnancy     .)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,biaxin,124,5524,5567,"\n', '\n', '     oselabeledaefromdruguse \n', '   oselabeledaefromdruguse  including  oselabeledaefromdruguse  and  oselabeledaefromdruguse and/or cholestatic  oselabeledaefromdruguse  oselabeledaefromdruguse  with or without  nonoseaemanifestationorcomplication  has been reported with clarithromycin.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
125,biaxin,125,5567,5578,This  oselabeledaefromdruguse may be severe and is usually reversible.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,biaxin,126,5578,5604,"In some instances,  oselabeledaefromdruguse with  nonoseaegeneralterm outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,biaxin,127,5604,5648,"Discontinue clarithromycin immediately if signs and symptoms of  nonoseaeaeonlyasinstruction occur.\n', '\n', '    Drug Interactions\n', '\n', '  Serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,biaxin,128,5648,5724,"These include  nonoseaeaefromdruginteraction with colchicine;  nonoseaeaefromdruginteraction with simvastatin, lovastatin, and atorvastatin; and  nonoseaeaefromdruginteraction with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) (see CONTRAINDICATIONS  and PRECAUTIONS   -   Drug Interactions  ).\n', '\n', ' Life-threatening and  nonoseaegeneralterm  nonoseaeaefromdruginteraction have been reported in patients treated with clarithromycin and colchicine.",0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
129,biaxin,129,5724,5744,Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,biaxin,130,5744,5771,"If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, the dose of colchicine should be reduced.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,biaxin,131,5771,5936,"Patients should be monitored for clinical symptoms of  nonoseaeaeonlyasinstruction  Concomitant administration of clarithromycin and colchicine is contraindicated in patients with  notaecandidatepreexistingconditionorriskfactor or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor (see CONTRAINDICATIONS  and PRECAUTIONS - Drug Interactions  ).\n', '\n', '     Clostridium difficile  Associated Diarrhea\n', '\n', '    oselabeledaefromdruguse  has been reported with use of nearly all antibacterial agents, including BIAXIN, and may range in severity from mild  oselabeledaefromdruguse to  nonoseaegeneralterm  oselabeledaefromdruguse  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of  nonoseaeaeonlyasinstruction  .\n', '\n', '   nonoseaeaeonlyasinstruction  produces toxins A and B which contribute to the development of  nonoseaeaeonlyasinstruction  Hypertoxin producing strains of  nonoseaeaeonlyasinstruction  cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
132,biaxin,132,5936,5952,nonoseaeaeonlyasinstruction must be considered in all patients who present with  nonoseaeaeonlyasinstruction following antibiotic use.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,biaxin,133,5952,6004,"Careful medical history is necessary since  oselabeledaeclasseffect has been reported to occur over two months after the administration of antibacterial agents.\n', '\n', ' If  nonoseaeaeonlyasinstruction is suspected or confirmed, ongoing antibiotic use not directed against  nonoseaeaeonlyasinstruction  may need to be discontinued.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,biaxin,134,6004,6213,"Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of  nonoseaeaeonlyasinstruction  , and surgical evaluation should be instituted as clinically indicated.\n', '\n', ' For information about warnings of other drugs indicated in combination with BIAXIN, refer to the WARNINGS  section of their package inserts.\n', '\n', ' Due to the risk for  oselabeledaefromdruguse clarithromycin should be used with caution in patients with a medical condition associated with an increased tendency toward  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor  .\n', '\n', ' In the event of severe acute  oselabeledaefromdruguse  such as  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse , and  oselabeledaefromdruguse clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.\n', '\n', '    Oral Hypoglycemic Agents/Insulin\n', '\n', '  The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant  nonoseaeaefromdruginteraction  With certain  nonoseaeaeonlyasinstruction drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause  nonoseaeaefromdruginteraction when used concomitantly.",1,0,1,0,0,1,0,0,0,0,0,0,0,0,0
135,biaxin,135,6213,6265,"Careful monitoring of glucose is recommended.\n', '\n', '    Oral Anticoagulants\n', '\n', '  There is a risk of serious  nonoseaeaefromdruginteraction and significant  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction in INR and  nonoseaeaefromdruginteraction when clarithromycin is co-administered with warfarin.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
136,biaxin,136,6265,6319,"INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.\n', '\n', '    HMG-CoA Reductase Inhibitors\n', '\n', '  Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see CONTRAINDICATIONS  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,biaxin,137,6319,6338,"As with other macrolides, clarithromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,biaxin,138,6338,6353,Rare reports of  nonoseaeaefromdruginteraction have been reported in patients taking these drugs concomitantly.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
139,biaxin,139,6353,6379,"Patients should be monitored for signs and symptoms of  nonoseaeaeonlyasinstruction \n', '\n', ' Rare reports of  nonoseaeaefromdruginteraction ']",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
0,folotyn,0,0,57,"['    6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are described below and elsewhere in the labeling:\n', '\n', '\n', '\n', ' *   oselabeledaefromdruguse [see Warnings and Precautions (  5.1  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,folotyn,1,57,64,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,folotyn,2,64,76,[see Warnings and Precautions (  5.2  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,folotyn,3,76,83,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,folotyn,4,83,95,[see Warnings and Precautions (  5.3  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,folotyn,5,95,102,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,folotyn,6,102,114,[see Warnings and Precautions (  5.4  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,folotyn,7,114,121,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,folotyn,8,121,133,[see Warnings and Precautions (  5.5  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,folotyn,9,133,201,"\n', '    The most common adverse reactions observed in patients with  notaecandidateindication (PTCL) treated with FOLOTYN were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', ' \n', '\n', '   EXCERPT:   Most common adverse reactions (>35%) are mucositis, thrombocytopenia, nausea, and fatigue.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
10,folotyn,10,201,223,"Most common serious adverse reactions are pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, and thrombocytopenia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,folotyn,11,223,228,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,folotyn,12,228,273,"\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Allos Therapeutics, Inc at 1-888-ALLOS88 (1-888-255-6788) or    www.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,folotyn,13,273,285,FOLOTYN.com    or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,folotyn,14,285,322,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,folotyn,15,322,423,"Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The safety of FOLOTYN was evaluated in 111  notaecandidateindication patients in a single-arm clinical study in which patients received a starting dose of 30 mg/m  2  once weekly for 6 weeks in 7-week cycles.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
16,folotyn,16,423,567,"The median duration of treatment was 70 days (range 1-540 days).\n', '\n', '\n', '\n', '     Most Frequent Adverse Reactions  \n', '\n', '\n', '\n', '   Table 4  summarizes the most frequent adverse reactions, regardless of causality, using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0).\n', '\n', '\n', '\n', ' Table 4 Adverse Reactions Occurring in PTCL Patients (Incidence >= 10% of patients) \n', '                                                                N=111     \n', '   Total                                                        Grade 3      Grade 4     \n', '   Preferred Term                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,folotyn,17,567,610,"N       %       N       %       N       %      \n', '  \n', '  a oselabeledaefromdruguse or  oselabeledaefromdruguse the  oselabeledaefromdruguse and genitourinary  oselabeledaefromdruguse  oselabeledaefromdruguse the gastrointestinal and  oselabeledaefromdruguse .    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,folotyn,18,610,621,"\n', '  bFive patients with  oselabeledaefromdruguse                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,folotyn,19,621,642,"\n', '  c oselabeledaefromdruguse  aspartate aminotransferase, and transaminases  oselabeledaefromdruguse  oselabeledaefromdruguse  and transaminases  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,folotyn,20,642,646,oselabeledaefromdruguse  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,folotyn,21,646,743,"\n', '  \n', ' Any Adverse Event                                            111     100     48      43      34      31       \n', '         oselabeledaefromdruguse  a                                          78      70      19      17      4       4        \n', '         oselabeledaefromdruguse  b                                   45      41      15      14      21      19  b     \n', '         oselabeledaefromdruguse                                                44      40      4       4       0       0        \n', '         oselabeledaefromdruguse                                               40      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,folotyn,22,743,753,36      5       5       2       2        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,folotyn,23,753,764,"\n', '         oselabeledaefromdruguse                                                38      34      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,folotyn,24,764,766,17      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,folotyn,25,766,772,15      2       2        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,folotyn,26,772,802,"\n', '         oselabeledaefromdruguse                                          37      33      0       0       0       0        \n', '         oselabeledaefromdruguse                                               36      32      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,folotyn,27,802,810,1       1       1       1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,folotyn,28,810,821,"\n', '         oselabeledaefromdruguse                                                 33      30      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,folotyn,29,821,840,"1       1       0       0        \n', '         oselabeledaefromdruguse                                                 31      28      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,folotyn,30,840,876,"1       1       0       0        \n', '         oselabeledaefromdruguse                                             29      26      0       0       0       0        \n', '         oselabeledaefromdruguse                                              28      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,folotyn,31,876,878,25      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,folotyn,32,878,897,"2       2       0       0        \n', '         oselabeledaefromdruguse                                           27      24      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,folotyn,33,897,899,14      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,folotyn,34,899,901,13      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,folotyn,35,901,905,8       7        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,folotyn,36,905,912,"\n', '         oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,folotyn,37,912,927,"23      21      2       2       0       0        \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,folotyn,38,927,931,'         oselabeledaefromdruguse                                               ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,folotyn,39,931,950,"21      19      8       7       0       0        \n', '         oselabeledaefromdruguse                                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,folotyn,40,950,952,17      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,folotyn,41,952,954,15      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,folotyn,42,954,971,"3       3       0       0        \n', '         oselabeledaefromdruguse                                           17      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,folotyn,43,971,981,15      4       4       1       1        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,folotyn,44,981,1011,"\n', '         oselabeledaefromdruguse                                                  17      15      0       0       0       0        \n', '         oselabeledaefromdruguse                                              16      14      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,folotyn,45,1011,1030,"2       2       0       0        \n', '         oselabeledaefromdruguse                                15      14      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,folotyn,46,1030,1045,"1       1       0       0        \n', '         oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,folotyn,47,1045,1051,c                       14      13      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,folotyn,48,1051,1097,"6       5       0       0        \n', '         oselabeledaefromdruguse                                        13      12      4       4       0       0        \n', '         oselabeledaefromdruguse                                     13      12      0       0       0       0        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,folotyn,49,1097,1108,"\n', '         oselabeledaefromdruguse                                             12      11      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,folotyn,50,1108,1125,"3       3       0       0        \n', '         oselabeledaefromdruguse                                            12      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,folotyn,51,1125,1127,11      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,folotyn,52,1127,1135,3       3       4       4        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,folotyn,53,1135,1165,"\n', '         oselabeledaefromdruguse                                          12      11      0       0       0       0        \n', '         oselabeledaefromdruguse                                              11      10      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,folotyn,54,1165,1182,"1       1       0       0        \n', '         oselabeledaefromdruguse                                           11      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,folotyn,55,1182,1186,10      0       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,folotyn,56,1186,1220,"0       0       0        \n', '         oselabeledaefromdruguse                     11      10      1       1       0       0        \n', '                 Serious Adverse Events  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,folotyn,57,1220,1262,"\n', ' \n', '\n', ' Forty-four percent of patients (n = 49) experienced a serious adverse event while on study or within 30 days after their last dose of FOLOTYN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,folotyn,58,1262,1296,"The most common serious adverse events (> 3%), regardless of causality, were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,folotyn,59,1296,1318,One  nonoseaegeneralterm from  nonoseaeaeonlyasinstruction in a patient with  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction was reported in this trial.  ,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
60,folotyn,60,1318,1411,"nonoseaegeneralterm from  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  oselabeledaefromdruguse occurred in 1.2% of patients treated on all FOLOTYN trials at doses ranging from 30 to 325 mg/m  2  .\n', '\n', '\n', '\n', '     Discontinuations  \n', '\n', '\n', '\n', ' Twenty-three percent of patients (n = 25) discontinued treatment with FOLOTYN due to adverse reactions.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
61,folotyn,61,1411,1502,"The adverse reactions reported most frequently as the reason for discontinuation of treatment were  oselabeledaefromdruguse (6%, n = 7) and  oselabeledaefromdruguse (5%, n = 5).\n', '\n', '\n', '\n', '     Dose Modifications  \n', '\n', '\n', '\n', ' The target dose of FOLOTYN was 30 mg/m  2  once weekly for 6 weeks in 7-week cycles.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,folotyn,62,1502,1525,"The majority of patients (69%, n = 77) remained at the target dose for the duration of treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,folotyn,63,1525,1647,"Overall, 85% of scheduled doses were administered.\n', '\n', '\n', '\n', '   6.2 Post Marketing Experience\n', '\n', '  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '     Dermatologic Reactions  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse  sometimes  nonoseaegeneralterm  has been reported during post-marketing use of FOLOTYN.  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
64,folotyn,64,1647,1721,"nonoseaegeneralterm cases have been reported following the first dose of FOLOTYN, including when a reduced dose is given, and have been reported in patients with  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *  Thrombocytopenia, neutropenia, and anemia: Monitor blood counts and omit and/or reduce dose for hematologic toxicities.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
65,folotyn,65,1721,1743,"(  2.2  ,  5.1  ) \n', ' *  Mucositis: Monitor at least weekly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,folotyn,66,1743,1757,"If >= Grade 2 mucositis is observed, omit and/or reduce dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,folotyn,67,1757,1795,"(  2.2  ,  5.2  ) \n', ' *  Dermatologic reactions: Reactions, including fatal reactions, have occurred and may be progressive and increase in severity with further treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,folotyn,68,1795,1807,"Monitor closely, and omit and/or reduce dose or discontinue FOLOTYN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,folotyn,69,1807,1820,"(  2.2  ,  5.3  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,folotyn,70,1820,1834,"*  Tumor lysis syndrome: Anticipate, monitor, and treat promptly.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,folotyn,71,1834,1852,"(  5.4  ) \n', ' *  Hepatic toxicity: Monitor for toxicity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,folotyn,72,1852,1874,"For liver function test abnormalities Grade 3 or greater, omit until recovery then reduce dose or discontinue therapy as required.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,folotyn,73,1874,1916,"(  2.2  ,  5.5  ) \n', ' *  Risk of increased toxicity with renal impairment: Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,folotyn,74,1916,1929,Monitor patients for renal function and systemic toxicity and adjust dosing accordingly.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,folotyn,75,1929,1952,Avoid FOLOTYN use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,folotyn,76,1952,1965,"(  2.2  ,  5.6  ,  6.2  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,folotyn,77,1965,1966,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,folotyn,78,1966,1987,"', ' *  Embryo-Fetal toxicity: Women should avoid becoming pregnant while being treated with FOLOTYN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,folotyn,79,1987,1998,Inform pregnant women of the potential harm to the fetus.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,folotyn,80,1998,2007,"(  5.7  ,  8.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,folotyn,81,2007,2068,"\n', '    \n', ' \n', '\n', '   5.1 Bone Marrow Suppression\n', '\n', '\n', '\n', '  FOLOTYN can cause  oselabeledaefromdruguse  manifested by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication  Monitor complete blood counts and omit",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
82,folotyn,82,2068,2093,and/or reduce the dose based on ANC and platelet count prior to each dose as outlined in Section  2.2     Table 2  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,folotyn,83,2093,2210,"Administer vitamin B12and instruct patients to take folic acid to reduce the risk of treatment-related  nonoseaeaeonlyasinstruction [ see Dosage and Administration (  2.1  )(  2.2  ) and Adverse Reactions (  6.1  )  ].\n', '\n', '\n', '\n', '    5.2 Mucositis\n', '\n', '\n', '\n', '  FOLOTYN can cause  oselabeledaefromdruguse  Monitor for  nonoseaeaeonlyasinstruction weekly and if >= Grade 2  nonoseaeaeonlyasinstruction is observed, omit and/or reduce the dose as outlined in Section  2.2     Table 1  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,folotyn,84,2210,2342,"Administer vitamin B12and instruct patients to take folic acid to reduce the risk of  nonoseaeaeonlyasinstruction [ see Dosage and Administration (  2.1  )(2.2  ) and Adverse Reactions (  6.1  )  ].\n', '\n', '\n', '\n', '    5.3 Dermatologic Reactions\n', '\n', '\n', '\n', '  FOLOTYN can cause severe  oselabeledaefromdruguse  which may result in  nonoseaegeneralterm  These  oselabeledaefromdruguse have been reported in clinical studies (14/663 patients [2.1%]) and post marketing experience, and have included  oselabeledaefromdruguse  oselabeledaefromdruguse exfoliation,  oselabeledaefromdruguse  and  oselabeledaefromdruguse (TEN).  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
85,folotyn,85,2342,2381,"They may be progressive and increase in severity with further treatment, and may involve skin and subcutaneous sites of known  notaecandidateindication   Monitor patients with  nonoseaeaeonlyasinstruction closely, and if severe, withhold or discontinue FOLOTYN",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
86,folotyn,86,2381,2405,"[ see Adverse Reactions (  6.2  ) and Use in Specific Populations (  8.7  )  ].\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,folotyn,87,2405,2448,"'\n', '\n', '\n', '    5.4 Tumor Lysis Syndrome\n', '\n', '\n', '\n', '  FOLOTYN can cause  oselabeledaefromdruguse (TLS).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,folotyn,88,2448,2521,"Monitor patients who are at increased risk of  nonoseaeaeonlyasinstruction and treat promptly.\n', '\n', '\n', '\n', '    5.5 Hepatic Toxicity\n', '\n', '\n', '\n', '  FOLOTYN can cause  oselabeledaefromdruguse and  oselabeledaefromdruguse  Persistent  nonoseaeaeonlyasinstruction may be indicators of  nonoseaeaeonlyasinstruction and require dose modification or discontinuation.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,folotyn,89,2521,2526,Monitor liver function tests.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,folotyn,90,2526,2605,"Omit dose until recovery, adjust or discontinue therapy based on the severity of the  nonoseaeaeonlyasinstruction [ see Dosage and Administration (  2.2  ) and Use in Specific Populations (  8.6  )  ].\n', '\n', '\n', '\n', '       5.6 Risk of Increased Toxicity in the Presence of Impaired Renal Function\n', '\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,folotyn,91,2605,2628,"\n', '     Patients with moderate to severe  notaecandidatepreexistingconditionorriskfactor may be at greater risk for increased exposure and toxicity.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
92,folotyn,92,2628,2684,"Monitor patients for renal function and systemic toxicity and adjust dosing accordingly.\n', '\n', '\n', '\n', '    Serious adverse drug reactions including  oselabeledaefromdruguse and  oselabeledaefromdruguse were reported in patients with  notaecandidatepreexistingconditionorriskfactor (ESRD) undergoing dialysis who were administered FOLOTYN therapy.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
93,folotyn,93,2684,2789,"Avoid FOLOTYN use in patients with  notaecandidatepreexistingconditionorriskfactor including those undergoing dialysis unless the potential benefit justifies the potential risk [ see Dosage and Administration (  2.2  ), Adverse Reactions (  6.2  ), Use in Specific Populations (  8.7  ), and Clinical Pharmacology (  12.3  )  ].\n', '\n', '\n', '\n', '    5.7  oselabeledaefromdruguse \n', '\n', '\n', '  FOLOTYN can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
94,folotyn,94,2789,2801,FOLOTYN was  nonoseaeaeanimal and  nonoseaeaeanimal in rats and rabbits.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
95,folotyn,95,2801,2834,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while taking this drug, the patient should be apprised of the potential  oselabeledaefromdruguse ']",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,mekinist,0,0,57,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in another section of the label:\n', '\n', '\n', '\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.1)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,mekinist,1,57,74,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.2)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,mekinist,2,74,91,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.3)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,mekinist,3,91,108,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.4)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,mekinist,4,108,125,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.5)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,mekinist,5,125,142,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.6)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,mekinist,6,142,161,"\n', ' *    Serious  oselabeledaefromdruguse [see Warnings and Precautions (5.7)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,mekinist,7,161,180,"\n', ' *    Serious  oselabeledaefromdruguse [see Warnings and Precautions (5.8)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,mekinist,8,180,197,"\n', ' *     oselabeledaefromdruguse [see Warnings and Precautions (5.9)]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,mekinist,9,197,228,"\n', '   *    Most common adverse reactions (>=20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,mekinist,10,228,233,(  6.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,mekinist,11,233,293,"\n', ' *    Most common adverse reactions (>=20%) for MEKINIST in combination with dabrafenib include pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,mekinist,12,293,299,(  6.1   )  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,mekinist,13,299,307,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,mekinist,14,307,335,"To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,mekinist,15,335,368,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,mekinist,16,368,452,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' The data described in the Warnings and Precautions section and below reflect exposure to MEKINIST as a single agent and in combination with dabrafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,mekinist,17,452,493,MEKINIST as a single agent was evaluated in 329 patients including 107 (33%) exposed for greater than or equal to 6 months and 30 (9%) exposed for greater than or equal to one year.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,mekinist,18,493,533,"MEKINIST as a single agent was studied in open-label, single-arm trials (N = 118) or in an open-label, randomized, active-controlled trial (N = 211).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,mekinist,19,533,570,"The median age was 54 years, 60% were male, >99% were white, and all patients had  notaecandidateindication  All patients received 2 mg once-daily doses of MEKINIST.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
20,mekinist,20,570,657,"The incidence of RPED and RVO are obtained from the 1,749 patients from all clinical trials with MEKINIST.\n', '\n', '\n', '\n', ' The safety of MEKINIST in combination with dabrafenib was evaluated in Trial 2 and other trials consisting of 202 patients with BRAF V600 mutation-positive unresectable or  notaecandidateindication who received MEKINIST 2 mg orally once daily in combination with dabrafenib 150 mg orally twice daily until disease progression or unacceptable toxicity.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
21,mekinist,21,657,714,"Among these 202 patients, 68 (34%) were exposed to MEKINIST and 66 (33%) were exposed to dabrafenib for greater than 6 to 12 months while 36 (18%) were exposed to MEKINIST and 40 (20%) were exposed to dabrafenib for greater than one year.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,mekinist,22,714,834,"The median age was 54 years, 57% were male and >99% were white.\n', '\n', '\n', '\n', ' Table 3 presents adverse reactions identified from analyses of Trial 1, a randomized, open-label trial of patients with BRAF V600E or V600K mutation-positive  notaecandidateindication receiving MEKINIST (N = 211) 2 mg orally once daily or chemotherapy (N = 99) (either dacarbazine 1,000 mg/m  2  every 3 weeks or paclitaxel 175 mg/m  2  every 3 weeks)  [see Clinical Studies (14.1)]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
23,mekinist,23,834,869,"Patients with  notaecandidatepreexistingconditionorriskfactor  history of  notaecandidatepreexistingconditionorriskfactor within 6 months, or current evidence of Class II or greater  notaecandidatepreexistingconditionorriskfactor (New York Heart Association) were excluded from Trial 1.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
24,mekinist,24,869,880,The median duration of treatment with MEKINIST was 4.3 months.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,mekinist,25,880,901,"In Trial 1, 9% of patients receiving MEKINIST experienced adverse reactions resulting in permanent discontinuation of trial medication.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,mekinist,26,901,927,"The most common adverse reactions resulting in permanent discontinuation of MEKINIST were  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,mekinist,27,927,943,Adverse reactions led to dose reductions in 27% of patients treated with MEKINIST.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,mekinist,28,943,977,"oselabeledaefromdruguse and  oselabeledaefromdruguse were the most common reasons cited for dose reductions of MEKINIST.\n', '\n', '\n', '\n', '   Table 3.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,mekinist,29,977,1001,Selected Adverse Reactions Occurring in >=10% of Patients Receiving MEKINIST and at a Higher Incidence (>=5%),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,mekinist,30,1001,1020,Than in the Chemotherapy Arm or >=2% (Grades 3 or 4) Adverse Reactions  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,mekinist,31,1020,1046,"\n', '\n', '\n', '\n', '\n', '  Adverse Reactions                          MEKINIST         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,mekinist,32,1046,1048,Chemotherapy     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,mekinist,33,1048,1076,"\n', '  N = 211                                    N = 99           \n', '  All  Gradesa                               Grades  3 and 4b    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,mekinist,34,1076,1086,All  Gradesa     Grades  3 and 4b    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,mekinist,35,1086,1093,"\n', '   nonoseaegeneralterm                                                                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,mekinist,36,1093,1098,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,mekinist,37,1098,1108,oselabeledaefromdruguse                                    57               8                10               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,mekinist,38,1108,1117,"\n', '      oselabeledaefromdruguse                    19               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,mekinist,39,1117,1183,"<1               1                0                \n', '      oselabeledaefromdruguse                                11               0                0                0                \n', '      oselabeledaefromdruguse                                10               2                1                0                \n', '      oselabeledaefromdruguse                              10               0                1                0                \n', '   nonoseaegeneralterm                                                                                     \n', '      oselabeledaefromdruguse                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,mekinist,40,1183,1187,43               0                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,mekinist,41,1187,1191,16               2                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,mekinist,42,1191,1243,"\n', '      oselabeledaefromdruguse                              15               2                2                0                \n', '      oselabeledaefromdruguse                          13               1                5                1                \n', '   nonoseaegeneralterm                                                                                             \n', '      oselabeledaefromdruguse                              32               1                4                0                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,mekinist,43,1243,1662,"\n', '      oselabeledaefromdruguse                            15               12               7                3                \n', '      oselabeledaefromdruguse                              13               <1               0                0                \n', '             a  National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.\n', ' \n', '\n', '   b  Grade 4 adverse reactions limited to  oselabeledaefromdruguse (n = 1) in trametinib arm and  nonoseaeaeonlyasinstruction (n = 1) in chemotherapy arm.\n', '\n', '\n', '\n', '   c  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '   d  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '   e  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '   f  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' Other clinically important adverse reactions observed in <=10% of patients (N = 329) treated with MEKINIST were:\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse \n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '\n', '\n', '   Table 4.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,mekinist,44,1662,1708,Percent-Patient Incidence of Laboratory Abnormalities Occurring at a Higher Incidence in Patients Treated With MEKINIST in Trial 1 (Between-Arm Difference of >=5% [All Grades] or >=2% [Grades 3 or 4]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,mekinist,45,1708,1737,"a  )  \n', '\n', '\n', '\n', '\n', '  Test                                         MEKINIST    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,mekinist,46,1737,1739,Chemotherapy    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,mekinist,47,1739,1748,"\n', '  N = 211                                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,mekinist,48,1748,1752,N = 99     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,mekinist,49,1752,1761,"\n', '  All  Grades                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,mekinist,50,1761,1767,Grades  3 and 4    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,mekinist,51,1767,1773,All  Grades    Grades  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,mekinist,52,1773,1777,3 and 4    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,mekinist,53,1777,1792,"\n', '   oselabeledaefromdruguse aspartate  oselabeledaefromdruguse (AST)    60         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,mekinist,54,1792,1796,2          16         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,mekinist,55,1796,1798,1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,mekinist,56,1798,1812,"\n', '   oselabeledaefromdruguse (ALT)     39         3          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,mekinist,57,1812,1814,20         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,mekinist,58,1814,1816,3          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,mekinist,59,1816,1829,"\n', '   oselabeledaefromdruguse                              42         2          23         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,mekinist,60,1829,1831,1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,mekinist,61,1831,1840,"\n', '   oselabeledaefromdruguse                                       38         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,mekinist,62,1840,1842,2          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,mekinist,63,1842,1844,26         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,mekinist,64,1844,1853,"3          \n', '   oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,mekinist,65,1853,1855,24         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,mekinist,66,1855,1857,2          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,mekinist,67,1857,1859,18         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,mekinist,68,1859,1872,"3          \n', '          *       a  No Grade",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,mekinist,69,1872,1881,4 events were reported in either treatment arm.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,mekinist,70,1881,1983,"\n', '    Table 5 presents adverse reactions from Trial 2, a multicenter, open-label, randomized trial of 162 patients with BRAF V600E or V600K mutation-positive  notaecandidateindication receiving MEKINIST 2 mg once daily in combination with dabrafenib 150 mg twice daily (N = 55), MEKINIST 1 mg once daily in combination with dabrafenib 150 mg twice daily (N = 54), and dabrafenib as a single agent 150 mg twice daily (N = 53)  [see Clinical Studies (14.1)]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
71,mekinist,71,1983,2049,"Patients with  notaecandidatecontraindication  history of  notaecandidatepreexistingconditionorriskfactor within 6 months, current evidence of Class II or greater  notaecandidatepreexistingconditionorriskfactor (New York Heart Association), history of  notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  treatment  notaecandidatepreexistingconditionorriskfactor  uncontrolled  notaecandidatepreexistingconditionorriskfactor  history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  or a known history of  notaecandidatepreexistingconditionorriskfactor were excluded.",0,0,1,0,0,0,0,0,0,0,0,1,0,0,0
72,mekinist,72,2049,2145,"The median duration of treatment was 10.9 months for both MEKINIST (2-mg once-daily treatment group) and dabrafenib when used in combination, 10.6 months for both MEKINIST (1-mg once-daily treatment group) and dabrafenib when used in combination, and 6.1 months for dabrafenib as a single agent.\n', ' \n', '\n', ' In Trial 2, 13% of patients receiving MEKINIST in combination with dabrafenib at the recommended dose experienced adverse reactions resulting in permanent discontinuation of trial medication(s).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,mekinist,73,2145,2162,The most common adverse reaction resulting in permanent discontinuation was  oselabeledaefromdruguse (4%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,mekinist,74,2162,2188,Adverse reactions led to dose reductions in 49% and dose interruptions in 67% of patients treated with MEKINIST in combination with dabrafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,mekinist,75,2188,2207,"oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were the most common reasons cited for dose reductions, and  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,mekinist,76,2207,2213,oselabeledaefromdruguse   oselabeledaefromdruguse  and  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,mekinist,77,2213,2250,"oselabeledaefromdruguse were the most common reasons cited for dose interruptions of MEKINIST and dabrafenib when used in combination.\n', '\n', '\n', '\n', '   Table 5.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,mekinist,78,2250,2287,Common Adverse Drug Reactions Occurring in >10% (All Grades) or >=5% (Grades 3 or 4) of Patients Treated With MEKINIST in Combination With Dabrafenib in Trial 2  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,mekinist,79,2287,2321,"\n', '\n', '\n', '\n', '\n', '   Adverse Reactions              MEKINIST 2 mg plus Dabrafenib    N = 55      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,mekinist,80,2321,2327,MEKINIST 1 mg plus Dabrafenib    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,mekinist,81,2327,2331,N = 54      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,mekinist,82,2331,2333,Dabrafenib    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,mekinist,83,2333,2337,N = 53     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,mekinist,84,2337,2342,"\n', '   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,mekinist,85,2342,2350,All    Grades  a               Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,mekinist,86,2350,2354,3 and 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,mekinist,87,2354,2358,All    Grades  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,mekinist,88,2358,2362,a        Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,mekinist,89,2362,2366,3 and 4      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,mekinist,90,2366,2374,All    Grades  a        Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,mekinist,91,2374,2388,"3 and 4     \n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,mekinist,92,2388,2414,"General disorders and administrative site conditions    \n', '      oselabeledaefromdruguse                     71            5              69            9             26           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,mekinist,93,2414,2433,"\n', '      oselabeledaefromdruguse                      58            2              50            2             17           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,mekinist,94,2433,2450,"\n', '      oselabeledaefromdruguse                     53            4              57            2             40           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,mekinist,95,2450,2452,6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,mekinist,96,2452,2467,"\n', '      oselabeledaefromdruguse            31            0              28            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,mekinist,97,2467,2469,17           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,mekinist,98,2469,2471,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,mekinist,99,2471,2478,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,mekinist,100,2478,2516,"\n', '      oselabeledaefromdruguse                        45            0              43            2             53           0             \n', '      oselabeledaefromdruguse                24            0              15            0             6            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,mekinist,101,2516,2527,"\n', '      oselabeledaefromdruguse                    18            0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,mekinist,102,2527,2531,9             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,mekinist,103,2531,2535,6            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,mekinist,104,2535,2554,"\n', '      oselabeledaefromdruguse        16            0              11            0             4            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,mekinist,105,2554,2565,"\n', '      oselabeledaefromdruguse           15            0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,mekinist,106,2565,2569,7             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,mekinist,107,2569,2571,9            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,mekinist,108,2571,2573,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,mekinist,109,2573,2656,"\n', '      oselabeledaefromdruguse                    15            0              6             0             2            0             \n', '      oselabeledaefromdruguse                    11            0              11            0             13           0             \n', '   nonoseaegeneralterm     \n', '      oselabeledaefromdruguse                      44            2              46            6             21           0             \n', '      oselabeledaefromdruguse                    40            2              43            4             15           0             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
110,mekinist,110,2656,2671,"\n', '      oselabeledaefromdruguse                    36            2              26            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,mekinist,111,2671,2673,28           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,mekinist,112,2673,2675,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,mekinist,113,2675,2676,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,mekinist,114,2676,2713,"', '      oselabeledaefromdruguse              33            2              24            2             21           2             \n', '      oselabeledaefromdruguse                22            0              17            2             11           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,mekinist,115,2713,2773,"\n', '      oselabeledaefromdruguse                   11            0              11            0             6            0             \n', '   nonoseaegeneralterm       \n', '      oselabeledaefromdruguse                    29            0              37            2             28           0             \n', '      oselabeledaefromdruguse                   16            0              13            0             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,mekinist,116,2773,2777,9            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,mekinist,117,2777,2784,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
118,mekinist,118,2784,2799,"\n', '      oselabeledaefromdruguse                       29            0              11            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,mekinist,119,2799,2803,21           0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,mekinist,120,2803,2814,"\n', '      oselabeledaefromdruguse          13            0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,mekinist,121,2814,2818,7             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,mekinist,122,2818,2820,0            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,mekinist,123,2820,2822,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,mekinist,124,2822,2829,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
125,mekinist,125,2829,2844,"\n', '      oselabeledaefromdruguse                  27            0              44            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,mekinist,126,2844,2846,34           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,mekinist,127,2846,2848,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,mekinist,128,2848,2863,"\n', '      oselabeledaefromdruguse                     22            2              24            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,mekinist,129,2863,2865,23           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,mekinist,130,2865,2867,2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,mekinist,131,2867,2882,"\n', '      oselabeledaefromdruguse                   18            5              11            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,mekinist,132,2882,2897,"11           2             \n', '      oselabeledaefromdruguse               16            0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,mekinist,133,2897,2901,2             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,mekinist,134,2901,2905,4            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,mekinist,135,2905,2931,"\n', '      oselabeledaefromdruguse           16            0              11            2             19           0             \n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
136,mekinist,136,2931,2946,"\n', '      oselabeledaefromdruguse          22            0              30            0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,mekinist,137,2946,2950,19           0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,mekinist,138,2950,2961,"\n', '      oselabeledaefromdruguse                 11            0              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,mekinist,139,2961,2963,6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,mekinist,140,2963,2965,2             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,mekinist,141,2965,2969,2            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,mekinist,142,2969,2991,"\n', '   nonoseaegeneralterm          \n', '      oselabeledaefromdruguse                    18            0              11            0             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
143,mekinist,143,2991,2993,8            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,mekinist,144,2993,3002,"2             \n', '   nonoseaegeneralterm             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
145,mekinist,145,3002,3011,"\n', '      oselabeledaefromdruguse                  16            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,mekinist,146,3011,3017,5              11            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,mekinist,147,3017,3021,2            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,mekinist,148,3021,3028,"\n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
149,mekinist,149,3028,3039,"\n', '      oselabeledaefromdruguse     13            2              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,mekinist,150,3039,3043,6             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,mekinist,151,3043,3045,9            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,mekinist,152,3045,3054,"2             \n', '   nonoseaegeneralterm    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
153,mekinist,153,3054,3061,"\n', '      oselabeledaefromdruguse               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,mekinist,154,3061,3069,7             7              2             0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,mekinist,155,3069,3073,0            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,mekinist,156,3073,3095,"\n', '            *       a  National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,mekinist,157,3095,3123,"\n', ' *       b  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  \n', ' *       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,mekinist,158,3123,3153,"c  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,mekinist,159,3153,3155,*       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,mekinist,160,3155,3179,"d  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  \n', ' *       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,mekinist,161,3179,3213,"e  Includes the following terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,mekinist,162,3213,3215,*       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,mekinist,163,3215,3275,"f  Includes the following terms:  oselabeledaefromdruguse and  oselabeledaefromdruguse  \n', '    Other clinically important adverse reactions (N = 202) observed in <10% of patients treated with MEKINIST in combination with dabrafenib were:\n', ' \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
164,mekinist,164,3275,3298,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
165,mekinist,165,3298,3317,"', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
166,mekinist,166,3317,3343,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
167,mekinist,167,3343,3376,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm Benign,  nonoseaegeneralterm  and Unspecified (including cysts and polyps):   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,mekinist,168,3376,3377,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,mekinist,169,3377,3402,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
170,mekinist,170,3402,3421,"', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
171,mekinist,171,3421,3441,"\n', '\n', '\n', '\n', '   Table 6.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,mekinist,172,3441,3513,"Treatment-Emergent Laboratory Abnormalities Occurring at >=10% (All Grades) or >=2% (Grades 3 or 4) of Patients Treated With MEKINIST in Combination With Dabrafenib in Trial 2  \n', '\n', '\n', '\n', '\n', '  Test                                MEKINIST 2 mg plus Dabrafenib  N = 55    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,mekinist,173,3513,3529,MEKINIST 1 mg plus Dabrafenib  N = 54    Dabrafenib  N = 53    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,mekinist,174,3529,3538,"\n', '  All  Grades                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,mekinist,175,3538,3548,Grades  3 and 4    All  Grades    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,mekinist,176,3548,3554,Grades  3 and 4    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,mekinist,177,3554,3560,All  Grades    Grades  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,mekinist,178,3560,3564,3 and 4a    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,mekinist,179,3564,3571,"\n', '   nonoseaegeneralterm                          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
180,mekinist,180,3571,3590,"\n', '      oselabeledaefromdruguse                       62           5            46            4            21          0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,mekinist,181,3590,3595,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,mekinist,182,3595,3605,oselabeledaefromdruguse                      55           22           59            19           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,mekinist,183,3605,3628,"40          6             \n', '      oselabeledaefromdruguse                      55           13           37            2            9           2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,mekinist,184,3628,3647,"\n', '      oselabeledaefromdruguse                           55           4            46            7            28          0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,mekinist,185,3647,3666,"\n', '      oselabeledaefromdruguse                 31           4            31            2            8           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,mekinist,186,3666,3673,"\n', '   nonoseaegeneralterm                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
187,mekinist,187,3673,3692,"\n', '      oselabeledaefromdruguse                    60           5            54            0            15          0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,mekinist,188,3692,3699,"\n', '      oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
189,mekinist,189,3699,3730,"60           2            67            6            26          2             \n', '      oselabeledaefromdruguse                    42           4            35            4            11          0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,mekinist,190,3730,3741,"\n', '      oselabeledaefromdruguse               15           0            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,mekinist,191,3741,3756,"7             4            0           0             \n', '   nonoseaegeneralterm                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
192,mekinist,192,3756,3771,"\n', '      oselabeledaefromdruguse                    58           5            67            6            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,mekinist,193,3771,3782,"49          2             \n', '      oselabeledaefromdruguse                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,mekinist,194,3782,3788,56           11           54            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,mekinist,195,3788,3799,"17           38          2             \n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
196,mekinist,196,3799,3832,"oselabeledaefromdruguse                     55           11           48            15           36          2             \n', '      oselabeledaefromdruguse                  53           0            43            2            23          0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,mekinist,197,3832,3866,"\n', '      oselabeledaefromdruguse                 47           5            41            11           40          0             \n', '      oselabeledaefromdruguse                      29           2            15            2            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,mekinist,198,3866,3889,"23          6             \n', '      oselabeledaefromdruguse             24           5            20            2            9           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,mekinist,199,3889,3894,"\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,mekinist,200,3894,3908,oselabeledaefromdruguse                   18           2            2             0            6           0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,mekinist,201,3908,3946,"\n', '      oselabeledaefromdruguse                     18           0            22            0            15          4             \n', '      oselabeledaefromdruguse                    15           0            19            2            4           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,mekinist,202,3946,3965,"\n', '      oselabeledaefromdruguse                     13           0            20            0            9           0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
203,mekinist,203,3965,3984,"\n', '            *       a  No Grade 4 events were reported in dabrafenib arm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,mekinist,204,3984,4005,"\n', ' *     ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; GGT = Gamma glutamyltransferase.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,mekinist,205,4005,4012,"\n', '       oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,mekinist,206,4012,4055,"In Trial 2,  oselabeledaefromdruguse to >500 msec occurred in 4% (2/55) of patients treated with MEKINIST in combination with dabrafenib and in 2% (1/53) of patients treated with dabrafenib as a single agent.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,mekinist,207,4055,4099,"The  oselabeledaefromdruguse was  oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   Review the Full Prescribing Information for dabrafenib prior to initiation of MEKINIST in combination with dabrafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,mekinist,208,4099,4196,"The following serious adverse reactions of dabrafenib as a single agent, which may occur when MEKINIST is used in combination with dabrafenib, are not described in the Full Prescribing Information for MEKINIST:  \n', '\n', '\n', '\n', ' *      nonoseaeaefromofflabel in patients with  notaecandidatepreexistingconditionorriskfactor  \n', ' *      oselabeledaefromdruguse  \n', '   *    New primary malignancies, cutaneous and non-cutaneous, can occur when MEKINIST is used in combination with dabrafenib.",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
209,mekinist,209,4196,4218,"Monitor patients for new malignancies prior to initiation of therapy while on therapy, and following discontinuation of the combination treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
210,mekinist,210,4218,4249,"(  5.1  ,  2.3  ) \n', ' *    Hemorrhage: Major hemorrhagic events can occur in patients receiving MEKINIST in combination with dabrafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,mekinist,211,4249,4262,"Monitor for signs and symptoms of bleeding (  5.2  ,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,mekinist,212,4262,4265,2.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,mekinist,213,4265,4274,"\n', ' *    Venous Thromboembolism:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
214,mekinist,214,4274,4291,Deep vein thrombosis and pulmonary embolism can occur in patients receiving MEKINIST in combination with dabrafenib.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,mekinist,215,4291,4301,"(  5.3  ,  2.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,mekinist,216,4301,4328,"\n', ' *    Cardiomyopathy: Assess LVEF before treatment, after one month of treatment, then every 2 to 3 months thereafter.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,mekinist,217,4328,4354,"(  5.4  ,  2.3  ) \n', ' *    Ocular Toxicities: Perform ophthalmologic evaluation for any visual disturbances.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,mekinist,218,4354,4366,"For Retinal Vein Occlusion (RVO), permanently discontinue MEKINIST.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,mekinist,219,4366,4398,"(  5.5  ,  2.3  ) \n', ' *    Interstitial Lung Disease (ILD): Withhold MEKINIST for new or progressive unexplained pulmonary symptoms.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,mekinist,220,4398,4409,Permanently discontinue MEKINIST for treatment-related ILD or pneumonitis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,mekinist,221,4409,4438,"(  5.6  ,  2.3  ) \n', ' *    Serious Febrile Reactions can occur when MEKINIST is used in combination with dabrafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,mekinist,222,4438,4466,"(  5.7  ,  2.3  ) \n', ' *    Serious Skin Toxicity: Monitor for skin toxicities and for secondary infections.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,mekinist,223,4466,4488,"Discontinue for intolerable Grade 2, or Grade 3 or 4 rash not improving within 3 weeks despite interruption of MEKINIST.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
224,mekinist,224,4488,4519,"(  5.8  ,  2.3  ) \n', ' *    Hyperglycemia: Monitor serum glucose levels in patients with pre-existing diabetes or hyperglycemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,mekinist,225,4519,4542,"(  5.9  ,  2.3  ) \n', ' *    Embryofetal Toxicity: Can cause fetal harm.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,mekinist,226,4542,4554,Advise females of reproductive potential of potential risk to the fetus.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,mekinist,227,4554,4567,"(  5.10  ,  8.1  ,  8.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,mekinist,228,4567,4593,"\n', '      EXCERPT:   \n', ' \n', '\n', '    5.1 New Primary Malignancies  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
229,mekinist,229,4593,4651,"\n', '\n', '\n', '\n', '   New primary  oselabeledaefromdruguse  oselabeledaefromdruguse  cutaneous and  oselabeledaefromdruguse  can occur when MEKINIST is used in combination with dabrafenib and with dabrafenib as a single agent [refer to Full Prescribing Information for dabrafenib]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,mekinist,230,4651,4742,"\n', '\n', '\n', '\n', '   Cutaneous Malignancies:    \n', '\n', '\n', '\n', '  In Trial 2, the incidence of  oselabeledaefromdruguse was increased in patients receiving MEKINIST in combination with dabrafenib, with an incidence of 9% (5/55) in patients receiving MEKINIST in combination with dabrafenib compared with 2% (1/53) in patients receiving dabrafenib as a single agent.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,mekinist,231,4742,4779,The range of time to diagnosis of  oselabeledaefromdruguse was 28 to 249 days in patients receiving MEKINIST in combination with dabrafenib and was 197 days for the patient receiving dabrafenib as a single agent.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,mekinist,232,4779,4829,"\n', '\n', '\n', '\n', '   oselabeledaefromdruguse (SCC), including  oselabeledaefromdruguse  occurred in 7% of patients receiving MEKINIST in combination with dabrafenib and 19% of patients receiving dabrafenib as a single agent.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,mekinist,233,4829,4864,The range of time to diagnosis of  oselabeledaefromdruguse was 136 to 197 days in the combination arm and was 9 to 197 days in the arm receiving dabrafenib as a single agent.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,mekinist,234,4864,4908,"\n', '\n', '\n', '\n', '   nonoseaenegation occurred in 2% (1/53) of patients receiving dabrafenib and in none of the 55 patients receiving MEKINIST in combination with dabrafenib.  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
235,mekinist,235,4908,4957,"\n', '\n', '\n', '\n', '  Perform dermatologic evaluations prior to initiation of MEKINIST in combination with dabrafenib, every 2 months while on therapy, and for up to 6 months following discontinuation of the combination.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,mekinist,236,4957,5052,"No dose modifications of MEKINIST or dabrafenib are recommended in patients who develop new primary  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '   Non-Cutaneous Malignancies:    \n', '\n', '\n', '\n', '  Based on its mechanism of action, dabrafenib may promote growth and development of  nonoseaeaeonlyasinstruction with activation of RAS through mutation or other mechanisms [refer to the Full Prescribing Information for dabrafenib]  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,mekinist,237,5052,5104,"In patients receiving MEKINIST in combination with dabrafenib, four cases of  oselabeledaefromdruguse were identified:  oselabeledaefromdruguse  oselabeledaefromdruguse (n = 1),  oselabeledaefromdruguse (n = 1),  oselabeledaefromdruguse (n = 1), and  oselabeledaefromdruguse (n = 1).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,mekinist,238,5104,5118,Monitor patients receiving the combination closely for signs or symptoms of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,mekinist,239,5118,5215,"If used in combination with dabrafenib, no dose modification is required for MEKINIST in patients who develop  nonoseaeaeonlyasinstruction  Permanently discontinue dabrafenib in patients who develop  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '     5.2 Hemorrhage  \n', '\n', '\n', '\n', '    oselabeledaefromdruguse  including  oselabeledaefromdruguse defined as symptomatic  oselabeledaefromdruguse in a critical area or organ, can occur when MEKINIST is used in combination with dabrafenib.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,mekinist,240,5215,5286,"\n', '\n', '\n', '\n', '  In Trial 2, treatment with MEKINIST in combination with dabrafenib resulted in an increased incidence and severity of any  oselabeledaefromdruguse  16% (9/55) of patients treated with MEKINIST in combination with dabrafenib compared with 2% (1/53) of patients treated with dabrafenib as a single agent.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,mekinist,241,5286,5331,The major  oselabeledaefromdruguse of  oselabeledaefromdruguse or gastric  oselabeledaefromdruguse  oselabeledaefromdruguse occurred in 5% (3/55) of patients treated with MEKINIST in combination with dabrafenib compared with none of the 53 patients treated with dabrafenib as a single agent.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,mekinist,242,5331,5340,oselabeledaefromdruguse was fatal in two (4%),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,mekinist,243,5340,5350,patients receiving the combination of MEKINIST and dabrafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,mekinist,244,5350,5399,"\n', '\n', '\n', '\n', '  Permanently discontinue MEKINIST, and also permanently discontinue dabrafenib if administered in combination, for all Grade 4  nonoseaeaeonlyasinstruction and for any Grade 3 hemorrhagic events that do not improve.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,mekinist,245,5399,5421,Withhold MEKINIST for up to 3 weeks for Grade 3  nonoseaeaeonlyasinstruction  if improved resume at a lower dose level.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,mekinist,246,5421,5439,Withhold dabrafenib for Grade 3  nonoseaeaeonlyasinstruction  if improved resume at a lower dose level.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,mekinist,247,5439,5490,"\n', '\n', '\n', '\n', '     5.3 Venous Thromboembolism  \n', '\n', '\n', '\n', '    oselabeledaefromdruguse can occur when MEKINIST is used in combination with dabrafenib.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,mekinist,248,5490,5561,"\n', '\n', '\n', '\n', '  In Trial 2, treatment with MEKINIST in combination with dabrafenib resulted in an increased incidence of  oselabeledaefromdruguse  and  oselabeledaefromdruguse : 7% (4/55) of patients treated with MEKINIST in combination with dabrafenib compared with none of the 53 patients treated with dabrafenib as a single agent.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,mekinist,249,5561,5581,oselabeledaefromdruguse was  nonoseaegeneralterm in one (2%) patient receiving the combination of MEKINIST and dabrafenib.  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
250,mekinist,250,5581,5672,"\n', '\n', '\n', '\n', '  Advise patients to immediately seek medical care if they develop symptoms of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  such as  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  or  nonoseaemanifestationorcomplication or leg  nonoseaemanifestationorcomplication  nonoseaeaeonlyasinstruction  Permanently discontinue MEKINIST and dabrafenib for life threatening  nonoseaeaeonlyasinstruction  Withhold MEKINIST for uncomplicated  nonoseaeaeonlyasinstruction and  nonoseaeaeonlyasinstruction for up to 3 weeks; if improved, MEKINIST may be resumed at a lower dose level.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
251,mekinist,251,5672,5691,Do not modify the dose of dabrafenib [see Dosage and Administration (2.3)]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,mekinist,252,5691,5748,"\n', '\n', '\n', '\n', '     5.4 Cardiomyopathy  \n', '\n', '\n', '\n', '    oselabeledaefromdruguse can occur when MEKINIST is administered as a single agent or when used in combination with dabrafenib.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,mekinist,253,5748,5811,"\n', '\n', '\n', '\n', '  In Trial 1,  oselabeledaefromdruguse (defined as  oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse [LVEF]) occurred in 7% (14/211) of patients treated with MEKINIST; no chemotherapy-treated patients in Trial 1 developed  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
254,mekinist,254,5811,5846,"In Trial 2,  oselabeledaefromdruguse occurred in 9% (5/55) of patients treated with MEKINIST in combination with dabrafenib and in none of patients treated with dabrafenib as a single agent.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
255,mekinist,255,5846,5889,The median time to onset of  oselabeledaefromdruguse in patients treated with MEKINIST was 63 days (range: 16 to 156 days) for Trial 1 and 86 days (range: 27 to 253 days) for Trial 2.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
256,mekinist,256,5889,5935,"\n', '\n', '\n', '\n', '   oselabeledaefromdruguse was identified within the first month of treatment with MEKINIST in 5 of 14 patients in Trial 1 and in 2 of 5 patients in Trial 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,mekinist,257,5935,5977,"Development of  nonoseaeaeonlyasinstruction resulted in dose reduction (7/211) and/or discontinuation (4/211) of study drug in Trial 1, and resulted in dose reduction (4/55) and/or dose interruption (1/55) in Trial 2.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
258,mekinist,258,5977,6001,nonoseaeaeonlyasinstruction resolved in 10 of 14 (71%) patients in Trial 1 and in all 5 patients in Trial 2.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
259,mekinist,259,6001,6082,"\n', '\n', '\n', '\n', '  Across clinical trials of MEKINIST administered either as a single agent (N = 329), or in combination with dabrafenib (N = 202), 11% and 8% of patients, respectively, developed evidence of  oselabeledaefromdruguse ( oselabeledaefromdruguse below institutional lower limits of normal with an absolute  oselabeledaefromdruguse >=10% below baseline).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,mekinist,260,6082,6122,"Five percent and 2% in single-agent and in combination trials, respectively, demonstrated a  oselabeledaefromdruguse below institutional lower limits of normal with an absolute  oselabeledaefromdruguse of >=20% below baseline.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
261,mekinist,261,6122,6180,"\n', '\n', '\n', '\n', '  Assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of MEKINIST as a single agent and in combination with dabrafenib, one month after initiation, and then at 2- to 3-month intervals while on treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,mekinist,262,6180,6209,Withhold treatment with MEKINIST for up to 4 weeks if absolute  nonoseaeaeonlyasinstruction by 10% from pretreatment values and is less than the lower limit of normal.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,mekinist,263,6209,6234,"For symptomatic  nonoseaeaeonlyasinstruction or persistent, asymptomatic  nonoseaeaeonlyasinstruction that does not resolve within 4 weeks, permanently discontinue MEKINIST and withhold dabrafenib.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
264,mekinist,264,6234,6257,Resume dabrafenib at the same dose upon recovery of cardiac function [see Dosage and Administration (2.3)]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
265,mekinist,265,6257,6301,"\n', '\n', '\n', '\n', '     5.5 Ocular Toxicities  \n', '\n', '\n', '\n', '     oselabeledaefromdruguse (RVO):    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,mekinist,266,6301,6338,"\n', '\n', '\n', '\n', '  Across all clinical trials of MEKINIST, the incidence of  oselabeledaefromdruguse was 0.2% (4/1,749).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
267,mekinist,267,6338,6426,"nonoseaeaeonlyasinstruction may lead to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication   \n', '\n', '\n', '\n', '  Urgently (within 24 hours) perform ophthalmological evaluation for patient-reported  nonoseaeaeonlyasinstruction or other  nonoseaeaeonlyasinstruction  Permanently discontinue MEKINIST in patients with documented  nonoseaeaeonlyasinstruction  If MEKINIST is used in combination with dabrafenib, do not modify dabrafenib dose [see Dosage and Administration (2.3)]  .  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
268,mekinist,268,6426,6452,"\n', '\n', '\n', '\n', '   Retinal Pigment Epithelial Detachment (RPED):    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
269,mekinist,269,6452,6529,"\n', '\n', '\n', '\n', '   oselabeledaeclasseffect  can occur when MEKINIST is administered as a single agent or when used in combination with dabrafenib  .\n', '\n', '\n', '\n', '  In Trial 1 and Trial 2, ophthalmologic examinations including retinal evaluation were performed pretreatment and at regular intervals during treatment.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,mekinist,270,6529,6574,"\n', '\n', '\n', '\n', '  In Trial 1, one patient (0.5%) receiving MEKINIST developed  oselabeledaefromdruguse and no cases of RPED were identified in chemotherapy-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
271,mekinist,271,6574,6594,"Across all clinical trials of MEKINIST, the incidence of  oselabeledaefromdruguse was 0.8% (14/1,749).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
272,mekinist,272,6594,6611,"oselabeledaefromdruguse were often bilateral and multifocal, occurring in the macular region of the retina.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
273,mekinist,273,6611,6654,"oselabeledaefromdruguse led to  nonoseaemanifestationorcomplication that resolved after a median of 11.5 days (range: 3 to 71 days) following the interruption of dosing with MEKINIST, although  nonoseaemanifestationorcomplication persisted beyond a month in at least several cases.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
274,mekinist,274,6654,6727,"\n', '\n', '\n', '\n', '  In Trial 2, one patient (2%) receiving MEKINIST in combination with dabrafenib developed  oselabeledaefromdruguse   \n', '\n', '\n', '\n', '  Perform ophthalmological evaluation at any time a patient reports  nonoseaeaeonlyasinstruction and compare with baseline, if available.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,mekinist,275,6727,6734,Withhold MEKINIST if RPED is diagnosed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,mekinist,276,6734,6758,"If resolution of the  nonoseaeaeonlyasinstruction is documented on repeat ophthalmological evaluation within 3 weeks, resume MEKINIST at a lower dose level.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
277,mekinist,277,6758,6760,Discontinue MEKINIST,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
278,mekinist,278,6760,6767,if no improvement after 3 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
279,mekinist,279,6767,6795,"If MEKINIST is used in combination with dabrafenib, do not modify the dose of dabrafenib [see Dosage and Administration (2.3)]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
280,mekinist,280,6795,6817,"\n', '\n', '\n', '\n', '   Uveitis and Iritis:    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,mekinist,281,6817,6867,"\n', '\n', '\n', '\n', '   oselabeledaefromdruguse and  oselabeledaefromdruguse can occur when MEKINIST is used in combination with dabrafenib and with dabrafenib as a single agent [refer to Full Prescribing Information for dabrafenib]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,mekinist,282,6867,6903,"\n', '\n', '\n', '\n', '   oselabeledaefromdruguse occurred in 1% (2/202) of patients treated with MEKINIST in combination with dabrafenib.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,mekinist,283,6903,6933,"\n', '\n', '\n', '\n', '  Symptomatic treatment employed in clinical trials included steroid and mydriatic ophthalmic drops.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
284,mekinist,284,6933,6953,"Monitor patients for visual signs and symptoms of  nonoseaeaeonlyasinstruction (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
285,mekinist,285,6953,6975,"If diagnosed, withhold dabrafenib for up to 6 weeks until  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction resolves to Grade 0-1.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,mekinist,286,6975,6983,"If not improved, permanently discontinue dabrafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,mekinist,287,6983,7011,"If MEKINIST is used in combination with dabrafenib, do not modify the dose of MEKINIST [see Dosage and Administration (2.3)]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,mekinist,288,7011,7075,"\n', '\n', '\n', '\n', '    5.6 Interstitial Lung Disease\n', '\n', '\n', '\n', '  In clinical trials of MEKINIST (N = 329) as a single agent,  oselabeledaefromdruguse or  oselabeledaefromdruguse occurred in 2% of patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,mekinist,289,7075,7102,"In Trial 1, 2% (5/211) of patients treated with MEKINIST developed  oselabeledaefromdruguse or  oselabeledaefromdruguse  all five patients required hospitalization.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,mekinist,290,7102,7170,"The median time to first presentation of  oselabeledaefromdruguse or  oselabeledaefromdruguse was 160 days (range: 60 to 172 days).\n', '\n', '\n', '\n', ' Withhold MEKINIST in patients presenting with new or progressive pulmonary symptoms and findings including  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  pending clinical investigations.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,mekinist,291,7170,7213,"Permanently discontinue MEKINIST for patients diagnosed with treatment-related  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  If MEKINIST is used in combination with dabrafenib, do not modify the dose of dabrafenib [see Dosage and Administration (2.3)].    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,mekinist,292,7213,7264,"\n', '\n', '\n', '\n', '     5.7 Serious Febrile Reactions  \n', '\n', '\n', '\n', '   Serious  oselabeledaefromdruguse and  oselabeledaefromdruguse of any severity accompanied by  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
293,mekinist,293,7264,7306,oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse  can occur when MEKINIST is used in combination with dabrafenib and with dabrafenib as a single agent [refer to Full Prescribing Information for dabrafenib]  .  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
294,mekinist,294,7306,7311,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,mekinist,295,7311,7358,"', '\n', '\n', '  The incidence and severity of  oselabeledaefromdruguse are increased when MEKINIST is used in combination with dabrafenib compared with dabrafenib as a single agent [see Adverse Reactions (6.1)]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,mekinist,296,7358,7422,"\n', '\n', '\n', '\n', '  In Trial 2, the incidence of  oselabeledaefromdruguse (serious and non-serious) was 71% (39/55) in patients treated with MEKINIST in combination with dabrafenib and 26% (14/53) in patients treated with dabrafenib as a single agent.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
297,mekinist,297,7422,7475,Serious  oselabeledaefromdruguse and  oselabeledaefromdruguse of any severity accompanied by  oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse occurred in 25% (14/55) of patients treated with MEKINIST in combination with dabrafenib compared with 2% (1/53) of patients treated with dabrafenib as a single agent.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
298,mekinist,298,7475,7523,"oselabeledaefromdruguse was complicated with  oselabeledaefromdruguse  oselabeledaefromdruguse in 51% (28/55),  oselabeledaefromdruguse in 9% (5/55),  oselabeledaefromdruguse in 4% (2/55), and  oselabeledaefromdruguse in 4% (2/55) of patients in Trial 2.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
299,mekinist,299,7523,7583,"In patients treated with MEKINIST in combination with dabrafenib, the median time to initial onset of  oselabeledaefromdruguse was 30 days compared with 19 days in patients treated with dabrafenib as a single agent; the median duration of  oselabeledaefromdruguse was 6 days with the combination compared with 4 days with dabrafenib as a single agent.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,mekinist,300,7583,7629,"\n', '\n', '\n', '\n', '  Across clinical trials of MEKINIST administered in combination with dabrafenib (N = 202), the incidence of  oselabeledaefromdruguse was 57% (116/202).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,mekinist,301,7629,7656,"\n', '\n', '\n', '\n', '  Withhold dabrafenib for  nonoseaeaeonlyasinstruction of 101.3oF or higher.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,mekinist,302,7656,7724,Withhold MEKINIST for  nonoseaeaeonlyasinstruction higher than 104oF. Withhold dabrafenib and MEKINIST for any serious  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction accompanied by  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  and evaluate for signs and symptoms of  nonoseaeaeonlyasinstruction  Refer to Table 2 for recommended dose modifications for adverse reactions [see Dosage and Administration (2.3)]  .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,mekinist,303,7724,7737,Prophylaxis with antipyretics may be required when resuming MEKINIST or dabrafenib.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,mekinist,304,7737,7795,"\n', '\n', '\n', '\n', '    5.8 Serious Skin Toxicity\n', '\n', '\n', '\n', '   Serious  oselabeledaefromdruguse can occur when MEKINIST is administered as a single agent or when used in combination with dabrafenib.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,mekinist,305,7795,7819,Serious  nonoseaeaeonlyasinstruction can also occur with dabrafenib as a single agent [refer to Full Prescribing Information for dabrafenib]  .  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,mekinist,306,7819,7858,"\n', '\n', '\n', '\n', ' In Trial 1, the overall incidence of any  oselabeledaefromdruguse  the most common of which were  oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
307,mekinist,307,7858,7881,oselabeledaefromdruguse  and  oselabeledaefromdruguse  was 87% in patients treated with MEKINIST and 13% in chemotherapy-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
308,mekinist,308,7881,7895,Severe  oselabeledaefromdruguse occurred in 12% of patients treated with MEKINIST.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,mekinist,309,7895,7943,"oselabeledaefromdruguse requiring hospitalization occurred in 6% of patients treated with MEKINIST, most commonly for secondary  nonoseaemanifestationorcomplication requiring intravenous antibiotics or severe  oselabeledaefromdruguse without  nonoseaenegation  In comparison, no patients treated with chemotherapy required hospitalization for severe  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  ",1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
310,mekinist,310,7943,7962,The median time to onset of  oselabeledaefromdruguse in patients treated with MEKINIST was 15 days (range:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,mekinist,311,7962,7987,1 to 221 days) and median time to resolution of  oselabeledaefromdruguse was 48 days (range: 1 to 282 days).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,mekinist,312,7987,8013,Reductions in the dose of MEKINIST were required in 12% and permanent discontinuation of MEKINIST was required in 1% of patients with  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,mekinist,313,8013,8074,"\n', '\n', '\n', '\n', '  In Trial 2, the incidence of any  oselabeledaefromdruguse was similar for patients receiving MEKINIST in combination with dabrafenib (65% [36/55]) compared with patients receiving dabrafenib as a single agent (68% [36/53]).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
314,mekinist,314,8074,8122,The median time to onset of  oselabeledaefromdruguse in patients treated with MEKINIST in combination with dabrafenib was 37 days (range: 1 to 225 days) and median time to resolution of  oselabeledaefromdruguse was 33 days (range: 3 to 421 days).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,mekinist,315,8122,8198,"No patient required dose reduction or permanent discontinuation of MEKINIST or dabrafenib for  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '  Across clinical trials of MEKINIST administered in combination with dabrafenib (n = 202), severe  oselabeledaefromdruguse and secondary  nonoseaemanifestationorcomplication requiring hospitalization occurred in 2.5% (5/202) of patients treated with MEKINIST in combination with dabrafenib.  ",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
316,mekinist,316,8198,8266,"\n', '\n', '\n', '\n', '  Withhold MEKINIST, and dabrafenib if used in combination, for intolerable or severe  nonoseaeaeonlyasinstruction  MEKINIST and dabrafenib may be resumed at lower dose levels in patients with improvement or recovery from  nonoseaeaeonlyasinstruction within 3 weeks [see Dosage and Administration (2.3)]  .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,mekinist,317,8266,8323,"\n', '\n', '\n', '\n', '     5.9 Hyperglycemia  \n', '\n', '\n', '\n', '    oselabeledaefromdruguse can occur when MEKINIST is used in combination with dabrafenib and with dabrafenib as a single agent.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,mekinist,318,8323,8360,"nonoseaeaeonlyasinstruction requiring an increase in the dose of, or initiation of insulin or oral hypoglycemic agent therapy occurred with dabrafenib as a single agent [refer to Full Prescribing Information for dabrafenib]  .  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,mekinist,319,8360,8425,"\n', '\n', '\n', '\n', '  In Trial 2, the incidence of Grade 3  oselabeledaefromdruguse based on laboratory values was 5% (3/55) in patients treated with MEKINIST in combination with dabrafenib compared with 2% (1/53) in patients treated with dabrafenib as a single agent.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,mekinist,320,8425,8532,"\n', '\n', '\n', '\n', '  Monitor serum glucose levels as clinically appropriate during treatment with MEKINIST in combination with dabrafenib in patients with pre-existing  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor  Advise patients to report symptoms of severe  nonoseaeaeonlyasinstruction   \n', '\n', '\n', '\n', '    5.10  oselabeledaefromdruguse \n', '\n', '\n', '  Based on its mechanism of action, MEKINIST can cause  oselabeledaefromdruguse when administered to a  notaecandidatepreexistingconditionorriskfactor woman.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
321,mekinist,321,8532,8564,MEKINIST was  nonoseaeaeanimal and  nonoseaeaeanimal in rabbits at doses greater than or equal to those resulting in exposures approximately 0.3 times the human exposure at the recommended clinical dose.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
322,mekinist,322,8564,8607,"If this drug is used during  notaecandidatepreexistingconditionorriskfactor  or if the patient becomes  nonoseaeaeonlyasinstruction while taking this drug, the patient should be apprised of the potential  oselabeledaefromdruguse [see Use in Specific Populations (8.1)].  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
323,mekinist,323,8607,8645,"\n', '\n', '\n', '\n', ' Advise female patients of reproductive potential to use highly effective contraception during treatment with MEKINIST and for 4 months after treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,mekinist,324,8645,8676,"Advise patients to use a highly effective non-hormonal method of contraception when MEKINIST is administered in combination with dabrafenib, since dabrafenib can render hormonal contraceptives ineffective.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
325,mekinist,325,8676,8695,Advise patients to contact their healthcare provider if they become  nonoseaeaeonlyasinstruction  or if  notaecandidatepreexistingconditionorriskfactor '],1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,victoza,0,0,89,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are described below or elsewhere in the prescribing information:\n', '\n', ' *    Risk of  nonoseaeaeanimal [see  Warnings and Precautions (5.1)  ]  \n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  \n', ' *    Use with Medications Known to Cause  nonoseaeaefromdruginteraction [see    ",0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
1,victoza,1,89,111,"Warnings and Precautions (5.4)    ]  \n', ' *     oselabeledaefromdruguse [see    Warnings and Precautions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,victoza,2,111,127,"(5.5)    ]  \n', ' *     oselabeledaefromdruguse [see    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,victoza,3,127,180,"Warnings and Precautions (5.6)    ]  \n', '   *    The most common adverse reactions, reported in >=5% of patients treated with VICTOZA are:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  (6.1)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,victoza,4,180,223,"\n', ' *     oselabeledaefromdruguse  including  oselabeledaefromdruguse  were more common among VICTOZA-treated patients (0.8%) than among comparator-treated patients (0.4%) in clinical trials  (6.2)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,victoza,5,223,231,"\n', '      EXCERPT:     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,victoza,6,231,259,"To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc. at 1-877-484-2869 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,victoza,7,259,292,"\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,victoza,8,292,385,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '   Common Adverse Reactions  \n', '\n', ' The data in Table 1 are derived from 5 glycemic control, placebo-controlled trials  [see      Clinical Studies (14.1)      ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,victoza,9,385,406,These data reflect exposure of 1673 patients to VICTOZA and a mean duration of exposure to VICTOZA of 37.3 weeks.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,victoza,10,406,428,"The mean age of patients was 58 years, 4% were 75 years or older and 54% were male.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,victoza,11,428,455,"The population was 79% White, 6% Black or African American, 13% Asian; 4% were of Hispanic or Latino ethnicity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,victoza,12,455,475,At baseline the population had  notaecandidateindication for an average of 9.1 years and a mean HbA1cof 8.4%.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,victoza,13,475,529,"Baseline estimated  notaecandidatepreexistingconditionorriskfactor was normal or  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor was normal or mildly impaired in 88.1% and  notaecandidatepreexistingconditionorriskfactor in 11.9% of the pooled population.\n', '\n', ' Table 1 shows common adverse reactions, excluding  nonoseaenegation  associated with the use of VICTOZA.",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
14,victoza,14,529,600,"These adverse reactions occurred more commonly on VICTOZA than on placebo and occurred in at least 5% of patients treated with VICTOZA.\n', '\n', '   Table 1 Adverse reactions reported in >= 5% of VICTOZA-treated patients  \n', '\n', '\n', '                                    Placebo  N=661       Liraglutide 1.2 mg  N= 645    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,victoza,15,600,607,Liraglutide 1.8 mg  N= 1024    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,victoza,16,607,627,"\n', '  Adverse Reaction                  (%)                  (%)                  (%)                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,victoza,17,627,636,"\n', '   oselabeledaefromdruguse                            5                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,victoza,18,636,649,"18                   20                   \n', '   oselabeledaefromdruguse                          4                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,victoza,19,649,677,"10                   12                   \n', '   oselabeledaefromdruguse                          7                    11                   10                   \n', '   oselabeledaefromdruguse                   8                    9                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,victoza,20,677,692,"10                   \n', '   oselabeledaefromdruguse                          2                    6                    9                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,victoza,21,692,701,"\n', '   oselabeledaefromdruguse                1                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,victoza,22,701,725,"10                   9                    \n', '   oselabeledaefromdruguse                         1                    4                    7                    \n', '   oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,victoza,23,725,757,"6                    7                    6                    \n', '   oselabeledaefromdruguse                      1                    5                    5                    \n', '   oselabeledaefromdruguse                         3                    4                    5                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,victoza,24,757,786,"\n', '          Cumulative proportions were calculated combining studies using Cochran-Mantel-Haenszel weights.\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,victoza,25,786,889,"In an analysis of placebo- and active-controlled trials, the types and frequency of common adverse reactions, excluding  nonoseaenegation  were similar to those listed in Table 1.\n', '\n', '   Other Adverse Reactions  \n', '\n', '   Gastrointestinal Adverse Reactions  \n', '\n', ' In the pool of 5 glycemic control, placebo-controlled clinical trials, withdrawals due to  oselabeledaefromdruguse  occurred in 4.3% of VICTOZA-treated patients and 0.5% of placebo-treated patients.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
26,victoza,26,889,968,"Withdrawal due to  oselabeledaefromdruguse mainly occurred during the first 2-3 months of the trials.\n', '\n', '   Injection site reactions  \n', '\n', '  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse  oselabeledaefromdruguse rash,  oselabeledaefromdruguse  were reported in approximately 2% of VICTOZA-treated patients in the five double-blind, glycemic control trials of at least 26 weeks duration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,victoza,27,968,993,"Less than 0.2% of VICTOZA-treated patients discontinued due to  oselabeledaefromdruguse \n', '\n', '   Hypoglycemia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,victoza,28,993,1018,"\n', '\n', '   Hypoglycemia requiring the assistance of another person in placebo-controlled trials  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,victoza,29,1018,1067,"'\n', ' In 5 glycemic control, placebo-controlled clinical trials of at least 26 weeks duration,  oselabeledaefromdruguse requiring the assistance of another person for treatment occurred in 8 VICTOZA-treated patients (7.5 events per 1000 patient-years).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,victoza,30,1067,1122,"Of these 8 VICTOZA-treated patients, 7 patients were concomitantly using a sulfonylurea.\n', '\n', ' Table 2 Incidence (%) and Rate (episodes/patient year) of  oselabeledaefromdruguse in 26-Week Combination Therapy Placebo-controlled Trials \n', '                                                                  Placebo Comparator           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,victoza,31,1122,1130,"\n', '                                                                                               VICTOZA Treatment            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,victoza,32,1130,1157,"\n', '                                                                \n', '  Add-on to Metformin              Placebo +  Metformin  (N = 121)                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,victoza,33,1157,1188,"(N = 724)                     \n', '                                 VICTOZA +  Metformin           \n', '  Patient not able to self-treat                                  0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,victoza,34,1188,1194,"\n', '                                                                                              0.1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,victoza,35,1194,1230,"(0.001)                   \n', '                                                                \n', '  Patient able to self-treat                                     2.5 (0.06)                    \n', '                                                                                              3.6 (0.05)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,victoza,36,1230,1256,"\n', '                                                                \n', '  Add-on to Glimepiride                                           Placebo +                    \n', '                                 Glimepiride                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,victoza,37,1256,1313,"\n', '                                (N = 114)                     \n', '                                                                                               VICTOZA +                    \n', '                                 Glimepiride                  \n', '                                (N = 695)                     \n', '                                                                \n', '  Patient not able to self-treat                                  0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,victoza,38,1313,1323,"\n', '                                                                                              0.1 (0.003)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,victoza,39,1323,1355,"\n', '                                                                \n', '  Patient able to self-treat                                     2.6 (0.17)                    \n', '                                                                                              7.5 (0.38)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,victoza,40,1355,1455,"\n', '                                                                \n', '  Not classified                                                 0                             \n', '                                                                                              0.9 (0.05)                    \n', '                                                                \n', '  Add-on to Metformin + Rosiglitazone                                   Placebo +                    \n', '                                 Metformin + Rosiglitazone    \n', '                                 (N = 175)                                                    (N = 355)                     \n', '                                 VICTOZA +  Metformin +  Rosiglitazone    \n', '  Patient not able to self-treat                                  0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,victoza,41,1455,1462,"\n', '                                                                                              0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,victoza,42,1462,1470,"\n', '                                                                \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,victoza,43,1470,1494,"'  Patient able to self-treat                                     4.6 (0.15)                    \n', '                                                                                              7.9 (0.49)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,victoza,44,1494,1495,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,victoza,45,1495,1558,"', '                                                                \n', '  Not classified                                                 1.1 (0.03)                    \n', '                                                                                              0.6 (0.01)                    \n', '                                                                \n', '  Add-on to Metformin + Glimepiride                                   Placebo +                    \n', '                                 Metformin +                  \n', '                                 Glimepiride                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,victoza,46,1558,1588,"\n', '                                 (N = 114)                                                    (N = 230)                     \n', '                                 VICTOZA +  Metformin +  Glimepiride    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,victoza,47,1588,1603,"\n', '  Patient not able to self-treat                                  0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,victoza,48,1603,1635,"\n', '                                                                                              2.2 (0.06)                    \n', '                                                                \n', '  Patient able to self-treat                                     16.7 (0.95)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,victoza,49,1635,1645,"\n', '                                                                                              27.4 (1.16)                   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,victoza,50,1645,1646,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,victoza,51,1646,1667,"', '                                                                \n', '  Not classified                                                 0                             \n', '                                                                                              0                             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,victoza,52,1667,1764,"\n', '                                                                \n', '         ""Patient not able to self-treat"" is defined as an event requiring the assistance of another person for treatment.\n', ' \n', '\n', '   Papillary thyroid carcinoma  \n', '\n', ' In glycemic control trials of VICTOZA, there were 7 reported cases of  oselabeledaefromdruguse in patients treated with VICTOZA and 1 case in a comparator-treated patient (1.5 vs. 0.5 cases per 1000 patient-years).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,victoza,53,1764,1845,"Most of these  nonoseaeaeonlyasinstruction were <1 cm in greatest diameter and were diagnosed in surgical pathology specimens after thyroidectomy prompted by findings on protocol-specified screening with serum calcitonin or thyroid ultrasound.\n', '\n', '   Cholelithiasis and cholecystitis  \n', '\n', ' In glycemic control trials of VICTOZA, the incidence of  nonoseaeaeratelteqplacebo was 0.3% in both VICTOZA-treated and placebo-treated patients.",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
54,victoza,54,1845,1878,"The incidence of  nonoseaeaeratelteqplacebo was 0.2% in both VICTOZA-treated and placebo-treated patients.\n', '\n', ' In the LEADER trial  [see  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
55,victoza,55,1878,1937,"Clinical Studies (14.2)  ]  , the incidence of  oselabeledaefromdruguse was 1.5% (3.9 cases per 1000 patient years of observation) in VICTOZA-treated and 1.1% (2.8 cases per 1000 patient years of observation) in placebo-treated patients, both on a background of standard of care.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,victoza,56,1937,2067,"The incidence of  oselabeledaefromdruguse was 1.1% (2.9 cases per 1000 patient years of observation) in VICTOZA-treated and 0.7% (1.9 cases per 1000 patient years of observation) in placebo-treated patients.\n', '\n', '   Laboratory Tests  \n', '\n', '   Bilirubin  \n', '\n', ' In the five glycemic control trials of at least 26 weeks duration, mildly  oselabeledaefromdruguse concentrations (elevations to no more than twice the upper limit of the reference range) occurred in 4.0% of VICTOZA-treated patients, 2.1% of placebo-treated patients and 3.5% of active-comparator-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,victoza,57,2067,2076,This finding was not accompanied by  nonoseaenegation  ,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
58,victoza,58,2076,2119,"The significance of this isolated finding is unknown.\n', '\n', '   Calcitonin  \n', '\n', ' Calcitonin, a biological marker of  nonoseaeaeonlyasinstruction  was measured throughout the clinical development program.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,victoza,59,2119,2153,"At the end of the glycemic control trials, adjusted mean serum  oselabeledaefromdruguse in VICTOZA-treated patients compared to placebo-treated patients but not compared to patients receiving active comparator.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,victoza,60,2153,2171,Between group differences in adjusted mean serum calcitonin values were approximately 0.1 ng/L or less.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,victoza,61,2171,2219,"Among patients with pretreatment calcitonin <20 ng/L,  oselabeledaefromdruguse to >20 ng/L occurred in 0.7% of VICTOZA-treated patients, 0.3% of placebo-treated patients, and 0.5% of active-comparator-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,victoza,62,2219,2329,"The clinical significance of these findings is unknown.\n', '\n', '   Lipase and Amylase  \n', '\n', ' In one glycemic control trial in  notaecandidatepreexistingconditionorriskfactor patients, a mean  oselabeledaefromdruguse of 33% for  oselabeledaefromdruguse  oselabeledaefromdruguse of 33% for lipase and 15% for  oselabeledaefromdruguse from baseline was observed for VICTOZA-treated patients while placebo-treated patients had a mean  nonoseaeaeonlyasinstruction of 3% and a mean  nonoseaeaeonlyasinstruction of 1%.\n', '\n', ' In the LEADER trial, serum lipase and amylase were routinely measured.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
63,victoza,63,2329,2421,"Among VICTOZA-treated patients, 7.9% had a  oselabeledaefromdruguse at any time during treatment of  oselabeledaefromdruguse compared with 4.5% of placebo-treated patients, and 1% of VICTOZA-treated patients had an  oselabeledaefromdruguse at any time during treatment of  oselabeledaefromdruguse versus 0.7% of placebo-treated patients.\n', '\n', ' The clinical significance of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction with VICTOZA is unknown in the absence of other signs and symptoms of  nonoseaeaeonlyasinstruction  [see      ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,victoza,64,2421,2431,Warnings and Precautions (5.2)  ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,victoza,65,2431,2445,"\n', '\n', '   Vital signs  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,victoza,66,2445,2476,", '\n', ' VICTOZA did not have  nonoseaenegation  Mean  oselabeledaefromdruguse  from basel oselabeledaefromdruguse  in  oselabeledaefromdruguse of 2 to 3 beats per minute",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
67,victoza,67,2476,2518,"have been observed with VICTOZA compared to placebo.\n', '\n', '   6.2 Immunogenicity\n', '\n', '  Consistent with the potentially  nonoseaeaeonlyasinstruction  patients treated with VICTOZA may develop  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,victoza,68,2518,2535,The detection of  nonoseaeaeonlyasinstruction is highly dependent on the sensitivity and specificity of the assay.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,victoza,69,2535,2582,"Additionally, the observed incidence of  nonoseaeaeonlyasinstruction (including neutralizing antibody)  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,victoza,70,2582,2648,"For these reasons, the incidence of  nonoseaeaeonlyasinstruction cannot be directly compared with the incidence of  nonoseaeaeonlyasinstruction \n', '\n', ' Approximately 50-70% of VICTOZA-treated patients in five double-blind clinical trials of 26 weeks duration or longer were tested for the presence of  nonoseaeaeonlyasinstruction at the end of treatment.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,victoza,71,2648,2672,Low titers (concentrations not requiring dilution of serum) of  oselabeledaefromdruguse in 8.6% of these VICTOZA-treated patients.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,victoza,72,2672,2716,oselabeledaefromdruguse  occurred in 6.9% of the VICTOZA-treated patients in the double-blind 52-week monotherapy trial and in 4.8% of the VICTOZA-treated patients in the double-blind 26-week add-on combination therapy trials.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,victoza,73,2716,2740,These  nonoseaeaeonlyasinstruction were not tested for  nonoseaeaeonlyasinstruction  and thus the potential for clinically significant  nonoseaeaeonlyasinstruction was not assessed.   ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,victoza,74,2740,2823,"oselabeledaefromdruguse effect on liraglutide in an  in vitro  assay occurred in 2.3% of the VICTOZA-treated patients in the double-blind 52-week monotherapy trial and in 1.0% of the VICTOZA-treated patients in the double-blind 26-week add-on combination therapy trials.\n', '\n', '  nonoseaeaeonlyasinstruction was not associated with reduced efficacy of VICTOZA when comparing mean HbA1c of all  nonoseaeaeonlyasinstruction and all  nonoseaeaeonlyasinstruction patients.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,victoza,75,2823,2844,"However, the 3 patients with the highest titers of  nonoseaeaeonlyasinstruction had no reduction in HbA1c with VICTOZA treatment.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,victoza,76,2844,2902,"\n', '\n', ' In five double-blind glycemic control trials of VICTOZA, events from a composite of adverse events potentially related to  oselabeledaefromdruguse (e.g.  oselabeledaefromdruguse   oselabeledaefromdruguse  occurred among 0.8% of VICTOZA-treated patients and among 0.4% of comparator-treated patients.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,victoza,77,2902,2921,oselabeledaefromdruguse accounted for approximately one-half of the events in this composite for VICTOZA-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,victoza,78,2921,2986,"Patients who developed  nonoseaeaeonlyasinstruction were not more likely to develop events from the  nonoseaeaeonlyasinstruction composite than were patients who did not develop  nonoseaeaeonlyasinstruction \n', '\n', ' In the LEADER trial  [see  Clinical Studies (14.2)  ]  ,  oselabeledaefromdruguse were detected in 11 out of the 1247 (0.9%)",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,victoza,79,2986,2992,VICTOZA-treated patients with  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,victoza,80,2992,2995,nonoseaeaeonlyasinstruction measurements.\n',1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,victoza,81,2995,3036,", '\n', ' Of the 11 VICTOZA-treated patients who developed  oselabeledaefromdruguse  none were observed to develop  nonoseaenegation  and 5 patients (0.4%) developed  oselabeledaefromdruguse \n', '\n",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
82,victoza,82,3036,3069,"', '   6.3 Post-Marketing Experience\n', '\n', '  The following additional adverse reactions have been reported during post-approval use of VICTOZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,victoza,83,3069,3154,"Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' *     oselabeledaefromdruguse [see  Warnings and Precautions (5.1)  ]  \n', ' *     oselabeledaefromdruguse resulting from  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  [see  Warnings and Precautions (5.5)  and  Patient Counseling Information",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,victoza,84,3154,3163,"(17)  ]  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,victoza,85,3163,3179,' *     oselabeledaefromdruguse   oselabeledaefromdruguse or worsening of  oselabeledaefromdruguse  sometimes requiring hemodialysis.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,victoza,86,3179,3194,[see  Warnings and Precautions (5.5)  and  Patient Counseling Information,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,victoza,87,3194,3204,"(17)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,victoza,88,3204,3273,"*     oselabeledaefromdruguse and  oselabeledaefromdruguse  [see  Contraindications (4)  ,  Warnings and Precautions (5.6)  ,    Patient Counseling Information (17)    ]  \n', ' *     nonoseaegeneralterm   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', ' *     oselabeledaefromdruguse   oselabeledaefromdruguse and necrotizing  oselabeledaefromdruguse  oselabeledaefromdruguse sometimes resulting in death [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
89,victoza,89,3273,3282,Warnings and Precautions (5.2  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,victoza,90,3282,3298,"\n', ' *     nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
91,victoza,91,3298,3309,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,victoza,92,3309,3372,"WARNING:  RISK OF THYROID C-CELL TUMORS\n', '\n', '  WARNING:  RISK OF THYROID C-CELL TUMORS\n', '\n', '    *  Liraglutide causes dose-dependent and treatment-duration-dependent  nonoseaeaeanimal at clinically relevant exposures in both genders of rats and mice.",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
93,victoza,93,3372,3419,"It is unknown whether VICTOZA causes  nonoseaeaeonlyasinstruction  including  nonoseaeaeonlyasinstruction , in humans, as the human relevance of liraglutide-induced rodent  nonoseaeaeonlyasinstruction has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,victoza,94,3419,3446,"\n', ' *  VICTOZA is contraindicated in patients with a personal or family history of  notaecandidatecontraindication and in patients with  notaecandidatecontraindication .",0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
95,victoza,95,3446,3480,Counsel patients regarding the potential risk for  nonoseaeaeonlyasinstruction with the use of VICTOZA and inform them of symptoms of  nonoseaeaeonlyasinstruction (e.g. a  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction .,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,victoza,96,3480,3500,Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of  nonoseaeaeonlyasinstruction    ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,victoza,97,3500,3532,"5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *     Thyroid C-cell Tumors : See Boxed Warning  (5.1)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,victoza,98,3532,3554,"\n', ' *     Pancreatitis : Postmarketing reports, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,victoza,99,3554,3561,Discontinue promptly if pancreatitis is suspected.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,victoza,100,3561,3574,Do not restart if pancreatitis is confirmed (  5.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,victoza,101,3574,3600,"\n', ' *     Never share a VICTOZA pen between patients, even if the needle is changed  (5.3)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,victoza,102,3600,3609,"\n', ' *     Serious Hypoglycemia :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,victoza,103,3609,3647,"When VICTOZA is used with an insulin secretagogue (e.g. a sulfonylurea) or insulin, consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia  (5.4)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,victoza,104,3647,3676,"\n', ' *     Renal Impairment : Postmarketing, usually in association with nausea, vomiting, diarrhea, or dehydration which may sometimes require hemodialysis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,victoza,105,3676,3696,Use caution when initiating or escalating doses of VICTOZA in patients with renal impairment  (5.5)  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,victoza,106,3696,3719,"\n', ' *     Hypersensitivity : Postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,victoza,107,3719,3732,Discontinue VICTOZA and promptly seek medical advice  (5.6)  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,victoza,108,3732,3759,"\n', ' *     Acute Gallbladder Disease : If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated  (5.7)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,victoza,109,3759,3843,"\n', '    \n', ' \n', '\n', '   5.1 Risk of Thyroid C-cell Tumors\n', '\n', '  Liraglutide causes dose-dependent and treatment-duration-dependent  nonoseaeaeanimal  nonoseaeaeanimal (adenomas and/or  nonoseaeaeanimal  nonoseaeaeanimal ( nonoseaeaeanimal and/or carcinomas) at clinically relevant exposures in both genders of rats and mice [see   Nonclinical Toxicology (13.1)    ].  ",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
110,victoza,110,3843,3851,nonoseaeaeanimal were detected in rats and mice.,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
111,victoza,111,3851,4023,"It is unknown whether VICTOZA will cause  nonoseaeaeonlyasinstruction  including  nonoseaeaeonlyasinstruction , in humans, as the human relevance of liraglutide-induced rodent  nonoseaeaeonlyasinstruction has not been determined.\n', '\n', ' Cases of  oselabeledaefromdruguse in patients treated with VICTOZA have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between  nonoseaeaeonlyasinstruction and VICTOZA use in humans.\n', '\n', ' VICTOZA is contraindicated in patients with a personal or family history of  notaecandidatecontraindication or in patients with  notaecandidatecontraindication  Counsel patients regarding the potential risk for  nonoseaeaeonlyasinstruction with the use of VICTOZA and inform them of symptoms of  nonoseaeaeonlyasinstruction (e.g. a  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction .\n', '\n', ' Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of  nonoseaeaeonlyasinstruction in patients treated with VICTOZA.",1,0,0,0,0,0,0,0,0,0,0,1,0,0,0
112,victoza,112,4023,4050,"Such monitoring may increase the risk of unnecessary procedures, due to low test specificity for serum calcitonin and a high background incidence of  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,victoza,113,4050,4085,"Significantly  nonoseaemanifestationorcomplication may indicate  nonoseaeaeonlyasinstruction and patients with  nonoseaeaeonlyasinstruction usually have  nonoseaemanifestationorcomplication  If serum calcitonin is measured and found to be elevated, the patient should be further evaluated.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
114,victoza,114,4085,4161,"Patients with  nonoseaemanifestationorcomplication noted on physical examination or neck imaging should also be further evaluated.\n', '\n', '    \n', '\n', '    5.2 Pancreatitis\n', '\n', '   Based on spontaneous postmarketing reports,  oselabeledaefromdruguse  including fatal and non-fatal  oselabeledaefromdruguse or necrotizing  oselabeledaefromdruguse  oselabeledaefromdruguse  has been observed in patients treated with VICTOZA.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
115,victoza,115,4161,4196,"After initiation of VICTOZA, observe patients carefully for signs and symptoms of  nonoseaeaeonlyasinstruction (including persistent severe  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication and which may or may not be accompanied by  nonoseaemanifestationorcomplication .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
116,victoza,116,4196,4214,"If  nonoseaeaeonlyasinstruction is suspected, VICTOZA should promptly be discontinued and appropriate management should be initiated.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,victoza,117,4214,4227,"If  nonoseaeaeonlyasinstruction is confirmed, VICTOZA should not be restarted.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,victoza,118,4227,4279,"\n', '\n', '  In glycemic control trials of VICTOZA, there have been 13 cases of  oselabeledaefromdruguse among VICTOZA-treated patients and 1 case in a comparator (glimepiride) treated patient (2.7 vs. 0.5 cases per 1000 patient-years).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,victoza,119,4279,4329,"Nine of the 13 cases with VICTOZA were reported as  oselabeledaefromdruguse and four were reported as  oselabeledaefromdruguse  In one case in a VICTOZA-treated patient,  oselabeledaefromdruguse   oselabeledaefromdruguse  was observed and led to death; however clinical causality could not be established.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,victoza,120,4329,4376,"Some patients had other risk factors for  nonoseaeaeonlyasinstruction  such as a history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor   \n', '\n', '  VICTOZA has been studied in a limited number of patients with a history of  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
121,victoza,121,4376,4440,"It is unknown if patients with a history of  notaecandidatepreexistingconditionorriskfactor are at higher risk for development of  nonoseaeaeonlyasinstruction on VICTOZA  .\n', '\n', '    5.3 Never Share a VICTOZA Pen Between Patients\n', '\n', '  VICTOZA pens must never be shared between patients, even if the needle is changed.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
122,victoza,122,4440,4499,"Pen-sharing poses a risk for  nonoseaeaefromofflabel \n', '\n', '    5.4 Use with Medications Known to Cause Hypoglycemia\n', '\n', '  Patients receiving VICTOZA in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of  nonoseaeaefromdruginteraction  ",0,0,0,0,0,1,0,0,0,0,1,0,0,0,0
123,victoza,123,4499,4546,"The risk of  nonoseaeaeonlyasinstruction may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin [see  Dosage and Administration (2.2)  ,     Adverse Reactions (6.1)  ].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,victoza,124,4546,4561,"\n', '\n', '    5.5  oselabeledaefromdruguse \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,victoza,125,4561,4623,"'  VICTOZA has not been found to be directly  nonoseaenegation in animal studies or clinical trials.\n', '\n', ' There have been postmarketing reports of  oselabeledaefromdruguse and worsening of  oselabeledaefromdruguse  which may sometimes require  nonoseaemanifestationorcomplication in VICTOZA-treated patients [see  Adverse Reactions (6.2)  ]  .",0,0,0,0,1,0,0,1,0,0,0,0,0,0,0
126,victoza,126,4623,4671,Some of these events were reported in patients without known underlying  notaecandidatepreexistingconditionorriskfactor  A majority of the reported events occurred in patients who had experienced  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6.1)  ]  .,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
127,victoza,127,4671,4694,Some of the reported events occurred in patients receiving one or more medications known to affect renal function or hydration status.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,victoza,128,4694,4717,"nonoseaeaeonlyasinstruction has been reversed in many of the reported cases with supportive treatment and discontinuation of potentially causative agents, including VICTOZA.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,victoza,129,4717,4731,Use caution when initiating or escalating doses of VICTOZA in patients with  notaecandidatepreexistingconditionorriskfactor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
130,victoza,130,4731,4734,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,victoza,131,4734,4742,Use in Specific Populations (8.6)  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,victoza,132,4742,4790,"]  .\n', '\n', '     5.6 Hypersensitivity Reactions  \n', '\n', '   There have been postmarketing reports of serious  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse and  oselabeledaefromdruguse  in patients treated with VICTOZA.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,victoza,133,4790,4814,"If a  nonoseaeaeonlyasinstruction occurs, discontinue VICTOZA; treat promptly per standard of care, and monitor until signs and symptoms resolve.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,victoza,134,4814,4837,Do not use in patients with a previous  notaecandidatepreexistingconditionorriskfactor to VICTOZA [see     Contraindications (4)     ].  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
135,victoza,135,4837,4859,"\n', '\n', '   nonoseaeaeforanotherdruginclass and  nonoseaeaeforanotherdruginclass have been reported with other GLP-1 receptor agonists.",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
136,victoza,136,4859,4896,Use caution in a patient with a history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor with another GLP-receptor agonist because it is unknown whether such patients will be predisposed to these reactions with VICTOZA.  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
137,victoza,137,4896,4912,"\n', '\n', '     5.7 Acute Gallbladder Disease  \n'",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,victoza,138,4912,4950,", '\n', '   In the LEADER trial [see  Clinical Studies (14.2)  ]  , 3.1% of Victoza-treated patients versus 1.9% of placebo-treated patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,victoza,139,4950,4963,reported an  oselabeledaefromdruguse  such as  oselabeledaefromdruguse or  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,victoza,140,4963,4972,The majority of events required hospitalization or cholecystectomy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,victoza,141,4972,4977,If  nonoseaeaeonlyasinstruction '],1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,celebrex,0,0,5,['  6.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,celebrex,1,5,43,"ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in greater detail in other sections of the labeling:\n', '\n', ' *   oselabeledaefromdruguse [ see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,celebrex,2,43,51,Warnings and Precautions (5.1)   ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,celebrex,3,51,85,"\n', ' *   oselabeledaefromdruguse  oselabeledaefromdruguse Bleeding, Ulceration and  oselabeledaefromdruguse  oselabeledaefromdruguse Bleeding,  oselabeledaefromdruguse and Perforation [ see  Warnings and Precautions (5.2)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,celebrex,4,85,103,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.3)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,celebrex,5,103,121,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.4)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,celebrex,6,121,142,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [ see  Warnings and Precautions (5.5)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,celebrex,7,142,162,"\n', ' *   oselabeledaeclasseffect and  oselabeledaeclasseffect [ see  Warnings and Precautions (5.6)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,celebrex,8,162,181,"] \n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.7)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,celebrex,9,181,217,"\n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.9)   ] \n', ' *   oselabeledaefromdruguse [ see  Warnings and Precautions (5.11)   ]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,celebrex,10,217,388,"\n', '      EXCERPT:   Most common adverse reactions in arthritis trials (>2% and >placebo) are: abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, rash (  6.1  ).\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,celebrex,11,388,509,"The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.\n', '\n', ' Of the CELEBREX-treated patients in the pre-marketing controlled clinical trials, approximately 4,250 were patients with  notaecandidateindication  approximately 2,100 were patients with  notaecandidateindication  and approximately 1,050 were patients with  notaecandidateindication  More than 8,500 patients received a total daily dose of CELEBREX of 200 mg (100 mg twice daily or 200 mg once daily) or more, including more than 400 treated at 800 mg (400 mg twice daily).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
12,celebrex,12,509,614,"Approximately 3,900 patients received CELEBREX at these doses for 6 months or more; approximately 2,300 of these have received it for 1 year or more and 124 of these have received it for 2 years or more.\n', '\n', '     Pre-marketing Controlled Arthritis Trials  \n', '\n', ' Table 1 lists all adverse events, regardless of causality, occurring in >=2% of patients receiving CELEBREX from 12 controlled studies conducted in patients with  notaecandidateindication or  notaecandidateindication that included a placebo and/or a positive control group.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
13,celebrex,13,614,688,"Since these 12 trials were of different durations, and patients in the trials may not have been exposed for the same duration of time, these percentages do not capture cumulative rates of occurrence.\n', '\n', ' Table 1: Adverse Events Occurring in >=2% of CELEBREX Patients from Pre-marketing Controlled Arthritis Trials \n', '                                   CBXN=4146     PlaceboN=1864     NAPN=1366        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,celebrex,14,688,692,DCFN=387        IBUN=345      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,celebrex,15,692,749,"\n', '  \n', ' CBX = CELEBREX 100 - 200 mg twice daily or 200 mg once daily;   \n', ' NAP = Naproxen 500 mg twice daily;   \n', ' DCF = Diclofenac 75 mg twice daily;   \n', ' IBU =",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,celebrex,16,749,757,Ibuprofen 800 mg three times daily.   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,celebrex,17,757,769,"\n', '  \n', '    nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
18,celebrex,18,769,791,"\n', '    oselabeledaefromdruguse                     4.1%            2.8%            7.7%            9.0%            9.0%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,celebrex,19,791,813,"\n', '    oselabeledaefromdruguse                           5.6%            3.8%            5.3%            9.3%            5.8%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,celebrex,20,813,835,"\n', '    oselabeledaefromdruguse                          8.8%            6.2%           12.2%           10.9%           12.8%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,celebrex,21,835,857,"\n', '    oselabeledaefromdruguse                         2.2%            1.0%            3.6%            4.1%            3.5%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,celebrex,22,857,879,"\n', '    oselabeledaefromdruguse                             3.5%            4.2%            6.0%            3.4%            6.7%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,celebrex,23,879,886,"\n', '    nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,celebrex,24,886,908,"\n', '    oselabeledaefromdruguse                          2.8%            3.6%            2.2%            2.6%            0.9%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,celebrex,25,908,952,"\n', '    oselabeledaefromdruguse                   2.1%            1.1%            2.1%            1.0%            3.5%        \n', '    oselabeledaefromdruguse                  2.9%            2.3%            3.0%            2.6%            3.2%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,celebrex,26,952,1003,"\n', '    nonoseaegeneralterm                                                                                     \n', '    oselabeledaefromdruguse                          2.0%            1.7%            2.6%            1.3%            2.3%        \n', '    oselabeledaefromdruguse                          15.8%           20.2%           14.5%           15.5%           15.4%        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
27,celebrex,27,1003,1010,"\n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,celebrex,28,1010,1032,"\n', '    oselabeledaefromdruguse                           2.3%            2.3%            2.9%            1.3%            1.4%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,celebrex,29,1032,1039,"\n', '    nonoseaegeneralterm                                                                                                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,celebrex,30,1039,1061,"\n', '    oselabeledaefromdruguse                        2.3%            1.1%            1.7%            1.6%            2.6%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,celebrex,31,1061,1083,"\n', '    oselabeledaefromdruguse                           2.0%            1.3%            2.4%            2.3%            0.6%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,celebrex,32,1083,1105,"\n', '    oselabeledaefromdruguse                          5.0%            4.3%            4.0%            5.4%            5.8%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,celebrex,33,1105,1127,"\n', '    oselabeledaefromdruguse        8.1%            6.7%            9.9%            9.8%            9.9%        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,celebrex,34,1127,1192,"\n', '    nonoseaegeneralterm                                                                                                           \n', '    oselabeledaefromdruguse                               2.2%            2.1%            2.1%            1.3%            1.2%        \n', '            In placebo- or active-controlled clinical trials, the discontinuation rate due to adverse events was 7.1% for patients receiving CELEBREX and 6.1% for patients receiving placebo.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
35,celebrex,35,1192,1233,"Among the most common reasons for discontinuation due to adverse events in the CELEBREX treatment groups were  oselabeledaefromdruguse and  oselabeledaefromdruguse (cited as reasons for discontinuation in 0.8% and 0.7% of CELEBREX patients, respectively).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,celebrex,36,1233,1338,"Among patients receiving placebo, 0.6% discontinued due to  nonoseaeaeonlyasinstruction and 0.6% withdrew due to  nonoseaeaeonlyasinstruction \n', ' \n', '\n', '     The following adverse reactions occurred in 0.1 - 1.9% of patients treated with CELEBREX (100 - 200 mg twice daily or 200 mg once daily):  \n', '\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
37,celebrex,37,1338,1352,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,celebrex,38,1352,1402,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,celebrex,39,1402,1414,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,celebrex,40,1414,1426,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,celebrex,41,1426,1442,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse (including  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,celebrex,42,1442,1472,"\n', '\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,celebrex,43,1472,1504,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm     :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,celebrex,44,1504,1560,"\n', '\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '      nonoseaegeneralterm  :   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,celebrex,45,1560,1565,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,celebrex,46,1565,1600,"nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
47,celebrex,47,1600,1670,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '     The following serious adverse events (causality not evaluated) occurred in <0.1% of patients:  \n', '\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
48,celebrex,48,1670,1692,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
49,celebrex,49,1692,1702,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,celebrex,50,1702,1707,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,celebrex,51,1707,1711,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,celebrex,52,1711,1744,"oselabeledaefromdruguse \n', '    nonoseaegeneralterm  :   oselabeledaefromdruguse \n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse  [see Drug Interactions (7.1)]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,celebrex,53,1744,1753,"\n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,celebrex,54,1753,1757,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
55,celebrex,55,1757,1758,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,celebrex,56,1758,1772,"\n', '     The Celecoxib Long-Term  notaecandidateindication Safety Study",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
57,celebrex,57,1772,1792,"[see    Special Studies (14.6)    ]  \n', '\n', '      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,celebrex,58,1792,1794,nonoseaegeneralterm    ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
59,celebrex,59,1794,1848,:  The incidence of clinically significant  oselabeledaefromdruguse (>2 g/dL) was lower in patients on CELEBREX 400 mg twice daily (0.5%) compared to patients on either diclofenac 75 mg twice daily (1.3%) or ibuprofen 800 mg three times daily 1.9%.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,celebrex,60,1848,1869,The lower incidence of events with CELEBREX was maintained with or without aspirin use [  see  Clinical Pharmacology (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,celebrex,61,1869,1873,12.2)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,celebrex,62,1873,1921,".\n', '\n', '      nonoseaegeneralterm  nonoseaegeneralterm    :  Kaplan-Meier cumulative rates at 9 months for withdrawals due to adverse events for CELEBREX, diclofenac and ibuprofen were 24%, 29%, and 26%, respectively.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
63,celebrex,63,1921,2060,"Rates for serious adverse events (i.e., causing hospitalization or felt to be life-threatening or otherwise medically significant), regardless of causality, were not different across treatment groups (8%, 7%, and 8%, respectively).\n', '\n', '     Juvenile Rheumatoid Arthritis Study  \n', '\n', ' In a 12-week, double-blind, active-controlled study, 242  notaecandidateindication patients 2 years to 17 years of age were treated with celecoxib or naproxen; 77  notaecandidateindication patients were treated with celecoxib 3 mg/kg twice daily, 82 patients were treated with celecoxib 6 mg/kg twice daily, and 83 patients were treated with naproxen 7.5 mg/kg twice daily.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
64,celebrex,64,2060,2102,"The most commonly occurring (>=5%) adverse events in celecoxib treated patients were  oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,celebrex,65,2102,2145,The most commonly occurring (>=5%) adverse experiences for naproxen-treated patients were  nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass   nonoseaeaeforanotherdruginclass  and  nonoseaeaeforanotherdruginclass (Table 2).,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
66,celebrex,66,2145,2185,"Compared with naproxen, celecoxib at doses of 3 and 6 mg/kg twice daily had no observable  nonoseaenegation growth and  nonoseaenegation  nonoseaenegation and development during the course of the 12-week double-blind study.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
67,celebrex,67,2185,2245,"There was no substantial difference in the number of clinical  nonoseaeaeonlyasinstruction or systemic features of  notaecandidateindication among treatment groups.\n', '\n', ' In a 12-week, open-label extension of the double-blind study described above, 202  notaecandidateindication patients were treated with celecoxib 6 mg/kg twice daily.",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
68,celebrex,68,2245,2309,"The incidence of adverse events was similar to that observed during the double-blind study; no unexpected adverse events of clinical importance emerged.\n', '\n', '   Table 2: Adverse Events Occurring in >=5% of JRA Patients in Any Treatment Group, by System Organ Class (% of patients with events)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,celebrex,69,2309,2339,"\n', '\n', '\n', '                                           All Doses Twice Daily   \n', ' System Organ Class  Preferred Term        Celecoxib3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,celebrex,70,2339,2343,mg/kgN=77  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,celebrex,71,2343,2344,Celecoxib6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,celebrex,72,2344,2348,mg/kgN=82  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,celebrex,73,2348,2353,Naproxen7.5 mg/kgN=83   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,celebrex,74,2353,2394,"\n', '  \n', '   Any Event                                        64                    70                    72            \n', '    oselabeledaefromdruguse                                    5                     5                     5             \n', '    nonoseaegeneralterm                                 26                    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
75,celebrex,75,2394,2431,"24                    36            \n', '    oselabeledaefromdruguse NOS                               4                     7                     7             \n', '    oselabeledaefromdruguse                             8                     6                     10            \n', '    oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,celebrex,76,2431,2505,"NOS                                     3                     6                     11            \n', '    oselabeledaefromdruguse NOS                                     5                     4                     8             \n', '    oselabeledaefromdruguse                                           7                     4                     11            \n', '    nonoseaegeneralterm                                          13                    11                    18            \n', '    oselabeledaefromdruguse                                          8                     9                     11            \n', '    oselabeledaefromdruguse                                       25                    20                    27            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,celebrex,77,2505,2550,"\n', '    oselabeledaefromdruguse                                  5                     6                     5             \n', '    nonoseaegeneralterm                             4                     6                     5             \n', '    nonoseaegeneralterm [note:  nonoseaegeneralterm  which include:  oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
78,celebrex,78,2550,2571,"NOS present,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,celebrex,79,2571,2580,"NOS  oselabeledaefromdruguse   oselabeledaefromdruguse present,  oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,celebrex,80,2580,2607,"NOS  oselabeledaefromdruguse   oselabeledaefromdruguse NOS]              3                     11                    7             \n', '    nonoseaegeneralterm                                  8                     10                    17            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
81,celebrex,81,2607,2690,"\n', '    oselabeledaefromdruguse                                       3                     7                     4             \n', '    nonoseaegeneralterm                                   17                    11                    21            \n', '    oselabeledaefromdruguse NOS                                     13                    10                    16            \n', '    oselabeledaefromdruguse (excl  nonoseaenegation                          1                     1                     7             \n', '    nonoseaegeneralterm                                      8                     15                    15            \n', '    oselabeledaefromdruguse                                            7                     7                     8             ",0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
82,celebrex,82,2690,2704,"\n', '    nonoseaegeneralterm                              10                    7                     18            \n",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
83,celebrex,83,2704,2714,"', '              Other Pre-Approval Studies  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,celebrex,84,2714,2716,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,celebrex,85,2716,2754,", ' \n', '\n', '     Adverse Events from  notaecandidateindication Studies:  A total of 378 patients were treated with CELEBREX in placebo- and active-controlled  notaecandidateindication studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
86,celebrex,86,2754,2764,Doses up to 400 mg once daily were studied.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,celebrex,87,2764,2821,"The types of adverse events reported in the  notaecandidateindication studies were similar to those reported in the  notaecandidateindication  notaecandidateindication studies.\n', '\n', '     Adverse Events from  notaecandidateindication and  notaecandidateindication Studies:  Approximately 1,700 patients were treated with CELEBREX in  notaecandidateindication and  notaecandidateindication studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
88,celebrex,88,2821,2835,All patients in  notaecandidateindication studies received a single dose of study medication.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
89,celebrex,89,2835,2855,Doses up to 600 mg/day of CELEBREX were studied in primary  notaecandidateindication and  notaecandidateindication studies.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
90,celebrex,90,2855,2878,The types of adverse events in the  notaecandidateindication and  notaecandidateindication studies were similar to those reported in  notaecandidateindication studies.,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
91,celebrex,91,2878,2958,"The only additional adverse event reported was  oselabeledaefromdruguse ( oselabeledaefromdruguse  in the  notaecandidateindication studies.\n', '\n', '     The APC and PreSAP Trials  \n', '\n', '     Adverse reactions from long-term, placebo-controlled  notaecandidatepreexistingconditionorriskfactor prevention studies  : Exposure to CELEBREX in the APC and PreSAP trials was 400 to 800 mg daily for up to 3 years [  see  ",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
92,celebrex,92,2958,2969,Special Studies  notaecandidatepreexistingconditionorriskfactor Prevention Studies (14.6)    ],0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
93,celebrex,93,2969,3023,".\n', '\n', ' Some adverse reactions occurred in higher percentages of patients than in the  notaecandidateindication pre-marketing trials (treatment durations up to 12 weeks; see  Adverse events from  CELEBREX    pre-marketing controlled  notaecandidateindication trials    , above).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
94,celebrex,94,3023,3105,"The adverse reactions for which these differences in patients treated with CELEBREX were greater as compared to the  notaecandidateindication pre-marketing trials were as follows:\n', '\n', ' CELEBREX \n', '                                                     (400 to 800 mg daily)N = 2285        PlaceboN=1303         \n', '  \n', '  oselabeledaefromdruguse                                                      10.5%                      7.0%              \n', '  oselabeledaefromdruguse                               4.7%                       3.1%              ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
95,celebrex,95,3105,3118,"\n', '  oselabeledaefromdruguse                                                        6.8%                       5.3%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,celebrex,96,3118,3131,"\n', '  oselabeledaefromdruguse                                                      3.2%                       2.1%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,celebrex,97,3131,3144,"\n', '  oselabeledaefromdruguse                                                       2.8%                       1.6%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,celebrex,98,3144,3157,"\n', '  oselabeledaefromdruguse                                                  12.5%                      9.8%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,celebrex,99,3157,3170,"\n', '  oselabeledaefromdruguse                                               2.1%                       0.8%              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,celebrex,100,3170,3258,"\n', '         The following additional adverse reactions occurred in >=0.1% and <1% of patients taking CELEBREX, at an incidence greater than placebo in the long-term  notaecandidatepreexistingconditionorriskfactor prevention studies, and were either not reported during the controlled  notaecandidateindication pre-marketing trials or occurred with greater frequency in the long-term, placebo-controlled  notaecandidatepreexistingconditionorriskfactor prevention studies:\n', ' \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse",0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
101,celebrex,101,3258,3270,"\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,celebrex,102,3270,3275,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,celebrex,103,3275,3279,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
104,celebrex,104,3279,3280,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,celebrex,105,3280,3285,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,celebrex,106,3285,3303,"nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
107,celebrex,107,3303,3307,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
108,celebrex,108,3307,3308,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,celebrex,109,3308,3313,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,celebrex,110,3313,3317,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,celebrex,111,3317,3318,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,celebrex,112,3318,3323,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,celebrex,113,3323,3327,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,celebrex,114,3327,3331,oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,celebrex,115,3331,3332,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,celebrex,116,3332,3342,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
117,celebrex,117,3342,3372,"\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during post approval use of CELEBREX.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,celebrex,118,3372,3405,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,celebrex,119,3405,3418,"'\n', '    nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
120,celebrex,120,3418,3428,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,celebrex,121,3428,3433,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,celebrex,122,3433,3460,"nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '    nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
123,celebrex,123,3460,3470,"\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
124,celebrex,124,3470,3475,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,celebrex,125,3475,3493,"nonoseaegeneralterm    :   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  oselabeledaefromdruguse \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
126,celebrex,126,3493,3497,nonoseaegeneralterm    :   ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
127,celebrex,127,3497,3499,oselabeledaefromdruguse \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,celebrex,128,3499,3510,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,celebrex,129,3510,3512,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,celebrex,130,3512,3521,"RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,celebrex,131,3521,3529,"'\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,celebrex,132,3529,3540,"RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,celebrex,133,3540,3549,"'\n', '  EXCERPT:   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,celebrex,134,3549,3551,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,celebrex,135,3551,3576,"RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS\n', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,celebrex,136,3576,3584,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,celebrex,137,3584,3615,"*  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,celebrex,138,3615,3631,This risk may occur early in the treatment and may increase with duration of use.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,celebrex,139,3631,3656,"(5.1) \n', ' *  CELEBREX is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,celebrex,140,3656,3661,"(4, 5.1)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,celebrex,141,3661,3665,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,celebrex,142,3665,3698,"*  NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,celebrex,143,3698,3712,These events can occur at any time during use and without warning symptoms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,celebrex,144,3712,3736,Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,celebrex,145,3736,3761,"(5.2) \n', '    \n', ' \n', '\n', '      Cardiovascular Thrombotic Events    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,celebrex,146,3761,3769,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,celebrex,147,3769,3802,*  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious  oselabeledaeclasseffect  including  oselabeledaeclasseffect  and  oselabeledaeclasseffect  which can be  nonoseaegeneralterm  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
148,celebrex,148,3802,3818,This risk may occur early in the treatment and may increase with duration of use.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,celebrex,149,3818,3827,[see Warnings and Precautions (5.1)],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,celebrex,150,3827,3849,"\n', ' *  CELEBREX is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,celebrex,151,3849,3863,[see Contraindications (4) and Warnings and Precautions (5.1)],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,celebrex,152,3863,3876,"\n', '          Gastrointestinal Bleeding, Ulceration, and Perforation    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,celebrex,153,3876,3941,"\n', ' \n', '\n', ' *  NSAIDs cause an increased risk of serious  oselabeledaeclasseffect  oselabeledaeclasseffect (GI) adverse events including bleeding,  oselabeledaeclasseffect  oselabeledaeclasseffect (GI) adverse events including  oselabeledaeclasseffect  ulceration, and  oselabeledaeclasseffect  oselabeledaeclasseffect the stomach or  oselabeledaeclasseffect  which can be  nonoseaegeneralterm  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
154,celebrex,154,3941,3955,These events can occur at any time during use and without warning symptoms.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,celebrex,155,3955,3980,Elderly patients and patients with a prior history of  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor are at greater risk for serious ( nonoseaeaeonlyasinstruction    5.,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
156,celebrex,156,3980,4008,"WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    *   Hepatotoxicity : Inform patients of warning signs and symptoms of hepatotoxicity.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,celebrex,157,4008,4031,Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop (  5.3  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,celebrex,158,4031,4055,"\n', ' *   Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,celebrex,159,4055,4067,"Monitor blood pressure (  5.4  ,  7  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,celebrex,160,4067,4077,"\n', ' *   Heart Failure and Edema",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,celebrex,161,4077,4104,: Avoid use of CELEBREX in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure (  5.5  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,celebrex,162,4104,4113,"\n', ' *   Renal Toxicity :",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,celebrex,163,4113,4132,"Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,celebrex,164,4132,4158,Avoid use of CELEBREX in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function (  5.6  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,celebrex,165,4158,4162,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,celebrex,166,4162,4180,*   Anaphylactic Reactions : Seek emergency help if an anaphylactic reaction occurs (  5.7  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,celebrex,167,4180,4205,"\n', ' *   Exacerbation of Asthma Related to Aspirin Sensitivity : CELEBREX is contraindicated in patients with aspirin-sensitive asthma.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,celebrex,168,4205,4259,"Monitor patients with preexisting asthma (without aspirin sensitivity) (  5.8  ) \n', ' *   Serious Skin Reactions : Discontinue CELEBREX at first appearance of skin rash or other signs of hypersensitivity (  5.9  ) \n', ' *   Premature Closure of Fetal Ductus",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,celebrex,169,4259,4261,Arteriosus :,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,celebrex,170,4261,4281,"Avoid use in pregnant women starting at 30 weeks of gestation (  5.10  ,  8.1  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,celebrex,171,4281,4401,"\n', ' *   Hematologic Toxicity : Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia (  5.11  ,  7  ) \n', '    \n', ' \n', '\n', '   5.1 Cardiovascular Thrombotic Events\n', '\n', '   Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious  oselabeledaeclasseffect  including  oselabeledaeclasseffect  and  oselabeledaeclasseffect  which can be  nonoseaegeneralterm  Based on available data, it is unclear that the risk for  nonoseaeaeonlyasinstruction is similar for all NSAIDs.",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
172,celebrex,172,4401,4433,The relative increase in serious  nonoseaeaeonlyasinstruction over baseline conferred by NSAID use appears to be similar in those with and without known  notaecandidatepreexistingconditionorriskfactor or risk factors for  notaecandidatepreexistingconditionorriskfactor  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
173,celebrex,173,4433,4461,"However, patients with known  notaecandidatepreexistingconditionorriskfactor or risk factors had a higher absolute incidence of excess serious  nonoseaeaeonlyasinstruction  due to their increased baseline rate.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
174,celebrex,174,4461,4483,Some observational studies found that this increased risk of serious  oselabeledaeclasseffect began as early as the first weeks of treatment.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,celebrex,175,4483,4498,The increase in  nonoseaeaeonlyasinstruction has been observed most consistently at higher doses.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,celebrex,176,4498,4570,"\n', '\n', '  In the APC ( notaecandidatepreexistingconditionorriskfactor Prevention with Celecoxib) trial, the hazard ratio for the composite endpoint of  oselabeledaefromdruguse   oselabeledaefromdruguse  or  oselabeledaefromdruguse was 3.4 (95% CI 1.4 - 8.5) for CELEBREX 400 mg twice daily and 2.8 (95% CI 1.1 - 7.2) with CELEBREX 200 mg twice daily compared to placebo.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
177,celebrex,177,4570,4608,"Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects), respectively, compared to 0.9% (6/679 subjects) with placebo treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,celebrex,178,4608,4633,The increases in both celecoxib dose groups versus placebo-treated patients were mainly due to an increased incidence of  oselabeledaefromdruguse [ see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,celebrex,179,4633,4642,Clinical Studies (14.6)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,celebrex,180,4642,4677,"\n', '\n', '  To minimize the potential risk for an  nonoseaeaeonlyasinstruction in NSAID-treated patients, use the lowest effective dose for the shortest duration possible.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,celebrex,181,4677,4726,"Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous  nonoseaenegation  Patients should be informed about the symptoms of serious  nonoseaeaeonlyasinstruction and the steps to take if they occur.  ",1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
182,celebrex,182,4726,4758,"\n', '\n', '  There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious  nonoseaeaeonlyasinstruction associated with NSAID use.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,celebrex,183,4758,4781,"The concurrent use of aspirin and an NSAID, such as celecoxib, increases the risk of serious  nonoseaeaefromdruginteraction [ see  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
184,celebrex,184,4781,4791,Warnings and Precautions (5.2)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,celebrex,185,4791,4809,"\n', '\n', '    Status Post Coronary Artery Bypass Graft (CABG)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,celebrex,186,4809,4877,"Surgery  \n', '\n', '  Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of  notaecandidatepreexistingconditionorriskfactor in the first 10-14 days following CABG surgery found an increased incidence of  nonoseaeaefromofflabel and  nonoseaeaefromofflabel  NSAIDs are contraindicated in the setting of CABG [ see  Contraindications (4)    ].  ",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
187,celebrex,187,4877,4944,"\n', '\n', '    Post-MI Patients  \n', '\n', '  Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post- notaecandidatepreexistingconditionorriskfactor period were at increased risk of  oselabeledaefromdruguse   oselabeledaefromdruguse  and all-cause  nonoseaegeneralterm beginning in the first week of treatment.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
188,celebrex,188,4944,4985,"In this same cohort, the incidence of  nonoseaegeneralterm in the first year post- notaecandidatepreexistingconditionorriskfactor was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
189,celebrex,189,4985,5025,Although the absolute rate of  nonoseaegeneralterm declined somewhat after the first year post- notaecandidatepreexistingconditionorriskfactor  the increased relative risk of  nonoseaegeneralterm in NSAID users persisted over at least the next four years of follow-up.  ,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
190,celebrex,190,5025,5026,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,celebrex,191,5026,5193,"', '\n', '  Avoid the use of Celebrex in patients with a recent  notaecandidatepreexistingconditionorriskfactor unless the benefits are expected to outweigh the risk of recurrent  nonoseaeaeonlyasinstruction  If Celebrex is used in patients with a recent  notaecandidatepreexistingconditionorriskfactor  monitor patients for signs of  nonoseaeaeonlyasinstruction   \n', '\n', '    5.2 Gastrointestinal Bleeding, Ulceration, and Perforation\n', '\n', '  NSAIDs, including celecoxib cause serious  oselabeledaefromdruguse  oselabeledaefromdruguse (GI) adverse events including  oselabeledaefromdruguse  oselabeledaefromdruguse (GI) adverse events including inflammation, bleeding,  oselabeledaefromdruguse  oselabeledaefromdruguse (GI) adverse events including inflammation,  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse esophagus, stomach,  oselabeledaefromdruguse  oselabeledaefromdruguse esophagus,  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse the esophagus, stomach, small intestine, or  oselabeledaefromdruguse  which can be  nonoseaegeneralterm  ",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
192,celebrex,192,5193,5215,"These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with CELEBREX.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,celebrex,193,5215,5233,Only one in five patients who develop a serious  nonoseaeaeonlyasinstruction on NSAID therapy is symptomatic.  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,celebrex,194,5233,5279,"oselabeledaeclasseffect  oselabeledaeclasseffect ulcers,  oselabeledaeclasseffect  oselabeledaeclasseffect ulcers, gross bleeding, or  oselabeledaeclasseffect caused by NSAIDs occurred in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,celebrex,195,5279,5352,"However, even short-term NSAID therapy is not without risk.\n', '\n', '    Risk Factors for GI Bleeding, Ulceration, and Perforation  \n', '\n', ' Patients with a prior history of  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor who used NSAIDs had a greater than 10-fold increased risk for developing a  oselabeledaeclasseffect compared to patients without these risk factors.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
196,celebrex,196,5352,5407,"Other factors that increase the risk of  nonoseaeaeonlyasinstruction in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
197,celebrex,197,5407,5422,Most postmarketing reports of  nonoseaegeneralterm  oselabeledaefromdruguse occurred in elderly or debilitated patients.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
198,celebrex,198,5422,5479,"Additionally, patients with advanced  notaecandidatepreexistingconditionorriskfactor and/or  notaecandidatepreexistingconditionorriskfactor are at increased risk for  nonoseaeaeonlyasinstruction \n', '\n', ' Complicated and symptomatic  oselabeledaefromdruguse rates were 0.78% at nine months for all patients in the CLASS trial, and 2.19% for the subgroup on low-dose ASA.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
199,celebrex,199,5479,5515,"Patients 65 years of age and older had an incidence of 1.40% at nine months, 3.06% when also taking ASA [see  Clinical Studies (14.6)  ].\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,celebrex,200,5515,5555,"'\n', '    Strategies to Minimize the GI Risks in NSAID-treated patients:  \n', '\n', ' *  Use the lowest effective dosage for the shortest possible duration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
201,celebrex,201,5555,5572,"\n', ' *  Avoid administration of more than one NSAID at a time.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
202,celebrex,202,5572,5618,"\n', ' *  Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of  nonoseaeaeonlyasinstruction  For such patients, as well as those with active  notaecandidatepreexistingconditionorriskfactor  consider alternate therapies other than NSAIDs.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
203,celebrex,203,5618,5643,"\n', ' *  Remain alert for signs and symptoms of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ulceration and  nonoseaeaeonlyasinstruction during NSAID therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,celebrex,204,5643,5675,"\n', ' *  If a serious  nonoseaeaeonlyasinstruction is suspected, promptly initiate evaluation and treatment, and discontinue CELEBREX until a serious  nonoseaeaeonlyasinstruction is ruled out.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
205,celebrex,205,5675,5716,"\n', ' *  In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of  nonoseaeaeonlyasinstruction [ see  Drug Interactions (7)   ].",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,celebrex,206,5716,5725,"\n', '       5.3  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,celebrex,207,5725,5773,"\n', '\n', '   oselabeledaeclasseffect ALT or  oselabeledaeclasseffect  oselabeledaeclasseffect or AST (three or more times the upper limit of normal [ULN]) have been reported in approximately 1% of NSAID-treated patients in clinical trials.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
208,celebrex,208,5773,5958,"In addition, rare, sometimes  nonoseaegeneralterm  cases of severe  oselabeledaeclasseffect  including  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported.\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse ALT or  oselabeledaefromdruguse (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs including celecoxib.\n', '\n', ' In controlled clinical trials of CELEBREX, the incidence of borderline  oselabeledaefromdruguse (greater than or equal to 1.2 times and less than 3 times the upper limit  oselabeledaefromdruguse normal) of  oselabeledaefromdruguse was 6% for CELEBREX and 5% for placebo, and approximately 0.2% of patients taking CELEBREX and 0.3% of patients taking placebo had notable  nonoseaeaeratelteqplacebo of ALT and  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo and AST.\n', '\n', ' Inform patients of the warning signs and symptoms of  nonoseaeaeonlyasinstruction (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication .",1,1,0,0,1,0,1,0,0,0,0,0,0,0,0
209,celebrex,209,5958,6221,"If clinical signs and symptoms consistent with  nonoseaeaeonlyasinstruction develop, or if systemic manifestations occur (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  etc.), discontinue CELEBREX immediately, and perform a clinical evaluation of the patient.\n', '\n', '    5.4 Hypertension\n', '\n', '  NSAIDs, including CELEBREX can lead to new onset of  oselabeledaefromdruguse or  oselabeledaefromdruguse  either of which may contribute to the increased incidence of  nonoseaemanifestationorcomplication  Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazide diuretics or loop diuretics may have impaired response to these therapies when taking NSAIDs [ see  Drug Interactions (7)    ].\n', '\n', ' The rates of  oselabeledaefromdruguse from the CLASS trial in the CELEBREX, ibuprofen and diclofenac-treated patients were 2.4%, 4.2% and 2.5%, respectively [see   Clinical Studies (14.6)    ].\n', '\n', ' Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy.\n', '\n', '    5.5 Heart Failure and Edema\n', '\n', ""   The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for  oselabeledaefromdruguse in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
210,celebrex,210,6221,6277,"In a Danish National Registry study of patients with  notaecandidatepreexistingconditionorriskfactor  NSAID use increased the risk of  oselabeledaeclasseffect  hospitalization for  oselabeledaeclasseffect  and  nonoseaegeneralterm   \n"", '\n', '  Additionally,  oselabeledaeclasseffect and  oselabeledaeclasseffect have been observed in some patients treated with NSAIDs.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
211,celebrex,211,6277,6311,"Use of celecoxib may blunt the  nonoseaeaeonlyasinstruction of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs])",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,celebrex,212,6311,6323,[ see  Drug Interactions (7)    ].  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
213,celebrex,213,6323,6408,"\n', '\n', '  In the CLASS study [ see  Clinical Studies (14.6)    ], the Kaplan-Meier cumulative rates at 9 months of  oselabeledaefromdruguse in patients on CELEBREX 400 mg twice daily (4-fold and 2-fold the recommended  notaecandidateindication and  notaecandidateindication doses, respectively), ibuprofen 800 mg three times daily and diclofenac 75 mg twice daily were 4.5%, 6.9% and 4.7%, respectively.  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
214,celebrex,214,6408,6409,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,celebrex,215,6409,6539,"', '\n', '  Avoid the use of CELEBREX in patients with severe  notaecandidatepreexistingconditionorriskfactor unless the benefits are expected to outweigh the risk of  nonoseaeaeonlyasinstruction  If CELEBREX is used in patients with severe  notaecandidatepreexistingconditionorriskfactor  monitor patients for signs of  nonoseaeaeonlyasinstruction   \n', '\n', '    5.6 Renal Toxicity and Hyperkalemia\n', '\n', '   Renal Toxicity  \n', '\n', ' Long-term administration of NSAIDs has resulted in  oselabeledaeclasseffect and other  oselabeledaeclasseffect \n', '\n', '  oselabeledaeclasseffect has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
216,celebrex,216,6539,6619,"In these patients, administration of an NSAID may cause a dose-dependent  nonoseaemanifestationorcomplication prostaglandin formation and, secondarily, in  nonoseaemanifestationorcomplication  nonoseaeaeonlyasinstruction and, secondarily, in renal blood flow, which may precipitate overt  nonoseaemanifestationorcomplication  Patients at greatest risk of this reaction are those with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor ,   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  those taking diuretics, ACE-inhibitors or the ARBs, and the elderly.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
217,celebrex,217,6619,6698,"Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.\n', '\n', ' No information is available from controlled clinical studies regarding the use of CELEBREX in patients with advanced  notaecandidatepreexistingconditionorriskfactor  The  nonoseaeaeonlyasinstruction of CELEBREX may hasten the  oselabeledaefromdruguse in patients with preexisting  notaecandidatepreexistingconditionorriskfactor \n', '\n', ' Correct volume status in  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor patients prior to initiating CELEBREX.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
218,celebrex,218,6698,6713,Monitor renal function in patients with  notaecandidatepreexistingconditionorriskfactor or hepatic  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor   ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
219,celebrex,219,6713,6736,notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor during use of CELEBREX [ see  Drug Interactions (7)    ] .  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
220,celebrex,220,6736,6781,"Avoid the use of CELEBREX in patients with advanced  notaecandidatepreexistingconditionorriskfactor unless the benefits are expected to outweigh the risk of  nonoseaeaeonlyasinstruction  If CELEBREX is used in patients with advanced  notaecandidatepreexistingconditionorriskfactor  monitor patients for signs of  nonoseaeaeonlyasinstruction \n',",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
221,celebrex,221,6781,6789,"'\n', '    Hyperkalemia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,celebrex,222,6789,6820,"\n', '\n', '  oselabeledaeclasseffect  including  oselabeledaeclasseffect  have been reported with use of NSAIDs, even in some patients without  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
223,celebrex,223,6820,6878,"In patients with normal renal function, these effects have been attributed to a  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.7 Anaphylactic Reactions\n', '\n', '  Celecoxib has been associated with  oselabeledaefromdruguse in patients with and without known  notaecandidatecontraindication and in patients with  notaecandidatecontraindication  ",0,0,1,0,0,0,0,0,0,0,0,1,0,0,0
224,celebrex,224,6878,6907,Celebrex is a sulfonamide and both NSAIDs and sulfonamides may cause  oselabeledaefromdruguse including  oselabeledaefromdruguse and life-threatening or less severe  oselabeledaefromdruguse in certain susceptible people,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,celebrex,225,6907,6965,"[see   Contraindications (4)  and  Warnings and Precautions (5.8)    ].\n', '\n', ' Seek emergency help if any  nonoseaeaeonlyasinstruction occurs.\n', '\n', '    5.8 Exacerbation of Asthma Related to Aspirin Sensitivity\n', '\n', '  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,celebrex,226,6965,7045,"A subpopulation of patients with  notaecandidatepreexistingconditionorriskfactor may have  notaecandidatecontraindication which may include chronic  notaecandidatepreexistingconditionorriskfactor complicated by  notaecandidatepreexistingconditionorriskfactor  severe, potentially  nonoseaegeneralterm  notaecandidatepreexistingconditionorriskfactor  and/or  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor aspirin and other  notaecandidatepreexistingconditionorriskfactor  Because  notaecandidatepreexistingconditionorriskfactor between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, CELEBREX is contraindicated in patients with this form of aspirin sensitivity [ see  Contraindications (4)    ].",0,1,1,0,0,0,0,0,0,0,0,1,0,0,0
227,celebrex,227,7045,7122,"When CELEBREX is used in patients with preexisting  notaecandidatepreexistingconditionorriskfactor (without known  nonoseaenegation , monitor patients for changes in the signs and symptoms of  nonoseaeaeonlyasinstruction \n', '\n', '    5.9 Serious Skin Reactions\n', '\n', '  Serious  oselabeledaefromdruguse have occurred following treatment with Celebrex, including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse ,  oselabeledaefromdruguse , and  oselabeledaefromdruguse .",1,0,1,0,0,0,0,1,0,0,0,0,0,0,0
228,celebrex,228,7122,7134,These serious events may occur without warning and can be  nonoseaegeneralterm,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
229,celebrex,229,7134,7250,"\n', '\n', ' Inform patients about the signs and symptoms of serious  nonoseaeaeonlyasinstruction  and to discontinue the use of CELEBREX at the first appearance of  nonoseaemanifestationorcomplication or any other sign of  nonoseaeaeonlyasinstruction  CELEBREX is contraindicated in patients with previous serious  notaecandidatecontraindication [ see  Contraindications (4)    ].\n', '\n', '    5.10 Premature Closure of Fetal Ductus Arteriosus\n', '\n', '  Celecoxib may cause  oselabeledaefromdruguse  Avoid use of NSAIDs, including CELEBREX, in  notaecandidatepreexistingconditionorriskfactor women starting at 30 weeks of gestation (third trimester) [ see  ",1,0,1,0,1,0,0,0,0,0,0,1,0,0,0
230,celebrex,230,7250,7259,Use in Specific Populations (8.1)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
231,celebrex,231,7259,7285,".\n', '\n', '    5.11  oselabeledaefromdruguse \n', '   oselabeledaeclasseffect has occurred in NSAID-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
232,celebrex,232,7285,7305,This may be due to occult or gross  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or an incompletely described  notaecandidatepreexistingconditionorriskfactor  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
233,celebrex,233,7305,7322,If a patient treated with CELEBREX has any signs or symptoms of  nonoseaeaeonlyasinstruction  monitor hemoglobin,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,celebrex,234,7322,7331,"or hematocrit.\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,celebrex,235,7331,7351,In controlled clinical trials the incidence of  oselabeledaefromdruguse was 0.6% with CELEBREX and 0.4% with placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,celebrex,236,7351,7401,"Patients on long-term treatment with CELEBREX should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction \n', '\n', ' NSAIDs, including CELEBREX, may increase the risk of  oselabeledaefromdruguse events.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,celebrex,237,7401,7445,"Co-morbid conditions such as  notaecandidatepreexistingconditionorriskfactor or concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
238,celebrex,238,7445,7453,Monitor these patients for signs of  nonoseaeaeonlyasinstruction,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,celebrex,239,7453,7459,[ see  Drug Interactions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,celebrex,240,7459,7463,7)    ],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,celebrex,241,7463,7588,".\n', '\n', '    5.12 Masking of Inflammation and Fever\n', '\n', '  The pharmacological activity of CELEBREX in  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction inflammation, and possibly  nonoseaeaeonlyasinstruction  may diminish the utility of diagnostic signs in detecting  nonoseaeaeonlyasinstruction \n', '\n', '    5.13 Laboratory Monitoring\n', '\n', '  Because serious  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically [ see  Warnings and Precautions (5.2  ,  5.3  ,  5.6)    ]",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,celebrex,242,7588,7616,".\n', '\n', ' In controlled clinical trials,  oselabeledaefromdruguse occurred more frequently in patients receiving CELEBREX compared with patients on placebo.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,celebrex,243,7616,7632,This  nonoseaegeneralterm was also seen in patients who received comparator NSAIDs in these studies.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
244,celebrex,244,7632,7698,"The clinical significance of this abnormality has not been established.\n', '\n', '    5.14 Disseminated Intravascular Coagulation (DIC)\n', '\n', '  Because of the risk of  oselabeledaefromdruguse with use of CELEBREX in pediatric patients with systemic onset  notaecandidateindication  monitor patients for signs and symptoms of  nonoseaemanifestationorcomplication or  nonoseaemanifestationorcomplication ']",0,0,0,1,1,0,0,0,0,0,0,0,0,0,0
0,kerydin,0,0,48,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Common adverse reactions occurring in >=1% in subjects treated with KERYDIN included application site exfoliation, ingrown toenail, application site erythema, and application site dermatitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,kerydin,1,48,106,"(  6.1  )\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Anacor Pharmaceuticals at 1-844-4ANACOR [1-844-426-2267] or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch    .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,kerydin,2,106,143,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,kerydin,3,143,214,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In two clinical trials, 791 subjects were treated with KERYDIN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,kerydin,4,214,285,"The most commonly reported adverse reactions are listed below (  Table 1  ).\n', '\n', '\n', '\n', ' Table 1: Adverse Reactions Occurring in >=1% of KERYDIN Topical Solution, 5%-Treated Subjects and at a Greater Frequency than Observed with Vehicle \n', '   Preferred Term                                          KERYDINN=791    n(%)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,kerydin,5,285,287,VehicleN=395    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,kerydin,6,287,290,n(%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,kerydin,7,290,303,"\n', '  oselabeledaefromdruguse                            21 (2.7%)               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,kerydin,8,303,309,1 (0.3%)                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,kerydin,9,309,328,"\n', '  oselabeledaefromdruguse                                         20 (2.5%)               1 (0.3%)                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,kerydin,10,328,342,"\n', '  oselabeledaefromdruguse                               13 (1.6%)               0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,kerydin,11,342,347,(0%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,kerydin,12,347,361,"\n', '  oselabeledaefromdruguse                             10 (1.3%)               0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,kerydin,13,361,366,(0%)                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,kerydin,14,366,386,"\n', '         A cumulative irritancy study revealed the potential for KERYDIN to cause  oselabeledaefromdruguse ']",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,latuda,0,0,72,"['    6 ADVERSE REACTIONS\n', '\n', '  The following adverse reactions are discussed in more detail in other sections of the labeling:\n', '\n', '\n', '\n', ' *  Increased  nonoseaegeneralterm in Elderly Patients with  notaecandidatepreexistingconditionorriskfactor [see  Boxed Warning  and Warnings and Precautions (  5.1  )]  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
1,latuda,1,72,88,"\n', ' *   oselabeledaeclasseffect  oselabeledaeclasseffect Thoughts and  oselabeledaeclasseffect [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,latuda,2,88,102,Boxed Warning  and Warnings and Precautions (  5.2  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,latuda,3,102,130,"\n', ' *   nonoseaeaefromofflabel  Including  nonoseaeaefromofflabel  in Elderly Patients with  notaecandidatepreexistingconditionorriskfactor [see Warnings and Precautions (5.23)]  ",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
4,latuda,4,130,137,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,latuda,5,137,149,[see Warnings and Precautions (  5.4  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,latuda,6,149,168,"\n', ' *   oselabeledaeclasseffect [see Warnings and Precautions (  5.5  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,latuda,7,168,199,"\n', ' *   oselabeledaeclasseffect ( oselabeledaeclasseffect and  notaecandidatepreexistingconditionorriskfactor   oselabeledaeclasseffect  and  oselabeledaeclasseffect  [see Warnings and Precautions (  5.6  )]  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
8,latuda,8,199,206,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,latuda,9,206,218,[see Warnings and Precautions (  5.7  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,latuda,10,218,243,"\n', ' *   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect [see Warnings and Precautions (  5.8  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,latuda,11,243,265,"\n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see Warnings and Precautions (  5.9  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,latuda,12,265,284,"\n', ' *   nonoseaeaeratelteqplacebo [see Warnings and Precautions (  5.10  )]  ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
13,latuda,13,284,288,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,latuda,14,288,312,*  Potential for  oselabeledaefromdruguse and Motor  oselabeledaefromdruguse  oselabeledaefromdruguse [see Warnings and Precautions (  5.11  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,latuda,15,312,331,"\n', ' *   oselabeledaeclasseffect [see Warnings and Precautions (  5.12  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,latuda,16,331,335,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,latuda,17,335,350,*   nonoseaeaeonlyasinstruction [see Warnings and Precautions (  5.13  )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,latuda,18,350,374,"\n', ' *   oselabeledaeclasseffect Mania/ oselabeledaeclasseffect  oselabeledaeclasseffect Hypomania [see Warnings and Precautions (  5.14  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,latuda,19,374,393,"\n', ' *   oselabeledaeclasseffect [see Warnings and Precautions (  5.15  )]  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,latuda,20,393,408,"\n', ' *   oselabeledaefromdruguse in Patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
21,latuda,21,408,420,[see Warnings and Precautions (  5.16  )]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,latuda,22,420,561,"\n', '      EXCERPT:   Commonly observed adverse reactions (incidence >= 5% and at least twice the rate for placebo) were (  6.1  ):\n', ' \n', '\n', ' *  Schizophrenia: somnolence, akathisia, extrapyramidal symptoms, and nausea \n', ' *  Bipolar depression: akathisia, extrapyramidal symptoms, and somnolence \n', '      To report SUSPECTED ADVERSE REACTIONS, contact Sunovion Pharmaceuticals Inc. at 1-877-737-7226 or FDA at 1-800-FDA-1088 or    www.fda.gov/medwatch  .\n', ' \n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,latuda,23,561,660,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' The information below is derived from an integrated clinical study database for LATUDA consisting of 3799 patients exposed to one or more doses of LATUDA for the treatment of  notaecandidateindication and  notaecandidateindication in placebo-controlled studies.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
24,latuda,24,660,673,This experience corresponds with a total experience of 1250.9 patient-years.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,latuda,25,673,750,"A total of 1106 LATUDA-treated patients had at least 24 weeks and 371 LATUDA-treated patients had at least 52 weeks of exposure.\n', '\n', '\n', '\n', ' Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,latuda,26,750,762,Adverse experiences were recorded by clinical investigators using their own terminology.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,latuda,27,762,878,"In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.\n', '\n', '\n', '\n', '     Schizophrenia  \n', '\n', '\n', '\n', ' The following findings are based on the short-term, placebo-controlled premarketing studies for  notaecandidateindication in which LATUDA was administered at daily doses ranging from 20 to 160 mg (n=1508).\n', '\n', '\n', '\n', '     Commonly Observed Adverse Reactions:  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
28,latuda,28,878,914,The most common adverse reactions (incidence >= 5% and at least twice the rate of placebo) in patients treated with LATUDA were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,latuda,29,914,931,"\n', '\n', '\n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,latuda,30,931,969,Adverse Reactions Associated with Discontinuation of Treatment:  A total of 9.5% (143/1508) LATUDA-treated patients and 9.3% (66/708) of placebo-treated patients discontinued due to adverse reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,latuda,31,969,1136,"There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.\n', '\n', '\n', '\n', '     Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients:  Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with schizophrenia) are shown in  Table 15  .\n', '\n', '\n', '\n', ' Table 15: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Short-term Schizophrenia Studies \n', '  Note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,latuda,32,1136,1167,"Figures rounded to the nearest integer    \n', '  *  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,latuda,33,1167,1172,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,latuda,34,1172,1173,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,latuda,35,1173,1214,*  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,latuda,36,1214,1329,"\n', '  \n', '                            Percentage of Patients Reporting Reaction     \n', '                            LATUDA      \n', '   Body System or    Organ Class      Placebo    (N=708)    (%)      20    mg/day    (N=71)    (%)      40    mg/day    (N=487)    (%)      80    mg/day    (N=538)    (%)      120    mg/day    (N=291)    (%)      160    mg/day    (N=121)    (%)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,latuda,37,1329,1341,All    LATUDA    (N=1508)    (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,latuda,38,1341,1343,\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,latuda,39,1343,1348,", '    nonoseaegeneralterm                                                                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,latuda,40,1348,1359,"\n', '       oselabeledaefromdruguse              5            11          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,latuda,41,1359,1361,10          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,latuda,42,1361,1363,9           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,latuda,43,1363,1390,"13          7           10             \n', '       oselabeledaefromdruguse            6            7           6           9           9           7           8              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,latuda,44,1390,1440,"\n', '       oselabeledaefromdruguse           5            11          6           5           8           6           6              \n', '       oselabeledaefromdruguse  <1           1           1           2           4           2           2              \n', '    nonoseaegeneralterm                                                                                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,latuda,45,1440,1485,"\n', '       oselabeledaefromdruguse           2            0           4           3           4           0           3              \n', '    nonoseaegeneralterm                                                                                            \n', '       oselabeledaefromdruguse          7            15          16          15          26          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
46,latuda,46,1485,1487,8           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,latuda,47,1487,1510,"17             \n', '       oselabeledaefromdruguse           3            6           11          12          22          7           13             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,latuda,48,1510,1553,"\n', '       oselabeledaefromdruguse *  6            6           11          12          22          13          14             \n', '       oselabeledaefromdruguse           2            6           4           4           5           6           4              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,latuda,49,1553,1594,"\n', '    nonoseaegeneralterm                                                                                            \n', '       oselabeledaefromdruguse            8            8           10          11          9           7           10             \n', '       oselabeledaefromdruguse           4            10          7           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
50,latuda,50,1594,1602,3           6           5           5              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,latuda,51,1602,1607,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,latuda,52,1607,1613,oselabeledaefromdruguse             4            3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,latuda,53,1613,1634,"6           4           7           3           5              \n', '       oselabeledaefromdruguse        1            1           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,latuda,54,1634,1640,3           1           3           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,latuda,55,1640,1681,"2           2              \n', '                  Dose-Related Adverse Reactions in the Schizophrenia Studies  \n', ' \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse were dose-related.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,latuda,56,1681,1727,"The frequency of  oselabeledaefromdruguse increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 10.7% for LATUDA 40 mg, 12.3% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,latuda,57,1727,1745,oselabeledaefromdruguse was reported by 7.4% (9/121) of patients receiving 160 mg/day.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,latuda,58,1745,1755,nonoseaeaeonlyasinstruction occurred in 3.0% of subjects receiving placebo.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,latuda,59,1755,1820,"The frequency of  oselabeledaefromdruguse increased with dose up to 120 mg/day (5.6% for LATUDA 20 mg, 11.5% for LATUDA 40 mg, 11.9% for LATUDA 80 mg, and 22.0% for LATUDA 120 mg).\n', '\n', '\n', '\n', '     Bipolar Depression (Monotherapy)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,latuda,60,1820,1926,"\n', '\n', '\n', '\n', ' The following findings are based on the short-term, placebo-controlled premarketing study for  notaecandidateindication in which LATUDA was administered at daily doses ranging from 20 to 120 mg (n=331).\n', '\n', '\n', '\n', '     Commonly Observed Adverse Reactions:  The most common adverse reactions (incidence >= 5%, in either dose group, and at least twice the rate of placebo) in patients treated with LATUDA were  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
61,latuda,61,1926,1930,oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,latuda,62,1930,1936,oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,latuda,63,1936,1941,oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,latuda,64,1941,1958,"\n', '\n', '\n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,latuda,65,1958,1996,Adverse Reactions Associated with Discontinuation of Treatment:  A total of 6.0% (20/331) LATUDA-treated patients and 5.4% (9/168) of placebo-treated patients discontinued due to adverse reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,latuda,66,1996,2159,"There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.\n', '\n', '\n', '\n', '     Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients:  Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with  notaecandidateindication  are shown in  Table 16  .\n', '\n', '\n', '\n', ' Table 16: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in a Short-term Monotherapy  notaecandidateindication",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
67,latuda,67,2159,2161,Study \n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,latuda,68,2161,2167,"', '  Note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,latuda,69,2167,2221,"Figures rounded to the nearest integer    \n', '  * oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,latuda,70,2221,2226,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,latuda,71,2226,2227,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,latuda,72,2227,2284,"*  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    \n', '  \n', '                                                 Percentage of Patients Reporting Reaction     \n', '   Body System or Organ Class       Dictionary-derived Term    Placebo    (N=168)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,latuda,73,2284,2297,(%)      LATUDA    20-60 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,latuda,74,2297,2330,(N=164)    (%)      LATUDA    80-120 mg/day    (N=167)    (%)      All LATUDA(N=331)    (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,latuda,75,2330,2344,"\n', '    nonoseaegeneralterm                   \n', '       oselabeledaefromdruguse                                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
76,latuda,76,2344,2346,8              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,latuda,77,2346,2348,10             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,latuda,78,2348,2350,17          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,latuda,79,2350,2352,14             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,latuda,80,2352,2367,"\n', '       oselabeledaefromdruguse                                4              6              4           5              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,latuda,81,2367,2404,"\n', '       oselabeledaefromdruguse                                 2              2              6           4              \n', '       oselabeledaefromdruguse                                 2              5              3           4              \n', '    nonoseaegeneralterm                  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
82,latuda,82,2404,2426,"\n', '       oselabeledaefromdruguse                          1              4              4           4              \n', '       oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,latuda,83,2426,2428,1              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,latuda,84,2428,2442,"<1             2           2              \n', '       oselabeledaefromdruguse                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,latuda,85,2442,2447,<1             2              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,latuda,86,2447,2449,1           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,latuda,87,2449,2458,"2              \n', '    nonoseaegeneralterm     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
88,latuda,88,2458,2465,"\n', '       oselabeledaefromdruguse                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,latuda,89,2465,2470,<1             3              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,latuda,90,2470,2487,"<1          2              \n', '    nonoseaegeneralterm                     \n', '       ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
91,latuda,91,2487,2497,oselabeledaefromdruguse                  2              5              9           7              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,latuda,92,2497,2517,"\n', '       oselabeledaefromdruguse                                2              8              11          9              \n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,latuda,93,2517,2518,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,latuda,94,2518,2528,*                             7              7              14          11             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
95,latuda,95,2528,2535,"\n', '    nonoseaegeneralterm                        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
96,latuda,96,2535,2578,"\n', '       oselabeledaefromdruguse                                  1              4              5           4              \n', '                 Dose-Related Adverse Reactions in the Monotherapy Study:  \n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,latuda,97,2578,2607,"In the short-term, placebo-controlled study (involving lower and higher LATUDA dose ranges) [see Clinical Studies (  14.2  )]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,latuda,98,2607,2862,"the adverse reactions that occurred with a greater than 5% incidence in the patients treated with LATUDA in any dose group and greater than placebo in both groups were  oselabeledaefromdruguse (10.4%, 17.4%),  oselabeledaefromdruguse (7.3%, 13.8%),  oselabeledaefromdruguse (7.9%, 10.8%), and  oselabeledaefromdruguse (4.9%, 9.0%) for LATUDA 20 to 60 mg/day and LATUDA 80 to 120 mg/day, respectively.\n', '\n', '\n', '\n', '     Bipolar Depression  \n', '\n', '\n', '\n', '     Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' The following findings are based on two short-term, placebo-controlled premarketing studies for  notaecandidateindication in which LATUDA was administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with lithium or valproate (n=360).\n', '\n', '\n', '\n', '     Commonly Observed Adverse Reactions:  The most common adverse reactions (incidence >= 5% and at least twice the rate of placebo) in subjects treated with LATUDA were  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '\n', '\n",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
99,latuda,99,2862,2875,"', '     Adverse Reactions Associated with Discontinuation of Treatment:  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,latuda,100,2875,2904,A total of 5.8% (21/360) LATUDA-treated patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,latuda,101,2904,3076,"There were no adverse reactions associated with discontinuation in subjects treated with LATUDA that were at least 2% and at least twice the placebo rate.\n', '\n', '\n', '\n', '     Adverse Reactions Occurring at an Incidence of 2% or More in LATUDA-Treated Patients:  Adverse reactions associated with the use of LATUDA (incidence of 2% or greater, rounded to the nearest percent and LATUDA incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with  notaecandidateindication  are shown in  Table 17  .\n', '\n', '\n', '\n', ' Table 17: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Short-term Adjunctive Therapy Bipolar Depression Studies \n', '  Note:",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
102,latuda,102,3076,3130,"Figures rounded to the nearest integer    \n', '  * oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
103,latuda,103,3130,3135,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,latuda,104,3135,3136,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,latuda,105,3136,3210,"*  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    \n', '  \n', '                                              Percentage of Patients Reporting Reaction     \n', '   Body System or Organ Class       Dictionary-derived Term    Placebo    (N=334)    (%)      LATUDA        20 to 120 mg/day    (N=360)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,latuda,106,3210,3214,(%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,latuda,107,3214,3219,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
108,latuda,108,3219,3221,nonoseaegeneralterm                ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
109,latuda,109,3221,3230,"\n', '       oselabeledaefromdruguse                                10          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,latuda,110,3230,3232,14                             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,latuda,111,3232,3243,"\n', '       oselabeledaefromdruguse                              1           4                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,latuda,112,3243,3250,"\n', '    nonoseaegeneralterm                         ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
113,latuda,113,3250,3268,"\n', '       oselabeledaefromdruguse                               1           3                              \n', '    nonoseaegeneralterm               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
114,latuda,114,3268,3279,"\n', '       oselabeledaefromdruguse                       2           4                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,latuda,115,3279,3286,"\n', '    nonoseaegeneralterm                            ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
116,latuda,116,3286,3291,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,latuda,117,3291,3293,oselabeledaefromdruguse                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,latuda,118,3293,3305,"<1          3                              \n', '    nonoseaegeneralterm        ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
119,latuda,119,3305,3321,"\n', '       oselabeledaefromdruguse                    1           3                              \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,latuda,120,3321,3323,nonoseaegeneralterm                  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
121,latuda,121,3323,3340,"\n', '       oselabeledaefromdruguse               9           14                             \n', '       oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,latuda,122,3340,3463,"*                          5           11                             \n', '       oselabeledaefromdruguse                             5           11                             \n', '    nonoseaegeneralterm                     \n', '       oselabeledaefromdruguse                          <1          4                              \n', '               Extrapyramidal Symptoms  \n', ' \n', '\n', '     Schizophrenia  \n', '\n', '\n', '\n', ' In the short-term, placebo-controlled  notaecandidateindication studies, for LATUDA-treated patients, the incidence of reported events related to  oselabeledaefromdruguse , excluding  nonoseaenegation and  nonoseaenegation  was 13.5% versus 5.8% for placebo-treated patients.",0,1,0,1,0,0,0,1,0,0,0,0,0,0,0
123,latuda,123,3463,3485,The incidence of  oselabeledaefromdruguse for LATUDA-treated patients was 12.9% versus 3.0% for placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,latuda,124,3485,3568,"Incidence of  oselabeledaefromdruguse by dose is provided in  Table 18  .\n', '\n', '\n', '\n', ' Table 18: Incidence of EPS Compared to Placebo in Schizophrenia Studies \n', '  Note: Figures rounded to the nearest integer    \n', '  *  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,latuda,125,3568,3573,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
126,latuda,126,3573,3574,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
127,latuda,127,3574,3603,*  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,latuda,128,3603,3739,"\n', '  \n', '                                                         LATUDA                                   \n', '   Adverse Event Term        Placebo    (N=708)    (%)      20 mg/day    (N=71)    (%)      40 mg/day    (N=487)    (%)      80 mg/day    (N=538)    (%)      120 mg/day    (N=291)    (%)      160 mg/day    (N=121)    (%)     \n', '   All  oselabeledaefromdruguse events            9             10            21            23            39            20             \n', '   All  oselabeledaefromdruguse events, excluding  nonoseaenegation  nonoseaenegation      6             ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
129,latuda,129,3739,3758,"6             11            12            22            13             \n', '       oselabeledaefromdruguse            3             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,latuda,130,3758,3775,"6             11            12            22            7                \n', '       oselabeledaefromdruguse             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,latuda,131,3775,3780,<1            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,latuda,132,3780,3782,4             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,latuda,133,3782,3784,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,latuda,134,3784,3788,7             2                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,latuda,135,3788,3796,"\n', '       oselabeledaefromdruguse *       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,latuda,136,3796,3798,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,latuda,137,3798,3800,6             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,latuda,138,3800,3802,9             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,latuda,139,3802,3804,8             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,latuda,140,3804,3819,"17            11               \n', '       oselabeledaefromdruguse         1             1             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,latuda,141,3819,3821,3             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,latuda,142,3821,3823,1             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,latuda,143,3823,3827,3             2                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,latuda,144,3827,3850,"\n', '                 Bipolar Depression  \n', ' \n', '\n', '     Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,latuda,145,3850,3914,"\n', '\n', '\n', '\n', ' In the short-term, placebo-controlled monotherapy  notaecandidateindication study, for LATUDA-treated patients, the incidence of reported events related to  oselabeledaefromdruguse  excluding  nonoseaenegation and  nonoseaenegation was 6.9% versus 2.4% for placebo-treated patients.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
146,latuda,146,3914,3936,The incidence of  nonoseaenegation for LATUDA-treated patients was 9.4% versus 2.4% for placebo-treated patients.,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
147,latuda,147,3936,4003,"Incidence of  oselabeledaefromdruguse by dose groups is provided in  Table 19  .\n', '\n', '\n', '\n', ' Table 19: Incidence of EPS Compared to Placebo in the Monotherapy Bipolar Depression Study \n', '                                                         LATUDA                    \n', '   Adverse Event Term        Placebo    (N=168)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
148,latuda,148,4003,4007,(%)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,latuda,149,4007,4014,20 to 60 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,latuda,150,4014,4037,(N=164)    (%)      80 to 120 mg/day    (N=167)    (%)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,latuda,151,4037,4053,"\n', '   All  oselabeledaefromdruguse events            5             12            20                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,latuda,152,4053,4071,"\n', '   All  oselabeledaefromdruguse events, excluding  nonoseaenegation  nonoseaenegation      2             ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
153,latuda,153,4071,4073,5             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,latuda,154,4073,4075,9                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,latuda,155,4075,4076,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,latuda,156,4076,4087,"', '  \n', '  Note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,latuda,157,4087,4122,"Figures rounded to the nearest integer    \n', '  *  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,latuda,158,4122,4127,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,latuda,159,4127,4128,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,latuda,160,4128,4159,*  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
161,latuda,161,4159,4173,"\n', '  \n', '       oselabeledaefromdruguse            2             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,latuda,162,4173,4175,8             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
163,latuda,163,4175,4177,11                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,latuda,164,4177,4186,"\n', '       oselabeledaefromdruguse             0             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,latuda,165,4186,4188,0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,latuda,166,4188,4190,2                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,latuda,167,4190,4204,"\n', '       oselabeledaefromdruguse *       2             5             8                           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,latuda,168,4204,4211,"\n', '       oselabeledaefromdruguse         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,latuda,169,4211,4216,<1            0             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,latuda,170,4216,4218,3                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,latuda,171,4218,4285,"\n', '               Adjunctive Therapy with Lithium or Valproate  \n', ' \n', '\n', ' In the short-term, placebo-controlled adjunctive therapy  notaecandidateindication studies, for LATUDA-treated patients, the incidence of  oselabeledaefromdruguse  excluding  nonoseaenegation and  nonoseaenegation  was 13.9% versus 8.7% for placebo.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
172,latuda,172,4285,4307,The incidence of  oselabeledaefromdruguse for LATUDA-treated patients was 10.8% versus 4.8% for placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,latuda,173,4307,4365,"Incidence of  oselabeledaefromdruguse is provided in  Table 20  .\n', '\n', '\n', '\n', ' Table 20: Incidence of EPS Compared to Placebo in the Adjunctive Therapy Bipolar Depression Studies \n', '   Adverse Event Term        Placebo    (N=334)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
174,latuda,174,4365,4395,"(%)           LATUDA        20 to 120 mg/day(N=360)    (%)     \n', '   All  oselabeledaefromdruguse events            13                                  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,latuda,175,4395,4415,"24                                       \n', '   All  oselabeledaefromdruguse events, excluding  nonoseaenegation  nonoseaenegation      9                                   ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
176,latuda,176,4415,4417,14                                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,latuda,177,4417,4418,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,latuda,178,4418,4429,"', '  \n', '  Note:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,latuda,179,4429,4464,"Figures rounded to the nearest integer    \n', '  *  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,latuda,180,4464,4469,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,latuda,181,4469,4470,*,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,latuda,182,4470,4501,*  oselabeledaefromdruguse includes adverse event terms:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,latuda,183,4501,4517,"\n', '  \n', '       oselabeledaefromdruguse            5                                   11                                         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,latuda,184,4517,4534,"\n', '       oselabeledaefromdruguse             <1                                  1                                          \n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,latuda,185,4534,4541,oselabeledaefromdruguse *       8                                   13                                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,latuda,186,4541,4546,"\n', '       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,latuda,187,4546,4553,oselabeledaefromdruguse         <1                                  4                                          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,latuda,188,4553,4613,"\n', '         In the short-term, placebo-controlled  notaecandidateindication and  notaecandidateindication studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for  oselabeledaefromdruguse , the Barnes Akathisia Scale (BAS) for  nonoseaeaeonlyasinstruction and the  nonoseaeaeonlyasinstruction Movement Scale (AIMS) for  nonoseaeaeonlyasinstruction",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
189,latuda,189,4613,4628,"\n', ' \n', '\n', '     Schizophrenia  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
190,latuda,190,4628,4690,"\n', '\n', '\n', '\n', ' The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes  nonoseaeaeonlyasinstruction Scale global score (LATUDA, 0.1; placebo, 0.0).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
191,latuda,191,4690,4787,"The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 14.4%; placebo, 7.1%), the SAS (LATUDA, 5.0%; placebo, 2.3%) and the AIMS (LATUDA, 7.4%; placebo, 5.8%).\n', '\n', '\n', '\n', '     Bipolar Depression  \n', '\n', '\n', '\n', '     Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,latuda,192,4787,4828,"\n', '\n', '\n', '\n', ' The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,latuda,193,4828,4951,"The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.4%; placebo, 5.6%), the SAS (LATUDA, 3.7%; placebo, 1.9%) and the AIMS (LATUDA, 3.4%; placebo, 1.2%).\n', '\n', '\n', '\n', '   Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' The mean change from baseline for LATUDA-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,latuda,194,4951,5072,"The percentage of patients who shifted from normal to abnormal was greater in LATUDA-treated patients versus placebo for the BAS (LATUDA, 8.7%; placebo, 2.1%), the SAS (LATUDA, 2.8%; placebo, 2.1%) and the AIMS (LATUDA, 2.8%; placebo, 0.6%).\n', '\n', '\n', '\n', '     Dystonia  \n', '\n', '\n', '\n', '     Class Effect:  Symptoms of  oselabeledaeclasseffect  prolonged  oselabeledaeclasseffect  may occur in susceptible individuals during the first few days of treatment.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
195,latuda,195,5072,5126,"nonoseaeaeonlyasinstruction include:  nonoseaemanifestationorcomplication  sometimes progressing to  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication the  nonoseaemanifestationorcomplication  While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
196,latuda,196,5126,5221,"An elevated risk of  nonoseaeaeonlyasinstruction is observed in males and younger age groups.\n', '\n', '\n', '\n', '     Schizophrenia  \n', '\n', '\n', '\n', ' In the short-term, placebo-controlled  notaecandidateindication clinical studies,  oselabeledaefromdruguse occurred in 4.2% of LATUDA-treated subjects (0.0% LATUDA 20 mg, 3.5% LATUDA 40 mg, 4.5% LATUDA 80 mg, 6.5% LATUDA",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
197,latuda,197,5221,5226,120 mg and 2.5%,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
198,latuda,198,5226,5239,LATUDA 160 mg) compared to 0.8% of subjects receiving placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
199,latuda,199,5239,5310,"Seven subjects (0.5%, 7/1508) discontinued clinical trials due to dystonic events - four were receiving LATUDA 80 mg/day and three were receiving LATUDA 120 mg/day.\n', '\n', '\n', '\n', '     Bipolar Depression  \n', '\n', '\n', '\n', '     Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
200,latuda,200,5310,5389,"\n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled monotherapy  notaecandidateindication study,  oselabeledaefromdruguse occurred in 0.9% of LATUDA-treated subjects (0.0% and 1.8% for LATUDA 20 to 60 mg/day and LATUDA 80 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
201,latuda,201,5389,5484,"No subject discontinued the clinical study due to  nonoseaenegation \n', '\n', '\n', '\n', '     Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled adjunctive therapy  notaecandidateindication studies,  oselabeledaefromdruguse occurred in 1.1% of LATUDA-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
202,latuda,202,5484,5514,"No subject discontinued the clinical study due to  nonoseaenegation \n', '\n', '\n', '\n', '     Other Adverse Reactions",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
203,latuda,203,5514,5522,Observed During the Premarketing Evaluation of LATUDA  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
204,latuda,204,5522,5572,"\n', '\n', '\n', '\n', ' Following is a list of adverse reactions reported by patients treated with LATUDA at multiple doses of >= 20 mg once daily within the premarketing database of 2905 patients with  notaecandidateindication  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
205,latuda,205,5572,5600,"The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
206,latuda,206,5600,5620,Reactions listed in  Table 15  or those that appear elsewhere in the LATUDA label are not included.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
207,latuda,207,5620,6033,"Although the reactions reported occurred during treatment with LATUDA, they were not necessarily caused by it.\n', '\n', '\n', '\n', ' Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebo-controlled studies appear in this listing); those occurring in 1/100 to 1/1000 patients (infrequent); and those occurring in fewer than 1/1000 patients (rare).\n', '\n', '\n', '\n', '    nonoseaegeneralterm     Infrequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Infrequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse   oselabeledaefromdruguse     Infrequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Rare:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Rare:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  \n', '\n', '\n', '\n', '    nonoseaegeneralterm     Infrequent:     oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
208,latuda,208,6033,6038,Rare:     oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
209,latuda,209,6038,6064,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm     Infrequent:     oselabeledaefromdruguse   oselabeledaefromdruguse     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
210,latuda,210,6064,6075,Rare:     oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
211,latuda,211,6075,6080,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
212,latuda,212,6080,6106,"', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse   oselabeledaefromdruguse     Rare:     oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
213,latuda,213,6106,6188,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm     Frequent:     oselabeledaefromdruguse  \n', '\n', '\n', '\n', '     Clinical Laboratory Changes  \n', '\n', '\n', '\n', '   Schizophrenia\n', '\n', '\n', '\n', '   Serum Creatinine  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
214,latuda,214,6188,6226,": In short-term, placebo-controlled trials, the  oselabeledaefromdruguse was +0.05 mg/dL for LATUDA-treated patients compared to +0.02 mg/dL for placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
215,latuda,215,6226,6256,A  oselabeledaefromdruguse shift from normal to  oselabeledaefromdruguse occurred in 3.0% (43/1453) of LATUDA-treated patients and 1.6% (11/681) on placebo.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
216,latuda,216,6256,6333,"The threshold for  nonoseaeaeonlyasinstruction value varied from > 0.79 to > 1.3 mg/dL based on the centralized laboratory definition for each study (  Table 21  ).\n', '\n', '\n', '\n', ' Table 21: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in Schizophrenia Studies \n', '   Laboratory Parameter      Placebo    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
217,latuda,217,6333,6364,(N=708)      LATUDA 20mg/day    (N=71)      LATUDA 40mg/day    (N=487)      LATUDA 80mg/day    (N=538)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
218,latuda,218,6364,6374,LATUDA 120 mg/day    (N=291)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
219,latuda,219,6374,6383,LATUDA 160mg/day    (N=121)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
220,latuda,220,6383,6390,"\n', '    oselabeledaefromdruguse    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
221,latuda,221,6390,6408,2%           1%             2%             2%             5%             7%              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
222,latuda,222,6408,6429,"\n', '               Bipolar Depression\n', ' \n', '\n', '     Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
223,latuda,223,6429,6494,"\n', '\n', '\n', '\n', '     Serum Creatinine  : In the short-term, flexible-dose, placebo-controlled monotherapy  notaecandidateindication study, the  oselabeledaefromdruguse was +0.01 mg/dL for LATUDA-treated patients compared to -0.02 mg/dL for placebo-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
224,latuda,224,6494,6576,"A  oselabeledaefromdruguse shift from normal to  oselabeledaefromdruguse occurred in 2.8% (9/322) of LATUDA-treated patients and 0.6% (1/162) on placebo (  Table 22  ).\n', '\n', '\n', '\n', ' Table 22: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in a Monotherapy Bipolar Depression Study \n', '   Laboratory Parameter           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
225,latuda,225,6576,6600,Placebo    (N=168)      LATUDA20 to 60 mg/day    (N=164)      LATUDA80 to 120 mg/day    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
226,latuda,226,6600,6634,"(N=167)     \n', '    oselabeledaefromdruguse    <1%                     2%                        4%                       \n', '              Adjunctive Therapy with Lithium or Valproate  \n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
227,latuda,227,6634,6646,"', ' \n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
228,latuda,228,6646,6691,"Serum Creatinine  : In short-term, placebo-controlled premarketing adjunctive studies for  notaecandidateindication  the  oselabeledaefromdruguse was +0.04 mg/dL for LATUDA-treated patients compared to -0.01 mg/dL for placebo-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
229,latuda,229,6691,6727,A  oselabeledaefromdruguse shift from normal to  oselabeledaefromdruguse occurred in 4.3% (15/360) of LATUDA-treated patients and 1.6% (5/334) on placebo (  Table 23  ).\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
230,latuda,230,6727,6905,"', '\n', '\n', '\n', ' Table 23: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adjunctive Therapy  notaecandidateindication Studies \n', '   Laboratory Parameter           Placebo    (N=334)                 LATUDA    20 to 120 mg/day(N=360)     \n', '    oselabeledaefromdruguse \n', '\n', '    BOXED WARNING: WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '\n', '\n', '  WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS\n', '\n', '\n', '\n', '    *  Elderly patients with  notaecandidatepreexistingconditionorriskfactor treated with antipsychotic drugs are at an increased risk of  nonoseaegeneralterm [see Warnings and Precautions (5.1 )].",0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
231,latuda,231,6905,6932,"\n', ' *  LATUDA is not approved for use in patients with  notaecandidatepreexistingconditionorriskfactor [see Warnings and Precautions (5.1 )].",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
232,latuda,232,6932,6965,"\n', ' *  Antidepressants increased the risk of  oselabeledaeclasseffect  oselabeledaeclasseffect thoughts and  oselabeledaeclasseffect in children, adolescents, and young adults in short-term studies.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
233,latuda,233,6965,7018,These studies did not show an increase in the risk of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2)].,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
234,latuda,234,7018,7054,"\n', ' *  In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction     ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
235,latuda,235,7054,7112,"5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *   Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) (  5.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
236,latuda,236,7112,7135,"\n', ' *   Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (  5.4  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
237,latuda,237,7135,7154,"\n', ' *   Tardive Dyskinesia: Discontinue if clinically appropriate (  5.5  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
238,latuda,238,7154,7185,"\n', ' *  *  -   Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
239,latuda,239,7185,7198,Monitor glucose regularly in patients with diabetes or at risk for diabetes.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
240,latuda,240,7198,7208,"\n', ' *  -   Dyslipidemia:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
241,latuda,241,7208,7220,Undesirable alterations have been observed in patients treated with atypical antipsychotics.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
242,latuda,242,7220,7231,"\n', ' *  -   Weight Gain:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
243,latuda,243,7231,7239,Gain in body weight has been observed.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
244,latuda,244,7239,7242,Monitor weight.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
245,latuda,245,7242,7250,"\n', '    Metabolic Changes:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
246,latuda,246,7250,7267,Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
247,latuda,247,7267,7284,"These metabolic changes include hyperglycemia, dyslipidemia, and weight gain (  5.6  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
248,latuda,248,7284,7302,"\n', ' *   Hyperprolactinemia: Prolactin elevations may occur (  5.7  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
249,latuda,249,7302,7345,"\n', ' *   Leukopenia, Neutropenia, and Agranulocytosis: Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
250,latuda,250,7345,7369,Consider discontinuing LATUDA if a clinically significant decline in WBC occurs in the absence of other causative factors (  5.8  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
251,latuda,251,7369,7396,"\n', ' *   Orthostatic Hypotension and Syncope: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
252,latuda,252,7396,7426,"In patients with known cardiovascular or cerebrovascular disease, and in antipsychotic-naive patients, consider a lower starting dose and slower titration (  5.9  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
253,latuda,253,7426,7539,"\n', '    \n', ' \n', '\n', '   5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis\n', '\n', '\n', '\n', '  Elderly patients with  notaecandidatepreexistingconditionorriskfactor treated with antipsychotic drugs are at an increased risk of  nonoseaegeneralterm  Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of  nonoseaegeneralterm in drug-treated patients of between 1.6- to 1.7-times the risk of  nonoseaegeneralterm in placebo-treated patients.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
254,latuda,254,7539,7577,"Over the course of a typical 10-week controlled trial, the rate of  nonoseaegeneralterm in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
255,latuda,255,7577,7619,"Although the causes of  nonoseaegeneralterm were varied, most of the  nonoseaegeneralterm  nonoseaeaefromofflabel appeared to be either  nonoseaeaefromofflabel (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction (e.g.,  nonoseaeaeonlyasinstruction  in nature.",1,1,0,0,0,0,0,0,0,0,1,0,0,0,0
256,latuda,256,7619,7639,"Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may  nonoseaeaeonlyasinstruction  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
257,latuda,257,7639,7671,The extent to which the findings of  nonoseaegeneralterm in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
258,latuda,258,7671,7686,LATUDA is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor [see  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
259,latuda,259,7686,7691,Boxed Warning  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
260,latuda,260,7691,7748,".\n', '\n', '\n', '\n', '    5.2 Suicidal Thoughts and Behaviors in Adolescents and Young Adults\n', '\n', '\n', '\n', '  Patients with  notaecandidatepreexistingconditionorriskfactor , both adult and pediatric, may experience  nonoseaeaeonlyasinstruction",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
261,latuda,261,7748,7785,"and/or the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction ideation and  nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
262,latuda,262,7785,7811,nonoseaeaeonlyasinstruction is a known risk of  nonoseaeaeonlyasinstruction and certain other  nonoseaeaeonlyasinstruction  and these disorders themselves are the strongest predictors of  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
263,latuda,263,7811,8009,"There has been a long-standing concern, however, that antidepressants may have a role in inducing  oselabeledaeclasseffect and the  oselabeledaeclasseffect in certain patients during the early phases of treatment.\n', '\n', '\n', '\n', ' Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of  oselabeledaeclasseffect  oselabeledaeclasseffect thinking and  oselabeledaeclasseffect  in children, adolescents, and young adults (ages 18-24) with  notaecandidatepreexistingconditionorriskfactor  and other  notaecandidatepreexistingconditionorriskfactor  Short-term studies did not show an  nonoseaenegation with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.\n', '\n', '\n', '\n', ' The pooled analyses of placebo-controlled trials in children and adolescents with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor , or other  notaecandidatepreexistingconditionorriskfactor included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients.",0,0,1,0,0,0,0,1,0,0,0,0,0,0,0
264,latuda,264,8009,8051,"The pooled analyses of placebo-controlled trials in adults with  notaecandidatepreexistingconditionorriskfactor or other  notaecandidatepreexistingconditionorriskfactor included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
265,latuda,265,8051,8082,"There was considerable variation in risk of  nonoseaeaeonlyasinstruction  oselabeledaefromdruguse among drugs, but a tendency toward an  oselabeledaefromdruguse in the younger patients for almost all drugs studied.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
266,latuda,266,8082,8104,"There were differences in absolute risk of  nonoseaeaeonlyasinstruction across the different indications, with the highest incidence in  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
267,latuda,267,8104,8126,"The risk of differences (drug vs. placebo), however, were relatively stable within age strata and across indications.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
268,latuda,268,8126,8278,"These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in  Table 2  .\n', '\n', '\n', '\n', ' Table 2 \n', '  Age Range                                          Drug-Placebo Difference in Number of Cases of  oselabeledaeclasseffect per 1000 Patients Treated     \n', '                                                     oselabeledaeclasseffect Compared to Placebo                        \n', ' <18                                                14 additional cases                                  \n', ' 18-24                                              5 additional cases                                   \n', '                                                    Decreases Compared to Placebo                        \n', ' 25-64                                              1 fewer case                                         \n', ' >=65                                               6 fewer cases                                        \n', '        No  nonoseaenegation occurred in any of the pediatric trials.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
269,latuda,269,8278,8335,"There were  nonoseaeaeonlyasinstruction in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on  nonoseaeaeonlyasinstruction \n', ' \n', '\n', ' It is unknown whether the  nonoseaeaeonlyasinstruction extends to longer-term use, i.e., beyond several months.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
270,latuda,270,8335,8434,"However, there is substantial evidence from placebo-controlled maintenance trials in adults with  notaecandidatepreexistingconditionorriskfactor that the use of antidepressants can delay the recurrence of  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '  All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening,  nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction  especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
271,latuda,271,8434,8510,"\n', '\n', '\n', '\n', ' The following symptoms,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect ( oselabeledaeclasseffect ,  oselabeledaeclasseffect  and  oselabeledaeclasseffect  have been reported in adult and pediatric patients being treated with antidepressants for  notaecandidatepreexistingconditionorriskfactor as well as for other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
272,latuda,272,8510,8722,"Although a causal link between the emergence of such symptoms and either the  nonoseaeaeonlyasinstruction and/or the emergence of  nonoseaeaeonlyasinstruction has not been established, there is concern that such symptoms may represent precursors to emerging  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', "" Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose  notaecandidatepreexistingconditionorriskfactor is persistently worse, or who are experiencing  nonoseaeaeonlyasinstruction or symptoms that might be precursors to worsening  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.\n"", '\n', '\n', '\n', '  Families and caregivers of patients being treated with antidepressants for  notaecandidatepreexistingconditionorriskfactor or other indications, both  notaecandidatepreexistingconditionorriskfactor and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and the other symptoms described above, as well as the emergence of  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction thoughts and  nonoseaeaeonlyasinstruction  and to report such symptoms immediately to health care providers.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
273,latuda,273,8722,8733,Such monitoring should include daily observation by families and caregivers.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
274,latuda,274,8733,8761,"Prescriptions for LATUDA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
275,latuda,275,8761,8766,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
276,latuda,276,8766,8853,"', '\n', '\n', '    5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis\n', '\n', '\n', '\n', '  In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with  notaecandidatepreexistingconditionorriskfactor  there was a higher incidence of  oselabeledaefromdruguse ( oselabeledaeclasseffect and  oselabeledaeclasseffect , including  nonoseaegeneralterm  compared to placebo-treated subjects.",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
277,latuda,277,8853,8882,LATUDA is not approved for the treatment of patients with  notaecandidatepreexistingconditionorriskfactor [see also Boxed Warning and Warnings and Precautions (  5.1  )].  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
278,latuda,278,8882,8995,"\n', '\n', '\n', '\n', '    5.4 Neuroleptic Malignant Syndrome\n', '\n', '\n', '\n', '  A potentially  nonoseaegeneralterm symptom complex sometimes referred to as  oselabeledaefromdruguse  has been reported in association with administration of antipsychotic drugs, including LATUDA.\n', '\n', '\n', '\n', ' Clinical manifestations of  nonoseaeaeonlyasinstruction are  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and evidence of  nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication pulse or  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication .",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
279,latuda,279,8995,9036,"Additional signs may include  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication , and  nonoseaemanifestationorcomplication \n', '\n', '\n', '\n', ' The diagnostic evaluation of patients with this syndrome is complicated.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
280,latuda,280,9036,9067,"It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g.,  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and untreated or inadequately treated  nonoseaeaeonlyasinstruction .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
281,latuda,281,9067,9153,"Other important considerations in the differential diagnosis include  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and primary central nervous system pathology.\n', '\n', '\n', '\n', ' The management of  nonoseaeaeonlyasinstruction should include: 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
282,latuda,282,9153,9206,"There is no general agreement about specific pharmacological treatment regimens for  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' If a patient requires antipsychotic drug treatment after recovery from  nonoseaeaeonlyasinstruction  the potential reintroduction of drug therapy should be carefully considered.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
283,latuda,283,9206,9282,"If reintroduced, the patient should be carefully monitored, since recurrences of  nonoseaeaeonlyasinstruction have been reported.\n', '\n', '\n', '\n', '    5.5 Tardive Dyskinesia\n', '\n', '\n', '\n', '   oselabeledaeclasseffect is a syndrome consisting of potentially irreversible, involuntary,  nonoseaemanifestationorcomplication that can develop in patients treated with antipsychotic drugs.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
284,latuda,284,9282,9327,"Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
285,latuda,285,9327,9393,"Whether antipsychotic drug products differ in their potential to cause  nonoseaeaeonlyasinstruction is unknown.\n', '\n', '\n', '\n', ' The risk of developing  nonoseaeaeonlyasinstruction and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
286,latuda,286,9393,9456,"However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.\n', '\n', '\n', '\n', ' There is no known treatment for established cases of  nonoseaeaeonlyasinstruction  although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
287,latuda,287,9456,9486,"Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
288,latuda,288,9486,9590,"The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.\n', '\n', '\n', '\n', ' Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of  nonoseaeaeonlyasinstruction  Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
289,latuda,289,9590,9616,"In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
290,latuda,290,9616,9660,"The need for continued treatment should be reassessed periodically.\n', '\n', '\n', '\n', ' If signs and symptoms of  nonoseaeaeonlyasinstruction appear in a patient on LATUDA, drug discontinuation should be considered.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
291,latuda,291,9660,9727,"However, some patients may require treatment with LATUDA despite the presence of the syndrome.\n', '\n', '\n', '\n', '    5.6 Metabolic Changes\n', '\n', '\n', '\n', '  Atypical antipsychotic drugs have been associated with  oselabeledaeclasseffect that may increase cardiovascular/cerebrovascular risk.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
292,latuda,292,9727,9831,"These metabolic changes include  oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  While all of the drugs in the class have been shown to produce some  oselabeledaeclasseffect  each drug has its own specific risk profile.\n', '\n', '\n', '\n', '    Hyperglycemia and Diabetes Mellitus  \n', '\n', '\n', '\n', '  oselabeledaeclasseffect  in some cases extreme and associated with  oselabeledaefromdruguse or  oselabeledaefromdruguse or  nonoseaegeneralterm  has been reported in patients treated with atypical antipsychotics.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
293,latuda,293,9831,9872,Assessment of the relationship between atypical antipsychotic use and  nonoseaeaeonlyasinstruction is complicated by the possibility of an increased background risk of  notaecandidatepreexistingconditionorriskfactor in patients with  notaecandidateindication and the increasing incidence of  notaecandidatepreexistingconditionorriskfactor in the general population.,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0
294,latuda,294,9872,9890,"Given these confounders, the relationship between atypical antipsychotic use and  nonoseaeaeonlyasinstruction is not completely understood.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
295,latuda,295,9890,9912,"However, epidemiological studies suggest an increased risk of treatment-emergent  oselabeledaeclasseffect in patients treated with the atypical antipsychotics.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
296,latuda,296,9912,10012,"Because LATUDA was not marketed at the time these studies were performed, it is not known if LATUDA is associated with this increased risk.\n', '\n', '\n', '\n', ' Patients with an established diagnosis of  notaecandidatepreexistingconditionorriskfactor who are started on atypical antipsychotics should be monitored regularly for  nonoseaeaeonlyasinstruction  Patients with risk factors for  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
297,latuda,297,10012,10057,Any patient treated with atypical antipsychotics should be monitored for symptoms of  nonoseaeaeonlyasinstruction including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication  Patients who develop symptoms of  nonoseaeaeonlyasinstruction during treatment with atypical antipsychotics should undergo fasting blood glucose testing.,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
298,latuda,298,10057,10231,"In some cases,  nonoseaeaeonlyasinstruction has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.\n', '\n', '\n', '\n', '  Schizophrenia  \n', '\n', '\n', '\n', ' Pooled data from short-term, placebo-controlled  notaecandidateindication studies are presented in  Table 3  .\n', '\n', '\n', '\n', ' Table 3: Change in Fasting Glucose in Schizophrenia Studies \n', '                                                  LATUDA                                          \n', '                     Placebo        20 mg/day     40 mg/day       80 mg/day       120 mg/day      160 mg/day     \n', '   oselabeledaefromdruguse (mg/dL)     \n', '                    n=680          n=71          n=478           ",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
299,latuda,299,10231,10233,n=508           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
300,latuda,300,10233,10235,n=283           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
301,latuda,301,10235,10247,"n=113           \n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
302,latuda,302,10247,10274,"oselabeledaefromdruguse      -0.0           -0.6          +2.6            -0.4            +2.5            + 2.5           \n', '  Proportion of Patients with Shifts",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
303,latuda,303,10274,10282,to >= 126 mg/dL     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
304,latuda,304,10282,10304,"\n', '  oselabeledaefromdruguse   8.3%(52/628)   11.7%(7/60)   12.7%( 57/449)  6.8%(32/472)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
305,latuda,305,10304,10310,10.0%(26/260)   5.6%(6/108)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
306,latuda,306,10310,10410,"\n', '             In the uncontrolled, longer-term  notaecandidateindication studies (primarily open-label extension studies), LATUDA was associated with a  oselabeledaefromdruguse of +1.8 mg/dL at week 24 (n=355), +0.8 mg/dL at week 36 (n=299) and +2.3 mg/dL at week 52 (n=307).\n', ' \n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
307,latuda,307,10410,10487,"\n', '\n', '\n', '\n', ' Data from the short-term, flexible-dose, placebo-controlled monotherapy  notaecandidateindication study are presented in  Table 4  .\n', '\n', '\n', '\n', ' Table 4: Change in Fasting Glucose in the Monotherapy Bipolar Depression Study \n', '                                                            LATUDA                  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
308,latuda,308,10487,10488,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
309,latuda,309,10488,10508,"', '                                   Placebo                  20 to 60 mg/day         80 to 120 mg/day        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
310,latuda,310,10508,10520,"\n', '   oselabeledaefromdruguse (mg/dL)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
311,latuda,311,10520,10620,"\n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo    \n', '  \n', '                                   n=148                    n=140                   n=143                   \n', '  oselabeledaefromdruguse                    +1.8                     -0.8                    +1.8                     \n', '  Proportion of Patients with Shifts to >= 126 mg/dL     \n', '  oselabeledaefromdruguse       4.3%(6/141)              2.2%(3/138)             6.4%(9/141)              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
312,latuda,312,10620,10625,"\n', '          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
313,latuda,313,10625,10744,"In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who received LATUDA as monotherapy in the short-term study and continued in the longer-term study, had a  oselabeledaefromdruguse of +1.2 mg/dL at week 24 (n=129).\n', ' \n', '\n', '    Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' Data from the short-term, flexible-dosed, placebo-controlled adjunctive therapy  notaecandidateindication studies are presented in  Table 5  .\n', '\n',",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
314,latuda,314,10744,10774,"'\n', '\n', ' Table 5: Change in Fasting Glucose in the Adjunctive Therapy Bipolar Depression Studies \n', '                                                                          LATUDA                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
315,latuda,315,10774,10788,"\n', '                                           Placebo                        20 to 120 mg/day                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
316,latuda,316,10788,10800,"\n', '   oselabeledaefromdruguse (mg/dL)        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
317,latuda,317,10800,10834,"\n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
318,latuda,318,10834,10846,"\n', '  \n', '                                           n=302                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
319,latuda,319,10846,10848,n=319                           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
320,latuda,320,10848,10878,"\n', '  oselabeledaefromdruguse                            -0.9                           +1.2                             \n', '  Proportion of Patients with Shifts to >= 126 mg/dL     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
321,latuda,321,10878,10891,"\n', '  oselabeledaefromdruguse               1.0%(3/290)                    1.3%(4/316)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
322,latuda,322,10891,10950,"\n', '         In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who received LATUDA as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a  oselabeledaefromdruguse (n=88).\n', ' \n',",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
323,latuda,323,10950,10958,"'\n', '     oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
324,latuda,324,10958,11133,"\n', '\n', '\n', '\n', '  oselabeledaeclasseffect have been observed in patients treated with atypical antipsychotics.\n', '\n', '\n', '\n', '    Schizophrenia  \n', '\n', '\n', '\n', ' Pooled data from short-term, placebo-controlled  notaecandidateindication studies are presented in  Table 6  .\n', '\n', '\n', '\n', ' Table 6: Change in Fasting Lipids in Schizophrenia Studies \n', '                                                  LATUDA                                          \n', '                     Placebo        20 mg/day     40 mg/day       80 mg/day       120 mg/day      160 mg/day      \n', '   oselabeledaefromdruguse (mg/dL)     \n', '                     n=660          n=71          n=466           n=499           n=268           n=115           ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
325,latuda,325,11133,11152,"\n', '  \n', '  oselabeledaefromdruguse  oselabeledaefromdruguse (mg/dL)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
326,latuda,326,11152,11169,"\n', '                     n=660          n=71          n=466           n=499           n=268           n=115           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
327,latuda,327,11169,11177,"\n', '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
328,latuda,328,11177,11189,' Total Cholesterol  -5.8           -12.3         -5.7            -6.2            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
329,latuda,329,11189,11191,-3.8            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
330,latuda,330,11191,11202,"-6.9             \n', '  oselabeledaefromdruguse      -13.4          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
331,latuda,331,11202,11223,"-29.1         -5.1            -13.0           -3.1            -10.6            \n', '  Proportion of Patients with Shifts     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
332,latuda,332,11223,11233,"\n', '  oselabeledaefromdruguse   5.3%(30/571)   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
333,latuda,333,11233,11239,13.8%(8/58)   6.2%(25/402)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
334,latuda,334,11239,11242,5.3%(23/434)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
335,latuda,335,11242,11248,3.8%(9/238)     4.0%(4/101)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
336,latuda,336,11248,11258,"\n', '  oselabeledaefromdruguse   10.1%(53/526)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
337,latuda,337,11258,11264,14.3%(7/49)   10.8%(41/379)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
338,latuda,338,11264,11267,6.3%(25/400)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
339,latuda,339,11267,11273,10.5%(22/209)   7.0%(7/100)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
340,latuda,340,11273,11278,"\n', '             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
341,latuda,341,11278,11313,"In the uncontrolled, longer-term  notaecandidateindication studies (primarily open-label extension studies), LATUDA was associated with a  oselabeledaefromdruguse  oselabeledaefromdruguse total cholesterol and  oselabeledaefromdruguse of -3.8",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
342,latuda,342,11313,11334,"(n=356) and -15.1 (n=357) mg/dL at week 24, -3.1 (n=303) and -4.8",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
343,latuda,343,11334,11352,(n=303) mg/dL at week 36 and -2.5 (n=307) and -6.9 (n=307,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
344,latuda,344,11352,11359,) mg/dL at week 52,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
345,latuda,345,11359,11395,", respectively.\n', ' \n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
346,latuda,346,11395,11473,"\n', '\n', '\n', '\n', ' Data from the short-term, flexible-dosed, placebo-controlled, monotherapy  notaecandidateindication study are presented in  Table 7  .\n', '\n', '\n', '\n', ' Table 7: Change in Fasting Lipids in the Monotherapy Bipolar Depression Study \n', '                                                     LATUDA                        ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
347,latuda,347,11473,11553,"\n', '                      Placebo                        20 to 60 mg/day               80 to 120 mg/day     \n', '   oselabeledaefromdruguse (mg/dL)     \n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo    \n', '  \n', '                      n=147                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
348,latuda,348,11553,11555,n=140                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
349,latuda,349,11555,11557,n=144       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
350,latuda,350,11557,11571,"\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse (mg/dL)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
351,latuda,351,11571,11618,"\n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo    \n', '  \n', '                      n=147                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
352,latuda,352,11618,11620,n=140                         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
353,latuda,353,11620,11622,n=144       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
354,latuda,354,11622,11663,"\n', ' Total cholesterol   -3.2                           +1.2                          -4.6         \n', '  oselabeledaefromdruguse       +6.0                           +5.6                          +0.4         \n', '  Proportion of Patients with Shifts     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
355,latuda,355,11663,11671,"\n', '  oselabeledaefromdruguse   4.2%(5/118",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
356,latuda,356,11671,11689,")                    4.4%(5/113)                   4.4%(5/114)   \n', '  oselabeledaefromdruguse   4.8%(6/126)                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
357,latuda,357,11689,11692,10.1%(12/119)                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
358,latuda,358,11692,11695,9.8%(12/122)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
359,latuda,359,11695,11747,"\n', '           In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who received LATUDA as monotherapy in the short-term and continued in the longer-term study had a  oselabeledaefromdruguse  oselabeledaefromdruguse of -0.5 (n=130) and -1.0",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
360,latuda,360,11747,11760,"(n=130) mg/dL at week 24, respectively.\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
361,latuda,361,11760,11883,"' \n', '\n', '  Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' Data from the short-term, flexible-dosed, placebo-controlled, adjunctive therapy  notaecandidateindication studies are presented in  Table 8  .\n', '\n', '\n', '\n', ' Table 8: Change in Fasting Lipids in the Adjunctive Therapy Bipolar Depression Studies \n', '                                                                LATUDA                                    \n', '                      Placebo                                   20 to 120 mg/day                          \n', '   oselabeledaefromdruguse (mg/dL)     ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
362,latuda,362,11883,11917,"\n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
363,latuda,363,11917,11925,"\n', '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
364,latuda,364,11925,11979,"'                      n=303                                     n=321                                     \n', '  oselabeledaefromdruguse  oselabeledaefromdruguse (mg/dL)     \n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
365,latuda,365,11979,11987,"\n', '  \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
366,latuda,366,11987,12027,"'                      n=303                                     n=321                                     \n', ' Total cholesterol   -2.9                                      -3.1                                       \n', '  oselabeledaefromdruguse       -4.6                                      +4.6                                       \n', '  Proportion of Patients with Shifts     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
367,latuda,367,12027,12040,"\n', '  oselabeledaefromdruguse   5.7%(15/263)                              5.4%(15/276)                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
368,latuda,368,12040,12050,"\n', '  oselabeledaefromdruguse   8.6%(21/243)                              ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
369,latuda,369,12050,12053,10.8%(28/260)                              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
370,latuda,370,12053,12146,"\n', '         In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who received LATUDA, as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a  oselabeledaefromdruguse  oselabeledaefromdruguse total cholesterol and  oselabeledaefromdruguse of -0.9 (n=88) and +5.3 (n=88) mg/dL at week 24, respectively.\n', ' \n', '\n', '    Weight Gain  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
371,latuda,371,12146,12172,"\n', '\n', '\n', '\n', '  oselabeledaeclasseffect has been observed with atypical antipsychotic use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
372,latuda,372,12172,12232,"Clinical monitoring of weight is recommended.\n', '\n', '\n', '\n', '    Schizophrenia  \n', '\n', '\n', '\n', ' Pooled data from short-term, placebo-controlled schizophrenia studies are presented in  Table 9  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
373,latuda,373,12232,12256,The mean  oselabeledaefromdruguse was +0.43 kg for LATUDA-treated patients compared to -0.02 kg for placebo-treated patients.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
374,latuda,374,12256,12278,nonoseaeaeonlyasinstruction for olanzapine was +4.15 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
375,latuda,375,12278,12292,"[see Clinical Studies (  14.1  )]  , respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
376,latuda,376,12292,12362,"The proportion of patients with a >= 7%  oselabeledaefromdruguse in  oselabeledaefromdruguse (at Endpoint) was 4.8% for LATUDA-treated patients versus 3.3% for placebo-treated patients.\n', '\n', '\n', '\n', ' Table 9:  oselabeledaefromdruguse (kg) from Baseline in Schizophrenia Studies \n', '                                             LATUDA                                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
377,latuda,377,12362,12403,"\n', '                Placebo(n=696)     20 mg/day(n=71)     40 mg/day(n=484)     80 mg/day(n=526)     120 mg/day(n=291)     160 mg/day      (n=114)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
378,latuda,378,12403,12407,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
379,latuda,379,12407,12412,All Patients  -0.02         ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
380,latuda,380,12412,12472,"-0.15          +0.22           +0.54             +0.68           +0.60              \n', '             In the uncontrolled, longer-term  notaecandidateindication studies (primarily open-label extension studies), LATUDA was associated with a  oselabeledaefromdruguse of -0.69 kg at week 24 (n=755), -0.59 kg at week 36",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
381,latuda,381,12472,12517,"(n=443) and -0.73 kg at week 52 (n=377).\n', ' \n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
382,latuda,382,12517,12559,"\n', '\n', '\n', '\n', ' Data from the short-term, flexible-dosed, placebo-controlled monotherapy  notaecandidateindication study are presented in  Table 10  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
383,latuda,383,12559,12582,The mean  oselabeledaefromdruguse was +0.29 kg for LATUDA-treated patients compared to -0.04 kg for placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
384,latuda,384,12582,12663,"The proportion of patients with a >= 7%  oselabeledaefromdruguse in  oselabeledaefromdruguse (at Endpoint) was 2.4% for LATUDA-treated patients versus 0.7% for placebo-treated patients.\n', '\n', '\n', '\n', ' Table 10:  oselabeledaefromdruguse (kg) from Baseline in the Monotherapy Bipolar Depression Study \n', '                                                     LATUDA                        \n', '                      Placebo(n=151)                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
385,latuda,385,12663,12689,"20 to 60 mg/day(n=143)        80 to 120 mg/day(n=147)     \n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
386,latuda,386,12689,12844,"Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo    \n', '  \n', ' All Patients        -0.04                          +0.56                         +0.02        \n', '           In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who received LATUDA as monotherapy in the short-term and continued in the longer-term study had a  oselabeledaefromdruguse at week 24 (n=130).\n', ' \n', '\n', '    Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' Data from the short-term, flexible-dosed, placebo-controlled adjunctive therapy  notaecandidateindication studies are presented in  Table 11  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
387,latuda,387,12844,12868,The mean  oselabeledaefromdruguse was +0.11 kg for LATUDA-treated patients compared to +0.16 kg for placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
388,latuda,388,12868,12992,"The proportion of patients with a >= 7%  oselabeledaefromdruguse in  oselabeledaefromdruguse (at Endpoint) was 3.1% for LATUDA-treated patients versus 0.3% for placebo-treated patients.\n', '\n', '\n', '\n', ' Table 11:  oselabeledaefromdruguse (kg) from Baseline in the Adjunctive Therapy Bipolar Depression Studies \n', '                                                                LATUDA                                    \n', '                      Placebo(n=307)                            20 to 120 mg/day(n=327)                   \n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
389,latuda,389,12992,13001,"\n', '  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
390,latuda,390,13001,13015,"All Patients        +0.16                                     +0.11                                      \n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
391,latuda,391,13015,13139,"In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who were treated with LATUDA, as adjunctive therapy with either lithium or valproate in the short-term and continued in the longer-term study, had a  oselabeledaefromdruguse of +1.28 kg at week 24 (n=86).\n', ' \n', '\n', '    5.7  oselabeledaefromdruguse \n', '\n', '\n', '  As with other drugs that antagonize dopamine D2receptors, LATUDA  oselabeledaefromdruguse \n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction may  nonoseaemanifestationorcomplication  resulting in  nonoseaemanifestationorcomplication  ",1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
392,latuda,392,13139,13155,"This, in turn, may  nonoseaemanifestationorcomplication in both female and male patients.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
393,latuda,393,13155,13159,oselabeledaeclasseffect   oselabeledaeclasseffect   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
394,latuda,394,13159,13173,oselabeledaeclasseffect  and  oselabeledaeclasseffect have been reported with prolactin-elevating compounds.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
395,latuda,395,13173,13207,Long-standing  nonoseaeaeonlyasinstruction  when associated with  nonoseaeaeonlyasinstruction  may lead to  nonoseaeaeonlyasinstruction in both female and male patients [see Adverse Reactions (  6  )]  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
396,latuda,396,13207,13266,".\n', '\n', '\n', '\n', ' Tissue culture experiments indicate that approximately one-third of human  nonoseaeaeonlyasinstruction are prolactin-dependent in vitro  , a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected  notaecandidatepreexistingconditionorriskfactor  ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
397,latuda,397,13266,13303,As is common with compounds which  nonoseaeaeonlyasinstruction  an  nonoseaeaeanimal was observed in a LATUDA  nonoseaeaeonlyasinstruction study conducted in rats and mice [see Nonclinical Toxicology (  13  )].  ,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
398,latuda,398,13303,13403,"Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and  nonoseaeaeonlyasinstruction in humans, but the available evidence is too limited to be conclusive.\n', '\n', '\n', '\n', '  Schizophrenia  \n', '\n', '\n', '\n', ' In short-term, placebo-controlled  notaecandidateindication studies, the  oselabeledaefromdruguse for LATUDA-treated patients was +0.4 ng/mL and was -1.9",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
399,latuda,399,13403,13413,ng/mL in the placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
400,latuda,400,13413,13525,"The median change from baseline to endpoint for males was +0.5 ng/mL and for females was -0.2 ng/mL.  nonoseaeaeonlyasinstruction by dose are shown in  Table 12  .\n', '\n', '\n', '\n', ' Table 12:  oselabeledaefromdruguse in Schizophrenia Studies \n', '                                               LATUDA                                            \n', '  \n', '                 Placebo        20 mg/day      40 mg/day          80 mg/day       120 mg/day     160 mg/day     \n', ' All Patients   -1.9(n=672)    ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
401,latuda,401,13525,13528,-1.1(n=70)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
402,latuda,402,13528,13531,-1.4(n=476)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
403,latuda,403,13531,13538,-0.2(n=495)     +3.3(n=284)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
404,latuda,404,13538,13542,+3.3(n=115)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
405,latuda,405,13542,13551,"\n', ' Females        -5.1(n=200)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
406,latuda,406,13551,13554,-0.7(n=19)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
407,latuda,407,13554,13557,-4.0(n=149)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
408,latuda,408,13557,13568,-0.2(n=150)     +6.7(n=70)     +7.1(n=36)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
409,latuda,409,13568,13577,"\n', ' Males          -1.3(n=472)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
410,latuda,410,13577,13580,-1.2(n=51)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
411,latuda,411,13580,13583,-0.7(n=327)        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
412,latuda,412,13583,13590,-0.2(n=345)     +3.1(n=214)    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
413,latuda,413,13590,13594,+2.4(n=79)      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
414,latuda,414,13594,13634,"\n', '             The proportion of patients with  oselabeledaefromdruguse >= 5* upper limit of normal (ULN) was 2.8% for LATUDA-treated patients versus 1.0% for placebo-treated patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
415,latuda,415,13634,13664,The proportion of female patients with  oselabeledaefromdruguse >= 5x ULN was 5.7% for LATUDA-treated patients versus 2.0% for placebo-treated female patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
416,latuda,416,13664,13736,"The proportion of male patients with  oselabeledaefromdruguse >= 5x ULN was 1.6% versus 0.6% for placebo-treated male patients.\n', ' \n', '\n', ' In the uncontrolled longer-term  notaecandidateindication studies (primarily open-label extension studies), LATUDA was associated with a  oselabeledaefromdruguse of -0.9 ng/mL at week 24 (n=357),",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
417,latuda,417,13736,13756,-5.3ng/mL at week 36 (n=190) and -2.2 ng/mL at week 52 (n=307).\n',0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
418,latuda,418,13756,13793,", '\n', '\n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
419,latuda,419,13793,13878,"\n', '\n', '\n', '\n', ' The  oselabeledaefromdruguse to endpoint in  oselabeledaefromdruguse  in the short-term, flexible-dosed, placebo-controlled monotherapy  notaecandidateindication study, was +1.7 ng/mL and +3.5 ng/mL with LATUDA 20 to 60 mg/day and 80 to 120 mg/day, respectively compared to +0.3 ng/mL with placebo-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
420,latuda,420,13878,14020,"The median change from baseline to endpoint for males was +1.5 ng/mL and for females was +3.1 ng/mL.  nonoseaeaeonlyasinstruction by dose range are shown in  Table 13  .\n', '\n', '\n', '\n', ' Table 13:  oselabeledaefromdruguse (ng/mL) from Baseline in the Monotherapy Bipolar Depression Study \n', '                                                     LATUDA                        \n', '                      Placebo                        20 to 60 mg/day               80 to 120 mg/day     \n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 60 mg/day, LATUDA 80 to 120 mg/day, or placebo    \n', '  \n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
421,latuda,421,14020,14044,"All Patients        +0.3(n=147)                    +1.7(n=140)                   +3.5(n=144)   \n', ' Females             0.0(n=82)                      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
422,latuda,422,14044,14052,+1.8(n=78)                    +5.3(n=88)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
423,latuda,423,14052,14056,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
424,latuda,424,14056,14070,Males               +0.4(n=65)                     +1.2(n=62)                    +1.9(n=56)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
425,latuda,425,14070,14075,"\n', '           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
426,latuda,426,14075,14109,The proportion of patients with  oselabeledaefromdruguse >= 5x upper limit of normal (ULN) was 0.4% for LATUDA-treated patients versus 0.0% for placebo-treated patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
427,latuda,427,14109,14139,The proportion of female patients with  oselabeledaefromdruguse >= 5x ULN was 0.6% for LATUDA-treated patients versus 0% for placebo-treated female patients.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
428,latuda,428,14139,14317,"The proportion of male patients with  oselabeledaefromdruguse >= 5x ULN was 0% versus 0% for placebo-treated male patients.\n', ' \n', '\n', ' In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who were treated with LATUDA as monotherapy in the short-term and continued in the longer-term study, had a  oselabeledaefromdruguse of -1.15 ng/mL at week 24 (n=130).\n', '\n', '\n', '\n', '  Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' The  oselabeledaefromdruguse to endpoint in  oselabeledaefromdruguse  in the short-term, flexible-dosed, placebo-controlled adjunctive therapy  notaecandidateindication studies was +2.8 ng/mL with LATUDA 20 to 120 mg/day compared to 0.0 ng/mL with placebo-treated patients.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
429,latuda,429,14317,14439,"The median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown in  Table 14  .\n', '\n', '\n', '\n', ' Table 14:  oselabeledaefromdruguse in the Adjunctive Therapy Bipolar Depression Studies \n', '                                                                LATUDA                                    \n', '                      Placebo                                   20 to 120 mg/day                          \n', '  \n', '  Patients were randomized to flexibly dosed LATUDA 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
430,latuda,430,14439,14458,"\n', '  \n', ' All Patients        0.0(n=301)                                +2.8(n=321)                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
431,latuda,431,14458,14472,"\n', ' Females             +0.4(n=156)                               +3.2(n=162)                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
432,latuda,432,14472,14485,"\n', ' Males               -0.1(n=145)                               +2.4(n=159)                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
433,latuda,433,14485,14524,"\n', '         The proportion of patients with  nonoseaeaeratelteqplacebo >= 5x upper limit of normal (ULN) was 0.0% for LATUDA-treated patients versus 0.0% for placebo-treated patients.",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
434,latuda,434,14524,14554,The proportion of female patients with  nonoseaeaeratelteqplacebo >= 5x ULN was 0% for LATUDA-treated patients versus 0% for placebo-treated female patients.,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
435,latuda,435,14554,14646,"The proportion of male patients with  nonoseaeaeratelteqplacebo >= 5x ULN was 0% versus 0% for placebo-treated male patients.\n', ' \n', '\n', ' In the uncontrolled, open-label, longer-term  notaecandidateindication study, patients who were treated with LATUDA, as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a  oselabeledaefromdruguse of -2.9 ng/mL at week 24",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
436,latuda,436,14646,14699,"(n=88).\n', '\n', '\n', '\n', '    5.8 Leukopenia, Neutropenia and Agranulocytosis\n', '\n', '\n', '\n', '   oselabeledaeclasseffect  oselabeledaeclasseffect has been reported during treatment with antipsychotic agents.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
437,latuda,437,14699,14855,"nonoseaeaeforanotherdruginclass (including  nonoseaegeneralterm cases) has been reported with other agents in the class.\n', '\n', '\n', '\n', ' Possible risk factors for  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction include pre-existing  notaecandidatepreexistingconditionorriskfactor  and history of  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor leukopenia/ notaecandidatepreexistingconditionorriskfactor  Patients with a pre-existing  notaecandidatepreexistingconditionorriskfactor or a history of  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor leukopenia/ notaecandidatepreexistingconditionorriskfactor should have their complete blood count (CBC) monitored frequently during the first few months of therapy and LATUDA should be discontinued at the first sign of  nonoseaeaeonlyasinstruction  in the absence of other causative factors.\n', '\n', '\n', '\n', ' Patients with  nonoseaeaeonlyasinstruction should be carefully monitored for  nonoseaemanifestationorcomplication or other symptoms or signs of  nonoseaemanifestationorcomplication and treated promptly if such symptoms or signs occur.",1,1,1,0,1,0,0,0,0,0,0,0,1,0,0
438,latuda,438,14855,14928,"Patients with severe  nonoseaeaeonlyasinstruction ( nonoseaeaeonlyasinstruction  ) should discontinue LATUDA and have their WBC followed until recovery.\n', '\n', '\n', '\n', '    5.9 Orthostatic Hypotension and Syncope\n', '\n', '\n', '\n', '  LATUDA may cause  oselabeledaefromdruguse and  oselabeledaefromdruguse  perhaps due to its alpha1-adrenergic receptor antagonism.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
439,latuda,439,14928,14960,"Associated adverse reactions can include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  Generally, these risks are greatest at the beginning of treatment and during dose escalation.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
440,latuda,440,14960,15024,"Patients at increased risk of these adverse reactions or at increased risk of developing complications from  nonoseaeaeonlyasinstruction include those with  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  treatment with  nonoseaeaeonlyasinstruction  history of  notaecandidatepreexistingconditionorriskfactor (e.g.,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor , history of  notaecandidatepreexistingconditionorriskfactor  as well as patients who are antipsychotic-naive.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
441,latuda,441,15024,15197,"In such patients, consider using a lower starting dose and slower titration, and monitor orthostatic vital signs.\n', '\n', '\n', '\n', '  nonoseaeaeonlyasinstruction  as assessed by vital sign measurement, was defined by the following vital sign changes: >= 20 mm Hg  nonoseaeaeonlyasinstruction systolic  nonoseaeaeonlyasinstruction and >= 10 bpm  nonoseaeaeonlyasinstruction from sitting to standing or supine to standing position.\n', '\n', '\n', '\n', '    Schizophrenia  \n', '\n', '\n', '\n', ' The incidence of  oselabeledaefromdruguse and  oselabeledaefromdruguse reported as adverse events from short-term, placebo-controlled  notaecandidatepreexistingconditionorriskfactor studies was (LATUDA incidence, placebo incidence):  oselabeledaefromdruguse [0.3% (5/1508), 0.1% (1/708)] and  oselabeledaefromdruguse [0.1% (2/1508), 0% (",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
442,latuda,442,15197,15213,"0/708)].\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
443,latuda,443,15213,15307,"In short-term  notaecandidatepreexistingconditionorriskfactor clinical studies,  oselabeledaefromdruguse  as assessed by vital signs, occurred with a frequency of 0.8% with LATUDA 40 mg, 2.1% with LATUDA 80 mg, 1.7% with LATUDA 120 mg and 0.8% with LATUDA 160 mg compared to 0.7% with placebo.\n', '\n', '\n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
444,latuda,444,15307,15358,"\n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled monotherapy  notaecandidateindication study, there were no reported adverse events of  nonoseaenegation and  nonoseaenegation \n', '\n",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
445,latuda,445,15358,15693,"', '\n', '\n', '  oselabeledaefromdruguse  as assessed by vital signs, occurred with a frequency of 0.6% with LATUDA 20 to 60 mg and 0.6% with LATUDA 80 to 120 mg compared to 0% with placebo.\n', '\n', '\n', '\n', '  Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled adjunctive therapy  notaecandidateindication therapy studies, there were no reported adverse events of  nonoseaenegation and  nonoseaenegation   oselabeledaefromdruguse  as assessed by vital signs, occurred with a frequency of 1.1% with LATUDA 20 to 120 mg compared to 0.9% with placebo.\n', '\n', '\n', '\n', '    5.10 Seizures\n', '\n', '\n', '\n', '  As with other antipsychotic drugs, LATUDA should be used cautiously in patients with a  notaecandidatepreexistingconditionorriskfactor or with conditions that  nonoseaeaeonlyasinstruction  e.g.,  notaecandidatepreexistingconditionorriskfactor  Conditions that  nonoseaeaeonlyasinstruction may be more prevalent in patients 65 years or older.\n', '\n', '\n', '\n', '  Schizophrenia  \n', '\n', '\n', '\n', ' In short-term, placebo-controlled  notaecandidateindication studies,  nonoseaeaeratelteqplacebo  nonoseaeaeratelteqplacebo occurred in 0.1% (2/1508) of patients treated with LATUDA compared to 0.1% (1/708) placebo-treated patients.\n', '\n', '\n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",1,0,1,1,0,0,1,1,0,0,0,0,0,0,0
446,latuda,446,15693,15826,"\n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled monotherapy  notaecandidateindication study, no patient experienced  nonoseaenegation  nonoseaenegation \n', '\n', '\n', '\n', '    Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled adjunctive therapy  notaecandidateindication studies, no patient experienced  nonoseaenegation  nonoseaenegation \n', '\n', '\n', '\n', '    5.11 Potential for  oselabeledaefromdruguse and Motor  oselabeledaefromdruguse",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
447,latuda,447,15826,16037,"\n', '\n', '\n', '  LATUDA, like other antipsychotics, has the potential to  oselabeledaefromdruguse  oselabeledaefromdruguse judgment,  oselabeledaefromdruguse  oselabeledaefromdruguse judgment, thinking or  oselabeledaefromdruguse  Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely.\n', '\n', '\n', '\n', ' In clinical studies with LATUDA,  oselabeledaefromdruguse included:  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '    Schizophrenia  \n', '\n', '\n', '\n', ' In short-term, placebo-controlled  notaecandidateindication studies,  oselabeledaefromdruguse was reported by 17.0% (256/1508) of patients treated with LATUDA (15.5% LATUDA 20 mg, 15.6% LATUDA 40 mg, 15.2% LATUDA 80 mg, 26.5% LATUDA 120 mg and 8.3% LATUDA 160 mg/day) compared to 7.1% (50/708) of placebo patients.\n', '\n', '",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
448,latuda,448,16037,16068,"\n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
449,latuda,449,16068,16084,"\n', '\n', '\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
450,latuda,450,16084,16271,"In the short-term, flexible-dosed, placebo-controlled monotherapy  notaecandidateindication study,  oselabeledaefromdruguse was reported by 7.3% (12/164) and 13.8% (23/167) with LATUDA 20 to 60 mg and 80 to120 mg, respectively compared to 6.5% (11/168) of placebo patients.\n', '\n', '\n', '\n', '    Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' In the short-term, flexible-dosed, placebo-controlled adjunctive therapy  notaecandidateindication studies,  oselabeledaefromdruguse was reported by 11.4% (41/360) of patients treated with LATUDA 20-120 mg compared to 5.1% (17/334) of placebo patients.\n', '\n', '\n', '\n', '    5.12 Body Temperature Dysregulation\n', '\n', '\n', '\n', '   oselabeledaeclasseffect has been attributed to antipsychotic agents.",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
451,latuda,451,16271,16329,"Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an  nonoseaeaeonlyasinstruction  e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to  nonoseaeaeonlyasinstruction [see Patient Counseling Information (  17.9  )].  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
452,latuda,452,16329,16388,"\n', '\n', '\n', '\n', '    5.13 Suicide\n', '\n', '\n', '\n', '  The possibility of a  nonoseaeaeonlyasinstruction is inherent in psychotic illness and close supervision of high-risk patients should accompany drug therapy.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
453,latuda,453,16388,16449,"Prescriptions for LATUDA should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the risk of  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    Schizophrenia  \n', '\n', '\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
454,latuda,454,16449,16490,"In short-term, placebo-controlled  notaecandidateindication studies, the incidence of treatment-emergent  nonoseaeaeratelteqplacebo was 0.4% (6/1508) for LATUDA-treated patients compared to 0.8% (6/708) on placebo.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
455,latuda,455,16490,16539,"No  nonoseaenegation or  nonoseaenegation were reported in these studies.\n', '\n', '\n', '\n', '    Bipolar Depression  \n', '\n', '\n', '\n', '    Monotherapy  ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
456,latuda,456,16539,16605,"\n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled monotherapy  notaecandidateindication study, the incidence of treatment-emergent  nonoseaeaeratelteqplacebo was 0.0% (0/331) with LATUDA-treated patients compared to 0.0% (0/168) with placebo-treated patients.",0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
457,latuda,457,16605,16703,"No  nonoseaenegation or  nonoseaenegation were reported in this study.\n', '\n', '\n', '\n', '    Adjunctive Therapy with Lithium or Valproate  \n', '\n', '\n', '\n', ' In the short-term, flexible-dose, placebo-controlled adjunctive therapy  notaecandidateindication studies, the incidence of treatment-emergent  oselabeledaefromdruguse was 1.1% (4/360) for LATUDA-treated patients compared to 0.3% (1/334) on placebo.",0,0,0,1,0,0,0,1,0,0,0,0,0,0,0
458,latuda,458,16703,16877,"No  nonoseaenegation or  nonoseaenegation were reported in these studies.\n', '\n', '\n', '\n', '    5.14 Activation of Mania/Hypomania\n', '\n', '\n', '\n', '  Antidepressant treatment can increase the risk of developing a  oselabeledaeclasseffect or  oselabeledaeclasseffect  particularly in patients with  notaecandidatepreexistingconditionorriskfactor  Monitor patients for the emergence of such episodes.\n', '\n', '\n', '\n', ' In the  notaecandidateindication monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the LATUDA and placebo groups developed  nonoseaeaeratelteqplacebo or  nonoseaeaeratelteqplacebo \n', '\n', '\n', '\n', '    5.15  oselabeledaeclasseffect \n', '\n', '\n', '   oselabeledaeclasseffect and  oselabeledaeclasseffect have been associated with antipsychotic drug use.  ",0,0,1,1,0,0,1,1,0,0,0,0,0,0,0
459,latuda,459,16877,16979,"nonoseaeaeonlyasinstruction is a common cause of morbidity and mortality in elderly patients, in particular those with advanced  notaecandidatepreexistingconditionorriskfactor  LATUDA and other antipsychotic drugs should be used cautiously in patients at risk for  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', ""    5.16  oselabeledaefromdruguse in Patients with Parkinson's Disease or Dementia with Lewy Bodies\n"", '\n', '\n', '\n', '  Patients with  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor are reported to have an increased sensitivity to antipsychotic medication.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
460,latuda,460,16979,17007,Manifestations of this increased sensitivity include  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect with  nonoseaemanifestationorcomplication   oselabeledaeclasseffect  and clinical features consistent with the  oselabeledaeclasseffect '],0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
0,plavix,0,0,59,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed below and elsewhere in the labeling:\n', '\n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,plavix,1,59,94,"Warnings and Precautions (5.4)  ]  \n', '      EXCERPT:   Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,plavix,2,94,145,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,plavix,3,145,174,"\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,plavix,4,174,254,"Because clinical trials are conducted under widely varying conditions and durations of follow-up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' Plavix has been evaluated for safety in more than 54,000 patients, including over 21,000 patients treated for one year or more.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,plavix,5,254,353,"The clinically important adverse reactions observed in trials comparing Plavix plus aspirin to placebo plus aspirin and trials comparing Plavix alone to aspirin alone are discussed below.\n', '\n', '     Bleeding  \n', '\n', '   CURE\n', '\n', ' In CURE, Plavix use with aspirin was associated with an increase in major  oselabeledaefromdruguse  oselabeledaefromdruguse gastrointestinal and  oselabeledaefromdruguse  oselabeledaefromdruguse (primarily gastrointestinal and at puncture sites) compared to placebo with aspirin (see  Table 1  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,plavix,6,353,378,The incidence of  oselabeledaefromdruguse (0.1%) and  nonoseaegeneralterm  oselabeledaefromdruguse (0.2%) were the same in both groups.,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
7,plavix,7,378,439,"Other  oselabeledaefromdruguse events that were reported more frequently in the clopidogrel group were  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', ' The overall incidence of  nonoseaeaeonlyasinstruction is described in Table 1.\n', '\n', ' Table 1: CURE Incidence of  oselabeledaefromdruguse Complications (% patients)",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,plavix,8,439,449,"\n', ' Event                                               Plavix(+ aspirin)(n=6259)  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,plavix,9,449,450,Placebo(+,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,plavix,10,450,453,aspirin)(n=6303)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,plavix,11,453,467,"\n', '  \n', '   Major  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,plavix,12,467,482,[note: Life-threatening and other major  oselabeledaefromdruguse ]              3.7                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,plavix,13,482,484,2.7              ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,plavix,14,484,497,"\n', '   Life-threatening  oselabeledaefromdruguse                                    2.2                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,plavix,15,497,510,"1.8              \n', '      nonoseaegeneralterm                                                      0.2                        0.2              ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
16,plavix,16,510,535,"\n', '     5 g/dL  oselabeledaefromdruguse                                     0.9                        0.9              \n', '     Requiring surgical intervention                            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,plavix,17,535,659,"0.7                        0.7              \n', '      oselabeledaefromdruguse                                        0.1                        0.1              \n', '     Requiring inotropes                                        0.5                        0.5              \n', '     Requiring transfusion (>=4 units)                          1.2                        1.0              \n', '   Other major  oselabeledaefromdruguse                                         1.6                        1.0              \n', '     Significantly disabling                                    0.4                        0.3              \n', '      oselabeledaefromdruguse with significant  nonoseaemanifestationorcomplication            0.05                       0.03              \n', '     Requiring 2-3 units of blood                               1.3                        0.9              \n', '   Minor  oselabeledaefromdruguse   [note: Led to interruption of study medication.]              ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
18,plavix,18,659,680,"5.1                        2.4              \n', '           COMMIT\n', ' \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,plavix,19,680,792,"In COMMIT, similar rates of major  oselabeledaefromdruguse were observed in the Plavix and placebo groups, both of which also received aspirin (see  Table 2  ).\n', '\n', ' Table 2: Incidence of Bleeding Events in COMMIT (% patients) \n', ' Type of  oselabeledaefromdruguse                          Plavix(+ aspirin)(n=22961)  Placebo(+ aspirin)(n=22891)        p-value          \n', '  \n', ' Major [note: Major bleeds were cerebral bleeds or  oselabeledaefromdruguse  oselabeledaefromdruguse or  oselabeledaefromdruguse thought to have caused  nonoseaegeneralterm or that required transfusion.]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
20,plavix,20,792,802,oselabeledaefromdruguse or cerebral  oselabeledaefromdruguse  oselabeledaefromdruguse          0.6                   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,plavix,21,802,806,0.5                   0.59           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,plavix,22,806,820,"\n', '   Major noncerebral                               0.4                   0.3                   0.48           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,plavix,23,820,844,"\n', '    nonoseaegeneralterm                                           0.2                   0.2                   0.90           \n', '  oselabeledaefromdruguse                                0.2                   0.2                   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
24,plavix,24,844,846,0.91           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,plavix,25,846,870,"\n', '    nonoseaegeneralterm                                           0.2                   0.2                   0.81           \n', ' Other  oselabeledaefromdruguse (nonmajor)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,plavix,26,870,874,3.6                   3.1                  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,plavix,27,874,876,0.005           ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,plavix,28,876,949,"\n', ' Any  oselabeledaefromdruguse                          3.9                   3.4                  0.004           \n', '            CAPRIE (Plavix vs Aspirin)\n', ' \n', '\n', ' In CAPRIE,  oselabeledaefromdruguse occurred at a rate of 2.0% in those taking Plavix versus 2.7% in those taking aspirin;  oselabeledaefromdruguse requiring hospitalization occurred in 0.7% and 1.1%, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,plavix,29,949,1004,"The incidence of  oselabeledaefromdruguse was 0.4% for Plavix compared to 0.5% for aspirin.\n', '\n', ' Other  oselabeledaefromdruguse events that were reported more frequently in the Plavix group were  oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '     Other Adverse Events  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,plavix,30,1004,1053,"\n', '\n', ' In CURE and CHARISMA, which compared Plavix plus aspirin to aspirin alone, there was no difference in the rate of adverse events (other than  nonoseaeaeonlyasinstruction  between Plavix and placebo.\n', '\n', '",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,plavix,31,1053,1073,"In CAPRIE, which compared Plavix to aspirin,  oselabeledaefromdruguse was more frequently reported in those taking Plavix.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,plavix,32,1073,1122,"No other difference in the rate of adverse events (other than  nonoseaeaeonlyasinstruction  was reported.\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  The following adverse reactions have been identified during postapproval use of Plavix.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,plavix,33,1122,1204,"Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '  oselabeledaefromdruguse  including those with  nonoseaegeneralterm outcome, have been reported in patients treated with Plavix.\n', '\n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse (TTP),  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
34,plavix,34,1204,1207,"\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,plavix,35,1207,1236,"' *    nonoseaegeneralterm   oselabeledaefromdruguse (including  oselabeledaefromdruguse or lymphocytic  oselabeledaefromdruguse  oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse duodenal  oselabeledaefromdruguse  oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,plavix,36,1236,1237,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,plavix,37,1237,1263,"\n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse ,  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,plavix,38,1263,1276,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
39,plavix,39,1276,1289,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,plavix,40,1289,1303,"\n', ' *    nonoseaegeneralterm :  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,plavix,41,1303,1314,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
42,plavix,42,1314,1327,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
43,plavix,43,1327,1336,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
44,plavix,44,1336,1397,"\n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse  erythematous or exfoliative  oselabeledaefromdruguse  oselabeledaefromdruguse or exfoliative  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ( oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse \n', ' *    nonoseaegeneralterm   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,plavix,45,1397,1398,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,plavix,46,1398,1409,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,plavix,47,1409,1436,"WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,plavix,48,1436,1438,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,plavix,49,1438,1504,"DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE\n', '\n', '  EXCERPT:   WARNING:  DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE\n', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,plavix,50,1504,1512,"\n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,plavix,51,1512,1536,"*  Effectiveness of Plavix depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,plavix,52,1536,1541,"(5.1, 12.3)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,plavix,53,1541,1559,"\n', ' *  Tests are available to identify patients who are CYP2C19 poor metabolizers.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,plavix,54,1559,1583,"(12.5) \n', ' *  Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,plavix,55,1583,1586,(5.1),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,plavix,56,1586,1604,"\n', '    \n', ' \n', '\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,plavix,57,1604,1658,"The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19   [see   Warnings and Precautions (5.1)  ,   Clinical Pharmacology (12.3)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,plavix,58,1658,1682,Plavix at recommended doses forms less of  the active metabolite and so has a  nonoseaeaeonlyasinstruction in patients who are  notaecandidatepreexistingconditionorriskfactor  ,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
59,plavix,59,1682,1702,"(termed  notaecandidatepreexistingconditionorriskfactor    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
60,plavix,60,1702,1715,*  CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,plavix,61,1715,1720,(  5.1  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,plavix,62,1720,1724,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,plavix,63,1724,1728,*  Bleeding:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,plavix,64,1728,1734,Plavix increases risk of bleeding.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,plavix,65,1734,1739,(  5.2  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,plavix,66,1739,1743,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,plavix,67,1743,1755,*  Discontinuation: Premature discontinuation increases risk of cardiovascular events.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,plavix,68,1755,1770,Discontinue 5 days prior to elective surgery that has a major risk of bleeding.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,plavix,69,1770,1791,"(  5.3  ) \n', ' *  Thrombotic thrombocytopenic purpura (TTP) has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,plavix,70,1791,1811,"(  5.4  ) \n', ' *  Cross-reactivity among thienopyridines has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,plavix,71,1811,1858,"(  5.5  ) \n', '    \n', ' \n', '\n', '   5.1 Diminished Antiplatelet Activity in Patients with Impaired CYP2C19 Function\n', '\n', '  Clopidogrel is a prodrug.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,plavix,72,1858,1868,nonoseaeaeonlyasinstruction by clopidogrel is achieved through an active metabolite.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,plavix,73,1868,1891,The metabolism of clopidogrel to its active metabolite can be impaired by  notaecandidatepreexistingconditionorriskfactor [see  Boxed Warning  ].  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
74,plavix,74,1891,1919,"\n', '\n', ' The metabolism of clopidogrel can also be impaired by drugs that inhibit CYP2C19, such as omeprazole or esomeprazole.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,plavix,75,1919,1942,Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly  nonoseaeaefromdruginteraction of Plavix [see  Drug Interactions (7.1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
76,plavix,76,1942,2003,")  ]  .\n', '\n', '    5.2 General Risk of Bleeding\n', '\n', '  Thienopyridines, including Plavix, increase the risk of  oselabeledaefromdruguse \n', '\n', "" Thienopyridines  nonoseaeaeonlyasinstruction for the lifetime of the platelet (7-10 days).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,plavix,77,2003,2111,"Because the half-life of clopidogrel's active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.\n"", '\n', '    5.3 Discontinuation of Plavix\n', '\n', '  Discontinuation of Plavix increases the risk of  nonoseaeodorwithdrawal  If Plavix must be temporarily discontinued (e.g., to treat  notaecandidatepreexistingconditionorriskfactor or for surgery with a major risk of  notaecandidatepreexistingconditionorriskfactor , restart it as soon as possible.",0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
78,plavix,78,2111,2126,"When possible, interrupt therapy with Plavix for five days prior to such surgery.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,plavix,79,2126,2179,"Resume Plavix as soon as hemostasis is achieved.\n', '\n', '    5.4  oselabeledaefromdruguse \n', '\n', '   oselabeledaefromdruguse  sometimes fatal, has been reported following use of Plavix, sometimes after a short exposure (<2 weeks).  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,plavix,80,2179,2195,nonoseaeaeonlyasinstruction is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange).,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,plavix,81,2195,2235,"It is characterized by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication ( nonoseaemanifestationorcomplication [fragmented RBCs] seen on peripheral smear),  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication [see  Adverse Reactions (6.2)  ].  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
82,plavix,82,2235,2254,"\n', '\n', '    5.5 Cross-Reactivity among Thienopyridines\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,plavix,83,2254,2291,"', '   oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse or  oselabeledaefromdruguse has been reported in patients receiving Plavix, including patients with a  notaecandidatepreexistingconditionorriskfactor hypersensitivity or  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor ']",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
0,premarin,0,0,131,"['  6 ADVERSE REACTIONS\n', '\n', '  The following serious adverse reactions are discussed elsewhere in labeling:\n', '\n', ' *    oselabeledaeclasseffect  [see  Boxed Warning  ,  Warnings and Precautions (5.1)  ]  \n', ' *    oselabeledaeclasseffect  [see  Boxed Warning  ,  Warnings and Precautions (5.2)  ]  \n', '      EXCERPT:   Most common adverse reactions (>= 5 percent) are: abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,premarin,1,131,176,"(  6.1  )\n', ' \n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,premarin,2,176,205,"\n', '\n', ' \n', '\n', '  6.1 Clinical Study Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,premarin,3,205,343,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', ' During the first year of a 2-year clinical trial with 2,333  notaecandidatepreexistingconditionorriskfactor women with a uterus between 40 and 65 years of age (88 percent Caucasian), 1,012 women were treated with conjugated estrogens, and 332 were treated with placebo.\n', '\n', ' Table 1 summarizes treatment-related adverse reactions that occurred at a rate of >= 1 percent in any treatment group.\n', '\n', ' Table 1: TREATMENT RELATED ADVERSE",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
4,premarin,4,343,348,REACTIONS AT A FREQUENCY >,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,premarin,5,348,373,"= 1 PERCENT \n', '                                           PREMARIN0.625 mg(n=348)  PREMARIN0.45 mg (n=338)  PREMARIN0.3 mg(n=326)  Placebo(n=332)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,premarin,6,373,385,"\n', '  \n', '  nonoseaegeneralterm                                                                                                ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
7,premarin,7,385,411,"\n', '    oselabeledaefromdruguse                          38 (11)          28 (8)           30 (9)           21 (6)            ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,premarin,8,411,419,"\n', '    oselabeledaefromdruguse                                16",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,premarin,9,419,492,"(5)           8 (2)            14 (4)           3 (1)             \n', '    oselabeledaefromdruguse                               18 (5)           11 (3)           13 (4)           4 (1)             \n', '    oselabeledaefromdruguse                              2 (1)            3 (1)            4 (1)            2 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,premarin,10,492,493,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,premarin,11,493,519,"', '    nonoseaeaeratelteqplacebo                       7 (2)            6 (2)            4 (1)            8 (2)             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
12,premarin,12,519,531,"\n', '    oselabeledaefromdruguse                                45 (13)          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,premarin,13,531,532,47,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,premarin,14,532,542,(14)          44 (13)          46,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,premarin,15,542,661,"(14)           \n', '    oselabeledaefromdruguse                              5 (1)            4 (1)            4 (1)            1 (0)             \n', '    oselabeledaefromdruguse                                    17 (5)           10 (3)           12 (4)           14 (4)            \n', '    oselabeledaefromdruguse                             10 (3)           9 (3)            8 (2)            4 (1)             \n', '  nonoseaegeneralterm                                                                                          \n', '    oselabeledaefromdruguse                            4 (1)            4 (1)            7 (2)            5 (2)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
16,premarin,16,661,681,"\n', '    oselabeledaefromdruguse                                7 (2)            1 (0)            0                3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,premarin,17,681,690,"(1)             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,premarin,18,690,712,nonoseaeaeratelteqplacebo                             3 (1)            3 (1)            3 (1)            4 (1)             ,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
19,premarin,19,712,713,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,premarin,20,713,739,"', '    nonoseaeaeratelteqplacebo                          2 (1)            2 (1)            3 (1)            5 (2)             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
21,premarin,21,739,746,"\n', '  nonoseaegeneralterm                                                                                               ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
22,premarin,22,746,773,"\n', '    oselabeledaefromdruguse                            7 (2)            6 (2)            4 (1)            3 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,premarin,23,773,800,"\n', '    nonoseaeaeratelteqplacebo                                4 (1)            5 (1)            5 (2)            8 (2)             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
24,premarin,24,800,827,"\n', '    nonoseaeaeratelteqplacebo                               7 (2)            5 (1)            6 (2)            14 (4)            ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
25,premarin,25,827,854,"\n', '    oselabeledaefromdruguse                              1 (0)            1 (0)            4 (1)            1 (0)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,premarin,26,854,862,"\n', '    oselabeledaefromdruguse                              22",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,premarin,27,862,935,"(6)           18 (5)           13 (4)           8 (2)             \n', '    oselabeledaefromdruguse                      4 (1)            1 (0)            1 (0)            2 (1)             \n', '    nonoseaeaeratelteqplacebo                                  16 (5)           10 (3)           15 (5)           16 (5)            ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
28,premarin,28,935,942,"\n', '  nonoseaegeneralterm                                                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,premarin,29,942,996,"\n', '    oselabeledaefromdruguse                          2 (1)            4 (1)            3 (1)            2 (1)             \n', '    oselabeledaefromdruguse                        5 (1)            2 (1)            4 (1)            3 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,premarin,30,996,1001,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,premarin,31,1001,1030,"nonoseaeaeratelteqplacebo                             11 (3)           10 (3)           8 (2)            14 (4)            \n', '  nonoseaegeneralterm                                                                                         ",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
32,premarin,32,1030,1057,"\n', '    oselabeledaefromdruguse                              6 (2)            3 (1)            2 (1)            5 (2)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,premarin,33,1057,1089,"\n', '    oselabeledaefromdruguse                              10 (3)           5 (1)            9 (3)            4 (1)             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,premarin,34,1089,1111,oselabeledaefromdruguse                                 2 (1)            1 (0)            4 (1)            1 (0)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,premarin,35,1111,1118,"\n', '  nonoseaegeneralterm                                                                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
36,premarin,36,1118,1172,"\n', '    oselabeledaefromdruguse                                 6 (2)            4 (1)            2 (1)            4 (1)             \n', '    nonoseaeaeratelteqplacebo                              17 (5)           15 (4)           10 (3)           17 (5)            ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
37,premarin,37,1172,1261,"\n', '    oselabeledaefromdruguse                               9 (3)            7 (2)            4 (1)            5 (2)             \n', '    nonoseaeaeratelteqplacebo                      3 (1)            4 (1)            5 (2)            8 (2)             \n', '    oselabeledaefromdruguse                              1 (0)            1 (0)            5 (2)            3 (1)             \n', '    oselabeledaefromdruguse                                16",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
38,premarin,38,1261,1280,(5)           10 (3)           13 (4)           14 (4)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,premarin,39,1280,1341,"\n', '    oselabeledaefromdruguse                             9 (3)            12 (4)           2 (1)            6 (2)             \n', '  nonoseaegeneralterm                                                                                            \n', '    oselabeledaefromdruguse                                    3 (1)            1 (0)            8 (2)            3 (1)             ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
40,premarin,40,1341,1419,"\n', '    oselabeledaefromdruguse                                6 (2)            6 (2)            5 (2)            2 (1)             \n', '    oselabeledaefromdruguse                               4 (1)            2 (1)            1 (0)            0                 \n', '    oselabeledaefromdruguse                                11 (3)           11 (3)           10 (3)           3 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,premarin,41,1419,1446,"\n', '    oselabeledaefromdruguse                                    6 (2)            3 (1)            1 (0)            2 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,premarin,42,1446,1497,"\n', '    oselabeledaefromdruguse                      4 (1)            2 (1)            0                1 (0)             \n', '    nonoseaeaeratelteqplacebo                                4 (1)            1 (0)            3 (1)            4 (1)             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
43,premarin,43,1497,1531,"\n', '  nonoseaegeneralterm                                                                                              \n', '    nonoseaeaeratelteqplacebo                         6 (2)            3 (1)            3 (1)            6 (2)             ",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
44,premarin,44,1531,1558,"\n', '    oselabeledaefromdruguse                      3 (1)            4 (1)            7 (2)            3 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,premarin,45,1558,1585,"\n', '    nonoseaeaeratelteqplacebo                         4 (1)            4 (1)            7 (2)            7 (2)             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
46,premarin,46,1585,1635,"\n', '    oselabeledaefromdruguse                             37 (11)          39 (12)          24 (7)           26 (8)            \n', '    oselabeledaefromdruguse                         8 (2)            4 (1)            5 (2)            0                 ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,premarin,47,1635,1662,"\n', '    oselabeledaefromdruguse                            12 (3)           10 (3)           4 (1)            2 (1)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,premarin,48,1662,1698,"\n', '    oselabeledaefromdruguse                    4 (1)            2 (1)            2 (1)            0                 \n', '    oselabeledaefromdruguse                 16 (5)           ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,premarin,49,1698,1708,8 (2)            1 (0)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,premarin,50,1708,1710,0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,premarin,51,1710,1764,"\n', '    oselabeledaefromdruguse                              17 (5)           17 (5)           12 (4)           6 (2)             \n', '    oselabeledaefromdruguse                            11 (3)           4 (1)            3 (1)            1 (0)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,premarin,52,1764,1765,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,premarin,53,1765,1791,"', '    nonoseaeaeratelteqplacebo                 1 (0)            2 (1)            1 (0)            4 (1)             ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
54,premarin,54,1791,1826,"\n', '    oselabeledaefromdruguse               6 (2)            1 (0)            2 (1)            2 (1)             \n', '    oselabeledaefromdruguse                           11",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,premarin,55,1826,1845,(3)           5 (1)            3 (1)            2 (1)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,premarin,56,1845,1846,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,premarin,57,1846,1852,"', '    nonoseaeaeratelteqplacebo                         ",0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
58,premarin,58,1852,1857,1 (0)            ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,premarin,59,1857,1872,2 (1)            1 (0)            6 (2)             ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,premarin,60,1872,1877,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,premarin,61,1877,1896,oselabeledaefromdruguse                      46 (13)          13 (4)           6 (2)            0                 ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,premarin,62,1896,1901,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,premarin,63,1901,1950,"oselabeledaefromdruguse                      14 (4)           10 (3)           12 (4)           5 (2)             \n', '    oselabeledaefromdruguse                               18 (5)           7 (2)            9 (3)            1 (0)             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,premarin,64,1950,1978,"\n', '             6.2 Postmarketing Experience\n', '   The following additional adverse reactions have been identified during post-approval use of PREMARIN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,premarin,65,1978,2055,"Because these reactions are reported voluntarily from a population of uncertain size, it is not possible always to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '      nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse or pelvic  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,premarin,66,2055,2162,"\n', '\n', '      oselabeledaefromdruguse  oselabeledaefromdruguse  \n', '\n', ' Tenderness,  oselabeledaefromdruguse  oselabeledaefromdruguse  \n', '\n', ' Tenderness, enlargement,  oselabeledaefromdruguse  oselabeledaefromdruguse  \n', '\n', ' Tenderness, enlargement, pain,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse in males.\n', '\n', '      nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse and superficial  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,premarin,67,2162,2202,"\n', '\n', '      nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  increased incidence of  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,premarin,68,2202,2203,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,premarin,69,2203,2247,"\n', '\n', '      nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse or  oselabeledaefromdruguse that may persist when drug is discontinued,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,premarin,70,2247,2312,"\n', '\n', '      nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '      nonoseaegeneralterm  \n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse ,  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  possible  oselabeledaefromdruguse",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
71,premarin,71,2312,2359,"\n', '\n', '     Miscellaneous  \n', '\n', '  oselabeledaefromdruguse or decrease  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,premarin,72,2359,2360,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,premarin,73,2360,2371,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,premarin,74,2371,2394,"WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA\n', '\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,premarin,75,2394,2449,"ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA  \n', '\n', '  EXCERPT:   WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA\n', '\n', '   See full prescribing information for complete boxed warning.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,premarin,76,2449,2471,"\n', '\n', '   Estrogen-Alone Therapy  \n', '\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,premarin,77,2471,2643,"*  There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (5.2) \n', ' *  Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3) \n', "" *  Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) (5.1) \n"", ' *  The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older (5.3) \n', '      Estrogen Plus Progestin Therapy  \n', ' \n', '\n', ' *  Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia (5.1, 5.3) \n', ' *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,premarin,78,2643,2670,"The WHI estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI) (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,premarin,79,2670,2700,"5.1) \n', ' *  The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (5.2) \n', ' *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,premarin,80,2700,2725,The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,premarin,81,2725,2763,"(5.3) \n', '    \n', ' \n', '\n', '    Estrogen-Alone Therapy  \n', '\n', '     Endometrial Cancer  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,premarin,82,2763,2791,"\n', '\n', '   There is an increased risk of  oselabeledaeclasseffect in a woman with a uterus who uses unopposed estrogens.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,premarin,83,2791,2863,"Adding a progestin to estrogen therapy has been shown to reduce the risk of  nonoseaeaeonlyasinstruction  which may be a precursor to  nonoseaeaeonlyasinstruction  Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out  notaecandidatepreexistingconditionorriskfactor in  notaecandidatepreexistingconditionorriskfactor women with undiagnosed persistent or recurring  notaecandidatepreexistingconditionorriskfactor   [see   Warnings and Precautions (5.2)  ].    ",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
84,premarin,84,2863,2934,"\n', '\n', '     Cardiovascular Disorders and Probable Dementia  \n', '\n', '   Estrogen-alone therapy should not be used for the prevention of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor   [see   Warnings and Precautions (5.1,     5.3)  , and   Clinical Studies (14.5,     14.6)  ]  .  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
85,premarin,85,2934,3020,"\n', '\n', ""   The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of  oselabeledaeclasseffect and  oselabeledaeclasseffect  in  notaecandidatepreexistingconditionorriskfactor women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg]-alone, relative to placebo  [see   Warnings and Precautions (5.1)  , and   Clinical Studies (14.5)  ].    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
86,premarin,86,3020,3078,"\n"", '\n', '   The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable  oselabeledaeclasseffect in  notaecandidatepreexistingconditionorriskfactor women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
87,premarin,87,3078,3097,It is unknown whether this finding applies to younger  notaecandidatepreexistingconditionorriskfactor women   [see   Warnings and Precautions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
88,premarin,88,3097,3124,"(5.3)  ,   Use in Specific Populations (8.5)  , and   Clinical Studies (14.6)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,premarin,89,3124,3161,"\n', '\n', '   In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,premarin,90,3161,3200,"\n', '\n', '   Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,premarin,91,3200,3285,"\n', '\n', '     Estrogen Plus Progestin Therapy  \n', '\n', '     Cardiovascular Disorders and Probable Dementia  \n', '\n', '   Estrogen plus progestin therapy should not be used for the prevention of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor   [see   Warnings and Precautions (5.1,     5.3)  , and   Clinical Studies (14.5  ,   14.6)  ].    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
92,premarin,92,3285,3379,"\n', '\n', '   The WHI estrogen plus progestin substudy reported increased risks of  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction ,  nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction  in  notaecandidatepreexistingconditionorriskfactor women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE (0.625 mg) combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo   [see   Warnings and Precautions (5.1),   and   Clinical Studies (14.5)  ]  .  ",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
93,premarin,93,3379,3442,"\n', '\n', '   The WHIMS estrogen plus progestin ancillary study of the WHI, reported an increased risk of developing probable  nonoseaeaefromdruginteraction in  notaecandidatepreexistingconditionorriskfactor women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo.",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
94,premarin,94,3442,3461,It is unknown whether this finding applies to younger  notaecandidatepreexistingconditionorriskfactor women   [see   Warnings and Precautions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
95,premarin,95,3461,3488,"(5.3)  ,   Use in Specific Populations (8.5)  , and   Clinical Studies (14.6)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,premarin,96,3488,3540,"\n', '\n', '     Breast Cancer  \n', '\n', '   The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive  nonoseaeaefromdruginteraction    5 WARNINGS AND PRECAUTIONS\n', '\n', '   EXCERPT:    ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
97,premarin,97,3540,3578,"*  Estrogens increase the risk of gallbladder disease (  5.4  ) \n', ' *  Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs (  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,premarin,98,3578,3597,"5.5  ,  5.6  ,  5.11  ,  5.12  ) \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,premarin,99,3597,3614,"*  Monitor thyroid function in women on thyroid replacement therapy (  5.13  ,  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,premarin,100,3614,3617,5.18  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,premarin,101,3617,3661,"\n', '    \n', ' \n', '\n', '   5.1  oselabeledaefromdruguse \n', '  An increased risk of  oselabeledaeclasseffect and  oselabeledaeclasseffect has been reported with estrogen-alone therapy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,premarin,102,3661,3683,An increased risk of  nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction   nonoseaeaefromdruginteraction and  nonoseaeaefromdruginteraction has been reported with estrogen plus progestin therapy.,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
103,premarin,103,3683,3829,"Should any of these events occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.\n', '\n', ' Risk factors for  notaecandidatepreexistingconditionorriskfactor (for example,  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  and/or  notaecandidatepreexistingconditionorriskfactor  (for example, personal or family history of  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  and  notaecandidatepreexistingconditionorriskfactor  should be managed appropriately.\n', '\n', '    Stroke  \n', '\n', ' In the WHI estrogen-alone substudy, a statistically significant increased risk of  oselabeledaeclasseffect was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years).",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,premarin,104,3829,3852,The increase in risk was demonstrated in year 1 and persisted [see  Clinical Studies (14.5)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,premarin,105,3852,3917,"Should a  nonoseaeaeonlyasinstruction occur or be suspected, estrogen-alone therapy should be discontinued immediately.\n', '\n', ' Subgroup analyses of women 50 to 59 years of age suggest no increased risk of  nonoseaeaeratelteqplacebo for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).  ",1,0,0,0,0,0,1,0,0,0,0,0,0,0,0
106,premarin,106,3917,3919,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,premarin,107,3919,3986,"\n', '\n', ' In the WHI estrogen plus progestin substudy, a statistically significant increased risk of  nonoseaeaefromdruginteraction was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women-years)",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
108,premarin,108,3986,3998,[see  Clinical Studies (14.5)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,premarin,109,3998,4012,The increase in risk was demonstrated after the first year and persisted.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,premarin,110,4012,4014,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
111,premarin,111,4014,4035,"Should a  nonoseaeaeonlyasinstruction occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.\n', '\n",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,premarin,112,4035,4094,"', '    Coronary Heart Disease  \n', '\n', ' In the WHI estrogen-alone substudy, no overall effect on  nonoseaeaeratelteqplacebo  events (defined as nonfatal  nonoseaeaeratelteqplacebo   nonoseaeaeratelteqplacebo  or  nonoseaegeneralterm  was reported in women receiving estrogen-alone compared to placebo  2     ",0,1,0,0,0,0,1,0,0,0,0,0,0,0,0
113,premarin,113,4094,4103,[see Clinical Studies (14.5)]    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,premarin,114,4103,4163,".\n', '\n', ' Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in  nonoseaeaeratelteqplacebo events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since  notaecandidatepreexistingconditionorriskfactor (8 versus 16 per 10,000 women-years).  ",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0
115,premarin,115,4163,4165,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,premarin,116,4165,4170,"\n', '\n",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,premarin,117,4170,4227,"', ' In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of  nonoseaeaefromdruginteraction events reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
118,premarin,118,4227,4229,1  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,premarin,119,4229,4335,"An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 [see  Clinical Studies (14.5)  ]  .\n', '\n', ' In  notaecandidatepreexistingconditionorriskfactor women with documented  notaecandidatepreexistingconditionorriskfactor (n = 2,763, average 66.7 years of age), in a controlled clinical trial of secondary prevention of  notaecandidatepreexistingconditionorriskfactor (Heart and Estrogen/Progestin Replacement Study; HERS), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
120,premarin,120,4335,4399,"During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of  nonoseaenegation events in  notaecandidatepreexistingconditionorriskfactor women with established  notaecandidatepreexistingconditionorriskfactor  There were more  nonoseaeaefromdruginteraction events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years.",0,0,1,0,0,1,0,1,0,0,0,0,0,0,0
121,premarin,121,4399,4431,"Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,premarin,122,4431,4452,"Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
123,premarin,123,4452,4573,"Rates of  nonoseaeaefromdruginteraction were comparable among women in the CE (0.625 mg) plus MPA (2.5 mg) group and the placebo group in HERS, HERS II, and overall.\n', '\n', '    Venous Thromboembolism (VTE)  \n', '\n', ' In the WHI estrogen-alone substudy, the risk of  oselabeledaeclasseffect ( oselabeledaeclasseffect and  oselabeledaeclasseffect , was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of  oselabeledaeclasseffect reached statistical significance (23 versus 15 per 10,000 women-years).",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
124,premarin,124,4573,4601,The increase in  oselabeledaeclasseffect risk was demonstrated during the first 2 years  3   [see  Clinical Studies (14.5)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,premarin,125,4601,4675,"Should a  nonoseaeaeonlyasinstruction occur or be suspected, estrogen-alone therapy should be discontinued immediately.\n', '\n', ' In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of  nonoseaeaefromdruginteraction was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years).",1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
126,premarin,126,4675,4711,"Statistically significant increases in risk for both  nonoseaeaefromdruginteraction (26 versus 13 per 10,000 women-years) and  nonoseaeaefromdruginteraction (18 versus 8 per 10,000 women-years) were also demonstrated.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
127,premarin,127,4711,4740,The increase in  nonoseaeaefromdruginteraction risk was demonstrated during the first year and persisted  4   [see  Clinical Studies (14.5)  ]  .,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
128,premarin,128,4740,4847,"Should a  nonoseaeaeonlyasinstruction occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.\n', '\n', ' If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of  nonoseaeaeonlyasinstruction  or during periods of prolonged immobilization.\n', '\n', '    5.2  oselabeledaefromdruguse \n', '   Endometrial Cancer  \n', '\n', ' An increased risk of  oselabeledaeclasseffect has been reported with the use of unopposed estrogen therapy in a woman with a uterus.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,premarin,129,4847,4881,"The reported  oselabeledaeclasseffect risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,premarin,130,4881,4899,Most studies show no significant increased risk associated with use of estrogens for less than 1 year.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,premarin,131,4899,4967,"The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more, and this risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.\n', '\n', ' Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,premarin,132,4967,5026,"Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out  nonoseaeaeonlyasinstruction in  notaecandidatepreexistingconditionorriskfactor women with undiagnosed persistent or recurring abnormal  notaecandidatepreexistingconditionorriskfactor  There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
133,premarin,133,5026,5100,"Adding a progestin to  nonoseaeaeonlyasinstruction estrogen therapy has been shown to reduce the risk of  nonoseaeaeonlyasinstruction  which may be a precursor to  nonoseaeaeonlyasinstruction \n', '\n', '    Breast Cancer  \n', '\n', ' The most important randomized clinical trial providing information about  nonoseaeaeonlyasinstruction in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,premarin,134,5100,5142,"In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg)-alone was not associated with an increased risk of  nonoseaenegation [relative risk (RR) 0.80]    ",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
135,premarin,135,5142,5144,5   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,premarin,136,5144,5197,"[see  Clinical Studies (14.5)  ]  .\n', '\n', ' The most important randomized clinical trial providing information about  nonoseaeaeonlyasinstruction in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg).",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,premarin,137,5197,5228,"After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of  nonoseaeaefromdruginteraction in women who took daily CE plus MPA.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
138,premarin,138,5228,5252,"In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,premarin,139,5252,5285,"The relative risk of  nonoseaeaefromdruginteraction was 1.24, and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo.  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
140,premarin,140,5285,5287,6  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,premarin,141,5287,5328,"Among women who reported prior use of hormone therapy, the relative risk of  nonoseaeaefromdruginteraction was 1.86, and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
142,premarin,142,5328,5370,"Among women who reported no prior use of hormone therapy, the relative risk of  nonoseaeaefromdruginteraction was 1.09, and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
143,premarin,143,5370,5416,"In the same substudy,  nonoseaeaefromdruginteraction were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
144,premarin,144,5416,5430,"Metastatic disease was rare, with no apparent difference between the two groups.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,premarin,145,5430,5510,"Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups [see  Clinical Studies (14.5)  ]  .\n', '\n', ' Consistent with the WHI clinical trial, observational studies have also reported an increased risk of  oselabeledaeclasseffect for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
146,premarin,146,5510,5545,"The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
147,premarin,147,5545,5576,"Observational studies also suggest that the risk of  nonoseaeaefromdruginteraction was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
148,premarin,148,5576,5662,"However, these studies have not found significant variation in the risk of  nonoseaeaeonlyasinstruction among different estrogen plus progestin combinations, doses, or routes of administration.\n', '\n', ' The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in  oselabeledaeclasseffect  requiring further evaluation.\n', '\n', ' All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
149,premarin,149,5662,5753,"In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.\n', '\n', '    Ovarian Cancer  \n', '\n', '  The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of  nonoseaeaefromdruginteraction  After an average follow-up of 5.6 years, the relative risk for  nonoseaeaefromdruginteraction for CE plus MPA versus placebo was 1.58 (95 percent CI 0.77-3.24).",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
150,premarin,150,5753,5774,"The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
151,premarin,151,5774,5776,7    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,premarin,152,5776,5815,"\n', '\n', '  A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for  notaecandidateindication had an increased risk for  oselabeledaeclasseffect  ",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
153,premarin,153,5815,5836,"The primary analysis, using case-control comparisons, included 12,110  nonoseaeaeonlyasinstruction cases from the 17 prospective studies.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
154,premarin,154,5836,5905,The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years] vs. greater than 5 years [median of 10 years] of use before the  nonoseaeaeonlyasinstruction diagnosis).,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,premarin,155,5905,5954,"The relative risk associated with combined current and recent use (discontinued use within 5 years before  nonoseaeaeonlyasinstruction diagnosis) was 1.37 (95% CI 1.27-1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,premarin,156,5954,5976,"The exact duration of hormone therapy use associated with an increased risk of  nonoseaeaeonlyasinstruction  however, is unknown.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
157,premarin,157,5976,6068,"\n', '\n', '    5.3 Probable Dementia\n', '\n', '  In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo.\n', '\n', ' After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
158,premarin,158,6068,6092,The relative risk of probable  oselabeledaeclasseffect for CE-alone versus placebo was 1.49 (95 percent CI 0.83-2.66).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
159,premarin,159,6092,6190,"The absolute risk of probable  oselabeledaeclasseffect for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years  8   [see  Use in Specific Populations (8.5)  , and  Clinical Studies (14.6)  ]  .\n', '\n', ' In the WHIMS estrogen plus progestin ancillary study of WHI, a population of 4,532  notaecandidatepreexistingconditionorriskfactor women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
160,premarin,160,6190,6222,"After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable  nonoseaeaefromdruginteraction  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
161,premarin,161,6222,6246,The relative risk of probable  nonoseaeaefromdruginteraction for CE plus MPA versus placebo was 2.05 (95 percent CI 1.21-3.48).,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
162,premarin,162,6246,6295,"The absolute risk of probable  nonoseaeaefromdruginteraction for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years  8   [see  Use in Specific Populations (8.5)  , and  Clinical Studies (14.6)  ].  ",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
163,premarin,163,6295,6350,"\n', '\n', ' When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable  oselabeledaeclasseffect was 1.76 (95 percent CI 1.19-2.60).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
164,premarin,164,6350,6479,"Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger  notaecandidatepreexistingconditionorriskfactor women  8   [see  Use in Specific Populations (8.5)  , and  Clinical Studies (14.6)  ]  .\n', '\n', '    5.4 Gallbladder Disease\n', '\n', '  A 2- to 4-fold increase in the risk of  oselabeledaeclasseffect requiring surgery in  notaecandidatepreexistingconditionorriskfactor women receiving estrogens has been reported.\n', '\n', '    5.5 Hypercalcemia\n', '\n', '  Estrogen administration may lead to severe  oselabeledaeclasseffect in patients with  notaecandidatepreexistingconditionorriskfactor and  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
165,premarin,165,6479,6524,"If  nonoseaeaeonlyasinstruction occurs, use of the drug should be stopped and appropriate measures taken to  nonoseaeaeonlyasinstruction \n', '\n', '    5.6  oselabeledaefromdruguse \n', '   oselabeledaeclasseffect has been reported in patients receiving estrogens.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
166,premarin,166,6524,6555,Discontinue medication pending examination if there is sudden  nonoseaeaeonlyasinstruction or complete  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction  or a sudden onset of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or  nonoseaeaeonlyasinstruction  ,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
167,premarin,167,6555,6619,"If examination reveals  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  estrogens should be permanently discontinued.\n', '\n', '    5.7 Anaphylactic Reaction and Angioedema\n', '\n', '  Cases of  oselabeledaefromdruguse  which developed within minutes to hours after taking PREMARIN and require emergency medical management, have been reported in the postmarketing setting.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
168,premarin,168,6619,6662,"oselabeledaefromdruguse (hives, pruritis, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting)  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse lips- oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,premarin,169,6662,6790,"oselabeledaefromdruguse lips-tongue- oselabeledaefromdruguse  and either  oselabeledaefromdruguse (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting)  oselabeledaefromdruguse  oselabeledaefromdruguse  or  oselabeledaefromdruguse (abdominal pain, vomiting)  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse  involvement has been noted.\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse involving the tongue, larynx, face, hands, and  oselabeledaefromdruguse  oselabeledaefromdruguse involving the tongue, larynx, face,  oselabeledaefromdruguse  oselabeledaefromdruguse involving the tongue, larynx,  oselabeledaefromdruguse  oselabeledaefromdruguse involving the tongue,  oselabeledaefromdruguse  oselabeledaefromdruguse involving the  oselabeledaefromdruguse  larynx, face, hands, and feet requiring medical intervention has occurred postmarketing in patients taking PREMARIN.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,premarin,170,6790,6823,"If  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction involves the  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction involves the tongue,  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction involves the tongue, glottis, or  nonoseaeaeonlyasinstruction   nonoseaemanifestationorcomplication may occur.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
171,premarin,171,6823,6917,"Patients who develop an  nonoseaeaeonlyasinstruction with or without  nonoseaeaeonlyasinstruction after treatment with PREMARIN should not receive PREMARIN again.\n', '\n', '    5.8 Addition of a Progestin When a Woman Has Not Had a Hysterectomy\n', '\n', '  Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration or daily with estrogen in a continuous regimen, have reported a lowered incidence of  nonoseaeaeonlyasinstruction than would be induced by estrogen treatment alone.  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,premarin,172,6917,6958,"nonoseaeaeonlyasinstruction may be a precursor to  nonoseaeaeonlyasinstruction \n', '\n', ' There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
173,premarin,173,6958,7007,"These include an increased risk of  nonoseaeaefromdruginteraction \n', '\n', '    5.9 Elevated Blood Pressure\n', '\n', '  In a small number of case reports, substantial  oselabeledaeclasseffect have been attributed to idiosyncratic reactions to estrogens.",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
174,premarin,174,7007,7202,"In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen.\n', '\n', '    5.10 Hypertriglyceridemia\n', '\n', '  In women with pre-existing  notaecandidatepreexistingconditionorriskfactor  estrogen therapy may be associated with  oselabeledaeclasseffect leading to  nonoseaemanifestationorcomplication  Consider discontinuation of treatment if  nonoseaeaeonlyasinstruction occurs.\n', '\n', '    5.11 Hepatic Impairment and/or Past History of Cholestatic Jaundice\n', '\n', '  Estrogens may be poorly metabolized in patients with  notaecandidatepreexistingconditionorriskfactor  For women with a history of  notaecandidatepreexistingconditionorriskfactor associated with past estrogen use or with  notaecandidatepreexistingconditionorriskfactor  caution should be exercised, and in the case of recurrence, medication should be discontinued.\n', '\n', '    5.12 Hypothyroidism\n', '\n', '  Estrogen administration leads to  oselabeledaeclasseffect  Women with normal thyroid function can compensate for the  nonoseaeaeonlyasinstruction by making more thyroid hormone, thus maintaining free T4and T3serum concentrations in the normal range.",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
175,premarin,175,7202,7224,Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,premarin,176,7224,7271,"These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.\n', '\n', '    5.13 Fluid Retention\n', '\n', '  Estrogens may cause some degree of  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
177,premarin,177,7271,7408,"oselabeledaeclasseffect  Women with conditions that might be influenced by this factor, such as  notaecandidatepreexistingconditionorriskfactor or renal  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor  warrant careful observation when estrogen alone is prescribed.\n', '\n', '    5.14 Hypocalcemia\n', '\n', '  Estrogen therapy should be used with caution in individuals with  notaecandidatepreexistingconditionorriskfactor as estrogen-induced  oselabeledaeclasseffect may occur.\n', '\n', '    5.15 Hereditary Angioedema\n', '\n', '  Exogenous estrogens may  oselabeledaeclasseffect in women with  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.16  oselabeledaeclasseffect \n', '  A few cases of  oselabeledaeclasseffect have been reported in women treated post-hysterectomy with estrogen-alone therapy.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
178,premarin,178,7408,7730,"For women known to have residual  notaecandidatepreexistingconditionorriskfactor post-hysterectomy, the addition of progestin should be considered.\n', '\n', '    5.17 Exacerbation of Other Conditions\n', '\n', '  Estrogen therapy may cause an  oselabeledaeclasseffect  oselabeledaeclasseffect asthma,  oselabeledaeclasseffect  oselabeledaeclasseffect asthma, diabetes mellitus,  oselabeledaeclasseffect  oselabeledaeclasseffect asthma, diabetes mellitus, epilepsy,  oselabeledaeclasseffect  oselabeledaeclasseffect asthma, diabetes mellitus, epilepsy, migraine,  oselabeledaeclasseffect  oselabeledaeclasseffect asthma, diabetes mellitus, epilepsy, migraine, porphyria,  oselabeledaeclasseffect  oselabeledaeclasseffect asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and  oselabeledaeclasseffect and should be used with caution in women with these conditions.\n', '\n', '    5.18 Laboratory Tests\n', '\n', '  Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe  notaecandidateindication and moderate to severe symptoms of  notaecandidateindication and vaginal  notaecandidateindication  notaecandidateindication \n', '\n', ' Laboratory parameters may be useful in guiding dosage for the treatment of  notaecandidatepreexistingconditionorriskfactor due to  notaecandidatepreexistingconditionorriskfactor  castration and  notaecandidatepreexistingconditionorriskfactor \n', '\n', '    5.19 Drug-Laboratory Test Interactions\n', '\n', '   oselabeledaefromdruguse prothrombin time, partial thromboplastin time, and  oselabeledaefromdruguse  oselabeledaefromdruguse prothrombin time,  oselabeledaefromdruguse  oselabeledaefromdruguse  partial thromboplastin time, and platelet aggregation time;  oselabeledaefromdruguse   oselabeledaefromdruguse factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and  oselabeledaefromdruguse  oselabeledaefromdruguse factors  oselabeledaefromdruguse  VII antigen,",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
179,premarin,179,7730,7759,"VIII antigen, VIII coagulant activity, IX, X, XII, VII oselabeledaefromdruguse  complex, II- oselabeledaefromdruguse  oselabeledaefromdruguse factors II,  oselabeledaefromdruguse antigen,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,premarin,180,7759,7782,"VIII antigen, VIII coagulant activity, IX, X, XII, VII oselabeledaefromdruguse  oselabeledaefromdruguse  II, VII antigen,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
181,premarin,181,7782,7790,"VIII antigen, VIII coagulant activity, IX",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,premarin,182,7790,7803,", X,  oselabeledaefromdruguse  oselabeledaefromdruguse  II, VII antigen,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
183,premarin,183,7803,7810,"VIII antigen, VIII coagulant activity,",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
184,premarin,184,7810,7864,"I oselabeledaefromdruguse  oselabeledaefromdruguse  II, VII antigen, VIII antigen, VIII coagulant activity,  oselabeledaefromdruguse  oselabeledaefromdruguse  II, VII antigen,  oselabeledaefromdruguse antigen, VIII  oselabeledaefromdruguse  oselabeledaefromdruguse  II, VII antigen,  oselabeledaefromdruguse  oselabeledaefromdruguse  II,  oselabeledaefromdruguse  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
185,premarin,185,7864,7866,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
186,premarin,186,7866,7902,"VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin;  oselabeledaefromdruguse antifactor",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
187,premarin,187,7902,7931,"Xa and  oselabeledaefromdruguse  oselabeledaefromdruguse and antithrombin III,  oselabeledaefromdruguse   oselabeledaefromdruguse levels of  oselabeledaefromdruguse and fibrinogen  oselabeledaefromdruguse  oselabeledaefromdruguse and fibrinogen activity;  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
188,premarin,188,7931,7978,"oselabeledaefromdruguse antigen and  oselabeledaefromdruguse  oselabeledaefromdruguse and activity.\n', '\n', '  oselabeledaefromdruguse leading to  nonoseaemanifestationorcomplication as measured by protein-bound iodine (PBI), T4levels (by column or by radioimmunoassay) or T3levels by radioimmunoassay.  ",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
189,premarin,189,7978,7992,oselabeledaefromdruguse  reflecting the  nonoseaemanifestationorcomplication  Free T4and free T3concentrations are unaltered.,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
190,premarin,190,7992,8051,"Women on thyroid replacement therapy may require higher doses of thyroid hormone.\n', '\n', ' Other binding proteins may be  oselabeledaefromdruguse in serum, for example,  oselabeledaefromdruguse  oselabeledaefromdruguse in serum, for example, corticosteroid binding globulin (CBG),  oselabeledaefromdruguse , leading to  nonoseaemanifestationorcomplication  respectively.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
191,premarin,191,8051,8074,"Free hormone concentrations, such as  oselabeledaefromdruguse and estradiol, may be  oselabeledaefromdruguse  oselabeledaefromdruguse  may be  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
192,premarin,192,8074,8082,Other plasma proteins may be  oselabeledaefromdruguse (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
193,premarin,193,8082,8109,"angiotensinogen/renin substrate, alpha-1-antitrypsin,  oselabeledaefromdruguse  oselabeledaefromdruguse (angiotensinogen/renin substrate,  oselabeledaefromdruguse  oselabeledaefromdruguse (angiotensinogen/ oselabeledaefromdruguse  oselabeledaefromdruguse (",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
194,premarin,194,8109,8154,"oselabeledaefromdruguse renin substrate, alpha-1-antitrypsin, ceruloplasmin).\n', '\n', '  oselabeledaefromdruguse  oselabeledaeclasseffect plasma high-density lipoprotein (HDL) and  oselabeledaeclasseffect   oselabeledaefromdruguse   oselabeledaefromdruguse \n', '\n', '  oselabeledaefromdruguse ']",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,prepopik,0,0,59,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most common adverse reactions (>1%) are nausea, headache and vomiting (abdominal bloating, distension, pain/cramping, and watery diarrhea not requiring an intervention were not collected) (  6.1  )  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,prepopik,1,59,91,"To report SUSPECTED ADVERSE REACTIONS, contact Ferring at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or  www.fda.gov/medwatch.    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,prepopik,2,91,128,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,prepopik,3,128,223,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', '\n', '\n', ' In randomized, multicenter, controlled clinical trials,  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse were the most common adverse reactions (>1%) following Prepopik  (r)  administration.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,prepopik,4,223,233,The patients were not blinded to the study drug.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,prepopik,5,233,389,"Since  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  oselabeledaeclasseffect  and  oselabeledaeclasseffect are known to occur in response to colon cleansing preparations, these effects were documented as adverse events in the clinical trials only if they required medical intervention (such as a change in study drug or led to study discontinuation, therapeutic or diagnostic procedures, met the criteria for a serious adverse event), or showed clinically significant worsening during the study that was not in the frame of the usual clinical course, as determined by the investigator.\n', '\n', '\n', '\n', ' Prepopik  (r)  was compared for colon cleansing effectiveness with a preparation containing two liters (2L) of polyethylene glycol plus electrolytes solution (PEG + E) and two 5-mg bisacodyl tablets, all administered the day before the procedure.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,prepopik,6,389,546,"Table 1 displays the most common adverse reactions in Study 1 and Study 2 for the Prepopik  (r)  Split-Dose and Day-Before dosing regimens, respectively, each as compared to the comparator preparation.\n', '\n', '\n', '\n', ' Table 1: Treatment-Emergent Adverse Reactions observed in at Least (>1%) of Patients using the Split-Dose Regimen and Day-Before Regimen  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction bloating, distension, pain/ nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction cramping, and  nonoseaeaeonlyasinstruction not requiring an intervention were not collected \n', ' Adverse Reaction  Study 1: Split-Dose Regimen  Study 2: Day-Before Regimen   \n', ' PREPOPIK  (r)  (N=305)n (% = n/N)  2L PEG+Ewith",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,prepopik,7,546,547,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,prepopik,8,547,576,* 5-mg bisacodyl tablets(N=298)n (% = n/N)  PREPOPIK  (r)  (N=296)n (% = n/N)  2L,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,prepopik,9,576,578,PEG+Ewith 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,prepopik,10,578,582,* 5-mg bisacodyl tablets(N=302)n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,prepopik,11,582,590,(% = n/N)   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,prepopik,12,590,600,"\n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,prepopik,13,600,620,oselabeledaefromdruguse             8 (2.6)                 11 (3.7)                 9 (3.0)                 13 (4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,prepopik,14,620,684,")           \n', '  oselabeledaefromdruguse           5 (1.6)                  5 (1.7)                 8 (2.7)                  5 (1.7)           \n', '  oselabeledaefromdruguse           3 (1.0)                 10 (3.4)                 4 (1.4)                  6 (2.0)           \n', '               Electrolyte Abnormalities  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,prepopik,15,684,741,"\n', ' \n', '\n', ' In general, Prepopik  (r)  was associated with numerically higher rates of  oselabeledaefromdruguse shifts on the day of colonoscopy compared to the preparation containing 2L of PEG + E plus two * 5-mg bisacodyl tablets (Table 2).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,prepopik,16,741,808,"These shifts were transient in nature and numerically similar between treatment arms at the Day 30 visit.\n', '\n', '\n', '\n', ' Table 2: Shifts from Normal Baseline to Outside the Normal Range at Day 7 and Day 30 \n', ' Laboratory Parameter (direction of change)                 Visit  Study 1:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,prepopik,17,808,821,Split-Dose Regimen  Study 2: Day-Before Regimen   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,prepopik,18,821,838,"\n', ' PREPOPIK  (r)         2L PEG+E with 2* 5 mg",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,prepopik,19,838,857,bisacodyl tablets  PREPOPIK  (r)    2L PEG+E with 2* 5 mg bisacodyl tablets   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,prepopik,20,857,876,"\n', '                                                 n/N (%)          n/N (%)       ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,prepopik,21,876,886,"\n', '  \n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,prepopik,22,886,912,oselabeledaefromdruguse          Day of Colonoscopy   19/260 (7.3)    11/268 ( 4.1 )    13/274 (4.7)     13/271 (4.8)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,prepopik,23,912,942,"\n', '                                24-48 hours    3/302 (1.0)      2/294 (0.7)      3/287 (1.0)      5/292 (1.7)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,prepopik,24,942,970,"\n', '                                      Day 7   11/285 (3.9)      8/279 (2.9)      6/276 (2.2)     14/278 (5.0)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,prepopik,25,970,984,"\n', '                                     Day 30   11/284 (3.9)      8/278",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,prepopik,26,984,989,(2.9)      7/275,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,prepopik,27,989,994,(2.5)      8/284,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,prepopik,28,994,998,(2.8)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,prepopik,29,998,1003,"\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,prepopik,30,1003,1020,oselabeledaefromdruguse             Day of Colonoscopy   11/298 (3.7)      3/295 (1.0)      3/286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,prepopik,31,1020,1025,(1.0)      3/295,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,prepopik,32,1025,1040,"(1.0)     \n', '                                24-48 hours    1/303",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,prepopik,33,1040,1045,(0.3)      1/295,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,prepopik,34,1045,1059,(0.3)      1/288 (0.3)      1/293 (0.3)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,prepopik,35,1059,1073,"\n', '                                      Day 7    2/300 (0.7)      1/292",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,prepopik,36,1073,1078,(0.3)      1/285,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,prepopik,37,1078,1083,(0.4)      1/291,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,prepopik,38,1083,1110,"(0.3)     \n', '                                     Day 30    2/299( 0.7)      3/291 (1.0)      1/284( 0.4)      ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,prepopik,39,1110,1111,1/296,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,prepopik,40,1111,1142,"(0.3)     \n', '  oselabeledaefromdruguse           Day of Colonoscopy   11/301 (3.7)      1/298 (0.3)      3/287 (1.0)      0/297",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,prepopik,41,1142,1176,"(0.0)     \n', '                                24-48 hours    1/303 (0.3)      0/295 (0.0)      2/288 (0.7)      0/293 (0.0)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,prepopik,42,1176,1185,"\n', '                                      Day 7    1/303",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,prepopik,43,1185,1204,(0.3)      3/295 (1.0)      0/285 (0.0)      0/293 (0.0)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,prepopik,44,1204,1249,"\n', '                                     Day 30    2/302 (0.7)      3/294 (1.0)      0/285 (0.0)      0/298 (0.0)     \n', '  oselabeledaefromdruguse         Day of Colonoscopy   34/294 (11.6)     0/294",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,prepopik,45,1249,1259,(0.0)     25/288 (8.7)      1/289,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,prepopik,46,1259,1274,"(0.3)     \n', '                                24-48 hours    0/303",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,prepopik,47,1274,1279,(0.0)      0/295,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,prepopik,48,1279,1293,(0.0)      0/288 (0.0)      0/293 (0.0)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,prepopik,49,1293,1302,"\n', '                                      Day 7    0/297",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,prepopik,50,1302,1307,(0.0)      1/291,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,prepopik,51,1307,1321,(0.3)      1/286 (0.3)      1/285 (0.4)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,prepopik,52,1321,1340,"\n', '                                     Day 30    1/296 (0.3)      2/290 (0.7)      0/286",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,prepopik,53,1340,1349,(0.0)      0/290 (0.0)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,prepopik,54,1349,1361,"\n', '  oselabeledaefromdruguse            Day of Colonoscopy    2/292",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,prepopik,55,1361,1371,(0.7)      1/286 (0.3)      0/276,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,prepopik,56,1371,1380,(0.0)      2/282 (0.7)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,prepopik,57,1380,1406,"\n', '                                24-48 hours    0/303 (0.0)      0/295 (0.0)      0/288 (0.0)      0/293",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,prepopik,58,1406,1419,"(0.0)     \n', '                                      Day 7    0/293",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,prepopik,59,1419,1466,"(0.0)      1/283 (0.4)      0/274 (0.0)      0/278 (0.0)     \n', '                                     Day 30    0/292 (0.0)      1/282 (0.4)      0/274 (0.0)      1/283 (0.4)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,prepopik,60,1466,1477,"\n', '  oselabeledaefromdruguse        Day of Colonoscopy    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,prepopik,61,1477,1518,"5/260 (1.9)     13/268 (4.9)     12/266 (4.5)     16/270 (5.9)     \n', '                                24-48 hours    1/303 (0.3)      0/295 (0.0)      0/288",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,prepopik,62,1518,1523,(0.0)      0/293,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,prepopik,63,1523,1540,"(0.0)     \n', '                                      Day 7   10/264 (0.4)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,prepopik,64,1540,1545,13/267 (4.8)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,prepopik,65,1545,1555,10/264 (3.8)     10/265 (3.8)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,prepopik,66,1555,1576,"\n', '                                     Day 30   11/264 (4.2)      14/265(5.3)     18/264 (6.8)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,prepopik,67,1576,1597,"10/272 (3.7)     \n', '  oselabeledaefromdruguse               Day of Colonoscopy   22/221 (10.0)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
68,prepopik,68,1597,1608,17/214 (7.9)     26/199 (13.1)    25/224,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,prepopik,69,1608,1633,"(11.2)    \n', '                                24-48 hours   76/303 (25.1)    72/295 (24.4)    82/288",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,prepopik,70,1633,1660,"(28.5)    62/293 (21.2)    \n', '                                      Day 7   22/223 (10.0)    17/213 (8.0)     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,prepopik,71,1660,1682,"11/198 (5.6)     28/219 (12.8)    \n', '                                     Day 30   24/223(10.8)     21/211",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,prepopik,72,1682,1729,"(10.0)    21/199 (10.6)    24/224 (10.7)    \n', '              6.2 Postmarketing Experience\n', '   The following foreign spontaneous reports have been identified during use of formulations similar to Prepopik  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,prepopik,73,1729,1880,"Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', '\n', '\n', '     Allergic reactions  \n', '\n', '\n', '\n', ' Cases of  oselabeledaefromdruguse including  oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported.\n', '\n', '\n', '\n', '     Electrolyte abnormalities  \n', '\n', '\n', '\n', ' There have been reports of  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse with the use of Prepopik  (r)  for colon preparation prior to colonoscopy.\n', '\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,prepopik,74,1880,1890,"'\n', '\n', '     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,prepopik,75,1890,1939,"Gastrointestinal:  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse have been reported with the use of Prepopik  (r)  for colon preparation prior to colonoscopy.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,prepopik,76,1939,1971,There have been isolated reports of reversible aphthoid  oselabeledaefromdruguse   oselabeledaefromdruguse has been reported with the use of Prepopik  (r)  for colon preparation prior to colonoscopy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,prepopik,77,1971,2121,"However, a causal relationship between these  nonoseaeaeonlyasinstruction cases and the use of Prepopik  (r)  has not been established.\n', '\n', '\n', '\n', '     Neurologic,  \n', '\n', '\n', '\n', ' There have been reports of  oselabeledaefromdruguse associated with and without  oselabeledaefromdruguse in  notaecandidatepreexistingconditionorriskfactor     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *   Risk of fluid and electrolyte abnormalities, arrhythmia, seizures, and renal impairment: Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use (  5.1  ,  5.2  ,  5.3  ,  5.4  )",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
78,prepopik,78,2121,2143,"\n', ' *   Risks in patients with renal insufficiency or patients taking concomitant medications that affect renal function:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,prepopik,79,2143,2157,"Use caution, ensure adequate hydration and consider testing (  5.3  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,prepopik,80,2157,2166,"\n', ' *   Mucosal ulcerations:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,prepopik,81,2166,2189,Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease (  5.5  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,prepopik,82,2189,2201,"\n', ' *   Suspected GI obstruction or perforation:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,prepopik,83,2201,2215,"Rule out diagnosis before administration (  4  ,  5.6  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,prepopik,84,2215,2219,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,prepopik,85,2219,2319,"*   Patients at risk for aspiration: Observe during administration (  5.7  ) \n', ' *   Not for direct ingestion: Dissolve and take with additional water (  5.8  ) \n', '    \n', ' \n', '\n', '   5.1 Serious Fluid and Serum Chemistry Abnormalities\n', '\n', '\n', '\n', '  Advise patients to hydrate adequately before, during, and after the use of Prepopik  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
86,prepopik,86,2319,2330,Use caution in patients with  notaecandidatepreexistingconditionorriskfactor when replacing fluids.,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
87,prepopik,87,2330,2375,"If a patient develops significant  nonoseaeaeonlyasinstruction or signs of  nonoseaeaeonlyasinstruction including signs of  nonoseaeaeonlyasinstruction after taking Prepopik  (r)  , consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN) and treat accordingly.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,prepopik,88,2375,2427,"Approximately 20% of patients in both arms (Prepopik  (r)  , 2L of PEG + E plus two * 5-mg bisacodyl tablets) of clinical trials of Prepopik  (r)  had  oselabeledaefromdruguse (changes  oselabeledaefromdruguse  oselabeledaefromdruguse (changes in blood pressure",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,prepopik,89,2427,2447,and/or  oselabeledaefromdruguse  oselabeledaefromdruguse (changes in blood pressure and/or heart rate) on the day of colonoscopy.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,prepopik,90,2447,2461,In clinical trials  nonoseaeaeonlyasinstruction were documented out to seven days post colonoscopy.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,prepopik,91,2461,2532,"[see  Adverse Reactions (6.1  ,  6.2)  ]  \n', '\n', '\n', '\n', '  oselabeledaefromdruguse  oselabeledaefromdruguse can lead to serious adverse events including  oselabeledaefromdruguse or  oselabeledaefromdruguse and  oselabeledaefromdruguse   nonoseaeaeonlyasinstruction and electrolyte  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction should be corrected before treatment with Prepopik  (r)  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,prepopik,92,2532,2645,"In addition, use caution when prescribing Prepopik  (r)  for patients who have conditions or who are using medications that increase the risk for  nonoseaeaeonlyasinstruction and electrolyte  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction or that may increase the risk of adverse events of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  and  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.2 Seizures\n', '\n', '\n', '\n', '  There have been reports of  oselabeledaeclasseffect with the use of bowel preparation products in patients with no prior history of  notaecandidateother  ",1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
93,prepopik,93,2645,2672,"The  oselabeledaeclasseffect cases were associated with  oselabeledaefromdruguse (e.g.,  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect  and  oselabeledaeclasseffect  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,prepopik,94,2672,2868,"The  nonoseaegeneralterm resolved with correction of  nonoseaeaeonlyasinstruction and electrolyte  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', ' Use caution when prescribing Prepopik  (r)  for patients with a history of  notaecandidatepreexistingconditionorriskfactor and in patients at risk of  nonoseaeaeonlyasinstruction  such as patients taking medications that  nonoseaeaeonlyasinstruction (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, patients with known or suspected  notaecandidatepreexistingconditionorriskfactor  [see  Adverse Reactions (6.2)  ]  \n', '\n', '\n', '\n', '    5.3 Use in Patients with Renal Impairment\n', '\n', '\n', '\n', '  As in other magnesium containing bowel preparations, use caution when prescribing Prepopik  (r)  for patients with  notaecandidatepreexistingconditionorriskfactor or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs).",1,1,1,0,0,0,0,0,0,0,0,0,0,0,0
95,prepopik,95,2868,2903,"These patients may be at increased risk for  nonoseaeaeonlyasinstruction  Advise these patients of the importance of adequate hydration before, during and after the use of Prepopik  (r)  .",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,prepopik,96,2903,2924,"Consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,prepopik,97,2924,2994,"In patients with severely  notaecandidatecontraindication  notaecandidatepreexistingconditionorriskfactor ,  nonoseaeaeonlyasinstruction may occur.\n', '\n', '\n', '\n', '    5.4 Cardiac Arrhythmias\n', '\n', '\n', '\n', '  There have been rare reports of serious  oselabeledaeclasseffect associated with the use of ionic osmotic laxative products for bowel preparation.",1,0,1,0,0,0,0,0,0,0,0,1,0,0,0
98,prepopik,98,2994,3039,"Use caution when prescribing Prepopik  (r)  for patients at increased risk of  nonoseaeaeonlyasinstruction (e.g., patients with a history of  notaecandidatepreexistingconditionorriskfactor  uncontrolled  notaecandidatepreexistingconditionorriskfactor  recent  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or  notaecandidatepreexistingconditionorriskfactor .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
99,prepopik,99,3039,3041,Pre-,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
100,prepopik,100,3041,3123,"dose and post-colonoscopy ECGs should be considered in patients at increased risk of serious  nonoseaeaeonlyasinstruction \n', '\n', '\n', '\n', '    5.5 Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis\n', '\n', '\n', '\n', '  Osmotic laxatives may produce  oselabeledaeclasseffect and there have been reports of more serious cases of  oselabeledaeclasseffect requiring hospitalization.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
101,prepopik,101,3123,3141,Concurrent use of additional stimulant laxatives with Prepopik  (r)  may increase this risk.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
102,prepopik,102,3141,3244,"The potential for  nonoseaeaeonlyasinstruction should be considered when interpreting colonoscopy findings in patients with known or suspected  notaecandidatepreexistingconditionorriskfactor  [see  Adverse Reactions (6.2)  ]  \n', '\n', '\n', '\n', '    5.6 Use in Patients with Significant Gastrointestinal Disease\n', '\n', '\n', '\n', '  If  notaecandidatepreexistingconditionorriskfactor  notaecandidatepreexistingconditionorriskfactor obstruction or  notaecandidatepreexistingconditionorriskfactor is suspected, perform appropriate diagnostic studies to rule out these conditions before administering Prepopik  (r)  .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
103,prepopik,103,3244,3301,"Use with caution in patients with severe active  notaecandidatepreexistingconditionorriskfactor \n', '\n', '\n', '\n', '    5.7 Aspiration\n', '\n', '\n', '\n', '  Patients with  notaecandidatepreexistingconditionorriskfactor and patients prone to  notaecandidatepreexistingconditionorriskfactor or  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
104,prepopik,104,3301,3316,notaecandidatepreexistingconditionorriskfactor should be observed during the administration of Prepopik  (r)  .,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
105,prepopik,105,3316,3381,"Use with caution in these patients.\n', '\n', '\n', '\n', '    5.8 Not for Direct Ingestion\n', '\n', '\n', '\n', '  Each packet must be dissolved in 5 ounces of cold water and administered at separate times according to the dosing regimen.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,prepopik,106,3381,3391,Ingestion of additional water is important to patient tolerance.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,prepopik,107,3391,3414,Direct ingestion of the undissolved powder may increase the risk of  nonoseaeaefromofflabel   nonoseaeaefromofflabel   nonoseaeaefromofflabel  and  nonoseaeaefromofflabel '],0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
0,levaquin,0,0,257,"['  6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   The most common reactions (>=3%) were nausea, headache, diarrhea, insomnia, constipation and dizziness (  6.2  ).\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  .\n', '\n', ' \n', '\n', '  6.1 Serious and Otherwise Important Adverse Reactions\n', '\n', '  The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:\n', '\n', ' *   oselabeledaeclasseffect [see  Warnings and Precautions (5.1)  ]  \n', ' *   oselabeledaefromdruguse and  oselabeledaefromdruguse [see  Warnings and Precautions (5.2)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.3)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.4)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.5)  ]  \n', ' *  Other Serious and Sometimes  nonoseaegeneralterm Reactions [see  Warnings and Precautions (5.6)  ]  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
1,levaquin,1,257,264,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,levaquin,2,264,299,"[see  Warnings and Precautions (5.7)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.8)  ]  \n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
3,levaquin,3,299,368,"*    oselabeledaefromdruguse [see  Warnings and Precautions (5.9)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions (5.10)  ]  \n', ' *   oselabeledaefromdruguse in Pediatric Patients [see  Warnings and Precautions (5.11)  ]  \n', ' *   oselabeledaefromdruguse [see  Warnings and Precautions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,levaquin,4,368,389,"(5.12)  ]  \n', ' *   oselabeledaeclasseffect  oselabeledaeclasseffect [see  Warnings and Precautions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,levaquin,5,389,395,(5.13)  ]  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
6,levaquin,6,395,402,"\n', ' *   oselabeledaefromdruguse",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,levaquin,7,402,437,"[see  Warnings and Precautions (5.14)  ]  \n', '    Hypotension has been associated with rapid or bolus intravenous infusion of LEVAQUIN  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,levaquin,8,437,439,LEVAQUIN  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,levaquin,9,439,500,"(r)  should be infused slowly over 60 to 90 minutes, depending on dosage  [see  Dosage and Administration (2.5)  ]  .\n', ' \n', '\n', '  oselabeledaefromdruguse and  oselabeledaefromdruguse have been reported with quinolones, including LEVAQUIN  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,levaquin,10,500,630,"Therefore, adequate hydration of patients receiving LEVAQUIN  (r)  should be maintained to prevent the  nonoseaeaeonlyasinstruction  [see  Dosage and Administration (2.5)  ]  .\n', '\n', '   6.2 Clinical Trial Experience\n', '\n', '  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.\n', '\n', ' The data described below reflect exposure to LEVAQUIN  (r)  in 7537 patients in 29 pooled Phase 3 clinical trials.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,levaquin,11,630,670,"The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,levaquin,12,670,694,Patients were treated with LEVAQUIN  (r)  for a wide variety of infectious diseases  [see  Indications and Usage,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,levaquin,13,694,701,(1)  ]  .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,levaquin,14,701,729,"Patients received LEVAQUIN  (r)  doses of 750 mg once daily, 250 mg once daily, or 500 mg once or twice daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,levaquin,15,729,797,"Treatment duration was usually 3-14 days, and the mean number of days on therapy was 10 days.\n', '\n', ' The overall incidence, type and distribution of adverse reactions was similar in patients receiving LEVAQUIN  (r)  doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,levaquin,16,797,843,"Discontinuation of LEVAQUIN  (r)  due to adverse drug reactions occurred in 4.3% of patients overall, 3.8% of patients treated with the 250 mg and 500 mg doses and 5.4% of patients treated with the 750 mg dose.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
17,levaquin,17,843,896,"The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1.4%), primarily  oselabeledaefromdruguse (0.6%);  oselabeledaefromdruguse (0.4%);  oselabeledaefromdruguse (0.3%); and  oselabeledaefromdruguse (0.2%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,levaquin,18,896,1002,"The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1.2%), primarily  oselabeledaefromdruguse (0.6%),  oselabeledaefromdruguse (0.5%);  oselabeledaefromdruguse (0.3%); and  oselabeledaefromdruguse (0.3%).\n', '\n', ' Adverse reactions occurring in >=1% of LEVAQUIN  (r)  -treated patients and less common adverse reactions, occurring in 0.1 to <1% of LEVAQUIN  (r)  -treated patients, are shown in Table 4 and Table 5, respectively.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,levaquin,19,1002,1028,The most common adverse drug reactions (>=3%) are  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,levaquin,20,1028,1046,"\n', '\n', ' Table 4: Common (>=1%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,levaquin,21,1046,1055,Adverse Reactions Reported in Clinical Trials with LEVAQUIN(r),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,levaquin,22,1055,1059,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,levaquin,23,1059,1074,System/Organ Class                   Adverse Reaction                                      %(N = 7537)     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,levaquin,24,1074,1084,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,levaquin,25,1084,1088,nonoseaegeneralterm         oselabeledaefromdruguse                                                 ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
26,levaquin,26,1088,1090,1          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,levaquin,27,1090,1137,"\n', '    nonoseaegeneralterm               oselabeledaefromdruguse [note: N = 7274]   [see  Warnings and Precautions (5.4)  ]           4          \n', '    nonoseaegeneralterm            oselabeledaefromdruguse  oselabeledaefromdruguse  [see  Warnings and Precautions",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
28,levaquin,28,1137,1157,"(5.4)  ]          63          \n', '    nonoseaegeneralterm     oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
29,levaquin,29,1157,1160,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
30,levaquin,30,1160,1173,"(5.7)  ]           1          \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
31,levaquin,31,1173,1179,nonoseaegeneralterm          oselabeledaefromdruguse                                                     7          ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
32,levaquin,32,1179,1188,"\n', '  oselabeledaefromdruguse                             5                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
33,levaquin,33,1188,1197,"\n', '  oselabeledaefromdruguse                         3                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,levaquin,34,1197,1206,"\n', '  oselabeledaefromdruguse                       2                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,levaquin,35,1206,1215,"\n', '  oselabeledaefromdruguse                             2                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,levaquin,36,1215,1224,"\n', '  oselabeledaefromdruguse                            2                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,levaquin,37,1224,1236,"\n', '    nonoseaegeneralterm     oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
38,levaquin,38,1236,1245,Warnings and Precautions (5.7)  ]   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,levaquin,39,1245,1249,oselabeledaefromdruguse        21          ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,levaquin,40,1249,1258,"\n', '    nonoseaegeneralterm     oselabeledaefromdruguse                                           ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
41,levaquin,41,1258,1259,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,levaquin,42,1259,1262,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,levaquin,43,1262,1270,N = 3758 (women)]    ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,levaquin,44,1270,1281,"\n', '    nonoseaegeneralterm     oselabeledaefromdruguse                                                      1          ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
45,levaquin,45,1281,1299,"\n', '  oselabeledaefromdruguse              1                                                    \n', '  oselabeledaefromdruguse                           1                                                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,levaquin,46,1299,1315,"\n', '        Table 5: Less Common (0.1 to 1%)",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,levaquin,47,1315,1324,Adverse Reactions Reported in Clinical Trials with LEVAQUIN(r),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,levaquin,48,1324,1329,(N = 7537),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,levaquin,49,1329,1341,"\n', ' System/Organ Class                        Adverse Reaction                                               ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,levaquin,50,1341,1351,"\n', '  \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,levaquin,51,1351,1377,"nonoseaegeneralterm              oselabeledaefromdruguse                                             \n', '    nonoseaegeneralterm     oselabeledaefromdruguse hrombocytopeniagranulocytopenia  [see  Warnings and Precautions (5.6)  ]     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
52,levaquin,52,1377,1389,"\n', '    nonoseaegeneralterm                  oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
53,levaquin,53,1389,1401,"Warnings and Precautions (5.6,    5.7)  ]     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,levaquin,54,1401,1414,"\n', '    nonoseaegeneralterm       oselabeledaefromdruguse ypoglycemia  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
55,levaquin,55,1414,1425,Warnings and Precautions (5.12)  ]   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,levaquin,56,1425,1438,"\n', '    nonoseaegeneralterm                    oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
57,levaquin,57,1438,1443,oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,levaquin,58,1443,1446,[note:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,levaquin,59,1446,1454,N = 7274]   [see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,levaquin,60,1454,1469,Warnings and Precautions (5.4)  ]   oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,levaquin,61,1469,1483,"\n', '    nonoseaegeneralterm                 oselabeledaefromdruguse  oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
62,levaquin,62,1483,1506,Warnings and Precautions (5.4)  ]   oselabeledaefromdruguse  [see  Warnings and Precautions (5.3)  ]   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,levaquin,63,1506,1509,oselabeledaefromdruguse  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,levaquin,64,1509,1518,oniahyper oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,levaquin,65,1518,1527,"\n', '    nonoseaegeneralterm     oselabeledaefromdruguse                                                      ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
66,levaquin,66,1527,1547,"\n', '    nonoseaegeneralterm                        oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   \n', '    ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
67,levaquin,67,1547,1549,nonoseaegeneralterm                       ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
68,levaquin,68,1549,1551,oselabeledaefromdruguse                                                      ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
69,levaquin,69,1551,1564,"\n', '    nonoseaegeneralterm               oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
70,levaquin,70,1564,1568,oselabeledaefromdruguse  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,levaquin,71,1568,1573,oselabeledaefromdruguse  oselabeledaefromdruguse   C.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,levaquin,72,1573,1582,difficile   oselabeledaefromdruguse  oselabeledaefromdruguse  [see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,levaquin,73,1582,1591,Warnings and Precautions (5.9)  ]     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,levaquin,74,1591,1604,"\n', '    nonoseaegeneralterm                  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
75,levaquin,75,1604,1609,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,levaquin,76,1609,1616,nonoseaegeneralterm     oselabeledaefromdruguse  [see  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
77,levaquin,77,1616,1619,Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,levaquin,78,1619,1630,"(5.7)  ]             \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,levaquin,79,1630,1639,nonoseaegeneralterm     oselabeledaefromdruguse  oselabeledaefromdruguse  [see  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
80,levaquin,80,1639,1652,Warnings and Precautions (5.2)  ]   oselabeledaefromdruguse  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,levaquin,81,1652,1666,"\n', '    nonoseaegeneralterm              oselabeledaefromdruguse  oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
82,levaquin,82,1666,1680,"Warnings and Precautions (5.6)  ]     \n', '        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,levaquin,83,1680,1717,"In clinical trials using multiple-dose therapy,  oselabeledaefromdruguse  including  oselabeledaefromdruguse and  oselabeledaefromdruguse  have been noted in patients undergoing treatment with quinolones, including LEVAQUIN  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
84,levaquin,84,1717,1774,"The relationship of the drugs to these events is not presently established.\n', ' \n', '\n', '   6.3 Postmarketing Experience\n', '\n', '  Table 6 lists adverse reactions that have been identified during post-approval use of LEVAQUIN  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,levaquin,85,1774,1893,"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.\n', '\n', ' Table 6: Postmarketing Reports Of Adverse Drug Reactions \n', ' System/Organ Class                        Adverse Reaction                                               \n', '  \n', '    nonoseaegeneralterm     oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  [see  Warnings and Precautions (5.6)  ]   oselabeledaefromdruguse   \n', '    nonoseaegeneralterm                  oselabeledaefromdruguse  sometimes  nonoseaegeneralterm including:   oselabeledaefromdruguse anaphylactoid  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
86,levaquin,86,1893,1895,oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
87,levaquin,87,1895,1898,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,levaquin,88,1898,1911,"Warnings and Precautions (5.6  ,  5.7)  ]     ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,levaquin,89,1911,1932,"\n', '    nonoseaegeneralterm                    oselabeledaefromdruguse  oselabeledaefromdruguse solated reports of  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
90,levaquin,90,1932,1935,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,levaquin,91,1935,1944,Warnings and Precautions (5.4)  ]     ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
92,levaquin,92,1944,1956,"\n', '    nonoseaegeneralterm                 oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
93,levaquin,93,1956,1986,Warnings and Precautions (5.5)  ]   oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse (may be irreversible)  [see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
94,levaquin,94,1986,2036,"(5.3)  ]  isolated reports of  oselabeledaefromdruguse  oselabeledaefromdruguse (EEG) oselabeledaefromdruguse  oselabeledaefromdruguse  [see  Warnings and Precautions (5.4)  ]     \n', '    nonoseaegeneralterm                            oselabeledaefromdruguse  oselabeledaefromdruguse  including  oselabeledaefromdruguse isual  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
95,levaquin,95,2036,2040,oselabeledaefromdruguse  oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,levaquin,96,2040,2069,"\n', '    nonoseaegeneralterm              oselabeledaefromdruguse  oselabeledaefromdruguse                                             \n', '    nonoseaegeneralterm                       isolated reports of  oselabeledaefromdruguse  oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
97,levaquin,97,2069,2080,Warnings and Precautions (5.10)  ]   oselabeledaefromdruguse   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,levaquin,98,2080,2081,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
99,levaquin,99,2081,2089,"', '    nonoseaegeneralterm                       oselabeledaefromdruguse                                                 ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
100,levaquin,100,2089,2105,"\n', '    nonoseaegeneralterm    isolated reports of  oselabeledaefromdruguse  [see  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
101,levaquin,101,2105,2150,"Warnings and Precautions (5.6)  ]     \n', '    nonoseaegeneralterm                  oselabeledaefromdruguse (including  nonoseaegeneralterm cases) oselabeledaefromdruguse  oselabeledaefromdruguse  [see  Warnings and Precautions (5.6  ),  (5.8)  ]     ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
102,levaquin,102,2150,2172,"\n', '    nonoseaegeneralterm     oselabeledaefromdruguse to include:   oselabeledaefromdruguse   oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse   oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
103,levaquin,103,2172,2175,[see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
104,levaquin,104,2175,2194,Warnings and Precautions (5.6)  ]   oselabeledaefromdruguse  oselabeledaefromdruguse  [see  Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
105,levaquin,105,2194,2200,(5.13)  ]   ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
106,levaquin,106,2200,2207,"oselabeledaefromdruguse   \n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
107,levaquin,107,2207,2214,nonoseaegeneralterm     oselabeledaefromdruguse  [see  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
108,levaquin,108,2214,2234,"Warnings and Precautions (5.2)  ]   oselabeledaefromdruguse  oselabeledaefromdruguse injury, including  oselabeledaefromdruguse  oselabeledaefromdruguse   ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
109,levaquin,109,2234,2239,"\n', '    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
110,levaquin,110,2239,2277,"nonoseaegeneralterm              oselabeledaefromdruguse  [see  Warnings and Precautions (5.6)  ]     \n', '    nonoseaegeneralterm     oselabeledaefromdruguse  oselabeledaefromdruguse                                     \n', '    nonoseaegeneralterm                           oselabeledaefromdruguse  oselabeledaefromdruguse  ",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
111,levaquin,111,2277,2278,oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
112,levaquin,112,2278,2279,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
113,levaquin,113,2279,2290,"', '\n', '    BOXED WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
114,levaquin,114,2290,2292,WARNING:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
115,levaquin,115,2292,2312,"SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
116,levaquin,116,2312,2323,"GRAVIS\n', '\n', '    WARNING:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
117,levaquin,117,2323,2343,"SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
118,levaquin,118,2343,2400,"\n', '\n', '    *  Fluoroquinolones, including LEVAQUIN(r), have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1)], including: oselabeledaefromdruguse and  oselabeledaefromdruguse [see Warnings and Precautions (5.2)]",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
119,levaquin,119,2400,2416,oselabeledaefromdruguse [see Warnings and Precautions (5.3)] oselabeledaefromdruguse [see Warnings and Precautions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
120,levaquin,120,2416,2440,"(5.4)]Discontinue LEVAQUIN immediately and avoid the use of fluoroquinolones, including LEVAQUIN, in patients who experience any of these serious adverse reactions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
121,levaquin,121,2440,2449,[see Warnings and Precautions (5.1)],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
122,levaquin,122,2449,2492,"\n', ' *  Fluoroquinolones, including LEVAQUIN(r), may  oselabeledaefromdruguse in patients with  notaecandidatepreexistingconditionorriskfactor  Avoid LEVAQUIN(r) in patients with a known history of  notaecandidatepreexistingconditionorriskfactor [see Warnings and Precautions (5.5)].",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
123,levaquin,123,2492,2498,"\n', ' *  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
124,levaquin,124,2498,2540,"Because fluoroquinolones, including LEVAQUIN, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)], reserve LEVAQUIN for use in patients who have no alternative treatment options for the following indications:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
125,levaquin,125,2540,2562,Uncomplicated  notaecandidateindication [see Indications and Usage (1.12)] notaecandidateindication [see Indications and Usage (1.13)],0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
126,levaquin,126,2562,2569,notaecandidateindication    5 WARNINGS AND PRECAUTIONS\n',0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
127,levaquin,127,2569,2607,", '\n', '   EXCERPT:    *  Anaphylactic reactions and allergic skin reactions, serious, occasionally fatal, may occur after first dose (  4   ,   5.7  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
128,levaquin,128,2607,2611,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
129,levaquin,129,2611,2653,"*  Hematologic (including agranulocytosis, thrombocytopenia), and renal toxicities may occur after multiple doses (  5.6  ) \n', ' *  Hepatotoxicity: Severe, and sometimes fatal, hepatotoxicity has been reported.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
130,levaquin,130,2653,2667,Discontinue immediately if signs and symptoms of hepatitis occur (  5.8  ),0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
131,levaquin,131,2667,2687,"\n', ' *   Clostridium difficile -associated colitis: evaluate if diarrhea occurs (  5.9  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
132,levaquin,132,2687,2691,"\n', '",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
133,levaquin,133,2691,2709,*  Prolongation of the QT interval and isolated cases of torsade de pointes have been reported.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
134,levaquin,134,2709,2739,"Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval (  5.10  ,  8.5  )",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
135,levaquin,135,2739,2816,"\n', '    \n', ' \n', '\n', '   5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects\n', '\n', '   Fluoroquinolones, including LEVAQUIN, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
136,levaquin,136,2816,2852,Commonly seen adverse reactions include  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  severe  oselabeledaefromdruguse  and  oselabeledaefromdruguse .,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
137,levaquin,137,2852,2864,These reactions can occur within hours to weeks after starting LEVAQUIN.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
138,levaquin,138,2864,2901,"Patients of any age or without pre-existing risk factors have experienced these adverse reactions [ see  Warnings and Precautions (5.2  ,  5.3  ,  5.4)    ].  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
139,levaquin,139,2901,2925,"\n', '\n', '  Discontinue LEVAQUIN immediately at the first signs or symptoms of any serious adverse reaction.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
140,levaquin,140,2925,2953,"In addition, avoid the use of fluoroquinolones, including LEVAQUIN, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
141,levaquin,141,2953,3022,"\n', '\n', '    5.2 Tendinitis and Tendon Rupture\n', '\n', '  Fluoroquinolones, including LEVAQUIN  (r)  , have been associated with an increased risk of  oselabeledaefromdruguse and  oselabeledaefromdruguse in all ages [see  Warnings and Precautions (5.1)  and  Adverse Reactions (6.2)  ]  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
142,levaquin,142,3022,3060,"This adverse reaction most frequently involves the Achilles tendon And has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendon sites.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
143,levaquin,143,3060,3086,oselabeledaefromdruguse or  oselabeledaefromdruguse can occur within hours or days of starting LEVAQUIN or as long as several months after completion of fluoroquinolone therapy.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
144,levaquin,144,3086,3136,"oselabeledaefromdruguse and  oselabeledaefromdruguse can occur bilaterally.\n', '\n', ' The risk of developing  oselabeledaefromdruguse and  oselabeledaefromdruguse is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
145,levaquin,145,3136,3184,"Other factors that may independently increase the risk of  nonoseaeaeonlyasinstruction include strenuous physical activity,  notaecandidatepreexistingconditionorriskfactor  and previous  notaecandidatepreexistingconditionorriskfactor such as  notaecandidatepreexistingconditionorriskfactor   oselabeledaeclasseffect and  oselabeledaeclasseffect have been reported in patients taking fluoroquinolones who do not have the above risk factors.",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
146,levaquin,146,3184,3256,"Discontinue LEVAQUIN  (r)  immediately if the patient experiences  nonoseaemanifestationorcomplication  swelling, inflammation or rupture  nonoseaemanifestationorcomplication  nonoseaeaeonlyasinstruction  inflammation or rupture  nonoseaeaeonlyasinstruction  nonoseaemanifestationorcomplication or rupture  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  Patients should be advised to rest at the first sign of  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction  and to contact their healthcare provider regarding changing to a non-quinolone antimicrobial drug.",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
147,levaquin,147,3256,3368,"Avoid LEVAQUIN in patients who have a history of  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor [see  Adverse Reactions (6.3)    ;   Patient Counseling Information (17)  ]  .\n', '\n', '    5.3 Peripheral Neuropathy\n', '\n', '  Fluoroquinolones, including LEVAQUIN, have been associated with an increased risk of  oselabeledaefromdruguse  Cases of  oselabeledaefromdruguse or sensorimotor  oselabeledaefromdruguse  oselabeledaefromdruguse affecting small and/or large axons resulting in  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication and  nonoseaemanifestationorcomplication have been reported in patients receiving fluoroquinolones, including LEVAQUIN  (r)  .",0,0,1,0,1,0,0,0,0,0,0,0,0,0,0
148,levaquin,148,3368,3553,"Symptoms may occur soon after initiation of LEVAQUIN  (r)  and may be irreversible in some patients [see  Warnings and Precautions (5.1)  and  Adverse Reactions (6.1  ,  6.2)  ]  .\n', '\n', ' Discontinue LEVAQUIN  (r)  immediately if the patient experiences symptoms of  nonoseaeaeonlyasinstruction including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and/or  nonoseaemanifestationorcomplication or other  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication including  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication including light touch,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication including light touch, pain,  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication including light touch, pain, temperature, position  nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication sensation including light touch, pain, temperature, position sense, and  nonoseaemanifestationorcomplication  nonoseaeaeonlyasinstruction including light touch, pain, temperature, position sense, and  nonoseaemanifestationorcomplication  Avoid fluoroquinolones, including LEVAQUIN, in patients who have previously experienced  notaecandidatepreexistingconditionorriskfactor [see  Adverse Reactions (6)    ,   Patient Counseling Information (17",1,0,1,0,1,0,0,0,0,0,0,0,0,0,0
149,levaquin,149,3553,3608,")  ]  .\n', '\n', '    5.4 Central Nervous System Effects\n', '\n', '   Fluoroquinolones, including LEVAQUIN, have been associated with an increased risk of  oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse (including  oselabeledaefromdruguse  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
150,levaquin,150,3608,3672,"Fluoroquinolones may also cause  oselabeledaeclasseffect which may lead to  oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect   oselabeledaeclasseffect  and  oselabeledaeclasseffect   oselabeledaefromdruguse  and  oselabeledaefromdruguse  oselabeledaeclasseffect may also occur, especially in patients with a medical history of  notaecandidatepreexistingconditionorriskfactor  or an underlying risk factor for  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
151,levaquin,151,3672,3681,These reactions may occur following the first dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
152,levaquin,152,3681,3702,"If these reactions occur in patients receiving LEVAQUIN  (r)  , discontinue LEVAQUIN and institute appropriate measures.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
153,levaquin,153,3702,3774,"As with other fluoroquinolones, LEVAQUIN  (r)  should be used with caution in patients with a known or suspected  notaecandidatepreexistingconditionorriskfactor that may predispose them to  nonoseaeaeonlyasinstruction or  nonoseaeaeonlyasinstruction (e.g., severe  notaecandidatepreexistingconditionorriskfactor   notaecandidatepreexistingconditionorriskfactor  or in the presence of other risk factors that may predispose them to  notaecandidatepreexistingconditionorriskfactor or  notaecandidatepreexistingconditionorriskfactor (e.g., certain drug therapy,  notaecandidatepreexistingconditionorriskfactor .",1,0,1,0,0,0,0,0,0,0,0,0,0,0,0
154,levaquin,154,3774,3788,[see  Adverse Reactions (6)    ;   Drug Interactions (,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
155,levaquin,155,3788,3808,"7.4    ,   7.5)    ;   Patient Counseling Information (17)  ]  .  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
156,levaquin,156,3808,3849,"\n', '\n', '    5.5  oselabeledaefromdruguse \n', '  Fluoroquinolones, including LEVAQUIN  (r)  , have neuromuscular blocking activity and may  oselabeledaefromdruguse in patients with  notaecandidatepreexistingconditionorriskfactor  ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
157,levaquin,157,3849,3911,"Postmarketing serious adverse reactions including  nonoseaegeneralterm and requirement for ventilatory support, have been associated with fluoroquinolone use in patients with  notaecandidatepreexistingconditionorriskfactor  Avoid LEVAQUIN  (r)  in patients with a known history of  notaecandidatepreexistingconditionorriskfactor [see  Adverse Reactions (6.3)    ;   Patient Counseling Information (17)  ].  ",0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
158,levaquin,158,3911,3977,"\n', '\n', '    5.6 Other Serious and Sometimes Fatal Adverse Reactions\n', '\n', '  Other serious and sometimes  nonoseaegeneralterm adverse reactions, some due to  oselabeledaefromdruguse  and some due to uncertain etiology, have been reported rarely in patients receiving therapy with fluoroquinolones, including LEVAQUIN  (r)  .",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
159,levaquin,159,3977,3992,These events may be severe and generally occur following the administration of multiple doses.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
160,levaquin,160,3992,4220,"Clinical manifestations may include one or more of the following:\n', '\n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse  or severe  oselabeledaefromdruguse (e.g.,  oselabeledaefromdruguse   oselabeledaefromdruguse ; \n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  \n', ' *   oselabeledaefromdruguse  \n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse insufficiency or  oselabeledaefromdruguse  oselabeledaefromdruguse or failure; \n', ' *   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse necrosis or  oselabeledaefromdruguse  oselabeledaefromdruguse or failure; \n', ' *   oselabeledaefromdruguse  including  oselabeledaeclasseffect and  oselabeledaeclasseffect   oselabeledaefromdruguse  including  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and/or other  oselabeledaefromdruguse  \n', '    Discontinue LEVAQUIN immediately at the first appearance of  nonoseaeaeonlyasinstruction   nonoseaeaeonlyasinstruction  or any other sign of  nonoseaeaeonlyasinstruction and institute supportive measures [see  Adverse Reactions (6)  ;  Patient Counseling Information (17)  ]  .\n', ' \n', '\n', '    5.7 Hypersensitivity Reactions\n', '\n', '  Serious and occasionally  nonoseaemanifestationorcomplication  oselabeledaefromdruguse and/or  oselabeledaefromdruguse have been reported in patients receiving therapy with fluoroquinolones, including LEVAQUIN  (r)  .",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
161,levaquin,161,4220,4229,These reactions often occur following the first dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
162,levaquin,162,4229,4443,"Some reactions have been accompanied by  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication (including  nonoseaemanifestationorcomplication  laryngeal, throat, or facial edema/ nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  throat, or facial edema/ nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication  or facial edema/ nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication edema/ nonoseaemanifestationorcomplication  nonoseaemanifestationorcomplication swelling),  nonoseaemanifestationorcomplication (including  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and  nonoseaemanifestationorcomplication ,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  and other serious  nonoseaemanifestationorcomplication  LEVAQUIN  (r)  should be discontinued immediately at the first appearance of a  nonoseaeaeonlyasinstruction or any other sign of  nonoseaeaeonlyasinstruction  Serious acute  nonoseaeaeonlyasinstruction may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see  Adverse Reactions (6)  ;  Patient Counseling Information (17)  ]  .\n', '\n', '    5.8 Hepatotoxicity\n', '\n', '  Post-marketing reports of severe  oselabeledaefromdruguse (including  oselabeledaefromdruguse and  nonoseaegeneralterm events) have been received for patients treated with LEVAQUIN  (r).  ",1,1,0,0,1,0,0,0,0,0,0,0,0,0,0
163,levaquin,163,4443,4459,"No evidence of serious  nonoseaenegation was detected in clinical trials of over 7,000 patients.",0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
164,levaquin,164,4459,4479,Severe  oselabeledaefromdruguse generally occurred within 14 days of initiation of therapy and most cases occurred within 6 days.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
165,levaquin,165,4479,4504,Most cases of severe  nonoseaeaeonlyasinstruction were not associated with  nonoseaenegation [see  Warnings and Precautions (5.6)  ]  .,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
166,levaquin,166,4504,4571,The majority of  nonoseaegeneralterm  nonoseaeaeonlyasinstruction reports occurred in patients 65 years of age or older and most were not associated with  nonoseaenegation  LEVAQUIN  (r)  should be discontinued immediately if the patient develops signs and symptoms of  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6)  ;  Patient Counseling Information (17)  ].  ,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0
167,levaquin,167,4571,4696,"\n', '\n', '    5.9 Clostridium difficile-Associated Diarrhea\n', '\n', '    oselabeledaefromdruguse  has been reported with use of nearly all antibacterial agents, including LEVAQUIN  (r)  , and may range in severity from mild  oselabeledaefromdruguse to  nonoseaegeneralterm  oselabeledaefromdruguse  Treatment with antibacterial agents  nonoseaeaeonlyasinstruction leading to  nonoseaeaeonlyasinstruction  .\n', '\n', '   nonoseaeaeonlyasinstruction  produces toxins A and B which contribute to the development of  nonoseaeaeonlyasinstruction  Hypertoxin producing strains of  nonoseaeaeonlyasinstruction  cause increased morbidity and  nonoseaegeneralterm  as these  nonoseaeaeonlyasinstruction can be refractory to antimicrobial therapy and may require colectomy.  ",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
168,levaquin,168,4696,4712,nonoseaeaeonlyasinstruction must be considered in all patients who present with  nonoseaeaeonlyasinstruction following antibiotic use.,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
169,levaquin,169,4712,4764,"Careful medical history is necessary since  nonoseaeaeonlyasinstruction has been reported to occur over two months after the administration of antibacterial agents.\n', '\n', ' If  nonoseaeaeonlyasinstruction is suspected or confirmed, ongoing antibiotic use not directed against  nonoseaeaeonlyasinstruction  may need to be discontinued.",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
170,levaquin,170,4764,4859,"Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of  nonoseaeaeonlyasinstruction  , and surgical evaluation should be instituted as clinically indicated [see  Adverse Reactions (6.2)    ,   Patient Counseling Information (17)  ]  .\n', '\n', '    5.10 Prolongation of the QT Interval\n', '\n', '  Some fluoroquinolones, including LEVAQUIN  (r)  , have been associated with  oselabeledaefromdruguse on the electrocardiogram and infrequent cases of  oselabeledaefromdruguse  ",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
171,levaquin,171,4859,4884,"Rare cases of  oselabeledaefromdruguse have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including LEVAQUIN  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
172,levaquin,172,4884,4928,"LEVAQUIN  (r)  should be avoided in patients with known  notaecandidatepreexistingconditionorriskfactor  patients with uncorrected  notaecandidatepreexistingconditionorriskfactor  and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
173,levaquin,173,4928,5047,"Elderly patients may be more susceptible to  nonoseaeaeonlyasinstruction [see  Adverse Reactions (6.3)    ,   Use in Specific Populations (8.5)    , and   Patient Counseling Information (17)  ]  .\n', '\n', '    5.11 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals\n', '\n', '  LEVAQUIN  (r)  is indicated in pediatric patients (6 months of age and older) only for the prevention of  notaecandidateindication (post-exposure) and for  notaecandidateindication [see  Indications and Usage (1.7    ,   1.8)    ].",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
174,levaquin,174,5047,5083,An increased incidence of  oselabeledaefromdruguse ( oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse  compared to controls has been observed in pediatric patients receiving LEVAQUIN  (r)   [see  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
175,levaquin,175,5083,5096,"Use in Specific Populations (8.4)  ]  .\n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
176,levaquin,176,5096,5243,"'\n', ' In immature rats and dogs, the oral and intravenous administration of levofloxacin resulted in increased  nonoseaeaeanimal  Histopathological examination of the weight-bearing joints of immature dogs dosed with levofloxacin revealed persistent  nonoseaeaeanimal  Other fluoroquinolones also produce similar  nonoseaeaeanimal and other signs of  nonoseaeaeanimal in immature animals of various species [see  Animal Toxicology and/or Pharmacology (13.2)  ]  .\n', '\n', '    5.12 Blood Glucose Disturbances\n', '\n', '  As with other fluoroquinolones,  oselabeledaefromdruguse  including symptomatic  oselabeledaefromdruguse  and hypo oselabeledaefromdruguse  oselabeledaefromdruguse  have been reported with LEVAQUIN  (r)  , usually in diabetic patients receiving concomitant treatment with an oral  nonoseaeaeonlyasinstruction (e.g., glyburide) or with insulin.",1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
177,levaquin,177,5243,5255,"In these patients, careful monitoring of blood glucose is recommended.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
178,levaquin,178,5255,5337,"If a  nonoseaeaeonlyasinstruction reaction occurs in a patient being treated with LEVAQUIN  (r)  , LEVAQUIN  (r)  should be discontinued and appropriate therapy should be initiated immediately [see  Adverse Reactions (6.2)    ;   Drug Interactions (7.3)    ;   Patient Counseling Information (17)  ]  .\n', '\n', '    5.13 Photosensitivity/Phototoxicity\n', '\n',",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
179,levaquin,179,5337,5350,'  Moderate to severe  oselabeledaeclasseffect phototoxicity  oselabeledaeclasseffect  oselabeledaeclasseffect  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
180,levaquin,180,5350,5421,"the latter of which may manifest as exaggerated  nonoseaemanifestationorcomplication (e.g.,  nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication   nonoseaemanifestationorcomplication  involving areas exposed to light (typically the face, ""V"" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of fluoroquinolones after sun or UV light exposure.",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0
181,levaquin,181,5421,5434,"Therefore, excessive exposure to these sources of light should be avoided.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
182,levaquin,182,5434,5528,"Drug therapy should be discontinued if  nonoseaeaeonlyasinstruction  nonoseaeaeonlyasinstruction occurs [see  Adverse Reactions (6.3)    ;   Patient Counseling Information (17)  ]  .\n', '\n', '    5.14 Development of Drug Resistant Bacteria\n', '\n', '  Prescribing LEVAQUIN  (r)  in the absence of a proven or strongly suspected  nonoseaeaeonlyasinstruction or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the  oselabeledaefromdruguse ']",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
0,myrbetriq,0,0,92,"['    6 ADVERSE REACTIONS\n', '\n', '  EXCERPT:   Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache (  6.1  ).\n', '\n', '\n', '\n', '   To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
1,myrbetriq,1,92,129,"\n', '\n', '\n', '\n', ' \n', '\n', '  6.1 Clinical Trials Experience\n', '\n', '  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
2,myrbetriq,2,129,250,"Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.\n', '\n', '\n', '\n', ' In three, 12 week, double-blind, placebo-controlled, safety and efficacy studies in patients with  notaecandidateindication (Studies 1, 2, and 3), MYRBETRIQ  (r)  was evaluated for safety in 2736 patients  [see  Clinical Studies  (  14  )]  .",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
3,myrbetriq,3,250,258,Study 1 also included an active control.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
4,myrbetriq,4,258,306,"For the combined Studies 1, 2, and 3, 432 patients received MYRBETRIQ  (r)  25 mg, 1375 received MYRBETRIQ  (r)  50 mg, and 929 received MYRBETRIQ  (r)  100 mg once daily.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
5,myrbetriq,5,306,428,"In these studies, the majority of the patients were Caucasian (94%), and female (72%) with a mean age of 59 years (range 18 to 95 years).\n', '\n', '\n', '\n', ' MYRBETRIQ  (r)  was also evaluated for safety in 1632 patients who received MYRBETRIQ  (r)  50 mg once daily (n=812 patients) or MYRBETRIQ  (r)  100 mg (n=820 patients) in a 1 year, randomized, fixed dose, double-blind, active controlled, safety study in patients with  notaecandidateindication (Study 4).",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
6,myrbetriq,6,428,447,"Of these patients, 731 received MYRBETRIQ  (r)  in a previous 12 week study.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
7,myrbetriq,7,447,676,"In Study 4, 1385 patients received MYRBETRIQ  (r)  continuously for at least 6 months, 1311 patients received MYRBETRIQ  (r)  for at least 9 months, and 564 patients received MYRBETRIQ  (r)  for at least 1 year.\n', '\n', '\n', '\n', ' The most frequent adverse events (0.2%) leading to discontinuation in Studies 1, 2 and 3 for the 25 mg or 50 mg dose were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '\n', '\n', '  oselabeledaefromdruguse (0.2%) and  oselabeledaefromdruguse (0.1%) were reported as serious adverse events by more than 1 patient and at a rate greater than placebo.\n', '\n', '\n', '\n', '   Table 1  lists adverse reactions, derived from all adverse events, that were reported in Studies 1, 2 and 3 at an incidence greater than placebo and in 1% or more of patients treated with MYRBETRIQ  (r)  25 mg or 50 mg once daily for up to 12 weeks.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
8,myrbetriq,8,676,710,The most commonly reported adverse reactions (greater than 2% of MYRBETRIQ  (r)  patients and greater than placebo) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
9,myrbetriq,9,710,711,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
10,myrbetriq,10,711,756,"', '\n', '\n', '\n', ' Table 1: Percentages of Patients with Adverse Reactions, Derived from All Adverse Events, Exceeding Placebo Rate and Reported by 1% or More Patients Treated With MYRBETRIQ(r",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
11,myrbetriq,11,756,762,) 25 mg or 50 mg,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
12,myrbetriq,12,762,801,"Once Daily in Studies 1, 2, and 3 \n', '                                 Placebo  (%)           MYRBETRIQ(r) 25 mg  (%)    MYRBETRIQ(r) 50 mg  (%)    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
13,myrbetriq,13,801,810,"\n', '  Number of Patients             ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
14,myrbetriq,14,810,814,1380                   432                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
15,myrbetriq,15,814,816,1375                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
16,myrbetriq,16,816,843,"\n', '   oselabeledaefromdruguse ncludes reports of  oselabeledaefromdruguse  and  oselabeledaefromdruguse  occurring predominantly in subjects with baseline  notaecandidatepreexistingconditionorriskfactor     7.6                    ",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
17,myrbetriq,17,843,845,11.3                       ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
18,myrbetriq,18,845,847,7.5                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
19,myrbetriq,19,847,860,"\n', '   oselabeledaefromdruguse                2.5                    3.5                        3.9                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
20,myrbetriq,20,860,867,"\n', '   oselabeledaefromdruguse        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
21,myrbetriq,21,867,873,1.8                    4.2                        2.9                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
22,myrbetriq,22,873,882,"\n', '   oselabeledaefromdruguse                       3.0                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
23,myrbetriq,23,882,886,2.1                        3.2                        ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
24,myrbetriq,24,886,895,"\n', '   oselabeledaefromdruguse                   1.4                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
25,myrbetriq,25,895,912,"1.6                        1.6                        \n', '   oselabeledaefromdruguse    1.7                    2.1                        1.5                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
26,myrbetriq,26,912,921,"\n', '   oselabeledaefromdruguse                     1.1                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
27,myrbetriq,27,921,947,"1.6                        1.3                        \n', '   oselabeledaefromdruguse                       1.3                    1.2                        1.5                        \n', '   oselabeledaefromdruguse                    0.6                    ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
28,myrbetriq,28,947,977,"1.6                        1.2                        \n', '   oselabeledaefromdruguse                 0.7                    1.4                        0.6                        \n', '   oselabeledaefromdruguse                        1.0                    1.4                        1.2                        ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
29,myrbetriq,29,977,1040,"\n', '          Other adverse reactions reported by less than 1% of patients treated with MYRBETRIQ  (r)  in Studies 1, 2, or 3 included:\n', ' \n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse  [see  Clinical Pharmacology  (  12.2  )]",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
30,myrbetriq,30,1040,1047,nonoseaegeneralterm    oselabeledaefromdruguse  [see  ,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
31,myrbetriq,31,1047,1056,Clinical Pharmacology  (  12.2  )],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
32,myrbetriq,32,1056,1107,nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm  :  oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   nonoseaegeneralterm    oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
33,myrbetriq,33,1107,1108,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
34,myrbetriq,34,1108,1160,"', '\n', '\n', '   Table 2  lists the rates of the most commonly reported adverse reactions, derived from all adverse events in patients treated with MYRBETRIQ  (r)  50 mg for up to 52 weeks in Study 4.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
35,myrbetriq,35,1160,1273,"The most commonly reported adverse reactions (>3% of MYRBETRIQ  (r)  patients) were  oselabeledaefromdruguse   oselabeledaefromdruguse   oselabeledaefromdruguse  and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' Table 2: Percentages of Patients with Adverse Reactions, Derived from all Adverse Events, Reported by Greater Than 2% of Patients Treated With MYRBETRIQ(r) 50 mg Once Daily in Study 4 \n', '                                     MYRBETRIQ(r) 50 mg  (%)            Active Control  (%)                \n', '  Number of Patients                 812                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
36,myrbetriq,36,1273,1275,812                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
37,myrbetriq,37,1275,1286,"\n', '   oselabeledaefromdruguse                       9.2                                9.6                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
38,myrbetriq,38,1286,1295,"\n', '   oselabeledaefromdruguse            5.9                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
39,myrbetriq,39,1295,1297,6.4                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
40,myrbetriq,40,1297,1306,"\n', '   oselabeledaefromdruguse                           4.1                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
41,myrbetriq,41,1306,1308,2.5                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
42,myrbetriq,42,1308,1317,"\n', '   oselabeledaefromdruguse                    3.9                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
43,myrbetriq,43,1317,1319,3.1                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
44,myrbetriq,44,1319,1328,"\n', '   oselabeledaefromdruguse                          2.8                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
45,myrbetriq,45,1328,1330,1.6                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
46,myrbetriq,46,1330,1341,"\n', '   oselabeledaefromdruguse                       2.8                                2.7                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
47,myrbetriq,47,1341,1348,"\n', '   oselabeledaefromdruguse                          ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
48,myrbetriq,48,1348,1350,2.8                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
49,myrbetriq,49,1350,1352,8.6                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
50,myrbetriq,50,1352,1361,"\n', '   oselabeledaefromdruguse                          2.7                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
51,myrbetriq,51,1361,1363,2.6                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
52,myrbetriq,52,1363,1372,"\n', '   oselabeledaefromdruguse                          2.7                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
53,myrbetriq,53,1372,1374,1.5                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
54,myrbetriq,54,1374,1383,"\n', '   oselabeledaefromdruguse                          2.6                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
55,myrbetriq,55,1383,1385,3.4                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
56,myrbetriq,56,1385,1394,"\n', '   oselabeledaefromdruguse                         2.1                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
57,myrbetriq,57,1394,1396,2.0                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
58,myrbetriq,58,1396,1405,"\n', '   oselabeledaefromdruguse                           2.1                                ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
59,myrbetriq,59,1405,1407,2.3                                ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
60,myrbetriq,60,1407,1412,"\n', '         ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
61,myrbetriq,61,1412,1422,"In Study 4, in patients treated with MYRBETRIQ  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
62,myrbetriq,62,1422,1509,"(r)  50 mg once daily, adverse reactions leading to discontinuation reported by more than 2 patients and at a rate greater than active control included:  oselabeledaefromdruguse (0.9%),  oselabeledaefromdruguse (0.6%),  oselabeledaefromdruguse (0.5%),  oselabeledaefromdruguse (0.5%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%),  oselabeledaefromdruguse (0.4%), and  oselabeledaefromdruguse (0.4%).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
63,myrbetriq,63,1509,1537,Serious adverse events reported by at least 2 patients and exceeding active control included  oselabeledaefromdruguse (0.4%) and  oselabeledaefromdruguse (0.2%).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
64,myrbetriq,64,1537,1544,Serum  oselabeledaefromdruguse AST  oselabeledaefromdruguse  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
65,myrbetriq,65,1544,1592,"oselabeledaefromdruguse from baseline by greater than 10-fold in 2 patients (0.3%) taking MYRBETRIQ  (r)  50 mg, and these markers subsequently returned to baseline while both patients continued MYRBETRIQ  (r)  .\n', ' \n',",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
66,myrbetriq,66,1592,1648,"'\n', ' In Study 4, serious adverse events of neoplasm were reported by 0.1%, 1.3%, and 0.5% of patients treated with MYRBETRIQ  (r)  50 mg, MYRBETRIQ  (r)  100 mg and active control once daily, respectively.  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
67,myrbetriq,67,1648,1901,"oselabeledaefromdruguse reported by 2 patients treated with MYRBETRIQ  (r)  100 mg included  oselabeledaefromdruguse   oselabeledaefromdruguse and  oselabeledaefromdruguse \n', '\n', '\n', '\n', ' In a separate clinical study in Japan, a single case was reported as  nonoseaeaefromdruginteraction with  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction serum ALT,  nonoseaeaefromdruginteraction  nonoseaeaefromdruginteraction serum ALT, AST and  nonoseaeaefromdruginteraction in a patient taking MYRBETRIQ  (r)  100 mg as well as an herbal medication (Kyufu Gold).\n', '\n', '\n', '\n', '   6.2 Postmarketing Experience\n', '\n', '  Because these spontaneously reported events are from the worldwide postmarketing experience, from a population of uncertain size, the frequency of events and the role of mirabegron in their causation cannot be reliably determined.\n', '\n', '\n', '\n', ' The following events have been reported in association with mirabegron use in worldwide postmarketing experience:\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse  oselabeledaefromdruguse face,  oselabeledaefromdruguse  oselabeledaefromdruguse face, lips,  oselabeledaefromdruguse  oselabeledaefromdruguse face, lips, tongue, and  oselabeledaefromdruguse  with or without  nonoseaemanifestationorcomplication  [see  Warnings and Precautions  (  5.3  )]  ",0,1,0,0,1,1,0,0,0,0,0,0,0,0,0
68,myrbetriq,68,1901,1963,"\n', '\n', '\n', '\n', '    nonoseaegeneralterm    oselabeledaefromdruguse     5 WARNINGS AND PRECAUTIONS\n', '\n', '\n', '\n', '   EXCERPT:    *     Increases in Blood Pressure: MYRBETRIQ  (r)  can increase blood pressure.",0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
69,myrbetriq,69,1963,1975,"Periodic blood pressure determinations are recommended, especially in hypertensive patients.",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
70,myrbetriq,70,1975,1977,MYRBETRIQ  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
71,myrbetriq,71,1977,1997,(r)  is not recommended for use in severe uncontrolled hypertensive patients (  5.1  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
72,myrbetriq,72,1997,2021,"\n', ' *     Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Antimuscarinic Drugs for Overactive Bladder:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
73,myrbetriq,73,2021,2039,Administer with caution in these patients because of risk of urinary retention (  5.2  ).,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
74,myrbetriq,74,2039,2040,\n,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
75,myrbetriq,75,2040,2047,"', ' *     Angioedema:",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
76,myrbetriq,76,2047,2077,"Angioedema of the face, lips, tongue and/or larynx has been reported with MYRBETRIQ  (r)  (  5.3  ,  6.2  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
77,myrbetriq,77,2077,2086,"\n', ' *     Patients Taking Drugs",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
78,myrbetriq,78,2086,2090,Metabolized by CYP2D6:,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
79,myrbetriq,79,2090,2092,MYRBETRIQ  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
80,myrbetriq,80,2092,2103,(r)  is a moderate inhibitor of CYP2D6.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
81,myrbetriq,81,2103,2133,"Appropriate monitoring is recommended and dose adjustment may be necessary for narrow therapeutic index CYP2D6 substrates (  5.4  ,  7.1  ,  12.3  ).",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
82,myrbetriq,82,2133,2182,"\n', '    \n', ' \n', '\n', '   5.1 Increases in Blood Pressure\n', '\n', '\n', '\n', '  MYRBETRIQ  (r)  can  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
83,myrbetriq,83,2182,2195,"Periodic blood pressure determinations are recommended, especially in  notaecandidatepreexistingconditionorriskfactor patients.",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
84,myrbetriq,84,2195,2197,MYRBETRIQ  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
85,myrbetriq,85,2197,2219,(r)  is not recommended for use in patients with severe  notaecandidatepreexistingconditionorriskfactor (defined as  notaecandidatepreexistingconditionorriskfactor and/or  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
86,myrbetriq,86,2219,2224,notaecandidatepreexistingconditionorriskfactor  [see  ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
87,myrbetriq,87,2224,2233,Clinical Pharmacology  (  12.2  )],0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
88,myrbetriq,88,2233,2235,.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
89,myrbetriq,89,2235,2279,"\n', '\n', '\n', '\n', ' In two, randomized, placebo-controlled, healthy volunteer studies, MYRBETRIQ  (r)  was associated with dose-related  oselabeledaefromdruguse  ",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
90,myrbetriq,90,2279,2306,"In these studies, at the maximum recommended dose of 50 mg, the mean maximum  oselabeledaefromdruguse  oselabeledaefromdruguse in systolic/ oselabeledaefromdruguse was approximately 3.5/1.5 mm",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
91,myrbetriq,91,2306,2360,"Hg greater than placebo.\n', '\n', '\n', '\n', ' In contrast, in  notaecandidateindication patients in clinical trials, the mean  oselabeledaefromdruguse and diastolic  oselabeledaefromdruguse  oselabeledaefromdruguse in systolic and  oselabeledaefromdruguse at the maximum recommended dose of 50 mg was",0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
92,myrbetriq,92,2360,2371,approximately 0.5 - 1 mm Hg greater than placebo.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
93,myrbetriq,93,2371,2464,"oselabeledaefromdruguse was reported infrequently in MYRBETRIQ  (r)  patients.\n', '\n', '\n', '\n', '    5.2 Urinary Retention in Patients with Bladder Outlet Obstruction and in Patients Taking Antimuscarinic Medications for OAB\n', '\n', '\n', '\n', '   oselabeledaefromdruguse in patients with  notaecandidatepreexistingconditionorriskfactor (BOO) and in patients taking antimuscarinic medications for the treatment of  notaecandidateindication has been reported in postmarketing experience in patients taking mirabegron.",0,0,1,1,0,0,0,0,0,0,0,0,0,0,0
94,myrbetriq,94,2464,2546,"A controlled clinical safety study in patients with  notaecandidatepreexistingconditionorriskfactor did not demonstrate  nonoseaenegation in MYRBETRIQ  (r)  patients; however, MYRBETRIQ  (r)  should be administered with caution to patients with clinically significant  notaecandidatepreexistingconditionorriskfactor  MYRBETRIQ  (r)  should also be administered with caution to patients taking antimuscarinic medications for the treatment of  notaecandidateindication [see  Clinical Pharmacology  (  12.2  )].  ",0,0,1,1,0,0,0,1,0,0,0,0,0,0,0
95,myrbetriq,95,2546,2620,"\n', '\n', '\n', '\n', '    5.3 Angioedema\n', '\n', '\n', '\n', '    oselabeledaefromdruguse  oselabeledaefromdruguse face,  oselabeledaefromdruguse  oselabeledaefromdruguse  oselabeledaefromdruguse face, lips,  oselabeledaefromdruguse  oselabeledaefromdruguse face, lips, tongue, and/or  oselabeledaefromdruguse has been reported with MYRBETRIQ  (r)  .",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
96,myrbetriq,96,2620,2631,In some cases  oselabeledaefromdruguse occurred after the first dose.,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
97,myrbetriq,97,2631,2651,Cases of  oselabeledaefromdruguse have been reported to occur hours after the first dose or after multiple doses.  ,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
98,myrbetriq,98,2651,2658,nonoseaeaeonlyasinstruction associated with  nonoseaemanifestationorcomplication '],1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
